PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	BREO, DL				BREO, DL			MD-AIDED SUICIDE VOTED DOWN - BOTH SIDES SAY DEBATE TO CONTINUE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		HUMPHRY, FINAL EXIT; JEANS WAY	2	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 27	1991	266	20					2895	&		10.1001/jama.266.20.2895	http://dx.doi.org/10.1001/jama.266.20.2895			0	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GQ722	1942460				2022-12-24	WOS:A1991GQ72200041
J	MILNER, PF; KRAUS, AP; SEBES, JI; SLEEPER, LA; DUKES, KA; EMBURY, SH; BELLEVUE, R; KOSHY, M; MOOHR, JW; SMITH, J				MILNER, PF; KRAUS, AP; SEBES, JI; SLEEPER, LA; DUKES, KA; EMBURY, SH; BELLEVUE, R; KOSHY, M; MOOHR, JW; SMITH, J			SICKLE-CELL DISEASE AS A CAUSE OF OSTEONECROSIS OF THE FEMORAL-HEAD	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ALPHA-THALASSEMIA; AVASCULAR NECROSIS; ANEMIA; SEVERITY; GENE; HIP	Background and Methods. Osteonecrosis of the femoral head is an important complication of sickle cell disease. We studied 2590 patients who were over 5 years of age at entry and followed them for an average of 5.6 years. Patients were examined twice a year, and radiographs of the hips were taken at least twice: at study entry and approximately three years later. Results. At study entry, 9.8 percent of patients were found to have osteonecrosis of one or both femoral heads. On follow-up, patients with the hemoglobin SS genotype and alpha-thalassemia were at the greatest risk for osteonecrosis (age-adjusted incidence rate, 4.5 cases per 100 patient-years, as compared with 2.4 in patients with the hemoglobin SS genotype without alpha-thalassemia and 1.9 in those with the hemoglobin SC genotype). Although the rate of osteonecrosis in patients with the hemoglobin SC genotype did not differ significantly from that in patients with the hemoglobin SS genotype without alpha-thalassemia, osteonecrosis tended to develop in these patients later in life. Intermediate rates of osteonecrosis were observed among patients with the hemoglobin S-beta-0-thalassemia and the hemoglobin S-beta+-thalassemia genotypes (3.6 and 3.3 cases per 100 patient-years, respectively). Osteonecrosis was found in patients as young as five years old (1.8 cases per 100 patient-years for all genotypes). The frequency of painful crises and the hematocrit were positively associated with osteonecrosis. The mean corpuscular volume and serum aspartate aminotransferase level were negatively associated. Twenty-seven patients had hip arthroplasty during the study; 10 were under 25 years of age. Five of the 27 required reoperation 11 to 53 months after the initial operation. Conclusions. Osteonecrosis of the femoral head is common in patients with sickle cell disease, with an incidence ranging from about 2 to 4.5 cases per 100 patient-years. Patients with the hemoglobin SS genotype and alpha-thalassemia and those with frequent painful crises are at highest risk. The overall prevalence is about 10 percent. The results of hip arthroplasty are poor.	UNIV TENNESSEE CTR HLTH SCI, MEMPHIS, TN 38163 USA; NEW ENGLAND RES INST, WATERTOWN, MA USA; UNIV CALIF SAN FRANCISCO, SAN FRANCISCO, CA 94143 USA; INTERFAITH MED CTR, BROOKLYN, NY USA; UNIV ILLINOIS, CHICAGO, IL 60680 USA; UNIV ILLINOIS, CHICAGO, IL 60680 USA; WOODHULL SUNY HLTH SCI CTR, BROOKLYN, NY USA; COLUMBIA UNIV, HARLEM HOSP CTR, NEW YORK, NY 10027 USA	University of Tennessee System; University of Tennessee Health Science Center; HealthCore, Inc; University of California System; University of California San Francisco; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; Columbia University	MILNER, PF (corresponding author), MED COLL GEORGIA, ADULT SICKLE CELL CLIN, BLDG FR-100, AUGUSTA, GA 30912 USA.							BALLAS SK, 1989, HEMOGLOBIN, V13, P649, DOI 10.3109/03630268908998842; CHUNG SMK, 1969, J BONE JOINT SURG AM, VA 51, P33, DOI 10.2106/00004623-196951010-00003; CLARKE HJ, 1989, J BONE JOINT SURG BR, V71, P465, DOI 10.1302/0301-620X.71B3.2722941; CNAAN A, 1989, STAT MED, V8, P1255, DOI 10.1002/sim.4780081009; DIGGS LW, 1937, SOUTH MED J, V30, P249; EMBURY SH, 1982, NEW ENGL J MED, V306, P270, DOI 10.1056/NEJM198202043060504; EMBURY SH, 1979, J CLIN INVEST, V63, P1307, DOI 10.1172/JCI109426; EMBURY SH, 1980, J CLIN INVEST, V66, P1319, DOI 10.1172/JCI109984; ENSIGN MF, 1990, SEMIN ULTRASOUND CT, V11, P288; FARBER MD, 1985, J CHRON DIS, V38, P495, DOI 10.1016/0021-9681(85)90033-5; Ficat R P, 1983, Hip, P279; FICAT RP, 1985, J BONE JOINT SURG BR, V67, P3, DOI 10.1302/0301-620X.67B1.3155745; Fleiss J.L., 1986, DESIGN ANAL CLIN EXP; GASTON M, 1982, AM J PEDIAT HEMATOL, V4, P197; Glimcher M. J., 1979, CLIN ORTHOP RELAT R, V138, P284; GLIMCHER MJ, 1979, CLIN ORTHOP RELAT R, P273; GLIMCHER MJ, 1979, CLIN ORTHOP RELAT R, P283; Grinnan AG, 1935, AM J ROENTGENOL RADI, V34, P297; HANKER GJ, 1988, J BONE JOINT SURG AM, V70A, P499, DOI 10.2106/00004623-198870040-00004; HERNIGOU P, 1991, J BONE JOINT SURG AM, V73A, P81, DOI 10.2106/00004623-199173010-00011; HIGGS DR, 1982, NEW ENGL J MED, V306, P1441, DOI 10.1056/NEJM198206173062402; HUNGERFORD DS, 1989, ARTHRITIS RHEUM-US, V32, P801, DOI 10.1002/anr.1780320623; IWEGBU CG, 1985, J BONE JOINT SURG BR, V67, P29, DOI 10.1302/0301-620X.67B1.3968138; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; LEE REJ, 1981, CLIN RADIOL, V32, P205, DOI 10.1016/S0009-9260(81)80162-6; LIEINJO LE, 1981, NUCLEIC ACIDS RES, V9, P3707, DOI 10.1093/nar/9.15.3707; LILIENFELD AM, 1980, F EPIDEMIOLOGY; PLATT OS, 1991, NEW ENGL J MED, V325, P11, DOI 10.1056/NEJM199107043250103; RIVER GL, 1961, BLOOD, V18, P385, DOI 10.1182/blood.V18.4.385.385; SAITO S, 1989, CLIN ORTHOP RELAT R, V244, P198; SERJEANT GR, 1989, ANN NY ACAD SCI, V565, P109, DOI 10.1111/j.1749-6632.1989.tb24157.x; SERJEANT GR, 1973, BRIT J RADIOL, V46, P935, DOI 10.1259/0007-1285-46-551-935; SERJEANT GR, 1985, SICKLE CELL DISEASE, P246; STEINBERG MH, 1984, BLOOD, V63, P1353; STEINBERG MH, 1983, BRIT J HAEMATOL, V55, P487, DOI 10.1111/j.1365-2141.1983.tb02164.x; STEINBERG MH, 1986, BLOOD, V68, P985; STULBERG BN, 1990, CLIN ORTHOP RELAT R, V261, P186; SWEET DE, 1981, DIAGNOSIS BONE JOINT, V3, P2780; UEO T, 1985, ARCH ORTHOP TRAUM SU, V104, P145, DOI 10.1007/BF00454690	39	230	233	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 21	1991	325	21					1476	1481		10.1056/NEJM199111213252104	http://dx.doi.org/10.1056/NEJM199111213252104			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GQ406	1944426				2022-12-24	WOS:A1991GQ40600004
J	HEALY, B				HEALY, B			TL-201 ABNORMALITIES FOUND INDICATIVE OF ISCHEMIA IN HYPERTROPHIC CARDIOMYOPATHY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											HEALY, B (corresponding author), NIH,BETHESDA,MD 20892, USA.							1991, CIRCULATION, V83, P1660	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 6	1991	266	17					2341	2341						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GM790	1920737				2022-12-24	WOS:A1991GM79000008
J	KATZ, H; HOMAN, M; VELOSA, J; ROBERTSON, P; RIZZA, R				KATZ, H; HOMAN, M; VELOSA, J; ROBERTSON, P; RIZZA, R			EFFECTS OF PANCREAS TRANSPLANTATION ON POSTPRANDIAL GLUCOSE-METABOLISM	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DEPENDENT DIABETES-MELLITUS; INSULIN RESISTANCE; C-PEPTIDE; HYPERINSULINEMIA; GLUCONEOGENESIS; STIMULATION; RECIPIENTS; EXTRACTION; SECRETION; TRANSPORT	Background. Because a pancreas allograft is placed in the pelvis, pancreas transplantation abolishes the normal gradient between portal-vein and peripheralvein insulin concentrations and causes systemic hyperinsulinemia. Whether pancreas transplantation restores carbohydrate metabolism to normal is not known. Methods. We studied seven patients with insulin-dependent diabetes mellitus after pancreas-kidney transplantation, seven nondiabetic patients after kidney transplantation (to control for immunosuppression), and eight normal subjects. Measurements were made after an overnight fast and after ingestion of a mixed meal. Results. Although plasma glucose concentrations did not differ in the two transplant groups, plasma insulin concentrations were significantly higher in the diabetic pancreas-kidney recipients than in the nondiabetic kidney recipients, both before the meal (mean +/- SE, 102 +/- 15 vs. 53 +/- 6 pmol per liter; P < 0.05) and afterward (123 +/- 22 vs. 61 +/- 6 nmol per liter per six hours; P < 0.05). Plasma C-peptide concentrations were the same in both groups, indicating that hyperinsulinemia was due to decreased insulin clearance rather than increased insulin secretion. Despite drainage of the venous effluent from the transplanted pancreas into the systemic circulation, the values for splanchnic clearance of ingested glucose, suppression of hepatic glucose release, incorporation of carbon dioxide into glucose, stimulation of glucose oxidation, glucose uptake, and forearm glucose clearance were all similar in the transplant groups and differed minimally from the values in the normal group. The similar rates of glucose uptake in the presence of higher systemic insulin concentrations indicated that the extrahepatic tissues of the diabetic pancreas-kidney recipients were insulin-resistant. Conclusions. Despite systemic delivery of insulin, pancreas-kidney transplantation in patients with diabetes results in carbohydrate metabolism similar to that in nondiabetic subjects receiving the same immunosuppressive agents after kidney transplantation.	MAYO CLIN & MAYO FDN,DEPT MED,ROCHESTER,MN 55905; UNIV MINNESOTA,DEPT MED,MINNEAPOLIS,MN 55455	Mayo Clinic; University of Minnesota System; University of Minnesota Twin Cities					NCRR NIH HHS [RR-00585] Funding Source: Medline; NIDDK NIH HHS [DK-29953, DK-39994] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000585] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK029953, R01DK039994, R01DK029953] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BELL PM, 1986, J CLIN INVEST, V78, P1479, DOI 10.1172/JCI112739; BERGMAN RN, 1974, AM J PHYSIOL, V227, P1314, DOI 10.1152/ajplegacy.1974.227.6.1314; BLACKARD WG, 1970, DIABETES, V19, P302, DOI 10.2337/diab.19.5.302; BROSNAN JT, 1982, FED PROC, V41, P91; BUTLER PC, 1990, DIABETES, V39, P1373, DOI 10.2337/diabetes.39.11.1373; Consolazio CF., 1963, HDB PHYSL, P313; DEBODO RC, 1963, RECENT PROG HORM RES, V19, P445; DIEM P, 1990, DIABETES, V39, P534, DOI 10.2337/diabetes.39.5.534; FALHOLT K, 1991, METABOLISM, V40, P122, DOI 10.1016/0026-0495(91)90161-O; FALOONA GR, 1974, METHOD HORM RADIOIMM, P317; FIRTH RG, 1986, J CLIN INVEST, V77, P1525, DOI 10.1172/JCI112467; FRAYN KN, 1983, J APPL PHYSIOL, V55, P628, DOI 10.1152/jappl.1983.55.2.628; GAVIN JR, 1974, P NATL ACAD SCI USA, V71, P84, DOI 10.1073/pnas.71.1.84; HEDING LG, 1975, DIABETOLOGIA, V11, P201, DOI 10.1007/BF00422322; HERBERT V, 1965, J CLIN ENDOCR METAB, V25, P1375, DOI 10.1210/jcem-25-10-1375; HORWITZ DL, 1975, J CLIN INVEST, V55, P1278, DOI 10.1172/JCI108047; ISSEKUTZ B, 1977, METABOLISM, V26, P157, DOI 10.1016/0026-0495(77)90051-8; KAIHARA S, 1968, J LAB CLIN MED, V71, P400; KATZ J, 1985, AM J PHYSIOL, V248, pR391, DOI 10.1152/ajpregu.1985.248.4.R391; KRUSZYNSKA YT, 1987, METABOLISM, V36, P281, DOI 10.1016/0026-0495(87)90189-2; KRYSHAK EJ, 1990, DIABETES, V39, P142, DOI 10.2337/diabetes.39.2.142; LUZI L, 1990, DIABETOLOGIA, V33, P549, DOI 10.1007/BF00404143; MARCO J, 1973, NEW ENGL J MED, V288, P128, DOI 10.1056/NEJM197301182880305; MARSHALL S, 1980, J CLIN INVEST, V66, P763, DOI 10.1172/JCI109914; MCMAHON M, 1989, DIABETES, V38, P291, DOI 10.2337/diabetes.38.3.291; MCMAHON MM, 1989, DIABETES, V38, P97, DOI 10.2337/diabetes.38.1.97; MYERS SR, 1991, J CLIN INVEST, V87, P930, DOI 10.1172/JCI115100; OSEI K, 1990, DIABETES, V39, P1235, DOI 10.2337/diabetes.39.10.1235; OSTMAN J, 1989, DIABETES, V38, P88, DOI 10.2337/diab.38.1.S88; POLONSKY K, 1990, DIABETES S1, V39, pA15; POLONSKY KS, 1984, DIABETES, V33, P486, DOI 10.2337/diabetes.33.5.486; RADZIUK J, 1978, METABOLISM, V27, P657, DOI 10.1016/0026-0495(78)90003-3; RIZZA RA, 1985, DIABETOLOGIA, V28, P70; RIZZA RA, 1982, J CLIN ENDOCR METAB, V54, P131, DOI 10.1210/jcem-54-1-131; RIZZA RA, 1981, AM J PHYSIOL, V240, pE630, DOI 10.1152/ajpendo.1981.240.6.E630; RUDERMAN NB, 1968, AM J PHYSIOL, V214, P1346, DOI 10.1152/ajplegacy.1968.214.6.1346; STALMANS W, 1974, EUR J BIOCHEM, V41, P117; STEELE R, 1956, AM J PHYSIOL, V187, P15, DOI 10.1152/ajplegacy.1956.187.1.15; SUTHERLAND DE, 1986, CLIN CHEM S10, V10, pB83; WARDZALA LJ, 1985, J CLIN INVEST, V76, P460, DOI 10.1172/JCI111994; WOLFE RR, 1986, AM J PHYSIOL, V250, pE306, DOI 10.1152/ajpendo.1986.250.3.E306	41	129	129	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 31	1991	325	18					1278	1283		10.1056/NEJM199110313251804	http://dx.doi.org/10.1056/NEJM199110313251804			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GM041	1922222	Bronze			2022-12-24	WOS:A1991GM04100004
J	BUKRINSKY, MI; STANWICK, TL; DEMPSEY, MP; STEVENSON, M				BUKRINSKY, MI; STANWICK, TL; DEMPSEY, MP; STEVENSON, M			QUIESCENT LYMPHOCYTES-T AS AN INDUCIBLE VIRUS RESERVOIR IN HIV-1 INFECTION	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; IMMUNE-DEFICIENCY SYNDROME; HTLV-III/LAV ENVELOPE; PERIPHERAL-BLOOD; REVERSE TRANSCRIPTION; CELL ACTIVATION; AIDS VIRUS; TYPE-1; DNA; EXPRESSION	To better understand the basis for human immunodeficiency virus type 1 (HIV-1) persistence and latency, the form in which viral DNA exists in the peripheral T lymphocyte reservoir of infected individuals was investigated. In asymptomatic individuals, HIV-1 was harbored predominantly as full-length, unintegrated complementary DNA. These extrachromosomal DNA forms retained the ability to integrate upon T cell activation in vitro. In patients with acquired immunodeficiency syndrome (AIDS), there was an increase in integrated relative to extrachromosomal DNA forms. By analysis of DNA from patient lymphocyte subpopulations depleted of human lymphocyte antigen-Dr receptor-positive cells, quiescent T cells were identified as the source of extrachromosomal HIV-1 DNA. Thus quiescent T lymphocytes may be a major and inducible HIV-11 reservoir in infected individuals.	UNIV NEBRASKA,MED CTR,DEPT PATHOL & MICROBIOL,OMAHA,NE 68198; NATL INST MED RES,DIV VIROL,LONDON NW7 1AA,ENGLAND	University of Nebraska System; University of Nebraska Medical Center; MRC National Institute for Medical Research					NIAID NIH HHS [R01 AI049152, R01 AI032890] Funding Source: Medline; NIMH NIH HHS [R01 MH064411] Funding Source: Medline; PHS HHS [A124481, A130386] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BUKRINSKY MI, UNPUB; DEEN KC, 1988, NATURE, V331, P82, DOI 10.1038/331082a0; DORNER AJ, 1986, CELL, V45, P365, DOI 10.1016/0092-8674(86)90322-3; DUH EJ, 1989, P NATL ACAD SCI USA, V86, P5974, DOI 10.1073/pnas.86.15.5974; FAUCI AS, 1988, SCIENCE, V239, P617, DOI 10.1126/science.3277274; FOLKS TM, 1986, J EXP MED, V164, P280, DOI 10.1084/jem.164.1.280; GOEDERT JJ, 1987, JAMA-J AM MED ASSOC, V257, P331, DOI 10.1001/jama.257.3.331; GRANDGENETT DP, 1990, CELL, V60, P3, DOI 10.1016/0092-8674(90)90707-L; HARPER ME, 1986, P NATL ACAD SCI USA, V83, P772, DOI 10.1073/pnas.83.3.772; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; HO DD, 1987, NEW ENGL J MED, V317, P278; HU WS, 1990, SCIENCE, V250, P1227, DOI 10.1126/science.1700865; KESHET E, 1979, J VIROL, V31, P376, DOI 10.1128/JVI.31.2.376-388.1979; LANG W, 1987, JAMA-J AM MED ASSOC, V257, P326, DOI 10.1001/jama.257.3.326; LIFSON JD, 1986, NATURE, V323, P725, DOI 10.1038/323725a0; MCDOUGAL JS, 1985, J IMMUNOL, V135, P3151; MCELRATH MJ, 1989, P NATL ACAD SCI USA, V86, P675, DOI 10.1073/pnas.86.2.675; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; MULLINS JI, 1986, NATURE, V319, P333, DOI 10.1038/319333a0; PADMANABHAN R, 1988, ANAL BIOCHEM, V170, P341, DOI 10.1016/0003-2697(88)90640-9; PANG S, 1990, NATURE, V343, P85, DOI 10.1038/343085a0; PANGANIBAN AT, 1988, SCIENCE, V241, P1064, DOI 10.1126/science.2457948; PAUZA CD, 1990, J EXP MED, V172, P1035, DOI 10.1084/jem.172.4.1035; POMERANTZ RJ, 1990, CELL, V61, P1271, DOI 10.1016/0092-8674(90)90691-7; POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935; PSALLIDOPOULOS MC, 1989, J VIROL, V63, P4626, DOI 10.1128/JVI.63.11.4626-4631.1989; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; REINHERZ EL, 1979, J EXP MED, V150, P1472, DOI 10.1084/jem.150.6.1472; ROBINSON HL, 1990, J VIROL, V64, P4836, DOI 10.1128/JVI.64.10.4836-4841.1990; SCHNITTMAN SM, 1989, SCIENCE, V245, P305, DOI 10.1126/science.2665081; SHANK PR, 1978, CELL, V15, P1383, DOI 10.1016/0092-8674(78)90063-6; SHAW GM, 1984, SCIENCE, V226, P1165, DOI 10.1126/science.6095449; SODROSKI J, 1986, NATURE, V322, P470, DOI 10.1038/322470a0; SOMASUNDARAN M, 1987, J VIROL, V61, P3114, DOI 10.1128/JVI.61.10.3114-3119.1987; SOMMERFELT MA, 1990, VIROLOGY, V176, P58, DOI 10.1016/0042-6822(90)90230-O; STECK FT, 1966, VIROLOGY, V29, P642, DOI 10.1016/0042-6822(66)90288-1; STEVENSON M, 1988, CELL, V53, P483, DOI 10.1016/0092-8674(88)90168-7; STEVENSON M, 1990, EMBO J, V9, P1551, DOI 10.1002/j.1460-2075.1990.tb08274.x; STEVENSON M, 1990, J VIROL, V64, P2421, DOI 10.1128/JVI.64.5.2421-2425.1990; WEISS R, 1984, RNA TUMOR VIRUSES, V1, P209; WELLER SK, 1980, J VIROL, V33, P494, DOI 10.1128/JVI.33.1.494-506.1980; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L; ZAGURY D, 1986, SCIENCE, V231, P850, DOI 10.1126/science.2418502	43	529	542	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 18	1991	254	5030					423	427		10.1126/science.1925601	http://dx.doi.org/10.1126/science.1925601			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GK729	1925601	Green Accepted			2022-12-24	WOS:A1991GK72900047
J	STEWART, PL; BURNETT, RM; CYRKLAFF, M; FULLER, SD				STEWART, PL; BURNETT, RM; CYRKLAFF, M; FULLER, SD			IMAGE-RECONSTRUCTION REVEALS THE COMPLEX MOLECULAR-ORGANIZATION OF ADENOVIRUS	CELL			English	Article							CRYO-ELECTRON MICROSCOPY; 3-DIMENSIONAL STRUCTURE; SPHERICAL VIRUSES; POLYPEPTIDE-IX; HEXON; MICROGRAPHS; CHROMATIN; TYPE-2; CORE; VISUALIZATION	The three-dimensional structure of adenovirus has been determined by image reconstruction from cryoelectron micrographs. Comparison with the high resolution X-ray crystal structure of hexon, the major capsid protein, enabled an unusually detailed interpretation of the density map and confirmed the validity of the reconstruction. The hexon packing in the capsid shows more extensive intermolecular interfaces between facets than previously proposed. The reconstruction provides the first three-dimensional visualization of the vertex proteins, including the penton base and its associated protruding fiber. Three minor capsid proteins that stabilize and modulate capsomer interactions are revealed. One of these components stabilizes the group-of-nine hexons in the center of each facet and the other two bridge hexons in adjacent facets. The strategic positions of these proteins highlight the importance of cementing proteins in stabilizing a complex assembly.	EUROPEAN MOLEC BIOL LAB,BIOL STRUCT & BIOCOMP PROGRAMME,W-6900 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)	STEWART, PL (corresponding author), WISTAR INST,3601 SPRUCE ST,PHILADELPHIA,PA 19104, USA.				NCI NIH HHS [CA 10815, 2T32 CA 09171-13] Funding Source: Medline; NIAID NIH HHS [AI 17270] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009171, P30CA010815] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI017270] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADRIAN M, 1984, NATURE, V308, P32, DOI 10.1038/308032a0; ANDERSON CW, 1990, VIROLOGY, V177, P259, DOI 10.1016/0042-6822(90)90479-B; BAKER TS, 1988, P NATL ACAD SCI USA, V85, P422, DOI 10.1073/pnas.85.2.422; BROWN DT, 1975, J VIROL, V16, P366, DOI 10.1128/JVI.16.2.366-387.1975; BURNETT RM, 1990, USE OF X-RAY CRYSTALLOGRAPHY IN THE DESIGN OF ANTIVIRAL AGENTS, P35; BURNETT RM, 1985, J MOL BIOL, V185, P125, DOI 10.1016/0022-2836(85)90187-1; COLBY WW, 1981, J VIROL, V39, P977, DOI 10.1128/JVI.39.3.977-980.1981; CORDEN J, 1976, P NATL ACAD SCI USA, V73, P401, DOI 10.1073/pnas.73.2.401; CROWTHER RA, 1971, PHILOS T R SOC B, V261, P221, DOI 10.1098/rstb.1971.0054; EVERITT E, 1975, VIROLOGY, V67, P197, DOI 10.1016/0042-6822(75)90417-1; FULLER SD, 1987, CELL, V48, P923, DOI 10.1016/0092-8674(87)90701-X; FURCINITTI PS, 1989, EMBO J, V8, P3563, DOI 10.1002/j.1460-2075.1989.tb08528.x; GREEN NM, 1983, EMBO J, V2, P1357, DOI 10.1002/j.1460-2075.1983.tb01592.x; HOMO JC, 1984, J MICROSC-OXFORD, V136, P337, DOI 10.1111/j.1365-2818.1984.tb00543.x; JENG TW, 1989, J MOL BIOL, V205, P251, DOI 10.1016/0022-2836(89)90379-3; LAVER WG, 1969, VIROLOGY, V39, P599, DOI 10.1016/0042-6822(69)90111-1; MIRZA MA, 1982, BIOCHIM BIOPHYS ACTA, V696, P76, DOI 10.1016/0167-4781(82)90012-4; NERMUT MV, 1984, ADENOVIRUSES, P5; NEWCOMB WW, 1984, J VIROL, V51, P52, DOI 10.1128/JVI.51.1.52-56.1984; PEREIRA HG, 1974, J MOL BIOL, V85, P617, DOI 10.1016/0022-2836(74)90319-2; PHILIPSON L, 1983, CURR TOP MICROBIOL, V109, P1; PHILIPSON L, 1968, J VIROL, V2, P1064, DOI 10.1128/JVI.2.10.1064-1075.1968; PRASAD BVV, 1988, J MOL BIOL, V199, P269, DOI 10.1016/0022-2836(88)90313-0; ROBERTS MM, 1986, SCIENCE, V232, P1148, DOI 10.1126/science.3704642; ROBERTS RJ, 1984, J BIOL CHEM, V259, P3968; ROSSMANN MG, 1989, ANNU REV BIOCHEM, V58, P533, DOI 10.1146/annurev.bi.58.070189.002533; ROWE WP, 1953, P SOC EXP BIOL MED, V84, P570, DOI 10.3181/00379727-84-20714; RUIGROK RWH, 1990, J MOL BIOL, V215, P589, DOI 10.1016/S0022-2836(05)80170-6; RUSSELL WC, 1982, J GEN VIROL, V63, P69, DOI 10.1099/0022-1317-63-1-69; SCHRAG JD, 1989, CELL, V56, P651, DOI 10.1016/0092-8674(89)90587-4; STEWART PL, 1990, SEMIN VIROL, V1, P477; TATE VE, 1979, NUCLEIC ACIDS RES, V6, P2769, DOI 10.1093/nar/6.8.2769; TORBET J, 1983, EMBO J, V2, P63, DOI 10.1002/j.1460-2075.1983.tb01381.x; VANOOSTRUM J, 1987, J MOL BIOL, V198, P73, DOI 10.1016/0022-2836(87)90459-1; VANOOSTRUM J, 1985, J VIROL, V56, P439, DOI 10.1128/JVI.56.2.439-448.1985; VOGEL RH, 1986, NATURE, V320, P533, DOI 10.1038/320533a0	36	238	245	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 4	1991	67	1					145	154		10.1016/0092-8674(91)90578-M	http://dx.doi.org/10.1016/0092-8674(91)90578-M			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GJ320	1913814				2022-12-24	WOS:A1991GJ32000013
J	CORRALDEBRINSKI, M; STEPIEN, G; SHOFFNER, JM; LOTT, MT; KANTER, K; WALLACE, DC				CORRALDEBRINSKI, M; STEPIEN, G; SHOFFNER, JM; LOTT, MT; KANTER, K; WALLACE, DC			HYPOXEMIA IS ASSOCIATED WITH MITOCHONDRIAL-DNA DAMAGE AND GENE INDUCTION - IMPLICATIONS FOR CARDIAC DISEASE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OXIDATIVE-PHOSPHORYLATION; MYOCARDIAL ISCHEMIA; PARKINSONS-DISEASE; FREE-RADICALS; REPERFUSION; MUTATIONS; DELETION; INCREASE; SEQUENCE; NUCLEAR	Objective. - Oxidative phosphorylation (OXPHOS) deficiency due to hypoxemia or other causes was hypothesized to increase oxygen radical generation, damage mitochondrial DNA (mtDNA), and reduce adenosine triphosphate synthesis, resulting in compensatory OXPHOS gene induction. Therefore, we investigated the levels of mtDNA damage and OXPHOS transcripts in normal and ischemic hearts, and then in other forms of heart disease. Design. - DNA was extracted from the heart and the levels of the common 4977 base pair mtDNA deletion were quantitated as an index for mtDNA damage. Total RNA was extracted from hearts and analyzed for OXPHOS transcript levels. Results. - In control hearts, the 4977 base pair mtDNA deletion appeared at age 40 years and reached a maximum deletion of 0.0035%. Much higher levels were found in ischemic hearts (0.02% to 0.85%), as well as in three of 10 cases with other types of heart disease (0.017% to 0.16%). The OXPHOS transcripts were increased in all diseased hearts. Conclusion. - Ischemic hearts have increased mtDNA damage and OXPHOS gene expression, suggesting that mtDNA damage is associated with OXPHOS deficiency. Oxidative phosphorylation defects may also play a role in some other forms of cardiac disease.	EMORY UNIV, SCH MED,DEPT GENET & MOLEC MED, 3031 ROLLINS RES CTR,1510 CLIFTON RD, ATLANTA, GA 30322 USA; EMORY UNIV, SCH MED, DEPT NEUROL, ATLANTA, GA 30322 USA; EMORY UNIV, SCH MED, DEPT BIOCHEM, ATLANTA, GA 30322 USA; EMORY UNIV, SCH MED, DEPT PEDIAT, ATLANTA, GA 30322 USA; EMORY UNIV, SCH MED, DEPT SURG, ATLANTA, GA 30322 USA; CTR COCHIN GENET MOLEC, PARIS, FRANCE; UNIV PARIS 11, CNRS, F-91405 ORSAY, FRANCE	Emory University; Emory University; Emory University; Emory University; Emory University; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay				Lott, Marie/0000-0003-2035-479X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045572] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS001336, R01NS021328] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL45572] Funding Source: Medline; NINDS NIH HHS [NS21328, NS01336] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARROYO CM, 1987, FREE RADICAL BIO MED, V3, P313, DOI 10.1016/S0891-5849(87)80037-0; BANDY B, 1990, FREE RADICAL BIO MED, V8, P523, DOI 10.1016/0891-5849(90)90152-9; CORTOPASSI GA, 1990, NUCLEIC ACIDS RES, V18, P6927, DOI 10.1093/nar/18.23.6927; GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0; HATTORI K, 1991, AM HEART J, V121, P1735, DOI 10.1016/0002-8703(91)90020-I; IKEBE S, 1990, BIOCHEM BIOPH RES CO, V170, P1044, DOI 10.1016/0006-291X(90)90497-B; KOTAKA K, 1982, J MOL CELL CARDIOL, V14, P223, DOI 10.1016/0022-2828(82)90191-2; LOCHNER A, 1981, J MOL CELL CARDIOL, V13, P991, DOI 10.1016/0022-2828(81)90474-0; MCCORD JM, 1988, FREE RADICAL BIO MED, V4, P9, DOI 10.1016/0891-5849(88)90005-6; NECKELMANN N, 1987, P NATL ACAD SCI USA, V84, P7580, DOI 10.1073/pnas.84.21.7580; OTANI H, 1984, CIRC RES, V55, P168, DOI 10.1161/01.RES.55.2.168; OZAWA T, 1990, BIOCHEM BIOPH RES CO, V170, P830, DOI 10.1016/0006-291X(90)92166-W; PARKER WD, 1989, ANN NEUROL, V26, P719, DOI 10.1002/ana.410260606; PARKER WD, 1990, NEUROLOGY, V40, P1302, DOI 10.1212/WNL.40.8.1302; PIPER HM, 1985, J MOL CELL CARDIOL, V17, P885, DOI 10.1016/S0022-2828(85)80102-4; RICHTER C, 1988, P NATL ACAD SCI USA, V85, P6465, DOI 10.1073/pnas.85.17.6465; ROUSLIN W, 1983, AM J PHYSIOL, V244, pH743, DOI 10.1152/ajpheart.1983.244.6.H743; Sambrook J., 1989, MOL CLONING LAB MANU; SCHAPIRA AHV, 1990, J NEUROCHEM, V54, P823, DOI 10.1111/j.1471-4159.1990.tb02325.x; SCHON EA, 1989, SCIENCE, V244, P346, DOI 10.1126/science.2711184; SHOFFNER JM, 1989, P NATL ACAD SCI USA, V86, P7952, DOI 10.1073/pnas.86.20.7952; SHOFFNER JM, 1990, ADV HUM GENET, V19, P267; SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N; SHOFFNER JM, IN PRESS ANN NEUROL; TORRONI A, 1990, J BIOL CHEM, V265, P20589; TROUNCE I, 1989, LANCET, V1, P637, DOI 10.1016/S0140-6736(89)92143-0; WALLACE DC, 1988, CELL, V55, P601, DOI 10.1016/0092-8674(88)90218-8; WALLACE DC, 1987, CURR GENET, V12, P81, DOI 10.1007/BF00434661; WILKINSON L, 1989, SYSTAT SYSTEM STATIS; YEN TC, 1989, BIOCHEM BIOPH RES CO, V165, P994, DOI 10.1016/0006-291X(89)92701-0	30	302	308	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 2	1991	266	13					1812	1816		10.1001/jama.266.13.1812	http://dx.doi.org/10.1001/jama.266.13.1812			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG551	1890710				2022-12-24	WOS:A1991GG55100034
J	JARDETZKY, TS; LANE, WS; ROBINSON, RA; MADDEN, DR; WILEY, DC				JARDETZKY, TS; LANE, WS; ROBINSON, RA; MADDEN, DR; WILEY, DC			IDENTIFICATION OF SELF PEPTIDES BOUND TO PURIFIED HLA-B27	NATURE			English	Article							TOXIC LYMPHOCYTES-T; CLASS-I MOLECULES; MAJOR HISTOCOMPATIBILITY COMPLEX; AMINO-ACID SEQUENCES; HEAT-SHOCK PROTEIN; DEVELOPMENTAL BIOLOGY; ANTIGEN PRESENTATION; VIRAL PEPTIDES; HLA ANTIGENS; MHC	A pool of endogenous peptides bound to the human class I MHC molecule, HLA-B27, has been isolated. Microsequence analysis of the pool and of 11 HPLC-purified peptides provides information on the binding specificity of the HLA-B27 molecule. The peptides all seem to be nonamers, seven of which match to protein sequences in a database search. These self peptides derive from abundant cytosolic or nuclear proteins, such as histone, ribosomal proteins, and members of the 90K heat-shock protein family.	HARVARD UNIV,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02138; HARVARD UNIV,COMM HIGHER DEGREES BIOPHYS,CAMBRIDGE,MA 02138; HARVARD MICROCHEM FACIL,CAMBRIDGE,MA 02138	Harvard University; Howard Hughes Medical Institute; Harvard University; Harvard University	JARDETZKY, TS (corresponding author), HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,7 DIVIN AVE,CAMBRIDGE,MA 02138, USA.							ALBERTS B, 1989, MOL BIOL CELL, P496; ATTSCHUL SF, 1990, J MOL BIOL, V215, P403; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; CERUNDOLO V, 1990, NATURE, V345, P449, DOI 10.1038/345449a0; DEVERSON EV, 1990, NATURE, V348, P738, DOI 10.1038/348738a0; ELLIOTT T, 1991, NATURE, V351, P402, DOI 10.1038/351402a0; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; GARRETT TPJ, 1989, NATURE, V342, P692, DOI 10.1038/342692a0; HICKEY E, 1989, MOL CELL BIOL, V9, P2615, DOI 10.1128/MCB.9.6.2615; HUET S, 1990, INT IMMUNOL, V2, P311, DOI 10.1093/intimm/2.4.311; IGGO RD, 1991, MOL CELL BIOL, V11, P1326, DOI 10.1128/MCB.11.3.1326; KVIST S, 1990, NATURE, V348, P446, DOI 10.1038/348446a0; LAI BT, 1984, MOL CELL BIOL, V4, P2802, DOI 10.1128/MCB.4.12.2802; LANE WS, 1991, J PROTEIN CHEM, V10, P151, DOI 10.1007/BF01024778; LIE WR, 1990, NATURE, V344, P439, DOI 10.1038/344439a0; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; MADDEN DR, 1991, NATURE, V353, P321, DOI 10.1038/353321a0; MATZINGER P, 1977, CELL IMMUNOL, V29, P1, DOI 10.1016/0008-8749(77)90269-6; MONACO JJ, 1990, SCIENCE, V250, P1723, DOI 10.1126/science.2270487; MOORE MW, 1988, CELL, V54, P777, DOI 10.1016/S0092-8674(88)91043-4; MORRISON LA, 1986, J EXP MED, V163, P903, DOI 10.1084/jem.163.4.903; NIXON DF, 1988, NATURE, V336, P484, DOI 10.1038/336484a0; PARHAM P, 1977, J BIOL CHEM, V252, P7555; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; SAPER MA, 1991, J MOL BIOL, V219, P277, DOI 10.1016/0022-2836(91)90567-P; SCHUMACHER TNM, 1990, CELL, V62, P563, DOI 10.1016/0092-8674(90)90020-F; SILVER ML, 1991, NATURE, V350, P619, DOI 10.1038/350619a0; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; STONE KL, 1989, TECHNIQUES PROTEIN C, P377; STROMINGER JL, 1989, SCIENCE, V244, P943, DOI 10.1126/science.2658058; TERHORST C, 1977, P NATL ACAD SCI USA, V74, P4002, DOI 10.1073/pnas.74.9.4002; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1988, J EXP MED, V168, P1211, DOI 10.1084/jem.168.4.1211; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; TOWNSEND ARM, 1986, NATURE, V324, P575, DOI 10.1038/324575a0; TOWNSEND ARM, 1985, CELL, V42, P457, DOI 10.1016/0092-8674(85)90103-5; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; ULLRICH SJ, 1986, P NATL ACAD SCI USA, V83, P3121, DOI 10.1073/pnas.83.10.3121; VANBLEEK GM, 1990, NATURE, V348, P213; VANDENEYNDE B, 1991, J EXP MED, V173, P1373, DOI 10.1084/jem.173.6.1373; VONBOEHMER H, 1990, ANNU REV IMMUNOL, V8, P531, DOI 10.1146/annurev.iy.08.040190.002531; WATSON JD, 1987, MOL BIOL GENE, P466; ZINKERNA.RM, 1974, NATURE, V248, P701, DOI 10.1038/248701a0	46	857	892	0	19	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 26	1991	353	6342					326	329		10.1038/353326a0	http://dx.doi.org/10.1038/353326a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GG654	1922338				2022-12-24	WOS:A1991GG65400049
J	BERNAT, RL; DELANNOY, MR; ROTHFIELD, NF; EARNSHAW, WC				BERNAT, RL; DELANNOY, MR; ROTHFIELD, NF; EARNSHAW, WC			DISRUPTION OF CENTROMERE ASSEMBLY DURING INTERPHASE INHIBITS KINETOCHORE MORPHOGENESIS AND FUNCTION IN MITOSIS	CELL			English	Article							MAMMALIAN KINETOCHORE; CHROMOSOME CONDENSATION; CENP-B; CYTOPLASMIC DYNEIN; AUTOIMMUNE SERA; MOVEMENT; SCLERODERMA; ANTIBODIES; PROTEINS; ANAPHASE	The relationship between the kinetochore and the centromeric heterochromatin that surrounds it is unknown. Anti-centromere autoantibodies (ACAs) that recognize antigens found in the heterochromatin beneath the kinetochore disrupt mitotic events when microinjected into human cells. We show here that ACAs interfere with two different stages of centromere assembly during interphase, resulting in abnormal kinetochore structures during mitosis. Antibody injection prior to late G2 results in the subsequent failure to assemble a trilaminar kinetochore. Such chromosomes bind microtubules but are incapable of movement. Antibody disruption of events during G2 produces unstable kinetochores that prevent the normal transition into anaphase. These experiments present a novel way to examine events in the pathway of kinetochore assembly that occur during interphase, at a time when this structure cannot be visualized directly.	UNIV CONNECTICUT,CTR HLTH,DEPT MED,DIV RHEUMAT DIS,FARMINGTON,CT 06032	University of Connecticut	BERNAT, RL (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT CELL BIOL & ANAT,BALTIMORE,MD 21205, USA.		Earnshaw, William/AAY-7438-2020	Earnshaw, William/0000-0002-7191-0621	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035212] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM35212] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALCZON RD, 1987, J CELL BIOL, V105, P855, DOI 10.1083/jcb.105.2.855; BERNAT RL, 1990, J CELL BIOL, V111, P1519, DOI 10.1083/jcb.111.4.1519; BISCHOFF FR, 1990, P NATL ACAD SCI USA, V87, P8617, DOI 10.1073/pnas.87.21.8617; BRENNER S, 1981, J CELL BIOL, V91, P95, DOI 10.1083/jcb.91.1.95; BRINKLEY BR, 1966, CHROMOSOMA, V19, P28, DOI 10.1007/BF00332792; BRINKLEY BR, 1988, NATURE, V336, P251, DOI 10.1038/336251a0; COMPTON DA, 1991, J CELL BIOL, V112, P1083, DOI 10.1083/jcb.112.6.1083; COOKE CA, 1990, J CELL BIOL, V110, P1475, DOI 10.1083/jcb.110.5.1475; EARNSHAW W, 1986, J CLIN INVEST, V77, P426, DOI 10.1172/JCI112320; EARNSHAW WC, 1985, CHROMOSOMA, V91, P313, DOI 10.1007/BF00328227; EARNSHAW WC, 1989, CHROMOSOMA, V98, P1, DOI 10.1007/BF00293329; GORBSKY GJ, 1987, J CELL BIOL, V104, P9, DOI 10.1083/jcb.104.1.9; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; JOKELAINEN PT, 1967, J ULTRA MOL STRUCT R, V19, P19, DOI 10.1016/S0022-5320(67)80058-3; KINGWELL B, 1987, CHROMOSOMA, V95, P403, DOI 10.1007/BF00333991; LUYKX P, 1965, EXP CELL RES, V39, P643, DOI 10.1016/0014-4827(65)90068-6; MASUMOTO H, 1989, J CELL BIOL, V109, P1963, DOI 10.1083/jcb.109.5.1963; MOROI Y, 1980, P NATL ACAD SCI-BIOL, V77, P1627, DOI 10.1073/pnas.77.3.1627; NICKLAS RB, 1989, J CELL BIOL, V109, P2245, DOI 10.1083/jcb.109.5.2245; NICKLAS RB, 1969, J CELL BIOL, V43, P40, DOI 10.1083/jcb.43.1.40; NISHIMOTO T, 1978, CELL, V15, P475, DOI 10.1016/0092-8674(78)90017-X; OHTSUBO M, 1987, GENE DEV, V1, P585, DOI 10.1101/gad.1.6.585; PALMER DK, 1991, IN PRESS P NATL ACAD, V88; PANKOV R, 1990, CHROMOSOMA, V99, P95, DOI 10.1007/BF01735324; PFARR CM, 1990, NATURE, V345, P263, DOI 10.1038/345263a0; RATTNER JB, 1986, CHROMOSOMA, V93, P515, DOI 10.1007/BF00386793; RIEDER CL, 1982, INT REV CYTOL, V79, P1, DOI 10.1016/S0074-7696(08)61672-1; RIEDER CL, 1990, J CELL BIOL, V110, P81, DOI 10.1083/jcb.110.1.81; RIEDER CL, 1990, ELECTRON MICROSC REV, V3, P269, DOI 10.1016/0892-0354(90)90005-D; RIEDER CL, 1989, MECHANISMS CHROMOSOM, P185; RIS H, 1981, CHROMOSOMA, V82, P153, DOI 10.1007/BF00286101; ROOS UP, 1973, CHROMOSOMA, V41, P195, DOI 10.1007/BF00319696; SAWIN KE, 1991, J CELL BIOL, V112, P925, DOI 10.1083/jcb.112.5.925; SCHLIWA M, 1981, J CELL BIOL, V90, P222, DOI 10.1083/jcb.90.1.222; SIMERLY C, 1990, J CELL BIOL, V111, P1491, DOI 10.1083/jcb.111.4.1491; SLUDER G, 1979, J CELL BIOL, V80, P674, DOI 10.1083/jcb.80.3.674; SNYDER J A, 1985, European Journal of Cell Biology, V39, P373; STEUER ER, 1990, NATURE, V345, P266, DOI 10.1038/345266a0; TAYLOR EW, 1959, J BIOPHYS BIOCHEM CY, V6, P193, DOI 10.1083/jcb.6.2.193; TENHAGEN KG, 1990, MOL CELL BIOL, V10, P6348, DOI 10.1128/MCB.10.12.6348; WORDEMAN L, 1991, IN PRESS J CELL BIOL; YEN TJ, 1991, IN PRESS EMBO J, V10; ZIRKLE RE, 1970, RADIAT RES, V41, P516, DOI 10.2307/3572841	43	81	84	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 20	1991	66	6					1229	1238		10.1016/0092-8674(91)90045-Z	http://dx.doi.org/10.1016/0092-8674(91)90045-Z			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GG552	1913807				2022-12-24	WOS:A1991GG55200017
J	NIGHTINGALE, SL				NIGHTINGALE, SL			FDA MEDICAL BULLETIN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							FDA MED B; FDA DRUG B	2	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 18	1991	266	11					1482	1482						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GE458	1880875				2022-12-24	WOS:A1991GE45800006
J	KIYOSAWA, K; SODEYAMA, T; TANAKA, E; NAKANO, Y; FURUTA, S; NISHIOKA, K; PURCELL, RH; ALTER, HJ				KIYOSAWA, K; SODEYAMA, T; TANAKA, E; NAKANO, Y; FURUTA, S; NISHIOKA, K; PURCELL, RH; ALTER, HJ			HEPATITIS-C IN HOSPITAL EMPLOYEES WITH NEEDLESTICK INJURIES	ANNALS OF INTERNAL MEDICINE			English	Note						HEPATITIS VIRAL, NON-A, NON-B; HEPATITIS-C VIRUS; ACCIDENTS, OCCUPATIONAL; NEEDLESTICK INJURY; OCCUPATIONAL EXPOSURE	NON-A; B VIRUS	Of 357 needlestick accidents occurring at a university hospital between 1981 and 1989, 200 involved 196 health care workers who were then prospectively followed for 6 months; 110 of these 196 workers were exposed to blood from antibody to the hepatitis C virus (anti-HCV). Only 4 of these 110 exposed persons (4%; 95% CI, 1% to 9%) developed non-A, non-B hepatitis. Hepatitis was accompanied by anti-HCV seroconversion in 3 of these 4 persons. Three of the four were icteric, and each had a peak alanine aminotransferase level exceeding 8.5-mu-kat/L. There was no instance of anti-HCV seroconversion among the 106 recipients of an anti-HCV-positive needlestick who did not manifest biochemical or clinical evidence of hepatitis. This study documents that HCV-related non-A, non-B hepatitis can be transmitted infrequently by needlestick injury.	JAPANESE RED CROSS SOC, CENT BLOOD CTR, SHIBUYA KU, TOKYO 150, JAPAN; NIAID, HEPATITIS VIRUSES SECT, BETHESDA, MD 20892 USA; NIH, WARREN GRANT MAGNUSON CLIN CTR, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA	KIYOSAWA, K (corresponding author), SHINSHU UNIV, SCH MED, DEPT INTERNAL MED 2, 3-1-1 ASAHI, MATSUMOTO, NAGANO 390, JAPAN.							ALTER HJ, 1991, IN PRESS VIRAL HEPAT; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; EVERHART JE, 1990, ANN INTERN MED, V112, P544, DOI 10.7326/0003-4819-112-7-544; GIOVANNINI M, 1990, LANCET, V335, P1166, DOI 10.1016/0140-6736(90)91174-9; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; MASUKO K, 1985, GASTROENTEROLOGY, V88, P151, DOI 10.1016/S0016-5085(85)80147-5; PONZETTO A, 1987, J INFECT DIS, V155, P72, DOI 10.1093/infdis/155.1.72; SHIKATA T, 1977, J INFECT DIS, V136, P571, DOI 10.1093/infdis/136.4.571; XEEFF LB, 1979, GASTROENTEROLOGY, V77, P161; YOSHIZAWA H, 1982, GASTROENTEROLOGY, V82, P502	10	299	302	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1991	115	5					367	369		10.7326/0003-4819-115-5-367	http://dx.doi.org/10.7326/0003-4819-115-5-367			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GC065	1907441				2022-12-24	WOS:A1991GC06500006
J	WATSON, EK; MAYALL, E; CHAPPLE, J; DALZIEL, M; HARRINGTON, K; WILLIAMS, C; WILLIAMSON, R				WATSON, EK; MAYALL, E; CHAPPLE, J; DALZIEL, M; HARRINGTON, K; WILLIAMS, C; WILLIAMSON, R			SCREENING FOR CARRIERS OF CYSTIC-FIBROSIS THROUGH PRIMARY HEALTH-CARE SERVICES	BRITISH MEDICAL JOURNAL			English	Article							IDENTIFICATION; GENE	Objective - To evaluate the uptake of cystic fibrosis carrier testing offered through primary health care services. Design - Carrier testing for cystic fibrosis was offered to patients of reproductive age through primary health care services. Setting - Three general practice surgeries and four family planning clinics in South West Hertfordshire District Health Authority. Subjects - Over 1000 patients aged 16-44 attending two general practices and four family planning clinics and a stratified random sample of patients aged 16-44 from one general practice's age-sex register. Results - When screening was offered opportunistically the uptake was 66% in general practice and 87% in family planning clinics. Ten per cent of those offered a screening appointment by letter took up the invitation. Of the screened population, 76% had previously heard of cystic fibrosis, 35% realised it is inherited, and 18% realised that carriers need not have any family history. If they found themselves in an "at risk" partnership 39% would consider not having children and 26% would consider terminating an affected pregnancy, but in each case most people were unsure how they would react. Conclusions - Most people offered a cystic fibrosis test opportunistically wish to be tested, and the responses of those tested indicate that knowledge of carrier state would be considered in future reproductive decisions.	SW HERTFORDSHIRE DIST HLTH AUTHOR,WATFORD WD1 8UB,ENGLAND		WATSON, EK (corresponding author), UNIV LONDON IMPERIAL COLL SCI & TECHNOL,ST MARYS HOSP,SCH MED,DEPT BIOCHEM & MOLEC GENET,LONDON W2 1PG,ENGLAND.							CALNAN M, 1986, SOC SCI MED, V22, P673, DOI 10.1016/0277-9536(86)90039-0; CUTTING GR, 1990, NATURE, V346, P366, DOI 10.1038/346366a0; Cystic Fibrosis Genetic Anal Consortium, 1990, AM J HUM GENET, V47, P354; DODGE JA, 1988, LANCET, V2, P672; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; LENCH N, 1988, LANCET, V1, P1356; MANT D, 1990, BRIT MED J, V300, P916, DOI 10.1136/bmj.300.6729.916; MODELL B, 1990, J MED GENET, V27, P475, DOI 10.1136/jmg.27.8.475; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SKRABANEK P, 1986, LANCET, V1, P143; THOMPSON NF, 1990, BRIT J GEN PRACT, V40, P16; WATSON EK, 1990, HUM GENET, V85, P435, DOI 10.1007/BF02428303; WATSON EK, 1991, BRIT J GEN PRACT, V41, P237; WILLIAMSON R, 1989, PRENATAL DIAG, V9, P727, DOI 10.1002/pd.1970091008; 1990, CYSTIC FIBROSIS ADUL	16	105	105	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 31	1991	303	6801					504	507		10.1136/bmj.303.6801.504	http://dx.doi.org/10.1136/bmj.303.6801.504			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GD804	1912861	Green Published, Bronze			2022-12-24	WOS:A1991GD80400018
J	LEWIS, C; KRAMER, T; ROBINSON, S; HILVERT, D				LEWIS, C; KRAMER, T; ROBINSON, S; HILVERT, D			MEDIUM EFFECTS IN ANTIBODY-CATALYZED REACTIONS	SCIENCE			English	Article							HISTIDINE-DECARBOXYLASE; 6-NITROBENZISOXAZOLE-3-CARBOXYLATE; BINDING; ESTER	Catalytic antibody technology has been used to explore the contribution of medium effects to the overall rate of an enzyme-catalyzed reaction. An antibody generated against a derivative of 2-acetamido-1,5-napthalenedisulfonate efficiently catalyzes the decarboxylation of 5-nitro-3-carboxybenzisoxazole. This unimolecular reaction is not susceptible to general acid-base catalysis but is highly sensitive to microenvironment; thus, it provides a simple chemical model for biologically important decarboxylations. The 10(4)-fold rate acceleration observed for the antibody reflects the kinetic advantage of the low-dielectric environment of the binding pocket acting to destabilize the substrate by desolvation and to stabilize the charge-delocalized transition state through dispersion interactions. These results are pertinent to an understanding of solvent effects in enzymic reactions in general and suggest approaches for developing antibody catalysts for numerous other reactions that involve large changes in charge distribution as the reaction coordinate is traversed.	Scripps Res Inst, RES INST, DEPT CHEM, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA; Scripps Res Inst, RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute					NIGMS NIH HHS [GM38273] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM038273, R01GM038273] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABELL KWY, 1986, TETRAHEDRON LETT, V27, P1085, DOI 10.1016/S0040-4039(86)80055-7; ALSTON TA, 1987, BIOCHEMISTRY-US, V26, P4082, DOI 10.1021/bi00387a051; Azzi A, 1974, Methods Enzymol, V32, P234; BUNTON CA, 1975, J ORG CHEM, V40, P1321, DOI 10.1021/jo00897a031; BUNTON CA, 1973, J AM CHEM SOC, V95, P3262, DOI 10.1021/ja00791a032; CROSBY J, 1970, J AM CHEM SOC, V92, P2891, DOI 10.1021/ja00712a048; EFTINK MR, 1981, ANAL BIOCHEM, V114, P199, DOI 10.1016/0003-2697(81)90474-7; GALLAGHER T, 1989, J BIOL CHEM, V264, P12737; GRIMSHAW CE, 1989, BIOCHEMISTRY-US, V28, P5343, DOI 10.1021/bi00439a006; HILVERT D, 1990, BIOMIMETIC POLYMERS, P95; HILVERT D, 1988, P NATL ACAD SCI USA, V85, P4953, DOI 10.1073/pnas.85.14.4953; JENCKS WP, 1969, CATALYSIS CHEM ENZYM, P645; KEMP DS, 1978, TETRAHEDRON LETT, V8, P741; KLOTZ IM, 1946, J AM CHEM SOC, V68, P1486, DOI 10.1021/ja01212a030; KUNITAKE T, 1980, J AM CHEM SOC, V102, P7877, DOI 10.1021/ja00547a009; OLEARY MH, 1981, BIOCHEMISTRY-US, V20, P2743, DOI 10.1021/bi00513a007; PARKER AJ, 1969, CHEM REV, V69, P1, DOI 10.1021/cr60257a001; SCHMIDTCHEN FP, 1986, J CHEM SOC PERK T 2, P135, DOI 10.1039/p29860000135; SCHULTZ PG, 1990, CHEM ENG NEWS, V68, P26, DOI 10.1021/cen-v068n022.p026; SELIGER HH, 1978, METHOD ENZYMOL, V57, P560; SHAH SC, 1978, J AM CHEM SOC, V100, P1426, DOI 10.1021/ja00473a017; SMID J, 1975, J AM CHEM SOC, V97, P5932, DOI 10.1021/ja00853a058; STRYER L, 1968, SCIENCE, V162, P526, DOI 10.1126/science.162.3853.526; STRYER LUBERT, 1965, J MOL BIOL, V13, P482; SUH J, 1976, J AM CHEM SOC, V98, P7060, DOI 10.1021/ja00438a054; TURNER DC, 1968, BIOCHEMISTRY-US, V7, P3381, DOI 10.1021/bi00850a011; Williams J W, 1979, Methods Enzymol, V63, P437	27	75	76	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 30	1991	253	5023					1019	1022		10.1126/science.1887215	http://dx.doi.org/10.1126/science.1887215			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC982	1887215				2022-12-24	WOS:A1991GC98200042
J	THOMPSON, CC; BROWN, TA; MCKNIGHT, SL				THOMPSON, CC; BROWN, TA; MCKNIGHT, SL			CONVERGENCE OF ETS-RELATED AND NOTCH-RELATED STRUCTURAL MOTIFS IN A HETEROMERIC DNA-BINDING COMPLEX	SCIENCE			English	Article							CELL-CYCLE CONTROL; IMMUNOGLOBULIN ENHANCER-BINDING; NF-KAPPA-B; TRANSCRIPTION FACTOR; CONTROL PROTEINS; RNA-POLYMERASE; REL ONCOGENE; GENE; DROSOPHILA; SEQUENCE	Analysis of the heteromeric DNA binding protein GABP has revealed the interaction of two distinct peptide sequence motifs normally associated with proteins located in different cellular compartments. The alpha-subunit of GABP contains an 85-amino acid segment related to the Ets family of DNA binding proteins. The ETS domain of GABP-alpha facilitates weak binding to DNA and, together with an adjacent segment of 37 amino acids, mediates stable interaction with GABP-beta. The beta-subunit of GABP contains four imperfect repeats of a sequence present in several transmembrane proteins including the product of the Notch gene of Drosophila melanogaster. These amino-terminal repeats of GABP-beta mediate stable interaction with GABP-alpha and, when complexed with GABP-alpha, directly contact DNA. These observations provide evidence for a distinct biochemical role for the 33-amino acid repeats, and suggest that they may serve as a module for the generation of specific dimerization interfaces.			THOMPSON, CC (corresponding author), CARNEGIE INST WASHINGTON,DEPT EMBRYOL,HOWARD HUGHES RES LABS,BALTIMORE,MD 21210, USA.							ANDREWS BJ, 1989, NATURE, V342, P830, DOI 10.1038/342830a0; AUSTIN J, 1989, CELL, V58, P565, DOI 10.1016/0092-8674(89)90437-6; AVES SJ, 1985, EMBO J, V4, P457, DOI 10.1002/j.1460-2075.1985.tb03651.x; BAUERLE PA, 1988, CELL, V53, P211; BAUERLE PA, 1988, SCIENCE, V242, P540; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; BREEDEN L, 1987, NATURE, V329, P651, DOI 10.1038/329651a0; BROWN TB, UNPUB; CHODOSH L, 1988, CURRENT PROTOCOLS MO, V2; Cohn E. J., 1943, PROTEINS AMINO ACIDS, P370; GOEBL MG, 1990, CELL, V61, P1165, DOI 10.1016/0092-8674(90)90676-6; GREENWALD I, 1985, CELL, V43, P583, DOI 10.1016/0092-8674(85)90230-2; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HASKILL S, 1991, CELL, V65; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KIDD S, 1986, MOL CELL BIOL, V6, P3094, DOI 10.1128/MCB.6.9.3094; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LAMARCO KL, 1989, GENE DEV, V3, P1372, DOI 10.1101/gad.3.9.1372; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SHUMAN JD, 1990, SCIENCE, V249, P771, DOI 10.1126/science.2202050; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; SPENCE AM, 1990, CELL, V60, P981, DOI 10.1016/0092-8674(90)90346-G; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; THOMPSON C, UNPUB; TRIEZENBERG SL, 1989, GENE DEV, V3, P1372; URNESS LD, 1990, CELL, V63, P47, DOI 10.1016/0092-8674(90)90287-O; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; YOCHEM J, 1989, CELL, V58, P553, DOI 10.1016/0092-8674(89)90436-4; YOCHEM J, 1988, NATURE, V335, P547, DOI 10.1038/335547a0	37	435	440	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 16	1991	253	5021					762	768		10.1126/science.1876833	http://dx.doi.org/10.1126/science.1876833			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GB295	1876833				2022-12-24	WOS:A1991GB29500029
J	THORPEBEESTON, JG; NICOLAIDES, KH; FELTON, CV; BUTLER, J; MCGREGOR, AM				THORPEBEESTON, JG; NICOLAIDES, KH; FELTON, CV; BUTLER, J; MCGREGOR, AM			MATURATION OF THE SECRETION OF THYROID-HORMONE AND THYROID-STIMULATING HORMONE IN THE FETUS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FETAL; PREGNANCY; NEWBORN	Background. Data on human fetal thyroid function have largely been derived from histologic studies or studies of cord-blood samples obtained at hysterotomy or delivery. These data may not represent true normal values. Cordocentesis (ultrasound-guided blood sampling from the umbilical cord) is a technique that allows investigation of physiologic processes in fetuses not under stress. Methods. We measured serum thyroid-stimulating hormone, total and free thyroxine (T4), total and free triiodothyronine (T3), and thyroxine-binding globulin in blood samples from 62 fetuses. The samples were obtained by cordocentesis (n = 58) or cardiocentesis (n = 4) at 12 to 37 weeks of gestation. Maternal serum samples were obtained immediately before fetal blood sampling. Results. Fetal serum thyroid-stimulating hormone, thyroxine-binding globulin, and total and free T4 and T3 concentrations increased significantly with the length of gestation (P < 0.001). The only significant association among these variables, independent of the length of gestation, was between thyroid-stimulating hormone and free T4 (P < 0.0001). Maternal serum concentrations of these variables did not change during gestation, and there was no significant relation between fetal and maternal values. Most fetal serum concentrations of thyroid-stimulating hormone were higher, whereas most serum total and free T3 concentrations were lower than the respective values for normal adults. The fetal serum total T4, free T4, and thyroxine-binding globulin values reached the level of the mean adult values at approximately 36 weeks of gestation. Conclusions. The increases in fetal serum concentrations of thyroid-stimulating hormone, thyroxine-binding globulin, and total and free T4 and T3 during gestation reflect increasing maturation of the pituitary, thyroid, and liver. The finding of increasing fetal serum concentrations of thyroid-stimulating hormone in the presence of increasing thyroid hormone concentrations suggests that the sensitivity of the fetal pituitary gland to negative feedback is limited or is counterbalanced by increasing stimulation by thyrotropin-releasing hormone from the hypothalamus.	KINGS COLL,SCH MED & DENT,DEPT OBSTET & GYNAECOL,HARRIS BIRTHRIGHT RES CTR FETAL MED,LONDON SE5 8RX,ENGLAND; WYNN INST METAB RES,LONDON,ENGLAND; UNIV LONDON KINGS COLL,SCH MED & DENT,DEPT CLIN BIOCHEM,LONDON WC2R 2LS,ENGLAND; UNIV LONDON KINGS COLL,SCH MED & DENT,DEPT MED,LONDON WC2R 2LS,ENGLAND	University of London; King's College London; Imperial College London; University of London; King's College London; University of London; King's College London				Nicolaides, Kypros/0000-0003-1266-0711				BALLABIO M, 1989, CLIN ENDOCRINOL, V31, P565, DOI 10.1111/j.1365-2265.1989.tb01280.x; DEESCOBAR GM, 1987, HORM RES, V26, P12, DOI 10.1159/000180681; Fisher D A, 1976, Recent Prog Horm Res, V33, P59; FISHER DA, 1981, NEW ENGL J MED, V304, P702, DOI 10.1056/NEJM198103193041205; FISHER DA, 1983, CLIN PERINATOL, V10, P615, DOI 10.1016/S0095-5108(18)30954-0; FISHER DA, 1973, J CLIN ENDOCR METAB, V36, P397, DOI 10.1210/jcem-36-2-397; FISHER DA, 1970, PEDIATRICS, V46, P208; FUNG HYM, 1988, BRIT MED J, V296, P241, DOI 10.1136/bmj.296.6617.241; GREENBERG AH, 1970, J CLIN INVEST, V49, P1790, DOI 10.1172/JCI106397; KLEIN AH, 1982, EARLY HUM DEV, V6, P321, DOI 10.1016/0378-3782(82)90070-6; LARSEN PR, 1981, ENDOCR REV, V2, P87, DOI 10.1210/edrv-2-1-87; MAN EB, 1969, AM J OBSTET GYNECOL, V103, P338, DOI 10.1016/0002-9378(69)90492-X; MONIZ CF, 1985, J CLIN PATHOL, V38, P468, DOI 10.1136/jcp.38.4.468; MORRISS FH, 1974, BIOL NEONATE, V25, P44; NICOLAIDES KH, 1986, LANCET, V1, P1065; ROSEN F, 1966, J CLIN ENDOCR METAB, V26, P1343, DOI 10.1210/jcem-26-12-1343; SHEPARD TH, 1967, J CLIN ENDOCR METAB, V27, P945, DOI 10.1210/jcem-27-7-945; WU SY, 1978, ENDOCRINOLOGY, V103, P235, DOI 10.1210/endo-103-1-235	18	273	280	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 21	1991	324	8					532	536		10.1056/NEJM199102213240805	http://dx.doi.org/10.1056/NEJM199102213240805			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX918	1899469				2022-12-24	WOS:A1991EX91800005
J	OTTING, G; LIEPINSH, E; WUTHRICH, K				OTTING, G; LIEPINSH, E; WUTHRICH, K			PROTEIN HYDRATION IN AQUEOUS-SOLUTION	SCIENCE			English	Article							NUCLEAR MAGNETIC-RESONANCE; PANCREATIC TRYPSIN-INHIBITOR; SOLVENT SATURATION; WATER-MOLECULES; SPIN DIFFUSION; RELAXATION; NMR; SPECTROSCOPY; OXYTOCIN; CRYSTALS	High-resolution proton nuclear magnetic resonance studies of protein hydration in aqueous solution show that there are two qualitatively different types of hydration sites. A well-defined, small number of water molecules in the interior of the protein are in identical locations in the crystal structure and in solution, and their residence times are in the range from about 10(-2) to 10(-8) second. Hydration of the protein surface in solution is by water molecules with residence times in the subnanosecond range, even when they are located in hydration sites that contain well-ordered water in the x-ray structures of protein single crystals.			OTTING, G (corresponding author), SWISS FED INST TECHNOL,INST MOLEK BIOL & BIOPHYS,CH-8093 ZURICH,SWITZERLAND.		Otting, Gottfried/H-8413-2014	Otting, Gottfried/0000-0002-0563-0146				ABRAGAM A, 1961, PRINCIPLES NUCLEAR M; AYANT Y, 1977, J PHYS-PARIS, V38, P325, DOI 10.1051/jphys:01977003803032500; BERNDT K, UNPUB; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; Blundell T.L., 1976, PROTEIN CRYSTALLOGRA; BOTHNERBY AA, 1984, J AM CHEM SOC, V106, P811, DOI 10.1021/ja00315a069; BRYANT RG, 1980, BIOPHYS J, V32, P3, DOI 10.1016/S0006-3495(80)84912-5; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P567; DEISENHOFER J, 1975, ACTA CRYSTALLOGR B, V31, P238, DOI 10.1107/S0567740875002415; FUJIWARA T, 1985, J CHEM PHYS, V83, P3110, DOI 10.1063/1.449217; GILLEN KT, 1972, J CHEM PHYS, V57, P5117, DOI 10.1063/1.1678198; GLICKSON JD, 1976, BIOCHEMISTRY-US, V15, P1111, DOI 10.1021/bi00650a025; GLICKSON JD, 1975, PEPTIDES CHEM STRUCT, P787; HALLE B, 1981, J AM CHEM SOC, V103, P500, DOI 10.1021/ja00393a004; HRUBY VJ, 1981, TOPICS MOL PHARM, P100; KALK A, 1976, J MAGN RESON, V24, P343, DOI 10.1016/0022-2364(76)90115-3; KOENIG SH, 1988, BIOPHYS J, V53, P91, DOI 10.1016/S0006-3495(88)83069-8; KOSHLAND DE, 1966, BIOCHEMISTRY-US, V5, P365, DOI 10.1021/bi00865a047; MARANI R, UNPUB; MEIBOOM S, 1961, J CHEM PHYS, V34, P375, DOI 10.1063/1.1700960; MESSERLE BA, 1989, J MAGN RESON, V85, P608, DOI 10.1016/0022-2364(89)90252-7; OTTING G, 1991, J AM CHEM SOC, V113, P4363, DOI 10.1021/ja00011a068; OTTING G, 1991, Journal of Biomolecular NMR, V1, P209, DOI 10.1007/BF01877232; OTTING G, 1989, J AM CHEM SOC, V111, P1871, DOI 10.1021/ja00187a050; OTTING G, 1990, WATER IONS BIOMOLECU, P141; OTTING G, 1991, WATER IONS BIOMOLECU, V113, P4363; PITNER TP, 1974, NATURE, V250, P582, DOI 10.1038/250582a0; POLNASZEK CF, 1984, J CHEM PHYS, V81, P4038, DOI 10.1063/1.448147; Richards F. M., 1991, Scientific American, V264, P34; RICHARZ R, 1980, BIOCHEMISTRY-US, V19, P5189, DOI 10.1021/bi00564a006; RICHMOND TJ, 1984, J MOL BIOL, V178, P63, DOI 10.1016/0022-2836(84)90231-6; SAENGER W, 1987, ANNU REV BIOPHYS BIO, V16, P93; Schulz G. E., 1979, PRINCIPLES PROTEIN S; SOLOMON I, 1955, PHYS REV, V99, P559, DOI 10.1103/PhysRev.99.559; STOESZ JD, 1978, FEBS LETT, V91, P320, DOI 10.1016/0014-5793(78)81201-0; TEETER MM, 1984, P NATL ACAD SCI-BIOL, V81, P6014, DOI 10.1073/pnas.81.19.6014; WAGNER G, 1987, J MOL BIOL, V196, P611, DOI 10.1016/0022-2836(87)90037-4; WLODAWER A, 1984, J MOL BIOL, V180, P301, DOI 10.1016/S0022-2836(84)80006-6; WLODAWER A, 1987, J MOL BIOL, V198, P469, DOI 10.1016/0022-2836(87)90294-4; WOOD SP, 1986, SCIENCE, V232, P633, DOI 10.1126/science.3008332; WUTHRICH K, 1989, SCIENCE, V243, P45, DOI 10.1126/science.2911719; WUTHRICH K, 1989, ACCOUNTS CHEM RES, V22, P36, DOI 10.1021/ar00157a006; Wuthrich K., 1986, NMR PROTEINS NUCL AC	43	749	758	0	104	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 15	1991	254	5034					974	980		10.1126/science.1948083	http://dx.doi.org/10.1126/science.1948083			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GP883	1948083				2022-12-24	WOS:A1991GP88300035
J	SOMMER, A; TIELSCH, JM; KATZ, J; QUIGLEY, HA; GOTTSCH, JD; JAVITT, JC; MARTONE, JF; ROYALL, RM; WITT, KA; EZRINE, S				SOMMER, A; TIELSCH, JM; KATZ, J; QUIGLEY, HA; GOTTSCH, JD; JAVITT, JC; MARTONE, JF; ROYALL, RM; WITT, KA; EZRINE, S			RACIAL-DIFFERENCES IN THE CAUSE-SPECIFIC PREVALENCE OF BLINDNESS IN EAST BALTIMORE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GLAUCOMA; IMPAIRMENT; RACE	Background. Bilateral blindness unrelated to simple refractive error is twice as prevalent among blacks as among whites, although the difference narrows among the elderly. The reasons for this race- and age-related pattern are uncertain. Methods and Results. A randomly selected, stratified, multistage cluster sample of 2395 blacks and 2913 whites 40 years of age and older in East Baltimore underwent detailed ophthalmic examinations by a single team. We identified 64 subjects who were blind in both eyes. The leading causes of blindness were unoperated senile cataract (accounting for blindness in 27 of the total of 128 eyes), primary open-angle glaucoma (17 eyes), and age-related macular degeneration (16 eyes). Together, these three disorders accounted for 47 percent of all blindness in this sample. Unoperated cataract accounted for 27 percent of all blindness among blacks, among whom it was four times more common than among whites; whites were almost 50 percent more likely than blacks to have undergone cataract extraction before the age of 80 (P < 0.002). Primary open-angle glaucoma accounted for 19 percent of all blindness among blacks; it was six times as frequent among blacks as among whites and began 10 years earlier, on average. By contrast, age-related macular degeneration resulting in blindness was limited to whites, among whom it was the leading cause of blindness (prevalence, 2.7 per 1000; 95 percent confidence interval, 1.2 to 5.4); it affected 3 percent of all white subjects 80 years of age or older. Conclusions. The pattern of blindness in urban Baltimore appears to be different among blacks and whites. Whites are far more likely to have age-related macular degeneration, and blacks to have primary open-angle glaucoma. The high rate of unoperated cataracts among younger blacks and among elderly subjects of both races suggests that health services are underused. Half of all blindness in this urban population is probably preventable or reversible.	JOHNS HOPKINS UNIV HOSP,WILMER OPHTHALMOL INST,DANA CTR PREVENT OPHTHALMOL,BALTIMORE,MD 21205; SURVEY RES ASSOCIATES INC,BALTIMORE,MD; JOHNS HOPKINS UNIV HOSP,WILMER OPHTHALMOL INST,GLAUCOMA SERV,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV HOSP,WILMER OPHTHALMOL INST,CORNEAL SERV,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine	SOMMER, A (corresponding author), JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT BIOSTAT,1041 HYG BLDG,615 N WOLFE ST,BALTIMORE,MD 21205, USA.		Javitt, Jonathan/AAJ-5574-2021	Javitt, Jonathan/0000-0003-2371-1609; Katz, Joanne/0000-0002-5997-7823; Tielsch, James/0000-0002-1151-060X	NCRR NIH HHS [RR-04060] Funding Source: Medline; NEI NIH HHS [EY-03605, EY-05091] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR004060] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY003605] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		[Anonymous], 1981, OPHTHALMOLOGY, V88, P583; Cairns L, 1984, Trans Am Ophthalmol Soc, V82, P166; EDERER F, 1986, AM J PUBLIC HEALTH, V76, P160, DOI 10.2105/AJPH.76.2.160; FERRIS FL, 1982, AM J OPHTHALMOL, V94, P97, DOI 10.1016/0002-9394(82)90198-2; GANLEY JP, 1983, VITAL HLTH STATI 228, V11; GOLDSTEIN H, 1980, RES SERIES AM F BLIN, V26; GRANT WM, 1982, OPHTHALMOLOGY, V89, P991; JAVITT JC, 1989, OPHTHALMOLOGY, V96, P255; KAHN HA, 1973, DHEW NIH73427 NAT EY; KAHN HA, 1989, STATISTICAL METHODS; KIRCHNER C, 1979, VISUAL IMPAIRMENT BL, V73, P151; KOSOKO O, 1986, OPHTHALMOLOGY, V93, P882; Leibowitz H M, 1980, Surv Ophthalmol, V24, P335; MARTIN MJ, 1985, AM J OPHTHALMOL, V99, P383, DOI 10.1016/0002-9394(85)90001-7; MASON RP, 1989, OPHTHALMOLOGY, V96, P1363; PEARSON ES, 1958, BIOMETR TABLES ST, V1, P203; SOMMER A, 1991, ARCH OPHTHALMOL-CHIC, V109, P1090, DOI 10.1001/archopht.1991.01080080050026; SOMMER A, 1977, AM J OPHTHALMOL, V83, P334, DOI 10.1016/0002-9394(77)90729-2; SOMMER A, 1984, ARCH OPHTHALMOL-CHIC, V102, P1766; STARK WJ, 1989, ARCH OPHTHALMOL-CHIC, V107, P1441, DOI 10.1001/archopht.1989.01070020515030; Taylor J M, 1981, Ophthalmology, V88, p41A; TIELSCH JM, 1991, JAMA-J AM MED ASSOC, V266, P369, DOI 10.1001/jama.266.3.369; TIELSCH JM, 1990, ARCH OPHTHALMOL-CHIC, V108, P286, DOI 10.1001/archopht.1990.01070040138048; TIELSCH JM, 1991, ARCH OPHTHALMOL-CHIC, V109, P637, DOI 10.1001/archopht.1991.01080050051027; WILSON R, 1985, ANN OPHTHALMOL, V17, P653; 1985, ARCH OPHTHALMOL-CHIC, V103, P1796; 1983, NIH832469 DEP HLTH H, P12; 1980, VISION PROBLEMS S	28	551	579	0	8	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 14	1991	325	20					1412	1417		10.1056/NEJM199111143252004	http://dx.doi.org/10.1056/NEJM199111143252004			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GP524	1922252	Bronze			2022-12-24	WOS:A1991GP52400004
J	NIGHTINGALE, SL				NIGHTINGALE, SL			DIDANOSINE (DDI) APPROVED FOR ADVANCED HIV-INFECTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 13	1991	266	18					2528	2528						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GN660	1942388				2022-12-24	WOS:A1991GN66000006
J	KARALIS, K; SANO, H; REDWINE, J; LISTWAK, S; WILDER, RL; CHROUSOS, GP				KARALIS, K; SANO, H; REDWINE, J; LISTWAK, S; WILDER, RL; CHROUSOS, GP			AUTOCRINE OR PARACRINE INFLAMMATORY ACTIONS OF CORTICOTROPIN-RELEASING HORMONE INVIVO	SCIENCE			English	Article							CENTRAL NERVOUS-SYSTEM; FACTOR-LIKE IMMUNOREACTIVITY; WALL-INDUCED ARTHRITIS; RAT LEYDIG-CELLS; FACTOR RECEPTORS; BETA-ENDORPHIN; LEWIS RATS; BIOCHEMICAL MANIFESTATIONS; INDUCED SECRETION; MOUSE SPLEEN	Corticotropin-releasing hormone (CRH) functions as a regulator of the hypothalamic-pituitary-adrenal axis and coordinator of the stress response. CRH receptors exist in peripheral sites of the immune system, and CRH promotes several immune functions in vitro. The effect of systemic immunoneutralization of CRH was tested in an experimental model of chemically induced aseptic inflammation in rats. Intraperitoneal administration of rabbit antiserum to CRH caused suppression of both inflammatory exudate volume and cell concentration by approximately 50 to 60 percent. CRH was detected in the inflamed area but not in the systemic circulation. Immunoreactive CRH is therefore produced in peripheral inflammatory sites where, in contrast to its systemic indirect immunosuppressive effects, it acts as an autocrine or paracrine inflammatory cytokine.	NIAMSD,ARTHRIT & RHEUMATISM BRANCH,BETHESDA,MD 20892; NIMH,ALCOHOL DRUG ABUSE & MENTAL HLTH ADM,CLIN NEUROENDOCRINOL BRANCH,BETHESDA,MD 20892; NICHHD,DEV ENDOCRINOL BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)								AKIRA S, 1990, FASEB J, V4, P2860, DOI 10.1096/fasebj.4.11.2199284; BEUTLER B, 1989, ANNU REV IMMUNOL, V7, P625, DOI 10.1146/annurev.immunol.7.1.625; CALOGERO AE, 1989, PEPTIDES, V10, P189, DOI 10.1016/0196-9781(89)90096-X; CARR DJJ, 1990, J NEUROIMMUNOL, V28, P53, DOI 10.1016/0165-5728(90)90040-T; CASE JP, 1989, J CLIN INVEST, V84, P1731, DOI 10.1172/JCI114356; CHROUSOS GP, 1988, MECHANISMS PHYSICAL; CROFFORD LJ, UNPUB; CUMMINGS S, 1983, J NEUROSCI, V3, P1355; DAVE JR, 1985, ENDOCRINOLOGY, V116, P2152, DOI 10.1210/endo-116-6-2152; DESOUZA EB, 1985, J NEUROSCI, V5, P3189; DUNN AJ, 1990, BRAIN RES REV, V15, P71, DOI 10.1016/0165-0173(90)90012-D; FABBRI A, 1990, ENDOCRINOLOGY, V127, P1541, DOI 10.1210/endo-127-3-1541; FELTEN DL, 1987, IMMUNOL REV, V100, P225, DOI 10.1111/j.1600-065X.1987.tb00534.x; FUKUHARA M, 1969, BIOCHEM PHARMACOL, V18, P475; GOLD PW, 1988, NEW ENGL J MED, V319, P348, DOI 10.1056/NEJM198808113190606; GOLD PW, 1988, NEW ENGL J MED, V319, P413, DOI 10.1056/NEJM198808183190706; GRINO M, 1987, BIOCHEM BIOPH RES CO, V148, P1208, DOI 10.1016/S0006-291X(87)80261-9; GUILLEMIN R, 1955, ENDOCRINOLOGY, V57, P599, DOI 10.1210/endo-57-5-599; Guillemin R, 1985, NEURAL MODULATION IM; HARGREAVES KM, 1989, NEUROENDOCRINOLOGY, V49, P476, DOI 10.1159/000125155; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; IRWIN M, 1988, AM J PHYSIOL, V255, pR744, DOI 10.1152/ajpregu.1988.255.5.R744; IRWIN M, 1990, ENDOCRINOLOGY, V126, P2837, DOI 10.1210/endo-126-6-2837; IRWIN M R, 1987, Brain Behavior and Immunity, V1, P81, DOI 10.1016/0889-1591(87)90009-2; KARALIS K, 1991, PEDIATR RES, V29, pA80; KAVELAARS A, 1989, J IMMUNOL, V142, P2338; KAVELAARS A, 1990, ENDOCRINOLOGY, V126, P759, DOI 10.1210/endo-126-2-759; KELLER SE, 1988, P NATL ACAD SCI USA, V85, P9297, DOI 10.1073/pnas.85.23.9297; KELLER SE, 1983, SCIENCE, V221, P1301, DOI 10.1126/science.6612346; LAUE L, 1988, J STEROID BIOCHEM, V29, P591, DOI 10.1016/0022-4731(88)90156-2; LEE NM, 1980, PP NATL ACAD SCI US, V77, P3525; MARGIORIS AN, 1988, J CLIN ENDOCR METAB, V66, P922, DOI 10.1210/jcem-66-5-922; MCGILLIS JP, 1989, J NEUROSCI RES, V23, P346, DOI 10.1002/jnr.490230316; MUNCK A, 1984, ENDOCR REV, V5, P25, DOI 10.1210/edrv-5-1-25; OLSCHOWKA JA, 1982, PEPTIDES, V3, P995, DOI 10.1016/0196-9781(82)90071-7; PLOTSKY PM, 1987, ENDOCRINOLOGY, V120, P1361, DOI 10.1210/endo-120-4-1361; PLOTSKY PM, 1984, ENDOCRINOLOGY, V114, P164, DOI 10.1210/endo-114-1-164; POTTER E, 1991, NATURE, V349, P423, DOI 10.1038/349423a0; SAFFRAN M, 1955, ENDOCRINOLOGY, V57, P439, DOI 10.1210/endo-57-4-439; SANO H, 1990, J CELL BIOL, V110, P1417, DOI 10.1083/jcb.110.4.1417; SCHURMEYER TH, 1984, J CLIN ENDOCR METAB, V59, P1103, DOI 10.1210/jcem-59-6-1103; SINGH VK, 1989, J NEUROIMMUNOL, V23, P257, DOI 10.1016/0165-5728(89)90058-1; SINGH VK, 1988, IMMUNOL LETT, V18, P5, DOI 10.1016/0165-2478(88)90061-2; SINGH VK, 1990, NEUROSCI LETT, V120, P151, DOI 10.1016/0304-3940(90)90025-5; SMITH EM, 1986, NATURE, V321, P881, DOI 10.1038/321881a0; STEPHANOU A, 1990, BRAIN BEHAV IMMUN, V4, P67, DOI 10.1016/0889-1591(90)90007-D; STERNBERG EM, 1989, P NATL ACAD SCI USA, V86, P2374, DOI 10.1073/pnas.86.7.2374; STERNBERG EM, 1989, P NATL ACAD SCI USA, V86, P4771, DOI 10.1073/pnas.86.12.4771; TECOMA ES, 1985, LIFE SCI, V36, P1799, DOI 10.1016/0024-3205(85)90152-3; TSURUFUJI S, 1978, J PHARMACOBIO-DYNAM, V1, P8; UDELSMAN R, 1986, NATURE, V319, P147, DOI 10.1038/319147a0; ULISSE S, 1989, J BIOL CHEM, V264, P2156; VALE W, 1981, SCIENCE, V213, P1394, DOI 10.1126/science.6267699; VALE W, 1983, RECENT PROG HORM RES, V39, P245; WEBSTER EL, 1990, ENDOCRINOLOGY, V127, P440, DOI 10.1210/endo-127-1-440; WEBSTER EL, 1988, ENDOCRINOLOGY, V122, P609, DOI 10.1210/endo-122-2-609; WILDER RL, 1987, J CLIN INVEST, V79, P1160, DOI 10.1172/JCI112933	57	429	438	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 18	1991	254	5030					421	423		10.1126/science.1925600	http://dx.doi.org/10.1126/science.1925600			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GK729	1925600				2022-12-24	WOS:A1991GK72900046
J	HEALY, B				HEALY, B			MONONUCLEAR CELL SECRETORY PRODUCTS CONTRIBUTE TO BONE TURNOVER FOLLOWING OOPHORECTOMY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											HEALY, B (corresponding author), NIH,BETHESDA,MD 20892, USA.							1991, P NATL ACAD SCI USA, V88, P5134	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 16	1991	266	15					2054	2054						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GJ474	1920686				2022-12-24	WOS:A1991GJ47400008
J	CHO, SG; ATTAYA, M; MONACO, JJ				CHO, SG; ATTAYA, M; MONACO, JJ			NEW CLASS-II-LIKE GENES IN THE MURINE MHC	NATURE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; CHAIN GENE; NUCLEOTIDE-SEQUENCE; BETA-CHAIN; MOUSE; ALPHA; CDNA; HAPLOTYPE; SUBREGION; DISTINCT	MAJOR histocompatibility complex (MHC) class I molecules present endogenous antigens to CD8+ (cytotoxic) T cells. MHC class II molecules present primarily exogenously derived antigens to CD4+ T cells. Three new genes (Ma, Mb1 and Mb2) located between the Pb and Ob genes of the murine MHC have properties indicating that they are members of the MHC class II gene family, but they are the most divergent class II members so far identified and are almost as closely related in sequence to class I genes as they are to the known class II genes.			CHO, SG (corresponding author), VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT MICROBIOL & IMMUNOL,RICHMOND,VA 23298, USA.							BEALE D, 1976, Q REV BIOPHYS, V9, P135, DOI 10.1017/S0033583500002390; BRAUNSTEIN NS, 1986, EMBO J, V5, P2469, DOI 10.1002/j.1460-2075.1986.tb04523.x; CHO SG, 1991, P NATL ACAD SCI USA, V88, P5197, DOI 10.1073/pnas.88.12.5197; Compagnone-Post P, 1988, GENOMICS, V2, P8, DOI 10.1016/0888-7543(88)90103-6; COSGROVE D, IN PRESS CELL; DAS HK, 1983, P NATL ACAD SCI-BIOL, V80, P3543, DOI 10.1073/pnas.80.12.3543; HOOD L, 1983, ANNU REV IMMUNOL, V1, P529, DOI 10.1146/annurev.iy.01.040183.002525; JONSSON AK, 1987, J BIOL CHEM, V262, P8767; KELLY AP, 1991, NATURE, V353, P571, DOI 10.1038/353571a0; LARHAMMAR D, 1985, J BIOL CHEM, V260, P4111; LAWRANCE SK, 1985, NUCLEIC ACIDS RES, V13, P7515, DOI 10.1093/nar/13.20.7515; LIU CP, 1988, J IMMUNOL, V140, P3631; MALISSEN M, 1983, SCIENCE, V221, P750, DOI 10.1126/science.6410508; MALOY WL, 1981, J BIOL CHEM, V256, P2863; MATHIS DJ, 1983, CELL, V32, P745, DOI 10.1016/0092-8674(83)90060-0; PARNES JR, 1982, CELL, V29, P661, DOI 10.1016/0092-8674(82)90182-9; SAITO H, 1983, P NATL ACAD SCI-BIOL, V80, P5520, DOI 10.1073/pnas.80.18.5520; SCHREIER PH, 1986, NUCLEIC ACIDS RES, V14, P2381, DOI 10.1093/nar/14.5.2381; SHARMA S, 1987, IMMUNOL INVEST, V16, P425, DOI 10.3109/08820138709087096; TIEBER VL, 1986, J BIOL CHEM, V261, P2738; TONNELLE C, 1985, EMBO J, V4, P2839, DOI 10.1002/j.1460-2075.1985.tb04012.x; TROWSDALE J, 1985, EMBO J, V4, P2231, DOI 10.1002/j.1460-2075.1985.tb03919.x; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4	23	120	127	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 10	1991	353	6344					573	576		10.1038/353573a0	http://dx.doi.org/10.1038/353573a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GJ643	1922366				2022-12-24	WOS:A1991GJ64300073
J	HOLBROOK, SR; CHEONG, CJ; TINOCO, I; KIM, SH				HOLBROOK, SR; CHEONG, CJ; TINOCO, I; KIM, SH			CRYSTAL-STRUCTURE OF AN RNA DOUBLE HELIX INCORPORATING A TRACK OF NON-WATSON-CRICK BASE-PAIRS	NATURE			English	Article							DNA; MISMATCHES	THE crystal structure of the RNA dodecamer duplex (r-GGACUUCGGUCC)2 has been determined. The dodecamers stack end-to-end in the crystal, simulating infinite A-form helices with only a break in the phosphodiester chain. These infinite helices are held together in the crystal by hydrogen bonding between ribose hydroxyl groups and a variety of donors and acceptors. The four noncomplementary nucleotides in the middle of the sequence did not form an internal loop, but rather a highly regular double-helix incorporating the non-Watson-Crick base pairs, G . U and U . C. This is the first direct observation of a U . C (or T . C) base pair in a crystal structure. The U . C pairs each form only a single base-base hydrogen bond, but are stabilized by a water molecule which bridges between the ring nitrogens and by four waters in the major groove which link the bases and phosphates. The lack of distortion introduced in the double helix by the U . C mismatch may explain its low efficiency of repair in DNA. The G . U wobble pair is also stabilized by a minor-groove water which bridges between the unpaired guanine amino and the ribose hydroxyl of the uracil. This structure emphasizes the importance of specific hydrogen bonding between not only the nucleotide bases, but also the ribose hydroxyls, phosphate oxygens and tightly bound waters in stabilization of the intramolecular and intermolecular structures of double helical RNA.	UNIV CALIF BERKELEY,DEPT CHEM,BERKELEY,CA 94720	University of California System; University of California Berkeley	HOLBROOK, SR (corresponding author), UNIV CALIF BERKELEY LAWRENCE BERKELEY LAB,BERKELEY,CA 94720, USA.		Cheong, Chaejoon/GWC-3135-2022					ARNOTT S, 1972, BIOCHEM BIOPH RES CO, V48, P1392, DOI 10.1016/0006-291X(72)90867-4; BARFOD ET, 1989, MOL CELL BIOL, V9, P3657, DOI 10.1128/MCB.9.9.3657; BHATTACHARYYA A, 1989, J MOL BIOL, V209, P583, DOI 10.1016/0022-2836(89)90596-2; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; CECH TR, 1987, SCIENCE, V236, P1532, DOI 10.1126/science.2438771; CHEONG CJ, 1990, NATURE, V346, P680, DOI 10.1038/346680a0; COMARMOND MB, 1986, ACTA CRYSTALLOGR B, V42, P272, DOI 10.1107/S0108768186098233; DOCKBREGEON AC, 1989, J MOL BIOL, V209, P459, DOI 10.1016/0022-2836(89)90010-7; EISENSTEIN M, 1990, NUCLEIC ACIDS RES, V18, P3185, DOI 10.1093/nar/18.11.3185; HINGERTY B, 1978, J MOL BIOL, V124, P523, DOI 10.1016/0022-2836(78)90185-7; HOLBROOK SR, 1978, J MOL BIOL, V123, P631, DOI 10.1016/0022-2836(78)90210-3; HUNTER WN, 1987, J BIOL CHEM, V262, P9962; KNEALE G, 1985, J MOL BIOL, V186, P805, DOI 10.1016/0022-2836(85)90398-5; MODRICH P, 1987, ANNU REV BIOCHEM, V56, P435, DOI 10.1146/annurev.biochem.56.1.435; PATEL DJ, 1984, FED PROC, V43, P2663; PYLE AM, 1991, NATURE, V350, P628, DOI 10.1038/350628a0; SUGIMOTO N, 1989, NUCLEIC ACIDS RES, V17, P355, DOI 10.1093/nar/17.1.355; VARANI G, 1991, BIOCHEMISTRY-US, V30, P3280, DOI 10.1021/bi00227a016	18	318	319	0	18	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 10	1991	353	6344					579	581		10.1038/353579a0	http://dx.doi.org/10.1038/353579a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GJ643	1922368				2022-12-24	WOS:A1991GJ64300075
J	WRIGHT, JG; MCGEER, AJ; CHYATTE, D; RANSOHOFF, DF				WRIGHT, JG; MCGEER, AJ; CHYATTE, D; RANSOHOFF, DF			MECHANISMS OF GLOVE TEARS AND SHARP INJURIES AMONG SURGICAL PERSONNEL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; NEEDLESTICK INJURIES; HIV-INFECTION; RISK; SURGERY; OPERATIONS; BLOOD; CONTAMINATION; EXPOSURE	Objective. - The development of strategies to prevent exposure to blood for operating room personnel has been hampered by a lack of knowledge about the specific mechanisms of exposure. The purpose of this study was to classify the mechanisms of glove tears and sharp injuries in the operating room. Design. - During a 3-month period, a nurse interviewed operating room personnel immediately after a glove tear or sharp injury had occurred. Setting. - Yale-New Haven (Conn) Hospital is a tertiary care teaching hospital. Results. - There were 249 glove tears and 70 sharp injuries. Visible skin contact with the patient's blood occurred in 156 glove tears (63%). The mechanisms causing the tear could be identified in only 81 (33%). For 230 glove tears (92%), personnel were wearing single gloves. Of 70 sharp injuries, 47 (67%) were caused by needles and usually occurred during suturing. The following three mechanisms accounted for 40 sharp injuries (57%): (1) hands injured while stationary and holding an instrument, 11 (16%) - a position of risk not previously identified; (2) hands injured while retracting tissue, 12 (17%); and (3) injuries caused by sharp instruments not being used, 17 (24%). Instrument passage caused only four sharp injuries (6%). Conclusions. - The majority of glove tears have an unknown mechanism, and alteration in the manufacture or number of gloves worn may be helpful in reducing cutaneous blood exposures. The identification of specific mechanisms of sharp injuries should lead to effective strategies to prevent exposure to the human immunodeficiency virus and other blood-borne pathogens in the operating room.	YALE UNIV,SCH MED,DEPT SURG,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT EPIDEMIOL & INFECT CONTROL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT MED,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT EPIDEMIOL,NEW HAVEN,CT 06510	Yale University; Yale University; Yale University; Yale University			mcgeer, allison/H-7747-2014; McGeer, Allison/AAB-6885-2020	mcgeer, allison/0000-0001-5647-6137; McGeer, Allison/0000-0001-5647-6137				ADLER MW, 1987, BRIT MED J, V295, P1297, DOI 10.1136/bmj.295.6609.1297; BECKER CE, 1989, ANN INTERN MED, V110, P653, DOI 10.7326/0003-4819-110-8-653; BESSINGER CD, 1988, SURG GYNECOL OBSTET, V167, P287; COHN GM, 1990, AM J OBSTET GYNECOL, V162, P715, DOI 10.1016/0002-9378(90)90992-G; GERBERDING JL, 1991, JAMA-J AM MED ASSOC, V265, P1572, DOI 10.1001/jama.265.12.1572; GERBERDING JL, 1990, NEW ENGL J MED, V322, P1788, DOI 10.1056/NEJM199006213222506; HEALD AE, 1990, J GEN INTERN MED, V5, P389, DOI 10.1007/BF02599422; HUSSAIN SA, 1988, BRIT J SURG, V75, P314, DOI 10.1002/bjs.1800750407; LAFFERTY K, 1987, BRIT MED J, V295, P392, DOI 10.1136/bmj.295.6594.392-a; LOWENFELS AB, 1989, ARCH SURG-CHICAGO, V124, P1284; MARCUS R, 1988, NEW ENGL J MED, V319, P1118, DOI 10.1056/NEJM198810273191703; MATTA H, 1988, BRIT MED J, V297, P597, DOI 10.1136/bmj.297.6648.597; MCGEER A, 1990, J INFECT DIS, V162, P961, DOI 10.1093/infdis/162.4.961; MCKINNEY WP, 1990, INFECT CONT HOSP EP, V11, P243; MCLEOD GG, 1989, J BONE JOINT SURG BR, V71, P489, DOI 10.1302/0301-620X.71B3.2722946; MCNICHOLAS TA, 1989, BRIT J UROL, V63, P565, DOI 10.1111/j.1464-410X.1989.tb05246.x; PANLILIO AL, 1991, JAMA-J AM MED ASSOC, V265, P1533, DOI 10.1001/jama.265.12.1533; ROSENBERG J, 1989, STATE ART REV OCCU S, V4, P3; STOCK SR, 1990, CAN MED ASSS J, V143, P256; 1991, UNIVERSAL PRECAUTION, P237; 1989, RECOMMENDATIONS PREV; 1986, MMWR, V35, P221; 1991, HLTH POLICY BIOMED R, V34, P5	23	54	57	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 25	1991	266	12					1668	1671		10.1001/jama.266.12.1668	http://dx.doi.org/10.1001/jama.266.12.1668			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GF419	1886190				2022-12-24	WOS:A1991GF41900033
J	APARICIO, OM; BILLINGTON, BL; GOTTSCHLING, DE				APARICIO, OM; BILLINGTON, BL; GOTTSCHLING, DE			MODIFIERS OF POSITION EFFECT ARE SHARED BETWEEN TELOMERIC AND SILENT MATING-TYPE LOCI IN SACCHAROMYCES-CEREVISIAE	CELL			English	Article							AUTONOMOUSLY REPLICATING SEQUENCES; SACCHAROMYCES-CEREVISIAE; CHROMOSOME-III; DNA-SEQUENCES; SIR GENES; EFFECT VARIEGATION; YEAST; IDENTIFICATION; EXPRESSION; TRANSCRIPTION	Genes placed near telomeres in S. cerevisiae succumb to position-effect variegation. SIR2, SIR3, SIR4, NAT1, ARD1, and HHF2 (histone H4) were identified as modifiers of the position effect at telomeres, since transcriptional repression near telomeres was no longer observed when any of the modifier genes were mutated. These genes, in addition to SIR1, have previously been shown to repress transcription at the silent mating loci, HML and HMR. However, there were differences between transcriptional silencing at telomeres and the HM loci, as demonstrated by suppressor analysis and the lack of involvement of SIR1 in telomeric silencing. These findings provide insights into telomeric structure and function that are likely to apply to many eukaryotes. In addition, the distinctions between telomeres and the HM loci suggest a hierarchy of chromosomal silencing in S. cerevisiae.			APARICIO, OM (corresponding author), UNIV CHICAGO, DEPT MOLEC GENET & CELL BIOL, CHICAGO, IL 60637 USA.			Aparicio, Oscar/0000-0002-5591-0277	NATIONAL CANCER INSTITUTE [P30CA014599] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043893] Funding Source: NIH RePORTER; NCI NIH HHS [CA14599-16] Funding Source: Medline; NIGMS NIH HHS [GM43893] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAM J, 1984, J MOL BIOL, V176, P307, DOI 10.1016/0022-2836(84)90492-3; ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; ALBERTS B, 1989, MOL BIOL CELL, P1219; BECKER DM, 1991, METHOD ENZYMOL, V194, P182; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; BLOBEL G, 1985, P NATL ACAD SCI USA, V82, P8527, DOI 10.1073/pnas.82.24.8527; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BRAND AH, 1985, CELL, V41, P41, DOI 10.1016/0092-8674(85)90059-5; BRAND AH, 1987, CELL, V51, P709, DOI 10.1016/0092-8674(87)90094-8; BUCHMAN AR, 1988, MOL CELL BIOL, V8, P210, DOI 10.1128/MCB.8.1.210; BUTTON LL, 1986, MOL CELL BIOL, V6, P1352, DOI 10.1128/MCB.6.4.1352; CHAN CSM, 1983, J MOL BIOL, V168, P505, DOI 10.1016/S0022-2836(83)80299-X; CHAN CSM, 1983, CELL, V33, P563, DOI 10.1016/0092-8674(83)90437-3; CHUNG HMM, 1990, EMBO J, V9, P2611, DOI 10.1002/j.1460-2075.1990.tb07443.x; DIFFLEY JFX, 1989, NATURE, V342, P24, DOI 10.1038/342024a0; EISSENBERG JC, 1989, BIOESSAYS, V11, P14, DOI 10.1002/bies.950110105; FELDMAN JB, 1984, J MOL BIOL, V178, P815, DOI 10.1016/0022-2836(84)90313-9; FUSSELL CP, 1975, CHROMOSOMA, V50, P201, DOI 10.1007/BF00283240; GOTTLIEB S, 1989, CELL, V56, P771, DOI 10.1016/0092-8674(89)90681-8; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; HABER JE, 1979, GENETICS, V93, P13; HENIKOFF S, 1990, TRENDS GENET, V6, P422, DOI 10.1016/0168-9525(90)90304-O; HOCHSTRASSER M, 1986, J CELL BIOL, V102, P112, DOI 10.1083/jcb.102.1.112; HOPPER AK, 1975, GENETICS, V80, P77; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; IVY JM, 1986, MOL CELL BIOL, V6, P688, DOI 10.1128/MCB.6.2.688; IVY JM, 1985, GENETICS, V111, P735; JOHNSON LM, 1990, P NATL ACAD SCI USA, V87, P6286, DOI 10.1073/pnas.87.16.6286; KIM UJ, 1988, EMBO J, V7, P2211, DOI 10.1002/j.1460-2075.1988.tb03060.x; KIMMERLY WJ, 1987, MOL CELL BIOL, V7, P4225, DOI 10.1128/MCB.7.12.4225; KLAR AJS, 1979, GENETICS, V93, P37; KLAR AJS, 1981, NATURE, V289, P239, DOI 10.1038/289239a0; KOSTRIKEN R, 1983, CELL, V35, P167, DOI 10.1016/0092-8674(83)90219-2; KURTZ S, 1991, GENE DEV, V5, P616, DOI 10.1101/gad.5.4.616; LEVIS R, 1985, SCIENCE, V229, P558, DOI 10.1126/science.2992080; LIMADEFARIA A, 1983, MOL EVOLUTION ORG CH, P701; LOISON G, 1980, CURR GENET, V2, P39, DOI 10.1007/BF00445692; LONGTINE MS, 1989, CURR GENET, V16, P225, DOI 10.1007/BF00422108; MAHONEY DJ, 1991, GENE DEV, V5, P605, DOI 10.1101/gad.5.4.605; MAHONEY DJ, 1989, MOL CELL BIOL, V9, P4621, DOI 10.1128/MCB.9.11.4621; MCCARROLL RM, 1988, CELL, V54, P505, DOI 10.1016/0092-8674(88)90072-4; MEGEE PC, 1990, SCIENCE, V247, P841, DOI 10.1126/science.2106160; MULLEN JR, 1989, EMBO J, V8, P2067, DOI 10.1002/j.1460-2075.1989.tb03615.x; NASMYTH KA, 1982, CELL, V30, P567, DOI 10.1016/0092-8674(82)90253-7; NASMYTH KA, 1981, NATURE, V289, P244, DOI 10.1038/289244a0; PARK EC, 1990, MOL CELL BIOL, V10, P4932, DOI 10.1128/MCB.10.9.4932; PILLUS L, 1989, CELL, V59, P637, DOI 10.1016/0092-8674(89)90009-3; RAWLINS DJ, 1990, J MICROSC-OXFORD, V157, P83, DOI 10.1111/j.1365-2818.1990.tb02949.x; RINE J, 1979, GENETICS, V93, P877; RINE J, 1987, GENETICS, V116, P9; ROMAN H, 1956, COLD SPRING HARB SYM, V21, P175, DOI 10.1101/SQB.1956.021.01.015; ROSE M, 1984, MOL GEN GENET, V193, P557, DOI 10.1007/BF00382100; SCHNELL R, 1986, MOL CELL BIOL, V6, P494, DOI 10.1128/MCB.6.2.494; SHOEMAN RL, 1990, J BIOL CHEM, V265, P9055; SHORE D, 1987, EMBO J, V6, P461, DOI 10.1002/j.1460-2075.1987.tb04776.x; SHORE D, 1987, CELL, V51, P721, DOI 10.1016/0092-8674(87)90095-X; SHORE D, 1984, EMBO J, V3, P2817, DOI 10.1002/j.1460-2075.1984.tb02214.x; SPOFFORD JB, 1976, GENETICS BIOL DROS C, V1, P955; SPRADLING AC, 1990, GENETICS, V126, P779; SPRAGUE GF, 1991, METHOD ENZYMOL, V194, P77; STONE EM, 1991, MOL CELL BIOL, V11, P2253, DOI 10.1128/MCB.11.4.2253; STOTZ A, 1990, GENE, V95, P91, DOI 10.1016/0378-1119(90)90418-Q; STRATHERN JN, 1982, CELL, V31, P183, DOI 10.1016/0092-8674(82)90418-4; STRATHERN JN, 1979, CELL, V18, P309, DOI 10.1016/0092-8674(79)90050-3; TRAVERSE KL, 1989, CHROMOSOMA, V97, P261, DOI 10.1007/BF00371965; VANHOLDE KE, 1989, SPRINGER SERIES MOL, P497; White M.J.D., 1973, ANIMAL CYTOLOGY EVOL, P1; WHITEWAY M, 1987, MOL CELL BIOL, V7, P3713, DOI 10.1128/MCB.7.10.3713; WILSON C, 1990, ANNU REV CELL BIOL, V6, P679, DOI 10.1146/annurev.cellbio.6.1.679; YOSHIKAWA A, 1990, YEAST, V6, P383, DOI 10.1002/yea.320060504; ZAKIAN VA, 1989, ANNU REV GENET, V23, P579, DOI 10.1146/annurev.genet.23.1.579	71	620	647	0	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 20	1991	66	6					1279	1287		10.1016/0092-8674(91)90049-5	http://dx.doi.org/10.1016/0092-8674(91)90049-5			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GG552	1913809				2022-12-24	WOS:A1991GG55200021
J	SUNDELL, CL; SINGER, RH				SUNDELL, CL; SINGER, RH			REQUIREMENT OF MICROFILAMENTS IN SORTING OF ACTIN MESSENGER-RNA	SCIENCE			English	Article							LABEL INSITU HYBRIDIZATION; CYTOSKELETAL FRAMEWORK; ULTRASTRUCTURAL VISUALIZATION; PROTEIN-SYNTHESIS; HELA-CELLS; LOCALIZATION; ASSOCIATION; SEQUENCES; PATTERN; EMBRYOS	Specific messenger RNAs (mRNAs) can be sequestered within distinct cellular locations, but little is known about how this is accomplished. The participation of the Three major cellular filaments in the localization of actin mRNA was studied in chicken embryo fibroblasts. Movement of actin mRNA to the cell periphery and maintenance of that regionalization required intact microfilaments (composed of actin) but not microtubules or intermediate filaments. The results presented here suggest that actin-binding proteins may participate in mRNA sorting.	UNIV MASSACHUSETTS,SCH MED,DEPT CELL BIOL,WORCESTER,MA 01655	University of Massachusetts System; University of Massachusetts Worcester					NICHD NIH HHS [HD18066] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD018066] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ABERCROM.M, 1971, EXP CELL RES, V67, P359, DOI 10.1016/0014-4827(71)90420-4; ADAMS RJ, 1986, NATURE, V322, P754, DOI 10.1038/322754a0; BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; BONNEAU AM, 1985, J CELL BIOL, V100, P1209, DOI 10.1083/jcb.100.4.1209; BRODEUR RD, 1987, CELL MOTIL CYTOSKEL, V7, P129, DOI 10.1002/cm.970070205; CERVERA M, 1981, CELL, V23, P113, DOI 10.1016/0092-8674(81)90276-2; CHENG H, 1989, J MOL BIOL, V210, P541, DOI 10.1016/0022-2836(89)90130-7; FONTAINE B, 1988, EMBO J, V7, P603, DOI 10.1002/j.1460-2075.1988.tb02853.x; GARNER CC, 1988, NATURE, V336, P674, DOI 10.1038/336674a0; HOOCK TC, 1991, J CELL BIOL, V112, P653, DOI 10.1083/jcb.112.4.653; ISAACS W, 1987, P NATL ACAD SCI USA, V84, P408; JEFFERY WR, 1983, DEV BIOL, V99, P408, DOI 10.1016/0012-1606(83)90290-7; LAWRENCE JB, 1986, CELL, V45, P407, DOI 10.1016/0092-8674(86)90326-0; LENK R, 1977, CELL, V10, P67, DOI 10.1016/0092-8674(77)90141-6; LENK R, 1979, CELL, V16, P289, DOI 10.1016/0092-8674(79)90006-0; MACDONALD PM, 1988, NATURE, V336, P595, DOI 10.1038/336595a0; MCINTOSH JR, 1989, J BIOL CHEM, V264, P6001; MOON RT, 1983, DEV BIOL, V95, P447, DOI 10.1016/0012-1606(83)90046-5; ORNELLES DA, 1986, MOL CELL BIOL, V6, P1650, DOI 10.1128/MCB.6.5.1650; PAPANDRIKOPOULOU A, 1989, NATURE, V340, P650, DOI 10.1038/340650a0; SHEETZ MP, 1983, NATURE, V303, P31, DOI 10.1038/303031a0; SINGER RH, 1989, J CELL BIOL, V108, P2343, DOI 10.1083/jcb.108.6.2343; SUNDELL CL, 1990, J CELL BIOL, V111, P2397, DOI 10.1083/jcb.111.6.2397; TANEJA KL, UNPUB; TRAPP BD, 1987, P NATL ACAD SCI USA, V84, P7773, DOI 10.1073/pnas.84.21.7773; VANVENROOIJ WJ, 1981, EXP CELL RES, V135, P79, DOI 10.1016/0014-4827(81)90301-3; WEEKS DL, 1987, CELL, V51, P861, DOI 10.1016/0092-8674(87)90109-7; YANG F, 1990, NATURE, V347, P494, DOI 10.1038/347494a0; YISRAELI JK, 1990, DEVELOPMENT, V108, P289	29	233	235	1	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 13	1991	253	5025					1275	1277		10.1126/science.1891715	http://dx.doi.org/10.1126/science.1891715			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GE689	1891715				2022-12-24	WOS:A1991GE68900039
J	PIOMELLI, D; PILON, C; GIROS, B; SOKOLOFF, P; MARTRES, MP; SCHWARTZ, JC				PIOMELLI, D; PILON, C; GIROS, B; SOKOLOFF, P; MARTRES, MP; SCHWARTZ, JC			DOPAMINE ACTIVATION OF THE ARACHIDONIC-ACID CASCADE AS A BASIS FOR D1/D2 RECEPTOR SYNERGISM	NATURE			English	Article							SIGNAL TRANSDUCTION; ADENYLATE-CYCLASE; D1; METABOLITES; EXPRESSION; NEURONS; INHIBITION	UNDERSTANDING the actions of the neurotransmitter dopamine in the brain is important in view of its roles in neuropsychiatric illnesses 1. Dopamine D1 receptors, which stimulate both adenylyl cyclase 2 and phospholipase C3, and D2 receptors, which inhibit them 4,5, can nevertheless act synergistically to produce many electrophysiological and behavioural responses 6. Because this functional synergism can occur at the level of single neurons, another, as yet unidentified, signalling pathway activated by dopamine has been hypothesized 7. We report here that in Chinese hamster ovary (CHO) cells transfected with the D2 receptor complementary DNA, D2 agonists potently enhance arachidonic acid release, provided that such release has been initiated by stimulating constitutive purinergic receptors or by increasing intracellular Ca2+. In CHO cells expressing D1 receptors, D1 agonists exert no such effect. When D1 and D2 receptors are coexpressed, however, activation of both subtypes results in a marked synergistic potentiation of arachidonic acid release. The numerous actions of arachidonic acid and its metabolites in neuronal signal transduction 8 suggest that facilitation of its release may be implicated in dopaminergic responses, such as feedback inhibition mediated by D2 autoreceptors, and may constitute a molecular basis for D1/D2 receptor synergism.			PIOMELLI, D (corresponding author), CTR PAUL BROCA,INSERM,U109,UNITE NEUROBIOL & PHARMACOL,2TER RUE ALESIA,F-75014 PARIS,FRANCE.		GIROS, Bruno/ABD-5790-2021	GIROS, Bruno/0000-0001-5876-9822				BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERTORELLO AM, 1990, NATURE, V347, P386, DOI 10.1038/347386a0; BLEY KR, 1990, NEURON, V2, P379; BURCH RM, 1989, MOL NEUROBIOL, V3, P156; CARLSSON A, 1988, NEUROPSYCHOPHARMACOL, V1, P179, DOI 10.1016/0893-133X(88)90012-7; CLARK D, 1987, SYNAPSE, V1, P347, DOI 10.1002/syn.890010408; DALTOSO R, 1989, EMBO J, V8, P4025, DOI 10.1002/j.1460-2075.1989.tb08585.x; DECAMILLI P, 1979, NATURE, V278, P252, DOI 10.1038/278252a0; DUMUIS A, 1988, NATURE, V336, P68, DOI 10.1038/336068a0; EXTON JH, 1990, J BIOL CHEM, V265, P1; FITZPATRICK FA, 1989, PHARMACOL REV, V40, P229; FREEMAN EJ, 1991, J NEUROCHEM, V56, P1079, DOI 10.1111/j.1471-4159.1991.tb02032.x; GERFEN CR, 1990, SCIENCE, V250, P1429, DOI 10.1126/science.2147780; GIROS B, 1989, NATURE, V342, P923, DOI 10.1038/342923a0; GIROS B, 1990, CR ACAD SCI III-VIE, V311, P501; GUPTA SK, 1990, SCIENCE, V249, P662, DOI 10.1126/science.2166341; KANTERMAN RY, 1991, MOL PHARMACOL, V39, P364; KEBABIAN JW, 1972, P NATL ACAD SCI USA, V69, P2145, DOI 10.1073/pnas.69.8.2145; MAHAN LC, 1990, P NATL ACAD SCI USA, V87, P2196, DOI 10.1073/pnas.87.6.2196; PIOMELLI D, 1987, NATURE, V328, P38, DOI 10.1038/328038a0; SALMON JA, 1982, METHOD ENZYMOL, V86, P477; SCHWEITZER P, 1990, NATURE, V346, P464, DOI 10.1038/346464a0; SHIMIZU T, 1990, J NEUROCHEM, V55, P1, DOI 10.1111/j.1471-4159.1990.tb08813.x; SIDHU A, 1986, EUR J PHARMACOL, V128, P213, DOI 10.1016/0014-2999(86)90768-5; SOKOLOFF P, 1990, NATURE, V347, P146, DOI 10.1038/347146a0; STARKE K, 1989, PHYSIOL REV, V69, P864, DOI 10.1152/physrev.1989.69.3.864; Stoof JC, 1981, NATURE, V294, P366, DOI 10.1038/294366a0; VALLAR L, 1989, TRENDS PHARMACOL SCI, V10, P74, DOI 10.1016/0165-6147(89)90082-5	28	264	266	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 12	1991	353	6340					164	167		10.1038/353164a0	http://dx.doi.org/10.1038/353164a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GE731	1909771	Green Published			2022-12-24	WOS:A1991GE73100053
J	HUNZIKER, W; HARTER, C; MATTER, K; MELLMAN, I				HUNZIKER, W; HARTER, C; MATTER, K; MELLMAN, I			BASOLATERAL SORTING IN MDCK CELLS REQUIRES A DISTINCT CYTOPLASMIC DOMAIN DETERMINANT	CELL			English	Article							CANINE KIDNEY-CELLS; PLASMA-MEMBRANE PROTEINS; POLYMERIC IMMUNOGLOBULIN RECEPTOR; INFLUENZA-VIRUS HEMAGGLUTININ; COATED PIT LOCALIZATION; EPITHELIAL-CELLS; INTRACELLULAR-TRANSPORT; LYSOSOMAL MEMBRANE; VIRAL GLYCOPROTEINS; BIOGENESIS	In MDCK cells, Golgi to basolateral transport of several membrane proteins has been found to involve a cytoplasmic domain determinant. In some cases (Fc receptor, lysosomal glycoprotein Igp120), the determinant appears similar to that required for endocytosis via clathrin-coated pits; for Igp120, elimination of a single cytoplasmic domain tyrosine both blocks internalization and results in apical transport. In other cases (LDL receptor), the determinant does not involve the cytoplasmic domain tyrosine required for endocytosis. Thus, contrary to current models, basolateral transport in MCDK cells occurs not by default but depends on one or more cytoplasmic domain determinants, the precise nature of which is unknown. For some proteins, it is closely related to coated pit determinants. The fact that many membrane proteins can reach the apical surface in the absence of this determinant suggests that signals for apical transport are widely distributed.			HUNZIKER, W (corresponding author), YALE UNIV, SCH MED, DEPT CELL BIOL, NEW HAVEN, CT 06510 USA.		Mellman, Ira/ABG-5896-2020; Matter, Karl/C-4880-2008; Hunziker, Walter/GSM-8190-2022; Hunziker, Walter/B-3140-2010	Matter, Karl/0000-0001-8026-7220; Hunziker, Walter/0000-0002-5265-4933				AHLE S, 1988, EMBO J, V7, P919, DOI 10.1002/j.1460-2075.1988.tb02897.x; BARTLES JR, 1987, J CELL BIOL, V105, P1241, DOI 10.1083/jcb.105.3.1241; BREWER CB, 1991, J CELL BIOL, V114, P413, DOI 10.1083/jcb.114.3.413; BROWN DA, 1989, SCIENCE, V245, P1499, DOI 10.1126/science.2571189; CANFIELD WM, 1991, J BIOL CHEM, V266, P5682; CAPLAN M, 1989, FUNCTIONAL EPITHELIA, P71; CASANOVA JE, 1991, CELL, V66, P65, DOI 10.1016/0092-8674(91)90139-P; DAVIS CG, 1987, J BIOL CHEM, V262, P4075; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; GREEN SA, 1987, J CELL BIOL, V105, P1227, DOI 10.1083/jcb.105.3.1227; GRIFFITHS G, 1985, J CELL BIOL, V101, P949, DOI 10.1083/jcb.101.3.949; HOWE CL, 1988, P NATL ACAD SCI USA, V85, P7577, DOI 10.1073/pnas.85.20.7577; HUBBARD AL, 1989, ANNU REV PHYSIOL, V51, P755, DOI 10.1146/annurev.physiol.51.1.755; HUNZIKER W, 1989, J CELL BIOL, V109, P3291, DOI 10.1083/jcb.109.6.3291; HUNZIKER W, 1990, NATURE, V345, P628, DOI 10.1038/345628a0; HUNZIKER W, 1990, EMBO J, V9, P3515, DOI 10.1002/j.1460-2075.1990.tb07560.x; JOHNSON KF, 1990, P NATL ACAD SCI USA, V87, P10010, DOI 10.1073/pnas.87.24.10010; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LAZAROVITS J, 1988, CELL, V53, P743, DOI 10.1016/0092-8674(88)90092-X; LEBIVIC A, 1990, J CELL BIOL, V110, P1533, DOI 10.1083/jcb.110.5.1533; LEBIVIC A, 1990, J CELL BIOL, V111, P1351, DOI 10.1083/jcb.111.4.1351; LEWIS V, 1985, J CELL BIOL, V100, P1839, DOI 10.1083/jcb.100.6.1839; LI CX, 1991, J BIOL CHEM, V266, P9263; LIPPINCOTTSCHWARTZ J, 1987, CELL, V49, P669, DOI 10.1016/0092-8674(87)90543-5; LISANTI MP, 1989, J CELL BIOL, V109, P2145, DOI 10.1083/jcb.109.5.2145; LISANTI MP, 1988, P NATL ACAD SCI USA, V85, P9557, DOI 10.1073/pnas.85.24.9557; MATLIN KS, 1984, J CELL BIOL, V99, P2131, DOI 10.1083/jcb.99.6.2131; MATTER K, 1990, CELL, V60, P429, DOI 10.1016/0092-8674(90)90594-5; MIETTINEN HM, 1989, CELL, V58, P317, DOI 10.1016/0092-8674(89)90846-5; MISEK DE, 1984, CELL, V39, P537, DOI 10.1016/0092-8674(84)90460-4; MOSTOV KE, 1985, CELL, V43, P389, DOI 10.1016/0092-8674(85)90166-7; MOSTOV KE, 1987, J CELL BIOL, V105, P2031, DOI 10.1083/jcb.105.5.2031; MOSTOV KE, 1986, CELL, V47, P359, DOI 10.1016/0092-8674(86)90592-1; PATHAK RK, 1990, J CELL BIOL, V111, P347, DOI 10.1083/jcb.111.2.347; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PFEIFFER S, 1985, J CELL BIOL, V101, P470, DOI 10.1083/jcb.101.2.470; RINDLER MJ, 1984, J CELL BIOL, V98, P1304, DOI 10.1083/jcb.98.4.1304; RINDLER MJ, 1985, J CELL BIOL, V100, P136, DOI 10.1083/jcb.100.1.136; ROBINSON MS, 1987, J CELL BIOL, V104, P887, DOI 10.1083/jcb.104.4.887; RODRIGUEZBOULAN E, 1984, J CELL BIOL, V98, P308, DOI 10.1083/jcb.98.1.308; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; ROMAN LM, 1986, J CELL BIOL, V103, P2607, DOI 10.1083/jcb.103.6.2607; ROTH MG, 1987, J CELL BIOL, V104, P769, DOI 10.1083/jcb.104.3.769; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SARGIACOMO M, 1989, J MEMBRANE BIOL, V107, P277, DOI 10.1007/BF01871942; SERAFINI T, 1991, NATURE, V349, P214, DOI 10.1038/349215a0; SIMONS K, 1990, CELL, V62, P207, DOI 10.1016/0092-8674(90)90357-K; SZTUL E, 1991, CELL, V64, P81, DOI 10.1016/0092-8674(91)90210-P; VEGASALAS DE, 1987, J CELL BIOL, V104, P905, DOI 10.1083/jcb.104.4.905; VEGASALAS DE, 1987, J CELL BIOL, V104, P1249, DOI 10.1083/jcb.104.5.1249; WANDINGERNESS A, 1990, J CELL BIOL, V111, P987, DOI 10.1083/jcb.111.3.987; WANDINGERNESS A, 1990, INTRACELLULAR TRAFFI, P575; WILLIAMS MA, 1990, J CELL BIOL, V111, P955, DOI 10.1083/jcb.111.3.955	53	277	279	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 6	1991	66	5					907	920		10.1016/0092-8674(91)90437-4	http://dx.doi.org/10.1016/0092-8674(91)90437-4			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GE460	1909606				2022-12-24	WOS:A1991GE46000010
J	SARAGOVI, HU; FITZPATRICK, D; RAKTABUTR, A; NAKANISHI, H; KAHN, M; GREENE, MI				SARAGOVI, HU; FITZPATRICK, D; RAKTABUTR, A; NAKANISHI, H; KAHN, M; GREENE, MI			DESIGN AND SYNTHESIS OF A MIMETIC FROM AN ANTIBODY COMPLEMENTARITY-DETERMINING REGION	SCIENCE			English	Article							SEQUENCE; ANTIGEN	A technique for producing non-peptide compounds (mimetics) of designed specificities was developed that permitted the synthesis of a conformationally restricted molecule that mimicked the binding and functional properties of monoclonal antibody (MAb) 87.92.6, which recognizes the reovirus type 3 cellular receptor. Binding of either MAb 87.92.6, peptide analogs, or 87.1-mimetic to the cellular receptor inhibited cellular proliferation. The mimetic was a synthetic beta-loop structure that mimics the second complementarity-determining region of the MAb. These studies may lead to strategies for the synthetic design of antibody complementarity regions, ligands, and other pharmacologically active agents that are water soluble, resistant to proteolysis, and nonimmunogenic.	UNIV PENN, SCH MED, DEPT PATHOL & LAB MED, PHILADELPHIA, PA 19104 USA; UNIV ILLINOIS, DEPT CHEM, CHICAGO, IL 60680 USA	University of Pennsylvania; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital								BRUCK C, 1986, P NATL ACAD SCI USA, V83, P6578, DOI 10.1073/pnas.83.17.6578; CHEN SH, UNPUB; DELAPAZ P, 1986, EMBO J, V5, P415, DOI 10.1002/j.1460-2075.1986.tb04227.x; FULLER WD, 1990, J AM CHEM SOC, V112, P7414, DOI 10.1021/ja00176a063; HOFFMAN RV, 1990, TETRAHEDRON LETT, V31, P2953, DOI 10.1016/S0040-4039(00)88996-0; KAHN M, UNPUB; KANG CY, 1988, SCIENCE, V240, P1034, DOI 10.1126/science.3368787; Kieber-Emmons T, 1987, Int Rev Immunol, V2, P339, DOI 10.3109/08830188709044761; NEPOM J T, 1982, Survey of Immunologic Research, V1, P255; NOVOTNY J, 1986, J MOL BIOL, V189, P715, DOI 10.1016/0022-2836(86)90502-4; POLJAK RJ, 1974, P NATL ACAD SCI USA, V71, P3440, DOI 10.1073/pnas.71.9.3440; SARAGOVI HU, UNPUB; SEGAL DM, 1974, P NATL ACAD SCI USA, V71, P4298, DOI 10.1073/pnas.71.11.4298; TAUB R, 1989, J BIOL CHEM, V264, P259; WILLIAMS WV, 1991, J BIOL CHEM, V266, P5182; WILLIAMS WV, 1989, P NATL ACAD SCI USA, V86, P5537, DOI 10.1073/pnas.86.14.5537	16	153	204	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 16	1991	253	5021					792	795		10.1126/science.1876837	http://dx.doi.org/10.1126/science.1876837			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GB295	1876837				2022-12-24	WOS:A1991GB29500039
J	SMITH, I; COOK, B; BEASLEY, M				SMITH, I; COOK, B; BEASLEY, M			REVIEW OF NEONATAL SCREENING-PROGRAM FOR PHENYLKETONURIA	BRITISH MEDICAL JOURNAL			English	Article							DEFICIENCY; QUALITY	Objective-To review the neonatal screening programme during 1984-8. Design-Analysis of data from screening laboratories and paediatricians. Subjects-All live births in United Kingdom. Main outcome measures-Structure of programme; number of infants tested and number with phenylketonuria; number of infants missed; ages at testing and treatment. Results-The proportion of infants tested approached 100%. The incidence of phenylketonuria was 11.7/100 000 births (445 subjects): 273 had classic phenylketonuria and three had defects of cofactor metabolism. One child with phenylketonuria was known to have been missed compared with three in 1979-83 and six in 1974-8. Seven subjects had been missed over the 15 years due to negative test results. All seven had been tested with the bacterial inhibition assay, although only 53% of infants had been so tested; the difference between the expected and observed proportion was significant (Fisher's exact test, p = 0.017). Eleven infants with classic phenylketonuria were not tested by 14 days of age and 23 (8%) did not start treatment until after 20 days, an improvement compared with 36 (15%) in 1979-83. There were, however, wide regional variations (0% to 27% treated after 20 days). Conclusion-The screening programme achieves high coverage and effectiveness, although some children are still missed. A national practice for screening may help reduce regional variations.			SMITH, I (corresponding author), INST CHILD HLTH,DEPT CHILD HLTH,MRC,DEPT HLTH PHENYLKETONURIA REGISTER,LONDON WC1N 1EH,ENGLAND.							GRANT DB, 1988, BRIT MED J, V296, P1355, DOI 10.1136/bmj.296.6633.1355; GREEVES LG, 1990, EUR J PEDIATR, V149, P713, DOI 10.1007/BF01959529; HUNTER R, 1988, HEAL HEAL SCREENING; LEEMING RJ, 1984, ARCH DIS CHILD, V59, P58, DOI 10.1136/adc.59.1.58; MCCABE ERB, 1983, PEDIATRICS, V72, P390; OKANO Y, 1991, NEW ENGL J MED, V324, P1232, DOI 10.1056/NEJM199105023241802; SMITH I, 1986, ARCH DIS CHILD, V61, P130, DOI 10.1136/adc.61.2.130; SMITH I, 1990, ARCH DIS CHILD, V65, P472, DOI 10.1136/adc.65.5.472; SMITH I, 1990, INBORN METABOLIC DIS, P183; SMITH I, 1985, BUTTERWORTHS INT MED, V5, P166; WESTWOOD AS, 1982, EUR J PEDIATR, V71, P859; WHITEHEAD TP, 1981, J CLIN PATHOL, V34, P947, DOI 10.1136/jcp.34.9.947; 1981, SCREENING EARLY DETE; 1981, BMJ, V282, P1680	14	57	60	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 10	1991	303	6798					333	335		10.1136/bmj.303.6798.333	http://dx.doi.org/10.1136/bmj.303.6798.333			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA606	1912773	Bronze, Green Published			2022-12-24	WOS:A1991GA60600018
J	EWBANK, JJ; CREIGHTON, TE				EWBANK, JJ; CREIGHTON, TE			THE MOLTEN GLOBULE PROTEIN CONFORMATION PROBED BY DISULFIDE BONDS	NATURE			English	Article							ALPHA-LACTALBUMIN; STATE	THE molten globule is a compact protein conformation that has a secondary structure content like that of the native protein, but poorly defined tertiary structure. It is a stable state for a few proteins under particular conditions 1 and could be a ubiquitous kinetic intermediate in protein folding 2. The extent to which native interactions, above the level of the secondary structure, are preserved in this conformation is not so far known. Here we report that alpha-lactalbumin can adopt a molten globule conformation when one of its four disulphide bonds is reduced. In this state, the three other disulphide bonds rearrange spontaneously, at the same rate as when the protein is fully unfolded, to a number of different disulphide bond isomers that tend to maintain the molten globule conformation. That the molten globule state is compatible with a variety of disulphide bond pairings suggests that it is unlikely to be stabilized by many specific tertiary interactions.	MRC, MOLEC BIOL LAB, CAMBRIDGE CB2 2QH, ENGLAND	MRC Laboratory Molecular Biology			Ewbank, Jonathan J/G-4948-2010	Ewbank, Jonathan J/0000-0002-1257-6862				ACHARYA KR, 1989, J MOL BIOL, V208, P99, DOI 10.1016/0022-2836(89)90091-0; BAUM J, 1989, BIOCHEMISTRY-US, V28, P7, DOI 10.1021/bi00427a002; CREIGHTON TE, 1977, J MOL BIOL, V113, P313, DOI 10.1016/0022-2836(77)90144-9; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; DOLGIKH DA, 1981, FEBS LETT, V136, P311, DOI 10.1016/0014-5793(81)80642-4; GIVOL D, 1965, P NATL ACAD SCI USA, V53, P676, DOI 10.1073/pnas.53.3.676; GOLDENBERG DP, 1984, ANAL BIOCHEM, V138, P1, DOI 10.1016/0003-2697(84)90761-9; HOLLECKER M, 1989, PROTEIN STRUCTURE PR, P145; HUGHSON FM, 1990, SCIENCE, V249, P1544, DOI 10.1126/science.2218495; IYER KS, 1973, J BIOL CHEM, V248, P707; KRONMAN MJ, 1989, CRIT REV BIOCHEM MOL, V24, P565, DOI 10.3109/10409238909080054; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; KUWAJIMA K, 1990, BIOCHEMISTRY-US, V29, P8240, DOI 10.1021/bi00488a007; PFEIL W, 1986, FEBS LETT, V198, P287, DOI 10.1016/0014-5793(86)80422-7; PTITSYN OB, 1990, FEBS LETT, V262, P20, DOI 10.1016/0014-5793(90)80143-7; RAO KR, 1989, BIOCHEM BIOPH RES CO, V163, P1390, DOI 10.1016/0006-291X(89)91133-9; SHECHTER Y, 1973, BIOCHEMISTRY-US, V12, P3407, DOI 10.1021/bi00742a007; THOMPSON MP, 1988, BIOCHEM BIOPH RES CO, V157, P944, DOI 10.1016/S0006-291X(88)80965-3	18	139	140	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 11	1991	350	6318					518	520		10.1038/350518a0	http://dx.doi.org/10.1038/350518a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FG143	1901628				2022-12-24	WOS:A1991FG14300057
J	ROCHA, B; VONBOEHMER, H				ROCHA, B; VONBOEHMER, H			PERIPHERAL SELECTION OF THE T-CELL REPERTOIRE	SCIENCE			English	Article							TRANSGENIC MICE; MONOCLONAL-ANTIBODY; BETA-GENES; TOLERANCE; RECEPTOR; THYMUS; EXPRESSION; THYMOCYTES; ANTIGENS; DELETION	T lymphocytes undergo selection events not only in the thymus, but also after they leave the thymus and reside in the periphery. Peripheral selection was found to be dependent on T cell receptor (TCR)-ligand interactions but to differ from thymic selection with regard to specificity and mechanism. Unlike thymic selection, peripheral selection required binding of antigen to the TCR, and it induced expansion of T cell clones. Tolerance to self antigens that are restricted to the periphery occurred through the elimination of self-reactive T cells and by the clonal anergy, which was associated with down-regulation of the alpha-beta-TCR and CD8.	BASEL INST IMMUNOL,CH-4005 BASEL,SWITZERLAND		ROCHA, B (corresponding author), HOP NECKER ENFANTS MALAD,CNRS,UA 122,INSERM,U25,F-75730 PARIS 15,FRANCE.							BEHLKE MA, 1987, J EXP MED, V165, P257, DOI 10.1084/jem.165.1.257; BERG LJ, 1989, CELL, V58, P1035, DOI 10.1016/0092-8674(89)90502-3; BLUTHMANN H, 1988, NATURE, V334, P156, DOI 10.1038/334156a0; BURKLY LC, 1989, NATURE, V342, P564, DOI 10.1038/342564a0; DIALYNAS DP, 1983, J IMMUNOL, V131, P2445; FREITAS AA, 1975, EUR J IMMUNOL, V5, P831, DOI 10.1002/eji.1830051207; GOODNOW CC, 1989, NATURE, V342, P385, DOI 10.1038/342385a0; GOTTLIEB PD, 1980, IMMUNOGENETICS, V10, P454; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KAYE J, 1989, NATURE, V341, P746, DOI 10.1038/341746a0; KISIELOW P, 1982, EUR J IMMUNOL, V12, P463, DOI 10.1002/eji.1830120603; KISIELOW P, 1988, NATURE, V335, P730, DOI 10.1038/335730a0; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; KUBO RT, 1989, J IMMUNOL, V142, P2736; LEDERBERG J, 1959, SCIENCE, V129, P1649, DOI 10.1126/science.129.3364.1649; LO D, 1989, J EXP MED, V170, P87, DOI 10.1084/jem.170.1.87; MACDONALD HR, 1988, NATURE, V332, P40, DOI 10.1038/332040a0; MILLER JFAP, 1979, THYMUS, V1, P3; MILLER RA, 1984, J IMMUNOL, V133, P2925; MORAHAN G, 1989, NATURE, V339, P622, DOI 10.1038/339622a0; PENIT C, 1988, J IMMUNOL, V140, P3315; ROCHA B, 1990, EUR J IMMUNOL, V20, P1697, DOI 10.1002/eji.1830200812; ROCHA B, 1989, EUR J IMMUNOL, V19, P905, DOI 10.1002/eji.1830190518; ROCHA B, 1990, EUR J IMMUNOL, V20, P1919; SCOLLAY RG, 1980, EUR J IMMUNOL, V10, P210, DOI 10.1002/eji.1830100310; TEH HS, 1988, NATURE, V335, P229, DOI 10.1038/335229a0; UEMATSU Y, 1988, CELL, V52, P831, DOI 10.1016/0092-8674(88)90425-4	27	644	654	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 8	1991	251	4998					1225	1228		10.1126/science.1900951	http://dx.doi.org/10.1126/science.1900951			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FA691	1900951				2022-12-24	WOS:A1991FA69100039
J	NIGHTINGALE, SL				NIGHTINGALE, SL			NEW LABELING FOR SODIUM-NITROPRUSSIDE EMPHASIZES RISK OF CYANIDE TOXICITY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	21	21	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 20	1991	265	7					847	847		10.1001/jama.265.7.847	http://dx.doi.org/10.1001/jama.265.7.847			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX587	1899454				2022-12-24	WOS:A1991EX58700009
J	HEALY, B				HEALY, B			INVASIVE MANAGEMENT OF PATIENTS WITH ACUTE MYOCARDIAL-INFARCTION INCREASES RISK OF HEMORRHAGE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											HEALY, B (corresponding author), NIH,BETHESDA,MD 20892, USA.							1991, ANN INTERN MED, V115, P256	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 6	1991	266	17					2341	2341						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GM790	1920737				2022-12-24	WOS:A1991GM79000006
J	BRUNDAGE, RA; FOGARTY, KE; TUFT, RA; FAY, FS				BRUNDAGE, RA; FOGARTY, KE; TUFT, RA; FAY, FS			CALCIUM GRADIENTS UNDERLYING POLARIZATION AND CHEMOTAXIS OF EOSINOPHILS	SCIENCE			English	Article							CYTOLYTIC T-CELLS; AEQUORIN LUMINESCENCE; CONTRACTILE BASIS; AMEBOID MOVEMENT; POLYMORPHONUCLEAR LEUKOCYTES; SEQUENTIAL ACTIVATION; LIVING FIBROBLASTS; ACTIN-FILAMENTS; MYOSIN-I; ENDOCYTOSIS	The concentration of intracellular free calcium ([Ca2+]i) in polarized eosinophils was imaged during chemotaxis by monitoring fluorescence of the calcium-sensitive dye Fura-2 with a modified digital imaging microscope. Chemotactic stimuli caused [Ca2+]i to increase in a nonuniform manner that was related to cell activity. In cells moving persistently in one direction, [Ca2+]i was highest at the rear and lowest at the front of the cell. Before cells turned, [Ca2+]i transiently increased. The region of the cell that became the new leading edge had the lowest [Ca2+]i. These changes in [Ca2+]i provide a basis for understanding the organization and local activity of cytoskeletal proteins thought to underlie the directed migration of many cells.			BRUNDAGE, RA (corresponding author), UNIV MASSACHUSETTS,SCH MED,DEPT PHYSIOL,BIOMED IMAGING GRP,PROGRAM MOLEC MED,WORCESTER,MA 01605, USA.				NHLBI NIH HHS [HL14523] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL014523, R37HL014523] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRAY D, 1988, SCIENCE, V239, P883, DOI 10.1126/science.3277283; BRUNDAGE RT, UNPUB; CASSIMERIS L, 1990, J CELL BIOL, V110, P1067, DOI 10.1083/jcb.110.4.1067; COLLINS K, 1990, J CELL BIOL, V110, P1137, DOI 10.1083/jcb.110.4.1137; FORSCHER P, 1988, J CELL BIOL, V107, P1505, DOI 10.1083/jcb.107.4.1505; FUKUI Y, 1989, NATURE, V341, P328, DOI 10.1038/341328a0; GRAY LS, 1988, J IMMUNOL, V141, P2424; KAMM KE, 1985, ANNU REV PHARMACOL, V25, P593, DOI 10.1146/annurev.pharmtox.25.1.593; KOONCE MP, 1984, J CELL BIOL, V98, P1999, DOI 10.1083/jcb.98.6.1999; KURODA K, 1988, PROTOPLASMA, V144, P64, DOI 10.1007/BF01320282; MARKS PW, 1990, J CELL BIOL, V110, P43, DOI 10.1083/jcb.110.1.43; MARKS PW, 1991, J CELL BIOL, V112, P149, DOI 10.1083/jcb.112.1.149; MCKENNA NM, 1989, J CELL BIOL, V109, P1163, DOI 10.1083/jcb.109.3.1163; MOORE EDW, 1990, CELL CALCIUM, V11, P157, DOI 10.1016/0143-4160(90)90068-6; POENIE M, 1987, EMBO J, V6, P2223, DOI 10.1002/j.1460-2075.1987.tb02494.x; POENIE M, 1990, CELL CALCIUM, V11, P85, DOI 10.1016/0143-4160(90)90062-Y; POZZAN T, 1983, SCIENCE, V221, P1413, DOI 10.1126/science.6310757; SAWYER DW, 1985, SCIENCE, V230, P663, DOI 10.1126/science.4048951; SCANLON M, 1987, J BIOL CHEM, V262, P6308; SMITH SJ, 1988, SCIENCE, V242, P708, DOI 10.1126/science.3055292; SNYDERMAN R, 1981, SCIENCE, V213, P830, DOI 10.1126/science.6266014; STOSSEL TP, 1985, ANNU REV CELL BIOL, V1, P353, DOI 10.1146/annurev.cb.01.110185.002033; TAYLOR DL, 1982, PHILOS T ROY SOC B, V299, P185, DOI 10.1098/rstb.1982.0125; TAYLOR DL, 1980, J CELL BIOL, V86, P599, DOI 10.1083/jcb.86.2.599; Trinkaus J.P., 1984, CELLS ORGANS; WANG Y, 1982, P NATL ACAD SCI-BIOL, V79, P4660, DOI 10.1073/pnas.79.15.4660; WANG YL, 1985, J CELL BIOL, V101, P597, DOI 10.1083/jcb.101.2.597; YIN HL, 1979, NATURE, V281, P583, DOI 10.1038/281583a0; ZIGMOND SH, 1978, J CELL BIOL, V77, P269, DOI 10.1083/jcb.77.2.269	29	239	243	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 1	1991	254	5032					703	706		10.1126/science.1948048	http://dx.doi.org/10.1126/science.1948048			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GN474	1948048				2022-12-24	WOS:A1991GN47400039
J	MANIOTIS, A; SCHLIWA, M				MANIOTIS, A; SCHLIWA, M			MICROSURGICAL REMOVAL OF CENTROSOMES BLOCKS CELL REPRODUCTION AND CENTRIOLE GENERATION IN BSC-1 CELLS	CELL			English	Article							SEA-URCHIN EGGS; MICROTUBULE ORGANIZING CENTERS; HAMSTER OVARY CELLS; SPINDLE POLES; PROTEIN-SYNTHESIS; GOLGI-APPARATUS; MOUSE OOCYTES; BASAL BODIES; M-PHASE; CYCLE	We have removed the centrosome from cultured BSC-1 cells by microsurgery, leaving enough cytoplasm with the nucleated cell fragment (karyoplast) to ensure survival and growth. In each experiment, we followed the fate of the karyoplast as well as the anucleate cell fragment (cytoplast) containing the original pair of centrioles. Experimental karyoplasts reestablish a juxtanuclear microtubule-organizing center, an astral array of microtubules, and a compact Golgi apparatus. They enter and presumably complete S phase, and they grow beyond the size of an average BSC-1 cell. However, they do not regenerate centrioles in time periods equivalent to more than 10 cell cycles and do not undergo cell division. Control-operated cells with centrosomes left in the karyoplast progress through the cell cycle, duplicate the centrosome, and form clonal cell colonies. We conclude that the removal of centrioles uncouples cell growth from cell reproduction and impedes centriole biogenesis and centrosome duplication.	UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720	University of California System; University of California Berkeley								BAILLY E, 1989, EMBO J, V8, P3985, DOI 10.1002/j.1460-2075.1989.tb08581.x; Bornens M., 1984, MEMBRANE STRUCTURE F, P99; BOVERI T, 1988, Z NATURWISS, V22, P865; BRE MH, 1987, J CELL BIOL, V105, P1283, DOI 10.1083/jcb.105.3.1283; BRENNER S, 1977, J CELL BIOL, V72, P368, DOI 10.1083/jcb.72.2.368; CALARCOGILLAM PD, 1983, CELL, V35, P621, DOI 10.1016/0092-8674(83)90094-6; COOPER MS, 1990, CELL, V61, P135, DOI 10.1016/0092-8674(90)90221-Y; DEBEC A, 1982, BIOL CELL, V44, P133; DELOZANNE A, 1987, SCIENCE, V236, P1086, DOI 10.1126/science.3576222; DESSEV G, 1991, J CELL BIOL, V112, P523, DOI 10.1083/jcb.112.4.523; DIETZ R, 1966, CHROMOSOMES TODAY, V1, P161; DIPPELL RV, 1968, P NATL ACAD SCI USA, V61, P461, DOI 10.1073/pnas.61.2.461; DIRKSEN ER, 1961, J BIOPHYS BIOCHEM CY, V11, P244, DOI 10.1083/jcb.11.1.244; FULTON C, 1971, J CELL BIOL, V51, P826, DOI 10.1083/jcb.51.3.826; FULTON C, 1971, ORIGIN CONTINUITY CE, V1, P170; GARD DL, 1990, J CELL BIOL, V110, P2033, DOI 10.1083/jcb.110.6.2033; HALL JL, 1989, CELL, V59, P121, DOI 10.1016/0092-8674(89)90875-1; HEPLER PK, 1974, ANNU REV PLANT PHYS, V25, P309, DOI 10.1146/annurev.pp.25.060174.001521; JOHNSON DE, 1991, J CELL BIOL, V113, P339, DOI 10.1083/jcb.113.2.339; JOHNSON KA, 1990, CELL, V62, P615, DOI 10.1016/0092-8674(90)90105-N; KALLENBACH RJ, 1982, CELL BIOL INT REP, V6, P1025, DOI 10.1016/0309-1651(82)90018-2; KARSENTI E, 1984, J CELL BIOL, V98, P1763, DOI 10.1083/jcb.98.5.1763; KOCHANSKI RS, 1990, J CELL BIOL, V110, P1599, DOI 10.1083/jcb.110.5.1599; KREIS TE, 1990, CELL MOTIL CYTOSKEL, V15, P67, DOI 10.1002/cm.970150202; KURIYAMA R, 1981, J CELL BIOL, V91, P814, DOI 10.1083/jcb.91.3.814; KURIYAMA R, 1989, CELL MOTIL CYTOSKEL, V12, P90, DOI 10.1002/cm.970120204; KURIYAMA R, 1984, J CELL SCI, V66, P277; LAMB NJC, 1990, CELL, V60, P151, DOI 10.1016/0092-8674(90)90725-T; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; LIPSKY NG, 1985, SCIENCE, V228, P745, DOI 10.1126/science.2581316; LUSCHER B, 1991, EMBO J, V10, P865, DOI 10.1002/j.1460-2075.1991.tb08019.x; LWOFF A, 1950, KINETOSOMES DEV REPR; MARO B, 1985, J CELL BIOL, V101, P1665, DOI 10.1083/jcb.101.5.1665; MAZIA D, 1960, J BIOPHYS BIOCHEM CY, V7, P1, DOI 10.1083/jcb.7.1.1; MAZIA D, 1987, INT REV CYTOL, V100, P49; MAZIA D, 1984, EXP CELL RES, V153, P1, DOI 10.1016/0014-4827(84)90442-7; MAZIA D, 1978, UCLA S MOL CELL BIOL, V12, P1; MCNIVEN MA, 1988, J CELL BIOL, V106, P1593, DOI 10.1083/jcb.106.5.1593; NIGG EA, 1985, CELL, V41, P1039, DOI 10.1016/S0092-8674(85)80084-2; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PHILLIPS SG, 1976, J CELL BIOL, V70, P9, DOI 10.1083/jcb.70.1.9; PICARD A, 1987, NATURE, V327, P170, DOI 10.1038/327170a0; Pickett-Heaps J.D., 1969, CYTOBIOS, V3, P257; PRESCOTT DM, 1956, EXP CELL RES, V11, P86, DOI 10.1016/0014-4827(56)90192-6; RAFF EC, 1979, INT REV CYTOL, V39, P2; RAFF JW, 1988, J CELL BIOL, V107, P2009, DOI 10.1083/jcb.107.6.2009; SCHATTEN H, 1986, P NATL ACAD SCI USA, V83, P105, DOI 10.1073/pnas.83.1.105; SCHLIWA M, 1981, J CELL BIOL, V90, P222, DOI 10.1083/jcb.90.1.222; SLUDER G, 1990, J CELL BIOL, V110, P2025, DOI 10.1083/jcb.110.6.2025; SLUDER G, 1989, CELL MOTIL CYTOSKEL, V13, P264, DOI 10.1002/cm.970130405; SLUDER G, 1985, J CELL SCI, V76, P35; SLUDER G, 1985, J CELL BIOL, V100, P887, DOI 10.1083/jcb.100.3.887; SLUDER G, 1990, ADV CELL BIOL, V3, P221; SONNEBORN TM, 1970, S INT SOC CELL BIOL, V9; van Beneden E., 1876, B ACAD R BELG, V41, P1160; VANDRE DD, 1984, P NATL ACAD SCI-BIOL, V81, P4439, DOI 10.1073/pnas.81.14.4439; VERDE F, 1991, J CELL BIOL, V112, P1177, DOI 10.1083/jcb.112.6.1177; VOROBJEV IA, 1987, INT REV CYTOL, V106, P227, DOI 10.1016/S0074-7696(08)61714-3; WEISENBERG RC, 1984, J CELL BIOL, V99, P1527, DOI 10.1083/jcb.99.4.1527; WHEATLEY DN, 1982, CENTRIOLE CENTRAL EN; Wilson EB., 1925, CELL DEV HEREDITY, V3rd edition; YATSU N, 1905, J EXP ZOOL, V2, P289; ZORN GA, 1979, CELL, V18, P659, DOI 10.1016/0092-8674(79)90121-1	63	181	186	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 1	1991	67	3					495	504		10.1016/0092-8674(91)90524-3	http://dx.doi.org/10.1016/0092-8674(91)90524-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GN664	1934057				2022-12-24	WOS:A1991GN66400006
J	MOREL, P; GOETZ, FC; MOUDRYMUNNS, K; FREIER, E; SUTHERLAND, DER				MOREL, P; GOETZ, FC; MOUDRYMUNNS, K; FREIER, E; SUTHERLAND, DER			LONG-TERM GLUCOSE CONTROL IN PATIENTS WITH PANCREATIC TRANSPLANTS	ANNALS OF INTERNAL MEDICINE			English	Article							DEPENDENT DIABETES-MELLITUS; MYOCARDIAL-INFARCTION; RETINOPATHY; RECIPIENTS; PREVALENCE; DIAGNOSIS; NEUROPATHY; ALLOGRAFTS; GLYCEMIA; RISK	Objective: To evaluate the long-term effect on blood glucose levels of successful transplantation of part or all of an intact human pancreas in patients with insulin-dependent diabetes mellitus (IDDM). Design: Cohort study. Setting: Referral medical center. Patients: Thirty-seven patients with adequate data, representative of a group of 62 patients with functioning grafts (that is, insulin-independent) at 2 years after transplantation. The 62 patients came from a total of 178 patients in the University of Minnesota series as of July 1987, for a 2-year success rate of 35% (95% CI, 27.8% to 41.8%). These patients were compared to two diabetic control groups (18 patients with IDDM under standard insulin treatment in a university diabetes clinic and 11 patients with IDDM whose pancreas grafts had failed) and to two nondiabetic groups (14 nondiabetic patients who received immunosuppressive drugs after kidney transplantation and 196 healthy control subjects). Measurements: Glycosylated hemoglobin was measured by the high-pressure liquid chromatography method, as total A1 (Hb A1) and the A1C subfraction (Hb A1C); results were expressed as a percentage of total hemoglobin. Main Results: Before pancreas transplantation, the 37 patients in the study group had a mean Hb A1 of 10.8%, consistent with moderate to marked hyperglycemia and not statistically different from the levels in the diabetic control groups. All 37 patients had values above the therapeutic target range of 5.4% to 7.4%. However, at 1 and 2 years after transplantation, the mean Hb A1 value had fallen sharply to 6.7% and 6.5%, respectively, well within target range (CI of the difference, 3.4% to 4.8%; P < 0.001). These levels did not differ from the mean Hb A1 in the nondiabetic kidney transplant recipients but were slightly above the 6.2% value for the 196 healthy controls (CI of the difference at 1 year, 0.2% to 0.8%). Serial values were available on 6 subjects for 5 years; these values were all well within target range. As expected, Hb A1C values were parallel to those of Hb A1. Conclusions: Pancreas transplantation, in our successful cases, lowered glycosylated hemoglobin to normal or near-normal levels that were sustained for as long as 5 years. These results compare favorably with those in our patients on standard treatment, and also with those in similar patients on intensive control reported by others. Further effort to improve transplant methods appears to be warranted.	UNIV MINNESOTA, MINNEAPOLIS, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities					NCRR NIH HHS [RR/400] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BILOUS RW, 1989, NEW ENGL J MED, V321, P80, DOI 10.1056/NEJM198907133210204; BILOUS RW, 1987, DIABETES S1, V36, pA43; BOUDREAUX JP, 1987, TRANSPLANTATION, V44, P376, DOI 10.1097/00007890-198709000-00010; BOULTON AJM, 1984, DIABETOLOGIA, V26, P15; CORRY RJ, 1986, SURG GYNECOL OBSTET, V162, P547; COSIMI AB, 1988, ARCH SURG-CHICAGO, V123, P621; DCCT Res Grp, 1990, DIABETES CARE, V13, P427; HANSSEN KF, 1986, DIABETOLOGIA, V29, P677, DOI 10.1007/BF00870275; KENNEDY WR, 1990, NEW ENGL J MED, V322, P1031, DOI 10.1056/NEJM199004123221503; KLEIN BEK, 1987, DIABETES CARE, V10, P273, DOI 10.2337/diacare.10.3.273; KLEIN R, 1984, ARCH OPHTHALMOL-CHIC, V102, P527, DOI 10.1001/archopht.1984.01040030405011; KLEIN R, 1984, ARCH OPHTHALMOL-CHIC, V102, P520, DOI 10.1001/archopht.1984.01040030398010; LIPSETT L, 1990, DIABETES S1, V39, pA126; LITTLE RR, 1986, CLIN CHEM, V32, P1146; MOREL P, 1990, TRANSPLANTATION, V49, P294, DOI 10.1097/00007890-199002000-00014; NAVARRO X, 1990, DIABETES, V39, P802, DOI 10.2337/diabetes.39.7.802; OSWALD GA, 1984, LANCET, V1, P1264; PETERSON CM, 1986, DIABETES ANN, P137; POZZA G, 1983, DIABETOLOGIA, V24, P244; RAMSAY RC, 1988, NEW ENGL J MED, V318, P208, DOI 10.1056/NEJM198801283180403; SELAM JL, 1989, INT HDB PANCREAS TRA, P479; SINGER DE, 1989, ANN INTERN MED, V110, P125, DOI 10.7326/0003-4819-110-2-125; SMITH JL, 1989, TRANSPLANTATION, V47, P304, DOI 10.1097/00007890-198902000-00023; SUTHERLAND DER, 1989, ANN SURG, V210, P274, DOI 10.1097/00000658-198909000-00003; SUTHERLAND DER, 1981, ANN INTERN MED, V95, P537, DOI 10.7326/0003-4819-95-5-537; SUTHERLAND DER, 1988, SURGERY, V104, P453; TYDEN G, 1989, DIABETES, V38, P94, DOI 10.2337/diab.38.1.S94; VANDERVLIET JA, 1988, TRANSPLANTATION, V45, P368, DOI 10.1097/00007890-198802000-00024; WHITE LJ, 1984, ANN INTERN MED, V101, P710, DOI 10.7326/0003-4819-101-5-710; WISEMAN M, 1984, DIABETOLOGIA, V26, P401; YUDKIN JS, 1988, DIABETOLOGIA, V31, P201, DOI 10.1007/BF00290585	31	67	68	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1991	115	9					694	699		10.7326/0003-4819-115-9-694	http://dx.doi.org/10.7326/0003-4819-115-9-694			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GL697	1929037				2022-12-24	WOS:A1991GL69700005
J	WONG, ND; WILSON, PWF; KANNEL, WB				WONG, ND; WILSON, PWF; KANNEL, WB			SERUM-CHOLESTEROL AS A PROGNOSTIC FACTOR AFTER MYOCARDIAL-INFARCTION - THE FRAMINGHAM-STUDY	ANNALS OF INTERNAL MEDICINE			English	Article							CORONARY HEART-DISEASE; MIDDLE-AGED MEN; FOLLOW-UP; LIPOPROTEIN CHOLESTEROL; COLESTIPOL-NIACIN; DRUG PROJECT; RISK-FACTORS; MORTALITY; ATHEROSCLEROSIS; PREVENTION	Objective: To determine the relation between serum cholesterol levels and the long-term risk for reinfarction, death from coronary heart disease, and all-cause mortality in persons who recover from myocardial infarction. Design: Prospective, longitudinal study. Setting: A geographically defined population-based cohort of adults participating in the Framingham Heart Study. Patients: Men (n = 260) and women (n = 114), 33 to 88 years of age (mean age, 62 years), who had a history of myocardial infarction. Measurements: A complete physical examination, including electrocardiographic evaluation, blood pressure measurement, height and weight measurements, determination of smoking habits, and casual determinations of blood glucose and serum cholesterol, was done approximately 1 year after recovery from initial myocardial infarction. Patients were followed after infarction for the occurrence of reinfarction or death (mean follow-up, 10.5 years; range, 0.8 to 31.6 years). Main Results: The mean cholesterol level after infarction was 5.21 mmol/L (242.8 mg/dL); 20% of patients had levels below 5.17 mmol/L (200 mg/dL), and 22% had levels of 7.11 mmol/L (275 mg/dL) or more. Compared with patients who had cholesterol levels below 5.17 mmol/L, patients with levels of 7.11 mmol/L or more were at increased risk for reinfarction (relative risk, 3.8; 95% CI, 1.6 to 8.7), death from coronary heart disease (relative risk, 2.6; CI, 1.4 to 4.8), and all-cause mortality (relative risk, 1.9; CI, 1.2 to 2.9) based on multivariate Cox regression analyses adjusted for other coronary risk factors. Intermediate cholesterol levels (5.17 mmol/L to 7.11 mmol/L) were generally not associated with increased risk. The association between elevated serum cholesterol and increased risk was strongest in men; however, elevated cholesterol levels were found to be most strongly related to death from coronary disease and to all-cause mortality in persons who were 65 years of age or more. Conclusions: Patients who have recovered from a myocardial infarction and who have high cholesterol levels are at an increased long-term risk for reinfarction, death from coronary heart disease, and all-cause mortality. Our results confirm the prognostic value of cholesterol levels measured after myocardial infarction and support the role of lipid management in this population.	FRAMINGHAM HEART DIS EPIDEMIOL STUDY, FRAMINGHAM, MA USA	Framingham Heart Study	WONG, ND (corresponding author), UNIV CALIF IRVINE, COLL MED, PREVENT CARDIOL PROGRAM, C240 MED SCI 1, IRVINE, CA 92717 USA.		Wilson, Peter W.F./J-2455-2016					ABELL LL, 1952, J BIOL CHEM, V195, P357; ANDERSON KM, 1987, JAMA-J AM MED ASSOC, V257, P2176, DOI 10.1001/jama.257.16.2176; ARONOW WS, 1989, J AM GERIATR SOC, V37, P501, DOI 10.1111/j.1532-5415.1989.tb05679.x; BLANKENHORN DH, 1987, JAMA-J AM MED ASSOC, V257, P3233, DOI 10.1001/jama.257.23.3233; BROWN G, 1990, NEW ENGL J MED, V323, P1289, DOI 10.1056/NEJM199011083231901; BUCHWALD H, 1990, NEW ENGL J MED, V323, P946, DOI 10.1056/NEJM199010043231404; CANNER PL, 1986, J AM COLL CARDIOL, V8, P1245, DOI 10.1016/S0735-1097(86)80293-5; CARLSON LA, 1988, ACTA MED SCAND, V223, P405; CASHINHEMPHILL L, 1990, JAMA-J AM MED ASSOC, V264, P3013, DOI 10.1001/jama.264.23.3013; CASTELLI WP, 1986, JAMA-J AM MED ASSOC, V256, P2835, DOI 10.1001/jama.256.20.2835; COX DR, 1972, J R STAT SOC B, V34, P187; DAWBER TR, 1951, AM J PUBLIC HEALTH, V41, P279; DIXON WJ, 1985, BMDP STATISTICAL SOF; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; FROST PH, 1987, AM HEART J, V113, P1356, DOI 10.1016/0002-8703(87)90648-X; GOLDBOURT U, 1985, BMJ-BRIT MED J, V290, P1239, DOI 10.1136/bmj.290.6477.1239; GORDON T, 1973, DHEW NIH74478 PUBL; HELIOVAARA M, 1982, AM J CARDIOL, V55, P325; JENKINS CD, 1976, CIRCULATION, V53, P342, DOI 10.1161/01.CIR.53.2.342; JOHANSSON S, 1984, AM J EPIDEMIOL, V119, P610, DOI 10.1093/oxfordjournals.aje.a113778; KHAW KT, 1986, J CARDIOPULM REHABIL, V6, P474; PEKKANEN J, 1990, NEW ENGL J MED, V322, P1700, DOI 10.1056/NEJM199006143222403; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351; SCHLANT RC, 1982, CIRCULATION, V66, P401, DOI 10.1161/01.CIR.66.2.401; ULVENSTAM G, 1984, PREV MED, V13, P355, DOI 10.1016/0091-7435(84)90027-6; WEDEL H, 1989, 29TH ANN M AHA COUNC; WEINBLATT E, 1973, AM J PUBLIC HEALTH, V63, P577, DOI 10.2105/AJPH.63.7.577; WONG ND, 1989, AM J EPIDEMIOL, V130, P469, DOI 10.1093/oxfordjournals.aje.a115360	28	148	155	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1991	115	9					687	693		10.7326/0003-4819-115-9-687	http://dx.doi.org/10.7326/0003-4819-115-9-687			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GL697	1929036				2022-12-24	WOS:A1991GL69700004
J	HOFFMAN, BJ; MEZEY, E; BROWNSTEIN, MJ				HOFFMAN, BJ; MEZEY, E; BROWNSTEIN, MJ			CLONING OF A SEROTONIN TRANSPORTER AFFECTED BY ANTIDEPRESSANTS	SCIENCE			English	Article							BRAIN GABA TRANSPORTER; BLOOD-PLATELETS; MEMBRANE-VESICLES; UPTAKE INHIBITOR; 5-HYDROXYTRYPTAMINE; EXPRESSION; SYSTEM; CDNA; <H-3>IMIPRAMINE; DISORDERS	A complementary DNA clone for a serotonin (5HT) transporter has been isolated from rat basophilic leukemia cells. The complementary DNA sequence predicts a 653-amino acid protein with 12 to 13 putative transmembrane domains. The 5HT transporter has significant homology to the gamma-aminobutyric acid, dopamine, and norepinephrine transporters. Uptake by CV-1 cells expressing the transporter complementary DNA resembles 5HT uptake by platelets and brain synaptosomes; it is sensitive to antidepressants, amphetamine derivatives, and cocaine.	SEMMELWEIS UNIV MED,SCH MED,DEPT ANAT 1,H-1085 BUDAPEST 8,HUNGARY	Semmelweis University	HOFFMAN, BJ (corresponding author), NIMH,CELL BIOL LAB,BETHESDA,MD 20892, USA.		Brownstein, Michael/B-8609-2009; Mezey, Eva/A-8105-2008	Mezey, Eva/0000-0002-5907-4691				AGHAJANIAN GK, 1967, J PHARMACOL EXP THER, V156, P23; ANDERSEN PH, 1989, EUR J PHARMACOL, V166, P493, DOI 10.1016/0014-2999(89)90363-4; AXELROD J, 1963, J PHARMACOL EXP THER, V141, P161; BLACKBURN K. J., 1967, LIFE SCI, V6, P1653, DOI 10.1016/0024-3205(67)90176-2; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; COOPER SJ, 1989, TRENDS PHARMACOL SCI, V10, P56, DOI 10.1016/0165-6147(89)90076-X; FUERST TR, 1987, MOL CELL BIOL, V7, P2538, DOI 10.1128/MCB.7.7.2538; FULLER RW, 1990, NEUROPHARMACOLOGY SE, V600, P68; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HOFFMAN BM, UNPUB; HYTTEL J, 1982, PROG NEURO-PSYCHOPH, V6, P277, DOI 10.1016/S0278-5846(82)80179-6; KANNER BI, 1985, BIOCHIM BIOPHYS ACTA, V816, P403, DOI 10.1016/0005-2736(85)90508-5; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KUHAR MJ, 1978, J NEUROCHEM, V31, P251, DOI 10.1111/j.1471-4159.1978.tb12456.x; KUHAR MJ, 1972, J PHARMACOL-PARIS, V181, P36; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANGER SZ, 1983, NEUROPHARMACOLOGY, V22, P407, DOI 10.1016/0028-3908(83)90190-9; LINGJAERDE O, 1971, ACTA PHYSIOL SCAND, V81, P75, DOI 10.1111/j.1748-1716.1971.tb04878.x; NELSON H, 1990, FEBS LETT, V269, P181, DOI 10.1016/0014-5793(90)81149-I; OKAYAMA H, 1987, METHOD ENZYMOL, V154, P3; PACHOLCZYK T, 1991, NATURE, V350, P350, DOI 10.1038/350350a0; PLETSCHER A, 1987, INT J CARDIOL, V14, P177, DOI 10.1016/0167-5273(87)90007-6; RICUARTE G, 1985, SCIENCE, V229, P986; RITZ MC, 1989, J PHARMACOL EXP THER, V248, P1010; RUDNICK G, 1977, J BIOL CHEM, V252, P2170; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; Sneddon J M, 1973, Prog Neurobiol, V1, P151, DOI 10.1016/0301-0082(73)90019-1; STACEY RS, 1961, BRIT J PHARM CHEMOTH, V16, P284, DOI 10.1111/j.1476-5381.1961.tb01087.x; STAHL SM, 1977, ARCH GEN PSYCHIAT, V34, P509; USDIN T, IN PRESS P NATL ACAD; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WHITE MK, 1989, NATURE, V340, P103, DOI 10.1038/340103b0; WOOD MD, 1986, NEUROPHARMACOLOGY, V25, P519, DOI 10.1016/0028-3908(86)90178-4	34	524	536	1	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 25	1991	254	5031					579	580		10.1126/science.1948036	http://dx.doi.org/10.1126/science.1948036			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GL799	1948036				2022-12-24	WOS:A1991GL79900053
J	MCCONNELL, SK; KAZNOWSKI, CE				MCCONNELL, SK; KAZNOWSKI, CE			CELL-CYCLE DEPENDENCE OF LAMINAR DETERMINATION IN DEVELOPING NEOCORTEX	SCIENCE			English	Article							VISUAL CORTICAL-NEURONS; CEREBRAL-CORTEX; MIGRATION PATTERNS; REELER MOUSE; LINEAGE; DIFFERENTIATION; TRANSPLANTATION; INVITRO; FERRET; RETINA	The neocortex is patterned in layers of neurons that are generated in an orderly sequence during development. This correlation between cell birthday and laminar fate prompted an examination of how neuronal phenotypes are determined in the developing cortex. At various times after labeling with [H-3]thymidine, embryonic progenitor cells were transplanted into older host brains. The laminar fate of transplanted neurons correlates with the position of their progenitors in the cell cycle at the time of transplantation. Daughters of cells transplanted in S-phase migrate to layer 2/3, as do host neurons. Progenitors transplanted later in the cell cycle, however, produce daughters that are committed to their normal, deep-layer fates. Thus, environmental factors are important determinants of laminar fate, but embryonic progenitors undergo cyclical changes in their ability to respond to such cues.			MCCONNELL, SK (corresponding author), STANFORD UNIV,DEPT BIOL SCI,STANFORD,CA 94305, USA.				NEI NIH HHS [EY08411] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY008411] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANDERSON DJ, 1989, NEURON, V3, P1, DOI 10.1016/0896-6273(89)90110-4; ANGEVINE JB, 1961, NATURE, V192, P766, DOI 10.1038/192766b0; AUSTIN CP, 1990, DEVELOPMENT, V110, P713; DRAGER UC, 1981, J COMP NEUROL, V201, P555, DOI 10.1002/cne.902010407; HOY CA, 1987, J BIOL CHEM, V262, P11927; HUETTNER JE, 1986, J NEUROSCI, V6, P3044; JACKSON CA, 1989, J NEUROSCI, V9, P1242; KIM GY, IN PRESS J NEUROBIOL; LEMMON V, 1981, J NEUROSCI, V1, P83, DOI 10.1523/JNEUROSCI.01-01-00083.1981; LUSKIN MB, 1985, J COMP NEUROL, V242, P611, DOI 10.1002/cne.902420409; LUSKIN MB, 1988, NEURON, V1, P635, DOI 10.1016/0896-6273(88)90163-8; MCCONNELL SK, 1991, ANNU REV NEUROSCI, V14, P269, DOI 10.1146/annurev.ne.14.030191.001413; MCCONNELL SK, 1988, J NEUROSCI, V8, P945; MCCONNELL SK, 1985, SCIENCE, V229, P1268, DOI 10.1126/science.4035355; MCCONNELL SK, 1989, TRENDS NEUROSCI, V12, P342, DOI 10.1016/0166-2236(89)90041-6; NOWAKOWSKI RS, 1989, J NEUROCYTOL, V18, P311, DOI 10.1007/BF01190834; PINTOLORD MC, 1982, DEV BRAIN RES, V4, P379, DOI 10.1016/0165-3806(82)90181-X; PRICE J, 1988, DEVELOPMENT, V104, P473; RAKIC P, 1974, SCIENCE, V183, P425, DOI 10.1126/science.183.4123.425; REH TA, 1989, J NEUROSCI, V9, P4179; REH TA, 1986, DEV BIOL, V114, P463, DOI 10.1016/0012-1606(86)90210-1; SHATZ CJ, 1990, COLD SPRING HARB SYM, V55, P469; von Waechter R, 1972, Brain Res, V46, P235; WALSH C, 1990, EXPERIENTIA, V46, P940, DOI 10.1007/BF01939387; WALSH C, 1988, SCIENCE, V241, P1342, DOI 10.1126/science.3137660; WATANABE T, 1990, NEURON, V4, P461, DOI 10.1016/0896-6273(90)90058-N	26	635	638	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 11	1991	254	5029					282	285		10.1126/science.1925583	http://dx.doi.org/10.1126/science.1925583			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GJ642	1925583				2022-12-24	WOS:A1991GJ64200038
J	GARCHON, HJ; BEDOSSA, P; ELOY, L; BACH, JF				GARCHON, HJ; BEDOSSA, P; ELOY, L; BACH, JF			IDENTIFICATION AND MAPPING TO CHROMOSOME-1 OF A SUSCEPTIBILITY LOCUS FOR PERIINSULITIS IN NONOBESE DIABETIC MICE	NATURE			English	Article							MELLITUS; MOUSE; PANCREAS; INSULITIS; ISLETS; GENE; HLA	INSULIN-DEPENDENT diabetes mellitus (IDDM) is a polygenic disease caused by autoimmune destruction of insulin-producing beta-cells in the islets of Langerhans 1,2. Its onset is preceded by a long and variable period in which lymphoid cells infiltrate the pancreas but first remain outside the islets (peri-insulitis) before invading them (insulitis) 3-7. Among susceptibility loci, only the major histocompatibility complex (MHC) has been clearly assigned 8-12. Genetic study of the nonobese diabetic (NOD) mouse model for insulin-dependent diabetes mellitus has revealed genetic linkage of insulitis and of early onset diabetes with two non-MHC loci mapping to chromosome 3 and 11 respectively 13. Here we report a close association of periinsulitis with a third non-MHC locus mapping to chromosome 1. Successive stages in the progression of diabetic disease thus appear to be controlled by distinct genes or sets of genes.	HOP ANTOINE BECLERE, SERV ANAT PATHOL, F-92140 CLAMART, FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Antoine-Beclere - APHP	GARCHON, HJ (corresponding author), HOP NECKER ENFANTS MALAD, INSERM, U25, 161 RUE SEVRES, F-75743 PARIS 15, FRANCE.			Bedossa, Pierre/0000-0002-8487-7322				AITMAN TJ, IN PRESS MAMMALIAN G; ASAMOTO H, 1984, Journal of the Japan Diabetes Society, V27, P775; BEDOSSA P, 1989, EUR J IMMUNOL, V19, P1947, DOI 10.1002/eji.1830191028; CAHILL GF, 1981, NEW ENGL J MED, V304, P1454, DOI 10.1056/NEJM198106113042403; CORNALL RJ, IN PRESS GENOMICS; FOULIS AK, 1984, DIABETOLOGIA, V26, P456; FOULIS AK, 1986, DIABETOLOGIA, V29, P267, DOI 10.1007/BF00452061; GEPTS W, 1981, AM J MED, V70, P105, DOI 10.1016/0002-9343(81)90417-4; GOILLOT E, 1991, CLIN IMMUNOL IMMUNOP, V59, P462, DOI 10.1016/0090-1229(91)90041-8; GORSUCH AN, 1981, LANCET, V2, P1363; HATTORI M, 1986, SCIENCE, V231, P733, DOI 10.1126/science.3003909; HEARNE CM, IN PRESS MAMMALIAN G; KESSLER HS, 1968, AM J PATHOL, V52, P671; LOVE JM, 1990, NUCLEIC ACIDS RES, V18, P4123, DOI 10.1093/nar/18.14.4123; LUDWIG H, 1977, GUT, V18, P311, DOI 10.1136/gut.18.4.311; MIYAGAWA J, 1986, VIRCHOWS ARCH B, V51, P215, DOI 10.1007/BF02899031; NADEAU JH, 1990, GENETIC VARIANTS STR, P506; OKAZAKI K, 1989, INT J PANCREATOL, V5, P359; PROCHAZKA M, 1987, SCIENCE, V237, P286, DOI 10.1126/science.2885918; SIGNORE A, 1989, DIABETOLOGIA, V32, P282, DOI 10.1007/BF00265543; SVEJGAARD A, 1983, IMMUNOL REV, V70, P193, DOI 10.1111/j.1600-065X.1983.tb00715.x; TODD JA, 1991, NATURE, V351, P542, DOI 10.1038/351542a0; TODD JA, 1987, NATURE, V329, P599, DOI 10.1038/329599a0; WHALEY K, 1973, Q J MED, V42, P279; WICKER LS, 1987, J EXP MED, V165, P1639, DOI 10.1084/jem.165.6.1639	25	139	140	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 19	1991	353	6341					260	262		10.1038/353260a0	http://dx.doi.org/10.1038/353260a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GF674	1896073				2022-12-24	WOS:A1991GF67400060
J	BURNEY, PGJ				BURNEY, PGJ			THE HEALTH OF THE NATION - RESPONSES - STRATEGY FOR ASTHMA	BRITISH MEDICAL JOURNAL			English	Article							ADULT ASTHMA; MANAGEMENT; ENGLAND; WALES; ADMISSIONS; PREVALENCE; MORTALITY; EDUCATION; INCREASE				BURNEY, PGJ (corresponding author), UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,DEPT PUBL HLTH MED,ST THOMAS CAMPUS,LONDON SE1 7EH,ENGLAND.			Burney, Peter/0000-0001-8635-5678				Alderson M., 1987, POP TRENDS, V49, P18; ALI NJ, 1991, THORAX, V46, P160, DOI 10.1136/thx.46.3.160; [Anonymous], 1990, BMJ, V301, P651; BEASLEY R, 1989, THORAX, V44, P200, DOI 10.1136/thx.44.3.200; BLAINEY D, 1991, HLTH TRENDS, V22, P151; BUCKNALL CE, 1988, LANCET, V1, P748; BUCKNALL CE, 1988, BRIT MED J, V296, P1637, DOI 10.1136/bmj.296.6637.1637; BURNEY P, 1988, J EPIDEMIOL COMMUN H, V42, P316, DOI 10.1136/jech.42.4.316; BURNEY PGJ, 1986, LANCET, V2, P323; BURNEY PGJ, 1990, BRIT MED J, V300, P1306, DOI 10.1136/bmj.300.6735.1306; BURR M L, 1989, Archives of Disease in Childhood, V64, P1452, DOI 10.1136/adc.64.10.1452; CHARLTON I, 1990, BRIT MED J, V301, P1355, DOI 10.1136/bmj.301.6765.1355; FLEMING DM, 1987, BRIT MED J, V294, P279, DOI 10.1136/bmj.294.6567.279; HAY I, 1987, LANCET, V1, P609; HILL AM, 1989, BRIT MED J, V298, P1479, DOI 10.1136/bmj.298.6686.1479; HILL RA, 1989, ARCH DIS CHILD, V64, P246, DOI 10.1136/adc.64.2.246; HILTON S, 1986, LANCET, V1, P26; JOHNSON AJ, 1984, BRIT MED J, V288, P1870, DOI 10.1136/bmj.288.6434.1870; MAIMAN LA, 1979, JAMA-J AM MED ASSOC, V241, P1919; MAYO PH, 1990, ANN INTERN MED, V112, P864, DOI 10.7326/0003-4819-112-11-864; NOCON A, 1991, ARCH DIS CHILD, V66, P458, DOI 10.1136/adc.66.4.458; REES PJ, 1991, BMJ, V302, P1166; SEARS MR, 1990, LANCET, V336, P1391, DOI 10.1016/0140-6736(90)93098-A; WARNER JO, 1989, ARCH DIS CHILD, V64, P165; WOLTHERS OD, 1991, BMJ-BRIT MED J, V303, P163, DOI 10.1136/bmj.303.6795.163; 1991, CM1523; 1990, BMJ, V301, P797	27	12	13	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 7	1991	303	6802					571	573		10.1136/bmj.303.6802.571	http://dx.doi.org/10.1136/bmj.303.6802.571			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GE948	1912890	Green Published, Bronze			2022-12-24	WOS:A1991GE94800029
J	CHALEPAKIS, G; FRITSCH, R; FICKENSCHER, H; DEUTSCH, U; GOULDING, M; GRUSS, P				CHALEPAKIS, G; FRITSCH, R; FICKENSCHER, H; DEUTSCH, U; GOULDING, M; GRUSS, P			THE MOLECULAR-BASIS OF THE UNDULATED PAX-1 MUTATION	CELL			English	Article							DEVELOPING EXCRETORY SYSTEM; PAIRED-BOX; HORMONE RECEPTORS; MAMMALIAN-CELLS; PROTO-ONCOGENE; AMINO-ACIDS; W-LOCUS; PROTEINS; DNA; GENES	The murine paired box gene Pax-1 has been associated with the mouse developmental mutant undulated (un), which exhibits malformations in the vertebral column. In un mice, a point mutation leading to a Gly-Ser exchange in a conserved part of the paired domain of Pax-1 is present. Here we show that Pax-1 encodes a DNA-binding protein with transcriptional activating properties. The DNA-binding specificity of the Pax-1 protein has been extensively analyzed in gel shift assays, and in conjunction with binding interference experiments, a DNA-binding core motif was defined. Comparison of the DNA-binding properties of wild-type and un Pax-1 proteins demonstrates that the Gly-Ser replacement at position 15 within the paired domain dramatically decreases the DNA-binding affinity of the un Pax-1 protein and alters its DNA-binding specificity. These results decipher the molecular basis of the un mutation.			CHALEPAKIS, G (corresponding author), MAX PLANCK INST BIOPHYS CHEM, DEPT MOLEC CELL BIOL, W-3400 GOTTINGEN, GERMANY.		Fickenscher, Helmut/A-3004-2010; Fickenscher, Helmut/J-9655-2019	Fickenscher, Helmut/0000-0003-0043-1153; Deutsch, Urban/0000-0003-4265-6262				BALLING R, 1988, CELL, V55, P531, DOI 10.1016/0092-8674(88)90039-6; BASH PA, 1983, SCIENCE, V222, P1325, DOI 10.1126/science.222.4630.1325; BAUMGARTNER S, 1987, GENE DEV, V1, P1247, DOI 10.1101/gad.1.10.1247; Blandova ZK, 1975, MOUSE NEWS LETT, V52, P43; BOPP D, 1986, CELL, V47, P1033, DOI 10.1016/0092-8674(86)90818-4; BOPP D, 1989, EMBO J, V8, P3447, DOI 10.1002/j.1460-2075.1989.tb08509.x; BURRI M, 1989, EMBO J, V8, P1183, DOI 10.1002/j.1460-2075.1989.tb03490.x; CATO ACB, 1986, EMBO J, V5, P2237, DOI 10.1002/j.1460-2075.1986.tb04490.x; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; COTE S, 1987, EMBO J, V6, P2793, DOI 10.1002/j.1460-2075.1987.tb02575.x; DANIELSEN M, 1989, CELL, V57, P1131, DOI 10.1016/0092-8674(89)90050-0; DEUTSCH U, 1988, CELL, V53, P617, DOI 10.1016/0092-8674(88)90577-6; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DRESSLER GR, 1988, DEVELOPMENT, V104, P181; DRESSLER GR, 1990, DEVELOPMENT, V109, P787; FAHRNER K, 1987, EMBO J, V6, P1265, DOI 10.1002/j.1460-2075.1987.tb02363.x; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; GREEN N, 1982, CELL, V28, P477, DOI 10.1016/0092-8674(82)90202-1; GRUNEBERG H, 1954, J GENET, V52, P441, DOI 10.1007/BF02981536; GRUNEBERG H, 1950, J GENET, V50, P142, DOI 10.1007/BF02986800; HOEY T, 1988, NATURE, V332, P858, DOI 10.1038/332858a0; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; JOSTES B, 1990, MECH DEVELOP, V33, P27, DOI 10.1016/0925-4773(90)90132-6; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI S, 1990, NATURE, V347, P528, DOI 10.1038/347528a0; MADER S, 1989, NATURE, V338, P271, DOI 10.1038/338271a0; MATTHIAS P, 1989, NUCLEIC ACIDS RES, V17, P6418, DOI 10.1093/nar/17.15.6418; Maxam A M, 1980, Methods Enzymol, V65, P499; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NORNES HO, 1990, DEVELOPMENT, V109, P797; PEARSON WR, 1990, METHOD ENZYMOL, V183, P63; PLACHOV D, 1990, DEVELOPMENT, V110, P643; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHOLER HR, 1989, EMBO J, V8, P2543, DOI 10.1002/j.1460-2075.1989.tb08392.x; SIEBENLIST U, 1980, P NATL ACAD SCI-BIOL, V77, P122, DOI 10.1073/pnas.77.1.122; SIRACUSA LD, 1990, GENOMICS, V6, P491, DOI 10.1016/0888-7543(90)90479-E; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; TREISMAN J, 1991, GENE DEV, V5, P594, DOI 10.1101/gad.5.4.594; TREISMAN J, 1989, CELL, V59, P553; TRUSS M, 1990, P NATL ACAD SCI USA, V87, P7180, DOI 10.1073/pnas.87.18.7180; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; WALLACE ME, 1985, J HERED, V76, P271, DOI 10.1093/oxfordjournals.jhered.a110091; WALTHER C, 1991, IN PRESS GENOMICS; WRIGHT ME, 1947, HEREDITY, V1, P137, DOI 10.1038/hdy.1947.10	55	248	250	0	1	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 6	1991	66	5					873	884		10.1016/0092-8674(91)90434-Z	http://dx.doi.org/10.1016/0092-8674(91)90434-Z			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GE460	1889089				2022-12-24	WOS:A1991GE46000007
J	LAROSA, GJ; WEINHOLD, K; PROFY, AT; LANGLOIS, AJ; DREESMAN, GR; BOSWELL, RN; SHADDUCK, P; BOLOGNESI, DP; MATTHEWS, TJ; EMINI, EA; PUTNEY, SD				LAROSA, GJ; WEINHOLD, K; PROFY, AT; LANGLOIS, AJ; DREESMAN, GR; BOSWELL, RN; SHADDUCK, P; BOLOGNESI, DP; MATTHEWS, TJ; EMINI, EA; PUTNEY, SD			CONSERVED SEQUENCE AND STRUCTURAL ELEMENTS IN THE HIV-1 PRINCIPAL NEUTRALIZING DETERMINANT - FURTHER CLARIFICATIONS	SCIENCE			English	Article									BIOTECH RESOURCES INC,SAN ANTONIO,TX 78249; WILFORD HALL USAF MED CTR,DEPT MED,LACKLAND AFB,TX 78236; MERCK SHARP & DOHME LTD,W POINT,PA 19486; DUKE UNIV,SCH MED,DEPT SURG,DURHAM,NC 27710	United States Department of Defense; United States Air Force; Merck & Company; Duke University	LAROSA, GJ (corresponding author), REPLIGEN CORP,CAMBRIDGE,MA 02139, USA.		Shadduck MD DrHC, Phillip/AAZ-9781-2021	Shadduck MD DrHC, Phillip/0000-0002-7519-4319				LAROSA GJ, 1990, SCIENCE, V249, P932, DOI 10.1126/science.2392685	1	19	20	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 6	1991	253	5024					1146	1146		10.1126/science.1887238	http://dx.doi.org/10.1126/science.1887238			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GD808	1887238				2022-12-24	WOS:A1991GD80800035
J	WAHLE, E				WAHLE, E			A NOVEL POLY(A)-BINDING PROTEIN ACTS AS A SPECIFICITY FACTOR IN THE 2ND PHASE OF MESSENGER-RNA POLYADENYLATION	CELL			English	Article							BINDING-PROTEIN; POLY(A) POLYMERASE; AAUAAA SEQUENCE; CLEAVAGE; NUCLEAR; SITE; RECOGNITION; INVITRO; DOMAIN; TAIL	Polyadenylation of mRNA precursors by poly(A) polymerase depends on a specificity factor, CPF, recognizing the polyadenylation signal AAUAAA. This paper describes an apparently novel poly(A)-binding protein that acts as a second specificity factor, mediating the recognition of the growing poly(A) tail. A transition from a slow initiation phase of polyadenylation to rapid elongation occurs when the growing tail is long enough to serve as a binding site for the poly(A)-binding protein. Elongation of an RNA carrying a tail of 10 or more adenylate residues can occur independently of CPF. A sharp decrease in the poly(A) chain growth rate after the addition of approximately 200 adenylate residues invites speculations about a role of the poly(A)-binding protein in poly(A) tail length control.			WAHLE, E (corresponding author), UNIV BASEL,BIOCTR,DEPT CELL BIOL,KINGELBERGSTR 70,CH-4056 BASEL,SWITZERLAND.			Wahle, Elmar/0000-0003-2504-0677				ADAM SA, 1986, MOL CELL BIOL, V6, P2932, DOI 10.1128/MCB.6.8.2932; BARDWELL VJ, 1990, MOL CELL BIOL, V10, P295, DOI 10.1128/MCB.10.1.295; BARDWELL VJ, 1991, CELL, V65, P125, DOI 10.1016/0092-8674(91)90414-T; BIENROTH S, 1991, IN PRESS J BIOL CHEM, V266; BIRNSTIEL ML, 1985, CELL, V41, P349, DOI 10.1016/S0092-8674(85)80007-6; BLOBEL G, 1973, P NATL ACAD SCI USA, V70, P924, DOI 10.1073/pnas.70.3.924; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHRISTOFORI G, 1989, MOL CELL BIOL, V9, P193, DOI 10.1128/MCB.9.1.193; CHRISTOFORI G, 1988, CELL, V54, P75; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DREYFUSS G, 1988, TRENDS BIOCHEM SCI, V13, P86, DOI 10.1016/0968-0004(88)90046-1; FITZGERALD M, 1981, CELL, V24, P251, DOI 10.1016/0092-8674(81)90521-3; FOX CA, 1989, GENE DEV, V3, P2151, DOI 10.1101/gad.3.12b.2151; GILMARTIN GM, 1989, GENE DEV, V3, P2180, DOI 10.1101/gad.3.12b.2180; GRANGE T, 1987, NUCLEIC ACIDS RES, V15, P4771, DOI 10.1093/nar/15.12.4771; KELLY RC, 1976, J BIOL CHEM, V251, P7240; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINGNER J, 1991, J BIOL CHEM, V266, P8741; MEANS GE, 1968, BIOCHEMISTRY-US, V7, P2192, DOI 10.1021/bi00846a023; MOORE CL, 1984, CELL, V36, P581, DOI 10.1016/0092-8674(84)90337-4; MOORE CL, 1985, CELL, V41, P845, DOI 10.1016/S0092-8674(85)80065-9; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PROUDFOOT N, 1991, CELL, V64, P671, DOI 10.1016/0092-8674(91)90495-K; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; QUERY CC, 1989, CELL, V57, P89, DOI 10.1016/0092-8674(89)90175-X; SACHS AB, 1985, MOL CELL BIOL, V5, P1993, DOI 10.1128/MCB.5.8.1993; SACHS AB, 1986, CELL, V45, P827, DOI 10.1016/0092-8674(86)90557-X; SACHS AB, 1987, MOL CELL BIOL, V7, P3268, DOI 10.1128/MCB.7.9.3268; SACHS AB, 1989, CELL, V58, P857, DOI 10.1016/0092-8674(89)90938-0; Sambrook J., 1989, MOL CLONING LAB MANU; SETYONO B, 1981, CELL, V24, P775, DOI 10.1016/0092-8674(81)90103-3; SHEETS MD, 1989, GENE DEV, V3, P1401, DOI 10.1101/gad.3.9.1401; SHEETS MD, 1990, NUCLEIC ACIDS RES, V18, P5799, DOI 10.1093/nar/18.19.5799; SHUMAN S, 1988, J BIOL CHEM, V263, P8405; TAKAGAKI Y, 1988, CELL, V52, P731, DOI 10.1016/0092-8674(88)90411-4; TAKAGAKI Y, 1989, GENE DEV, V3, P1711, DOI 10.1101/gad.3.11.1711; TSIAPALIS CM, 1975, J BIOL CHEM, V250, P4486; WAHLE LE, 1991, J BIOL CHEM, V266, P3131; WICKENS M, 1984, SCIENCE, V226, P1045, DOI 10.1126/science.6208611; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P277, DOI 10.1016/0968-0004(90)90054-F; ZARKOWER D, 1986, MOL CELL BIOL, V6, P2317, DOI 10.1128/MCB.6.7.2317; ZELUS BD, 1989, MOL CELL BIOL, V9, P2756, DOI 10.1128/MCB.9.6.2756	42	244	245	3	15	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 23	1991	66	4					759	768		10.1016/0092-8674(91)90119-J	http://dx.doi.org/10.1016/0092-8674(91)90119-J			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GC745	1878970				2022-12-24	WOS:A1991GC74500014
J	NIGHTINGALE, SL				NIGHTINGALE, SL			ALGLUCERASE APPROVED FOR GAUCHERS-DISEASE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							1990, JAMA-J AM MED ASSOC, V264, P1239	1	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 12	1991	265	22					2934	2934						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FP635	1903461				2022-12-24	WOS:A1991FP63500007
J	ROSSI, G; JIANG, Y; NEWMAN, AP; FERRONOVICK, S				ROSSI, G; JIANG, Y; NEWMAN, AP; FERRONOVICK, S			DEPENDENCE OF YPT1 AND SEC4 MEMBRANE ATTACHMENT ON BET2	NATURE			English	Article							RAS PROTEINS; YEAST; SECRETION; BINDING; SUPPRESSION; MUTANTS; GENES	MANY small GTP-binding proteins are synthesized as soluble proteins that are post-translationally modified as a prerequisite for membrane attachment 1. Ypt1 and Sec4 are homologous Raslike GTP-binding proteins that have been proposed to regulate the specificity of vesicular traffic at different stages of the secretory pathway by cycling on and off membranes 2-6. Here we show that BET2, initially identified as a gene required for transport from endoplasmic reticulum to Golgi apparatus in yeast 7, encodes a factor that is needed for the membrane attachment of Ypt1 and Sec4. DNA sequence analysis has revealed that Bet2 is homologous to Dpr1 (Ram1), an essential component of a protein prenyltransferase that modifies Ras 8, enabling it to attach to membranes 9,10. We propose that Bet2 modifies Ypt1 and Sec4 in an analogous manner.	YALE UNIV,SCH MED,DEPT CELL BIOL,333 CEDAR ST,NEW HAVEN,CT 06510	Yale University								BACON RA, 1989, J CELL BIOL, V109, P1015, DOI 10.1083/jcb.109.3.1015; BAKER D, 1990, P NATL ACAD SCI USA, V87, P355, DOI 10.1073/pnas.87.1.355; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOURNE HR, 1988, CELL, V53, P669, DOI 10.1016/0092-8674(88)90081-5; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; FUJIYAMA A, 1987, EMBO J, V6, P223, DOI 10.1002/j.1460-2075.1987.tb04742.x; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GOODMAN LE, 1988, YEAST, V4, P271, DOI 10.1002/yea.320040405; GOUD B, 1988, CELL, V53, P753, DOI 10.1016/0092-8674(88)90093-1; GROESCH ME, 1990, J CELL BIOL, V111, P45, DOI 10.1083/jcb.111.1.45; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; MALTESE WA, 1985, J CLIN INVEST, V76, P1748, DOI 10.1172/JCI112165; MARSHALL MS, 1987, MOL CELL BIOL, V7, P2309, DOI 10.1128/MCB.7.7.2309; MOLENAAR CMT, 1988, EMBO J, V7, P971, DOI 10.1002/j.1460-2075.1988.tb02903.x; NEWMAN AP, 1987, J CELL BIOL, V105, P1587, DOI 10.1083/jcb.105.4.1587; PETERSENBJORN S, 1990, YEAST, V6, P345, DOI 10.1002/yea.320060407; POWERS S, 1986, CELL, V47, P413, DOI 10.1016/0092-8674(86)90598-2; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; RUOHOLA H, 1988, J CELL BIOL, V107, P1456; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; SCHAFER WR, 1990, SCIENCE, V249, P1133, DOI 10.1126/science.2204115; SCHAFER WR, 1989, SCIENCE, V245, P379, DOI 10.1126/science.2569235; SEGEV N, 1988, CELL, V52, P915, DOI 10.1016/0092-8674(88)90433-3; WALWORTH NC, 1989, EMBO J, V8, P1685, DOI 10.1002/j.1460-2075.1989.tb03560.x	25	103	106	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 9	1991	351	6322					158	161		10.1038/351158a0	http://dx.doi.org/10.1038/351158a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL035	1903184				2022-12-24	WOS:A1991FL03500055
J	CASTILLA, A; PRIETO, J; FAUSTO, N				CASTILLA, A; PRIETO, J; FAUSTO, N			TRANSFORMING GROWTH FACTOR-BETA-1 AND FACTOR-ALPHA IN CHRONIC LIVER-DISEASE - EFFECTS OF INTERFERON ALFA THERAPY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHRONIC HEPATITIS-B; FACTOR-BETA; EXTRACELLULAR-MATRIX; COLLAGEN FORMATION; CONTROLLED TRIAL; RAT HEPATOCYTES; DNA-SYNTHESIS; DISSE SPACE; ITO CELL; FIBROSIS	Background. Cirrhosis is a diffuse process of hepatic fibrosis and regenerative nodule formation of unknown pathogenesis. Transforming growth factor (TGF) beta-1 induces the production of extracellular matrix proteins by liver cells and has been implicated in the pathogenesis of hepatic fibrosis in laboratory animals. TGF-alpha is a hepatocyte mitogen that participates in liver regeneration. Methods. Using Northern blot analysis, we studied the expression of TGF-beta-1 messenger RNA (mRNA) in liver specimens from 42 patients with chronic hepatitis and cirrhosis and 12 subjects with either normal or fatty livers. The results were correlated with measurements of procollagen Type I mRNA in liver tissue, procollagen Type III peptide in serum, and the degree of histologic injury. We also investigated whether TGF-alpha mRNA would be detectable in biopsy specimens of livers with proliferative activity. Results. TGF-beta-1 mRNA expression correlated closely with the expression of procollagen Type I mRNA (r = 0.94) and serum procollagen Type III peptide (r = 0.89) and with the histologic activity index (r = 0.73). All patients with increased fibrogenic activity (serum procollagen Type III peptide level, > 11.9-mu-g per liter) had increased levels of TGF-beta-1 mRNA (2 to 14 times the levels in the control group or in patients with normal fibrogenic activity), and both TGF-alpha and H3 histone (a marker of DNA synthesis) mRNAs were detectable in patients with regenerative nodules. Six of eight patients with hepatitis C treated with interferon alfa for one year had sustained clinical responses with normalization of serum procollagen Type III peptide and aminotransferase activity. All these patients had normal levels of TGF-beta-1 mRNA in liver specimens obtained at the end of the year. Conclusions. TGF-beta-1 may have an important role in the pathogenesis of fibrosis in patients with chronic liver disease, and TGF-alpha expression may be associated with liver regeneration in these patients.	UNIV NAVARRA,UNIV CLIN,CTR BIOMED RES,DEPT INTERNAL MED,PAMPLONA,SPAIN; BROWN UNIV,DEPT PATHOL & LAB MED,DIV BIOL & MED,PROVIDENCE,RI 02912	University of Navarra; Brown University			Yang, Chen/G-1379-2010	Prieto, Jesus/0000-0002-1091-9593	NATIONAL CANCER INSTITUTE [R37CA023226, R01CA023226, R01CA035249] Funding Source: NIH RePORTER; NCI NIH HHS [CA-35249, CA-23226] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANNONI G, 1990, GASTROENTEROLOGY, V98, P197, DOI 10.1016/0016-5085(90)91310-3; ARMENDARIZBORUNDA J, 1990, FASEB J, V4, P215, DOI 10.1096/fasebj.4.2.2298342; BIAGINI G, 1989, J HEPATOL, V8, P115, DOI 10.1016/0168-8278(89)90170-0; Bissell D.M., 1990, HEPATOLOGY TXB LIVER, P424; BISSELL DM, 1990, HEPATOLOGY, V11, P488, DOI 10.1002/hep.1840110322; BISSELL M, 1990, PROGR LIVER DISEASES, V9, P143; BRAUN L, 1988, P NATL ACAD SCI USA, V85, P1539, DOI 10.1073/pnas.85.5.1539; Brouwer A, 1988, LIVER BIOL PATHOBIOL, P665; CAMPS J, 1989, Journal of Hepatology, V9, pS17, DOI 10.1016/0168-8278(89)90210-9; CARR BI, 1986, CANCER RES, V46, P2330; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHU ML, 1982, NUCLEIC ACIDS RES, V10, P5925, DOI 10.1093/nar/10.19.5925; CONN HO, 1987, DIS LIVER, P725; CZAJA MJ, 1989, J CELL BIOL, V108, P2477, DOI 10.1083/jcb.108.6.2477; CZAJA MJ, 1989, HEPATOLOGY, V10, P795, DOI 10.1002/hep.1840100508; DAVIS GL, 1989, NEW ENGL J MED, V321, P1501, DOI 10.1056/NEJM198911303212203; DIBISCEGLIE AM, 1989, NEW ENGL J MED, V321, P1506, DOI 10.1056/NEJM198911303212204; EDWARDS DR, 1987, EMBO J, V6, P1899, DOI 10.1002/j.1460-2075.1987.tb02449.x; FAUSTO N, 1989, LAB INVEST, V60, P4; FRENCH SW, 1988, AM J PATHOL, V132, P73; GEERTS A, 1987, CIRRHOSIS LIVER METH, P83; GEWIRTZ AM, 1989, SCIENCE, V245, P180, DOI 10.1126/science.2665077; HAHN EG, 1987, CIRRHOSIS LIVER METH, P63; HOOFNAGLE JH, 1986, NEW ENGL J MED, V315, P1575, DOI 10.1056/NEJM198612183152503; HORN T, 1986, J HEPATOL, V3, P333, DOI 10.1016/S0168-8278(86)80486-X; IGNOTZ RA, 1986, J BIOL CHEM, V261, P4337; IRABURU M, 1989, J MED VIROL, V27, P39, DOI 10.1002/jmv.1890270109; KERSHENOBICH D, 1988, NEW ENGL J MED, V318, P1709, DOI 10.1056/NEJM198806303182602; KNODELL RG, 1981, HEPATOLOGY, V1, P431, DOI 10.1002/hep.1840010511; MAHER JJ, 1990, J CLIN INVEST, V86, P1641, DOI 10.1172/JCI114886; MAK KM, 1984, GASTROENTEROLOGY, V87, P188; MATSUOKA M, 1990, HEPATOLOGY, V11, P599, DOI 10.1002/hep.1840110412; MCMAHON JB, 1986, CANCER RES, V46, P4665; MEAD JE, 1989, P NATL ACAD SCI USA, V86, P1558, DOI 10.1073/pnas.86.5.1558; MILANI S, 1990, AM J PATHOL, V137, P59; MINATO Y, 1983, HEPATOLOGY, V3, P559; MORELLO D, 1990, MOL CELL BIOL, V10, P3185, DOI 10.1128/MCB.10.6.3185; NAKAMURA T, 1985, BIOCHEM BIOPH RES CO, V133, P1042, DOI 10.1016/0006-291X(85)91241-0; NAKATSUKASA H, 1990, LAB INVEST, V63, P171; NAKATSUKASA H, 1990, J CLIN INVEST, V85, P1833, DOI 10.1172/JCI114643; OKANOUE T, 1983, ARCH PATHOL LAB MED, V107, P459; PRIETO J, 1989, HEPATOLOGY, V9, P720, DOI 10.1002/hep.1840090511; RAGHOW R, 1987, J CLIN INVEST, V79, P1285, DOI 10.1172/JCI112950; RICKLES R, 1982, P NATL ACAD SCI-BIOL, V79, P749, DOI 10.1073/pnas.79.3.749; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; Roberts AB, 1990, HDB EXPT PHARM, V95, P419; ROJKIND M, 1988, LIVER BIOL PATHOBIOL, P1269; RUWART MJ, 1989, HEPATOLOGY, V10, P801, DOI 10.1002/hep.1840100509; SESHADRI T, 1990, SCIENCE, V247, P205, DOI 10.1126/science.2104680; SHERLOCK S, 1989, DISEASES LIVER BILIA, P410; THOMSON BJ, 1987, LANCET, V1, P539; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; TSUKAMOTO H, 1986, HEPATOLOGY, V6, P814, DOI 10.1002/hep.1840060503; WEINER FR, 1990, HEPATOLOGY, V11, P111, DOI 10.1002/hep.1840110119; ZERN MA, 1990, CONNECTIVE TISSUE HL, P99	55	667	681	0	12	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 4	1991	324	14					933	940		10.1056/NEJM199104043241401	http://dx.doi.org/10.1056/NEJM199104043241401			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FE376	1900574				2022-12-24	WOS:A1991FE37600001
J	KITAMURA, D; ROES, J; KUHN, R; RAJEWSKY, K				KITAMURA, D; ROES, J; KUHN, R; RAJEWSKY, K			A B-CELL-DEFICIENT MOUSE BY TARGETED DISRUPTION OF THE MEMBRANE EXON OF THE IMMUNOGLOBULIN MU-CHAIN GENE	NATURE			English	Article							PRE-B; MONOCLONAL-ANTIBODY; LYMPHOCYTES-B; HEAVY-CHAINS; LIGHT-CHAIN; BONE-MARROW; STEM-CELLS; REARRANGEMENT; LAMBDA-5; LOCUS	OF the various classes of antibodies that B lymphocytes can produce, class M (IgM) is the first to be expressed on the membrane of the developing cells. Pre-B cells, the precursors of B-lymphocytes, produce the heavy chain of IgM (mu-chain), but not light chains 1. Recent data suggest that pre-B cells express mu-chains on the membrane together with the 'surrogate' light chains lambda-5 and VpreB (refs 2-7). This complex could control pre-B-cell differentiation, in particular the rearrangement of the light-chain genes 8. We have now assessed the importance of the membrane form of the mu-chain in B-cell development by generating mice lacking this chain. We disrupted one of the membrane exons of the gene encoding the mu-chain constant region by gene targeting 9 in mouse embryonic stem cells 10. From these cells we derived mice heterozygous or homozygous for the mutation. B-cell development in the heterozygous mice seemed to be normal, but in homozygous animals B cells were absent, their development already being arrested at the stage of pre-B-cell maturation.	UNIV COLOGNE,INST GENET,WEYERTAL 121,W-5000 COLOGNE 41,GERMANY	University of Cologne			Kühn, Ralf/U-1278-2017	Kühn, Ralf/0000-0003-1694-9803; Roes, Jurgen/0000-0003-3235-2345				CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; Coffman R L, 1982, Immunol Rev, V69, P5; COFFMAN RL, 1981, NATURE, V289, P681, DOI 10.1038/289681a0; COFFMAN RL, 1983, J MOL CELL IMMUNOL, V1, P31; COOPER MD, 1989, FUNDAMENTAL IMMUNOLO, P1033; COOPER MD, 1989, IMMUNOGLOBULIN GENES, P1; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; Forster I, 1989, Int Immunol, V1, P321, DOI 10.1093/intimm/1.4.321; GRUTZMANN R, 1981, THEISIS U COLOGNE; Guise J. W., 1989, Immunoglobulin genes., P275; Kerr W G, 1989, Int Immunol, V1, P355, DOI 10.1093/intimm/1.4.355; KIM HS, 1988, NUCLEIC ACIDS RES, V16, P8887, DOI 10.1093/nar/16.18.8887; KUDO A, 1987, EMBO J, V6, P2267, DOI 10.1002/j.1460-2075.1987.tb02500.x; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MANZ J, 1988, J EXP MED, V168, P1363, DOI 10.1084/jem.168.4.1363; NISHIKAWA SI, 1986, IMMUNOGENETICS, V23, P137, DOI 10.1007/BF00377976; OPITZ HG, 1982, IMMUNOBIOLOGY, V160, P438, DOI 10.1016/S0171-2985(82)80007-7; OPSTELTEN D, 1983, J IMMUNOL, V131, P2635; OSMOND DG, 1986, IMMUNOL REV, V93, P103, DOI 10.1111/j.1600-065X.1986.tb01504.x; PILLAI S, 1987, NATURE, V329, P172, DOI 10.1038/329172a0; RETH M, 1987, EMBO J, V6, P3299, DOI 10.1002/j.1460-2075.1987.tb02649.x; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; SAKAGUCHI N, 1986, NATURE, V324, P579, DOI 10.1038/324579a0; SCHUPPEL R, 1987, EUR J IMMUNOL, V17, P739, DOI 10.1002/eji.1830170527; TAKEMORI T, 1990, EMBO J, V9, P2493, DOI 10.1002/j.1460-2075.1990.tb07428.x; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; TSUBATA T, 1990, J EXP MED, V172, P973, DOI 10.1084/jem.172.3.973	29	1535	1604	1	16	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 4	1991	350	6317					423	426		10.1038/350423a0	http://dx.doi.org/10.1038/350423a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FF042	1901381				2022-12-24	WOS:A1991FF04200050
J	YOOL, AJ; SCHWARZ, TL				YOOL, AJ; SCHWARZ, TL			ALTERATION OF IONIC SELECTIVITY OF A K+ CHANNEL BY MUTATION OF THE H5 REGION	NATURE			English	Article							POTASSIUM CHANNELS; SHAKER LOCUS; XENOPUS OOCYTES; DROSOPHILA; BRAIN; CDNA; EXPRESSION; CATIONS; CLONING	THE high ionic selectivity of K+ channels is a unifying feature of this diverse class of membrane proteins. Though K+ channels differ widely in regulation and kinetics, physiological studies have suggested a common structure: a single file pore containing mulitiple ion-binding sites and having broader vestibules at both ends 1-5. We have used site-directed mutagenesis and single-channel recordings to identify a molecular region that influences ionic selectivity in a cloned A-type K+ channel from Drosophila. Single amino-acid substitutions in H5, the fifth hydrophobic region 6, enhanced the passage of NH4+ and Rb+, ions with diameters larger than K+, without compromising the ability of the channel to exclude the smaller cation, Na+. The mutations that substantially altered selectivity had little effect on the gating properties of the channel. We conclude that the H5 region is likely to line the pore of the K+ channel.			YOOL, AJ (corresponding author), STANFORD UNIV,MED CTR,DEPT MOLEC & CELLULAR PHYSIOL,STANFORD,CA 94305, USA.		Yool, Andrea/AAK-9907-2020	Yool, Andrea/0000-0003-1283-585X				ARMSTRONG CM, 1975, QUART REV BIOPH, V7, P179; BEZANILLA F, 1972, J GEN PHYSIOL, V60, P558; BLACHLYDYSON E, 1990, SCIENCE, V247, P1233, DOI 10.1126/science.1690454; BUTLER A, 1989, SCIENCE, V243, P943, DOI 10.1126/science.2493160; EISENMAN G, 1983, J MEMBRANE BIOL, V76, P197, DOI 10.1007/BF01870364; FRECH GC, 1989, NATURE, V340, P642, DOI 10.1038/340642a0; GUY HR, 1989, MONOVALENT CATIONS B; HILLE B, 1973, J GEN PHYSIOL, V61, P669, DOI 10.1085/jgp.61.6.669; HILLE B, 1978, J GEN PHYSIOL, V72, P409, DOI 10.1085/jgp.72.4.409; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; IVERSON LE, 1988, P NATL ACAD SCI USA, V85, P5723, DOI 10.1073/pnas.85.15.5723; JAN LY, 1990, NATURE, V345, P672, DOI 10.1038/345672a0; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LATORRE R, 1983, J MEMBRANE BIOL, V71, P11, DOI 10.1007/BF01870671; MACKINNON R, 1990, SCIENCE, V250, P276, DOI 10.1126/science.2218530; MATTESON DR, 1986, J GEN PHYSIOL, V87, P795, DOI 10.1085/jgp.87.5.795; SCHWARZ TL, 1988, NATURE, V331, P137, DOI 10.1038/331137a0; STUHMER W, 1989, EMBO J, V8, P3235, DOI 10.1002/j.1460-2075.1989.tb08483.x; TAYLOR PS, 1987, J PHYSIOL-LONDON, V388, P437, DOI 10.1113/jphysiol.1987.sp016623; TEMPEL BL, 1988, NATURE, V332, P837, DOI 10.1038/332837a0; TEMPEL BL, 1987, SCIENCE, V237, P770, DOI 10.1126/science.2441471; TIMPE LC, 1988, NATURE, V331, P143, DOI 10.1038/331143a0; TIMPE LC, 1988, NEURON, V1, P659, DOI 10.1016/0896-6273(88)90165-1; VANDERLEY P, 1986, J BIOL CHEM, V261, P2222; ZAGOTTA WN, 1989, P NATL ACAD SCI USA, V86, P7243, DOI 10.1073/pnas.86.18.7243	25	374	382	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 21	1991	349	6311					700	704		10.1038/349700a0	http://dx.doi.org/10.1038/349700a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EY627	1899917				2022-12-24	WOS:A1991EY62700049
J	ROBEY, EA; FOWLKES, BJ; GORDON, JW; KIOUSSIS, D; VONBOEHMER, H; RAMSDELL, F; AXEL, R				ROBEY, EA; FOWLKES, BJ; GORDON, JW; KIOUSSIS, D; VONBOEHMER, H; RAMSDELL, F; AXEL, R			THYMIC SELECTION IN CD8 TRANSGENIC MICE SUPPORTS AN INSTRUCTIVE MODEL FOR COMMITMENT TO A CD4 OR CD8 LINEAGE	CELL			English	Article							T-CELL RECEPTOR; ANTIGEN RECEPTOR; POSITIVE SELECTION; LYMPHOCYTES-T; GENE; MOLECULES; EXPRESSION; RECOGNITION; ACTIVATION; ENGAGEMENT	Immature thymocytes, which coexpress CD4 and CD8, give rise to mature CD4+CD8- and CD4-CD8+ T cells. Only those T cells that recognize self-MHC are selected to mature, a process known as positive selection. The specificity of the T cell antigen receptor (TCR) for class I or class II MHC influences the commitment to a CD4 or CD8 lineage. This may occur by a directed mechanism or by stochastic commitment followed by a selection step that allows only CD8+, class I-specific and CD4+, class II-specific cells to survive. We have generated a mouse line expressing a CD8 transgene under the control of the T cell-specific CD2 regulatory sequences. Although constitutive CD8 expression does not affect thymic selection of CD4+ cells, selection of a class I-specific TCR in the CD8 subset is substantially improved. This outcome is consistent with a model for positive selection in which selection occurs at a developmental stage in which both CD4 and CD8 are expressed, and positive selection by class I MHC generates an instructive signal that directs differentiation to a CD8 lineage.	COLUMBIA UNIV, HOWARD HUGHES MED INST, NEW YORK, NY 10032 USA; NIAID, CELLULAR & MOLEC IMMUNOL LAB, BETHESDA, MD 20892 USA; CUNY MT SINAI SCH MED, DEPT OBSTET GYNECOL & REPROD SCI, NEW YORK, NY 10029 USA; CUNY MT SINAI SCH MED, DEPT BIOCHEM, NEW YORK, NY 10029 USA; NATL INST MED RES, GENE STRUCT & EXPRESS LAB, LONDON NW7 1AA, ENGLAND; BASEL INST IMMUNOL, CH-4005 BASEL, SWITZERLAND	Columbia University; Howard Hughes Medical Institute; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; MRC National Institute for Medical Research	ROBEY, EA (corresponding author), COLUMBIA UNIV, DEPT BIOCHEM & MOLEC BIOPHYS, NEW YORK, NY 10032 USA.			Axel, Richard/0000-0002-3141-4076				BENOIST C, 1989, CELL, V58, P1027, DOI 10.1016/0092-8674(89)90501-1; BERG LJ, 1989, CELL, V58, P1035, DOI 10.1016/0092-8674(89)90502-3; BERG LJ, 1990, CELL, V60, P1043, DOI 10.1016/0092-8674(90)90352-F; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; CHOTHIA C, 1988, EMBO J, V7, P3745, DOI 10.1002/j.1460-2075.1988.tb03258.x; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; DOYLE C, 1987, NATURE, V330, P256, DOI 10.1038/330256a0; EMMRICH F, 1986, P NATL ACAD SCI USA, V83, P8298, DOI 10.1073/pnas.83.21.8298; FOWLKES BJ, 1989, ADV IMMUNOL, V44, P207; GABERT J, 1987, CELL, V50, P545, DOI 10.1016/0092-8674(87)90027-4; GORDON JW, 1980, P NATL ACAD SCI-BIOL, V77, P7380, DOI 10.1073/pnas.77.12.7380; GOTTLIEB PD, 1980, IMMUNOGENETICS, V10, P545, DOI 10.1007/BF01572589; GREAVES DR, 1989, CELL, V56, P979, DOI 10.1016/0092-8674(89)90631-4; GUIDOS CJ, 1990, J EXP MED, V172, P835, DOI 10.1084/jem.172.3.835; JANEWAY CA, 1988, NATURE, V335, P208, DOI 10.1038/335208a0; KAYE J, 1989, NATURE, V341, P746, DOI 10.1038/341746a0; KISIELOW P, 1988, NATURE, V335, P730, DOI 10.1038/335730a0; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; LIAO NS, 1989, J EXP MED, V170, P135, DOI 10.1084/jem.170.1.135; MAGE MG, 1984, METHOD ENZYMOL, V108, P118; MAISSEN M, 1988, CELL, V55, P49; NORMENT AM, 1988, NATURE, V336, P79, DOI 10.1038/336079a0; OHASHI PS, 1990, NATURE, V346, P861, DOI 10.1038/346861a0; PIRCHER H, 1989, NATURE, V342, P559, DOI 10.1038/342559a0; RAMSDELL F, 1989, J IMMUNOL, V143, P1467; Robey E A, 1990, Semin Immunol, V2, P25; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SALTER RD, 1990, NATURE, V345, P41, DOI 10.1038/345041a0; SALTO T, 1989, J IMMUNOL, V143, P3379; SHA WC, 1988, NATURE, V335, P271, DOI 10.1038/335271a0; TEH HS, 1989, J EXP MED, V169, P795, DOI 10.1084/jem.169.3.795; TEH HS, 1988, NATURE, V335, P229, DOI 10.1038/335229a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VEILLETTE A, 1989, J EXP MED, V170, P1671, DOI 10.1084/jem.170.5.1671; VONBOEHMER H, 1986, IMMUNOL TODAY, V7, P333; VONBOEHMER H, 1990, SCIENCE, V248, P1369, DOI 10.1126/science.1972594; VONBOEHMER H, 1990, ANNU REV IMMUNOL, V8, P531, DOI 10.1146/annurev.iy.08.040190.002531; YOUN HJ, 1988, IMMUNOGENETICS, V28, P353, DOI 10.1007/BF00364234; YOUN HJ, 1988, IMMUNOGENETICS, V28, P345, DOI 10.1007/BF00364233; ZAMOYSKA R, 1985, CELL, V43, P153, DOI 10.1016/0092-8674(85)90020-0; ZUNIGAPFLUCKER JC, 1990, J EXP MED, V171, P427, DOI 10.1084/jem.171.2.427	41	217	218	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 11	1991	64	1					99	107		10.1016/0092-8674(91)90212-H	http://dx.doi.org/10.1016/0092-8674(91)90212-H			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ET175	1898873				2022-12-24	WOS:A1991ET17500012
J	SEELEY, DG; BROWNER, WS; NEVITT, MC; GENANT, HK; SCOTT, JC; CUMMINGS, SR				SEELEY, DG; BROWNER, WS; NEVITT, MC; GENANT, HK; SCOTT, JC; CUMMINGS, SR			WHICH FRACTURES ARE ASSOCIATED WITH LOW APPENDICULAR BONE MASS IN ELDERLY WOMEN	ANNALS OF INTERNAL MEDICINE			English	Article						OSTEOPOROSIS, POSTMENOPAUSAL; FRACTURES; BONE DENSITY; GERIATRICS; WOMENS HEALTH	HIP FRACTURE; OSTEOPOROSIS; RISK	Objective: To determine which types of fractures have an increased incidence in elderly women with low appendicular bone mass. Design: Prospective cohort study. Setting: Four clinical centers in the United States (Baltimore, Maryland; Minneapolis, Minnesota; Portland, Oregon; Monangehela Valley, Pennsylvania); and one coordinating center in San Francisco, California. Subjects: Ambulatory, nonblack women (9704) aged 65 years or more who were recruited from population-based listings. Measurements: We measured bone mass at the distal and proximal radius and calcaneus using single-photon absorptiometry. Fractures were verified radiographically. Associations were calculated as age-adjusted hazard ratios (with 95% CIs) per standard deviation decrease in bone mass. Main Results: During a mean follow-up of 2.23 years, 841 nonspinal fractures occurred in 753 women. The risks for fractures of the wrist, foot, humerus, hip, rib, toe, leg, pelvis, hand, and clavicle were significantly related to reduced bone mass (P < 0.05). These fractures represented 74% of nonspinal fractures. The overall hazard ratio for the occurrence of one or more of these fractures was 1.65 (CI, 1.49 to 1.82) at the distal radius. In a subsample of the cohort, vertebral fractures were also related to low bone mass. Fractures of the ankle, elbow, finger, and face, however, were not associated with bone mass at any measurement site; the overall hazard ratio for these fractures was 1.12 (CI, 0.96 to 1.30) at the distal radius. Conclusion: Most types of fractures have an increased incidence in elderly women with low bone mass.	UNIV MARYLAND, BALTIMORE, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	SEELEY, DG (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT EPIDEMIOL & BIOSTAT, 74 NEW MONTGOMERY, SUITE 600, SAN FRANCISCO, CA 94105 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035582] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR35582] Funding Source: Medline; NIA NIH HHS [AG05394, AG05407] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		COX DR, 1972, J R STAT SOC B, V34, P187; CUMMINGS SR, 1989, J GERONTOL, V44, pM107; CUMMINGS SR, 1985, EPIDEMIOL REV, V7, P178, DOI 10.1093/oxfordjournals.epirev.a036281; CUMMINGS SR, 1990, JAMA-J AM MED ASSOC, V263, P665, DOI 10.1001/jama.263.5.665; ESSES SI, 1989, J BONE MINER RES, V4, P715; GARDSELL P, 1989, CALCIFIED TISSUE INT, V44, P235, DOI 10.1007/BF02553757; HUI SL, 1989, ANN INTERN MED, V111, P355, DOI 10.7326/0003-4819-111-5-355; JENSEN GF, 1983, ACTA MED SCAND, V213, P61; LIPS P, 1987, INT S OSTEOPORSIS, P362; MELTON LJ, 1986, AM J EPIDEMIOL, V124, P254, DOI 10.1093/oxfordjournals.aje.a114383; MELTON LJ, 1982, CLIN ORTHOP RELAT R, V162, P144; MeltonIII L. J., 1988, OSTEOPOROSIS ETIOLOG, P133; OWEN RA, 1982, AM J PUBLIC HEALTH, V72, P605, DOI 10.2105/AJPH.72.6.605; Vega E, 1991, Osteoporos Int, V1, P81, DOI 10.1007/BF01880448; WASNICH RD, 1985, AM J OBSTET GYNECOL, V153, P745, DOI 10.1016/0002-9378(85)90338-2; 1984, JAMA-J AM MED ASSOC, V252, P799	16	495	506	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1991	115	11					837	842		10.7326/0003-4819-115-11-837	http://dx.doi.org/10.7326/0003-4819-115-11-837			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GR171	1952469				2022-12-24	WOS:A1991GR17100001
J	HEALD, A; FLEPP, M; CHAVE, JP; MALINVERNI, R; RUTTIMANN, S; GABRIEL, V; RENOLD, C; SUGAR, A; HIRSCHEL, B				HEALD, A; FLEPP, M; CHAVE, JP; MALINVERNI, R; RUTTIMANN, S; GABRIEL, V; RENOLD, C; SUGAR, A; HIRSCHEL, B			TREATMENT FOR CEREBRAL TOXOPLASMOSIS PROTECTS AGAINST PNEUMOCYSTIS-CARINII PNEUMONIA IN PATIENTS WITH AIDS	ANNALS OF INTERNAL MEDICINE			English	Article							PYRIMETHAMINE; CLINDAMYCIN	Objective: To determine whether long-term maintenance treatment for toxoplasmosis protects against Pneumocystis carinii Pneumonia in patients with the acquired immunodeficiency syndrome (AIDS). Design: Cohort study. Setting: Switzerland. Patients: A total of 453 patients with human immunodeficiency virus (HIV) entered the Swiss HIV Cohort Study. Ninety-nine patients with cerebral toxoplasmosis but no previous or simultaneous P. carinii pneumonia were compared with 240 patients with AIDS and other severe opportunistic infections (Centers for Disease Control [CDC] stage IVC1 infection other than toxoplasmosis and P. carinii pneumonia) as well as with 114 patients receiving inhaled pentamidine in a study of primary pneumocystis prophylaxis in patients infected with HIV. Measurements: Life-table analysis for P. carinii-free survival. Main Results: Six of 99 (6%) patients with toxoplasmosis, 50 of 240 (21%) patients with other severe opportunistic infections, and 8 of 114 (6%) patients receiving inhaled pentamidine developed P. carinii pneumonia. Life-table analysis showed that the incidence of pneumonia was substantially lower in patients with toxoplasmosis compared with that in patients with other severe opportunistic infections and was similar to the incidence in patients receiving pentamidine as prophylaxis. Analysis of the medication records from patients with toxoplasmosis showed that pyrimethamine and sulfonamides were administered 50% of the time; pyrimethamine and clindamycin, 25% of the time; and pyrimethamine alone, 9.9% of the time but that only one of the six patients with toxoplasmosis who developed P. carinii pneumonia received pyrimethamine and sulfonamides in the month before diagnosis. Conclusion: Patients with cerebral toxoplasmosis have a low risk for subsequently developing P. carinii pneumonia. This decreased risk is probably the result of chronic suppressive treatment with pyrimethamine and sulfonamides.	UNIV GENEVA, DIV MALAD INFECT, 24 RUE MICHELI CREST, CH-1211 GENEVA 4, SWITZERLAND; MED POLIKLIN BERN, BERN, SWITZERLAND; MED POLIKLIN, BASEL, SWITZERLAND; CHU VAUDOIS, CH-1011 LAUSANNE, SWITZERLAND	University of Geneva; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)								CAMPOS N, 1988, COMPUT METH PROG BIO, V27, P223, DOI 10.1016/0169-2607(88)90086-7; GIRARD PM, 1989, LANCET, V1, P1459; HIRSCHEL B, 1991, NEW ENGL J MED, V324, P1079, DOI 10.1056/NEJM199104183241602; HUGHES WT, 1978, J PEDIATR-US, V92, P285, DOI 10.1016/S0022-3476(78)80028-6; JACQUIER P, 1989, CONTRIBUTION ETUDE T; KIRBY HB, 1971, ANN INTERN MED, V75, P505, DOI 10.7326/0003-4819-75-4-505; KOVACS JA, 1989, J INFECT DIS, V160, P312, DOI 10.1093/infdis/160.2.312; QUEENER SF, 1988, ANTIMICROB AGENTS CH, V32, P807, DOI 10.1128/AAC.32.6.807; SANDE MA, 1990, MED MANAGEMENT AIDS, P241; STURCHLER D, 1987, SCHWEIZ MED WSCHR, V117, P161; [No title captured]	11	28	28	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1991	115	10					760	763		10.7326/0003-4819-115-10-760	http://dx.doi.org/10.7326/0003-4819-115-10-760			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GP800	1929023				2022-12-24	WOS:A1991GP80000002
J	KUHN, R; RAJEWSKY, K; MULLER, W				KUHN, R; RAJEWSKY, K; MULLER, W			GENERATION AND ANALYSIS OF INTERLEUKIN-4 DEFICIENT MICE	SCIENCE			English	Article							STIMULATORY FACTOR-I; MURINE B-CELLS; MONOCLONAL-ANTIBODIES; T-CELL; MAST-CELLS; STEM-CELLS; SWITCH; IGE; RECOMBINATION; INDUCTION	Interleukin-4 (IL-4) promotes the growth and differentiation of many hematopoietic cells in vitro; in particular, it directs the immunoglobulin (Ig) class switch to IgG1 and IgE. Mice homozygous for a mutation that inactivates the IL-4 gene were generated to test the requirement for IL-4 in vivo. In the mutant mice T and B cell development was normal, but the serum levels of IgGl and IgE were strongly reduced. The IgG1 dominance in a T cell-dependent immune response was lost, and IgE was not detectable upon nematode infection. Thus, some but not all of the in vitro properties of IL-4 are critical for the physiology of the immune system in vivo.			KUHN, R (corresponding author), UNIV COLOGNE, INST GENET, W-5000 COLOGNE 41, GERMANY.		Muller, Werner/B-9044-2008; Kühn, Ralf/U-1278-2017	Muller, Werner/0000-0002-1297-9725; Kühn, Ralf/0000-0003-1694-9803				BANIYASH M, 1984, EUR J IMMUNOL, V14, P799, DOI 10.1002/eji.1830140907; BHATTACHARYA A, 1981, J IMMUNOL, V127, P2488; BROWN MA, 1987, CELL, V50, P809, DOI 10.1016/0092-8674(87)90339-4; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CARDING SR, 1991, IMMUNOL TODAY, V12, P239, DOI 10.1016/0167-5699(91)90037-T; COFFMAN RL, 1986, J IMMUNOL, V136, P4538; DIALYNAS DP, 1983, J IMMUNOL, V131, P2445; ESSER C, 1989, EMBO J, V8, P483, DOI 10.1002/j.1460-2075.1989.tb03401.x; FINKELMAN FD, 1986, P NATL ACAD SCI USA, V83, P9675, DOI 10.1073/pnas.83.24.9675; FINKELMAN FD, 1991, INT IMMUNOL, V3, P599, DOI 10.1093/intimm/3.6.599; FINKELMAN FD, 1990, ANNU REV IMMUNOL, V8, P303, DOI 10.1146/annurev.iy.08.040190.001511; GRUTZMANN R, 1981, THESIS U COLOGNE; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; ILLGES H, 1990, MOL BIOL B CELL DEV, V3, P109; ISAKSON PC, 1982, J EXP MED, V155, P734, DOI 10.1084/jem.155.3.734; KENDALL C, 1984, J IMMUNOL METHODS, V56, P319; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; KUHN R, UNPUB; LEBRUN P, 1987, J IMMUNOL, V139, P1459; LEDBETTER JA, 1979, IMMUNOL REV, V47, P63, DOI 10.1111/j.1600-065X.1979.tb00289.x; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MOSMANN T, 1991, IMMUNOL TODAY, V12, P257, DOI 10.1016/0167-5699(91)90121-9; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; MULLER W, 1989, EUR J IMMUNOL, V19, P923, DOI 10.1002/eji.1830190520; OHARA J, 1985, NATURE, V315, P333, DOI 10.1038/315333a0; OI VT, 1979, MOL IMMUNOL, V16, P1005, DOI 10.1016/0161-5890(79)90034-8; OTSUKA T, 1987, NUCLEIC ACIDS RES, V15, P333, DOI 10.1093/nar/15.1.333; PAUL WE, 1987, ANNU REV IMMUNOL, V5, P429, DOI 10.1146/annurev.iy.05.040187.002241; RADBRUCH A, 1986, P NATL ACAD SCI USA, V83, P3954, DOI 10.1073/pnas.83.11.3954; RENNICK D, 1987, P NATL ACAD SCI USA, V84, P6889, DOI 10.1073/pnas.84.19.6889; RETH M, 1981, THESIS U COLOGNE; ROTHMAN P, 1988, J EXP MED, V168, P2385, DOI 10.1084/jem.168.6.2385; SAVELKOUL HFJ, 1991, J IMMUNOL, V146, P1801; SEEMANN G, 1981, THESIS U COLOGNE; SIDERAS P, 1985, EUR J IMMUNOL, V15, P593, DOI 10.1002/eji.1830150612; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; WILLIAMS RL, 1988, NATURE, V336, P684, DOI 10.1038/336684a0; YENOFSKY RL, 1990, P NATL ACAD SCI USA, V87, P3435, DOI 10.1073/pnas.87.9.3435; ZLOTNIK A, 1987, J IMMUNOL, V138, P4275	39	1146	1184	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 1	1991	254	5032					707	710		10.1126/science.1948049	http://dx.doi.org/10.1126/science.1948049			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GN474	1948049				2022-12-24	WOS:A1991GN47400040
J	ROTHMAN, DL; MAGNUSSON, I; KATZ, LD; SHULMAN, RG; SHULMAN, GI				ROTHMAN, DL; MAGNUSSON, I; KATZ, LD; SHULMAN, RG; SHULMAN, GI			QUANTITATION OF HEPATIC GLYCOGENOLYSIS AND GLUCONEOGENESIS IN FASTING HUMANS WITH C-13 NMR	SCIENCE			English	Article							CONSCIOUS DOG; FASTED HUMANS; GLUCOSE-LOAD; INVIVO; SPECTROSCOPY; METABOLISM; PATHWAYS; LIVER	The rate of net hepatic glycogenolysis was assessed in humans by serially measuring hepatic glycogen concentration at 3- to 12-hour intervals during a 68-hour fast with C-13 nuclear magnetic resonance spectroscopy. The net rate of gluconeogenesis was calculated by subtracting the rate of net hepatic glycogenolysis from the rate of glucose production in the whole body measured with tritiated glucose. Gluconeogenesis accounted for 64 +/- 5% (mean +/- standard error of the mean) of total glucose production during the first 22 hours of fasting. In the subsequent 14-hour and 18-hour periods of the fast, gluconeogenesis accounted for 82 +/- 5% and 96 +/- 1% of total glucose production, respectively. These data show that gluconeogenesis accounts for a substantial fraction of total glucose production even during the first 22 hours of a fast in humans.	YALE UNIV,SCH MED,DEPT INTERNAL MED,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT DIAGNOST RADIOL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06510	Yale University; Yale University; Yale University			Shulman, Gerald I./P-7176-2019	Shulman, Gerald I./0000-0003-1529-5668	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000125] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040936, P01DK034576] Funding Source: NIH RePORTER; NCRR NIH HHS [MO1-RR-00125-26] Funding Source: Medline; NIDDK NIH HHS [R01 DK040936, DK-40936, DK-34576] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABUMRAD NN, 1982, AM J PHYSIOL, V242, pE398, DOI 10.1152/ajpendo.1982.242.6.E398; ADKINS BA, 1987, J CLIN INVEST, V79, P557, DOI 10.1172/JCI112847; BJOKMAN O, 1990, DIABETES, V39, P747; BJORKMAN O, 1982, DIABETES, V31, P516, DOI 10.2337/diabetes.31.6.516; BOTTOMLEY PA, 1989, MAGNET RESON MED, V12, P348, DOI 10.1002/mrm.1910120307; CHERRINGTON AD, 1986, HORMONAL CONTROL GLU, P15; CONSOLI A, 1987, J CLIN INVEST, V80, P1301; GRUETTER R, 1991, MAGNET RESON MED, V20, P327, DOI 10.1002/mrm.1910200216; HAASE A, 1986, J MAGN RESON, V67, P258, DOI 10.1016/0022-2364(86)90433-6; HETENYI G, 1983, BIOCHEM MED METAB B, V29, P372, DOI 10.1016/0006-2944(83)90073-X; HETENYI G, 1986, HORMONAL CONTROL GLU, P79; HULL WE, 1987, 6TH ANN M SOC MAGN R, P488; JACKSON CL, 1989, BIOCHEMISTRY-US, V28, P5024, DOI 10.1021/bi00438a018; JUE T, 1989, P NATL ACAD SCI USA, V86, P4489, DOI 10.1073/pnas.86.12.4489; KATZ J, 1985, AM J PHYSIOL, V248, pR391, DOI 10.1152/ajpregu.1985.248.4.R391; KREBS HA, 1963, ADV ENZYME REGUL, V1, P385; KREBS HA, 1966, BIOCHEM J, V101, P242, DOI 10.1042/bj1010242; KREISBERG RA, 1972, J CLIN ENDOCR METAB, V34, P876, DOI 10.1210/jcem-34-5-876; MAGNUSSON I, 1987, J CLIN INVEST, V80, P1748, DOI 10.1172/JCI113267; MCGARRY JD, 1984, J CLIN INVEST, V74, P1901; NILSSON LH, 1973, SCAND J CLIN LAB INV, V32, P325, DOI 10.3109/00365517309084355; ORDIDGE RJ, 1986, J MAGN RESON, V66, P283, DOI 10.1016/0022-2364(86)90031-4; OWEN OE, 1969, J CLIN INVEST, V48, P574, DOI 10.1172/JCI106016; SCHUMANN WC, 1991, J BIOL CHEM, V266, P6985; SHALWITZ RA, 1987, MAGNET RESON MED, V5, P462, DOI 10.1002/mrm.1910050508; SHULMAN GI, 1990, AM J PHYSIOL, V259, pE335, DOI 10.1152/ajpendo.1990.259.3.E335; SHULMAN GI, 1988, J BIOL CHEM, V263, P5027; SILLERUD LO, 1983, BIOCHEMISTRY-US, V22, P1987; SILVER MS, 1984, NATURE, V310, P681, DOI 10.1038/310681a0; STRISOWER EH, 1952, J BIOL CHEM, V198, P115; TAYLOR R, UNPUB; WAHREN J, 1972, J CLIN INVEST, V51, P1870, DOI 10.1172/JCI106989; WEINMAN E, 1952, PHYSIOL REV, V37, P252; ZANG LH, 1990, BIOCHEMISTRY-US, V29, P6815, DOI 10.1021/bi00481a009	34	423	431	0	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 25	1991	254	5031					573	576		10.1126/science.1948033	http://dx.doi.org/10.1126/science.1948033			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GL799	1948033				2022-12-24	WOS:A1991GL79900050
J	HARTLEY, SB; CROSBIE, J; BRINK, R; KANTOR, AB; BASTEN, A; GOODNOW, CC				HARTLEY, SB; CROSBIE, J; BRINK, R; KANTOR, AB; BASTEN, A; GOODNOW, CC			ELIMINATION FROM PERIPHERAL LYMPHOID-TISSUES OF SELF-REACTIVE LYMPHOCYTES-B RECOGNIZING MEMBRANE-BOUND ANTIGENS	NATURE			English	Article							PROTEIN TYROSINE PHOSPHORYLATION; TRANSGENIC MICE; CLONAL DELETION; CELL TOLERANCE; T-CELLS; RECEPTOR; EXPRESSION; MATURE; STIMULATION; MECHANISMS	THE long-standing hypothesis 1,2 that tolerance to self antigens is mediated by either elimination 3-8 or functional inactivation (anergy; refs 9-11) of self-reactive lymphocytes is now accepted, but little is known about the factors responsible for initiating one process rather than the other. In the B-cell lineage, tolerant self-reactive cells persist in the peripheral lymphoid organs of transgenic mice expressing lysozyme and anti-lysozyme immunoglobulin genes 9, but are eliminated in similar transgenic mice expressing anti-major histocompatibility complex immunoglobulin genes 8. By modifying the structure of the lysozyme transgene and the isotype of the anti-lysozyme immunoglobulin genes, we demonstrate here that induction of anergy or deletion is not due to differences in antibody affinity or isotype, but to recognition of monomeric or oligomeric soluble antigen versus highly multivalent membrane-bound antigen. Our findings indicate that the degree of receptor crosslinking can have qualitatively distinct signalling consequences for lymphocyte development.	STANFORD UNIV, HOWARD HUGHES MED INST, STANFORD, CA 94305 USA; STANFORD UNIV, DEPT MICROBIOL & IMMUNOL, STANFORD, CA 94305 USA; STANFORD UNIV, BECKMAN CTR MOLEC & GENET MED, DEPT GENET, STANFORD, CA 94305 USA	Howard Hughes Medical Institute; Stanford University; Stanford University; Stanford University	HARTLEY, SB (corresponding author), UNIV SYDNEY, CENTENARY INST CANC MED & CELL BIOL, SYDNEY, NSW 2006, AUSTRALIA.		Brink, Robert/B-7910-2010; Goodnow, Christopher C/V-8108-2018	Brink, Robert/0000-0002-9586-3655; Goodnow, Christopher C/0000-0001-5296-6155				BRUNSWICK M, 1991, P NATL ACAD SCI USA, V88, P1311, DOI 10.1073/pnas.88.4.1311; Burnet F., 1959, CLONAL SELECTION THE, DOI DOI 10.5962/BHL.TITLE.8281; CAMBIER JC, 1987, ANNU REV IMMUNOL, V5, P175, DOI 10.1146/annurev.immunol.5.1.175; CAMPBELL MA, 1990, EMBO J, V9, P2125, DOI 10.1002/j.1460-2075.1990.tb07381.x; COFFMAN RL, 1983, IMMUNOL REV, V69, P5, DOI 10.1111/j.1600-065X.1983.tb00446.x; DEFRANCO AL, 1987, ANNU REV CELL BIOL, V3, P143; DINTZIS RZ, 1983, J IMMUNOL, V131, P2196; Forster I, 1989, Int Immunol, V1, P321, DOI 10.1093/intimm/1.4.321; GASCOIGNE NRJ, 1987, P NATL ACAD SCI USA, V84, P2936, DOI 10.1073/pnas.84.9.2936; GOLD MR, 1990, NATURE, V345, P810, DOI 10.1038/345810a0; GOODNOW CC, 1989, IMMUNE RESPONSE TO STRUCTURALLY DEFINED PROTEINS : THE LYSOZYME MODEL, P389; GOODNOW CC, 1989, NATURE, V342, P385, DOI 10.1038/342385a0; GOODNOW CC, 1988, NATURE, V334, P676, DOI 10.1038/334676a0; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; HARNETT MM, 1988, IMMUNOL TODAY, V9, P315, DOI 10.1016/0167-5699(88)91325-4; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KAPPLER JW, 1988, NATURE, V332, P35, DOI 10.1038/332035a0; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; KLAUS GGB, 1976, BRIT MED BULL, V32, P141, DOI 10.1093/oxfordjournals.bmb.a071346; MACDONALD HR, 1988, NATURE, V332, P40, DOI 10.1038/332040a0; MORELLO D, 1986, EMBO J, V5, P1877, DOI 10.1002/j.1460-2075.1986.tb04439.x; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; NEMAZEE D, 1989, P NATL ACAD SCI USA, V86, P8039, DOI 10.1073/pnas.86.20.8039; NEMAZEE DA, 1989, NATURE, V337, P562, DOI 10.1038/337562a0; NOSSAL GJV, 1983, ANNU REV IMMUNOL, V1, P33, DOI 10.1146/annurev.iy.01.040183.000341; PARKS DR, 1986, HDB EXPT IMMUNOLOGY, V1, P291; RAFF MC, 1975, J EXP MED, V142, P1052, DOI 10.1084/jem.142.5.1052; RAMMENSEE HG, 1989, NATURE, V339, P541, DOI 10.1038/339541a0; RAMSDELL F, 1989, SCIENCE, V246, P1038, DOI 10.1126/science.2511629; RETH M, 1991, IMMUNOL TODAY, V12, P196, DOI 10.1016/0167-5699(91)90053-V; SCHONRICH G, 1991, CELL, V65, P293, DOI 10.1016/0092-8674(91)90163-S; SHA WC, 1988, NATURE, V336, P73, DOI 10.1038/336073a0; SIDMAN CL, 1975, NATURE, V257, P149, DOI 10.1038/257149a0; SMITHGILL SJ, 1984, J IMMUNOL, V132, P963; STALL AM, 1988, P NATL ACAD SCI USA, V85, P3546, DOI 10.1073/pnas.85.10.3546; WEISS E, 1983, EMBO J, V2, P453, DOI 10.1002/j.1460-2075.1983.tb01444.x; Wyllie A H, 1980, Int Rev Cytol, V68, P251	37	589	592	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 24	1991	353	6346					765	769		10.1038/353765a0	http://dx.doi.org/10.1038/353765a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GL696	1944535				2022-12-24	WOS:A1991GL69600072
J	JACOBS, GH; NEITZ, J; DEEGAN, JF				JACOBS, GH; NEITZ, J; DEEGAN, JF			RETINAL RECEPTORS IN RODENTS MAXIMALLY SENSITIVE TO ULTRAVIOLET-LIGHT	NATURE			English	Article							SPECTRAL SENSITIVITY; PHOTOSENSITIVITY; SCIUREUS; MONKEYS; SAIMIRI; SYSTEM; RAT	HIGH sensitivity to near-ultraviolet light is a fundamental feature of vision in many invertebrates 1,2. Among vertebrates there are some amphibians, birds and fishes that are also sensitive to near-ultraviolet wavelengths 3-6. This sensitivity can be achieved through a class of cone photoreceptor containing an ultraviolet-sensitive pigment 7-9. Although these receptors were thought not to exist in the eyes of mammals, we now report that some rodents have a retinal mechanism that is maximally sensitive to ultraviolet light.			JACOBS, GH (corresponding author), UNIV CALIF SANTA BARBARA,DEPT PSYCHOL,SANTA BARBARA,CA 93106, USA.							BAYLOR DA, 1987, J PHYSIOL-LONDON, V390, P145, DOI 10.1113/jphysiol.1987.sp016691; BENSHOFF HM, 1987, BRAIN RES, V420, P397, DOI 10.1016/0006-8993(87)91264-9; DOUGLAS RH, 1986, J COMP PHYSIOL A, V159, P415, DOI 10.1007/BF00603986; EBREY TG, 1977, VISION RES, V17, P147, DOI 10.1016/0042-6989(77)90213-9; EMMERTON J, 1980, J COMP PHYSIOL, V141, P47, DOI 10.1007/BF00611877; GOLDSMITH TH, 1980, SCIENCE, V207, P786, DOI 10.1126/science.7352290; HAROSI FI, 1983, SCIENCE, V222, P1021, DOI 10.1126/science.6648514; HAWRYSHYN CW, 1985, VISION RES, V25, P11, DOI 10.1016/0042-6989(85)90075-6; JACOBS GH, 1989, EXPERIENTIA, V45, P317, DOI 10.1007/BF01957461; JACOBS GH, 1983, VISION RES, V23, P239, DOI 10.1016/0042-6989(83)90112-8; JACOBS GH, 1987, P NATL ACAD SCI USA, V84, P2545, DOI 10.1073/pnas.84.8.2545; Jacobs GH, 1981, COMP COLOR VISION; Menzel R, 1979, HDB SENSORY PHYSL, VVII/6A, P503; NEITZ J, 1986, J COMP PSYCHOL, V100, P21, DOI 10.1037/0735-7036.100.1.21; NEITZ J, 1984, J OPT SOC AM A, V1, P1175, DOI 10.1364/JOSAA.1.001175; PERRY RJ, 1991, J PHYSIOL-LONDON, V443, P561; RAPP LM, 1990, INVEST OPHTHAL VVIS, V31, P1187; STARK WS, 1982, PHOTOCHEM PHOTOBIOL, V36, P371, DOI 10.1111/j.1751-1097.1982.tb04389.x; VANNORREN D, 1990, VISION RES, V30, P1517, DOI 10.1016/0042-6989(90)90032-G; [No title captured]	20	318	324	4	31	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 17	1991	353	6345					655	656		10.1038/353655a0	http://dx.doi.org/10.1038/353655a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GK672	1922382				2022-12-24	WOS:A1991GK67200068
J	KELLY, A; POWIS, SH; GLYNNE, R; RADLEY, E; BECK, S; TROWSDALE, J				KELLY, A; POWIS, SH; GLYNNE, R; RADLEY, E; BECK, S; TROWSDALE, J			2ND PROTEASOME-RELATED GENE IN THE HUMAN MHC CLASS-II REGION	NATURE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; MULTICATALYTIC PROTEINASE; ANTIGEN PRESENTATION; LYMPHOCYTE-T; TRANSPORTERS; CELLS; SEQUENCES; PATHWAY; CLONING; CDNA	ANTIGEN processing involves the generation of peptides from cytosolic proteins and their transport into the endoplasmic reticulum where they associate with major histocompatibility complex (MHC) class I molecules 1-6. Two genes have been identified in the MHC class II region, RING4 and RING11 in humans, which are believed to encode the peptide transport proteins 7-12. Attention is now focused on how the transporters are provided with peptides. The proteasome, a large complex of subunits with multiple proteolytic activities, is a candidate for this function 13-16. Recently we reported a proteasome-related sequence, RING1O, mapping between the transporter genes 17. Here we describe a second human proteasome-like gene, RING12, immediately centromeric of the RING4 locus. Therefore RING12, 4, 10 and 11 form a tightly linked cluster of interferon-inducible genes within the MHC with an essential role in antigen processing.			KELLY, A (corresponding author), IMPERIAL CANC RES FUND,LINCOLNS INN FIELDS,LONDON WC2A 3PX,ENGLAND.							ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; BAIROCH A, 1990, PROSITE DICT PROTEIN; BANKIER AT, 1987, METHOD ENZYMOL, V155, P51; BLANCK G, 1988, J IMMUNOL, V141, P1734; DEVERSON EV, 1990, NATURE, V348, P738, DOI 10.1038/348738a0; Dupont B, 1989, IMMUNOBIOLOGY HLA, V1st; FRIEDMAN RL, 1985, NATURE, V314, P637, DOI 10.1038/314637a0; GLYNNE R, 1991, NATURE, V353, P357, DOI 10.1038/353357a0; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LAWLOR DA, 1990, ANNU REV IMMUNOL, V8, P23, DOI 10.1146/annurev.iy.08.040190.000323; LEE LW, 1990, BIOCHIM BIOPHYS ACTA, V1037, P178, DOI 10.1016/0167-4838(90)90165-C; LILLEY KS, 1990, FEBS LETT, V262, P327, DOI 10.1016/0014-5793(90)80220-D; Maniatis T., 1982, MOL CLONING; MONACO JJ, 1990, SCIENCE, V250, P1723, DOI 10.1126/science.2270487; MONACO JJ, 1982, P NATL ACAD SCI-BIOL, V79, P3001, DOI 10.1073/pnas.79.9.3001; MONACO JJ, 1986, HUM IMMUNOL, V15, P416, DOI 10.1016/0198-8859(86)90019-4; MONACO JJ, 1984, NATURE, V309, P797, DOI 10.1038/309797a0; MOORE MW, 1988, CELL, V54, P777, DOI 10.1016/S0092-8674(88)91043-4; MORRISON LA, 1986, J EXP MED, V163, P903, DOI 10.1084/jem.163.4.903; PARHAM P, 1990, NATURE, V348, P674, DOI 10.1038/348674a0; POWIS SH, UNPUB P NATN ACAD SC; RIVETT AJ, 1989, ARCH BIOCHEM BIOPHYS, V268, P1, DOI 10.1016/0003-9861(89)90558-4; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; STADEN R, 1990, COMPUT APPL BIOSCI, V6, P387; TAMURA T, 1991, BIOCHIM BIOPHYS ACTA, V1089, P95, DOI 10.1016/0167-4781(91)90090-9; TIWARI JL, 1985, HLA DISEASE ASS; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; TOWNSEND ARM, 1985, CELL, V42, P457, DOI 10.1016/0092-8674(85)90103-5; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; YEWDELL JW, 1990, CELL, V62, P203, DOI 10.1016/0092-8674(90)90356-J	33	344	353	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 17	1991	353	6345					667	668		10.1038/353667a0	http://dx.doi.org/10.1038/353667a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GK672	1922385				2022-12-24	WOS:A1991GK67200073
J	RAZA, MW; BLACKWELL, CC; MOLYNEAUX, P; JAMES, VS; OGILVIE, MM; INGLIS, JM; WEIR, DM				RAZA, MW; BLACKWELL, CC; MOLYNEAUX, P; JAMES, VS; OGILVIE, MM; INGLIS, JM; WEIR, DM			ASSOCIATION BETWEEN SECRETOR STATUS AND RESPIRATORY VIRAL ILLNESS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ABO BLOOD-GROUP; NEISSERIA-MENINGITIDIS; DIABETES-MELLITUS; GROUP ANTIGENS; ORAL CARRIAGE; INFECTION; SUSCEPTIBILITY; ETIOLOGY; WOMEN	Objective - To determine whether non-secretion of blood group antigens is associated with respiratory virus diseases. Design - Study of secretor status in patients with respiratory virus diseases determined by an enzyme linked immunosorbent assay (ELISA) developed to identify Lewis (Le) blood group antigen phenotypes (Le(a) non-secretor; Le(b) secretor). Subjects - Patients aged 1 month to 90 years in hospital with respiratory virus diseases (584 nasal specimens). Main outcome measures - Criteria for validation of ELISA (congruence between results on ELISA testing of 1155 saliva samples from a previous study and previously established results on haemagglutination inhibition (HAI) testing, proportions of Le(a), Le(b), and Le- phenotypes in 872 samples of nasal washings from a previous study compared with the normal population). Secretor status of patients determined by ELISA and viruses isolated. Results - Agreement between HAI and ELISA for 1155 saliva samples was 97%. Lewis antigens were detected by ELISA in 854 (97.9%) of nasal washings (Le(a) 233 (26.7%), Le(b) 621 (71.2%), and Le- 18 (2.1%)) in proportions predicted for a northern European population. Secretors were significantly overrepresented among patients from whom influenza viruses A and B (55/64, 86%; p < 0.025), rhinoviruses (63/72, 88%; p < 0.01), respiratory syncytial virus (97/109, 89%; p < 0.0005), and echo-viruses (44/44, p < 0.0005) had been isolated compared with the distribution of secretors in the local population. Conclusion - Secretion of blood group antigens is associated with respiratory virus diseases.	UNIV EDINBURGH, SCH MED, DEPT MED MICROBIOL, EDINBURGH EH8 9AG, MIDLOTHIAN, SCOTLAND; CITY HOSP EDINBURGH, EDINBURGH EH10 5SB, MIDLOTHIAN, SCOTLAND	University of Edinburgh								ANDERSEN J, 1960, DIABETES, V9, P20, DOI 10.2337/diab.9.1.20; BLACKWELL CC, 1990, EPIDEMIOL INFECT, V104, P203, DOI 10.1017/S0950268800059367; BLACKWELL CC, 1987, BRIT MED J, V295, P1024, DOI 10.1136/bmj.295.6605.1024; BLACKWELL CC, 1989, EPIDEMIOL INFECT, V102, P1, DOI 10.1017/S0950268800029629; BLACKWELL CC, 1986, LANCET, V2, P284; BLACKWELL CC, 1987, J CLIN LAB IMMUNOL, V22, P133; BLACKWELL CC, 1986, LANCET, V2, P687; BLACKWELL CC, 1989, DIABETES RES CLIN EX, V12, P101; BLACKWELL CC, 1989, P ROYAL COLLEGE PHYS, V19, P129; BURFORDMASON AP, 1988, J MED VET MYCOL, V26, P49; CHAUDHURI A, 1978, T ROY SOC TROP MED H, V72, P664, DOI 10.1016/0035-9203(78)90031-7; COLLIER A, 1988, BRIT MED J, V296, P1162, DOI 10.1136/bmj.296.6630.1162; HAVERKORN MJ, 1969, AM J HUM GENET, V21, P360; KINANE DF, 1982, BRIT MED J, V285, P7, DOI 10.1136/bmj.285.6334.7; MACKENZIE JS, 1978, J HYG-CAMBRIDGE, V80, P21, DOI 10.1017/S0022172400053365; MAY S J, 1989, FEMS (Federation of European Microbiological Societies) Microbiology Immunology, V47, P407, DOI 10.1016/0378-1097(89)90266-8; MCDONALD JC, 1962, BRIT MED J, P89, DOI 10.1136/bmj.2.5297.89; MOLLISON PL, 1979, BLOOD TRANSFUSION CL, P414; Mourant AE., 1976, DISTRIBUTION HUMAN B; POTTER CW, 1969, J HYG-CAMB, V67, P67, DOI 10.1017/S0022172400041437; RAHAT A, 1990, VOX SANG, V59, P101, DOI 10.1111/j.1423-0410.1990.tb05019.x; SHINEBAUM R, 1987, BRIT MED J, V294, P208, DOI 10.1136/bmj.294.6566.208; THOM SM, 1989, FEMS MICROBIOL IMMUN, V7, P401	23	63	65	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 5	1991	303	6806					815	818		10.1136/bmj.303.6806.815	http://dx.doi.org/10.1136/bmj.303.6806.815			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GH946	1932971	Green Published, Bronze			2022-12-24	WOS:A1991GH94600021
J	BONHOEFFER, T; GRINVALD, A				BONHOEFFER, T; GRINVALD, A			ISO-ORIENTATION DOMAINS IN CAT VISUAL-CORTEX ARE ARRANGED IN PINWHEEL-LIKE PATTERNS	NATURE			English	Article							MONKEY STRIATE CORTEX; FUNCTIONAL ARCHITECTURE; INTRINSIC SIGNALS; ORGANIZATION; COLUMNS; GEOMETRY	THE mammalian cortex is organized in a columnar fashion: neurons lying below each other from the pia to the white matter usually share many functional properties. Across the cortical surface, cells with similar response properties are also clustered together, forming elongated bands or patches. Some response properties, such as orientation preference in the visual cortex, change gradually across the cortical surface forming 'orientation maps'. To determine the precise layout of iso-orientation domains, knowledge of responses not only to one but to many stimulus orientations is essential. Therefore, the exact depiction of orientation maps has been hampered by technical difficulties and remained controversial for almost thirty years. Here we use in vivo optical imaging based on intrinsic signals to gather information on the responses of a piece of cortex to gratings in many different orientations. This complete set of responses then provides detailed information on the structure of the orientation map in a large patch of cortex from area 18 of the cat. We find that cortical regions that respond best to one orientation form highly ordered patches rather than elongated bands. These iso-orientation patches are organized around 'orientation centres', producing pinwheel-like patterns in which the orientation preference of cells is changing continuously across the cortex. We have also analysed our data for fast changes in orientation preference and find that these 'fractures' are limited to the orientation centres. The pinwheels and orientation centres are such a prominent organizational feature that it should be important to understand their development as well as their function in the processing of visual information.	ROCKEFELLER UNIV,NEUROBIOL LAB,NEW YORK,NY 10021; IBM CORP,DIV RES,YORKTOWN HTS,NY 10598; WEIZMANN INST SCI,IL-76100 REHOVOT,ISRAEL	Rockefeller University; International Business Machines (IBM); Weizmann Institute of Science			Bonhoeffer, Tobias/B-9481-2009	Bonhoeffer, Tobias/0000-0001-7897-6634				Batschelet E, 1981, CIRCULAR STAT BIOL; BLASDEL GG, 1986, NATURE, V321, P579, DOI 10.1038/321579a0; BRAITENBERG V, 1979, BIOL CYBERN, V33, P179, DOI 10.1007/BF00337296; DURBIN R, 1990, NATURE, V343, P644, DOI 10.1038/343644a0; FROSTIG RD, 1990, P NATL ACAD SCI USA, V87, P6082, DOI 10.1073/pnas.87.16.6082; GOTZ KG, 1987, BIOL CYBERN, V56, P107, DOI 10.1007/BF00317985; GRINVALD A, 1986, NATURE, V324, P361, DOI 10.1038/324361a0; HUBEL DH, 1978, J COMP NEUROL, V177, P361, DOI 10.1002/cne.901770302; HUBEL DH, 1974, J COMP NEUROL, V158, P267, DOI 10.1002/cne.901580304; HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106, DOI 10.1113/jphysiol.1962.sp006837; LINSKER R, 1986, P NATL ACAD SCI USA, V83, P8779, DOI 10.1073/pnas.83.22.8779; LOWEL S, 1987, J COMP NEUROL, V255, P401, DOI 10.1002/cne.902550307; OBERMAYER K, 1990, P NATL ACAD SCI USA, V90, P8245; RATZLAFF EH, 1991, J NEUROSCI METH, V36, P127, DOI 10.1016/0165-0270(91)90038-2; SWINDALE NV, 1982, PROC R SOC SER B-BIO, V215, P211, DOI 10.1098/rspb.1982.0038; SWINDALE NV, 1987, J NEUROSCI, V7, P1414; TSO DY, 1990, SCIENCE, V249, P417, DOI 10.1126/science.2165630; von Seelen W, 1970, Kybernetik, V7, P89	18	630	638	1	24	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 3	1991	353	6343					429	431		10.1038/353429a0	http://dx.doi.org/10.1038/353429a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GH606	1896085				2022-12-24	WOS:A1991GH60600056
J	RUBIN, EM; KRAUSS, RM; SPANGLER, EA; VERSTUYFT, JG; CLIFT, SM				RUBIN, EM; KRAUSS, RM; SPANGLER, EA; VERSTUYFT, JG; CLIFT, SM			INHIBITION OF EARLY ATHEROGENESIS IN TRANSGENIC MICE BY HUMAN APOLIPOPROTEIN-A-I	NATURE			English	Article							HIGH-DENSITY-LIPOPROTEIN; DETERMINING ATHEROSCLEROSIS SUSCEPTIBILITY; CHOLESTEROL; GENE; PATHOGENESIS; DISEASE; MOUSE	EPIDEMIOLOGICAL surveys have identified a strong inverse relationship between the amount in the plasma of high density lipoproteins (HDL), apolipoprotein AI (ApoA-I), the major protein component of HDL, and the risk for atherosclerosis in humans 1,2. It is not known if this relationship arises from a direct antiatherogenic effect of these plasma components or if it is the result of other factors also associated with increases in ApoA-I and HDL levels. Because some strains of mice are susceptible to diet-induced formation of preatherosclerotic fatty streak lesions, and because of available techniques for the genetic manipulation of this organism, the murine system offers a unique setting in which to investigate the process of early atherogenesis. To test the hypothesis that induction of a high plasma concentration of ApoA-I and HDL would inhibit this process, we studied the effects of atherogenic diets on transgenic mice expressing high amounts of human ApoA-I. We report that transgenic mice with high plasma ApoA-I and HDL levels were significantly protected from the development of fatty streak lesions.	UNIV CALIF BERKELEY LAWRENCE BERKELEY LAB,DIV CELL & MOLEC BIOL,BERKELEY,CA 94720	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	RUBIN, EM (corresponding author), UNIV CALIF BERKELEY LAWRENCE BERKELEY LAB,DIV RES MED & RADIAT BIOPHYS,BERKELEY,CA 94720, USA.							BRINTON EA, 1991, J CLIN INVEST, V87, P536, DOI 10.1172/JCI115028; CHEUNG MC, 1991, J LIPID RES, V32, P383; GORDON DJ, 1989, NEW ENGL J MED, V321, P1311; GORDON DJ, 1989, CIRCULATION, V79, P8, DOI 10.1161/01.CIR.79.1.8; ISHIDA B, 1989, GENETIC FACTORS ATHE, P198; IZZO C, 1981, CLIN CHEM, V27, P371; LEBOEUF RC, 1990, J LIPID RES, V31, P9; MCGILL HC, 1984, ARTERIOSCLEROSIS, V4, P443, DOI 10.1161/01.ATV.4.5.443; MILLER NE, 1978, LIPIDS, V13, P914, DOI 10.1007/BF02533850; MILLER NE, 1987, AM HEART J, V113, P589, DOI 10.1016/0002-8703(87)90638-7; NICHOLS AV, 1986, METHOD ENZYMOL, V128, P417; NISHINA PM, 1990, J LIPID RES, V31, P859; PAIGEN B, 1989, GENETICS, V122, P163; PAIGEN B, 1987, P NATL ACAD SCI USA, V84, P3763, DOI 10.1073/pnas.84.11.3763; PAIGEN B, 1990, ARTERIOSCLEROSIS, V10, P316, DOI 10.1161/01.ATV.10.2.316; PAIGEN B, 1987, ATHEROSCLEROSIS, V68, P231, DOI 10.1016/0021-9150(87)90202-4; PATSCH J, 1983, P NATL ACAD SCI USA, V80, P1435; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; RUBIN EM, 1991, P NATL ACAD SCI USA, V88, P434, DOI 10.1073/pnas.88.2.434; RUDEL LL, 1973, J LIPID RES, V14, P364; SORCITHOMAS M, 1988, J BIOL CHEM, V263, P5183; STEWARTPHILLIPS JL, 1989, CLIN INVEST MED, V12, P121; WALSH A, 1989, J BIOL CHEM, V264, P6488	23	862	922	0	27	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 19	1991	353	6341					265	267		10.1038/353265a0	http://dx.doi.org/10.1038/353265a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GF674	1910153				2022-12-24	WOS:A1991GF67400062
J	GULLIFORD, MC; PETRUCKEVITCH, A; BURNEY, PGJ				GULLIFORD, MC; PETRUCKEVITCH, A; BURNEY, PGJ			SURVIVAL WITH BLADDER-CANCER, EVALUATION OF DELAY IN TREATMENT, TYPE OF SURGEON, AND MODALITY OF TREATMENT	BRITISH MEDICAL JOURNAL			English	Article							HOSPITAL DEATH RATES; GEOGRAPHICAL VARIATION; MORTALITY; QUALITY; RADIOTHERAPY; CYSTECTOMY; CARCINOMA; SEVERITY; ILLNESS; CARE	Objective-To determine whether length of delay before treatment; specialty and grade of the surgeon; and use made of surgery, radiotherapy, and chemotherapy influenced the survival of patients with cancer of the bladder, after adjusting for case severity. Design-Retrospective cohort study. Setting-South East and South West Thames health regions. Patients-609 men aged under 75 resident in the South Thames regions who had been registered as new cases of bladder cancer in 1982, 35 of whom were excluded, leaving 574 eligible patients. Analysis was based on 75% retrieval rate for case notes. Main outcome measures-Duration of survival from date of diagnosis of the bladder tumour. Results-10 prognostic variables were used to adjust for case severity. The median delay from referral to first treatment was 48 (interquartile range 27-84) days. Treatment after a short delay was associated with shorter survival because of the early treatment of more severe cases. Consultants treated 68% of patients, trainee surgeons treated less severe cases. Initial treatment was by a urologist in 67% of cases, but the specialty of the surgeon was not associated with prognosis. The associations of radiotherapy, cystectomy, and systemic chemotherapy with survival were interpreted in terms of selection bias as well as therapeutic effect. Conclusions-Case severity was the most important influence on survival and influenced length of delay before treatment, grade and specialty of the surgeon, and main treatment allocation. After adjusting for case severity variations in these processes of care were not strongly associated with variations in survival.			GULLIFORD, MC (corresponding author), UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,DEPT PUBL HLTH MED,ST THOMAS CAMPUS,LONDON SE1 7EH,ENGLAND.		Gulliford, Martin C/I-8606-2018	Gulliford, Martin C/0000-0003-1898-9075; Burney, Peter/0000-0001-8635-5678	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABEL PD, 1988, BRIT J UROL, V62, P103, DOI 10.1111/j.1464-410X.1988.tb04286.x; ASO Y, 1986, PROG CLIN BIOL RES, V162, P257; BISHOP MC, 1990, BRIT J UROL, V65, P433, DOI 10.1111/j.1464-410X.1990.tb14781.x; Buck N, 1987, REPORT CONFIDENTIAL; CHARLTON JRH, 1983, LANCET, V1, P691; DELAMOTHE T, 1990, BRIT MED J, V301, P1011; DIXON WJ, 1990, BMDP STATISTICAL SOF, V2, P759; DUBOIS RW, 1987, AM J PUBLIC HEALTH, V77, P1162, DOI 10.2105/AJPH.77.9.1162; DUBOIS RW, 1987, NEW ENGL J MED, V317, P1674, DOI 10.1056/NEJM198712243172626; GREEN J, 1990, JAMA-J AM MED ASSOC, V263, P241, DOI 10.1001/jama.263.2.241; GULLIFORD MC, 1991, BRIT MED J, V302, P1128, DOI 10.1136/bmj.302.6785.1128; HOLLAND WW, 1988, EUROPEAN COMMUNITY A; HOPESTONE HF, 1984, UROLOGY, V24, P315, DOI 10.1016/0090-4295(84)90199-7; Hopkins A., 1990, MEASURING QUALITY ME; KARJALAINEN S, 1990, J EPIDEMIOL COMMUN H, V44, P210, DOI 10.1136/jech.44.3.210; MAMEGHAN H, 1989, BRIT J UROL, V63, P251, DOI 10.1111/j.1464-410X.1989.tb05185.x; MOMMSEN S, 1983, SCAND J UROL NEPHROL, V17, P163, DOI 10.3109/00365598309180162; MOULD RF, 1986, LANCET, V1, P1385; PARK RE, 1990, JAMA-J AM MED ASSOC, V264, P484; RAGHAVAN D, 1990, NEW ENGL J MED, V322, P1129, DOI 10.1056/NEJM199004193221607; RICHARDS B, 1986, PROG CLIN BIOL RES, V162, P271; SHEARER RJ, 1988, BRIT J UROL, V62, P558, DOI 10.1111/j.1464-410X.1988.tb04426.x; Silman A J, 1981, Community Med, V3, P291, DOI 10.1007/BF02549184; SOLOWAY MS, 1987, CANCER, V60, P502, DOI 10.1002/1097-0142(19870801)60:3+<502::AID-CNCR2820601512>3.0.CO;2-W; SPIESSL B, 1989, UICC TNM ATLAS, P245; TONKIN K, 1988, MANAGEMENT BLADDER C, P228; TRUNKEY D, 1989, BRIT MED J, V299, P31, DOI 10.1136/bmj.299.6690.31; WALLACE DM, 1965, LANCET, V2, P332; 1990, REV NATIONAL CANCER, P9; 1980, BMJ, V280, P590; 1982, CANCER STATISTIC MB1	31	54	54	1	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 24	1991	303	6800					437	440		10.1136/bmj.303.6800.437	http://dx.doi.org/10.1136/bmj.303.6800.437			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GC465	1912834	Green Published, Bronze			2022-12-24	WOS:A1991GC46500014
J	PIERETTI, M; ZHANG, FP; FU, YH; WARREN, ST; OOSTRA, BA; CASKEY, CT; NELSON, DL				PIERETTI, M; ZHANG, FP; FU, YH; WARREN, ST; OOSTRA, BA; CASKEY, CT; NELSON, DL			ABSENCE OF EXPRESSION OF THE FMR-1 GENE IN FRAGILE-X SYNDROME	CELL			English	Article								We previously reported the isolation of a gene (FMR-1) expressed in brain at the fragile X locus. One exon of this gene lies within an EcoRI fragment that exhibits length variation in fragile X patients. This exon also contains the CGG repeat within the CpG island hypermethylated in fragile X patients. To study the involvement of the FMR-1 gene in the fragile X syndrome, its expression was studied in lymphoblastoid cell lines and leukocytes derived from patients and normal controls. FMR-1 mRNA was absent in the majority of male fragile X patients, suggesting a close involvement of this gene in development of the syndrome. Normal individuals and carriers all show expression. The methylation status of the BssHII site at the CpG island was also studied by Southern blot analysis of DNA from patients, carriers, and controls. The minority of fragile X affected males that show expression of FMR-1 demonstrated an associated incomplete methylation of the BssHII site.	ERASMUS UNIV,DEPT CELL BIOL,3000 DR ROTTERDAM,NETHERLANDS; EMORY UNIV,SCH MED,DEPT BIOCHEM,ATLANTA,GA 30322; EMORY UNIV,SCH MED,DEPT PEDIAT,ATLANTA,GA 30322	Erasmus University Rotterdam; Emory University; Emory University	PIERETTI, M (corresponding author), BAYLOR COLL MED,HOWARD HUGHES MED INST,HUMAN GENOME CTR,INST MOLEC GENET,HOUSTON,TX 77030, USA.		Warren, Stephen T/A-2498-2012		NICHD NIH HHS [HD20521] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD020521, R01HD020521] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BELL MV, 1991, CELL, V64, P861, DOI 10.1016/0092-8674(91)90514-Y; DIETRICH A, 1991, NUCLEIC ACIDS RES, V19, P2567, DOI 10.1093/nar/19.10.2567; GIBBS RA, 1989, P NATL ACAD SCI USA, V86, P1919, DOI 10.1073/pnas.86.6.1919; HEITZ D, 1991, SCIENCE, V251, P1236, DOI 10.1126/science.2006411; HIRST MC, 1991, GENOMICS, V10, P243, DOI 10.1016/0888-7543(91)90506-A; KREMER EJ, 1991, SCIENCE, V252, P1711, DOI 10.1126/science.1675488; McKusick VA, 1990, MENDELIAN INHERITANC; NELSON DL, 1991, P NATL ACAD SCI USA, V88, P6157, DOI 10.1073/pnas.88.14.6157; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; OOSTRA BA, 1990, GENOMICS, V6, P129, DOI 10.1016/0888-7543(90)90457-6; ROUSSEAU F, 1991, AM J HUM GENET, V48, P108; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; VINCENT A, 1991, NATURE, V349, P624, DOI 10.1038/349624a0; WARREN ST, 1990, P NATL ACAD SCI USA, V87, P3856, DOI 10.1073/pnas.87.10.3856; YU S, 1991, SCIENCE, V252, P1179, DOI 10.1126/science.252.5009.1179	15	1207	1226	1	58	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 23	1991	66	4					817	822		10.1016/0092-8674(91)90125-I	http://dx.doi.org/10.1016/0092-8674(91)90125-I			6	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GC745	1878973				2022-12-24	WOS:A1991GC74500020
J	NIGHTINGALE, SL				NIGHTINGALE, SL			INTERNATIONAL-CONFERENCE ON HARMONIZING TECHNICAL REQUIREMENTS FOR DRUG APPROVALS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 12	1991	265	22					2934	2934						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FP635	1903461				2022-12-24	WOS:A1991FP63500005
J	LUBS, MLE; BAUER, MS; FORMAS, ME; DJOKIC, B				LUBS, MLE; BAUER, MS; FORMAS, ME; DJOKIC, B			LISCH NODULES IN NEUROFIBROMATOSIS TYPE-1	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							VONRECKLINGHAUSEN NEUROFIBROMATOSIS; IRIS HAMARTOMATA		MIAMI CHILDRENS HOSP, MIAMI, FL 33155 USA; UNIV MIAMI, SCH MED, DEPT PEDIAT, DIV GENET, MIAMI, FL 33152 USA	University of Miami								[Anonymous], 1988, ARCH NEUROL-CHICAGO, V45, P575, DOI 10.1097/00005537-199606000-00007; BARKER D, 1987, SCIENCE, V236, P1100, DOI 10.1126/science.3107130; CAWTHON, 1990, CELL, V62, P609; CAWTHON RM, 1990, CELL, V62, P193, DOI 10.1016/0092-8674(90)90253-B; CHARLES SJ, 1989, ARCH OPHTHALMOL-CHIC, V107, P1571, DOI 10.1001/archopht.1989.01070020649012; CROWE FW, 1956, CLIN PATHOLOGICAL GE, V146, P153; FLUELER U, 1986, NEUROPEDIATRICS, V17, P183, DOI 10.1055/s-2008-1052525; GOODMAN LA, 1954, J AM STAT ASSOC, V49, P732, DOI 10.2307/2281536; HUSON SM, 1988, BRAIN, V111, P1355, DOI 10.1093/brain/111.6.1355; Kendall M. G., 1955, RANK CORRELATION MET; LEWIS RA, 1984, OPHTHALMOLOGY, V91, P929; LEWIS RA, 1981, OPHTHALMOLOGY, V88, P348; Lisch K, 1937, Z AUGENHEILKD, V93, P137; LITTLER M, 1990, J MED GENET, V27, P307, DOI 10.1136/jmg.27.5.307; MURPHY E A, 1973, Birth Defects Original Article Series, V9, P19; Riccardi V, 1986, NEUROFIBROMATOSIS PH, P29; Riccardi V M, 1981, Adv Neurol, V29, P1; Siegel S., 2009, NONPARAMETRIC STAT B, V2nd; VISKOCHIL D, 1990, CELL, V62, P187, DOI 10.1016/0092-8674(90)90252-A; WAARDENBURG PJ, 1918, NED TIJDSCHR GENEES, V2, P1453; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; WARD K, 1990, AM J HUM GENET, V46, P943; ZEHAVI C, 1986, CLIN GENET, V29, P51	23	96	100	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 2	1991	324	18					1264	1266		10.1056/NEJM199105023241807	http://dx.doi.org/10.1056/NEJM199105023241807			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FJ823	1901624				2022-12-24	WOS:A1991FJ82300007
J	ERICKSON, JW; CLINE, TW				ERICKSON, JW; CLINE, TW			MOLECULAR NATURE OF THE DROSOPHILA SEX DETERMINATION SIGNAL AND ITS LINK TO NEUROGENESIS	SCIENCE			English	Article							SCUTE GENE-COMPLEX; DOSAGE COMPENSATION; N-MYC; MELANOGASTER; ACHAETE; EXPRESSION; LETHAL; PROTEINS; ELEMENT; DAUGHTERLESS	In 1921 it was discovered that the sexual fate of Drosophila is determined by the ratio of X chromosomes to sets of autosomes. Only recently has it been found that the X chromosome to autosome (X:A) ratio is communicated in part by the dose of sisterless-b (sis-b), an X-linked genetic element located within the achaete-scute complex of genes involved in neurogenesis. In this report, the molecular nature of the primary sex determination signal and its relation to these proneural genes was determined by analysis of sis-b+ germline transformants. The sis-b+ function is conferred by protein T4, a member of the helix-loop-helix family of transcription factors. Although T4 is shared by sis-b and scute-alpha, the regulatory regions of sis-b, which control T4 expression in sex determination, are both separable from and simpler than those of scute-alpha, which control T4 expression in neurogenesis. Dose-sensitive cooperative interactions in the assembly or binding of sis-dependent transcription factors may directly determine the activity of the female-specific promoter of Sex-lethal, the master regulator of sexual development. In this model there is no need to invoke the existence of analogous autosomal negative regulators of Sex-lethal.			ERICKSON, JW (corresponding author), UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,DIV GENET,BERKELEY,CA 94720, USA.				NIGMS NIH HHS [GM 23468] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023468] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADHYA S, 1989, ANNU REV GENET, V23, P227, DOI 10.1146/annurev.genet.23.1.227; ALONSO LG, 1986, ROUX ARCH DEV BIOL, V195, P259, DOI 10.1007/BF02438959; ALONSO MC, 1988, EMBO J, V7, P2585, DOI 10.1002/j.1460-2075.1988.tb03108.x; BAKER BS, 1989, NATURE, V340, P521, DOI 10.1038/340521a0; BELL LR, 1988, CELL, V55, P1037, DOI 10.1016/0092-8674(88)90248-6; BELL LR, IN PRESS CELL; BENEZRA R, 1990, CELL, V61, P45; Bridges CB, 1925, AM NAT, V59, P127, DOI 10.1086/280023; Bridges CB, 1921, SCIENCE, V54, P252, DOI 10.1126/science.54.1394.252; CABRERA CV, 1987, CELL, V50, P425, DOI 10.1016/0092-8674(87)90496-X; CAMPUZANO S, 1985, CELL, V40, P327, DOI 10.1016/0092-8674(85)90147-3; CLINE TL, UNPUB; CLINE TW, 1988, GENETICS, V119, P829; CLINE TW, 1983, DEV BIOL, V95, P260, DOI 10.1016/0012-1606(83)90027-1; DAMBLYCHAUDIERE C, 1987, GENE DEV, V1, P1297; ELLIS HM, 1990, CELL, V61, P27, DOI 10.1016/0092-8674(90)90212-W; ENGELS WR, 1987, GENETICS, V117, P745; GARCIABELLIDO A, 1979, GENETICS, V91, P491; GARELL J, 1990, CELL, V61, P39; HODGKIN J, 1990, NATURE, V344, P721, DOI 10.1038/344721a0; KEYES L, UNPUB; LENARDO M, 1989, EMBO J, V8, P3351, DOI 10.1002/j.1460-2075.1989.tb08497.x; LINDSLEY DL, 1985, DROSOPHILA INFO SER, V62; LINDSLEY DL, 1990, DROSOPHILA INFO SER, V68; LINDSLEY DL, 1987, DROSOPHILA INFO SER, V65; LINDSLEY DL, 1986, DROSOPHILA INFO SER, V64; LUCCHESI JC, 1987, ADV GENET, V24, P371, DOI 10.1016/S0065-2660(08)60013-9; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; PARKHURST SM, 1990, CELL, V63, P1179, DOI 10.1016/0092-8674(90)90414-A; Pirrotta V, 1988, VECTORS SURVEY MOL C, P437; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; ROMANI S, 1987, EMBO J, V6, P2085, DOI 10.1002/j.1460-2075.1987.tb02474.x; ROMANI S, 1989, GENE DEV, V3, P997, DOI 10.1101/gad.3.7.997; RUIZGOMEZ M, 1987, GENE DEV, V1, P1238, DOI 10.1101/gad.1.10.1238; RUSHLOW CA, 1989, EMBO J, V8, P3095, DOI 10.1002/j.1460-2075.1989.tb08461.x; SALZ HK, 1989, GENE DEV, V3, P708, DOI 10.1101/gad.3.5.708; SALZ HK, 1987, GENETICS, V117, P221; SHAPIRA SK, 1983, GENE, V25, P71, DOI 10.1016/0378-1119(83)90169-5; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; STEINMANNZWICKY H, 1990, ADV GENET, V27, P189; TORRES M, 1989, EMBO J, V8, P3079, DOI 10.1002/j.1460-2075.1989.tb08459.x; VILLARES R, 1987, CELL, V50, P415, DOI 10.1016/0092-8674(87)90495-8; Villeneuve A.M., 1990, Advances in Genetics, V27, P117	44	75	75	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 1	1991	251	4997					1071	1074		10.1126/science.1900130	http://dx.doi.org/10.1126/science.1900130			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EZ665	1900130				2022-12-24	WOS:A1991EZ66500050
J	IMBERTI, L; SOTTINI, A; BETTINARDI, A; PUOTI, M; PRIMI, D				IMBERTI, L; SOTTINI, A; BETTINARDI, A; PUOTI, M; PRIMI, D			SELECTIVE DEPLETION IN HIV-INFECTION OF T-CELLS THAT BEAR SPECIFIC T-CELL RECEPTOR-V-BETA SEQUENCES	SCIENCE			English	Article							STAPHYLOCOCCAL ENTEROTOXINS; SUPERANTIGENS; INDUCTION; MURINE; CHAIN	The mechanism of T cell depletion during infection with the human immunodeficiency virus (HIV) is unclear. Examination of the repertoire of T cell receptor V (variable) regions m persons infected with HIV revealed the absence of a common set of V-beta-regions, whereas V-alpha usage was normal. The lack of these V-beta-segments did not appear to correlate with opportunistic infections. The selective elimination of T cells that express a defined set of V-beta-sequences may indicate the presence of an HIV-encoded superantigen, similar to those encoded by the long terminal repeat of the mouse mammary tumor virus.	OSPED CIVILE,DIV MALATTIE INFETT 1,BRESCIA,ITALY	Hospital Spedali Civili Brescia	IMBERTI, L (corresponding author), UNIV BRESCIA,SCH MED,INST CHEM,CNR,CONSORZIO BIOTECNOL,P SPEDALI CIVILI 1,I-25123 BRESCIA,ITALY.		Puoti, Massimo/AAA-6580-2020	Imberti, Luisa/0000-0002-2075-8391; Puoti, Massimo/0000-0003-3278-7138				ACHAORBEA H, 1991, NATURE, V350, P207, DOI 10.1038/350207a0; BACCALA R, 1991, P NATL ACAD SCI USA, V88, P2908, DOI 10.1073/pnas.88.7.2908; CERNY A, 1990, J EXP MED, V171, P315, DOI 10.1084/jem.171.1.315; CHOI YW, 1989, P NATL ACAD SCI USA, V86, P8941, DOI 10.1073/pnas.86.22.8941; CHOI YW, 1991, NATURE, V350, P203, DOI 10.1038/350203a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVIS MM, 1985, ANNU REV IMMUNOL, V3, P537, DOI 10.1146/annurev.iy.03.040185.002541; DYASON PJ, 1991, NATURE, V349, P531; FRANKEL WN, 1991, NATURE, V349, P526, DOI 10.1038/349526a0; HERMAN A, 1990, J EXP MED, V172, P709, DOI 10.1084/jem.172.3.709; HUGIN AW, 1991, SCIENCE, V252, P424, DOI 10.1126/science.1850169; JANEWAY C, 1991, NATURE, V349, P459, DOI 10.1038/349459a0; JANEWAY CA, 1990, CELL, V63, P659, DOI 10.1016/0092-8674(90)90130-7; KAPPLER J, 1989, SCIENCE, V244, P811, DOI 10.1126/science.2524876; KAPPLER JW, 1988, NATURE, V332, P35, DOI 10.1038/332035a0; MACDONALD HR, 1988, J EXP MED, V167, P2005, DOI 10.1084/jem.167.6.2005; MANTERO G, 1991, CLIN CHEM, V37, P422; MARRACK P, 1991, NATURE, V349, P524, DOI 10.1038/349524a0; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; SOTTINI A, 1991, EUR J IMMUNOL, V21, P461, DOI 10.1002/eji.1830210231; STROMINGER JL, 1989, SCIENCE, V244, P943, DOI 10.1126/science.2658058; WILSON RK, 1988, IMMUNOL REV, V101, P149, DOI 10.1111/j.1600-065X.1988.tb00736.x; WOODLAND DL, 1991, NATURE, V349, P529, DOI 10.1038/349529a0	23	349	355	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 8	1991	254	5033					860	862		10.1126/science.1948066	http://dx.doi.org/10.1126/science.1948066			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GN833	1948066				2022-12-24	WOS:A1991GN83300046
J	MARGOLIS, P; DRIKS, A; LOSICK, R				MARGOLIS, P; DRIKS, A; LOSICK, R			ESTABLISHMENT OF CELL TYPE BY COMPARTMENTALIZED ACTIVATION OF A TRANSCRIPTION FACTOR	SCIENCE			English	Article							DUPLICATED SPORULATION GENES; BACILLUS-SUBTILIS; RNA-POLYMERASE; SIGMA-FACTOR; ENDOSPORE FORMATION; EXPRESSION; SPOIIA; PROMOTER; MUTATIONS; PROTEINS	Early in the process of spore formation in Bacillus subtilis a septum is formed that partitions the sporangium into daughter cells called the forespore and the mother cell. The daughter cells each have their own chromosome but follow dissimilar programs of gene expression. Differential gene expression in the forespore is now shown to be established by the compartmentalized activity of the transcription factor sigma-F. The sigma-F factor is produced prior to septation, but is active only in the forespore compartment of the post-septation sporangium. The sigma-F factor is controlled by the products of sporulation operons spoIIA and spoIIE, which may be responsible for confining its activity to one of the daughter cells.	HARVARD UNIV,BIOL LABS,DEPT CELLULAR & DEV BIOL,CAMBRIDGE,MA 02138	Harvard University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM018568, R01GM018568] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM18568] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CUTTING S, 1991, GENE DEV, V5, P456, DOI 10.1101/gad.5.3.456; DRIKS A, IN PRESS P NAT ACAD; DRIKS A, UNPUB; ERRINGTON J, 1985, FEBS LETT, V188, P184, DOI 10.1016/0014-5793(85)80368-9; ERRINGTON J, 1986, J GEN MICROBIOL, V132, P2967; ERRINGTON J, 1990, GENETICS BIOTECHNOLO, V3, P257; FORT P, 1984, J GEN MICROBIOL, V130, P2147; FOULGER D, 1989, MOL MICROBIOL, V3, P1247, DOI 10.1111/j.1365-2958.1989.tb00275.x; FRANCESCONI SC, 1988, J BACTERIOL, V170, P5963, DOI 10.1128/jb.170.12.5963-5967.1988; GARDELLA T, 1989, J MOL BIOL, V206, P579, DOI 10.1016/0022-2836(89)90567-6; GHOLAMHOSEINIAN A, 1989, J BACTERIOL, V171, P5747, DOI 10.1128/jb.171.10.5747-5749.1989; GUZMAN PL, COMMUNICATION; IGO M, 1987, J BACTERIOL, V169, P3464, DOI 10.1128/jb.169.8.3464-3469.1987; IGO MM, 1986, J MOL BIOL, V191, P615, DOI 10.1016/0022-2836(86)90449-3; ILLING N, 1991, J BACTERIOL, V173, P3159, DOI 10.1128/JB.173.10.3159-3169.1991; JONAS RM, 1989, J BACTERIOL, V171, P5226, DOI 10.1128/jb.171.9.5226-5228.1989; JONAS RM, 1988, J BACTERIOL, V170, P507, DOI 10.1128/jb.170.2.507-511.1988; KARMAZYNCAMPELLI C, 1989, GENE DEV, V3, P150, DOI 10.1101/gad.3.2.150; LABELL TL, 1987, P NATL ACAD SCI USA, V84, P1784, DOI 10.1073/pnas.84.7.1784; LOSICK R, 1986, ANNU REV GENET, V20, P625, DOI 10.1146/annurev.ge.20.120186.003205; MARGOLIS PS, UNPUB; MASON JM, 1988, J BACTERIOL, V170, P239, DOI 10.1128/jb.170.1.239-244.1988; PARTRIDGE SR, 1991, MOL MICROBIOL, V5, P757, DOI 10.1111/j.1365-2958.1991.tb00746.x; PIGGOT PJ, 1976, BACTERIOL REV, V40, P908, DOI 10.1128/MMBR.40.4.908-962.1976; PIGGOT PJ, 1984, J GEN MICROBIOL, V130, P2123; RATHER PN, 1990, J BACTERIOL, V172, P709, DOI 10.1128/jb.172.2.709-715.1990; RAY C, 1988, J BACTERIOL, V170, P900, DOI 10.1128/jb.170.2.900-907.1988; SAVVA D, 1986, J GEN MICROBIOL, V132, P3005; SCHMIDT R, 1990, P NATL ACAD SCI USA, V87, P9221, DOI 10.1073/pnas.87.23.9221; SIEGELE DA, 1989, J MOL BIOL, V206, P591, DOI 10.1016/0022-2836(89)90568-8; STRAGIER P, 1990, MOL MICROBIOL, V4, P1801, DOI 10.1111/j.1365-2958.1990.tb02028.x; STRAGIER P, 1986, FEBS LETT, V195, P9, DOI 10.1016/0014-5793(86)80119-3; STRAGIER P, 1988, CELL, V52, P697, DOI 10.1016/0092-8674(88)90407-2; STRAGIER P, 1991, IN PRESS PROCARYOTIC, V47; SUN DX, 1991, J BACTERIOL, V173, P2977, DOI 10.1128/JB.173.9.2977-2984.1991; SUN DX, 1989, GENE DEV, V3, P141, DOI 10.1101/gad.3.2.141; SUSSMAN MD, 1991, J BACTERIOL, V173, P291, DOI 10.1128/jb.173.1.291-300.1991; TREMPY JE, 1985, J BACTERIOL, V161, P340, DOI 10.1128/JB.161.1.340-346.1985; WU JJ, 1989, J BACTERIOL, V171, P692, DOI 10.1128/jb.171.2.692-698.1989; YUDKIN MD, 1987, J GEN MICROBIOL, V133, P475; ZHENG LB, 1990, J MOL BIOL, V212, P645, DOI 10.1016/0022-2836(90)90227-D	41	153	156	1	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 25	1991	254	5031					562	565		10.1126/science.1948031	http://dx.doi.org/10.1126/science.1948031			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GL799	1948031				2022-12-24	WOS:A1991GL79900046
J	SHIMADA, S; KITAYAMA, S; LIN, CL; PATEL, A; NANTHAKUMAR, E; GREGOR, P; KUHAR, M; UHL, G				SHIMADA, S; KITAYAMA, S; LIN, CL; PATEL, A; NANTHAKUMAR, E; GREGOR, P; KUHAR, M; UHL, G			CLONING AND EXPRESSION OF A COCAINE-SENSITIVE DOPAMINE TRANSPORTER COMPLEMENTARY-DNA	SCIENCE			English	Article							XENOPUS-LAEVIS OOCYTES; RAT STRIATUM; UPTAKE SITES; BINDING; NOREPINEPHRINE; INHIBITION; RECEPTORS; LIGAND; GABA	A rat dopamine (DA) transporter complementary DNA has been isolated with combined complementary DNA homology and expression approaches. The DA transporter is a 619-amino acid protein with 12 hydrophobic putative membrane-spanning domains and homology to the norepinephrine and gamma-aminobutyric acid transporters. The expressed complementary DNA confers transport of [H-3]DA in Xenopus oocytes and in COS cells. Binding of the cocaine analog [H-3]CFT {[H-3]2-beta-carbomethoxy-3-beta-(4-fluorophenyl)tropane} to transfected COS cell membranes yields a pharmacological profile similar to that in striatal membranes.	JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROL,BALTIMORE,MD 21224; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21224	Johns Hopkins University; Johns Hopkins University			Lin, Chien-liang G/E-3513-2011					BANNON MJ, 1990, J NEUROCHEM, V54, P706, DOI 10.1111/j.1471-4159.1990.tb01929.x; BERGER P, 1985, EUR J PHARMACOL, V107, P289, DOI 10.1016/0014-2999(85)90075-5; BERGMAN J, 1989, J PHARMACOL EXP THER, V251, P150; BLAKELY RD, 1988, P NATL ACAD SCI USA, V85, P9846, DOI 10.1073/pnas.85.24.9846; BOJA JW, 1989, EUR J PHARMACOL, V173, P215, DOI 10.1016/0014-2999(89)90524-4; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; HORN AS, 1990, PROG NEUROBIOL, V34, P387, DOI 10.1016/0301-0082(90)90033-D; HYTTEL J, 1982, PROG NEURO-PSYCHOPH, V6, P277, DOI 10.1016/S0278-5846(82)80179-6; IVERSEN LL, 1976, HDB PSYCHOPHARMACOLO, P381; JAVITCH JA, 1984, MOL PHARMACOL, V26, P35; JAVORYAGID F, 1985, N-S ARCH PHARMACOL, V329, P227; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KUHAR MJ, 1978, J NEUROCHEM, V31, P251, DOI 10.1111/j.1471-4159.1978.tb12456.x; KUHAR MJ, 1990, EUR NEUROL, V30, P15; MADRAS BK, 1989, MOL PHARMACOL, V36, P518; PACHOLCZYK T, 1991, NATURE, V350, P350, DOI 10.1038/350350a0; RITZ MC, 1987, SCIENCE, V237, P1219, DOI 10.1126/science.2820058; RITZ MC, 1990, LIFE SCI, V46, P635, DOI 10.1016/0024-3205(90)90132-B; SCHAEFFERJC, 1991, MOL BRAIN RES, V9, P271; SCHOEMAKER H, 1985, N-S ARCH PHARMACOL, V329, P227, DOI 10.1007/BF00501873; UHL GR, 1991, MOL BRAIN RES, V9, P23, DOI 10.1016/0169-328X(91)90126-I	21	548	564	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 25	1991	254	5031					576	578		10.1126/science.1948034	http://dx.doi.org/10.1126/science.1948034			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GL799	1948034				2022-12-24	WOS:A1991GL79900051
J	NELSON, KE; VLAHOV, D; COHN, S; LINDSAY, A; SOLOMON, L; ANTHONY, JC				NELSON, KE; VLAHOV, D; COHN, S; LINDSAY, A; SOLOMON, L; ANTHONY, JC			HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION IN DIABETIC INTRAVENOUS-DRUG-USERS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RISK-FACTORS; ABUSERS; EXCHANGE; AIDS	Objective. - To evaluate the association between diabetes and human immunodeficiency virus (HIV) seroprevalence in a population of intravenous (IV) drug users. Design. - Cross-sectional survey in a cohort of IV drug users. Setting. - Community-based study clinic. Subjects. - The study included 2921 individuals with a history of IV drug use in the past 10 years; over 90% had injected drugs in the past year and 77% in the past month; only 15% were receiving drug treatment. Outcome Measures. - The HIV seroprevalence among IV drug users with and without a history of diabetes. Results. - Those IV drug users with a history of diabetes had significantly lower HIV seroprevalence (9.8%) than nondiabetic IV drug users (24.3%; P =.03). Despite similar duration and intensity of drug use and sexual practices, diabetic IV drug users tended not to share injection paraphernalia and were less likely to attend shooting galleries than nondiabetic IV drug users. Conclusion. - Our data suggest that the apparent protective effect of diabetes against HIV infection in IV drug users is most likely due to their safer injection practices afforded by their ready access to sterile injection equipment.	JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT MENTAL HYG,BALTIMORE,MD 21218	Johns Hopkins University; Maryland Department of Health & Mental Hygiene	NELSON, KE (corresponding author), JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT EPIDEMIOL,624 N BROADWAY ST,ROOM 763,BALTIMORE,MD 21218, USA.		Anthony, Jim/H-3637-2011	Anthony, Jim/0000-0001-7176-0929	NIDA NIH HHS [DA0S664, DA04334] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA004334, R37DA004334] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Allen J, 1981, INFECTION COMPROMISE, P229; BUNING EC, 1986, LANCET, V1, P1435; CHAISSON RE, 1987, AM J PUBLIC HEALTH, V77, P169, DOI 10.2105/AJPH.77.2.169; ELIASHIV A, 1978, ARCH SURG-CHICAGO, V113, P1180; HART GJ, 1989, AIDS, V3, P261, DOI 10.1097/00002030-198905000-00002; HAVERKOS HW, 1990, J INFECT DIS, V161, P894, DOI 10.1093/infdis/161.5.894; MARMOR M, 1987, AIDS, V1, P39; NELSON KE, 1991, J INFECT DIS, V164, P457, DOI 10.1093/infdis/164.3.457; ROBERTSON JR, 1986, BRIT MED J, V292, P527, DOI 10.1136/bmj.292.6519.527; ROBERTSON JR, 1990, AIDS DRUG MISUSE; ROSEMAN JM, NIH851468 US DEP HLT, P1; SCHOENBAUM EE, 1989, NEW ENGL J MED, V321, P874, DOI 10.1056/NEJM198909283211306; STIMSON GV, 1989, AIDS, V3, P253, DOI 10.1097/00002030-198905000-00001; TAN JS, 1975, J LAB CLIN MED, V85, P26; TIRELLI U, 1986, JAMA-J AM MED ASSOC, V255, P2289, DOI 10.1001/jama.1986.03370170053010; VLAHOV D, 1990, AM J EPIDEMIOL, V132, P847, DOI 10.1093/oxfordjournals.aje.a115727; Vlahov D, 1991, NIDA Res Monogr, V109, P75	17	35	35	1	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 23	1991	266	16					2259	2261		10.1001/jama.266.16.2259	http://dx.doi.org/10.1001/jama.266.16.2259			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GK661	1920726				2022-12-24	WOS:A1991GK66100035
J	OSMANI, AH; MCGUIRE, SL; OSMANI, SA				OSMANI, AH; MCGUIRE, SL; OSMANI, SA			PARALLEL ACTIVATION OF THE NIMA AND P34CDC2 CELL CYCLE-REGULATED PROTEIN-KINASES IS REQUIRED TO INITIATE MITOSIS IN ASPERGILLUS-NIDULANS	CELL			English	Article							MATURATION-PROMOTING FACTOR; GERMINAL VESICLE BREAKDOWN; XENOPUS CDC2 PROTEIN; HISTONE H-1 KINASE; CONTROL GENE CDC2+; FISSION YEAST; ASPERGILLUS-NIDULANS; M-PHASE; TYROSINE PHOSPHORYLATION; MEIOTIC MATURATION	We show that in Aspergillus nidulans, p34cdc2 tyrosine dephosphorylation accompanies activation of p34cdc2 as an H1 kinase at mitosis. However, the nimA5 mutation arrests cells in G2 with p34cdc2 tyrosine dephosphorylated and fully active as an H1 kinase. Activation of NIMA is therefore not required for p34Cdc2 activation. Furthermore, mutation of nimT, which encodes a protein with 50% similarity to fission yeast cdc25, causes a G2 arrest and prevents tyrosine dephosphorylation of p34cdc2 but does not prevent full activation of the NIMA protein kinase. Mitotic activation of p34cdc2 by tyrosine dephosphorylation is therefore not required for activation of NIMA. These data suggest that activation of either the p34cdc2 protein kinase or the NIMA protein kinase alone is not sufficient to initiate mitosis. Parallel activation of both cell cycle-regulated protein kinases is required to trigger mitosis.			OSMANI, AH (corresponding author), BAYLOR COLL MED, DEPT CELL BIOL, HOUSTON, TX 77030 USA.		Osmani, Stephen A./AAS-3904-2021		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042564] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM42564] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALFA CE, 1990, NATURE, V347, P680, DOI 10.1038/347680a0; ARION D, 1988, CELL, V55, P371, DOI 10.1016/0092-8674(88)90060-8; BEACH D, 1982, NATURE, V300, P706, DOI 10.1038/300706a0; BENDAVID Y, 1991, EMBO J, V10, P317, DOI 10.1002/j.1460-2075.1991.tb07952.x; BERGEN LG, 1984, J BACTERIOL, V159, P114, DOI 10.1128/JB.159.1.114-119.1984; BOOHER RN, 1989, CELL, V58, P485, DOI 10.1016/0092-8674(89)90429-7; BRIZUELA L, 1989, P NATL ACAD SCI USA, V86, P4362, DOI 10.1073/pnas.86.12.4362; DAVIS FM, 1983, P NATL ACAD SCI-BIOL, V80, P2926, DOI 10.1073/pnas.80.10.2926; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; DUNPHY WG, 1989, CELL, V58, P181, DOI 10.1016/0092-8674(89)90414-5; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; ENGLE DB, 1988, CELL MOTIL CYTOSKEL, V10, P432, DOI 10.1002/cm.970100310; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GHIARA JB, 1991, CELL, V65, P163, DOI 10.1016/0092-8674(91)90417-W; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HINDLEY J, 1984, GENE, V31, P129, DOI 10.1016/0378-1119(84)90203-8; KISHIMOTO T, 1976, NATURE, V260, P321, DOI 10.1038/260321a0; LABBE JC, 1989, CELL, V57, P253, DOI 10.1016/0092-8674(89)90963-X; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; MEIJER L, 1989, EMBO J, V8, P2275, DOI 10.1002/j.1460-2075.1989.tb08353.x; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; MORRIS NR, 1975, GENET RES, V26, P237, DOI 10.1017/S0016672300016049; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OAKLEY BR, 1983, J CELL BIOL, V96, P1155, DOI 10.1083/jcb.96.4.1155; OSMANI AH, 1990, J CELL BIOL, V111, P543, DOI 10.1083/jcb.111.2.543; OSMANI AH, 1991, EMBO J, V10, P2669, DOI 10.1002/j.1460-2075.1991.tb07810.x; OSMANI SA, 1988, CELL, V53, P237, DOI 10.1016/0092-8674(88)90385-6; OSMANI SA, 1988, CELL, V52, P241, DOI 10.1016/0092-8674(88)90513-2; OSMANI SA, 1987, J CELL BIOL, V104, P1495, DOI 10.1083/jcb.104.6.1495; RUSSELL P, 1987, CELL, V49, P569, DOI 10.1016/0092-8674(87)90459-4; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; SIMANIS V, 1986, CELL, V45, P261, DOI 10.1016/0092-8674(86)90390-9; SUNKARA PS, 1979, P NATL ACAD SCI USA, V76, P2799, DOI 10.1073/pnas.76.6.2799; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V; TACHIBANA K, 1987, J CELL SCI, V88, P273; VANDRE DD, 1984, P NATL ACAD SCI-BIOL, V81, P4439, DOI 10.1073/pnas.81.14.4439	44	209	225	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 18	1991	67	2					283	291		10.1016/0092-8674(91)90180-7	http://dx.doi.org/10.1016/0092-8674(91)90180-7			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GL470	1913824				2022-12-24	WOS:A1991GL47000008
J	NOMURA, A; STEMMERMANN, GN; CHYOU, PH; KATO, I; PEREZPEREZ, GI; BLASER, MJ				NOMURA, A; STEMMERMANN, GN; CHYOU, PH; KATO, I; PEREZPEREZ, GI; BLASER, MJ			HELICOBACTER-PYLORI INFECTION AND GASTRIC-CARCINOMA AMONG JAPANESE-AMERICANS IN HAWAII	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CAMPYLOBACTER-PYLORI; ANTIBODY PREVALENCE; ATROPHIC GASTRITIS; PEPTIC-ULCER; CANCER; POPULATIONS; DISEASE; ASSOCIATION; RISKS; MEN	Background. Helicobacter pylori are gram-negative spiral bacteria that are associated with chronic gastritis, a known precursor of gastric carcinoma. Persons at high risk for gastric carcinoma have been shown to have a high prevalence of H. pylori infection. Methods. We studied the relation of H. pylori infection and gastric carcinoma in a cohort of Japanese American men living in Hawaii. The 5908 men were enrolled and examined from 1967 to 1970. By 1989, 109 cases of pathologically confirmed gastric carcinoma had been identified. The stored serum of each patient with gastric carcinoma and of each matched control subject was tested for the presence of serum IgG antibody to H. pylori. Results. Ninety-four percent of the men with gastric carcinoma and 76 percent of the matched control subjects had a positive test for H. pylori antibodies, for an odds ratio of 6.0 (95 percent confidence interval, 2.1 to 17.3). As the level of antibody to H. pylori increased, there was a progressive increase in the risk of gastric carcinoma (P for trend = 0.0009). The association was strong even for men in whom the diagnosis was made 10 or more years after the serum sample was obtained (odds ratio, 10.5; 95 percent confidence interval, 2.5 to 44.8). Conclusions. Infection with H. pylori is strongly associated with an increased risk of gastric carcinoma. However, most persons infected with H. pylori will never have gastric carcinoma. Therefore, other factors that increase the risk of gastric carcinoma among persons infected with H. pylori need to be identified.	VANDERBILT UNIV,MED CTR,SCH MED,DIV INFECT DIS,NASHVILLE,TN 37232; VET AFFAIRS MED CTR,NASHVILLE,TN	Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	NOMURA, A (corresponding author), KUAKINI MED CTR,JAPAN HAWAII CANC STUDY,347 N KUAKINI ST,HONOLULU,HI 96817, USA.		Perez, Guillermo Perez/AAJ-3761-2020	Perez Perez, Guillermo/0000-0002-0131-5798	NCI NIH HHS [R01-CA-33644] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA033644] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMES BN, 1990, SCIENCE, V249, P970, DOI 10.1126/science.2136249; [Anonymous], 1983, LANCET, V1, P1273; BEAHRS OH, 1978, MANUAL STAGING CANCE, P71; BLASER MJ, 1991, REV INFECT DIS, V13, pS704; BLASER MJ, 1990, J INFECT DIS, V161, P626, DOI 10.1093/infdis/161.4.626; BLASER MJ, 1990, NEW ANTIBACTERIAL ST, P143; BLOT WJ, 1991, JAMA-J AM MED ASSOC, V265, P1287, DOI 10.1001/jama.265.10.1287; BRESLOW NE, 1980, IARC SCI PUBL, V32, P164; BUCK GE, 1986, J INFECT DIS, V153, P664, DOI 10.1093/infdis/153.4.664; CORREA P, 1983, CANCER SURV, V2, P437; CORREA P, 1990, CANCER-AM CANCER SOC, V66, P2569, DOI 10.1002/1097-0142(19901215)66:12<2569::AID-CNCR2820661220>3.0.CO;2-I; CORREA P, 1973, JNCI-J NATL CANCER I, V51, P1449, DOI 10.1093/jnci/51.5.1449; DOLL R, 1970, CANCER INCIDENCE 5 C, V2; DOOLEY CP, 1988, ANN INTERN MED, V108, P70, DOI 10.7326/0003-4819-108-1-70; DOOLEY CP, 1989, NEW ENGL J MED, V321, P1562, DOI 10.1056/NEJM198912073212302; DRUMM B, 1990, NEW ENGL J MED, V322, P359, DOI 10.1056/NEJM199002083220603; EKBOM A, 1990, NEW ENGL J MED, V323, P1228, DOI 10.1056/NEJM199011013231802; EVANS DJ, 1989, GASTROENTEROLOGY, V96, P1004, DOI 10.1016/0016-5085(89)91616-8; FORMAN D, 1990, INT J CANCER, V46, P608, DOI 10.1002/ijc.2910460410; GLASSMAN MS, 1990, DIGEST DIS SCI, V35, P993, DOI 10.1007/BF01537248; GRAHAM DY, 1989, GASTROENTEROLOGY, V96, P615, DOI 10.1016/S0016-5085(89)80057-5; Harrell F., 1983, SUGI SUPPLEMENTAL LI, P267; HOWSON CP, 1986, EPIDEMIOL REV, V8, P1; IMAI K, 1991, HELICOBACTER PYLORI, V3, P26; KAGAN A, 1974, J CHRON DIS, V27, P345, DOI 10.1016/0021-9681(74)90014-9; KRAKOWKA S, 1987, INFECT IMMUN, V55, P2789, DOI 10.1128/IAI.55.11.2789-2796.1987; LAUREN P, 1965, ACTA PATHOL MIC SC, V64, P31, DOI 10.1111/apm.1965.64.1.31; LOFFELD RJLF, 1990, HISTOPATHOLOGY, V17, P537, DOI 10.1111/j.1365-2559.1990.tb00793.x; MAI EUH, 1991, J CLIN INVEST, V87, P894; MARSHALL BJ, 1984, LANCET, V1, P1311; MARSHALL BJ, 1985, MED J AUSTRALIA, V142, P436, DOI 10.5694/j.1326-5377.1985.tb113443.x; MEGRAUD F, 1989, J CLIN MICROBIOL, V27, P1870; MORRIS AJ, 1991, ANN INTERN MED, V114, P662, DOI 10.7326/0003-4819-114-8-662; MUIR CS, 1987, IARC SCI PUBLICATION, V88; Nomura A, 1982, CANCER EPIDEMIOL, P624; PARSONNET J, 1991, JNCI-J NATL CANCER I, V83, P640, DOI 10.1093/jnci/83.9.640; PARSONNET J, IN PRESS GASTROENTER; PEREZPEREZ GI, 1988, ANN INTERN MED, V109, P11, DOI 10.7326/0003-4819-109-1-11; PEREZPEREZ GI, 1990, J INFECT DIS, V161, P1237, DOI 10.1093/infdis/161.6.1237; SITAS F, 1991, GUT, V32, P25, DOI 10.1136/gut.32.1.25; SIURALA M, 1985, SCAND J GASTROENTERO, V20, P69, DOI 10.3109/00365528509103939; STRAUSS RM, 1990, AM J MED, V89, P464, DOI 10.1016/0002-9343(90)90377-P; STRICKLAND RG, 1973, AM J DIG DIS, V18, P426, DOI 10.1007/BF01071995; TALLEY NJ, IN PRESS J NATL CANC; TALLEY NJ, 1990, REV ESP ENFERM DIG S, V78, pS7; TAYLOR DN, IN PRESS EPIDEMIOL R; WALKER IR, 1971, GUT, V12, P906, DOI 10.1136/gut.12.11.906; WALTER SD, 1978, INT J EPIDEMIOL, V7, P175, DOI 10.1093/ije/7.2.175; WORTH RM, 1970, J CHRON DIS, V23, P389, DOI 10.1016/0021-9681(70)90022-6; YOUNG JL, 1981, NCI MONOGRAPH, V57; 1991, CANCER FACTS FIGURES, P3	51	1638	1682	2	50	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 17	1991	325	16					1132	1136		10.1056/NEJM199110173251604	http://dx.doi.org/10.1056/NEJM199110173251604			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GK538	1891021	Bronze			2022-12-24	WOS:A1991GK53800004
J	PULVERER, BJ; KYRIAKIS, JM; AVRUCH, J; NIKOLAKAKI, E; WOODGETT, JR				PULVERER, BJ; KYRIAKIS, JM; AVRUCH, J; NIKOLAKAKI, E; WOODGETT, JR			PHOSPHORYLATION OF C-JUN MEDIATED BY MAP KINASES	NATURE			English	Article							V-JUN; PROTEIN; AP-1; TRANSCRIPTION; ACTIVATION; ENCODES	THE proto-oncogene c-jun is a component of the AP-1 transcription factor family involved in the mediation of nuclear events elicited by extracellular stimuli 1-3. The c-jun protein is negatively regulated by phosphorylation of residues near the carboxy terminus which are dephosphorylated in response to phorbol esters 4. Here we identify two serine residues in the amino terminal A1 transactivation domain which are phosphorylated in response to a variety of mitogens, phorbol esters and activated ras (ref. 5). We present evidence that mitogen-activated protein-serine (MAP) kinases (pp54 and pp42/44) specifically phosphorylate these sites and that their phosphorylation positively regulates the transacting activity of c-jun. The MAP kinase enzymes pp54 and pp42/44 are regulated by tyrosine as well as serine/threonine phosphorylation 6,7. MAP kinase activation of c-jun may underlie the common stimulation of this transcription factor by mitogens, growth factors and oncogenes.	LUDWIG INST CANC RES,91 RIDING HOUSE ST,LONDON W1P 8BT,ENGLAND; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; MASSACHUSETTS GEN HOSP,DIABET UNIT,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,MED SERV,BOSTON,MA 02114	Ludwig Institute for Cancer Research; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital			Woodgett, Jim/F-1087-2010	Woodgett, Jim/0000-0003-3731-5797				ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; BAICHWAL VR, 1991, NATURE, V352, P165, DOI 10.1038/352165a0; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; DARROW AL, 1990, METHOD ENZYMOL, V190, P110; KYRAIKIS JM, 1991, FASEB J, V5, pA797; KYRIAKIS JM, 1990, J BIOL CHEM, V265, P17355; KYRIAKIS JM, 1991, J BIOL CHEM, V266, P10043; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; SCHANENKING C, 1991, NEURON, V6, P915, DOI 10.1016/0896-6273(91)90232-O; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; VICENDO P, 1991, BIOCHEM J, V278, P435, DOI 10.1042/bj2780435; WOODGETT JR, 1990, SEMIN CANCER BIOL, V4, P389	20	1405	1437	0	21	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 17	1991	353	6345					670	674		10.1038/353670a0	http://dx.doi.org/10.1038/353670a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GK672	1922387				2022-12-24	WOS:A1991GK67200075
J	WANG, CY; LOONEY, DJ; LI, ML; WALFIELD, AM; YE, J; HOSEIN, B; TAM, JP; WONGSTAAL, F				WANG, CY; LOONEY, DJ; LI, ML; WALFIELD, AM; YE, J; HOSEIN, B; TAM, JP; WONGSTAAL, F			LONG-TERM HIGH-TITER NEUTRALIZING ACTIVITY INDUCED BY OCTAMERIC SYNTHETIC HIV-1 ANTIGEN	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; MATERNAL ANTIBODIES; GLYCOPROTEIN GP120; ENVELOPE PROTEIN; TYPE-1 ENVELOPE; AIDS VACCINES; T-CELL; PEPTIDE; CHIMPANZEES; DETERMINANT	A titer for homologous viral neutralization activity (> 1:19,683) was observed after a 3.5-year immunization period with an octameric, branching peptide representing the principal neutralizing determinant (PND) of the human immunodeficiency virus-1IIIB envelope protein. Booster immunizations elicited persistent and potent antibodies in guinea pigs, exceeding responses produced by a conventional bovine serum albumin conjugate by 100-fold. Peptide length, central presentation of a conserved sequence, and inclusion of an upstream sequence contributed to immunogenicity. Titers (> 1:1,000) of heterotypic neutralizing antibodies also developed. Octameric PND peptides are a promising approach for an acquired immunodeficiency syndrome (AIDS) vaccine.	VET ADM MED CTR,SAN DIEGO,CA 92161; VET ADM MED CTR,SAN DIEGO,CA 92161; UNIV CALIF SAN DIEGO,DEPT MED,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093; ROCKEFELLER UNIV,NEW YORK,NY 10021	US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Diego; University of California System; University of California San Diego; Rockefeller University	WANG, CY (corresponding author), UNITED BIOMED INC,LAKE SUCCESS,NY 11042, USA.		Tam, James P/A-2176-2011	Tam, James P/0000-0003-4433-198X	NIAID NIH HHS [IU01-AI-30238] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI030238] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BERMAN PW, 1990, NATURE, V345, P622, DOI 10.1038/345622a0; CHESEBRO B, 1988, J VIROL, V62, P3779, DOI 10.1128/JVI.62.10.3779-3788.1988; DEVASH Y, 1990, P NATL ACAD SCI USA, V87, P3445, DOI 10.1073/pnas.87.9.3445; EMINI EA, 1990, J VIROL, V64, P3674, DOI 10.1128/JVI.64.8.3674-3678.1990; FREED EO, 1991, J VIROL, V65, P190, DOI 10.1128/JVI.65.1.190-194.1991; GIRARD M, 1991, P NATL ACAD SCI USA, V88, P542, DOI 10.1073/pnas.88.2.542; GOUDSMIT J, 1988, P NATL ACAD SCI USA, V85, P4478, DOI 10.1073/pnas.85.12.4478; JAVAHERIAN K, 1989, P NATL ACAD SCI USA, V86, P6768, DOI 10.1073/pnas.86.17.6768; JAVAHERIAN K, 1990, SCIENCE, V250, P1590, DOI 10.1126/science.1703322; KOFF WC, 1988, SCIENCE, V241, P426, DOI 10.1126/science.3293212; LAROSA GJ, 1990, SCIENCE, V249, P932, DOI 10.1126/science.2392685; LOONEY DJ, 1988, SCIENCE, V241, P357, DOI 10.1126/science.3388046; MATTHEWS TJ, 1988, SCI AM, V259, P120, DOI 10.1038/scientificamerican1088-120; MELOEN RH, 1989, J GEN VIROL, V70, P1505, DOI 10.1099/0022-1317-70-6-1505; PALKER TJ, 1988, P NATL ACAD SCI USA, V85, P1932, DOI 10.1073/pnas.85.6.1932; POSNETT DN, 1988, J BIOL CHEM, V263, P1719; ROSSI P, 1989, P NATL ACAD SCI USA, V86, P8055, DOI 10.1073/pnas.86.20.8055; RUSCHE JR, 1988, P NATL ACAD SCI USA, V85, P3198, DOI 10.1073/pnas.85.9.3198; SCOTT CF, 1990, P NATL ACAD SCI USA, V87, P8597, DOI 10.1073/pnas.87.21.8597; TAM JP, 1990, J EXP MED, V171, P299, DOI 10.1084/jem.171.1.299; TAM JP, 1989, P NATL ACAD SCI USA, V86, P9084, DOI 10.1073/pnas.86.23.9084; TAM JP, 1988, P NATL ACAD SCI USA, V85, P5409, DOI 10.1073/pnas.85.15.5409; TSCHACHLER E, 1990, J VIROL, V64, P2250, DOI 10.1128/JVI.64.5.2250-2259.1990; Wang C.-W., UNPUB; WANG CY, 1989, Patent No. 328403; WANG JJG, 1986, P NATL ACAD SCI USA, V83, P6159, DOI 10.1073/pnas.83.16.6159	26	124	140	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 11	1991	254	5029					285	288		10.1126/science.1925584	http://dx.doi.org/10.1126/science.1925584			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GJ642	1925584				2022-12-24	WOS:A1991GJ64200039
J	TRULOCK, EP; COOPER, JD; KAISER, LR; PASQUE, MK; ETTINGER, NA; DRESLER, CM				TRULOCK, EP; COOPER, JD; KAISER, LR; PASQUE, MK; ETTINGER, NA; DRESLER, CM			THE WASHINGTON-UNIVERSITY BARNES-HOSPITAL EXPERIENCE WITH LUNG TRANSPLANTATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SINGLE; EMPHYSEMA; DISEASE	Objective. - To review our experience with lung transplantation, emphasizing recipient selection, choice of procedure, functional results, and outcome. Design. - Retrospective review of patients who received lung transplants at Barnes Hospital, St Louis, Mo, between July 1, 1988, and January 31, 1991. Setting. - Washington University School of Medicine, St Louis, Mo, and Barnes Hospital, a medical school and its affiliated referral hospital, respectively. Patients. - Sixty-nine lung transplant procedures were performed in 66 recipients. Patients with clinically and physiologically severe lung disease were selected according to predetermined guidelines. Underlying diseases in the recipients included chronic obstructive pulmonary disease, alpha-1-antitrypsin deficiency emphysema, cystic fibrosis, pulmonary fibrosis, primary pulmonary hypertension, Eisenmenger's syndrome associated with an atrial septal defect, bronchiectasis, eosinophilic granuloma, and lymphangiomyomatosis. Intervention. - Double-lung, bilateral sequential, and single-lung transplantations were performed. Eight patients underwenten bloc double-lung transplantations or a modification of this procedure with separate bronchial anastomoses. Thereafter, the bilateral sequential approach to replacement of both lungs was performed in 26 patients. Thirty-two patients underwent single-lung transplantations. Main Outcome Measures. - Pulmonary function tests, arterial blood gas levels, pulmonary artery pressure, pulmonary vascular resistance, and actuarial survival. Results. - Actuarial survival at 1 year for the 66 lung transplant recipients was 79%. Actuarial survival at 1 year was 82% for the bilateral lung transplant recipients and was 90% for the single-lung transplant recipients. In patients with either restrictive or obstructive lung disease, pulmonary function tests and arterial blood gas levels improved markedly after lung transplantation. In patients with primary pulmonary hypertension or Eisenmenger's syndrome, the pulmonary artery pressure decreased and the cardiac index increased into the normal range after single-lung transplantation. Conclusions. - In carefully selected patients with end-stage lung disease, single-lung and bilateral lung transplantations can significantly improve functional capacity, with promising early actuarial survival statistics after 1 year.	WASHINGTON UNIV, SCH MED, DIV CARDIOTHORAC SURG, ST LOUIS, MO 63110 USA	Washington University (WUSTL)	TRULOCK, EP (corresponding author), WASHINGTON UNIV, SCH MED, DIV RESP & CRIT CARE, GEN THORAC SURG SECT, BOX 8052, ST LOUIS, MO 63110 USA.		Kaiser, Larry/L-7940-2019					[Anonymous], 1988, JAMA, V259, P2258; BATES DV, 1970, NEW ENGL J MED, V282, P277, DOI 10.1056/NEJM197001292820511; COOPER JD, 1986, NEW ENGL J MED, V314, P1140; COOPER JD, 1989, AM REV RESPIR DIS, V139, P303, DOI 10.1164/ajrccm/139.2.303; COOPER JD, 1987, J THORAC CARDIOV SUR, V93, P173; EGAN TM, 1991, CHEST, V99, P867, DOI 10.1378/chest.99.4.867; ETTINGER NA, 1991, AM REV RESPIR DIS, V143, P1386, DOI 10.1164/ajrccm/143.6.1386; GROSSMAN RF, 1990, NEW ENGL J MED, V322, P727, DOI 10.1056/NEJM199003153221104; HENES G, 1991, Journal of the American College of Cardiology, V17, p372A; LEVINE SM, 1990, CHEST, V98, P1107, DOI 10.1378/chest.98.5.1107; LIMA O, 1981, J THORAC CARDIOV SUR, V82, P211; LIMA O, 1982, J THORAC CARDIOV SUR, V83, P418; MAL H, 1989, AM REV RESPIR DIS, V140, P797, DOI 10.1164/ajrccm/140.3.797; MIYOSHI S, 1990, CHEST, V97, P1130, DOI 10.1378/chest.97.5.1130; MORGAN E, 1982, J THORAC CARDIOV SUR, V84, P204; PASQUE MK, 1990, ANN THORAC SURG, V49, P785, DOI 10.1016/0003-4975(90)90023-Y; PATTERSON GA, 1988, ANN THORAC SURG, V45, P626, DOI 10.1016/S0003-4975(10)64763-7; STEVENS PM, 1970, NEW ENGL J MED, V282, P245, DOI 10.1056/NEJM197001292820504; THEODORE J, 1990, NEW ENGL J MED, V322, P772, DOI 10.1056/NEJM199003153221110; TRULOCK EP, 1989, CHEST, V96, P738, DOI 10.1378/chest.96.4.738; Veith F J, 1974, Vasc Surg, V8, P273; VEITH FJ, 1973, ANN SURG, V178, P463, DOI 10.1097/00000658-197310000-00009; Wildevuur C R, 1970, Ann Thorac Surg, V9, P489	23	67	70	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 9	1991	266	14					1943	1946		10.1001/jama.266.14.1943	http://dx.doi.org/10.1001/jama.266.14.1943			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GH406	1895470				2022-12-24	WOS:A1991GH40600018
J	PATERSON, CM; SAUNDERS, NJS				PATERSON, CM; SAUNDERS, NJS			MODE OF DELIVERY AFTER ONE CESAREAN-SECTION - AUDIT OF CURRENT PRACTICE IN A HEALTH REGION	BRITISH MEDICAL JOURNAL			English	Article							CESAREAN-SECTION; VAGINAL DELIVERY; BIRTH	Objective - To audit the subsequent obstetric management of women who had had one previous baby delivered by caesarean section. Design - Retrospective analysis of a regional obstetric database. Setting - Data derived from the 17 obstetric units in North West Thames region. Subjects - 1059 women who delivered a singleton fetus of at least 37 weeks' gestation with a cephalic presentation in 1988 who had a history of one previous caesarean section and no other deliveries. Main outcome measures - Mode of delivery, postnatal morbidity, and duration of hospital stay. Results - 395 (37%) women were delivered by elective repeat caesarean section and 664 (63%) were allowed a trial of labour. Maternal height and birth weight of the previous infant differed significantly between those who were and those who were not allowed to labour. 471 (71%) of those allowed to labour achieved a vaginal delivery. In individual units there was no significant correlation between the proportion of patients allowed to labour and the rate of the successful trial of labour. There was a trend towards greater success rates in units that allowed a longer duration of labour (p < 0.05) and units with greater use of oxytocin for augmentation of labour (not significant). Both elective and intrapartum caesarean section was associated with a significantly higher rate of postnatal infection than vaginal delivery (14.7% and 16.0% v 3.4%). Conclusions - In patients with a history of caesarean section there is no evidence that the likelihood of successful vaginal delivery after trial of labour is modified by the proportion of such patients allowed the option of attempted vaginal delivery. Until selection criteria of adequate prognostic value can be identified a more liberal approach to allowing women a trial of labour seems justified.			PATERSON, CM (corresponding author), ST MARYS HOSP,IMPERIAL COLL SCI TECHNOL & MED,SCH MED,LONDON W2 1PG,ENGLAND.							DUFF P, 1988, OBSTET GYNECOL, V71, P380; EVRARD JR, 1977, OBSTET GYNECOL, V50, P594; FLAMM BL, 1989, OBSTET GYNECOL, V74, P694; GARDNER MJ, 1989, CONFIDENCE INTERVAL; LAVIN JP, 1982, OBSTET GYNECOL, V59, P135; MEEHAN FP, 1988, EUR J OBSTET GYN R B, V31, P109; MOLLOY BG, 1987, BRIT MED J, V294, P1645, DOI 10.1136/bmj.294.6588.1645; PHELAN JP, 1987, AM J OBSTET GYNECOL, V157, P1510, DOI 10.1016/S0002-9378(87)80252-1; WHITESIDE DC, 1983, J REPROD MED, V28, P785; [No title captured]	10	26	26	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 5	1991	303	6806					818	821		10.1136/bmj.303.6806.818	http://dx.doi.org/10.1136/bmj.303.6806.818			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GH946	1932972	Bronze, Green Published			2022-12-24	WOS:A1991GH94600022
J	MENNELLA, JA; BEAUCHAMP, GK				MENNELLA, JA; BEAUCHAMP, GK			THE TRANSFER OF ALCOHOL TO HUMAN-MILK - EFFECTS ON FLAVOR AND THE INFANTS BEHAVIOR	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							EARLY EXPERIENCE; LACTATING WOMEN; BREAST-MILK; MOTHERS	Background. The amount of alcohol ingested by a breast-fed infant is only a small fraction of that consumed by its mother, but even this small amount may have an effect on the infant. We investigated whether the ingestion of alcohol by a lactating woman altered the odor of her milk and whether exposure to a small amount of alcohol in the mother's milk had immediate effects on the behavior of the infant. Methods. Twelve lactating women and their infants were tested on two days separated by an interval of one week. On each testing day, the mother expressed a small quantity of breast milk and then drank either orange juice or orange juice containing a small quantity of ethanol (0.3 g per kilogram of body weight). Additional milk samples were obtained at fixed intervals after the ingestion of the beverage and analyzed to determine their ethanol content. The samples were also evaluated by a panel of adults of determine whether any difference in the odor of the milk was detectable after alcohol ingestion. The infants were weighed before and after nursing to assess the amount of milk they ingested, and their behavior during breast-feeding was monitored by videotape. Results. Short-term alcohol consumption by lactating women significantly and uniformly increased the perceived intensity of the odor of their milk as assessed by the panel; this increase in the intensity of the odor peaked 30 minutes to 1 hour after the alcohol was consumed and decreased thereafter. The alteration in the odor of the milk closely paralleled the changes in the concentration of ethanol in the milk (mean range, 0 to 6.9 mmol per liter [0 to 32 mg per deciliter]). The infants sucked more frequently during the first minute of feedings after their mothers had consumed alcohol (67.0 +/- 6.5 sucks, as compared with 58.4 +/- 5.9 sucks for feedings after the consumption of the nonalcoholic beverage; P < 0.05), but they consumed significantly less milk (120.4 +/- 9.5 ml vs. 156.4 +/- 8.2 ml, P < 0.001) during the testing sessions in which their mothers drank the alcoholic beverage. Conclusions. Although the mechanisms underlying this reduction in milk intake remain to be elucidated, this study shows that short-term alcohol consumption by nursing mothers has an immediate effect on the sensory characteristics (odor) or their milk and the feeding behavior of their infants.			MENNELLA, JA (corresponding author), MONELL CHEM SENSES CTR,3500 MARKET ST,PHILADELPHIA,PA 19104, USA.			Mennella, Julie/0000-0002-8855-0204	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC000882] Funding Source: NIH RePORTER; NICHD NIH HHS [HD07375] Funding Source: Medline; NIDCD NIH HHS [DC00882] Funding Source: Medline	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Bernt E, 1974, METHOD ENZYMAT AN, V3, P1499; BLUME S, 1987, JAMA-J AM MED ASSOC, V258, P2126; BUTTE NF, 1988, AM J CLIN NUTR, V47, P815, DOI 10.1093/ajcn/47.5.815; CAMPBELL RG, 1976, ANIM PROD, V23, P417, DOI 10.1017/S0003356100031536; CAPRETTA PJ, 1975, NATURE, V254, P689, DOI 10.1038/254689a0; COBO E, 1969, AM J OBSTET GYNECOL, V105, P877, DOI 10.1016/0002-9378(69)90094-5; COBO E, 1973, AM J OBSTET GYNECOL, V115, P817, DOI 10.1016/0002-9378(73)90526-7; Fazzalari F.A., 1978, COMPILATION ODOR TAS; Fildes V.A., 1986, BREASTS BOTTLES BABI; FOMON SJ, 1987, AM J CLIN NUTR, V46, P171, DOI 10.1093/ajcn/46.1.171; GALEF BG, 1973, J COMP PHYSIOL PSYCH, V83, P374, DOI 10.1037/h0034665; GALEF BG, 1972, J COMP PHYSIOL PSYCH, V78, P213, DOI 10.1037/h0032186; JONES KL, 1973, LANCET, V1, P1267; JONES KL, 1973, LANCET, V2, P999; KESANIEMI YA, 1974, J OBSTET GYN BR COMM, V81, P84; LAWRENCE RA, 1989, BREASTFEEDING GUIDE; LAWTON ME, 1985, AUST NZ J OBSTET GYN, V25, P71, DOI 10.1111/j.1479-828X.1985.tb00609.x; LEGUENNEC JC, 1987, PEDIATRICS, V79, P264; LITTLE RE, 1989, NEW ENGL J MED, V321, P425, DOI 10.1056/NEJM198908173210703; LITTLE RE, 1984, AM J EPIDEMIOL, V120, P794, DOI 10.1093/oxfordjournals.aje.a113949; MAINARDI M, 1989, BIOL BEHAV, V14, P185; MENNELLA JA, 1991, PEDIATRICS, V88, P737; NEVILLE MC, 1988, AM J CLIN NUTR, V48, P1375, DOI 10.1093/ajcn/48.6.1375; NICLOUX M, 1899, C R SOC BIOL, V51, P982; PHILLIPS DS, 1976, PHYSIOL PSYCHOL, V4, P473; PIKKARAINEN PH, 1967, PEDIATR RES, V1, P165, DOI 10.1203/00006450-196705000-00001; Siegel S., 1956, NONPARAMETRIC STAT B; SUBRAMANIAN MG, 1988, ALCOHOL, V5, P95, DOI 10.1016/0741-8329(88)90002-X; THIRY L, 1985, LANCET, V2, P891; WALTER M, 1975, B NEW YORK ACAD MED, V51, P870	30	206	207	0	12	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 3	1991	325	14					981	985		10.1056/NEJM199110033251401	http://dx.doi.org/10.1056/NEJM199110033251401			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GH447	1886634	Bronze			2022-12-24	WOS:A1991GH44700001
J	TURELLI, M; HOFFMANN, AA				TURELLI, M; HOFFMANN, AA			RAPID SPREAD OF AN INHERITED INCOMPATIBILITY FACTOR IN CALIFORNIA DROSOPHILA	NATURE			English	Article							LONG-DISTANCE MIGRATION; CYTOPLASMIC INCOMPATIBILITY; UNIDIRECTIONAL INCOMPATIBILITY; REPRODUCTIVE INCOMPATIBILITY; NATURAL-POPULATIONS; MITOCHONDRIAL-DNA; GENE FLOW; SIMULANS; MELANOGASTER; POLYMORPHISM	IN Drosophila simulans in California, an inherited cytoplasmic incompatibility factor reduces egg hatch when infected males mate with uninfected females 1-7. The infection is spreading at a rate of more than 100 km per year; populations in which the infection was rare have become almost completely infected within three years. Analyses of the spread using estimates of selection in the field suggest dispersal distances far higher than those found by direct observation of flies. Hence, occasional long-distance dispersal, possibly coupled with local extinction and recolonization, may be important to the dynamics. Incompatibility factors that can readily spread through natural populations may be useful for population manipulation and important as a post-mating isolating mechanism.	UNIV CALIF DAVIS, CTR POPULAT BIOL, DAVIS, CA 95616 USA; LA TROBE UNIV, DEPT GENET & HUMAN VARIAT, BUNDOORA, VIC 1083, AUSTRALIA	University of California System; University of California Davis; La Trobe University	TURELLI, M (corresponding author), UNIV CALIF DAVIS, DEPT GENET, DAVIS, CA 95616 USA.		Hoffmann, Ary/R-2972-2019; Hoffmann, Ary/C-2961-2011	Hoffmann, Ary/0000-0001-9497-7645; 				BARTON NH, 1979, HEREDITY, V43, P341, DOI 10.1038/hdy.1979.87; BINNINGTON KC, 1989, J INVERTEBR PATHOL, V54, P344, DOI 10.1016/0022-2011(89)90118-3; BREEUWER JAJ, 1990, NATURE, V346, P558, DOI 10.1038/346558a0; CASPARI E, 1959, EVOLUTION, V13, P568, DOI 10.1111/j.1558-5646.1959.tb03045.x; COYNE JA, 1987, AM NAT, V130, P70, DOI 10.1086/284698; COYNE JA, 1982, AM NAT, V119, P589, DOI 10.1086/283936; FINE PEM, 1978, J INVERTEBR PATHOL, V31, P10, DOI 10.1016/0022-2011(78)90102-7; Fisher RA, 1937, ANN EUGENIC, V7, P355, DOI 10.1111/j.1469-1809.1937.tb02153.x; FLEURIET A, 1988, EVOL BIOL, V23, P1; HALE LR, 1990, EVOLUTION, V44, P1383, DOI 10.1111/j.1558-5646.1990.tb05241.x; HOFFMANN AA, 1988, GENETICS, V119, P435; HOFFMANN AA, 1986, EVOLUTION, V40, P692, DOI 10.1111/j.1558-5646.1986.tb00531.x; HOFFMANN AA, 1990, GENETICS, V126, P933; HOFFMANN AA, 1988, ENTOMOL EXP APPL, V48, P61, DOI 10.1007/BF00343386; JONES JS, 1981, GENETICS, V98, P157; JONES JS, 1987, AM NAT, V130, P83, DOI 10.1086/284699; KELLEN WR, 1981, J INVERTEBR PATHOL, V37, P273, DOI 10.1016/0022-2011(81)90087-2; LEU SJC, 1989, J INVERTEBR PATHOL, V54, P248, DOI 10.1016/0022-2011(89)90035-9; LOUIS C, 1989, J INVERTEBR PATHOL, V54, P39, DOI 10.1016/0022-2011(89)90137-7; Model Gressel J., 1986, PESTICIDE RESISTANCE, P54; Murray J. D., 1989, MATH BIOL, DOI DOI 10.1007/978-3-662-08539-4; NIGRO L, 1990, GENETICS, V125, P551; NODA H, 1984, ENTOMOL EXP APPL, V35, P263, DOI 10.1007/BF00369142; ONEILL SL, 1990, NATURE, V348, P178, DOI 10.1038/348178a0; SKINNER SW, 1985, GENETICS, V109, P745; SLATKIN M, 1985, ANNU REV ECOL SYST, V16, P393, DOI 10.1146/annurev.ecolsys.16.1.393; STEVENS L, 1989, J INVERTEBR PATHOL, V53, P78, DOI 10.1016/0022-2011(89)90076-1; Subbarao S.K., 1982, P313; TURELLI M, 1986, DROS INFORM SERV, V63, P131	29	483	495	0	47	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	OCT 3	1991	353	6343					440	442		10.1038/353440a0	http://dx.doi.org/10.1038/353440a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GH606	1896086				2022-12-24	WOS:A1991GH60600060
J	NUSSLEINVOLHARD, C				NUSSLEINVOLHARD, C			FROM EGG TO ORGANISM - STUDIES ON EMBRYONIC PATTERN-FORMATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							BICOID PROTEIN; DROSOPHILA; POLARITY				NUSSLEINVOLHARD, C (corresponding author), MAX PLANCK INST ENTWICKLUNGSBIOL,GENET ABT 3,SPEMANNSTR 35-111,W-7400 TUBINGEN,GERMANY.							DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; DRIEVER W, 1989, NATURE, V337, P138, DOI 10.1038/337138a0; NUSSLEINVOLHARD C, 1987, SCIENCE, V238, P1675, DOI 10.1126/science.3686007; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; NUSSLEINVOLHARD C, 1984, ROUX ARCH DEV BIOL, V193, P267, DOI 10.1007/BF00848156	5	1	1	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 2	1991	266	13					1848	1849		10.1001/jama.266.13.1848	http://dx.doi.org/10.1001/jama.266.13.1848			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG551	1890716				2022-12-24	WOS:A1991GG55100043
J	LARSEN, JP				LARSEN, JP			PARKINSONS-DISEASE AS COMMUNITY-HEALTH PROBLEM - STUDY IN NORWEGIAN NURSING-HOMES	BRITISH MEDICAL JOURNAL			English	Article							EPIDEMIOLOGY	Objective - To examine the extent of underdiagnosis and overdiagnosis of Parkinson's disease and to determine quality of treatment in a defined population. Design - Clinical evaluation of an elderly population. Setting - 40 Norwegian nursing homes. Subjects - 3322 residents of nursing homes, of whom 500 were selected by nursing staff for evaluation on the basis of a structured information programme on Parkinson's disease and 269 were examined in detail by neurologists. Main outcome measures - Patients' scores on clinical rating scales, diagnosis of parkinsonism, and effect of changing drug treatment. Results - 169 (5.1%) patients were found to have clinical idiopathic Parkinson's disease, 31 of whom had not had the disease diagnosed previously. In addition, 31 patients without the disease were taking antiparkinsonian drugs unnecessarily. Eighty patients were judged to be receiving "optimal" treatment. In the remaining 58, the treatment was changed, and 36 patients showed a definite functional improvement after a 12 week observation period. Conclusions - The quality of life of many elderly patients with Parkinson's disease could be improved by increasing medical and neurological services.			LARSEN, JP (corresponding author), CENT HOSP ROGALAND,DEPT NEUROL,N-4011 STAVANGER,NORWAY.							BARBEAU A, 1984, CLIN NEUROL NEUROSUR, V86, P164, DOI 10.1016/0303-8467(84)90193-8; CROXSON S, 1989, GENERAL PRACTIT 1027, P4; DEPEDRO J, 1987, ACTA NEUROL SCA S112, V75, P40; Gottfries C G, 1982, Arch Gerontol Geriatr, V1, P311, DOI 10.1016/0167-4943(82)90031-0; HOEHN MM, 1967, NEUROLOGY, V17, P427, DOI 10.1212/WNL.17.5.427; LARSEN J P, 1988, Tidsskrift for den Norske Laegeforening, V108, P1377; LARSEN J P, 1988, Tidsskrift for den Norske Laegeforening, V108, P1380; MARSDEN CD, 1990, LANCET, V335, P948, DOI 10.1016/0140-6736(90)91006-V; MARSDEN CD, 1987, MOVEMENT DISORD, V2, P65; MARTILA RJ, 1987, HDB PARKINSONS DISEA, P38; MARTTILA RJ, 1976, ACTA NEUROL SCAND, V53, P81; MUTCH WJ, 1986, BRIT MED J, V292, P534, DOI 10.1136/bmj.292.6519.534; PLAYFER J, 1989, GERIATRIC MED, V19, P77; QUINN NP, 1986, BRIT MED J, V293, P379, DOI 10.1136/bmj.293.6543.379; RAJPUT AH, 1984, ANN NEUROL, V16, P278, DOI 10.1002/ana.410160303; SCHOENBERG BS, 1985, NEUROLOGY, V35, P841, DOI 10.1212/WNL.35.6.841; SCHOENBERG BS, 1987, MOVEMENT DISORD, V2, P17; WEBSTER DD, 1968, MOD TREAT, V5, P257	18	44	44	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 28	1991	303	6805					741	743		10.1136/bmj.303.6805.741	http://dx.doi.org/10.1136/bmj.303.6805.741			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG981	1932932	Green Published, Bronze			2022-12-24	WOS:A1991GG98100017
J	DENNIS, M; WARLOW, C				DENNIS, M; WARLOW, C			THE HEALTH OF THE NATION - RESPONSES - STRATEGY FOR STROKE	BRITISH MEDICAL JOURNAL			English	Article							DISEASE; MORTALITY; TRENDS				DENNIS, M (corresponding author), WESTERN GEN HOSP,DEPT CLIN NEUROSCI,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND.							BALARAJAN R, 1991, BMJ-BRIT MED J, V302, P560, DOI 10.1136/bmj.302.6776.560; BAMFORD J, 1988, J NEUROL NEUROSUR PS, V51, P1373, DOI 10.1136/jnnp.51.11.1373; BONITA R, 1986, BRIT MED J, V292, P191, DOI 10.1136/bmj.292.6514.191; BONITA R, 1990, STROKE, V21, P989, DOI 10.1161/01.STR.21.7.989; CAMERON HM, 1981, J PATHOL, V133, P273, DOI 10.1002/path.1711330402; CARSTAIRS V R M, 1990, Health Bulletin (Edinburgh), V48, P162; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; ISARD P, IN PRESS DISEASES; LAW MR, 1991, BMJ-BRIT MED J, V302, P819, DOI 10.1136/bmj.302.6780.819; MALMGREN R, 1987, LANCET, V2, P1196; ROSE G, 1981, BMJ-BRIT MED J, V282, P1847, DOI 10.1136/bmj.282.6279.1847; SHINTON R, 1989, BMJ-BRIT MED J, V298, P789, DOI 10.1136/bmj.298.6676.789; 1991, LANCET, V337, P1235; 1988, BMJ, V297, P126; 1988, PREVALENCE DISABILIT; 1988, BMJ, V296, P320; 1991, CM1523; 1991, BMJ, V302, P1057	18	21	21	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 14	1991	303	6803					636	638		10.1136/bmj.303.6803.636	http://dx.doi.org/10.1136/bmj.303.6803.636			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GF675	1932911	Green Published			2022-12-24	WOS:A1991GF67500031
J	HAYWOOD, GA; JOY, MD; CAMM, AJ				HAYWOOD, GA; JOY, MD; CAMM, AJ			INFLUENCE OF POSTURE AND REFERENCE POINT ON CENTRAL VENOUS-PRESSURE MEASUREMENT	BRITISH MEDICAL JOURNAL			English	Article									ST GEORGE HOSP,SCH MED,LONDON SW17 0RE,ENGLAND; ST PETERS HOSP,CHERTSEY KT16 0PZ,SURREY,ENGLAND	St Georges University London								Blomqvist CG., 1983, COMPR PHYSIOL, V3, P1025, DOI DOI 10.1002/CPHY.CP020328; SYKES M K, 1963, Ann R Coll Surg Engl, V33, P185; WILSON JN, 1962, ARCH SURG-CHICAGO, V85, P563	3	7	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 14	1991	303	6803					626	627		10.1136/bmj.303.6803.626	http://dx.doi.org/10.1136/bmj.303.6803.626			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GF675	1932904	Green Published, Bronze			2022-12-24	WOS:A1991GF67500024
J	ONG, ELC; BILTON, D; ABBOTT, J; WEBB, AK; MCCARTNEY, RA; CAUL, EO				ONG, ELC; BILTON, D; ABBOTT, J; WEBB, AK; MCCARTNEY, RA; CAUL, EO			INFLUENZA VACCINATION IN ADULTS WITH CYSTIC-FIBROSIS	BRITISH MEDICAL JOURNAL			English	Article									MONSALL HOSP,ADULT CYST FIBROSIS UNIT,MANCHESTER M10 8WR,ENGLAND; MONSALL HOSP,REG DEPT INFECT DIS & TROP MED,MANCHESTER M10 8WR,ENGLAND; REG PUBL HLTH & DIST VIROL LAB,BRISTOL BS2 8EL,ENGLAND					Ong, Edmund/0000-0002-6594-0509; Bilton, Diana/0000-0002-1913-9171				DAVIES JR, 1989, EPIDEMIOL INFECT, V102, P325, DOI 10.1017/S0950268800030004; EICKHOFF TC, 1961, JAMA-J AM MED ASSOC, V176, P776, DOI 10.1001/jama.1961.03040220024005; GRILLI EA, 1983, J HYG-CAMBRIDGE, V91, P147, DOI 10.1017/S0022172400060125; ONG ELC, 1989, THORAX, V4, P739; WANG EEL, 1984, NEW ENGL J MED, V311, P1653, DOI 10.1056/NEJM198412273112602	5	23	25	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 7	1991	303	6802					557	557		10.1136/bmj.303.6802.557	http://dx.doi.org/10.1136/bmj.303.6802.557			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GE948	1912886	Green Published, Bronze			2022-12-24	WOS:A1991GE94800024
J	ISACOFF, EY; JAN, YN; JAN, LY				ISACOFF, EY; JAN, YN; JAN, LY			PUTATIVE RECEPTOR FOR THE CYTOPLASMIC INACTIVATION GATE IN THE SHAKER K+ CHANNEL	NATURE			English	Article							POTASSIUM CHANNELS; SODIUM-CHANNEL; DROSOPHILA MUSCLE; XENOPUS-OOCYTES; RAT-BRAIN; CLONING	INACTIVATION of ion channels is important in the control of membrane excitability. For example, delayed-rectifier K+ channels, which regulate action potential repolarization, are inactivated only slowly, whereas A-type K+ channels, which affect action potential duration and firing frequency, have both fast and slow inactivation 1. Fast inactivation of Na+ and K+ channels may result from the blocking of the permeation pathway by a positively charged cytoplasmic gate 2 such as the one encoded by the first 20 amino acids of the Shaker B (ShB) K+ channel 3,4. We report here that mutation of five highly conserved residues between the proposed membrane-spanning segments S4 and S5 (also termed H4) 5 of ShB affects the stability of the inactivated state and alters channel conductance. One such mutation stabilizes the inactivated state of ShB as well as the inactivated state induced in the delayed-rectifier type K+ channel drk1 (ref. 6) by the cytoplasmic application of the ShB N-terminal peptide. The S4-S5 loop, therefore, probably forms part of a receptor for the inactivation gate and lies near the channel's permeation pathway.	UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco	ISACOFF, EY (corresponding author), UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143, USA.		isacoff, ehud/AAP-1459-2020	Jan, Lily/0000-0003-3938-8498; Jan, Yuh Nung/0000-0003-1367-6299; Isacoff, Ehud Y./0000-0003-4775-9359				ARMSTRON.CM, 1969, J GEN PHYSIOL, V54, P553, DOI 10.1085/jgp.54.5.553; ARMSTRONG CM, 1977, J GEN PHYSIOL, V70, P567, DOI 10.1085/jgp.70.5.567; ARMSTRONG CM, 1971, J GEN PHYSIOL, V58, P413, DOI 10.1085/jgp.58.4.413; BAUMANN A, 1988, EMBO J, V7, P2457, DOI 10.1002/j.1460-2075.1988.tb03092.x; CATTERALL WA, 1986, ANNU REV BIOCHEM, V55, P953, DOI 10.1146/annurev.bi.55.070186.004513; CHOI KL, 1991, P NATL ACAD SCI USA, V88, P5092, DOI 10.1073/pnas.88.12.5092; FRECH GC, 1989, NATURE, V340, P642, DOI 10.1038/340642a0; GREENBLATT RE, 1985, FEBS LETT, V193, P125, DOI 10.1016/0014-5793(85)80136-8; GUY HR, 1986, P NATL ACAD SCI USA, V83, P508, DOI 10.1073/pnas.83.2.508; GUY HR, 1990, TRENDS NEUROSCI, V13, P201; HARTMANN HA, 1991, SCIENCE, V251, P942, DOI 10.1126/science.2000495; Hille B, 1984, IONIC CHANNELS EXCIT; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; ISACOFF E, 1990, COLD SPRING HARB SYM, V55, P9; ISACOFF EY, 1990, NATURE, V345, P530, DOI 10.1038/345530a0; JAN LY, 1990, TRENDS NEUROSCI, V13, P415, DOI 10.1016/0166-2236(90)90123-R; MACKINNON R, 1990, SCIENCE, V250, P276, DOI 10.1126/science.2218530; MCCORMACK T, 1990, P NATL ACAD SCI USA, V87, P5227, DOI 10.1073/pnas.87.13.5227; NODA M, 1986, NATURE, V320, P188, DOI 10.1038/320188a0; PAPAZIAN DM, 1991, NATURE, V349, P305, DOI 10.1038/349305a0; PFAFFINGER PJ, 1991, J NEUROSCI, V11, P918; RIBERA AB, 1990, NEURON, V5, P691, DOI 10.1016/0896-6273(90)90223-3; ROBERDS SL, 1991, P NATL ACAD SCI USA, V88, P1798, DOI 10.1073/pnas.88.5.1798; SCHWARZ TL, 1988, NATURE, V331, P137, DOI 10.1038/331137a0; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494; YOOL AJ, 1991, NATURE, V349, P700, DOI 10.1038/349700a0; ZAGOTTA WN, 1990, J GEN PHYSIOL, V95, P29, DOI 10.1085/jgp.95.1.29; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520; ZAGOTTA WN, 1989, P NATL ACAD SCI USA, V86, P7243, DOI 10.1073/pnas.86.18.7243	30	309	314	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 5	1991	353	6339					86	90		10.1038/353086a0	http://dx.doi.org/10.1038/353086a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GD805	1881453				2022-12-24	WOS:A1991GD80500066
J	INGOLD, AL; LANDEL, C; KNALL, C; EVANS, GA; POTTER, TA				INGOLD, AL; LANDEL, C; KNALL, C; EVANS, GA; POTTER, TA			CO-ENGAGEMENT OF CD8 WITH THE T-CELL RECEPTOR IS REQUIRED FOR NEGATIVE SELECTION	NATURE			English	Article							PROTEIN KINASE P56LCK; I ALPHA-3 DOMAIN; TRANSGENIC MICE; LYMPHOCYTES-T; RECOGNITION; DELETION; MOLECULE; ANTIGEN; SELF; SUBSTITUTION	ALTHOUGH it is established that the CD8 and CD4 co-receptors are involved in T-lymphocyte recognition and activation in the periphery, it is less clear whether these molecules participate in thymic selection events. Analysis of thymic selection in mice transgenic for T cell-receptor genes 1-4 or for major histocompatibility complex (MHC) genes 5, or mice injected with antibodies against CD8, CD4 or MHC molecules 6-8, is consistent with the participation of CD8 and CD4 in thymic selection. But antibody-mediated crosslinking of surface receptors in thymic organ cultures 9 has indicated that CD8 is not involved in thymic deletion. We show here that mice transgenic for a mutant MHC class I molecule that cannot interact with CD8 do not delete CD8-dependent T cells reactive with the wild-type molecule. This finding unequivocally establishes that for negative selection in the thymus, CD8 must interact with the same MHC class I molecule as the T cell receptor.	UNIV COLORADO,HLTH SCI CTR,DEPT MICROBIOL & IMMUNOL,DENVER,CO 80206; UNIV COLORADO,HLTH SCI CTR,CTR CANC,DENVER,CO 80206; SALK INST BIOL STUDIES,MOLEC GENET LAB,SAN DIEGO,CA 92138	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Salk Institute	INGOLD, AL (corresponding author), NATL JEWISH CTR IMMUNOL & RESP MED,DIV BASIC IMMUNOL,DENVER,CO 80206, USA.							BARBER EK, 1989, P NATL ACAD SCI USA, V86, P3277, DOI 10.1073/pnas.86.9.3277; BERG LJ, 1989, CELL, V58, P1035, DOI 10.1016/0092-8674(89)90502-3; BIEBERICH C, 1986, MOL CELL BIOL, V6, P1339, DOI 10.1128/MCB.6.4.1339; CONNOLLY JM, 1988, J EXP MED, V168, P325, DOI 10.1084/jem.168.1.325; CONNOLLY JM, 1990, P NATL ACAD SCI USA, V87, P2137, DOI 10.1073/pnas.87.6.2137; FOWLKES BJ, 1988, NATURE, V334, P620, DOI 10.1038/334620a0; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; JANEWAY CA, 1989, IMMUNOL REV, V109, P77, DOI 10.1111/j.1600-065X.1989.tb00020.x; KALINKE U, 1990, NATURE, V348, P642, DOI 10.1038/348642a0; KAYE J, 1989, NATURE, V341, P746, DOI 10.1038/341746a0; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; LOH DY, 1989, COLD SH Q B, V54, P147, DOI 10.1101/SQB.1989.054.01.018; MACDONALD HR, 1988, NATURE, V335, P174, DOI 10.1038/335174a0; MCDONALD HR, 1982, IMMUNOL REV, V68, P89; POTTER TA, 1987, J EXP MED, V166, P956, DOI 10.1084/jem.166.4.956; POTTER TA, 1989, NATURE, V337, P73, DOI 10.1038/337073a0; SALTER RD, 1990, NATURE, V345, P41, DOI 10.1038/345041a0; SWAIN SL, 1983, IMMUNOL REV, V74, P129, DOI 10.1111/j.1600-065X.1983.tb01087.x; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; YACHELINI P, 1990, J IMMUNOL, V145, P1382; YOSHIOKA T, 1987, J IMMUNOL, V139, P3861; ZUNIGAPFLUCKER JC, 1989, COLD SPRING HARB SYM, V54, P153	23	85	85	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 22	1991	352	6337					721	723		10.1038/352721a0	http://dx.doi.org/10.1038/352721a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC064	1908563				2022-12-24	WOS:A1991GC06400060
J	MUELLER, LD; GUO, PZ; AYALA, FJ				MUELLER, LD; GUO, PZ; AYALA, FJ			DENSITY-DEPENDENT NATURAL-SELECTION AND TRADE-OFFS IN LIFE-HISTORY TRAITS	SCIENCE			English	Article							FOOD-LIMITED ENVIRONMENTS; POPULATION-GROWTH; K-SELECTION; REGULATED SELECTION; DROSOPHILA MODEL; ESCHERICHIA-COLI; R-SELECTION; EVOLUTION; PLEIOTROPY	Theories of density-dependent natural selection state that at extreme population densities evolution produces alternative life histories due to trade-offs. The trade-offs are presumed to arise because those genotypes with highest fitness at high population densities will not also have high fitness at low density and vice-versa. These predictions were tested by taking samples from six populations of Drosophila melanogaster kept at low population densities (r-populations) for nearly 200 generations and placing them in crowded cultures (K-populations). After 25 generations in the crowded cultures, the derived K-populations showed growth rate and productivity that at high densities were elevated relative to the controls, but at low density were depressed.			MUELLER, LD (corresponding author), UNIV CALIF IRVINE,DEPT ECOL & EVOLUTIONARY BIOL,IRVINE,CA 92717, USA.				NCRR NIH HHS [S07 RR07008] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR007008] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ANDERSON WW, 1971, AM NAT, V105, P489, DOI 10.1086/282741; ANDERSON WW, 1983, AM NAT, V121, P649, DOI 10.1086/284092; ASMUSSEN MA, 1983, GENETICS, V103, P335; BARCLAY HJ, 1981, AM NAT, V117, P944, DOI 10.1086/283779; BRADSHAW WE, 1989, AM NAT, V133, P869, DOI 10.1086/284957; CHARLESWORTH B, 1971, ECOLOGY, V52, P469, DOI 10.2307/1937629; CLARKE B, 1972, AM NAT, V106, P1, DOI 10.1086/282747; GUO P, UNPUB; HAYMER DS, 1983, GENETICS, V104, P343; LENSKI RE, 1988, EVOLUTION, V42, P433, DOI 10.1111/j.1558-5646.1988.tb04150.x; Loeschcke V, 1987, GENETIC CONSTRAINTS; LUCKINBILL LS, 1978, SCIENCE, V202, P1201, DOI 10.1126/science.202.4373.1201; MAC ARTHUR ROBERT H., 1967; MACARTHUR RH, 1962, P NATL ACAD SCI USA, V48, P1893, DOI 10.1073/pnas.48.11.1893; MUELLER LD, 1988, P NATL ACAD SCI USA, V85, P4383, DOI 10.1073/pnas.85.12.4383; MUELLER LD, 1988, AM NAT, V132, P786, DOI 10.1086/284890; MUELLER LD, 1990, EVOL ECOL, V4, P290, DOI 10.1007/BF02270928; MUELLER LD, 1981, P NATL ACAD SCI-BIOL, V78, P1303, DOI 10.1073/pnas.78.2.1303; MUELLER LD, 1986, EVOLUTION, V40, P1354, DOI 10.1111/j.1558-5646.1986.tb05761.x; MUELLER LD, 1988, EVOLUTION, V42, P1090; REZNICK D, 1985, OIKOS, V44, P257, DOI 10.2307/3544698; ROSE MR, 1985, THEOR POPUL BIOL, V28, P342, DOI 10.1016/0040-5809(85)90034-6; ROSE MR, 1984, EVOLUTION, V38, P1004, DOI 10.1111/j.1558-5646.1984.tb00370.x; ROUGHGARDEN J, 1971, ECOLOGY, V52, P453, DOI 10.2307/1937628; Roughgarden J., 1979, THEORY POPULATION GE; TAYLOR CE, 1980, EVOLUTION, V34, P1183, DOI 10.1111/j.1558-5646.1980.tb04064.x	26	95	95	0	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 26	1991	253	5018					433	435		10.1126/science.1907401	http://dx.doi.org/10.1126/science.1907401			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FY288	1907401	Green Submitted			2022-12-24	WOS:A1991FY28800036
J	CROW, YJ; ALBERTI, KGMM; PARKIN, JM				CROW, YJ; ALBERTI, KGMM; PARKIN, JM			INSULIN-DEPENDENT DIABETES IN CHILDHOOD AND MATERIAL DEPRIVATION IN NORTHERN ENGLAND, 1977-86	BRITISH MEDICAL JOURNAL			English	Article							SOCIAL-CLASS; MELLITUS; IDDM	Objective - To determine the incidence of insulin dependent diabetes in the Northern region of England in children less than 16 years old in the period 1977 to 1986 and to relate the incidence data to an index of deprivation. Design - Retrospective analysis of hospital case records identified from the regional health authority's computer; validation of the primary source with hospital clinic registers and community paediatric registers. Setting - Northern region, excluding South Cumbria District Health Authority (659 300 children under 16 in 1981). Patients - All children diagnosed with insulin dependent diabetes before the age of 16 and resident in the region at time of diagnosis. Main outcome measures - Incidence rates for the 10 year period and analysis of incidence rates within categories of deprivation. Results - 919 incident cases were identified. The validation procedure covered 54% of all cases identified and gave 95% completeness of ascertainment. The average annual incidence over the 10 year period was 14.8/100 000 for girls and 13.4/100 000 for boys. The annual incidence for the most and least deprived areas of the region was 18.7/100 000 (95% confidence interval 16.2 to 21.5) for boys and 7/100 000 (5.6 to 8.8) for girls. There was a highly significant trend (p < 0.001) of decreasing incidence with decreasing level of deprivation. Conclusions - In the north of England the incidence of childhood diabetes is related to material deprivation.			CROW, YJ (corresponding author), UNIV NEWCASTLE UPON TYNE,SCH MED,DEPT MED,HUMAN DIABET & METAB RES CTR,NEWCASTLE TYNE NE2 4HH,ENGLAND.		Crow, Yanick J/N-6120-2014	Crow, Yanick J/0000-0001-7211-7564				AKERBLOM HK, 1985, DIABETES CARE, V8, P10, DOI 10.2337/diacare.8.1.S10; ARMITAGE P, 1987, STATISTICAL METHODS, P372; BINGLEY PJ, 1989, BRIT MED J, V298, P558, DOI 10.1136/bmj.298.6673.558; Diabetes Epidemiology Research International Group, 1988, DIABETES, V37, P1113; HILL AB, 1984, SHORT TXB MED STATIS, P168; LAPORTE RE, 1981, AM J EPIDEMIOL, V114, P379, DOI 10.1093/oxfordjournals.aje.a113205; LILIENFELD AM, 1980, F EPIDEMIOLOGY, P337; SIEMIATYCKI J, 1988, DIABETES, V37, P1096, DOI 10.2337/diabetes.37.8.1096; STEWARTBROWN S, 1983, BRIT MED J, V286, P1855, DOI 10.1136/bmj.286.6381.1855; Townsend PP., 1988, HLTH DEPRIVATION INE; WILSON RM, 1986, JAMA-J AM MED ASSOC, V256, P877, DOI 10.1001/jama.256.7.877; 1981, CENSUS 1981; 1990, DIABETES, V39, P858; 1987, BMJ, V295, P479	14	33	33	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 20	1991	303	6795					158	160		10.1136/bmj.303.6795.158	http://dx.doi.org/10.1136/bmj.303.6795.158			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FX578	1878639	Green Published, Bronze			2022-12-24	WOS:A1991FX57800021
J	SWAT, W; IGNATOWICZ, L; VONBOEHMER, H; KISIELOW, P				SWAT, W; IGNATOWICZ, L; VONBOEHMER, H; KISIELOW, P			CLONAL DELETION OF IMMATURE CD4+8+ THYMOCYTES IN SUSPENSION-CULTURE BY EXTRATHYMIC ANTIGEN-PRESENTING CELLS	NATURE			English	Article							TRANSGENIC MICE; T-CELLS; TOLERANCE; RECEPTOR; THYMUS	ONE mechanism ensuring self tolerance of T cells is the clonal deletion of thymocytes bearing alpha-beta T-cell receptors 1-4. The stage of thymocyte development at which the interaction with antigen-presenting cells (APCs) leads to deletion, however, has not been determined directly. Indirect evidence suggests that intrathymic APCs induce deletion of CD4+8+ thymocytes 3-6 (which die by apoptosis 7) but deletion at less 8 and more mature 9 developmental stages has also been implied. It is also not clear if clonal elimination of thymocytes can be triggered by peripheral antigens carried on extrathymic APCs migrating through the thymus 10. Here we show antigen-specific induction of apoptosis in CD4+8+ thymocytes cultured in suspension, by thymic as well as splenic APCs. Thus the recognition of antigen by CD4+8+ thymocytes may lead to deletion, suggesting that this is the central mechanism of tolerance induction, which is not limited by the antigen-presenting ability of the thymic stroma.	POLISH ACAD SCI,INST IMMUNOL & EXPTL THERAPY,UL CZERSKA 12,PL-53114 WROCLAW,POLAND; BASEL INST IMMUNOL,CH-4005 BASEL,SWITZERLAND	Polish Academy of Sciences; Hirszfeld Institute of Immunology & Experimental Therapy of the Polish Academy of Sciences								CEREDIG R, 1983, J EXP MED, V158, P1654, DOI 10.1084/jem.158.5.1654; FOWLKES BJ, 1988, NATURE, V334, P620, DOI 10.1038/334620a0; JENKINSON EJ, 1989, EUR J IMMUNOL, V19, P2175, DOI 10.1002/eji.1830191132; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; LONGO DL, 1980, NATURE, V287, P44, DOI 10.1038/287044a0; MACDONALD HR, 1990, NATURE, V343, P642, DOI 10.1038/343642a0; MACDONALD HR, 1988, NATURE, V332, P40, DOI 10.1038/332040a0; MACDONALD HR, 1988, NATURE, V335, P174, DOI 10.1038/335174a0; MATZINGER P, 1989, NATURE, V338, P74, DOI 10.1038/338074a0; ROTZSCHKE O, 1990, SCIENCE, V249, P283, DOI 10.1126/science.1695760; SHA WC, 1988, NATURE, V335, P271, DOI 10.1038/335271a0; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; SWAT W, 1991, J IMMUNOL METHODS, V137, P79, DOI 10.1016/0022-1759(91)90396-W; Teh H S, 1990, Dev Immunol, V1, P1, DOI 10.1155/1990/18208; VONBOEHMER H, 1990, SCIENCE, V248, P1369, DOI 10.1126/science.1972594; VONBOEHMER H, 1990, ANNU REV IMMUNOL, V8, P531, DOI 10.1146/annurev.iy.08.040190.002531; WHITE J, 1989, CELL, V56, P27, DOI 10.1016/0092-8674(89)90980-X	18	268	269	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 9	1991	351	6322					150	153		10.1038/351150a0	http://dx.doi.org/10.1038/351150a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL035	1903182				2022-12-24	WOS:A1991FL03500052
J	OLDSTONE, MBA; NERENBERG, M; SOUTHERN, P; PRICE, J; LEWICKI, H				OLDSTONE, MBA; NERENBERG, M; SOUTHERN, P; PRICE, J; LEWICKI, H			VIRUS-INFECTION TRIGGERS INSULIN-DEPENDENT DIABETES-MELLITUS IN A TRANSGENIC MODEL - ROLE OF ANTI-SELF (VIRUS) IMMUNE-RESPONSE	CELL			English	Article							LYMPHOCYTIC CHORIOMENINGITIS VIRUS; PANCREATIC BETA-CELLS; COXSACKIE-B-VIRUS; CLASS-II MHC; DIFFERENTIATED FUNCTIONS; AUTOIMMUNE-DISEASE; PROTEIN-STRUCTURE; CROSS-REACTIVITY; MICE; EXPRESSION	We investigated the potential association between viruses and insulin-dependent (type 1) diabetes (IDDM) by developing a transgenic mouse model. By inserting into these mice a unique viral protein that was then expressed as a self-antigen in the pancreatic islets of Langerhans, we could study the effect on that expressed antigen alone, or in concert with an induced antiviral (i.e., autoimmune) response manifested later in life in causing IDDM. Our results indicate that a viral gene introduced as early as an animal's egg stage, incorporated into the germline, and expressed in islet cells does not produce tolerance when the host is exposed to the same virus later in life. We observed that the induced anti-self (viral) CTL response leads to selective and progressive damage of beta-cells, resulting in IDDM.			OLDSTONE, MBA (corresponding author), SCRIPPS CLIN & RES FDN,DEPT NEUROPHARMACOL,VIROL SERV,10666 N TORREY PINES RD,LA JOLLA,CA 92037, USA.				NIAID NIH HHS [AI-09484] Funding Source: Medline; NIA NIH HHS [AG-04342] Funding Source: Medline; NINDS NIH HHS [NS-01330] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI009484, R01AI009484] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG004342] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALLISON J, 1988, NATURE, V333, P529, DOI 10.1038/333529a0; BAEKKESKOV S, 1990, CURR TOP MICROBIOL, V164, P1; BOHME J, 1989, SCIENCE, V244, P1179, DOI 10.1126/science.2499048; BOTTAZZO GF, 1983, LANCET, V2, P1115; BUCHMEIER MJ, 1981, VIROLOGY, V113, P73, DOI 10.1016/0042-6822(81)90137-9; BUCHMEIER MJ, 1979, VIROLOGY, V99, P111, DOI 10.1016/0042-6822(79)90042-4; BUCHMEIER MJ, 1978, VIROLOGY, V89, P133, DOI 10.1016/0042-6822(78)90047-8; DEMOTZ S, 1990, SCIENCE, V249, P1028, DOI 10.1126/science.2118680; DOLSTONE MBA, 1990, J EXP MED, V171, P2077; DOLSTONE MBA, 1989, SCI AM, V260, P42; DYRBERG T, 1990, CURR TOP MICROBIOL, V156, P1; EISENBARTH GS, 1986, NEW ENGL J MED, V314, P1360; Gamble D R, 1980, Epidemiol Rev, V2, P49; GLADISCH R, 1976, Z KARDIOL, V65, P837; HAMAFURA T, 1988, DIABETES, V37, P204; HANAHAN D, 1989, SCIENCE, V246, P1265, DOI 10.1126/science.2686032; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; Hogan B., 1986, MANIPULATING MOUSE E; HORN GT, 1988, P NATL ACAD SCI USA, V85, P6012, DOI 10.1073/pnas.85.16.6012; HULTQUIST G, 1973, UPSALA J MED SCI, V78, P139, DOI 10.3109/03009737309178618; JENSON AB, 1984, PROG MED VIROL, V29, P197; JENSON AB, 1980, LANCET, V2, P354; KING ML, 1983, LANCET, V1, P1397; KLAVINSKIS LS, 1989, J IMMUNOL, V143, P2013; KLAVINSKIS LS, 1989, J VIROL, V63, P4311, DOI 10.1128/JVI.63.10.4311-4316.1989; KLAVINSKIS LS, 1989, VIROLOGY, V168, P232, DOI 10.1016/0042-6822(89)90262-6; KLAVINSKIS LS, 1987, J GEN VIROL, V68, P1867, DOI 10.1099/0022-1317-68-7-1867; KOEVARY S, 1983, SCIENCE, V220, P727, DOI 10.1126/science.6836309; LERNER RA, 1971, SCIENCE, V173, P60, DOI 10.1126/science.173.3991.60; LERNMARK A, 1985, DIABETOLOGIA, V28, P195; LO D, 1988, CELL, V53, P159, DOI 10.1016/0092-8674(88)90497-7; LOHR JM, 1990, LANCET, P644; Maniatis T., 1982, MOL CLONING; MENSER MA, 1978, LANCET, V1, P57; NOTKINS AL, 1984, CONCEPTS VIRAL PATHO, P241; OLDSTONE MBA, 1982, NATURE, V300, P360, DOI 10.1038/300360a0; OLDSTONE MBA, 1984, SCIENCE, V224, P1440, DOI 10.1126/science.6203172; OLDSTONE MBA, 1988, J EXP MED, V168, P559, DOI 10.1084/jem.168.2.559; OLDSTONE MBA, 1985, VIROLOGY, V142, P158, DOI 10.1016/0042-6822(85)90430-1; OLDSTONE MBA, 1986, NATURE, V321, P239, DOI 10.1038/321239a0; OLDSTONE MBA, 1980, J IMMUNOL, V124, P831; OLDSTONE MBA, 1982, SCIENCE, V218, P1125, DOI 10.1126/science.7146898; OLDSTONE MBA, 1987, CELL, V50, P819, DOI 10.1016/0092-8674(87)90507-1; OLDSTONE MBA, 1983, VIROLOGY, V127, P426, DOI 10.1016/0042-6822(83)90155-1; OLDSTONE MBA, 1978, UCLA S MOL CELLULAR, V9, P43; PAK CY, 1988, LANCET, V2, P1; PATTERSON K, 1981, LANCET, V1, P1048; ROMAN LM, 1990, CELL, V61, P383, DOI 10.1016/0092-8674(90)90521-F; SARVETNICK N, 1988, CELL, V52, P773, DOI 10.1016/0092-8674(88)90414-X; SARVETNICK N, 1990, NATURE, V346, P844, DOI 10.1038/346844a0; SISSONS JGP, 1980, P NATL ACAD SCI-BIOL, V77, P559, DOI 10.1073/pnas.77.1.559; SOUTHERN PJ, 1987, VIROLOGY, V157, P145, DOI 10.1016/0042-6822(87)90323-0; SOUTHERN PJ, 1986, VACCINES 86 MODERN A, P239; THOMSON G, 1988, AM J HUM GENET, V43, P799; TISHON A, 1988, J IMMUNOL, V140, P1280; TODD JA, 1988, SCIENCE, V240, P1003, DOI 10.1126/science.3368786; UNGER R H, 1985, P1018; WHITTON JL, 1989, J EXP MED, V170, P1033, DOI 10.1084/jem.170.3.1033; WHITTON JL, 1988, VIROLOGY, V162, P321, DOI 10.1016/0042-6822(88)90471-0; WHITTON JL, 1989, J VIROL, V63, P4303, DOI 10.1128/JVI.63.10.4303-4310.1989; WRIGHT KE, 1990, VIROLOGY, V177, P175, DOI 10.1016/0042-6822(90)90471-3; YOON JW, 1979, NEW ENGL J MED, V300, P1173, DOI 10.1056/NEJM197905243002102; ZINKERNAGEL RM, 1990, NATURE, V345, P68, DOI 10.1038/345068a0; [No title captured]	64	682	690	0	14	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 19	1991	65	2					319	331		10.1016/0092-8674(91)90165-U	http://dx.doi.org/10.1016/0092-8674(91)90165-U			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FH092	1901765				2022-12-24	WOS:A1991FH09200014
J	SWAN, IRC; GATEHOUSE, S				SWAN, IRC; GATEHOUSE, S			CLINICAL AND FINANCIAL AUDIT OF DIAGNOSTIC PROTOCOLS FOR LESIONS OF THE CEREBELLOPONTINE ANGLE	BRITISH MEDICAL JOURNAL			English	Article							AUDIOLOGIC EVALUATION; ACOUSTIC NEUROMA; TESTS	Objective-To assess the diagnostic efficiency and costs of protocols used for investigating patients with suspected lesions of the cerebellopontine angle. Design-Prospective evaluation of tests of auditory brain stem responses and acoustic reflex thresholds, electronystagmography, and calorics. Positive test results were confirmed or refuted by high resolution computed tomography with intravenous enhancement. Setting-Single general otolaryngology clinic in a teaching hospital. Patients-270 consecutive patients with sensorineural hearing loss requiring investigation to exclude a lesion of the cerebellopontine angle. Main outcome measures-Estimated costs of various diagnostic protocols and performance in detecting tumours of the cerebellopontine angle. Results-Protocols including tests of auditory brain stem responses and acoustic reflex thresholds as sifting tests before computed tomography were clinically acceptable and presented considerable savings over the use of computed tomography in all patients (74000 pounds or 84000 pounds v 122000 pounds). The use of electronystagmography and calorics could not be justified on clinical or financial grounds. Conclusions-Audiological tests of auditory brain stem responses and acoustic reflex thresholds followed by computed tomography constitute the most cost effective protocol for determining suspected lesions of the cerebellopontine angle. Implications-The cost effectiveness of diagnostic protocols should be evaluated throughout the health service.	GLASGOW ROYAL INFIRM,MRC,INST HEARING RES,SCOTTISH SECT,GLASGOW G4 0SF,SCOTLAND	University of Glasgow	SWAN, IRC (corresponding author), UNIV GLASGOW,ROYAL INFIRM,DEPT OTOLARYNGOL,GLASGOW G4 0SF,SCOTLAND.							BARRS DM, 1987, OTOLARYNG HEAD NECK, V96, P523, DOI 10.1177/019459988709600601; CASHMAN MZ, 1983, J OTOLARYNGOL, V12, P180; Harder H, 1988, Acta Otolaryngol Suppl, V452, P5; HART RG, 1981, NEUROSURGERY, V9, P450, DOI 10.1227/00006123-198110000-00021; JERGER S, 1983, AUDIOLOGY, V22, P144; JOHNSON EW, 1977, ARCH OTOLARYNGOL, V103, P152; Jongkees L B, 1973, Otolaryngol Clin North Am, V6, P73; JOSEY A F, 1987, Ear and Hearing, V8, p19S, DOI 10.1097/00003446-198708001-00006; MAIR IWS, 1988, SCAND AUDIOL, V17, P163, DOI 10.3109/01050398809042188; MOFFAT DA, 1989, J LARYNGOL OTOL, V103, P51, DOI 10.1017/S0022215100108023; MUSIEK FE, 1986, EAR HEARING, V7, P100, DOI 10.1097/00003446-198604000-00008; Norre M E, 1978, Acta Otorhinolaryngol Belg, V32, P421; PRIEDE VM, 1984, J LARYNGOL OTOL, V88, P641; REIMER A, 1987, SCAND AUDIOL, V16, P101, DOI 10.3109/01050398709042163; SANDERS JW, 1974, ARCH OTOLARYNGOL, V100, P283; THOMSEN J, 1988, ACTA OTOLARYNGOL S S, V452, P16; TURNER RG, 1984, EAR HEARING, V5, P187, DOI 10.1097/00003446-198407000-00002; 1988, LANCET, V2, P1294	18	12	12	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 23	1991	302	6778					701	704		10.1136/bmj.302.6778.701	http://dx.doi.org/10.1136/bmj.302.6778.701			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FE333	1902384	Green Published, Bronze			2022-12-24	WOS:A1991FE33300027
J	WHEELER, DA; KYRIACOU, CP; GREENACRE, ML; YU, Q; RUTILA, JE; ROSBASH, M; HALL, JC				WHEELER, DA; KYRIACOU, CP; GREENACRE, ML; YU, Q; RUTILA, JE; ROSBASH, M; HALL, JC			MOLECULAR TRANSFER OF A SPECIES-SPECIFIC BEHAVIOR FROM DROSOPHILA-SIMULANS TO DROSOPHILA-MELANOGASTER	SCIENCE			English	Article							COURTSHIP SONG RHYTHMS; PERIOD GENE; SPECTRAL-ANALYSIS; MUTANTS; LOCUS; DNA; CYCLES	Drosophila males modulate the interpulse intervals produced during their courtship songs. These song cycles, which are altered by mutations in the clock gene period, exhibit a species-specific variation that facilitates mating. We have used chimeric period gene constructs from Drosophila melanogaster and Drosophila simulans in germline transformation experiments to map the genetic control of their song rhythm difference to a small segment of the amino acid encoding information within this gene.	BRANDEIS UNIV,DEPT BIOL,WALTHAM,MA 02254; BRANDEIS UNIV,HOWARD HUGHES MED INST,WALTHAM,MA 02254; UNIV LEICESTER,DEPT GENET,LEICESTER LE1 7RH,ENGLAND	Brandeis University; Brandeis University; Howard Hughes Medical Institute; University of Leicester					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021473, P01GM033205] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-21473, GM-33205] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENNETCLARK HC, 1969, ANIM BEHAV, V17, P755, DOI 10.1016/S0003-3472(69)80023-0; CITRI Y, 1987, NATURE, V326, P42, DOI 10.1038/326042a0; COLOT HV, 1988, EMBO J, V7, P3929, DOI 10.1002/j.1460-2075.1988.tb03279.x; COWLING DE, 1981, ANIM BEHAV, V29, P924, DOI 10.1016/S0003-3472(81)80030-9; CROSSLEY SA, 1988, ANIM BEHAV, V36, P1098, DOI 10.1016/S0003-3472(88)80069-1; EWING AW, 1988, ANIM BEHAV, V36, P1091, DOI 10.1016/S0003-3472(88)80068-X; Hall J.C., 1990, Advances in Insect Physiology, V22, P221, DOI 10.1016/S0065-2806(08)60007-7; HAMBLEN M, 1986, J NEUROGENET, V3, P249, DOI 10.3109/01677068609106855; HAMBLENCOYLE M, 1989, J NEUROGENET, V5, P229, DOI 10.3109/01677068909066210; JACKSON FR, 1986, NATURE, V320, P185, DOI 10.1038/320185a0; KONOPKA RJ, 1971, P NATL ACAD SCI USA, V68, P2112, DOI 10.1073/pnas.68.9.2112; KYRIACOU CP, 1982, ANIM BEHAV, V30, P794, DOI 10.1016/S0003-3472(82)80152-8; KYRIACOU CP, 1990, BEHAV GENET, V20, P617, DOI 10.1007/BF01065875; KYRIACOU CP, 1980, P NATL ACAD SCI-BIOL, V77, P6729, DOI 10.1073/pnas.77.11.6729; KYRIACOU CP, 1986, SCIENCE, V232, P494, DOI 10.1126/science.3083506; KYRIACOU CP, 1989, ANIM BEHAV, V37, P850, DOI 10.1016/0003-3472(89)90069-9; LOGAN IG, 1989, ANIM BEHAV, V37, P860, DOI 10.1016/0003-3472(89)90070-5; PETERSEN G, 1988, EMBO J, V7, P3939, DOI 10.1002/j.1460-2075.1988.tb03280.x; RAUP DM, 1988, SCIENCE, V241, P94, DOI 10.1126/science.241.4861.94; RAUP DM, 1984, P NATL ACAD SCI-BIOL, V81, P801, DOI 10.1073/pnas.81.3.801; ROBERTS DH, 1987, ASTRON J, V93, P968, DOI 10.1086/114383; RUTILA JE, 1986, J VIROL, V58, P526, DOI 10.1128/JVI.58.2.526-535.1986; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHILCHER FV, 1976, ANIM BEHAV, V24, P622, DOI DOI 10.1016/S0003-3472(76)80076-0; TAJIMA Y, 1990, NEUROSCIENCE, V39, P245, DOI 10.1016/0306-4522(90)90237-X; THACKERAY JR, 1990, J MOL EVOL, V31, P389, DOI 10.1007/BF02106054; WHEELER D, UNPUB; WHEELER DA, 1988, BEHAV GENET, V18, P675, DOI 10.1007/BF01066850; YU Q, 1987, NATURE, V326, P765, DOI 10.1038/326765a0	29	160	164	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 1	1991	251	4997					1082	1085		10.1126/science.1900131	http://dx.doi.org/10.1126/science.1900131			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EZ665	1900131				2022-12-24	WOS:A1991EZ66500054
J	FARNSWORTH, CL; MARSHALL, MS; GIBBS, JB; STACEY, DW; FEIG, LA				FARNSWORTH, CL; MARSHALL, MS; GIBBS, JB; STACEY, DW; FEIG, LA			PREFERENTIAL INHIBITION OF THE ONCOGENIC FORM OF RASH BY MUTATIONS IN THE GAP BINDING EFFECTOR DOMAIN	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; ACTIVATING PROTEIN; P21; PRODUCT; MUTANT; GTPASE; RAS-P21; GENES	The double mutation, D33H/P34S, reduced the transforming activity of oncogenic Ras(H) proteins, G12V and Q61L, 400- and 20-fold, respectively. Remarkably, this same mutation did not reduce the transforming activity of normal Ras(H), nor did it impair the ability of the protein to restore a functional Ras pathway in cells whose endogenous Ras proteins were inhibited. Another mutation in this region, D38N, had similar effects. The mutations reduced downstream coupling efficiency of normal Ras as assessed by yeast adenylyl cyclase stimulation. However, this was offset by decreased GTPase activating protein (GAP) binding, since the latter resulted in elevated GTP-bound mutant Ras in cells. The mutations produced a similar decrease in downstream coupling efficiency of oncogenic Ras, but decreased GAP binding did not compensate because the GTPase activity of oncogenic Ras is not stimulated by GAP. These results imply that preferential inactivation of oncogenic Ras in human tumors may be achieved by reagents designed to inhibit the GAP-binding/"effector" domain of Ras proteins.	MERCK SHARP & DOHME LTD,DEPT CANC RES,W POINT,PA 19486; CLEVELAND CLIN EDUC FDN,DEPT MOLEC BIOL,CLEVELAND,OH 44106	Merck & Company; Cleveland Clinic Foundation	FARNSWORTH, CL (corresponding author), TUFTS UNIV,DEPT BIOCHEM,HLTH SCI CAMPUS,BOSTON,MA 02111, USA.							ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BUSS JE, 1989, SCIENCE, V243, P1600, DOI 10.1126/science.2648572; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FEIG LA, 1988, MOL CELL BIOL, V8, P2472, DOI 10.1128/MCB.8.6.2472; FEIG LA, 1987, MOL ENDOCRINOL, V1, P127, DOI 10.1210/mend-1-2-127; FEIG LA, 1986, P NATL ACAD SCI USA, V83, P4607, DOI 10.1073/pnas.83.13.4607; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FIELD J, 1987, MOL CELL BIOL, V7, P2128, DOI 10.1128/MCB.7.6.2128; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GIBBS JB, 1989, P NATL ACAD SCI USA, V86, P6630, DOI 10.1073/pnas.86.17.6630; GIBBS JB, 1984, P NATL ACAD SCI-BIOL, V81, P5704, DOI 10.1073/pnas.81.18.5704; HATA Y, 1990, J BIOL CHEM, V265, P7104; KATAOKA T, 1985, CELL, V40, P19, DOI 10.1016/0092-8674(85)90304-6; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; MANNE V, 1985, P NATL ACAD SCI USA, V82, P376, DOI 10.1073/pnas.82.2.376; MCGRATH JP, 1984, NATURE, V310, P644, DOI 10.1038/310644a0; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; QUAIFE CJ, 1987, CELL, V48, P1023, DOI 10.1016/0092-8674(87)90710-0; REY I, 1989, MOL CELL BIOL, V9, P3904, DOI 10.1128/MCB.9.9.3904; SCHABER MD, 1989, PROTEINS, V6, P306, DOI 10.1002/prot.340060313; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4725, DOI 10.1073/pnas.83.13.4725; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P952, DOI 10.1073/pnas.83.4.952; SWEET RW, 1984, NATURE, V311, P273, DOI 10.1038/311273a0; TANAKA K, 1990, CELL, V60, P803, DOI 10.1016/0092-8674(90)90094-U; TANAKA K, 1989, MOL CELL BIOL, V9, P757, DOI 10.1128/MCB.9.2.757; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WALTER M, 1986, SCIENCE, V233, P649, DOI 10.1126/science.3487832; WEST M, 1990, FEBS LETT, V259, P245, DOI 10.1016/0014-5793(90)80019-F; WILLUMSEN BM, 1986, MOL CELL BIOL, V6, P2646, DOI 10.1128/MCB.6.7.2646; WOLFMAN A, 1990, SCIENCE, V248, P247; YATANI A, 1990, CELL, V61, P769, DOI 10.1016/0092-8674(90)90187-J	40	80	80	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 8	1991	64	3					625	633		10.1016/0092-8674(91)90246-U	http://dx.doi.org/10.1016/0092-8674(91)90246-U			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EX361	1899358				2022-12-24	WOS:A1991EX36100018
J	WATERS, MG; SERAFINI, T; ROTHMAN, JE				WATERS, MG; SERAFINI, T; ROTHMAN, JE			COATOMER - A CYTOSOLIC PROTEIN COMPLEX CONTAINING SUBUNITS OF NON-CLATHRIN-COATED GOLGI TRANSPORT VESICLES	NATURE			English	Article							BREFELDIN-A; ENDOPLASMIC-RETICULUM	GOLGI-derived coated vesicles contain a set of coat proteins of relative molecular mass 160,000 (M(r) 160K; alpha-COP), 110K (beta-COP), 98K (gamma-COP) and 61K (delta-COP), and several smaller subunits 1. We have now identified and purified a cytosolic complex containing the same four coat proteins as those of Golgi transport vesicles. We term this complex the Golgi coat promoter or 'coatomer'. The customer also contains polypeptides of M(r) 36K, 35K and 20K. It represents about 0.2% of soluble cytosolic protein. Gel filtration of unfractionated cytosol indicates that beta-COP resides exclusively in the coatomer complex. The complex seems to be a likely candidate for the unassembled precursor of Golgi coated vesicles, and its purification should help investigations of the role of coat proteins in membrane budding, for which it is necessary to use a refined cell-free system.			WATERS, MG (corresponding author), PRINCETON UNIV, DEPT MOLEC BIOL, PRINCETON, NJ 08544 USA.							ALLAN VJ, 1986, J CELL BIOL, V103, P2229, DOI 10.1083/jcb.103.6.2229; CLARY DO, 1990, J BIOL CHEM, V265, P10109; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; GOUD B, 1985, J CELL BIOL, V100, P521, DOI 10.1083/jcb.100.2.521; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; KEEN JH, 1990, ANNU REV BIOCHEM, V59, P415, DOI 10.1146/annurev.biochem.59.1.415; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; Morris SA, 1989, CURR OPIN CELL BIOL, V1, P684, DOI 10.1016/0955-0674(89)90034-3; SERAFINI T, 1991, NATURE, V349, P214, DOI 10.1038/349215a0; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350	15	434	447	0	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 17	1991	349	6306					248	251		10.1038/349248a0	http://dx.doi.org/10.1038/349248a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ET519	1898986				2022-12-24	WOS:A1991ET51900059
J	HANSENFLASCHEN, JH; BRAZINSKY, S; BASILE, C; LANKEN, PN				HANSENFLASCHEN, JH; BRAZINSKY, S; BASILE, C; LANKEN, PN			USE OF SEDATING DRUGS AND NEUROMUSCULAR BLOCKING-AGENTS IN PATIENTS REQUIRING MECHANICAL VENTILATION FOR RESPIRATORY-FAILURE - A NATIONAL SURVEY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CRITICALLY ILL PATIENTS; ICU; ATRACURIUM; VECURONIUM; INFUSIONS; CARE; ITU	Objective. - To assess current use of sedating drugs and neuromuscular blocking agents in patients requiring mechanical ventilation at US hospitals that participate in the training of pulmonary fellows. Design. - Surveys were mailed in September 1990 to the head nurses of medical intensive care units at 265 US hospitals that were listed in an annual guide listing pulmonary fellowship training programs. In the survey, sedating drugs were defined as medications prescribed to treat anxiety, agitation, or sleeplessness. These included opiates, anesthetics, or neuroleptic agents when used for any of these purposes. Survey Respondents. - Surveys were received from nurses at 164 hospitals (62% response rate) representing 93 medical schools and 100 pulmonary fellowship training programs. Nearly half of the respondents worked at university hospitals. Most worked as head nurses in medical (70%) or medical-surgical (21 %) intensive care units (ICUs). Results. - Sedating drugs were given to patients undergoing mechanical ventilation at virtually all the ICUs surveyed, and 36% used these drugs routinely (> 70% of patients). Opiates and benzodiazepines were employed most commonly; haloperidol lactate was widely used as well. Intermittent intravenous injection was the preferred method of administration; 62% of the ICUs also gave these drugs by continuous intravenous infusion. Neuromuscular blocking agents were also used at nearly all the ICUs surveyed; however, most gave these drugs to fewer than 20% of patients experiencing respiratory failure. Orders for the use of sedating drugs and neuromuscular blocking agents were written exclusively by house staff at 65% of the ICUs surveyed. Conclusions. - Sedating drugs and neuromuscular blocking agents are widely used for patients requiring mechanical ventilation in ICUs at US teaching hospitals. There is considerable variation in the choice, frequency, and method of administration. Given the expense (up to $1000 a day) and the potential hazards to patients of prolonged deep sedation and paralysis, more research is warranted to determine optimal use of these drugs during mechanical ventilation.			HANSENFLASCHEN, JH (corresponding author), HOSP UNIV PENN,DEPT MED,DEPT PULM & CRIT CARE,874 MALONEY BLDG,3600 SPRUCE ST,PHILADELPHIA,PA 19104, USA.			Hansen-Flaschen, John/0000-0003-1989-7244				AITKENHEAD AR, 1989, LANCET, V2, P704, DOI 10.1016/S0140-6736(89)90770-8; BEEMER GH, 1987, ANAESTH INTENS CARE, V15, P83, DOI 10.1177/0310057X8701500111; BEVAN DR, 1988, MUSCLE RELAXANTS CLI; BION JF, 1987, INTENS CARE MED, V13, P215; CRIPPEN DW, 1990, CRIT CARE CLIN, V6, P369; DURBIN CG, 1991, CRIT CARE CLIN, V7, P489, DOI 10.1016/S0749-0704(18)30292-6; FARINA ML, 1981, INTENS CARE MED, V7, P125, DOI 10.1007/BF01738615; FIGGE H, 1987, J CRIT CARE, V2, P199, DOI 10.1016/0883-9441(87)90008-6; FISHMAN AP, 1988, PULMONARY DISEASES D; GRAMSTAD L, 1985, BRIT J ANAESTH, V57, P1052, DOI 10.1093/bja/57.11.1052; GRIFFITHS RB, 1986, ANAESTHESIA, V41, P375, DOI 10.1111/j.1365-2044.1986.tb13221.x; HANSENFLASCHEN JH, 1991, PULMONARY DISEASES D, P383; HARRIS CE, 1985, ANAESTHESIA, V45, P366; KENDALL MJ, 1972, BMJ, V2, P354; MARTYN J, 1986, ANESTHESIOLOGY, V65, P67, DOI 10.1097/00000542-198607000-00011; MENZA MA, 1988, HEART LUNG, V17, P238; MERRIMAN HM, 1981, INTENS CARE MED, V7, P217, DOI 10.1007/BF01702623; MILLERJONES CMH, 1980, ANAESTHESIA, V35, P1104, DOI 10.1111/j.1365-2044.1980.tb05052.x; NAGASHIMA H, 1988, CAN J ANAESTH, V35, P134, DOI 10.1007/BF03010652; OLDENHOF H, 1988, CLIN PHARMACOL THER, V43, P263, DOI 10.1038/clpt.1988.31; PARKER CJR, 1988, BRIT J ANAESTH, V61, P531, DOI 10.1093/bja/61.5.531; PARKER MM, 1984, CRIT CARE MED, V12, P69, DOI 10.1097/00003246-198401000-00018; PEAT SJ, 1988, ANAESTHESIA, V43, P962, DOI 10.1111/j.1365-2044.1988.tb05663.x; ROGERS RM, 1990, AM REV RESPIR DIS, V142, P495, DOI 10.1164/ajrccm/142.3.495; SEGREDO V, 1990, ANESTHESIOLOGY, V72, P566, DOI 10.1097/00000542-199003000-00030; SHOEMAKER W, 1989, TXB CRITICAL CARE; SLATER RM, 1988, ANAESTHESIA, V43, P250; Stevens DS, 1990, J INTENSIVE CARE MED, V5, P258; VESELIS RA, 1990, CRIT CARE CLIN, V6, P295; VIBYMOGENSEN J, 1982, BRIT J ANAESTH, V54, P209, DOI 10.1093/bja/54.2.209; WADON AJ, 1986, BRIT J ANAESTH, V58, pS64, DOI 10.1093/bja/58.suppl_1.64S; 1990, AM REV RESPIR DIS, V142, P955; 1989, AM HOSPITAL ASS GUID; 1991, AM BOARD INTERNA SPR	34	218	222	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 27	1991	266	20					2870	2875		10.1001/jama.266.20.2870	http://dx.doi.org/10.1001/jama.266.20.2870			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GQ722	1942456				2022-12-24	WOS:A1991GQ72200037
J	WAGNER, JL; HERDMAN, RC; WADHWA, S				WAGNER, JL; HERDMAN, RC; WADHWA, S			COST-EFFECTIVENESS OF COLORECTAL-CANCER SCREENING IN THE ELDERLY	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							OCCULT BLOOD-TEST; LARGE BOWEL; CONVENIENT APPROXIMATION; FLEXIBLE SIGMOIDOSCOPY; LIFE EXPECTANCY; POLYPS; CARCINOMA; SENSITIVITY; STAGE; RISK	Objective: To assess the cost effectiveness of a periodic program of colorectal cancer screening in the elderly. Design: A model was constructed of four strategies for the periodic screening of persons 65 to 85 years of age. The effect of each strategy on life expectancy and health care costs was estimated under assumptions that were uniformly unfavorable to screening. Cost and added years of life were discounted at 5% per year. Cost per year of life gained from screening was calculated for each screening strategy. Data Sources: Assumptions used in the model were based on a review of pertinent studies; those studies with results more unfavorable to screening were given more weight. Strengths and weaknesses of studies are discussed. Main Results: A program of annual fecal occult blood testing (FOBT) in the elderly would detect at least 17% of the expected cases of cancer and could cost $35 000 per year of life saved. Screening schedules that include periodic sigmoidoscopy would prevent more cases of cancer but could cost between $43 000 and $47 000 per year of life gained. These estimates are based on uncertain assumptions, but results were not extremely sensitive to further relaxation of the values of the most uncertain assumptions. In no case did the cost per year of life gained from annual FOBT exceed $55 000 or did the cost per year of life gained from FOBT with sigmoidoscopy every 5 years exceed $61 000. Conclusions: Although colorectal cancer screening is costly in the aggregate, its potential medical benefits make it a reasonably cost-effective preventive intervention for the elderly.			WAGNER, JL (corresponding author), US OFF TECHNOL ASSESSMENT, WASHINGTON, DC USA.							AHLQUIST D, 1991, Gastroenterology, V100, pA346; AHLQUIST DA, 1989, CANCER, V63, P1826; AHLQUIST DA, 1990, GASTROENTEROLOGY, V100, pA1; ALLISON JE, 1985, DIGEST DIS SCI, V30, P860, DOI 10.1007/BF01309517; ARMINSKI T. C., 1964, DIS COLON RECTUM, V7, P249, DOI 10.1007/BF02630528; BANG KM, 1986, J OCCUP ENVIRON MED, V28, P709, DOI 10.1097/00043764-198608000-00033; BARRY MJ, 1987, GASTROENTEROLOGY, V93, P301, DOI 10.1016/0016-5085(87)91019-5; BECK JR, 1982, AM J MED, V73, P883, DOI 10.1016/0002-9343(82)90786-0; BECK JR, 1982, AM J MED, V73, P889, DOI 10.1016/0002-9343(82)90787-2; BERG JW, 1970, CANCER, V25, P1076, DOI 10.1002/1097-0142(197005)25:5<1076::AID-CNCR2820250511>3.0.CO;2-L; Blatt LJ., 1961, DIS COLON RECTUM, V4, P277; CHAPMAN I, 1963, ANN SURG, V157, P223, DOI 10.1097/00000658-196302000-00007; CORREA P, 1977, CANCER, V39, P2258; DEMERS RY, 1985, PREV MED, V14, P55, DOI 10.1016/0091-7435(85)90020-9; EDDY D, 1987, BREAST CANCER SCREEN; EDDY DM, 1990, ANN INTERN MED, V113, P373, DOI 10.7326/0003-4819-113-5-373; EDDY DM, 1987, GASTROENTEROLOGY, V92, P682, DOI 10.1016/0016-5085(87)90018-7; EDDY DM, 1980, SCREENING CANCER THE; ENGLAND WL, 1989, MED DECIS MAKING, V9, P3, DOI 10.1177/0272989X8900900103; FENOGLIO CM, 1974, CANCER, V34, P819, DOI 10.1002/1097-0142(197409)34:3+<819::AID-CNCR2820340706>3.0.CO;2-S; FIELDING LP, 1989, LANCET, V1, P595; FLEISCHER DE, 1989, JAMA-J AM MED ASSOC, V261, P580, DOI 10.1001/jama.261.4.580; GNAUCK R, 1984, CA-CANCER J CLIN, V34, P134, DOI 10.3322/canjclin.34.3.134; GOODWIN JS, 1986, J AM GERIATR SOC, V34, P20, DOI 10.1111/j.1532-5415.1986.tb06335.x; GRINNELL RS, 1964, ANN SURG, V159, P132, DOI 10.1097/00000658-196401000-00023; HAYWARD RSA, 1991, ANN INTERN MED, V114, P758, DOI 10.7326/0003-4819-114-9-758; HOFF G, 1986, SCAND J GASTROENTERO, V21, P853, DOI 10.3109/00365528609011130; HOFF G, 1987, SCAND J GASTROENTERO, V22, P769, DOI 10.3109/00365528708991912; HOLMES FF, 1981, J AM GERIATR SOC, V29, P55, DOI 10.1111/j.1532-5415.1981.tb01227.x; Hughes L E, 1968, Aust N Z J Surg, V38, P30; IRVIN TT, 1988, BRIT J SURG, V75, P419, DOI 10.1002/bjs.1800750508; KRONBORG O, 1975, BR J SURG S, V72, pS26; KUNE GA, 1987, BRIT J SURG, V74, P1064, DOI 10.1002/bjs.1800741135; MACRAE FA, 1982, GASTROENTEROLOGY, V82, P891; MANDEL JS, 1989, GASTROENTEROLOGY, V97, P597, DOI 10.1016/0016-5085(89)90629-X; MILLER AB, 1990, INT J CANCER, V46, P761, DOI 10.1002/ijc.2910460502; MOR V, 1988, J AM GERIATR SOC, V36, P873, DOI 10.1111/j.1532-5415.1988.tb05778.x; MORSON B, 1974, P ROY SOC MED, V67, P451, DOI 10.1177/00359157740676P115; NEUGUT AI, 1985, CANCER, V55, P1586, DOI 10.1002/1097-0142(19850401)55:7<1586::AID-CNCR2820550729>3.0.CO;2-I; OTT DJ, 1989, COLON CANCER DIAGNOS; RANSOHOFF DF, 1991, ANN INTERN MED, V114, P177, DOI 10.7326/0003-4819-114-3-177; RESTREPO C, 1981, DIS COLON RECTUM, V24, P29, DOI 10.1007/BF02603446; RHOADS GG, 1987, JAMA-J AM MED ASSOC, V258, P3254, DOI 10.1001/jama.1987.03400220053020; RIBET A, 1980, LANCET, V1, P417; RICKERT RR, 1979, CANCER-AM CANCER SOC, V43, P1847, DOI 10.1002/1097-0142(197905)43:5<1847::AID-CNCR2820430538>3.0.CO;2-L; ROBERTS SD, 1980, ANN INTERN MED, V92, P243, DOI 10.7326/0003-4819-92-2-243; SEIDMAN H, 1985, CA-CANCER J CLIN, V35, P36, DOI 10.3322/canjclin.35.1.36; SELBY JV, 1989, JAMA-J AM MED ASSOC, V261, P595; SIMON JB, 1985, GASTROENTEROLOGY, V88, P820, DOI 10.1016/0016-5085(85)90158-1; STEMMERMANN GN, 1973, CANCER-AM CANCER SOC, V31, P1260, DOI 10.1002/1097-0142(197305)31:5<1260::AID-CNCR2820310535>3.0.CO;2-N; STEVENSON G, 1989, COLON CANCER DIAGNOS; SUGARBAKER PH, 1985, CANCER PRINCIPLES PR; WILLIAMS AR, 1982, GUT, V23, P835, DOI 10.1136/gut.23.10.835; WILLIAMS CB, 1982, ENDOSCOPY, V14, P74, DOI 10.1055/s-2007-1021584; WINAWER SJ, 1980, CANCER, V45, P2959, DOI 10.1002/1097-0142(19800615)45:12<2959::AID-CNCR2820451212>3.0.CO;2-E; WINDELER J, 1987, INT J COLORECTAL DIS, V2, P223, DOI 10.1007/BF01649510; 1989, ANN REPORT C; 1988, BASIC CLIN PERSPECTI; 1979, OTA PUBLICATION H, V96; 1990, OTA BPH65 PUBL; 1990, CANCER LETT, V11, P3; 1989, NIH892789 PUBL; 1990, OTA PUBLICATION H, V416	63	123	124	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1991	115	10					807	817		10.7326/0003-4819-115-10-807	http://dx.doi.org/10.7326/0003-4819-115-10-807			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GP800	1929029				2022-12-24	WOS:A1991GP80000011
J	FLANCE, IJ				FLANCE, IJ			SCAR CANCER OF THE LUNG	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											FLANCE, IJ (corresponding author), WASHINGTON UNIV,SCH MED,ST LOUIS,MO 63110, USA.							CHAUDHURI MR, 1973, INDIAN J MED RES, V61, P858; KUNG ITM, 1985, AM J SURG PATHOL, V9, P391; MADRI JA, 1984, HUM PATHOL, V15, P625, DOI 10.1016/S0046-8177(84)80286-5; MEYER EC, 1965, CANCER-AM CANCER SOC, V18, P322, DOI 10.1002/1097-0142(196503)18:3<322::AID-CNCR2820180310>3.0.CO;2-J; MONTGOMERY GL, 1947, BRIT J SURG, V31, P292; ROSAI J, 1989, ACKERMANS SURGICAL P, V1, P297	6	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 9	1991	266	14					2003	2004		10.1001/jama.266.14.2003	http://dx.doi.org/10.1001/jama.266.14.2003			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GH406	1895484				2022-12-24	WOS:A1991GH40600033
J	DEKEYSER, J; DEKLIPPEL, N; EBINGER, G				DEKEYSER, J; DEKLIPPEL, N; EBINGER, G			THROMBOCYTOSIS AND ISCHEMIC COMPLICATIONS IN GIANT-CELL ARTERITIS	BRITISH MEDICAL JOURNAL			English	Article							TEMPORAL ARTERITIS; MANIFESTATIONS				DEKEYSER, J (corresponding author), VRIJE UNIV BRUSSELS,ACAD ZIEKENHUIS,DEPT NEUROL,B-1090 BRUSSELS,BELGIUM.		De Keyser, Jacques/D-3725-2013	De Keyser, Jacques/0000-0002-3394-7757				BENGTSSON BA, 1982, ACTA MED SCAND S, V658, P1; CALAMIA KT, 1980, CLIN RHEUM DIS, V6, P389; GOODMAN BW, 1979, AM J MED, V67, P839, DOI 10.1016/0002-9343(79)90744-7; REICH KA, 1990, AM J MED, V89, P67, DOI 10.1016/0002-9343(90)90100-R; SELROOS O, 1973, ACTA MED SCAND, V193, P431	5	34	34	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 5	1991	303	6806					825	825		10.1136/bmj.303.6806.825	http://dx.doi.org/10.1136/bmj.303.6806.825			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GH946	1932974	Green Published, Bronze			2022-12-24	WOS:A1991GH94600025
J	GATELEY, CA; MADDOX, PR; MANSEL, RE				GATELEY, CA; MADDOX, PR; MANSEL, RE			PNEUMOTHORAX - A COMPLICATION OF FINE NEEDLE ASPIRATION OF THE BREAST	BRITISH MEDICAL JOURNAL			English	Article									UNIV HOSP S MANCHESTER,DEPT SURG,MANCHESTER M20 8LR,LANCS,ENGLAND; UNIV WALES COLL MED,DEPT SURG,CARDIFF CF4 4XN,S GLAM,WALES	Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital; Cardiff University								BEVELAQUA FA, 1982, CHEST, V81, P693, DOI 10.1378/chest.81.6.693; DIXON JM, 1984, BRIT J SURG, V71, P593, DOI 10.1002/bjs.1800710809; DIXON JM, 1991, BRIT MED J, V302, P428, DOI 10.1136/bmj.302.6774.428; LEAHY BC, 1986, MED INT, V35, P1446; THOMPSON AM, 1988, J HAND SURG-BRIT EUR, V13B, P195, DOI 10.1016/0266-7681(88)90137-4	5	14	14	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 14	1991	303	6803					627	628		10.1136/bmj.303.6803.627	http://dx.doi.org/10.1136/bmj.303.6803.627			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GF675	1932905	Green Published, Bronze			2022-12-24	WOS:A1991GF67500025
J	NEWMAN, LG; WALLER, J; PALESTRO, CJ; SCHWARTZ, M; KLEIN, MJ; HERMANN, G; HARRINGTON, E; HARRINGTON, M; ROMAN, SH; STAGNAROGREEN, A				NEWMAN, LG; WALLER, J; PALESTRO, CJ; SCHWARTZ, M; KLEIN, MJ; HERMANN, G; HARRINGTON, E; HARRINGTON, M; ROMAN, SH; STAGNAROGREEN, A			UNSUSPECTED OSTEOMYELITIS IN DIABETIC FOOT ULCERS - DIAGNOSIS AND MONITORING BY LEUKOCYTE SCANNING WITH INDIUM IN-111 OXYQUINOLINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LOWER-EXTREMITY INFECTIONS; CONCISE COMMUNICATION; PEDAL OSTEOMYELITIS; CIPROFLOXACIN; MELLITUS; SCINTIGRAPHY; THERAPY; DISEASE; BONE	Objective. - The prevalence of osteomyelitis in diabetic foot ulcers is unknown. Early diagnosis of this infection is critical, as prompt antibiotic treatment decreases the rate of amputation. We therefore assessed the prevalence of osteomyelitis in 35 diabetic patients with 41 foot ulcers. We compared results of roentgenograms, leukocyte scans with indium in 111 oxyquinoline, and bone scans with the diagnostic criterion standards of bone histologic and culture findings. Leukocyte scans were repeated at 2- to 3-week intervals during antibiotic treatment. Design. - Cohort study Setting. - Institutional and private, ambulatory and hospitalized patients. Patients. - Consecutive sample of 54 diabetic patients. Thirty-five patients with 41 foot ulcers were included. Results. - As determined by bone biopsy and culture, osteomyelitis was found to underlie 28 (68%) of 41 diabetic foot ulcers. Only nine (32%) of the 28 cases were diagnosed clinically by the referring physician. Underscoring the clinically silent nature of osteomyelitis in these ulcers, 19 (68%) of 28 occurred in outpatients, 19 (68%) of 28 occurred in ulcers not exposing bone, and 18 (64%) of 28 had no evidence of inflammation on physical examination. All patients with ulcers that exposed bone had osteomyelitis. Of the imaging tests, the leukocyte scan had the highest sensitivity, 89%. In patients with osteomyelitis, the leukocyte scan image intensity decreased by 16 to 34 days of antibiotic treatment and normalized by 36 to 54 days. Conclusion. - The majority of diabetic foot ulcers have an underlying osteomyelitis that is clinically unsuspected. Leukocyte scans are highly sensitive for diagnosing osteomyelitis in diabetic foot ulcers and may be useful for monitoring the efficacy of antibiotic treatment. We recommend that diabetic patients with foot ulcers that expose bone should be treated for osteomyelitis. Diabetic patients with foot ulcers that do not expose bone should undergo leukocyte scanning, which eliminates the risk of bone biopsy in diagnosing osteomyelitis and allows for the diagnosis and treatment of this well-known but often silent precursor of lower extremity amputation.	MT SINAI MED CTR, DEPT SURG, DIV ORTHOPED SURG, NEW YORK, NY 10029 USA; MT SINAI MED CTR, DIV VASC SURG, NEW YORK, NY 10029 USA; MT SINAI MED CTR, DEPT NUCL MED, NEW YORK, NY 10029 USA; MT SINAI MED CTR, DEPT PATHOL, NEW YORK, NY 10029 USA; MT SINAI MED CTR, DEPT RADIOL, NEW YORK, NY 10029 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	NEWMAN, LG (corresponding author), MT SINAI MED CTR, DEPT MED, DIV ENDOCRINOL & METAB, BOX 1087, 1 GUSTAVE L LEVY PL, NEW YORK, NY 10029 USA.			Stagnaro-Green, Alex/0000-0003-2434-3852				ALAZRAKI N, 1985, AM J ROENTGENOL, V145, P767, DOI 10.2214/ajr.145.4.767; BAMBERGER DM, 1987, AM J MED, V83, P653, DOI 10.1016/0002-9343(87)90894-1; BEAM TR, 1988, 2ND INT S NEW QUIN G; EYMONTT MJ, 1981, RADIOLOGY, V140, P475, DOI 10.1148/radiology.140.2.6454901; FIERER J, 1979, REV INFECT DIS, V1, P210; GELFAND MJ, 1977, JAMA-J AM MED ASSOC, V237, P245, DOI 10.1001/jama.237.3.245; GREENBERG RN, 1987, ANTIMICROB AGENTS CH, V31, P151, DOI 10.1128/AAC.31.2.151; HOOGKAMPKORSTANJE JAA, 1989, J ANTIMICROB CHEMOTH, V23, P427, DOI 10.1093/jac/23.3.427; KEENAN AM, 1989, ARCH INTERN MED, V149, P2262, DOI 10.1001/archinte.149.10.2262; KOLYVAS E, 1978, CLIN NUCL MED, V3, P461, DOI 10.1097/00003072-197812000-00003; LESLIE C A, 1989, Comprehensive Therapy, V15, P23; MAURER AH, 1981, J NUCL MED, V22, P941; MAURER AH, 1986, RADIOLOGY, V161, P221, DOI 10.1148/radiology.161.1.3763871; MCCARTHY K, 1988, J NUCL MED, V29, P1015; NORRBY SR, 1989, SCAND J INFECT DIS, P74; PARK HM, 1982, J NUCL MED, V23, P569; PETERSON LR, 1989, AM J MED, V86, P801, DOI 10.1016/0002-9343(89)90476-2; RATOPOULOS V, 1982, AM J ROENTGENOL, V139, P1077; ROSENBLATT DS, 1989, CLIN DIABETES, V7, P85; SCHAUWECKER DS, 1988, J NUCL MED, V29, P1651; SCHER KS, 1988, SURGERY, V104, P661; SELDIN DW, 1985, J NUCL MED, V26, P988; SINHA S, 1972, MEDICINE, V51, P191, DOI 10.1097/00005792-197205000-00006; THAKUR ML, 1977, J NUCL MED, V18, P1022; WALDVOGEL FA, 1970, NEW ENGL J MED, V282, P316, DOI 10.1056/NEJM197002052820606; WALDVOGEL FA, 1989, REV INFECT DIS, V11, pS1259; WHEAT J, 1985, AM J MED, V78, P218, DOI 10.1016/0002-9343(85)90388-2; WHEAT LJ, 1986, ARCH INTERN MED, V146, P1935, DOI 10.1001/archinte.146.10.1935; 1980, NIH812284 PUBL, P5	29	250	251	2	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 4	1991	266	9					1246	1251		10.1001/jama.266.9.1246	http://dx.doi.org/10.1001/jama.266.9.1246			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GC858	1908030				2022-12-24	WOS:A1991GC85800034
J	DAGOSTINO, RB; BELANGER, AJ; KANNEL, WB; CRUICKSHANK, JM				DAGOSTINO, RB; BELANGER, AJ; KANNEL, WB; CRUICKSHANK, JM			RELATION OF LOW DIASTOLIC BLOOD-PRESSURE TO CORONARY HEART-DISEASE DEATH IN PRESENCE OF MYOCARDIAL-INFARCTION - THE FRAMINGHAM-STUDY	BRITISH MEDICAL JOURNAL			English	Article							REGRESSION DILUTION BIAS; PROLONGED DIFFERENCES; RISK-FACTORS; FOLLOW-UP; J-CURVE; HYPERTENSION; REDUCTION; STROKE	Objective - To examine the hypothesis that a J curve relation between blood pressure and death from coronary heart disease is confined to high risk subjects with myocardial infarction. Design - Cohort longitudinal epidemiological study with biennial examinations since 1950. Setting - Framingham, Massachusetts, USA. Subjects - 5209 subjects in the Framingham study cohort followed up by a person examination approach. Main outcome measures - Coronary heart disease deaths and non-cardiovascular disease deaths in men and women with or without myocardial infarction relative to blood pressure. Results - Among subjects without myocardial infarction non-cardiovascular disease deaths were twice to three times as common as coronary heart disease deaths. Furthermore, there was no significant relation between non-cardiovascular disease death and diastolic or systolic blood pressure. Also coronary heart disease deaths were linearly related to diastolic and systolic blood pressures. Among high risk patients (that is, people with myocardial infarction but free of congestive heart failure) death from coronary heart disease was more common than non-cardiovascular disease death. There. was a significant U shaped relation between coronary heart disease death and diastolic blood pressure. Although there was an apparent U shaped relation between coronary heart disease death and systolic blood pressure, it did not attain statistical significance when controlling for age and change in systolic blood pressure from the pre-myocardial infarction level. None of the above conclusions changed when adjustments were made for risk factors such as serum cholesterol concentration, antihypertensive treatment, and left ventricular function. The U shaped relation between diastolic blood pressure and high risk subjects existed for both those given antihypertensive treatment and those not. Conclusions - These data suggest that an age and sex independent U curve relation exists for diastolic blood pressure and coronary heart disease deaths in patients with myocardial infarction but not for low risk subjects without myocardial infarction. The relation seems to be independent of left ventricular function and antihypertensive treatment.	BOSTON UNIV,STAT UNIT,BOSTON,MA 02215; BOSTON UNIV,SCH MED,DEPT PREVENT MED,BOSTON,MA 02118; WYTHENSHAWE HOSP,DEPT CARDIAC,MANCHESTER M23 9LT,LANCS,ENGLAND	Boston University; Boston University; Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital	DAGOSTINO, RB (corresponding author), BOSTON UNIV,COLL LIBERAL ARTS,DEPT MATH,BOSTON,MA 02215, USA.				NHLBI NIH HHS [HL-40423] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R55HL040423, R01HL040423] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALDERMAN MH, 1989, JAMA-J AM MED ASSOC, V262, P920, DOI 10.1001/jama.262.7.920; ANDERSON TW, 1978, LANCET, V2, P1139; COOPE J, 1990, J HUM HYPERTENS, V4, P1; CRUICKSHANK JM, 1988, BMJ-BRIT MED J, V297, P1227, DOI 10.1136/bmj.297.6658.1227; CRUICKSHANK JM, 1987, LANCET, V1, P581; CUPPLES LA, 1988, STAT MED, V7, P205, DOI 10.1002/sim.4780070122; Cupples LA, 1987, FRAMINGHAM HEART STU; DAGOSTINO RB, 1990, STAT MED, V9, P1501, DOI 10.1002/sim.4780091214; Dawber TR., 1980, FRAMINGHAM STUDY EPI, DOI DOI 10.4159/HARVARD.9780674492097; FLETCHER AE, 1988, J HUM HYPERTENS, V2, P11; LEW EA, 1973, AM J MED, V55, P281, DOI 10.1016/0002-9343(73)90130-7; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; SAMUELSSON OG, 1990, J HYPERTENS, V8, P547, DOI 10.1097/00004872-199006000-00008; STAESSEN J, 1989, BMJ-BRIT MED J, V298, P1552, DOI 10.1136/bmj.298.6687.1552; STEWART IMG, 1979, LANCET, V1, P861; STOKES J, 1987, CIRCULATION, V75, P65; WALLER PC, 1988, J HUM HYPERTENS, V2, P7	17	191	194	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 17	1991	303	6799					385	389		10.1136/bmj.303.6799.385	http://dx.doi.org/10.1136/bmj.303.6799.385			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GB599	1912805	Bronze, Green Published			2022-12-24	WOS:A1991GB59900014
J	FOOTE, J; MILSTEIN, C				FOOTE, J; MILSTEIN, C			KINETIC MATURATION OF AN IMMUNE-RESPONSE	NATURE			English	Article							SOMATIC MUTATION; ANTIBODY; ANTI-2-PHENYLOXAZOLONE; 2-PHENYLOXAZOLONE; SEQUENCES; OXAZOLONE; MOUSE	IS the affinity maturation of antibodies under thermodynamic or kinetic control, or both? We compared the physical constants of hapten binding by antibodies from 2-phenyl-5-oxazolone-specific hybridomas from primary, secondary and tertiary responses. In addition to an increase in equilibrium constant, there was a shift in the antibody repertoire after the primary response towards an immunoglobulin family with an extremely high on-rate constant. This shift occurred in spite of the average or below-average affinity of this group of antibodies. This is consistent with B-lymphocyte proliferation being subject to a kinetic selection, with a premium on binding target antigens rapidly, in parallel with a thermodynamic selection based on binding tightly.			FOOTE, J (corresponding author), MRC, MOLEC BIOL LAB, HILLS RD, CAMBRIDGE CB2 2QH, ENGLAND.							ALZARI PM, 1990, EMBO J, V9, P3807, DOI 10.1002/j.1460-2075.1990.tb07598.x; Benson S. W., 1960, FOUNDATIONS CHEMICAL, P81; BEREK C, 1987, EUR J IMMUNOL, V17, P1121, DOI 10.1002/eji.1830170808; BEREK C, 1985, NATURE, V316, P412, DOI 10.1038/316412a0; DAY LA, 1963, ANN NY ACAD SCI, V103, P611, DOI 10.1111/j.1749-6632.1963.tb53721.x; DENIZOT FC, 1979, MOL IMMUNOL, V16, P509, DOI 10.1016/0161-5890(79)90078-6; DILDROP R, 1984, IMMUNOL TODAY, V5, P85, DOI 10.1016/0167-5699(84)90034-3; EISEN H N, 1964, Methods Med Res, V10, P115; EVEN J, 1985, EMBO J, V4, P3439, DOI 10.1002/j.1460-2075.1985.tb04102.x; GRIFFITHS GM, 1984, NATURE, V312, P271, DOI 10.1038/312271a0; KAARTINEN M, 1983, NATURE, V304, P320, DOI 10.1038/304320a0; MAKELA O, 1978, J EXP MED, V148, P1644, DOI 10.1084/jem.148.6.1644; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; MASON DW, 1986, HDB EXPT IMMUNOLOGY, V1; SCHLESINGER DH, 1975, NATURE, V255, P423, DOI 10.1038/255423a0; SEGAL I, 1975, ENZYME KINETICS, P73; SEHON AH, 1963, ANN NY ACAD SCI, V103, P626, DOI 10.1111/j.1749-6632.1963.tb53722.x; SMITH TW, 1975, BIOCHEMISTRY-US, V14, P1496, DOI 10.1021/bi00678a023; TITMAN JJ, 1991, J CHEM SOC CHEM COMM, P419, DOI 10.1039/c39910000419; WINTER G, 1991, NATURE, V349, P293, DOI 10.1038/349293a0	20	262	286	0	15	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	AUG 8	1991	352	6335					530	532		10.1038/352530a0	http://dx.doi.org/10.1038/352530a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GA226	1907716				2022-12-24	WOS:A1991GA22600063
J	STEIN, D; ROTH, S; VOGELSANG, E; NUSSLEINVOLHARD, C				STEIN, D; ROTH, S; VOGELSANG, E; NUSSLEINVOLHARD, C			THE POLARITY OF THE DORSOVENTRAL AXIS IN THE DROSOPHILA EMBRYO IS DEFINED BY AN EXTRACELLULAR SIGNAL	CELL			English	Article							MATERNAL-EFFECT MUTATIONS; FEMALE-STERILE MUTATIONS; RECEPTOR TYROSINE KINASE; DORSAL-VENTRAL POLARITY; DNA-BINDING SUBUNIT; WILD-TYPE CYTOPLASM; TOLL GENE-PRODUCT; FAINT-LITTLE-BALL; NF-KAPPA-B; REL ONCOGENE	Twelve maternal effect loci are required for the production of Drosophila embryos with a correct dorsoventral axis. Analysis of mosaic females indicates that the expression of the genes nudel, pipe, and windbeutel is required in the somatic tissue, presumably in the follicle cells that surround the oocyte. Thus, information coming from outside the egg cell influences dorsoventral pattern formation during embryogenesis. In transplantation experiments, the perivitelline fluid from the compartment surrounding the embryo can restore dorsoventral pattern to embryos from females mutant for nudel, pipe, or windbeutel. The positioning of the transplanted pervitelline fluid also determines the polarity of the restored dorsoventral axis. We propose that the polarizing activity, normally present at the ventral side of the egg, is a ligand for the Toll receptor. Presumably, local activation of the Toll protein by the ligand initiates the formation of the nuclear concentration gradient of the dorsal protein, thereby determining dorsoventral pattern.			STEIN, D (corresponding author), MAX PLANCK INST ENTWICKLUNGSBIOL, SPEMANNSTR 35, W-7400 TUBINGEN, GERMANY.		Roth, Siegfried/E-8241-2010	Roth, Siegfried/0000-0001-5772-3558; Vogelsang, Lisa/0000-0002-6817-5953				ANDERSON KV, 1987, TRENDS GENET, V3, P91, DOI 10.1016/0168-9525(87)90191-0; ANDERSON KV, 1985, CELL, V42, P791, DOI 10.1016/0092-8674(85)90275-2; ANDERSON KV, 1985, CELL, V42, P779, DOI 10.1016/0092-8674(85)90274-0; ANDERSON KV, 1984, NATURE, V311, P223, DOI 10.1038/311223a0; ANDERSON KV, 1986, GAMETOGENESIS EARLY, P177; BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; BUSSON D, 1983, GENETICS, V105, P309; CamposOrtega J. A., 1985, EMBRYONIC DEV DROSOP, P9, DOI DOI 10.1007/978-3-662-22489-2_2; CASANOVA J, 1989, GENE DEV, V3, P2025, DOI 10.1101/gad.3.12b.2025; DRIEVER W, 1988, CELL, V54, P95, DOI 10.1016/0092-8674(88)90183-3; FASANO L, 1988, DEVELOPMENT, V104, P245; FROHNHOFER HG, 1986, NATURE, V324, P120, DOI 10.1038/324120a0; GELINAS C, 1988, ONCOGENE, V3, P349; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GROSSNIKLAUS U, 1989, DEVELOPMENT, V107, P189; HASHIMOTO C, 1988, CELL, V52, P269, DOI 10.1016/0092-8674(88)90516-8; HIROMI Y, 1985, CELL, V43, P603, DOI 10.1016/0092-8674(85)90232-6; IP YT, 1991, CELL, V64, P439; KEITH FJ, 1990, EMBO J, V9, P4299, DOI 10.1002/j.1460-2075.1990.tb07878.x; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; King R. C., 1970, OVARIAN DEV DROSOPHI; KLINGLER M, 1988, NATURE, V335, P275, DOI 10.1038/335275a0; KONRAD KD, 1988, DEV BIOL, V127, P133, DOI 10.1016/0012-1606(88)90195-9; KONRAD KD, 1988, ROUX ARCH DEV BIOL, V197, P75, DOI 10.1007/BF00375930; LEHMANN R, 1986, CELL, V47, P141, DOI 10.1016/0092-8674(86)90375-2; LEHMANN R, 1987, DEV BIOL, V119, P402, DOI 10.1016/0012-1606(87)90045-5; LIND JH, 1990, SLAVON E EUR REV, V68, P1; LINDSLEY DL, 1968, CARNEGIE I WASH PUBL, V627; LINDSLEY DL, 1987, DROS INF SERV, V65, P40; MACDONALD PM, 1986, NATURE, V324, P537, DOI 10.1038/324537a0; Mahowald A.P., 1980, Genetics and Biology of Drosophila, V2d, P141; MANSEAU LJ, 1989, GENE DEV, V3, P1437, DOI 10.1101/gad.3.9.1437; N?sslein-Volhard C., 1979, DETERMINANTS SPATIAL, P185; NUSSLEINVOLHARD C, 1987, SCIENCE, V238, P1675, DOI 10.1126/science.3686007; NUSSLEINVOLHARD C, 1989, CIBA F SYMP, V144, P37; NUSSLEINVOLHARD C, 1980, NATURE, V283, P474, DOI 10.1038/283474a0; PRICE JV, 1989, CELL, V56, P1085, DOI 10.1016/0092-8674(89)90641-7; RICE TB, 1973, THESIS YALE U NEW HA; Roberts D.B., 1986, P1; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; RUSHLOW CA, 1989, CELL, V59, P1165, DOI 10.1016/0092-8674(89)90772-1; SANTAMARIA P, 1983, EMBO J, V2, P1695, DOI 10.1002/j.1460-2075.1983.tb01644.x; SCHEJTER ED, 1989, CELL, V56, P1093, DOI 10.1016/0092-8674(89)90642-9; SCHUPBACH T, 1989, GENETICS, V121, P101; SCHUPBACH T, 1986, DEV BIOL, V113, P443, DOI 10.1016/0012-1606(86)90179-X; SCHUPBACH T, 1987, CELL, V49, P699, DOI 10.1016/0092-8674(87)90546-0; SEIFERT E, 1987, ROUX ARCH DEV BIOL, V196, P78, DOI 10.1007/BF00402028; SPRENGER F, 1989, NATURE, V338, P478, DOI 10.1038/338478a0; STEVENS LM, 1990, NATURE, V346, P660, DOI 10.1038/346660a0; STEVENS LM, 1991, CELL CELL ITNERACTIO; STEWARD R, 1989, CELL, V59, P1179, DOI 10.1016/0092-8674(89)90773-3; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; Tearle R., 1987, DROSOPHILA INFORMATI, V66, P209; THISSE B, 1988, EMBO J, V7, P2175, DOI 10.1002/j.1460-2075.1988.tb03056.x; Van der Meer JM., 1977, DROS INFORM SERV, V52, P160; WARN RM, 1982, DEV BIOL, V89, P540, DOI 10.1016/0012-1606(82)90344-X; Wieschaus E., 1986, P199	58	220	226	0	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 31	1991	65	5					725	735		10.1016/0092-8674(91)90381-8	http://dx.doi.org/10.1016/0092-8674(91)90381-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FP516	1904007				2022-12-24	WOS:A1991FP51600004
J	PACKER, GJ; GORING, CC; GAYNER, AD; CRAXFORD, AD				PACKER, GJ; GORING, CC; GAYNER, AD; CRAXFORD, AD			AUDIT OF ANKLE INJURIES IN AN ACCIDENT AND EMERGENCY DEPARTMENT	BRITISH MEDICAL JOURNAL			English	Article								Objective-To determine whether the treatment of ankle injuries in an accident and emergency department could be improved by an audit of existing treatment and the creation and use of a protocol. Design-The study consisted of three parts: a review of the current treatment and published reports on treatment, the formation of a protocol, and a study of treatment after introducing the protocol. Setting-Accident and emergency department of a district general hospital. Patients-550 patients attending the department with ankle injuries over four months. Results-The review of treatment showed that patients with fractures were detected and treated adequately, but most had radiography. Patients with ligamentous injuries may have been undertreated. After introducing the protocol the number of patients undergoing radiography was reduced from 205 (80%) to 186 (70%) (0.0027 < p < 0.01). In 87% of the notes reviewed the protocol had been completed. Sixty six patients with ligamentous injuries were reviewed in the department or soft tissue clinic compared with 20 before the protocol was introduced. There was a 53% reduction in inappropriate referrals to the fracture clinic (13 before upsilon nine after). Conclusions-Using a protocol can, at little expense, improve the treatment of ankle injuries and reduce the cost of radiology in an accident and emergency department. Implication-Treatment of other conditions may be improved by introducing a protocol.			PACKER, GJ (corresponding author), N TYNESIDE GEN HOSP,N SHIELDS NE29 8NH,TYNE & WEAR,ENGLAND.							BROOKS SC, 1981, BRIT MED J, V282, P607, DOI 10.1136/bmj.282.6264.607; MONTAGUE AP, 1985, INJURY, V16, P545, DOI 10.1016/0020-1383(85)90082-8; 1990, LANCET, V335, P1313	3	11	11	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 13	1991	302	6781					885	887		10.1136/bmj.302.6781.885	http://dx.doi.org/10.1136/bmj.302.6781.885			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FG421	1902753	Bronze, Green Published			2022-12-24	WOS:A1991FG42100025
J	NIGHTINGALE, SL				NIGHTINGALE, SL			NEW CONTRACEPTIVE IMPLANT SYSTEM APPROVED	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	21	21	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 20	1991	265	7					847	847		10.1001/jama.265.7.847	http://dx.doi.org/10.1001/jama.265.7.847			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX587	1899454				2022-12-24	WOS:A1991EX58700010
J	HO, PS; KAGAWA, TF; TSENG, K; SCHROTH, GP; ZHOU, GW				HO, PS; KAGAWA, TF; TSENG, K; SCHROTH, GP; ZHOU, GW			PREDICTION OF A CRYSTALLIZATION PATHWAY FOR Z-DNA HEXANUCLEOTIDES	SCIENCE			English	Article							CRYSTAL-STRUCTURE; BASE-PAIRS; MOLECULAR-STRUCTURE; B-DNA; TRANSITION; FRAGMENT	Crystallization of macromolecules for structural studies has long been a hit-or-miss process. The crystallization of hexanucleotides as Z-DNA was studied, and it was shown that the cation concentration for crystal formation could be predicted from solvation free energy (SFE) calculations. Solution studies on the conformation and solubilities of the hexanucleotides showed that a critical concentration of the DNA in the Z-conformation must be present in solution to effect crystallization. The SFE calculations therefore predict the propensity of the hexanucleotides to adopt the left-handed conformation and the driving force required to reach this critical concentration relative to the intrinsic solubility of Z-DNA for crystallization.			HO, PS (corresponding author), OREGON STATE UNIV,DEPT BIOCHEM & BIOPHYS,CORVALLIS,OR 97331, USA.		Ho, Pui/AAF-8838-2020; Ho, Pui S/F-6186-2014	Ho, Pui/0000-0002-8082-4311; Ho, Pui S/0000-0002-8082-4311				COLL M, 1988, NUCLEIC ACIDS RES, V16, P8695, DOI 10.1093/nar/16.17.8695; COLL M, 1986, J BIOMOL STRUCT DYN, V4, P157, DOI 10.1080/07391102.1986.10506337; FUJII S, 1982, NUCLEIC ACIDS RES, V10, P7879, DOI 10.1093/nar/10.23.7879; HO PS, 1988, J PHYS CHEM-US, V92, P939, DOI 10.1021/j100315a017; JOVIN TM, 1987, ANNU REV PHYS CHEM, V38, P521, DOI 10.1146/annurev.physchem.38.1.521; KAGAWA TF, 1989, BIOCHEMISTRY-US, V28, P6642, DOI 10.1021/bi00442a017; Tseng K. T., UNPUB; WANG AHJ, 1979, NATURE, V282, P680, DOI 10.1038/282680a0; WANG AHJ, 1984, CELL, V37, P321, DOI 10.1016/0092-8674(84)90328-3; ZHOU GW, 1990, BIOCHEMISTRY-US, V29, P7229, DOI 10.1021/bi00483a010	10	12	12	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 15	1991	254	5034					1003	1006		10.1126/science.1948069	http://dx.doi.org/10.1126/science.1948069			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GP883	1948069				2022-12-24	WOS:A1991GP88300044
J	YU, GL; BLACKBURN, EH				YU, GL; BLACKBURN, EH			DEVELOPMENTALLY PROGRAMMED HEALING OF CHROMOSOMES BY TELOMERASE IN TETRAHYMENA	CELL			English	Article							TERMINAL TRANSFERASE-ACTIVITY; SACCHAROMYCES-CEREVISIAE; EUPLOTES-CRASSUS; MACRONUCLEAR DNA; OXYTRICHA-NOVA; SEQUENCE; YEAST; THERMOPHILA; CLONING; RNA	Healing of a broken chromosome end in eukaryotes involves acquisition of a telomere. During macronuclear development in ciliated protozoans, germline chromosomes are fragmented into linear subchromosomes, whose ends are healed by de novo addition of telomeres. We showed previously that the ribonucleoprotein enzyme telomerase elongates preexisting telomeres by synthesizing one telomeric DNA strand, using a template sequence in the RNA moiety of the enzyme. By marking telomerase with a mutation in the telomerase RNA template, which causes synthesis of novel telomeric sequences, we now show that in the ciliate Tetrahymena, telomerase directly adds telomeric DNA onto nontelomeric sequences during developmentally controlled chromosome healing. Unexpectedly, one telomerase RNA template mutation converted telomerase from an enzyme that normally synthesizes precisely templated sequences to a less precise polymerase that sometimes synthesizes irregular telomeric repeats in vivo.	UNIV CALIF SAN FRANCISCO,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco					NIGMS NIH HHS [GM26259, GM32565] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032565, R37GM026259, R01GM026259] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAIRD SE, 1989, GENE DEV, V3, P585, DOI 10.1101/gad.3.5.585; BAROIN A, 1987, NUCLEIC ACIDS RES, V15, P1717, DOI 10.1093/nar/15.4.1717; BLACKBURN EH, 1990, SCIENCE, V249, P489, DOI 10.1126/science.2200120; BLACKBURN EH, 1989, GENOME, V31, P553, DOI 10.1139/g89-104; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; BROWN WRA, 1989, NATURE, V338, P774, DOI 10.1038/338774a0; Bruns P.J., 1986, P27; BUDARF M, 1987, NUCLEIC ACIDS RES, V15, P6273, DOI 10.1093/nar/15.15.6273; BUDARF ML, 1986, J BIOL CHEM, V261, P363; CHALLONER PB, 1986, NUCLEIC ACIDS RES, V14, P6299, DOI 10.1093/nar/14.15.6299; CHENG JF, 1989, NUCLEIC ACIDS RES, V17, P6109, DOI 10.1093/nar/17.15.6109; CHIOU S, 1981, P NATL ACAD SCI USA, V78, P2263; CROSS SH, 1989, NATURE, V338, P771, DOI 10.1038/338771a0; EMERY HS, 1981, CELL, V26, P411, DOI 10.1016/0092-8674(81)90210-5; FORNEY JD, 1988, MOL CELL BIOL, V8, P251, DOI 10.1128/MCB.8.1.251; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; GREIDER CW, 1991, MOL CELL BIOL, V11, P4572, DOI 10.1128/MCB.11.9.4572; GREIDER CW, 1987, CELL, V51, P887, DOI 10.1016/0092-8674(87)90576-9; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; HERRICK G, 1987, J PROTOZOOL, V34, P429, DOI 10.1111/j.1550-7408.1987.tb03207.x; JACQUES JP, 1991, GENE DEV, V5, P707, DOI 10.1101/gad.5.5.707; Karrer K.M., 1986, P85; KING BO, 1982, CELL, V31, P177, DOI 10.1016/0092-8674(82)90417-2; KISS GB, 1981, MOL CELL BIOL, V1, P535, DOI 10.1128/MCB.1.6.535; KLOBUTCHER LA, 1984, CELL, V36, P1045, DOI 10.1016/0092-8674(84)90054-0; LARSON DD, 1986, CELL, V47, P229, DOI 10.1016/0092-8674(86)90445-9; Maniatis T., 1982, MOL CLONING; McDonald B.B., 1973, P287; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; Orias E., 1986, P45; PAN W, 1991, Acta Genetica Sinica, V18, P127; PENNOCK DG, 1988, MOL CELL BIOL, V8, P2681, DOI 10.1128/MCB.8.7.2681; PONZI M, 1985, EMBO J, V4, P2991, DOI 10.1002/j.1460-2075.1985.tb04034.x; RIETHMAN HC, 1989, P NATL ACAD SCI USA, V86, P6240, DOI 10.1073/pnas.86.16.6240; SHAMPAY J, 1984, NATURE, V310, P154, DOI 10.1038/310154a0; SHAMPAY J, 1988, P NATL ACAD SCI USA, V85, P534, DOI 10.1073/pnas.85.2.534; SHIPPENLENTZ D, 1990, SCIENCE, V247, P546, DOI 10.1126/science.1689074; SHIPPENLENTZ D, 1989, MOL CELL BIOL, V9, P2761, DOI 10.1128/MCB.9.6.2761; SPANGLER EA, 1988, NUCLEIC ACIDS RES, V16, P5569, DOI 10.1093/nar/16.12.5569; SZOSTAK JW, 1982, CELL, V29, P245, DOI 10.1016/0092-8674(82)90109-X; WANG SS, 1990, MOL CELL BIOL, V10, P4415, DOI 10.1128/MCB.10.8.4415; YAO MC, 1987, CELL, V48, P779, DOI 10.1016/0092-8674(87)90075-4; YOKOYAMA R, 1986, NUCLEIC ACIDS RES, V14, P2109, DOI 10.1093/nar/14.5.2109; YU GL, 1989, P NATL ACAD SCI USA, V86, P8487, DOI 10.1073/pnas.86.21.8487; ZAHLER AM, 1988, NUCLEIC ACIDS RES, V16, P6953, DOI 10.1093/nar/16.14.6953	45	191	210	0	18	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 15	1991	67	4					823	832		10.1016/0092-8674(91)90077-C	http://dx.doi.org/10.1016/0092-8674(91)90077-C			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GQ407	1934071				2022-12-24	WOS:A1991GQ40700019
J	OTOOLE, TE; MANDELMAN, D; FORSYTH, J; SHATTIL, SJ; PLOW, EF; GINSBERG, MH				OTOOLE, TE; MANDELMAN, D; FORSYTH, J; SHATTIL, SJ; PLOW, EF; GINSBERG, MH			MODULATION OF THE AFFINITY OF INTEGRIN-ALPHA-IIB-BETA-3 (GPIIB-IIIA) BY THE CYTOPLASMIC DOMAIN OF ALPHA-IIB	SCIENCE			English	Article							MEMBRANE GLYCOPROTEIN-IIB; FIBRINOGEN RECEPTOR; PLATELET ACTIVATION; MONOCLONAL-ANTIBODY; ADHESION; BINDING; EXPRESSION; INTEGRINS; SEQUENCE; SUBUNITS	Intracellular signaling alters integrin adhesive functions in inflammation, immune responses, hemostasis, thrombosis, and retinal development. By truncating the cytoplasmic domain of alpha-IIb, the affinity of integrin alpha-IIb-beta-3, for ligand was increased. Reconstitution with the cytoplasmic domain from integrin alpha-5 did not reverse the increased affinity. Thus, the cytoplasmic domain of the alpha-subunit of GPIIb-IIIa controls ligand binding affinity, which suggests mechanisms for inside-out transmembrane signaling through integrins. These findings imply the existence of hitherto unappreciated hereditary and acquired thrombotic disorders in humans.	SCRIPPS RES INST, COMM VASC BIOL, LA JOLLA, CA 92037 USA; UNIV PENN, CTR CANC, PHILADELPHIA, PA 19104 USA	Scripps Research Institute; University of Pennsylvania			O'Toole, Timothy/I-4172-2013		NHLBI NIH HHS [HL16411, HL 39150, HL28235] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL016411, R01HL039150, R01HL028235] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTIERI DC, 1988, J CELL BIOL, V107, P1893, DOI 10.1083/jcb.107.5.1893; BENNETT JS, 1979, J CLIN INVEST, V64, P1393, DOI 10.1172/JCI109597; BRASS LF, 1986, J BIOL CHEM, V261, P6838; COLLER BS, 1983, J CLIN INVEST, V72, P325, DOI 10.1172/JCI110973; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; FRELINGER AL, 1990, J BIOL CHEM, V265, P6346; FROJMOVIC MM, 1991, BLOOD, V78, P369; HIBBS ML, 1991, SCIENCE, V251, P1611, DOI 10.1126/science.1672776; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; KUNICKI TJ, 1981, J CLIN INVEST, V67, P717, DOI 10.1172/JCI110088; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LOFTUS JC, 1988, J BIOL CHEM, V263, P11025; Maniatis T., 1982, MOL CLONING; MARGUERIE GA, 1980, J BIOL CHEM, V255, P154; MCEVER RP, 1983, J BIOL CHEM, V258, P5269; MUNKER R, 1991, HEMATOLOGY BASIC PRI, P817; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NEUGEBAUER KM, 1991, NATURE, V350, P68, DOI 10.1038/350068a0; OTOOLE TE, 1990, CELL REGUL, V1, P883, DOI 10.1091/mbc.1.12.883; OTOOLE TE, 1989, BLOOD, V74, P14; PLOW EF, 1981, J BIOL CHEM, V256, P9477; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SHATTIL SJ, 1987, J BIOL CHEM, V262, P992; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; SHAW LM, 1990, J CELL BIOL, V110, P2167, DOI 10.1083/jcb.110.6.2167; SOLOWSKA J, 1989, J CELL BIOL, V109, P853, DOI 10.1083/jcb.109.2.853; SUZUKI S, 1987, J BIOL CHEM, V262, P14080; TAMURA RN, IN PRESS P NATL ACAD; TAUB R, 1989, J BIOL CHEM, V264, P259; WOODS VL, 1986, J BIOL CHEM, V261, P5242	30	311	316	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 8	1991	254	5033					845	847		10.1126/science.1948065	http://dx.doi.org/10.1126/science.1948065			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GN833	1948065				2022-12-24	WOS:A1991GN83300041
J	BEZANILLA, F; PEROZO, E; PAPAZIAN, DM; STEFANI, E				BEZANILLA, F; PEROZO, E; PAPAZIAN, DM; STEFANI, E			MOLECULAR-BASIS OF GATING CHARGE IMMOBILIZATION IN SHAKER POTASSIUM CHANNELS	SCIENCE			English	Article							SODIUM-CHANNEL; XENOPUS OOCYTES; SQUID AXON; DROSOPHILA; INACTIVATION; ACTIVATION; CURRENTS; LOCUS; GENE; CDNA	Voltage-dependent ion channels respond to changes in the membrane potential by means of charged voltage sensors intrinsic to the channel protein. Changes in transmembrane potential cause movement of these charged residues, which results in conformational changes in the channel. Movements of the charged sensors can be detected as currents known as gating currents. Measurement of the gating currents of the Drosophila Shaker potassium channel indicates that the charge on the voltage sensor of the channels is progressively immobilized by prolonged depolarizations. The charge is not immobilized in a mutant of the channel that lacks inactivation. These results show that the region of the molecule responsible for inactivation interacts, directly or indirectly, with the voltage sensor to prevent the return of the charge to its original position. The gating transitions between closed states of the channel appear not to be independent, suggesting that the channel subunits interact during activation.	BAYLOR COLL MED,DEPT PHYSIOL & MOLEC BIOPHYS,HOUSTON,TX 77030	Baylor College of Medicine	BEZANILLA, F (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,DEPT PHYSIOL,LOS ANGELES,CA 90024, USA.				NHLBI NIH HHS [HL37044] Funding Source: Medline; NIGMS NIH HHS [R01 GM043459-12, R01 GM043459-16, R01 GM043459-15S1, R01 GM043459-09, R01 GM043459-11, GM43459, R01 GM043459-15, GM30376, R01 GM043459-17, R01 GM043459-13, R01 GM043459, R01 GM043459-10, R01 GM043459-14] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL037044] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030376, R01GM030376, R01GM043459] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Almers W, 1978, Rev Physiol Biochem Pharmacol, V82, P96, DOI 10.1007/BFb0030498; ARMSTRONG CM, 1977, J GEN PHYSIOL, V70, P567, DOI 10.1085/jgp.70.5.567; BAUMANN A, 1987, EMBO J, V6, P3419, DOI 10.1002/j.1460-2075.1987.tb02665.x; BEZANILLA F, 1982, J GEN PHYSIOL, V79, P21, DOI 10.1085/jgp.79.1.21; BEZANILLA F, 1977, J GEN PHYSIOL, V70, P549, DOI 10.1085/jgp.70.5.549; CHOI KL, 1991, P NATL ACAD SCI USA, V88, P5092, DOI 10.1073/pnas.88.12.5092; COLE KS, 1960, BIOPHYS J, V1, P161; GILLY WF, 1982, J GEN PHYSIOL, V79, P935, DOI 10.1085/jgp.79.6.935; HODGKIN AL, 1952, J PHYSIOL-LONDON, V117, P500, DOI 10.1113/jphysiol.1952.sp004764; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; KAMB A, 1987, CELL, V50, P405, DOI 10.1016/0092-8674(87)90494-6; KAMB A, 1988, NEURON, V1, P421, DOI 10.1016/0896-6273(88)90192-4; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; MACKINNON R, 1991, Biophysical Journal, V59, p404A; NODA M, 1984, NATURE, V312, P121, DOI 10.1038/312121a0; PAPAZIAN DM, 1987, SCIENCE, V237, P749, DOI 10.1126/science.2441470; PAPAZIAN DM, 1991, NATURE, V349, P305, DOI 10.1038/349305a0; SCHWARZ TL, 1988, NATURE, V331, P137, DOI 10.1038/331137a0; STIMERS JR, 1987, J GEN PHYSIOL, V89, P521, DOI 10.1085/jgp.89.4.521; STIMERS JR, 1985, J GEN PHYSIOL, V85, P65, DOI 10.1085/jgp.85.1.65; STUHMER W, 1991, PFLUG ARCH EUR J PHY, V418, P423, DOI 10.1007/BF00550881; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; TAGLIALATELA M, IN PRESS BIOPHYS J; TAGLIALATELA M, UNPUB; TAYLOR RE, 1983, J GEN PHYSIOL, V81, P773, DOI 10.1085/jgp.81.6.773; TEMPEL BL, 1987, SCIENCE, V237, P770, DOI 10.1126/science.2441471; TIMPE LC, 1988, NATURE, V331, P143, DOI 10.1038/331143a0; TIMPE LC, 1988, NEURON, V1, P659, DOI 10.1016/0896-6273(88)90165-1; TORO L, IN PRESS NEUR SOC AB; WHITE MM, 1985, J GEN PHYSIOL, V85, P539, DOI 10.1085/jgp.85.4.539; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494; ZAGOTTA WN, 1990, J GEN PHYSIOL, V95, P29, DOI 10.1085/jgp.95.1.29; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520	33	186	189	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 1	1991	254	5032					679	683		10.1126/science.1948047	http://dx.doi.org/10.1126/science.1948047			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GN474	1948047				2022-12-24	WOS:A1991GN47400031
J	FRANKS, NP; LIEB, WR				FRANKS, NP; LIEB, WR			STEREOSPECIFIC EFFECTS OF INHALATIONAL GENERAL ANESTHETIC OPTICAL ISOMERS ON NERVE ION CHANNELS	SCIENCE			English	Article							APLYSIA NEURONS; RECEPTORS; STEREOISOMERS; PHARMACOLOGY; INHIBITION; RESPONSES; HALOTHANE; BINDING; SYSTEM; SITES	Although it is generally agreed that general anesthetics ultimately act on neuronal ion channels, there is considerable controversy over whether this occurs by direct binding to protein or secondarily by nonspecific perturbation of lipids. Very pure optical isomers of the inhalational general anesthetic isoflurane exhibited clear stereoselectivity in their effects on particularly sensitive ion channels in identified molluscan central nervous system neurons. At the human median effect dose (ED50) for general anesthesia, the (+)-isomer was about twofold more effective than the (-)-isomer both in eliciting the anesthetic-activated potassium current I(K)(An) and in inhibiting a current mediated by neuronal nicotinic acetylcholine receptors. For inhibiting the much less sensitive transient potassium current I(A), the (-)-isomer was marginally more potent than the (+)-isomer. Both isomers were equally effective at disrupting lipid bilayers.			FRANKS, NP (corresponding author), IMPERIAL COLL SCI TECHNOL & MED,BLACKETT LAB,PRINCE CONSORT RD,LONDON SW7 2BZ,ENGLAND.			Franks, Nicholas/0000-0003-4874-4212	NIGMS NIH HHS [GM 41609] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041609] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALIFIMOFF JK, 1987, ANESTHESIOLOGY, V66, P55, DOI 10.1097/00000542-198701000-00010; ANDREWS PR, 1982, ANESTHESIOLOGY, V57, P314, DOI 10.1097/00000542-198210000-00014; ARIMURA H, 1986, BRIT J PHARMACOL, V89, P573, DOI 10.1111/j.1476-5381.1986.tb11158.x; CHEMERIS NK, 1982, J PHYSIOL-LONDON, V323, P1; COTE IL, 1980, J PHARMACOL EXP THER, V214, P161; DLUZEWSKI AR, 1983, MOL ASPECTS MED, V6, P459, DOI 10.1016/0098-2997(83)90001-8; EDAMURA FY, 1970, 159TH NAT M AM CHEM; FRANKS NP, 1987, TRENDS PHARMACOL SCI, V8, P169, DOI 10.1016/0165-6147(87)90160-X; FRANKS NP, 1982, NATURE, V300, P487, DOI 10.1038/300487a0; FRANKS NP, 1988, NATURE, V333, P662, DOI 10.1038/333662a0; FRANKS NP, 1984, NATURE, V310, P599, DOI 10.1038/310599a0; HILL MW, 1974, BIOCHIM BIOPHYS ACTA, V356, P117, DOI 10.1016/0005-2736(74)90299-5; HUANG LYM, 1980, SCIENCE, V207, P195, DOI 10.1126/science.7350656; JUDGE SE, 1982, BRIT J PHARMACOL, V75, P353, DOI 10.1111/j.1476-5381.1982.tb08793.x; KEHOE J, 1972, J PHYSIOL-LONDON, V225, P115, DOI 10.1113/jphysiol.1972.sp009931; KENDIG JJ, 1973, ANESTHESIOLOGY, V39, P518, DOI 10.1097/00000542-197311000-00011; LAASBERG LH, 1971, J BIOL CHEM, V246, P4886; MARIETTA MP, 1977, J PHARMACOL EXP THER, V202, P157; MEINWALD J, 1991, SCIENCE, V251, P560, DOI 10.1126/science.1846702; MILLER KW, 1973, MOL PHARMACOL, V9, P131; MILLER KW, 1985, INT REV NEUROBIOL, V27, P1, DOI 10.1016/S0074-7742(08)60555-3; PFEIFFER CC, 1956, SCIENCE, V124, P29, DOI 10.1126/science.124.3210.29; RICHARDS CD, 1980, TOPICAL REV ANAESTHE, V1, P1; SKOLNICK P, 1982, BRAIN RES, V233, P143, DOI 10.1016/0006-8993(82)90936-2; STEWARD A, 1973, BRIT J ANAESTH, V45, P282, DOI 10.1093/bja/45.3.282; TICKU MK, 1981, BRAIN RES, V211, P127, DOI 10.1016/0006-8993(81)90071-8; WAHLSTROM G, 1984, BRAIN RES, V310, P261, DOI 10.1016/0006-8993(84)90149-5; WEISKOPF RB, 1989, ANESTHESIOLOGY, V70, P793, DOI 10.1097/00000542-198905000-00015; WHITE PF, 1980, ANESTHESIOLOGY, V52, P231, DOI 10.1097/00000542-198003000-00008; WOLFSON B, 1978, ANESTHESIOLOGY, V48, P187	30	250	257	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 18	1991	254	5030					427	430		10.1126/science.1925602	http://dx.doi.org/10.1126/science.1925602			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GK729	1925602				2022-12-24	WOS:A1991GK72900048
J	MACAYA, RF; GILBERT, DE; MALEK, S; SINSHEIMER, JS; FEIGON, J				MACAYA, RF; GILBERT, DE; MALEK, S; SINSHEIMER, JS; FEIGON, J			STRUCTURE AND STABILITY OF X.G.C MISMATCHES IN THE 3RD STRAND OF INTRAMOLECULAR TRIPLEXES	SCIENCE			English	Article							DIMENSIONAL NMR-SPECTRA; C-MYC GENE; HELIX FORMATION; H-DNA; BASE-PAIRS; SEQUENCE; CLEAVAGE; INHIBITION; COMPLEXES; BINDING	Intramolecular DNA triplexes that contain eight base triplets formed from the folding of a single DNA strand tolerate a single X.G.C mismatch in the third strand at acidic pH. The structure and relative stability of all four triplets that are possible involving a G.C Watson-Crick base pair were determined with one- and two-dimensional proton nuclear magnetic resonance techniques. Triplexes containing A.G.C, G.G.C, or T.G.C triplets were less stable than the corresponding parent molecule containing a C.G.C triplet. However, all mismatched bases formed specific hydrogen bonds in the major groove of the double helix. The relative effect of these mismatches on the stability of the triplex differs from the effect assayed (under different conditions) by two-dimensional gel electrophoresis and DNA cleavage with oligonucleotide EDTA.Fe(II).	UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles	MACAYA, RF (corresponding author), UNIV CALIF LOS ANGELES,DEPT CHEM & BIOCHEM,LOS ANGELES,CA 90024, USA.			Malek, Shiva/0000-0002-9526-7968; Macaya, Roman/0000-0001-8335-3984	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008185, R01GM037254, T32GM008375] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM 37254-01, GM-08375, GM-08185] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNOTT S, 1974, J MOL BIOL, V88, P509, DOI 10.1016/0022-2836(74)90498-7; BELOTSERKOVSKII BP, 1990, NUCLEIC ACIDS RES, V18, P6621, DOI 10.1093/nar/18.22.6621; BERNUES J, 1990, NUCLEIC ACIDS RES, V18, P4067, DOI 10.1093/nar/18.14.4067; BROWN T, 1989, J MOL BIOL, V207, P455, DOI 10.1016/0022-2836(89)90268-4; Cantor C. R., 1980, BIOPHYSICAL CHEM 3; COLLIER DA, 1988, J BIOL CHEM, V263, P7397; COONEY M, 1988, SCIENCE, V241, P456, DOI 10.1126/science.3293213; DELOSSANTOS C, 1989, BIOCHEMISTRY-US, V28, P7282, DOI 10.1021/bi00444a021; DOAN TL, 1987, NUCLEIC ACIDS RES, V15, P7749; FELSENFELD G, 1957, J AM CHEM SOC, V79, P2023, DOI 10.1021/ja01565a074; FRANCOIS JC, 1989, BIOCHEMISTRY-US, V28, P9617, DOI 10.1021/bi00451a011; FRANCOIS JC, 1989, J BIOL CHEM, V264, P5891; GAO XL, 1988, J AM CHEM SOC, V110, P5178, DOI 10.1021/ja00223a045; GRIFFIN LC, 1989, SCIENCE, V245, P967, DOI 10.1126/science.2549639; HANER R, 1990, BIOCHEMISTRY-US, V29, P9761, DOI 10.1021/bi00494a001; HANVEY JC, 1990, NUCLEIC ACIDS RES, V18, P157, DOI 10.1093/nar/18.1.157; HANVEY JC, 1989, J BIOL CHEM, V264, P5950; HTUN H, 1988, SCIENCE, V241, P1791, DOI 10.1126/science.3175620; KATO M, 1990, BIOCHEM J, V268, P175, DOI 10.1042/bj2680175; KINNIBURGH AJ, 1989, NUCLEIC ACIDS RES, V17, P7771, DOI 10.1093/nar/17.19.7771; KOHWI Y, 1988, P NATL ACAD SCI USA, V85, P3781, DOI 10.1073/pnas.85.11.3781; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; LEE JS, 1979, NUCLEIC ACIDS RES, V6, P3073, DOI 10.1093/nar/6.9.3073; LEE JS, 1989, GENE, V82, P191, DOI 10.1016/0378-1119(89)90044-9; LEE JS, 1987, NUCLEIC ACIDS RES, V15, P1047, DOI 10.1093/nar/15.3.1047; LETAI AG, 1988, BIOCHEMISTRY-US, V27, P9108, DOI 10.1021/bi00426a007; MACAYA RF, UNPUB; MAHER LJ, 1989, SCIENCE, V245, P725, DOI 10.1126/science.2549631; MANZINI G, 1990, J MOL BIOL, V213, P833, DOI 10.1016/S0022-2836(05)80267-0; MARCK C, 1978, NUCLEIC ACIDS RES, V5, P1017, DOI 10.1093/nar/5.3.1017; MARION D, 1989, J MAGN RESON, V84, P425, DOI 10.1016/0022-2364(89)90391-0; MCCARTHY JG, 1987, NUCLEIC ACIDS RES, V15, P8069, DOI 10.1093/nar/15.19.8069; MIRKIN SM, 1987, NATURE, V330, P495, DOI 10.1038/330495a0; MOOREN MMW, 1990, NUCLEIC ACIDS RES, V18, P6523, DOI 10.1093/nar/18.22.6523; MOSER HE, 1987, SCIENCE, V238, P645, DOI 10.1126/science.3118463; PILCH DS, 1990, P NATL ACAD SCI USA, V87, P1942, DOI 10.1073/pnas.87.5.1942; PLUM GE, 1990, P NATL ACAD SCI USA, V87, P9436, DOI 10.1073/pnas.87.23.9436; PRASEUTH D, 1988, P NATL ACAD SCI USA, V85, P1349, DOI 10.1073/pnas.85.5.1349; RAJAGOPAL P, 1989, BIOCHEMISTRY-US, V28, P7859, DOI 10.1021/bi00445a048; RAJAGOPAL P, 1989, NATURE, V339, P637, DOI 10.1038/339637a0; SAENGER W, 1984, PRINCIPLES NUCLEIC A; SKLENAR V, 1990, NATURE, V345, P836, DOI 10.1038/345836a0; SKLENAR V, 1987, J MAGN RESON, V74, P469, DOI 10.1016/0022-2364(87)90269-1; STROBEL SA, 1988, J AM CHEM SOC, V110, P7927, DOI 10.1021/ja00231a082; WANG EG, UNPUB; WELLS RD, 1988, FASEB J, V2, P2939, DOI 10.1096/fasebj.2.14.3053307	46	63	63	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 11	1991	254	5029					270	274		10.1126/science.1925581	http://dx.doi.org/10.1126/science.1925581			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GJ642	1925581				2022-12-24	WOS:A1991GJ64200034
J	SEARS, MR; BURROWS, B; FLANNERY, EM; HERBISON, GP; HEWITT, CJ; HOLDAWAY, MD				SEARS, MR; BURROWS, B; FLANNERY, EM; HERBISON, GP; HEWITT, CJ; HOLDAWAY, MD			RELATION BETWEEN AIRWAY RESPONSIVENESS AND SERUM IGE IN CHILDREN WITH ASTHMA AND IN APPARENTLY NORMAL-CHILDREN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BRONCHIAL REACTIVITY; POPULATION-SAMPLE; CHILDHOOD ASTHMA; NEW-ZEALAND; HISTAMINE; METHACHOLINE; ATOPY; HYPERRESPONSIVENESS; PREVALENCE; ALLERGY	Background. Although asthma diagnosed by a physician is known to be related to serum IgE levels, it is not known whether there is a relation between the level of IgE and airway hyperresponsiveness to a methacholine challenge. The characteristics of asymptomatic persons that predispose them to airway hyperresponsiveness are also unknown. Methods. We studied the relation between the serum total IgE level and airway hyperresponsiveness in the presence or absence of asthma and other atopic diseases in a birth cohort of children. Data from a questionnaire regarding respiratory symptoms, plus measurements of the serum total IgE level and airway responsiveness to inhaled methacholine, were obtained for 562 11-year-olds in New Zealand. Results. The boys had a higher prevalence than the girls of current diagnosed asthma (13 percent vs. 6 percent), current symptoms of wheezing (22 percent vs. 15 percent), and airflow obstruction at base line (6 percent vs. 1 percent) and had a wider distribution of IgE levels, although mean IgE levels (120.8 IU per milliliter in the boys and 98.1 IU per milliliter in the girls) did not differ significantly between the sexes. The prevalence of diagnosed asthma was strongly related to the serum IgE level (P for trend < 0.0001). No asthma was reported in children with IgE levels < 32 IU per milliliter, whereas 36 percent of those with IgE levels greater-than-or-equal-to 1000 IU per milliliter were reported to have asthma. This relation with the serum IgE level was not explained by a concomitant diagnosis of allergic rhinitis or eczema. Airway hyperresponsiveness to a methacholine challenge also correlated very highly (P < 0.0001) with the serum IgE level. This relation remained significant even after the exclusion of children with diagnosed asthma (P < 0.0001) and of all children with a history of wheezing, allergic rhinitis, or eczema (P < 0.0001). Conclusions. Even in children who have been asymptomatic throughout their lives and have no history of atopic disease, airway hyperresponsiveness appears to be closely linked to an allergic diathesis, as reflected by the serum total IgE level.	UNIV ARIZONA,COLL MED,DIV RESP SCI,TUCSON,AZ 85721; UNIV OTAGO,SCH MED,DEPT MED,DUNEDIN,NEW ZEALAND; UNIV OTAGO,SCH MED,DEPT PREVENT & SOCIAL MED,DUNEDIN,NEW ZEALAND; UNIV OTAGO,SCH MED,DEPT PAEDIAT & CHILD HLTH,DUNEDIN,NEW ZEALAND	University of Arizona; University of Otago; University of Otago; University of Otago				Herbison, Graham Peter/0000-0002-5684-024X	NHLBI NIH HHS [HL-14136] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL014136] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARNES PJ, 1989, J ALLERGY CLIN IMMUN, V83, P1013, DOI 10.1016/0091-6749(89)90441-7; BOULET LP, 1983, J ALLERGY CLIN IMMUN, V71, P399, DOI 10.1016/0091-6749(83)90069-6; BRYANT DH, 1976, CLIN ALLERGY, V6, P373, DOI 10.1111/j.1365-2222.1976.tb01919.x; BURROWS B, 1983, CHEST, V84, P657, DOI 10.1378/chest.84.6.657; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; CLINE MG, 1989, THORAX, V44, P425, DOI 10.1136/thx.44.5.425; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; COCKCROFT DW, 1984, ANN ALLERGY, V53, P26; DAVIES RJ, 1976, THORAX, V31, P419, DOI 10.1136/thx.31.4.419; GRAINGER DN, 1990, CLIN EXP ALLERGY, V20, P181, DOI 10.1111/j.1365-2222.1990.tb02665.x; JOHANSSON SGO, 1976, CLIN ALLERGY, V6, P91, DOI 10.1111/j.1365-2222.1976.tb01417.x; JONES DT, 1987, BRIT J DIS CHEST, V81, P332, DOI 10.1016/0007-0971(87)90181-1; LAM S, 1983, J ALLERGY CLIN IMMUN, V72, P134, DOI 10.1016/0091-6749(83)90520-1; LEE DA, 1983, BRIT MED J, V286, P1256, DOI 10.1136/bmj.286.6373.1256; MALO JL, 1983, AM REV RESPIR DIS, V128, P8, DOI 10.1164/arrd.1983.128.1.8; MURANAKA M, 1974, J ALLERGY CLIN IMMUN, V54, P32, DOI 10.1016/S0091-6749(74)80006-0; OCONNOR GT, 1989, AM REV RESPIR DIS, V140, P1520, DOI 10.1164/ajrccm/140.6.1520; RIJCKEN B, 1988, AM REV RESPIR DIS, V137, P826, DOI 10.1164/ajrccm/137.4.826; RYAN G, 1982, THORAX, V37, P423, DOI 10.1136/thx.37.6.423; SALOME CM, 1987, CLIN ALLERGY, V17, P271, DOI 10.1111/j.1365-2222.1987.tb02015.x; SEARS MR, 1986, THORAX, V41, P283, DOI 10.1136/thx.41.4.283; Silva P A, 1990, Paediatr Perinat Epidemiol, V4, P76, DOI 10.1111/j.1365-3016.1990.tb00621.x; TOWNLEY RG, 1975, J ALLERGY CLIN IMMUN, V56, P429; WOOLCOCK AJ, 1978, CLIN ALLERGY, V8, P155, DOI 10.1111/j.1365-2222.1978.tb00460.x; ZIMMERMAN B, 1988, J ALLERGY CLIN IMMUN, V81, P63, DOI 10.1016/0091-6749(88)90221-7	26	655	670	0	14	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 10	1991	325	15					1067	1071		10.1056/NEJM199110103251504	http://dx.doi.org/10.1056/NEJM199110103251504			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GJ108	1891008				2022-12-24	WOS:A1991GJ10800004
J	MORIN, GB				MORIN, GB			RECOGNITION OF A CHROMOSOME TRUNCATION SITE ASSOCIATED WITH ALPHA-THALASSEMIA BY HUMAN TELOMERASE	NATURE			English	Article							TERMINAL TRANSFERASE-ACTIVITY; PROTOZOAN OXYTRICHA-NOVA; MACRONUCLEAR DNA; TETRAHYMENA; SEQUENCES; BREAKAGE; RIBONUCLEOPROTEIN; IDENTIFICATION; DELETIONS; REPEATS	TELOMERES define the ends of chromosomes; they consist of short tandemly repeated DNA sequences loosely conserved in eukaryotes (G1-8(T/A)1-4) 1. Telomerase is a ribonucleoprotein which, in vitro, recognizes a single-stranded G-rich telomere primer and adds multiple telomeric repeats to its 3' end by using a template in the RNA moiety 2-6. In conjunction with other components, telomerase may balance the loss of telomeric repeats due to DNA replication 7. Another role of telomerase may be the de novo formation of telomeres. In eukaryotes like Tetrahymena, this process is an integral part of the formation of macronuclear chromosomes 8. In other eukaryotes this process stabilizes broken chromosomes. A case of human alpha-thalassaemia is caused by a truncation of chromosome 16 that has been healed by the addition of telomeric repeats (TTAGGG)n (ref. 9). Using an in vitro assay 4, I show here that human telomerase correctly recognizes the chromosome 16 breakpoint sequence and adds (TTAGGG)n repeats. The DNA sequence requirements are minimal and seem to define two modes of DNA recognition by telomerase.	YALE UNIV,HOWARD HUGHES MED INST,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06510	Howard Hughes Medical Institute; Yale University			Morin, Gregg B/E-9123-2012	Morin, Gregg B/0000-0001-8949-4374				ADAM RD, 1991, MOL CELL BIOL, V11, P3326, DOI 10.1128/MCB.11.6.3326; BAROIN A, 1987, NUCLEIC ACIDS RES, V15, P1717, DOI 10.1093/nar/15.4.1717; BLACKBURN EH, 1986, ANNU REV GENET, V20, P501; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; BLACKBURN EH, 1984, CELL, V37, P7, DOI 10.1016/0092-8674(84)90295-2; FORNEY JD, 1988, MOL CELL BIOL, V8, P251, DOI 10.1128/MCB.8.1.251; GILLEY D, 1988, MOL CELL BIOL, V8, P4765, DOI 10.1128/MCB.8.11.4765; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; GREIDER CW, 1987, CELL, V51, P887, DOI 10.1016/0092-8674(87)90576-9; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; GUSELLA JF, 1985, NATURE, V318, P75, DOI 10.1038/318075a0; HENDERSON E, 1987, CELL, V51, P899, DOI 10.1016/0092-8674(87)90577-0; HERRICK G, 1987, GENE DEV, V1, P1047, DOI 10.1101/gad.1.10.1047; KAMPER J, 1989, MOL CELL BIOL, V9, P3931; KLOBUTCHER LA, 1986, MOL CELL BIOL, V6, P3606, DOI 10.1128/MCB.6.11.3606; KLOBUTCHER LA, 1984, CELL, V36, P1045, DOI 10.1016/0092-8674(84)90054-0; KLOBUTCHER LA, 1988, NUCLEIC ACIDS RES, V16, P251, DOI 10.1093/nar/16.1.251; LEDBETTER DH, 1989, P NATL ACAD SCI USA, V86, P5136, DOI 10.1073/pnas.86.13.5136; MATSUMOTO T, 1987, MOL CELL BIOL, V7, P4424, DOI 10.1128/MCB.7.12.4424; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; MURRAY AW, 1988, MOL CELL BIOL, V8, P4642, DOI 10.1128/MCB.8.11.4642; POLOGE LG, 1988, CELL, V55, P869, DOI 10.1016/0092-8674(88)90142-0; SHIPPENLENTZ D, 1990, SCIENCE, V247, P546, DOI 10.1126/science.1689074; SHIPPENLENTZ D, 1989, MOL CELL BIOL, V9, P2761, DOI 10.1128/MCB.9.6.2761; SUNDQUIST WI, 1989, NATURE, V342, P825, DOI 10.1038/342825a0; WILKIE AOM, 1990, NATURE, V346, P868, DOI 10.1038/346868a0; WILLIAMSON JR, 1989, CELL, V59, P871, DOI 10.1016/0092-8674(89)90610-7; YAO MC, 1987, CELL, V48, P779, DOI 10.1016/0092-8674(87)90075-4; YAO MC, 1990, CELL, V63, P763, DOI 10.1016/0092-8674(90)90142-2; YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0; ZAHLER AM, 1991, NATURE, V350, P718, DOI 10.1038/350718a0	31	191	199	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 3	1991	353	6343					454	456		10.1038/353454a0	http://dx.doi.org/10.1038/353454a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GH606	1896089				2022-12-24	WOS:A1991GH60600065
J	CASH, JD				CASH, JD			HIGH POTENCY FACTOR-VIII CONCENTRATES - VALUE NOT PROVED	BRITISH MEDICAL JOURNAL			English	Article											CASH, JD (corresponding author), SCOTTISH NATL BLOOD TRANSFUS SERV,HEADQUARTERS MED UNIT,EDINBURGH EH1 1JH,SCOTLAND.							BELL BA, 1990, LANCET, V336, P638, DOI 10.1016/0140-6736(90)93444-T; BURNOUF T, 1991, VOX SANG, V60, P8, DOI 10.1111/j.1423-0410.1991.tb00864.x; CASH JD, 1988, LANCET, V1, P1270; CASH JD, 1991, BRIT MED J, V302, P849, DOI 10.1136/bmj.302.6780.849-b; KESSLER GM, 1990, LANCET, V335, P1403; MONTORO JB, 1991, LANCET, V338, P1222	6	10	10	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 14	1991	303	6803					633	634		10.1136/bmj.303.6803.633	http://dx.doi.org/10.1136/bmj.303.6803.633			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GF675	1932909	Green Published, Bronze			2022-12-24	WOS:A1991GF67500029
J	LAZARUS, NB; KAPLAN, GA; COHEN, RD; LEU, DJ				LAZARUS, NB; KAPLAN, GA; COHEN, RD; LEU, DJ			CHANGE IN ALCOHOL-CONSUMPTION AND RISK OF DEATH FROM ALL CAUSES AND FROM ISCHEMIC-HEART-DISEASE	BRITISH MEDICAL JOURNAL			English	Article							ALAMEDA COUNTY; MORTALITY; LINKAGE; WOMEN; MEN	Objective - To examine the association between alcohol consumption and mortality from all causes and from ischaemic heart disease with a focus on differentiating between long term abstainers and more recent non-drinkers. Design - Cohort study of changes in alcohol consumption from 1965 to 1974 and mortality from all causes and ischaemic heart disease during 1974-84. Setting - Population based study of adult residents of Alameda County, California. Subjects - 2225 women and 1845 men aged 35 and over in 1965. Main outcome measures - Alcohol consumption in 1964 and 1974 and mortality from all causes and from ischaemic heart disease during 1974-84. Results - There was a significantly higher risk of death from all causes and from ischaemic heart disease in women who gave up drinking between 1965 and 1974 than in women who continued to drink (relative risk 1.72, 95% confidence interval 1.11 to 2.66, and 2.75, 1.44 to 5.23, for all causes and ischaemic heart disease respectively). A significant increase in risk was not seen in men who gave up drinking (1.32, 0.87 to 2.01, and 0.95, 0.41 to 2.20, respectively). Among men, long term abstainers compared with drinkers were at increased risk of death from all causes and from ischaemic heart disease, though the associations were not significant (1.40, 0.98 to 2.00, and 1.40, 0.76 to 2.58, for all causes and ischaemic heart disease respectively). Conclusion- Some of the increased risk of death from all causes and from ischaemic heart disease associated with not drinking in women seems to be accounted for by higher risks among those who gave up drinking. Men who are long term abstainers may also be at an increased risk of death. The heterogeneity of the non-drinking group should be considered when comparisons are made with drinkers.	CALIF DEPT HLTH SCI,HUMAN POPULAT LAB,BERKELEY,CA 94704; CALIF PUBL HLTH FDN,HUMAN POPULAT LAB,BERKELEY,CA 94704	California Department of Public Health			Kaplan, George/AAJ-2398-2020					ARELLANO MG, 1984, AM J PUBLIC HEALTH, V74, P1324, DOI 10.2105/AJPH.74.12.1324; BELLOC NB, 1973, HEALTH SERV REP, V88, P344, DOI 10.2307/4594792; Berkman LF, 1983, HLTH WAYS LIVING ALA; Boffetta P, 1990, Epidemiology, V1, P342, DOI 10.1097/00001648-199009000-00003; CAMACHO TC, 1987, J CHRON DIS, V40, P229, DOI 10.1016/0021-9681(87)90158-5; CASTELLI WP, 1977, LANCET, V2, P153; COLSHER PL, 1989, ANNU REV PUBL HEALTH, V10, P203, DOI 10.1146/annurev.pu.10.050189.001223; CRIQUI MH, 1985, BEHAVIORAL EPIDEMIOL, P67; DYER AR, 1980, PREV MED, V9, P78, DOI 10.1016/0091-7435(80)90060-2; DYER AR, 1977, CIRCULATION, V56, P1067, DOI 10.1161/01.CIR.56.6.1067; Ellison R C, 1990, Epidemiology, V1, P337; ERNST N, 1980, CIRCULATION, V62, P41; FREZZA M, 1990, NEW ENGL J MED, V322, P95, DOI 10.1056/NEJM199001113220205; JACKSON R, 1991, BRIT MED J, V303, P211, DOI 10.1136/bmj.303.6796.211; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; KLATSKY AL, 1974, ANN INTERN MED, V81, P294, DOI 10.7326/0003-4819-81-3-294; MARMOT MG, 1981, LANCET, V1, P580; MEADE TW, 1979, BMJ-BRIT MED J, V1, P153, DOI 10.1136/bmj.1.6157.153; MOORE RD, 1986, MEDICINE, V65, P242, DOI 10.1097/00005792-198607000-00004; SEEMAN TE, 1987, AM J EPIDEMIOL, V126, P714, DOI 10.1093/oxfordjournals.aje.a114711; STAMPFER MJ, 1988, NEW ENGL J MED, V319, P267, DOI 10.1056/NEJM198808043190503; WANNAMETHEE G, 1988, INT J EPIDEMIOL, V17, P307, DOI 10.1093/ije/17.2.307; YANO K, 1984, AM J EPIDEMIOL, V119, P653, DOI 10.1093/oxfordjournals.aje.a113787; YANO K, 1977, NEW ENGL J MED, V297, P405, DOI 10.1056/NEJM197708252970801; 1974, 2ND US DEP HLTH ED W	25	68	68	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 7	1991	303	6802					553	556		10.1136/bmj.303.6802.553	http://dx.doi.org/10.1136/bmj.303.6802.553			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GE948	1912885	Green Submitted, Green Published, Bronze			2022-12-24	WOS:A1991GE94800023
J	SAKAI, T; OHTANI, N; MCGEE, TL; ROBBINS, PD; DRYJA, TP				SAKAI, T; OHTANI, N; MCGEE, TL; ROBBINS, PD; DRYJA, TP			ONCOGENIC GERM-LINE MUTATIONS IN SP1 AND ATF SITES IN THE HUMAN RETINOBLASTOMA GENE	NATURE			English	Article							DNA-BINDING; REPORTER GENE; EXPRESSION; SEQUENCE; PROTEINS	THE transcription of a eukaryotic gene is a consequence of intricate interactions between members of a set of transcription factors 1. We describe here evidence indicating that at least two distinct DNA-binding factors play an important part in the transcription of the human retinoblastoma gene (Rb). One of the factors reacts with a sequence overlapping with a potential Sp1 recognition sequence in the promoter region of the gene, the other with a nearby ATF recognition sequence. We have identified two naturally occurring point mutations in these recognition sequences that cause hereditary retinoblastoma. The nuclear factors do not bind to the mutant sequences. We infer that these nuclear factors are necessary for the expression of the Rb gene and the suppression of cancer.	HARVARD UNIV,MASSACHUSETTS EYE & EAR INFIRM,SCH MED,DEPT OPHTHALMOL,BOSTON,MA 02114; UNIV PITTSBURGH,SCH MED,DEPT MOLEC GENET & BIOCHEM,PITTSBURGH,PA 15261	Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh				Ohtani, Naoko/0000-0001-8934-0797				BOOKSTEIN R, 1990, P NATL ACAD SCI USA, V87, P7762, DOI 10.1073/pnas.87.19.7762; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DISTEL RJ, 1987, CELL, V49, P835, DOI 10.1016/0092-8674(87)90621-0; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HONG FD, 1989, P NATL ACAD SCI USA, V86, P5502, DOI 10.1073/pnas.86.14.5502; KADONAGA JT, 1988, SCIENCE, V242, P1566, DOI 10.1126/science.3059495; MACKLIN MT, 1960, AM J HUM GENET, V12, P1; MCGEE TL, 1989, GENE, V80, P119, DOI 10.1016/0378-1119(89)90256-4; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; ORITA M, 1989, GENOMICS, V5, P871; SAMBROOK J, 1989, MOL CLONING LAB MANU, V3, P16; SASSONECORSI P, 1990, ONCOGENE, V5, P427	14	214	219	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 5	1991	353	6339					83	90		10.1038/353083a0	http://dx.doi.org/10.1038/353083a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GD805	1881452				2022-12-24	WOS:A1991GD80500065
J	FERNANDEZMORENO, MA; CABALLERO, JL; HOPWOOD, DA; MALPARTIDA, F				FERNANDEZMORENO, MA; CABALLERO, JL; HOPWOOD, DA; MALPARTIDA, F			THE ACT CLUSTER CONTAINS REGULATORY AND ANTIBIOTIC EXPORT GENES, DIRECT TARGETS FOR TRANSLATIONAL CONTROL BY THE BLDA TRANSFER-RNA GENE OF STREPTOMYCES	CELL			English	Article							TETRACYCLINE-RESISTANCE GENE; NUCLEOTIDE-SEQUENCE ANALYSIS; ANION-EXCHANGE PROTEIN; COELICOLOR A3(2); ESCHERICHIA-COLI; TRANSCRIPTIONAL REGULATION; HETEROLOGOUS HOST; CLONING; BIOSYNTHESIS; EXPRESSION	The actII region, flanked by biosynthetic genes in the 25 kb act cluster of S. coelicolor, consists of four open reading frames, including a transcriptional activator for the biosynthetic genes, and genes controlling antibiotic export. A TTA codon (extremely rare in Streptomyces) is present both in actII-ORF2 (encoding a putative transmembrane export protein) and actII-ORF4 (the transcriptional activator gene). Change of the TTA in ORF4 to TTG reverses the normal interruption of actinorhodin synthesis caused by mutation in the pleiotropic regulatory gene bldA (which encodes the cell's tRNA(UUA)Leu). We conclude that initiation of actinorhodin synthesis via the actII-ORF4 product, and the final step in production, antibiotic export, are twin targets via which bldA exerts developmental control of actinorhodin production.	JOHN INNES INST,JOHN INNES INST,NORWICH NR4 7UH,NORFOLK,ENGLAND	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center	FERNANDEZMORENO, MA (corresponding author), CTR NACL BIOTECNOL,SERRANO 115,E-28006 MADRID,SPAIN.		Malpartida, Francisco/D-2563-2009; Fernandez-Moreno, Miguel Angel/K-4425-2017; Caballero, José L./L-2067-2014	Fernandez-Moreno, Miguel Angel/0000-0002-3461-0726; Caballero, José L./0000-0002-2678-4849				ADAMIDIS T, 1990, J BACTERIOL, V172, P2962, DOI 10.1128/jb.172.6.2962-2969.1990; ANZAI H, 1987, J BACTERIOL, V169, P3482, DOI 10.1128/jb.169.8.3482-3488.1987; BERNARDI A, 1984, NUCLEIC ACIDS RES, V12, P9415, DOI 10.1093/nar/12.24.9415; BIBB MJ, 1984, GENE, V30, P157, DOI 10.1016/0378-1119(84)90116-1; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; CABALLERO JL, 1991, IN PRESS MOL GEN GEN; CHAMPNESS WC, 1988, J BACTERIOL, V170, P1168, DOI 10.1128/jb.170.3.1168-1174.1988; CHATER KF, 1983, GENE, V26, P67, DOI 10.1016/0378-1119(83)90037-9; CHATER KF, 1989, TRENDS GENET, V5, P372, DOI 10.1016/0168-9525(89)90172-8; COVARRUBIAS L, 1982, GENE, V17, P79, DOI 10.1016/0378-1119(82)90103-2; CUNDLIFFE E, 1989, ANNU REV MICROBIOL, V43, P207, DOI 10.1146/annurev.micro.43.1.207; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FEITELSON JS, 1983, MOL GEN GENET, V190, P394, DOI 10.1007/BF00331065; GUTHRIE EP, 1990, J BACTERIOL, V172, P6189, DOI 10.1128/jb.172.11.6189-6193.1990; HALLAM SE, 1988, GENE, V74, P305, DOI 10.1016/0378-1119(88)90165-5; HARA O, 1983, J GEN MICROBIOL, V129, P2939; HARRISON SC, 1990, ANNU REV BIOCHEM, V59, P933, DOI 10.1146/annurev.bi.59.070190.004441; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HIGGINS CF, 1990, J BIOENERG BIOMEMBR, V22, P571, DOI 10.1007/BF00762962; Hopwood D. A., 1985, GENETIC MANIPULATION; HOPWOOD DA, 1988, PROC R SOC SER B-BIO, V235, P121, DOI 10.1098/rspb.1988.0067; HOPWOOD DA, 1986, REGULATION SECONDARY, P23; HORINOUCHI S, 1990, GENE, V95, P49, DOI 10.1016/0378-1119(90)90412-K; HOSHINO T, 1985, GENE, V37, P131; KANAZAWA S, 1988, MOL CELL BIOL, V8, P664, DOI 10.1128/MCB.8.2.664; KLOCK G, 1985, J BACTERIOL, V161, P326, DOI 10.1128/JB.161.1.326-332.1985; KOPITO RR, 1985, NATURE, V316, P234, DOI 10.1038/316234a0; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAWLOR EJ, 1987, GENE DEV, V1, P1305, DOI 10.1101/gad.1.10.1305; LESKIW BK, 1991, P NATL ACAD SCI USA, V88, P2461, DOI 10.1073/pnas.88.6.2461; LIRAS P, 1990, TRENDS BIOTECHNOL, V8, P184, DOI 10.1016/0167-7799(90)90170-3; LUX SE, 1989, P NATL ACAD SCI USA, V86, P9089, DOI 10.1073/pnas.86.23.9089; MALPARTIDA F, 1986, MOL GEN GENET, V205, P66, DOI 10.1007/BF02428033; MALPARTIDA F, 1990, GENE, V93, P91, DOI 10.1016/0378-1119(90)90141-D; MALPARTIDA F, 1984, NATURE, V309, P462, DOI 10.1038/309462a0; Maniatis T., 1982, MOL CLONING; MARTIN JF, 1989, ANNU REV MICROBIOL, V43, P173, DOI 10.1146/annurev.micro.43.1.173; MARTIN JF, 1980, MICROBIOL REV, V44, P230, DOI 10.1128/MMBR.44.2.230-251.1980; MERRICK MJ, 1976, J GEN MICROBIOL, V96, P299, DOI 10.1099/00221287-96-2-299; NARVA KE, 1990, J BACTERIOL, V172, P326, DOI 10.1128/JB.172.1.326-333.1990; NORMARK S, 1983, ANNU REV GENET, V17, P499, DOI 10.1146/annurev.ge.17.120183.002435; NORRANDER J, 1983, GENE, V26, P102; OCHI K, 1987, J BACTERIOL, V169, P3608, DOI 10.1128/jb.169.8.3608-3616.1987; OHNUKI T, 1985, J BACTERIOL, V164, P85, DOI 10.1128/JB.164.1.85-94.1985; PABO LO, 1984, ANN REV BIOCH, V34, P293; PASSANTINO R, 1991, IN PRESS J GEN MICRO; PEDEN KWC, 1983, GENE, V22, P277, DOI 10.1016/0378-1119(83)90112-9; PIEPERSBERG W, 1988, BIOL ACTINOMYCETES, P92; POSTLE K, 1984, NUCLEIC ACIDS RES, V12, P4849, DOI 10.1093/nar/12.12.4849; REYNES JP, 1988, J GEN MICROBIOL, V134, P585; RODICIO MR, 1985, GENE, V34, P283, DOI 10.1016/0378-1119(85)90137-4; RUDD BAM, 1979, J GEN MICROBIOL, V114, P35, DOI 10.1099/00221287-114-1-35; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCRUTTON NS, 1990, NATURE, V343, P38, DOI 10.1038/343038a0; SENO ET, 1989, REG SEC MET ACT, P1; STEIN D, 1989, J BACTERIOL, V171, P2258, DOI 10.1128/jb.171.4.2258-2261.1989; WATERS SH, 1983, NUCLEIC ACIDS RES, V11, P6089, DOI 10.1093/nar/11.17.6089; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YAZYU H, 1984, J BIOL CHEM, V259, P4320	60	310	335	4	23	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 23	1991	66	4					769	780		10.1016/0092-8674(91)90120-N	http://dx.doi.org/10.1016/0092-8674(91)90120-N			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GC745	1878971				2022-12-24	WOS:A1991GC74500015
J	LOCKYER, MJ				LOCKYER, MJ			PREVALENCE OF MULTIPLE-SCLEROSIS IN 5 RURAL SUFFOLK PRACTICES	BRITISH MEDICAL JOURNAL			English	Article								Objective-To determine a point prevalence of multiple sclerosis in part of Suffolk. Design-Multiple source search for patients with multiple sclerosis in five general practices. Patients were reviewed and categorised by using general practice notes. Setting-Five rural general practices in Suffolk, 12 May 1988. Subjects-31 379 patients registered with five practices. Main outcome measures-Multiple sclerosis diagnosed by a specialist. Results-The search produced a provisional list of 62 eligible patients with multiple sclerosis. Review of case notes showed that 48 had probable disease, 10 early disease, and four possible disease. The probable cases gave a crude prevalence of 153/100 000 population (95% confidence interval 109/100 000 to 196/100 000). Conclusions-Although the results should be interpreted cautiously because of the small sample size, they suggest that the prevalence of multiple sclerosis in Suffolk is higher than has been estimated from hospital data.			LOCKYER, MJ (corresponding author), IXWORTH SURG,BURY ST EDMUNDS IP31 2HD,SUFFOLK,ENGLAND.							Allison RS, 1954, ULSTER MED J      S2, V23, P5; FOG M, 1966, ACTA NEUROL SCAND, VS 42, P9; OBRIEN B, 1987, MULTIPLE SCLEROSIS; POSKANZER DC, 1963, J NEUROL NEUROSUR PS, V26, P368, DOI 10.1136/jnnp.26.4.368; POSKANZER DC, 1980, J EPIDEMIOL COMMUN H, V34, P229, DOI 10.1136/jech.34.4.229; SHEPHERD DI, 1980, J NEUROL NEUROSUR PS, V43, P310, DOI 10.1136/jnnp.43.4.310	6	16	16	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 10	1991	303	6798					347	348		10.1136/bmj.303.6798.347	http://dx.doi.org/10.1136/bmj.303.6798.347			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GA606	1912778	Bronze, Green Published			2022-12-24	WOS:A1991GA60600024
J	NAUMANN, D; HELM, D; LABISCHINSKI, H				NAUMANN, D; HELM, D; LABISCHINSKI, H			MICROBIOLOGICAL CHARACTERIZATIONS BY FT-IR SPECTROSCOPY	NATURE			English	Article								Infrared signals of microorganisms are highly specific fingerprint-like patterns that can be used for probing the identity of microorganisms. The simplicity and versatility of Fourier-transform infrared spectroscopy (FT-IR) makes it a versatile technique for rapid differentiation, classification, identification and large-scale screening at the subspecies level.			NAUMANN, D (corresponding author), BUNDESGESUNDHEITSAMT,ROBERT KOCH INST,NORDUFER 20,W-1000 BERLIN 65,GERMANY.							HELM D, 1991, J GEN MICROBIOL, V137, P69, DOI 10.1099/00221287-137-1-69; NAUMANN D, 1988, J MOL STRUCT, V174, P165, DOI 10.1016/0022-2860(88)80152-2; NAUMANN D, 1988, MIKROCHIM ACTA, V1, P373, DOI 10.1007/BF01205910; NAUMANN D, IN PRESS MODERN TECH; THRELKELD CH, 1982, J FOOD SCI, V47, P1222, DOI 10.1111/j.1365-2621.1982.tb07652.x	5	752	785	7	150	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 2	1991	351	6321					81	82		10.1038/351081a0	http://dx.doi.org/10.1038/351081a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FK193	1902911				2022-12-24	WOS:A1991FK19300066
J	JAMJOOM, AB; KANE, N; SANDEMAN, D; CUMMINS, B				JAMJOOM, AB; KANE, N; SANDEMAN, D; CUMMINS, B			EPILEPSY RELATED TO TRAUMATIC EXTRADURAL HEMATOMAS	BRITISH MEDICAL JOURNAL			English	Article									FRENCHAY HOSP,DEPT NEUROSURG,BRISTOL BS16 1LE,AVON,ENGLAND									ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; JENNETT B, 1975, J NEUROL NEUROSUR PS, V38, P378, DOI 10.1136/jnnp.38.4.378; JENNETT B, 1975, EPILEPSY NONMISSILE, P136	3	10	10	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 23	1991	302	6774					448	448		10.1136/bmj.302.6774.448	http://dx.doi.org/10.1136/bmj.302.6774.448			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ033	1900725	Bronze, Green Published			2022-12-24	WOS:A1991EZ03300022
J	HELD, PJ; LEVIN, NW; BOVBJERG, RR; PAULY, MV; DIAMOND, LH				HELD, PJ; LEVIN, NW; BOVBJERG, RR; PAULY, MV; DIAMOND, LH			MORTALITY AND DURATION OF HEMODIALYSIS-TREATMENT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DIALYSIS	Decrease in the average duration of hemodialysis treatment time is a continuing phenomenon. We investigated the relationship of 3-year mortality to duration of dialysis in a 1984-1985 national random sample of 600 hemodialysis patients from 36 dialysis units. Mortality was negatively associated with duration of dialysis treatments, as shown by the Cox model, adjusted for other patient and dialysis unit covariates. With adjustment for other covariates, patients receiving an average dialysis treatment duration of less than 3.5 hours had relative mortality risks of 1.17 to 2.18 compared with those with treatments longer than 3.5 hours (mortality risk of 1.0). Reverse causation (the possibility that more seriously ill patients received dialysis for a shorter time) appears unlikely. We conclude that duration of the dialysis procedure is an important element in determining patient mortality as one of the factors determining the adequacy of dialysis.	BETH ISRAEL MED CTR,DEPT NEPHROL,NEW YORK,NY 10003; UNIV PENN,WHARTON SCH,PHILADELPHIA,PA 19104; GEORGETOWN UNIV,DEPT NEPHROL,WASHINGTON,DC 20057; DIST COLUMBIA GEN HOSP,WASHINGTON,DC 20003	Harvard University; Beth Israel Deaconess Medical Center; University of Pennsylvania; Georgetown University	HELD, PJ (corresponding author), URBAN INST,RENAL RES PROGRAM,2100 M ST NW,WASHINGTON,DC 20037, USA.							ALEXANDER VD, 1984, SAMPLE DESIGN NATION; DAUGIRDAS JT, 1989, INT J ARTIF ORGANS, V12, P411; GILL RD, 1988, ANN STAT, V16, P1069, DOI 10.1214/aos/1176350948; GOTCH FA, 1990, AM J KIDNEY DIS, V15, P511, DOI 10.1016/S0272-6386(12)70369-4; GOTCH FA, 1985, KIDNEY INT, V28, P526, DOI 10.1038/ki.1985.160; HARRELL F, 1980, SAS SUPPLEMENTAL LIB, P119; HELD PJ, 1987, JAMA-J AM MED ASSOC, V257, P645, DOI 10.1001/jama.257.5.645; HELD PJ, 1987, EFFECTS 1983 COMPOSI; HELD PJ, AM J KIDNEY DIS, V15, P441; KMENTA J, 1973, ELEMENTS ECONOMETRIC; KRAKAUER H, 1986, ISRAEL J MED SCI, V22, P3; LAIRD NM, 1983, KIDNEY INT, pS101; LOWRIE EG, 1990, AM J KIDNEY DIS, V15, P458, DOI 10.1016/S0272-6386(12)70364-5; SANTIAGO G, 1983, KIDNEY INT S13, V23, pS95; SARGENT JA, 1983, KIDNEY INT S13, V23, pS19; VARDI Y, 1982, ANN STAT, V10, P616, DOI 10.1214/aos/1176345802; 1990, USRDS 1990 ANN DATA; 1987, RES REPORT END STAGE; 1989, INSTRUCTION MANUAL R; 1983, FED REG         0511, V48, P21254	20	211	213	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 20	1991	265	7					871	875		10.1001/jama.265.7.871	http://dx.doi.org/10.1001/jama.265.7.871			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX587	1899455				2022-12-24	WOS:A1991EX58700037
J	GRAHAM, R; GILMAN, M				GRAHAM, R; GILMAN, M			DISTINCT PROTEIN TARGETS FOR SIGNALS ACTING AT THE C-FOS SERUM RESPONSE ELEMENT	SCIENCE			English	Article							MEDIATES TRANSCRIPTIONAL RESPONSE; GROWTH-FACTOR; PHORBOL ESTERS; BINDING-SITE; CYCLIC-AMP; GENE; IDENTIFICATION; INDUCTION; YEAST; EXPRESSION	The c-fos serum response element (SRE) is a primary nuclear target for intracellular signal transduction pathways triggered by growth factors. It is the target for both protein kinase C (PKC)-dependent and -independent signals. Function of the SRE requires binding of a cellular protein, termed serum response factor (SRF). A second protein, p62TCP, recognizes the SRE-SRF complex to form a ternary complex. A mutated SRE that bound SRF but failed to form the ternary complex selectively lost response to PKC activators, but retained response to PKC-independent signals. Thus, two different signaling pathways act through discrete nuclear targets at the SRE. At least one of these pathways functions by recruitment of a pathway-specific accessory factor (p62TCF). These results offer a molecular mechanism to account for the biological specificity of signals that appear to act through common DNA sequence elements.	COLD SPRING HARBOR LAB,POB 100,COLD SPRING HARBOR,NY 11724	Cold Spring Harbor Laboratory				graham, regina/0000-0003-0103-2971	NATIONAL CANCER INSTITUTE [R01CA045642, P01CA046370] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI027270] Funding Source: NIH RePORTER; NCI NIH HHS [CA46370, CA45642] Funding Source: Medline; NIAID NIH HHS [AI27270] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMMERER G, 1990, GENE DEV, V4, P299, DOI 10.1101/gad.4.2.299; BERKOWITZ LA, 1989, MOL CELL BIOL, V9, P4272, DOI 10.1128/MCB.9.10.4272; BUSCHER M, 1988, ONCOGENE, V3, P301; CHAVRIER P, 1989, MOL CELL BIOL, V9, P787, DOI 10.1128/MCB.9.2.787; CHRISTY B, 1989, MOL CELL BIOL, V9, P4889, DOI 10.1128/MCB.9.11.4889; COLLINS MKL, 1984, J CELL PHYSIOL, V118, P133, DOI 10.1002/jcp.1041180205; Curran T, 1988, ONCOGENE HDB, P307; ERREDE B, 1989, GENE DEV, V3, P1349, DOI 10.1101/gad.3.9.1349; FISCH TM, 1987, MOL CELL BIOL, V7, P3490, DOI 10.1128/MCB.7.10.3490; GILMAN MZ, 1988, GENE DEV, V2, P394, DOI 10.1101/gad.2.4.394; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; GRAHAM R, UNPUB; GREENBERG ME, 1987, MOL CELL BIOL, V7, P1217, DOI 10.1128/MCB.7.3.1217; HAYES TE, 1988, GENE DEV, V2, P1713, DOI 10.1101/gad.2.12b.1713; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; HERSKOWITZ I, 1989, NATURE, V342, P749, DOI 10.1038/342749a0; JARVIS EE, 1989, GENE DEV, V3, P936, DOI 10.1101/gad.3.7.936; JARVIS EE, 1988, MOL CELL BIOL, V8, P309, DOI 10.1128/MCB.8.1.309; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; LEUNG S, 1989, NUCLEIC ACIDS RES, V17, P1177, DOI 10.1093/nar/17.3.1177; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; ORITA S, 1989, GENE, V75, P13; PASSMORE S, 1989, GENE DEV, V3, P921, DOI 10.1101/gad.3.7.921; PRYWES R, 1986, CELL, V47, P777, DOI 10.1016/0092-8674(86)90520-9; RIVERA VM, 1990, GENE DEV, V4, P255, DOI 10.1101/gad.4.2.255; RYAN WA, 1989, EMBO J, V8, P1785, DOI 10.1002/j.1460-2075.1989.tb03572.x; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SHENG M, 1988, MOL CELL BIOL, V8, P2787, DOI 10.1128/MCB.8.7.2787; SIEGFRIED Z, 1989, ONCOGENE, V4, P3; STUMPO DJ, 1988, J BIOL CHEM, V263, P1611; TAN S, 1990, NATURE, V62, P367; Treisman R, 1990, Semin Cancer Biol, V1, P47; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2	33	238	241	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 11	1991	251	4990					189	192		10.1126/science.1898992	http://dx.doi.org/10.1126/science.1898992			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ET173	1898992				2022-12-24	WOS:A1991ET17300038
J	MCLAUCHLIN, J; HALL, SM; VELANI, SK; GILBERT, RJ				MCLAUCHLIN, J; HALL, SM; VELANI, SK; GILBERT, RJ			HUMAN LISTERIOSIS AND PATE - A POSSIBLE ASSOCIATION	BRITISH MEDICAL JOURNAL			English	Article							MONOCYTOGENES; EPIDEMIOLOGY; BRITAIN	Objectives - To study trends in human listeriosis and determine possible sources of infection. Design - Descriptive analysis of laboratory reports of human listeriosis together with a survey of subtypes of Listeria monocytogenes isolated from patients and foodstuffs and an interview survey of patients to obtain food histories. Setting - United Kingdom and Republic of Ireland 1985 to 1990. Results - There was a near doubling in the incidence of human listeriosis in England, Wales, and Northern Ireland between 1985 and mid-1989 followed by a sharp decline. The upsurge in cases was caused largely by two strains of L monocytogenes, which accounted for 30-54% of the annual totals. These strains were less common before 1987 and after July 1989. A survey of pate in England and Wales in July 1989 showed that it frequently contained L monocytogenes. A similar survey in July 1990 showed a reduction in the proportions of samples contaminated. In 1989 pates from a single plant (manufacturer Y) were more likely to be contaminated by L monocytogenes and at higher levels than those from other producers. Most strains of L monocytogenes recovered from manufacturer Y's pate in 1989 were indistinguishable from those responsible for the 1987-9 upsurge in human listeriosis and were uncommon among isolates from pates from other manufacturers and from a wide range of other foodstuffs. Patients infected with the types of L monocytogenes found in pate were significantly more likely to have recently eaten pate than those affected by other strains. The start of the decline in numbers of cases of listeriosis coincided with government health warnings on pate consumption and the suspension of supplies from manufacturer Y. Conclusions - Contamination of pate was a likely contributory cause of the increase in the incidence of listeriosis between 1987 and 1989.	CENT PUBL HLTH LAB,PUBL HLTH LAB SERV,FOOD HYG LAB,LONDON NW9 5HT,ENGLAND; COMMUNICABLE DIS SURVEILLANCE CTR,PUBL HLTH LAB SERV,LONDON NW9 5EQ,ENGLAND	Public Health England; Public Health England	MCLAUCHLIN, J (corresponding author), CENT PUBL HLTH LAB,PUBL HLTH LAB SERV,DIV MICROBIOL REAGENTS & QUAL CONTROL,LONDON NW9 5HT,ENGLAND.							CAMPBELL DM, 1990, J INFECTION, V20, P241, DOI 10.1016/0163-4453(90)91219-4; Gilbert R. J., 1989, PHLS (Public Health Laboratory Service) Microbiology Digest, V6, P33; JOHNSON JL, 1990, J FOOD PROTECT, V53, P81, DOI 10.4315/0362-028X-53.1.81; JONES D, 1990, LANCET, V336, P1171, DOI 10.1016/0140-6736(90)92778-G; MCLAUCHLIN J, 1987, J APPL BACTERIOL, V63, P1, DOI 10.1111/j.1365-2672.1987.tb02411.x; MCLAUCHLIN J, 1989, J INFECTION, V18, P179, DOI 10.1016/S0163-4453(89)91290-5; MCLAUCHLIN J, 1986, J MED MICROBIOL, V22, P367, DOI 10.1099/00222615-22-4-367; MCLAUCHLIN J, 1990, EPIDEMIOL INFECT, V104, P191, DOI 10.1017/S0950268800059355; MORRIS IJ, 1989, LANCET, V2, P1285; SAUNDERS NA, 1989, ACTA MICROBIOL HUNG, V36, P205; 1989, LISTERIA FOUND PATE; 1989, ADVICE VULNERABLE GR; 1989, DHSS PLCMO893 DEP HL	13	188	194	1	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 28	1991	303	6805					773	775		10.1136/bmj.303.6805.773	http://dx.doi.org/10.1136/bmj.303.6805.773			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG981	1932944	Bronze, Green Published			2022-12-24	WOS:A1991GG98100029
J	IRWIG, L; GLASZIOU, P; WILSON, A; MACASKILL, P				IRWIG, L; GLASZIOU, P; WILSON, A; MACASKILL, P			ESTIMATING AN INDIVIDUALS TRUE CHOLESTEROL LEVEL AND RESPONSE TO INTERVENTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DENSITY LIPOPROTEIN CHOLESTEROL; CORONARY HEART-DISEASE; SERUM-CHOLESTEROL; APOLIPOPROTEIN MEASUREMENTS; SCREENING PROGRAMS; PLASMA-CHOLESTEROL; RELIABILITY; TRIGLYCERIDE; VARIABILITY; PREVALENCE	An individual's blood cholesterol measurement may differ from the true level because of short-term biological and technical measurement variability. Using data on the within-individual and population variance of serum cholesterol, we addressed the following clinical concerns: Given a cholesterol measurement, what is the individual's likely true level? The confidence interval for the true level is wide and asymmetrical around extreme measurements because of regression to the mean. Of particular concern is the misclassification of people with a screening measurement below 5.2 mmol/L who may be advised that their cholesterol level is "desirable" when their true level warrants further action. To what extent does blood cholesterol change in response to an intervention? In general, confidence intervals are too wide to allow decision making and patient feedback about an individual's cholesterol response to a dietary intervention, even with multiple measurements. If no change is observed in an individual's cholesterol value based on three measurements before and three after dietary intervention, the 80% confidence interval ranges from a true increase of 4% to a true decrease of 9%.	WESTMEAD HOSP, DEPT COMMUNITY MED, SYDNEY, AUSTRALIA	University of Sydney	IRWIG, L (corresponding author), UNIV SYDNEY, DEPT PUBL HLTH, SYDNEY, NSW 2006, AUSTRALIA.		Glasziou, Paul/A-7832-2008	Glasziou, Paul/0000-0001-7564-073X; Wilson, Andrew/0000-0002-1809-7846; Macaskill, Petra/0000-0001-5879-6193				[Anonymous], 1988, CLIN CHEM, V34, P193; BELSEY R, 1990, JAMA-J AM MED ASSOC, V263, P1250, DOI 10.1001/jama.263.9.1250; Berger J.O., 1985, STAT DECISION THEORY, P74; BYERS T, 1989, AM J EPIDEMIOL, V130, P853; CLEEMAN JI, 1988, ARCH INTERN MED, V148, P36, DOI 10.1001/archinte.148.1.36; COOPER GR, 1988, CLIN CHEM, V34, pB95; DEGROOT MH, 1986, PROBABILITY STATISTI; DEMACKER PNM, 1982, ATHEROSCLEROSIS, V45, P259, DOI 10.1016/0021-9150(82)90227-1; EHNHOLM C, 1982, NEW ENGL J MED, V307, P850, DOI 10.1056/NEJM198209303071403; FULWOOD R, PHS861686 US DEP HLT; GARDNER MJ, 1973, J CHRON DIS, V26, P781, DOI 10.1016/0021-9681(73)90013-1; HJERMANN I, 1981, LANCET, V2, P1303; Hjermann I, 1980, J Oslo City Hosp, V30, P3; JACOBS DR, 1982, AM J EPIDEMIOL, V116, P878, DOI 10.1093/oxfordjournals.aje.a113490; KAUFMAN HW, 1990, JAMA-J AM MED ASSOC, V263, P1245, DOI 10.1001/jama.263.9.1245; KEIL U, 1989, INT J EPIDEMIOL, V18, pS46; KINLAY S, 1990, BRIT MED J, V300, P1545, DOI 10.1136/bmj.300.6739.1545; MANN JI, 1988, BRIT MED J, V296, P1702, DOI 10.1136/bmj.296.6638.1702; MANNINEN V, 1988, JAMA-J AM MED ASSOC, V260, P641, DOI 10.1001/jama.260.5.641; MORRISON JA, 1979, PEDIATRICS, V64, P197; NAITO HK, 1988, CLIN CHEM, V34, pB84; NAUGHTON MJ, 1990, JAMA-J AM MED ASSOC, V263, P1213, DOI 10.1001/jama.263.9.1213; Nunnally JC, 1978, PSYCHOMETRIC THEORY, V2nd, DOI DOI 10.1037/018882; OBRIEN RC, 1990, MED J AUSTRALIA, V152, P480, DOI 10.5694/j.1326-5377.1990.tb125308.x; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P365; ROBERTS L, 1987, SCIENCE, V238, P482, DOI 10.1126/science.3659924; ROBERTS WC, 1989, AM J CARDIOL, V64, P693, DOI 10.1016/0002-9149(89)90511-0; ROTTERDAM EP, 1987, CLIN CHEM, V33, P1913; SHEPARD DS, 1981, J CHRON DIS, V34, P191, DOI 10.1016/0021-9681(81)90064-3; THOMPSON SG, 1990, J CLIN EPIDEMIOL, V43, P783, DOI 10.1016/0895-4356(90)90238-K; TUNSTALLPEDOE H, 1989, LANCET, V1, P540; TYROLER HA, 1987, CIRCULATION, V76, P515, DOI 10.1161/01.CIR.76.3.515; WEISSFELD JL, 1990, MED DECIS MAKING, V10, P135, DOI 10.1177/0272989X9001000208	33	45	47	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 25	1991	266	12					1678	1685		10.1001/jama.266.12.1678	http://dx.doi.org/10.1001/jama.266.12.1678			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GF419	1886192				2022-12-24	WOS:A1991GF41900035
J	ROBERTS, SB; SEGIL, N; HEINTZ, N				ROBERTS, SB; SEGIL, N; HEINTZ, N			DIFFERENTIAL PHOSPHORYLATION OF THE TRANSCRIPTION FACTOR OCT1 DURING THE CELL-CYCLE	SCIENCE			English	Article							SV40 DNA-REPLICATION; HISTONE H2B GENE; CONSENSUS ELEMENT; MAMMALIAN-CELLS; PROTEIN-KINASE; FISSION YEAST; H-1 GENE; S-PHASE; MITOSIS; ACTIVATION	Orderly progression through the somatic cell division cycle is accompanied by phase-specific transcription of a variety of different genes. During S phase, transcription of mammalian histone H2B genes requires a specific promoter element and its cognate transcription factor Oct1 (OTF1). A possible mechanism for regulating histone H2B transcription during the cell cycle is direct modulation of Oct1 activity by phase-specific posttranslational modifications. Analysis of Oct1 during progression through the cell cycle revealed a complex temporal program of phosphorylation. A p34cdc2-related protein kinase that is active during mitosis may be responsible for one mitotic phosphorylation of Oct1. However, the temporally controlled appearance of Oct1 phosphopeptides suggests the involvement of multiple kinases and phosphatases. These results support the idea that cell cycle-regulated transcription factors may be direct substrates for phase-specific regulatory enzymes.			ROBERTS, SB (corresponding author), ROCKEFELLER UNIV,HOWARD HUGHES MED INST,MOLEC BIOL LAB,1230 YORK AVE,NEW YORK,NY 10021, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032544, F32GM013752] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 32544, GM 13752] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARTISHEVSKY A, 1987, NATURE, V328, P823, DOI 10.1038/328823a0; ARTISHEVSKY A, 1984, MOL CELL BIOL, V4, P2364, DOI 10.1128/MCB.4.11.2364; BRIZUELA L, 1987, EMBO J, V6, P3507, DOI 10.1002/j.1460-2075.1987.tb02676.x; DALTON S, 1988, EMBO J, V7, P49, DOI 10.1002/j.1460-2075.1988.tb02782.x; DALTON S, 1988, MOL CELL BIOL, V8, P4576, DOI 10.1128/MCB.8.10.4576; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DRAETTA G, 1990, TRENDS BIOL SCI, V15, P178; FLETCHER C, 1987, CELL, V51, P773, DOI 10.1016/0092-8674(87)90100-0; GALLINARI P, 1989, MOL CELL BIOL, V9, P1566, DOI 10.1128/MCB.9.4.1566; GERACE L, 1980, CELL, V19, P277, DOI 10.1016/0092-8674(80)90409-2; HARLOW E, 1988, ANTIBODIES LABORATOR; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HARVEY RP, 1982, NUCLEIC ACIDS RES, V10, P7851, DOI 10.1093/nar/10.23.7851; HEALD R, 1990, CELL, V61, P579, DOI 10.1016/0092-8674(90)90470-Y; HEINTZ N, 1984, P NATL ACAD SCI-BIOL, V81, P2713, DOI 10.1073/pnas.81.9.2713; HEINTZ N, 1983, MOL CELL BIOL, V3, P539, DOI 10.1128/MCB.3.4.539; HEMMINGS HC, 1984, J BIOL CHEM, V259, P4491; HEREFORD L, 1982, CELL, V30, P305, DOI 10.1016/0092-8674(82)90036-8; JOHNSON DG, 1990, MOL CELL BIOL, V10, P982, DOI 10.1128/MCB.10.3.982; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; LABELLA F, 1988, GENE DEV, V2, P32, DOI 10.1101/gad.2.1.32; LABELLA F, 1989, GENE DEV, V3, P982; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCVEY D, 1989, NATURE, V341, P503, DOI 10.1038/341503a0; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; MURPHY S, 1989, CELL, V59, P1071, DOI 10.1016/0092-8674(89)90763-0; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; NUSSE M, 1984, CELL TISSUE KINET, V17, P13, DOI 10.1111/j.1365-2184.1984.tb00564.x; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; ONEILL EA, 1988, SCIENCE, V241, P1210, DOI 10.1126/science.3413485; OTTAVIANO Y, 1985, J BIOL CHEM, V260, P624; PEDRALINOY G, 1980, NUCLEIC ACIDS RES, V8, P377, DOI 10.1093/nar/8.2.377; PERRY M, 1985, J MOL BIOL, V185, P479, DOI 10.1016/0022-2836(85)90065-8; PIERANI A, 1990, MOL CELL BIOL, V10, P6204, DOI 10.1128/MCB.10.12.6204; PONDAVEN P, 1990, GENE DEV, V4, P9, DOI 10.1101/gad.4.1.9; PRIVES C, 1990, CELL, V61, P735, DOI 10.1016/0092-8674(90)90179-I; ROBERTS SA, UNPUB; SEGIL N, UNPUB; SITTMAN DB, 1983, P NATL ACAD SCI-BIOL, V80, P1849, DOI 10.1073/pnas.80.7.1849; SIVE HL, 1986, P NATL ACAD SCI USA, V83, P6382, DOI 10.1073/pnas.83.17.6382; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; TANAKA M, 1988, GENE DEV, V2, P1764, DOI 10.1101/gad.2.12b.1764; VIRSHUP DM, 1989, EMBO J, V8, P3891, DOI 10.1002/j.1460-2075.1989.tb08568.x; ZIEVE GW, 1980, EXP CELL RES, V126, P397, DOI 10.1016/0014-4827(80)90279-7; [No title captured]	48	129	130	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 30	1991	253	5023					1022	1026		10.1126/science.1887216	http://dx.doi.org/10.1126/science.1887216			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC982	1887216				2022-12-24	WOS:A1991GC98200043
J	WADE, MJ; GOODNIGHT, CJ				WADE, MJ; GOODNIGHT, CJ			WRIGHT SHIFTING BALANCE THEORY - AN EXPERIMENTAL-STUDY	SCIENCE			English	Article							GROUP SELECTION; SMALL POPULATIONS; FINITE POPULATIONS; GENETIC VARIANCE; FOUNDER EVENTS; SEX-RATIO; DIFFERENTIATION; MIGRATION; TRIBOLIUM	Experimental confirmation of Wright's shifting balance theory of evolution, one of the most comprehensive theories of adaptive evolution, is presented. The theory is regarded by many as a cornerstone of modern evolutionary thought, but there has been little direct empirical evidence supporting it. Some of its underlying assumptions are viewed as contradictory, and the existence and efficacy of the theory's fundamental adaptive process, interdemic selection, is the focus of controversy. Interdemic selection was imposed on large arrays of laboratory populations of the flour beetle Tribolium castaneum in the manner described by Wright: the differential dispersion of individuals from demes of high fitness into demes of low fitness. A significant increase in average fitness was observed in the experimental arrays when compared to control populations with equivalent but random migration rates. The response was not proportional to the selection differential: The largest response occurred with interdemic selection every two generations rather than every generation or every three generations. The results indicate that the interdemic phase of Wright's shifting balance theory can increase average fitness and suggest that gene interactions are involved in the observed response.	UNIV VERMONT,DEPT ZOOL,BURLINGTON,VT 05405	University of Vermont	WADE, MJ (corresponding author), UNIV CHICAGO,DEPT ECOL & EVOLUT,CHICAGO,IL 60637, USA.		Goodnight, Charles/K-3208-2019		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022523] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM22523] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		COCKERHAM CC, 1988, P NATL ACAD SCI USA, V85, P1563, DOI 10.1073/pnas.85.5.1563; COLLIAS NE, 1991, ANIM BEHAV, V41, P613, DOI 10.1016/S0003-3472(05)80900-5; CRAIG DM, 1982, EVOLUTION, V36, P271, DOI 10.1111/j.1558-5646.1982.tb05041.x; CROW JF, 1990, EVOLUTION, V44, P233, DOI [10.2307/2409403, 10.1111/j.1558-5646.1990.tb05194.x]; DOBZHANSKY T, 1977, EVOLUTION, P164; Falconer D. S., 1981, INTRO QUANTITATIVE G; Futuyma DJ, 1986, EVOL BIOL; GOODNIGHT CJ, 1985, EVOLUTION, V39, P545, DOI 10.1111/j.1558-5646.1985.tb00394.x; GOODNIGHT CJ, 1987, EVOLUTION, V41, P80, DOI 10.1111/j.1558-5646.1987.tb05772.x; GOODNIGHT CJ, 1988, EVOLUTION, V42, P441, DOI 10.1111/j.1558-5646.1988.tb04151.x; HARTL DL, 1989, PRINCIPLES POPULATIO, P324; HARTL DL, 1980, PRINCIPLES POPULATIO, P343; HILL WG, 1972, BIOMETRICS, V28, P767, DOI 10.2307/2528761; LOVELESS MD, 1984, ANNU REV ECOL SYST, V15, P65, DOI 10.1146/annurev.es.15.110184.000433; Mettler L.E., 1988, POPULATION GENETICS; NEI M, 1987, MOL EVOLUTIONARY GEN, P422; Provine W. B., 1986, SEWALL WRIGHT EVOLUT; TACHIDA H, 1989, GENET RES, V53, P63, DOI 10.1017/S0016672300027877; Templeton A.R., 1982, P15; WADE MJ, 1984, GENET RES, V43, P249, DOI 10.1017/S0016672300026045; WADE MJ, 1982, EVOLUTION, V36, P949, DOI 10.1111/j.1558-5646.1982.tb05465.x; WADE MJ, 1984, EVOLUTION, V38, P1047, DOI 10.1111/j.1558-5646.1984.tb00375.x; WADE MJ, 1978, Q REV BIOL, V53, P101, DOI 10.1086/410450; WADE MJ, 1976, P NATL ACAD SCI USA, V73, P4604, DOI 10.1073/pnas.73.12.4604; WADE MJ, 1980, EVOLUTION, V34, P799, DOI [10.2307/2408034, 10.1111/j.1558-5646.1980.tb04019.x]; WADE MJ, 1977, EVOLUTION, V31, P134, DOI [10.2307/2407552, 10.1111/j.1558-5646.1977.tb00991.x]; WADE MJ, 1980, GENET RES, V36, P10; WADE MJ, 1991, EVOLUTION, V44, P2004; WILSON DS, 1981, EVOLUTION, V35, P882, DOI 10.1111/j.1558-5646.1981.tb04952.x; Wright S, 1931, GENETICS, V16, P0097; WRIGHT S, 1982, EVOLUTION, V36, P427, DOI 10.1111/j.1558-5646.1982.tb05065.x; Wright S., 1969, THEORY GENE FREQUENC, V2, P520; Wright S., 1978, EVOLUTION GENETICS P, V4; WRIGHT S, 1977, EVOLUTION GENETICS P, V3, P454; [No title captured]	35	113	114	0	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 30	1991	253	5023					1015	1018		10.1126/science.1887214	http://dx.doi.org/10.1126/science.1887214			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC982	1887214				2022-12-24	WOS:A1991GC98200041
J	RENFRANZ, PJ; CUNNINGHAM, MG; MCKAY, RDG				RENFRANZ, PJ; CUNNINGHAM, MG; MCKAY, RDG			REGION-SPECIFIC DIFFERENTIATION OF THE HIPPOCAMPAL STEM-CELL LINE HIB5 UPON IMPLANTATION INTO THE DEVELOPING MAMMALIAN BRAIN	CELL			English	Article							FLUORESCENT LATEX MICROSPHERES; INTERMEDIATE FILAMENT PROTEIN; MEDIATED GENE-TRANSFER; CHICKEN OPTIC TECTUM; RAT FASCIA DENTATA; PRECURSOR CELLS; VISUAL-CORTEX; RECOMBINANT RETROVIRUS; COMMON PROGENITOR; MOLECULAR LAYER	Proliferating precursors to the distinct cell types constituting the mammalian brain can be identified by the presence of the nestin intermediate filament. We report the establishment of a nestin-positive cell line, HiB5, from embryonic precursor cells to the rat hippocampus. Since it was immortalized using the temperature-sensitive allele tsA58 of SV40 large T antigen, these cells grow continuously at 33-degrees-C, but not at 39-degrees-C, the body temperature of rodents. To test their developmental capacity, HiB5 cells were implanted into both the neonatal hippocampus and cerebellum. The cells integrated into the host tissue and acquired morphologies characteristic of the neurons and glial cells found at the implant site. HiB5 cells might thus be useful in characterizing the signals regulating cell type determination in the mammalian brain.	MIT,DEPT BRAIN & COGNIT SCI,CAMBRIDGE,MA 02139; HARVARD UNIV,SCH MED,BOSTON,MA 02115; MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT); Harvard University; Harvard Medical School; Massachusetts Institute of Technology (MIT)								ABERCROMBIE M, 1946, ANAT REC, V94, P239, DOI 10.1002/ar.1090940210; ALTMAN J, 1963, ANAT REC, V145, P573, DOI 10.1002/ar.1091450409; ALTMAN J, 1972, J COMP NEUROL, V145, P353, DOI 10.1002/cne.901450305; ALTMAN J, 1972, J COMP NEUROL, V145, P465, DOI 10.1002/cne.901450403; ALTMAN J, 1990, J COMP NEUROL, V301, P365, DOI 10.1002/cne.903010304; ALTMAN J, 1965, J COMP NEUROL, V124, P319, DOI 10.1002/cne.901240303; ANGEVINE JB, 1965, EXP NEUROL        S2, V13, P1; BANKER GA, 1977, BRAIN RES, V126, P397, DOI 10.1016/0006-8993(77)90594-7; BARTLETT PF, 1988, P NATL ACAD SCI USA, V85, P3255, DOI 10.1073/pnas.85.9.3255; BAYER SA, 1980, J COMP NEUROL, V190, P87, DOI 10.1002/cne.901900107; BJORKLUND A, 1976, NATURE, V262, P787, DOI 10.1038/262787a0; Brodal A, 1981, NEUROLOGICAL ANATOMY; Cajal S.R., 1894, NEW IDEAS STRUCTURE; CATTANEO E, 1990, NATURE, V347, P762, DOI 10.1038/347762a0; CEPKO C, 1988, TRENDS NEUROSCI, V11, P6, DOI 10.1016/0166-2236(88)90039-2; CEPKO CL, 1989, ANNU REV NEUROSCI, V12, P47, DOI 10.1146/annurev.ne.12.030189.000403; CLAIBORNE BJ, 1990, J COMP NEUROL, V302, P206, DOI 10.1002/cne.903020203; FREDERIKSEN K, 1988, J NEUROSCI, V8, P1144; FREDERIKSEN K, 1988, NEURON, V1, P439, DOI 10.1016/0896-6273(88)90175-4; FROTSCHER M, 1983, J COMP NEUROL, V215, P299, DOI 10.1002/cne.902150306; GALILEO DS, 1990, P NATL ACAD SCI USA, V87, P458, DOI 10.1073/pnas.87.1.458; GODEMENT P, 1987, DEVELOPMENT, V101, P697; GOSSLER A, 1986, P NATL ACAD SCI USA, V83, P9065, DOI 10.1073/pnas.83.23.9065; GRAY GE, 1988, P NATL ACAD SCI USA, V85, P7356, DOI 10.1073/pnas.85.19.7356; HOCKFIELD S, 1985, J NEUROSCI, V5, P3310; HOLT CE, 1988, NEURON, V1, P15, DOI 10.1016/0896-6273(88)90205-X; HONIG MG, 1986, J CELL BIOL, V103, P171, DOI 10.1083/jcb.103.1.171; HONIG MG, 1989, TRENDS NEUROSCI, V12, P333, DOI 10.1016/0166-2236(89)90040-4; JAT PS, 1989, MOL CELL BIOL, V9, P1672, DOI 10.1128/MCB.9.4.1672; KAPLAN MP, 1990, J NEUROSCI, V10, P2735; KATZ LC, 1990, NEUROSCIENCE, V34, P511, DOI 10.1016/0306-4522(90)90159-2; KATZ LC, 1987, J NEUROSCI, V7, P1223; KATZ LC, 1984, NATURE, V310, P498, DOI 10.1038/310498a0; LANDER AD, 1987, MOL NEUROBIOL, V1, P213, DOI 10.1007/BF02936609; LEE HJ, 1990, J NEUROSCI, V10, P1779; LENDAHL U, 1990, TRENDS NEUROSCI, V13, P132, DOI 10.1016/0166-2236(90)90004-T; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; LOGIN GR, 1985, AM J PATHOL, V120, P230; LUBBERS K, 1987, ANAT EMBRYOL, V177, P1, DOI 10.1007/BF00325285; MCCONNELL SK, 1988, J NEUROSCI, V8, P945; NOLAN GP, 1988, P NATL ACAD SCI USA, V85, P2603, DOI 10.1073/pnas.85.8.2603; Palay S. L., 1974, CEREBELLAR CORTEX CY; PRICE J, 1988, DEVELOPMENT, V104, P473; PRICE J, 1987, P NATL ACAD SCI USA, V84, P156, DOI 10.1073/pnas.84.1.156; RAKIC P, 1974, SCIENCE, V183, P425, DOI 10.1126/science.183.4123.425; ROBERTSON E, 1986, NATURE, V323, P445, DOI 10.1038/323445a0; ROGERS A, 1967, TECHNIQUES QAUTORADI; RYDER EF, 1990, J NEUROBIOL, V21, P356, DOI 10.1002/neu.480210209; SANDELL JH, 1988, J HISTOCHEM CYTOCHEM, V36, P555, DOI 10.1177/36.5.3356898; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; SCHLESSINGER AR, 1978, ANAT EMBRYOL, V154, P153, DOI 10.1007/BF00304660; SCHLESSINGER AR, 1975, J COMP NEUROL, V159, P149, DOI 10.1002/cne.901590202; SCHLESSINGER J, 1977, SCIENCE, V195, P307, DOI 10.1126/science.556653; SCHMUED LC, 1986, BRAIN RES, V377, P147, DOI 10.1016/0006-8993(86)91199-6; TEMPLE S, 1989, NATURE, V340, P471, DOI 10.1038/340471a0; THANOS S, 1987, J COMP NEUROL, V261, P155, DOI 10.1002/cne.902610114; TOPP WC, 1981, VIROLOGY, V113, P408, DOI 10.1016/0042-6822(81)90168-9; TURNER DL, 1990, NEURON, V4, P833, DOI 10.1016/0896-6273(90)90136-4; TURNER DL, 1987, NATURE, V328, P131, DOI 10.1038/328131a0; WETTS R, 1988, SCIENCE, V239, P1142, DOI 10.1126/science.2449732; Witter MP, 1989, HIPPOCAMPUS NEW VIST, P53; YEN SE, 1982, J CELL BIOL, V88, P115	62	440	469	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 23	1991	66	4					713	729		10.1016/0092-8674(91)90116-G	http://dx.doi.org/10.1016/0092-8674(91)90116-G			17	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GC745	1878969				2022-12-24	WOS:A1991GC74500011
J	WANG, C; LEHMANN, R				WANG, C; LEHMANN, R			NANOS IS THE LOCALIZED POSTERIOR DETERMINANT IN DROSOPHILA	CELL			English	Article							SEGMENTATION GENE HUNCHBACK; EGF-LIKE REPEATS; BICOID PROTEIN; MATERNAL GENE; ABDOMINAL SEGMENTATION; PATTERN-FORMATION; ANTERIOR PATTERN; NEUROGENIC GENE; EMBRYO; MELANOGASTER	Segmental pattern in the Drosophila embryo is established by two maternal factors localized to the anterior and posterior poles of the egg cell. Here we provide molecular evidence that the localized posterior factor is the RNA of the nanos (nos) gene. nos RNA is localized to the posterior pole of early embryos, and nos protein acts at a distance to direct abdomen formation. Synthetic nos RNA has biological activity identical to that of the posterior pole plasm. Injection of nos RNA rescues the segmentation defect of embryos derived from females mutant for all nine known posterior group genes. Injection of nos RNA into the anterior is able to direct formation of ectopic posterior structures. Our results demonstrate that a localized source of nos RNA is sufficient to specify abdominal segmentation and imply that other posterior group genes are required for localization, stabilization, or distribution of the nos gene product.	MIT,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02142; MIT,DEPT BIOL,CAMBRIDGE,MA 02142	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	WANG, C (corresponding author), MIT,WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142, USA.							ALTON AK, 1988, GENETICS, V118, P235; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BANDZIULIS RJ, 1989, GENE DEV, V3, P431, DOI 10.1101/gad.3.4.431; BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; BOSWELL RE, 1985, CELL, V43, P97, DOI 10.1016/0092-8674(85)90015-7; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; DRIEVER W, 1989, NATURE, V337, P138, DOI 10.1038/337138a0; DRIEVER W, 1988, CELL, V54, P95, DOI 10.1016/0092-8674(88)90183-3; ELDON ED, 1991, DEVELOPMENT, V111, P367; FRIGERIO G, 1986, CELL, V47, P735, DOI 10.1016/0092-8674(86)90516-7; FROHNHOFER HG, 1986, NATURE, V324, P120, DOI 10.1038/324120a0; FROHNHOFER HG, 1986, J EMBRYOL EXP MORPH, V97, P169; FROHNHOFER HG, 1987, GENE DEV, V1, P880, DOI 10.1101/gad.1.8.880; FYRBERG EA, 1983, CELL, V33, P115, DOI 10.1016/0092-8674(83)90340-9; GAUL U, 1987, CELL, V51, P549, DOI 10.1016/0092-8674(87)90124-3; HULSKAMP M, 1990, NATURE, V346, P577, DOI 10.1038/346577a0; HULSKAMP M, 1989, NATURE, V338, P629, DOI 10.1038/338629a0; INGHAM PW, 1988, NATURE, V335, P25, DOI 10.1038/335025a0; IRISH V, 1989, NATURE, V338, P646, DOI 10.1038/338646a0; KLINGLER M, 1988, NATURE, V335, P275, DOI 10.1038/335275a0; KRAUT R, 1991, DEVELOPMENT, V111, P601; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; LEHMANN R, 1989, DEVELOPMENT, V107, P21; LEHMANN R, 1988, DEVELOPMENT, V104, P17; LEHMANN R, 1991, DEVELOPMENT, V112, P679; LEHMANN R, 1986, CELL, V47, P141, DOI 10.1016/0092-8674(86)90375-2; LEHMANN R, 1987, NATURE, V329, P167, DOI 10.1038/329167a0; MANSEAU LJ, 1989, GENE DEV, V3, P1437, DOI 10.1101/gad.3.9.1437; NAUBER U, 1988, NATURE, V336, P489, DOI 10.1038/336489a0; NUSSLEINVOLHARD C, 1987, SCIENCE, V238, P1675, DOI 10.1126/science.3686007; NUSSLEINVOLHARD C, 1977, ROUX ARCH DEV BIOL, V183, P249, DOI 10.1007/BF00867325; PIGNONI F, 1990, CELL, V62, P151, DOI 10.1016/0092-8674(90)90249-E; Sambrook J., 1989, MOL CLONING LAB MANU; SCHUPBACH T, 1986, ROUX ARCH DEV BIOL, V195, P302, DOI 10.1007/BF00376063; STJOHNSTON D, 1989, DEVELOPMENT, V107, P13; STRUHL G, 1989, NATURE, V338, P741, DOI 10.1038/338741a0; STRUHL G, 1989, CELL, V57, P1259, DOI 10.1016/0092-8674(89)90062-7; TAUTZ D, 1988, NATURE, V332, P281, DOI 10.1038/332281a0; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; VASSIN H, 1987, GENETICS, V116, P433; VASSIN H, 1987, EMBO J, V6, P3431, DOI 10.1002/j.1460-2075.1987.tb02666.x; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; WHARTON RP, 1989, CELL, V59, P881, DOI 10.1016/0092-8674(89)90611-9; Wieschaus E., 1986, P199	47	423	436	1	37	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 23	1991	66	4					637	647		10.1016/0092-8674(91)90110-K	http://dx.doi.org/10.1016/0092-8674(91)90110-K			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GC745	1908748				2022-12-24	WOS:A1991GC74500005
J	KRISTIANSEN, IS; EGGEN, AE; THELLE, DS				KRISTIANSEN, IS; EGGEN, AE; THELLE, DS			COST-EFFECTIVENESS OF INCREMENTAL PROGRAMS FOR LOWERING SERUM-CHOLESTEROL CONCENTRATION - IS INDIVIDUAL INTERVENTION WORTH WHILE	BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; PRIMARY-PREVENTION; SMOKING; THERAPY; HEALTH; TRIAL; MEN	Objective - To evaluate the relative cost effectiveness of various cholesterol lowering programmes. Design - Retrospective analysis. Setting - Norwegian cholesterol lowering programme in Norwegian male population aged 40-49 (n = 200 000), whose interventions comprise a population based promotion of healthier eating habits, dietary treatment (subjects with serum cholesterol concentration 6.0-7.9 mmol/l), and dietary and drug treatment combined (serum cholesterol concentration greater-than-or-equal-to 8.0 mmol/l). Main outcome measure - Marginal cost effectiveness ratios - that is, the ratio of net treatment costs (cost of treatment minus savings in treatment costs for coronary heart disease) to life years gained and to quality of life years (QALYs) saved. Results - The cost per life year gained over 20 years of a population based strategy was projected to be L12. For an individual strategy based on dietary treatment the cost was about L12 400 per life year gained and L111 600 if drugs were added for 50% of the subjects with serum cholesterol concentrations greater-than-or-equal-to 8.0 mmol/l. Conclusions - The results underline the importance of marginal cost effectiveness analyses for incremental programmes of health care. The calculations of QALYs, though speculative, indicate that individual intervention should be implemented cautiously and within more selected groups than currently recommended. Drugs should be reserved for subjects with genetic hypercholesterolaemia or who are otherwise at very high risk of arteriosclerotic disease.			KRISTIANSEN, IS (corresponding author), UNIV TROMSO,INST COMMUNITY MED,N-9000 TROMSO,NORWAY.		Thelle, Dag Steinar/ABD-1867-2020	Thelle, Dag Steinar/0000-0002-4417-5967				BJARTVEIT K, 1988, Tidsskrift for den Norske Laegeforening, V108, P2285; BLOOM JR, 1981, AM J PUBLIC HEALTH, V71, P1228, DOI 10.2105/AJPH.71.11.1228; EGGEN A E, 1989, Tidsskrift for den Norske Laegeforening, V109, P857; FINKLER SA, 1982, ANN INTERN MED, V96, P102, DOI 10.7326/0003-4819-96-1-102; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; GOLDMAN L, 1988, NEW ENGL J MED, V319, P152, DOI 10.1056/NEJM198807213190306; GOLDMAN L, 1989, CIRCULATION, V80, P254, DOI 10.1161/01.CIR.80.2.254; HALL J P, 1988, Medical Journal of Australia, V148, P273; HJERMANN I, 1981, LANCET, V2, P1303; HOLME I, 1988, STAT MED, V7, P1109, DOI 10.1002/sim.4780071104; KINLAY S, 1990, BRIT MED J, V300, P1545, DOI 10.1136/bmj.300.6739.1545; KINOSIAN BP, 1988, JAMA-J AM MED ASSOC, V259, P2249, DOI 10.1001/jama.259.15.2249; MARTENS LL, 1989, AM J MED S4A, V87, P54; OSTER G, 1986, AM J PUBLIC HEALTH, V76, P647, DOI 10.2105/AJPH.76.6.647; OSTER G, 1987, JAMA-J AM MED ASSOC, V258, P2381, DOI 10.1001/jama.258.17.2381; READ JL, 1984, MED DECIS MAKING, V4, P315, DOI 10.1177/0272989X8400400307; SALONEN JT, 1981, AM J EPIDEMIOL, V114, P81, DOI 10.1093/oxfordjournals.aje.a113177; SLATTEBREKK OV, 1990, STF81A90003 NORW I H; STEIN EA, 1989, AM J MED S4A, V87, P20; STOATE HG, 1989, J ROY COLL GEN PRACT, V39, P193; THURMER H, 1991, INT J RISK SOC MED, V1, P267; WEINSTEIN MC, 1982, CIRCULATION, V66, P56; WEINSTEIN MC, 1985, ANNU REV PUBL HEALTH, V6, P41; WEINSTEIN MC, 1977, NEW ENGL J MED, V296, P716, DOI 10.1056/NEJM197703312961304; Weinstein MC, 1980, CLIN DECISION ANAL; WESTLUND K, 1972, SCAND J CLIN IN S127, V30, P3; WILLIAMS A, 1985, BRIT MED J, V291, P326, DOI 10.1136/bmj.291.6491.326; WYSOWSKI DK, 1990, JAMA-J AM MED ASSOC, V263, P2185, DOI 10.1001/jama.263.16.2185; 1982, JAMA-J AM MED ASSOC, V248, P1465; 1988, ARCH INTERN MED, V148, P36; 1990, COST EFFECTIVENESS O; 1988, CARDIOVASCULAR DISEA; 1986, CAUSES DEATH 1985; 1984, JAMA-J AM MED ASSOC, V251, P365; 1984, JAMA-J AM MED ASSOC, V251, P351; 1988, EUR HEART J, V9, P571	36	64	65	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 11	1991	302	6785					1119	1122		10.1136/bmj.302.6785.1119	http://dx.doi.org/10.1136/bmj.302.6785.1119			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL439	1904286	Green Published, Bronze			2022-12-24	WOS:A1991FL43900018
J	SURTEES, SJ; STOCKTON, MG; GIETZEN, TW				SURTEES, SJ; STOCKTON, MG; GIETZEN, TW			ALLERGY TO PENICILLIN - FABLE OR FACT	BRITISH MEDICAL JOURNAL			English	Article							SKIN	Objective - To assess whether, on the basis of one blood test, penicillin allergy might be excluded sufficiently for general practitioners to give oral penicillin to patients claiming a history of penicillin allergy. Design - Prospective study of patients referred by general practioners. Setting - Outpatient allergy clinic in a district general hospital. Patients - 175 referred patients who gave a history of immediate type reaction to penicillin, of whom 144 attended as requested and 132 completed the investigations. Main outcome measures - History and examination, serum radioallergosorbent test to phenoxymethyl-penicillin and benzylpenicillin, and oral challenge with penicillin. Results - Of 132 patients, four were confirmed to have penicillin allergy by the radioallergosorbent test and 128 had an oral penicillin challenge without ill effect. Conclusions - Most patients who gave a history of penicillin allergy are not so allergic, and their actual allergic state should be substantiated whenever feasible. For patients reporting minor or vague reactions negative findings with a radioallergosorbent test to phenoxymethylpenicillin and benzylpenicillin provide sufficient evidence to give oral penicillin safely.			SURTEES, SJ (corresponding author), DIST GEN HOSP,DEPT CLIN CHEM,EASTBOURNE BN21 2UD,E SUSSEX,ENGLAND.							BEELEY L, 1984, BRIT MED J, V288, P511, DOI 10.1136/bmj.288.6416.511-a; CHANDRA RK, 1980, ARCH DIS CHILD, V55, P857, DOI 10.1136/adc.55.11.857; FOX AM, 1965, BMJ-BRIT MED J, V2, P206, DOI 10.1136/bmj.2.5455.206; HOLGATE ST, 1988, BRIT MED J, V296, P1213, DOI 10.1136/bmj.296.6631.1213; JARISCH R, 1981, CLIN ALLERGY, V11, P155, DOI 10.1111/j.1365-2222.1981.tb01579.x; KIRK CR, 1988, BRIT MED J, V296, P1236, DOI 10.1136/bmj.296.6631.1236; MYERS PC, 1985, BRIT MED J, V291, P450; OSWALD NTA, 1983, BRIT MED J, V287, P265, DOI 10.1136/bmj.287.6387.265; Pearce S. J., 1982, ADVERSE DRUG REACT, V94, P344; SIMMONDS J, 1978, BRIT MED J, V2, P1404, DOI 10.1136/bmj.2.6149.1404; SMITH AG, 1989, ADVERSE DRUG REACT, V134, P500; Sorensen H T, 1986, Scand J Prim Health Care, V4, P252	12	65	68	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 4	1991	302	6784					1051	1052		10.1136/bmj.302.6784.1051	http://dx.doi.org/10.1136/bmj.302.6784.1051			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FK563	1903664	Green Published, Bronze			2022-12-24	WOS:A1991FK56300021
J	HAN, JW; MCCORMICK, F; MACARA, IG				HAN, JW; MCCORMICK, F; MACARA, IG			REGULATION OF RAS-GAP AND THE NEUROFIBROMATOSIS-1 GENE-PRODUCT BY EICOSANOIDS	SCIENCE			English	Article							GTPASE ACTIVATING PROTEIN	Ras-GAP (GTPase activating protein) is a regulatory protein that stimulates the intrinsic guanosine triphosphatase (GTPase) activity of the proto-oncogene product p21ras. A domain of the neurofibromatosis gene product (NF1) that has sequence similarity to the catalytic domain of Ras-GAP and to yeast IRA gene products also has a specific stimulatory activity toward p21ras GTPase. Arachidonic acid and phosphatidic acid inactivate GAP, but no agents have been identified that stimulate GAP and thereby switch p21ras off. With the use of recombinant Ha-c-Ras and Ras-GAP, NF1, and GAP catalytic domains, it was found that prostaglandins PGF2-alpha and PGA2 stimulated Ras-GAP and that prostacyclin PGI2 inhibited Ras-GAP. The stimulatory effect of PGF2-alpha was saturable and structure-specific and competed with the inhibitory effect of arachidonic acid. Arachidonic acid also inhibited the catalytic activity of NF1, but prostaglandins were not stimulatory. These results suggest a mechanism for the allosteric control of Ras function through the modulation of arachidonate metabolism.	CETUS CORP,DEPT MOLEC BIOL,EMERYVILLE,CA 94608		HAN, JW (corresponding author), UNIV ROCHESTER,MED CTR,DEPT BIOPHYS,CTR ENVIRONM HLTH SCI,ROCHESTER,NY 14642, USA.				NATIONAL CANCER INSTITUTE [R01CA038888] Funding Source: NIH RePORTER; NCI NIH HHS [CA 38888] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BENNETT A, 1979, PRACTICAL APPLICATIO, P149; BUCHBERG AM, 1990, NATURE, V347, P291, DOI 10.1038/347291a0; CAWTHON RM, 1990, CELL, V62, P193, DOI 10.1016/0092-8674(90)90253-B; DOWNWARD J, 1990, P NATL ACAD SCI USA, V87, P5998, DOI 10.1073/pnas.87.15.5998; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; HALLENBECK R, 1990, J BIOL CHEM, V265, P21922; HAN JW, 1990, P NATL ACAD SCI USA, V87, P3373, DOI 10.1073/pnas.87.9.3373; LIN AH, 1989, J BIOL CHEM, V264, P17379; MAIER JAM, 1990, J BIOL CHEM, V265, P10805; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MOORE PK, 1985, PROSTANOIDS PHARM PH, P32; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; TSAI MH, 1989, SCIENCE, V243, P522, DOI 10.1126/science.2536192; TSAI MH, 1990, SCIENCE, V250, P982, DOI 10.1126/science.2237442; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; WEST M, 1990, FEBS LETT, V259, P245, DOI 10.1016/0014-5793(90)80019-F; WOLFMAN A, 1989, J BIOL CHEM, V264, P10820; WOLFMAN A, 1990, SCIENCE, V248, P67, DOI 10.1126/science.2181667; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9; YU CL, 1990, MOL CELL BIOL, V10, P6683, DOI 10.1128/MCB.10.12.6683	26	101	101	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 26	1991	252	5005					576	579		10.1126/science.1902323	http://dx.doi.org/10.1126/science.1902323			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FJ127	1902323				2022-12-24	WOS:A1991FJ12700051
J	RAUB, W				RAUB, W			INTERFERON-GAMMA PREVENTS INFECTION IN CHRONIC GRANULOMATOUS-DISEASE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											RAUB, W (corresponding author), NIH,BLDG 31,ROOM 2B23,BETHESDA,MD 20892, USA.							1991, NEW ENGL J MED, V324, P509	1	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 3	1991	265	13					1633	1633						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD659	1900541				2022-12-24	WOS:A1991FD65900006
J	CLASSEN, DC; PESTOTNIK, SL; EVANS, RS; BURKE, JP				CLASSEN, DC; PESTOTNIK, SL; EVANS, RS; BURKE, JP			COMPUTERIZED SURVEILLANCE OF ADVERSE DRUG EVENTS IN HOSPITAL PATIENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MEDICAL INPATIENTS; INDUCED ILLNESS; PROGRAM	Objective. - To develop a new method to improve the detection and characterization of adverse drug events (ADEs) in hospital patients. Design. - Prospective study of all patients admitted to our hospital over an 18-month period. Setting. - LDS Hospital, Salt Lake City, Utah, a 520-bed tertiary care center affiliated with the University of Utah School of Medicine, Salt Lake City. Patients. - We developed a computerized ADE monitor, and computer programs were written using an integrated hospital information system to allow for multiple source detection of potential ADEs occurring in hospital patients. Signals of potential ADEs, both voluntary and automated, included sudden medication stop orders, antidote ordering, and certain abnormal laboratory values. Each day, a list of all potential ADEs from these sources was generated, and a pharmacist reviewed the medical records of all patients with possible ADEs for accuracy and causality. Verified ADEs were characterized as mild, moderate, or severe and as type A (dose-dependent or predictable) or type B (idiosyncratic or allergic) reactions, and causality was further measured using a standardized scoring method. Outcome Measure. - The number and characterization of ADEs detected. Results. - Over 18 months, we monitored 36 653 hospitalized patients. There were 731 verified ADEs identified in 648 patients, 701 ADEs were characterized as moderate or severe, and 664 were classified as type A reactions. During this same period, only nine ADEs were identified using traditional detection methods. Physicians, pharmacists, and nurses voluntarily reported 92 of the 731 ADEs detected using this automated system. The other 631 ADEs were detected from automated signals, the most common of which were diphenhydramine hydrochloride and naloxone hydrochloride use, high serum drug levels, leukopenia, and the use of phytonadione and antidiarrheals. The most common symptoms and signs were pruritus, nausea and/or vomiting, rash, and confusion-lethargy. The most common drug classes involved were analgesics, anti-infectives, and cardiovascular agents. Conclusion. - We believe that screening for ADEs with a computerized hospital information system offers a potential method for improving the detection and characterization of these events in hospital patients.	UNIV UTAH,SCH MED,DIV INFECT DIS MED,SALT LAKE CITY,UT 84112	Utah System of Higher Education; University of Utah	CLASSEN, DC (corresponding author), LATTER DAY ST HOSP,DEPT CLIN EPIDEMIOL,8TH AVE & C ST,SALT LAKE CITY,UT 84143, USA.				AHRQ HHS [HS06028] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		[Anonymous], 1969, World Health Organ Tech Rep Ser, V425, P5; BENNETT BS, 1977, AM J HOSP PHARM, V34, P931, DOI 10.1093/ajhp/34.9.931; BERRY LL, 1988, AM J HOSP PHARM, V45, P1534, DOI 10.1093/ajhp/45.7.1534; CARANASOS GJ, 1974, JAMA-J AM MED ASSOC, V228, P713, DOI 10.1001/jama.228.6.713; CLASSEN DC, 1990, 6TH INT C PHARM AN; CLUFF LE, 1975, MAJOR PROBLEMS INTER, P5; EDLAVITCH SA, 1988, ARCH INTERN MED, V148, P1499, DOI 10.1001/archinte.148.7.1499; GURWITZ JH, 1991, ANN INTERN MED, V114, P956, DOI 10.7326/0003-4819-114-11-956; JACINTO MS, 1983, AM J HOSP PHARM, V40, P444, DOI 10.1093/ajhp/40.3.444; JICK H, 1974, NEW ENGL J MED, V291, P824, DOI 10.1056/NEJM197410172911605; JICK H, 1984, J ALLERGY CLIN IMMUN, V74, P555, DOI 10.1016/0091-6749(84)90106-4; KARCH FE, 1975, JAMA-J AM MED ASSOC, V234, P1236, DOI 10.1001/jama.234.12.1236; LEAPE LL, 1991, NEW ENGL J MED, V324, P377, DOI 10.1056/NEJM199102073240605; MALIEKAL J, 1990, HOSP FORMUL, V25, P436; MCCOLLAM A, 1989, INFUSION, V12, P3; MELMON KL, 1971, NEW ENGL J MED, V284, P1361; MICHEL DJ, 1986, AM J HOSP PHARM, V43, P1709, DOI 10.1093/ajhp/43.7.1709; MILLER RR, 1974, ARCH INTERN MED, V134, P219, DOI 10.1001/archinte.134.2.219; MILLER RR, 1977, AM J HOSP PHARM, V34, P753, DOI 10.1093/ajhp/34.7.753; MILLER RR, 1973, AM J HOSP PHARM, V30, P584, DOI 10.1093/ajhp/30.7.584; MIWA LJ, 1989, J PHARM PRACT, V2, P214; NARANJO CA, 1981, CLIN PHARMACOL THER, V30, P239, DOI 10.1038/clpt.1981.154; NELSON RW, 1983, AM J HOSP PHARM, V40, P445, DOI 10.1093/ajhp/40.3.445; OUSLANDER JG, 1981, ANN INTERN MED, V95, P711, DOI 10.7326/0003-4819-95-6-711; PEARSON KC, 1989, J PHARM PRACT, V2, P209; PORTER J, 1977, JAMA-J AM MED ASSOC, V237, P879, DOI 10.1001/jama.237.9.879; PRYOR TA, 1991, INFECT CONT HOSP EP, V12, P239; RAWLINS MD, 1981, BRIT MED J, V282, P974, DOI 10.1136/bmj.282.6268.974; ROGERS AS, 1988, ARCH INTERN MED, V148, P1596, DOI 10.1001/archinte.148.7.1596; ROSSI AC, 1988, JAMA-J AM MED ASSOC, V259, P1203, DOI 10.1001/jama.259.8.1203; SALAZAR TA, 1989, J PHARM P, V2, P245; SANAZARO PJ, 1991, JAMA-J AM MED ASSOC, V265, P1977, DOI 10.1001/jama.265.15.1977; SEIDL LG, 1966, B JOHNS HOPKINS HOSP, V119, P299; SHAPIRO S, 1971, J AMER MED ASSOC, V216, P467, DOI 10.1001/jama.216.3.467; STEEL K, 1981, NEW ENGL J MED, V304, P638, DOI 10.1056/NEJM198103123041104; TALLEY RB, 1974, JAMA-J AM MED ASSOC, V229, P1043, DOI 10.1001/jama.1974.03230460011003; TATRO DS, 1979, AM J HOSP PHARM, V36, P198, DOI 10.1093/ajhp/36.2.198; 1991, ACCREDITATION MANUAL; 1984, WHO DEMNC84153E PUBL	39	549	567	0	18	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 27	1991	266	20					2847	2851		10.1001/jama.266.20.2847	http://dx.doi.org/10.1001/jama.266.20.2847			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GQ722	1942452	Green Published			2022-12-24	WOS:A1991GQ72200032
J	NESS, RB; KELLY, JV; KILLIAN, CD				NESS, RB; KELLY, JV; KILLIAN, CD			HOUSE STAFF RECRUITMENT TO MUNICIPAL AND VOLUNTARY NEW-YORK-CITY RESIDENCY PROGRAMS DURING THE AIDS EPIDEMIC	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACQUIRED IMMUNODEFICIENCY SYNDROME; MEDICAL-STUDENTS ATTITUDES; INTERNAL MEDICINE	Objective. - To determine the impact on house staff recruitment of large numbers of patients with the acquired immunodeficiency syndrome (AIDS). Design. - Trends in yearly survey data from the National Resident Matching Program from 1983 to 1990 were examined for residency programs in New York City, NY, where AIDS is epidemic, in the four largest US cities with the fewest AIDS cases, and nationally. Within New York City, trends were compared for residency programs serving large numbers of AIDS patients (high AIDS) and for other programs (low AIDS). Main Outcome Measures. - Number of matches in each study year as compared with the baseline year of 1983 and the yearly percentage of positions offered that were filled by matches. Results. - During the study period, New York City experienced a greater decline in US graduate matches than did the four low-AIDS cities or the nation. Within New York City, recruitment to municipal programs, all with large AIDS patient populations, dropped from 241 to 173 matches (28.2%) despite a 3.6% increase in positions. However, recruitment to both high-AIDS and low-AIDS voluntary programs improved in all years except 1990. After controlling for numbers of offered positions, high-AIDS and low-AIDS voluntary programs again showed similar trends until 1990. Conclusions. - These observations cannot be attributed to AIDS alone. Multiple economic and social factors, including AIDS, may have contributed.	ASSOC AMER MED COLL,WASHINGTON,DC 20036	Association of American Medical Colleges	NESS, RB (corresponding author), UNIV PENN,DEPT MED,CEU,ROOM 332R,NEB 6095,420 SERV DR,PHILADELPHIA,PA 19104, USA.				AHRQ HHS [HS06428-01] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		BERNSTEIN CA, 1990, ACAD MED, V65, P458, DOI 10.1097/00001888-199007000-00010; BRENNAN TA, 1987, ANN INTERN MED, V107, P581, DOI 10.7326/0003-4819-107-4-581; COOKE M, 1989, NEW ENGL J MED, V321, P1334, DOI 10.1056/NEJM198911093211911; CURREY CJ, 1990, ACAD MED, V65, P472, DOI 10.1097/00001888-199007000-00015; GRAETTINGER JS, 1988, ANN INTERN MED, V108, P101, DOI 10.7326/0003-4819-108-1-101; IMPERATO PJ, 1988, NEW YORK STATE J MED, V88, P223; KELLY JA, 1987, J MED EDUC, V62, P549; KLUG J, 1988, CLIN PSYCHIATR NEWS, V2, P21; LINK RN, 1988, AM J PUBLIC HEALTH, V78, P455, DOI 10.2105/AJPH.78.4.455; NESS R, 1989, ACAD MED, V64, P588, DOI 10.1097/00001888-198910000-00009; THOMAS RI, 1990, ACAD MED, V65, P482, DOI 10.1097/00001888-199007000-00019; WACHTER RM, 1986, NEW ENGL J MED, V314, P177, DOI 10.1056/NEJM198601163140310; WHALEN JP, 1987, J MED EDUC, V62, P53; YEDIDIA M, 1990, FACTORS INFLUENCING; 1987, ANN SURVEY HOSPITALS; 1988, JAMA-J AM MED ASSOC, V159, P2817; 1987, MMWR, V36, P285; 1988, ANN SURVEY HOSPITALS; 1990, NRMP DATA APRIL 1990; 1989, AIDS DATA COMP ADULT; 1986, MMWR, V35, P757; 1987, NRMP DATA APRIL 1987; 1990, HIV AIDS SURVEILLANC, P1	23	14	14	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 27	1991	266	20					2843	2846						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GQ722	1942451				2022-12-24	WOS:A1991GQ72200031
J	NEGLIA, JP; MEADOWS, AT; ROBISON, LL; KIM, TH; NEWTON, WA; RUYMANN, FB; SATHER, HN; HAMMOND, GD				NEGLIA, JP; MEADOWS, AT; ROBISON, LL; KIM, TH; NEWTON, WA; RUYMANN, FB; SATHER, HN; HAMMOND, GD			2ND NEOPLASMS AFTER ACUTE LYMPHOBLASTIC-LEUKEMIA IN CHILDHOOD	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CANCER STUDY-GROUP; ACUTE LYMPHOCYTIC-LEUKEMIA; MALIGNANT NEOPLASMS; CHILDREN; THERAPY; RADIOTHERAPY; CHEMOTHERAPY; PROPHYLAXIS; SURVIVAL; SARCOMAS	Background. Effective forms of treatment for acute lymphoblastic leukemia (ALL) in childhood now result in survival rates above 70 percent at five years, but the treatments are potentially carcinogenic. To determine the magnitude of this risk and identify possible risk factors for the development of second neoplasms, we studied a large cohort of children treated for ALL. Methods and Results. We undertook a retrospective cohort study of 9720 children who had been given a diagnosis of ALL between June 1972 and August 1988 and had been treated according to the therapeutic protocols of the Children's Cancer Study Group. The median follow-up was 4.7 years (range, 2 months to 16 years). We found that 43 second neoplasms occurred among the children in the cohort, including 24 neoplasms of the central nervous system, 10 new leukemias and lymphomas, and 9 other neoplasms. This represented a 7-fold excess of all cancers and a 22-fold excess of neoplasms of the central nervous system. The estimated cumulative proportion of children in whom a second neoplasm developed was 2.53 percent 15 years after diagnosis (95 percent confidence limits, 1.74 percent and 3.38 percent). An even higher risk, particularly of central nervous system tumors, was evident in children five years of age or less at the time of the diagnosis of ALL (P = 0.012). All central nervous system neoplasms developed in children who had previously undergone irradiation. There was no association with exposure to cyclophosphamide or anthracyclines. Conclusions. There is a substantial excess of second neoplasms, especially of the central nervous system, among children treated for ALL. Children five years old or younger and those receiving radiation are at higher risk, especially for second tumors arising in the central nervous system.	CHILDRENS CANC STUDY GRP,440 E HUNTINGTON DR,SUITE 300,POB 60012,ARCADIA,CA 91066; CHILDRENS HOSP,COLUMBUS,OH 43205; UNIV SO CALIF,SCH MED,LOS ANGELES,CA 90033; UNIV MINNESOTA,SCH MED,MINNEAPOLIS,MN 55455; ABBOTT NW HOSP,MINNEAPOLIS,MN; CHILDRENS HOSP PHILADELPHIA,PHILADELPHIA,PA	University System of Ohio; Ohio State University; Nationwide Childrens Hospital; University of Southern California; University of Minnesota System; University of Minnesota Twin Cities; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia			Robison, Leslie/N-8122-2018	Neglia, Joseph/0000-0002-5525-0598	NATIONAL CANCER INSTITUTE [K08CA001240] Funding Source: NIH RePORTER; NCI NIH HHS [CA 01240] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albo V, 1985, P AN M AM SOC CLIN, V4, P172; BAILAR JC, 1964, BIOMETRICS, V20, P639; BRESLOW N, 1974, BIOMETRICS, V30, P89, DOI 10.2307/2529620; COCCIA PF, 1983, LEUKEMIA RES ADV CEL, P241; FARWELL J, 1984, NEW ENGL J MED, V311, P749, DOI 10.1056/NEJM198409203111201; FRIED M, 1987, CANCER, V60, P2548, DOI 10.1002/1097-0142(19871115)60:10<2548::AID-CNCR2820601033>3.0.CO;2-H; GAYNON PS, 1988, AM J PEDIAT HEMATOL, V10, P42; Goldes J, 1984, Pediatr Dermatol, V1, P295, DOI 10.1111/j.1525-1470.1984.tb01132.x; HAMMOND G D, 1986, Cancer, V58, P407, DOI 10.1002/1097-0142(19860715)58:2+<407::AID-CNCR2820581302>3.0.CO;2-U; HAWKINS MM, 1987, BRIT J CANCER, V56, P339, DOI 10.1038/bjc.1987.200; Kalbfleisch JD, 1980, STATISTICAL ANAL FAI, P14; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LABOTKA RJ, 1983, CANCER, V52, P846, DOI 10.1002/1097-0142(19830901)52:5<846::AID-CNCR2820520517>3.0.CO;2-B; LI FP, 1982, JAMA-J AM MED ASSOC, V247, P2692, DOI 10.1001/jama.247.19.2692; LITTMAN P, 1987, INT J RADIAT ONCOL, V13, P1443, DOI 10.1016/0360-3016(87)90308-7; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MALONE M, 1986, CANCER, V57, P1979, DOI 10.1002/1097-0142(19860515)57:10<1979::AID-CNCR2820571016>3.0.CO;2-R; MANTEL N, 1974, J AM STAT ASSOC, V69, P81, DOI 10.2307/2285503; MEADOWS AT, 1977, CANCER, V40, P1903, DOI 10.1002/1097-0142(197710)40:4+<1903::AID-CNCR2820400822>3.0.CO;2-E; MEADOWS AT, 1989, NEW ENGL J MED, V321, P1830; MEADOWS AT, 1985, J CLIN ONCOL, V3, P532, DOI 10.1200/JCO.1985.3.4.532; MIKE V, 1982, LANCET, V2, P1326; MILLER DR, 1983, CANCER, V51, P1041, DOI 10.1002/1097-0142(19830315)51:6<1041::AID-CNCR2820510612>3.0.CO;2-G; MOSIJCZUK AD, 1981, AM J DIS CHILD, V135, P313, DOI 10.1001/archpedi.1981.02130280003002; NESBIT ME, 1982, CANCER RES, V42, P674; ORTEGA JA, 1977, CANCER RES, V37, P535; Parkin D. M, 1988, IARC SCI PUBLICATION, V87; PETO R, 1972, J R STAT SOC SER A-G, V135, P185, DOI 10.2307/2344317; PINKEL D, 1987, CANCER, V59, P1683, DOI 10.1002/1097-0142(19870515)59:10<1683::AID-CNCR2820591002>3.0.CO;2-G; PRATT C B, 1988, Pediatric Research, V23, p345A; PUI CH, 1989, NEW ENGL J MED, V321, P136, DOI 10.1056/NEJM198907203210302; R&DEG;rth M., 1991, P AN M AM SOC CLIN, V10, P221; RIMM IJ, 1987, CANCER, V59, P1506, DOI 10.1002/1097-0142(19870415)59:8<1506::AID-CNCR2820590819>3.0.CO;2-P; SILVERBERG E, 1990, CA-CANCER J CLIN, V40, P9, DOI 10.3322/canjclin.40.1.9; STEINHERZ PG, 1986, J CLIN ONCOL, V4, P744, DOI 10.1200/JCO.1986.4.5.744; SULLIVAN MP, 1982, BLOOD, V60, P948; SUSSMAN A, 1990, CANCER CAUSE CONTROL, V1, P75, DOI 10.1007/BF00053186; TUCKER MA, 1987, NEW ENGL J MED, V317, P588, DOI 10.1056/NEJM198709033171002; ZARRABI MH, 1983, CANCER, V52, P1712, DOI 10.1002/1097-0142(19831101)52:9<1712::AID-CNCR2820520927>3.0.CO;2-I; 1989, NIH8292789 NCI PUBL	40	434	442	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 7	1991	325	19					1330	1336		10.1056/NEJM199111073251902	http://dx.doi.org/10.1056/NEJM199111073251902			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GN470	1922234	Bronze			2022-12-24	WOS:A1991GN47000002
J	HONIGMAN, B; LOWENSTEIN, SR; MOORE, EE; ROWEDER, K; PONS, P				HONIGMAN, B; LOWENSTEIN, SR; MOORE, EE; ROWEDER, K; PONS, P			THE ROLE OF THE PNEUMATIC ANTISHOCK GARMENT IN PENETRATING CARDIAC WOUNDS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LIFE SUPPORT; MAST SUIT; TRAUMA; TROUSERS; RESUSCITATION; EMERGENCY; TAMPONADE	Objective. - To determine the impact of the pneumatic antishock garment on survival in patients with cardiac wounds. Design. - A retrospective review of a 6.5-year experience in a population of patients with gunshot or stab wounds to the heart (N = 70). Setting. - The city and county of Denver, Colo, where all patients were transported by paramedic ambulances to Denver General Hospital, an urban, level 1 trauma center. Patients. - All patients were analyzed, including those transported to the emergency department with no vital signs at the trauma scene. Only patients with definite penetrating cardiac injuries were included. Methods. - Paramedic trip sheets and emergency department, operating room, in-hospital, and autopsy records were reviewed. Demographic, clinical outcome, and treatment data were collected. A multiple logistic regression model was developed to determine which characteristics and treatment variables were independently predictive of patient outcome. The ability of each independent variable to predict outcome was determined by calculating adjusted odds ratios (ORs) and 95% confidence intervals (Cls). Results. - Seventy patients (31 gunshot and 39 stab wounds) had a revised trauma score of 2.8 +/- 4.0 (mean +/- SD; range, 0-1 2; median, 0). Thirty-two (46%) had cardiac tamponade. Overall, 21 (30%) of the patients survived. In the logistic model, the presence of cardiac tamponade (OR, 9.1; 95% Cl, 1.5 to 56. 1) and a higher revised trauma score were associated with higher survival. Inflation of the pneumatic antishock garment was associated with sevenfold lower survival (adjusted OR, 0.14; 95% Cl, 0.02 to 0.86); the effect was negative across all trauma score groups. Conclusion. - Survival in patients with penetrating cardiac wounds is highly associated with anatomic and physiologic factors, while application of the pneumatic antishock garment appears to be detrimental.	UNIV COLORADO,HLTH SCI CTR,EMERGENCY MED RES CTR,DENVER,CO 80262; DENVER GEN HOSP,DEPT SURG,DENVER,CO 80204; DENVER GEN HOSP,DEPT EMERGENCY MED,DENVER,CO 80204	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Denver Health Medical Center; Denver Health Medical Center	HONIGMAN, B (corresponding author), UNIV COLORADO,HLTH SCI CTR,DEPT SURG,EMERGENCY MED & TRAUMA SECT,4200 E 9TH AVE,DENVER,CO 80262, USA.							BICKELL WH, 1985, ANN EMERG MED, V14, P218, DOI 10.1016/S0196-0644(85)80443-1; BIVINS HG, 1982, ANN EMERG MED, V11, P409, DOI 10.1016/S0196-0644(82)80036-X; Carrasquilla C, 1972, Ann Thorac Surg, V13, P208; CHAMPION HR, 1988, TRAUMA; Civetta J M, 1976, JACEP, V5, P581, DOI 10.1016/S0361-1124(76)80216-X; COGBILL TH, 1983, J TRAUMA, V23, P453, DOI 10.1097/00005373-198306000-00002; COPASS MK, 1984, AM J SURG, V148, P20, DOI 10.1016/0002-9610(84)90284-8; DAVIS JW, 1981, ANN EMERG MED, V10, P185, DOI 10.1016/S0196-0644(81)80158-8; DEMETRIADES D, 1986, ANN SURG, V203, P315, DOI 10.1097/00000658-198603000-00018; IVATURY RR, 1988, J TRAUMA, V27, P1066; JACOBS LM, 1984, J TRAUMA, V24, P8, DOI 10.1097/00005373-198401000-00002; JONES EW, 1982, ARCH SURG-CHICAGO, V96, P671; KABACK KR, 1984, JAMA-J AM MED ASSOC, V252, P2598, DOI 10.1001/jama.252.18.2598; KARREL R, 1982, ANN EMERG MED, V11, P504; MACKERSIE RC, 1984, J TRAUMA, V24, P882, DOI 10.1097/00005373-198410000-00003; MATTOX KL, 1989, J TRAUMA, V29, P1104, DOI 10.1097/00005373-198908000-00007; MATTOX KL, 1986, J TRAUMA, V26, P779, DOI 10.1097/00005373-198609000-00002; MORENO C, 1986, J TRAUMA, V26, P821, DOI 10.1097/00005373-198609000-00007; PALAFOX BA, 1981, J TRAUMA, V21, P55, DOI 10.1097/00005373-198101000-00012; PONS PT, 1985, J TRAUMA, V25, P828, DOI 10.1097/00005373-198509000-00003; RANSOM K, 1978, J AM COLL EMERG PHYS, V7, P15; Schlesselman JJ, 1982, CASE CONTROL STUDIES; SMITH JP, 1985, J TRAUMA, V25, P65, DOI 10.1097/00005373-198501000-00011; SUGG WL, 1968, J THORAC CARDIOV SUR, V56, P531, DOI 10.1016/S0022-5223(19)42812-2; TRINKLE JK, 1974, ANN THORAC SURG, V17, P230, DOI 10.1016/S0003-4975(10)65641-X; TRUNKEY DD, 1984, J TRAUMA, V24, P86, DOI 10.1097/00005373-198401000-00017; WECHSLER AS, 1974, J THORAC CARDIOVASC, V69, P847; 1985, INJURY AM CONTINUING	28	12	12	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 6	1991	266	17					2398	2401		10.1001/jama.266.17.2398	http://dx.doi.org/10.1001/jama.266.17.2398			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GM790	1920746				2022-12-24	WOS:A1991GM79000026
J	MATSUOKA, M; NAGAWA, F; OKAZAKI, K; KINGSBURY, L; YOSHIDA, K; MULLER, U; LARUE, DT; WINER, JA; SAKANO, H				MATSUOKA, M; NAGAWA, F; OKAZAKI, K; KINGSBURY, L; YOSHIDA, K; MULLER, U; LARUE, DT; WINER, JA; SAKANO, H			DETECTION OF SOMATIC DNA RECOMBINATION IN THE TRANSGENIC MOUSE-BRAIN	SCIENCE			English	Article							HEAVY-CHAIN GENES; BETA-ACTIN GENE; NUCLEOTIDE-SEQUENCE; IMMUNE-SYSTEM; IMMUNOGLOBULIN; TRANSCRIPTION; SEGMENTS; ELEMENTS; NUCLEUS; REGION	A DNA construct containing the bacterial beta-galactosidase gene (lacZ) was used to study somatic DNA recombination in the transgenic mouse brain. Recombination-positive areas of the adult brain were stained blue with X-gal, a substrate of beta-galactosidase. Blue-colored cells appeared soon after birth, and continued to emerge in postnatal tissue. Staining was prominent in sensory as opposed to motor regions of the brain, and was present in more than 70 discrete areas of the nervous system. The possibility of DNA rearrangement is discussed with respect to the development of the central nervous system.	UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,DIV NEUROBIOL,BERKELEY,CA 94720; INST PHYS & CHEM RES,TSUKUBA LIFE SCI CTR,IBARAKI 305,JAPAN; BASEL INST IMMUNOL,CH-4005 BASEL,SWITZERLAND	University of California System; University of California Berkeley; RIKEN	MATSUOKA, M (corresponding author), UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,DIV IMMUNOL,BERKELEY,CA 94720, USA.		Okazaki, Kenji/H-4393-2012	Matsuoka, Masao/0000-0002-0473-754X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI018790, R01AI018790] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS016832] Funding Source: NIH RePORTER; NIAID NIH HHS [AI18790] Funding Source: Medline; NINDS NIH HHS [NS16832] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKIRA S, 1987, SCIENCE, V238, P1134, DOI 10.1126/science.3120312; ALT FW, 1982, P NATL ACAD SCI-BIOL, V79, P4118, DOI 10.1073/pnas.79.13.4118; BRINSTER RL, 1985, P NATL ACAD SCI USA, V82, P4438, DOI 10.1073/pnas.82.13.4438; CHUN JJM, 1989, CELL, V59, P189; DREYER WJ, 1965, P NATL ACAD SCI USA, V54, P864, DOI 10.1073/pnas.54.3.864; EARLY P, 1980, CELL, V19, P981, DOI 10.1016/0092-8674(80)90089-6; FREGIEN N, 1986, GENE, V48, P1, DOI 10.1016/0378-1119(86)90346-X; GILLIES SD, 1983, CELL, V33, P717, DOI 10.1016/0092-8674(83)90014-4; HU H, 1986, BRAIN RES, V368, P201, DOI 10.1016/0006-8993(86)91064-4; Jerne N., 1967, NEUROSCIENCES STUDY, P200; KOST TA, 1983, NUCLEIC ACIDS RES, V11, P8287, DOI 10.1093/nar/11.23.8287; LEDOUX JE, 1990, J NEUROSCI, V10, P1062; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; Neff WD, 1975, HDB SENSORY PHYSIOLO, P307; PARNES JR, 1987, IMMUNOL REV, V100, P109, DOI 10.1111/j.1600-065X.1987.tb00529.x; QUEEN C, 1983, CELL, V33, P741, DOI 10.1016/0092-8674(83)90016-8; SAKANO H, 1979, NATURE, V280, P288, DOI 10.1038/280288a0; SAKANO H, 1980, NATURE, V286, P676, DOI 10.1038/286676a0; SAKANO H, 1981, NATURE, V290, P562, DOI 10.1038/290562a0; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; Sarnat H. B., 1981, EVOLUTION NERVOUS SY, V2nd; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SUBRAMANI S, 1981, MOL CELL BIOL, V1, P854, DOI 10.1128/MCB.1.9.854; WHITLOCK CA, 1982, P NATL ACAD SCI-BIOL, V79, P3608, DOI 10.1073/pnas.79.11.3608; WINER JA, 1988, J COMP NEUROL, V274, P422, DOI 10.1002/cne.902740310; YAMAMORI T, 1989, SCIENCE, V246, P1412, DOI 10.1126/science.2512641	26	104	111	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 4	1991	254	5028					81	86		10.1126/science.1925563	http://dx.doi.org/10.1126/science.1925563			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GH605	1925563				2022-12-24	WOS:A1991GH60500031
J	GARROW, J				GARROW, J			THE HEALTH OF THE NATION - RESPONSES - IMPORTANCE OF OBESITY	BRITISH MEDICAL JOURNAL			English	Article							CARDIOVASCULAR-DISEASE; BODY-WEIGHT; RISK FACTOR; OVERWEIGHT; TIME				GARROW, J (corresponding author), ST BARTHOLOMEWS HOSP,HUMAN NUTR,LONDON EC1A 7BE,ENGLAND.							BINGHAM S, 1991, BRIT MED J, V303, P353, DOI 10.1136/bmj.303.6798.353; BORKAN GA, 1986, AM J EPIDEMIOL, V124, P410, DOI 10.1093/oxfordjournals.aje.a114411; BORTZ WM, 1969, AM J MED, V47, P325, DOI 10.1016/0002-9343(69)90159-4; Bush A., 1988, Journal of Human Nutrition and Dietetics, V1, P429, DOI 10.1111/j.1365-277X.1988.tb00216.x; DIXON AS, 1973, PRESCRIBERS J, V13, P41; DUBLIN LI, 1953, NEW ENGL J MED, V248, P971, DOI 10.1056/NEJM195306042482304; FORDE OH, 1986, ACTA MED SCAND, V219, P167; FRIEDMAN CI, 1985, CLIN OBSTET GYNECOL, V28, P645, DOI 10.1097/00003081-198528030-00019; GARFINKEL L, 1985, ANN INTERN MED, V103, P1034, DOI 10.7326/0003-4819-103-6-1034; Garrow J.S., 1988, OBESITY RELATED DISE; GARROW JS, 1991, BRIT MED J, V302, P803, DOI 10.1136/bmj.302.6780.803; GARROW JS, IN PRESS OVERWEIGHT; Gregory F., 1990, DIETARY NUTR SURVEY; HALL A, 1989, NEW ZEAL MED J, V102, P134; HUBERT HB, 1983, CIRCULATION, V67, P968, DOI 10.1161/01.CIR.67.5.968; HUBERT HB, 1986, ANNU REV PUBL HEALTH, V7, P493, DOI 10.1146/annurev.pu.07.050186.002425; JEANRENAUD B, 1991, PROG OBES R, P409; KEYS A, 1972, ANN INTERN MED, V77, P15, DOI 10.7326/0003-4819-77-1-15; MODAN M, 1985, J CLIN INVEST, V75, P809, DOI 10.1172/JCI111776; NOMURA F, 1986, INT J OBESITY, V10, P349; PENTECOST BL, 1991, MED ASPECTS EXERCISE; REUBEN A, 1985, CLIN SCI, V69, P71, DOI 10.1042/cs0690071; RISSANEN A, 1990, BRIT MED J, V301, P835, DOI 10.1136/bmj.301.6756.835; SHAPER AG, 1988, CORONARY HEART DISEA; Sims E A, 1973, Recent Prog Horm Res, V29, P457; SONNEHOLM S, 1986, BRIT MED J, V292, P586, DOI 10.1136/bmj.292.6520.586; 1991, CM1523	27	59	60	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 21	1991	303	6804					704	706		10.1136/bmj.303.6804.704	http://dx.doi.org/10.1136/bmj.303.6804.704			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GG980	1912920	Bronze, Green Published			2022-12-24	WOS:A1991GG98000028
J	RICHET, E; VIDALINGIGLIARDI, D; RAIBAUD, O				RICHET, E; VIDALINGIGLIARDI, D; RAIBAUD, O			A NEW MECHANISM FOR COACTIVATION OF TRANSCRIPTION INITIATION - REPOSITIONING OF AN ACTIVATOR TRIGGERED BY THE BINDING OF A 2ND ACTIVATOR	CELL			English	Article							ESCHERICHIA-COLI; SUPERCOILED DNA; MALT PRODUCT; PROMOTERS; PROTEIN; OPERON; MUTATIONS; REGION; CRP; EXPRESSION	The cAMP receptor protein (CRP) and MalT, the maltose regulon activator, synergistically activate transcription from the E. coli malKp promoter. The malKp regulatory region comprises two series of MalT-binding sites separated by three CRP-binding sites. By combining genetic and biochemical studies, we demonstrate that the promoter-proximal region contains two overlapping sets of three MalT-binding sites. Occupation of the higher affinity set of sites, which occurs in the absence of CRP, does not lead to malKp activation. In contrast, in the presence of CRP, MalT binds to the lower affinity set of sites and triggers transcription initiation because, unlike the high affinity set, the low affinity set of sites is properly positioned with respect to the Pribnow box. The CRP effect requires the malKp-distal MalT-binding sites. The synergistic action of MalT and CRP therefore relies on MalT repositioning via the formation of a nucleoprotein structure involving the entire regulatory region.			RICHET, E (corresponding author), INST PASTEUR,UNITE GENET MOLEC,CNRS,URA 1149,25 RUE DR ROUX,F-75724 PARIS 15,FRANCE.							AIBA H, 1981, J BIOL CHEM, V256, P1905; BEDOUELLE H, 1983, J MOL BIOL, V170, P861, DOI 10.1016/S0022-2836(83)80192-2; BOLES TC, 1990, J MOL BIOL, V213, P931, DOI 10.1016/S0022-2836(05)80272-4; BUC H, 1987, RNA POLYMERASE REGUL, P115; CHAPON C, 1985, J BACTERIOL, V164, P639, DOI 10.1128/JB.164.2.639-645.1985; CLAVERIEMARTIN F, 1991, P NATL ACAD SCI USA, V88, P1631, DOI 10.1073/pnas.88.5.1631; COHEN RS, 1988, NATURE, V332, P856, DOI 10.1038/332856a0; DEBARBOUILLE M, 1982, MOL GEN GENET, V185, P88, DOI 10.1007/BF00333795; DECROMBRUGGHE B, 1984, SCIENCE, V224, P831, DOI 10.1126/science.6372090; DEVARGAS LM, 1991, P NATL ACAD SCI USA, V88, P588, DOI 10.1073/pnas.88.2.588; EISMANN ER, 1990, J MOL BIOL, V213, P763, DOI 10.1016/S0022-2836(05)80262-1; GASTON K, 1990, CELL, V62, P733, DOI 10.1016/0092-8674(90)90118-X; GERMOND JE, 1975, P NATL ACAD SCI USA, V72, P1843, DOI 10.1073/pnas.72.5.1843; GUTIERREZ C, 1985, BIOCHIMIE, V67, P145, DOI 10.1016/S0300-9084(85)80241-8; GUTIERREZ C, 1984, J MOL BIOL, V177, P69, DOI 10.1016/0022-2836(84)90058-5; HOFNUNG M, 1974, J BACTERIOL, V117, P40, DOI 10.1128/JB.117.1.40-47.1974; HOOVER TR, 1990, CELL, V63, P11, DOI 10.1016/0092-8674(90)90284-L; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LICHENSTEIN HS, 1987, J BACTERIOL, V169, P811, DOI 10.1128/jb.169.2.811-822.1987; LIUJOHNSON HN, 1986, CELL, V47, P995, DOI 10.1016/0092-8674(86)90814-7; LOBELL RB, 1991, J MOL BIOL, V218, P45, DOI 10.1016/0022-2836(91)90872-4; LOBELL RB, 1990, SCIENCE, V250, P528, DOI 10.1126/science.2237403; MENENDEZ M, 1987, EMBO J, V6, P4227, DOI 10.1002/j.1460-2075.1987.tb02771.x; Miller J.H., 1972, EXPT MOL GENETICS; RAIBAUD O, 1983, J MOL BIOL, V163, P395, DOI 10.1016/0022-2836(83)90065-7; RAIBAUD O, 1985, J BACTERIOL, V161, P1201, DOI 10.1128/JB.161.3.1201-1208.1985; RAIBAUD O, 1989, J MOL BIOL, V205, P471, DOI 10.1016/0022-2836(89)90218-0; RAIBAUD O, 1987, J BACTERIOL, V169, P3059, DOI 10.1128/jb.169.7.3059-3061.1987; REITZER LJ, 1985, P NATL ACAD SCI USA, V82, P1979, DOI 10.1073/pnas.82.7.1979; RICHET E, 1991, J MOL BIOL, V218, P529; RICHET E, 1986, CELL, V46, P1011, DOI 10.1016/0092-8674(86)90700-2; RICHET E, 1989, EMBO J, V8, P981, DOI 10.1002/j.1460-2075.1989.tb03461.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASSEDWIGHT S, 1988, J MOL BIOL, V202, P107, DOI 10.1016/0022-2836(88)90523-2; Schwartz M, 1987, ESCHERICHIA COLI SAL, P1482; SOGAARDANDERSEN L, 1991, MOL MICROBIOL, V5, P969, DOI 10.1111/j.1365-2958.1991.tb00772.x; TAKAHASHI K, 1986, NATURE, V319, P121, DOI 10.1038/319121a0; USHIDA C, 1990, NUCLEIC ACIDS RES, V18, P6325, DOI 10.1093/nar/18.21.6325; VALENTINHANSEN P, 1982, EMBO J, V1, P317, DOI 10.1002/j.1460-2075.1982.tb01167.x; VALENTINHANSEN P, 1991, MOL MICROBIOL, V5, P433, DOI 10.1111/j.1365-2958.1991.tb02126.x; VIDALINGIGLIARDI D, 1991, P NATL ACAD SCI USA, V88, P229, DOI 10.1073/pnas.88.1.229; VIDALINGIGLIARDI D, 1985, NUCLEIC ACIDS RES, V13, P5919, DOI 10.1093/nar/13.16.5919; VIDALINGIGLIARDI D, 1991, J MOL BIOL, V218, P323, DOI 10.1016/0022-2836(91)90715-I; VIDALINGIGLIARDI D, 1985, NUCLEIC ACIDS RES, V13, P1163, DOI 10.1093/nar/13.4.1163	44	80	81	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 20	1991	66	6					1185	1195		10.1016/0092-8674(91)90041-V	http://dx.doi.org/10.1016/0092-8674(91)90041-V			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GG552	1913806				2022-12-24	WOS:A1991GG55200013
J	PENNINGTON, BF; GILGER, JW; PAULS, D; SMITH, SA; SMITH, SD; DEFRIES, JC				PENNINGTON, BF; GILGER, JW; PAULS, D; SMITH, SA; SMITH, SD; DEFRIES, JC			EVIDENCE FOR MAJOR GENE TRANSMISSION OF DEVELOPMENTAL DYSLEXIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							READING-DISABILITY	Objective. - There is strong evidence that developmental dyslexia is both familial and heritable, but the mode of genetic transmission has remained unclear. In this article, we examine specific genetic hypotheses about the mode of transmission of developmental dyslexia by performing complex segregation analyses. Design. - A family study method was applied, whereby the relatives of dyslexic probands were examined for dyslexia. The families studied represent four independently ascertained samples. Setting. - The four samples of families were primarily from rural and suburban communities of Colorado, Washington State, and Iowa. Participants. - A total of 204 families and 1698 individuals in the four samples combined. Main Outcome Measures. - The complex segregation program, POINTER, was used to test competing genetic hypotheses of how a categorical trait (dyslexia) is transmitted in families. Results. - The results were consistent with major locus transmission in three of four samples and with polygenic transmission in the fourth. In these three samples, the estimates of penetrance for the AA, Aa, and aa genotypes (where A is the abnormal allele) were, respectively, 1.000, 1.000, and 0.001 to 0.039 in males, and 0.560 to 1.000, 0.550 to 0.897, and 0.000 in females. The estimated gene frequency of the major locus was between 3% and 5%. Conclusions. - Sex-influenced, additive, or dominant transmission occurs in a significant proportion of dyslexic families. Other evidence indicates, however, that dyslexia is etiologically heterogeneous and that there is genetic heterogeneity even among families selected for apparent dominant transmission. Thus, while no single major locus may account for all of dyslexia, it is important to pursue potential major loci for dyslexia using linkage techniques.	BOYSTOWN NATL INST COMMUN DISORDERS CHILDREN, OMAHA, NE USA; SEQUIM WASHINGTON SCH DISTRICT, SEQUIM, WA USA; YALE UNIV, SCH MED, DEPT PSYCHIAT, NEW HAVEN, CT 06510 USA; YALE UNIV, SCH MED, DEPT HUMAN GENET, NEW HAVEN, CT 06510 USA; UNIV COLORADO, INST BEHAV GENET, DENVER, CO 80202 USA	Yale University; Yale University; University of Colorado System; University of Colorado Denver	PENNINGTON, BF (corresponding author), UNIV DENVER, DEPT PSYCHOL, 2155 S RACE ST, DENVER, CO 80208 USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [K05MH000419] Funding Source: NIH RePORTER; NIMH NIH HHS [MH00419, MH38870, MH15442] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BISGAARD ML, 1987, CLIN GENET, V32, P118; DEFRIES JC, 1987, NATURE, V329, P537, DOI 10.1038/329537a0; DeFries JC, 1991, READING BRAIN BIOL B; Dunn L. M., 1970, MANUAL PEABODY INDIV; EAVES LJ, 1983, AM J HUM GENET, V35, P1179; FINUCCI JM, 1976, ANN HUM GENET, V40, P1, DOI 10.1111/j.1469-1809.1976.tb00161.x; Fisher J. H., 1905, OPHTHALMIC REV, V24, P315; FULKER DW, 1991, READ WRIT INTERDISCI, V4, P107; GILGER J, 1991, READ WRIT, V4, P13; Gray W. S., 1963, GRAY ORAL READING TE; Hallgren B, 1950, ACTA PSYCH NEUROL SU, P1; HIERONYMOUS AN, 1986, MANUAL SCH ADM ITBS, P111; Hinshelwood J, 1911, BRIT MED J, V1911, P608, DOI 10.1136/bmj.1.2620.608; Hinshelwood J, 1907, BRIT MED J, V1907, P1229; HOLLINGSHEAD AB, 1975, 4 FACTOR INDEX SOCIA, V1; Jastak J.F., 1978, WRAT WIDE RANGE ACHI; KERR J, 1896, J R STAT SOC, V60, P613; LALOUEL JM, 1981, HUM HERED, V31, P312, DOI 10.1159/000153231; LALOUEL JM, 1983, AM J HUM GENET, V35, P816; LEFLY DL, IN PRESS ANN DYSLEXI; LEWITTER FI, 1980, BEHAV GENET, V10, P9, DOI 10.1007/BF01067316; Lindgren SD, 1986, DEV NEUROPSYCHOL, V2, P173, DOI 10.1080/87565648609540340; MCGUFFIN P, 1987, J CHILD PSYCHOL PSYC, V28, P215, DOI 10.1111/j.1469-7610.1987.tb00205.x; MCGUFFIN P, 1990, AM J HUM GENET, V46, P994; Morgan W.P., 1896, BMJ-BRIT MED J, V2, P1543, DOI [10.1136/bmj.2.1871.1378, DOI 10.1136/BMJ.2.1871.1378]; Pennington B.F., 1984, CONTINUITIES DISCONT, P123; PENNINGTON BF, 1990, J CHILD PSYCHOL PSYC, V31, P193, DOI 10.1111/j.1469-7610.1990.tb01561.x; PLOMIN R, 1989, AM PSYCHOL, V44, P105, DOI 10.1037/0003-066X.44.2.105; Raven J. C., 1938, STANDARD PROGRESSIVE; RAVEN JC, 1984, COLOURED PROGR MATRI; REICH T, 1981, GENETIC RES STRATEGI; Reiss AlbertJ JR, 1961, OCCUPATIONS SOCIAL S; Richman L. C., 1983, ADV DEV BEHAVIORAL P, V4, P87; SHAYWITZ SE, 1990, JAMA-J AM MED ASSOC, V264, P998, DOI 10.1001/jama.264.8.998; SLADEN BK, 1970, B ORTON SOC, V20, P30; SMITH SD, 1990, J AM ACAD CHILD PSY, V29, P204, DOI 10.1097/00004583-199003000-00008; SMITH SD, 1983, SCIENCE, V219, P1345, DOI 10.1126/science.6828864; SMITH SD, 1991, READ WRIT, V4, P92; Stephenson S., 1907, OPHTHALMOSCOPE, V5, P482; Thomas C. J., 1905, OPHTHALMOSCOPE, V3, P380; VOGEL SA, 1990, J LEARN DISABIL-US, V23, P44, DOI 10.1177/002221949002300111; 1980, DIAGNOSTIC STATISTIC; MANUAL TEACHERS ADM	43	150	152	0	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 18	1991	266	11					1527	1534		10.1001/jama.266.11.1527	http://dx.doi.org/10.1001/jama.266.11.1527			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GE458	1880884				2022-12-24	WOS:A1991GE45800033
J	MCCARTY, DR; HATTORI, T; CARSON, CB; VASIL, V; LAZAR, M; VASIL, IK				MCCARTY, DR; HATTORI, T; CARSON, CB; VASIL, V; LAZAR, M; VASIL, IK			THE VIVIPAROUS-1 DEVELOPMENTAL GENE OF MAIZE ENCODES A NOVEL TRANSCRIPTIONAL ACTIVATOR	CELL			English	Article							AMINO-ACID-SEQUENCE; ZEA-MAYS-L; ABSCISIC-ACID; WILD-TYPE; POLYACRYLAMIDE GELS; SECONDARY-STRUCTURE; WHEAT EMBRYOS; PROTEIN; EXPRESSION; DNA	The Viviparous-1 (Vp1) gene of maize is specifically required for expression of the maturation program in seed development. We show that Vp1 encodes a 73,335 dalton protein with no detectable homology to known proteins. An acidic transcriptional activation sequence was identified by fusion to the GAL4 DNA-binding domain. Expression of VP1 in maize protoplasts resulted in strong activation (> 130-fold) of a reporter gene fused to the promoter of a presumptive target gene. The acidic domain in VP1 was essential for transactivation and could be functionally replaced by the activator sequence of the herpes simplex virus VP16 protein. Our results indicate that VP1 is a novel transcription factor possibly involved in potentiation of a seed-specific hormone response.			MCCARTY, DR (corresponding author), UNIV FLORIDA, DEPT VEGETABLE CROPS, GAINESVILLE, FL 32611 USA.		Vasil, Indra K/F-6192-2011	Vasil, Indra K/0000-0002-8900-4897				ANDERSON DJ, 1983, METHOD ENZYMOL, V96, P111; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; CUMING AC, 1984, EUR J BIOCHEM, V145, P351, DOI 10.1111/j.1432-1033.1984.tb08561.x; DOONER HK, 1985, PLANT PHYSIOL, V77, P486, DOI 10.1104/pp.77.2.486; DURE L, 1981, BIOCHEMISTRY-US, V20, P4162, DOI 10.1021/bi00517a033; DURE L, 1989, PLANT MOL BIOL, V12, P475, DOI 10.1007/BF00036962; EISENBERG D, 1984, P NATL ACAD SCI-BIOL, V81, P140, DOI 10.1073/pnas.81.1.140; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GINIGER E, 1987, NATURE, V330, P670, DOI 10.1038/330670a0; GOFF SA, 1991, GENE DEV, V5, P298, DOI 10.1101/gad.5.2.298; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; GUILTINAN MJ, 1990, SCIENCE, V250, P267, DOI 10.1126/science.2145628; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; Jefferson RA, 1987, PLANT MOL BIOL REP, V5, P387, DOI [DOI 10.1007/BF02667740, 10.1007/bf02667740]; JONES RJ, 1987, PLANT PHYSIOL, V83, P905, DOI 10.1104/pp.83.4.905; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KRIZ AR, 1990, PLANT PHYSIOL, V92, P538, DOI 10.1104/pp.92.2.538; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUTCKE HA, 1987, EMBO J, V6, P43, DOI 10.1002/j.1460-2075.1987.tb04716.x; MA J, 1988, NATURE, V334, P631, DOI 10.1038/334631a0; Maniatis T., 1982, MOL CLONING; MARCOTTE WR, 1988, NATURE, V335, P454, DOI 10.1038/335454a0; MARCOTTE WR, 1989, PLANT CELL, V1, P969, DOI 10.2307/3868997; MCCARTY DR, 1989, DEV GENET, V10, P473, DOI 10.1002/dvg.1020100608; MCCARTY DR, 1989, PLANT CELL, V1, P523, DOI 10.1105/tpc.1.5.523; MCCARTY DR, 1991, PHYSIOL PLANTARUM, V81, P267, DOI 10.1111/j.1399-3054.1991.tb02140.x; McCarty DR, 1986, MAIZE GEN COOP NEWSL, V60, P61; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; NEILL SJ, 1986, PLANTA, V169, P87, DOI 10.1007/BF01369779; NEILL SJ, 1987, PLANTA, V171, P358, DOI 10.1007/BF00398681; OLESEN JT, 1990, GENE DEV, V4, P1714, DOI 10.1101/gad.4.10.1714; PAZARES J, 1987, EMBO J, V6, P3553, DOI 10.1002/j.1460-2075.1987.tb02684.x; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; PELLETT PE, 1985, P NATL ACAD SCI USA, V82, P5870, DOI 10.1073/pnas.82.17.5870; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; ROBERTSON DS, 1955, GENETICS, V40, P744; ROBICHAUD C, 1987, J PLANT PHYSIOL, V130, P181, DOI 10.1016/S0176-1617(87)80222-5; ROBICHAUD C, 1986, J PLANT PHYSIOL, V126, P235, DOI 10.1016/S0176-1617(86)80025-6; ROBICHAUD CS, 1980, DEV GENET, V1, P325, DOI 10.1002/dvg.1020010405; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SKRIVER K, 1990, PLANT CELL, V2, P503, DOI 10.1105/tpc.2.6.503; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; TRIEZENBERG SJ, 1988, GENE DEV, V2, P730, DOI 10.1101/gad.2.6.730; VASIL V, 1989, PLANT PHYSIOL, V91, P1575, DOI 10.1104/pp.91.4.1575; WILLIAMSON JD, 1988, PLANT PHYSIOL, V86, P208, DOI 10.1104/pp.86.1.208	56	547	603	2	51	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 6	1991	66	5					895	905		10.1016/0092-8674(91)90436-3	http://dx.doi.org/10.1016/0092-8674(91)90436-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GE460	1889090				2022-12-24	WOS:A1991GE46000009
J	REID, GS; ROBERTSON, AJ; BISSETT, C; SMITH, J; WAUGH, N; HALKERSTON, R				REID, GS; ROBERTSON, AJ; BISSETT, C; SMITH, J; WAUGH, N; HALKERSTON, R			CERVICAL SCREENING IN PERTH AND KINROSS SINCE INTRODUCTION OF THE NEW CONTRACT	BRITISH MEDICAL JOURNAL			English	Article								Objective-To determine changes in the cervical screening service since the introduction of the new general practitioner contract on 1 April 1990. Design-Analysis of computerised records of cervical screening both before and after introduction of the new contract. Setting-General practices in Perth and Kinross Unit, Tayside. Patients-A total of 30 071 women aged 21-60 on 26 general practitioner partnership lists. Main outcome measures-Percentage average of target population for cervical screening in each practice for first three quarters on introduction of the contract. Results-Perth and Kinross Unit completed a computerised cervical screening call programme in July 1989, which produced an increase from 71% to 78% in the mean percentage of women aged 20-60 who had had cervical smear tests within 5.5 years. Six months after the introduction of the new general practitioner contract the mean population coverage was increased to 85% in women aged 21-60 and only four practices had not attained the 80% upper target compared with 10 on 1 April 1990. Detailed examination of randomly selected practices immediately before the new contract was introduced showed an average artificial list inflation of 4.3% in health board records when compared with practice records, a hysterectomy rate of 6.2%, and an additional 3% of women who were considered to be ineligible for smear testing due to putative virginity or illness or infirmity, or both. There was a considerable shift away from use of well woman clinics (2.7% of smears in 1990 compared with 5.6% in 1988) for taking cervical smears, potentially threatening the long term viability of the clinics. Conclusion-The introduction of the new contract for general practitioners has brought about a further sustained increase in population coverage for cervical screening in a small Scottish unit with a stable population, well motivated general practitioners, and a fully integrated computerised call and recall system based on the community health index. To optimise the screening service revision of the targets levels is necessary.	PERTH ROYAL INFIRM,DEPT PATHOL,PERTH PH1 1NX,SCOTLAND; TAYSIDE HLTH BOARD,DEPT PUBL HLTH MED,DUNDEE,SCOTLAND; MARYFIELD HOSP,E COAST SCOTLAND COMP CONSORTIUM,DUNDEE,SCOTLAND									CHAMBERLAIN J, 1984, BRIT MED J, V289, P853, DOI 10.1136/bmj.289.6449.853; CHOMET J, 1990, BRIT MED J, V300, P1504, DOI 10.1136/bmj.300.6738.1504; GEMMELL J, 1990, BRIT J OBSTET GYNAEC, V97, P58, DOI 10.1111/j.1471-0528.1990.tb01717.x; Robertson A J, 1990, Cytopathology, V1, P3, DOI 10.1111/j.1365-2303.1990.tb00320.x; SEFTON C, 1990, PULSE            DEC, P41; SHROFF KJ, 1988, BRIT MED J, V297, P1317, DOI 10.1136/bmj.297.6659.1317; WAUGH NR, 1990, BRIT MED J, V301, P238, DOI 10.1136/bmj.301.6745.238; 1986, STATEMENT FEES ALLOW; 1985, CERVICAL CANCER SCRE; 1985, LANCET, V2, P363; 1988, CERVICAL CANCER SCRE; 1988, HLTH B EDINB, V46, P146; 1990, STATEMENT FEES ALLOW, P57	13	20	20	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 24	1991	303	6800					447	450		10.1136/bmj.303.6800.447	http://dx.doi.org/10.1136/bmj.303.6800.447			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GC465	1912838	Green Published, Bronze			2022-12-24	WOS:A1991GC46500018
J	FINBERG, RW; WAHL, SM; ALLEN, JB; SOMAN, G; STROM, TB; MURPHY, JR; NICHOLS, JC				FINBERG, RW; WAHL, SM; ALLEN, JB; SOMAN, G; STROM, TB; MURPHY, JR; NICHOLS, JC			SELECTIVE ELIMINATION OF HIV-1-INFECTED CELLS WITH AN INTERLEUKIN-2 RECEPTOR SPECIFIC CYTOTOXIN	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HIV-INFECTED CELLS; FUSION PROTEIN; DIPHTHERIA-TOXIN; ENVELOPE GLYCOPROTEIN; LYMPHOCYTES; ACTIVATION; ENTRY; MONOCYTES; CD4	Infection by human immunodeficiency virus type 1 (HIV-1) is associated with cellular activation and expression of the interleukin-2 (IL-2) receptor. A genetically engineered fusion toxin, DAB486 IL-2, that contains the enzymatic site and translocation domain of diphtheria toxin and the receptor binding domain of IL-2 specifically kills cells that express high-affinity IL-2 receptors. This toxin selectively eliminated the HIV-1-infected cells from mixed cultures of infected and uninfected cells and inhibited production of viral proteins and infectious virus. Thus, cellular activation antigens present a target for early antiviral intervention.	SERAGEN,HOPKINTON,MA 01748; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; NIDR,IMMUNOL LAB,BETHESDA,MD 20892; BETH ISRAEL HOSP,CHARLES A DANA RES INST,BOSTON,MA 02215; HARVARD UNIV,BETH ISRAEL HOSP,THORNDIKE LAB,BOSTON,MA 02215; BETH ISRAEL HOSP,DEPT MED,BOSTON,MA 02215; BOSTON UNIV MED,BOSTON UNIV HOSP,BOSTON,MA 02118	Harvard University; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Boston University	FINBERG, RW (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,INFECT DIS LAB,BOSTON,MA 02115, USA.		Finberg, Robert W/E-3323-2010					ALLEN JB, 1990, J CLIN INVEST, V85, P192, DOI 10.1172/JCI114412; CHAUDHARY VK, 1988, NATURE, V335, P369, DOI 10.1038/335369a0; DAAR ES, 1990, P NATL ACAD SCI USA, V87, P6574, DOI 10.1073/pnas.87.17.6574; FAUCI AS, 1988, SCIENCE, V239, P617, DOI 10.1126/science.3277274; FIELDS AP, 1988, NATURE, V333, P278, DOI 10.1038/333278a0; FINBERG RW, UNPUB; GARTNER S, 1986, SCIENCE, V233, P215, DOI 10.1126/science.3014648; GEYER SJ, 1989, 5TH INT C AIDS INT A, P636; GOWDA SD, 1989, J IMMUNOL, V142, P773; HAREGEWOIN A, 1989, NATURE, V340, P309, DOI 10.1038/340309a0; HORAK ID, 1990, NATURE, V348, P557, DOI 10.1038/348557a0; KIRKMAN RL, 1989, TRANSPLANTATION, V47, P327, DOI 10.1097/00007890-198902000-00028; KIYOKAWA T, 1989, CANCER RES, V49, P4042; KORNFELD H, 1988, NATURE, V335, P445, DOI 10.1038/335445a0; LEMAISTRE F, 1990, BLOOD, V76, pA314; MIOSSEC P, 1990, ARTHRITIS RHEUM, V33, P1688, DOI 10.1002/art.1780331112; MITTLER RS, 1989, SCIENCE, V245, P1380, DOI 10.1126/science.2571187; Nichols Johanna, UNPUB; PANKEWYCZ O, 1989, TRANSPLANTATION, V47, P318, DOI 10.1097/00007890-198902000-00026; RIECKMANN P, 1991, J EXP MED, V173, P1, DOI 10.1084/jem.173.1.1; SPIRA TJ, 1987, J CLIN MICROBIOL, V25, P97, DOI 10.1128/JCM.25.1.97-99.1987; TILL MA, 1988, SCIENCE, V242, P1166, DOI 10.1126/science.2847316; WAHL LM, 1984, CELL IMMUNOL, V85, P373, DOI 10.1016/0008-8749(84)90251-X; WAHL SM, 1989, J IMMUNOL, V142, P3553; WATERS CA, 1990, EUR J IMMUNOL, V20, P785, DOI 10.1002/eji.1830200412; WILLIAMS DP, 1987, PROTEIN ENG, V1, P493, DOI 10.1093/protein/1.6.493; WOODWORTH T, 1991, 4TH INT C HUM RETR M; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L	28	49	52	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 21	1991	252	5013					1703	1705		10.1126/science.1904628	http://dx.doi.org/10.1126/science.1904628			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FT114	1904628				2022-12-24	WOS:A1991FT11400045
J	WILSON, DK; RUDOLPH, FB; QUIOCHO, FA				WILSON, DK; RUDOLPH, FB; QUIOCHO, FA			ATOMIC-STRUCTURE OF ADENOSINE-DEAMINASE COMPLEXED WITH A TRANSITION-STATE ANALOG - UNDERSTANDING CATALYSIS AND IMMUNODEFICIENCY MUTATIONS	SCIENCE			English	Article							POINT MUTATION; XANTHINE-OXIDASE; ESCHERICHIA-COLI; INHIBITORS; PROTEIN; BINDING; IDENTIFICATION; EXPRESSION; TRANSPORT; CRYSTALLOGRAPHY	The crystal structure of a murine adenosine deaminase complexed with 6-hydroxyl-1,6-dihydropurine ribonucleoside, a nearly ideal transition-state analog, has been determined and refined at 2.4 angstrom resolution. The structure is folded as an eight-stranded parallel alpha/beta-barrel with a deep pocket at the beta-barrel COOH-terminal end wherein the inhibitor and a zinc are bound and completely sequestered. The presence of the zinc cofactor and the precise structure of the bound analog were not previously known. The 6R isomer of the analog is very tightly held in place by the coordination of the 6-hydroxyl to the zinc and the formation of nine hydrogen bonds. On the basis of the structure of the complex a stereoselective addition-elimination or S(N)2 mechanism of the enzyme is proposed with the zinc atom and the Glu and Asp residues playing key roles. A molecular explanation of a hereditary disease caused by several point mutations of an enzyme is also presented.	BAYLOR UNIV,HOWARD HUGHES MED INST,HOUSTON,TX 77030; RICE UNIV,DEPT BIOCHEM & CELL BIOL,HOUSTON,TX 77005	Baylor University; Howard Hughes Medical Institute; Rice University					NATIONAL CANCER INSTITUTE [R01CA014030] Funding Source: NIH RePORTER; NCI NIH HHS [CA14030] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGARWAL RP, 1982, PHARMACOL THERAPEUT, V17, P399, DOI 10.1016/0163-7258(82)90023-7; AKESON AL, 1987, P NATL ACAD SCI USA, V84, P5947, DOI 10.1073/pnas.84.16.5947; AKESON AL, 1989, J CELL BIOCHEM, V39, P217, DOI 10.1002/jcb.240390302; AKESON AL, 1988, J BIOL CHEM, V263, P16291; ASHTON D, 1987, EUR J PHARMACOL, V142, P403, DOI 10.1016/0014-2999(87)90079-3; BONTHRON DT, 1985, J CLIN INVEST, V76, P894, DOI 10.1172/JCI112050; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CHA S, 1975, BIOCHEM PHARMACOL, V24, P2187, DOI 10.1016/0006-2952(75)90051-9; CHANG Z, 1991, BIOCHEMISTRY-US, V30, P2273, DOI 10.1021/bi00222a033; CHINSKY JM, 1990, DIFFERENTIATION, V42, P172, DOI 10.1111/j.1432-0436.1990.tb00759.x; CHRISTIANSON DW, 1989, ACCOUNTS CHEM RES, V22, P62, DOI 10.1021/ar00158a003; COOPER BT, UNPUB; COWAN MJ, 1983, P NATL ACAD SCI USA, V83, P1089; DAWICKI DD, 1988, BIOCHEM PHARMACOL, V37, P621, DOI 10.1016/0006-2952(88)90134-7; EVANS BE, 1973, BIOCHEMISTRY-US, V12, P392, DOI 10.1021/bi00727a005; FARBER GK, 1990, TRENDS BIOCHEM SCI, V15, P228, DOI 10.1016/0968-0004(90)90035-A; FRICK L, 1987, BIOORG CHEM, V15, P100, DOI 10.1016/0045-2068(87)90011-3; GAN TE, 1987, BLOOD, V69, P1376; GLAZER RI, 1980, CANCER CHEMOTH PHARM, V4, P227; GROSS RL, 1980, PHYSIOL REV, V60, P188, DOI 10.1152/physrev.1980.60.1.188; HAMPTON A, 1972, BIOCHEMISTRY-US, V11, P4736, DOI 10.1021/bi00775a016; Harrison MP., UNPUB; HIRSCHHORN R, 1989, J CLIN INVEST, V83, P497, DOI 10.1172/JCI113909; HONG L, 1991, BIOL REPROD, V44, P83, DOI 10.1095/biolreprod44.1.83; IKEHARA M, 1974, BIOCHIM BIOPHYS ACTA, V338, P512, DOI 10.1016/0304-4165(74)90313-4; IKEHARA M, 1972, BIOCHIM BIOPHYS ACTA, V11, P4736; JONES W, 1989, BIOCHEMISTRY-US, V28, P12242; KANNO H, 1988, JPN J EXP MED, V58, P1; KATI WM, 1989, SCIENCE, V243, P1591, DOI 10.1126/science.2928795; KREDICH NM, 1989, METABOLIC BASIS INHE, P1045; KURZ LC, 1987, BIOCHEMISTRY-US, V26, P8450, DOI 10.1021/bi00399a063; KURZ LC, 1983, BIOCHEMISTRY-US, V22, P382, DOI 10.1021/bi00271a023; KURZ LC, 1980, BIOCHEMISTRY-US, V19, P1616; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LEE PC, 1973, DEV BIOL, V31, P227, DOI 10.1016/0012-1606(73)90259-5; LOLIS E, 1990, ANNU REV BIOCHEM, V59, P597, DOI 10.1146/annurev.bi.59.070190.003121; MAQUIRE MH, 1971, EUR J BIOCHEM, V23, P22; MARTIN DW, 1981, ANNU REV BIOCHEM, V50, P845, DOI 10.1146/annurev.bi.50.070181.004213; MATTHEWS BW, 1988, ACCOUNTS CHEM RES, V21, P333, DOI 10.1021/ar00153a003; Mcilwain H., 1983, CENTRAL NERVOUS SYST, P3; MILLER DM, 1983, J BIOL CHEM, V258, P3665; ORSI BA, 1972, BIOCHEMISTRY-US, V11, P3386, DOI 10.1021/bi00768a011; QUIOCHO FA, 1989, NATURE, V340, P404, DOI 10.1038/340404a0; RENOUF JA, 1989, CLIN CHEM, V35, P1478; SACK JS, 1988, J MOL GRAPHICS, V6, P224, DOI 10.1016/S0263-7855(98)80040-4; SAWA T, 1967, J ANTIBIOT, V20, P317; SCHRAMM VL, 1985, BIOCHEMISTRY-US, V24, P641, DOI 10.1021/bi00324a016; VALERIO D, 1986, EMBO J, V5, P113, DOI 10.1002/j.1460-2075.1986.tb04184.x; VYAS NK, 1988, SCIENCE, V242, P1290, DOI 10.1126/science.3057628; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WEISS PM, 1987, BIOCHEMISTRY-US, V26, P7378, DOI 10.1021/bi00397a027; WILSON DJ, UNPUB; WILSON DK, 1988, J MOL BIOL, V200, P613, DOI 10.1016/0022-2836(88)90549-9; WOLFENDEN R, 1967, J BIOL CHEM, V242, P977; WOLFENDEN R, 1969, BIOCHEMISTRY-US, V8, P2412, DOI 10.1021/bi00834a024; WOLFENDEN R, 1969, BIOCHEMISTRY-US, V16, P5071; WOO PWK, 1974, J HETEROCYCLIC CHEM, V11, P641, DOI 10.1002/jhet.5570110438; YEUNG CY, 1985, J BIOL CHEM, V260, P299; ZIELKE CL, 1971, ENZYMES, V4, P47	60	454	464	1	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 31	1991	252	5010					1278	1284		10.1126/science.1925539	http://dx.doi.org/10.1126/science.1925539			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FN857	1925539				2022-12-24	WOS:A1991FN85700031
J	BARDWELL, VJ; WICKENS, M; BIENROTH, S; KELLER, W; SPROAT, BS; LAMOND, AI				BARDWELL, VJ; WICKENS, M; BIENROTH, S; KELLER, W; SPROAT, BS; LAMOND, AI			SITE-DIRECTED RIBOSE METHYLATION IDENTIFIES 2'-OH GROUPS IN POLYADENYLATION SUBSTRATES CRITICAL FOR AAUAAA RECOGNITION AND POLY(A) ADDITION	CELL			English	Article							RNA INTERACTIONS; CLEAVAGE; INVITRO; POLYMERASE; SNRNP; OLIGONUCLEOTIDES; SEQUENCE	The importance of sugar contacts for the sequence-specific recognition that occurs during polyadenylation of mRNAs was investigated with chemically synthesized substrates containing 2'-O-CH3 groups at selected riboses. An RNA (5'-CUGCAAUAAACAAGUUAA-3') with 2'-O-CH3 ribose at each nucleotide except for the AAUAAA sequence and 3'-terminal adenosine was efficiently polyadenylated in vitro. Methylation of single riboses within AAUAAA inhibited both poly(A) addition and binding of the specificity factor, but the magnitude of inhibition varied greatly at different nucleotides. Nucleotides that showed sensitivity to base substitutions did not necessarily show sensitivity to ribose methylation, and vice versa. The data indicate that the specificity factor interacts with AAUAAA through RNA-protein contacts involving essential recognition of both sugars and bases at different nucleotide positions.	UNIV WISCONSIN,COLL AGR & LIFE SCI,DEPT BIOCHEM,MADISON,WI 53706; UNIV WISCONSIN,COLL AGR & LIFE SCI,MOLEC BIOL PROGRAM,MADISON,WI 53706; UNIV BASEL,BIOCTR,CH-4056 BASEL,SWITZERLAND; EUROPEAN MOLEC BIOL LAB,W-6900 HEIDELBERG,GERMANY	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Basel; European Molecular Biology Laboratory (EMBL)				Lamond, Angus/0000-0001-6204-6045	NIGMS NIH HHS [GM31892, GM00521] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031892, K04GM000521, R37GM031892] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARABINO SML, 1990, CELL, V63, P293, DOI 10.1016/0092-8674(90)90162-8; BARABINO SML, 1989, EMBO J, V8, P4171, DOI 10.1002/j.1460-2075.1989.tb08602.x; BARDWELL VJ, 1990, MOL CELL BIOL, V10, P295, DOI 10.1128/MCB.10.1.295; BARDWELL VJ, 1990, MOL CELL BIOL, V10, P846, DOI 10.1128/MCB.10.2.846; BEIJER B, 1990, NUCLEIC ACIDS RES, V18, P5143, DOI 10.1093/nar/18.17.5143; BLENCOWE BJ, 1989, CELL, V59, P531, DOI 10.1016/0092-8674(89)90036-6; BOBST AM, 1969, J MOL BIOL, V46, P221, DOI 10.1016/0022-2836(69)90418-5; CHRISTOFORI G, 1988, CELL, V54, P875, DOI 10.1016/S0092-8674(88)91263-9; CHRISTOFORI G, 1989, MOL CELL BIOL, V9, P193, DOI 10.1128/MCB.9.1.193; GILMARTIN GM, 1989, GENE DEV, V3, P2180, DOI 10.1101/gad.3.12b.2180; HINGERTY B, 1974, BIOCHEM BIOPH RES CO, V61, P875, DOI 10.1016/0006-291X(74)90237-X; HOLMES KC, 1980, TRENDS BIOCHEM SCI, V5, P4, DOI 10.1016/S0968-0004(80)80066-1; HUMPHREY T, 1987, EMBO J, V6, P4159, DOI 10.1002/j.1460-2075.1987.tb02762.x; INOUE H, 1987, NUCLEIC ACIDS RES, V15, P6131, DOI 10.1093/nar/15.15.6131; LESLIE AGW, 1978, J MOL BIOL, V119, P399, DOI 10.1016/0022-2836(78)90222-X; Maniatis T., 1982, MOL CLONING; MOORE CL, 1988, EMBO J, V7, P3159, DOI 10.1002/j.1460-2075.1988.tb03183.x; MOORE CL, 1985, CELL, V41, P845, DOI 10.1016/S0092-8674(85)80065-9; RYNER LC, 1989, MOL CELL BIOL, V9, P4229, DOI 10.1128/MCB.9.10.4229; SHEETS MD, 1987, MOL CELL BIOL, V7, P1518, DOI 10.1128/MCB.7.4.1518; SHEETS MD, 1990, NUCLEIC ACIDS RES, V18, P5799, DOI 10.1093/nar/18.19.5799; SPROAT BS, 1989, NUCLEIC ACIDS RES, V17, P3373, DOI 10.1093/nar/17.9.3373; TAKAGAKI Y, 1988, CELL, V52, P731, DOI 10.1016/0092-8674(88)90411-4; WAHLE E, 1991, IN PRESS J BIOL CHEM; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P277, DOI 10.1016/0968-0004(90)90054-F; WIGLEY PL, 1990, MOL CELL BIOL, V10, P1705, DOI 10.1128/MCB.10.4.1705; ZARKOWER D, 1987, EMBO J, V6, P177, DOI 10.1002/j.1460-2075.1987.tb04736.x; ZMUDZKA B, 1969, BIOCHEM BIOPH RES CO, V37, P895, DOI 10.1016/0006-291X(69)90215-0	28	60	60	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 5	1991	65	1					125	133		10.1016/0092-8674(91)90414-T	http://dx.doi.org/10.1016/0092-8674(91)90414-T			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FF773	1901516				2022-12-24	WOS:A1991FF77300015
J	RAUB, W				RAUB, W			THERAPY APPEARS SAFE, EFFECTIVE AGAINST SPONTANEOUS ANIMAL TUMORS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											RAUB, W (corresponding author), NIH,BLDG 31,ROOM 2B23,BETHESDA,MD 20892, USA.							1991, J NATL CANCER I, V83, P18	1	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 3	1991	265	13					1633	1633						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD659	1900541				2022-12-24	WOS:A1991FD65900003
J	GUTHRIE, PB; SEGAL, M; KATER, SB				GUTHRIE, PB; SEGAL, M; KATER, SB			INDEPENDENT REGULATION OF CALCIUM REVEALED BY IMAGING DENDRITIC SPINES	NATURE			English	Article							LONG-TERM POTENTIATION; SYNAPTIC TRANSMISSION; PYRAMIDAL CELLS; HIPPOCAMPAL; NEURONS; ACCUMULATION; 4-AMINOPYRIDINE; STIMULATION; ENHANCEMENT; MICROSCOPY	THE dendritic spine is a basic structural unit of neuronal organization. It is assumed to be a primary locus of synaptic plasticity, and to undergo long-term morphological and functional changes 1-6, at least some of which are regulated by intracellular calcium concentrations 7-11. It is known that physiological stimuli can cause marked increases in intracellular calcium levels in hippocampal dendritic shafts 12,13, but it is completely unknown to what extent such changes in the dendrites would also be seen by calcium-sensing structures within spines. Will calcium levels in all spines change in parallel with the dendrite or will there be a heterogeneous response? This study, through direct visualization and measurement of intracellular calcium concentrations in individual living spines, demonstrates that experimentally evoked changes in calcium concentrations in the dendritic shaft ([Ca2+]d) are frequently not parallelled in the spine ([Ca2+]s). This isolation is not caused by a physical diffusion barrier. This report provides, to our knowledge, the first direct demonstration of autonomous spine function.	COLORADO STATE UNIV, DEPT ANAT & NEUROBIOL, PROGRAM NEURONAL GROWTH & DEV, FT COLLINS, CO USA; WEIZMANN INST SCI, CTR NEUROSCI, IL-76100 REHOVOT, ISRAEL	Colorado State University; Weizmann Institute of Science			SEGAL, MENAHEM/K-1577-2012					ANDREWS SB, 1988, P NATL ACAD SCI USA, V85, P1682, DOI 10.1073/pnas.85.5.1682; BENTLEY D, 1991, J NEUROSCI, V11, P1300; Brown T.H., 1989, NEURAL MODELS PLASTI, P266; BUCKLE PJ, 1982, J PHYSIOL-LONDON, V326, P109, DOI 10.1113/jphysiol.1982.sp014180; CONNOR JA, 1986, P NATL ACAD SCI USA, V83, P6179, DOI 10.1073/pnas.83.16.6179; COSS RG, 1985, BEHAV NEURAL BIOL, V44, P151, DOI 10.1016/S0163-1047(85)90170-0; FIFKOVA E, 1989, ANN NY ACAD SCI, V568, P131; FIFKOVA E, 1985, CELL MOL NEUROBIOL, V5, P47, DOI 10.1007/BF00711085; FIFKOVA E, 1983, BRAIN RES, V266, P163, DOI 10.1016/0006-8993(83)91322-7; FIFKOVA E, 1977, J NEUROCYTOL, V6, P211, DOI 10.1007/BF01261506; GAMBLE E, 1987, SCIENCE, V236, P1311, DOI 10.1126/science.3495885; HARRIS KM, 1989, J NEUROSCI, V9, P2982; HOLMES WR, 1990, J NEUROPHYSIOL, V63, P1148, DOI 10.1152/jn.1990.63.5.1148; KAWATO M, 1983, J THEOR BIOL, V103, P507, DOI 10.1016/0022-5193(83)90280-1; LEVRAM V, 1987, BIOPHYS J, V52, P571, DOI 10.1016/S0006-3495(87)83246-0; LYNCH G, 1983, NATURE, V305, P719, DOI 10.1038/305719a0; MALENKA RC, 1988, SCIENCE, V242, P81, DOI 10.1126/science.2845577; MATTSON MP, 1990, DEV BRAIN RES, V52, P201, DOI 10.1016/0165-3806(90)90236-R; MATTSON MP, 1988, J NEUROSCI RES, V20, P331, DOI 10.1002/jnr.490200307; MILLER JP, 1985, BRAIN RES, V325, P325, DOI 10.1016/0006-8993(85)90333-6; PONGRACZ F, 1985, NEUROSCIENCE, V15, P933, DOI 10.1016/0306-4522(85)90244-1; REGEHR WG, 1990, NATURE, V345, P807, DOI 10.1038/345807a0; REGEHR WG, 1989, NATURE, V341, P533, DOI 10.1038/341533a0; SEGAL M, 1984, J NEUROSCI, V4, P604; SEGAL M, 1987, BRAIN RES, V414, P285, DOI 10.1016/0006-8993(87)90008-4; SEGEV I, 1988, J NEUROPHYSIOL, V60, P499, DOI 10.1152/jn.1988.60.2.499; SHEPHERD GM, 1985, P NATL ACAD SCI USA, V82, P2192, DOI 10.1073/pnas.82.7.2192; SMITH SJ, 1983, NATURE, V304, P350, DOI 10.1038/304350a0; TSIEN RY, 1985, CELL CALCIUM, V6, P145, DOI 10.1016/0143-4160(85)90041-7; WICKENS J, 1988, PROG NEUROBIOL, V31, P507, DOI 10.1016/0301-0082(88)90013-5; WILLIAMS S, 1989, NEURON, V3, P583, DOI 10.1016/0896-6273(89)90268-7; WINSLOW RL, 1989, P NATL ACAD SCI USA, V86, P387, DOI 10.1073/pnas.86.1.387	32	216	217	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 7	1991	354	6348					76	80		10.1038/354076a0	http://dx.doi.org/10.1038/354076a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GN829	1944573				2022-12-24	WOS:A1991GN82900062
J	TELFER, JC; RUDD, CE				TELFER, JC; RUDD, CE			A 32-KD GTP-BINDING PROTEIN ASSOCIATED WITH THE CD4-P56LCK AND CD8-P56LCK T-CELL RECEPTOR COMPLEXES	SCIENCE			English	Article							TYROSINE KINASE P56LCK; HUMAN LYMPHOCYTES-T; PHOSPHOLIPASE-C; CROSS-LINKING; ACTIVATION; CD4; RAS; POLYPEPTIDES; PRODUCT	The guanosine triphosphate (GTP)-binding proteins include signal-transducing heterotrimeric G proteins (for example, G(s), G(i)), smaller GTP-binding proteins that function in protein sorting, and the oncogenic protein p21(ras). The T cell receptor complexes CD4-p56lck and CD8-p56lck were found to include a 32- to 33-kilodalton phosphoprotein (p32) that was recognized by an antiserum to a consensus GTP-binding region in G proteins. Immununoprecipitated CD4 and CD8 complexes bound GTP and hydrolyzed it to guanosine diphosphate (GDP). The p32 protein was covalently linked to [alpha-P-32]GTP by ultraviolet photoaffinity labeling. These results demonstrate an interaction between T cell receptor complexes and an intracellular GTP-binding protein.	HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DIV TUMOR IMMUNOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School			Rudd, Christopher E/GOH-2021-2022; Rudd, Christopher E/ABF-7259-2021	Rudd, Christopher E/0000-0001-5295-9019; 				ANDERSON P, 1987, J IMMUNOL, V139, P678; BARBER EK, 1989, P NATL ACAD SCI USA, V86, P3277, DOI 10.1073/pnas.86.9.3277; BURGESS KE, 1991, EUR J IMMUNOL, V21, P1663, DOI 10.1002/eji.1830210712; CARNEY WP, 1989, HUMAN TUMOR ANTIGENS, P53; CASEY PJ, 1990, J BIOL CHEM, V265, P2383; CHURCH JG, 1988, J BIOL CHEM, V263, P4242; COCKCROFT S, 1985, NATURE, V314, P534, DOI 10.1038/314534a0; DISANTO JP, 1987, LEUCOCYTE TYPING 3 W, P210; EICHMANN K, 1987, EUR J IMMUNOL, V17, P643, DOI 10.1002/eji.1830170510; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; HARNETT MM, 1988, IMMUNOL TODAY, V9, P315, DOI 10.1016/0167-5699(88)91325-4; LETOURNEUR F, 1990, P NATL ACAD SCI USA, V87, P2339, DOI 10.1073/pnas.87.6.2339; MEUER SC, 1984, CELL, V36, P897, DOI 10.1016/0092-8674(84)90039-4; MEUER SC, 1982, P NATL ACAD SCI-BIOL, V79, P4395, DOI 10.1073/pnas.79.14.4395; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PESSAMORIKAWA T, 1990, J IMMUNOL, V144, P2690; RUDD CE, 1990, IMMUNOL TODAY, V11, P400, DOI 10.1016/0167-5699(90)90159-7; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; RUDD CE, 1985, J BIOL CHEM, V260, P1927; SCHMIDT RE, 1985, NATURE, V318, P289, DOI 10.1038/318289a0; SMITH CD, 1986, SCIENCE, V232, P97, DOI 10.1126/science.3006254; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SWEET RW, 1984, NATURE, V311, P273, DOI 10.1038/311273a0; TELFER J, UNPUB; VEILLETTE A, 1988, ONCOGENE RES, V2, P385; VIELLETTE A, 1988, CELL, V55, P301; WANG P, 1989, J BIOCHEM-TOKYO, V105, P461, DOI 10.1093/oxfordjournals.jbchem.a122687; ZAMOYSKA R, 1989, NATURE, V342, P278, DOI 10.1038/342278a0	30	70	71	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 18	1991	254	5030					439	441		10.1126/science.1925604	http://dx.doi.org/10.1126/science.1925604			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GK729	1925604				2022-12-24	WOS:A1991GK72900052
J	FRANCO, B; GUIOLI, S; PRAGLIOLA, A; INCERTI, B; BARDONI, B; TONLORENZI, R; CARROZZO, R; MAESTRINI, E; PIERETTI, M; TAILLONMILLER, P; BROWN, CJ; WILLARD, HF; LAWRENCE, C; PERSICO, MG; CAMERINO, G; BALLABIO, A				FRANCO, B; GUIOLI, S; PRAGLIOLA, A; INCERTI, B; BARDONI, B; TONLORENZI, R; CARROZZO, R; MAESTRINI, E; PIERETTI, M; TAILLONMILLER, P; BROWN, CJ; WILLARD, HF; LAWRENCE, C; PERSICO, MG; CAMERINO, G; BALLABIO, A			A GENE DELETED IN KALLMANNS SYNDROME SHARES HOMOLOGY WITH NEURAL CELL-ADHESION AND AXONAL PATH-FINDING MOLECULES	NATURE			English	Article							AMINO-ACID-SEQUENCE; SYNDROME HYPOGONADOTROPIC HYPOGONADISM; HUMAN X-CHROMOSOME; DISTAL SHORT ARM; IMMUNOGLOBULIN SUPERFAMILY; STEROID SULFATASE; TYROSINE KINASE; MESSENGER-RNA; Y-CHROMOSOME; CDNA CLONE	Kallmann's syndrome (clinically characterized by hypogonadotropic hypogonadism and inability to smell) is caused by a defect in the migration of olfactory neurons, and neurons producing hypothalamic gonadotropin-releasing hormone. A gene has now been isolated from the critical region on Xp22.3 to which the syndrome locus has been assigned: this gene escapes X inactivation, has a homologue on the Y chromosome, and shows an unusual pattern of conservation across species. The predicted protein has significant similarities with proteins involved in neural cell adhesion and axonal pathfinding, as well as with protein kinases and phosphatases, which suggests that this gene could have a specific role in neuronal migration.	BAYLOR COLL MED,INST MOLEC GENET,1 BAYLOR PLAZA,HOUSTON,TX 77030; INST G GASLINI,GENOA,ITALY; NAPLES UNIV,DEPT PEDIAT,I-80138 NAPLES,ITALY; BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030; INT INST GENET & BIOPHYS,I-80125 NAPLES,ITALY; WASHINGTON UNIV,SCH MED,CTR GENET MED,ST LOUIS,MO 63110; STANFORD UNIV,MED CTR,SCH MED,DEPT GENET,STANFORD,CA 94305; IST BIOCHIM GENET EVOLUZION ST,PAVIA,ITALY	Baylor College of Medicine; University of Genoa; IRCCS Istituto Giannina Gaslini; University of Naples Federico II; Baylor College of Medicine; Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR); Washington University (WUSTL); Stanford University			BALLABIO, Andrea/AAL-2672-2020; Bardoni, Barbara/F-9918-2013; Maestrini, Elena/K-7508-2012; Tonlorenzi, Rossana/AAN-2241-2020; Brown, Carolyn J/A-5159-2014; FRANCO, Brunella/S-2882-2018	BALLABIO, Andrea/0000-0003-1381-4604; Maestrini, Elena/0000-0001-5924-3179; Brown, Carolyn J/0000-0002-8959-0101; Bardoni, Barbara/0000-0001-6411-1517; Guioli, Silvana/0000-0002-4920-7745; FRANCO, Brunella/0000-0001-5588-4569; Tonlorenzi, Rossana/0000-0002-6060-8208				BALLABIO A, 1989, ANN HUM GENET, V53, P9, DOI 10.1111/j.1469-1809.1989.tb01117.x; BALLABIO A, 1986, HUM GENET, V72, P237, DOI 10.1007/BF00291885; BALLABIO A, 1990, GENOMICS, V8, P263, DOI 10.1016/0888-7543(90)90281-X; BARDONI B, 1991, GENOMICS, V11, P443, DOI 10.1016/0888-7543(91)90153-6; BARDONI B, 1988, Genomics, V3, P32, DOI 10.1016/0888-7543(88)90155-3; BASLER K, 1988, CELL, V54, P299; BENIAN GM, 1989, NATURE, V342, P45, DOI 10.1038/342045a0; BIEBER AJ, 1989, CELL, V59, P447, DOI 10.1016/0092-8674(89)90029-9; BIRCHMEIER C, 1990, P NATL ACAD SCI USA, V87, P4799, DOI 10.1073/pnas.87.12.4799; BORSANI G, 1991, NATURE, V351, P325, DOI 10.1038/351325a0; BRESLOW EA, 1979, REV BIOCH, V48, P251; BROWN CJ, 1991, NATURE, V349, P882; CARLE GF, 1984, NUCLEIC ACIDS RES, V12, P5647, DOI 10.1093/nar/12.14.5647; DEAR TN, 1988, CANCER RES, V48, P5203; DODD J, 1988, SCIENCE, V242, P692, DOI 10.1126/science.3055291; DRENTH J, 1980, J BIOL CHEM, V255, P2652; EINHEBER S, 1990, P NATL ACAD SCI USA, V87, P2157, DOI 10.1073/pnas.87.6.2157; ELKINS T, 1990, CELL, V60, P565, DOI 10.1016/0092-8674(90)90660-7; FISHER EH, 1991, SCIENCE, V253, P401; FRASER N, 1987, DEVELOPMENT, V101, P127; FURLEY AJ, 1990, CELL, V61, P157, DOI 10.1016/0092-8674(90)90223-2; GENNARINI G, 1989, J CELL BIOL, V109, P775, DOI 10.1083/jcb.109.2.775; GREEN ED, 1990, P NATL ACAD SCI USA, V87, P1213, DOI 10.1073/pnas.87.3.1213; GUERRIERO V, 1986, BIOCHEMISTRY-US, V25, P8372, DOI 10.1021/bi00374a007; HENNINGHAUSEN LG, 1982, NUCLEIC ACIDS RES, V10, P3733, DOI 10.1093/nar/10.12.3733; HERMANUSSEN M, 1985, CLIN GENET, V28, P106; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; Kallmann FJ, 1944, AM J MENT DEF, V48, P203; KATO I, 1979, FED PROC, V38, P832; KEITGES E, 1985, NATURE, V315, P226, DOI 10.1038/315226a0; KORNBLIHTT AR, 1985, EMBO J, V4, P1755, DOI 10.1002/j.1460-2075.1985.tb03847.x; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KRAMER H, 1991, NATURE, V352, P207, DOI 10.1038/352207a0; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANDER AD, 1989, TRENDS NEUROSCI, V12, P189, DOI 10.1016/0166-2236(89)90070-2; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; LIPKIN VM, 1989, FEBS LETT, V254, P69, DOI 10.1016/0014-5793(89)81011-7; MEITINGER T, 1990, AM J HUM GENET, V47, P664; MOOS M, 1988, NATURE, V334, P701, DOI 10.1038/334701a0; NELSON DL, 1991, P NATL ACAD SCI USA, V88, P6157, DOI 10.1073/pnas.88.14.6157; PETIT C, 1990, P NATL ACAD SCI USA, V87, P3680, DOI 10.1073/pnas.87.10.3680; PIERETTI M, 1991, NUCLEIC ACIDS RES, V19, P2795, DOI 10.1093/nar/19.10.2795; RANSCHT B, 1988, J CELL BIOL, V107, P1561, DOI 10.1083/jcb.107.4.1561; ROSS MT, 1990, GENOMICS, V6, P528, DOI 10.1016/0888-7543(90)90482-A; Sambrook J., 1989, MOL CLONING LAB MANU; SCHWANKHAUS JD, 1989, NEUROLOGY, V39, P223, DOI 10.1212/WNL.39.2.223; SCHWANZELFUKUDA M, 1989, MOL BRAIN RES, V6, P311, DOI 10.1016/0169-328X(89)90076-4; SHAPIRO LJ, 1979, SCIENCE, V204, P1224, DOI 10.1126/science.156396; SMALL SJ, 1987, J CELL BIOL, V105, P2335, DOI 10.1083/jcb.105.5.2335; STETLER G, 1986, NUCLEIC ACIDS RES, V14, P7883, DOI 10.1093/nar/14.20.7883; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; STREULI M, 1988, J EXP MED, V168, P1553; SUNOHARA N, 1986, ANN NEUROL, V19, P174, DOI 10.1002/ana.410190211; SUZUKI S, 1990, EMBO J, V9, P757, DOI 10.1002/j.1460-2075.1990.tb08170.x; WEGENKE JD, 1975, CLIN GENET, V7, P368; WHITE BJ, 1983, AM J MED GENET, V15, P417, DOI 10.1002/ajmg.1320150307; WIEDOW O, 1990, J BIOL CHEM, V265, P14791; WRAY S, 1989, P NATL ACAD SCI USA, V86, P8132, DOI 10.1073/pnas.86.20.8132; YEN PH, 1988, CELL, V55, P1123, DOI 10.1016/0092-8674(88)90257-7; YEN PH, 1990, CELL, V61, P603, DOI 10.1016/0092-8674(90)90472-Q	60	681	693	0	15	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 10	1991	353	6344					529	536		10.1038/353529a0	http://dx.doi.org/10.1038/353529a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GJ643	1922361				2022-12-24	WOS:A1991GJ64300057
J	KHOURI, RK; KOUDSI, B; REDDI, H				KHOURI, RK; KOUDSI, B; REDDI, H			TISSUE TRANSFORMATION INTO BONE INVIVO - A POTENTIAL PRACTICAL APPLICATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BIOLOGICAL PRINCIPLE; INDUCED OSTEOGENESIS; INDUCTIVE PROTEIN; RECONSTRUCTION; DIFFERENTIATION; DEFECTS; GRAFTS; REPAIR; RATS	The transformation of mesenchymal tissue, such as muscle, into cartilage and bone can be induced by the recently purified osteoinductive factor, osteogenin, and by its parent substratum, demineralized bone matrix. We investigated the possibility of transforming readily available muscle flaps into vascularized bone grafts of various shapes that could be used as skeletal replacement parts. In a rat experimental model, thigh adductor muscle island flaps were placed inside bivalved silicone rubber molds. Prior to closure of the mold, 18 flaps were injected with osteogenin and coated with demineralized bone matrix. Five flaps served as controls and were injected with the vehicle only, and not coated with demineralized bone matrix. The molds were implanted subcutaneously in the rats' flanks and reopened 10 days later. The control flaps consisted of intact muscle without any evidence of tissue transformation, whereas the flaps treated with osteogenin and demineralized bone matrix were entirely transformed into cancellous bone that matched the exact shape of the mold. Using tissue transformation, we were able to generate in vivo, autogenous, well-perfused bones in the shapes of femoral heads and mandibles.	NIDR,BONE CELL BIOL SECT,BETHESDA,MD 20892; WASHINGTON UNIV,SCH MED,PLAST SURG RES LAB,ST LOUIS,MO 63110	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Washington University (WUSTL)	KHOURI, RK (corresponding author), WASHINGTON UNIV,SCH MED,DEPT SURG,DIV PLAST SURG,ONE BARNES HOSP PLAZA,SUITE 17424,ST LOUIS,MO 63110, USA.				PHS HHS [22-3335 44901A] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BANIS JC, 1984, ARCH SURG-CHICAGO, V119, P673; BLEIBERG I, 1987, EXP HEMATOL, V15, P309; CHALMERS J, 1975, J BONE JOINT SURG BR, VB 57, P36, DOI 10.1302/0301-620X.57B1.36; FISHER J, 1988, PLAST RECONSTR SURG, V82, P857, DOI 10.1097/00006534-198811000-00021; GLOWACKI J, 1981, LANCET, V1, P959; HABAL MB, 1987, ADV PLASTIC RECONSTR; HIDALGO DA, 1990, PLAST RECONSTR SURG, V86, P492, DOI 10.1097/00006534-199009000-00019; HOLLINGER J, 1989, J ORAL MAXIL SURG, V47, P1182, DOI 10.1016/0278-2391(89)90009-8; KABAN LB, 1989, J ORAL MAXIL SURG, V47, P1187, DOI 10.1016/0278-2391(89)90010-4; KABAN LB, 1984, J DENT RES, V63, P998, DOI 10.1177/00220345840630071801; KHOURI RK, 1989, J TRAUMA, V29, P1086, DOI 10.1097/00005373-198908000-00005; KHOURI RK, 1991, PLAST RECONSTR SURG, V87, P108, DOI 10.1097/00006534-199101000-00017; KHOURI RK, 1988, SURG FORUM, V439, P597; KHOURI RK, 1991, J TRAUMA, P1029; KHOURI RK, 1991, PLASTIC SURGERY, P1029; LACROIX P, 1945, NATURE, V156, P576, DOI 10.1038/156576a0; LUYTEN FP, 1989, J BIOL CHEM, V264, P13377; MARK DE, 1990, PLAST RECONSTR SURG, V86, P623, DOI 10.1097/00006534-199010000-00001; MULLIKEN JB, 1984, J SURG RES, V37, P487, DOI 10.1016/0022-4804(84)90218-X; MUTHUKUMARAN N, 1988, COLLAGEN REL RES, V8, P433; NILSSON OS, 1986, J BONE JOINT SURG BR, V68, P635, DOI 10.1302/0301-620X.68B4.3733844; REDDI AH, 1987, ORTHOP CLIN N AM, V18, P207; REDDI AH, 1972, P NATL ACAD SCI USA, V69, P1601, DOI 10.1073/pnas.69.6.1601; SAMPATH TK, 1987, P NATL ACAD SCI USA, V84, P7109, DOI 10.1073/pnas.84.20.7109; SPORN MB, 1990, HDB EXPT PHARM; TAYLOR GI, 1983, CLIN PLAST SURG, V10, P185; URIST MR, 1983, SCIENCE, V220, P680, DOI 10.1126/science.6403986; URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893; URIST MR, 1981, CLIN ORTHOP RELAT R, V154, P97; WEILAND AJ, 1984, PLAST RECONSTR SURG, V74, P368, DOI 10.1097/00006534-198409000-00006; WEINTROUB S, 1990, CALCIFIED TISSUE INT, V46, P38; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241	32	139	146	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 9	1991	266	14					1953	1955		10.1001/jama.266.14.1953	http://dx.doi.org/10.1001/jama.266.14.1953			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GH406	1895472				2022-12-24	WOS:A1991GH40600020
J	PEASE, RJ; HARRISON, GB; SCOTT, J				PEASE, RJ; HARRISON, GB; SCOTT, J			COTRANSLOCATIONAL INSERTION OF APOLIPOPROTEIN-B INTO THE INNER LEAFLET OF THE ENDOPLASMIC-RETICULUM	NATURE			English	Article							PROTEIN TRANSLOCATION; MICROSOMAL-MEMBRANES; TRANSLATION SYSTEM; STOP-TRANSFER; SEQUENCE; CORONAVIRUS; FRACTIONS; INVITRO	APOLIPOPROTEIN (apo) B100 is required for the distribution of hepatic triglyceride to peripheral tissues as very-low-density lipoproteins. The translocation of apo B100 into the endoplasmic reticulum (ER) and its subsequent assembly into lipoprotein particles is of particular interest as the protein is both very large (relative molecular mass 512,000) and insoluble in water. It has been proposed that apo B translocation occurs in discrete stages and is completed post-translationally 1. Several sites of arrest of translocation were reported to be present in apo B15 (the N-terminal 15% of the protein). We have re-examined this question by in vitro translation coupled with translocation into microsomes, and find no evidence for transmembrane segments in truncated apo B proteins. Translocated apo B17 is strongly associated with the membrane of the ER, being only partially releasable with alkaline carbonate, and remaining bound to the microsomes following disruption with saponin. The efficient binding of short segments of apo B, despite the absence of transmembrane domains, suggests that apo B is cotranslationally inserted into the inner leaflet of the ER. This will obviate problems caused by the size and insolubility of apo B100, because the growing hydrophobic protein chains will never exist in a lipid-free form during translocation. From the inner leaflet, apo B in association with membrane-derived lipid can bud into the lumen of the ER to form nascent lipoprotein particles.			PEASE, RJ (corresponding author), MRC,CLIN RES CTR,DIV MOLEC MED,WATFORD RD,HARROW HA1 3UJ,MIDDX,ENGLAND.							ARMSTRONG J, 1984, NATURE, V308, P751, DOI 10.1038/308751a0; BOSTROM K, 1988, J BIOL CHEM, V263, P4432; CHUCK SL, 1990, NATURE, V346, P382, DOI 10.1038/346382a0; DAVIS RA, 1990, J BIOL CHEM, V265, P10005; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; HOWELL KE, 1982, J CELL BIOL, V92, P822, DOI 10.1083/jcb.92.3.822; KAMINSKI A, 1990, EMBO J, V9, P3753, DOI 10.1002/j.1460-2075.1990.tb07588.x; KASSENBROCK CK, 1988, NATURE, V333, P90, DOI 10.1038/333090a0; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KNOTT TJ, 1986, NUCLEIC ACIDS RES, V14, P7501, DOI 10.1093/nar/14.18.7501; KNOTT TJ, 1986, NATURE, V323, P734, DOI 10.1038/323734a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWN RM, 1980, CELL, V21, P647, DOI 10.1016/0092-8674(80)90428-6; ROGERS G, 1982, J BIOL CHEM, V257, P4179; ROTTIER P, 1984, P NATL ACAD SCI-BIOL, V81, P1421, DOI 10.1073/pnas.81.5.1421; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHEELE G, 1983, METHOD ENZYMOL, V96, P94; SPIESS M, 1989, J BIOL CHEM, V264, P19117; WALTER P, 1983, METHOD ENZYMOL, V96, P84; YOST CS, 1990, NATURE, V343, P669, DOI 10.1038/343669a0	20	76	76	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 3	1991	353	6343					448	450		10.1038/353448a0	http://dx.doi.org/10.1038/353448a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GH606	1896087	Green Published, Bronze			2022-12-24	WOS:A1991GH60600063
J	TUNSTALLPEDOE, H				TUNSTALLPEDOE, H			THE DUNDEE CORONARY RISK-DISK FOR MANAGEMENT OF CHANGE IN RISK-FACTORS	BRITISH MEDICAL JOURNAL			English	Article							SCOTTISH-HEART-HEALTH; DISEASE-PREVENTION-PROJECT; CHOLESTEROL; MORTALITY	Objective - To devise a simplified system for grading and monitoring modifiable coronary risk in primary care, to be used with an action plan. Methods - The risk equation came from 5203 men aged 40-59 in the United Kingdom heart disease prevention project, who had 331 coronary events over five years; the population rank (reading 1-100) was obtained by scoring 10359 participants in the Scottish heart health study. Calculation of rank was embodied in the Dundee coronary risk-disk; the formula was tested against the Whitehall study; disk and action plan were evaluated in primary care. Results - The system measures modifiable coronary risk from smoking, blood pressure, and blood cholesterol concentration by a sex and age related rank running from 1 (high risk, priority action) to 100 (low risk, general advice). The formula predicted outcome acceptably in the Whitehall study and is built into a circular slide rule. Only eight (11%) of 76 general practitioners and practice nurses surveyed already used risk factor scores. After evaluation most thought they should use one and proposed to incorporate the Dundee coronary risk-disk and the associated action plan into their routines. Conclusion - The Dundee coronary risk-disk readout of Dundee rank, standardised on a scale of 1 to 100 by age and sex, is a simple, valid means of assessing and monitoring modifiable coronary risk. It puts single risk factors (such as cholesterol concentration) in perspective and can aid selective testing. Understood by medical staff and patients, it should improve the efficiency and effectiveness of the high risk approach to coronary prevention.			TUNSTALLPEDOE, H (corresponding author), UNIV DUNDEE,NINEWELLS HOSP & MED SCH,CARDIOVASC EPIDEMIOL UNIT,DUNDEE DD1 9SY,SCOTLAND.							CHAMBLESS LE, 1990, STAT MED, V9, P385, DOI 10.1002/sim.4780090410; HELLER RF, 1984, BRIT MED J, V288, P1409, DOI 10.1136/bmj.288.6428.1409; JARRETT RJ, 1982, BRIT MED J, V285, P535, DOI 10.1136/bmj.285.6341.535; LEE AJ, 1990, J CLIN EPIDEMIOL, V43, P913, DOI 10.1016/0895-4356(90)90075-Z; PETRIE JC, 1986, BRIT MED J, V293, P611, DOI 10.1136/bmj.293.6547.611; ROSE G, 1983, LANCET, V1, P1062; Shaper A G, 1987, Health Trends, V19, P37; SMITH WCS, 1989, SCOT MED J, V34, P550, DOI 10.1177/003693308903400603; SMITH WCS, 1990, J CLIN EPIDEMIOL, V43, P637, DOI 10.1016/0895-4356(90)90033-L; THORSEN RD, 1979, PREV MED, V8, P548, DOI 10.1016/0091-7435(79)90330-X; TUNSTALLPEDOE H, 1989, BMJ-BRIT MED J, V298, P1593, DOI 10.1136/bmj.298.6688.1593; TUNSTALLPEDOE H, 1989, LANCET, V1, P540; 1989, BMJ, V298, P694; 1991, BMJ, V303, P748; 1988, J CLIN EPIDEMIOL, V41, P105; 1991, BMJ, V302, P1057; [No title captured]	17	117	119	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 28	1991	303	6805					744	747		10.1136/bmj.303.6805.744	http://dx.doi.org/10.1136/bmj.303.6805.744			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG981	1932933	Green Published, Bronze			2022-12-24	WOS:A1991GG98100018
J	TUNSTALLPEDOE, H				TUNSTALLPEDOE, H			THE HEALTH OF THE NATION - RESPONSES - CORONARY HEART-DISEASE	BMJ-BRITISH MEDICAL JOURNAL			English	Article											TUNSTALLPEDOE, H (corresponding author), UNIV DUNDEE, NINEWELLS HOSP & MED SCH, CARDIOVASC EPIDEMIOL UNIT, DUNDEE DD1 9SY, SCOTLAND.							Gregory F., 1990, DIETARY NUTR SURVEY; ROSE G, 1983, EUR HEART J, V4, P141; THELLE DS, 1983, BRIT HEART J, V49, P205, DOI 10.1136/hrt.49.3.205; TUNSTALLPEDOE H, 1989, LANCET, V1, P540; *WHO MONICA PROJ P, 1988, J CLIN EPIDEMIOL, V41, P105, DOI [DOI 10.1016/0895-4356(88)90084-4, 10.1016/0895-4356(88)90084-4]; 1990, HLTH UPDATE, V1; 1985, PROMOTING HLTH PREVE; 1990, WHO TECH REP SER, P797; 1989, 208 NAT AUD OFF HOUS; 1984, CORONARY HEART DISEA; 1989, WORLDWIDE MONITORING; 1990, WORLD HLTH STATISTIC; 1989, 26TH HOUS COMM COMM; 1988, ACTION UK 1984 1987; 1991, CM1523; 1991, DEP HLTH REPORT HLTH, V4	16	19	19	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 21	1991	303	6804					701	704		10.1136/bmj.303.6804.701	http://dx.doi.org/10.1136/bmj.303.6804.701			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG980	1912919	Green Published, Bronze			2022-12-24	WOS:A1991GG98000027
J	JOLY, E; MUCKE, L; OLDSTONE, MBA				JOLY, E; MUCKE, L; OLDSTONE, MBA			VIRAL PERSISTENCE IN NEURONS EXPLAINED BY LACK OF MAJOR HISTOCOMPATIBILITY CLASS-1 EXPRESSION	SCIENCE			English	Article							LYMPHOCYTIC CHORIOMENINGITIS VIRUS; CENTRAL NERVOUS-SYSTEM; CLASS-II REGION; UNIQUE CLEARANCE PATTERN; MESSENGER-RNA LEVELS; MONOCLONAL-ANTIBODIES; INTERFERON-GAMMA; ANTIGEN PRESENTATION; SURFACE EXPRESSION; INFECTION REVEALS	Viruses frequently persist in neurons, suggesting that these cells can evade immune surveillance. In a mouse model, 5 x 10(6) cytotoxic T lymphocytes (CTLs), specific for lymphocytic choriomeningitis virus (LCMV), did not lyse infected neurons or cause immunopathologic injury. In contrast, intracerebral injection of less than 10(3) CTL caused disease and death when viral antigens were expressed on leptomeningial and choroid plexus cells of the nervous system. The neuronal cell tine OBL21 expresses little or no major histocompatibility (MHC) class I surface glycoproteins and when infected with LCMV, resisted lysis by virus-specific CTLs. Expression of MHC heavy chain messenger RNA was limited, but beta-2-microglobulin messenger RNA and protein was made normally. OBL21 cells were made sensitive to CTL lysis by transfection with a fusion gene encoding another MHC class I molecule. Hence, neuronal cells probably evade immune surveillance by failing to express MHC class I molecules.	SCRIPPS RES INST, DEPT NEUROPHARMACOL, DIV VIROL, LA JOLLA, CA 92037 USA	Scripps Research Institute			Joly, Etienne/A-5644-2009	Joly, Etienne/0000-0002-7264-2681; Mucke, Lennart/0000-0001-6256-9559				AHMED R, 1990, FIELDS VIROLOGY, V1, P241; ALLEN H, 1986, P NATL ACAD SCI USA, V83, P7447, DOI 10.1073/pnas.83.19.7447; ARCEGOMEZ B, 1978, TISSUE ANTIGENS, V11, P96, DOI 10.1111/j.1399-0039.1978.tb01233.x; BROWN P, 1968, ARCH GES VIRUSFORSCH, V24, P220, DOI 10.1007/BF01241294; BURKE PA, 1989, J EXP MED, V169, P1309, DOI 10.1084/jem.169.4.1309; BYRNE JA, 1984, J VIROL, V51, P682, DOI 10.1128/JVI.51.3.682-686.1984; COLLINS T, 1986, P NATL ACAD SCI USA, V83, P446, DOI 10.1073/pnas.83.2.446; DANIEL F, 1983, EMBO J, V2, P1061, DOI 10.1002/j.1460-2075.1983.tb01546.x; DELALUNA S, 1988, GENE, V62, P121; DELLABONA P, 1989, J IMMUNOL, V142, P2902; DEVERSON EV, 1990, NATURE, V348, P738, DOI 10.1038/348738a0; DOHERTY PC, 1984, CONCEPTS VIRAL PATHO, P53; GILDEN DH, 1972, J EXP MED, V135, P874, DOI 10.1084/jem.135.4.874; ISRAEL A, 1987, P NATL ACAD SCI USA, V84, P2653, DOI 10.1073/pnas.84.9.2653; JOHNSON RT, 1980, BRAIN, V103, P447, DOI 10.1093/brain/103.3.447; JOLY E, 1991, GENE, V97, P213, DOI 10.1016/0378-1119(91)90054-F; KLAR D, 1989, EMBO J, V8, P475, DOI 10.1002/j.1460-2075.1989.tb03400.x; KLAVINSKIS LS, 1989, J IMMUNOL, V143, P2013; LEHMANNGRUBE F, 1988, ANN NY ACAD SCI, V532, P238, DOI 10.1111/j.1749-6632.1988.tb36343.x; LEMKE H, 1979, IMMUNOL REV, V47, P175, DOI 10.1111/j.1600-065X.1979.tb00293.x; LIPKIN WI, 1988, BRAIN RES, V451, P333; Mims C.A., 1984, VIRAL PATHOGENESIS I; MONACO JJ, 1990, SCIENCE, V250, P1723, DOI 10.1126/science.2270487; MUCKE L, 1991, NEW BIOL, V3, P465; OLDSTONE MB, 1969, J EXP MED, V129, P483, DOI 10.1084/jem.129.3.483; OLDSTONE MBA, 1988, J EXP MED, V168, P559, DOI 10.1084/jem.168.2.559; OLDSTONE MBA, 1986, NATURE, V321, P239, DOI 10.1038/321239a0; OLDSTONE MBA, 1989, SCI AM, V261, P42, DOI 10.1038/scientificamerican0889-42; OLDSTONE MBA, 1989, CELL, V56, P517, DOI 10.1016/0092-8674(89)90573-4; OZATO K, 1980, J IMMUNOL, V125, P2473; OZATO K, 1982, TRANSPLANTATION, V34, P113, DOI 10.1097/00007890-198209000-00001; PARHAM P, 1990, NATURE, V346, P793, DOI 10.1038/346793a0; RAHMSDORF HJ, 1986, J IMMUNOL, V136, P2293; ROCK KL, 1991, P NATL ACAD SCI USA, V88, P301, DOI 10.1073/pnas.88.1.301; RYDER EF, 1990, J NEUROBIOL, V21, P356, DOI 10.1002/neu.480210209; Sambrook J., 1989, MOL CLONING LAB MANU; SCHILLING G, UNPUB; SEGE K, 1981, BIOCHEMISTRY-US, V20, P4523, DOI 10.1021/bi00519a003; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; WEKERLE H, 1986, TRENDS NEUROSCI, V9, P271, DOI 10.1016/0166-2236(86)90077-9; WHITTON JL, 1989, J VIROL, V63, P4303, DOI 10.1128/JVI.63.10.4303-4310.1989; WHITTON JL, 1988, J VIROL, V62, P687, DOI 10.1128/JVI.62.3.687-695.1988; WONG GHW, 1984, EUR J IMMUNOL, V14, P52, DOI 10.1002/eji.1830140110; WONG GHW, 1984, NATURE, V310, P688, DOI 10.1038/310688a0; YOUNG LHY, 1989, J EXP MED, V169, P2159, DOI 10.1084/jem.169.6.2159; ZINKERNAGEL RM, 1977, J EXP MED, V145, P644, DOI 10.1084/jem.145.3.644	49	261	264	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 13	1991	253	5025					1283	1285		10.1126/science.1891717	http://dx.doi.org/10.1126/science.1891717			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GE689	1891717				2022-12-24	WOS:A1991GE68900042
J	HALL, MH				HALL, MH			HEALTH OF PREGNANT-WOMEN	BRITISH MEDICAL JOURNAL			English	Article											HALL, MH (corresponding author), ABERDEEN ROYAL INFIRM,ABERDEEN AB9 2ZB,SCOTLAND.							BANTA D, 1989, EFFECTIVE CARE PREGN, P1449; BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; BERAL V, 1979, BRIT MED J, V2, P632, DOI 10.1136/bmj.2.6191.632; BRYCE R, 1989, EFFECTIVE CARE PREGN, P1313; Carstairs V., 1991, DEPRIVATION HLTH SCO; Chalmers I, 1989, EFFECTIVE CARE PREGN; FORREST CG, 1982, BRIT MED J, V285, P1475; FRANCOME C, 1986, ABORTION PRACTICE BR; FRANKEL S, 1991, LANCET, V337, P1588, DOI 10.1016/0140-6736(91)93276-F; HOLLAND WW, 1988, EUROPEAN COMMUNITY A; KLINE J, 1990, EARLY PREGNANCY FAIL, P240; MACFARLANE A, 1984, BIRTH COUNTS STATIST; Oakley Ann, 1990, MISCARRIAGE; TEMMERMAN M, 1991, EUR J OBSTET GYN R B, V39, P13; Townsend P., 1988, INEQUALITIES HLTH BL; 1991, REPORT UK 1985 7	16	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 24	1991	303	6800					460	462		10.1136/bmj.303.6800.460	http://dx.doi.org/10.1136/bmj.303.6800.460			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GC465	1912841	Green Published, Bronze			2022-12-24	WOS:A1991GC46500021
J	MONTESANO, R; SCHALLER, G; ORCI, L				MONTESANO, R; SCHALLER, G; ORCI, L			INDUCTION OF EPITHELIAL TUBULAR MORPHOGENESIS INVITRO BY FIBROBLAST-DERIVED SOLUBLE FACTORS	CELL			English	Article							TUMOR-CELL INVASION; MESENCHYMAL INTERACTIONS; POLARIZED EPITHELIUM; SCATTER FACTOR; GROWTH-FACTOR; MDCK CYSTS; LINE MDCK; MEMBRANE; DIFFERENTIATION; EXPRESSION	We have designed an in vitro system in which Madin-Darby canine kidney (MDCK) epithelial cells are cocultured in collagen gels with fibroblasts under conditions precluding heterocellular contact. Using this experimental approach, we have obtained evidence that fibroblast-derived soluble factors play a crucial role in the control of epithelial morphogenesis. First, MDCK cells suspended alone in collagen gels form spherical cysts, whereas in the presence of fibroblasts they form branching tubules. Second, MDCK cells grown as a monolayer on fibroblast-containing collagen gels invade the underlying matrix, within which they form a network of tubules. Third, fibroblast-conditioned medium mimics the effects of coculture by eliciting tubulogenesis by MDCK cells. These results demonstrate the involvement of diffusible paracrine factors in morphogenetic epithelial-mesenchymal interactions and provide a strategy for their molecular characterization.			MONTESANO, R (corresponding author), UNIV GENEVA, MED CTR, DEPT MORPHOL, CH-1211 GENEVA 4, SWITZERLAND.							BARCELLOSHOFF MH, 1989, DEVELOPMENT, V105, P223; BARRETT AJ, 1986, RES MONOG CELL TISSU, V12, P515; BEHRENS J, 1989, J CELL BIOL, V108, P2435, DOI 10.1083/jcb.108.6.2435; BENNETT DC, 1980, NATURE, V285, P657, DOI 10.1038/285657a0; BENYA PD, 1982, CELL, V30, P215, DOI 10.1016/0092-8674(82)90027-7; Bernfield M., 1984, ROLE EXTRACELLULAR M, P545; BISSELL MJ, 1982, J THEOR BIOL, V99, P31, DOI 10.1016/0022-5193(82)90388-5; CEREIJIDO M, 1978, J CELL BIOL, V77, P853, DOI 10.1083/jcb.77.3.853; CHAMBARD M, 1981, J CELL BIOL, V91, P157, DOI 10.1083/jcb.91.1.157; CUNHA GR, 1985, CELL DIFFER DEV, V17, P137, DOI 10.1016/0045-6039(85)90481-6; EDELMAN GM, 1990, MORPHOREGULATORY MOL; Ekblom P, 1984, ROLE EXTRACELLULAR M, P173; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; GOSPODAROWICZ D, 1984, J CELL BIOL, V99, P947, DOI 10.1083/jcb.99.3.947; GRANTHAM JJ, 1989, KIDNEY INT, V35, P1379, DOI 10.1038/ki.1989.137; GROBSTEIN C, 1956, ADV CANCER RES, V4, P187, DOI 10.1016/S0065-230X(08)60725-3; GURDON JB, 1987, DEVELOPMENT, V99, P285; HADLEY MA, 1985, J CELL BIOL, V101, P1511, DOI 10.1083/jcb.101.4.1511; HALL HG, 1982, P NATL ACAD SCI-BIOL, V79, P4672, DOI 10.1073/pnas.79.15.4672; HODGES GM, 1982, BR SOC CELL BIOL S, V5, P333; LEIGHTON J, 1970, CANCER-AM CANCER SOC, V26, P1022, DOI 10.1002/1097-0142(197011)26:5<1022::AID-CNCR2820260509>3.0.CO;2-M; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LOUVARD D, 1980, P NATL ACAD SCI-BIOL, V77, P4132, DOI 10.1073/pnas.77.7.4132; MANGOOKARIM R, 1989, P NATL ACAD SCI USA, V86, P6007, DOI 10.1073/pnas.86.15.6007; MCATEER JA, 1987, ANAT REC, V217, P229, DOI 10.1002/ar.1092170303; McRoberts J. A., 1981, FUNCTIONALLY DIFFERE, P117; MERCOLA M, 1988, DEVELOPMENT, V102, P451; MISFELDT DS, 1976, P NATL ACAD SCI USA, V73, P1212, DOI 10.1073/pnas.73.4.1212; MONTESANO R, 1985, CELL, V42, P469, DOI 10.1016/0092-8674(85)90104-7; MONTESANO R, 1983, J CELL BIOL, V97, P935, DOI 10.1083/jcb.97.3.935; MONTESANO R, 1990, CELL, V62, P435, DOI 10.1016/0092-8674(90)90009-4; MOSCATELLI D, 1988, BIOCHIM BIOPHYS ACTA, V948, P67, DOI 10.1016/0304-419X(88)90005-4; NAKANISHI Y, 1989, BIOESSAYS, V11, P163, DOI 10.1002/bies.950110602; OJAKIAN GK, 1987, AM J PHYSIOL, V253, pC433, DOI 10.1152/ajpcell.1987.253.3.C433; PICTET RL, 1977, CELL INTERACTIONS DI, P339; RICHARDSON JCW, 1981, BIOCHIM BIOPHYS ACTA, V673, P26, DOI 10.1016/0304-4165(81)90307-X; RICHMAN PI, 1988, J PATHOL, V156, P197, DOI 10.1002/path.1711560305; RINDLER MJ, 1979, J CELL BIOL, V81, P635, DOI 10.1083/jcb.81.3.635; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; SAWYER RH, 1983, EPITHELIAL MESENCHYM; Saxen L., 1976, CELL SURFACE ANIMAL, P331; Saxen L., 1987, ORGANOGENESIS KIDNEY; SCHOR SL, 1987, BIOESSAYS, V7, P200, DOI 10.1002/bies.950070503; SCHOR SL, 1987, EXP CELL BIOL, V55, P11; SIMONS K, 1985, ANNU REV CELL BIOL, V1, P243, DOI 10.1146/annurev.cb.01.110185.001331; SLACK JMW, 1989, LANCET, V1, P1312; SPOONER BS, 1986, REGULATION MATRIX AC, P339; SPORN MB, 1990, PEPTIDE GROWTH FACTO, V1; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; TAKAHASHI Y, 1991, DEVELOPMENT, V111, P327; TAUB M, 1990, P NATL ACAD SCI USA, V87, P4002, DOI 10.1073/pnas.87.10.4002; UENO N, 1990, Progress in Growth Factor Research, V2, P113, DOI 10.1016/0955-2235(90)90027-H; VANDENHOOFF A, 1988, ADV CANCER RES, V50, P159, DOI 10.1016/S0065-230X(08)60437-6; WANG AZ, 1990, J CELL SCI, V95, P137; WANG AZ, 1990, J CELL SCI, V95, P153; WARREN SL, 1987, MOL CELL BIOL, V7, P1326, DOI 10.1128/MCB.7.4.1326; WARREN SL, 1988, MOL CELL BIOL, V8, P632, DOI 10.1128/MCB.8.2.632; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; WELLER A, 1991, DEV BIOL, V144, P248, DOI 10.1016/0012-1606(91)90419-4; YANG J, 1979, P NATL ACAD SCI USA, V76, P3401, DOI 10.1073/pnas.76.7.3401	60	460	477	0	9	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	AUG 23	1991	66	4					697	711		10.1016/0092-8674(91)90115-F	http://dx.doi.org/10.1016/0092-8674(91)90115-F			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GC745	1878968				2022-12-24	WOS:A1991GC74500010
J	WARD, RHR; CAPON, DJ; JETT, CM; MURTHY, KK; MORDENTI, J; LUCAS, C; FRIE, SW; PRINCE, AM; GREEN, JD; EICHBERG, JW				WARD, RHR; CAPON, DJ; JETT, CM; MURTHY, KK; MORDENTI, J; LUCAS, C; FRIE, SW; PRINCE, AM; GREEN, JD; EICHBERG, JW			PREVENTION OF HIV-1 IIIB INFECTION IN CHIMPANZEES BY CD4 IMMUNOADHESIN	NATURE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; RECOMBINANT SOLUBLE CD4; TYPE-1; IMMUNIZATION	THE first step in infection by the human immunodeficiency virus (HIV) is the specific binding of gp120, the envelope glycoprotein of HIV, to its cellular receptor, CD4 (see ref. 1 for review). To inhibit this interaction, soluble CD4 analogues that compete for gp120 binding and block HIV infection in vitro have been developed 2-8. To determine whether these analogues can protect an uninfected individual from challenge with HIV, we used the chimpanzee model system of cell-free HIV infection. Chimpanzees are readily infected with the IIIB strain of HIV-1, becoming viraemic within about 4-6 weeks of challenge, although they do not develop the profound CD4+ T-cell depletion and immunodeficiency characteristic of HIV infection in humans 9. CD4 immunoadhesin (CD4-IgG), a chimaeric molecule consisting of the N-terminal two immunoglobulin-like regions of CD4 joined to the Fc region of human IgG1 (refs 8, 10), was selected as the CD4 analogue for testing because it has a longer half-life than CD4, contributed by the IgG Fc portion of the molecule. In humans, this difference results in a 25-fold increased concentration of CD4-IgG in the blood compared with recombinant CD4 (ref. 11). Here we report that pretreatment with CD4-IgG can prevent the infection of chimpanzees with HIV-1. The need for a preventative agent is particularly acute in perinatal HIV transmission. As recombinant CD4-IgG, like the parent IgG molecule, efficiently crosses the primate placenta 10, it may be possible to set up an immune state in a fetus before HIV transfer occurs, thus preventing infection.	CELL GENESYS INC,FOSTER CITY,CA 94404; SW FDN BIOMED RES,SAN ANTONIO,TX 78284; NEW YORK BLOOD CTR,LINDSLEY F KIMBALL RES INST,NEW YORK,NY 10021	Cell Genesys Inc; Texas Biomedical Research Institute; New York Blood Center	WARD, RHR (corresponding author), GENENTECH INC,460 PT SAN BRUNO BLVD,S SAN FRANCISCO,CA 94080, USA.							ANDERSON KP, 1989, J INFECT DIS, V160, P960, DOI 10.1093/infdis/160.6.960; BERGER EA, 1988, P NATL ACAD SCI USA, V85, P2357, DOI 10.1073/pnas.85.7.2357; BERMAN PW, 1990, NATURE, V345, P622, DOI 10.1038/345622a0; BERNARD N, 1990, NEW ENGL J MED, V323, P916; BLANCHE S, 1989, NEW ENGL J MED, V320, P1643, DOI 10.1056/NEJM198906223202502; BYRN RA, 1990, NATURE, V344, P667, DOI 10.1038/344667a0; CAPON D, 1991, REV IMMUNOL, V9, P649; CAPON DJ, 1989, NATURE, V337, P525, DOI 10.1038/337525a0; DAAR ES, 1990, P NATL ACAD SCI USA, V87, P6574, DOI 10.1073/pnas.87.17.6574; DEEN KC, 1988, NATURE, V331, P82, DOI 10.1038/331082a0; EICHBERG JW, 1990, ANIMAL MODELS AIDS, P47; FISHER RA, 1988, NATURE, V331, P76, DOI 10.1038/331076a0; GIRARD M, 1991, P NATL ACAD SCI USA, V88, P542, DOI 10.1073/pnas.88.2.542; HU SL, 1987, NATURE, V328, P721, DOI 10.1038/328721a0; HUSSEY RE, 1988, NATURE, V331, P78, DOI 10.1038/331078a0; LANGE JMA, 1990, NEW ENGL J MED, V322, P1375, DOI 10.1056/NEJM199005103221907; MARRIN LN, 1990, 8TH A S NONH PRIM MO; MCCUNE JM, 1990, SCIENCE, V247, P564, DOI 10.1126/science.2300816; MORDENTI J, IN PRESS PHARM RES; SAIKI RK, 1985, SCIENCE, V230, P487; SMITH DH, 1987, SCIENCE, V238, P1704, DOI 10.1126/science.3500514; THOMAS RM, 1989, B LOND MATH SOC, V21, P463, DOI 10.1112/blms/21.5.463; TRAUNECKER A, 1988, NATURE, V331, P84, DOI 10.1038/331084a0	23	59	68	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 1	1991	352	6334					434	436		10.1038/352434a0	http://dx.doi.org/10.1038/352434a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FZ346	1907354	Bronze			2022-12-24	WOS:A1991FZ34600066
J	KARA, CJ; GLIMCHER, LH				KARA, CJ; GLIMCHER, LH			INVIVO FOOTPRINTING OF MHC CLASS-II GENES - BARE PROMOTERS IN THE BARE LYMPHOCYTE SYNDROME	SCIENCE			English	Article							DR-ALPHA GENE; B-CELL VARIANT; HLA-DR; NUCLEOTIDE-SEQUENCE; CHAIN GENE; EXPRESSION; BINDING; PROTEIN; ENHANCER; HYBRIDS	Major histocompatibility complex (MHC) class II genes are coordinately regulated and show tissue-specific expression. With the use of in vivo footprinting, common promoter sites in these genes were found to be occupied only in cells that expressed the genes, in spite of the presence of the promoter binding proteins. In vivo analysis of mutant cell lines that exhibited coordinate loss of class II MHC expression, including several from individuals with bare lymphocyte syndrome, revealed two in vivo phenotypes. One suggests a defect in gene activation, whereas the other suggests a defect in promoter accessibility.	HARVARD UNIV,SCH PUBL HLTH,DEPT CANC BIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,PROGRAM IMMUNOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI021163] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036864] Funding Source: NIH RePORTER; NIAID NIH HHS [AI21163] Funding Source: Medline; NIGMS NIH HHS [GM36864] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACCOLLA RS, 1983, J EXP MED, V157, P1053, DOI 10.1084/jem.157.3.1053; ACCOLLA RS, 1985, P NATL ACAD SCI USA, V82, P5145, DOI 10.1073/pnas.82.15.5145; BECKER PB, 1987, CELL, V51, P435, DOI 10.1016/0092-8674(87)90639-8; BENOIST C, 1990, ANNU REV IMMUNOL, V8, P681, DOI 10.1146/annurev.immunol.8.1.681; BOOTHBY M, 1989, J IMMUNOL, V142, P1005; DAS HK, 1983, P NATL ACAD SCI-BIOL, V80, P3543, DOI 10.1073/pnas.80.12.3543; DEDRICK RL, 1990, MOL CELL BIOL, V10, P593, DOI 10.1128/MCB.10.2.593; DEPREVAL C, 1985, NATURE, V318, P291, DOI 10.1038/318291a0; FINN PW, 1990, EMBO J, V9, P1543, DOI 10.1002/j.1460-2075.1990.tb08273.x; FORRESTER WC, 1987, NUCLEIC ACIDS RES, V15, P10159, DOI 10.1093/nar/15.24.10159; GLADSTONE P, 1978, NATURE, V271, P459, DOI 10.1038/271459a0; GLADSTONE P, 1980, SOMAT CELL GENET, V6, P285, DOI 10.1007/BF01538802; Griscelli C, 1989, Immunodefic Rev, V1, P135; HUME CR, 1989, HUM IMMUNOL, V26, P288, DOI 10.1016/0198-8859(89)90007-4; KARA C, UNPUB; KOBR M, 1990, MOL CELL BIOL, V10, P965, DOI 10.1128/MCB.10.3.965; LIOU HC, 1990, SCIENCE, V247, P1581, DOI 10.1126/science.2321018; MALISSEN M, 1983, SCIENCE, V221, P750, DOI 10.1126/science.6410508; MUELLER PR, 1988, GENE DEV, V2, P412, DOI 10.1101/gad.2.4.412; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; REITH W, 1988, CELL, V53, P897, DOI 10.1016/S0092-8674(88)90389-3; SAKURAI M, 1988, P NATL ACAD SCI USA, V85, P6909, DOI 10.1073/pnas.85.18.6909; SHERMAN PA, 1989, P NATL ACAD SCI USA, V86, P6739, DOI 10.1073/pnas.86.17.6739; SHERMAN PA, 1987, P NATL ACAD SCI USA, V84, P4254, DOI 10.1073/pnas.84.12.4254; SLOAN JH, 1988, P NATL ACAD SCI USA, V85, P8186, DOI 10.1073/pnas.85.21.8186; TSANG SY, 1990, MOL CELL BIOL, V10, P711, DOI 10.1128/MCB.10.2.711; TSANG SY, 1988, P NATL ACAD SCI USA, V85, P8598, DOI 10.1073/pnas.85.22.8598; WEINTRAUB H, 1985, CELL, V42, P705, DOI 10.1016/0092-8674(85)90267-3; WORKMAN JL, 1988, CELL, V55, P211, DOI 10.1016/0092-8674(88)90044-X	29	175	176	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 3	1991	252	5006					709	712		10.1126/science.1902592	http://dx.doi.org/10.1126/science.1902592			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FK185	1902592				2022-12-24	WOS:A1991FK18500050
J	HE, JJ; QUIOCHO, FA				HE, JJ; QUIOCHO, FA			A NONCONSERVATIVE SERINE TO CYSTEINE MUTATION IN THE SULFATE-BINDING PROTEIN, A TRANSPORT RECEPTOR	SCIENCE			English	Article							SALMONELLA-TYPHIMURIUM	Serine 130 is one of seven residues that form a total of seven hydrogen bonds with the sulfate completely sequestered deep in the cleft between the two lobes of the bilobate sulfate-binding protein from Salmonella typhimurium. This residue has been replaced with Cys, Ala, and Gly by site-directed mutagenesis in an Escherichia coli expression system. Replacement with the isosteric Cys caused a 3200-fold decrease in the sulfate-binding activity relative to the wild-type activity, whereas replacement with Ala and Gly resulted in only 100- and 15-fold decreases, respectively. The effect of the Cys substitution is attributed largely to steric effect, whereas the Gly substitution more nearly reflects the loss of one hydrogen bond to the bound sulfate with a strength of only 1.6 kilocalories per mole.	BAYLOR UNIV,HOWARD HUGHES MED INST,HOUSTON,TX 77030; BAYLOR UNIV,DEPT BIOCHEM,HOUSTON,TX 77030	Baylor University; Howard Hughes Medical Institute; Baylor University								AMES GFL, 1986, ANNU REV BIOCHEM, V55, P397, DOI 10.1146/annurev.biochem.55.1.397; FREY MN, 1973, ACTA CRYSTALLOGR B, VB 29, P876, DOI 10.1107/S0567740873003481; FURLONG CE, 1987, CELLULAR MOL BIOL, P768; HIGAKI JN, 1989, BIOCHEMISTRY-US, V28, P9256, DOI 10.1021/bi00450a004; ISHIHARA H, 1980, J BIOL CHEM, V255, P4614; JACOBSON BL, 1988, J MOL BIOL, V204, P783, DOI 10.1016/0022-2836(88)90369-5; JACOBSON BL, IN PRESS J BIOL CHEM; KERR KA, 1975, ACTA CRYSTALLOGR B, V31, P2022, DOI 10.1107/S0567740875006772; KISTENMACHER TJ, 1974, ACTA CRYSTALLOGR B, V30, P2573, DOI 10.1107/S0567740874007618; LUECKE H, 1990, NATURE, V347, P402, DOI 10.1038/347402a0; MCGRATH ME, 1989, BIOCHEMISTRY-US, V28, P9264, DOI 10.1021/bi00450a005; NEET KE, 1966, P NATL ACAD SCI USA, V56, P1606, DOI 10.1073/pnas.56.5.1606; PARDEE AB, 1966, J BIOL CHEM, V241, P5886; PFLUGRATH JW, 1988, J MOL BIOL, V200, P163, DOI 10.1016/0022-2836(88)90341-5; PFLUGRATH JW, 1985, NATURE, V314, P257, DOI 10.1038/314257a0; POLGAR L, 1966, J AM CHEM SOC, V88, P153; QUIOCHO FA, 1990, PHILOS T R SOC B, V326, P341, DOI 10.1098/rstb.1990.0016; QUIOCHO FA, 1987, NATURE, V329, P561, DOI 10.1038/329561a0; SACK JS, UNPUB	19	176	183	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 22	1991	251	5000					1479	1481		10.1126/science.1900953	http://dx.doi.org/10.1126/science.1900953			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FC853	1900953				2022-12-24	WOS:A1991FC85300046
J	HAN, HQ; NICHOLS, RA; RUBIN, MR; BAHLER, M; GREENGARD, P				HAN, HQ; NICHOLS, RA; RUBIN, MR; BAHLER, M; GREENGARD, P			INDUCTION OF FORMATION OF PRESYNAPTIC TERMINALS IN NEUROBLASTOMA-CELLS BY SYNAPSIN-IIB	NATURE			English	Article							GLIOMA HYBRID-CELLS; PHOSPHOPROTEIN; PROTEIN-1	THE synapsins are a family of closely related phosphoproteins (termed synapsins Ia, Ib, IIa and IIb) associated with synaptic vesicles and implicated in the short-term regulation of neurotransmitter release from nerve endings 1-5. During development, expression of the synapsins correlates temporally with synapse formation 6, but there has been no direct evidence that they are involved in synaptogenesis. Here we report that overexpression of synapsin IIb in the neuroblastoma x glioma hybrid clonal cell line NG108-15 leads, during cell differentiation, to marked increases in the number of neuritic varicosities and in the numbers of small clear vesicles and large dense core vesicles per varicosity, as well as to the appearance of synapse-like cell-cell contacts. Thus, synapsin IIb may be involved in the regulation of synapse formation and, as a result, in long-term neuronal signalling.			HAN, HQ (corresponding author), ROCKEFELLER UNIV,MOLEC & CELLULAR NEUROSCI LAB,1230 YORK AVE,NEW YORK,NY 10021, USA.							BAHLER M, 1990, BIOESSAYS, V12, P259, DOI 10.1002/bies.950120603; CHANDLER CE, 1985, J CELL PHYSIOL, V125, P367, DOI 10.1002/jcp.1041250303; CZERNIK AJ, IN PRESS METH ENZYM; DECAMILLI P, 1990, ANNU REV CELL BIOL, V6, P433, DOI 10.1146/annurev.cellbio.6.1.433; FURUYA S, 1983, TISSUE CELL, V15, P903, DOI 10.1016/0040-8166(83)90057-5; GRAY DB, 1990, J NEUROSCI, V10, P2687; KELLY RB, 1988, NEURON, V1, P431, DOI 10.1016/0896-6273(88)90174-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LLINAS R, 1985, P NATL ACAD SCI USA, V82, P3035, DOI 10.1073/pnas.82.9.3035; LOWRY OH, 1951, J BIOL CHEM, V193, P265; NAVONE F, 1986, J CELL BIOL, V103, P2511, DOI 10.1083/jcb.103.6.2511; NELSON P, 1976, P NATL ACAD SCI USA, V73, P123, DOI 10.1073/pnas.73.1.123; Nestler E. J., 1984, PROTEIN PHOSPHORYLAT; NESTLER EJ, 1982, SCIENCE, V217, P357, DOI 10.1126/science.6124039; NESTLER EJ, 1981, SCIENCE, V212, P1162, DOI 10.1126/science.6785886; NICHOLS RA, 1990, NATURE, V343, P647, DOI 10.1038/343647a0; NIRENBERG M, 1983, SCIENCE, V222, P794, DOI 10.1126/science.6314503; ROMANO C, 1987, J NEUROSCI, V7, P1294; SAMBROOCK J, 1989, MOL CLONING LABORATO; SUDHOF TC, 1989, SCIENCE, V245, P1474, DOI 10.1126/science.2506642	20	163	167	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 21	1991	349	6311					697	700		10.1038/349697a0	http://dx.doi.org/10.1038/349697a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EY627	1899916				2022-12-24	WOS:A1991EY62700048
J	COCKRELL, JL; SCHEINMAN, MM; TITUS, C; HELMY, I; LANGBERG, JJ; LEE, MA; GRIFFIN, JC				COCKRELL, JL; SCHEINMAN, MM; TITUS, C; HELMY, I; LANGBERG, JJ; LEE, MA; GRIFFIN, JC			SAFETY AND EFFICACY OF ORAL FLECAINIDE THERAPY IN PATIENTS WITH ATRIOVENTRICULAR REENTRANT TACHYCARDIA	ANNALS OF INTERNAL MEDICINE			English	Article							PARKINSON-WHITE SYNDROME; SUPRAVENTRICULAR ARRHYTHMIAS; JUNCTIONAL TACHYCARDIAS; ATRIAL-FIBRILLATION; CLINICAL EFFICACY; ACETATE; ENCAINIDE; PATHWAYS; ISOPROTERENOL	Objective: To assess the short- and long-term safety and efficacy of oral flecainide therapy in patients with symptomatic tachycardia and an extranodal accessory pathway. Design: Open-label, uncontrolled trial with a mean follow-up of 24 months. Setting: Referral-based, teaching medical center. Patients: Sixty-three patients with symptomatic tachycardia and an extranodal accessory pathway. Interventions: Patients had electrophysiologic testing before and after the initiation of oral flecainide therapy and were followed long-term for the presence of symptoms, new physical limitations, and adverse effects of therapy. Measurements and Main Results: Flecainide therapy prevented or slowed (324 +/- 59 ms to 398 +/- 55 ms; P < 0.001) inducible sustained atrioventricular reciprocating tachycardia in 44 of 63 patients (70%). Of the 44 patients discharged from the hospital, 33 (75%) have continued to receive flecainide therapy and have shown no adverse effects (mean follow-up, 24 +/- 10 months). Adverse cardiac reactions (proarrhythmia or sinus node suppression) attributable to flecainide occurred in 11 of 63 patients (17%); in 9 (82%) of these 11 patients, events were detected during either in-hospital monitoring or the electrophysiologic study done before discharge. Structural heart disease was detected by two-dimensional echocardiography in 8 of 11 patients who had adverse cardiac events and in 6 of 52 patients who did not have such events (P < 0.001). Isoproterenol reversed the effects of flecainide therapy in 11 of 21 patients; 7 of the 11 patients had spontaneous clinical recurrences of tachycardia or palpitations during the follow-up period, but these symptoms occurred in only 1 of 10 patients who did not show isoproterenol-induced reversal (P = 0.02). Conclusions: Oral flecainide therapy was effective in 33 of 63 patients who had tachycardia and an extranodal accessory connection. Hospital monitoring during initial therapy is recommended, and flecainide should be used with caution, if at all, in patients with structural heart disease. An isoproterenol challenge appears to be helpful in predicting late recurrence of tachycardia.	UNIV CALIF SAN FRANCISCO, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco	COCKRELL, JL (corresponding author), LETTERMAN ARMY MED CTR, DEPT MED, CARDIOL SERV, SAN FRANCISCO, CA 94129 USA.							ABDOLLAH H, 1984, AM J CARDIOL, V54, P544, DOI 10.1016/0002-9149(84)90245-5; AKHTAR M, 1988, AM J CARDIOL, V62, pL45, DOI 10.1016/0002-9149(88)90015-X; ANDERSON JL, 1988, AM J CARDIOL, V62, pD62; [Anonymous], 1989, NEW ENGL J MED, V321, P406; BEXTON RS, 1983, EUR HEART J, V4, P92, DOI 10.1093/oxfordjournals.eurheartj.a061432; BREMBILLAPERROT B, 1985, EUR HEART J, V6, P1074, DOI 10.1093/oxfordjournals.eurheartj.a061812; CRIJNS HJGM, 1988, AM HEART J, V115, P1317, DOI 10.1016/0002-8703(88)90032-4; FAUCHIER JP, 1985, ARCH MAL COEUR VAISS, V78, P81; GOY JJ, 1985, EUR HEART J, V6, P518, DOI 10.1093/oxfordjournals.eurheartj.a061897; HAISSAGUERRE M, 1987, ARCH MAL COEUR VAISS, V80, P357; HELLESTRAND KJ, 1983, AM J CARDIOL, V51, P770, DOI 10.1016/S0002-9149(83)80131-3; HELMY I, 1991, IN PRESS J AM COLL C; KAPPENBERGER LJ, 1985, CLIN CARDIOL, V8, P321, DOI 10.1002/clc.4960080603; KIM SS, 1986, AM J CARDIOL, V58, P80, DOI 10.1016/0002-9149(86)90245-6; NEUSS H, 1988, AM J CARDIOL, V62, pD56; NEUSS H, 1983, EUR HEART J, V4, P347, DOI 10.1093/oxfordjournals.eurheartj.a061472; PRYSTOWSKY EN, 1984, CIRCULATION, V69, P278, DOI 10.1161/01.CIR.69.2.278; TILL JA, 1987, ARCH DIS CHILD, V62, P247, DOI 10.1136/adc.62.3.247; WARD DE, 1986, AM J CARDIOL, V57, P787, DOI 10.1016/0002-9149(86)90614-4; WELLENS HJJ, 1980, AM J CARDIOL, V46, P665, DOI 10.1016/0002-9149(80)90518-4; WREN C, 1987, BRIT HEART J, V57, P171; ZEECHENG CS, 1988, AM J CARDIOL, V62, pD23	22	25	25	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1991	114	3					189	194		10.7326/0003-4819-114-3-189	http://dx.doi.org/10.7326/0003-4819-114-3-189			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EV339	1898629				2022-12-24	WOS:A1991EV33900003
J	HAGAN, P; BLUMENTHAL, UJ; DUNN, D; SIMPSON, AJG; WILKINS, HA				HAGAN, P; BLUMENTHAL, UJ; DUNN, D; SIMPSON, AJG; WILKINS, HA			HUMAN IGE, IGG4 AND RESISTANCE TO REINFECTION WITH SCHISTOSOMA-HAEMATOBIUM	NATURE			English	Article							PROTECTIVE IMMUNITY; ANTIBODIES; MANSONI; CELLS; RESPONSES; MACROPHAGES; INVITRO; GAMMA	A WELL recognized feature of the immune response to parasitic helminth infections, including schistosomiasis, is the production of large amounts of specific and nonspecific IgE 1,2. Immunological pathways involving IgE can lead to damage to the developing schistosomulum 3-9 and it has been suggested that responses involving IgE could have evolved as protection against helminth infections 10,11. There has been no epidemiological evidence to support this idea and the only significant IgE responses known in man are those involved in the pathogenesis of allergic disease 12. Here we measure serological response during reinfection with S. haematobium and demonstrate that IgE antibodies in man can be beneficial. Our results support the hypothesis that the slow build-up of IgE to high levels and the early production of IgG4 antibodies, which may block IgE pathways 13,14, are responsible for delaying the development of protective immunity to S. haematobium.	UNIV LIVERPOOL, LIVERPOOL SCH TROP MED, LIVERPOOL L3 5QA, ENGLAND; UNIV LONDON LONDON SCH HYG & TROP MED, LONDON WC1E 7HT, ENGLAND; MRC LABS, FAJARA, SENEGAMBIA	Liverpool School of Tropical Medicine; University of Liverpool; University of London; London School of Hygiene & Tropical Medicine	HAGAN, P (corresponding author), NATL INST MED RES, DIV PARASITOL, LONDON NW7 1AA, ENGLAND.		Simpson, Amelia/HGB-1823-2022	Dunn, David/0000-0003-1836-4446; Hagan, Paul/0000-0002-3516-2283				AURIAULT C, 1990, J CLIN MICROBIOL, V28, P1918, DOI 10.1128/JCM.28.9.1918-1924.1990; Bundy DAP, 1990, PARASITISM HOST BEHA; BUTTERWORTH AE, 1974, NATURE, V252, P503, DOI 10.1038/252503a0; CAPRON A, 1975, NATURE, V253, P474, DOI 10.1038/253474a0; CAPRON A, 1989, CIBA F SYMP, V147, P153; CAPRON A, 1977, AM J TROP MED HYG, V26, P39, DOI 10.4269/ajtmh.1977.26.39; CAPRON A, 1977, PATHOL BIOL, V25, P287; CAPRON A, 1980, AM J TROP MED HYG, V29, P849, DOI 10.4269/ajtmh.1980.29.849; CAPRON A, 1982, PROG ALLERGY, V31, P234; Capron M., 1980, T ROY SOC TROP MED H, V74, P44, DOI [10.1016/0035-9203(80)90272-2, DOI 10.1016/0035-9203(80)90272-2]; CHRETIEN I, 1988, J IMMUNOL, V141, P3128; DEAN DA, 1974, AM J TROP MED HYG, V23, P420, DOI 10.4269/ajtmh.1974.23.420; DESSAINT JP, 1975, CLIN EXP IMMUNOL, V20, P427; DUNNE DW, 1988, EUR J IMMUNOL, V18, P123, DOI 10.1002/eji.1830180119; HAGAN P, 1985, PARASITE IMMUNOL, V7, P625, DOI 10.1111/j.1365-3024.1985.tb00106.x; HAGAN P, 1987, T ROY SOC TROP MED H, V81, P938, DOI 10.1016/0035-9203(87)90359-2; HUSSAIN R, 1986, J IMMUNOL, V136, P1859; ISHIZAKA A, 1990, CLIN EXP IMMUNOL, V79, P392; ISKANDER R, 1981, INT ARCH ALLER A IMM, V66, P200, DOI 10.1159/000232819; JAMES SL, 1982, CELL IMMUNOL, V67, P255, DOI 10.1016/0008-8749(82)90218-0; KHALIFE J, 1986, J EXP MED, V164, P1626, DOI 10.1084/jem.164.5.1626; OGILVIE BM, 1964, NATURE, V204, P91, DOI 10.1038/204091a0; OTTESEN EA, 1985, J IMMUNOL, V134, P2707; PENE J, 1988, J IMMUNOL, V141, P1218; PENE J, 1988, P NATL ACAD SCI USA, V85, P6880, DOI 10.1073/pnas.85.18.6880; STANWORTH D R, 1973, Clinical Allergy, V3, P37, DOI 10.1111/j.1365-2222.1973.tb01307.x; STURROCK RF, 1983, T ROY SOC TROP MED H, V77, P363, DOI 10.1016/0035-9203(83)90166-9; TURNER KJ, 1989, CIBA F SYMP, V147, P205; WILKINS HA, 1987, T ROY SOC TROP MED H, V81, P29, DOI 10.1016/0035-9203(87)90273-2; WILKINS HA, 1988, BIOL SCHISTOSOMES	30	579	592	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 17	1991	349	6306					243	245		10.1038/349243a0	http://dx.doi.org/10.1038/349243a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ET519	1898985				2022-12-24	WOS:A1991ET51900057
J	GARNICK, DW; HENDRICKS, AM; BRENNAN, TA				GARNICK, DW; HENDRICKS, AM; BRENNAN, TA			CAN PRACTICE GUIDELINES REDUCE THE NUMBER AND COSTS OF MALPRACTICE CLAIMS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PROFESSIONAL LIABILITY; PHYSICIANS; STANDARDS; SYSTEM; CARE	Practice guidelines have the potential to reduce the number of malpractice cases and the costs of settling them. However, for practice guidelines to exert any influence, they must be assumed to be (1) developed for conditions or procedures that frequently lead to events for which negligence claims are filed; (2) widely accepted in the medical profession; (3) fully integrated into clinical practice; and (4) straightforward and readily interpreted in a litigation setting. Because the validity of each of these assumptions can be questioned, the idea that inserting practice guidelines into the existing litigation process will generate large savings in the near future is overly optimistic.	BRIGHAM & WOMENS HOSP, DIV GEN MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	GARNICK, DW (corresponding author), HARVARD UNIV, SCH PUBL HLTH, PROGRAM HLTH CARE FINANCING & INSURANCE, BOSTON, MA 02115 USA.		Garnick, Deborah w/I-9009-2012					ABRAHAM KS, 1988, JAMA-J AM MED ASSOC, V260, P68, DOI 10.1001/jama.260.1.68; [Anonymous], 1986, COSTS COMPENSATION P; BIERIG JR, 1990, MAR CAP CONS C APPR; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; BRENNAN TA, 1989, U PITT LAW REV, V51, P1; BRENNAN TA, 1991, J HEALTH POLIT POLIC, V16, P67, DOI 10.1215/03616878-16-1-67; CHASSIN MR, 1988, INQUIRY-J HEALTH CAR, V25, P437; DANZON P, 1989, LIABILITY PERSPECTIV; Danzon P.M, 1985, MED MALPRACTICE; EDDY DM, 1990, JAMA-J AM MED ASSOC, V263, P3077, DOI 10.1001/jama.263.22.3077; EDDY DM, 1988, HEALTH AFFAIR, V7, P19, DOI 10.1377/hlthaff.7.1.19; EICHHORN JH, 1989, ANESTHESIOLOGY, V70, P572, DOI 10.1097/00000542-198904000-00002; FEILD DJ, 1987, J AM COLL CARDIOL, V10, P935, DOI 10.1016/S0735-1097(87)80294-2; Field MJ, 1990, CLIN PRACTICE GUIDEL; FRANKLIN M, 1987, TORT LAW ALTERNATIVE; GRILLI R, 1991, MED CARE, V29, P50, DOI 10.1097/00005650-199101000-00005; HARVEY IM, 1987, LANCET, V1, P145; HAYWARD RSA, 1991, ANN INTERN MED, V114, P758, DOI 10.7326/0003-4819-114-9-758; HENDERSON JA, 1986, LAW CONTEMP PROBL, V49, P243, DOI 10.2307/1191425; HIRSHFELD EB, 1990, JAMA-J AM MED ASSOC, V263, P1556; Holzer J F, 1990, QRB Qual Rev Bull, V16, P71; HUGHES D, 1990, MED PROFESSIONAL LIA, P2; Kelly J T, 1990, QRB Qual Rev Bull, V16, P54; KOSECOFF J, 1987, JAMA-J AM MED ASSOC, V258, P2708, DOI 10.1001/jama.258.19.2708; Leape L L, 1990, QRB Qual Rev Bull, V16, P42; LEAPE LL, 1991, NEW ENGL J MED, V324, P377, DOI 10.1056/NEJM199102073240605; LOMAS J, 1989, NEW ENGL J MED, V321, P1306, DOI 10.1056/NEJM198911093211906; MANUEL BM, 1990, NEW ENGL J MED, V322, P627, DOI 10.1056/NEJM199003013220912; PUSEY A, 1991, ANNOTATED DIRECTORY, P2; RELMAN AS, 1990, NEW ENGL J MED, V322, P626, DOI 10.1056/NEJM199003013220911; REYNOLDS RA, 1987, JAMA-J AM MED ASSOC, V257, P2776, DOI 10.1001/jama.257.20.2776; ROBINSON GO, 1986, LAW CONTEMP PROBL, V49, P5, DOI 10.2307/1191413; ROPER WL, 1988, NEW ENGL J MED, V319, P1197, DOI 10.1056/NEJM198811033191805; SALES P, 1987, TECH REV, V10, P43; STEPHENSON GM, 1990, REP MED GUIDELINES O, V1, P7; WEILER P, 1990, CALL ACTION, V2; WESSEL, 1988, JURIMETRICS J, V28, P379; 1988, MONITORING HLTH CARE; 1990, GAOTHRD9024 GEN ACC; 1988, PROFESSIONAL LIABILI; 1990, PATIENTS DOCTORS LAW; 1989, LISTING PRACTICE GUI	42	56	57	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 27	1991	266	20					2856	2860		10.1001/jama.266.20.2856	http://dx.doi.org/10.1001/jama.266.20.2856			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GQ722	1942453				2022-12-24	WOS:A1991GQ72200034
J	SAKAI, K; MIYASHITA, Y				SAKAI, K; MIYASHITA, Y			NEURAL ORGANIZATION FOR THE LONG-TERM-MEMORY OF PAIRED ASSOCIATES	NATURE			English	Article							INFERIOR TEMPORAL NEURONS; CORTEX; MONKEY; LOBECTOMY; CORRELATE; STIMULUS; MACAQUE	MOST of our long-term memories of episodes or objects are organized so that we can retrieve them by association. Clinical neuropsychologists assess human memory by the paired-associate learning test, in which a series of paired words or figures is presented and the subject is then asked to retrieve the other pair member associated with each cue 1. Patients with lesions of the temporal lobe show marked impairment in this test 2-6. In our study, we trained monkeys in a pair-association task 7 using a set of computer-generated paired patterns. We found two types of task-related neurons in the anterior temporal cortex. One type selectively responded to both pictures of the paired associates. The other type, which had the strongest response to one picture during the cue presentation, exhibited increasing activity during the delay period when the associate of that picture was used as a cue. These results provide new evidence that single neurons acquire selectivity for visual patterns through associative learning. They also indicate neural mechanisms for storage and retrieval in the long-term memory of paired associates.			SAKAI, K (corresponding author), UNIV TOKYO,SCH MED,DEPT PHYSIOL,7-3-1 HONGO,BUNKYO KU,TOKYO 113,JAPAN.		Miyashita, Yasushi/B-7171-2019; Rohlf, F J/A-8710-2008	Miyashita, Yasushi/0000-0003-3496-8637; 				ARTOLA A, 1987, NATURE, V330, P649, DOI 10.1038/330649a0; BRUCE CJ, 1985, J NEUROPHYSIOL, V53, P603, DOI 10.1152/jn.1985.53.3.603; Darley, 1967, BRAIN MECH UNDERLY, P122; DESIMONE R, 1984, J NEUROSCI, V4, P2051; FREGNAC Y, 1988, NATURE, V333, P367, DOI 10.1038/333367a0; FUNAHASHI S, 1989, J NEUROPHYSIOL, V61, P331, DOI 10.1152/jn.1989.61.2.331; GOLDSTEIN LH, 1988, CORTEX, V24, P41, DOI 10.1016/S0010-9452(88)80016-9; GROSS CG, 1972, J NEUROPHYSIOL, V35, P96, DOI 10.1152/jn.1972.35.1.96; INSAUSTI R, 1987, J COMP NEUROL, V264, P356, DOI 10.1002/cne.902640306; JONES MK, 1974, NEUROPSYCHOLOGIA, V12, P21, DOI 10.1016/0028-3932(74)90023-2; MAURITZ KH, 1986, EXP BRAIN RES, V61, P229; MEYER V, 1955, J NEUROL NEUROSUR PS, V18, P44, DOI 10.1136/jnnp.18.1.44; Milner B, 1972, Clin Neurosurg, V19, P421; MIYASHITA Y, 1988, NATURE, V331, P68, DOI 10.1038/331068a0; MIYASHITA Y, 1988, NATURE, V335, P817, DOI 10.1038/335817a0; MURRAY E A, 1988, Society for Neuroscience Abstracts, V14, P2; PERRETT DI, 1982, EXP BRAIN RES, V47, P329; PETRIDES M, 1985, NEUROPSYCHOLOGIA, V23, P601, DOI 10.1016/0028-3932(85)90062-4; ROLLS ET, 1989, J NEUROSCI, V9, P1835; SCHWARTZ EL, 1983, P NATL ACAD SCI-BIOL, V80, P5776, DOI 10.1073/pnas.80.18.5776; Snedecor GW, 1989, STAT METHODS, P97; Squire L. R., 1984, MEMORY CONSOLIDATION, P185; WEBSTER MJ, 1991, J NEUROSCI, V11, P1095; Wechsler D., 1987, WMS R WECHSLER MEMOR; ZAHN CT, 1972, IEEE T COMPUT, VC 21, P269, DOI 10.1109/TC.1972.5008949	25	513	517	0	21	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 14	1991	354	6349					152	155		10.1038/354152a0	http://dx.doi.org/10.1038/354152a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GP880	1944594				2022-12-24	WOS:A1991GP88000061
J	SLOANE, DL; LEUNG, R; CRAIK, CS; SIGAL, E				SLOANE, DL; LEUNG, R; CRAIK, CS; SIGAL, E			A PRIMARY DETERMINANT FOR LIPOXYGENASE POSITIONAL SPECIFICITY	NATURE			English	Article							LOW-DENSITY-LIPOPROTEIN; HUMAN RETICULOCYTE 15-LIPOXYGENASE; MOLECULAR-CLONING; SUBSTRATE-SPECIFICITY; HUMAN 5-LIPOXYGENASE; IRON ENVIRONMENT; EXPRESSION; PROTEIN; CDNA; 12-LIPOXYGENASE	THE three mammalian lipoxygenases are named according to the carbon position (5, 12 or 15) at which they catalyse the oxygenation of arachidonic acid 1; they are implicated in inflammatory disorders, for example 15-lipoxygenase is induced in atherosclerosis 2 and can oxidize low-density lipoprotein to its atherogenic form 3,4. To identify what determines this positional specificity, we have exchanged conserved differences in the isoforms of 12- and 15-lipoxygenases. Substitution of methionine with valine at position 418 of human 15-lipoxygenase results in an enzyme that performs 12- and 15-lipoxygenation equally. This effect can be mimicked by incubating wild-type 15-lipoxygenase with a synthetically altered substrate which has its doubly allylic methylene carbons shifted by one carbon relative to arachidonic acid. Other mutations at the neighbouring amino acids 416 and 417 give an enzyme which performs 12- and 15-lipoxygenation in a ratio of 15:1. These results indicate that this region might position the substrate in the active site.	UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco								BALCAREK JM, 1988, J BIOL CHEM, V263, P13937; BRYANT RW, 1982, J BIOL CHEM, V257, P6050; CRAIK CS, 1985, SCIENCE, V228, P291, DOI 10.1126/science.3838593; DEMARZO N, IN PRESS AM J PHYSL; DIXON RAF, 1988, P NATL ACAD SCI USA, V85, P416, DOI 10.1073/pnas.85.2.416; DUNHAM WR, 1990, EUR J BIOCHEM, V190, P611, DOI 10.1111/j.1432-1033.1990.tb15616.x; FERSHT AR, 1985, NATURE, V314, P235, DOI 10.1038/314235a0; FUNK CD, 1990, P NATL ACAD SCI USA, V87, P5638, DOI 10.1073/pnas.87.15.5638; HAMBERG M, 1967, J BIOL CHEM, V242, P5329; KUHN H, 1990, J BIOL CHEM, V265, P16300; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MATSUMOTO T, 1988, P NATL ACAD SCI USA, V85, P26, DOI 10.1073/pnas.85.1.26; NAVARATNAM S, 1988, BIOCHIM BIOPHYS ACTA, V956, P70, DOI 10.1016/0167-4838(88)90299-3; NGUYEN T, IN PRESS J BIOL CHEM; PISTORIUS EK, 1974, J BIOL CHEM, V249, P3183; PONDER JW, 1987, J MOL BIOL, V1939, P7751; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIBATA D, 1988, J BIOL CHEM, V263, P6816; SIGAL E, 1988, BIOCHEM BIOPH RES CO, V157, P457, DOI 10.1016/S0006-291X(88)80271-7; SIGAL E, 1990, J BIOL CHEM, V265, P5113; SLOANE DL, 1990, BIOMED BIOCHIM ACTA, V49, pS11; SPARROW CP, 1988, J LIPID RES, V29, P745; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; WELLS JA, 1987, P NATL ACAD SCI USA, V84, P5167, DOI 10.1073/pnas.84.15.5167; WILKS HM, 1988, SCIENCE, V242, P1541, DOI 10.1126/science.3201242; YLAHERTTUALA S, 1990, P NATL ACAD SCI USA, V87, P6959, DOI 10.1073/pnas.87.18.6959; YOSHIMOTO T, 1990, P NATL ACAD SCI USA, V87, P2142, DOI 10.1073/pnas.87.6.2142	28	190	193	0	11	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 14	1991	354	6349					149	152		10.1038/354149a0	http://dx.doi.org/10.1038/354149a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GP880	1944593				2022-12-24	WOS:A1991GP88000060
J	WASHINGTON, AE; KATZ, P				WASHINGTON, AE; KATZ, P			COST OF AND PAYMENT SOURCE FOR PELVIC INFLAMMATORY DISEASE - TRENDS AND PROJECTIONS, 1983 THROUGH 2000	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INFERTILE WOMEN; UNITED-STATES	Pelvic inflammatory disease (PID) and its sequelae affect millions of women in the United States at substantial costs. To estimate these total costs annually and to determine payment sources, we analyzed data from local, state, and national sources. Direct costs for PID and PID-associated ectopic pregnancy and infertility were estimated to be $2.7 billion, and indirect costs were estimated to be $1.5 billion, for a total cost of $4.2 billion in 1990. Overall, private insurance covered the largest portion of the direct costs of PID (41%), followed by public payment sources (30%). However, the proportion of payments made by private insurance appears to be decreasing, while that by public payment sources is increasing. In the year 2000, costs associated with PID are projected to approach $10 billion if the current PID incidence persists, with an increasing proportion of this expense burdening public institutions. Prevention of PID is needed both to reduce human suffering and to contain rising costs.	UNIV CALIF SAN FRANCISCO,SCH MED,DEPT OBSTET GYNECOL & REPROD SCI,SAN FRANCISCO,CA 94109; UNIV CALIF SAN FRANCISCO,SCH MED,DEPT EPIDEMIOL & BIOSTAT,SAN FRANCISCO,CA 94109	University of California System; University of California San Francisco; University of California System; University of California San Francisco	WASHINGTON, AE (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,CTR REPROD HLTH POLICY RES,INST HLTH POLICY STUDIES,SAN FRANCISCO,CA 94109, USA.				NIAID NIH HHS [AI24768] Funding Source: Medline; PHS HHS [282-88-0018] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI024768] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BLENDON RJ, 1986, NEW ENGL J MED, V314, P1160, DOI 10.1056/NEJM198605013141806; CATES W, 1990, EPIDEMIOL REV, V12, P199, DOI 10.1093/oxfordjournals.epirev.a036054; FORREST J, 1989, NEED AVAILABILITY FI; GUMP DW, 1983, AM J OBSTET GYNECOL, V146, P153, DOI 10.1016/0002-9378(83)91044-X; HIRSCH MB, 1987, FERTIL STERIL, V47, P618; METHOD MW, 1987, J REPROD MED, V32, P759; NETTLEMAN MD, 1989, SEX TRANSM DIS, V16, P36, DOI 10.1097/00007435-198901000-00008; Rice D P, 1985, Health Care Financ Rev, V7, P61; ROLFS RT, 1990, SEP P CTR DIS CONTR; SCHIFF RL, 1986, NEW ENGL J MED, V314, P552, DOI 10.1056/NEJM198602273140905; SWEET RL, 1990, INFECT DIS FEMALE GE, P241; WASHINGTON AE, 1991, JAMA-J AM MED ASSOC, V266, P2574, DOI 10.1001/jama.266.18.2574; WASHINGTON AE, 1984, JAMA-J AM MED ASSOC, V251, P2529, DOI 10.1001/jama.251.19.2529; WASHINGTON AE, 1986, JAMA-J AM MED ASSOC, V255, P1735, DOI 10.1001/jama.255.13.1735; WASHINGTON AE, 1985, J ADOLESCENT HEALTH, V6, P298, DOI 10.1016/S0197-0070(85)80067-X; WESTROM L, 1981, BRIT MED J, V282, P15, DOI 10.1136/bmj.282.6257.15; WESTROM L, 1980, AM J OBSTET GYNECOL, V138, P880, DOI 10.1016/0002-9378(80)91077-7; 1987, PHS871589 US DEP HLT; 1989, PATIENT DISCHARGE DA; 1989, INT CLASSIFICATION D; 1989, SOCIOECONOMIC CHARAC; 1989, STATISTICAL ABSTRACT; 1991, MMWR-MORBID MORTAL W, V40, pS1; 1988, SEXUALLY TRANSMITTED; 1990, MMWR-MORBID MORTAL W, V39, P401	25	153	158	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 13	1991	266	18					2565	2569		10.1001/jama.266.18.2565	http://dx.doi.org/10.1001/jama.266.18.2565			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GN660	1942401				2022-12-24	WOS:A1991GN66000032
J	CUNNINGHAM, BC; ULTSCH, M; DEVOS, AM; MULKERRIN, MG; CLAUSER, KR; WELLS, JA				CUNNINGHAM, BC; ULTSCH, M; DEVOS, AM; MULKERRIN, MG; CLAUSER, KR; WELLS, JA			DIMERIZATION OF THE EXTRACELLULAR DOMAIN OF THE HUMAN GROWTH-HORMONE RECEPTOR BY A SINGLE HORMONE MOLECULE	SCIENCE			English	Article							MONOCLONAL-ANTIBODIES; SCANNING MUTAGENESIS; PROLACTIN RECEPTOR; ESCHERICHIA-COLI; SUPERFAMILY; FAMILY	Human growth hormone (hGH) forms a 1:2 complex with the extracellular domain of its receptor-binding protein (hGHbp) as studied by crystallization, size exclusion chromatography, calorimetry, and a previously undescribed fluorescence quenching assay. These and other experiments with protein engineered variants of hGH have led to the identification of the binding determinants for two distinct but adjacent sites on hGH for the hGHbp, and the data indicated that there are two overlapping binding sites on the hGHbp for hGH. Furthermore, the binding of hGH to the hGHbp occurred sequentially; a first hGHbp molecule bound to site 1 on hGH and then a second hGHbp bound to site 2. Hormone-induced receptor dimerization is proposed to be relevant to the signal transduction mechanism for the hGH receptor and other related cytokine receptors.	GENENTECH INC,DEPT PROT ENGN,460 POINT SAN BRUNO BLVD,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT MED & ANALYT CHEM,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT PROT CHEM,S SAN FRANCISCO,CA 94080	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech			Wells, Jim A/O-9854-2016	Clauser, Karl/0000-0002-1052-9456				ABDELMEGUID SS, 1987, P NATL ACAD SCI USA, V84, P6434, DOI 10.1073/pnas.84.18.6434; BARNARD R, 1985, BIOCHEM J, V231, P459, DOI 10.1042/bj2310459; BARNARD R, 1984, ENDOCRINOLOGY, V115, P1805, DOI 10.1210/endo-115-5-1805; BASS S, 1990, PROTEINS, V8, P309, DOI 10.1002/prot.340080405; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BEWLEY TA, 1970, ARCH BIOCHEM BIOPHYS, V138, P338, DOI 10.1016/0003-9861(70)90315-2; BINDER L, 1990, MOL ENDOCRINOL, V4, P7; CLARK RD, UNPUB; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; CUNNINGHAM BA, UNPUB; CUNNINGHAM BC, 1991, P NATL ACAD SCI USA, V88, P3407, DOI 10.1073/pnas.88.8.3407; CUNNINGHAM BC, 1990, SCIENCE, V247, P1461, DOI 10.1126/science.2321008; CUNNINGHAM BC, 1989, SCIENCE, V243, P1330, DOI 10.1126/science.2466339; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DEVOS B, UNPUB; DUKOVICH M, 1987, NATURE, V327, P518, DOI 10.1038/327518a0; ELBERG G, 1990, J BIOL CHEM, V265, P14770; FENDLEY B, UNPUB; FUH G, 1990, J BIOL CHEM, V265, P3111; GRIEP MA, 1988, BIOCHEMISTRY-US, V27, P5210, DOI 10.1021/bi00414a040; GUNTHER N, 1990, J BIOL CHEM, V265, P22082; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; LAX I, 1991, J BIOL CHEM, V266, P13828; LOWMAN HB, 1991, J BIOL CHEM, V260, P10982; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; McPherson A., 1989, PREPARATION ANAL PRO; MULKERRIN MG, UNPUB; OLSON KB, UNPUB; PATTHY L, 1990, CELL, V61, P13, DOI 10.1016/0092-8674(90)90208-V; TESHIGAWARA K, 1987, J EXP MED, V165, P223, DOI 10.1084/jem.165.1.223; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	32	841	892	0	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 8	1991	254	5033					821	825		10.1126/science.1948064	http://dx.doi.org/10.1126/science.1948064			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GN833	1948064				2022-12-24	WOS:A1991GN83300034
J	HENNECKE, F; KOLMAR, H; BRUNDL, K; FRITZ, HJ				HENNECKE, F; KOLMAR, H; BRUNDL, K; FRITZ, HJ			THE VSR GENE-PRODUCT OF ESCHERICHIA-COLI K-12 IS A STRAND-SPECIFIC AND SEQUENCE-SPECIFIC DNA MISMATCH ENDONUCLEASE	NATURE			English	Article							SHORT PATCH REPAIR; ESCHERICHIA-COLI; POLYMERASE-I; LAMBDA; 5-METHYL-CYTOSINE; RECOMBINATION; METHYLATION; GLYCOSYLASE; REPRESSOR; MECHANISM	IN Escherichia coli K-12, the Dcm methyltransferase catalyses methylation of the inner cytosine residue in the sequence CC(A)/(T)GG 1,2. Hydrolytic deamination of 5-methylcytosine bases in DNA leads to thymine residues, and hence to T/G mismatches, pre-mutagenic DNA lesions consisting of two natural DNA constituents and thus devoid of an obvious marker of the damaged DNA strand. These mismatches are corrected by the VSP repair pathway, which is characterized by very short patches of DNA repair synthesis 3,4. It depends on genes vsr 5 and polA 6 and is strongly stimulated by mutL and mutS 7-9. The vsr gene product (Vsr; M(r) 18,000) was purified and characterized as a DNA mismatch endonuclease, a unique and hitherto unknown type of enzyme. Vsr endonuclease nicks double-stranded DNA within the sequence CT(A)/(T)GN or NT(A)/(T)GG next to the underlined thymidine residue, which is mismatched to 2'-deoxyguanosine. The incision is mismatch-dependent and strand-specific. These results illustrate how Vsr endonuclease initiates VSP mismatch repair.			HENNECKE, F (corresponding author), UNIV GOTTINGEN,INST MOLEK GENET,GRISEBACHSTR 8,W-3400 GOTTINGEN,GERMANY.		Kolmar, Harald/AAK-8316-2021	Kolmar, Harald/0000-0002-8210-1993				AU KG, 1989, P NATL ACAD SCI USA, V86, P8877, DOI 10.1073/pnas.86.22.8877; BAMBARA RA, 1978, J BIOL CHEM, V253, P413; BEAUCAGE SL, 1981, TETRAHEDRON LETT, V22, P1859, DOI 10.1016/S0040-4039(01)90461-7; CARTWRIGHT SJ, 1984, BIOCHEM J, V221, P505, DOI 10.1042/bj2210505; COULONDRE C, 1978, NATURE, V274, P775, DOI 10.1038/274775a0; DZIDIC S, 1989, MOL GEN GENET, V217, P254, DOI 10.1007/BF02464889; HANCK T, 1989, NUCLEIC ACIDS RES, V17, P5844, DOI 10.1093/nar/17.14.5844; JONES M, 1987, J MOL BIOL, V194, P155, DOI 10.1016/0022-2836(87)90724-8; KRAMER B, 1984, CELL, V38, P879, DOI 10.1016/0092-8674(84)90283-6; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LIEB M, 1987, J BACTERIOL, V169, P5241, DOI 10.1128/jb.169.11.5241-5246.1987; LIEB M, 1985, MOL GEN GENET, V199, P465; LIEB M, 1986, GENETICS, V114, P1041; LIEB M, 1983, MOL GEN GENET, V191, P118, DOI 10.1007/BF00330898; Maniatis T., 1982, MOL CLONING; MARINUS MG, 1973, MOL GEN GENET, V127, P47, DOI 10.1007/BF00267782; Maxam A M, 1980, Methods Enzymol, V65, P499; POHLNER J, 1987, NATURE, V325, P458, DOI 10.1038/325458a0; REYNAUD CA, 1987, CELL, V48, P379, DOI 10.1016/0092-8674(87)90189-9; SCHLAGMAN S, 1976, J BACTERIOL, V126, P990, DOI 10.1128/JB.126.2.990-996.1976; SOHAIL A, 1990, J BACTERIOL, V172, P4214, DOI 10.1128/jb.172.8.4214-4221.1990; STANSSENS P, 1989, NUCLEIC ACIDS RES, V17, P4441, DOI 10.1093/nar/17.12.4441; VONWILCKENBERGMANN B, 1982, P NATL ACAD SCI-BIOL, V79, P2427; WIEBAUER K, 1990, P NATL ACAD SCI USA, V87, P5842, DOI 10.1073/pnas.87.15.5842; WYSOCKI LJ, 1989, ANNU REV BIOCHEM, V58, P509; ZELL R, 1987, EMBO J, V6, P1809, DOI 10.1002/j.1460-2075.1987.tb02435.x	26	125	128	1	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 24	1991	353	6346					776	778		10.1038/353776a0	http://dx.doi.org/10.1038/353776a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GL696	1944537				2022-12-24	WOS:A1991GL69600075
J	WALSH, BW; SCHIFF, I; ROSNER, B; GREENBERG, L; RAVNIKAR, V; SACKS, FM				WALSH, BW; SCHIFF, I; ROSNER, B; GREENBERG, L; RAVNIKAR, V; SACKS, FM			EFFECTS OF POSTMENOPAUSAL ESTROGEN REPLACEMENT ON THE CONCENTRATIONS AND METABOLISM OF PLASMA-LIPOPROTEINS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LOW-DENSITY LIPOPROTEIN; POST-MENOPAUSAL WOMEN; APOLIPOPROTEIN-B; HEART-DISEASE; TRIGLYCERIDE KINETICS; SERUM-LIPOPROTEINS; LONG-TERM; ESTRADIOL; HORMONE; CHOLESTEROL	Background. Postmenopausal estrogen-replacement therapy may reduce the risk of cardiovascular disease, and this beneficial effect may be mediated in part by favorable changes in plasma lipid levels. However, the effects on plasma lipoprotein levels of postmenopausal estrogens in the low doses currently used have not been precisely quantified, and the mechanism of these effects is unknown. Methods. We conducted two randomized, double-blind crossover studies in healthy postmenopausal women who had normal lipid values at base line. In study 1, 31 women received placebo and conjugated estrogens at two doses (0.625 mg and 1.25 mg per day), each treatment for three months. In study 2, nine women received placebo, oral micronized estradiol (2 mg per day), and transdermal estradiol (0.1 mg twice a week), each treatment for six weeks. The metabolism of very-low-density lipoprotein (VLDL) and low-density lipoprotein (LDL) was measured by endogenously labeling their protein component, apolipoprotein B. Results. In study 1, the conjugated estrogens at doses of 0.625 mg per day and 1.25 mg per day decreased the mean LDL cholesterol level by 15 percent (95 percent confidence interval, 11 to 19 percent; P < 0.0001) and 19 percent (95 percent confidence interval, 15 to 23 percent; P < 0.0001), respectively; increased the HDL cholesterol level by 16 percent (95 percent confidence interval, 12 to 20 percent; P < 0.0001) and 18 percent (95 percent confidence interval, 14 to 22 percent; P < 0.0001), respectively; and increased VLDL triglyceride levels by 24 percent (95 percent confidence interval, 8 to 40 percent; P < 0.003) and 42 percent (95 percent confidence interval, 26 to 58 percent; P < 0.0001), respectively. In study 2, oral estradiol increased the mean concentration of large VLDL apolipoprotein B by 30 +/- 10 percent (P = 0.05) by increasing its production rate by 82 +/- 18 percent P < 0.01). Most of this additional large VLDL was cleared directly from the circulation and was not converted to small VLDL or LDL. Oral estradiol reduced LDL cholesterol concentrations by 14 +/- 3 percent (P < 0.005), because LDL catabolism increased by 36 +/- 7 percent (P < 0.005). The oral estradiol increased the HDL cholesterol level by 15 +/- 2 percent (P < 0.0001). Transdermal estradiol had no effect. Conclusions. The postmenopausal use of oral estrogens in low doses favorably alters LDL and HDL levels that may protect women against atherosclerosis, while minimizing potentially adverse effects on triglyceride levels. The decrease in LDL levels results from accelerated LDL catabolism; the increase in triglyceride levels results from increased production of large, triglyceride-rich VLDL.	BRIGHAM & WOMENS HOSP, DEPT MED, CHANNING LAB, 180 LONGWOOD AVE, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT CLIN EPIDEMIOL & BIOSTAT, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT GYNECOL, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, CLIN RES CTR, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital					NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR002635] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034980] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-02635] Funding Source: Medline; NHLBI NIH HHS [HL-34980] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bachorik P S, 1986, Methods Enzymol, V129, P78; BARBARAS R, 1987, BIOCHEM BIOPH RES CO, V142, P63, DOI 10.1016/0006-291X(87)90451-7; BARRETTCONNOR E, 1989, JAMA-J AM MED ASSOC, V261, P2095, DOI 10.1001/jama.261.14.2095; BUSH TL, 1987, CIRCULATION, V75, P1102, DOI 10.1161/01.CIR.75.6.1102; CHETKOWSKI RJ, 1986, NEW ENGL J MED, V314, P1615, DOI 10.1056/NEJM198606193142505; CRYER DR, 1986, J LIPID RES, V27, P508; EGUSA G, 1983, J LIPID RES, V24, P1261; ERIKSSON M, 1989, J CLIN INVEST, V84, P802, DOI 10.1172/JCI114239; GLUECK CJ, 1975, METABOLISM, V24, P537, DOI 10.1016/0026-0495(75)90078-5; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HENDERSON BE, 1986, AM J OBSTET GYNECOL, V154, P1181, DOI 10.1016/0002-9378(86)90696-4; HENDERSON BE, 1991, ARCH INTERN MED, V151, P75, DOI 10.1001/archinte.151.1.75; JENSEN J, 1987, AM J OBSTET GYNECOL, V156, P66, DOI 10.1016/0002-9378(87)90204-3; KISSEBAH AH, 1973, HORM METAB RES, V5, P184, DOI 10.1055/s-0028-1093969; KLETZKY OA, 1975, AM J OBSTET GYNECOL, V121, P688, DOI 10.1016/0002-9378(75)90474-3; LINDGREN FT, 1972, BLOOD LIPIDS LIPOPRO, P181; LINDSAY R, 1984, OBSTET GYNECOL, V63, P759; LOBO RA, 1980, AM J OBSTET GYNECOL, V138, P714, DOI 10.1016/0002-9378(80)90094-0; MANDEL FP, 1983, J CLIN ENDOCR METAB, V57, P133, DOI 10.1210/jcem-57-1-133; MANNINEN V, 1988, JAMA-J AM MED ASSOC, V260, P641, DOI 10.1001/jama.260.5.641; MASHCHAK CA, 1982, AM J OBSTET GYNECOL, V144, P511, DOI 10.1016/0002-9378(82)90218-6; MILLER KW, 1984, J BIOL CHEM, V259, P5277; OHTA T, 1988, J LIPID RES, V29, P721; OHTA T, 1989, ARTERIOSCLEROSIS, V9, P90, DOI 10.1161/01.ATV.9.1.90; PACKARD CJ, 1984, J CLIN INVEST, V74, P2178, DOI 10.1172/JCI111644; PUCHOIS P, 1987, ATHEROSCLEROSIS, V68, P35, DOI 10.1016/0021-9150(87)90091-8; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P365; ROSNER B, 1989, J AM STAT ASSOC, V84, P373, DOI 10.2307/2289920; ROSNER B, 1982, FUNDAMENTALS BIOSTAT, P189; ROSS RK, 1981, LANCET, V1, P858; ROSS RK, 1988, AM J PUBLIC HEALTH, V78, P516, DOI 10.2105/AJPH.78.5.516; SACKS FM, 1990, ANN NY ACAD SCI, V592, P272; SHARF M, 1985, GYNECOL OBSTET INVES, V19, P207, DOI 10.1159/000299035; SIMONS LA, 1983, J LIPID RES, V24, P192; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; STANCZYK FZ, 1988, AM J OBSTET GYNECOL, V159, P1540, DOI 10.1016/0002-9378(88)90591-1; TASKINEN MR, 1987, LIPOPROTEIN LIPASE, P201; TIKKANEN MJ, 1985, FEBS LETT, V181, P160, DOI 10.1016/0014-5793(85)81134-0; VAITUKAITIS JL, 1973, J CLIN ENDOCR METAB, V37, P653, DOI 10.1210/jcem-37-5-653; VELDHUIS JD, 1985, ENDOCRINOLOGY, V117, P1321, DOI 10.1210/endo-117-4-1321; WEISS NS, 1980, NEW ENGL J MED, V303, P1195, DOI 10.1056/NEJM198011203032102; WINDLER EET, 1980, J BIOL CHEM, V255, P464; WOLFE BM, 1989, J CLIN INVEST, V83, P40, DOI 10.1172/JCI113882; ZILVERSMIT DB, 1960, AM J MED, V29, P832, DOI 10.1016/0002-9343(60)90117-0; NIH801527 DIV HEART, V1; 1988, SAS USERS GUIDE STAT	46	1055	1084	1	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 24	1991	325	17					1196	1204		10.1056/NEJM199110243251702	http://dx.doi.org/10.1056/NEJM199110243251702			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GL282	1922206				2022-12-24	WOS:A1991GL28200002
J	SCHOENLEIN, RW; PETEANU, LA; MATHIES, RA; SHANK, CV				SCHOENLEIN, RW; PETEANU, LA; MATHIES, RA; SHANK, CV			THE 1ST STEP IN VISION - FEMTOSECOND ISOMERIZATION OF RHODOPSIN	SCIENCE			English	Article							PICOSECOND LASER PHOTOLYSIS; CIS-TRANS ISOMERIZATION; ABSORPTION-SPECTRA; ROOM-TEMPERATURE; BATHORHODOPSIN; DYNAMICS; PHOTORHODOPSIN	The kinetics of the primary event in vision have been resolved with the use of femtosecond optical measurement techniques. The 11-cis retinal prosthetic group of rhodopsin is excited with a 35-femtosecond pump pulse at 500 nanometers, and the transient changes in absorption are measured between 450 and 580 nanometers with a 10-femtosecond probe pulse. Within 200 femtoseconds, an increased absorption is observed between 540 and 580 nanometers, indicating the formation of photoproduct on this time scale. These measurements demonstrate that the first step in vision, the 11-cis --> 11-trans torsional isomerization of the rhodopsin chromophore, is essentially complete in only 200 femtoseconds.	UNIV CALIF BERKELEY,DEPT CHEM,BERKELEY,CA 94720	University of California System; University of California Berkeley	SCHOENLEIN, RW (corresponding author), UNIV CALIF BERKELEY LAWRENCE BERKELEY LAB,BERKELEY,CA 94720, USA.		Schoenlein, Robert W/D-1301-2014; Peteanu, Linda/O-5581-2017	Schoenlein, Robert W/0000-0002-6066-7566; Peteanu, Linda/0000-0003-0075-6521	NATIONAL EYE INSTITUTE [R01EY002051, T32EY007043, R37EY002051] Funding Source: NIH RePORTER; NEI NIH HHS [T32EY07043, EY 02051] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BIRGE RR, 1980, J AM CHEM SOC, V102, P2195, DOI 10.1021/ja00527a008; BIRGE RR, 1990, ANNU REV PHYS CHEM, V41, P683, DOI 10.1146/annurev.pc.41.100190.003343; BIRGE RW, COMMUNICATION; BUSCH GE, 1972, P NATL ACAD SCI USA, V69, P2802, DOI 10.1073/pnas.69.10.2802; DOIG SJ, 1991, J PHYS CHEM-US, V95, P6372, DOI 10.1021/j100169a054; DOUKAS AG, 1984, P NATL ACAD SCI-BIOL, V81, P4790, DOI 10.1073/pnas.81.15.4790; EYRING G, 1980, BIOCHEMISTRY-US, V19, P2410, DOI 10.1021/bi00552a020; FHAYWARD G, 1981, SCIENCE, V211, P942; FORK RL, 1987, OPT LETT, V12, P483, DOI 10.1364/OL.12.000483; FRAGNITO HL, 1989, CHEM PHYS LETT, V160, P101, DOI 10.1016/0009-2614(89)87564-5; HURLEY J, 1977, PURE APPL CHEM, V49, P341; KANDORI H, 1989, BIOPHYS J, V56, P453, DOI 10.1016/S0006-3495(89)82692-X; LOPPNOW GR, 1988, BIOPHYS J, V54, P35, DOI 10.1016/S0006-3495(88)82928-X; MATHIES RA, 1988, SCIENCE, V240, P777, DOI 10.1126/science.3363359; MONGER TG, 1979, BIOPHYS J, V27, P105, DOI 10.1016/S0006-3495(79)85205-4; PALINGS I, 1987, BIOCHEMISTRY-US, V26, P254; POLLARD WT, 1990, CHEM PHYS LETT, V168, P239, DOI 10.1016/0009-2614(90)85603-A; POLLARD WT, 1990, J CHEM PHYS, V92, P4012, DOI 10.1063/1.457815; SCHOENLEIN RW, 1991, APPL PHYS LETT, V58, P801, DOI 10.1063/1.104494; SHANK CV, 1986, SCIENCE, V233, P1276, DOI 10.1126/science.233.4770.1276; SHICHIDA Y, 1984, PHOTOBIOCH PHOTOBIOP, V7, P221; SPALINK JD, 1983, P NATL ACAD SCI-BIOL, V80, P1887, DOI 10.1073/pnas.80.7.1887; WALD G, 1968, SCIENCE, V162, P230, DOI 10.1126/science.162.3850.230; WEISS RM, 1979, J AM CHEM SOC, V101, P6131, DOI 10.1021/ja00514a051; YOSHIZAWA T, 1963, NATURE, V197, P1279, DOI 10.1038/1971279a0	25	710	721	2	170	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 18	1991	254	5030					412	415		10.1126/science.1925597	http://dx.doi.org/10.1126/science.1925597			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GK729	1925597				2022-12-24	WOS:A1991GK72900043
J	KOSMAN, D; IP, YT; LEVINE, M; ARORA, K				KOSMAN, D; IP, YT; LEVINE, M; ARORA, K			ESTABLISHMENT OF THE MESODERM-NEUROECTODERM BOUNDARY IN THE DROSOPHILA EMBRYO	SCIENCE			English	Article							SCUTE GENE-COMPLEX; SINGLE-MINDED GENE; NUCLEAR-LOCALIZATION; DORSOVENTRAL PATTERN; NERVOUS-SYSTEM; EXPRESSION; PROTEIN; MELANOGASTER; CELLS; NEUROGENESIS	A gradient of the maternal morphogen dorsal establishes asymmetric patterns of gene expression along the dorsal-ventral axis of early embryos and activates the regulatory genes twist and snail, which are responsible for the differentiation of the ventral mesoderm. Expression of snail is restricted to the presumptive mesoderm, and the sharp lateral limits of this expression help to define the mesoderm-neuroectoderm boundary by repressing the expression of regulatory genes that are responsible for the differentiation of the neuroectoderm. The snail gene encodes a zinc finger protein, and neuroectodermal genes that are normally restricted to ventral-lateral regions of early embryos are expressed throughout ventral regions of snail- mutants. The formation of the sharp snail border involves dosage-sensitive interactions between dorsal and twist, which encode regulatory proteins that are related to the mammalian transcription factors NF-kB and MyoD, respectively.			KOSMAN, D (corresponding author), UNIV CALIF SAN DIEGO,CTR MOLEC GENET,DEPT BIOL,LA JOLLA,CA 92093, USA.			Levine, Michael/0000-0001-7629-0081	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046638, R37GM046638] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 46638] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERGA A, 1991, DEVELOPMENT, V111, P983; ALONSON MC, 1988, EMBO J, V7, P2588; BIER E, 1990, GENE DEV, V4, P190, DOI 10.1101/gad.4.2.190; BOULAY JL, 1987, NATURE, V330, P395, DOI 10.1038/330395a0; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; CABRERA CV, 1987, CELL, V50, P425, DOI 10.1016/0092-8674(87)90496-X; CAMPOSORTEGA JA, 1990, EUR J BIOCHEM, V190, P1, DOI 10.1111/j.1432-1033.1990.tb15538.x; CREWS ST, 1988, CELL, V52, P143, DOI 10.1016/0092-8674(88)90538-7; HAENLIN M, 1990, DEVELOPMENT, V110, P905; HULSKAMP M, 1990, NATURE, V346, P577, DOI 10.1038/346577a0; IP YT, 1991, CELL, V64, P439; KOSMAN D, UNPUB; LEPTIN M, 1991, GENE DEV, V5, P1568, DOI 10.1101/gad.5.9.1568; LEPTIN M, 1990, DEVELOPMENT, V110, P73; LIN YS, 1990, NATURE, V345, P359, DOI 10.1038/345359a0; MAYER U, 1988, GENE DEV, V2, P1496, DOI 10.1101/gad.2.11.1496; MCCLAY DR, 1987, ANNU REV CELL BIOL, V3, P319, DOI 10.1146/annurev.cellbio.3.1.319; MITCHISON TJ, 1983, DEV BIOL, V99, P261, DOI 10.1016/0012-1606(83)90275-0; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NAMBU JR, 1990, CELL, V63, P63, DOI 10.1016/0092-8674(90)90288-P; ROMANI S, 1987, EMBO J, V6, P2085, DOI 10.1002/j.1460-2075.1987.tb02474.x; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; Rushlow C, 1990, Semin Cell Biol, V1, P137; SIMPSON P, 1983, GENETICS, V105, P615; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; THISSE B, 1987, GENE DEV, V1, P709, DOI 10.1101/gad.1.7.709; THISSE B, 1988, EMBO J, V7, P2175, DOI 10.1002/j.1460-2075.1988.tb03056.x; THOMAS JB, 1988, CELL, V52, P133, DOI 10.1016/0092-8674(88)90537-5; VILLARES R, 1987, CELL, V50, P415, DOI 10.1016/0092-8674(87)90495-8	30	205	206	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 4	1991	254	5028					118	122		10.1126/science.1925551	http://dx.doi.org/10.1126/science.1925551			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GH605	1925551				2022-12-24	WOS:A1991GH60500043
J	HARRINGTON, LA; GREIDER, CW				HARRINGTON, LA; GREIDER, CW			TELOMERASE PRIMER SPECIFICITY AND CHROMOSOME HEALING	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; TERMINAL TRANSFERASE; DNA; TETRAHYMENA; IDENTIFICATION	CHROMOSOME healing by de novo telomere addition at non-telomeric sites has been well characterized in several organisms 1-9. The Tetrahymena telomerase ribonucleoprotein uses an internal RNA template to catalyse d(TTGGGG)n telomere addition to the 3' end of telomeric sequence in vitro and in vivo 10,11. Studies of telomerase RNA indicated that hybridization of the RNA template region, 5'-CAACCCCAA-3', to the 3' end of single-stranded telomeric oligonucleotides might be important for primer recognition and utilization 10. The apparent requirement of telomerase for pre-existing telomeric sequence has raised questions regarding its role in chromosome healing 12,13. We report here that Tetrahymena telomerase can specifically elongate single-stranded DNA oligonucleotides whose termini are not complementary to the RNA template sequence 5'-CAACCCCAA-3'. These data suggest that telomerase may be able to heal chromosomes directly in vivo.	COLD SPRING HARBOR LAB,POB 100,COLD SPRING HARBOR,NY 11724	Cold Spring Harbor Laboratory								BAROIN A, 1987, NUCLEIC ACIDS RES, V15, P1717, DOI 10.1093/nar/15.4.1717; FORNEY JD, 1988, MOL CELL BIOL, V8, P251, DOI 10.1128/MCB.8.1.251; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; GREIDER CW, 1987, CELL, V51, P887, DOI 10.1016/0092-8674(87)90576-9; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; HABER JE, 1984, GENETICS, V106, P207; HENDERSON E, 1987, CELL, V51, P899, DOI 10.1016/0092-8674(87)90577-0; HENDERSON ER, 1990, BIOCHEMISTRY-US, V29, P732, DOI 10.1021/bi00455a020; JOHNSTON RF, 1990, ELECTROPHORESIS, V11, P355, DOI 10.1002/elps.1150110503; MATSUMOTO T, 1987, MOL CELL BIOL, V7, P4424, DOI 10.1128/MCB.7.12.4424; Maxam A M, 1980, Methods Enzymol, V65, P499; McClintock B, 1941, GENETICS, V26, P234; MCCLINTOCK B, 1942, GENETICS, V28, P458; MURRAY A, 1990, NATURE, V346, P797, DOI 10.1038/346797a0; MURRAY AW, 1988, MOL CELL BIOL, V8, P4642, DOI 10.1128/MCB.8.11.4642; POLOGE LG, 1988, CELL, V55, P869, DOI 10.1016/0092-8674(88)90142-0; RICHARDS EJ, 1988, CELL, V53, P127, DOI 10.1016/0092-8674(88)90494-1; SEN D, 1990, NATURE, V344, P410, DOI 10.1038/344410a0; SEN D, 1988, NATURE, V334, P364, DOI 10.1038/334364a0; SPANGLER EA, 1988, NUCLEIC ACIDS RES, V16, P5569, DOI 10.1093/nar/16.12.5569; SUNDQUIST WI, 1989, NATURE, V342, P825, DOI 10.1038/342825a0; WHITE CI, 1990, EMBO J, V9, P663, DOI 10.1002/j.1460-2075.1990.tb08158.x; WILKIE AOM, 1990, NATURE, V346, P868, DOI 10.1038/346868a0; WILLIAMSON JR, 1989, CELL, V59, P871, DOI 10.1016/0092-8674(89)90610-7; Yao MC, 1989, MOBILE DNA, P715; YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0; ZAHLER AM, 1991, NATURE, V350, P718, DOI 10.1038/350718a0; ZAKIAN VA, 1990, TRENDS GENET, V6	28	158	169	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 3	1991	353	6343					451	454		10.1038/353451a0	http://dx.doi.org/10.1038/353451a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GH606	1896088				2022-12-24	WOS:A1991GH60600064
J	PADIAN, NS; SHIBOSKI, SC; JEWELL, NP				PADIAN, NS; SHIBOSKI, SC; JEWELL, NP			FEMALE-TO-MALE TRANSMISSION OF HUMAN-IMMUNODEFICIENCY-VIRUS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HETEROSEXUAL PARTNERS; HIV; ADULTS; WOMEN; AIDS; RISK	Objective. - To examine rates of heterosexual transmission of human immunodeficiency virus (HIV) and associated risk factors and to determine the relative efficiency of female-to-female and male-to-female transmission. Design. - Survey of infected individuals and their heterosexual partners recruited since 1985. Setting. - Participants were recruited from various HIV counseling and testing sites throughout California but were generally interviewed and tested in their homes. Participants. - Data from 379 couples at entry to the study are reported: 72 male partners of infected women and 307 female partners of infected men. The infected index case had a well-established source of risk; couples were eliminated if the direction of transmission could not be established. The majority of couples were monogamous since 1978, white, and in their 30s. Most partners did not know their serostatus at entry into the study. Main Outcome Measure. - HIV serostatus in the exposed sexual partner. Results. - We observed one probable instance (1%) of female-to-male transmission compared with 20% transmission rates in the female partners of infected men. All couples were sampled in the same way. Male index cases were more likely to be symptomatic than female index cases. Conclusions. - The odds of male-to-female transmission were signifiicantly greater than female-to-male transmission. The one case of female-to-male transmission was unique in that the couple reported numerous unprotected sexual contacts and noted several instances of vaginal and penile bleeding during intercourse.	UNIV CALIF SAN FRANCISCO,DEPT EPIDEMIOL & BIOSTAT,SAN FRANCISCO,CA 94143; UNIV CALIF BERKELEY,DEPT BIOSTAT,BERKELEY,CA 94720; UNIV CALIF BERKELEY,DEPT STAT,BERKELEY,CA 94720	University of California System; University of California San Francisco; University of California System; University of California Berkeley; University of California System; University of California Berkeley								ALNOZHA M, 1990, J ACQ IMMUN DEF SYND, V3, P193; BENETUCCI J, 1990, 6TH INT C AIDS SAN F; CHIODO F, 1990, 6TH INT C AIDS SAN F; COSTIGIOLA P, 1989, 5TH INT C AIDS MONTR; DAVIDSON S, 1989, 5TH INT C AIDS MONTR; DEVINCENZI I, 1989, 5TH INT C AIDS MONTR; DEVINCENZI I, 1990, 6TH INT C AIDS SAN F; FISCHL MA, 1987, JAMA-J AM MED ASSOC, V257, P640, DOI 10.1001/jama.257.5.640; GUINAN ME, 1987, JAMA-J AM MED ASSOC, V257, P2039; HIRA S, 1988, 4TH INT C AIDS STOCK; JOHNSON AM, 1989, AIDS, V3, P367, DOI 10.1097/00002030-198906000-00005; LAGA M, 1988, 4TH INT C AIDS STOCK; LEKATSAS AM, 1987, 3 INT C AIDS WASH; NICOLOSI A, 1990, 6TH INT C AIDS SAN F; PADIAN N, 1987, JAMA-J AM MED ASSOC, V258, P788, DOI 10.1001/jama.258.6.788; PADIAN N, 1989, 5TH INT C AIDS MONTR; PADIAN NS, 1987, REV INFECT DIS, V9, P947; PADIAN NS, 1990, J INFECT DIS, V161, P883, DOI 10.1093/infdis/161.5.883; PADIAN NS, 1990, AM J PUBLIC HEALTH, V80, P990, DOI 10.2105/AJPH.80.8.990; PAPE JW, 1987, CLIN RES, V35, P486; PETERMAN TA, 1988, JAMA-J AM MED ASSOC, V259, P55, DOI 10.1001/jama.259.1.55; PIOT P, 1989, BRIT MED J, V298, P623, DOI 10.1136/bmj.298.6674.623; POTTERAT JJ, 1987, JAMA-J AM MED ASSOC, V258, P1727; REHNET S, 1990, 6TH INT C AIDS SAN F; SION FS, 1990, 6TH INT C AIDS SAN F; STASZEWSKI S, 1989, 5 INT C AIDS MONTR; STEIGBIGEL NH, 1988, 4TH INT C AIDS STOCK; STEWART GJ, 1985, LANCET, V2, P581; VIGEVANI GM, 1988, 4TH INT C AIDS STOCK; WYKOFF RF, 1986, JAMA-J AM MED ASSOC, V255, P1704, DOI 10.1001/jama.1986.03370130059011; 1991, HIV AIDS SURVEILLANC	31	221	224	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 25	1991	266	12					1664	1667						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GF419	1886189				2022-12-24	WOS:A1991GF41900032
J	DALESSIO, DJ				DALESSIO, DJ			THYROXINE - TREATMENT FOR HEADACHE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											DALESSIO, DJ (corresponding author), SCRIPPS CLIN & RES FDN,LA JOLLA,CA 92037, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 18	1991	266	11					1573	1573						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GE458	1880895				2022-12-24	WOS:A1991GE45800043
J	GALIONE, A; LEE, HC; BUSA, WB				GALIONE, A; LEE, HC; BUSA, WB			CA2+-INDUCED CA2+ RELEASE IN SEA-URCHIN EGG HOMOGENATES - MODULATION BY CYCLIC ADP-RIBOSE	SCIENCE			English	Article							MUSCLE RYANODINE RECEPTOR; INOSITOL TRISPHOSPHATE; CALCIUM RELEASE; SARCOPLASMIC-RETICULUM; ENDOPLASMIC-RETICULUM; SYMPATHETIC NEURONS; CHROMAFFIN CELLS; XENOPUS-LAEVIS; CA-2+ RELEASE; FERTILIZATION	Calcium-induced calcium release (CICR) may function widely in calcium-mediated cell signaling, but has been most thoroughly characterized in muscle cells. In a homogenate of sea urchin eggs, which display transients in the intracellular free calcium concentration ([Ca2+]i) during fertilization and anaphase, addition of Ca2+ triggered CICR. Ca2+ release was also induced by the CICR modulators ryanodine and caffeine. Responses to both Ca2+ and CICR modulators (but not Ca2+ release mediated by inositol 1,4,5-trisphosphate) were inhibited by procaine and ruthenium red, inhibitors of CICR. Intact eggs also displayed transients of [Ca2+]i when microinjected with ryanodine. Cyclic ADP-ribose, a metabolite with potent Ca2+-releasing properties, appears to act by way of the CICR mechanism and may thus be an endogenous modulator of CICR. A CICR mechanism is present in these nonmuscle cells as is assumed in various models of intracellular Ca2+ wave propagation.	UNIV MINNESOTA, DEPT PHYSIOL, MINNEAPOLIS, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	GALIONE, A (corresponding author), JOHNS HOPKINS UNIV, DEPT BIOL, BALTIMORE, MD 21218 USA.		Lee, Hon Cheung/C-4329-2009; Galione, Antony/E-5884-2011	Galione, Antony/0000-0002-4132-7646	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD017484, R01HD022879, R29HD022879] Funding Source: NIH RePORTER; NICHD NIH HHS [HD22879, HD17484] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1988, FASEB J, V2, P3074, DOI 10.1096/fasebj.2.15.2847949; BURGOYNE RD, 1989, NATURE, V342, P72, DOI 10.1038/342072a0; BUSA WB, 1985, J CELL BIOL, V100, P1325, DOI 10.1083/jcb.100.4.1325; BUSA WB, 1985, J CELL BIOL, V101, P677, DOI 10.1083/jcb.101.2.677; CLAPPER DL, 1987, J BIOL CHEM, V262, P9561; CORNELLBELL AH, 1990, SCIENCE, V247, P470, DOI 10.1126/science.1967852; DARGE PJ, 1989, CELL REGUL, V1, P279; EISEN A, 1984, J CELL BIOL, V99, P1878, DOI 10.1083/jcb.99.5.1878; EISEN A, 1984, J CELL BIOL, V99, P1647, DOI 10.1083/jcb.99.5.1647; ELLISMAN MH, 1990, NEURON, V5, P135, DOI 10.1016/0896-6273(90)90304-X; ENDO M, 1985, CURR TOP MEMBR TRANS, V25, P181; FABIATO A, 1983, AM J PHYSIOL, V245, pC1; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; FUJIWARA A, 1990, DEV GROWTH DIFFER, V32, P303; GALIONE A, UNPUB; GILKEY JC, 1978, J CELL BIOL, V76, P448, DOI 10.1083/jcb.76.2.448; JAFFE LF, 1990, NATO ADV SCI I H-CEL, V45, P389; LAI FA, 1989, J BIOENERG BIOMEMBR, V21, P227, DOI 10.1007/BF00812070; LEE HC, 1989, J BIOL CHEM, V264, P1608; LIPSCOMBE D, 1988, NEURON, V1, P355, DOI 10.1016/0896-6273(88)90185-7; MALGAROLI A, 1990, J BIOL CHEM, V265, P3005; MARTY A, 1989, J PHYSIOL-LONDON, V419, P665, DOI 10.1113/jphysiol.1989.sp017892; MIYAZAKI S, 1986, DEV BIOL, V118, P259, DOI 10.1016/0012-1606(86)90093-X; OSIPCHUK YV, 1990, EMBO J, V9, P697, DOI 10.1002/j.1460-2075.1990.tb08162.x; PALADE P, 1989, J BIOENERG BIOMEMBR, V21, P295, DOI 10.1007/BF00812074; PALADE P, 1983, J BIOL CHEM, V258, P8098; RAKOW TL, 1990, P NATL ACAD SCI USA, V87, P9285, DOI 10.1073/pnas.87.23.9285; RODGERS MT, UNPUB; ROONEY TA, 1990, J BIOL CHEM, V265, P10792; SCHMID A, 1990, NATURE, V346, P374, DOI 10.1038/346374a0; SHOSHANBARMATZ V, 1990, FEBS LETT, V263, P317, DOI 10.1016/0014-5793(90)81403-B; SWANN K, 1986, J CELL BIOL, V103, P2333, DOI 10.1083/jcb.103.6.2333; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; THAYER SA, 1988, MOL PHARMACOL, V34, P664; WAKUI M, 1990, CELL, V63, P1025, DOI 10.1016/0092-8674(90)90505-9; WALSETH TF, J CELL BIOL, V111, pA467; WHITAKER M, 1984, NATURE, V312, P636, DOI 10.1038/312636a0; WHITAKER MJ, 1985, BIOL FERTILIZATION, V3, P167	39	577	585	0	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 6	1991	253	5024					1143	1146		10.1126/science.1909457	http://dx.doi.org/10.1126/science.1909457			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GD808	1909457				2022-12-24	WOS:A1991GD80800034
J	WANG, H; KAVANAUGH, MP; NORTH, RA; KABAT, D				WANG, H; KAVANAUGH, MP; NORTH, RA; KABAT, D			CELL-SURFACE RECEPTOR FOR ECOTROPIC MURINE RETROVIRUSES IS A BASIC-AMINO-ACID TRANSPORTER	NATURE			English	Article							ENVELOPE GLYCOPROTEIN; LEUKEMIA VIRUSES; SACCHAROMYCES-CEREVISIAE; GENE; INTERFERENCE; MEMBRANE; ERYTHROLEUKEMIA; EXPRESSION; INFECTION; PROTEINS	THE complementary DNA sequence encoding the cell-surface receptor for ecotropic host-range murine retroviruses (ecoR) shows that it contains 622 amino acids and 14 hydrophobic potentially membrane-spanning sequences 1. Because this receptor occurs on many or all murine cells 2 and is probably essential for viability of cultured fibroblasts 3, its normal function might be to transport an essential metabolite. We expressed ecoR in Xenopus laevis oocytes by injecting RNA transcribed from the cloned cDNA. These oocytes specifically bound the gp70 envelope glycoprotein from an ecotropic murine leukaemia virus. An inward current was recorded electrophysiologically when a mixture of amino-acids was applied: this resulted from a stereoselective, saturable uptake of lysine, arginine and ornithine; it was independent of sodium and not substantially altered by gp70. Cysteine and homoserine were also taken up, but sodium was necessary for their transport. These properties of ecoR correspond to those of the y+ amino-acid transporter 4-6. Our results demonstrate the subversion of a ubiquitous cell membrane protein, in this case a basic amino acid transporter, for use as a retroviral receptor.	OREGON HLTH SCI UNIV, VOLLUM INST, PORTLAND, OR 97201 USA	Oregon Health & Science University	WANG, H (corresponding author), OREGON HLTH SCI UNIV, DEPT BIOCHEM, PORTLAND, OR 97201 USA.		North, Richard/GQA-6156-2022					ALBRITTON LM, 1989, CELL, V57, P659, DOI 10.1016/0092-8674(89)90134-7; CHRISTENSEN HN, 1966, J BIOL CHEM, V241, P5542; CHRISTENSEN HN, 1969, P NATL ACAD SCI USA, V63, P948, DOI 10.1073/pnas.63.3.948; CHRISTENSEN HN, 1989, METHOD ENZYMOL, V173, P576; CHRISTENSEN HN, 1984, BIOCHIM BIOPHYS ACTA, V779, P255, DOI 10.1016/0304-4157(84)90012-1; CHRISTIE MJ, 1989, SCIENCE, V244, P221, DOI 10.1126/science.2539643; CIANCIOLO GJ, 1985, SCIENCE, V230, P453, DOI 10.1126/science.2996136; DELARCO J, 1976, CELL, V8, P365, DOI 10.1016/0092-8674(76)90148-3; DELWART EL, 1989, J VIROL, V63, P273, DOI 10.1128/JVI.63.1.273-280.1989; HANDELIN BL, 1985, VIROLOGY, V140, P183, DOI 10.1016/0042-6822(85)90458-1; HOFFMANN W, 1985, J BIOL CHEM, V260, P1831; IHLE JN, 1984, ADV VIRAL ONCOL, V4, P95; KABAT D, 1989, CURR TOP MICROBIOL, V148, P1; KABAT D, 1989, VIROLOGY, V171, P467, DOI 10.1016/0042-6822(89)90616-8; KLEINERMAN ES, 1987, J IMMUNOL, V139, P2329; MACLEOD CL, 1990, MOL CELL BIOL, V10, P3663, DOI 10.1128/MCB.10.7.3663; McGrath M S, 1980, Contemp Top Immunobiol, V11, P157; MITANI M, 1987, P NATL ACAD SCI USA, V84, P237, DOI 10.1073/pnas.84.1.237; MOORE JP, 1991, J VIROL, V65, P1133, DOI 10.1128/JVI.65.3.1133-1140.1991; NIKAWA J, 1990, J BIOL CHEM, V265, P15996; OHARA B, 1990, CELL GROWTH DIFFER, V1, P119; REIN A, 1982, VIROLOGY, V120, P251, DOI 10.1016/0042-6822(82)90024-1; SEGAL S, 1989, METABOLIC BASIS INHE, P2479; SITBON M, 1986, CELL, V47, P851, DOI 10.1016/0092-8674(86)90800-7; SOMMERFELT MA, 1990, VIROLOGY, V176, P58, DOI 10.1016/0042-6822(90)90230-O; STEVENSON M, 1988, CELL, V53, P483, DOI 10.1016/0092-8674(88)90168-7; SZUREK PF, 1988, J VIROL, V62, P357, DOI 10.1128/JVI.62.1.357-360.1988; TANAKA J, 1985, GENE, V38, P205, DOI 10.1016/0378-1119(85)90219-7; WEISS R, 1984, RNA TUMOR VIRUSES, P209; WHITE MF, 1985, BIOCHIM BIOPHYS ACTA, V822, P355, DOI 10.1016/0304-4157(85)90015-2; WHITE MF, 1982, J BIOL CHEM, V257, P4443	31	395	402	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 22	1991	352	6337					729	731		10.1038/352729a0	http://dx.doi.org/10.1038/352729a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC064	1908564				2022-12-24	WOS:A1991GC06400063
J	BALZER, I; HARDELAND, R				BALZER, I; HARDELAND, R			PHOTOPERIODISM AND EFFECTS OF INDOLEAMINES IN A UNICELLULAR ALGA, GONYAULAX-POLYEDRA	SCIENCE			English	Article							MELATONIN; PINEAL; DINOFLAGELLATE; ANOLIS; CLOCK	Mediation of photoperiodic effects by indoleamines, especially melatonin, is known in higher vertebrates. A similar mechanism may occur in a unicellular alga, the dinoflagellate Gonyaulax polyedra. This organism entered the dormant stage of a cyst upon short-day treatment at lowered temperatures. Interruption of darkness by 2 hours of light prevented cyst formation, even when the overall duration of light was the same as in cyst-inducing short days. When given in a noninducing photoperiod, melatonin and an analog, 5-methoxytryptamine, substances that had previously been shown to occur in Gonyaulax, provoked cyst formation. Methoxylated indoleamines may play a role as mediators of darkness in this unicellular, in a similar way as in vertebrates, suggesting a common biochemical basis of photoperiodism.			BALZER, I (corresponding author), UNIV GOTTINGEN, INST ZOOL, BERLINER STR 28, W-3400 GOTTINGEN, GERMANY.							ANDERSON DM, 1987, NATURE, V325, P616, DOI 10.1038/325616a0; ANDERSON DM, 1989, RED TIDES BIOL ENV S, P461; ARENDT J, 1986, OXFORD REV REPROD B, V8, P266; BALZER I, 1991, COMP BIOCHEM PHYS C, V98, P395, DOI 10.1016/0742-8413(91)90223-G; Balzer I., 1990, EUR J CELL BIOL S30, V51, P52; FINOCCHIARO L, 1988, J NEUROCHEM, V50, P382, DOI 10.1111/j.1471-4159.1988.tb02923.x; HARDELAND R, 1991, Journal of Interdisciplinary Cycle Research, V22, P122; HOFFMANN K, 1973, J COMP PHYSIOL, V85, P267, DOI 10.1007/BF00694233; MENAKER M, 1983, P NATL ACAD SCI-BIOL, V80, P6119, DOI 10.1073/pnas.80.19.6119; Menaker M., 1982, P1; MORITA M, 1984, J EXP ZOOL, V231, P273, DOI 10.1002/jez.1402310212; POGGELER B, 1989, ACTA ENDOCR-COP   S1, V120, P97; POGGELER B, IN PRESS NATURWISSEN; Reiter R J, 1980, Endocr Rev, V1, P109; REITER RJ, 1984, PINEAL GLAND; REITER RJ, 1985, HDB PHARM METHODOLOG, P331; Taylor F.J.R., 1987, BIOL DINOFLAGELLATES; UEMURA T, 1984, PROGR TRYPTOPHAN SER, P673; UNDERWOOD H, 1985, J COMP PHYSIOL A, V157, P57, DOI 10.1007/BF00611095; VIVIENROELS B, 1984, NEUROSCI LETT, V49, P153, DOI 10.1016/0304-3940(84)90152-6; VOLKNANDT W, 1984, COMP BIOCHEM PHYS B, V77, P493, DOI 10.1016/0305-0491(84)90264-5; WETTERBERG L, 1987, CHRONOBIOLOGIA, V14, P377	22	132	140	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 16	1991	253	5021					795	797		10.1126/science.1876838	http://dx.doi.org/10.1126/science.1876838			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GB295	1876838				2022-12-24	WOS:A1991GB29500040
J	MAKELA, M; HELIOVAARA, M				MAKELA, M; HELIOVAARA, M			PREVALENCE OF PRIMARY FIBROMYALGIA IN THE FINNISH POPULATION	BRITISH MEDICAL JOURNAL			English	Article							FIBROSITIS; PAIN	Objective - To obtain descriptive epidemiological data on fibromyalgia and its components in a representative sample of the Finnish population. Design - Cross sectional study of 8000 Finns aged 30 or more invited for screening and a main examination for musculoskeletal disorders and other major disorders. Setting - A mobile clinic. Population - 7217 subjects who attended the screening phase; 3434 subjects positive on screening who attended the main examination for musculoskeletal disorders. Main outcome measures - Musculoskeletal, mental, and other symptoms detected by interview and questionnaire; results of standardised clinical examination of the musculoskeletal system; operational definition of fibromyalgia; mortality at 10 years. Results - The prevalence of fibromyalgia was low (54 cases; 0.75%) and related to age (peak prevalence at 55-64 years), female sex (twice as prevalent in women), occupation (no cases among 1596 white collar professionals), level of education (strong inverse gradient), and high levels of physical stress at work. No significant associations were found with body mass index, smoking, or mental stress at work. The prevalence of fibromyalgia was sensitive to even minor modifications of the definition. Fibromyalgia was strongly coincident with many other disorders, especially musculoskeletal conditions. Fibromyalgia did not predict mortality. Conclusion - Descriptive epidemiological data offer little support for the concept of fibromyalgia.			MAKELA, M (corresponding author), SOCIAL INSURANCE INST,SOCIAL SECUR RES INST,POB 78,SF-00381 HELSINKI,FINLAND.							AROMAA A, 1989, EXECUTION MINIFINL 1; CAMPBELL SM, 1983, ARTHRITIS RHEUM, V26, P817, DOI 10.1002/art.1780260701; CATHEY MA, 1986, AM J MED, V81, P78, DOI 10.1016/0002-9343(86)90882-X; COX DR, 1972, J R STAT SOC B, V34, P187; FORSLIND K, 1990, BRIT J RHEUMATOL, V29, P368; Goldberg DP, 1972, DETECTION PSYCHIAT I; GOLDENBERG DL, 1988, SEMIN ARTHRITIS RHEU, V18, P111, DOI 10.1016/0049-0172(88)90003-0; Haberman S. J., 1978, ANAL QUALITATIVE DAT, V1; HAWLEY DJ, 1988, J RHEUMATOL, V15, P1551; Kish L, 1965, SURVEY SAMPLING; MOLDOFSKY H, 1990, ADV PAIN RES THERAPY, V17; TAKALA J, 1979, ACTA PSYCHIAT SCAND, V59, P294, DOI 10.1111/j.1600-0447.1979.tb06968.x; Wing J. K. C., 1974, MEASUREMENT CLASSIFI; YUNUS M, 1981, SEMIN ARTHRITIS RHEU, V11, P151, DOI 10.1016/0049-0172(81)90096-2; YUNUS MB, 1989, CLIN EXP RHEUMATOL, V7, P63	15	138	145	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 27	1991	303	6796					216	219		10.1136/bmj.303.6796.216	http://dx.doi.org/10.1136/bmj.303.6796.216			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FZ563	1884057	Green Published, Bronze			2022-12-24	WOS:A1991FZ56300020
J	BAICHWAL, VR; PARK, A; TJIAN, R				BAICHWAL, VR; PARK, A; TJIAN, R			V-SRC AND EJ RAS ALLEVIATE REPRESSION OF C-JUN BY A CELL-SPECIFIC INHIBITOR	NATURE			English	Article							PROTO-ONCOGENE; FIBROBLASTS; AP-1; GENE; TPA; TRANSCRIPTION	THE AP-1 family of transcription factors, which includes the proto-oncogene products c-Jun and c-Fos 1, controls the stimulation of cellular genes by growth factors and the expression of oncogenes, including src and ras 2-8. Transcriptional activation by c-Jun is regulated by a cell-type-specific inhibitor that represses the activity of a transcriptional activation domain (A1) of c-Jun by operating through the adjacent negative regulatory region (delta) (refs 9-11). Here we show that cotransfection of the src or ras oncogene enhances the transcriptional activity of a GAL4:c-Jun hybrid that includes the delta-A1 region of c-Jun, suggesting that the DNA binding and dimerization domain of c-Jun is not required for stimulation by Src or Ras. Moreover, induction of c-Jun activity by Src and Ras occurs in cell lines containing the c-Jun inhibitor but not in a cell line lacking it. The region in c-Jun essential for the stimulatory action of these oncogenes maps to domain A1. These findings suggest the existence of signal-transduction pathways that result in an increase in transcriptional activity of c-Jun and AP-1 by disrupting the c-Jun:inhibitor interaction.	UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720	University of California System; University of California Berkeley	BAICHWAL, VR (corresponding author), UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,BERKELEY,CA 94720, USA.							ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; BOHMANN D, 1989, CELL, V59, P909; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DECLUE JE, 1989, J VIROL, V63, P542, DOI 10.1128/JVI.63.2.542-554.1989; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; QUANTIN B, 1988, NATURE, V334, P538, DOI 10.1038/334538a0; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x	17	84	88	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 11	1991	352	6331					165	168		10.1038/352165a0	http://dx.doi.org/10.1038/352165a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FW097	1906140				2022-12-24	WOS:A1991FW09700060
J	POWERS, S; GONZALES, E; CHRISTENSEN, T; CUBERT, J; BROEK, D				POWERS, S; GONZALES, E; CHRISTENSEN, T; CUBERT, J; BROEK, D			FUNCTIONAL CLONING OF BUD5, A CDC25-RELATED GENE FROM SACCHAROMYCES-CEREVISIAE THAT CAN SUPPRESS A DOMINANT-NEGATIVE RAS2 MUTANT	CELL			English	Article							DEPENDENT PROTEIN-KINASE; SACCHAROMYCES-CEREVISIAE; ADENYLATE-CYCLASE; CDC25 GENE; CATALYTIC SUBUNITS; BUDDING YEAST; WILD-TYPE; ACTIVATION; SEQUENCE; DNA	By searching for genes that behave like CDC25 of S. cerevisiae in their ability to counteract a dominant-negative RAS2 mutant in a wild-type RAS-dependent manner, we have isolated a CDC25-like homolog, BUD5. BUD5 is tightly linked to the MAT locus. Although overexpressed BUD5 cannot substitute for CDC25 function, we present evidence that its gene product can bind to the guanine nucleotide binding-deficient RAS2val19ala22 gene product and thereby counteract its dominant-negative effect. We propose that BUD5 is a member of a family of CDC25-related genes that encode activators of RAS and RAS-like proteins.	UNIV SO CALIF,SCH MED,DEPT BIOCHEM,LOS ANGELES,CA 90033	University of Southern California	POWERS, S (corresponding author), UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,PISCATAWAY,NJ 08854, USA.			Powers, Scott/0000-0003-2769-1932	NCI NIH HHS [CA50261] Funding Source: Medline; NIGMS NIH HHS [GM41258] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050261] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041258] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASTELL CR, 1981, CELL, V27, P15, DOI 10.1016/0092-8674(81)90356-1; BENDER A, 1989, P NATL ACAD SCI USA, V86, P9976, DOI 10.1073/pnas.86.24.9976; BOYMARCOTTE E, 1989, GENE, V77, P21, DOI 10.1016/0378-1119(89)90355-7; BROEK D, 1987, CELL, V48, P789, DOI 10.1016/0092-8674(87)90076-6; BROEK D, 1985, CELL, V41, P763, DOI 10.1016/S0092-8674(85)80057-X; BURNE HR, 1990, NATURE, V348, P125; CAMONIS JH, 1986, EMBO J, V5, P375, DOI 10.1002/j.1460-2075.1986.tb04222.x; CHANT J, 1991, CELL, V65; CRECHET JB, 1990, SCIENCE, V248, P866, DOI 10.1126/science.2188363; DANIEL J, 1987, MOL CELL BIOL, V7, P3857, DOI 10.1128/MCB.7.10.3857; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HUGHES DA, 1990, NATURE, V344, P355, DOI 10.1038/344355a0; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JOHNSON KE, 1987, J BIOL CHEM, V262, P8636; KATAOKA T, 1985, CELL, V43, P493, DOI 10.1016/0092-8674(85)90179-5; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; MARTEGANI E, 1984, EUR J BIOCHEM, V144, P205, DOI 10.1111/j.1432-1033.1984.tb08450.x; POWERS S, 1989, MOL CELL BIOL, V9, P390, DOI 10.1128/MCB.9.2.390; ROBINSON LC, 1987, SCIENCE, V235, P1218, DOI 10.1126/science.3547648; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STRYER L, 1986, ANNU REV NEUROSCI, V9, P87, DOI 10.1146/annurev.ne.09.030186.000511; TODA T, 1988, GENE DEV, V2, P517, DOI 10.1101/gad.2.5.517; TODA T, 1987, CELL, V50, P277, DOI 10.1016/0092-8674(87)90223-6; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; WEST M, 1990, FEBS LETT, V259, P2465; WICKNER RB, 1987, YEAST, V3, P51, DOI 10.1002/yea.320030108; WIGLER M, 1988, COLD SPRING HARB SYM, V53, P649, DOI 10.1101/SQB.1988.053.01.074; WIGLER MH, 1990, NATURE, V346, P696, DOI 10.1038/346696a0	29	93	95	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 28	1991	65	7					1225	1231		10.1016/0092-8674(91)90017-S	http://dx.doi.org/10.1016/0092-8674(91)90017-S			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FU899	1905982				2022-12-24	WOS:A1991FU89900014
J	RUBINFELD, B; MUNEMITSU, S; CLARK, R; CONROY, L; WATT, K; CROSIER, WJ; MCCORMICK, F; POLAKIS, P				RUBINFELD, B; MUNEMITSU, S; CLARK, R; CONROY, L; WATT, K; CROSIER, WJ; MCCORMICK, F; POLAKIS, P			MOLECULAR-CLONING OF A GTPASE ACTIVATING PROTEIN-SPECIFIC FOR THE KREV-1 PROTEIN P21RAP1	CELL			English	Article							RAS-RELATED PROTEIN; BINDING-PROTEINS; HUMAN-PLATELETS; SUPPRESSOR ACTIVITY; KINASE SUBSTRATE; EFFECTOR DOMAIN; POINT MUTATIONS; RAS-P21 GTPASE; GENE-PRODUCT; BOVINE BRAIN	The rap1/Krev-1 gene encodes a ras-related protein that suppresses transformation by ras oncogenes. We have purified an 88 kd GTPase activating protein (GAP), specific for the rap1/Krev-1 gene product, from bovine brain. Based on partial amino acid sequences obtained from this protein, a 3.3 kb cDNA was isolated f rom a human brain library. Expression of the cDNA in insect Sf9 cells resulted in high level production of an 85-95 kd rap1GAP that specifically stimulated the GTPase activity of p2l(rap1). The complete deduced amino acid sequence is not homologous to any known protein sequences, including GAPs specific for p2l(ras). Northern and Western blotting analysis indicate that raplGAP is not ubiquitously expressed and appears most abundant in fetal tissues and certain tumor cell lines, particularly the Wilms' kidney tumor, SK-NEP-1, and the melanoma, SK-MEL-3, cell lines.			RUBINFELD, B (corresponding author), CETUS CORP,1400 53RD ST,EMERYVILLE,CA 94608, USA.			Rubinfeld, Bonnee/0000-0001-9861-6775	NATIONAL CANCER INSTITUTE [U01CA051992] Funding Source: NIH RePORTER; NCI NIH HHS [CA51992-02] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALCH WE, 1990, TRENDS BIOCHEM SCI, V15, P473, DOI 10.1016/0968-0004(90)90301-Q; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BIELINSKI DF, 1989, J BIOL CHEM, V264, P18363; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURSTEIN ES, 1991, J BIOL CHEM, V266, P2689; CAMPA MJ, 1991, BIOCHEM BIOPH RES CO, V174, P1, DOI 10.1016/0006-291X(91)90475-M; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; FISCHER TH, 1987, BIOCHEM BIOPH RES CO, V149, P700, DOI 10.1016/0006-291X(87)90424-4; FISCHER TH, 1990, J BIOL CHEM, V265, P19405; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; GARRETT MD, 1989, J BIOL CHEM, V264, P10; GRUSSENMEYER T, 1985, P NATL ACAD SCI USA, V82, P7952, DOI 10.1073/pnas.82.23.7952; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; HALENBECK R, 1990, J BIOL CHEM, V265, P21922; HALL A, 1990, CELL, V61, P921, DOI 10.1016/0092-8674(90)90054-I; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HATA Y, 1990, J BIOL CHEM, V265, P7104; HAUBRUCK H, 1991, J CELL BIOCH B S, V15, P138; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAWATA M, 1989, J BIOL CHEM, V264, P15688; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KIKUCHI A, 1989, J BIOL CHEM, V264, P9133; KITAYAMA H, 1990, P NATL ACAD SCI USA, V87, P4284, DOI 10.1073/pnas.87.11.4284; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KORN LJ, 1987, SCIENCE, V236, P840, DOI 10.1126/science.3554510; KOZAK M, 1984, NATURE, V308, P241, DOI 10.1038/308241a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPETINA EG, 1989, P NATL ACAD SCI USA, V86, P3131, DOI 10.1073/pnas.86.9.3131; LATHE R, 1985, J MOL BIOL, V183, P1, DOI 10.1016/0022-2836(85)90276-1; Maniatis T., 1982, MOL CLONING; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MESSING J, 1981, NUCLEIC ACIDS RES, V9, P309, DOI 10.1093/nar/9.2.309; MIAORELLA B, 1988, BIOTECHNOLOGY, V6, P1506; MULCAHY LS, 1985, NATURE, V313, P2541; MUNEMITSU S, 1990, MOL CELL BIOL, V10, P5977, DOI 10.1128/MCB.10.11.5977; NAGATA K, 1989, BIOCHEM BIOPH RES CO, V160, P235, DOI 10.1016/0006-291X(89)91646-X; PIZON V, 1988, NUCLEIC ACIDS RES, V16, P7719, DOI 10.1093/nar/16.15.7719; PIZON V, 1988, ONCOGENE, V3, P201; POLAKIS PG, 1991, P NATL ACAD SCI USA, V88, P239, DOI 10.1073/pnas.88.1.239; POLAKIS PG, 1989, J BIOL CHEM, V264, P16383; QUINN MT, 1989, NATURE, V342, P198, DOI 10.1038/342198a0; SANDERS DA, 1990, CELL GROWTH DIFFER, V1, P251; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH GE, 1983, MOL CELL BIOL, V3, P2156, DOI 10.1128/MCB.3.12.2156; Summers MD, 1987, TEXAS AGR EXPT STATI; TOUCHOT N, 1987, P NATL ACAD SCI USA, V84, P8210, DOI 10.1073/pnas.84.23.8210; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; ULLRICH A, 1977, SCIENCE, V196, P1313, DOI 10.1126/science.325648; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; VONMOLLARD GF, 1991, NATURE, V349, P79, DOI 10.1038/349079a0; WALDO GL, 1987, BIOCHEM J, V246, P431, DOI 10.1042/bj2460431; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9	55	240	250	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 14	1991	65	6					1033	1042		10.1016/0092-8674(91)90555-D	http://dx.doi.org/10.1016/0092-8674(91)90555-D			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FR047	1904317				2022-12-24	WOS:A1991FR04700014
J	STOVER, CK; DELACRUZ, VF; FUERST, TR; BURLEIN, JE; BENSON, LA; BENNETT, LT; BANSAL, GP; YOUNG, JF; LEE, MH; HATFULL, GF; SNAPPER, SB; BARLETTA, RG; JACOBS, WR; BLOOM, BR				STOVER, CK; DELACRUZ, VF; FUERST, TR; BURLEIN, JE; BENSON, LA; BENNETT, LT; BANSAL, GP; YOUNG, JF; LEE, MH; HATFULL, GF; SNAPPER, SB; BARLETTA, RG; JACOBS, WR; BLOOM, BR			NEW USE OF BCG FOR RECOMBINANT VACCINES	NATURE			English	Article							ESCHERICHIA-COLI; STRESS PROTEINS; LYMPHOCYTES-T; INVIVO; MYCOBACTERIA; EXPRESSION; SEQUENCE; TUBERCULOSIS; CLONING; OPERON	BCG, a live attenuated tubercle bacillus, is the most widely used vaccine in the world and is also a useful vaccine vehicle for delivering protective antigens of multiple pathogens. Extrachromosomal and integrative expression vectors carrying the regulatory sequences for major BCG heat-shock proteins have been developed to allow expression of foreign antigens in BCG. These recombinant BCG strains can elicit long-lasting humoral and cellular immune responses to foreign antigens in mice.	UNIV PITTSBURGH, DIV BIOL SCI, PITTSBURGH, PA 15260 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, HOWARD HUGHES MED INST, BRONX, NY 10461 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Howard Hughes Medical Institute; Yeshiva University; Albert Einstein College of Medicine	STOVER, CK (corresponding author), MEDIMMUNE INC, GAITHERSBURG, MD 20878 USA.		Barletta, Raul G./V-9053-2019	Stover, Charles/0000-0002-7406-1696; Lee, Mong-Hong/0000-0001-8675-8215; Jacobs, William/0000-0003-3321-3080				[Anonymous], 1927, VACCINATION PREVENTI; ARMSTRONG JA, 1975, J EXP MED, V142, P1, DOI 10.1084/jem.142.1.1; AUSUBEL FM, 1987, CURR PROTOCOLS MOL B; BLOOM BR, 1989, NATURE, V342, P115, DOI 10.1038/342115a0; BUCHMEIER NA, 1990, SCIENCE, V248, P730, DOI 10.1126/science.1970672; CARBONE FR, 1990, J EXP MED, V171, P377, DOI 10.1084/jem.171.2.377; CERRONE MC, 1991, INFECT IMMUN, V59, P79, DOI 10.1128/IAI.59.1.79-90.1991; CONVIT, 1982, INT J LEPROSY, V50, P514; CONVIT J, 1987, LANCET, V1, P401; CURRY RC, 1987, J IMMUNOL METHODS, V104, P137, DOI 10.1016/0022-1759(87)90497-2; CURTISS R, 1989, IMMUNOL INVEST, V18, P583, DOI 10.3109/08820138909112265; DELIBERO G, 1988, EUR J IMMUNOL, V18, P59, DOI 10.1002/eji.1830180110; HALPERN JL, 1990, INFECT IMMUN, V58, P1004, DOI 10.1128/IAI.58.4.1004-1009.1990; HART P D, 1974, Infection and Immunity, V10, P742; HENDERSON RH, 1989, ANN NY ACAD SCI, V569, P45; JACOBS WR, 1987, NATURE, V327, P532, DOI 10.1038/327532a0; KAUFMANN SHE, 1988, IMMUNOL TODAY, V9, P168, DOI 10.1016/0167-5699(88)91292-3; LAMB JR, 1982, J IMMUNOL, V129, P1465; LATHIGRA R, IN PRESS MOL MICROBI; LEE MH, 1991, P NATL ACAD SCI USA, V88, P3111, DOI 10.1073/pnas.88.8.3111; LOTTE, 1988, B INT UNION TB LUNG, V63, P47; MILSTIEN JB, 1989, WHOEPIGEN893 DOC; MULLER I, 1987, INFECT IMMUN, V55, P2037; RAMMENSEE HG, 1989, IMMUNOGENETICS, V30, P296, DOI 10.1007/BF02421334; RAUZIER J, 1988, GENE, V71, P315, DOI 10.1016/0378-1119(88)90048-0; RUSSELL SM, 1979, NATURE, V280, P147, DOI 10.1038/280147a0; SARMIENTOS P, 1983, CELL, V32, P1337, DOI 10.1016/0092-8674(83)90314-8; SCHERLE PA, 1986, J EXP MED, V164, P1114, DOI 10.1084/jem.164.4.1114; SNAPPER SB, 1988, P NATL ACAD SCI USA, V85, P6987, DOI 10.1073/pnas.85.18.6987; STOVER CK, 1990, INFECT IMMUN, V58, P1360, DOI 10.1128/IAI.58.5.1360-1368.1990; TAKAHASHI H, 1990, J EXP MED, V171, P571, DOI 10.1084/jem.171.2.571; THOLE JER, 1987, INFECT IMMUN, V55, P1466, DOI 10.1128/IAI.55.6.1466-1475.1987; VODKIN MH, 1988, J BACTERIOL, V170, P1227, DOI 10.1128/jb.170.3.1227-1234.1988; WALSH JA, 1986, STRATEGIES PRIMARY H, P1; YOUNG D, 1988, P NATL ACAD SCI USA, V85, P4267, DOI 10.1073/pnas.85.12.4267; YOUNG RA, 1990, ANNU REV IMMUNOL, V8, P401, DOI 10.1146/annurev.immunol.8.1.401; 1990, STATE WORLDS CHILDRE	37	1238	1455	4	55	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 6	1991	351	6326					456	460		10.1038/351456a0	http://dx.doi.org/10.1038/351456a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FP758	1904554	Bronze			2022-12-24	WOS:A1991FP75800046
J	KASLOW, DC; ISAACS, SN; QUAKYI, IA; GWADZ, RW; MOSS, B; KEISTER, DB				KASLOW, DC; ISAACS, SN; QUAKYI, IA; GWADZ, RW; MOSS, B; KEISTER, DB			INDUCTION OF PLASMODIUM-FALCIPARUM TRANSMISSION-BLOCKING ANTIBODIES BY RECOMBINANT VACCINIA VIRUS	SCIENCE			English	Article							SEXUAL STAGES; EXPRESSION; ANTIGENS; SURFACE	Many candidate antigens of malaria vaccines have limited immunological recognition. One exception is Pfs25, a cysteine-rich, 25-kilodalton sexual stage surface protein of Plasmodium falciparum. Pfs25 is a target of monoclonal antibodies that block transmission of malaria from vertebrate host to mosquito vector. The surface of mammalian cells infected with a recombinant vaccinia virus that expressed Pfs25 specifically bound transmission-blocking monoclonal antibodies. Furthermore, major histocompatibility complex-disparate congenic mouse strains immunized with recombinant Pfs25 elicited transmission-blocking antibodies, demonstrating that the capacity to develop transmission-blocking antibodies is not genetically restricted in mice. Live recombinant viruses may provide an inexpensive, easily administered alternative to subunit vaccines prepared from purified recombinant proteins to block transmission of malaria in developing countries.	NIAID,VIRAL DIS LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	KASLOW, DC (corresponding author), NIAID,PARASIT DIS LAB,BETHESDA,MD 20892, USA.		Isaacs, Stuart/HGA-3405-2022	Moss, Bernard/0000-0002-2154-8564				ANDREW ME, 1989, IMMUNOL CELL BIOL, V67, P331, DOI 10.1038/icb.1989.48; CARTER R, 1988, PROG ALLERGY, V41, P193; FALKNER FG, 1988, J VIROL, V62, P1849, DOI 10.1128/JVI.62.6.1849-1854.1988; GOOD MF, 1988, SCIENCE, V242, P574, DOI 10.1126/science.2902690; ISAACS S, UNPUB; KASLOW DC, 1988, NATURE, V333, P74, DOI 10.1038/333074a0; KASLOW DC, UNPUB; LANGFORD CJ, 1986, MOL CELL BIOL, V6, P3191, DOI 10.1128/MCB.6.9.3191; MILLER LH, 1986, SCIENCE, V234, P1349, DOI 10.1126/science.2431481; PONNUDURAI T, 1987, T ROY SOC TROP MED H, V81, P491, DOI 10.1016/0035-9203(87)90172-6; QUAKYI I, UNPUB; QUAKYI IA, 1987, J IMMUNOL, V139, P4213; QUAKYI IA, 1980, TROP MED PARASITOL, V42, P325; SADOFF J, COMMUNICATION; SAVAGE CR, 1972, J BIOL CHEM, V247, P7612; VERMEULEN AN, 1985, J EXP MED, V162, P1460, DOI 10.1084/jem.162.5.1460	16	70	74	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 31	1991	252	5010					1310	1313		10.1126/science.1925544	http://dx.doi.org/10.1126/science.1925544			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FN857	1925544				2022-12-24	WOS:A1991FN85700041
J	WILSON, TE; FAHRNER, TJ; JOHNSTON, M; MILBRANDT, J				WILSON, TE; FAHRNER, TJ; JOHNSTON, M; MILBRANDT, J			IDENTIFICATION OF THE DNA-BINDING SITE FOR NGFI-B BY GENETIC SELECTION IN YEAST	SCIENCE			English	Article							HORMONE RECEPTOR SUPERFAMILY; COUP TRANSCRIPTION FACTOR; SEQUENCE-ANALYSIS; ACTIVATOR PROTEIN; MAMMALIAN-CELLS; GLUCOCORTICOID RECEPTOR; ESTROGEN-RECEPTOR; INDUCIBLE MEMBER; GAMMA-SUBUNIT; II GENE	An in vivo selection system for isolating targets of DNA binding proteins in yeast was developed and used to identify the DNA binding site for the NGFI-B protein, a member of the steroid-thyroid hormone receptor superfamily. The feasibility of the technique was verified by selecting DNA fragments that contained binding sites for GCN4, a well-characterized yeast transcriptional activator. The DNA binding domain of NGFI-B, expressed as part of a LexA-NGFI-B-GAL4 chimeric activator, was then used to isolate a rat genomic DNA fragment that contained an NGFI-B binding site. The NGFI-B response element (NBRE) is similar to but functionally distinct from elements recognized by the estrogen and thyroid hormone receptors and the hormone receptor-like proteins COUP-TF, CF1, and H-2RIIBP. Cotransfection experiments in mammalian cells demonstrated that NGFI-B can activate transcription from the NBRE with or without its putative ligand binding domain.	WASHINGTON UNIV,SCH MED,DEPT INTERNAL MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT GENET,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)	MILBRANDT, J (corresponding author), WASHINGTON UNIV,SCH MED,DEPT PATHOL,DIV LAB MED,ST LOUIS,MO 63110, USA.		Johnston, Mark/R-6156-2019; Johnston, Mark/K-3543-2019	Johnston, Mark/0000-0002-4932-7229; Milbrandt, Jeffrey/0000-0002-5477-7689	NCI NIH HHS [P01 CA49712] Funding Source: Medline; NINDS NIH HHS [NS01018] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA049712] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS001018] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADLER S, 1988, CELL, V52, P685, DOI 10.1016/0092-8674(88)90406-0; BALCKHART BD, 1986, J BIOL CHEM, V261, P15364; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BRENT R, 1984, NATURE, V312, P612, DOI 10.1038/312612a0; BRENT R, 1981, P NATL ACAD SCI-BIOL, V78, P4204, DOI 10.1073/pnas.78.7.4204; BRENT R, 1985, CELL, V43, P729, DOI 10.1016/0092-8674(85)90246-6; CHAPLIN DD, 1986, P NATL ACAD SCI USA, V83, P9601, DOI 10.1073/pnas.83.24.9601; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COOK JS, 1988, P NATL ACAD SCI USA, V85, P2949, DOI 10.1073/pnas.85.9.2949; CROWDER CM, 1988, MOL CELL BIOL, V8, P5257, DOI 10.1128/MCB.8.12.5257; DEMMER LA, 1987, J BIOL CHEM, V262, P2458; DEPINHO RA, 1986, P NATL ACAD SCI USA, V83, P1827, DOI 10.1073/pnas.83.6.1827; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; EVANS BA, 1985, EMBO J, V4, P133, DOI 10.1002/j.1460-2075.1985.tb02327.x; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FAHRNER TJ, 1990, MOL CELL BIOL, V10, P6454, DOI 10.1128/MCB.10.12.6454; GLASS CK, 1988, CELL, V54, P321; GODOWSKI PJ, 1987, NATURE, V325, P365, DOI 10.1038/325365a0; Greene LA., 1982, ADV CELL NEUROBIOL, V3, P373, DOI [10.1016/B978-0-12-008303-9.50016-5, DOI 10.1016/B978-0-12-008303-9.50016-5]; GRONEMEYER H, 1987, EMBO J, V6, P3985, DOI 10.1002/j.1460-2075.1987.tb02741.x; HAMADA K, 1989, P NATL ACAD SCI USA, V86, P8289, DOI 10.1073/pnas.86.21.8289; HILL DE, 1986, SCIENCE, V234, P451, DOI 10.1126/science.3532321; HOLLENBERG SM, 1987, CELL, V49, P39, DOI 10.1016/0092-8674(87)90753-7; HWUNG YP, 1988, MOL CELL BIOL, V8, P2070, DOI 10.1128/MCB.8.5.2070; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KINZLER KW, 1990, MOL CELL BIOL, V10, P634, DOI 10.1128/MCB.10.2.634; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LORCH Y, 1985, J MOL BIOL, V186, P821, DOI 10.1016/0022-2836(85)90400-0; MILLBRANDT J, 1988, NEURON, V1, P183; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MOROHASHI K, 1987, J BIOCHEM-TOKYO, V101, P879, DOI 10.1093/oxfordjournals.jbchem.a121955; OLIPHANT AR, 1986, GENE, V44, P177, DOI 10.1016/0378-1119(86)90180-0; OLIPHANT AR, 1989, MOL CELL BIOL, V9, P2944, DOI 10.1128/MCB.9.7.2944; OSUMI T, 1987, J BIOL CHEM, V262, P8138; PROTTER AA, 1984, DNA-J MOLEC CELL BIO, V3, P449, DOI 10.1089/dna.1.1984.3.449; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; RAUSCHER FJ, 1988, CELL, V52, P471, DOI 10.1016/S0092-8674(88)80039-4; SASAKI H, 1985, GENE, V37, P191; SHEA MJ, 1990, GENE DEV, V4, P1128, DOI 10.1101/gad.4.7.1128; SHERMAN F, 1986, LABORATORY COURSE MA; SHIBAHARA S, 1983, EMBO J, V2, P775, DOI 10.1002/j.1460-2075.1983.tb01499.x; SOMPAYRAC L, 1990, P NATL ACAD SCI USA, V87, P3274, DOI 10.1073/pnas.87.9.3274; STRUHL K, 1987, CELL, V50, P841, DOI 10.1016/0092-8674(87)90511-3; SWEETSER DA, 1987, J BIOL CHEM, V262, P16060; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; WANG LH, 1989, NATURE, V340, P163, DOI 10.1038/340163a0; WATSON MA, 1989, MOL CELL BIOL, V9, P4213, DOI 10.1128/MCB.9.10.4213; WILSON T, UNPUB; ZIMARINO V, 1987, NATURE, V327, P727, DOI 10.1038/327727a0; [No title captured]	54	503	520	2	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 31	1991	252	5010					1296	1300		10.1126/science.1925541	http://dx.doi.org/10.1126/science.1925541			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FN857	1925541				2022-12-24	WOS:A1991FN85700036
J	EZEKOWITZ, RAB; WILLIAMS, DJ; KOZIEL, H; ARMSTRONG, MYK; WARNER, A; RICHARDS, FF; ROSE, RM				EZEKOWITZ, RAB; WILLIAMS, DJ; KOZIEL, H; ARMSTRONG, MYK; WARNER, A; RICHARDS, FF; ROSE, RM			UPTAKE OF PNEUMOCYSTIS-CARINII MEDIATED BY THE MACROPHAGE MANNOSE RECEPTOR	NATURE			English	Article							INVITRO; ZYMOSAN; PHAGOCYTOSIS	HUMAN exposure to Pneumocystis carinii is common 1,2 but, in the absence of acquired 3 or genetic 4 dysfunction of either cellular or humoral immunity, exposure rarely leads to illness. Although alveolar macrophages can degrade P. carinii 5,6, macrophage receptors involved in P. carinii recognition have not been clearly defined. Characterization of a predominant surface glycoprotein of the high mannose type 7,8 led us to investigate the role of the macrophage mannose receptor in this process. We report here that binding and uptake of cultured rat P. carinii by human and rat alveolar macrophages is reduced by 90% in the presence of competitive inhibitors of mannose receptor activity and by adherence of alveolar macrophages to mannan-coated surfaces. Further, only those COS cells transfected with the human macrophage mannose receptor complementary DNA that express surface mannose receptors bind and ingest P. carinii. These studies establish that the macrophage mannose receptor is sufficient for uptake of P. carinii and emphasize the role of the alveolar macrophage in first-line host defence against P. carinii.	HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DEPT PEDIAT, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, MACARTHUR CTR MOLE PARASITOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT INTERNAL MED, PULM & CRIT CARE SECT, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT EPIDEMIOL & PUBL HLTH, BOSTON, MA 02115 USA; HARVARD UNIV, NEW ENGLAND DEACONESS HOSP, SCH MED, DIV PULM & CRIT CARE MED, BOSTON, MA 02215 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT RESP BIOL, BOSTON, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	EZEKOWITZ, RAB (corresponding author), CHILDRENS HOSP MED CTR, DIV HEMATOL ONCOL, BOSTON, MA 02115 USA.							ARMSTRONG MYK, 1989, J PROTOZOOL, V36, pS24, DOI 10.1111/j.1550-7408.1989.tb05816.x; BERTON G, 1983, IMMUNOLOGY, V49, P705; EZEKOWITZ RAB, 1985, J CLIN INVEST, V76, P2368, DOI 10.1172/JCI112249; EZEKOWITZ RAB, 1988, J CELL SCI, P121; EZEKOWITZ RAB, 1990, J EXP MED, V172, P1785, DOI 10.1084/jem.172.6.1785; EZEKOWITZ RAB, 1989, NAT IMMUN, P15; HARMSEN AG, 1990, J EXP MED, V172, P937, DOI 10.1084/jem.172.3.937; LEE YC, 1976, BIOCHEMISTRY-US, V15, P3956, DOI 10.1021/bi00663a008; MASUR H, 1978, J EXP MED, V147, P157, DOI 10.1084/jem.147.1.157; MASUR H, 1981, NEW ENGL J MED, V305, P1431, DOI 10.1056/NEJM198112103052402; MEUWISSEN JHET, 1977, J INFECT DIS, V136, P43, DOI 10.1093/infdis/136.1.43; MURRAY JF, 1987, AM REV RESPIR DIS, V135, P504; NAKAMURA Y, 1989, J PROTOZOOL, V36, pS58, DOI 10.1111/j.1550-7408.1989.tb05832.x; PIFER LL, 1978, PEDIATRICS, V61, P35; POTTRATZ ST, 1990, J CLIN INVEST, V86, P1678, DOI 10.1172/JCI114891; POTTRATZ ST, 1990, J CLIN INVEST, V85, P351, DOI 10.1172/JCI114445; RADDING JA, 1989, INFECT IMMUN, V57, P2149, DOI 10.1128/IAI.57.7.2149-2157.1989; SHELLITO J, 1990, J CLIN INVEST, V85, P1686, DOI 10.1172/JCI114621; SUNG SSJ, 1983, J CELL BIOL, V96, P160, DOI 10.1083/jcb.96.1.160; TAYLOR ME, 1990, J BIOL CHEM, V265, P12156; VONBEHREN LA, 1978, AM REV RESPIR DIS, V118, P1051	21	374	379	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 9	1991	351	6322					155	158		10.1038/351155a0	http://dx.doi.org/10.1038/351155a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL035	1903183				2022-12-24	WOS:A1991FL03500054
J	FOOTE, A; ERFURT, JC				FOOTE, A; ERFURT, JC			THE BENEFIT TO COST RATIO OF WORK-SITE BLOOD-PRESSURE CONTROL PROGRAMS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTH-CARE COSTS; HYPERTENSION; PROMOTION; TRIAL	Reduction in the cost of health care claims among hypertensive employees was examined over a 4-year period after exposure to a 3-year blood pressure control program, to see whether work-site monitoring and counseling produced a subsequent benefit. Hypertensive employees at three experimental sites (N = 183 to 367 subjects) were compared with subjects at a control site (N = 169) who had received no postscreening follow-up or monitoring, and with matched normotensive employees. The cost of subsequent health care claims for hypertensive employees at the experimental sites was lower than claims for those at the control site, but there was no significant difference across the sites in claims for normotensive employees. After adjusting to a standard 1982 dollar, the data showed from $1.89 to $2.72 in reduced health care claims per dollar spent operating the hypertension control program.			FOOTE, A (corresponding author), UNIV MICHIGAN,INST LABOR & IND RELAT,WORKER HLTH PROGRAM,1111 E CATHERINE,ANN ARBOR,MI 48109, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028929] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL28929] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALDERMAN MH, 1979, PREV MED, V8, P123; ALDERMAN MH, 1976, B NEW YORK ACAD MED, V52, P697; ALDERMAN MH, 1983, HYPERTENSION S5, V5, P138; BLY JL, 1986, JAMA-J AM MED ASSOC, V256, P3235, DOI 10.1001/jama.256.23.3235; ERFURT JC, 1984, J OCCUP ENVIRON MED, V26, P892, DOI 10.1097/00043764-198412000-00007; ERFURT JC, 1990, J OCCUP ENVIRON MED, V32, P513, DOI 10.1097/00043764-199006000-00007; ERFURT JC, 1982, PB83113399; FIELDING JE, 1982, J OCCUP ENVIRON MED, V24, P907; FOOTE A, 1983, NEW ENGL J MED, V308, P809, DOI 10.1056/NEJM198304073081404; GIBBS JO, 1985, J OCCUP ENVIRON MED, V27, P826, DOI 10.1097/00043764-198511000-00016; HELGELAND A, 1980, AM J MED, V69, P725, DOI 10.1016/0002-9343(80)90438-6; LOGAN AG, 1979, LANCET, V2, P1175; WARNER KE, 1988, J OCCUP ENVIRON MED, V30, P106; 1970, JAMA-J AM MED ASSOC, V212, P1143; 1990, JAMA-J AM MED ASSOC, V263, P1795; 1982, NEW ENGL J MED, V307, P976; 1980, LANCET, V1, P1261; 1979, JAMA-J AM MED ASSOC, V242, P2562	18	24	24	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 13	1991	265	10					1283	1286		10.1001/jama.265.10.1283	http://dx.doi.org/10.1001/jama.265.10.1283			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FA511	1899894				2022-12-24	WOS:A1991FA51100023
J	RUPPERSBERG, JP; FRANK, R; PONGS, O; STOCKER, M				RUPPERSBERG, JP; FRANK, R; PONGS, O; STOCKER, M			CLONED NEURONAL IK(A) CHANNELS REOPEN DURING RECOVERY FROM INACTIVATION	NATURE			English	Article							POTASSIUM CHANNELS; DIVERSITY	THE kinetic behaviour and functional role of potassium ion (K+) channels mediating a fast-inactivating K+ current (I(K)(A)) has been widely discussed 1. Activating in the subthreshold range of excitation, I(K)(A) channels are assumed to reduce the excitatory effect of depolarizing membrane currents in a time-dependent manner. Here we report that I(K)(A) channels not only open in response to a depolarization but open again after repolarization of the membrane. Although the current in response to the depolarization is rapidly inactivating, the current elicited by repolarization declines slowly and produces long-lasting after hyperpolarizations under current-clamp conditions. This implies an additional physiological role for I(K)(A) channels, particularly those that activate positive to the threshold of excitation. The underlying biophysical mechanism was studied by fast-application of peptides corresponding to the N-terminal end of the I(K)(A) channel proteins. It was found to be a voltage-dependent release of the inactivation gate.	ZENTRUM MOLEK BIOL,W-6900 HEIDELBERG,GERMANY; RUHR UNIV BOCHUM,LEHRSTUHL BIOCHEM,W-4300 BOCHUM,GERMANY	Ruprecht Karls University Heidelberg; Ruhr University Bochum	RUPPERSBERG, JP (corresponding author), MAX PLANCK INST MED RES,ZELLPHYSIOL ABT,JAHNSTR 29,W-6900 HEIDELBERG 1,GERMANY.		Stocker, Martin/C-1844-2008					CASTRO B, 1977, J CHEM RES, V182, P2118; FRANK R, 1988, MODERN METHODS PROTE, V3, P42; FRANKE C, 1987, NEUROSCI LETT, V77, P199, DOI 10.1016/0304-3940(87)90586-6; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; LANCASTER B, 1986, J NEUROPHYSIOL, V55, P1268, DOI 10.1152/jn.1986.55.6.1268; LANCASTER B, 1984, NEUROSCIENCE, V127, P267; LANCASTER B, 1986, J PHYSIOL-LONDON, V389, P187; MCCORMICK DA, 1985, J NEUROPHYSIOL, V54, P782, DOI 10.1152/jn.1985.54.4.782; PAK MD, 1991, P NATL ACAD SCI USA, V88, P4386, DOI 10.1073/pnas.88.10.4386; RUDY B, 1988, NEUROSCIENCE, V25, P729, DOI 10.1016/0306-4522(88)90033-4; RUPPERSBERG JP, 1991, NATURE, V352, P711, DOI 10.1038/352711a0; SCHROTER KH, 1991, FEBS LETT, V278, P211, DOI 10.1016/0014-5793(91)80119-N; STUHMER W, 1989, EMBO J, V8, P3235, DOI 10.1002/j.1460-2075.1989.tb08483.x; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520	14	133	135	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 17	1991	353	6345					657	660		10.1038/353657a0	http://dx.doi.org/10.1038/353657a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GK672	1922383				2022-12-24	WOS:A1991GK67200069
J	LEFRAK, S				LEFRAK, S			TUBERCULOSIS SCREENING IN A NURSING-HOME - INDICATIONS FOR PREVENTIVE THERAPY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											LEFRAK, S (corresponding author), WASHINGTON UNIV,JEWISH HOSP ST LOUIS,MED CTR,ST LOUIS,MO 63110, USA.							1990, MMWR, V39, P7; [No title captured]; 1990, MMWR, V39, P1	3	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 9	1991	266	14					2000	&						0	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GH406	1895483				2022-12-24	WOS:A1991GH40600032
J	TUTEUR, PG				TUTEUR, PG			THE RISK OF SIDESTREAM SMOKE TO PIPE SMOKERS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							PASSIVE SMOKING; TOBACCO-SMOKE; LUNG-CANCER; COTININE; EXPOSURE; CHILDREN				TUTEUR, PG (corresponding author), WASHINGTON UNIV,SCH MED,ST LOUIS,MO 63110, USA.							DALAGER NA, 1986, CANCER RES, V46, P4808; DOLL R, 1978, J EPIDEMIOL COMMUN H, V32, P303, DOI 10.1136/jech.32.4.303; EVANS D, 1987, AM REV RESPIR DIS, V135, P567; GREENBERG RA, 1984, NEW ENGL J MED, V310, P1075, DOI 10.1056/NEJM198404263101703; MASI MA, 1988, AM REV RESPIR DIS, V138, P296, DOI 10.1164/ajrccm/138.2.296; MATSUKURA S, 1984, NEW ENGL J MED, V311, P828, DOI 10.1056/NEJM198409273111305; TAGER IB, 1983, NEW ENGL J MED, V309, P699, DOI 10.1056/NEJM198309223091204; TAGER IB, 1988, NEW ENGL J MED, V138, P296; WEISS ST, 1986, AM REV RESPIR DIS, V133, P1; 1982, DHHS PHS8250179 PUBL	10	2	2	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 9	1991	266	14					2000	2000						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GH406	1895482				2022-12-24	WOS:A1991GH40600031
J	DAVIDSON, HW; REID, PA; LANZAVECCHIA, A; WATTS, C				DAVIDSON, HW; REID, PA; LANZAVECCHIA, A; WATTS, C			PROCESSED ANTIGEN BINDS TO NEWLY SYNTHESIZED MHC CLASS II MOLECULES IN ANTIGEN-SPECIFIC LYMPHOCYTES-B	CELL			English	Article							RESTRICTED T-CELLS; INVARIANT CHAIN; PRESENTING CELLS; HLA-DR; TRANSFERRIN RECEPTOR; PEPTIDE COMPLEXES; PROTEIN ANTIGENS; VIRAL PEPTIDES; BREFELDIN-A; ALPHA-CHAIN	We describe the direct detection of radiolabeled antigen fragments bound to class II MHC molecules following immunoglobulin-mediated endocytosis and processing of native antigen in B lymphoblastoid cells. Tris-Tricine SDS gels revealed six distinct iodinated processing products that could be detected on class II MHC 1 hr after antigen endocytosis and persisted for at least 20 hr. These physiological processed antigen-class II complexes were remarkably stable, as judged by the fact that class II-alpha-beta dimers, which remain associated in SDS, became labeled with the same set of processed peptides. Using a lectin-binding assay, we show that these physiological processing products bind to the newly maturing population of MHC molecules rather than binding to the preexisting cell surface population; in contrast, an exogenous peptide binds predominantly to the latter population. A direct T cell-independent assay for processed peptide-MHC complex formation should facilitate additional studies on the exogenous antigen processing pathway.	BASEL INST IMMUNOL,CH-4005 BASEL,SWITZERLAND		DAVIDSON, HW (corresponding author), UNIV DUNDEE,INST MED SCI,DEPT BIOCHEM,DUNDEE DD1 4HN,SCOTLAND.			Watts, Colin/0000-0001-6183-2087	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADORINI L, 1990, NATURE, V346, P63, DOI 10.1038/346063a0; ADORINI L, 1989, NATURE, V342, P800, DOI 10.1038/342800a0; BAKKE O, 1990, CELL, V63, P707, DOI 10.1016/0092-8674(90)90137-4; BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BLUM JS, 1988, P NATL ACAD SCI USA, V85, P3975, DOI 10.1073/pnas.85.11.3975; BRACIALE TJ, 1991, IMMUNOL TODAY, V12, P124, DOI 10.1016/0167-5699(91)90096-C; BRODSKY FM, 1991, ANNU REV IMMUNOL, V9, P707; BUSCH R, 1990, INT IMMUNOL, V2, P443, DOI 10.1093/intimm/2.5.443; BUUS S, 1988, SCIENCE, V242, P1045, DOI 10.1126/science.3194755; CEPPELLINI R, 1989, NATURE, V339, P392, DOI 10.1038/339392a0; CRESSWELL P, 1977, EUR J IMMUNOL, V7, P636, DOI 10.1002/eji.1830070911; CRESSWELL P, 1985, P NATL ACAD SCI USA, V82, P8188, DOI 10.1073/pnas.82.23.8188; Cresswell P, 1990, Semin Immunol, V2, P273; DAVIDSON HW, 1989, J CELL BIOL, V109, P85, DOI 10.1083/jcb.109.1.85; DAVIDSON HW, 1990, J IMMUNOL, V144, P4101; DAVIS JE, 1990, J IMMUNOL, V144, P990; DEMOTZ S, 1989, NATURE, V342, P682, DOI 10.1038/342682a0; DEMOTZ S, 1989, J IMMUNOL, V142, P394; DORNMAIR K, 1989, COLD SPRING HARB SYM, V54, P409; DUNN WA, 1980, J BIOL CHEM, V255, P5971; EISENLOHR LC, 1988, J IMMUNOL, V141, P1870; ELLIOTT WL, 1987, J IMMUNOL, V138, P2949; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; GUAGLIARDI LE, 1990, NATURE, V343, P133, DOI 10.1038/343133a0; GUY K, 1982, EUR J IMMUNOL, V12, P942, DOI 10.1002/eji.1830121109; HARDING CV, 1989, P NATL ACAD SCI USA, V86, P4230, DOI 10.1073/pnas.86.11.4230; HARDING CV, 1991, CELL, V64, P393, DOI 10.1016/0092-8674(91)90647-H; HARDING CV, 1990, EUR J IMMUNOL, V20, P323, DOI 10.1002/eji.1830200214; HARDING CV, 1989, J IMMUNOL, V142, P12; JARAQUEMADA D, 1990, J EXP MED, V172, P947, DOI 10.1084/jem.172.3.947; JENSEN PE, 1990, J EXP MED, V171, P1779, DOI 10.1084/jem.171.5.1779; KOCH N, 1989, TRENDS BIOCHEM SCI, V14, P383, DOI 10.1016/0968-0004(89)90013-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANZAVECCHIA A, 1985, NATURE, V314, P537, DOI 10.1038/314537a0; LEE JM, 1990, J IMMUNOL, V144, P1829; LEE P, 1988, J IMMUNOL, V140, P1063; LONG EO, 1989, IMMUNOL TODAY, V10, P232, DOI 10.1016/0167-5699(89)90259-4; LOTTEAU V, 1990, NATURE, V348, P600, DOI 10.1038/348600a0; MACHY P, 1990, J IMMUNOL, V145, P1350; MELLINS E, 1990, NATURE, V343, P71, DOI 10.1038/343071a0; NADIMI F, 1991, EUR J IMMUNOL, V21, P1255, DOI 10.1002/eji.1830210524; NEEFJES JJ, 1990, CELL, V61, P171, DOI 10.1016/0092-8674(90)90224-3; NUCHTERN JG, 1990, NATURE, V343, P74, DOI 10.1038/343074a0; OSULLIVAN D, 1990, J IMMUNOL, V145, P1799; PETERS PJ, 1991, NATURE, V349, P669, DOI 10.1038/349669a0; PETERSON M, 1990, NATURE, V345, P172, DOI 10.1038/345172a0; REID PA, 1990, NATURE, V346, P655, DOI 10.1038/346655a0; ROCHE PA, 1990, J IMMUNOL, V144, P1849; ROCHE PA, 1990, NATURE, V345, P615, DOI 10.1038/345615a0; ROOSNEK E, 1988, J IMMUNOL, V140, P4079; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; SALAMERO J, 1990, EMBO J, V9, P3489, DOI 10.1002/j.1460-2075.1990.tb07557.x; SCHUMACHER TNM, 1991, NATURE, V350, P703, DOI 10.1038/350703a0; SCHUMACHER TNM, 1990, CELL, V62, P563, DOI 10.1016/0092-8674(90)90020-F; SETTE A, 1989, J IMMUNOL, V143, P1265; SHAGGER H, 1987, ANAL BIOCHEM, V166, P368; SHIMONKEVITZ R, 1983, J EXP MED, V158, P303, DOI 10.1084/jem.158.2.303; SNIDER MD, 1985, J CELL BIOL, V100, P826, DOI 10.1083/jcb.100.3.826; SPRINGER TA, 1977, J BIOL CHEM, V252, P6201; STPIERRE Y, 1990, J IMMUNOL, V145, P812; TEYTON L, 1990, NATURE, V348, P39, DOI 10.1038/348039a0; THOMPSON JA, 1987, BIOCHEMISTRY-US, V26, P743, DOI 10.1021/bi00377a014; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; UNANUE ER, 1984, ANNU REV IMMUNOL, V2, P95; VANBLEEK GM, 1990, NATURE, V348, P213; WATTS C, 1988, EMBO J, V7, P1937, DOI 10.1002/j.1460-2075.1988.tb03031.x; Watts C, 1990, Semin Immunol, V2, P247; WATTS C, 1989, COLD SH Q B, V54, P345; WATTS C, 1985, J CELL BIOL, V100, P633, DOI 10.1083/jcb.100.2.633; WEBER DA, 1990, J MOL CELL IMMUNOL, V4, P255; YEWDELL JW, 1990, CELL, V62, P203, DOI 10.1016/0092-8674(90)90356-J; ZIEGLER HK, 1982, P NATL ACAD SCI-BIOL, V79, P175, DOI 10.1073/pnas.79.1.175	75	180	180	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 4	1991	67	1					105	116		10.1016/0092-8674(91)90575-J	http://dx.doi.org/10.1016/0092-8674(91)90575-J			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GJ320	1913812				2022-12-24	WOS:A1991GJ32000010
J	NIGHTINGALE, SL				NIGHTINGALE, SL			CONCENTRATED MORPHINE APPROVED FOR USE IN CONTINUOUS MICROINFUSION DEVICES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 2	1991	266	13					1751	1751						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG551	1890706				2022-12-24	WOS:A1991GG55100004
J	OLUBODUN, JOB; JAIYESIMI, AEA; FAKOYA, EA; OLASODE, OA				OLUBODUN, JOB; JAIYESIMI, AEA; FAKOYA, EA; OLASODE, OA			MALNUTRITION IN PRISONERS ADMITTED TO A MEDICAL WARD IN A DEVELOPING COMMUNITY	BRITISH MEDICAL JOURNAL			English	Article									OGUN STATE UNIV,TEACHING HOSP,DEPT MED,PMB,SHAGAMU 2001,NIGERIA				Olasode, Olayinka/AAL-6831-2020					BAKER JP, 1982, NEW ENGL J MED, V306, P969, DOI 10.1056/NEJM198204223061606; BURGESS RC, 1956, LANCET, V2, P411; OLUBODUN JOB, IN PRESS TROP GEOGR; SMITH R, 1984, BRIT MED J, V288, P995, DOI 10.1136/bmj.288.6422.995; WATERLOW JC, 1972, BRIT MED J, V3, P566, DOI 10.1136/bmj.3.5826.566	5	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 21	1991	303	6804					693	694		10.1136/bmj.303.6804.693	http://dx.doi.org/10.1136/bmj.303.6804.693			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GG980	1912916	Bronze, Green Published			2022-12-24	WOS:A1991GG98000022
J	DUMLER, JS; TAYLOR, JP; WALKER, DH				DUMLER, JS; TAYLOR, JP; WALKER, DH			CLINICAL AND LABORATORY FEATURES OF MURINE TYPHUS IN SOUTH TEXAS, 1980 THROUGH 1987	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MOUNTAIN SPOTTED-FEVER; MICROIMMUNOFLUORESCENCE TEST; EPIDEMIOLOGICAL FEATURES	Objective. - The clinical and laboratory features of patients with murine typhus have not been extensively reviewed since 1946. We have updated these findings in patients from south Texas who were examined by modern clinical and laboratory methods from 1980 through 1987. Design. - Patients were identified by serological methods in this case series, and clinical, epidemiologic, laboratory, and therapeutic data were compiled and analyzed. Setting. - The majority of patients (77 of 80) were identified in a primary care community hospital setting; the remainder (3 of 80) were ambulatory hospital outpatients. Patients. - From 1980 through 1987, a total of 345 patients were diagnosed with murine typhus; 90 of these patients were seen at four hospitals in south Texas; of these, 80 had clinical and laboratory data available for review. Main Outcome Measures. - The frequency of common clinical manifestations (eg, headache, fever, and rash) and laboratory findings (eg, leukocyte and platelet counts and serum chemistry abnormalities) of patients with infectious diseases was tabulated. Clinical severity was semiquantitatively assessed and was correlated with clinical, laboratory, and therapeutic results. Results. - Most cases (69%) occurred from April through August. Rash occurred in 54%; the triad of fever, headache, and rash was observed in only 12.5% of patients when first examined by a physician; respiratory and gastrointestinal symptoms were also frequent. Multiple organ involvement was documented by frequent abnormal laboratory findings of the hematologic, respiratory, hepatic, and renal systems. Disease severity was related to older patient age, the presence of renal dysfunction, leukocytosis, and hypoalbuminemia, and previous therapy with sulfa antibiotics. Conclusions. - Infection by Rickettsia typhi causes a systemic illness with clinical and laboratory abnormalities not previously recognized or described. Early clinical diagnosis and treatment are needed to avoid undue morbidity and mortality.	TEXAS DEPT HLTH, DIV EPIDEMIOL, AUSTIN, TX USA	Texas Department of State Health Services	DUMLER, JS (corresponding author), UNIV TEXAS, MED BRANCH, DEPT PATHOL, 101 KEILLER BLDG, F09, GALVESTON, TX 77550 USA.							ALAWADI AR, 1982, B WORLD HEALTH ORGAN, V60, P283; AZAD AF, 1985, AM J TROP MED HYG, V34, P555, DOI 10.4269/ajtmh.1985.34.555; BELTRAN RR, 1991, RICKETTSIAE RICKETTS, P714; BETZ TG, 1983, TEX MED, V79, P48; BINFORD CH, 1947, AM J CLIN PATHOL, V17, P797; BOTROS BAM, 1989, J TROP MED HYG, V92, P373; BROWN AE, 1989, AM J TROP MED HYG, V92, P373; BURGDORFER W, 1976, TROPICAL MED, P110; BUTTERY CMG, 1984, TEX MED, V80, P53; FAN MY, 1987, REV INFECT DIS, V9, P823; FARHANGAZAD A, 1984, J MED ENTOMOL, V21, P675, DOI 10.1093/jmedent/21.6.675; FARHANGAZAD A, 1988, BIOL RICKETTSIAL DIS, V1, P51; GROSS EM, 1984, B WORLD HEALTH ORGAN, V62, P301; HECHEMY KE, 1979, J CLIN MICROBIOL, V9, P292; HECHEMY KE, 1981, J CLIN MICROBIOL, V13, P214, DOI 10.1128/JCM.13.1.214-216.1981; HELMICK CG, 1984, J INFECT DIS, V150, P480, DOI 10.1093/infdis/150.4.480; Irons J. V., 1944, AMER JOUR TROP MED, V24, P359; KIRK JL, 1990, MEDICINE, V69, P35, DOI 10.1097/00005792-199001000-00003; LOVE GJ, 1960, PUBLIC HEALTH REP, V75, P429, DOI 10.2307/4590821; MAXCY K. F., 1926, Public Health Reports, V41, P2967, DOI 10.2307/4578110; MILLER ES, 1946, MEDICINE, V25, P1; OLDER JJ, 1970, J AMER MED ASSOC, V214, P2011, DOI 10.1001/jama.214.11.2011; PETERSON JC, 1947, J PEDIATR, V30, P495, DOI 10.1016/S0022-3476(47)80046-0; PHILIP RN, 1976, J CLIN MICROBIOL, V3, P51; QUINBY GE, 1953, AM J PUBLIC HEALTH, V43, P160; RAOULT D, 1986, J INFECTION, V12, P111, DOI 10.1016/S0163-4453(86)93508-5; RAOULT D, 1986, AM J TROP MED HYG, V35, P845, DOI 10.4269/ajtmh.1986.35.845; SAMRA Y, 1989, ARCH INTERN MED, V149, P949, DOI 10.1001/archinte.149.4.949; SMADEL JE, 1959, ANN INTERN MED, V51, P421, DOI 10.7326/0003-4819-51-3-421; SNYDER JC, 1946, RICKETTSIAL DISEASES, P169; STASKO T, 1982, J AM ACAD DERMATOL, V7, P377, DOI 10.1016/S0190-9622(82)80318-6; STUART BM, 1945, ANN INTERN MED, V23, P520, DOI 10.7326/0003-4819-23-4-520; TAYLOR JP, 1986, JAMA-J AM MED ASSOC, V255, P2173; Traub R, 1978, Trop Dis Bull, V75, P237; TSELENTIS Y, 1986, J INFECTION, V13, P91, DOI 10.1016/S0163-4453(86)92371-6; WALKER DH, 1989, AM J CLIN PATHOL, V91, P720, DOI 10.1093/ajcp/91.6.720; WALKER DH, 1980, J INFECT DIS, V142, P771, DOI 10.1093/infdis/142.5.771; WOODRUFF PWR, 1988, T ROY SOC TROP MED H, V82, P761, DOI 10.1016/0035-9203(88)90229-5; WOODWARD TE, 1988, BIOL RICKETTSIAL DIS, V1, P79; 1990, MMWR, V38, P47	40	177	184	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 11	1991	266	10					1365	1370		10.1001/jama.266.10.1365	http://dx.doi.org/10.1001/jama.266.10.1365			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GD807	1880866				2022-12-24	WOS:A1991GD80700030
J	MUSIERFORSYTH, K; USMAN, N; SCARINGE, S; DOUDNA, J; GREEN, R; SCHIMMEL, P				MUSIERFORSYTH, K; USMAN, N; SCARINGE, S; DOUDNA, J; GREEN, R; SCHIMMEL, P			SPECIFICITY FOR AMINOACYLATION OF AN RNA HELIX - AN UNPAIRED, EXOCYCLIC AMINO GROUP IN THE MINOR GROOVE	SCIENCE			English	Article							PHENYLALANINE TRANSFER-RNA; CHEMICAL SYNTHESIS; RECOGNITION; OLIGORIBONUCLEOTIDES; RESOLUTION; IDENTITY; BINDING; ALANINE	An acceptor stem G3.U70 base pair is a major determinant of the identity of an alanine transfer RNA. Hairpin helices and RNA duplexes consisting of complementary single strands are aminoacylated with alanine if they contain G3.U70. Chemical synthesis of RNA duplexes enabled the introduction of base analogs that tested the role of specific functional groups in the major and minor grooves of the RNA helix. The results of these experiments indicate that an unpaired guanine 2-amino group at a specific position in the minor groove of an RNA helix marks a molecule for aminoacylation with alanine.	MASSACHUSETTS GEN HOSP, DEPT MOLEC BIOL, BOSTON, MA 02114 USA; UNIV COLORADO, DEPT CHEM & BIOCHEM, BOULDER, CO 80309 USA	Harvard University; Massachusetts General Hospital; University of Colorado System; University of Colorado Boulder					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM037641, R37GM015539, R01GM015539] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM37641, GM15539] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNOTT S, 1967, J MOL BIOL, V27, P525, DOI 10.1016/0022-2836(67)90056-3; DOUDNA JA, 1990, J ORG CHEM, V55, P5547, DOI 10.1021/jo00308a003; FRANCKLYN C, 1989, NATURE, V337, P478, DOI 10.1038/337478a0; FRANCKLYN C, 1990, P NATL ACAD SCI USA, V87, P8655, DOI 10.1073/pnas.87.21.8655; FRANCKLYN C, UNPUB; FRANCKLYN CS, 1990, CHEM REV, V90, P1327, DOI 10.1021/cr00105a013; GREEN R, NUCLEIC ACIDS RES; HOU YM, 1988, NATURE, V333, P140, DOI 10.1038/333140a0; KIM SH, 1974, SCIENCE, V185, P435, DOI 10.1126/science.185.4149.435; MCCLAIN WH, 1988, SCIENCE, V242, P1681, DOI 10.1126/science.2462282; MUSIERFORSYTH K, 1991, P NATL ACAD SCI USA, V88, P209, DOI 10.1073/pnas.88.1.209; OLLIS DL, 1987, CHEM REV, V87, P981, DOI 10.1021/cr00081a006; PABO CO, 1984, ANNU REV BIOCHEM, V53, P293, DOI 10.1146/annurev.bi.53.070184.001453; PARK SJ, 1989, BIOCHEMISTRY-US, V28, P2740, DOI 10.1021/bi00432a056; ROBERTUS JD, 1974, NATURE, V250, P546, DOI 10.1038/250546a0; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; SCARINGE SA, 1990, NUCLEIC ACIDS RES, V18, P5433, DOI 10.1093/nar/18.18.5433; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; SHI JP, 1990, BIOCHEMISTRY-US, V29, P3621, DOI 10.1021/bi00467a005; STEITZ TA, 1990, Q REV BIOPHYS, V23, P205, DOI 10.1017/S0033583500005552	20	149	150	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 16	1991	253	5021					784	786		10.1126/science.1876835	http://dx.doi.org/10.1126/science.1876835			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GB295	1876835				2022-12-24	WOS:A1991GB29500036
J	SIEGEL, JM; NIENHUIS, R; FAHRINGER, HM; PAUL, R; SHIROMANI, P; DEMENT, WC; MIGNOT, E; CHIU, C				SIEGEL, JM; NIENHUIS, R; FAHRINGER, HM; PAUL, R; SHIROMANI, P; DEMENT, WC; MIGNOT, E; CHIU, C			NEURONAL-ACTIVITY IN NARCOLEPSY - IDENTIFICATION OF CATAPLEXY-RELATED CELLS IN THE MEDIAL MEDULLA	SCIENCE			English	Article							RETICULAR-FORMATION NEURONS; LOWER BRAIN-STEM; UNRESTRAINED CAT; REM-SLEEP; CHOLINE-ACETYLTRANSFERASE; BEHAVIORAL ORGANIZATION; PONTINE TEGMENTUM; MOVEMENTS; ATONIA; PROJECTIONS	Narcolepsy is a neurological disorder characterized by sleepiness and episodes of cataplexy. Cataplexy is an abrupt loss of muscle tone, most often triggered by sudden, strong emotions. A subset of cells in the medial medulla of the narcoleptic dog discharged at high rates only in cataplexy and rapid eye movement (REM) sleep. These cells were noncholinergic and were localized to ventromedial and caudal portions of the nucleus magnocellularis. The localization and discharge pattern of these cells indicate that cataplexy results from a triggering in waking of the neurons responsible for the suppression of muscle tone in REM sleep. However, most medullary cells were inactive during cataplexy but were active during REM sleep. These data demonstrate that cataplexy is a distinct behavioral state, differing from other sleep and waking states in its pattern of brainstem neuronal activity.	VET AFFAIRS MED CTR,DEPT PSYCHIAT,SAN DIEGO,CA; STANFORD UNIV,MED CTR,SCH MED,DEPT PSYCHIAT,STANFORD,CA 94305; UNIV CALIF SAN DIEGO,LA JOLLA,CA 92093; UNIV CALIF LOS ANGELES,SCH MED,DEPT PSYCHIAT,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,BRAIN RES INST,LOS ANGELES,CA 90024	US Department of Veterans Affairs; Veterans Health Administration (VHA); Stanford University; University of California System; University of California San Diego; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	SIEGEL, JM (corresponding author), VET AFFAIRS MED CTR,SEPULVEDA,CA 91343, USA.			Chiu, Charles/0000-0003-2915-2094	NHLBI NIH HHS [R01 HL041370, HL41370, R37 HL041370] Funding Source: Medline; NIMH NIH HHS [R01 MH064109] Funding Source: Medline; NINDS NIH HHS [NS23724, R01 NS014610, P50 NS023724, R37 NS014610, NS14610] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041370, R37HL041370] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS014610, P50NS023724, P01NS023724, R37NS014610] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALDRICH MS, 1989, SLEEP, V12, P254, DOI 10.1093/sleep/12.3.254; Baker TL, 1985, BRAIN MECH SLEEP, P199; BILLIARD M, 1985, ANN CLIN RES, V17, P220; CHASE MH, 1989, J NEUROSCI, V9, P743; CHASE MH, 1983, INT REV NEUROBIOL, V24, P213, DOI 10.1016/S0074-7742(08)60223-8; FORT P, 1990, CR ACAD SCI III-VIE, V311, P205; GUILLEMINAULT C, 1988, LANCET, V2, P511; GUILLEMINAULT C, 1976, NARCOLEPSY, P125; HENLEY K, 1974, ACTA NEUROBIOL EXP, V34, P215; Honda Y, 1984, FOLIA PSYCHIATR NEUR, V38, P360; JANKOWSKA E, 1968, ARCH ITAL BIOL, V106, P124; JOUVET M, 1965, CR SOC BIOL, V159, P895; KILDUFF TS, 1986, SLEEP, V9, P102, DOI 10.1093/sleep/9.1.102; LAI YY, 1988, J NEUROSCI, V8, P4790; LAI YY, 1989, SOC NEUR ABSTR, V17, P391; Lim R. K. S., 1960, STEREOTAXIC ATLAS DO; MCGINTY DJ, 1976, SCIENCE, V193, P240; MIGNOT E, 1989, BRAIN RES, V500, P1; MITLER MM, 1987, PSYCHIAT CLIN N AM, V10, P593; MITLER MM, 1974, EXP NEUROL, V45, P332, DOI 10.1016/0014-4886(74)90122-8; MORALES FR, 1982, SLEEP RES, V11, P26; MORI S, 1987, PROG NEUROBIOL, V28, P161, DOI 10.1016/0301-0082(87)90010-4; NETICK A, 1977, BRAIN RES, V120, P197, DOI 10.1016/0006-8993(77)90900-3; RECHTSCHAFFEN A, 1963, ELECTROEN CLIN NEURO, V15, P599, DOI 10.1016/0013-4694(63)90032-4; SAKAI K, 1990, BRAIN RES BULL, V24, P437, DOI 10.1016/0361-9230(90)90098-K; Sakai K., 1980, RETICULAR FORMATION, P427; SCHENKEL E, 1989, NEUROSCI LETT, V98, P159, DOI 10.1016/0304-3940(89)90503-X; SHIROMANI PJ, 1990, BRAIN RES, V517, P224, DOI 10.1016/0006-8993(90)91030-K; SHIROMANI PJ, 1988, SLEEP, V11, P1; Siegel J., UNPUB; SIEGEL JM, 1979, EXP NEUROL, V65, P691, DOI 10.1016/0014-4886(79)90055-4; SIEGEL JM, 1978, SCIENCE, V199, P207; SIEGEL JM, 1979, BRAIN RES REV, V1, P69, DOI 10.1016/0165-0173(79)90017-1; SIEGEL JM, 1983, J NEUROPHYSIOL, V50, P696, DOI 10.1152/jn.1983.50.3.696; SIEGEL JM, 1983, J NEUROPHYSIOL, V50, P717, DOI 10.1152/jn.1983.50.3.717; SIEGEL JM, 1979, BRAIN RES, V179, P49, DOI 10.1016/0006-8993(79)90488-8; SUZUKI SS, 1989, BRAIN RES, V484, P78, DOI 10.1016/0006-8993(89)90350-8; TOHYAMA M, 1979, BRAIN RES, V173, P383, DOI 10.1016/0006-8993(79)90237-3; VINCENT SR, 1987, BRAIN RES BULL, V18, P371, DOI 10.1016/0361-9230(87)90015-3	39	109	110	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 31	1991	252	5010					1315	1318		10.1126/science.1925546	http://dx.doi.org/10.1126/science.1925546			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FN857	1925546	Green Accepted			2022-12-24	WOS:A1991FN85700043
J	SERAFINI, T; STENBECK, G; BRECHT, A; LOTTSPEICH, F; ORCI, L; ROTHMAN, JE; WIELAND, FT				SERAFINI, T; STENBECK, G; BRECHT, A; LOTTSPEICH, F; ORCI, L; ROTHMAN, JE; WIELAND, FT			A COAT SUBUNIT OF GOLGI-DERIVED NON-CLATHRIN-COATED VESICLES WITH HOMOLOGY TO THE CLATHRIN-COATED VESICLE COAT PROTEIN BETA-ADAPTIN	NATURE			English	Article							CELL-FREE SYSTEM; LUMINAL ER PROTEINS; BREFELDIN-A; ENDOPLASMIC-RETICULUM; PLASMA-MEMBRANE; INTERCOMPARTMENTAL TRANSPORT; SUCCESSIVE COMPARTMENTS; INTRACELLULAR-TRANSPORT; VESICULAR TRANSPORT; SECRETORY PROTEINS	Four high-molecular-weight proteins form the main subunits of the coat of Golgi-derived (non-clathrin) coated vesicles. One of these coat proteins, beta-COP, is identical to a Golgi-associated protein of relative mass 110,000 (110K) that shares homology with the adaptin proteins of clathrin-coated vesicles. This connection, and the comparable molecular weights of the coat proteins of Golgi-derived and clathrin-coated vesicles, indicates that they may be structurally related. The identification of beta-COP as the 110K protein explains the blocking of secretion by the drug brefeldin A.	PRINCETON UNIV,DEPT MOLEC BIOL,PRINCETON,NJ 08544; UNIV HEIDELBERG,INST BIOCHEM 1,W-6900 HEIDELBERG,GERMANY; MAX PLANCK INST BIOCHEM,GENZENTRUM,W-8033 MARTINSRIED,GERMANY; UNIV GENEVA,DEPT MORPHOL,CH-1211 GENEVA 4,SWITZERLAND	Princeton University; Ruprecht Karls University Heidelberg; Max Planck Society; University of Geneva	SERAFINI, T (corresponding author), STANFORD UNIV,DEPT BIOCHEM,STANFORD,CA 94305, USA.							AHLE S, 1989, J BIOL CHEM, V264, P20089; AHLE S, 1988, EMBO J, V7, P919, DOI 10.1002/j.1460-2075.1988.tb02897.x; ALLAN VJ, 1986, J CELL BIOL, V103, P2229, DOI 10.1083/jcb.103.6.2229; BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; BALCH WE, 1985, ARCH BIOCHEM BIOPHYS, V240, P413, DOI 10.1016/0003-9861(85)90046-3; BALCH WE, 1984, CELL, V39, P525, DOI 10.1016/0092-8674(84)90459-8; BALCH WE, 1983, METHOD ENZYMOL, V98, P37; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; GLICK BS, 1987, NATURE, V326, P309, DOI 10.1038/326309a0; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; GRIFFITHS G, 1985, J CELL BIOL, V101, P949, DOI 10.1083/jcb.101.3.949; HARRI E, 1963, HELV CHIM ACTA, V46, P1235, DOI 10.1002/hlca.19630460419; JAMIESON JD, 1967, J CELL BIOL, V34, P577, DOI 10.1083/jcb.34.2.577; KARRENBAUER A, 1990, CELL, V63, P259, DOI 10.1016/0092-8674(90)90159-C; KEEN JH, 1990, ANNU REV BIOCHEM, V59, P415, DOI 10.1146/annurev.biochem.59.1.415; KEEN JH, 1987, J CELL BIOL, V105, P1989, DOI 10.1083/jcb.105.5.1989; KEEN JH, 1979, CELL, V16, P303, DOI 10.1016/0092-8674(79)90007-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; MALHOTRA V, 1988, CELL, V54, P221, DOI 10.1016/0092-8674(88)90554-5; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; Morris SA, 1989, CURR OPIN CELL BIOL, V1, P684, DOI 10.1016/0955-0674(89)90034-3; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; ODA K, 1987, FEBS LETT, V214, P135, DOI 10.1016/0014-5793(87)80028-5; ORCI L, 1985, P NATL ACAD SCI USA, V82, P5385, DOI 10.1073/pnas.82.16.5385; ORCI L, 1989, CELL, V56, P357, DOI 10.1016/0092-8674(89)90239-0; ORCI L, 1986, CELL, V46, P171, DOI 10.1016/0092-8674(86)90734-8; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; PEARSE BMF, 1975, J MOL BIOL, V97, P93, DOI 10.1016/S0022-2836(75)80024-6; PEARSE BMF, 1982, P NATL ACAD SCI-BIOL, V79, P451, DOI 10.1073/pnas.79.2.451; PEARSE BMF, 1984, EMBO J, V3, P1951, DOI 10.1002/j.1460-2075.1984.tb02075.x; PEARSE BMF, 1988, EMBO J, V7, P3331, DOI 10.1002/j.1460-2075.1988.tb03204.x; PEARSE BMF, 1981, ANNU REV BIOCHEM, V50, P85, DOI 10.1146/annurev.bi.50.070181.000505; PELHAM HRB, 1988, EMBO J, V7, P913, DOI 10.1002/j.1460-2075.1988.tb02896.x; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; ROBINSON MS, 1990, J CELL BIOL, V111, P2319, DOI 10.1083/jcb.111.6.2319; ROTHMAN JE, 1984, J CELL BIOL, V99, P248, DOI 10.1083/jcb.99.1.248; ROTHMAN JE, 1984, J CELL BIOL, V99, P260, DOI 10.1083/jcb.99.1.260; SCHOOK W, 1979, P NATL ACAD SCI USA, V76, P116, DOI 10.1073/pnas.76.1.116; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0; WIELAND FT, 1987, CELL, V50, P289, DOI 10.1016/0092-8674(87)90224-8; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0; ZAREMBA S, 1983, J CELL BIOL, V97, P1339, DOI 10.1083/jcb.97.5.1339	51	311	318	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 17	1991	349	6306					214	220		10.1038/349215a0	http://dx.doi.org/10.1038/349215a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ET519	1898984				2022-12-24	WOS:A1991ET51900046
J	HENKIN, R				HENKIN, R			COOLING THE BURN FROM HOT PEPPERS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											HENKIN, R (corresponding author), TASTE & SMELL CLIN,WASHINGTON,DC, USA.								0	10	10	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 20	1991	266	19					2766	2766						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GP691	1942431				2022-12-24	WOS:A1991GP69100037
J	WONG, MMY; FOSKETT, JK				WONG, MMY; FOSKETT, JK			OSCILLATIONS OF CYTOSOLIC SODIUM DURING CALCIUM OSCILLATIONS IN EXOCRINE ACINAR-CELLS	SCIENCE			English	Article							MANDIBULAR SALIVARY-GLAND; AGONIST-INDUCED ACTIVATION; NA+/H+ EXCHANGE; INTRACELLULAR PH; SECRETION; AMILORIDE; FLUID	In acinar cells from rat salivary glands, cholinergic agonists cause oscillations in cytoplasmic free calcium concentration, which then drive oscillations of cell volume that reflect oscillating cell solute content and fluid secretion. By quantitative fluorescence ratio microscopy of an intracellular indicator dye for sodium, it has now been shown that large amplitude oscillations of sodium concentration were associated with the calcium and cell volume oscillations. Both calcium and sodium oscillations were dependent on the continued presence of calcium in the extracellular medium and were abolished by the specific sodium-potassium adenosine triphosphatase inhibitor ouabain. Thus, calcium oscillations in salivary acinar cells, by modulating the activities of ion transport pathways in the plasma membrane, can cause significant oscillations of monovalent ions that may in turn feed back to regulate calcium oscillations and fluid secretion.	HOSP SICK CHILDREN,RES INST,DIV CELL BIOL,555 UNIV AVE,TORONTO M5G 1X8,ONTARIO,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)			Foskett, Kevin/R-2549-2019	Foskett, J. Kevin/0000-0002-8854-0268				BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; CASE RM, 1984, J PHYSIOL-LONDON, V349, P619, DOI 10.1113/jphysiol.1984.sp015177; DISSING S, 1990, AM J PHYSIOL, V259, pG1044, DOI 10.1152/ajpgi.1990.259.6.G1044; FOSKETT JK, 1988, AM J PHYSIOL, V255, pC566, DOI 10.1152/ajpcell.1988.255.4.C566; FOSKETT JK, 1990, AM J PHYSIOL, V259, pC998; FOSKETT JK, 1991, J BIOL CHEM, V266, P14535; FOSKETT JK, 1989, SCIENCE, V244, P1582, DOI 10.1126/science.2500708; FOSKETT JK, 1991, J BIOL CHEM, V266, P2778; FOSKETT JK, IN PRESS AM J PHYSL; JACOB R, 1990, BIOCHIM BIOPHYS ACTA, V1052, P427, DOI 10.1016/0167-4889(90)90152-4; LAU KR, 1990, J PHYSIOL-LONDON, V425, P407, DOI 10.1113/jphysiol.1990.sp018111; MANGANEL M, 1989, J MEMBRANE BIOL, V111, P191, DOI 10.1007/BF01871782; MANGANEL M, 1990, J BIOL CHEM, V265, P4284; MARTINEZ JR, 1989, EUR J PHARMACOL, V164, P335, DOI 10.1016/0014-2999(89)90474-3; MELVIN JE, 1988, J BIOL CHEM, V263, P19564; MINTA A, 1989, J BIOL CHEM, V264, P19449; NOVAK I, 1989, PFLUG ARCH EUR J PHY, V414, P68, DOI 10.1007/BF00585628; PIRANI D, 1987, PFLUG ARCH EUR J PHY, V408, P178, DOI 10.1007/BF00581349; POULSEN JH, 1987, J DENT RES, V66, P608, DOI 10.1177/00220345870660024401; SMAJE LH, 1986, PFLUEGERS ARCH, V406, P4925; SOLTOFF SP, 1989, J GEN PHYSIOL, V93, P285, DOI 10.1085/jgp.93.2.285; STEWARD MC, 1989, PFLUG ARCH EUR J PHY, V414, P200, DOI 10.1007/BF00580964; TURNER RJ, 1986, J MEMBRANE BIOL, V94, P143, DOI 10.1007/BF01871194; Wong M, UNPUB	24	60	60	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 15	1991	254	5034					1014	1016		10.1126/science.1948071	http://dx.doi.org/10.1126/science.1948071			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GP883	1948071				2022-12-24	WOS:A1991GP88300047
J	SPAINK, HP; SHEELEY, DM; VANBRUSSEL, AAN; GLUSHKA, J; YORK, WS; TAK, T; GEIGER, O; KENNEDY, EP; REINHOLD, VN; LUGTENBERG, BJJ				SPAINK, HP; SHEELEY, DM; VANBRUSSEL, AAN; GLUSHKA, J; YORK, WS; TAK, T; GEIGER, O; KENNEDY, EP; REINHOLD, VN; LUGTENBERG, BJJ			A NOVEL HIGHLY UNSATURATED FATTY-ACID MOIETY OF LIPO-OLIGOSACCHARIDE SIGNALS DETERMINES HOST SPECIFICITY OF RHIZOBIUM	NATURE			English	Article							LEGUMINOSARUM BV VICIAE; SYM PLASMID PRL1JI; ROOT EXUDATE; NODULATION REGION; NOD GENE; MELILOTI; PROTEIN; ENCODES; NODULES; MUTANTS	In Rhizobium leguminosarum biovar viciae, the nodABC and nodFEL operons are involved in the production of lipo-oligosaccharide signals which mediate host specificity. The structure of these metabolites and those produced in nod mutants links the nodE and nodL genes to specific chemical features of the signal molecules. A nodE-determined, highly unsaturated fatty acid and a nodL-determined O-acetyl substituent are essential for the ability of the signals to induce nodule meristems on the host plant Vicia sativa.	HARVARD UNIV,SCH PUBL HLTH,DEPT NUTR,BOSTON,MA 02115; COMPLEX CARBOHYDRATE RES CTR,ATHENS,GA 30602; HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School	SPAINK, HP (corresponding author), LEIDEN UNIV,DEPT PLANT MOLEC BIOL,NONNENST 3,2311 VJ LEIDEN,NETHERLANDS.		Geiger, Otto/F-6356-2019; Spaink, Herman P./S-3586-2017	Geiger, Otto/0000-0002-7794-1568; Spaink, Herman P./0000-0003-4128-9501				BARKER SA, 1958, J CHEM SOC, V451, P2218; BIBB MJ, 1989, EMBO J, V8, P2727, DOI 10.1002/j.1460-2075.1989.tb08414.x; Breitmaier E., 1987, CARBON 13 NMR SPECTR; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; DEMAAGD RA, 1989, J BACTERIOL, V171, P6764, DOI 10.1128/jb.171.12.6764-6770.1989; DOWNIE JA, 1983, EMBO J, V2, P947, DOI 10.1002/j.1460-2075.1983.tb01526.x; DOWNIE JA, 1990, MOL GEN GENET, V222, P81, DOI 10.1007/BF00283027; DOWNIE JA, 1989, MOL MICROBIOL, V3, P1649, DOI 10.1111/j.1365-2958.1989.tb00150.x; ECONOMOU A, 1990, EMBO J, V9, P349, DOI 10.1002/j.1460-2075.1990.tb08117.x; FINAN TM, 1985, CELL, V40, P869, DOI 10.1016/0092-8674(85)90346-0; GEIGER O, 1991, J BACTERIOL, V173, P2872, DOI 10.1128/JB.173.9.2872-2878.1991; HAHN MG, IN PRESS MOL PLANT P, pCH2; HOOYKAAS PJJ, 1982, PLASMID, V8, P73, DOI 10.1016/0147-619X(82)90042-7; LEROUGE P, 1990, NATURE, V344, P781, DOI 10.1038/344781a0; LONG SR, 1989, CELL, V56, P203, DOI 10.1016/0092-8674(89)90893-3; MUSSO RE, 1973, BIOCHEMISTRY-US, V12, P553, DOI 10.1021/bi00727a031; RECOURT K, 1991, PLANT MOL BIOL, V16, P841, DOI 10.1007/BF00015076; RECOURT K, 1991, THESIS U LEIDEN; ROCHE P, 1991, J BIOL CHEM, V266, P10933; ROCHE P, 1991, ADV MOL GENETICS PLA, V1, P119; SCHWEDOCK J, 1990, NATURE, V348, P644, DOI 10.1038/348644a0; SHEARMAN CA, 1986, EMBO J, V5, P647, DOI 10.1002/j.1460-2075.1986.tb04262.x; SHEELEY DM, 1991, ANAL BIOCHEM, V193, P240, DOI 10.1016/0003-2697(91)90016-M; SPAINK HP, 1989, EMBO J, V8, P2811, DOI 10.1002/j.1460-2075.1989.tb08427.x; SPAINK HP, 1987, PLANT MOL BIOL, V9, P27, DOI 10.1007/BF00017984; SPAINK HP, 1991, ADV MOL GENETICS PLA, V1, P142; SPAINK HP, IN PRESS MOL PL MICR; STELLNER K, 1973, ARCH BIOCHEM BIOPHYS, V155, P464, DOI 10.1016/0003-9861(73)90138-0; TRUCHET G, 1989, PROTOPLASMA, V149, P82, DOI 10.1007/BF01322980; TRUCHET G, 1991, NATURE, V351, P670, DOI 10.1038/351670a0; TRUCHET G, 1980, DIFFERENTIATION, V16, P163, DOI 10.1111/j.1432-0436.1980.tb01072.x; VANBRUSSEL AAN, 1986, J BACTERIOL, V165, P517, DOI 10.1128/jb.165.2.517-522.1986; VANBRUSSEL AAN, 1990, J BACTERIOL, V172, P5394, DOI 10.1128/jb.172.9.5394-5401.1990; WIJFFELMAN CA, 1985, ARCH MICROBIOL, V143, P225, DOI 10.1007/BF00411240	34	452	468	3	40	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 14	1991	354	6349					125	130		10.1038/354125a0	http://dx.doi.org/10.1038/354125a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GP880	1944592				2022-12-24	WOS:A1991GP88000051
J	SCHLOTTERER, C; AMOS, B; TAUTZ, D				SCHLOTTERER, C; AMOS, B; TAUTZ, D			CONSERVATION OF POLYMORPHIC SIMPLE SEQUENCE LOCI IN CETACEAN SPECIES	NATURE			English	Article							DNA; EVOLUTION	LENGTH polymorphisms within simple-sequence loci occur ubiquitously in non-coding eukaryotic DNA and can be highly informative in the analysis of natural populations 1-4. Simple-sequence length polymorphisms (SSLP) in the long-finned pilot whale Globicephala melas (Delphinidae) have provided useful information on the mating system as well as on the genetic structure of populations 5. We have therefore tested whether the polymerase chain reaction primers designed for Globicephala could also be used to uncover variability in other whale species. Homologous loci could indeed be amplified from a diverse range of whales, including all toothed (Odontoceti) and baleen whales (Mysticeti) tested. Cloning and sequencing these loci from 11 different species revealed an unusually high conservation of sequences flanking the simple-sequence stretches, averaging 3.2% difference over 35-40 Myr. This represents the lowest divergence rate for neutral nucleotide positions found for any species group so far and raises the possible need for a re-evaluation of the age of the modern whales. On the other hand, the high conservation of non-coding sequences in whales simplifies the application of SSLP DNA fingerprinting in cetacean species, as primers designed for one species will often uncover variability in other species.	UNIV MUNICH,INST GENET,W-8000 MUNICH 19,GERMANY; UNIV CAMBRIDGE,DEPT GENET,CAMBRIDGE CB2 3EH,ENGLAND	University of Munich; University of Cambridge			Schlötterer, Christian/Q-5264-2019; Tautz, Diethard/D-4304-2011; Schlötterer, Christian/G-6326-2010; Tautz, Diethard/H-8436-2014	Schlötterer, Christian/0000-0003-4710-6526; Schlötterer, Christian/0000-0003-4710-6526; Tautz, Diethard/0000-0002-0460-5344				Amos W., 1991, REP INT WHAL COMMN, P255; BARNES LG, 1985, MAR MAMMAL SCI, V1, P15, DOI 10.1111/j.1748-7692.1985.tb00530.x; BULMER M, 1987, NATURE, V325, P728, DOI 10.1038/325728a0; FORDYCE RE, 1980, PALAEOGEOGR PALAEOCL, V31, P319, DOI 10.1016/0031-0182(80)90024-3; HOELZEL AR, 1988, NATURE, V333, P305, DOI 10.1038/333305a0; HOELZEL AR, 1991, REP INT WHALING COMM, V13, P171; LI WH, 1987, J MOL EVOL, V25, P330, DOI 10.1007/BF02603118; LITT M, 1989, AM J HUM GENET, V44, P397; MOORE SS, 1991, GENOMICS, V10, P654, DOI 10.1016/0888-7543(91)90448-N; PENTREATH RJ, 1979, 3RD P NEA SEM MAR EC; SAKAI RK, 1988, SCIENCE, V239, P487; TAUTZ D, 1990, BIOESSAYS, V12, P44, DOI 10.1002/bies.950120111; TAUTZ D, 1984, NUCLEIC ACIDS RES, V12, P4127, DOI 10.1093/nar/12.10.4127; TAUTZ D, 1986, NATURE, V322, P652, DOI 10.1038/322652a0; TAUTZ D, 1989, NUCLEIC ACIDS RES, V17, P6463, DOI 10.1093/nar/17.16.6463; WEBER JL, 1989, AM J HUM GENET, V44, P388; WILSON AC, 1987, TRENDS GENET, V3, P241, DOI 10.1016/0168-9525(87)90257-5	17	292	320	1	32	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 7	1991	354	6348					63	65		10.1038/354063a0	http://dx.doi.org/10.1038/354063a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GN829	1944571				2022-12-24	WOS:A1991GN82900058
J	DESCOMBES, P; SCHIBLER, U				DESCOMBES, P; SCHIBLER, U			A LIVER-ENRICHED TRANSCRIPTIONAL ACTIVATOR PROTEIN, LAP, AND A TRANSCRIPTIONAL INHIBITORY PROTEIN, LIP, ARE TRANSLATED FROM THE SAME MESSENGER-RNA	CELL			English	Article							DNA-BINDING PROTEINS; LEUCINE ZIPPER PROTEINS; AUG INITIATOR CODON; EUKARYOTIC RIBOSOMES; MAMMALIAN-CELLS; C/EBP FAMILY; ALBUMIN GENE; SEQUENCE; EXPRESSION; DOMAIN	LAP, a transcriptional activator, and LIP, a transcriptional repressor, are translated from a single mRNA species by using two AUGs within the same reading frame. These two proteins share the 145 C-terminal amino acids that contain the basic DNA-binding domain and the leucine zipper dimerization helix. Probably owing to its higher affinity for its DNA cognate sequences, LIP can attenuate the transcriptional stimulation by LAP in substoichiometric amounts. As revealed by transient transfection experiments, a moderate increase in the LAP/LIP ratio results in a significantly higher transcriptional activation of an appropriate target gene. The LAP/LIP ratio increases about 5-fold during terminal rat liver differentiation and is thus likely to modulate the activity of LAP in the intact animal.			DESCOMBES, P (corresponding author), DEPT BIOL MOLEC SCI 2,30 QUAI ERNEST ANSERMET,CH-1211 GENEVA 4,SWITZERLAND.							ACKLAND P, 1990, NATURE, V343, P662; AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; AUWERX J, 1991, CELL, V64, P983, DOI 10.1016/0092-8674(91)90322-P; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; BOUCHE G, 1987, P NATL ACAD SCI USA, V84, P6770, DOI 10.1073/pnas.84.19.6770; CHANG CJ, 1990, MOL CELL BIOL, V10, P6642, DOI 10.1128/MCB.10.12.6642; CHOE J, 1989, J VIROL, V63, P1743, DOI 10.1128/JVI.63.4.1743-1755.1989; CLEMENS MJ, 1984, TRANSCRIPTION TRANSL, P211; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; FALVEY E, 1991, FASEB J, V5, P309, DOI 10.1096/fasebj.5.3.2001790; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; HINNEBUSCH AG, 1990, TRENDS BIOCHEM SCI, V15, P148, DOI 10.1016/0968-0004(90)90215-W; HU JC, 1990, SCIENCE, V250, P1400, DOI 10.1126/science.2147779; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P3873, DOI 10.1093/nar/12.9.3873; KOZAK M, 1981, NUCLEIC ACIDS RES, V9, P5233, DOI 10.1093/nar/9.20.5233; KOZAK M, 1986, CELL, V47, P481, DOI 10.1016/0092-8674(86)90609-4; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBERT PF, 1990, J VIROL, V64, P950, DOI 10.1128/JVI.64.2.950-956.1990; LAMBERT PF, 1987, CELL, V50, P69, DOI 10.1016/0092-8674(87)90663-5; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LICHTSTEINER S, 1987, CELL, V51, P963, DOI 10.1016/0092-8674(87)90583-6; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MUELLER CR, 1990, CELL, V61, P279, DOI 10.1016/0092-8674(90)90808-R; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; PEABODY DS, 1989, J BIOL CHEM, V264, P5031; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; Ptashne M., 1986, A GENETIC SWITCH; RUSCONI S, 1990, GENE, V89, P211, DOI 10.1016/0378-1119(90)90008-F; Sambrook J., 1989, MOL CLONING LAB MANU; SARIS CJM, 1991, EMBO J, V10, P655, DOI 10.1002/j.1460-2075.1991.tb07994.x; STRUHL G, 1989, CELL, V57, P1259, DOI 10.1016/0092-8674(89)90062-7; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; TREACY MN, 1991, NATURE, V350, P577, DOI 10.1038/350577a0; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; WUARIN J, 1990, CELL, V63, P1257, DOI 10.1016/0092-8674(90)90421-A	44	925	938	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 1	1991	67	3					569	579		10.1016/0092-8674(91)90531-3	http://dx.doi.org/10.1016/0092-8674(91)90531-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GN664	1934061				2022-12-24	WOS:A1991GN66400013
J	LENARDO, MJ				LENARDO, MJ			INTERLEUKIN-2 PROGRAMS MOUSE ALPHA-BETA-LYMPHOCYTES-T FOR APOPTOSIS	NATURE			English	Article							STAPHYLOCOCCAL ENTEROTOXIN-B; CELL ANTIGEN RECEPTOR; STIMULATORY FACTOR-I; MONOCLONAL-ANTIBODY; PROLIFERATION; INVIVO; ACTIVATION; CLONES; UNRESPONSIVENESS; THYMOCYTES	ANTIGEN receptor stimulation of mature alpha-beta-T lymphocytes can lead either to proliferation or death 1-4. Programmed cell death, termed apoptosis, leads to the clonal deletion of both thymocytes and mature T cells that establishes tolerance 5-9. How a mature T cell selects between proliferation and death is not understood. Here I show that interleukin-2 (IL-2) is a critical determinant of the choice between these two fates. Both CD4+ and CD8+ T cells previously exposed to IL-2 undergo apoptosis after antigen-receptor stimulation. Antibody blockade of IL-2 but not IL-4 reverses the marked reduction of lymph node V-beta-38+ T cells caused in mice by the bacterial superantigen Staphylococcus aureus enterotoxin B. IL-2 may thus participate in a feedback regulatory mechanism by predisposing mature T lymphocytes to apoptosis.			LENARDO, MJ (corresponding author), NIAID,IMMUNOL LAB,BLDG 10,RM 11N311,BETHESDA,MD 20892, USA.							ASHWELL JD, 1986, J IMMUNOL, V137, P2572; CRISPE IN, 1985, NATURE, V317, P627, DOI 10.1038/317627a0; FINKELMAN FD, 1986, P NATL ACAD SCI USA, V83, P9675, DOI 10.1073/pnas.83.24.9675; HASKINS K, 1984, J EXP MED, V160, P452, DOI 10.1084/jem.160.2.452; HECHT TT, 1983, J IMMUNOL, V131, P1049; JANSSEN O, 1991, J IMMUNOL, V146, P35; JONES LA, 1990, SCIENCE, V250, P1726, DOI 10.1126/science.2125368; KANAGAWA O, 1989, J EXP MED, V170, P1513, DOI 10.1084/jem.170.5.1513; KAWABE Y, 1991, NATURE, V349, P245, DOI 10.1038/349245a0; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LIU Y, 1990, Journal of Experimental Medicine, V172, P1735, DOI 10.1084/jem.172.6.1735; MACDONALD HR, 1990, NATURE, V343, P642, DOI 10.1038/343642a0; MALEK TR, 1984, J IMMUNOL, V133, P1976; MARRACK P, 1990, J EXP MED, V171, P455, DOI 10.1084/jem.171.2.455; MONOD J, 1961, COLD SPRING HARB SYM, V26, P389, DOI 10.1101/SQB.1961.026.01.048; MUELLER DL, 1989, J IMMUNOL, V142, P2617; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; NAU GJ, 1987, J IMMUNOL, V139, P114; OHARA J, 1985, NATURE, V315, P333, DOI 10.1038/315333a0; PENIT C, 1988, J IMMUNOL, V140, P3315; ROCHA B, 1991, SCIENCE, V251, P1225, DOI 10.1126/science.1900951; RUSSELL JH, 1991, P NATL ACAD SCI USA, V88, P2151, DOI 10.1073/pnas.88.6.2151; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; STAERZ UD, 1985, J IMMUNOL, V134, P3994; TENTORI L, 1988, J EXP MED, V168, P1741, DOI 10.1084/jem.168.5.1741; WEAVER CT, 1988, P NATL ACAD SCI USA, V85, P8181, DOI 10.1073/pnas.85.21.8181; WEBB S, 1990, CELL, V63, P1249, DOI 10.1016/0092-8674(90)90420-J; WHITE J, 1989, CELL, V56, P27, DOI 10.1016/0092-8674(89)90980-X; WILLIAMS ME, 1990, J IMMUNOL, V144, P1208	29	970	1004	0	12	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 31	1991	353	6347					858	861		10.1038/353858a0	http://dx.doi.org/10.1038/353858a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GM732	1944559				2022-12-24	WOS:A1991GM73200064
J	COLLEY, NJ; BAKER, EK; STAMNES, MA; ZUKER, CS				COLLEY, NJ; BAKER, EK; STAMNES, MA; ZUKER, CS			THE CYCLOPHILIN HOMOLOG NINAA IS REQUIRED IN THE SECRETORY PATHWAY	CELL			English	Article							CIS-TRANS-ISOMERASE; A-BINDING-PROTEIN; CRYSTALLOID ENDOPLASMIC-RETICULUM; CYCLOSPORIN-A; DROSOPHILA-MELANOGASTER; MESSENGER-RNA; NEUROSPORA-CRASSA; PERIPHERAL PHOTORECEPTORS; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI	In Drosophila, the major rhodopsin Rh1 is synthesized in endoplasmic reticulum (ER)-bound ribosomes of the R1-R6 photoreceptor cells and is then transported to the rhabdomeres where it functions in phototransduction. Mutations in the cyclophilin homolog ninaA lead to a 90% reduction in Rh1 opsin. Cyclophilins have been shown to be peptidyl-prolyl cis-trans isomerases and have been implicated in catalyzing protein folding. We now show that mutations in the ninaA gene severely inhibit opsin transport from the ER, leading to dramatic accumulations of ER cisternae in the photoreceptor cells. These results demonstrate that ninaA functions in the ER. Interestingly, ninaA and Rh1 also colocalize to secretory vesicles, suggesting that Rh1 may require ninaA as it travels through the distal compartments of the secretory pathway. These results are discussed in relation to the possible role of cyclophilins in protein folding and intracellular protein trafficking.	UNIV CALIF SAN DIEGO,DEPT BIOL,SAN DIEGO,CA 92103; UNIV CALIF SAN DIEGO,DEPT NEUROSCI,SAN DIEGO,CA 92103	University of California System; University of California San Diego; University of California System; University of California San Diego	COLLEY, NJ (corresponding author), UNIV CALIF SAN DIEGO,HOWARD HUGHES MED INST,SAN DIEGO,CA 92103, USA.			Stamnes, Mark/0000-0002-5869-7985	NATIONAL EYE INSTITUTE [R01EY008768] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY008768] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANDERSON RGW, 1983, J CELL SCI, V63, P1; BACHINGER HP, 1987, J BIOL CHEM, V262, P17144; BAUMANN O, 1989, CELL TISSUE RES, V255, P511, DOI 10.1007/BF00218786; BICKEL M, 1987, P NATL ACAD SCI USA, V84, P3274, DOI 10.1073/pnas.84.10.3274; BLEST AD, 1988, ADV INSECT PHYSIOL, V20, P1, DOI 10.1016/S0065-2806(08)60021-1; BOREL JF, 1976, AGENTS ACTIONS, V6, P468, DOI 10.1007/BF01973261; BOREL JF, 1976, IMMUNOLOGY, V31, P631; CARONI P, 1991, J BIOL CHEM, V266, P10739; CHIN DJ, 1982, P NATL ACAD SCI-BIOL, V79, P1185, DOI 10.1073/pnas.79.4.1185; DAVIS JM, 1989, J BIOL CHEM, V264, P8956; DECOUET HG, 1987, EUR J CELL BIOL, V44, P50; DOI T, 1990, P NATL ACAD SCI USA, V87, P4991, DOI 10.1073/pnas.87.13.4991; DRUGGE RJ, 1988, TRANSPL P, V20, P301; ELDRED WD, 1983, J HISTOCHEM CYTOCHEM, V31, P285, DOI 10.1177/31.2.6339606; ELLIOTT JF, 1984, SCIENCE, V226, P1439, DOI 10.1126/science.6334364; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; FEILER R, 1988, NATURE, V333, P737, DOI 10.1038/333737a0; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; GRANELLIPIPERNO A, 1988, J EXP MED, V168, P1649, DOI 10.1084/jem.168.5.1649; HEROLD KC, 1986, J IMMUNOL, V136, P1315; HILLMAN P, 1983, PHYSIOL REV, V63, P668, DOI 10.1152/physrev.1983.63.2.668; HOHMAN R J, 1990, New Biologist, V2, P663; HUBER A, 1990, J BIOL CHEM, V265, P17906; HULTSCH T, 1990, J IMMUNOL, V144, P2659; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; IWAI N, 1990, KIDNEY INT, V37, P1460, DOI 10.1038/ki.1990.136; KAHAN BD, 1989, NEW ENGL J MED, V321, P1725; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; KAWAMUKAI M, 1989, J BACTERIOL, V171, P4525, DOI 10.1128/JB.171.8.4525-4529.1989; KIEFHABER T, 1990, BIOCHEMISTRY-US, V29, P3053, DOI 10.1021/bi00464a023; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KOSER PL, 1990, NUCLEIC ACIDS RES, V18, P1643, DOI 10.1093/nar/18.6.1643; KRONKE M, 1984, P NATL ACAD SCI-BIOL, V81, P5214, DOI 10.1073/pnas.81.16.5214; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANG K, 1987, NATURE, V329, P268, DOI 10.1038/329268a0; LARRIVEE DC, 1981, J GEN PHYSIOL, V78, P521, DOI 10.1085/jgp.78.5.521; LINDSLEY DL, 1968, CARNEGIE I WASH PUBL, V627; LIU J, 1990, P NATL ACAD SCI USA, V87, P4028, DOI 10.1073/pnas.87.11.4028; LODISH HF, 1988, J BIOL CHEM, V263, P2107; MATTILA PS, 1990, EMBO J, V9, P4425, DOI 10.1002/j.1460-2075.1990.tb07893.x; MINKE B, 1975, J COMP PHYSIOL, V98, P345, DOI 10.1007/BF00709805; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; OTOUSA JE, 1985, CELL, V40, P839, DOI 10.1016/0092-8674(85)90343-5; PACIFICI M, 1988, J BIOL CHEM, V263, P2483; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PELHAM HRB, 1990, TRENDS BIOCHEM SCI, V15, P483, DOI 10.1016/0968-0004(90)90303-S; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; PRICE ER, 1991, P NATL ACAD SCI USA, V88, P1903, DOI 10.1073/pnas.88.5.1903; QUESNIAUX VFJ, 1987, EUR J IMMUNOL, V17, P1359, DOI 10.1002/eji.1830170921; RANDAK C, 1990, EMBO J, V9, P2529, DOI 10.1002/j.1460-2075.1990.tb07433.x; ROSE JK, 1988, ANNU REV CELL BIOL, V4, P257, DOI 10.1146/annurev.cellbio.4.1.257; ROTHMAN JE, 1987, CELL, V50, P521, DOI 10.1016/0092-8674(87)90024-9; SCHNEUWLY S, 1989, P NATL ACAD SCI USA, V86, P5390, DOI 10.1073/pnas.86.14.5390; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SHEVACH EM, 1985, ANNU REV IMMUNOL, V3, P397; SHIEH BH, 1989, NATURE, V338, P67, DOI 10.1038/338067a0; SIGAL NH, 1990, BIOCHEM PHARMACOL, V40, P2201, DOI 10.1016/0006-2952(90)90712-T; SIGAL NH, 1991, J EXP MED, V173, P619, DOI 10.1084/jem.173.3.619; SPIK G, 1991, J BIOL CHEM, V266, P10735; Stamnes MA, 1990, CURR OPIN CELL BIOL, V2, P1104, DOI 10.1016/0955-0674(90)90163-9; STAMNES MA, 1991, CELL, V65, P219, DOI 10.1016/0092-8674(91)90156-S; STARK WS, 1988, J NEUROCYTOL, V17, P499, DOI 10.1007/BF01189805; STEPHENSON RS, 1983, BIOL PHOTORECEPTION, P477; STJULES RS, 1989, EXP EYE RES, V48, P653, DOI 10.1016/0014-4835(89)90007-9; TAKAHASHI N, 1989, NATURE, V337, P473, DOI 10.1038/337473a0; TOKUYASU KT, 1989, HISTOCHEM J, V21, P163, DOI 10.1007/BF01007491; TOKUYASU KT, 1986, J MICROSC-OXFORD, V143, P139, DOI 10.1111/j.1365-2818.1986.tb02772.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRENN G, 1989, J IMMUNOL, V142, P3796; TROPSCHUG M, 1989, NATURE, V342, P953, DOI 10.1038/342953a0; TROPSCHUG M, 1990, NUCLEIC ACIDS RES, V18, P190, DOI 10.1093/nar/18.1.190; TROPSCHUG M, 1988, J BIOL CHEM, V263, P14433; VANVACTOR D, 1988, CELL, V52, P281, DOI 10.1016/0092-8674(88)90517-X; WRIGHT R, 1988, J CELL BIOL, V107, P101, DOI 10.1083/jcb.107.1.101; ZUKER CS, 1985, CELL, V40, P851, DOI 10.1016/0092-8674(85)90344-7; ZUKER CS, 1988, CELL, V55, P475	79	303	305	0	13	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 18	1991	67	2					255	263		10.1016/0092-8674(91)90177-Z	http://dx.doi.org/10.1016/0092-8674(91)90177-Z			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GL470	1913822				2022-12-24	WOS:A1991GL47000005
J	PARSONNET, J; FRIEDMAN, GD; VANDERSTEEN, DP; CHANG, Y; VOGELMAN, JH; ORENTREICH, N; SIBLEY, RK				PARSONNET, J; FRIEDMAN, GD; VANDERSTEEN, DP; CHANG, Y; VOGELMAN, JH; ORENTREICH, N; SIBLEY, RK			HELICOBACTER-PYLORI INFECTION AND THE RISK OF GASTRIC-CARCINOMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CAMPYLOBACTER-PYLORI; IMMUNE-RESPONSE; CANCER; ASSOCIATION; EPIDEMIOLOGY; POPULATION; STOMACH; DIET	Background. Infection with Helicobacter pylori has been linked with chronic atrophic gastritis, an inflammatory precursor of gastric adenocarcinoma. In a nested case-control study, we explored whether H. pylori infection increases the risk of gastric carcinoma. Methods. From a cohort of 128,992 persons followed since the mid-1960s at a health maintenance organization, 186 patients with gastric carcinoma were selected as case patients and were matched according to age, sex, and race with 186 control subjects without gastric carcinoma. Stored serum samples collected during the 1960s were tested for IgG antibodies to H. pylori by enzyme-linked immunosorbent assay. Data on cigarette use, blood group, ulcer disease, and gastric surgery were obtained from questionnaires administered at enrollment. Tissue sections and pathology reports were reviewed to confirm the histologic results. Results. The mean time between serum collection and the diagnosis of gastric carcinoma was 14.2 years. Of the 109 patients with confirmed gastric adenocarcinoma (excluding tumors of the gastroesophageal junction), 84 percent had been infected previously with H. pylori, as compared with 61 percent of the matched control subjects (odds ratio, 3.6; 95 percent confidence interval, 1.8 to 7.3). Tumors of the gastroesophageal junction were not linked to H. pylori infection, nor were tumors in the gastric cardia. H. pylori was a particularly strong risk factor for stomach cancer in women (odds ratio, 18) and blacks (odds ratio, 9). A history of gastric surgery was independently associated with the development of cancer (odds ratio, 17; P = 0.03), but a history of peptic ulcer disease was negatively associated with subsequent gastric carcinoma (odds ratio, 0.2; P = 0.02). Neither blood group nor smoking history affected risk. Conclusions. Infection with H. pylori is associated with an increased risk of gastric adenocarcinoma and may be a cofactor in the pathogenesis of this malignant condition.	ORENTREICH FDN ADVANCEMENT SCI INC, NEW YORK, NY 10021 USA; STANFORD UNIV, MED CTR, SCH MED, DEPT PATHOL, STANFORD, CA 94305 USA; KAISER PERMANENTE MED CARE PROGRAM, DIV RES, OAKLAND, CA USA	Stanford University; Kaiser Permanente	PARSONNET, J (corresponding author), STANFORD UNIV, MED CTR,SCH MED,DEPT MED,HRP BLDG, RM 109A, STANFORD, CA 94305 USA.		Chang, Yuan/F-4146-2011	Chang, Yuan/0000-0003-1125-4041; Parsonnet, Julie/0000-0001-7342-5366	NCI NIH HHS [R35CA49761] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA049761] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMES BN, 1990, SCIENCE, V249, P970, DOI 10.1126/science.2136249; ARMIJO R, 1981, INT J EPIDEMIOL, V10, P53, DOI 10.1093/ije/10.1.53; BUIATTI E, 1990, INT J CANCER, V45, P896, DOI 10.1002/ijc.2910450520; COLLEN MF, 1969, JOM-J OCCUP MED, V11, P355; CORREA P, 1970, J NATL CANCER I, V44, P297; CORREA P, 1983, JNCI-J NATL CANCER I, V70, P673; CORREA P, 1985, SEMIN ONCOL, V12, P2; CORREA P, 1976, JNCI-J NATL CANCER I, V57, P1027, DOI 10.1093/jnci/57.5.1027; CORREA P, 1990, CANCER RES, V50, P4737; CORREA P, 1982, EPIDEMIOLOGY CANCER, P58; EVANS DJ, 1989, GASTROENTEROLOGY, V96, P1004, DOI 10.1016/0016-5085(89)91616-8; FAULDE M, 1991, J CLIN MICROBIOL, V29, P323, DOI 10.1128/JCM.29.2.323-327.1991; FORMAN D, 1990, INT J CANCER, V46, P608, DOI 10.1002/ijc.2910460410; FOX JG, 1989, AM J GASTROENTEROL, V84, P775; FRIEDMAN GD, 1986, AM J EPIDEMIOL, V123, P781, DOI 10.1093/oxfordjournals.aje.a114307; FRIEDMAN GD, 1974, NEW ENGL J MED, V290, P469, DOI 10.1056/NEJM197402282900901; GAREWAL HS, 1989, PREV MED, V18, P749, DOI 10.1016/0091-7435(89)90046-7; GOODWIN CS, 1987, J INFECT DIS, V155, P488, DOI 10.1093/infdis/155.3.488; GOODWIN CS, 1989, INT J SYST BACTERIOL, V39, P397, DOI 10.1099/00207713-39-4-397; HAENSZEL W, 1972, JNCI-J NATL CANCER I, V49, P969; HIRSCHL AM, 1988, EUR J CLIN MICROBIOL, V7, P570, DOI 10.1007/BF01962618; HOWSON CP, 1986, EPIDEMIOL REV, V8, P1; JASKIEWICZ K, 1989, S AFR MED J, V75, P417; LAUREN P, 1965, ACTA PATHOL MIC SC, V64, P31, DOI 10.1111/apm.1965.64.1.31; LOFFELD RJLF, 1990, HISTOPATHOLOGY, V17, P537, DOI 10.1111/j.1365-2559.1990.tb00793.x; MORRIS A, 1989, J CLIN PATHOL, V42, P727, DOI 10.1136/jcp.42.7.727; MUIR CS, 1987, IARC SCI PUBLICATION, V88; MUNOZ N, 1971, INT J CANCER, V8, P158, DOI 10.1002/ijc.2910080119; MUNOZ N, 1968, INT J CANCER, V3, P809, DOI 10.1002/ijc.2910030614; PARKIN DM, 1988, INT J CANCER, V41, P184, DOI 10.1002/ijc.2910410205; PARKIN DM, 1986, IARC SCI PUBLICATION, V75; PARSONNET J, 1991, JNCI-J NATL CANCER I, V83, P640, DOI 10.1093/jnci/83.9.640; PARSONNET J, 1989, CAMPYLOBACTER PYLORI, P51; PEREZPEREZ GI, 1988, ANN INTERN MED, V109, P11, DOI 10.7326/0003-4819-109-1-11; PEREZPEREZ GI, 1990, J INFECT DIS, V161, P1237, DOI 10.1093/infdis/161.6.1237; RAUWS EAJ, 1989, CAMPYLOBACTER PYLORI, P187; ROBINS J, 1986, AM J EPIDEMIOL, V124, P719, DOI 10.1093/oxfordjournals.aje.a114447; SCOTT N, 1990, LANCET, V335, P728, DOI 10.1016/0140-6736(90)90845-V; SIPPONEN P, 1987, SCAND J GASTROENTERO, V22, P865, DOI 10.3109/00365528708991927; STRAUSS RM, 1990, AM J MED, V89, P464, DOI 10.1016/0002-9343(90)90377-P; TALLEY NJ, IN PRESS J NATL CANC	41	3410	3524	8	365	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 17	1991	325	16					1127	1131		10.1056/NEJM199110173251603	http://dx.doi.org/10.1056/NEJM199110173251603			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GK538	1891020				2022-12-24	WOS:A1991GK53800003
J	DARGIE, HJ; GRANT, S				DARGIE, HJ; GRANT, S			EXERCISE	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; PHYSICAL-ACTIVITY; LEISURE-TIME; RISK-FACTORS; ATTACK; HEALTH; DEATH		UNIV GLASGOW, DEPT PHYS EDUC & SPORTS SCI, GLASGOW G12 8QQ, SCOTLAND	University of Glasgow	DARGIE, HJ (corresponding author), WESTERN INFIRM & ASSOCIATED HOSP, GLASGOW G11 6NT, SCOTLAND.							[Anonymous], 1990, Med Sci Sports Exerc, V22, P265; BOUCHARD C, 1988, EXERCISE FITNESS HLT, P3; BRAY GA, 1988, EXERCISE FITNESS HLT, P497; COOPER KH, 1976, JAMA-J AM MED ASSOC, V236, P166, DOI 10.1001/jama.236.2.166; DISHMAN RK, 1990, 24 P WORLD C SPORTS, P11; DUNCAN JJ, 1985, JAMA-J AM MED ASSOC, V254, P2609, DOI 10.1001/jama.254.18.2609; DURNIN JVG, 1984, UNPUB COMA COMMITTEE; FENTEM P, 1987, EXERCISE HEART HLTH, P110; Fentem P.H., 1988, NEW CASE EXERCISE; FIATARONE MA, 1990, JAMA-J AM MED ASSOC, V263, P3029, DOI 10.1001/jama.263.22.3029; FOLKINS CH, 1981, AM PSYCHOL, V36, P373, DOI 10.1037/0003-066X.36.4.373; GARFINKEL PE, 1988, EXERCISE FITNESS HLT, P455; GOLDBERG AP, 1986, NEPHRON, V42, P311, DOI 10.1159/000183694; GOLDBERG L, 1987, SPORTS MED, V4, P307, DOI 10.2165/00007256-198704050-00001; LAW MR, 1991, BMJ-BRIT MED J, V303, P453, DOI 10.1136/bmj.303.6800.453; Leon A S, 1977, Ann N Y Acad Sci, V301, P561, DOI 10.1111/j.1749-6632.1977.tb38230.x; MARCUS BH, 1991, AM J CARDIOL, V68, P406, DOI 10.1016/0002-9149(91)90843-A; MORRIS JN, 1953, LANCET, V265, P1053; MORRIS JN, 1990, BRIT HEART J, V63, P325; MORRIS JN, 1973, LANCET, V1, P333; NORTHCOTE RJ, 1984, SPORTS MED, V1, P181, DOI 10.2165/00007256-198401030-00002; OCONNOR GT, 1989, CIRCULATION, V80, P234, DOI 10.1161/01.CIR.80.2.234; PAFFENBARGER RS, 1978, AM J EPIDEMIOL, V108, P161, DOI 10.1093/oxfordjournals.aje.a112608; POOLE GW, 1984, SPORTS MED, V1, P341, DOI 10.2165/00007256-198401050-00002; POWELL KE, 1987, ANNU REV PUBL HEALTH, V8, P253, DOI 10.1146/annurev.publhealth.8.1.253; SHEPHARD RJ, 1986, SPORTS MED, V3, P26, DOI 10.2165/00007256-198603010-00004; SMITH EL, 1987, PHYSICIAN SPORTSMED, V15, P91; SULLIVAN MJ, 1988, CIRCULATION, V78, P506, DOI 10.1161/01.CIR.78.3.506; TODD IC, 1990, BRIT HEART J, V64, P14; TUNSTALLPEDOE H, 1989, SCOT MED J, V34, P556, DOI 10.1177/003693308903400604; TUNSTALLPEDOE H, 1975, LANCET, V2, P833; WORK JA, 1989, PHYSICIAN SPORTSMED, V17, P226, DOI 10.1080/00913847.1989.11709746; 1991, HLTH ED SCOTLAND NAT; 1987, BRIT HEART J, V57, P188; 1990, PREVENTION CORONARY; 1991, J R COLL PHYSICIANS, V25, P193; 1991, CM1523; [No title captured]	38	9	9	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 12	1991	303	6807					910	912		10.1136/bmj.303.6807.910	http://dx.doi.org/10.1136/bmj.303.6807.910			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GK221	1933009	Green Published, Bronze			2022-12-24	WOS:A1991GK22100029
J	CARRELL, RW; EVANS, DL; STEIN, PE				CARRELL, RW; EVANS, DL; STEIN, PE			MOBILE REACTIVE CENTER OF SERPINS AND THE CONTROL OF THROMBOSIS	NATURE			English	Article							CRYSTAL-STRUCTURE; ALPHA-1-PROTEINASE INHIBITOR; CONFORMATIONAL CHANGE; OVALBUMIN; ALPHA-1-ANTITRYPSIN; ABSENCE; MODEL	TWO protease inhibitors in human plasma play a key part in the control of thrombosis: antithrombin inhibits coagulation and the plasminogen activator inhibitor PAI-1 inhibits fibrinolysis, the dissolving of clots. Both inhibitors are members of the serpin family and both exist in the plasma in latent or inactive forms. We show here that the reactive centre of the serpins can adopt varying conformations and that mobility of the reactive centre is necessary for the function of antithrombin and its binding and activation by heparin; the identification of a new locked conformation explains the latent inactive state of PAI-1. This ability to vary conformation not only allows the modulation of inhibitory activity but also protects the circulating inhibitor against proteolytic attack. Together these findings explain the retention by the serpins of a large and unconstrained reactive centre as compared to the small fixed peptide loop of other families of serine protease inhibitors.			CARRELL, RW (corresponding author), UNIV CAMBRIDGE,CTR MRC,DEPT HAEMATOL,HILLS RD,CAMBRIDGE CB2 2QH,ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AUSTIN RC, 1991, FEBS LETT, V280, P254, DOI 10.1016/0014-5793(91)80305-M; BODE W, 1987, EUR J BIOCHEM, V166, P673, DOI 10.1111/j.1432-1033.1987.tb13566.x; CARRELL RW, 1986, NATURE, V322, P730; DEURAJKIZUK R, 1988, BLOOD, V72, P1518; ENGH RA, 1990, PROTEIN ENG, V3, P469, DOI 10.1093/protein/3.6.469; GETTINS P, 1989, J BIOL CHEM, V264, P3781; HEKMAN CM, 1985, J BIOL CHEM, V260, P11581; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; KATAGIRI K, 1988, EUR J BIOCHEM, V176, P81, DOI 10.1111/j.1432-1033.1988.tb14253.x; KRESS LF, 1981, BIOCHEMISTRY-US, V20, P7432, DOI 10.1021/bi00529a017; LOEBERMANN H, 1984, J MOL BIOL, V177, P531, DOI 10.1016/0022-2836(84)90298-5; PERRY DJ, 1989, FEBS LETT, V254, P174, DOI 10.1016/0014-5793(89)81033-6; PERRY DJ, 1991, FEBS LETT, V286, P2; POWELL LM, 1990, THESIS U NEWCASTLE U; SCHULZE AJ, 1990, EUR J BIOCHEM, V194, P51, DOI 10.1111/j.1432-1033.1990.tb19425.x; SKRIVER K, 1991, J BIOL CHEM, V14, P9216; STEIN P, 1991, J MOL BIOL, V221, P615, DOI 10.1016/0022-2836(91)80076-7; STEIN PE, 1989, BIOCHEM J, V262, P103, DOI 10.1042/bj2620103; STEIN PE, 1990, NATURE, V347, P99, DOI 10.1038/347099a0; VILLANUEVA GB, 1983, J BIOL CHEM, V258, P1010; WRIGHT HT, 1990, J MOL BIOL, V213, P518	21	292	299	0	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 10	1991	353	6344					576	578		10.1038/353576a0	http://dx.doi.org/10.1038/353576a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GJ643	1922367				2022-12-24	WOS:A1991GJ64300074
J	SIEGEL, MJ; CAREL, C; SURRATT, S				SIEGEL, MJ; CAREL, C; SURRATT, S			ULTRASONOGRAPHY OF ACUTE ABDOMINAL-PAIN IN CHILDREN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							ACUTE APPENDICITIS; ACUTE ABDOMEN; SONOGRAPHY; US	Objective. To determine the ability of ultrasonography to detect appendicitis and to identify other conditions responsible for symptoms in children with acute abdominal pain. Design. Cohort study. The accuracy of ultrasonographic results was assessed in relation to final diagnoses established by surgery or by composite clinical data and follow-up. Setting. Metropolitan, pediatric hospital; ambulatory and hospitalized patients. Patients. Consecutive sample of 178 pediatric patients who were referred for ultrasonography because of suspected acute appendicitis, but in whom the diagnosis could not be definitely established by clinical criteria. Results. Appendicitis was proven at surgery in 38 patients. Ultrasonography demonstrated the findings of appendicitis (noncompressible appendix with or without concomitant periappendiceal fluid collection or appendicolith) in 31 (82%) of these patients. Among the 140 children without appendicitis, other specific diagnoses were established by clinical, laboratory, and radiologic findings in 58 patients (including gynecologic diseases in 25, gastrointestinal tract abnormalities in 17, renal diseases in six, and extra-abdominal disease in 10). Ultrasonography aided in the diagnosis of other conditions in 34 (59%) of these 58 patients. No definitive clinical diagnosis was established in the remaining 82 patients. There were no false-positive results of ultrasonography. Conclusion. Approximately half of children referred for suspected appendicitis will have a final diagnosis of abdominal pain of unknown origin. In the remainder, ultrasonography is useful, both to establish the diagnosis of appendicitis and to aid in diagnosing other causes of acute abdominal pain.			SIEGEL, MJ (corresponding author), WASHINGTON UNIV,SCH MED,EDWARD MALLINCKRODT INST RADIOL,510 S KINGSHIGHWAY BLVD,ST LOUIS,MO 63110, USA.							ABUYOUSEF MM, 1987, AM J ROENTGENOL, V149, P53, DOI 10.2214/ajr.149.1.53; CAMPBELL JPM, 1988, BRIT J SURG, V75, P554, DOI 10.1002/bjs.1800750616; FEEDYSHIN P, 1984, AJR AM J ROENTGENOL, V143, P99; FRANKEN EA, 1989, AM J ROENTGENOL, V153, P921, DOI 10.2214/ajr.153.5.921; GAENSLER EHL, 1989, AM J ROENTGENOL, V152, P49, DOI 10.2214/ajr.152.1.49; JEFFREY RB, 1987, RADIOLOGY, V163, P11, DOI 10.1148/radiology.163.1.3547490; JEFFREY RB, 1988, RADIOLOGY, V167, P327, DOI 10.1148/radiology.167.2.3282253; JOFFE N, 1975, Critical Reviews in Clinical Radiology and Nuclear Medicine, V7, P97; JONES PF, 1976, BRIT MED J, V2, P551, DOI 10.1136/bmj.2.6035.551; MENDELSON RM, 1987, BRIT J RADIOL, V60, P414, DOI 10.1259/0007-1285-60-712-414; PARELUKAR SG, 1983, J ULTRASOUNDMED, V2, P59; PUYLAERT JBCM, 1987, NEW ENGL J MED, V317, P666, DOI 10.1056/NEJM198709103171103; PUYLAERT JBCM, 1986, RADIOLOGY, V158, P355, DOI 10.1148/radiology.158.2.2934762; RUBIN SZ, 1990, J PEDIATR SURG, V25, P737, DOI 10.1016/S0022-3468(05)80008-9; VIGNAULT F, 1990, RADIOLOGY, V176, P501, DOI 10.1148/radiology.176.2.2195594; WINSEY HS, 1967, BMJ-BRIT MED J, V1, P653, DOI 10.1136/bmj.1.5541.653	16	68	70	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 9	1991	266	14					1987	1989		10.1001/jama.266.14.1987	http://dx.doi.org/10.1001/jama.266.14.1987			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GH406	1895479				2022-12-24	WOS:A1991GH40600027
J	YAZIGI, RA; ODEM, RR; POLAKOSKI, KL				YAZIGI, RA; ODEM, RR; POLAKOSKI, KL			DEMONSTRATION OF SPECIFIC BINDING OF COCAINE TO HUMAN SPERMATOZOA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							H-3 COCAINE; ASSOCIATION; RECEPTORS	Exposure of males to cocaine has been linked to abnormal development of their offspring. To investigate the possible role of sperm, this study examined the interaction of cocaine with human spermatozoa. Washed sperm were incubated with tritiated cocaine (6.7 nmol/L) with or without unlabeled cocaine (670-mu-mol/L), and the samples were filtered and the remaining radioactivity quantitated. The specific binding was optimal at 20 minutes and 23-degrees-C. Competition studies with tritiated cocaine (3.4 to 66.6 nmol/L) indicated the presence of approximately 3.6 x 10(3) binding sites per cell, with a high affinity receptor dissociation constant (K(d) = 12.6 nmol/L). Cocaine concentrations as high as 670-mu-mol/L had no detectable effect on either the motility or viability of the cells. These results support the hypothesis that the sperm may act as a vector to transport cocaine into an ovum. This novel mechanism could be involved in the abnormal development of offspring of cocaine-exposed males.	WASHINGTON UNIV,SCH MED,DEPT OBSTET & GYNECOL,ST LOUIS,MO 63110	Washington University (WUSTL)	YAZIGI, RA (corresponding author), TEMPLE UNIV,HLTH SCI CTR,SCH MED,DEPT OBSTET & GYNECOL,3401 N BROAD ST,PHILADELPHIA,PA 19140, USA.							ABEL EL, 1987, ALCOHOL CLIN EXP RES, V11, P533, DOI 10.1111/j.1530-0277.1987.tb00168.x; ABEL EL, 1989, J ANDROL, V10, P17; AHMED MS, 1990, LIFE SCI, V46, P553, DOI 10.1016/0024-3205(90)90122-8; BOJA JW, 1989, EUR J PHARMACOL, V173, P215, DOI 10.1016/0014-2999(89)90524-4; BRACKEN MB, 1990, FERTIL STERIL, V53, P315; BRACKETT BG, 1971, P NATL ACAD SCI USA, V68, P353, DOI 10.1073/pnas.68.2.353; BRIGGS M, 1974, ACTA ENDOCRINOL-COP, V75, P785, DOI 10.1530/acta.0.0750785; CALLIGARO DO, 1987, J PHARMACOL EXP THER, V243, P61; CICERO TJ, 1985, ANAL BIOCHEM, V150, P67, DOI 10.1016/0003-2697(85)90441-5; ELMAGHRABI EA, 1988, LIFE SCI, V42, P1675, DOI 10.1016/0024-3205(88)90447-X; ERICSSON RJ, 1967, NATURE, V214, P403, DOI 10.1038/214403a0; FRIEDLER G, 1987, RES COMMUN SUBSTANCE, V8, P109; GERBER N, 1976, LIFE SCI, V19, P782; JATLOW P, 1988, YALE J BIOL MED, V61, P105; LITTLE RE, 1986, NEW ENGL J MED, V314, P1644, DOI 10.1056/NEJM198606193142516; MADRAS BK, 1989, J PHARMACOL EXP THER, V251, P131; MULE SJ, 1977, COCAINE OTHER STIMUL, P215; PAULSON JD, 1977, FERTIL STERIL, V28, P178; REITH MEA, 1980, LIFE SCI, V27, P1055, DOI 10.1016/0024-3205(80)90029-6; REITH MEA, 1980, J NEUROCHEM, V46, P309; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SWEET F, 1987, ENDOCR REV, V8, P154, DOI 10.1210/edrv-8-2-154; WOZNIAK DF, 1991, PSYCHOPHARMACOLOGY, V43, P74; Zaneweld LJD, 1977, TECHNIQUES HUMAN AND, P147	24	65	66	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 9	1991	266	14					1956	1959		10.1001/jama.266.14.1956	http://dx.doi.org/10.1001/jama.266.14.1956			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GH406	1895473				2022-12-24	WOS:A1991GH40600021
J	RIZZO, T; METZGER, BE; BURNS, WJ; BURNS, K				RIZZO, T; METZGER, BE; BURNS, WJ; BURNS, K			CORRELATIONS BETWEEN ANTEPARTUM MATERNAL METABOLISM AND INTELLIGENCE OF OFFSPRING	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PREGNANCY; INFANT	Background. It is not clear to what extent maternal metabolism during pregnancy affects the cognitive and behavioral function of the offspring by altering brain development in utero. To investigate this question, we correlated measures of metabolism in pregnant diabetic and nondiabetic women with the intellectual development of their offspring. Methods. The study included 223 pregnant women and their singleton offspring: 89 women had diabetes before pregnancy (pregestational diabetes mellitus), 99 had the onset of diabetes during pregnancy (gestational diabetes mellitus), and 35 had normal carbohydrate metabolism during their pregnancy. We correlated measures of maternal glucose and lipid metabolism (fasting plasma glucose levels, hemoglobin A1c levels, episodes of hypoglycemia, episodes of acetonuria, and plasma beta-hydroxybutyrate and free fatty acid levels) with two measures of intellectual development in the offspring - the mental-development index of the Bayley Scales of Infant Development, given at the age of two years, and the Stanford-Binet Intelligence Scale, given at the ages of three, four, and five years and expressed as an average of the three scores. Results. After correction for socioeconomic status, race or ethnic origin, and patient group, the children's mental-development-index scores at the age of two years correlated inversely with the mothers' third-trimester plasma beta-hydroxybutyrate levels (r = -0.21, P < 0.01); the average Stanford-Binet scores correlated inversely with third-trimester plasma beta-hydroxybutyrate (r = -0.20, P < 0.02) and free fatty acid (r = -0.27, P < 0.002) levels. No other correlations were significant. Including various perinatal events (e.g., prematurity and acidemia) in the analyses did not alter the results. Conclusions. Maternal diabetes during pregnancy may affect behavioral and intellectual development in the offspring. The associations between gestational ketonemia in the mother and a lower IQ in the child warrant continued efforts to avoid ketoacidosis and accelerated starvation in all pregnant women.	NORTHWESTERN UNIV,SCH MED,DEPT MED,CHICAGO,IL 60611; NORTHWESTERN UNIV,CTR ENDOCRINOL METAB & NUTR,SCH MED,CHICAGO,IL 60611; NW MEM HOSP,PRENTICE WOMENS HOSP,CHICAGO,IL 60611	Northwestern University; Northwestern University; Northwestern Memorial Hospital	RIZZO, T (corresponding author), NORTHWESTERN UNIV,SCH MED,DEPT PSYCHIAT,SEARLE BLDG 10-526,303 E CHICAGO AVE,CHICAGO,IL 60611, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007169, R01DK010699] Funding Source: NIH RePORTER; NICHD NIH HHS [HD11021] Funding Source: Medline; NIDDK NIH HHS [DK10699, DK07169] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bayley N., 1969, BAYLEY SCALES INFANT; BERENDES HW, 1975, EARLY DIABETES EARLY, P135; BIBERGEIL H, 1975, EARLY DIABETES EARLY, P427; Brazelton T. B., 1973, CLIN DEV MED, V50; Castellan N J Jr, 1965, Psychol Bull, V64, P330; CHURCHIL.JA, 1969, AM J OBSTET GYNECOL, V105, P257, DOI 10.1016/0002-9378(69)90067-2; Cornblath M, 1976, DISORDERS CARBOHYDRA, V2nd; Dobbing J, 1981, SCI F PAEDIATRICS, P744; DUBOWITZ LM, 1970, J PEDIATR-US, V77, P1, DOI 10.1016/S0022-3476(70)80038-5; FREINKEL N, 1980, DIABETES, V29, P1023, DOI 10.2337/diabetes.29.12.1023; Freinkel N, 1979, CARBOHYD METABOL, P1; Freinkel N, 1979, CIBA F S, P3; FREINKEL N, 1979, 10TH P C INT DIAB FE, P731; LI PK, 1980, CLIN CHEM, V26, P1713; LUBCHENCO LO, 1963, PEDIATRICS, V32, P793; MCCALL RB, 1972, AM PSYCHOL, V27, P728, DOI 10.1037/h0033148; MCNEMAR Q, 1962, PSYCHOL STATISTICS, P139; MENARD L, 1980, CLIN CHEM, V26, P1598; METZGER BE, 1980, DIABETES CARE, V3, P402, DOI 10.2337/diacare.3.3.402; MORRIS MA, 1988, DIABETES S1, V37, pA112; NAEYE RL, 1979, CIBA F S, V63, P227; OSULLIVAN JB, 1964, DIABETES, V13, P278; PEDERSEN J, 1977, PREGNANT DIABETIC HE; PEDERSEN JF, 1984, OBSTET GYNECOL, V64, P351; PETERSEN MB, 1988, BRIT MED J, V296, P598, DOI 10.1136/bmj.296.6622.598; RIZZO T, 1990, AM J OBSTET GYNECOL, V163, P1458, DOI 10.1016/0002-9378(90)90606-8; SCARR S, 1981, RACE SOCIAL CLASS IN; STEHBENS JA, 1977, AM J OBSTET GYNECOL, V127, P408; TERMAN LM, 1973, STANFORDBINET INTELL; TRIVELLI LA, 1971, NEW ENGL J MED, V284, P353, DOI 10.1056/NEJM197102182840703; Wechsler D., 1997, WAIS 3 WECHSLER ADUL, V3rd, DOI 10.1111/j.1749-6632.1989.tb21005.x; Yssing M, 1975, EARLY DIABETES EARLY, P575; 1988, SPSS PCPLUS V2 0 BAS, pB153; 1985, DIABETES S2, V34, P123; 1988, SPSS PCPLUS ADV STAT, P103	35	314	318	0	13	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 26	1991	325	13					911	916		10.1056/NEJM199109263251303	http://dx.doi.org/10.1056/NEJM199109263251303			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GF856	1881416				2022-12-24	WOS:A1991GF85600003
J	HARGREAVES, AD; LOGAN, RL; THOMSON, M; ELTON, RA; OLIVER, MF; RIEMERSMA, RA				HARGREAVES, AD; LOGAN, RL; THOMSON, M; ELTON, RA; OLIVER, MF; RIEMERSMA, RA			TOTAL CHOLESTEROL, LOW-DENSITY-LIPOPROTEIN CHOLESTEROL, AND HIGH-DENSITY-LIPOPROTEIN CHOLESTEROL AND CORONARY HEART-DISEASE IN SCOTLAND	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MAJOR RISK FACTOR; MIDDLE-AGED MEN; SERUM-CHOLESTEROL; FRAMINGHAM	Objective - To investigate long term changes in total cholesterol, high density lipoprotein cholesterol, and low density lipoprotein cholesterol concentrations and in measures of other risk factors for coronary heart disease and to assess their importance for the development of coronary heart disease in Scottish men. Design - Longitudinal study entailing follow up in 1988-9 of men investigated during a study in 1976. Setting - Edinburgh, Scotland. Subjects - 107 men from Edinburgh who had taken part in a comparative study of risk factors for heart disease with Swedish men in 1976 when aged 40. Intervention - The men were invited to attend a follow up clinic in 1988-9 for measurement of cholesterol concentrations and other risk factor measurements. Eighty three attended and 24 refused to or could not attend. Main outcome measures - Changes in total cholesterol, high density lipoprotein cholesterol, and low density lipoprotein cholesterol concentrations, body weight, weight to height index, prevalence of smoking, and alcohol intake; number of coronary artery disease events. Results - Mean serum total cholesterol concentration increased over the 12 years mainly due to an increase in the low density lipoprotein cholesterol fraction (from 3.53 (SD 0.09) to 4.56 (0.11) mmol/l) despite a reduction in high density lipoprotein cholesterol concentration. Body weight and weight to height index increased. Fewer men smoked more than 15 cigarettes/day in 1988-9 than in 1976. Blood pressure remained stable and fasting triglyceride concentrations did not change. The frequency of corneal arcus doubled. Alcohol consumption decreased significantly. Eleven men developed clinical coronary heart disease. High low density lipoprotein and low high density lipoprotein cholesterol concentrations in 1976, but not total cholesterol concentration, significantly predicted coronary heart disease (p = 0.05). Almost all of the men who developed coronary heart disease were smokers (91% v 53%, p < 0.05). Conclusion - Over 12 years the lipid profile deteriorated significantly in this healthy cohort of young men. Smoking, a low high density lipoprotein concentration and a raised low density lipoprotein concentration were all associated with coronary heart disease in middle aged Scottish men, whereas there was no association for total cholesterol concentration. The findings have implications for screening programmes.	UNIV EDINBURGH, DEPT MED, EDINBURGH EH8 9XF, SCOTLAND; UNIV EDINBURGH, DEPT COMMUNITY MED, MED STAT UNIT, EDINBURGH EH8 9YL, MIDLOTHIAN, SCOTLAND	University of Edinburgh; University of Edinburgh	HARGREAVES, AD (corresponding author), UNIV EDINBURGH, DEPT CARDIOL, CARDIOVASC RES UNIT, EDINBURGH EH8 9XF, SCOTLAND.							CASTELLI WP, 1986, JAMA-J AM MED ASSOC, V256, P2835, DOI 10.1001/jama.256.20.2835; CLARK DA, 1967, AM J CLIN NUTR, V20, P743, DOI 10.1093/ajcn/20.7.743; CRIQUI MH, 1983, AM J EPIDEMIOL, V118, P52, DOI 10.1093/oxfordjournals.aje.a113616; ELFORD J, 1989, LANCET, V1, P343; GIDEZ LI, 1984, CLIN METABOLIC ASPEC, P415; GORDON T, 1977, AM J MED, V62, P707, DOI 10.1016/0002-9343(77)90874-9; KANNEL WB, 1979, ANN INTERN MED, V90, P85, DOI 10.7326/0003-4819-90-1-85; KEYS A, 1984, INT J EPIDEMIOL, V13, P428, DOI 10.1093/ije/13.4.428; KROMHOUT D, 1983, AM J CLIN NUTR, V38, P591, DOI 10.1093/ajcn/38.4.591; LOGAN RL, 1978, LANCET, V1, P949; MILLER NE, 1977, LANCET, V1, P965, DOI 10.1016/S0140-6736(77)92274-7; OLIVER MF, 1975, EUR J CLIN INVEST, V5, P507, DOI 10.1111/j.1365-2362.1975.tb00483.x; POCOCK SJ, 1986, BMJ-BRIT MED J, V292, P515, DOI 10.1136/bmj.292.6519.515; POCOCK SJ, 1989, BMJ-BRIT MED J, V298, P998, DOI 10.1136/bmj.298.6679.998; ROSE G, 1977, BRIT J PREV SOC MED, V31, P42; SHAPER AG, 1981, BRIT MED J, V283, P179, DOI 10.1136/bmj.283.6285.179; SMITH WCS, 1989, SCOT MED J, V34, P550, DOI 10.1177/003693308903400603; STAMLER J, 1986, JAMA-J AM MED ASSOC, V256, P2823, DOI 10.1001/jama.256.20.2823; THOMAS DG, 1971, APPLIED STATISTICS, V20, P105, DOI DOI 10.2307/2346643; THOMSON M, 1982, HUM NUTR-APPL NUTR, V36, P272; TUNSTALLPEDOE H, 1989, SCOT MED J, V34, P556, DOI 10.1177/003693308903400604; WOOD DA, 1987, LANCET, V1, P177; 1987, WORLD HLTH STAT Q, V40, P171	23	13	13	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 21	1991	303	6804					678	681		10.1136/bmj.303.6804.678	http://dx.doi.org/10.1136/bmj.303.6804.678			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG980	1912914	Bronze, Green Published			2022-12-24	WOS:A1991GG98000019
J	IWAKURA, Y; TOSU, M; YOSHIDA, E; TAKIGUCHI, M; SATO, K; KITAJIMA, I; NISHIOKA, K; YAMAMOTO, K; TAKEDA, T; HATANAKA, M; YAMAMOTO, H; SEKIGUCHI, T				IWAKURA, Y; TOSU, M; YOSHIDA, E; TAKIGUCHI, M; SATO, K; KITAJIMA, I; NISHIOKA, K; YAMAMOTO, K; TAKEDA, T; HATANAKA, M; YAMAMOTO, H; SEKIGUCHI, T			INDUCTION OF INFLAMMATORY ARTHROPATHY RESEMBLING RHEUMATOID-ARTHRITIS IN MICE TRANSGENIC FOR HTLV-I	SCIENCE			English	Article							T-CELL LEUKEMIA; ACQUIRED IMMUNODEFICIENCY SYNDROME; VIRUS TYPE-I; GENE; PROMOTER; PROTEIN; EXPRESSION; ACTIVATION; DISEASE; INVITRO	Human T cell leukemia virus type-I (HTLV-I) is the etiologic agent of adult T cell leukemia and has also been suggested to be involved in other diseases such as chronic arthritis or myelopathy. To elucidate pathological roles of the virus in disease, transgenic mice were produced that carry the HTLV-I genome. At 2 to 3 months of age, many of the mice developed chronic arthritis resembling rheumatoid arthritis. Synovial and periarticular inflammation with articular erosion caused by invasion of granulation tissues were marked. These observations suggest a possibility that HTLV-I is one of the etiologic agents of chronic arthritis in humans.	TOKYO WOMENS MED COLL, INST RHEUMATOL, SHINJUKU KU, TOKYO 163, JAPAN; UNIV TOKYO, FAC MED, BUNKYO KU, TOKYO 113, JAPAN; KYOTO UNIV, CHEST DIS RES INST, SAKYO KU, KYOTO 606, JAPAN; KYOTO UNIV, INST VIRUS RES, SAKYO KU, KYOTO 606, JAPAN; KOHNO CLIN MED RES INST, SHINAGAWA KU, TOKYO 140, JAPAN	Tokyo Women's Medical University; University of Tokyo; Kyoto University; Kyoto University	IWAKURA, Y (corresponding author), UNIV TOKYO, INST MED SCI, 4-6-1 SHIROKANEDAI, MINATO KU, TOKYO 108, JAPAN.		Takiguchi, Masafumi/E-7468-2013; Iwakura, Yoichiro/E-5457-2011; Yamamoto, Kazuhiko/N-5096-2015	Iwakura, Yoichiro/0000-0002-9934-5775; 				AREND WP, 1990, ARTHRITIS RHEUM-US, V33, P305, DOI 10.1002/art.1780330302; BENTIN J, 1990, ARTHRITIS RHEUM, V33, P268, DOI 10.1002/art.1780330217; CHEEVERS WP, 1988, LAB INVEST, V58, P510; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLE BC, 1979, ARTHRITIS RHEUM, V22, P1375, DOI 10.1002/art.1780221209; Decker J L, 1984, Ann Intern Med, V101, P810; ESPINOZA LR, 1988, ARTHRITIS RHEUM-US, V31, P1034, DOI 10.1002/art.1780310815; FELBER BK, 1985, SCIENCE, V229, P675, DOI 10.1126/science.2992082; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; GREEN JE, 1989, NATURE, V341, P72, DOI 10.1038/341072a0; HANG L, 1982, J EXP MED, V155, P1690, DOI 10.1084/jem.155.6.1690; HINRICHS SH, 1987, SCIENCE, V237, P1340, DOI 10.1126/science.2888191; IWAKURA Y, 1988, EMBO J, V7, P3757, DOI 10.1002/j.1460-2075.1988.tb03259.x; IWAKURA Y, UNPUB; KITAJIMA I, 1989, ARTHRITIS RHEUM, V32, P1342, DOI 10.1002/anr.1780321030; KOGA T, 1985, INFECT IMMUN, V50, P27, DOI 10.1128/IAI.50.1.27-34.1985; KRANE SM, 1985, ARTHRITIS ALLIED CON, P593; KRIEG AM, 1990, J AUTOIMMUN, V3, P137, DOI 10.1016/0896-8411(90)90137-H; MARUYAMA M, 1987, CELL, V48, P343, DOI 10.1016/0092-8674(87)90437-5; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MIYASAKA N, IN PRESS J AUTOIMMUN; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; NISHIOKA K, 1989, LANCET, V1, P441; SABE H, 1988, INT J CANCER, V41, P880, DOI 10.1002/ijc.2910410619; TAKIGUCHI M, UNPUB; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; TOSU M, UNPUB; VANDENBROEK MF, 1989, J EXP MED, V170, P449, DOI 10.1084/jem.170.2.449; VANEDEN W, 1985, P NATL ACAD SCI USA, V82, P5117; WANO Y, 1987, J CLIN INVEST, V80, P911, DOI 10.1172/JCI113152; WINCHESTER R, 1987, ANN INTERN MED, V106, P19, DOI 10.7326/0003-4819-106-1-19; ZIEGLER B, 1988, Arthritis and Rheumatism, V31, pS35	32	305	315	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 30	1991	253	5023					1026	1028		10.1126/science.1887217	http://dx.doi.org/10.1126/science.1887217			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC982	1887217				2022-12-24	WOS:A1991GC98200044
J	REITNER, A; SHARPE, LT; ZRENNER, E				REITNER, A; SHARPE, LT; ZRENNER, E			IS COLOR-VISION POSSIBLE WITH ONLY RODS AND BLUE-SENSITIVE CONES	NATURE			English	Article							SPECTRAL SENSITIVITY; ACHROMATOPSIA; MONOCHROMACY	AT night all cats are grey, but with the approach of dawn they take on colour. By starlight, a single class of photoreceptors, the rods, function, whereas by daylight, three classes, the blue-, green- and red-sensitive cones, are active and provide colour vision. Only by comparing the rates of quantal absorption in more than one photoreceptor class is colour vision possible. Although the comparisons generally take place between the cones, they can involve the rods as well 1-4. Here we investigate the wavelength discrimination of an extremely rare group of individuals, blue-cone monochromats, who have only rods and one class of cones 5-8. We find that these individuals can distinguish wavelengths (440 to 500 nm) in the twilight region where the rods and blue-sensitive cones are simultaneously active.	UNIV FREIBURG,NEUROL KLIN,W-7800 FREIBURG,GERMANY; UNIV TUBINGEN,HOSP EYE,DEPT PATHOPHYSIOL VIS & NEUROOPHTHALMOL,W-7400 TUBINGEN 1,GERMANY	University of Freiburg; Eberhard Karls University of Tubingen	REITNER, A (corresponding author), ZWEITE UNIV VIENNA,AUGENKLIN,ALSERSTR 4,A-1090 VIENNA,AUSTRIA.							ALPERN M, 1965, ARCH OPHTHALMOL-CHIC, V74, P334; ALPERN M, 1971, J PHYSIOL-LONDON, V212, P211, DOI 10.1113/jphysiol.1971.sp009318; BLACKWELL HR, 1961, VISION RES, V1, P62, DOI 10.1016/0042-6989(61)90022-0; Boynton R. M., 1979, HUMAN COLOR VISION; Clarke F. J. J., 1960, OPT ACTA, V7, P355; DZMURA M, 1986, VISION RES, V26, P1273, DOI 10.1016/0042-6989(86)90108-2; GOURAS P, 1966, J PHYSIOL-LONDON, V184, P499, DOI 10.1113/jphysiol.1966.sp007928; GOURAS P, 1965, SCIENCE, V147, P1593, DOI 10.1126/science.147.3665.1593; HANSEN E, 1978, NATURE, V276, P390, DOI 10.1038/276390a0; HESS RF, 1989, J PHYSIOL-LONDON, V417, P123, DOI 10.1113/jphysiol.1989.sp017794; INGLING CR, 1977, VISION RES, V17, P1083, DOI 10.1016/0042-6989(77)90014-1; MCCANN JJ, 1972, SCIENCE, V176, P1255, DOI 10.1126/science.176.4040.1255; MOLLON JD, 1977, PHILOS T ROY SOC B, V278, P207, DOI 10.1098/rstb.1977.0038; NATHANS J, 1989, SCIENCE, V245, P831, DOI 10.1126/science.2788922; PALMER DA, 1978, J OPT SOC AM, V68, P1501, DOI 10.1364/JOSA.68.001501; REITNER A, IN  PRESS VISION RES; SHARPE LT, 1989, SCIENCE, V244, P354, DOI 10.1126/science.2711186; SMITH VC, 1983, INVEST OPHTH VIS SCI, V24, P451; SMITH VC, 1972, VISION RES, V12, P2059, DOI 10.1016/0042-6989(72)90058-2; SMITH VC, 1977, J OPT SOC AM, V67, P213, DOI 10.1364/JOSA.67.000213; STABELL B, 1974, VISION RES, V14, P1389, DOI 10.1016/0042-6989(74)90013-3; TREZONA PW, 1970, VISION RES, V10, P317, DOI 10.1016/0042-6989(70)90103-3; TREZONA PW, 1973, VISION RES, V13, P9, DOI 10.1016/0042-6989(73)90161-2; van den Berg T J, 1978, Mod Probl Ophthalmol, V19, P341; WILLMER EN, 1960, J THEOR BIOL, V2, P141; Wright WD, 1937, P PHYS SOC, V49, P329, DOI 10.1088/0959-5309/49/4/301; Wyszecki G., 1982, COLOR SCI; YOUNG RSL, 1985, INVEST OPHTH VIS SCI, V26, P1543; ZRENNER E, 1988, KLIN MONATSBL AUGENH, V193, P510, DOI 10.1055/s-2008-1050292	29	75	75	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 29	1991	352	6338					798	800		10.1038/352798a0	http://dx.doi.org/10.1038/352798a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC964	1881435				2022-12-24	WOS:A1991GC96400058
J	OGRADY, JG; WENDON, J; TAN, KC; POTTER, D; COTTAM, S; COHEN, AT; GIMSON, AES; WILLIAMS, R				OGRADY, JG; WENDON, J; TAN, KC; POTTER, D; COTTAM, S; COHEN, AT; GIMSON, AES; WILLIAMS, R			LIVER-TRANSPLANTATION AFTER PARACETAMOL OVERDOSE	BRITISH MEDICAL JOURNAL			English	Article							FULMINANT HEPATIC-FAILURE	Objective - To evaluate the role of liver transplantation after paracetamol overdose. Design - Prospective study of consecutive candidates for transplantation and performance of transplantation over 18 months. Setting - Liver unit, King's College Hospital, London. Main outcome measures - Fulfilment of indicators of poor prognosis, selection for transplantation, transplantation, survival. Results - 30 of 37 patients considered to have a reasonable prognosis with intensive medical care survived. Of 14 of 29 patients considered to have a very poor prognosis and registered for urgent liver transplantation, six received liver transplants, four of whom survived, while seven died and one survived without a transplant. Three of 15 patients with poor prognostic indicators but not selected for transplantation survived. Conclusion - Liver transplantation will have a definite but limited role in the management of fulminant hepatic failure induced by paracetamol.	UNIV LONDON KINGS COLL HOSP,SCH MED & DENT,INST LIVER STUDIES,DENMARK HILL,LONDON SE5 8RX,ENGLAND	King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London				opoku, anita/0000-0001-7243-8157				BISMUTH H, 1989, TRANSPLANT REV, V3, P47; BREMS JJ, 1987, AM J SURG, V154, P137; EMOND JC, 1989, GASTROENTEROLOGY, V96, P1583, DOI 10.1016/0016-5085(89)90530-1; HARRISON PM, 1990, LANCET, V335, P1572, DOI 10.1016/0140-6736(90)91388-Q; HARRISON PM, 1990, BMJ-BRIT MED J, V301, P964, DOI 10.1136/bmj.301.6758.964; IWATSUKI S, 1989, TRANSPLANT P, V21, P2431; OGRADY JG, 1989, BAILLIERE CLIN GASTR, V3, P75, DOI 10.1016/0950-3528(89)90047-X; OGRADY JG, 1988, Q J MED, V69, P817; OGRADY JG, 1988, GASTROENTEROLOGY, V94, P1186, DOI 10.1016/0016-5085(88)90011-X; OGRADY JG, 1989, GASTROENTEROLOGY, V97, P439, DOI 10.1016/0016-5085(89)90081-4; SCHAFER DF, 1989, SEMIN LIVER DIS, V9, P189, DOI 10.1055/s-2008-1040512; VICKERS C, 1988, J HEPATOL, V7, P143, DOI 10.1016/S0168-8278(88)80475-6; 1987, LANCET, V2, P1248	13	75	76	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 27	1991	303	6796					221	223		10.1136/bmj.303.6796.221	http://dx.doi.org/10.1136/bmj.303.6796.221			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FZ563	1884059	Green Published, Bronze			2022-12-24	WOS:A1991FZ56300023
J	SEGEV, N				SEGEV, N			MEDIATION OF THE ATTACHMENT OR FUSION STEP IN VESICULAR TRANSPORT BY THE GTP-BINDING YPT1 PROTEIN	SCIENCE			English	Article							ENDOPLASMIC-RETICULUM; GOLGI-APPARATUS; CHROMAFFIN GRANULES; SECRETORY VESICLES; GENE-PRODUCT; YEAST; MEMBRANE; RECONSTITUTION; COMPARTMENTS; INVITRO	The function of the guanosine triphosphate (GTP)-binding protein Ypt1 in regulating vesicular traffic was studied in a cell-free system that reconstitutes transport from the endoplasmic reticulum to the Golgi. Blocking the Ypt1 protein activity resulted in accumulation of vesicles that act as an intermediate passing between the two compartments. The Ypt1 protein was found on the outer side of these vesicles. The transport process is completed by fusion of these vesicles with the acceptor compartment, and Ypt1 protein activity was needed for this step. Thus, a specific GTP-binding protein is required for either attachment or fusion (or both) of secretory vesicles with the acceptor compartment during protein secretion.	UNIV CHICAGO,BEN MAY INST,CHICAGO,IL 60637	University of Chicago	SEGEV, N (corresponding author), UNIV CHICAGO,DEPT PHARMACOL & PHYSIOL SCI,CHICAGO,IL 60637, USA.							BACON RA, 1989, J CELL BIOL, V109, P1015, DOI 10.1083/jcb.109.3.1015; BAKER D, 1990, P NATL ACAD SCI USA, V87, P355, DOI 10.1073/pnas.87.1.355; BAKER D, 1988, CELL, V54, P335, DOI 10.1016/0092-8674(88)90196-1; BECKERS CJM, 1989, J CELL BIOL, V108, P1245, DOI 10.1083/jcb.108.4.1245; BOURNE HR, 1988, CELL, V53, P669, DOI 10.1016/0092-8674(88)90081-5; BURGOYNE RD, 1989, TRENDS BIOCHEM SCI, V14, P394, DOI 10.1016/0968-0004(89)90281-8; BURGOYNE RD, 1989, FEBS LETT, V245, P122, DOI 10.1016/0014-5793(89)80204-2; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; DARCHEN F, 1990, P NATL ACAD SCI USA, V87, P5692, DOI 10.1073/pnas.87.15.5692; DOUCET JP, 1989, FEBS LETT, V247, P127, DOI 10.1016/0014-5793(89)81254-2; FISCHER, 1990, P NATL ACAD SCI USA, V87, P1988; FRANZUSOFF A, 1989, EMBO J, V8, P2695, DOI 10.1002/j.1460-2075.1989.tb08410.x; GALLWITZ D, 1983, NATURE, V306, P707; GODA Y, 1988, CELL, V55, P309, DOI 10.1016/0092-8674(88)90054-2; GOUD B, 1990, NATURE, V345, P553, DOI 10.1038/345553a0; GOUD B, 1988, CELL, V53, P753, DOI 10.1016/0092-8674(88)90093-1; GROESCH ME, 1990, J CELL BIOL, V111, P45, DOI 10.1083/jcb.111.1.45; HAUBRUCK H, 1987, EMBO J, V6, P4049, DOI 10.1002/j.1460-2075.1987.tb02750.x; HOPFIELD JJ, 1974, P NATL ACAD SCI USA, V71, P4135, DOI 10.1073/pnas.71.10.4135; JEDD G, UNPUB; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAYORGA LS, 1989, SCIENCE, V244, P1475, DOI 10.1126/science.2499930; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; PADFIELD PJ, 1989, J CELL BIOL, V109, P299; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; RUBINS J, 1989, J CELL BIOL, V109, P298; RUOHOLA H, 1988, J CELL BIOL, V107, P1465, DOI 10.1083/jcb.107.4.1465; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; SCHMITT HD, 1988, CELL, V53, P635, DOI 10.1016/0092-8674(88)90579-X; SCHMITT HD, 1986, CELL, V47, P401, DOI 10.1016/0092-8674(86)90597-0; SEGEV N, 1988, CELL, V52, P915, DOI 10.1016/0092-8674(88)90433-3; SEGEV N, UNPUB; THOMPSON RC, 1988, TRENDS BIOCHEM SCI, V13, P91, DOI 10.1016/0968-0004(88)90047-3; TOOZE SA, 1990, NATURE, V347, P207, DOI 10.1038/347207a0; TOUCHOT N, 1987, P NATL ACAD SCI USA, V84, P8210, DOI 10.1073/pnas.84.23.8210; WIDEY GM, 1989, J CELL BIOL, V109, P293; WRIGHT R, 1988, J CELL BIOL, V107, P101, DOI 10.1083/jcb.107.1.101	40	130	133	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 14	1991	252	5012					1553	1556		10.1126/science.1904626	http://dx.doi.org/10.1126/science.1904626			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FR040	1904626				2022-12-24	WOS:A1991FR04000049
J	BERRY, GT; HEIDENREICH, R; KAPLAN, P; LEVINE, F; MAZUR, A; PALMIERI, MJ; YUDKOFF, M; SEGAL, S				BERRY, GT; HEIDENREICH, R; KAPLAN, P; LEVINE, F; MAZUR, A; PALMIERI, MJ; YUDKOFF, M; SEGAL, S			BRANCHED-CHAIN AMINO-ACID FREE PARENTERAL-NUTRITION IN THE TREATMENT OF ACUTE METABOLIC DECOMPENSATION IN PATIENTS WITH MAPLE SYRUP URINE DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									UNIV PENN,SCH MED,DEPT PEDIAT & MED,PHILADELPHIA,PA 19104	University of Pennsylvania	BERRY, GT (corresponding author), CHILDRENS HOSP PHILADELPHIA,DIV BIOCHEM DEV & MOLEC DIS,34TH ST & CIVIC CTR BLVD,PHILADELPHIA,PA 19104, USA.		Levine, Fred/L-2693-2013	Levine, Fred/0000-0002-7336-2526; Berry, Gerard/0000-0001-5299-3313	NCRR NIH HHS [RR240] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Danner DJ, 1989, METABOLIC BASIS INHE, P671; ELSAS LJ, 1988, MODERN NUTRITION HLT, P1337; RUTLEDGE SL, 1990, J PEDIATR-US, V116, P125, DOI 10.1016/S0022-3476(05)81661-0; TOWNSEND I, 1982, AM J CLIN NUTR, V36, P359, DOI 10.1093/ajcn/36.2.359; WENDEL U, 1982, J INHERIT METAB DIS, V5, P25, DOI 10.1007/BF01799811; 1985, WHO TECH REP SER, V724, P71; 1989, RECOMMENDED DIETARY	7	25	27	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 17	1991	324	3					175	179		10.1056/NEJM199101173240307	http://dx.doi.org/10.1056/NEJM199101173240307			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ER471	1898534				2022-12-24	WOS:A1991ER47100007
J	HANNIGAN, GE; WILLIAMS, BRG				HANNIGAN, GE; WILLIAMS, BRG			SIGNAL TRANSDUCTION BY INTERFERON-ALPHA THROUGH ARACHIDONIC-ACID METABOLISM	SCIENCE			English	Article							INDUCED NUCLEAR FACTORS; SYNTHETASE GENE; PROMOTER ELEMENT; BINDING-PROTEIN; GROWTH-FACTOR; CELLS; ACTIVATION; EXPRESSION; ENHANCER; RAS	Molecular mechanisms that mediate signal transduction by growth inhibitory cytokines are poorly understood. Type I (alpha and beta) interferons (IFNs) are potent growth inhibitory cytokines whose biological activities depend on induced changes in gene expression. IFN-alpha induced the transient activation of phospholipase A2 in 3T3 fibroblasts and rapid hydrolysis of [H-3]arachidonic acid (AA) from prelabeled phospholipid pools. The phospholipase inhibitor, bromophenacyl bromide (BPB), specifically blocked IFN-induced binding of nuclear factors to a conserved, IFN-regulated enhancer element, the interferon-stimulated response element (ISRE). BPB also caused a dose-dependent inhibition of IFN-alpha-induced ISRE-dependent transcription in transient transfection assays. Specific inhibition of AA oxygenation by eicosatetraynoic acid prevented IFN-alpha induction of factor binding to the ISRE. Treatment of intact cells with inhibitors of fatty acid cyclooxygenase or lipoxygenase enzymes resulted in amplification of IFN-alpha-induced ISRE binding and gene expression. Thus, IFN-alpha-receptor-coupled AA hydrolysis may function in activation of latent transcription factors by IFN-alpha and provides a system for studying the role of AA metabolism in transduction of growth inhibitory signals.	HOSP SICK CHILDREN,RES INST,TORONTO M5G 1X8,ONTARIO,CANADA; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO M5S 1A1,ONTARIO,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto			Hannigan, Greg/A-5092-2009; Williams, Bryan R. G./A-5021-2009	Williams, Bryan R. G./0000-0002-4969-1151				BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BURCH RM, 1986, P NATL ACAD SCI USA, V83, P7201, DOI 10.1073/pnas.83.19.7201; COHEN B, 1988, EMBO J, V7, P1411, DOI 10.1002/j.1460-2075.1988.tb02958.x; CREAGAN ET, 1988, CANCER, V61, P1787, DOI 10.1002/1097-0142(19880501)61:9<1787::AID-CNCR2820610911>3.0.CO;2-Q; DALE TC, 1989, P NATL ACAD SCI USA, V86, P1203, DOI 10.1073/pnas.86.4.1203; DIAZ MO, 1990, NEW ENGL J MED, V322, P77, DOI 10.1056/NEJM199001113220202; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FITZPATRICK FA, 1980, J IMMUNOL, V125, P431; FITZPATRICK FA, 1989, PHARMACOL REV, V40, P229; GARCIABLANCO MA, 1989, MOL CELL BIOL, V9, P1060, DOI 10.1128/MCB.9.3.1060; GOODBOURN S, 1986, CELL, V45, P601, DOI 10.1016/0092-8674(86)90292-8; HAMMARSTROM S, 1977, BIOCHIM BIOPHYS ACTA, V487, P517, DOI 10.1016/0005-2760(77)90221-1; HAMMARSTROM S, 1975, P NATL ACAD SCI USA, V72, P5130, DOI 10.1073/pnas.72.12.5130; HANNIGAN G, 1986, EMBO J, V5, P1607, DOI 10.1002/j.1460-2075.1986.tb04403.x; HANNIGAN GE, UNPUB; HONG SL, 1981, J BIOL CHEM, V256, P5215; HORIGUCHI J, 1989, MOL CELL BIOL, V9, P252, DOI 10.1128/MCB.9.1.252; KIM B, 1989, SURGERY, V106, P248; LEVY DE, 1988, GENE DEV, V2, P383, DOI 10.1101/gad.2.4.383; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; MILLS GB, 1985, 2 5A SYSTEM, P357; Pace-Asciak CR, 1983, ENZYMES LIPID ENZYMO, VXVI, P543; PORTER ACG, 1988, EMBO J, V7, P85, DOI 10.1002/j.1460-2075.1988.tb02786.x; RUTHERFORD MN, 1988, EMBO J, V7, P751, DOI 10.1002/j.1460-2075.1988.tb02872.x; SAMID D, 1987, MOL CELL BIOL, V7, P2196, DOI 10.1128/MCB.7.6.2196; SHIER WT, 1979, P NATL ACAD SCI USA, V76, P195, DOI 10.1073/pnas.76.1.195; SHIER WT, 1982, J CELL PHYSIOL, V112, P171, DOI 10.1002/jcp.1041120204; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; SWEATT JD, 1986, J BIOL CHEM, V261, P8667; TSAI MH, 1989, SCIENCE, V243, P522, DOI 10.1126/science.2536192; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4	34	156	157	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 11	1991	251	4990					204	207		10.1126/science.1898993	http://dx.doi.org/10.1126/science.1898993			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ET173	1898993				2022-12-24	WOS:A1991ET17300043
J	HUNZIKER, W; WHITNEY, JA; MELLMAN, I				HUNZIKER, W; WHITNEY, JA; MELLMAN, I			SELECTIVE-INHIBITION OF TRANSCYTOSIS BY BREFELDIN-A IN MDCK CELLS	CELL			English	Article							POLYMERIC IMMUNOGLOBULIN RECEPTOR; CANINE KIDNEY-CELLS; ENDOPLASMIC-RETICULUM; INTRACELLULAR-TRANSPORT; SECRETORY PROTEINS; RAT HEPATOCYTES; GOLGI PROTEINS; EXPRESSION; ENDOSOMES; PATHWAYS	Treatment of most cells with brefeldin A (BFA) leads to the retrieval of the Golgi complex to the endoplasmic reticulum, presumably reflecting an inhibition of cytoplasmic coat protein binding to Golgi membranes. Although BFA has been thought to act only on biosynthetic organelles, we now show that this drug also reversibly blocks polymeric immunoglobulin receptor-mediated transcytosis in MDCK cells. The action of BFA on transcytosis was selective, since internalization, recycling, and intracellular degradation were unaffected. The block occurred early on the transcytotic pathway, probably before the translocation of IgA-containing vesicles from the basal to the apical cytoplasm. Although BFA caused MDCK cell endosomes to become more tubular, the organization of the Golgi and binding of the 110 kd Golgi coat protein beta-COP was surprisingly unaffected. These results suggest that in MDCK cells, endocytic organelles contain a BFA-sensitive coat that regulates their organization and function even though the Golgi coat is BFA resistant.			HUNZIKER, W (corresponding author), YALE UNIV, SCH MED, DEPT CELL BIOL, NEW HAVEN, CT 06510 USA.		Mellman, Ira/ABG-5896-2020; Hunziker, Walter/GSM-8190-2022; Hunziker, Walter/B-3140-2010	Hunziker, Walter/0000-0002-5265-4933				ALLAN VJ, 1986, J CELL BIOL, V103, P2229, DOI 10.1083/jcb.103.6.2229; BARTLES JR, 1987, J CELL BIOL, V105, P1241, DOI 10.1083/jcb.105.3.1241; BOMSEL M, 1990, CELL, V62, P719, DOI 10.1016/0092-8674(90)90117-W; BRANDLI AW, 1990, J CELL BIOL, V111, P2909, DOI 10.1083/jcb.111.6.2909; BREITFELD PP, 1990, J CELL BIOL, V111, P2365, DOI 10.1083/jcb.111.6.2365; BREITFELD PP, 1989, J CELL BIOL, V109, P475, DOI 10.1083/jcb.109.2.475; CASANOVA JE, 1990, SCIENCE, V248, P742, DOI 10.1126/science.2110383; COOPER MS, 1990, CELL, V61, P135, DOI 10.1016/0092-8674(90)90221-Y; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; GEUZE HJ, 1984, CELL, V37, P195, DOI 10.1016/0092-8674(84)90315-5; HOPPE CA, 1985, J CELL BIOL, V101, P2113, DOI 10.1083/jcb.101.6.2113; HUNZIKER W, 1989, J CELL BIOL, V109, P3291, DOI 10.1083/jcb.109.6.3291; HUNZIKER W, 1991, CELL, V66, P907, DOI 10.1016/0092-8674(91)90437-4; HUNZIKER W, 1990, EMBO J, V9, P3515, DOI 10.1002/j.1460-2075.1990.tb07560.x; KTISTAKIS NT, 1991, J CELL BIOL, V113, P1009, DOI 10.1083/jcb.113.5.1009; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LUZIO JP, 1990, BIOCHEM J, V270, P97, DOI 10.1042/bj2700097; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; MOSTOV KE, 1985, CELL, V43, P389, DOI 10.1016/0092-8674(85)90166-7; MOSTOV KE, 1986, CELL, V46, P613, DOI 10.1016/0092-8674(86)90887-1; NUCHTERN JG, 1989, NATURE, V339, P223, DOI 10.1038/339223a0; ODA K, 1987, FEBS LETT, V214, P135, DOI 10.1016/0014-5793(87)80028-5; ORCI L, 1986, CELL, V46, P171, DOI 10.1016/0092-8674(86)90734-8; ORCI L, 1991, CELL, V64, P1183; PARTON RG, 1989, J CELL BIOL, V109, P3259, DOI 10.1083/jcb.109.6.3259; SANDVIG K, 1991, IN PRESS J CELL BIOL; SCHMID SL, 1988, CELL, V52, P73, DOI 10.1016/0092-8674(88)90532-6; SERAFINI T, 1991, NATURE, V349, P214, DOI 10.1038/349215a0; SZTUL E, 1991, CELL, V64, P81, DOI 10.1016/0092-8674(91)90210-P	35	255	257	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 1	1991	67	3					617	627		10.1016/0092-8674(91)90535-7	http://dx.doi.org/10.1016/0092-8674(91)90535-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GN664	1934063				2022-12-24	WOS:A1991GN66400017
J	GOLDBERG, RJ; GORE, JM; ALPERT, JS; OSGANIAN, V; DEGROOT, J; BADE, J; CHEN, Z; FRID, D; DALEN, JE				GOLDBERG, RJ; GORE, JM; ALPERT, JS; OSGANIAN, V; DEGROOT, J; BADE, J; CHEN, Z; FRID, D; DALEN, JE			CARDIOGENIC-SHOCK AFTER ACUTE MYOCARDIAL-INFARCTION - INCIDENCE AND MORTALITY FROM A COMMUNITY-WIDE PERSPECTIVE, 1975 TO 1988	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							AORTIC BALLOON COUNTERPULSATION; TISSUE PLASMINOGEN-ACTIVATOR; LUMINAL CORONARY ANGIOPLASTY; WORCESTER-HEART-ATTACK; CARE UNIT; TRIAL; STREPTOKINASE; PROGNOSIS; EMERGENCY; THERAPY	Background. Cardiogenic shock resulting from acute myocardial infarction is a serious complication with a high mortality rate, but little is known about whether its incidence or outcome has changed over time. As part of an ongoing population-based study of acute myocardial infarction, we examined trends over time in the incidence and mortality rate of cardiogenic shock after acute myocardial infarction. Methods. We studied 4762 patients with acute myocardial infarction who were admitted to 16 hospitals in the Worcester, Massachusetts, metropolitan area between 1975 and 1988. We determined the incidence of and short-term and long-term mortality due to cardiogenic shock in each of six years during this study period. Results. The incidence of cardiogenic shock complicating acute myocardial infarction remained relatively constant, averaging 7.5 percent. Multivariate regression analysis that controlled for variables affecting incidence revealed significant though inconsistent temporal trends in the incidence of cardiogenic shock. As compared with the risk in 1975, the adjusted relative risk (with 95 percent confidence interval) was 0.83 (0.54 to 1.28) in 1978, 0.96 (0.63 to 1.48) in 1981, 0.68 (0.42 to 1.12) in 1984, 1.16 (0.70 to 1.92) in 1986, and 1.65 (0.99 to 2.77) in 1988. The overall in-hospital mortality rate among patients with cardiogenic shock was significantly higher than that among patients without this complication (77.7 percent vs. 13.5 percent, P < 0.001). The in-hospital mortality among the patients with shock did not improve between 1975 (73.7 percent) and 1988 (81.7 percent). Long-term survival during the 14-year follow-up period was significantly worse among patients who survived cardiogenic shock during hospitalization than among patients who did not have shock (P < 0.001). Conclusions. The results of this observational, community-wide study suggest that neither the incidence nor the prognosis of cardiogenic shock resulting from acute myocardial infarction has improved over time. Both in-hospital and long-term survival remain poor for patients with this complication.			GOLDBERG, RJ (corresponding author), UNIV MASSACHUSETTS, SCH MED, DEPT MED, 55 LAKE AVE N, WORCESTER, MA 01655 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035434] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL-35434] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AFIFI AA, 1974, AM J CARDIOL, V33, P826, DOI 10.1016/0002-9149(74)90628-6; ALONSO DR, 1973, CIRCULATION, V48, P588, DOI 10.1161/01.CIR.48.3.588; ALTHOUSE R, 1990, AM J CARDIOL, V66, P1298, DOI 10.1016/0002-9149(90)91157-2; [Anonymous], 1986, LANCET, V1, P397; [Anonymous], 1986, LANCET, V2, P57; BINDER MJ, 1955, AM J MED, V18, P622, DOI 10.1016/0002-9343(55)90463-0; BOLOOKI H, 1990, JAMA-J AM MED ASSOC, V263, P1237, DOI 10.1001/jama.263.9.1237; BRAUNWALD E, 1985, CIRCULATION, V71, P1087, DOI 10.1161/01.CIR.71.6.1087; CAULFIELD JB, 1972, ARCH PATHOL, V93, P532; CHATTERJEE K, 1976, CIRCULATION, V53, P797, DOI 10.1161/01.CIR.53.5.797; CHEITLIN MD, 1988, JAMA-J AM MED ASSOC, V260, P2894, DOI 10.1001/jama.260.19.2894; CHESEBRO JH, 1987, CIRCULATION, V76, P142, DOI 10.1161/01.CIR.76.1.142; COBB LA, 1975, CIRCULATION, V52, P223; DALEN JE, 1984, CHEST, V86, P257, DOI 10.1378/chest.86.2.257; DEWOOD MA, 1980, CIRCULATION, V61, P1105, DOI 10.1161/01.CIR.61.6.1105; GHEORGHIADE M, 1988, AM HEART J, V116, P1212; GOLDBERG R, 1979, JOHNS HOPKINS MED J, V144, P73; GOLDBERG RJ, 1987, AM HEART J, V113, P273, DOI 10.1016/0002-8703(87)90265-1; GOLDBERG RJ, 1988, AM HEART J, V115, P761, DOI 10.1016/0002-8703(88)90876-9; GOLDBERG RJ, 1986, JAMA-J AM MED ASSOC, V255, P2774, DOI 10.1001/jama.255.20.2774; GOLDBERG RJ, 1987, CLIN CARDIOL, V10, P3, DOI 10.1002/clc.4960100103; GORE JM, 1987, ARCH INTERN MED, V147, P1729, DOI 10.1001/archinte.147.10.1729; GORE JM, 1989, JAMA-J AM MED ASSOC, V261, P2829; GUNNAR RM, 1974, SHOCK MYOCARDIAL INF, P113; GUTOVITZ AL, 1978, AM J CARDIOL, V41, P469, DOI 10.1016/0002-9149(78)90001-2; GUYTON RA, 1987, CIRCULATION, V76, P22; HARTZLER GO, 1988, AM J CARDIOL, V61, pG33, DOI 10.1016/S0002-9149(88)80030-4; JUGDUTT BI, 1988, CIRCULATION, V78, P906, DOI 10.1161/01.CIR.78.4.906; KENNEDY JW, 1985, AM J CARDIOL, V55, P871, DOI 10.1016/0002-9149(85)90709-X; KILLIP T, 1967, AM J CARDIOL, V20, P457, DOI 10.1016/0002-9149(67)90023-9; KOBAYASHI M, 1984, JPN CIRC J, V48, P650, DOI 10.1253/jcj.48.650; KUHN LA, 1967, AM HEART J, V74, P578, DOI 10.1016/0002-8703(67)90019-1; LEE L, 1988, CIRCULATION, V78, P1345, DOI 10.1161/01.CIR.78.6.1345; LEINBACH RC, 1972, CIRCULATION, V45, P845, DOI 10.1161/01.CIR.45.4.845; MALACH M, 1960, AM J CARDIOL, V5, P487, DOI 10.1016/0002-9149(60)90106-5; MAROKO PR, 1972, CIRCULATION, V45, P1150, DOI 10.1161/01.CIR.45.6.1150; MEINERTZ T, 1988, AM J CARDIOL, V62, P347, DOI 10.1016/0002-9149(88)90956-3; MERRELL M, 1955, J Chronic Dis, V1, P12, DOI 10.1016/0021-9681(55)90018-7; MUELLER H, 1971, J CLIN INVEST, V50, P1885, DOI 10.1172/JCI106681; MUELLER HS, 1990, CLIN CARDIOL, V13, P239, DOI 10.1002/clc.4960130403; MUNDTH ED, 1970, NEW ENGL J MED, V283, P1382, DOI 10.1056/NEJM197012172832506; OROURKE MF, 1981, AM J CARDIOL, V47, P815, DOI 10.1016/0002-9149(81)90179-X; PAGE DL, 1971, NEW ENGL J MED, V285, P133, DOI 10.1056/NEJM197107152850301; REICHENBACH DD, 1975, CIRCULATION, V52, P60; ROTHBAUM DA, 1987, J AM COLL CARDIOL, V10, P264, DOI 10.1016/S0735-1097(87)80006-2; SCHEIDT S, 1970, AM J CARDIOL, V26, P556, DOI 10.1016/0002-9149(70)90407-8; SCHEIDT S, 1973, NEW ENGL J MED, V288, P979, DOI 10.1056/NEJM197305102881901; SIMOONS ML, 1988, LANCET, V1, P199; TAKANO T, 1984, JPN CIRC J, V48, P678, DOI 10.1253/jcj.48.678; TOPOL EJ, 1987, NEW ENGL J MED, V317, P581, DOI 10.1056/NEJM198709033171001; WALKER SH, 1967, BIOMETRIKA, V54, P167, DOI 10.2307/2333860; WILLERSON JT, 1975, AM J MED, V58, P183, DOI 10.1016/0002-9343(75)90568-9; YUSUF S, 1988, JAMA-J AM MED ASSOC, V260, P2088, DOI 10.1001/jama.260.14.2088	53	334	352	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 17	1991	325	16					1117	1122		10.1056/NEJM199110173251601	http://dx.doi.org/10.1056/NEJM199110173251601			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GK538	1891019	Bronze			2022-12-24	WOS:A1991GK53800001
J	ORTIZNAVARRETE, V; SEELIG, A; GERNOLD, M; FRENTZEL, S; KLOETZEL, PM; HAMMERLING, GJ				ORTIZNAVARRETE, V; SEELIG, A; GERNOLD, M; FRENTZEL, S; KLOETZEL, PM; HAMMERLING, GJ			SUBUNIT OF THE 20S PROTEASOME (MULTICATALYTIC PROTEINASE) ENCODED BY THE MAJOR HISTOCOMPATIBILITY COMPLEX	NATURE			English	Article							CLASS-II REGION; ANTIGEN PRESENTATION; CELLS; IDENTIFICATION; TRANSPORTERS; INTERFERON; GENE; EXPRESSION; PARTICLES; PATHWAY	CYTOTOXiC T lymphocytes recognize fragments (peptides) of protein antigens presented by major histocompatibility complex (MHC) class I molecules. In general, the peptides are derived from cytosolic proteins and are then transported to the endoplasmic reticulum where they assemble with the MHC class I heavy chains and beta-2-microglobulin to form stable and functional class I molecules 1-4. The proteases involved in the generation of these peptides are unknown. One candidate is the proteasome, a nonlysosomal proteinase complex abundantly present in the cytosol. Proteasomes have several proteolytically active sites and are complexes of high relative molecular mass (M(r) about 600K), consisting of about 20-30 subunits with M(r)s between 15 and 30K (refs 5-10). Here we show that at least one of these subunits is encoded by the mouse MHC in the region between the K locus and the MHC class II region, and inducible by interferon-gamma. This raises the intriguing possibility that the MHC encodes not only the MHC class I molecules themselves but also proteases involved in the formation of MHC-binding peptides.	GERMAN CANC RES CTR,INST IMMUNOL & GENET,NEUENHEIMER FELD 280,W-6900 HEIDELBERG,GERMANY; UNIV HEIDELBERG,ZMBH,W-6900 HEIDELBERG,GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg			Ortiz-Navarrete, Vianney/H-1932-2016	Ortiz-Navarrete, Vianney/0000-0001-6546-9713				ARRIGO AP, 1987, J MOL EVOL, V25, P141, DOI 10.1007/BF02101756; CERUNDOLO V, 1990, NATURE, V345, P349; DAHLMANN B, 1989, FEBS LETT, V251, P125, DOI 10.1016/0014-5793(89)81441-3; DEMARS R, 1985, P NATL ACAD SCI USA, V82, P8183, DOI 10.1073/pnas.82.23.8183; DEVERSON EV, 1990, NATURE, V348, P738, DOI 10.1038/348738a0; FALKENBURG PE, 1989, J BIOL CHEM, V264, P6660; FUJIWARA T, 1990, J BIOL CHEM, V265, P16604; HAASS C, 1990, GENE, V90, P235, DOI 10.1016/0378-1119(90)90185-T; HOSKEN NA, 1990, SCIENCE, V248, P367, DOI 10.1126/science.2326647; KLAR D, 1989, EMBO J, V8, P475, DOI 10.1002/j.1460-2075.1989.tb03400.x; KLOETZEL PM, 1987, MOL BIOL REP, V12, P223, DOI 10.1007/BF00356912; KLOETZEL PM, 1991, BIOMED BIOCHIM ACTA, V50, P451; KOCH N, 1982, J IMMUNOL, V128, P1155; KOPP F, 1986, BIOCHIM BIOPHYS ACTA, V872, P253, DOI 10.1016/0167-4838(86)90278-5; LINDAHL P, 1973, P NATL ACAD SCI USA, V70, P2785, DOI 10.1073/pnas.70.10.2785; MONACO JJ, 1990, SCIENCE, V250, P1723, DOI 10.1126/science.2270487; MONACO JJ, 1982, P NATL ACAD SCI-BIOL, V79, P3001, DOI 10.1073/pnas.79.9.3001; MONACO JJ, 1986, HUM IMMUNOL, V15, P416, DOI 10.1016/0198-8859(86)90019-4; MONACO JJ, 1984, NATURE, V309, P797, DOI 10.1038/309797a0; MOORE MW, 1988, CELL, V54, P777, DOI 10.1016/S0092-8674(88)91043-4; MORRISON LA, 1986, J EXP MED, V163, P903, DOI 10.1084/jem.163.4.903; PARHAM P, 1990, NATURE, V348, P674, DOI 10.1038/348674a0; RIVETT AJ, 1989, ARCH BIOCHEM BIOPHYS, V268, P1, DOI 10.1016/0003-9861(89)90558-4; SEELIG A, IN PRESS BIOCH J; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; TANAKA K, 1988, J BIOL CHEM, V263, P16209; TANAKA K, 1986, J BIOL CHEM, V261, P5197; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND ARM, 1985, CELL, V42, P457, DOI 10.1016/0092-8674(85)90103-5; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; UEMATSU Y, 1988, IMMUNOGENETICS, V27, P96, DOI 10.1007/BF00351082; WALLACH D, 1982, NATURE, V299, P833, DOI 10.1038/299833a0	33	244	248	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 17	1991	353	6345					662	664		10.1038/353662a0	http://dx.doi.org/10.1038/353662a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GK672	1922384				2022-12-24	WOS:A1991GK67200071
J	LIN, YS; HA, I; MALDONADO, E; REINBERG, D; GREEN, MR				LIN, YS; HA, I; MALDONADO, E; REINBERG, D; GREEN, MR			BINDING OF GENERAL TRANSCRIPTION FACTOR TFIIB TO AN ACIDIC ACTIVATING REGION	NATURE			English	Article							RNA POLYMERASE-II; GAL4 DERIVATIVES; TATA-BOX; INITIATION; MECHANISM; CLONING; DOMAIN	A CENTRAL issue in eukaryotic transcriptional regulation is the mechanism by which promoter-specific transcription factors (activators) stimulate transcription. Two lines of evidence indicate that the general transcription factor TFIIB is a pivotal component in the mechanism by which an acidic activator functions. First, during assembly of the preinitiation complex TFIIB binding is a rate-limiting step enhanced by an acidic activator 1. Second, the TFIIB activity in a HeLa cell nuclear extract is specifically retained on a column containing an acidic activating region 1. But because our previous study monitored only TFIIB activity, it remains possible that the interaction between TFIIB and the acidic activating region is mediated through additional proteins, for example, those designated as adaptors 2, coactivators 3 or mediators 4,5. A complementary clone encoding TFIIB has recently been isolated and shown to encode a polypeptide of relative molecular mass 35,000 (ref. 6). Here we report that TFIIB expressed in and purified from Escherichia coli (recombinant TFIIB) binds directly to the potent acidic activating region of the herpes simplex virus-1 VP16 protein.	UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,PISCATAWAY,NJ 08854	Rutgers State University New Brunswick; Rutgers State University Medical Center	LIN, YS (corresponding author), UNIV MASSACHUSETTS,MED CTR,PROGRAM MOLEC MED,373 PLANTAT ST,WORCESTER,MA 01605, USA.			Reinberg, Danny/0000-0003-4288-2016				BERGER SL, 1990, CELL, V61, P1199, DOI 10.1016/0092-8674(90)90684-7; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FLANAGAN PM, 1991, NATURE, V350, P436, DOI 10.1038/350436a0; HORIKOSHI M, 1989, NATURE, V341, P299, DOI 10.1038/341299a0; INGLES CJ, 1991, NATURE, V351, P588, DOI 10.1038/351588a0; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; KELLEHER RJ, 1990, CELL, V61, P1209, DOI 10.1016/0092-8674(90)90685-8; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; LIN YS, 1990, NATURE, V345, P359, DOI 10.1038/345359a0; LIN YS, 1988, CELL, V54, P659, DOI 10.1016/S0092-8674(88)80010-2; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; TANAKA M, 1988, GENE DEV, V2, P1764, DOI 10.1101/gad.2.12b.1764	19	340	349	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 10	1991	353	6344					569	571		10.1038/353569a0	http://dx.doi.org/10.1038/353569a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GJ643	1922364				2022-12-24	WOS:A1991GJ64300071
J	NOVICK, AC; GEPHARDT, G; GUZ, B; STEINMULLER, D; TUBBS, RR				NOVICK, AC; GEPHARDT, G; GUZ, B; STEINMULLER, D; TUBBS, RR			LONG-TERM FOLLOW-UP AFTER PARTIAL REMOVAL OF A SOLITARY KIDNEY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PROGRESSIVE RENAL-FAILURE; CELL-CARCINOMA; UNILATERAL NEPHRECTOMY; CONSERVATIVE SURGERY; GLOMERULAR INJURY; VERAPAMIL; PROTEIN; DONORS; MASS; RATS	Background. The removal of more than one kidney in animals leads to proteinuria and progressive renal failure due to focal segmental glomerulosclerosis. This injury may be the result of chronic glomerular hyperfiltration. The purpose of this study was to determine the effect of a reduction in renal mass of more than 50 percent on residual renal function and morphology in humans. Methods. We evaluated long-term renal function in 14 patients with a solitary kidney who had undergone partial nephrectomy for renal-cell or transitional-cell carcinoma. In 12, the first kidney had been removed 2 months to 21 years previously for the same type of cancer; in 2, the other kidney was congenitally atrophic. Before surgery, no patient had clinical or histopathological evidence of primary renal disease. All 14 patients underwent partial nephrectomy to remove a localized tumor, with 25 to 75 percent of the solitary kidney being excised. They were evaluated 5 to 17 years after surgery (mean, 7.7). Results. Twelve patients had stable postoperative renal function, and end-stage renal failure developed in two. There were no changes in blood pressure in any patient during follow-up. Nine patients had proteinuria, which was mild (0.15 to 0.8 g of urinary protein per day) in four and moderate to severe (0.9 to 6.7 g per day) in five. The extent of proteinuria was inversely correlated with the amount of remaining renal tissue (P = 0.0065) and directly correlated with the duration of follow-up (P = 0.0005). Four patients with moderate-to-severe proteinuria had renal biopsies, which revealed focal segmental glomerulosclerosis in three patients and global glomerulosclerosis in one. Conclusions. Long-term renal function remains stable in most patients with a reduction in renal mass of more than 50 percent. These patients are, however, at increased risk for proteinuria, glomerulopathy, and progressive renal failure.	CLEVELAND CLIN EDUC FDN,DEPT NEPHROL,CLEVELAND,OH 44106; CLEVELAND CLIN EDUC FDN,DEPT PATHOL & HYPERTENS,CLEVELAND,OH 44106	Cleveland Clinic Foundation; Cleveland Clinic Foundation	NOVICK, AC (corresponding author), CLEVELAND CLIN FDN,DEPT UROL,1 CLIN CTR DR,CLEVELAND,OH 44195, USA.							ANDERSON CF, 1985, MAYO CLIN PROC, V60, P367, DOI 10.1016/S0025-6196(12)60845-3; BOVEE KC, 1979, INVEST UROL, V16, P378; BRAS G, 1969, J INFECT DIS, V120, P131, DOI 10.1093/infdis/120.1.131; BRENNER BM, 1985, AM J PHYSIOL, V249, pF324, DOI 10.1152/ajprenal.1985.249.3.F324; BRUNNER FP, 1989, KIDNEY INT, V36, P969, DOI 10.1038/ki.1989.289; FOSTER MH, 1991, AM J KIDNEY DIS, V17, P261, DOI 10.1016/S0272-6386(12)80471-9; GEPHARDT GN, 1986, ARCH PATHOL LAB MED, V110, P902; GOLDSTEIN AE, 1988, TRANSPLANTATION, V45, P59; HAKIM RM, 1984, KIDNEY INT, V25, P930, DOI 10.1038/ki.1984.112; HARRIS DCH, 1987, KIDNEY INT, V31, P41, DOI 10.1038/ki.1987.6; HOSTETTER TH, 1981, AM J PHYSIOL, V241, pF85, DOI 10.1681/ASN.V1261315; HOSTETTER TH, 1986, KIDNEY INT, V30, P509, DOI 10.1038/ki.1986.215; ICHIKAWA I, 1988, KIDNEY INT, V34, P638, DOI 10.1038/ki.1988.228; KAPPEL B, 1980, VIRCHOWS ARCH A, V387, P271, DOI 10.1007/BF00454830; KASISKE BL, 1988, CIRC RES, V62, P367, DOI 10.1161/01.RES.62.2.367; Kretschmer HL, 1943, J AMER MED ASSOC, V121, P473, DOI 10.1001/jama.1943.02840070001001; LHOTTA K, 1991, AM J KIDNEY DIS, V17, P266, DOI 10.1016/S0272-6386(12)80472-0; MEYER TW, 1985, AM J MED, V79, P31, DOI 10.1016/0002-9343(85)90077-4; NOVICK AC, 1987, UROL CLIN N AM, V14, P419; NOVICK AC, 1989, J UROLOGY, V141, P835, DOI 10.1016/S0022-5347(17)41026-3; ROBITAILLE P, 1985, LANCET, V1, P1297; SCHIMAMURA T, 1975, AM J PATHOL, V79, P95; SOLOMON LR, 1985, BRIT MED J, V291, P1610, DOI 10.1136/bmj.291.6509.1610; STAHL RAK, 1988, KLIN WOCHENSCHR, V66, P508, DOI 10.1007/BF01876174; VINCENTI F, 1983, TRANSPLANTATION, V36, P626, DOI 10.1097/00007890-198336060-00006; ZIEGELBAUM M, 1987, J UROLOGY, V138, P1146, DOI 10.1016/S0022-5347(17)43529-4	26	250	257	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 10	1991	325	15					1058	1062		10.1056/NEJM199110103251502	http://dx.doi.org/10.1056/NEJM199110103251502			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GJ108	1891007	Bronze			2022-12-24	WOS:A1991GJ10800002
J	MADDEN, DR; GORGA, JC; STROMINGER, JL; WILEY, DC				MADDEN, DR; GORGA, JC; STROMINGER, JL; WILEY, DC			THE STRUCTURE OF HLA-B27 REVEALS NONAMER SELF-PEPTIDES BOUND IN AN EXTENDED CONFORMATION	NATURE			English	Article							CLASS-I MOLECULES; DIRECT BINDING; HISTOCOMPATIBILITY ANTIGEN; VIRAL PEPTIDES; INTACT-CELLS; T-CELLS; INVITRO; RECOGNITION; PROTEIN; CHAINS	X-ray crystallography reveals electron density in the antigen-binding site of HLA-B27 that is an interpretable image of nonameric peptides in a largely extended conformation. Clear density exists for the main chain and several side chains and is consistent with the sequence of 11 nonameric self-peptides eluted from HLA-B27 (see accompanying article 1). Pockets in the antigen-binding cleft bind four side chains and the amino and carboxyl termini of the peptide.	HARVARD UNIV,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02138; HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138	Harvard University; Howard Hughes Medical Institute; Harvard University	MADDEN, DR (corresponding author), HARVARD UNIV,COMM HIGHER DEGREES BIOPHYS,7 DIVIN AVE,CAMBRIDGE,MA 02138, USA.							BENJAMIN RJ, 1991, NATURE, V351, P74, DOI 10.1038/351074a0; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BLUM M, 1987, J APPL CRYSTALLOGR, V20, P235, DOI 10.1107/S0021889887086783; BRICOGNE G, 1976, ACTA CRYSTALLOGR A, V32, P832, DOI 10.1107/S0567739476001691; BRUNGER AT, 1988, X PLOR MANUAL VERSIO; CERUNDOLO V, 1991, EUR J IMMUNOL, V21, P2069, DOI 10.1002/eji.1830210915; CHEN BP, 1989, NATURE, V337, P743, DOI 10.1038/337743a0; CROWTHER RA, 1967, ACTA CRYSTALLOGR, V23, P544, DOI 10.1107/S0365110X67003172; CROWTHER RA, 1972, MOL REPLACEMENT METH; DORNMAIR K, 1991, P NATL ACAD SCI USA, V88, P1335, DOI 10.1073/pnas.88.4.1335; DURBIN RM, 1986, SCIENCE, V232, P1127, DOI 10.1126/science.3704639; ELLIOTT TJ, 1990, P NATL ACAD SCI USA, V87, P5213, DOI 10.1073/pnas.87.13.5213; ELVIN J, 1991, EUR J IMMUNOL, V21, P2025, DOI 10.1002/eji.1830210909; FALK K, 1990, NATURE, V348, P248, DOI 10.1038/348248a0; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; GARRETT TPJ, 1989, NATURE, V342, P692, DOI 10.1038/342692a0; GORGA JC, IN PRESS PROTEINS; HUET S, 1990, INT IMMUNOL, V2, P311, DOI 10.1093/intimm/2.4.311; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; JARDETZKY TS, 1990, EMBO J, V9, P1797, DOI 10.1002/j.1460-2075.1990.tb08304.x; JONES TA, 1986, EMBO J, V5, P819, DOI 10.1002/j.1460-2075.1986.tb04287.x; JONES TA, 1982, COMPUTATIONAL CRYSTA, P303; KHAN MA, 1987, ANKYLOSING SPONDYLIT, V1, P23; KRIEGER JI, 1991, J IMMUNOL, V146, P2331; KVIST S, 1990, NATURE, V348, P446, DOI 10.1038/348446a0; LATTMAN EE, 1970, ACTA CRYSTALL B-STRU, VB 26, P1854, DOI 10.1107/S0567740870004995; MARYANSKI JL, 1990, CELL, V60, P63, DOI 10.1016/0092-8674(90)90716-R; NIXON DF, 1988, NATURE, V336, P484, DOI 10.1038/336484a0; PARHAM P, 1988, P NATL ACAD SCI USA, V85, P4005, DOI 10.1073/pnas.85.11.4005; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; SAPER MA, 1991, J MOL BIOL, V219, P227; SCHUMACHER TNM, 1990, CELL, V62, P563, DOI 10.1016/0092-8674(90)90020-F; SETTE A, 1989, P NATL ACAD SCI USA, V86, P3296, DOI 10.1073/pnas.86.9.3296; SETTE A, 1989, J IMMUNOL, V143, P3289; SETTE A, 1987, NATURE, V328, P395, DOI 10.1038/328395a0; SILVER ML, 1991, NATURE, V350, P619, DOI 10.1038/350619a0; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; VANBLEEK GM, 1990, NATURE, V348, P213	41	698	722	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 26	1991	353	6342					321	325		10.1038/353321a0	http://dx.doi.org/10.1038/353321a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GG654	1922337				2022-12-24	WOS:A1991GG65400048
J	NIGHTINGALE, SL				NIGHTINGALE, SL			PHARMACY-LINKED SYSTEMS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 18	1991	266	11					1482	1482						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GE458	1880875				2022-12-24	WOS:A1991GE45800005
J	CAMERON, DA; PUGH, EN				CAMERON, DA; PUGH, EN			DOUBLE CONES AS A BASIS FOR A NEW TYPE OF POLARIZATION VISION IN VERTEBRATES	NATURE			English	Article							ORIENTATION; LIGHT; PATTERNS; SENSITIVITY; GOLDFISH; RETINA; FISH	MANY invertebrates 1-4 and vertebrates 5-14 are sensitive to the polarization of light. The biophysical basis of invertebrate polarization sensitivity is an intrinsic dichroism, the alignment of chromophores along the photoreceptor microvilli 3. But such dichroism to axially propagating light is not present in vertebrate photoreceptors, whose chromophores are free to rotate in the plane of the outer-segment disc membranes, and a biophysical mechanism responsible for vertebrate polarization sensitivity has not been established. We hypothesize that the roughly elliptical cross-sectioned double-cone inner segment acts as a birefringent, polarization-sensitive dielectric waveguide, and that the double cone mosaic generates a 'polarization contrast' neural image. Here we confirm three predictions derived from these hypotheses: (1) 90-degrees periodicity for polarization sensitivity; (2) polarization sensitivity maxima corresponding to the absolute orientation of the axes of the double-cone inner-segment cross-sections; and (3) action spectrum for polarization sensitivity corresponding to the absorption spectrum of the double cones. We also present evidence for a polarization-opponent neural encoding in vertebrates.	UNIV PENN,SCH ARTS & SCI,DEPT PSYCHOL,PHILADELPHIA,PA 19104	University of Pennsylvania	CAMERON, DA (corresponding author), UNIV PENN,SCH ARTS & SCI,INST NEUROL SCI,3815 WALNUT ST,PHILADELPHIA,PA 19104, USA.							AALTO E, 1985, MED BIOL ENG COMPUT, V23, P111; ABLE KP, 1982, NATURE, V299, P550, DOI 10.1038/299550a0; ADAMS MJ, 1979, ELECTRON LETT, V15, P298, DOI 10.1049/el:19790212; ADLER K, 1985, J COMP PHYSIOL A, V156, P547, DOI 10.1007/BF00613978; Ali M.A., 1976, RETINAS FISHES ATLAS; BOEHLERT GW, 1978, SCIENCE, V202, P309, DOI 10.1126/science.694534; BRINES ML, 1982, J EXP BIOL, V96, P69; CHARMAN WN, 1973, VISION RES, V13, P1, DOI 10.1016/0042-6989(73)90160-0; DEARRY A, 1987, J GEN PHYSIOL, V89, P745, DOI 10.1085/jgp.89.5.745; Easter S.S. Jr., 1975, P609; ENGSTROM KJELL, 1963, ACTA ZOOL, V44, P179; FRISCH K V, 1949, Experientia, V5, P142; HAWRYSHYN CW, 1987, J COMP PHYSIOL A, V160, P459, DOI 10.1007/BF00615079; HELBIG AJ, 1989, NATURWISSENSCHAFTEN, V76, P227, DOI 10.1007/BF00627697; HUBBARD E, 1971, EXPL EYE RES, V12, P175; KUNZ YW, 1980, EXPERIENTIA, V36, P1371, DOI 10.1007/BF01960104; LYALL AH, 1957, Q J MICROSC SCI, V98, P189; LYTHGOE JN, 1967, NATURE, V213, P893, DOI 10.1038/213893a0; MENZEL R, 1975, LIGHT ECOLOGICAL FAC, P289; Northmore D. P. M., 1975, VISION FISHES, P689; POWERS MK, 1978, VISION RES, V18, P1137, DOI 10.1016/0042-6989(78)90097-4; Snyder A.W., 1975, PHOTORECEPTOR OPTICS; TAYLOR DH, 1973, SCIENCE, V181, P285, DOI 10.1126/science.181.4096.285; THORNTON JE, 1983, SCIENCE, V219, P191, DOI 10.1126/science.6849131; WALDVOGEL J, 1980, AM CI, V78, P342; WATERMAN TH, 1970, NATURE, V228, P85, DOI 10.1038/228085a0; Waterman TH, 1981, HDB SENSORY PHYSL, VVII/6B, P283; WATERMAN TH, 1975, LIGHT ECOLOGICAL FAC, P305; WEHNER R, 1976, SCI AM, V235, P106, DOI 10.1038/scientificamerican0776-106; WEHNER R, 1989, TRENDS NEUROSCI, V12, P353, DOI 10.1016/0166-2236(89)90043-X	30	100	102	0	23	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 12	1991	353	6340					161	164		10.1038/353161a0	http://dx.doi.org/10.1038/353161a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GE731	1891046				2022-12-24	WOS:A1991GE73100052
J	COSGROVE, D; GRAY, D; DIERICH, A; KAUFMAN, J; LEMEUR, M; BENOIST, C; MATHIS, D				COSGROVE, D; GRAY, D; DIERICH, A; KAUFMAN, J; LEMEUR, M; BENOIST, C; MATHIS, D			MICE LACKING MHC CLASS-II MOLECULES	CELL			English	Article							T-CELL-RECEPTOR; HISTOCOMPATIBILITY COMPLEX ANTIGEN; LYMPHOCYTE-B DEVELOPMENT; E-ALPHA-D; TRANSGENIC MICE; MONOCLONAL-ANTIBODIES; SURFACE EXPRESSION; ACCESSORY CELLS; A-BETA; DIFFERENTIATION ANTIGENS	We have produced mice that lack major histocompatibility complex class II antigens, permitting us to evaluate the role of these molecules in diverse aspects of T and B cell differentiation. The mutant mice show near-complete elimination of CD4+ T lymphocytes from the spleen and lymph nodes; the few remaining CD4-positive cells are preferentially localized to B cell follicles. Surprisingly, substantial numbers of CD4 single-positive cells reside in the thymus; however, these are not mature thymocytes as we currently recognize them. B lymphocytes occur in normal numbers and are capable of terminal differentiation to plasma cells. Nevertheless, several aberrations in the B cell compartment are demonstrable: a lack of germinal centers, fewer IgM+IgD+ cells in certain individuals, reduced production of serum IgG1, and complete inability to respond to T-dependent antigens. In short, the class II-negative mice have confirmed some old ideas about lymphocyte differentiation, but have provided some surprises.	BASEL INST IMMUNOL, CH-4058 BASEL, SWITZERLAND		COSGROVE, D (corresponding author), FAC MED STRASBOURG, INST CHIM BIOL,CNRS,GENET MOLEC EUCARYOTES LAB, INSERM, U184, F-67085 STRASBOURG, FRANCE.		Gray, David/L-8295-2013	Gray, David/0000-0003-3785-4934; Kaufman, Jim/0000-0002-7216-8422				ACHAORBEA H, 1985, EUR J IMMUNOL, V15, P31, DOI 10.1002/eji.1830150107; ANDERSON GD, 1989, J IMMUNOL, V143, P3757; ANDERSON GD, 1989, J EXP MED, V170, P1003, DOI 10.1084/jem.170.3.1003; ASHIDA ER, 1987, P NATL ACAD SCI USA, V84, P3395, DOI 10.1073/pnas.84.10.3395; BECK BN, 1986, J IMMUNOL, V136, P2953; BENOIST C, 1989, CELL, V58, P1027, DOI 10.1016/0092-8674(89)90501-1; BERG LJ, 1989, NATURE, V340, P559, DOI 10.1038/340559a0; BERG LJ, 1989, CELL, V58, P1035, DOI 10.1016/0092-8674(89)90502-3; BHATTACHARYA A, 1981, J IMMUNOL, V127, P2488; BILL J, 1989, J EXP MED, V169, P1405, DOI 10.1084/jem.169.4.1405; BILL J, 1990, J MOL CELL IMMUNOL, V4, P269; BLUESTONE JA, 1987, NATURE, V326, P82, DOI 10.1038/326082a0; BONIFACINO JS, 1990, NATURE, V344, P247, DOI 10.1038/344247a0; BORGULYA P, 1991, EMBO J, V10, P913, DOI 10.1002/j.1460-2075.1991.tb08024.x; BOSWELL HS, 1980, J IMMUNOL, V125, P1340; BOSWELL HS, 1980, J EXP MED, V152, P1194, DOI 10.1084/jem.152.5.1194; BRAUNSTEIN NS, 1987, P NATL ACAD SCI USA, V84, P2921, DOI 10.1073/pnas.84.9.2921; BRAUNSTEIN NS, 1986, EMBO J, V5, P2469, DOI 10.1002/j.1460-2075.1986.tb04523.x; BRUCE J, 1981, J IMMUNOL, V127, P2496; BUDD RC, 1987, J EXP MED, V166, P577, DOI 10.1084/jem.166.2.577; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; Carbone F. R., 1989, Fundamental immunology., P541; CEBRA JJ, 1984, ANNU REV IMMUNOL, V2, P493, DOI 10.1146/annurev.immunol.2.1.493; CEREDIG R, 1987, P NATL ACAD SCI USA, V84, P8578, DOI 10.1073/pnas.84.23.8578; CHUSED TM, 1976, J IMMUNOL, V116, P1579; COFFMAN RL, 1981, NATURE, V289, P681, DOI 10.1038/289681a0; CRISPE IN, 1987, NATURE, V329, P336, DOI 10.1038/329336a0; CRISPE IN, 1987, J IMMUNOL, V139, P3585; DIALYNAS DP, 1983, IMMUNOL REV, V74, P29, DOI 10.1111/j.1600-065X.1983.tb01083.x; EGERTON M, 1990, P NATL ACAD SCI USA, V87, P2579, DOI 10.1073/pnas.87.7.2579; EGERTON M, 1990, INT IMMUNOL, V2, P157, DOI 10.1093/intimm/2.2.157; ESSER C, 1990, ANNU REV IMMUNOL, V8, P717, DOI 10.1146/annurev.iy.08.040190.003441; FINKELMAN FD, 1990, ANNU REV IMMUNOL, V8, P303, DOI 10.1146/annurev.iy.08.040190.001511; FOWLKES BJ, 1987, NATURE, V329, P251, DOI 10.1038/329251a0; FOWLKES BJ, 1989, ADV IMMUNOL, V44, P207; FULTZ MJ, 1982, J IMMUNOL, V129, P992; GERMAIN RN, 1986, NATURE, V320, P72, DOI 10.1038/320072a0; GOODMAN T, 1989, J EXP MED, V170, P1569, DOI 10.1084/jem.170.5.1569; GOSSLER A, 1986, P NATL ACAD SCI USA, V83, P9065, DOI 10.1073/pnas.83.23.9065; GRAY D, 1991, INT IMMUNOL, V3, P141, DOI 10.1093/intimm/3.2.141; Griscelli C, 1989, Immunodefic Rev, V1, P135; GUTMAN GA, 1972, IMMUNOLOGY, V23, P465; Hardy R R, 1990, Semin Immunol, V2, P197; HASHIMOTO Y, 1987, P NATL ACAD SCI USA, V84, P5883, DOI 10.1073/pnas.84.16.5883; HASKINS K, 1984, J EXP MED, V160, P452, DOI 10.1084/jem.160.2.452; HEINEN E, 1988, IMMUNOL TODAY, V9, P240, DOI 10.1016/0167-5699(88)91223-6; HERZENBERG LA, 1989, COLD SH Q B, V54, P219; HODES RJ, 1989, FUNDAMENTAL IMMUNOLO, P587; HOLUB M, 1989, IMMUNOLOGY NUDE MICE; HUGO P, 1991, EUR J IMMUNOL, V21, P835, DOI 10.1002/eji.1830210346; HUGO P, 1990, INT IMMUNOL, V2, P209, DOI 10.1093/intimm/2.3.209; KARLSSON L, 1991, NATURE, V351, P485, DOI 10.1038/351485a0; KAUFMAN J, 1990, J IMMUNOL, V144, P2258; KAUFMAN J, 1990, J IMMUNOL, V144, P2243; KAYE J, 1989, NATURE, V341, P746, DOI 10.1038/341746a0; KIMOTO M, 1989, IMMUNOLOGY, V67, P154; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; KRUISBEEK AM, 1985, J EXP MED, V161, P1029, DOI 10.1084/jem.161.5.1029; KRUISBEEK AM, 1983, J EXP MED, V157, P1932, DOI 10.1084/jem.157.6.1932; KUBO RT, 1989, J IMMUNOL, V142, P2736; LAMERS MC, 1989, EUR J IMMUNOL, V19, P459, DOI 10.1002/eji.1830190308; LANDAIS D, 1986, J IMMUNOL, V137, P3002; LARHAMMAR D, 1985, J BIOL CHEM, V260, P4111; LEDBETTER JA, 1979, IMMUNOL REV, V47, P63, DOI 10.1111/j.1600-065X.1979.tb00289.x; LEFRANCOIS L, 1990, CELL, V63, P333, DOI 10.1016/0092-8674(90)90166-C; LEMEUR M, 1985, NATURE, V316, P38, DOI 10.1038/316038a0; LESLEY J, 1988, CELL IMMUNOL, V112, P40, DOI 10.1016/0008-8749(88)90274-2; LIAO NS, 1989, J EXP MED, V170, P135, DOI 10.1084/jem.170.1.135; LYNCH F, 1989, EUR J IMMUNOL, V19, P223, DOI 10.1002/eji.1830190202; MACPHAIL S, 1987, J IMMUNOL, V139, P4007; MACPHAIL S, 1988, P NATL ACAD SCI USA, V85, P5205, DOI 10.1073/pnas.85.14.5205; MALISSEN B, 1986, P NATL ACAD SCI USA, V83, P3958, DOI 10.1073/pnas.83.11.3958; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MATHIS DJ, 1983, P NATL ACAD SCI-BIOL, V80, P273, DOI 10.1073/pnas.80.1.273; MATIS LA, 1989, SCIENCE, V245, P746, DOI 10.1126/science.2528206; MATSUBAYASHI Y, 1989, IMMUNOBIOLOGY, V180, P33, DOI 10.1016/S0171-2985(89)80028-2; MATSUMOTO K, 1989, EUR J IMMUNOL, V19, P1203, DOI 10.1002/eji.1830190708; MATSUNAGA M, 1990, J EXP MED, V171, P577, DOI 10.1084/jem.171.2.577; MCCARTHY SA, 1988, NATURE, V336, P76, DOI 10.1038/336076a0; MCKNIGHT SL, 1980, NUCLEIC ACIDS RES, V8, P5949, DOI 10.1093/nar/8.24.5949; MIESCHER GC, 1987, J IMMUNOL, V138, P1959; MILLER J, 1986, J EXP MED, V164, P1478, DOI 10.1084/jem.164.5.1478; MOND JJ, 1987, IMMUNOL REV, V99, P105, DOI 10.1111/j.1600-065X.1987.tb01174.x; MORRISSEY PJ, 1981, J IMMUNOL, V127, P1345; NAKAYAMA T, 1990, SCIENCE, V249, P1558, DOI 10.1126/science.2120773; NIKOLICZUGIC J, 1990, INT IMMUNOL, V2, P135, DOI 10.1093/intimm/2.2.135; OZATO K, 1980, J IMMUNOL, V124, P533; PATERSON DJ, 1987, J EXP MED, V166, P1603, DOI 10.1084/jem.166.5.1603; PIERRES A, 1984, J IMMUNOL, V132, P2775; PIERRES M, 1981, IMMUNOGENETICS, V14, P481, DOI 10.1007/BF00350120; QUILL H, 1986, J IMMUNOL, V136, P3351; RELLAHAN BL, 1991, J EXP MED, V173, P503, DOI 10.1084/jem.173.2.503; Robertson E. J., 1987, TERATOCARCINOMAS EMB; ROBEY EA, 1991, CELL, V64, P99, DOI 10.1016/0092-8674(91)90212-H; Robinson M. A., 1989, Fundamental immunology., P489; ROUSE RV, 1982, J IMMUNOL, V128, P2243; SANT AJ, 1987, P NATL ACAD SCI USA, V84, P8065, DOI 10.1073/pnas.84.22.8065; SANT AJ, 1989, CELL, V57, P797, DOI 10.1016/0092-8674(89)90794-0; SCHUURMAN HJ, 1985, HUM IMMUNOL, V13, P69, DOI 10.1016/0198-8859(85)90014-X; SCOTT B, 1989, NATURE, V338, P591, DOI 10.1038/338591a0; SMITH AG, 1988, NATURE, V336, P688, DOI 10.1038/336688a0; SPENCER JS, 1989, J EXP MED, V169, P625, DOI 10.1084/jem.169.3.625; SPRINGER T, 1978, EUR J IMMUNOL, V8, P539, DOI 10.1002/eji.1830080802; TEW JG, 1990, IMMUNOL REV, V117, P185, DOI 10.1111/j.1600-065X.1990.tb00573.x; TOMONARI K, 1990, IMMUNOGENETICS, V31, P333, DOI 10.1007/BF02115007; TOMONARI K, 1988, IMMUNOGENETICS, V28, P455, DOI 10.1007/BF00355379; TROWBRIDGE IS, 1982, IMMUNOGENETICS, V15, P299, DOI 10.1007/BF00364338; VANVLIET E, 1984, EUR J IMMUNOL, V14, P524, DOI 10.1002/eji.1830140608; VELARDI A, 1985, BLOOD, V65, P149; VELARDI A, 1986, J CLIN IMMUNOL, V6, P205, DOI 10.1007/BF00918700; VELARDI A, 1986, J IMMUNOL, V137, P2808; VERNACHIO J, 1989, J IMMUNOL, V142, P48; VONBOEHMER H, 1988, ANNU REV IMMUNOL, V6, P309, DOI 10.1146/annurev.iy.06.040188.001521; VONBOEHMER H, 1990, ANNU REV IMMUNOL, V8, P531, DOI 10.1146/annurev.iy.08.040190.002531; WAKE CT, 1985, CELL, V42, P623, DOI 10.1016/0092-8674(85)90119-9; WALDMANN H, 1989, ANNU REV IMMUNOL, V7, P407, DOI 10.1146/annurev.iy.07.040189.002203; WU L, 1990, INT IMMUNOL, V2, P51, DOI 10.1093/intimm/2.1.51; ZUNIGAPFLUCKER JC, 1989, J EXP MED, V169, P2085, DOI 10.1084/jem.169.6.2085	118	776	801	0	12	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 6	1991	66	5					1051	1066		10.1016/0092-8674(91)90448-8	http://dx.doi.org/10.1016/0092-8674(91)90448-8			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GE460	1909605				2022-12-24	WOS:A1991GE46000021
J	MAHALANABIS, D				MAHALANABIS, D			BREAST-FEEDING AND VITAMIN-A-DEFICIENCY AMONG CHILDREN ATTENDING A DIARRHEA TREATMENT CENTER IN BANGLADESH - A CASE-CONTROL STUDY	BRITISH MEDICAL JOURNAL			English	Article							XEROPHTHALMIA; MORTALITY; MOTHERS; RISK	Objective - To determine the effect of breast feeding on the risk of xerophthalmia in children aged 6 months to 3 years attending a diarrhoea treatment centre in Bangladesh. Design - Case-control study based on stratified analysis (Mantel-Haenszel) and multivariate analysis (logistic regression) of data from a treatment centre based surveillance system. Setting - A large diarrhoea treatment centre in Dhaka, Bangladesh. Patients - 2687 children aged 6 months to 3 years representing a 4% systematic sample of all children in this age group treated yearly at the centre over three consecutive years. 66 of the children were cases of xerophthalmia (that is, they had Bitot's spots or corneal lesions or night blindness or night blindness plus conjunctival xerosis or any combination of these) and the remaining 2621 did not have signs or symptoms of vitamin A deficiency. This second group served as controls. Main outcome measure - Xerophthalmia and breast fed at onset of diarrhoea or presentation. Results - The odds ratio relating breast feeding to vitamin A deficiency after adjustment for a large number of confounding variables (0.26 (95% confidence interval 0.14 to 0.49); p < 0.001) reflected a 74% reduction in the risk of vitamin A deficiency among breast fed children. The estimated reduction of risk did not decline with age, and some 49% of children aged 24-35 months were still being breast fed. The odds ratio relating breast feeding to xerophthalmia in the third year of life (0.35 (95% confidence interval 0.35 to 0.86) reflected a 65% reduced risk of vitamin A deficiency. Other important risk factors or prognostic indicators for xerophthalmia as identified by multivariate analysis were recent measles, prolonged diarrhoea, severe protein energy malnutrition, and poor socioeconomic state. Conclusions - These results indicate that breast feeding was associated with a substantial reduction of the risk of vitamin A deficiency extending to the third year of life and support the recommendation that mothers in developing countries should be advised to breast feed for as long as possible.			MAHALANABIS, D (corresponding author), INT CTR DIARRHOEL DIS RES,DIV CLIN SCI,POB 128,DHAKA,BANGLADESH.							Becroft T C, 1967, Med J Aust, V2, P810; BRAKOHIAPA LA, 1988, LANCET, V2, P416; BROSS I, 1954, BIOMETRICS, V10, P478, DOI 10.2307/3001619; BROWN KH, 1982, AM J CLIN NUTR, V36, P878, DOI 10.1093/ajcn/36.5.878; COHEN N, 1985, SOC SCI MED, V21, P1269, DOI 10.1016/0277-9536(85)90276-X; DUALEH K A, 1989, Food and Nutrition Bulletin, V11, P43; GEBREMEDHIN M, 1976, AM J CLIN NUTR, V29, P441, DOI 10.1093/ajcn/29.4.441; HABTE D, 1989, 13 P NAT S INT VIT A, P7; MANTEL N, 1959, J NATL CANCER I, V22, P719; NEWELL DJ, 1963, BIOMETRICS, V19, P187, DOI 10.2307/2527585; ROY SK, 1984, J TROP MED HYG, V87, P11; ROY SK, 1989, VITAMIN A DEFICIENCY, P107; SCHLESSELMAN JJ, 1982, CASE CONTROL STUDIES, P137; SINHA DP, 1973, LANCET, V2, P228; SOMMER A, 1986, LANCET, V1, P1169; SOMMER A, 1983, LANCET, V2, P585; SOMMER A, 1977, GUIDELINES ERADICATI, P1; STOLL BJ, 1985, J TROP PEDIATRICS, V31, P36, DOI 10.1093/tropej/31.1.36; STOLL BJ, 1982, BRIT MED J, V285, P1185, DOI 10.1136/bmj.285.6349.1185; TARWOTJO I, 1982, AM J CLIN NUTR, V35, P574, DOI 10.1093/ajcn/35.3.574; VANSTEENBERGEN WM, 1981, J TROP PEDIATRICS, V27, P155, DOI 10.1093/tropej/27.3.155; Vis H L, 1981, Assignment Child, V55-56, P183; WEST KP, 1986, AM J CLIN NUTR, V44, P690; 1985, BANGLADESH NATIONAL; 1976, WHO TECH REP SER, V590, P35	25	40	40	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 31	1991	303	6801					493	496		10.1136/bmj.303.6801.493	http://dx.doi.org/10.1136/bmj.303.6801.493			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GD804	1912858	Green Published, Bronze			2022-12-24	WOS:A1991GD80400015
J	REAL, LA				REAL, LA			ANIMAL CHOICE BEHAVIOR AND THE EVOLUTION OF COGNITIVE ARCHITECTURE	SCIENCE			English	Article							FORAGING PREFERENCES; BUMBLE BEES; RISK-AVERSE; GREAT TIT; MEMORY; UNCERTAINTY; REPRESENTATION; FORAGERS; FALLACY; MODEL	Animals process sensory information according to specific computational rules and, subsequently, form representations of their environments that form the basis for decisions and choices. The specific computational rules used by organisms will often be evolutionarily adaptive by generating higher probabilities of survival, reproduction, and resource acquisition. Experiments with enclosed colonies of bumblebees constrained to foraging on artificial flowers suggest that the bumblebee's cognitive architecture is designed to efficiently exploit floral resources from spatially structured environments given limits on memory and the neuronal processing of information. A non-linear relationship between the biomechanics of nectar extraction and rates of net energetic gain by individual bees may account for sensitivities to both the arithmetic mean and variance in reward distributions in flowers. Heuristic rules that lead to efficient resource exploitation may also lead to subjective misperception of likelihoods. Subjective probability formation may then be viewed as a problem in pattern recognition subject to specific sampling schemes and memory constraints.			REAL, LA (corresponding author), UNIV N CAROLINA, DEPT BIOL, CHAPEL HILL, NC 27599 USA.							ANDERSON JR, 1987, BEHAV BRAIN SCI, V10, P467, DOI 10.1017/S0140525X00023554; ANGERMEIER WF, 1984, EVOLUTION OPERANT LE; BALDA RP, 1989, ANIM BEHAV, V38, P486, DOI 10.1016/S0003-3472(89)80041-7; BARNARD CJ, 1985, BEHAV ECOL SOCIOBIOL, V16, P161, DOI 10.1007/BF00295150; BATTALIO RC, 1990, J RISK UNCERTAINTY, V3, P25; BATTALIO RC, 1985, AM ECON REV, V75, P597; CARACO T, 1983, BEHAV ECOL SOCIOBIOL, V12, P63, DOI 10.1007/BF00296934; CARACO T, 1981, BEHAV ECOL SOCIOBIOL, V8, P213, DOI 10.1007/BF00299833; CARACO T, 1980, ANIM BEHAV, V28, P820, DOI 10.1016/S0003-3472(80)80142-4; CARACO T, 1986, QUANT ANAL BEHAV, V6, P1; CARTAR RV, 1990, BEHAV ECOL SOCIOBIOL, V26, P121, DOI 10.1007/BF00171581; CHENEY D, 1986, SCIENCE, V234, P1361, DOI 10.1126/science.3538419; CHENEY DL, 1990, COGNITION, V37, P167, DOI 10.1016/0010-0277(90)90022-C; CUTHILL IC, 1990, ANIM BEHAV, V40, P625, DOI 10.1016/S0003-3472(05)80692-X; DAVISON MC, 1969, J EXP ANAL BEHAV, V12, P247, DOI 10.1901/jeab.1969.12-247; DUKAS R, UNPUB; DUKAS R, IN PRESS ANIM BEHAV; FEINSINGER P, 1978, ECOL MONOGR, V48, P269, DOI 10.2307/2937231; French Simon, 1986, DECISION THEORY; Gallistel C. R., 1990, ORG LEARNING; GETTY T, 1985, AM NAT, V125, P239, DOI 10.1086/284339; GETTY T, 1985, AM NAT, V125, P39, DOI 10.1086/284327; GILLIAM JF, 1982, AM NAT, V119, P875, DOI 10.1086/283962; HARDER LD, 1987, ECOLOGY, V68, P1104, DOI 10.2307/1938384; HARVEY PH, 1990, SCIENCE, V249, P140, DOI 10.1126/science.2196673; Heinrich B., 1984, Life Sciences Research Report, P135; Henderson J., 1980, MICROECONOMIC THEORY, V3rd; HERRNSTEIN RJ, 1964, J EXP ANAL BEHAV, V7, P179, DOI 10.1901/jeab.1964.7-179; Holifield Robert J., 1987, DARWIN EMERGENCE EVO, P418; KAGEL JH, 1990, AM ECON REV, V80, P912; KAHNEMAN D, 1979, ECONOMETRICA, V47, P263, DOI 10.2307/1914185; Kahneman D., 1982, JUDGMENT UNCERTAINTY; KARMARKAR US, 1979, ORGAN BEHAV HUM PERF, V24, P67, DOI 10.1016/0030-5073(79)90016-3; Keeney R.L., 1976, DECISIONS MULTIPLE O, P96; KREBS JR, 1990, ANIM BEHAV, V39, P1127, DOI 10.1016/S0003-3472(05)80785-7; KREBS JR, 1991, BEHAVIOURAL ECOLOGY; Loria DE, 1990, BEHAV ECOL, V1, P24, DOI 10.1093/beheco/1.1.24; MACHINA MJ, 1982, ECONOMETRICA, V50, P277, DOI 10.2307/1912631; MACPHAIL EM, 1987, BEHAV BRAIN SCI, V10, P645, DOI 10.1017/S0140525X00054984; Markowitz H, 1959, PORTFOLIO SELECTION; MENZEL R, 1979, NATURE, V281, P368, DOI 10.1038/281368a0; Menzel R, 1985, EXPT BEHAV ECOLOGY, P55; MILLER GA, 1956, PSYCHOL REV, V63, P81, DOI 10.1037/h0043158; MOORE FR, 1986, EXPERIENTIA, V42, P1054, DOI 10.1007/BF01940730; Newell A., 1989, FDN COGNITIVE SCI, P93; PEARCE JM, 1987, INTRO ANIMAL COGNITI; PEARCE JM, 1989, ANNU REV PSYCHOL, V40, P155; PLEASANTS JM, 1979, OECOLOGIA, V41, P283, DOI 10.1007/BF00377432; POSSINGHAM HP, 1990, ECOLOGY, V71, P1622, DOI 10.2307/1938298; Pyke G.H., 1983, P7; REAL L, 1987, AM NAT, V130, P399, DOI 10.1086/284717; REAL L, 1990, ECOLOGY, V71, P1625, DOI 10.2307/1938299; REAL L, 1982, ECOLOGY, V63, P1617, DOI 10.2307/1940101; REAL L, 1986, ANNU REV ECOL SYST, V17, P371, DOI 10.1146/annurev.es.17.110186.002103; REAL LA, 1981, ECOLOGY, V62, P20, DOI 10.2307/1936663; REAL LA, UNPUB; REAL LA, 1989, BEHAVIORAL MECHANISM, P1; Roitblat H. L., 1987, INTRO COMP COGNITION; ROITBLAT HL, 1982, BEHAV BRAIN SCI, V5, P353, DOI 10.1017/S0140525X00012486; ROSETT RN, 1971, REV ECON STUD, V38, P481, DOI 10.2307/2296691; RUMMELHART DE, 1989, F COGNITIVE SCI, P133; RUMMELHART DE, 1986, PARALLEL DISTRIBUTED; SHERRY DF, 1987, PSYCHOL REV, V94, P439, DOI 10.1037/0033-295X.94.4.439; SHETTLEWORTH SJ, 1983, ADV ANAL BEHAV, P1; Sommer L, 1955, ECONOMETRICA, V23, P235, DOI 10.2307/1907897; STADDON JER, 1983, ADAPTIVE BEHAVIOR LE; Stephens D.W., 1986, pi; TOBIN J, 1957, REV ECON STUD, V25, P65; Torrance G W, 1989, Int J Technol Assess Health Care, V5, P559; TURELLI M, 1982, AM NAT, V119, P879, DOI 10.1086/283963; TVERSKY A, 1974, SCIENCE, V185, P1124, DOI 10.1126/science.185.4157.1124; VanLehn K., 1989, FDN COGNITIVE SCI, P1; WADDINGTON KD, 1981, ANIM BEHAV, V29, P779, DOI 10.1016/S0003-3472(81)80011-5; WASER NM, 1986, AM NAT, V127, P593, DOI 10.1086/284507; WILSON B, 1985, Q J EXP PSYCHOL-B, V37, P313, DOI 10.1080/14640748508401173; Wuketits FM., 1990, EVOLUTIONARY EPISTEM; WUNDERLE JM, 1985, BEHAV ECOL SOCIOBIOL, V17, P371, DOI 10.1007/BF00293215; YAARI ME, 1965, Q J ECON, V79, P278, DOI 10.2307/1880632	78	255	262	4	105	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 30	1991	253	5023					980	986		10.1126/science.1887231	http://dx.doi.org/10.1126/science.1887231			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC982	1887231				2022-12-24	WOS:A1991GC98200034
J	RUPPERSBERG, JP; STOCKER, M; PONGS, O; HEINEMANN, SH; FRANK, R; KOENEN, M				RUPPERSBERG, JP; STOCKER, M; PONGS, O; HEINEMANN, SH; FRANK, R; KOENEN, M			REGULATION OF FAST INACTIVATION OF CLONED MAMMALIAN IK(A) CHANNELS BY CYSTEINE OXIDATION	NATURE			English	Article							DELAYED RECTIFIER PROPERTIES; BRAIN POTASSIUM-CHANNEL; RAT-BRAIN; EXPRESSION; CLONING; FAMILY; APLYSIA; MEMBER; CDNA	MODULATION of neuronal excitability by regulation of K+ channels potentially plays a part in short-term memory 1 but has not yet been studied at the molecular level. Regulation of K+ channels by protein phosphorylation 2-5 and oxygen 6 has been described for various tissues and cell types; regulation of fast-inactivating K+ channels mediating I(K)(A) currents has not yet been described. Functional expression of cloned mammalian K+ channels 7-13 has provided a tool for studying their regulation at the molecular level. We report here that fast-inactivating K+ currents mediated by cloned K+ channel subunits derived from mammalian brain expressed in Xenopus oocytes are regulated by the reducing agent glutathione. This type of regulation may have a role in vivo to link metabolism to excitability and to regulate excitability in specific membrane areas of mammalian neurons.	MAX PLANCK INST BIOPHYS CHEM, MEMBRANBIOPHYS ABT, W-3400 GOTTINGEN, GERMANY; ZENTRUM MOLEK BIOL, W-6900 HEIDELBERG, GERMANY; RUHR UNIV BOCHUM, LEHRSTUHL BIOCHEM, W-4600 BOCHUM, GERMANY	Max Planck Society; Ruprecht Karls University Heidelberg; Ruhr University Bochum	RUPPERSBERG, JP (corresponding author), MAX PLANCK INST MED RES, ZELLPHYSIOL ABT, JAHNSTR 29, W-6900 HEIDELBERG 1, GERMANY.		Stocker, Martin/C-1844-2008	Heinemann, Stefan H./0000-0002-4144-0251				ABRAMS TW, 1988, TRENDS NEUROSCI, V11, P128, DOI 10.1016/0166-2236(88)90137-3; ALKON DL, 1982, SCIENCE, V215, P693, DOI 10.1126/science.7058334; BAUMANN A, 1988, EMBO J, V7, P2457, DOI 10.1002/j.1460-2075.1988.tb03092.x; CASTRO B, 1977, J CHEM RES, V182, P2118; CHRISTIE MJ, 1989, SCIENCE, V244, P221, DOI 10.1126/science.2539643; FRANK R, 1988, MODERN METHODS PROTE, V3; FRECH GC, 1989, NATURE, V340, P642, DOI 10.1038/340642a0; GRUPE A, 1990, EMBO J, V9, P1749, DOI 10.1002/j.1460-2075.1990.tb08299.x; HERLITZE S, 1990, GENE, V91, P143, DOI 10.1016/0378-1119(90)90177-S; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; KACZMAREK LK, 1988, ADV SEC MESS PHOSPH, V22, P113; KRAMER RH, 1990, NEURON, V4, P335, DOI 10.1016/0896-6273(90)90046-I; KUME H, 1989, NATURE, V341, P152, DOI 10.1038/341152a0; MCCORMACK T, 1990, P NATL ACAD SCI USA, V87, P5227, DOI 10.1073/pnas.87.13.5227; MCKINNON D, 1989, J BIOL CHEM, V264, P8230; RUPPERSBERG JP, 1990, NATURE, V345, P535, DOI 10.1038/345535a0; SCHROTER KH, 1991, FEBS LETT, V278, P211, DOI 10.1016/0014-5793(91)80119-N; STOCKER M, 1990, P NATL ACAD SCI USA, V87, P8903, DOI 10.1073/pnas.87.22.8903; STOCKER M, IN PRESS P R SOC L B; STRONG JA, 1986, J NEUROSCI, V6, P814; STUHMER W, 1988, FEBS LETT, V242, P199, DOI 10.1016/0014-5793(88)81015-9; STUHMER W, 1989, EMBO J, V8, P3235, DOI 10.1002/j.1460-2075.1989.tb08483.x; WALSH KB, 1988, SCIENCE, V242, P67, DOI 10.1126/science.2845575; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520	25	442	448	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 22	1991	352	6337					711	714		10.1038/352711a0	http://dx.doi.org/10.1038/352711a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC064	1908562				2022-12-24	WOS:A1991GC06400057
J	KING, MB; PATTISON, P				KING, MB; PATTISON, P			HOMOSEXUALITY AND PARENTHOOD	BRITISH MEDICAL JOURNAL			English	Article							HETEROSEXUAL MOTHERS; LESBIAN MOTHERS; CHILDREN; FATHERS; GAY		BURTON PATTISON SOLICITORS,LONDON W1X 7AA,ENGLAND		KING, MB (corresponding author), ROYAL FREE HOSP,SCH MED,LONDON NW3 2QG,ENGLAND.		King, Michael B/D-7477-2011	King, Michael B/0000-0003-4715-7171				Abel G G, 1988, Bull Am Acad Psychiatry Law, V16, P153; BANCROFT J, 1989, HUMAN SEXUALITY ITS; BELL AP, 1987, SEXUAL PREFERENCE IT; BIGNER JJ, 1989, J HOMOSEXUAL, V18, P173, DOI 10.1300/J082v18n01_09; BOZETT FW, 1989, J HOMOSEXUAL, V18, P137, DOI 10.1300/J082v18n01_07; Bradley D., 1987, INT J LAW FAMILY, V1, P155; BREWAEYS A, 1989, HUM REPROD, V4, P850, DOI 10.1093/oxfordjournals.humrep.a137000; CONTE JR, 1991, CLIN APPROACHES SEX, P11; GOLOMBOK S, 1983, J CHILD PSYCHOL PSYC, V24, P551, DOI 10.1111/j.1469-7610.1983.tb00132.x; GREEN R, 1986, ARCH SEX BEHAV, V15, P167, DOI 10.1007/BF01542224; GREEN R, 1978, PSYCHIATRY, V135, P692; HARRIS MB, 1985, J HOMOSEXUAL, V12, P101; HUGGINS SL, 1989, J HOMOSEXUAL, V18, P123, DOI 10.1300/J082v18n01_06; HUI TY, 1990, INDEPENDENT     1003, P25; Langevin R., 1983, SEXUAL STRANDS UNDER; LESTER D, 1975, UNUSUAL SEXUAL BEHAV; LEWIS KG, 1980, SOC WORK, V25, P198, DOI 10.1093/sw/25.3.198; MILLER B, 1979, FAMILY COORDINAT OCT, P544; MONEY J, 1988, GAY STRAIGHT BETWEEN; Money J., 1972, MAN WOMAN BOY GIRL; RIDDLE DI, 1978, J SOC ISSUES, V34, P38, DOI 10.1111/j.1540-4560.1978.tb02613.x; Socarides C., 1979, SEXUAL DEVIATION, P243; WAKELING A, 1979, SEXUAL DEVIATION, P1; 1980, FAMILY LAW REV, V1, P143; 1987, JAMA-J AM MED ASSOC, V258, P222; 1986, LESBIAN MOTHERS LEGA	26	4	4	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 3	1991	303	6797					295	297		10.1136/bmj.303.6797.295	http://dx.doi.org/10.1136/bmj.303.6797.295			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FZ721	1888934	Bronze, Green Published			2022-12-24	WOS:A1991FZ72100026
J	DALE, C; GALLUS, A; WYCHERLEY, A; LANGLOIS, S; HOWIE, D				DALE, C; GALLUS, A; WYCHERLEY, A; LANGLOIS, S; HOWIE, D			PREVENTION OF VENOUS THROMBOSIS WITH MINIDOSE WARFARIN AFTER JOINT REPLACEMENT	BRITISH MEDICAL JOURNAL			English	Article							INTERMITTENT CALF; COMPRESSION		FLINDERS UNIV,MED CTR,DEPT HAEMATOL,HAEMOSTASIS & THROMBOSIS LAB,BEDFORD PK,SA 5042,AUSTRALIA; UNIV ADELAIDE,ADELAIDE,SA 5001,AUSTRALIA; ROYAL ADELAIDE HOSP,RADIOL,ADELAIDE,SA 5000,AUSTRALIA; ROYAL ADELAIDE HOSP,ORTHOPAEDIC SURG & TRAUMA,ADELAIDE,SA 5000,AUSTRALIA; FLINDERS UNIV,MED CTR,NUCL MED,BEDFORD PK,SA 5042,AUSTRALIA	Flinders University South Australia; University of Adelaide; Royal Adelaide Hospital; Royal Adelaide Hospital; Flinders University South Australia				Gallus, Alexander/0000-0001-7347-9989; Howie, Donald/0000-0003-1702-3279				BERN MM, 1990, ANN INTERN MED, V112, P423, DOI 10.7326/0003-4819-76-3-112-6-423; GALLUS A, 1983, BRIT J SURG, V70, P17, DOI 10.1002/bjs.1800700106; Gallus A S, 1990, Baillieres Clin Haematol, V3, P651, DOI 10.1016/S0950-3536(05)80023-X; MCKENNA R, 1980, BRIT MED J, V280, P514, DOI 10.1136/bmj.280.6213.514; POLLER L, 1987, BRIT MED J, V295, P1309, DOI 10.1136/bmj.295.6609.1309	5	34	34	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 27	1991	303	6796					224	224		10.1136/bmj.303.6796.224	http://dx.doi.org/10.1136/bmj.303.6796.224			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FZ563	1884060	Bronze, Green Published			2022-12-24	WOS:A1991FZ56300024
J	DIEKMANN, D; BRILL, S; GARRETT, MD; TOTTY, N; HSUAN, J; MONFRIES, C; HALL, C; LIM, L; HALL, A				DIEKMANN, D; BRILL, S; GARRETT, MD; TOTTY, N; HSUAN, J; MONFRIES, C; HALL, C; LIM, L; HALL, A			BCR ENCODES A GTPASE-ACTIVATING PROTEIN FOR P21RAC	NATURE			English	Article							RAS P21; GENE-PRODUCT; ESCHERICHIA-COLI; GAP; LEUKEMIA; DOMAIN; CELLS; CDNA; IDENTIFICATION; INTERACTS	MORE than thirty small guanine nucleotide-binding proteins related to the ras-encoded oncoprotein, termed Ras or p21ras, are known 1. They regulate many fundamental processes in all eukaryotic cells, such as growth, vesicle traffic and cytoskeletal organization. GTPase-activating proteins (GAPs) accelerate the intrinsic rate of GTP hydrolysis of Ras-related proteins, leading to down-regulation of the active GTP-bound form 2. For p21ras, two GAP proteins are known, rasGAP and the neurofibromatosis (NF1) gene product 2-5. There is evidence that rasGAP may also be a target protein for regulation by Ras and be involved in downstream signalling 6-8. We have purified a GAP protein for p21rho, which is involved in the regulation of the actin cytoskeleton 9. Partial sequencing of rhoGAP reveals significant homology with the product of the bcr (breakpoint cluster region) gene, the translocation breakpoint in Philadelphia chromosome-positive chronic myeloid leukaemias. We show here that the carboxy-terminal domains of the bcr-encoded protein (Bcr) and of a Bcr-related protein, n-chimaerin, are both GAP proteins for the Ras-related GTP-binding protein, p21rac. This result suggests that Bcr could be a target for regulation by Rac and has important new implications for the role of bcr translocations in leukaemia.	INST CANC RES,CHESTER BEATTY LABS,237 FULHAM RD,LONDON SW3 6JB,ENGLAND; LUDWIG INST CANC RES,LONDON W1P 8BT,ENGLAND; INST NEUROL,LONDON WC1 1PJ,ENGLAND	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Ludwig Institute for Cancer Research; University of London; University College London			Hall, Christine/C-8390-2009; Hsuan, Justin/C-8825-2009	Hsuan, Justin/0000-0001-6083-7564; Tapon, Dagmar/0000-0003-3837-4764				ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; AMSON RB, 1989, ONCOGENE, V4, P243; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; GARRETT MD, 1989, J BIOL CHEM, V264, P10; GARRETT MD, IN PRESS BIOCH J; GEARING DP, 1989, BIO-TECHNOL, V7, P1157; HALL A, 1986, J BIOL CHEM, V261, P963; HALL A, 1990, SCIENCE, V249, P636; HALL C, 1990, J MOL BIOL, V211, P11, DOI 10.1016/0022-2836(90)90006-8; HARIHARAN IK, 1987, EMBO J, V6, P115, DOI 10.1002/j.1460-2075.1987.tb04727.x; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; KAWASAKI H, 1990, ANAL BIOCHEM, V186, P264, DOI 10.1016/0003-2697(90)90077-M; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; LI WJ, 1989, ONCOGENE, V4, P127; LIFSHITZ B, 1988, ONCOGENE, V2, P113; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; MUNEMITSU S, 1990, MOL CELL BIOL, V10, P5977, DOI 10.1128/MCB.10.11.5977; OTSU M, 1991, CELL, V65, P1; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; TRAHEY M, 1987, MOL CELL BIOL, V7, P541, DOI 10.1128/MCB.7.1.541; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; YATANI A, 1990, CELL, V61, P769, DOI 10.1016/0092-8674(90)90187-J	29	413	424	1	11	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 30	1991	351	6325					400	402		10.1038/351400a0	http://dx.doi.org/10.1038/351400a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FN856	1903516				2022-12-24	WOS:A1991FN85600056
J	HARDING, CV; COLLINS, DS; SLOT, JW; GEUZE, HJ; UNANUE, ER				HARDING, CV; COLLINS, DS; SLOT, JW; GEUZE, HJ; UNANUE, ER			LIPOSOME-ENCAPSULATED ANTIGENS ARE PROCESSED IN LYSOSOMES, RECYCLED, AND PRESENTED TO T-CELLS	CELL			English	Article							PH-SENSITIVE LIPOSOMES; MACROPHAGE ENDOSOMES; PINOCYTOSED FLUID; PROTEIN; ENDOCYTOSIS; EXCHANGE; MEMBRANE; BINDING; PEPTIDE; IA	Antigen processing required intracellular antigen catabolism to generate immunogenic peptides that bind to class II MHC molecules (MHC-II) for presentation to T-cells. We now provide direct evidence that these peptides are produced within dense lysosomes, as opposed to earlier endocytic compartments. The protein antigen hen egg lysozyme was targeted to endosomes or lysosomes by encapsulating it in liposomes of different membrane composition. Acid-sensitive liposomes released their contents in early endosomes, whereas acid-resistant liposomes sequestered their contents from potential endosomal processing events and released their contents only after delivery to lysosomes. Antigen encapsulated in acid-resistant liposomes was processed in a chloroquine-sensitive manner and presented more efficiently than soluble antigen or antigen encapsulated in acid-sensitive liposomes. Thus, peptides may be recycled from lysosomes, transported to endosomes to bind MHC-II, and then expressed at the cell surface.	STATE UNIV UTRECHT, SCH MED, DEPT CELL BIOL, 3584 CX UTRECHT, NETHERLANDS	Utrecht University	HARDING, CV (corresponding author), WASHINGTON UNIV, SCH MED, DEPT PATHOL, ST LOUIS, MO 63110 USA.							ADORINI L, 1989, NATURE, V342, P800, DOI 10.1038/342800a0; ALLEN PM, 1984, J IMMUNOL, V132, P1077; BESTERMAN JM, 1981, J CELL BIOL, V91, P716, DOI 10.1083/jcb.91.3.716; BUCKMASTER MJ, 1987, CELL BIOL INT REP, V11, P501, DOI 10.1016/0309-1651(87)90011-7; COLLINS D, 1989, BIOCHIM BIOPHYS ACTA, V987, P47, DOI 10.1016/0005-2736(89)90453-7; CONNOR J, 1984, P NATL ACAD SCI-BIOL, V81, P1715, DOI 10.1073/pnas.81.6.1715; DALEKE DL, 1990, BIOCHIM BIOPHYS ACTA, V1024, P352, DOI 10.1016/0005-2736(90)90365-U; DIMENT S, 1988, J BIOL CHEM, V263, P6901; DIMENT S, 1985, J BIOL CHEM, V260, P5311; DONERMEYER DL, 1989, J IMMUNOL, V142, P1063; DUZGUNES N, 1985, BIOCHEMISTRY-US, V24, P3091, DOI 10.1021/bi00334a004; FERRIS AL, 1987, J CELL BIOL, V105, P2703, DOI 10.1083/jcb.105.6.2703; GEUZE HJ, 1983, CELL, V32, P277, DOI 10.1016/0092-8674(83)90518-4; GUAGLIARDI LE, 1990, NATURE, V343, P133, DOI 10.1038/343133a0; HARDING CV, 1989, P NATL ACAD SCI USA, V86, P4230, DOI 10.1073/pnas.86.11.4230; HARDING CV, 1990, P NATL ACAD SCI USA, V87, P5553, DOI 10.1073/pnas.87.14.5553; HARDING CV, 1990, CELL REGUL, V1, P499, DOI 10.1091/mbc.1.7.499; HARDING CV, 1990, EUR J IMMUNOL, V20, P323, DOI 10.1002/eji.1830200214; HARDING CV, 1989, J IMMUNOL, V142, P12; LEYVACOBIAN F, 1988, J IMMUNOL, V141, P1445; LIPPINCOTTSCHWARTZ J, 1987, CELL, V49, P669, DOI 10.1016/0092-8674(87)90543-5; MAYORGA LS, 1989, J BIOL CHEM, V264, P5392; MONTE PD, 1989, J IMMUNOL, V142, P1437; MULLER WA, 1983, J CELL BIOL, V96, P29, DOI 10.1083/jcb.96.1.29; ROOF RW, 1990, P NATL ACAD SCI USA, V87, P1735, DOI 10.1073/pnas.87.5.1735; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SLOT JW, 1988, METHOD MICROBIOL, V20, P211, DOI 10.1016/S0580-9517(08)70053-9; STRAUBINGER RM, 1983, CELL, V32, P1069, DOI 10.1016/0092-8674(83)90291-X; STRUCK O, 1981, BIOCHEMISTRY-US, V23, P1532; SWANSON JA, 1985, J CELL BIOL, V100, P851, DOI 10.1083/jcb.100.3.851; VANBUSKIRK A, 1989, J EXP MED, V170, P1799, DOI 10.1084/jem.170.6.1799; YATVIN MB, 1980, SCIENCE, V210, P1253, DOI 10.1126/science.7434025	32	258	264	0	16	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 25	1991	64	2					393	401		10.1016/0092-8674(91)90647-H	http://dx.doi.org/10.1016/0092-8674(91)90647-H			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EV336	1899049				2022-12-24	WOS:A1991EV33600015
J	DIRITA, VJ; MEKALANOS, JJ				DIRITA, VJ; MEKALANOS, JJ			PERIPLASMIC INTERACTION BETWEEN 2 MEMBRANE REGULATORY PROTEINS, TOXR AND TOXS, RESULTS IN SIGNAL TRANSDUCTION AND TRANSCRIPTIONAL ACTIVATION	CELL			English	Article							ESCHERICHIA-COLI; CHOLERA-TOXIN; VIBRIO-CHOLERAE; GENETIC-ANALYSIS; IDENTIFICATION; DETERMINANTS; COLONIZATION	ToxR is a transmembrane, DNA-binding protein that can activate transcription of genes encoding cholera toxin (ctxAB). Here we characterize ToxS, a 19 kd transmembrane regulatory protein that interacts with ToxR and stimulates its activity. If a portion of the periplasmic domain of ToxR is deleted, productive interaction with ToxS is abolished. A ToxR-PhoA fusion protein that retains most of the ToxR periplasmic region remains dependent on ToxS for its ToxR activity. ToxS protects this fusion from proteolytic cleavage, suggesting that these two proteins interact within the periplasm. Mutations in a short cytoplasmic domain of ToxR were isolated that disrupt the periplasmic interaction between ToxR and ToxS. This domain is shared by other bacterial transcriptional activators, suggesting that it may play a common role in function of these proteins and in the molecular mechanism of signal transduction.	HARVARD UNIV,SCH MED,DEPT MICROBIOL & MOLEC GENET,BOSTON,MA 02115	Harvard University; Harvard Medical School				DiRita, Victor/0000-0003-3617-7011	NIAID NIH HHS [AI08050, AI8045] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALBRIGHT LM, 1989, ANNU REV GENET, V23, P311, DOI 10.1146/annurev.ge.23.120189.001523; AMES P, 1988, CELL, V55, P817, DOI 10.1016/0092-8674(88)90137-7; BOYD D, 1987, P NATL ACAD SCI USA, V84, P8525, DOI 10.1073/pnas.84.23.8525; DEGNEN GE, 1974, J BACTERIOL, V117, P477, DOI 10.1128/JB.117.2.477-487.1974; HALL MN, 1981, ANNU REV GENET, V15, P91, DOI 10.1146/annurev.ge.15.120181.000515; HICKMAN RK, 1988, J BACTERIOL, V170, P1715, DOI 10.1128/jb.170.4.1715-1720.1988; HIRST TR, 1987, J BACTERIOL, V169, P1037, DOI 10.1128/jb.169.3.1037-1045.1987; KUSHNER SR, 1987, ESCHERICHIA COLI SAL, P1225; Maniatis T., 1982, MOL CLONING; MANOIL C, 1985, P NATL ACAD SCI USA, V82, P8129, DOI 10.1073/pnas.82.23.8129; Miller J.H., 1972, EXPT MOL GENETICS; MILLER VL, 1984, P NATL ACAD SCI-BIOL, V81, P3471, DOI 10.1073/pnas.81.11.3471; MILLER VL, 1989, J BACTERIOL, V171, P1288, DOI 10.1128/jb.171.3.1288-1293.1989; MILLER VL, 1985, J BACTERIOL, V163, P580, DOI 10.1128/JB.163.2.580-585.1985; MILLER VL, 1987, CELL, V48, P271, DOI 10.1016/0092-8674(87)90430-2; MILLER VL, 1988, J BACTERIOL, V170, P2575, DOI 10.1128/JB.170.6.2575-2583.1988; PETERSON KM, 1988, INFECT IMMUN, V56, P2822, DOI 10.1128/IAI.56.11.2822-2829.1988; SCHLESIN.MJ, 1967, J BIOL CHEM, V242, P1604; Silhavy T.J., 1984, EXPT GENE FUSIONS; STRAUCH KL, 1988, P NATL ACAD SCI USA, V85, P1576, DOI 10.1073/pnas.85.5.1576; TAYLOR RK, 1987, P NATL ACAD SCI USA, V84, P2833, DOI 10.1073/pnas.84.9.2833; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P433	23	164	172	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 11	1991	64	1					29	37		10.1016/0092-8674(91)90206-E	http://dx.doi.org/10.1016/0092-8674(91)90206-E			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ET175	1898871				2022-12-24	WOS:A1991ET17500006
J	SUTHERLAND, GR; GEDEON, A; KORNMAN, L; DONNELLY, A; BYARD, RW; MULLEY, JC; KREMER, E; LYNCH, M; PRITCHARD, M; YU, S; RICHARDS, RI				SUTHERLAND, GR; GEDEON, A; KORNMAN, L; DONNELLY, A; BYARD, RW; MULLEY, JC; KREMER, E; LYNCH, M; PRITCHARD, M; YU, S; RICHARDS, RI			PRENATAL-DIAGNOSIS OF FRAGILE X-SYNDROME BY DIRECT DETECTION OF THE UNSTABLE DNA-SEQUENCE	NEW ENGLAND JOURNAL OF MEDICINE			English	Note									QUEEN VICTORIA HOSP,ADELAIDE,AUSTRALIA; ADELAIDE CHILDRENS HOSP INC,DEPT HISTOPATHOL,ADELAIDE,SA 5006,AUSTRALIA		SUTHERLAND, GR (corresponding author), ADELAIDE CHILDRENS HOSP INC,DEPT CYTOGENET & MOLEC GENET,ADELAIDE,SA 5006,AUSTRALIA.		Sutherland, Grant Robert/D-2606-2012; Kremer, EJ/P-9838-2019; Kremer, Eric J/D-3734-2013; Richards, Robert/ABE-6423-2020; Gedeon, Agi/G-7890-2011	Kremer, EJ/0000-0001-6114-7530; Byard, Roger/0000-0002-0524-5942; Richards, Robert Ian/0000-0002-5978-6453				JENKINS EC, 1991, AM J MED GENET, V38, P447, DOI 10.1002/ajmg.1320380262; KOGAN SC, 1987, NEW ENGL J MED, V317, P985, DOI 10.1056/NEJM198710153171603; KREMER EJ, 1991, SCIENCE, V252, P1711, DOI 10.1126/science.1675488; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; PURVISSMITH SG, 1988, AM J MED GENET, V30, P337, DOI 10.1002/ajmg.1320300134; RICHARDS RI, 1991, AM J HUM GENET, V48, P1051; SHERMAN SL, 1984, ANN HUM GENET, V48, P21, DOI 10.1111/j.1469-1809.1984.tb00830.x; Sutherland G, 1985, FRAGILE SITES HUMAN; SUTHERLAND GR, 1990, CLIN GENET, V37, P2; SUTHERS GK, 1991, AM J HUM GENET, V48, P460; YU S, 1991, SCIENCE, V252, P1179, DOI 10.1126/science.252.5009.1179	11	96	98	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 12	1991	325	24					1720	1722		10.1056/NEJM199112123252407	http://dx.doi.org/10.1056/NEJM199112123252407			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GU418	1944473				2022-12-24	WOS:A1991GU41800007
J	BARTEL, DP; ZAPP, ML; GREEN, MR; SZOSTAK, JW				BARTEL, DP; ZAPP, ML; GREEN, MR; SZOSTAK, JW			HIV-1 REV REGULATION INVOLVES RECOGNITION OF NON-WATSON-CRICK BASE-PAIRS IN VIRAL-RNA	CELL			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; BACTERIOPHAGE-T4 DNA-POLYMERASE; MESSENGER-RNA; TARGET SEQUENCE; RIBOSOMAL-RNA; TRANS-ACTIVATOR; SECONDARY STRUCTURE; RIBONUCLEIC-ACID; XENOPUS OOCYTES; BINDING-SITES	We have used an iterative in vitro genetic selection to identify the important structural features of the viral RNA element bound by the Rev protein of human immunodeficiency virus type 1 (HIV-1). Functional Rev-binding RNAs were selected from a pool of 10(13) variants of the wild-type Rev-binding domain. Bases conserved among the binding species define a 20 nucleotide core binding element. Covariation of some of these conserved bases indicates that the Rev-binding element is a stem-bulge-stem with a G:G base pair in the bulge. Mutational studies show that this non-Watson-Crick base pair is required for Rev binding in vitro and Rev responsiveness in vivo. We propose that the G:G base pair distorts the sugar-phosphate backbone of viral RNA and that this distortion is a critical determinant of recognition by Rev.	UNIV MASSACHUSETTS,MED CTR,PROGRAM MOLEC MED,WORCESTER,MA 01605	University of Massachusetts System; University of Massachusetts Worcester	BARTEL, DP (corresponding author), MASSACHUSETTS GEN HOSP,DEPT MOLEC BIOL,BOSTON,MA 02114, USA.							AMREIN H, 1988, CELL, V55, P1025, DOI 10.1016/0092-8674(88)90247-4; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BROWN BD, 1990, GENE DEV, V4, P1925, DOI 10.1101/gad.4.11.1925; CALNAN BJ, 1991, SCIENCE, V252, P1167, DOI 10.1126/science.252.5009.1167; CAREY J, 1983, BIOCHEMISTRY-US, V22, P2601, DOI 10.1021/bi00280a002; COCHRANE AW, 1990, P NATL ACAD SCI USA, V87, P1198, DOI 10.1073/pnas.87.3.1198; CULLEN BR, 1989, CELL, V58, P423, DOI 10.1016/0092-8674(89)90420-0; DALY TJ, 1989, NATURE, V342, P816, DOI 10.1038/342816a0; DAYTON ET, 1989, SCIENCE, V246, P1625, DOI 10.1126/science.2688093; ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0; EMERMAN M, 1989, CELL, V57, P1155, DOI 10.1016/0092-8674(89)90053-6; FEINBERG MB, 1986, CELL, V46, P807, DOI 10.1016/0092-8674(86)90062-0; FELBER BK, 1989, P NATL ACAD SCI USA, V86, P1495, DOI 10.1073/pnas.86.5.1495; GREEN R, 1990, NATURE, V347, P406, DOI 10.1038/347406a0; GUTELL RR, 1990, P NATL ACAD SCI USA, V87, P663, DOI 10.1073/pnas.87.2.663; HAMMARSKJOLD ML, 1989, J VIROL, V63, P1959; HEAPHY S, 1990, CELL, V60, P685, DOI 10.1016/0092-8674(90)90671-Z; HOLLAND SM, 1990, J VIROL, V64, P5966, DOI 10.1128/JVI.64.12.5966-5975.1990; HOPE TJ, 1990, P NATL ACAD SCI USA, V87, P7787, DOI 10.1073/pnas.87.19.7787; HOPE TJ, 1990, J VIROL, V64, P5360, DOI 10.1128/JVI.64.11.5360-5366.1990; HUANG XJ, 1991, J VIROL, V65, P2131, DOI 10.1128/JVI.65.4.2131-2134.1991; KJEMS J, 1991, P NATL ACAD SCI USA, V88, P683, DOI 10.1073/pnas.88.3.683; LEVITT M, 1969, NATURE, V224, P759, DOI 10.1038/224759a0; LIN YS, 1989, NATURE, V340, P656, DOI 10.1038/340656a0; MALIM MH, 1990, CELL, V60, P675, DOI 10.1016/0092-8674(90)90670-A; MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; OAKES MI, 1990, J MOL BIOL, V211, P907, DOI 10.1016/0022-2836(90)90083-X; OLIPHANT AR, 1989, MOL CELL BIOL, V9, P2944, DOI 10.1128/MCB.9.7.2944; OLSEN HS, 1990, SCIENCE, V247, P845, DOI 10.1126/science.2406903; POLLOCK R, 1990, NUCLEIC ACIDS RES, V18, P6197, DOI 10.1093/nar/18.21.6197; ROBERTSON DL, 1990, NATURE, V344, P467, DOI 10.1038/344467a0; ROSEN CA, 1988, P NATL ACAD SCI USA, V85, P2071, DOI 10.1073/pnas.85.7.2071; SAENGER W, 1984, PRINCIPLES NUCLEIC A; SODROSKI J, 1986, NATURE, V321, P412, DOI 10.1038/321412a0; STERN S, 1988, J MOL BIOL, V201, P683, DOI 10.1016/0022-2836(88)90467-6; SUGIMOTO N, 1987, BIOCHEMISTRY-US, V26, P4554, DOI 10.1021/bi00388a058; THIESEN HJ, 1990, NUCLEIC ACIDS RES, V18, P3203, DOI 10.1093/nar/18.11.3203; TRAUB W, 1982, NUCLEIC ACIDS RES, V10, P2701, DOI 10.1093/nar/10.8.2701; TUERK C, 1990, J MOL BIOL, V213, P749, DOI 10.1016/S0022-2836(05)80261-X; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; TUERK C, 1988, P NATL ACAD SCI USA, V85, P1364, DOI 10.1073/pnas.85.5.1364; WOESE CR, 1983, MICROBIOL REV, V47, P621, DOI 10.1128/MMBR.47.4.621-669.1983; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P8467, DOI 10.1073/pnas.87.21.8467; YISRAELI JK, 1990, DEVELOPMENT, V108, P289; ZAPP ML, 1991, P NATL ACAD SCI USA, V88, P7734, DOI 10.1073/pnas.88.17.7734; ZAPP ML, 1989, NATURE, V342, P714, DOI 10.1038/342714a0	49	373	403	0	15	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 1	1991	67	3					529	536		10.1016/0092-8674(91)90527-6	http://dx.doi.org/10.1016/0092-8674(91)90527-6			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GN664	1934059				2022-12-24	WOS:A1991GN66400009
J	SPITZER, MW; SEMPLE, MN				SPITZER, MW; SEMPLE, MN			INTERAURAL PHASE CODING IN AUDITORY MIDBRAIN - INFLUENCE OF DYNAMIC STIMULUS FEATURES	SCIENCE			English	Article							INFERIOR COLLICULUS; SOUND LOCALIZATION; MOVEMENT ANGLE; NEURONS; CAT; MECHANISMS; FREQUENCY; MOTION	A laterally located sound source stimulates the two ears at slightly different times, generating interaural phase disparities (IPDs) that are used for sound localization. Under natural conditions, such interaural cues are likely to be constantly changing, or dynamic. In the inferior colliculus of gerbils and cats, the nonlinearities in the coding of dynamic interaural phase cues are demonstrated. Responses to ecologically realistic phase cues are more reflective of the change of IPD than of the absolute IPDs over which that change occurs. This observation is inconsistent with the established view that directional information is coded in terms of absolute IPD.			SPITZER, MW (corresponding author), UNIV CALIF IRVINE,DEPT ANAT & NEUROBIOL,IRVINE,CA 92717, USA.				NIDCD NIH HHS [DC00364] Funding Source: Medline	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		ALTMAN JA, 1968, EXP NEUROL, V22, P13, DOI 10.1016/0014-4886(68)90016-2; GOLDBERG JM, 1969, J NEUROPHYSIOL, V32, P613, DOI 10.1152/jn.1969.32.4.613; GRANTHAM DW, 1986, J ACOUST SOC AM, V79, P1939, DOI 10.1121/1.393201; JEFFRESS LA, 1948, J COMP PHYSIOL PSYCH, V41, P35, DOI 10.1037/h0061495; KUWADA S, 1979, SCIENCE, V206, P586, DOI 10.1126/science.493964; Perrott D R, 1979, J Aud Res, V19, P277; PERROTT DR, 1977, J ACOUST SOC AM, V62, P1463, DOI 10.1121/1.381675; PERROTT DR, 1988, J ACOUST SOC AM, V83, P1522, DOI 10.1121/1.395908; REALE RA, 1990, J NEUROPHYSIOL, V64, P1247, DOI 10.1152/jn.1990.64.4.1247; ROSE JE, 1966, J NEUROPHYSIOL, V29, P288, DOI 10.1152/jn.1966.29.2.288; ROTH GL, 1980, J ACOUST SOC AM, V68, P1643, DOI 10.1121/1.385196; STRYBEL TZ, 1989, PERCEPT PSYCHOPHYS, V45, P371, DOI 10.3758/BF03204951; SULLIVAN WE, 1986, BRAIN BEHAV EVOLUT, V28, P109, DOI 10.1159/000118696; YIN TCT, 1990, J NEUROPHYSIOL, V64, P465, DOI 10.1152/jn.1990.64.2.465; YIN TCT, 1983, J NEUROPHYSIOL, V50, P1000, DOI 10.1152/jn.1983.50.4.1000	15	77	80	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 1	1991	254	5032					721	724		10.1126/science.1948053	http://dx.doi.org/10.1126/science.1948053			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GN474	1948053				2022-12-24	WOS:A1991GN47400045
J	WESTWOOD, JT; CLOS, J; WU, C				WESTWOOD, JT; CLOS, J; WU, C			STRESS-INDUCED OLIGOMERIZATION AND CHROMOSOMAL RELOCALIZATION OF HEAT-SHOCK FACTOR	NATURE			English	Article							DNA-BINDING PROPERTIES; DROSOPHILA-MELANOGASTER; TRANSCRIPTION FACTOR; RNA-POLYMERASE; PROTEINS; INVITRO; GENE; ACTIVATION; LOCALIZATION; UPSTREAM	The induction of heat-shock transcription factor (HSF) binding to DNA is accomplished by a heat-induced oligomerization. The transition to the induced state is accompanied by a chromosomal redistribution of HSF to the heat-shock puff sites. Over 150 additional chromosomal sites also accumulate HSF, including developmental loci that are repressed during heat shock. These findings suggest an unforeseen role for HSF as a repressor of normal gene activity during heat stress.			WESTWOOD, JT (corresponding author), NCI, BIOCHEM LAB, BG 37, RM 4C-09, BETHESDA, MD 20892 USA.							AMIN J, 1988, MOL CELL BIOL, V8, P3761, DOI 10.1128/MCB.8.9.3761; ANDERSSON LO, 1972, FEBS LETT, V20, P199, DOI 10.1016/0014-5793(72)80793-2; Ashburner M, 1972, Results Probl Cell Differ, V4, P101; ASHBURNER M, 1970, CHROMOSOMA, V31, P356, DOI 10.1007/BF00321231; BECKER J, 1990, EUR J BIOCHEM, V189, P553, DOI 10.1111/j.1432-1033.1990.tb15522.x; BONNER JJ, 1982, CHROMOSOMA, V85, P93, DOI 10.1007/BF00344596; BONNER JJ, 1976, CELL, V8, P43, DOI 10.1016/0092-8674(76)90183-5; Bridges CB, 1935, J HERED, V26, P60, DOI 10.1093/oxfordjournals.jhered.a104022; BURTIS KC, 1990, CELL, V61, P85, DOI 10.1016/0092-8674(90)90217-3; CLOS J, 1990, CELL, V63, P1085, DOI 10.1016/0092-8674(90)90511-C; DIGNAM AD, 1983, METHOD ENZYMOL, V191, P582; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; HOVEMANN B, 1986, MOL GEN GENET, V204, P334, DOI 10.1007/BF00425519; JAKOBSEN BK, 1991, EMBO J, V10, P369, DOI 10.1002/j.1460-2075.1991.tb07958.x; JAMRICH M, 1977, P NATL ACAD SCI USA, V74, P2079, DOI 10.1073/pnas.74.5.2079; KING WJ, 1984, NATURE, V307, P745, DOI 10.1038/307745a0; LAKHOTIA SC, 1987, J GENET, V66, P139, DOI 10.1007/BF02931660; LARSON JS, 1988, NATURE, V335, P372, DOI 10.1038/335372a0; Lefevre G., 1976, GENET BIOL DROSOPHIL, P31; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; LIS JT, 1981, GENE, V15, P67, DOI 10.1016/0378-1119(81)90105-0; LIS JT, 1981, NUCLEIC ACIDS RES, V9, P5297, DOI 10.1093/nar/9.20.5297; MASON PJ, 1982, J MOL BIOL, V156, P21, DOI 10.1016/0022-2836(82)90456-9; Morimoto RI, 1990, STRESS PROTEINS BIOL; MOSSER DD, 1990, P NATL ACAD SCI USA, V87, P3748, DOI 10.1073/pnas.87.10.3748; PALTER KB, 1986, MOL CELL BIOL, V6, P1187, DOI 10.1128/MCB.6.4.1187; PARDUE ML, 1977, CHROMOSOMA, V63, P135, DOI 10.1007/BF00292726; PARKER CS, 1984, CELL, V36, P357, DOI 10.1016/0092-8674(84)90229-0; PELHAM HRB, 1982, CELL, V30, P517, DOI 10.1016/0092-8674(82)90249-5; PELHAM HRB, 1990, STRESS PROTEINS BIOL, P287; PERISIC O, 1989, CELL, V59, P797, DOI 10.1016/0092-8674(89)90603-X; PERKINS LA, 1990, MOL CELL BIOL, V10, P3232, DOI 10.1128/MCB.10.6.3232; RABINDRAN SK, 1991, P NATL ACAD SCI USA, V88, P6906, DOI 10.1073/pnas.88.16.6906; RITOSSA F, 1962, EXPERIENTIA, V18, P571, DOI 10.1007/BF02172188; SARGE KD, IN PRESS GENES DEV; SCHARF KD, 1990, EMBO J, V9, P4495, DOI 10.1002/j.1460-2075.1990.tb07900.x; SCHUETZ TJ, 1991, P NATL ACAD SCI USA, V88, P6911, DOI 10.1073/pnas.88.16.6911; SEGRAVES WA, 1990, GENE DEV, V4, P204, DOI 10.1101/gad.4.2.204; SILVER LM, 1976, P NATL ACAD SCI USA, V73, P423, DOI 10.1073/pnas.73.2.423; SORGER PK, 1991, CELL, V65, P363, DOI 10.1016/0092-8674(91)90452-5; SORGER PK, 1989, CELL, V59, P807, DOI 10.1016/0092-8674(89)90604-1; SORGER PK, 1988, CELL, V54, P855, DOI 10.1016/S0092-8674(88)91219-6; SPRADLING A, 1977, J MOL BIOL, V109, P559, DOI 10.1016/S0022-2836(77)80091-0; THUMMEL CS, 1990, BIOESSAYS, V12, P561, DOI 10.1002/bies.950121202; URNESS LD, 1990, CELL, V63, P47, DOI 10.1016/0092-8674(90)90287-O; WELSHONS WV, 1984, NATURE, V307, P747, DOI 10.1038/307747a0; WIEDERRECHT G, 1988, CELL, V54, P841, DOI 10.1016/S0092-8674(88)91197-X; WIEDERRECHT G, 1987, CELL, V48, P507, DOI 10.1016/0092-8674(87)90201-7; WU C, 1984, NATURE, V311, P81, DOI 10.1038/311081a0; WU C, 1984, NATURE, V309, P229, DOI 10.1038/309229a0; WU C, 1987, SCIENCE, V238, P1247, DOI 10.1126/science.3685975; WU C, 1985, NATURE, V317, P84, DOI 10.1038/317084a0; WU C, 1990, STRESS PROTEINS BIOL, P429; XIAO H, 1988, SCIENCE, V239, P1139, DOI 10.1126/science.3125608; ZIMARINO V, 1990, SCIENCE, V249, P546, DOI 10.1126/science.2200124; ZINK B, 1989, NATURE, V337, P468, DOI 10.1038/337468a0	56	320	328	0	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 31	1991	353	6347					822	823		10.1038/353822a0	http://dx.doi.org/10.1038/353822a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GM732	1944557				2022-12-24	WOS:A1991GM73200051
J	LEGOUIS, R; HARDELIN, JP; LEVILLIERS, J; CLAVERIE, JM; COMPAIN, S; WUNDERLE, V; MILLASSEAU, P; LEPASLIER, D; COHEN, D; CATERINA, D; BOUGUELERET, L; DELEMARREVANDEWAAL, H; LUTFALLA, G; WEISSENBACH, J; PETIT, C				LEGOUIS, R; HARDELIN, JP; LEVILLIERS, J; CLAVERIE, JM; COMPAIN, S; WUNDERLE, V; MILLASSEAU, P; LEPASLIER, D; COHEN, D; CATERINA, D; BOUGUELERET, L; DELEMARREVANDEWAAL, H; LUTFALLA, G; WEISSENBACH, J; PETIT, C			THE CANDIDATE GENE FOR THE X-LINKED KALLMANN SYNDROME ENCODES A PROTEIN RELATED TO ADHESION MOLECULES	CELL			English	Article							STEROID SULFATASE GENE; AMINO-ACID-SEQUENCE; DISTAL SHORT ARM; IMMUNOGLOBULIN SUPERFAMILY; HYPOGONADOTROPIC HYPOGONADISM; Y-CHROMOSOME; FIBRONECTIN; MEMBER; DELETIONS; BINDING	Kallmann syndrome associates hypogonadotropic hypogonadism and anosmia and is probably due to a defect in the embryonic migration of olfactory and GnRH-synthesizing neurons. The Kallmann gene had been localized to Xp22.3. In this study 67 kb of genomic DNA, corresponding to a deletion interval containing at least part of the Kallmann gene, were sequenced. Two candidate exons, identified by multiparameter computer programs, were found in a cDNA encoding a protein of 679 amino acids. This candidate gene (ADMLX) is interrupted in its 3' coding region in the Kallmann patient, in which the proximal end of the KAL deletion interval was previously defined. A 5' end deletion was detected in another Kallmann patient. The predicted protein sequence shows homologies with the fibronectin type III repeat. ADMLX thus encodes a putative adhesion molecule, consistent with the defect of embryonic neuronal migration.	NIH, NATL LIB MED, NATL CTR BIOTECHNOL INFORMAT, BETHESDA, MD 20892 USA; GENETHON, F-91002 EVRY, FRANCE; CEPH, F-75010 PARIS, FRANCE; FREE UNIV AMSTERDAM HOSP, DEPT PAEDIAT, 1007 MB AMSTERDAM, NETHERLANDS; CNRS, UNITE ONCOL VIRALE, F-94801 VILLEJUIF, FRANCE	National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM); Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Centre National de la Recherche Scientifique (CNRS)	LEGOUIS, R (corresponding author), INST PASTEUR, CNRS, URA 1445, UNITE GENET MOLEC HUMAINE, F-75724 PARIS 15, FRANCE.		Lutfalla, Georges/AAW-9386-2021; Legouis, Renaud/S-1250-2017; Legouis, Renaud/G-9088-2014; Claverie, Jean-Michel/AAG-4889-2019; Claverie, Jean Michel/Z-2183-2019	Legouis, Renaud/0000-0002-2699-2584; Claverie, Jean-Michel/0000-0003-1424-0315; Le Paslier, Denis/0000-0003-4335-9956				ALBERTSEN HM, 1990, P NATL ACAD SCI USA, V87, P4256, DOI 10.1073/pnas.87.11.4256; ALTSCHUL SF, 1991, J MOL BIOL, V219, P555, DOI 10.1016/0022-2836(91)90193-A; ALTSCHUL SF, 1990, P NATL ACAD SCI USA, V87, P5509, DOI 10.1073/pnas.87.14.5509; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANDREWS PW, 1984, DEV BIOL, V103, P285, DOI 10.1016/0012-1606(84)90316-6; ARAKI K, 1989, BIOCHEM BIOPH RES CO, V164, P496, DOI 10.1016/0006-291X(89)91747-6; AURIVILLIUS M, 1990, FEBS LETT, V264, P267, DOI 10.1016/0014-5793(90)80264-J; BAIROCH A, 1991, NUCLEIC ACIDS RES, V19, P2241, DOI 10.1093/nar/19.suppl.2241; BALLABIO A, 1990, GENOMICS, V8, P263, DOI 10.1016/0888-7543(90)90281-X; BALLABIO A, 1989, P NATL ACAD SCI USA, V86, P10001, DOI 10.1073/pnas.86.24.10001; BALLABIO A, 1987, HUM GENET, V77, P338, DOI 10.1007/BF00291422; BELLANNECHANTELOT C, 1991, NUCLEIC ACIDS RES, V19, P505, DOI 10.1093/nar/19.3.505; BENIAN GM, 1989, NATURE, V342, P45, DOI 10.1038/342045a0; BOGUSKI M, 1991, IN PRESS PROTEIN ENG; BOULOUX PM, 1991, IN PRESS NUCL ACIDS; BRUMMENDORF T, 1989, NEURON, V2, P1351, DOI 10.1016/0896-6273(89)90073-1; CHANG S, 1987, J CELL BIOL, V104, P355, DOI 10.1083/jcb.104.2.355; CHAUSSAIN JL, 1988, HORM RES, V29, P202, DOI 10.1159/000181003; CLAVERIE JM, 1990, METHOD ENZYMOL, V183, P237; COULSON A, 1988, GENOME ANAL PRACTICA, P25; COX EC, 1990, NEURON, V4, P31, DOI 10.1016/0896-6273(90)90441-H; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; DAVIES JA, 1990, NEURON, V4, P11, DOI 10.1016/0896-6273(90)90439-M; De Morster G, 1954, SCHWEIZ ARCH NEUROL, V74, P309; DEAR TN, 1991, BIOCHEM BIOPH RES CO, V176, P247, DOI 10.1016/0006-291X(91)90916-U; EDELMAN GM, 1991, ANNU REV BIOCHEM, V60, P155, DOI 10.1146/annurev.bi.60.070191.001103; ERICKSON HP, 1984, NATURE, V311, P267, DOI 10.1038/311267a0; FISCHER G, 1986, J NEUROSCI, V6, P605; FOGERTY FJ, 1990, J CELL BIOL, V111, P699, DOI 10.1083/jcb.111.2.699; FURLEY AJ, 1990, CELL, V61, P157, DOI 10.1016/0092-8674(90)90223-2; GENNARINI G, 1991, NEURON, V6, P595, DOI 10.1016/0896-6273(91)90062-5; GOWER HJ, 1988, CELL, V55, P955, DOI 10.1016/0092-8674(88)90241-3; GRUMET M, 1991, J CELL BIOL, V113, P399; HARRELSON AL, 1988, SCIENCE, V242, P700, DOI 10.1126/science.3187519; HOWLEY PM, 1979, J BIOL CHEM, V254, P4876; JONES FS, 1989, P NATL ACAD SCI USA, V86, P1905, DOI 10.1073/pnas.86.6.1905; Jones J R, 1976, Obstet Gynecol Annu, V5, P443; JONES PCT, 1966, NATURE, V212, P365, DOI 10.1038/212365a0; JUAN AMD, 1856, SIGLO MED, V211; Kallmann FJ, 1944, AM J MENT DEF, V48, P203; KLEIN P, 1986, BIOPOLYMERS, V25, P1659, DOI 10.1002/bip.360250909; KLINGMULLER D, 1987, J CLIN ENDOCR METAB, V65, P581, DOI 10.1210/jcem-65-3-581; KNOWLTON RG, 1989, NUCLEIC ACIDS RES, V17, P423, DOI 10.1093/nar/17.1.423; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LEMMON V, 1989, NEURON, V2, P1597, DOI 10.1016/0896-6273(89)90048-2; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; MALES JL, 1973, ARCH INTERN MED, V131, P501, DOI 10.1001/archinte.131.4.501; MANFIOLETTI G, 1988, NUCLEIC ACIDS RES, V16, P2873, DOI 10.1093/nar/16.7.2873; MARCUS M, 1976, NATURE, V262, P63, DOI 10.1038/262063a0; McKusick VA, 1990, MENDELIAN INHERITANC; MOOS M, 1988, NATURE, V334, P701, DOI 10.1038/334701a0; NELSON DL, 1989, P NATL ACAD SCI USA, V86, P6686, DOI 10.1073/pnas.86.17.6686; NELSON DL, 1991, P NATL ACAD SCI USA, V88, P6157, DOI 10.1073/pnas.88.14.6157; ODERMATT E, 1985, P NATL ACAD SCI USA, V82, P6571, DOI 10.1073/pnas.82.19.6571; Pearson AA, 1941, J COMP NEUROL, V75, P39, DOI 10.1002/cne.900750104; PETIT C, 1990, GENOMICS, V6, P651, DOI 10.1016/0888-7543(90)90500-T; PETIT C, 1988, EMBO J, V7, P2369, DOI 10.1002/j.1460-2075.1988.tb03081.x; PETIT C, 1990, P NATL ACAD SCI USA, V87, P3680, DOI 10.1073/pnas.87.10.3680; RANSCHT B, 1988, J CELL BIOL, V107, P1561, DOI 10.1083/jcb.107.4.1561; RAPER JA, 1990, NEURON, V4, P21, DOI 10.1016/0896-6273(90)90440-Q; RATHJEN FG, 1987, J CELL BIOL, V104, P343, DOI 10.1083/jcb.104.2.343; RONNEKLEIV OK, 1990, ENDOCRINOLOGY, V126, P498, DOI 10.1210/endo-126-1-498; RUEGG MA, 1989, EMBO J, V8, P55, DOI 10.1002/j.1460-2075.1989.tb03348.x; RUTISHAUSER U, 1988, PHYSIOL REV, V68, P819, DOI 10.1152/physrev.1988.68.3.819; Sambrook J., 1989, MOL CLONING LAB MANU; SANTEN RJ, 1973, J CLIN ENDOCR METAB, V36, P47, DOI 10.1210/jcem-36-1-47; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; SCHWANKHAUS JD, 1989, NEUROLOGY, V39, P223, DOI 10.1212/WNL.39.2.223; SCHWANZELFUKUDA M, 1989, MOL BRAIN RES, V6, P311, DOI 10.1016/0169-328X(89)90076-4; SCHWANZELFUKUDA M, 1989, NATURE, V338, P161, DOI 10.1038/338161a0; SENAPATHY P, 1990, METHOD ENZYMOL, V183, P252; SHAPIRO LJ, 1985, ADV HUM GENET, V14, P331; SPARKES RS, 1968, ARCH INTERN MED, V121, P534, DOI 10.1001/archinte.121.6.534; STADEN R, 1982, NUCLEIC ACIDS RES, V10, P141, DOI 10.1093/nar/10.1.141; STADEN R, 1987, NUCLEIC ACID PROTEIN, P173; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; TIEPOLO L, 1980, HUM GENET, V54, P205, DOI 10.1007/BF00278973; Ulrich A., 1985, NATURE, V313, P756; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WEGENKE JD, 1975, CLIN GENET, V7, P368; WEISSENBACH J, 1989, CYTOGENET CELL GENET, V51, P438, DOI 10.1159/000132802; WHITE BJ, 1983, AM J MED GENET, V15, P417, DOI 10.1002/ajmg.1320150307; WIEDOW O, 1990, J BIOL CHEM, V265, P14791; WRAY S, 1989, P NATL ACAD SCI USA, V86, P8132, DOI 10.1073/pnas.86.20.8132; YEN PH, 1988, CELL, V55, P1123, DOI 10.1016/0092-8674(88)90257-7; YEN PH, 1990, CELL, V61, P603, DOI 10.1016/0092-8674(90)90472-Q	86	564	578	0	33	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 18	1991	67	2					423	435		10.1016/0092-8674(91)90193-3	http://dx.doi.org/10.1016/0092-8674(91)90193-3			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GL470	1913827				2022-12-24	WOS:A1991GL47000021
J	LEVY, F; GABATHULER, R; LARSSON, R; KVIST, S				LEVY, F; GABATHULER, R; LARSSON, R; KVIST, S			ATP IS REQUIRED FOR INVITRO ASSEMBLY OF MHC CLASS-I ANTIGENS BUT NOT FOR TRANSFER OF PEPTIDES ACROSS THE ER MEMBRANE	CELL			English	Article							TOXIC LYMPHOCYTES-T; MAJOR HISTOCOMPATIBILITY COMPLEX; CHAIN BINDING-PROTEIN; HLA-B ANTIGENS; H-2-DEFICIENT LYMPHOMA VARIANTS; ENDOPLASMIC-RETICULUM; INFLUENZA NUCLEOPROTEIN; LYMPHOBLASTOID CELLS; MULTIDRUG RESISTANCE; SYNTHETIC PEPTIDES	We have translated the HLA-B27 heavy chain in vitro and studied its assembly with beta-2-microglobulin and peptide in microsomes from human cells. The assembly process requires ATP. However, the translocation of peptide across the endoplasmic reticulum (ER) membrane does not require ATP, and binding of biotinylated peptide to BiP, an ER luminal protein, occurs after ATP depletion. Proteinase K treatment of the microsomes does not block peptide translocation. Thus, ATP is required in the lumen of the ER for efficient assembly to occur. Microsomes prepared from Raji and T1 cells show similar levels of assembly, whereas assembly in T2 microsomes is 10-fold lower. This difference remains after peptide stimulation of assembly. The inefficient assembly in T2 microsomes is not due to impaired peptide translocation across the ER membrane, as no difference was found compared with microsomes from T1 cells. Instead, the defect seems to reside in the lumen of the ER.			LEVY, F (corresponding author), LUDWIG INST CANC RES,BOX 60202,S-10401 STOCKHOLM,SWEDEN.							ARCEGOMEZ B, 1978, TISSUE ANTIGENS, V11, P96, DOI 10.1111/j.1399-0039.1978.tb01233.x; BARINAGA M, 1990, SCIENCE, V250, P1657, DOI 10.1126/science.2270477; BARNSTABLE CJ, 1978, CELL, V14, P9, DOI 10.1016/0092-8674(78)90296-9; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BLIGHT MA, 1990, MOL MICROBIOL, V4, P873, DOI 10.1111/j.1365-2958.1990.tb00660.x; BODMER HC, 1989, NATURE, V337, P653, DOI 10.1038/337653a0; BRACIALE TJ, 1987, J EXP MED, V166, P678, DOI 10.1084/jem.166.3.678; BURGERT HG, 1985, CELL, V41, P987, DOI 10.1016/S0092-8674(85)80079-9; CERUNDOLO V, 1990, NATURE, V345, P449, DOI 10.1038/345449a0; CLAYBERGER C, 1987, NATURE, V330, P763, DOI 10.1038/330763a0; DEGEN E, 1991, J CELL BIOL, V112, P1099, DOI 10.1083/jcb.112.6.1099; DEMARS R, 1985, P NATL ACAD SCI USA, V82, P8183, DOI 10.1073/pnas.82.23.8183; DEMARS R, 1984, HUM IMMUNOL, V11, P77, DOI 10.1016/0198-8859(84)90047-8; DEVERSON EV, 1990, NATURE, V348, P738, DOI 10.1038/348738a0; ELLIOTT TJ, 1990, P NATL ACAD SCI USA, V87, P5213, DOI 10.1073/pnas.87.13.5213; FALK K, 1990, NATURE, V348, P248, DOI 10.1038/348248a0; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; GAROFF H, 1978, J MOL BIOL, V124, P587, DOI 10.1016/0022-2836(78)90173-0; GOTCH F, 1987, NATURE, V326, P881, DOI 10.1038/326881a0; HAAS IG, 1983, NATURE, V306, P387, DOI 10.1038/306387a0; HUET S, 1990, INT IMMUNOL, V2, P311, DOI 10.1093/intimm/2.4.311; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; JACKSON RJ, 1983, METHOD ENZYMOL, V96, P50; KARRE K, 1986, NATURE, V319, P675, DOI 10.1038/319675a0; KASSENBROCK CK, 1988, NATURE, V333, P90, DOI 10.1038/333090a0; KETTLUN AM, 1982, PHYTOCHEMISTRY, V21, P551, DOI 10.1016/0031-9422(82)83139-7; KLAR D, 1989, EMBO J, V8, P475, DOI 10.1002/j.1460-2075.1989.tb03400.x; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; KVIST S, 1982, CELL, V29, P61, DOI 10.1016/0092-8674(82)90090-3; KVIST S, 1990, NATURE, V348, P446, DOI 10.1038/348446a0; LJUNGGREN HG, 1985, J EXP MED, V162, P1745, DOI 10.1084/jem.162.6.1745; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; LURQUIN C, 1989, CELL, V58, P293, DOI 10.1016/0092-8674(89)90844-1; MARYANSKI JL, 1986, NATURE, V324, P578, DOI 10.1038/324578a0; MCMICHAEL AJ, 1988, P NATL ACAD SCI USA, V85, P9194, DOI 10.1073/pnas.85.23.9194; MONACO JJ, 1990, SCIENCE, V250, P1723, DOI 10.1126/science.2270487; MOORE MW, 1988, CELL, V54, P777, DOI 10.1016/S0092-8674(88)91043-4; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; NIXON DF, 1988, NATURE, V336, P484, DOI 10.1038/336484a0; NUCHTERN JG, 1989, NATURE, V339, P223, DOI 10.1038/339223a0; OLDSTONE MBA, 1988, J EXP MED, V168, P559, DOI 10.1084/jem.168.2.559; PARHAM P, 1990, NATURE, V346, P793, DOI 10.1038/346793a0; PARHAM P, 1990, NATURE, V348, P674, DOI 10.1038/348674a0; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; PELHAM HRB, 1989, EMBO J, V8, P3171, DOI 10.1002/j.1460-2075.1989.tb08475.x; PLOEGH HL, 1979, P NATL ACAD SCI USA, V76, P2273, DOI 10.1073/pnas.76.5.2273; REDDEHASE MJ, 1989, NATURE, V337, P651, DOI 10.1038/337651a0; ROTHBARD JB, 1988, EMBO J, V7, P93, DOI 10.1002/j.1460-2075.1988.tb02787.x; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; SALTER RD, 1986, EMBO J, V5, P943, DOI 10.1002/j.1460-2075.1986.tb04307.x; SALTER RD, 1985, IMMUNOGENETICS, V21, P235, DOI 10.1007/BF00375376; SARASTE J, 1986, P NATL ACAD SCI USA, V83, P6425, DOI 10.1073/pnas.83.17.6425; SCHUMACHER TNM, 1990, CELL, V62, P563, DOI 10.1016/0092-8674(90)90020-F; SHIMIZU Y, 1986, MOL CELL BIOL, V6, P1074, DOI 10.1128/MCB.6.4.1074; SIMON SM, 1991, CELL, V65, P671; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; TAYLOR PM, 1987, IMMUNOGENETICS, V26, P267, DOI 10.1007/BF00346521; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X; TOWNSEND ARM, 1985, CELL, V42, P457, DOI 10.1016/0092-8674(85)90103-5; TRAVERSOCORI A, 1970, ARCH BIOCHEM BIOPHYS, V137, P133, DOI 10.1016/0003-9861(70)90420-0; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; VANBLEEK GM, 1990, NATURE, V348, P213; VANBUSKIRK A, 1989, J EXP MED, V170, P1799, DOI 10.1084/jem.170.6.1799; WALLNY HJ, 1990, NATURE, V343, P275, DOI 10.1038/343275a0; YEWDELL JW, 1989, SCIENCE, V244, P1072, DOI 10.1126/science.2471266	70	94	108	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 18	1991	67	2					265	274		10.1016/0092-8674(91)90178-2	http://dx.doi.org/10.1016/0092-8674(91)90178-2			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GL470	1913823				2022-12-24	WOS:A1991GL47000006
J	MURRELL, J; FARLOW, M; GHETTI, B; BENSON, MD				MURRELL, J; FARLOW, M; GHETTI, B; BENSON, MD			A MUTATION IN THE AMYLOID PRECURSOR PROTEIN ASSOCIATED WITH HEREDITARY ALZHEIMERS-DISEASE	SCIENCE			English	Article							GERSTMANN-STRAUSSLER SYNDROME; PRION PROTEIN; CYSTATIN-C; GENE; INHIBITOR; CDNA; LINKAGE; VARIANT; LOCUS	Alzheimer's disease is a form of localized amyloidosis characterized by cerebral cortical amyloid plaques, neurofibrillary tangles, and amyloid deposits within the walls of leptomeningeal vessels. Although most cases of Alzheimer's disease are sporadic, kindreds with autosomal-dominant inheritance of the syndrome suggest that a single mutation may be important in pathogenesis. Direct sequencing of DNA from a family with autopsy-proven Alzheimer's disease revealed a single amino acid substitution (Phe for Val) in the transmembrane domain of the amyloid precursor protein. This mutation correlates with the presence of Alzheimer's disease in all patients in this study, and may be the inherited factor causing both amyloid fibril formation and dementia.	INDIANA UNIV,SCH MED,DEPT MED,INDIANAPOLIS,IN 46202; INDIANA UNIV,SCH MED,DEPT MED & MOLEC GENET,INDIANAPOLIS,IN 46202; INDIANA UNIV,SCH MED,DEPT NEUROL,INDIANAPOLIS,IN 46202; INDIANA UNIV,SCH MED,DEPT PATHOL,INDIANAPOLIS,IN 46202; VET AFFAIRS RICHARD L ROUDEBUSH MED CTR,INDIANAPOLIS,IN 46202	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; US Department of Veterans Affairs; Veterans Health Administration (VHA); Richard L. Roudebush VA Medical Center					NCRR NIH HHS [RR-00750] Funding Source: Medline; NIA NIH HHS [U24 AG021886] Funding Source: Medline; PHS HHS [34881, 42111] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000750] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [U24AG021886] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Benson MD, 1989, METABOLIC BASIS INHE, P2439; CHRISTMANSON L, 1990, AMYLOID AMYLOIDOSIS, P635; DOHURA K, 1989, BIOCHEM BIOPH RES CO, V163, P974, DOI 10.1016/0006-291X(89)92317-6; GHISO J, 1986, P NATL ACAD SCI USA, V83, P2974, DOI 10.1073/pnas.83.9.2974; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V122, P1131, DOI 10.1016/0006-291X(84)91209-9; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GOLDGABER D, 1987, SCIENCE, V235, P877, DOI 10.1126/science.3810169; GYLLENSTEN UB, 1988, P NATL ACAD SCI USA, V85, P7652, DOI 10.1073/pnas.85.20.7652; HSIAO K, 1989, NATURE, V338, P342, DOI 10.1038/338342a0; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KITAGUCHI N, 1990, BIOCHIM BIOPHYS ACTA, V1038, P105, DOI 10.1016/0167-4838(90)90017-A; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; LEMAIRE HG, 1989, NUCLEIC ACIDS RES, V17, P517, DOI 10.1093/nar/17.2.517; LEVY E, 1989, J EXP MED, V169, P1771, DOI 10.1084/jem.169.5.1771; MURRELL JN, UNPUB; NARUSE S, 1991, LANCET, V337, P978, DOI 10.1016/0140-6736(91)91612-X; NICHOLS WC, 1990, GENOMICS, V8, P318, DOI 10.1016/0888-7543(90)90288-6; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; ROBAKIS NK, 1987, P NATL ACAD SCI USA, V84, P4190, DOI 10.1073/pnas.84.12.4190; SCHELLENBERG GD, 1991, AM J HUM GENET, V48, P563; TAGLIAVINI F, 1991, EMBO J, V10, P513, DOI 10.1002/j.1460-2075.1991.tb07977.x; TANZI RE, 1987, NATURE, V329, P156, DOI 10.1038/329156a0; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; VAN BROECKHOVEN C, 1987, NATURE, V329, P153; VITEK MP, 1988, MOL BRAIN RES, V4, P121, DOI 10.1016/0169-328X(88)90004-6; YOSHIKAI S, 1990, GENE, V87, P257, DOI 10.1016/0378-1119(90)90310-N	28	988	1089	0	53	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 4	1991	254	5028					97	99		10.1126/science.1925564	http://dx.doi.org/10.1126/science.1925564			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GH605	1925564				2022-12-24	WOS:A1991GH60500036
J	PADMORE, R; CAO, L; KLECKNER, N				PADMORE, R; CAO, L; KLECKNER, N			TEMPORAL COMPARISON OF RECOMBINATION AND SYNAPTONEMAL COMPLEX-FORMATION DURING MEIOSIS IN SACCHAROMYCES-CEREVISIAE	CELL			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; DROSOPHILA-MELANOGASTER FEMALES; MEIOTIC GENE CONVERSION; DOUBLE-STRAND BREAKS; CHROMOSOME SYNAPSIS; WILD-TYPE; INITIATION SITE; CROSSING-OVER; CELL-CYCLE; SEGREGATION	In synchronous cultures of S. cerevisiae undergoing meiosis, an early event in the meiotic recombination pathway, site-specific double strand breaks (DSBs), occurs early in prophase, in some instances well before tripartite synaptonemal complex (SC) begins to form. This observation, together with previous results, supports the view that events involving DSBs are required for SC formation. We discuss the possibility that the mitotic pathway for recombinational repair of DSBs served as the primordial mechanism for connecting homologous chromosomes during the evolution of meiosis. DSBs disappear during the period when tripartite SC structure is forming and elongating (zygotene); presumably, they are converted to another type of recombination intermediate. Neither DSBs nor mature recombinant molecules are present when SCs are full length (pachytene). Mature reciprocally recombinant molecules arise at the end of or just after pachytene. We suggest that the SC might coordinate recombinant maturation with other events of meiosis.			PADMORE, R (corresponding author), HARVARD UNIV, DEPT BIOCHEM & MOLEC BIOL, CAMBRIDGE, MA 02138 USA.		Cao, Liang/K-7806-2017	Cao, Liang/0000-0001-7293-8338	NIGMS NIH HHS [GM44794] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS AEM, 1984, J CELL BIOL, V98, P934, DOI 10.1083/jcb.98.3.934; ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; ALANI E, 1990, CELL, V61, P419, DOI 10.1016/0092-8674(90)90524-I; ALBINI SM, 1987, CHROMOSOMA, V95, P324, DOI 10.1007/BF00293179; BAILEY NTJ, 1981, STATISTICAL METHODS, P24; BAKER BS, 1976, ANNU REV GENET, V10, P53, DOI 10.1146/annurev.ge.10.120176.000413; BELL LR, 1982, COLD SPRING HARB SYM, V47, P829, DOI 10.1101/SQB.1983.047.01.095; BORTS RH, 1984, COLD SPRING HARB SYM, V49, P67, DOI 10.1101/SQB.1984.049.01.010; Bridges CB, 1925, GENETICS, V10, P418; BYERS B, 1975, P NATL ACAD SCI USA, V72, P5056, DOI 10.1073/pnas.72.12.5056; BYERS B, 1973, COLD SPRING HARB SYM, V38, P123, DOI 10.1101/SQB.1974.038.01.016; Byers B, 1981, MOL BIOL YEAST SACCH, P59; CAO L, 1990, CELL, V61, P1089, DOI 10.1016/0092-8674(90)90072-M; CARPENTER ATC, 1987, BIOESSAYS, V6, P232, DOI 10.1002/bies.950060510; CARPENTER ATC, 1981, CHROMOSOMA, V83, P59, DOI 10.1007/BF00286016; CARPENTER ATC, 1979, GENETICS, V92, P511; CARPENTER ATC, 1975, P NATL ACAD SCI USA, V72, P3186, DOI 10.1073/pnas.72.8.3186; COMINGS DE, 1970, NATURE, V227, P451, DOI 10.1038/227451a0; COMINGS DE, 1971, NATURE, V233, P48, DOI 10.1038/233048a0; DAVIDOW LS, 1984, GENETICS, V106, P165; DONAHUE TF, 1982, GENE, V18, P47, DOI 10.1016/0378-1119(82)90055-5; DRESSER ME, 1988, J CELL BIOL, V106, P567, DOI 10.1083/jcb.106.3.567; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; EGEL R, 1978, HEREDITY, V41, P233, DOI 10.1038/hdy.1978.92; ENGEBRECHT J, 1990, CELL, V62, P927, DOI 10.1016/0092-8674(90)90267-I; ENGEBRECHT J, 1990, MOL CELL BIOL, V10, P2379, DOI 10.1128/MCB.10.5.2379; Esposito R. E., 1981, MOL BIOL YEAST SACCH, V11, P211; FARNET C, 1988, UCLA S MOL CELL BIOL, V83, P201; FINK GR, 1984, NATURE, V310, P728, DOI 10.1038/310728a0; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GIROUX CN, 1989, GENOME, V31, P88, DOI 10.1139/g89-017; GIROUX CN, 1988, GENETIC RECOMBINATIO, P465; Hawley R.S., 1988, GENETIC RECOMBINATIO, P497; HENDERSON SA, 1970, ANNU REV GENET, V4, P295, DOI 10.1146/annurev.ge.04.120170.001455; HOLLIDAY R, 1977, PHILOS T R SOC B, V277, P359, DOI 10.1098/rstb.1977.0024; HOLLINGSWORTH NM, 1990, CELL, V61, P73, DOI 10.1016/0092-8674(90)90216-2; HORESH O, 1979, CHROMOSOMA, V75, P101, DOI 10.1007/BF00330628; Howard-Flanders P, 1968, Adv Biol Med Phys, V12, P299; HOWARDFL.P, 1968, ANNU REV BIOCHEM, V37, P175, DOI 10.1146/annurev.bi.37.070168.001135; HUTTER KJ, 1979, J GEN MICROBIOL, V113, P369, DOI 10.1099/00221287-113-2-369; JACKSON JA, 1985, GENETICS, V109, P303; JONES G H, 1987, P213; JONES GH, 1984, CONTROLLING EVENTS M, P293; KANE SM, 1974, J BACTERIOL, V118, P8, DOI 10.1128/JB.118.1.8-14.1974; KILMARTIN JV, 1984, J CELL BIOL, V98, P922, DOI 10.1083/jcb.98.3.922; KING JS, 1990, GENETICS, V126, P1127; King R. C., 1970, Int. Rev. Cytol., V28, P125, DOI 10.1016/S0074-7696(08)62542-5; KLECKNER N, 1991, IN PRESS COLD SPRING, V56; KOLODKIN AL, 1986, CELL, V46, P733, DOI 10.1016/0092-8674(86)90349-1; KUROIWA T, 1984, EXP CELL RES, V153, P259, DOI 10.1016/0014-4827(84)90469-5; MAGUIRE MP, 1978, EXP CELL RES, V112, P297, DOI 10.1016/0014-4827(78)90213-6; MAGUIRE MP, 1977, PHILOS T R SOC B, V277, P245, DOI 10.1098/rstb.1977.0015; MOENS PB, 1971, J CELL BIOL, V50, P344, DOI 10.1083/jcb.50.2.344; MOENS PB, 1969, CHROMOSOMA, V28, P1, DOI 10.1007/BF00325986; Moses M. J., 1968, Annual Review of Genetics, V2, P363, DOI 10.1146/annurev.ge.02.120168.002051; MOSES MJ, 1969, GENETICS, V61, P41; MOSES MJ, 1984, CONTROLLING EVENTS M, P245; MURRAY AW, 1985, ANNU REV CELL BIOL, V1, P289, DOI 10.1146/annurev.cellbio.1.1.289; NICOLAS A, 1989, NATURE, V338, P35, DOI 10.1038/338035a0; OLSON LW, 1978, MOL GEN GENET, V166, P151, DOI 10.1007/BF00285917; PERKINS DD, 1949, GENETICS, V34, P607; PETERSON JB, 1976, J CELL SCI, V22, P219; PETES TD, 1991, IN PRESS MOL BIOL YE; RASMUSSEN SW, 1986, CARLSBERG RES COMMUN, V51, P401, DOI 10.1007/BF02907315; RASMUSSEN SW, 1984, CONTROLLING EVENTS M, P271; RESNICK M A, 1987, P157; Rhoades MM., 1968, REPLICATION RECOMBIN, P229; ROCKMILL B, 1990, GENETICS, V126, P563; ROEDER GS, 1990, TRENDS GENET, V6, P385, DOI 10.1016/0168-9525(90)90297-J; ROMAN H, 1990, GENETICS, V124, P7; ROSE M, 1984, GENE, V29, P113, DOI 10.1016/0378-1119(84)90172-0; Sherman F., 1983, METHODS YEAST GENETI; SHUSTER EO, 1989, GENETICS, V123, P29; SMITHIES O, 1986, PHILOS T ROY SOC B, V312, P291, DOI 10.1098/rstb.1986.0008; SOLARI AJ, 1970, CHROMOSOMA, V31, P217, DOI 10.1007/BF00326080; SOLARI AJ, 1981, INT CELL BIOL 1980 1, P178; STERN H, 1987, P303; STERN H, 1975, P NATL ACAD SCI USA, V72, P961, DOI 10.1073/pnas.72.3.961; SUN H, 1991, CELL, V64, P1155, DOI 10.1016/0092-8674(91)90270-9; SUN H, 1989, NATURE, V338, P87, DOI 10.1038/338087a0; UEKI K, 1981, J GEN APPL MICROBIOL, V27, P1, DOI 10.2323/jgam.27.1; VONWETTSTEIN D, 1984, ANNU REV GENET, V18, P331, DOI 10.1146/annurev.ge.18.120184.001555; WANG HT, 1987, MOL CELL BIOL, V7, P1425, DOI 10.1128/MCB.7.4.1425; WILDENBERG J, 1970, GENETICS, V66, P291; WILLIAMSON DH, 1983, EXP CELL RES, V145, P209, DOI 10.1016/S0014-4827(83)80022-6; ZICKLER D, 1975, CHROMOSOMA, V50, P1; ZICKLER D, 1977, CHROMOSOMA, V61, P289, DOI 10.1007/BF00288615; ZOLAN ME, 1988, GENETICS, V120, P379	88	389	392	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 20	1991	66	6					1239	1256		10.1016/0092-8674(91)90046-2	http://dx.doi.org/10.1016/0092-8674(91)90046-2			18	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GG552	1913808				2022-12-24	WOS:A1991GG55200018
J	LLOYD, A; YANCHEVA, N; WASYLYK, B				LLOYD, A; YANCHEVA, N; WASYLYK, B			TRANSFORMATION SUPPRESSOR ACTIVITY OF A JUN TRANSCRIPTION FACTOR LACKING ITS ACTIVATION DOMAIN	NATURE			English	Article							C-JUN; GENE; EXPRESSION; CELLS	THE oncoprotein c-Jun is thought to be a mediator of ras transformation as both its synthesis and activity as a transcription factor are stimulated by ras expression 1,2. But c-Jun co-operates with ras in transformation assays 3, suggesting that they act along different pathways (reviewed in ref. 4). Here we show by means of a dominant-negative mutated transcription factor that c-Jun potentially in conjunction with other factors that interact with it is necessary for transformation by ras. The mutant Jun lacks an activation domain and blocks stimulation of transcription by several oncoproteins, including Ras, v-Src, polyoma middle T, c-Jun and c-Fos, as well as by the tumour promoter 12-O-tetradecanoylphorbol-13-acetate (TPA). The inhibition is specific for motifs that bind Jun: activation of an NF-kappa B/Rel motif is not affected. This Jun mutant acts as an anti-oncogene in ras-transformed cells, generating non-transformed revertants that have acquired anchorage and density-dependent growth, as well as reduced tumorigenicity in vivo. Mutants of other transcription factors designed to inhibit transformation will enable us to study their role in signal transduction.	FAC MED STRASBOURG,INST CHIM BIOL,CNRS,GENET MOLEC EUCARYOTES LAB,INSERM,U184,11 RUE HUMANN,F-67085 STRASBOURG,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			Wasylyk, Bohdan/ABG-6778-2020	Wasylyk, Bohdan/0000-0002-1718-1237				BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; GUTMAN A, 1991, TRENDS GENET, V7, P49, DOI 10.1016/0168-9525(91)90231-E; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; IMLER JL, 1988, NATURE, V332, P275, DOI 10.1038/332275a0; Kane S E, 1990, Semin Cancer Biol, V1, P127; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; LEDWITH BJ, 1990, MOL CELL BIOL, V10, P1545, DOI 10.1128/MCB.10.4.1545; MERCOLA D, 1988, GENE, V72, P253, DOI 10.1016/0378-1119(88)90151-5; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; NODA M, 1989, P NATL ACAD SCI USA, V86, P162, DOI 10.1073/pnas.86.1.162; RIABOWOL KT, 1988, MOL CELL BIOL, V8, P1670, DOI 10.1128/MCB.8.4.1670; SCHNEIKERT J, 1991, NUCLEIC ACIDS RES, V19, P783, DOI 10.1093/nar/19.4.783; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SISTONEN L, 1989, EMBO J, V8, P815, DOI 10.1002/j.1460-2075.1989.tb03442.x; WASYLYK C, 1989, EMBO J, V8, P3371, DOI 10.1002/j.1460-2075.1989.tb08500.x	17	181	184	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 15	1991	352	6336					632	638		10.1038/352635a0	http://dx.doi.org/10.1038/352635a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GB211	1907719				2022-12-24	WOS:A1991GB21100060
J	GILL, GV; ALBERTI, KGMM				GILL, GV; ALBERTI, KGMM			OUTCOME OF BRITTLE DIABETES	BRITISH MEDICAL JOURNAL			English	Article									UNIV NEWCASTLE UPON TYNE,SCH MED,DEPT MED,NEWCASTLE TYNE NE2 4HH,ENGLAND	Newcastle University - UK	GILL, GV (corresponding author), WALTON HOSP,CTR DIABET,LIVERPOOL L9 1AE,MERSEYSIDE,ENGLAND.							DORMAN JS, 1984, DIABETES, V33, P271, DOI 10.2337/diabetes.33.3.271; GILL GV, 1981, DIABETOLOGIA, V21, P507; Pirart J., 1978, DIABETES CARE, V1, P168, DOI 10.2337/diacare.1.3.168; TATTERSALL R, 1991, BRIT MED J, V302, P1240, DOI 10.1136/bmj.302.6787.1240; WILLIAMS G, 1988, DIABETES RES CLIN EX, V7, P13	5	10	11	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 3	1991	303	6797					285	286		10.1136/bmj.303.6797.285	http://dx.doi.org/10.1136/bmj.303.6797.285			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FZ721	1888928	Bronze, Green Published			2022-12-24	WOS:A1991FZ72100020
J	HUNTLEY, ME; LOPEZ, MDG; KARL, DM				HUNTLEY, ME; LOPEZ, MDG; KARL, DM			TOP PREDATORS IN THE SOUTHERN-OCEAN - A MAJOR LEAK IN THE BIOLOGICAL CARBON PUMP	SCIENCE			English	Article							MARGINAL ICE-ZONE; PHYTOPLANKTON GROWTH; WEDDELL SEA; AUTUMN	Primary productivity in the Southern Ocean is approximately 3.5 gigatons of carbon per year, which accounts for nearly 15 percent of the global total. The presence of high concentrations of nitrate in Antarctic waters suggests that it might be possible to increase primary production significantly and thereby alleviate the net accumulation of atmospheric carbon dioxide. An analysis of the food web for these waters implies that the Southern Ocean may be remarkably inefficient as a carbon sink. This inefficiency is caused by the large flux of carbon respired to the atmosphere by air-breathing birds and mammals, dominant predators in the unusually simple food web of Antarctic waters. These top predators may transfer into the atmosphere as much as 20 to 25 percent of photosynthetically fixed carbon.	UNIV HAWAII,SCH OCEAN & EARTH SCI & TECHNOL,HONOLULU,HI 96822	University of Hawaii System	HUNTLEY, ME (corresponding author), UNIV CALIF SAN DIEGO,SCRIPPS INST OCEANOG,LA JOLLA,CA 92093, USA.		Karl, David/AFP-3837-2022	Karl, David/0000-0002-6660-6721				BERGER WH, 1989, PRODUCTIVITY OCEAN P, P1; BROWN SG, 1984, ANTARCT ECOL, V2, P717; Conover R.J., 1978, Marine Ecology (London), V4, P221; CONOVER RJ, IN PRESS J MAR SYSTE; COTA GF, 1990, DEEP-SEA RES, V37, P1145, DOI 10.1016/0198-0149(90)90056-2; CROXALL JP, 1984, ANTARCT ECOL, V2, P533; DUCKLOW H, 1988, PROTOZOA THEIR ROLE, P431; EPPLEY RW, 1979, NATURE, V282, P677, DOI 10.1038/282677a0; Everson I., 1984, ANTARCT ECOL, V1, P783; Gordon AL, 1982, SO OCEAN ATLAS; HUMPHREYS WF, 1979, J ANIM ECOL, V48, P427, DOI 10.2307/4171; HUNTLEY ME, IN PRESS DEEP SEA RE; KARL DM, IN PRESS DEEP SEA RE; KARL DM, 1990, DEEP-SEA RES, V37, P1145; Kawamura A., 1970, Scient. Rep. Whales Res. Inst., Tokyo, VNo. 22, P127; Knox G. A., 1970, ANTARCT ECOL, V1, P69; LANCELOT C, 1989, BELGIAN SCI RES PROG, V1; Laws R.M., 1984, P621; LAWS RM, 1985, AM SCI, V73, P26; LWAS RM, 1984, ANTARCTIC ECOLOGY, V2; MARTIN JH, 1988, NATURE, V331, P341, DOI 10.1038/331341a0; Martin JH, 1990, PALEOCEANOGRAPHY, V5, P1, DOI 10.1029/PA005i001p00001; Redfield A. C, 1963, SEA, P26, DOI DOI 10.1016/J.ORGGEOCHEM.2014.06.002; Ricklefs RE, 1973, ECOLOGY; Romankevich E. A., 1984, GEOCHEMISTRY ORGANIC; SMETACEK V, COMMUNICATION; SMITH WO, 1990, LIMNOL OCEANOGR, V35, P809, DOI 10.4319/lo.1990.35.4.0809; SMITH WO, 1988, ANTARCTIC OCEAN RESO, P131, DOI DOI 10.1007/978-3-642-73724-4_10; Sundquist E.T., 1985, GEOPHYS MONOGR SER, V32, P5; TANS PP, 1990, SCIENCE, V247, P1431, DOI 10.1126/science.247.4949.1431; VERNET M, IN PRESS ANTARCT J U; VEZINA AF, 1989, MAR ECOL-PROG SER, V42, P269	32	87	88	2	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 5	1991	253	5015					64	66		10.1126/science.1905841	http://dx.doi.org/10.1126/science.1905841			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FV177	1905841				2022-12-24	WOS:A1991FV17700033
J	SIMON, SM; BLOBEL, G				SIMON, SM; BLOBEL, G			A PROTEIN-CONDUCTING CHANNEL IN THE ENDOPLASMIC-RETICULUM	CELL			English	Article							SIGNAL RECOGNITION PARTICLE; NUCLEAR-ENVELOPE PERMEABILITY; IMMUNOGLOBULIN LIGHT-CHAINS; NASCENT POLYPEPTIDES; ROUGH MICROSOMES; MEMBRANE; TRANSLOCATION; SEQUENCE; PREPROLACTIN; RECEPTOR	The existence of a protein-conducting channel in the endoplasmic reticulum membrane was demonstrated by electrophysiological techniques. Pancreatic rough microsome (RM) vesicles were fused to one side (cis) of a planar lipid bilayer separating two aqueous compartments of 50 mM salt. This exposed the cytoplasmic surface of the RMs, with its attached ribosomes, to the cis chamber. Addition of 100-mu-M puromycin to the cis side caused a large increase in membrane conductance, presumably the result of puromycin-induced clearance of nascent protein chains from the lumen of protein-conducting channels. When puromycin was added at low concentrations (0.33-mu-M), single channels of 220 pS were observed. These closed when the salt concentration was raised to levels at which ribosomes detach from the membrane (150-400 mM), indicating that the attached ribosome keeps the channel in an open conformation. A mechanism for a complete cycle of opening and closing of the protein-conducting channel is suggested.			SIMON, SM (corresponding author), ROCKEFELLER UNIV, HOWARD HUGHES MED INST, CELL BIOL LAB, NEW YORK, NY 10021 USA.			Simon, Sanford/0000-0002-8615-4224				ADELMAN MR, 1973, J CELL BIOL, V56, P206, DOI 10.1083/jcb.56.1.206; ARMSTRON.CM, 1969, J GEN PHYSIOL, V54, P553, DOI 10.1085/jgp.54.5.553; ARMSTRONG CM, 1977, J GEN PHYSIOL, V70, P567, DOI 10.1085/jgp.70.5.567; ARMSTRONG CM, 1971, J GEN PHYSIOL, V58, P413, DOI 10.1085/jgp.58.4.413; BLIGHT MA, 1990, MOL MICROBIOL, V4, P873, DOI 10.1111/j.1365-2958.1990.tb00660.x; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; Blobel G., 1971, BIOMEMBRANE, P193; BRECHER AS, 1969, BIOCHEM J, V112, P335, DOI 10.1042/bj1120335; BRIGGS MS, 1986, SCIENCE, V233, P206, DOI 10.1126/science.2941862; CHOU MM, 1990, J BIOL CHEM, V265, P2873; CONNOLLY T, 1989, J CELL BIOL, V108, P299, DOI 10.1083/jcb.108.2.299; CONNOLLY T, 1989, CELL, V57, P599, DOI 10.1016/0092-8674(89)90129-3; CORNELL DG, 1989, BIOCHEMISTRY-US, V28, P2789, DOI 10.1021/bi00433a008; DEVERSON EV, 1990, NATURE, V348, P738, DOI 10.1038/348738a0; DWORETZKY SI, 1988, J CELL BIOL, V107, P1279, DOI 10.1083/jcb.107.4.1279; DWORETZKY SI, 1988, J CELL BIOL, V106, P575, DOI 10.1083/jcb.106.3.575; ENGELMAN DM, 1981, CELL, V23, P411, DOI 10.1016/0092-8674(81)90136-7; EVANS EA, 1986, P NATL ACAD SCI USA, V83, P581, DOI 10.1073/pnas.83.3.581; GIERASCH LM, 1989, BIOCHEMISTRY-US, V28, P923, DOI 10.1021/bi00429a001; GILMORE R, 1983, CELL, V35, P677, DOI 10.1016/0092-8674(83)90100-9; GILMORE R, 1985, CELL, V42, P497, DOI 10.1016/0092-8674(85)90107-2; GILSON L, 1990, EMBO J, V9, P3875, DOI 10.1002/j.1460-2075.1990.tb07606.x; HERSH LB, 1981, J NEUROCHEM, V36, P1594, DOI 10.1111/j.1471-4159.1981.tb00605.x; HEYER EJ, 1976, J GEN PHYSIOL, V67, P703, DOI 10.1085/jgp.67.6.703; Hille B, 1984, IONIC CHANNELS EXCIT; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; JIANG LW, 1986, J CELL BIOL, V102, P853, DOI 10.1083/jcb.102.3.853; KILLIAN JA, 1990, EMBO J, V9, P815, DOI 10.1002/j.1460-2075.1990.tb08178.x; KRIEG UC, 1986, P NATL ACAD SCI USA, V83, P8604, DOI 10.1073/pnas.83.22.8604; KRIEG UC, 1989, J CELL BIOL, V109, P2033, DOI 10.1083/jcb.109.5.2033; KUCHLER K, 1989, EMBO J, V8, P3973, DOI 10.1002/j.1460-2075.1989.tb08580.x; KURZCHALIA TV, 1986, NATURE, V320, P634, DOI 10.1038/320634a0; LAKE JA, 1985, ANNU REV BIOCHEM, V54, P507, DOI 10.1146/annurev.biochem.54.1.507; MARCHAIS D, 1979, J PHYSIOL-LONDON, V297, P9, DOI 10.1113/jphysiol.1979.sp013025; MCGRATH JP, 1989, NATURE, V340, P400, DOI 10.1038/340400a0; MILSTEIN C, 1972, NATURE-NEW BIOL, V239, P117, DOI 10.1038/newbio239117a0; MUELLER P, 1963, J PHYS CHEM-US, V67, P534, DOI 10.1021/j100796a529; MUELLER P, 1962, NATURE, V194, P979, DOI 10.1038/194979a0; MUELLER P, 1969, LABORATORY TECHNIQUE, P141; MULLINS LJ, 1959, J GEN PHYSIOL, V42, P817, DOI 10.1085/jgp.42.4.817; NESMEYANOVA MA, 1989, FEBS LETT, V257, P203, DOI 10.1016/0014-5793(89)81534-0; NILES WD, 1987, J GEN PHYSIOL, V90, P703, DOI 10.1085/jgp.90.5.703; PAINE PL, 1975, NATURE, V254, P109, DOI 10.1038/254109a0; PERARA E, 1985, J CELL BIOL, V101, P2292, DOI 10.1083/jcb.101.6.2292; Pestka S, 1974, Methods Enzymol, V30, P261; PETERS R, 1983, J BIOL CHEM, V258, P1427; PORITZ MA, 1990, SCIENCE, V250, P1111, DOI 10.1126/science.1701272; REDMAN CM, 1966, P NATL ACAD SCI USA, V56, P608, DOI 10.1073/pnas.56.2.608; SABATINI DD, 1970, J CELL BIOL, V45, P146, DOI 10.1083/jcb.45.1.146; SAVITZ AJ, 1990, NATURE, V346, P540, DOI 10.1038/346540a0; SCHWARZ W, 1977, BIOPHYS J, V20, P343, DOI 10.1016/S0006-3495(77)85554-9; SHAW AS, 1988, P NATL ACAD SCI USA, V85, P7592, DOI 10.1073/pnas.85.20.7592; SIMON SM, 1989, P NATL ACAD SCI USA, V86, P6176, DOI 10.1073/pnas.86.16.6176; SINGER SJ, 1987, P NATL ACAD SCI USA, V84, P1960, DOI 10.1073/pnas.84.7.1960; SINGER SJ, 1990, ANNU REV CELL BIOL, V6, P247, DOI 10.1146/annurev.cb.06.110190.001335; SIUTAMANGANO P, 1981, J BIOL CHEM, V256, P2094; SKOGERSON L, 1968, ARCH BIOCHEM BIOPHYS, V125, P497, DOI 10.1016/0003-9861(68)90607-3; SUSZKIW JB, 1970, BIOCHEMISTRY-US, V9, P4008, DOI 10.1021/bi00822a021; TRAUT RR, 1964, J MOL BIOL, V10, P63, DOI 10.1016/S0022-2836(64)80028-0; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; VANHELDEN D, 1977, NATURE, V269, P711, DOI 10.1038/269711a0; VONHEIJNE G, 1979, EUR J BIOCHEM, V97, P175; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WALTER P, 1984, CELL, V38, P5, DOI 10.1016/0092-8674(84)90520-8; WICKNER W, 1980, SCIENCE, V210, P861, DOI 10.1126/science.7001628; WIEDMANN M, 1987, NATURE, V328, P830, DOI 10.1038/328830a0; WIEDMANN M, 1989, FEBS LETT, V257, P263, DOI 10.1016/0014-5793(89)81549-2; WOODBURY DJ, 1990, BIOPHYS J, V58, P833, DOI 10.1016/S0006-3495(90)82429-2; YAMAMOTO Y, 1990, BIOCHEMISTRY-US, V29, P8998, DOI 10.1021/bi00490a017; YONATH A, 1987, SCIENCE, V236, P813, DOI 10.1126/science.3576200; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520	72	526	545	3	27	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 3	1991	65	3					371	380		10.1016/0092-8674(91)90455-8	http://dx.doi.org/10.1016/0092-8674(91)90455-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FK182	1902142				2022-12-24	WOS:A1991FK18200004
J	MORRIS, F; TORDOFF, SG; WALLIS, D; SKINNER, DV				MORRIS, F; TORDOFF, SG; WALLIS, D; SKINNER, DV			CARDIOPULMONARY-RESUSCITATION SKILLS OF PREREGISTRATION HOUSE OFFICERS - 5 YEARS ON	BRITISH MEDICAL JOURNAL			English	Article									ST BARTHOLOMEWS HOSP,DEPT ANAESTHESIA,LONDON EC1A 7BE,ENGLAND	University of London; Queen Mary University London	MORRIS, F (corresponding author), ST BARTHOLOMEWS HOSP,DEPT ACCID & EMERGENCY,LONDON EC1A 7BE,ENGLAND.							BASKETT PJF, 1985, BRIT MED J, V290, P1531, DOI 10.1136/bmj.290.6481.1531; CASEY WF, 1984, J ROY SOC MED, V77, P921, DOI 10.1177/014107688407701105; CURRY L, 1987, CAN MED ASSOC J, V137, P491; SKINNER DV, 1985, BRIT MED J, V290, P1549, DOI 10.1136/bmj.290.6481.1549; 1987, J R COLL PHYSICIANS, V21, P175	5	34	35	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 16	1991	302	6777					626	627		10.1136/bmj.302.6777.626	http://dx.doi.org/10.1136/bmj.302.6777.626			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FC071	1878021	Green Published, Bronze			2022-12-24	WOS:A1991FC07100022
J	HILLNER, BE; SMITH, TJ				HILLNER, BE; SMITH, TJ			EFFICACY AND COST-EFFECTIVENESS OF ADJUVANT CHEMOTHERAPY IN WOMEN WITH NODE-NEGATIVE BREAST-CANCER - A DECISION-ANALYSIS MODEL	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BONE-MARROW TRANSPLANTATION; THERAPY; SURVIVAL; CARCINOMA	Background. In 1988 the National Cancer Institute issued a Clinical Alert that has been widely interpreted as recommending that all women with node-negative breast cancer receive adjuvant chemotherapy. Acceptance of this recommendation is controversial, since many women who would not have a recurrence would be treated. Methods. Using a decision-analysis model, we studied the cost effectiveness of chemotherapy in cohorts of 45-year-old and 60-year-old women with node-negative breast cancer by calculating life expectancy as adjusted for quality of life. The analysis evaluated different scenarios of the benefit of therapy: improved disease-free survival for five years, with a lesser effect on overall survival (base line); a lifelong benefit from chemotherapy; and a benefit in disease-free survival with no change in overall survival by year 10. The base-line analysis assumed a 30 percent reduction in the relative risk of recurrence for five years after treatment. Results. For the 45-year-old woman, the base-line analysis found an average lifetime benefit from chemotherapy of 5.1 quality-months at a cost of $15,400 per quality-year. The 60-year-old women gained 4.0 quality months at a cost of $18,800 per quality-year. Under the more and less optimistic scenarios, the benefit of chemotherapy varied from 1.4 to 14.0 quality-months for both groups. Conclusions. Chemotherapy substantially increases the quality-adjusted life expectancy of an average woman at a cost comparable to that of other widely accepted therapies. This benefit decreases markedly if the changes in long-term survival are less than in disease-free survival. Given its uncertain duration, the benefit may be too small for many women to choose chemotherapy. Selective use of chemotherapy to maximize the benefit to individual patients may be possible with refinements in risk stratification and explicit assessment of the patients' risk preferences.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,MASSEY CANC CTR,JOHN N DALTON ONCOL CLIN,RICHMOND,VA 23298	Virginia Commonwealth University	HILLNER, BE (corresponding author), VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT MED,DIV GEN INTERNAL MED,BOX 170,MCV STN,RICHMOND,VA 23298, USA.		Hillner, Bruce/A-6852-2009	Smith, Thomas/0000-0003-3040-6434				BAKER MS, 1989, CANCER CARE AND COST, P127; BECK JR, 1983, MED DECIS MAKING, V3, P419, DOI 10.1177/0272989X8300300403; BONADONNA G, 1987, SEMIN ONCOL, V14, P8; BONADONNA G, 1989, J CLIN ONCOL, V7, P1380, DOI 10.1200/JCO.1989.7.10.1380; CARTER CL, 1989, CANCER-AM CANCER SOC, V63, P181, DOI 10.1002/1097-0142(19890101)63:1<181::AID-CNCR2820630129>3.0.CO;2-H; CLARK GM, 1989, NEW ENGL J MED, V320, P627, DOI 10.1056/NEJM198903093201003; DETSKY AS, 1989, JAMA-J AM MED ASSOC, V262, P1795, DOI 10.1001/jama.262.13.1795; DEVITA VT, 1989, NEW ENGL J MED, V320, P527, DOI 10.1056/NEJM198902233200812; DURBIN M, 1988, PEDIATRICS, V82, P774; EDELSON JT, 1990, JAMA-J AM MED ASSOC, V263, P407, DOI 10.1001/jama.263.3.407; FISHER B, 1989, NEW ENGL J MED, V320, P473, DOI 10.1056/NEJM198902233200801; FISHER B, 1975, SURG GYNECOL OBSTET, V140, P528; FISHER ER, 1986, NATL CANCER I MONOGR, V1, P29; Fletcher RH, 1988, CLIN EPIDEMIOLOGY ES, V2nd; GINSBURG AD, 1989, CAN MED ASSOC J, V141, P381; GOLDSMITH M, 1987, ONCOLOGY, V1, P54; HENDERSON IC, 1987, J CLIN ONCOL, V5, P1135, DOI 10.1200/JCO.1987.5.8.1135; HENDERSON IC, 1987, SEMIN ONCOL, V14, P34; HENDERSON IC, 1988, NEW ENGL J MED, V318, P443, DOI 10.1056/NEJM198802183180709; HILLNER BE, 1986, AM J MED, V80, P1115, DOI 10.1016/0002-9343(86)90674-1; INGLE JN, 1990, NEW ENGL J MED, V322, P329, DOI 10.1056/NEJM199002013220511; MANSOUR EG, 1989, NEW ENGL J MED, V320, P485, DOI 10.1056/NEJM198902233200803; MCGUIRE WL, 1990, J NATL CANCER I, V82, P1006, DOI 10.1093/jnci/82.12.1006; MCGUIRE WL, 1989, NEW ENGL J MED, V320, P525, DOI 10.1056/NEJM198902233200811; MULLEY AG, 1989, MED CARE, V27, pS269, DOI 10.1097/00005650-198903001-00021; NELSON E C, 1989, Medical Care (Philadelphia), V27, pS77, DOI 10.1097/00005650-198903001-00007; NORTON L, 1985, SEMIN ONCOL, V12, P231; PAUKER SG, 1987, NEW ENGL J MED, V316, P250, DOI 10.1056/NEJM198701293160505; ROSEN PP, 1989, J CLIN ONCOL, V7, P355, DOI 10.1200/JCO.1989.7.3.355; SILVERBERG E, 1990, CA-CANCER J CLIN, V40, P9, DOI 10.3322/canjclin.40.1.9; SIMES RJ, 1989, P AN M AM SOC CLIN, V8, P52; SIMINOFF LA, 1989, J CLIN ONCOL, V7, P1192, DOI 10.1200/JCO.1989.7.9.1192; Sox HC, 1988, MED DECISION MAKING; STANGE PV, 1978, NEW ENGL J MED, V298, P372, DOI 10.1056/NEJM197802162980705; SULKES A, 1979, J NATL CANCER I, V62, P513, DOI 10.1093/jnci/62.3.513; TANNOCK IF, 1989, NEW ENGL J MED, V321, P471; TSEVAT J, 1989, MED DECIS MAKING, V9, P162, DOI 10.1177/0272989X8900900303; WEINSTEIN MC, 1982, CIRCULATION, V66, P56; Weinstein MC, 1980, CLIN DECISION ANAL; WEINSTEIN ND, 1989, SCIENCE, V246, P1232, DOI 10.1126/science.2686031; WELCH HG, 1989, NEW ENGL J MED, V321, P807, DOI 10.1056/NEJM198909213211207; [No title captured]; 1989, STATISTICAL ABSTRACT, P73; 1988, CLIN ALERT; 1985, JAMA-J AM MED ASSOC, V254, P3461; 1988, NEW ENGL J MED, V319, P1681; 1989, NEW ENGL J MED, V320, P491	47	193	194	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 17	1991	324	3					160	168		10.1056/NEJM199101173240305	http://dx.doi.org/10.1056/NEJM199101173240305			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ER471	1898533				2022-12-24	WOS:A1991ER47100005
J	GAHRTON, G; TURA, S; LJUNGMAN, P; BELANGER, C; BRANDT, L; CAVO, M; FACON, T; GRANENA, A; GORE, M; GRATWOHL, A; LOWENBERG, B; NIKOSKELAINEN, J; REIFFERS, JJ; SAMSON, D; VERDONCK, L; VOLIN, L				GAHRTON, G; TURA, S; LJUNGMAN, P; BELANGER, C; BRANDT, L; CAVO, M; FACON, T; GRANENA, A; GORE, M; GRATWOHL, A; LOWENBERG, B; NIKOSKELAINEN, J; REIFFERS, JJ; SAMSON, D; VERDONCK, L; VOLIN, L			ALLOGENEIC BONE-MARROW TRANSPLANTATION IN MULTIPLE-MYELOMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; STEM-CELL TRANSPLANTATION; HIGH-DOSE CHEMOTHERAPY; TOTAL-BODY IRRADIATION; 1ST REMISSION; GRAFT; MELPHALAN; SURVIVAL	Background and Methods. In contrast to autologous bone marrow transplants for hematologic cancers, allogeneic transplants contain no tumor cells that might cause a relapse. We report the results of such allogeneic bone marrow transplantation using HLA-compatible sibling donors in 90 patients with multiple myeloma performed in 26 European centers between 1983 and 1989. Results. At the time of the most recent follow-up, 79 months after the start of the study, 47 patients were alive and 43 were dead. The rate of complete remission after bone marrow transplantation was 43 percent for all patients and 58 percent for the patients who had engraftment. The actuarial survival at 76 months was 40 percent. The median duration of relapse-free survival among patients who were in complete remission after bone marrow transplantation was 48 months. The stage of the disease at diagnosis and the number of treatment regimens tried before bone marrow transplantation were predictive of the likelihood of complete remission after engraftment. There were trends toward longer survival among patients who were responsive to treatment before bone marrow transplantation, patients with Stage I disease at diagnosis, and patients who had received only first-line treatment before transplantation, as compared with those who were not responsive, those with Stage II or III disease at diagnosis, and those who had received three or more lines of treatment, but the differences in these factors were not statistically significant. Two post-transplantation factors predicted better long-term survival: complete remission after engraftment and grade I graft-versus-host disease, rather than grade II, III, or IV. Conclusions. Allogeneic bone marrow transplantation with the use of HLA-matched sibling donors appears to be a promising method of treatment for some patients with multiple myeloma.	KAROLINSKA INST, S-14186 HUDDINGE, SWEDEN; HOSP SAN ORSOLA, DEPT HEMATOL, BOLOGNA, ITALY; HOP COCHIN, DEPT HEMATOL, F-75674 PARIS 14, FRANCE; HOSP CLAUDE HURIEZ, SERV MALAD SANG, LILLE, FRANCE; CLIN HOSP BARCELONA, SCH HEMATOL, BARCELONA, SPAIN; ROYAL MARSDEN HOSP, INST CANC RES, LONDON, ENGLAND; UNIV HOSP BASEL, DEPT INTERNAL MED, DIV HEMATOL, CH-4031 BASEL, SWITZERLAND; DR DANIEL DENHOED CANC CTR, ROTTERDAM, NETHERLANDS; UNIV TURKU, DEPT MED, SF-20500 TURKU 50, FINLAND; CTR FRANCOIS MAGENDIE, SERV MALAD SANG, PESSAC, FRANCE; CHARING CROSS HOSP, DEPT HAEMATOL, LONDON W6 8RP, ENGLAND; STATE UNIV UTRECHT HOSP, DEPT HEMATOL, 3511 GV UTRECHT, NETHERLANDS; UNIV HELSINKI, DEPT MED 3, SF-00100 HELSINKI 10, FINLAND	Karolinska Institutet; IRCCS Azienda Ospedaliero-Universitaria di Bologna; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Universite de Lille - ISITE; CHU Lille; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of Basel; Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute; University of Turku; CHU Bordeaux; Imperial College London; Utrecht University; Utrecht University Medical Center; University of Helsinki	GAHRTON, G (corresponding author), HUDDINGE HOSP, DEPT MED, S-14186 HUDDINGE, SWEDEN.		CAVO, MICHELE/AAK-8274-2020	CAVO, MICHELE/0000-0003-4514-3227				ALEXANIAN R, 1969, J AMER MED ASSOC, V208, P1680, DOI 10.1001/jama.208.9.1680; ALEXANIAN R, 1991, AM J CLIN ONCOL-CANC, V14, P188, DOI 10.1097/00000421-199106000-00003; ANDERSON K, 1989, BLOOD S, V474, pA202; ANDERSON KC, 1991, BLOOD, V77, P712; APPERLEY JF, 1988, BRIT J HAEMATOL, V69, P239, DOI 10.1111/j.1365-2141.1988.tb07628.x; BARLOGIE B, 1987, BLOOD, V70, P869; BARLOGIE B, 1986, BLOOD, V67, P1298; BARLOGIE B, 1991, BONE MARROW TRANSPL, V7, P71; BUCKNER CD, 1989, EUR J HAEMATOL, V43, P186; DURIE BGM, 1975, CANCER, V36, P842, DOI 10.1002/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U; FERMAND JP, 1989, BLOOD, V73, P20; FRIEDENBERG WR, 1991, AM J HEMATOL, V36, P171, DOI 10.1002/ajh.2830360303; GAHRTON G, 1989, BONE MARROW TRANSPL, V4, P4; GAHRTON G, 1989, EUR J HAEMATOL, V43, P182; GAHRTON G, 1988, HEMATOL ONCOL, V6, P181, DOI 10.1002/hon.2900060219; GAHRTON G, 1986, ACTA MED SCAND, V219, P523; GAHRTON G, 1990, Bone Marrow Transplantation, V5, P2; GOBBI M, 1989, EUR J HAEMATOL, V43, P176; GOLDMAN JM, 1986, NEW ENGL J MED, V314, P202, DOI 10.1056/NEJM198601233140403; GOLDSTONE AH, 1986, BRIT J HAEMATOL, V64, P529, DOI 10.1111/j.1365-2141.1986.tb02209.x; GORIN NC, 1990, BLOOD, V75, P1606; HOROWITZ MM, 1990, BLOOD, V75, P555; JAGANNATH S, 1990, BLOOD, V76, P1860; KOEFFLER HP, 1981, NEW ENGL J MED, V304, P1201, DOI 10.1056/NEJM198105143042004; LOWENBERG B, 1984, CANCER, V54, P2840, DOI 10.1002/1097-0142(19841215)54:12<2840::AID-CNCR2820541204>3.0.CO;2-4; MANDELLI F, 1990, NEW ENGL J MED, V322, P1430, DOI 10.1056/NEJM199005173222005; MCELWAIN TJ, 1983, LANCET, V2, P822; MELLSTEDT H, 1989, EUR J HAEMATOL, V43, P124; OSTERBORG A, 1989, EUR J HAEMATOL, V43, P54; PALVA IP, 1990, EUR J HAEMATOL, V44, P120; REECE DE, 1989, BLOOD S, V74, pA202; REIFFERS J, 1989, LANCET, V2, P1336; REIFFERS J, 1989, BRIT J HAEMATOL, V72, P296, DOI 10.1111/j.1365-2141.1989.tb07705.x; SELBY PJ, 1987, BRIT J HAEMATOL, V66, P55, DOI 10.1111/j.1365-2141.1987.tb06890.x; SPORN JR, 1986, SEMIN ONCOL, V13, P318; THOMAS ED, 1977, BLOOD, V49, P511; THOMAS ED, 1986, ANN INTERN MED, V104, P155, DOI 10.7326/0003-4819-104-2-155; TURA S, 1986, SCAND J HAEMATOL, V36, P176; VENTURA GJ, 1990, BONE MARROW TRANSPL, V5, P265; WEIDEN PL, 1981, NEW ENGL J MED, V304, P1529, DOI 10.1056/NEJM198106183042507; YEAGER AM, 1986, NEW ENGL J MED, V315, P141, DOI 10.1056/NEJM198607173150301	41	344	355	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 31	1991	325	18					1267	1273		10.1056/NEJM199110313251802	http://dx.doi.org/10.1056/NEJM199110313251802			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GM041	1922221	Green Published			2022-12-24	WOS:A1991GM04100002
J	REPRESA, J; LEON, Y; MINER, C; GIRALDEZ, F				REPRESA, J; LEON, Y; MINER, C; GIRALDEZ, F			THE INT-2 PROTOONCOGENE IS RESPONSIBLE FOR INDUCTION OF THE INNER-EAR	NATURE			English	Article							CHICK-EMBRYO; SEQUENCE	THE int-2 proto-oncogene encodes several products related to the fibroblast growth factor (FGF) family 1,2. FGFs have been associated with mesoderm induction in the amphibian embryo 2,3 and int-2 has a distinct pattern of expression throughout development in vertebrates 4,5. But evidence for a function of int-2 in embryo-genesis has been lacking. In the mouse embryo, int-2 transcripts have been detected in the rhombencephalon at a developmental stage where classical experiments showed that the induction of the inner ear occurs 6,7. This raises the possibility that int-2 may constitute a signal for the induction of the otic vesicle, the primordium of the inner ear. We provide direct evidence for this view by showing that (1) the formation of the otic vesicle is inhibited by antisense oligonucleotides targeted to the secreted form of int-2, and by antibodies against int-2 oncoproteins, and (2) basic FGF (bFGF) can mimic the inductive signal in the absence of the rhombencephalon.	FAC MED VALLADOLID,DEPT BIOQUIM & BIOL MOLEC & FISIOL,E-47005 VALLADOLID,SPAIN; FAC MED VALLADOLID,DEPT CIENCIAS MORFOL,E-47005 VALLADOLID,SPAIN				Leon, Yolanda/ABG-6797-2020; Giraldez, Fernando/C-9821-2014	Leon Alvarez, Yolanda/0000-0002-4536-8373				ACLAND P, 1990, NATURE, V343, P662, DOI 10.1038/343662a0; ALVAREZ IS, 1990, ANAT RECORD, V228, P315, DOI 10.1002/ar.1092280311; DODGSON JB, 1983, J BIOL CHEM, V258, P2685; GIRALDEZ F, 1987, DEVELOPMENT, V100, P271; Gospodarowicz D, 1990, Curr Top Dev Biol, V24, P57, DOI 10.1016/S0070-2153(08)60084-8; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; LUMSDEN AGS, 1983, NATURE, V306, P786, DOI 10.1038/306786a0; MOORE R, 1986, EMBO J, V5, P919, DOI 10.1002/j.1460-2075.1986.tb04304.x; REPRESA J, 1990, DEVELOPMENT, V110, P1081; SCHOENWOLF GC, 1990, DEVELOPMENT, V109, P243; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; Waddington CH, 1937, J EXP BIOL, V14, P232; WILKINSON DG, 1989, DEVELOPMENT, V105, P131; WILKINSON DG, 1988, EMBO J, V7, P691, DOI 10.1002/j.1460-2075.1988.tb02864.x	14	163	164	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 10	1991	353	6344					561	563		10.1038/353561a0	http://dx.doi.org/10.1038/353561a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GJ643	1922362				2022-12-24	WOS:A1991GJ64300068
J	BLACKWELL, CC; JAMES, VS; DAVIDSON, S; WYLD, R; BRETTLE, RP; ROBERTSON, RJ; WEIR, DM				BLACKWELL, CC; JAMES, VS; DAVIDSON, S; WYLD, R; BRETTLE, RP; ROBERTSON, RJ; WEIR, DM			SECRETOR STATUS AND HETEROSEXUAL TRANSMISSION OF HIV	BRITISH MEDICAL JOURNAL			English	Article									CITY HOSP EDINBURGH,INFECT DIS UNIT,EDINBURGH EH10 5SB,MIDLOTHIAN,SCOTLAND; MUIRHOUSE MED GRP,EDINBURGH,SCOTLAND		BLACKWELL, CC (corresponding author), UNIV EDINBURGH,SCH MED,DEPT MED MICROBIOL,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BLACKWELL C C, 1989, FEMS (Federation of European Microbiological Societies) Microbiology Immunology, V47, P341, DOI 10.1016/0378-1097(89)90256-5; BLACKWELL CC, 1989, P ROYAL COLLEGE PHYS, V19, P129; RAZA MW, 1991, BMJ-BRIT MED J, V303, P815, DOI 10.1136/bmj.303.6806.815; 1989, BMJ, V298, P411	4	16	17	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 5	1991	303	6806					825	826		10.1136/bmj.303.6806.825-a	http://dx.doi.org/10.1136/bmj.303.6806.825-a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GH946	1932975	Green Published, Bronze			2022-12-24	WOS:A1991GH94600026
J	GALLAGHER, G; MACKAY, I				GALLAGHER, G; MACKAY, I			DOCTORS AND DROPS	BRITISH MEDICAL JOURNAL			English	Article									CHARING CROSS HOSP,LONDON W6 8RP,ENGLAND	Imperial College London								CHALTON R, 1985, BRIT MED J, V291, P788, DOI 10.1136/bmj.291.6498.788; STAMMBERGER H, 1986, OTOLARYNG HEAD NECK, V94, P143, DOI 10.1177/019459988609400202	2	11	11	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 28	1991	303	6805					761	761		10.1136/bmj.303.6805.761	http://dx.doi.org/10.1136/bmj.303.6805.761			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG981	1932938	Green Published, Bronze			2022-12-24	WOS:A1991GG98100023
J	CHAVKIN, W				CHAVKIN, W			MANDATORY TREATMENT FOR DRUG-USE DURING PREGNANCY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CIVIL COMMITMENT; INTERVENTIONS; RETENTION; ADDICTION		COLUMBIA UNIV,SCH PUBL HLTH,NEW YORK,NY 10027	Columbia University	CHAVKIN, W (corresponding author), BETH ISRAEL MED CTR,INST CHEM DEPENDENCY,1ST AVE & 16TH ST,NEW YORK,NY 10003, USA.							Allen A E, 1990, Womens Health Issues, V1, P37, DOI 10.1016/S1049-3867(05)80014-3; ANGLIN MD, 1988, RES MONOGRAPH SERIES, P8; BARRY E, 1989, HARVARD WOM LAW J, V12, P198; BENARIES O, 1986, INT J LAW PSYCHIAT, V8, P31; BESCHNER G, 1981, RES MONOGRAPH SERIES; BROWN BS, 1988, J DRUG ISSUES, V18, P663, DOI 10.1177/002204268801800410; BROWN SS, 1991, CHILDREN PARENTAL IL; CHASNOFF IJ, 1990, NEW ENGL J MED, V322, P1202, DOI 10.1056/NEJM199004263221706; Chavkin W, 1990, J Am Med Womens Assoc (1972), V45, P55; CHAVKIN W, 1990, AM J PUBLIC HEALTH, V80, P483, DOI 10.2105/AJPH.80.4.483; CHAVKIN W, 1991, J CLIN ETHICS, V1, P140; CHAVKIN W, 1991, EVALUATIVE STUDY EFF; DELEON G, 1988, RES MONOGRAPH SERIES, P160; FAMULARO R, 1989, CHILD ABUSE NEGLECT, V13, P507, DOI 10.1016/0145-2134(89)90054-9; FIZEK LS, 1988, EMPLOYEE ASSISTANCE, V4, P31; FOSTERCOOK L, 1988, RES MONOGRAPH SERIES, P99; FRANK B, 1990, CURRENT DRUG USE TRE; GERNSTEIN DR, 1990, I MED TREATING DRUG, V1; GURNACK AM, 1989, J ALCOHOL DRUG EDUC, V35, P45; HABEL L, 1988, NOV AM PUBL HLTH ASS; HATCH M, 1984, WOMENS HLTH HAZARDS, P161; HOLDEN RT, 1983, J RES CRIME DELINQ, V20, P55, DOI 10.1177/002242788302000105; HUBBARD RL, 1988, RES MONOGRAPH SERIES, P56; INCIARDI JA, 1988, RES MONOGRAPH SERIES, P126; IRUESTEMONTES AM, 1988, CHILD ABUSE NEGLECT, V12, P33, DOI 10.1016/0145-2134(88)90005-1; KOLDER VEB, 1987, NEW ENGL J MED, V316, P1192, DOI 10.1056/NEJM198705073161905; LEUKEFELD CG, 1988, RES MONOGRAPH SERIES, P236; MADDUX JF, 1988, RES MONOGRAPH SERIES, P35; MARINER WK, 1990, CRIM JUST ETHICS WIN, P30; MASI PA, 1987, EMPLOYEE ASSISTANCE, V12, P33; MCCARTY DA, 1986, J STUD ALCOHOL, V49, P1; MCNULTY M, 1987, REV LAW SOC CHANGE, V16, P277; MOISE R, 1981, INT J ADDICT, V16, P1295, DOI 10.3109/10826088109039187; MOORE KG, 1990, SUBSTANCE ABUSE PREG, P9; Moss Kary, 1990, Harv Women's Law J, V13, P278; NEWMAN RG, 1972, CONTEMP DRUG PROBL, V1, P183; NEWMAN RG, 1973, YALE REV LAW SOC ACT, V3, P246; NEWMAN RG, 1977, DRUG FORUM, V5, P1976; PALTROW L, 1989, CASE OVERVIEW ARGUME; PALTROW L, 1990, STATE STATE SUMMARY; PALTROW LM, 1990, CRIM JUST ETHICS WIN, P41; PLATT JJ, 1988, J DRUG ISSUES, V18, P505, DOI 10.1177/002204268801800402; POMPI KF, 1987, AM J DRUG ALCOHOL AB, V13, P309, DOI 10.3109/00952998709001516; PORTER L, 1986, LAW TREATMENT DRUG A; REED B, 1979, FAMILY DYNAMICS SELF, P114; ROOT MPP, 1989, AM J ORTHOPSYCHIAT, V59, P542, DOI 10.1111/j.1939-0025.1989.tb02744.x; ROSENTHAL MP, 1988, J DRUG ISSUES, V18, P641, DOI 10.1177/002204268801800409; RUBENSTEIN LS, 1986, AM J PSYCHIAT, V143, P1264; SCHOTTENFELD RS, 1989, PSYCHIATRY, V52, P164, DOI 10.1080/00332747.1989.11024441; SIMPSON D, 1988, RES MONOGRAPH SERIES, P81; WINICK C, 1988, J DRUG ISSUES, V19, P561; MASS ANNOTATED LAWS, P35; 1990, GAOHRD90138 GEN ACC; 1990, ADM901711; 1990, STATE STATE SURVEY C; 1990, WOM HLTH ISSUES  FAL, V1, P13; 1967, TASK FORCE REPORT NA; 1988, GUIDELINES IMPLEMENT; 1990, JAMA-J AM MED ASSOC, V264, P2663	59	40	40	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 18	1991	266	11					1556	1561		10.1001/jama.266.11.1556	http://dx.doi.org/10.1001/jama.266.11.1556			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GE458	1880889				2022-12-24	WOS:A1991GE45800038
J	MARMOT, M; BRUNNER, E				MARMOT, M; BRUNNER, E			ALCOHOL AND CARDIOVASCULAR-DISEASE - THE STATUS OF THE U-SHAPED CURVE	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; MYOCARDIAL-INFARCTION; MORTALITY; CONSUMPTION; DEATH; RISK; MEN; DRINKING				MARMOT, M (corresponding author), UCL, DEPT EPIDEMIOL & PUBL HLTH, LONDON WC1E 6EA, ENGLAND.		Brunner, Eric/H-2114-2011; Marmot, M G/Y-3920-2019	Brunner, Eric/0000-0002-0595-4474; Marmot, M G/0000-0002-2431-6419	Medical Research Council [G8802774] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		AENDERSON P, 1988, BMJ-BRIT MED J, V297, P824; Boffetta P, 1990, Epidemiology, V1, P342, DOI 10.1097/00001648-199009000-00003; CAMACHO TC, 1987, J CHRON DIS, V40, P229, DOI 10.1016/0021-9681(87)90158-5; CASTELLI WP, 1977, LANCET, V2, P153; CRIQUI MH, 1990, BRIT J ADDICT, V85, P854; CRIQUI MH, 1987, AM J EPIDEMIOL, V126, P629, DOI 10.1093/oxfordjournals.aje.a114702; CULLEN K, 1982, INT J EPIDEMIOL, V11, P67, DOI 10.1093/ije/11.1.67; DEAN G, 1977, 14 TOB RES COUNC P 1; DEBUSK RF, 1986, NEW ENGL J MED, V314, P161, DOI 10.1056/NEJM198601163140307; DUFFY JC, 1982, PSYCHOL REP, V50, P125, DOI 10.2466/pr0.1982.50.1.125; DYER AR, 1980, PREV MED, V9, P78, DOI 10.1016/0091-7435(80)90060-2; FRIEDMAN LA, 1986, AM J EPIDEMIOL, V124, P481, DOI 10.1093/oxfordjournals.aje.a114418; GORDON T, 1987, AM J EPIDEMIOL, V125, P263, DOI 10.1093/oxfordjournals.aje.a114525; HEGSTED DM, 1988, J NUTR, V118, P1184, DOI 10.1093/jn/118.10.1184; HENNEKENS CH, 1978, AM J EPIDEMIOL, V107, P196, DOI 10.1093/oxfordjournals.aje.a112525; JACKSON R, 1991, BRIT MED J, V303, P211, DOI 10.1136/bmj.303.6796.211; KITTNER SJ, 1983, AM J EPIDEMIOL, V117, P538, DOI 10.1093/oxfordjournals.aje.a113576; KLATSKY AL, 1986, AM J CARDIOL, V58, P710, DOI 10.1016/0002-9149(86)90342-5; KLATSKY AL, 1990, CIRCULATION, V81, P720; KLATSKY AL, 1979, ALCOHOL CLIN EXP RES, V3, P33, DOI 10.1111/j.1530-0277.1979.tb04764.x; KLATSKY AL, 1989, CIRCULATION, V80, P611; KONO S, 1986, INT J EPIDEMIOL, V15, P527, DOI 10.1093/ije/15.4.527; KOZAREVIC D, 1983, INT J EPIDEMIOL, V12, P145, DOI 10.1093/ije/12.2.145; LAZARUS NB, 1991, BRIT MED J, V303, P553, DOI 10.1136/bmj.303.6802.553; MARMOT MG, 1984, INT J EPIDEMIOL, V13, P160, DOI 10.1093/ije/13.2.160; MARMOT MG, 1981, LANCET, V1, P580; MEADE TW, 1979, BMJ-BRIT MED J, V1, P153, DOI 10.1136/bmj.1.6157.153; MILLER GJ, 1990, INT J EPIDEMIOL, V19, P923, DOI 10.1093/ije/19.4.923; ROSE G, 1990, BRIT MED J, V301, P1031, DOI 10.1136/bmj.301.6759.1031; ROSS RK, 1981, LANCET, V1, P858; SHAPER AG, 1990, BRIT J ADDICT, V85, P837; SHAPER AG, 1988, LANCET, V2, P1267; SISCOVICK DS, 1986, AM J EPIDEMIOL, V123, P490, DOI 10.1093/oxfordjournals.aje.a114265; STAMPFER MJ, 1988, NEW ENGL J MED, V319, P267, DOI 10.1056/NEJM198808043190503; STLEGER AS, 1979, LANCET, V1, P1017, DOI 10.1016/S0140-6736(79)92765-X; YANO K, 1977, NEW ENGL J MED, V297, P405, DOI 10.1056/NEJM197708252970801; 1988, LANCET, V2, P1292	37	318	322	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 7	1991	303	6802					565	568		10.1136/bmj.303.6802.565	http://dx.doi.org/10.1136/bmj.303.6802.565			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GE948	1912889	Green Published, Bronze			2022-12-24	WOS:A1991GE94800027
J	WILLIAMS, CJ				WILLIAMS, CJ			CANCER	BRITISH MEDICAL JOURNAL			English	Article							MORTALITY				WILLIAMS, CJ (corresponding author), ROYAL S HANS HOSP,MED ONCOL UNIT,SOUTHAMPTON SO9 4PE,HANTS,ENGLAND.							ANDERSSON I, 1988, BRIT MED J, V297, P943, DOI 10.1136/bmj.297.6654.943; Doll R, 1981, THE CAUSES OF CANCER; FINK K, 1968, PUBLIC HLTH REP, V63, P479; GRAY JAM, 1991, BREAST CANCER SCREEN; GUZICK DS, 1978, AM J PUBLIC HEALTH, V68, P125, DOI 10.2105/AJPH.68.2.125; LEW EA, 1979, J CHRON DIS, V32, P563, DOI 10.1016/0021-9681(79)90119-X; ROBERTS MM, 1989, BRIT MED J, V299, P1153, DOI 10.1136/bmj.299.6708.1153; RODGERS A, 1991, BRIT MED J, V302, P411, DOI 10.1136/bmj.302.6773.411-b; SKRABANEK P, 1985, LANCET, V2, P318; TUYNS AJ, 1977, B CANCER, V64, P45; WALD N, 1991, BRIT MED J, V302, P845, DOI 10.1136/bmj.302.6780.845; 1988, LANCET, V2, P41; 1991, HLTH NATION; 1987, TECHNICAL B AM COLLE, V105; 1982, TRENDS CANCER SURVIV	15	9	9	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 31	1991	303	6801					516	517		10.1136/bmj.303.6801.516	http://dx.doi.org/10.1136/bmj.303.6801.516			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GD804	1912867	Bronze, Green Published			2022-12-24	WOS:A1991GD80400024
J	EVANS, JG				EVANS, JG			THE HEALTH OF THE NATION - RESPONSES - CHALLENGE OF AGING	BRITISH MEDICAL JOURNAL			English	Article							LIFE				EVANS, JG (corresponding author), UNIV OXFORD,RADCLIFFE INFIRM,DIV GERIATR MED,OXFORD OX2 6HE,ENGLAND.							ACLAND H, 1854, MEMOIR CHOLERA OXFOR; BEAGLEHOLE R, 1991, BRIT MED J, V303, P69, DOI 10.1136/bmj.303.6794.69; BRANCH LG, 1984, AM J PUBLIC HEALTH, V74, P1126, DOI 10.2105/AJPH.74.10.1126; DOLL R, 1971, J R STAT SOC SER A-G, V134, P133, DOI 10.2307/2343871; EVANS JG, 1982, NEUROLOGICAL DISORDE, P1; EVANS JG, 1986, STROKE EPIDEMIOLOGIC, P33; FAIRWEATHER DS, 1991, METABOLIC MOL BASIS, V1, P213; FITZGERALD JF, 1988, NEW ENGL J MED, V319, P1392, DOI 10.1056/NEJM198811243192106; HARRIS J, 1987, J MED ETHICS, V13, P117, DOI 10.1136/jme.13.3.117; KATZ S, 1983, NEW ENGL J MED, V309, P1218, DOI 10.1056/NEJM198311173092005; KHAW KT, 1990, AGE AGEING, V19, P277, DOI 10.1093/ageing/19.5.277; Rees J L, 1982, Community Med, V4, P100, DOI 10.1007/BF02548823; 1988, SURVEY DISABILITY GR; 1991, CM1523	14	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 17	1991	303	6799					408	409		10.1136/bmj.303.6799.408	http://dx.doi.org/10.1136/bmj.303.6799.408			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GB599	1912811	Bronze, Green Published			2022-12-24	WOS:A1991GB59900023
J	MCCLURKIN, JW; OPTICAN, LM; RICHMOND, BJ; GAWNE, TJ				MCCLURKIN, JW; OPTICAN, LM; RICHMOND, BJ; GAWNE, TJ			CONCURRENT PROCESSING AND COMPLEXITY OF TEMPORALLY ENCODED NEURONAL MESSAGES IN VISUAL-PERCEPTION	SCIENCE			English	Article							TWO-DIMENSIONAL PATTERNS; SINGLE UNITS; CORTEX; STREAMS	The intrinsic neuronal code that carries visual information and the perceptual mechanism for decoding that information are not known. However, multivariate statistics and information theory show that neurons in four visual areas simultaneously carry multiple, stimulus-related messages by utilizing multiplexed temporal codes. The complexity of these temporal messages increases progressively across the visual system, yet the temporal codes overlap in time. Thus, visual perception may depend on the concurrent processing of multiplexed temporal messages from all visual areas.	NIMH, NEUROPSYCHOL LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	MCCLURKIN, JW (corresponding author), NEI, SENSORIMOTOR RES LAB, BETHESDA, MD 20892 USA.							Ahmed N., 1975, ORTHOGONAL TRANSFORM, P86; Barlow H B, 1972, Perception, V1, P371, DOI 10.1068/p010371; COBURN KL, 1990, BEHAV NEUROSCI, V104, P62, DOI 10.1037/0735-7044.104.1.62; DEYOE EA, 1988, TRENDS NEUROSCI, V11, P219, DOI 10.1016/0166-2236(88)90130-0; MCCLURKIN JW, IN PRESS J NEUROPHYS; MISHKIN M, 1983, TRENDS NEUROSCI, V6, P414, DOI 10.1016/0166-2236(83)90190-X; OPTICAN LM, 1987, J NEUROPHYSIOL, V57, P162, DOI 10.1152/jn.1987.57.1.162; RICHMOND BJ, 1990, J NEUROPHYSIOL, V64, P370, DOI 10.1152/jn.1990.64.2.370; RICHMOND BJ, 1987, J NEUROPHYSIOL, V57, P147, DOI 10.1152/jn.1987.57.1.147; RICHMOND BJ, 1988, SOC NEUR ABSTR, V14, P308; SHANNON CE, 1948, BELL SYST TECH J, V27, P379, DOI 10.1002/j.1538-7305.1948.tb01338.x; Uttal W.R., 1973, PSYCHOBIOLOGY SENSOR; VANESSEN DC, 1983, TRENDS NEUROSCI, V6, P370, DOI 10.1016/0166-2236(83)90167-4; ZEKI S, 1988, NATURE, V335, P311, DOI 10.1038/335311a0	14	100	100	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 9	1991	253	5020					675	677		10.1126/science.1908118	http://dx.doi.org/10.1126/science.1908118			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GA304	1908118				2022-12-24	WOS:A1991GA30400042
J	KERPPOLA, TK; CURRAN, T				KERPPOLA, TK; CURRAN, T			FOS-JUN HETERODIMERS AND JUN HOMODIMERS BEND DNA IN OPPOSITE ORIENTATIONS - IMPLICATIONS FOR TRANSCRIPTION FACTOR COOPERATIVITY	CELL			English	Article							INTEGRATION HOST FACTOR; LEUCINE ZIPPER; FACTOR AP-1; PROTEIN COMPLEXES; BINDING; SITE; REPLICATION; ELECTROPHORESIS; RECOGNITION; ACTIVATION	Association of Fos and Jun with the AP-1 site results in a conformational change in the basic amino acid regions that constitute the DNA-binding domain. We show that Fos and Jun induce a corresponding alteration in the conformation of the DNA helix. Circular permutation analysis indicated that both Fos-Jun heterodimers and Jun homodimers induce flexure at the AP-1 site. Phasing analysis demonstrated that Fos-Jun heterodimers and Jun homodimers induce DNA bends that are directed in opposite orientations. Fos-Jun heterodimers bend DNA toward the major groove, whereas Jun homodimers bend DNA toward the minor groove. Fos and Jun peptides encompassing the dimerization and DNA-binding domains bend DNA in the same orientations as the full-length proteins. However, additional regions of both proteins influence the magnitude of the DNA bend angle. Thus, despite the amino acid sequence similarity in the basic region Fos-Jun heterodimers and Jun homodimers form topologically distinct DNA-protein complexes.			KERPPOLA, TK (corresponding author), ROCHE INST MOLEC BIOL,DEPT MOLEC ONCOL & VIROL,NUTLEY,NJ 07110, USA.		Curran, Tom/F-5234-2018; Kerppola, Tom/AFK-6155-2022; Curran, Thomas/AAE-7631-2019; Curran, Tom/D-7515-2011; Kerppola, Tom/AAG-4457-2022; Curran, Tom/C-1164-2008	Curran, Tom/0000-0003-1444-7551; Kerppola, Tom/0000-0002-0611-9446; Curran, Thomas/0000-0003-1444-7551; Kerppola, Tom/0000-0002-0611-9446; Curran, Tom/0000-0003-1444-7551				ABATE C, 1991, MOL CELL BIOL, V11, P3624, DOI 10.1128/MCB.11.7.3624; ABATE C, 1990, CELL GROWTH DIFFER, V1, P455; ABATE C, 1990, P NATL ACAD SCI USA, V87, P1032, DOI 10.1073/pnas.87.3.1032; BAUR CP, 1988, J MOL BIOL, V203, P1009, DOI 10.1016/0022-2836(88)90125-8; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BRACCO L, 1989, EMBO J, V8, P4289, DOI 10.1002/j.1460-2075.1989.tb08615.x; BRENNAN RG, 1990, P NATL ACAD SCI USA, V87, P8165, DOI 10.1073/pnas.87.20.8165; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; COHEN DR, 1990, ONCOGENE, V5, P929; CURRAN T, 1991, IN PRESS TRANSCRIPTI; DEVARGAS LM, 1991, P NATL ACAD SCI USA, V88, P588, DOI 10.1073/pnas.88.2.588; DEVARGAS LM, 1989, SCIENCE, V244, P1457; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DISTEL RJ, 1987, CELL, V49, P835, DOI 10.1016/0092-8674(87)90621-0; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; GARTENBERG MR, 1990, P NATL ACAD SCI USA, V87, P6034, DOI 10.1073/pnas.87.16.6034; GOBER JW, 1990, GENE DEV, V4, P1494, DOI 10.1101/gad.4.9.1494; GOODMAN SD, 1989, NATURE, V341, P251, DOI 10.1038/341251a0; GUSTAFSON TA, 1989, P NATL ACAD SCI USA, V86, P2162, DOI 10.1073/pnas.86.7.2162; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HOOVER TR, 1990, CELL, V63, P11, DOI 10.1016/0092-8674(90)90284-L; HTUN H, 1988, SCIENCE, V241, P1791, DOI 10.1126/science.3175620; Kerppola TK, 1991, CURR OPIN STRUC BIOL, V1, P71, DOI 10.1016/0959-440X(91)90014-K; KIM J, 1989, GENE, V85, P15, DOI 10.1016/0378-1119(89)90459-9; KIM SH, 1990, CELL, V63, P773, DOI 10.1016/0092-8674(90)90143-3; KOO HS, 1990, BIOCHEMISTRY-US, V29, P4227, DOI 10.1021/bi00469a027; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LERMAN LS, 1982, BIOPOLYMERS, V21, P995, DOI 10.1002/bip.360210511; LEVENE SD, 1986, BIOCHEMISTRY-US, V25, P3988, DOI 10.1021/bi00362a003; LEVENE SD, 1989, SCIENCE, V245, P396, DOI 10.1126/science.2756426; LUMPKIN OJ, 1985, BIOPOLYMERS, V24, P1573, DOI 10.1002/bip.360240812; MCALLISTER CF, 1989, J BIOL CHEM, V264, P10451; ONEIL KT, 1990, SCIENCE, V249, P774, DOI 10.1126/science.2389143; PATEL L, 1990, NATURE, V347, P572, DOI 10.1038/347572a0; PECK LJ, 1981, NATURE, V292, P375, DOI 10.1038/292375a0; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; RHODES D, 1981, NATURE, V292, P378, DOI 10.1038/292378a0; RISSE G, 1989, EMBO J, V8, P3825, DOI 10.1002/j.1460-2075.1989.tb08560.x; ROJO F, 1990, J MOL BIOL, V211, P713, DOI 10.1016/0022-2836(90)90072-T; RYSECK RP, 1991, ONCOGENE, V6, P533; SALVO JJ, 1987, NUCLEIC ACIDS RES, V15, P9771, DOI 10.1093/nar/15.23.9771; SALVO JJ, 1988, EMBO J, V7, P3609, DOI 10.1002/j.1460-2075.1988.tb03239.x; SCHRECK R, 1990, NUCLEIC ACIDS RES, V18, P6497, DOI 10.1093/nar/18.22.6497; SNYDER UK, 1989, NATURE, V341, P255, DOI 10.1038/341255a0; SONNENBERG JL, 1989, SCIENCE, V246, P1622, DOI 10.1126/science.2512642; STEITZ TA, 1990, Q REV BIOPHYS, V23, P205, DOI 10.1017/S0033583500005552; TALANIAN RV, 1990, SCIENCE, V249, P769, DOI 10.1126/science.2389142; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; VIGNAIS ML, 1989, J BIOL CHEM, V264, P8463; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; WANG JC, 1988, SCIENCE, V240, P300, DOI 10.1126/science.3281259; WEISS MA, 1990, NATURE, V347, P575, DOI 10.1038/347575a0; WILLIAMS JS, 1988, MOL CELL BIOL, V8, P2763, DOI 10.1128/MCB.8.7.2763; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; ZAHN K, 1987, SCIENCE, V236, P416, DOI 10.1126/science.2951850; ZINKEL SS, 1987, NATURE, V328, P178, DOI 10.1038/328178a0	56	296	297	1	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 26	1991	66	2					317	326		10.1016/0092-8674(91)90621-5	http://dx.doi.org/10.1016/0092-8674(91)90621-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FY712	1906785				2022-12-24	WOS:A1991FY71200012
J	HOSHIJIMA, K; INOUE, K; HIGUCHI, I; SAKAMOTO, H; SHIMURA, Y				HOSHIJIMA, K; INOUE, K; HIGUCHI, I; SAKAMOTO, H; SHIMURA, Y			CONTROL OF DOUBLESEX ALTERNATIVE SPLICING BY TRANSFORMER AND TRANSFORMER-2 IN DROSOPHILA	SCIENCE			English	Article							CHROMOSOMALLY MALE DROSOPHILA; GENE-PRODUCT LEADS; SEX DETERMINATION; FEMALE DIFFERENTIATION; ECTOPIC EXPRESSION; RNA; MELANOGASTER; PROTEIN; ENCODES; LOCUS	Sex-specific alternative processing of doublesex (dsx) precursor messenger RNA (pre-mRNA) regulates somatic sexual differentiation in Drosophila melanogaster. Cotransfection analyses in which the dsx gene and the female-specific transformer (tra) and transformer-2 (tra-2) complementary DNAs were expressed in Drosophila Kc cells revealed that female-specific splicing of the dsx transcript was positively regulated by the products of the tra and tra-2 genes. Furthermore, analyses of mutant constructs of dsx showed that a portion of the female-specific exon sequence was required for regulation of dsx pre-messenger RNA splicing.	KYOTO UNIV,FAC SCI,DEPT BIOPHYS,KYOTO 606,JAPAN	Kyoto University								AMREIN H, 1988, CELL, V55, P1025, DOI 10.1016/0092-8674(88)90247-4; BAKER BS, 1980, GENETICS, V94, P383; BAKER BS, 1988, GENE DEV, V2, P477, DOI 10.1101/gad.2.4.477; BAKER BS, 1989, NATURE, V340, P521, DOI 10.1038/340521a0; BELOTE JM, 1982, P NATL ACAD SCI-BIOL, V79, P1568, DOI 10.1073/pnas.79.5.1568; BELOTE JM, 1989, DEV GENET, V10, P143, DOI 10.1002/dvg.1020100304; BELOTE JM, 1983, DEV BIOL, V95, P512, DOI 10.1016/0012-1606(83)90054-4; BURTIS KC, 1989, CELL, V56, P997, DOI 10.1016/0092-8674(89)90633-8; CLINE TW, 1985, ORIGIN EVOLUTION SEX, P301; GORALSKI TJ, 1989, CELL, V56, P1011, DOI 10.1016/0092-8674(89)90634-X; GREEN MR, 1986, ANNU REV GENET, V20, P671, DOI 10.1146/annurev.ge.20.120186.003323; HOSHIJIMA K, UNPUB; INOUE K, 1990, NATURE, V344, P461, DOI 10.1038/344461a0; MATTAJ IW, 1989, CELL, V57, P1, DOI 10.1016/0092-8674(89)90164-5; MCKEOWN M, 1988, CELL, V53, P887, DOI 10.1016/S0092-8674(88)90369-8; NAGOSHI RN, 1990, GENE DEV, V4, P89, DOI 10.1101/gad.4.1.89; NAGOSHI RN, 1988, CELL, V53, P229, DOI 10.1016/0092-8674(88)90384-4; NOTHIGER R, 1985, TRENDS GENET, V1, P209, DOI 10.1016/0168-9525(85)90082-4; QUERY CC, 1989, CELL, V57, P89, DOI 10.1016/0092-8674(89)90175-X; SAIKI RK, 1988, SCIENCE, V239, P427; SCHUPBACH T, 1982, DEV BIOL, V89, P117, DOI 10.1016/0012-1606(82)90300-1; SOSNOWSKI BA, 1989, CELL, V58, P449, DOI 10.1016/0092-8674(89)90426-1; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468	23	252	260	1	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 10	1991	252	5007					833	836		10.1126/science.1902987	http://dx.doi.org/10.1126/science.1902987			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL123	1902987				2022-12-24	WOS:A1991FL12300043
J	TIMSIT, Y; VILBOIS, E; MORAS, D				TIMSIT, Y; VILBOIS, E; MORAS, D			BASE-PAIRING SHIFT IN THE MAJOR GROOVE OF (CA)N TRACTS BY B-DNA CRYSTAL-STRUCTURES	NATURE			English	Article							A-DNA; SEQUENCES; CONFORMATION; REFINEMENT; HYDRATION; MUTATION; MISMATCH; EXCHANGE	THE crystal packing of the B-DNA dodecamer d(ACCGGCGCCACA). d(TGTGGCGCCGGT) is characterized by the reciprocal fit of double helices with specific base-backbone interactions in the major groove. Cooling the crystals below -10-degrees-C stabilizes a new conformational state with a long-range sequence-dependent one-step shift in the major-groove base pairing. The tilt of the bases leads to the disruption of the Watson-Crick pairing in the major groove and to the formation of interactions with the 5' neighbour of their complement. This alteration propagates along the helical axis over more than half a turn. As a result, the molecular structure is normal when seen from the minor groove side and mismatched in the major groove. Comparison with a parent isomorphous dodecamer structure corresponding to the codon 10-13 of the c-Ha-ras proto-oncogene shows that this new structural feature is sequence dependent and clearly favoured by (CA)n tracts. As(CA)n tracts of DNA are involved both in recombination and in transcription, this new recognition pattern should be considered in the analysis of the various processes involving the reading of the genetic information.			TIMSIT, Y (corresponding author), INST BIOL MOLEC & CELLULAIRE,CRISTALLOG BIOL LAB,15 RUE DESCARTES,F-67000 STRASBOURG,FRANCE.		Timsit, Youri/AAL-2412-2021	Timsit, Youri/0000-0003-0601-7201				BOLSHOY A, 1991, P NATL ACAD SCI USA, V88, P2312, DOI 10.1073/pnas.88.6.2312; CHEUNG S, 1984, P NATL ACAD SCI-BIOL, V81, P3665, DOI 10.1073/pnas.81.12.3665; COLL M, 1987, P NATL ACAD SCI USA, V84, P8385, DOI 10.1073/pnas.84.23.8385; COWIE A, 1988, MOL CELL BIOL, V8, P3122, DOI 10.1128/MCB.8.8.3122; FUCHS RPP, 1981, NATURE, V294, P657, DOI 10.1038/294657a0; HUNTER WN, 1987, NUCLEIC ACIDS RES, V15, P6589, DOI 10.1093/nar/15.16.6589; HUNTER WN, 1986, NATURE, V320, P552, DOI 10.1038/320552a0; JAIN S, 1989, BIOCHEMISTRY-US, V28, P2360, DOI 10.1021/bi00432a002; JARMAN AP, 1989, TRENDS GENET, V5, P367, DOI 10.1016/0168-9525(89)90171-6; KENNARD O, 1985, J BIOMOL STRUCT DYN, V3, P205, DOI 10.1080/07391102.1985.10508412; KUNKEL TA, 1988, J BIOL CHEM, V263, P14784; LU P, 1983, J BIOMOL STRUCT DYN, V1, P509, DOI 10.1080/07391102.1983.10507458; MCNAMARA PT, 1990, J BIOMOL STRUCT DYN, V8, P529, DOI 10.1080/07391102.1990.10507827; NELSON HCM, 1987, NATURE, V330, P221, DOI 10.1038/330221a0; PRIVE GG, 1987, SCIENCE, V238, P498, DOI 10.1126/science.3310237; PRIVE GG, 1991, J MOL BIOL, V217, P177, DOI 10.1016/0022-2836(91)90619-H; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; RODGERS J, 1983, NATURE, V305, P101; SHEN SH, 1981, CELL, V26, P191, DOI 10.1016/0092-8674(81)90302-0; STREISINGER G, 1966, COLD SPRING HARB SYM, V31, P77, DOI 10.1101/SQB.1966.031.01.014; SUSSMAN JL, 1977, ACTA CRYSTALLOGR A, V33, P800, DOI 10.1107/S0567739477001958; TIMSIT Y, 1989, NATURE, V341, P459, DOI 10.1038/341459a0; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; TRECO D, 1986, MOL CELL BIOL, V6, P3934, DOI 10.1128/MCB.6.11.3934; USDIN K, 1989, J BIOL CHEM, V264, P20736; WEBSTER GD, 1990, P NATL ACAD SCI USA, V87, P6693, DOI 10.1073/pnas.87.17.6693; WESTHOF E, 1985, J MOL BIOL, V184, P119, DOI 10.1016/0022-2836(85)90048-8	27	97	97	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 14	1991	354	6349					167	170		10.1038/354167a0	http://dx.doi.org/10.1038/354167a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GP880	1944598				2022-12-24	WOS:A1991GP88000066
J	SHAANAN, B; LIS, H; SHARON, N				SHAANAN, B; LIS, H; SHARON, N			STRUCTURE OF A LEGUME LECTIN WITH AN ORDERED N-LINKED CARBOHYDRATE IN COMPLEX WITH LACTOSE	SCIENCE			English	Article							X-RAY-DIFFRACTION; 3-DIMENSIONAL STRUCTURE; CONCANAVALIN-A; CRYSTAL-STRUCTURE; ERYTHRINA-CORALLODENDRON; SACCHARIDE-BINDING; FC-FRAGMENT; OLIGOSACCHARIDES; RECOGNITION; RESOLUTION	The three-dimensional structure of the lactose complex of the Erythrina corallodendron lectin (EcorL), a dimer of N-glycosylated subunits, was determined crystallographically and refined at 2.0 angstrom resolution to an R value of 0.19. The tertiary structure of the subunit is similar to that of other legume lectins, but interference by the bulky N-linked heptasaccharide, which is exceptionally well ordered in the crystal, forces the EcorL dimer into a drastically different quaternary structure. Only the galactose moiety of the lactose ligand resides within the combining site. The galactose moiety is oriented differently from ligands in the mannose-glucose specific legume lectins and is held by hydrophobic interactions with Ala88, Tyr106, Phe131, and Ala218, and by seven hydrogen bonds, four of which are to the conserved Asp89, Asn133, and NH of Gly107. The specificity of legume lectins toward the different C-4 epimers appears to be associated with extensive variations in the outline of the variable parts of the binding sites.	WEIZMANN INST SCI, DEPT BIOPHYS, IL-76100 REHOVOT, ISRAEL	Weizmann Institute of Science	SHAANAN, B (corresponding author), NIADDKD, MOLEC BIOL LAB, BETHESDA, MD 20892 USA.		Shaanan, Boaz/F-1202-2012	Shaanan, Boaz/0000-0001-8925-4362				ADAR R, 1989, FEBS LETT, V257, P81, DOI 10.1016/0014-5793(89)81791-0; AMZEL LM, 1979, ANNU REV BIOCHEM, V48, P961, DOI 10.1146/annurev.bi.48.070179.004525; ARANGO R, 1990, FEBS LETT, V264, P109, DOI 10.1016/0014-5793(90)80777-G; ASHFORD D, 1987, EUR J BIOCHEM, V166, P311, DOI 10.1111/j.1432-1033.1987.tb13516.x; ASHWELL G, 1974, ADV ENZYMOL RAMB, V41, P99; ASHWELL G, 1982, ANNU REV BIOCHEM, V51, P531, DOI 10.1146/annurev.bi.51.070182.002531; BECKER JW, 1975, J BIOL CHEM, V250, P1513; BECKER JW, 1991, T AM CRYSTALLOGR ASS, V25, P37; BODE W, 1989, BIOCHEMISTRY-US, V28, P1951, DOI 10.1021/bi00431a001; BOURNE Y, 1990, PROTEINS, V8, P365, DOI 10.1002/prot.340080410; BOURNE Y, 1990, J MOL BIOL, V214, P571, DOI 10.1016/0022-2836(90)90199-V; BOUWSTRA JB, 1990, EUR J BIOCHEM, V190, P113, DOI 10.1111/j.1432-1033.1990.tb15553.x; BRANDLEY BK, 1990, CELL, V63, P861, DOI 10.1016/0092-8674(90)90487-Y; BRISSON JR, 1983, BIOCHEMISTRY-US, V22, P3680, DOI 10.1021/bi00284a022; Brunger AT, 1988, CRYSTALLOGRAPHIC COM, V3, P126; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; Davies D R, 1975, Contemp Top Mol Immunol, V4, P127; DEBOECK H, 1984, ARCH BIOCHEM BIOPHYS, V234, P297, DOI 10.1016/0003-9861(84)90352-7; DEISENHOFER J, 1981, BIOCHEMISTRY-US, V20, P2361, DOI 10.1021/bi00512a001; DELBAERE LT, 1991, T AM CRYSTALLOGR ASS, V25, P51; DELBAERE LTJ, 1990, CAN J CHEM, V68, P1116, DOI 10.1139/v90-172; DEREWENDA Z, 1989, EMBO J, V8, P2189, DOI 10.1002/j.1460-2075.1989.tb08341.x; EDELMAN GM, 1972, P NATL ACAD SCI USA, V69, P2580, DOI 10.1073/pnas.69.9.2580; EINSPAHR H, 1986, J BIOL CHEM, V261, P6518; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; FUJINAGA M, 1987, J APPL CRYSTALLOGR, V20, P517, DOI 10.1107/S0021889887086102; HARDMAN KD, 1982, J MOL BIOL, V157, P69, DOI 10.1016/0022-2836(82)90513-7; HARDMAN KD, 1972, BIOCHEMISTRY-US, V11, P4910, DOI 10.1021/bi00776a006; HENDRICKSON WA, 1980, COMPUTING CRYSTALLOG; HOMANS SW, 1987, BIOCHEMISTRY-US, V26, P6553, DOI 10.1021/bi00394a040; HOMANS SW, 1987, BIOCHEMISTRY-US, V26, P6571, DOI 10.1021/bi00395a001; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; LIS H, 1985, PHYTOCHEMISTRY, V24, P2803, DOI 10.1016/0031-9422(85)80004-2; LOONTIENS FG, UNPUB; QUIOCHO FA, 1990, PHILOS T R SOC B, V326, P341, DOI 10.1098/rstb.1990.0016; QUIOCHO FA, 1986, ANNU REV BIOCHEM, V55, P287, DOI 10.1146/annurev.bi.55.070186.001443; REEKE GN, 1975, J BIOL CHEM, V250, P1525; REEKE GN, 1988, CURR TOP MICROBIOL, V139, P35; REEKE GN, 1986, SCIENCE, V234, P1108, DOI 10.1126/science.3775378; ROSEN SD, 1990, AM J RESP CELL MOL, V3, P397, DOI 10.1165/ajrcmb/3.5.397; SAPER MA, 1987, J MOL BIOL, V193, P823, DOI 10.1016/0022-2836(87)90363-9; SHAANAN B, UNPUB; SHARON N, 1990, FASEB J, V4, P3198, DOI 10.1096/fasebj.4.14.2227211; SHARON N, 1989, SCIENCE, V246, P227, DOI 10.1126/science.2552581; SKEHEL JJ, 1984, P NATL ACAD SCI-BIOL, V81, P1779, DOI 10.1073/pnas.81.6.1779; SUCK D, 1984, EMBO J, V3, P2423, DOI 10.1002/j.1460-2075.1984.tb02149.x; SUTTON BJ, 1983, BIOCHEM SOC T, V11, P130, DOI 10.1042/bst0110130; VARGHESE JN, 1983, NATURE, V303, P35, DOI 10.1038/303035a0; WEIS WI, 1990, J MOL BIOL, V212, P737, DOI 10.1016/0022-2836(90)90234-D; WILLIAMS RL, 1987, J BIOL CHEM, V262, P16020; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0; WRIGHT CS, 1990, J MOL BIOL, V215, P635, DOI 10.1016/S0022-2836(05)80174-3	54	265	268	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 8	1991	254	5033					862	866		10.1126/science.1948067	http://dx.doi.org/10.1126/science.1948067			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GN833	1948067				2022-12-24	WOS:A1991GN83300047
J	MEISTERERNST, M; ROEDER, RG				MEISTERERNST, M; ROEDER, RG			FAMILY OF PROTEINS THAT INTERACT WITH TFIID AND REGULATE PROMOTER ACTIVITY	CELL			English	Article							RNA POLYMERASE-II; GENERAL TRANSCRIPTION FACTOR; IMMEDIATE EARLY PROTEIN; MAJOR LATE PROMOTER; PREINITIATION COMPLEX; FUNCTIONAL DOMAINS; BINDING-PROTEIN; TATA FACTOR; INITIATION; ACTIVATION	A family of proteins was shown to bind cooperatively with TFIID to core promoters, as previously demonstrated for the general initiation factor TFIIA. These factors form distinct complexes with TFIID, fall to bind DNA in the absence of TFIID, differ chromatographically from TFIIA, and compete with TFIIA for binding to TFIID. Our results suggest the formation of heterogeneous preinitiation complexes at the step involving TFIIA interactions. This establishes a molecular switch that regulates basal level transcription in vitro and has consequences for transcriptional activation by gene-specific activators.			MEISTERERNST, M (corresponding author), ROCKEFELLER UNIV,BIOCHEM & MOLEC BIOL LAB,NEW YORK,NY 10021, USA.				NATIONAL CANCER INSTITUTE [R35CA042567] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI027397] Funding Source: NIH RePORTER; NCI NIH HHS [CA42567] Funding Source: Medline; NIAID NIH HHS [AI27397] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABMAYR SM, 1988, GENE DEV, V2, P542, DOI 10.1101/gad.2.5.542; BURATOWSKI S, 1988, NATURE, V334, P37, DOI 10.1038/334037a0; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CORMACK BP, 1991, CELL, V65, P341, DOI 10.1016/0092-8674(91)90167-W; GASCH A, 1990, NATURE, V346, P390, DOI 10.1038/346390a0; GILL G, 1991, CELL, V65, P333, DOI 10.1016/0092-8674(91)90166-V; HAHN S, 1989, EMBO J, V8, P3379, DOI 10.1002/j.1460-2075.1989.tb08501.x; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; HOFFMANN A, 1990, GENE DEV, V4, P1141, DOI 10.1101/gad.4.7.1141; HORIKOSHI M, 1990, CELL, V61, P1171, DOI 10.1016/0092-8674(90)90681-4; HORIKOSHI M, 1988, CELL, V54, P665, DOI 10.1016/S0092-8674(88)80011-4; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; INOSTROZA J, 1991, J BIOL CHEM, V266, P9304; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; MALIK S, 1991, IN PRESS P NATL ACAD; MATSUI T, 1980, J BIOL CHEM, V255, P1992; MEISTERERNST M, 1990, P NATL ACAD SCI USA, V87, P9153, DOI 10.1073/pnas.87.23.9153; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; POON D, 1991, IN PRESS MOL CELL BI; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; REDDY P, 1991, CELL, V65, P349, DOI 10.1016/0092-8674(91)90168-X; REINBERG D, 1987, J BIOL CHEM, V262, P3322; SAMUELS M, 1986, J BIOL CHEM, V261, P2003; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; SUMIMOTO H, 1990, P NATL ACAD SCI USA, V87, P9158, DOI 10.1073/pnas.87.23.9158; VANDYKE MW, 1988, SCIENCE, V241, P1335, DOI 10.1126/science.3413495; WORKMAN JL, 1988, CELL, V55, P211, DOI 10.1016/0092-8674(88)90044-X; WORKMAN JL, 1987, CELL, V51, P613, DOI 10.1016/0092-8674(87)90130-9; WORKMAN JL, 1990, EMBO J, V9, P1299, DOI 10.1002/j.1460-2075.1990.tb08239.x	39	281	285	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 1	1991	67	3					557	567		10.1016/0092-8674(91)90530-C	http://dx.doi.org/10.1016/0092-8674(91)90530-C			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GN664	1934060				2022-12-24	WOS:A1991GN66400012
J	MISBIN, RI				MISBIN, RI			PHYSICIANS AID IN DYING	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							ASSISTED SUICIDE; EUTHANASIA				MISBIN, RI (corresponding author), UNIV FLORIDA, GAINESVILLE, FL 32610 USA.							ALTMAN LK, 1991, NY TIMES        0724, pA10; ANGELL M, 1988, NEW ENGL J MED, V319, P1348, DOI 10.1056/NEJM198811173192010; ANNAS GJ, 1990, NEW ENGL J MED, V323, P686, DOI 10.1056/NEJM199009063231020; BEAUCHAMP TL, 1989, PRINCIPLES BIOMEDICA, P151; BEAUCHAMP TL, PRINCIPLES BIOMEDICA, V127, P89; CALLAHAN D, 1990, WHAT KIND LIFE LIMIT, P233; CASSEL CK, 1990, NEW ENGL J MED, V323, P750, DOI 10.1056/NEJM199009133231110; DEWACHTER MAM, 1989, JAMA-J AM MED ASSOC, V262, P3316, DOI 10.1001/jama.262.23.3316; Doerflinger R, 1989, Hastings Cent Rep, V19, P16, DOI 10.2307/3561965; GAYLIN W, 1988, JAMA-J AM MED ASSOC, V259, P2139; GIANELLI DM, 1991, WASHINGTON STATE PHY, P1; GIANELLI DM, 1991, AM MED NEWS     0107, P9; HECHINGER FM, 1991, NY TIMES        0124, pA22; HORAN DJ, 1980, DEATH DYING EUTHANAS, P127; JAKOBOVITS I, 1961, Harofe Haivri Heb Med J, V2, P242; ORENTLICHER D, 1989, JAMA-J AM MED ASSOC, V262, P1844, DOI 10.1001/jama.262.13.1844; QUILL TE, 1991, NEW ENGL J MED, V324, P691, DOI 10.1056/NEJM199103073241010; ROSNER F, 1986, MODERN MED JEWISH ET, P189; SINGER PA, 1990, NEW ENGL J MED, V322, P1881, DOI 10.1056/NEJM199006283222610; THOMASMA DC, 1990, EUTHANASIA ETHICAL S; WANZER SH, 1989, NEW ENGL J MED, V320, P844, DOI 10.1056/NEJM198903303201306; WEIR RF, 1989, ABATING TREATMENT CR; WERTHAM F, 1980, DEATH DYING EUTHANAS, P610; Wolf S M, 1989, Hastings Cent Rep, V19, P13, DOI 10.2307/3561964; 1988, JAMA-J AM MED ASSOC, V259, P272	25	37	37	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 31	1991	325	18					1307	1311		10.1056/NEJM199110313251811	http://dx.doi.org/10.1056/NEJM199110313251811			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GM041	1922229				2022-12-24	WOS:A1991GM04100011
J	CHAVRIER, P; GORVEL, JP; STELZER, E; SIMONS, K; GRUENBERG, J; ZERIAL, M				CHAVRIER, P; GORVEL, JP; STELZER, E; SIMONS, K; GRUENBERG, J; ZERIAL, M			HYPERVARIABLE C-TERMINAL DOMAIN OF RAB PROTEINS ACTS AS A TARGETING SIGNAL	NATURE			English	Article							GTP-BINDING-PROTEINS; MOLECULAR-CLONING; CELL-LINE; SECRETION; TRANSFERRIN; FAMILY; CDNAS; BRAIN; GENES; VIRUS	MAMMALIAN cells express many ras-like low molecular mass GTP-binding proteins (rab proteins) 1-6 that are highly homologous to the Ypt1 and Sec4 proteins involved in controlling secretion in yeast 7-9. Owing to their structural similarity and to their variety, rab proteins have been postulated to act as specific regulators of membrane traffic in exocytosis and endocytosis 10, and rab5 has been shown to be involved in early endosome fusion in vitro 11. In agreement with their postulated functions, all rab proteins studied so far have been found in distinct subcompartments along the exocytic or endocytic pathways 5,11-13. To define the region mediating their specific localization, we transiently expressed rab2, rab5 and rab7 hybrid proteins in BHK cells, and determined their intracellular localization by immunofluorescence confocal microscopy and subcellular fractionation. Here we present evidence that the highly variable C-terminal domain contains structural elements necessary for the association of rab proteins with their specific target membranes in the endocytic pathway.	EUROPEAN MOLEC BIOL LAB, POSTFACH 102209, W-6900 HEIDELBERG, GERMANY	European Molecular Biology Laboratory (EMBL)			CHAVRIER, Philippe/AAG-2645-2020; Stelzer, Ernst H K/A-7648-2011; CHAVRIER, Philippe/B-4707-2010; Gorvel, Jean-Pierre/O-1332-2018	CHAVRIER, Philippe/0000-0002-7351-733X; Stelzer, Ernst H K/0000-0003-1545-0736; CHAVRIER, Philippe/0000-0002-7351-733X; Gorvel, Jean-Pierre/0000-0002-2829-9804; Simons, Kai/0000-0002-9231-9996				BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BUCCI C, 1988, NUCLEIC ACIDS RES, V16, P9979, DOI 10.1093/nar/16.21.9979; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; CHAVRIER P, 1990, MOL CELL BIOL, V10, P6578, DOI 10.1128/MCB.10.12.6578; DESCHENES RJ, 1987, MOL CELL BIOL, V7, P2344, DOI 10.1128/MCB.7.7.2344; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GALLWITZ D, 1983, NATURE, V306, P704, DOI 10.1038/306704a0; GOUD B, 1990, NATURE, V345, P553, DOI 10.1038/345553a0; GROVEL JP, 1991, CELL, V64, P915; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HOPKINS CR, 1983, CELL, V35, P321, DOI 10.1016/0092-8674(83)90235-0; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; MATSUI Y, 1988, J BIOL CHEM, V263, P11071; MOLENAAR CMT, 1988, EMBO J, V7, P971, DOI 10.1002/j.1460-2075.1988.tb02903.x; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; SCHMID SL, 1988, CELL, V52, P73, DOI 10.1016/0092-8674(88)90532-6; SEGEV N, 1988, CELL, V52, P915, DOI 10.1016/0092-8674(88)90433-3; TOUCHOT N, 1987, P NATL ACAD SCI USA, V84, P8210, DOI 10.1073/pnas.84.23.8210; VONMOLLARD GF, 1990, P NATL ACAD SCI USA, V87, P1988, DOI 10.1073/pnas.87.5.1988; WALWORTH NC, 1989, EMBO J, V8, P1685, DOI 10.1002/j.1460-2075.1989.tb03560.x; WILLUMSEN BM, 1984, EMBO J, V3, P2581, DOI 10.1002/j.1460-2075.1984.tb02177.x; ZAHRAOUI A, 1989, J BIOL CHEM, V264, P12394; ZERIAL M, 1986, EMBO J, V5, P1543, DOI 10.1002/j.1460-2075.1986.tb04395.x	25	340	347	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 24	1991	353	6346					769	772		10.1038/353769a0	http://dx.doi.org/10.1038/353769a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GL696	1944536	Bronze			2022-12-24	WOS:A1991GL69600073
J	CORBIN, V; MICHELSON, AM; ABMAYR, SM; NEEL, V; ALCAMO, E; MANIATIS, T; YOUNG, MW				CORBIN, V; MICHELSON, AM; ABMAYR, SM; NEEL, V; ALCAMO, E; MANIATIS, T; YOUNG, MW			A ROLE FOR THE DROSOPHILA NEUROGENIC GENES IN MESODERM DIFFERENTIATION	CELL			English	Article							EPIDERMAL GROWTH-FACTOR; NEURONAL PRECURSOR CELLS; ACHAETE-SCUTE COMPLEX; EGF-LIKE REPEATS; NOTCH LOCUS; C-ELEGANS; MONONUCLEATED MYOBLASTS; TRANSLATIONAL CONTROL; NEURAL DEVELOPMENT; DIFFERENT PROTEINS	The neurogenic genes of Drosophila have long been known to regulate cell fate decisions in the developing ectoderm. In this paper we show that these genes also control mesoderm development. Embryonic cells that express the muscle-specific gene nautilus are overproduced in each of seven neurogenic mutants (Notch, Delta, Enhancer of split, big brain, mastermind, neuralized, and almondex), at the apparent expense of neighboring, nonexpressing mesodermal cells. The mesodermal defect does not appear to be a simple consequence of associated neural hypertrophy, suggesting that the neurogenic genes may function similarly and independently in establishing cell fates in both ectoderm and mesoderm. Altered patterns of beta-3-tubulin and myosin heavy chain gene expression in the mutants indicate a role for the neurogenic genes in development of most visceral and somatic muscles. We propose that the signal produced by the neurogenic genes is a general one, effective in both ectoderm and mesoderm.	ROCKEFELLER UNIV, HOWARD HUGHES MED INST, NEW YORK, NY 10021 USA; HARVARD UNIV, DEPT BIOCHEM & MOLEC BIOL, CAMBRIDGE, MA 02138 USA	Howard Hughes Medical Institute; Rockefeller University; Harvard University	CORBIN, V (corresponding author), ROCKEFELLER UNIV, GENET LAB, 1230 YORK AVE, NEW YORK, NY 10021 USA.		, 机智的马小跳和机智的羊不愁/ABC-5169-2020		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM029301] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM5-25103, 5P01GM29301] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APPELLA E, 1987, J BIOL CHEM, V262, P4437; ARTAVANISTSAKONAS S, 1988, TRENDS GENET, V4, P95, DOI 10.1016/0168-9525(88)90096-0; AUSTIN J, 1987, CELL, V51, P589, DOI 10.1016/0092-8674(87)90128-0; BALL EE, 1985, J NEUROSCI, V5, P1808; BARAD M, 1988, EMBO J, V7, P2151, DOI 10.1002/j.1460-2075.1988.tb03054.x; BATE M, 1990, DEVELOPMENT, V110, P791; BETTLER D, 1991, DEV BIOL, V144, P436, DOI 10.1016/0012-1606(91)90436-7; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BRAND M, 1988, ROUX ARCH DEV BIOL, V197, P457, DOI 10.1007/BF00385679; CABRERA CV, 1987, CELL, V50, P425, DOI 10.1016/0092-8674(87)90496-X; CAGAN RL, 1989, GENE DEV, V3, P1099, DOI 10.1101/gad.3.8.1099; CAMPOS AR, 1985, J NEUROGENET, V2, P197, DOI 10.3109/01677068509100150; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; CAMPOSORTEGA JA, 1988, TRENDS NEUROSCI, V11, P400, DOI 10.1016/0166-2236(88)90077-X; CAMPUZANO S, 1986, CELL, V44, P303, DOI 10.1016/0092-8674(86)90764-6; COFFMAN C, 1990, SCIENCE, V249, P1438, DOI 10.1126/science.2402639; COLMENARES C, 1991, MOL CELL BIOL, V11, P1167, DOI 10.1128/MCB.11.2.1167; Cramer L., 1980, DROS INFORM SERV, V55, P197; CROSS DP, 1978, J EMBRYOL EXP MORPH, V45, P173; CROSS DP, 1978, J EMBRYOL EXP MORPH, V45, P161; Dietrich U, 1984, J Neurogenet, V1, P315, DOI 10.3109/01677068409107094; DOE CQ, 1985, DEV BIOL, V111, P206, DOI 10.1016/0012-1606(85)90446-4; EMERSON CP, 1975, J MOL BIOL, V93, P431, DOI 10.1016/0022-2836(75)90238-7; ENDO T, 1987, CELL, V49, P515, DOI 10.1016/0092-8674(87)90454-5; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; GARCIAALONSO L, 1986, ROUX ARCH DEV BIOL, V195, P259; GARCIABELLIDO A, 1978, GENETICS, V88, P469; GARCIABELLIDO A, 1979, GENETICS, V91, P491; GASCH A, 1988, MOL GEN GENET, V211, P8, DOI 10.1007/BF00338387; GREENSPAN R J, 1990, New Biologist, V2, P595; GREENWALD I, 1985, CELL, V43, P583, DOI 10.1016/0092-8674(85)90230-2; HARTENSTEIN V, 1990, DEV BIOL, V142, P13, DOI 10.1016/0012-1606(90)90147-B; HARTENSTEIN V, 1984, ROUX ARCH DEV BIOL, V193, P308, DOI 10.1007/BF00848159; HARTLEY DA, 1987, EMBO J, V6, P3407, DOI 10.1002/j.1460-2075.1987.tb02664.x; HEITZLER P, 1991, CELL, V64, P1083, DOI 10.1016/0092-8674(91)90263-X; HOPPE PE, 1986, CELL, V46, P773, DOI 10.1016/0092-8674(86)90353-3; HOPPE PE, 1990, DEVELOPMENT, V109, P875; JAN LY, 1982, P NATL ACAD SCI-BIOL, V79, P2700, DOI 10.1073/pnas.79.8.2700; JIMENEZ F, 1990, NEURON, V5, P81, DOI 10.1016/0896-6273(90)90036-F; JIMENEZ F, 1979, NATURE, V282, P310, DOI 10.1038/282310a0; JIMENEZ F, 1987, J NEUROGENET, V4, P179, DOI 10.3109/01677068709102340; JOHANSEN KM, 1989, J CELL BIOL, V109, P2427, DOI 10.1083/jcb.109.5.2427; JONES FS, 1988, P NATL ACAD SCI USA, V85, P2186, DOI 10.1073/pnas.85.7.2186; KELLEY MR, 1987, CELL, V51, P539, DOI 10.1016/0092-8674(87)90123-1; KIDD S, 1986, MOL CELL BIOL, V6, P3094, DOI 10.1128/MCB.6.9.3094; KIDD S, 1989, GENE DEV, V3, P1113, DOI 10.1101/gad.3.8.1113; KLAMBT C, 1989, EMBO J, V8, P203, DOI 10.1002/j.1460-2075.1989.tb03365.x; KNUST E, 1987, EMBO J, V6, P4113, DOI 10.1002/j.1460-2075.1987.tb02757.x; KOPCZYNSKI CC, 1989, DEVELOPMENT, V107, P623; KOPCZYNSKI CC, 1988, GENE DEV, V2, P1723, DOI 10.1101/gad.2.12b.1723; KUROSAWA S, 1988, J BIOL CHEM, V263, P5993; LAMBIE EJ, 1991, DEVELOPMENT, V112, P231; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LAWLER J, 1986, J CELL BIOL, V103, P1635, DOI 10.1083/jcb.103.5.1635; LEHMANN R, 1983, ROUX ARCH DEV BIOL, V192, P62, DOI 10.1007/BF00848482; LEHNER CF, 1989, CELL, V56, P957, DOI 10.1016/0092-8674(89)90629-6; LEISS D, 1988, DEVELOPMENT, V104, P525; LINDSLEY D, 1985, DROS INFO SERV, V62; LINDSLEY D, 1990, DROS INFO SERV, V68; Lindsley D.L., 1968, GENETIC VARIATIONS D; MANN K, 1989, EMBO J, V8, P65, DOI 10.1002/j.1460-2075.1989.tb03349.x; MICHELSON AM, 1990, GENE DEV, V4, P2086, DOI 10.1101/gad.4.12a.2086; MONTELL DJ, 1988, CELL, V53, P463, DOI 10.1016/0092-8674(88)90166-3; MORRIS GE, 1976, EXP CELL RES, V99, P106, DOI 10.1016/0014-4827(76)90685-6; MOSS PS, 1976, DEV BIOL, V48, P431, DOI 10.1016/0012-1606(76)90104-4; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NGUYEN HT, 1983, CELL, V34, P281, DOI 10.1016/0092-8674(83)90159-9; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; PATERSON BM, 1991, P NATL ACAD SCI USA, V88, P3782, DOI 10.1073/pnas.88.9.3782; Poulson D. F., 1950, BIOL DROSOPHILA, P168; Poulson DF, 1940, J EXP ZOOL, V83, P271, DOI 10.1002/jez.1400830207; POULSON DF, 1945, AM NAT, V79, P340, DOI 10.1086/281269; PREISS A, 1988, EMBO J, V7, P3917, DOI 10.1002/j.1460-2075.1988.tb03278.x; PREISS JR, 1987, CELL, V51, P241; RAO Y, 1990, NATURE, V345, P163, DOI 10.1038/345163a0; ROMANI S, 1987, EMBO J, V6, P2085, DOI 10.1002/j.1460-2075.1987.tb02474.x; RUOHOLA H, 1991, CELL, V66, P433, DOI 10.1016/0092-8674(81)90008-8; SASAKI M, 1987, P NATL ACAD SCI USA, V84, P935, DOI 10.1073/pnas.84.4.935; SEYDOUX G, 1989, CELL, V57, P1237, DOI 10.1016/0092-8674(89)90060-3; SHANNON MP, 1973, J EXP ZOOL, V183, P383, DOI 10.1002/jez.1401830312; SHELLENBARGER DL, 1978, DEV BIOL, V62, P432, DOI 10.1016/0012-1606(78)90226-9; SIEGELMAN MH, 1989, SCIENCE, V243, P1165, DOI 10.1126/science.2646713; SIMPSON P, 1990, TRENDS GENET, V6, P343, DOI 10.1016/0168-9525(90)90260-D; SKOOG DA, 1982, FUNDAMENTALS ANAL CH, P55; SMOLLER D, 1990, GENE DEV, V4, P1688, DOI 10.1101/gad.4.10.1688; STANDART N, 1987, DEV BIOL, V124, P248, DOI 10.1016/0012-1606(87)90476-3; SUDHOF TC, 1985, SCIENCE, V228, P815, DOI 10.1126/science.2988123; SUZUKI K, 1987, EMBO J, V6, P1891, DOI 10.1002/j.1460-2075.1987.tb02448.x; SWENSON KI, 1986, CELL, V47, P861, DOI 10.1016/0092-8674(86)90801-9; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TECHNAU GM, 1986, ROUX ARCH DEV BIOL, V195, P445, DOI 10.1007/BF00375748; TROTTER JA, 1976, DEV BIOL, V49, P548, DOI 10.1016/0012-1606(76)90197-4; VASSIN H, 1987, EMBO J, V6, P3431, DOI 10.1002/j.1460-2075.1987.tb02666.x; VERTEL BM, 1976, DEV BIOL, V48, P438, DOI 10.1016/0012-1606(76)90105-6; WASSENBERG DR, 1987, J BIOL CHEM, V262, P10741; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WELSHONS WJ, 1965, SCIENCE, V150, P1122, DOI 10.1126/science.150.3700.1122; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; WRIGHT TRF, 1970, ADV GENET, V15, P261, DOI 10.1016/S0065-2660(08)60075-9; YOCHEM J, 1989, CELL, V58, P553, DOI 10.1016/0092-8674(89)90436-4	101	240	243	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 18	1991	67	2					311	323		10.1016/0092-8674(91)90183-Y	http://dx.doi.org/10.1016/0092-8674(91)90183-Y			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GL470	1913825				2022-12-24	WOS:A1991GL47000011
J	SKARFORS, ET; SELINUS, KI; LITHELL, HO				SKARFORS, ET; SELINUS, KI; LITHELL, HO			RISK-FACTORS FOR DEVELOPING NON-INSULIN-DEPENDENT DIABETES - A 10 YEAR FOLLOW-UP OF MEN IN UPPSALA	BRITISH MEDICAL JOURNAL			English	Article							IMPAIRED GLUCOSE-TOLERANCE; PIMA-INDIANS; ESSENTIAL-HYPERTENSION; RESISTANCE; OBESITY; METABOLISM; MELLITUS; HISTORY; SODIUM	Objective - To analyse anthropometric and metabolic characteristics as risk factors for development of non-insulin dependent diabetes mellitus in middle aged normoglycaemic men. Design - Prospective population study based on data collected in a health survey and follow up 10 years later. Setting - Uppsala, a middle sized city in Sweden. Subjects - 2322 men aged 47-53, of whom 1860 attended the follow up 7-14 years later, at which time they were aged 56-64. Main outcome measures - Incidence of non-insulin dependent diabetes. Results - In a multivariate logistic regression analysis, variations of 1 SD from the mean of the group that remained euglycaemic were used to calculate odds ratios and 95% confidence intervals. Blood glucose concentration 60 minutes after the start of an intravenous glucose tolerance test (odds ratio = 5.93, 95% confidence interval 3.05 to 11.5), fasting serum insulin concentration (2.12, 1.54 to 2.93), acute insulin increment at an intravenous glucose tolerance test (1.71, 1.21 to 2.43), body mass index (1.41, 1.01 to 1.97), and systolic blood pressure (1.23, 0.97 to 1.56) were independent predictors of diabetes. In addition, the use of antihypertensive drugs at follow up (selective or unselective beta-blocking agents, thiazides, or hydralazine) was an independent risk factor (1.70, 1.11 to 2.60). Conclusions - Metabolic and anthropometric characteristics associated with or reflecting insulin resistance as well as a poor acute insulin response to glucose challenge were important predictors of future diabetes in middle aged men. Antihypertensive drugs were found to constitute a further, iatrogenic risk factor.			SKARFORS, ET (corresponding author), UNIV UPPSALA,DEPT GERIATR,S-75012 UPPSALA,SWEDEN.							BARNETT AH, 1982, SERONO S, V47, P225; BENGTSSON C, 1984, BMJ-BRIT MED J, V289, P1495, DOI 10.1136/bmj.289.6457.1495; BOBERG J, 1976, SCAND J CLIN LAB INV, V36, P145, DOI 10.3109/00365517609055241; BURSTEIN M, 1960, CLIN CHIM ACTA, V5, P609, DOI 10.1016/0009-8981(60)90075-9; CERASI E, 1967, DIABETES, V16, P615, DOI 10.2337/diab.16.9.615; CERASI E, 1967, ACTA ENDOCRINOL-COP, V55, P278, DOI 10.1530/acta.0.0550278; COLLEN MF, 1969, ARCH INTERN MED, V123, P664, DOI 10.1001/archinte.123.6.664; DEFRONZO RA, 1988, DIABETES, V37, P667, DOI 10.2337/diab.37.6.667; DEFRONZO RA, 1975, J CLIN INVEST, V55, P845, DOI 10.1172/JCI107996; DIXON WJ, 1981, BMDP STATISTICAL SOF, P330; EDWARDS DAW, 1955, BRIT J NUTR, V9, P133, DOI 10.1079/BJN19550021; FERRANNINI E, 1987, NEW ENGL J MED, V317, P350, DOI 10.1056/NEJM198708063170605; HAFFNER SM, 1988, NEW ENGL J MED, V319, P1297, DOI 10.1056/NEJM198811173192001; HAFFNER SM, 1989, DIABETES S2, V38, pA92; HARVALD B, 1963, ACTA MED SCAND, V173, P459; HEDSTRAND H, 1975, SCAND J CLIN LAB INV, V35, P331, DOI 10.3109/00365517509095749; HESTRAND H, 1975, UPSALA J MED SCI S, V19, P28; HILTON PJ, 1986, NEW ENGL J MED, V314, P222, DOI 10.1056/NEJM198601233140407; IKKOS D, 1957, ACTA ENDOCRINOL-COP, V25, P312, DOI 10.1530/acta.0.0250312; KADOWAKI T, 1984, DIABETOLOGIA, V26, P44, DOI 10.1007/BF00252262; KEEN H, 1982, DIABETOLOGIA, V22, P73, DOI 10.1007/BF00254832; KNOWLER WC, 1981, AM J EPIDEMIOL, V113, P144, DOI 10.1093/oxfordjournals.aje.a113079; KNOWLER WC, 1989, DIABETES S2, V38, pA92; LEE ET, 1985, DIABETES CARE, V8, P107, DOI 10.2337/diacare.8.2.107; LILLIOJA S, 1988, NEW ENGL J MED, V318, P1217, DOI 10.1056/NEJM198805123181901; LITHELL H, 1984, ACTA MED SCAND, V215, P403; LUFT R, 1981, DIABETES CARE, V4, P58, DOI 10.2337/diacare.4.1.58; LUNDGREN H, 1988, BRIT MED J, V297, P1512, DOI 10.1136/bmj.297.6662.1512; LUNDGREN H, 1990, DIABETIC MED, V7, P407, DOI 10.1111/j.1464-5491.1990.tb01415.x; NAGULESPARAN M, 1979, DIABETES, V28, P980, DOI 10.2337/diabetes.28.11.980; OHLSON LO, 1985, DIABETES, V34, P1055, DOI 10.2337/diabetes.34.10.1055; OSULLIVAN JB, 1968, NEW ENGL J MED, V278, P1038, DOI 10.1056/NEJM196805092781904; POLLARE T, 1990, METABOLISM, V39, P167, DOI 10.1016/0026-0495(90)90071-J; POLLARE T, 1989, BRIT MED J, V298, P1152, DOI 10.1136/bmj.298.6681.1152; POLLARE T, 1989, NEW ENGL J MED, V321, P868, DOI 10.1056/NEJM198909283211305; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; ROWE JW, 1981, DIABETES, V30, P219, DOI 10.2337/diab.30.3.219; RUSH RL, 1971, ADV AUTOMAT ANAL, V1, P503; SAAD MF, 1988, NEW ENGL J MED, V319, P1500, DOI 10.1056/NEJM198812083192302; SAYEGH HAI, 1979, LANCET, V1, P431; SKARFORS ET, 1989, BRIT MED J, V298, P1147, DOI 10.1136/bmj.298.6681.1147; WAHLBERG F, 1966, ACTA MED SCAND S453, V180, P22; 1979, DIABETES, V28, P1039; 1985, WHO TECH REP SER, V724, P183	44	172	174	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 28	1991	303	6805					755	760		10.1136/bmj.303.6805.755	http://dx.doi.org/10.1136/bmj.303.6805.755			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG981	1932936	Bronze, Green Published			2022-12-24	WOS:A1991GG98100021
J	STEINHERZ, LJ; STEINHERZ, PG; TAN, CTC; HELLER, G; MURPHY, ML				STEINHERZ, LJ; STEINHERZ, PG; TAN, CTC; HELLER, G; MURPHY, ML			CARDIAC TOXICITY 4 TO 20 YEARS AFTER COMPLETING ANTHRACYCLINE THERAPY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CONGESTIVE HEART-FAILURE; DOXORUBICIN CARDIOTOXICITY; ADRIAMYCIN CARDIOTOXICITY; WEEKLY SCHEDULE; DAUNOMYCIN; EXPERIENCE; CHILDREN	Objective. - To assess the cardiac status of long-term survivors of pediatric malignancies who received chemotherapy, including anthracyclines. Design and Method. - Patients were evaluated by echocardiogram from 4 to 20 years (median, 7 years) after completion of anthracyclines, with prospective and retrospective analysis. Patients. - The consecutive sample of 201 patients had received a total anthracycline dose of 200 to 1275 mg/m2 (median, 450 mg/m2), and 51 patients had mediastinal radiotherapy. Main Outcome Measures. - The overall incidence and severity of abnormal systolic cardiac function were determined for the entire cohort. Risk factors of total anthracycline dose, mediastinal radiotherapy, age during treatment, and length of follow-up were examined. Results. - Twenty-three percent (47/201) of the cohort had abnormal cardiac function on noninvasive testing at long-term follow-up. Correlation between total cumulative dose, length of follow-up, and mediastinal irradiation with incidence of abnormalities was significant. Fifty-six patients were followed up for 10 years or more (median, 12 years), with a median anthracycline dose of 495 mg/m2. Thirty-eight percent (21/56) of these patients, compared with 18% (26/145) of patients evaluated after less than 10 years, had abnormal findings. Sixty-three percent of patients followed up for 10 years or more after receiving 500 mg/m2 or more of anthracyclines had abnormal findings. Nine of 201 patients had late symptoms, including cardiac failure and dysrhythmia, and three patients died suddenly. Microscopic examination of the myocardium on biopsy and autopsy revealed fibrosis. Conclusion. - The 23% incidence of late cardiac abnormalities warrants continued evaluation of patients after anthracyclines to guide patient care and the design of future chemotherapeutic protocols.	MEM SLOAN KETTERING CANC CTR,DEPT EPIDEMIOL & BIOSTAT,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center	STEINHERZ, LJ (corresponding author), MEM SLOAN KETTERING CANC CTR,DEPT PEDIAT,1275 YORK AVE,NEW YORK,NY 10021, USA.							BLOOM KR, 1978, CANCER, V41, P1265, DOI 10.1002/1097-0142(197804)41:4<1265::AID-CNCR2820410408>3.0.CO;2-R; BRISTOW MR, 1978, CANCER TREAT REP, V62, P873; BROSTOW MR, 1980, ANTHRACYCLINES CURRE, P255; DRESDALE A, 1983, CANCER, V52, P51, DOI 10.1002/1097-0142(19830701)52:1<51::AID-CNCR2820520111>3.0.CO;2-#; GILLADOGA AC, 1976, CANCER, V37, P1070, DOI 10.1002/1097-0142(197602)37:2+<1070::AID-CNCR2820370814>3.0.CO;2-6; LEFRAK EA, 1973, CANCER-AM CANCER SOC, V32, P302, DOI 10.1002/1097-0142(197308)32:2<302::AID-CNCR2820320205>3.0.CO;2-2; LEGHA SS, 1982, ANN INTERN MED, V96, P133, DOI 10.7326/0003-4819-96-2-133; LIPSHULTZ S E, 1988, Journal of the American College of Cardiology, V11, p135A; LIPSHULTZ SE, 1989, PEDIATR RES, V25, pA153; LIPSHULTZ SE, 1987, BLOOD, V70, pA234; PALMERI ST, 1986, AM J CARDIOL, V58, P607, DOI 10.1016/0002-9149(86)90284-5; SCHWARTZ RG, 1987, AM J MED, V82, P1109, DOI 10.1016/0002-9343(87)90212-9; SINGER J W, 1978, Cancer Treatment Reports, V62, P945; STEINHERZ L, 1985, WORLD C PEDIATR CARD, V2, P58; STEINHERZ L, 1986, PEDIATRIC CARDIOL, P1056; STEINHERZ L, 1989, P AN M AM SOC CLIN, V8, P296; STEINHERZ L, 1984, P AM SOC CLIN ONCOL, V3, P198; STEINHERZ LJ, 1987, MED PEDIATR ONCOL, V15, P326; TAN C, 1967, CANCER-AM CANCER SOC, V20, P333, DOI 10.1002/1097-0142(1967)20:3<333::AID-CNCR2820200302>3.0.CO;2-K; TORTI FM, 1983, ANN INTERN MED, V99, P745, DOI 10.7326/0003-4819-99-6-745; VONHOFF DD, 1977, AM J MED, V62, P200, DOI 10.1016/0002-9343(77)90315-1; VONHOFF DD, 1979, ANN INTERN MED, V91, P710, DOI 10.7326/0003-4819-91-5-710; WEISS AJ, 1977, CANCER, V40, P2046, DOI 10.1002/1097-0142(197711)40:5<2046::AID-CNCR2820400508>3.0.CO;2-5	23	766	783	2	28	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 25	1991	266	12					1672	1677		10.1001/jama.266.12.1672	http://dx.doi.org/10.1001/jama.266.12.1672			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GF419	1886191				2022-12-24	WOS:A1991GF41900034
J	SURKS, MI				SURKS, MI			THYROID-STIMULATING HORMONE - REFERENCE RANGE VALIDITY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							THYROTROPIN				SURKS, MI (corresponding author), MONTEFIORE MED CTR,ALBERT EINSTEIN COLL MED,BRONX,NY 10467, USA.							CHOPRA IJ, 1990, METABOLISM, V39, P538, DOI 10.1016/0026-0495(90)90014-4; NICOLOFF JT, 1990, J CLIN ENDOCR METAB, V71, P553, DOI 10.1210/jcem-71-3-553	2	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 18	1991	266	11					1573	1573						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GE458	1880894				2022-12-24	WOS:A1991GE45800044
J	DOUGLAS, AS; RAWLES, JM; ALEXANDER, E; ALLAN, TM				DOUGLAS, AS; RAWLES, JM; ALEXANDER, E; ALLAN, TM			WINTER PRESSURE ON HOSPITAL MEDICAL BEDS	BRITISH MEDICAL JOURNAL			English	Article									UNIV ABERDEEN,SCH MED,WELLCOME RES LIB,ABERDEEN AB9 1FX,SCOTLAND; GRAMPIAN AREA HLTH BOARD,DEPT COMMUNITY MED,ABERDEEN,SCOTLAND	University of Aberdeen; University of Aberdeen	DOUGLAS, AS (corresponding author), UNIV ABERDEEN,SCH MED,DEPT MED & THERAPEUT,ABERDEEN AB9 2ZB,SCOTLAND.							DOUGLAS AS, 1991, LANCET, P1393; QUETELET MA, 1842, TREATISE MAN DEV HIS, P34; Sothern R., 1972, PHYSIOL TEACH, V1, P1	3	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 31	1991	303	6801					508	509		10.1136/bmj.303.6801.508-a	http://dx.doi.org/10.1136/bmj.303.6801.508-a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GD804	1912863	Bronze, Green Published			2022-12-24	WOS:A1991GD80400020
J	CUNNINGHAM, BC; MULKERRIN, MG; WELLS, JA				CUNNINGHAM, BC; MULKERRIN, MG; WELLS, JA			DIMERIZATION OF HUMAN GROWTH-HORMONE BY ZINC	SCIENCE			English	Article							PITUITARY; PROLACTIN; RECEPTOR; PROTEIN	Size-exclusion chromatography and sedimentation equilibrium studies demonstrated that zinc ion (Zn 2+) induced the dimerization of human growth hormone (hGH). Scatchard analysis of Zn-65(2+) binding to hGH showed that two Zn+ ions associate per dimer of hGH in a cooperative fashion. Cobalt (II) can substitute for Zn2+ in the hormone dimer and gives a visible spectrum characteristic of cobalt coordinated in a tetrahedral fashion by oxygen- and nitrogen-containing ligands. Replacement of potential Zn2+ ligands (His 18, His 21, and Glu 174) in hGH with alanine weakened both Zn2+ binding and hGH dimer formation. The Zn+-hGH dimer was more stable than monomeric hGH to denaturation in guanidine-HCl. Formation of a Zn2+-hGH dimeric complex may be important for storage of hGH in secretory granules.	GENENTECH INC,DEPT PROT ENGN,SAN FRANCISCO,CA 94080	Roche Holding; Genentech								ABDELMEGUID SS, 1987, P NATL ACAD SCI USA, V84, P6434, DOI 10.1073/pnas.84.18.6434; ACKERS GK, 1965, P NATL ACAD SCI USA, V53, P342, DOI 10.1073/pnas.53.2.342; Bertini I, 1984, Adv Inorg Biochem, V6, P71; CUNNINGHAM BA, UNPUB; CUNNINGHAM BC, 1991, P NATL ACAD SCI USA, V88, P3407, DOI 10.1073/pnas.88.8.3407; CUNNINGHAM BC, 1990, SCIENCE, V250, P1709, DOI 10.1126/science.2270485; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DAUGHADAY WF, 1985, TXB ENDOCRINOLOGY, P577; HANDEL T, 1990, J AM CHEM SOC, V112, P6710, DOI 10.1021/ja00174a039; HO KY, 1987, J CLIN ENDOCR METAB, V64, P51, DOI 10.1210/jcem-64-1-51; LABELLA F, 1973, BIOCHEM BIOPH RES CO, V52, P786, DOI 10.1016/0006-291X(73)91006-1; LEWIS UJ, 1984, ANNU REV PHYSIOL, V46, P33; LORENSON MY, 1983, J BIOL CHEM, V258, P8618; LOWMAN HB, 1991, J BIOL CHEM, V266, P10982; LOWMAN HB, UNPUB; MARTIN MT, 1989, INORG CHEM, V36, P27; NICOLL CS, 1986, ENDOCR REV, V7, P169, DOI 10.1210/edrv-7-2-169; REGAN L, 1990, BIOCHEMISTRY-US, V29, P10878, DOI 10.1021/bi00501a003; ROOT AW, 1979, J NUTR, V109, P958, DOI 10.1093/jn/109.6.958; SHIRE SJ, IN PRESS BIOCHEMISTR; TAYLOR AL, 1969, J CLIN INVEST, V48, P2349, DOI 10.1172/JCI106201; THOMPSON RG, 1972, J CLIN INVEST, V51, P3193, DOI 10.1172/JCI107146; THORLACIUSUSSING O, 1987, NEUROENDOCRINOLOGY, V45, P233, DOI 10.1159/000124731; VALLEE BL, 1990, P NATL ACAD SCI USA, V87, P220, DOI 10.1073/pnas.87.1.220; YPHANTIS DA, 1964, BIOCHEMISTRY-US, V3, P297, DOI 10.1021/bi00891a003	25	205	222	0	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 2	1991	253	5019					545	548		10.1126/science.1907025	http://dx.doi.org/10.1126/science.1907025			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FZ347	1907025				2022-12-24	WOS:A1991FZ34700033
J	KRAUZLIS, RJ; LISBERGER, SG				KRAUZLIS, RJ; LISBERGER, SG			VISUAL-MOTION COMMANDS FOR PURSUIT EYE-MOVEMENTS IN THE CEREBELLUM	SCIENCE			English	Article							HORSERADISH-PEROXIDASE; RHESUS-MONKEY; VESTIBULOOCULAR REFLEX; PRIMATE FLOCCULUS; PURKINJE-CELLS; PROJECTIONS; MACAQUE; TRANSPORT; RESPONSES; NUCLEI	Eye movements that follow a target (pursuit eye movements) facilitate high acuity visual perception of moving targets by transforming visual motion inputs into motor commands that match eye motion to target motion. The performance of pursuit eye movements requires the cerebellar flocculus, which processes both visual motion and oculomotor signals. Electrophysiological recordings from floccular Purkinje cells have allowed the identification of their firing patterns during generation of the image velocity and image acceleration signals used for pursuit. Analysis with a method based on a behavioral model converted the time-varying spike trains of floccular Purkinje cells into a description of the firing rate contributed by three visual motion signals and one oculomotor input. The flocculus encodes all the signals needed to guide pursuit.	UNIV CALIF SAN FRANCISCO,GRAD PROGRAM NEUROSCI,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	KRAUZLIS, RJ (corresponding author), UNIV CALIF SAN FRANCISCO,WM KECK FDN CTR INTEGRAT NEUROSCI,DEPT PHYSIOL,SAN FRANCISCO,CA 94143, USA.			Richard, Krauzlis/0000-0002-1826-0447				BALABAN CD, 1981, NEUROSCI LETT, V27, P101, DOI 10.1016/0304-3940(81)90251-2; BRODAL P, 1982, J COMP NEUROL, V204, P44, DOI 10.1002/cne.902040106; BRODAL P, 1978, BRAIN, V101, P251, DOI 10.1093/brain/101.2.251; BRODAL P, 1979, NEUROSCIENCE, V4, P193, DOI 10.1016/0306-4522(79)90082-4; Gerrits NM, 1987, EXP BRAIN RES SUPPL, V17, P26; GLICKSTEIN M, 1980, J COMP NEUROL, V190, P209, DOI 10.1002/cne.901900202; GOLDREICH D, 1987, Society for Neuroscience Abstracts, V13, P170; GOLDREICH D, IN PRESS J NEUROPHYS; Krauzlis RJ, 1989, NEURAL COMPUT, V1, P116, DOI 10.1162/neco.1989.1.1.116; KRAUZLIS R J, 1987, Society for Neuroscience Abstracts, V13, P170; KRAUZLIS R J, 1988, Society for Neuroscience Abstracts, V14, P798; LANGER T, 1985, J COMP NEUROL, V235, P1, DOI 10.1002/cne.902350102; LANGER T, 1985, J COMP NEUROL, V235, P26, DOI 10.1002/cne.902350103; LISBERGER SG, 1987, ANNU REV NEUROSCI, V10, P97, DOI 10.1146/annurev.ne.10.030187.000525; LISBERGER SG, 1988, SCIENCE, V242, P771, DOI 10.1126/science.3142040; LISBERGER SG, 1978, J NEUROPHYSIOL, V41, P733, DOI 10.1152/jn.1978.41.3.733; MILES FA, 1975, SCIENCE, V189, P1000, DOI 10.1126/science.1083068; MILES FA, 1980, J NEUROPHYSIOL, V43, P1437, DOI 10.1152/jn.1980.43.5.1437; MORRIS E J, 1985, Society for Neuroscience Abstracts, V11, P79; NODA H, 1909, J PHYSIOL-LONDON, V294, P349; Pearlmutter BA, 1989, NEURAL COMPUT, V1, P263, DOI 10.1162/neco.1989.1.2.263; RASHBASS C, 1961, J PHYSIOL-LONDON, V159, P326, DOI 10.1113/jphysiol.1961.sp006811; STONE LS, 1990, J NEUROPHYSIOL, V63, P1241, DOI 10.1152/jn.1990.63.5.1241; STONE LS, 1990, J NEUROPHYSIOL, V63, P1262, DOI 10.1152/jn.1990.63.5.1262; STONE LS, 1989, EXP BRAIN RES S, V17, P299; ZEE DS, 1981, J NEUROPHYSIOL, V46, P878, DOI 10.1152/jn.1981.46.4.878	26	34	34	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 2	1991	253	5019					568	571		10.1126/science.1907026	http://dx.doi.org/10.1126/science.1907026			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FZ347	1907026				2022-12-24	WOS:A1991FZ34700041
J	HWANG, SS; BOYLE, TJ; LYERLY, HK; CULLEN, BR				HWANG, SS; BOYLE, TJ; LYERLY, HK; CULLEN, BR			IDENTIFICATION OF THE ENVELOPE V3 LOOP AS THE PRIMARY DETERMINANT OF CELL TROPISM IN HIV-1	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; IMMUNE-DEFICIENCY SYNDROME; CENTRAL NERVOUS-SYSTEM; T-CELL; MONONUCLEAR PHAGOCYTES; NEUTRALIZING DETERMINANT; AIDS PATIENTS; CD4 ANTIGEN; SOLUBLE CD4; INFECTION	Cells of the monocyte-macrophage lineage are targets for human immunodeficiency virus-1 (HIV-1) infection in vivo. However, many laboratory strains of HIV-l that efficiently infect transformed T cell lines replicate poorly in macrophages. A 20-amino acid sequence from the macrophage-tropic BaL isolate of HIV-1 was sufficient to confer macrophage tropism on HTLV-IIIB, a T cell line-tropic isolate. This small sequence element is in the V3 loop, the envelope domain that is the principal neutralizing determinant of HIV-1. Thus, the V3 loop not only serves as a target of the host immune response but is also pivotal in determining HIV-l tissue tropism.	DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT HISTOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT SURG,DURHAM,NC 27710	Duke University; Howard Hughes Medical Institute; Duke University; Duke University			Lyerly, Herbert K/B-6528-2014; Lyerly, Herbert Kim/AAX-4925-2020	Lyerly, Herbert K/0000-0002-0063-4770; Lyerly, Herbert Kim/0000-0002-0063-4770				ANDERSEN KB, 1987, J GEN VIROL, V68, P2193, DOI 10.1099/0022-1317-68-8-2193; ANDERSEN KB, 1989, J GEN VIROL, V70, P1921, DOI 10.1099/0022-1317-70-7-1921; APPLEYARD G, 1985, J GEN VIROL, V66, P363, DOI 10.1099/0022-1317-66-2-363; BALDWIN GC, 1990, P NATL ACAD SCI USA, V87, P3933, DOI 10.1073/pnas.87.10.3933; BOYLE TJ, UNPUB; Boyum A, 1968, SCAND J CLIN LAB I S, V97, P51; CAMERINI D, 1990, CELL, V60, P747, DOI 10.1016/0092-8674(90)90089-W; CHENGMAYER C, 1990, J VIROL, V64, P4390, DOI 10.1128/JVI.64.9.4390-4398.1990; CHENGMAYER C, 1988, SCIENCE, V240, P80, DOI 10.1126/science.2832945; CHOPPIN PW, 1980, REV INFECT DIS, V2, P40; CLAPHAM PR, 1989, NATURE, V337, P368, DOI 10.1038/337368a0; CLEMENTS GJ, 1991, AIDS RES HUM RETROV, V7, P3, DOI 10.1089/aid.1991.7.3; COLLMAN R, 1989, J EXP MED, V170, P1149, DOI 10.1084/jem.170.4.1149; COLLMAN R, 1990, J VIROL, V64, P4468, DOI 10.1128/JVI.64.9.4468-4476.1990; CROWL R, 1985, CELL, V41, P979, DOI 10.1016/S0092-8674(85)80078-7; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DEEN KC, 1988, NATURE, V331, P82, DOI 10.1038/331082a0; EVANS LA, 1987, J IMMUNOL, V138, P3415; FENYO EM, 1988, J VIROL, V62, P4414; FISHER RA, 1988, NATURE, V331, P76, DOI 10.1038/331076a0; FREED EO, 1991, J VIROL, V65, P190, DOI 10.1128/JVI.65.1.190-194.1991; GARRETT ED, 1991, J VIROL, V65, P1653, DOI 10.1128/JVI.65.3.1653-1657.1991; GARTNER S, 1986, SCIENCE, V233, P215, DOI 10.1126/science.3014648; GENDELMAN HE, 1989, AIDS, V3, P475, DOI 10.1097/00002030-198908000-00001; GOUDSMIT J, 1988, P NATL ACAD SCI USA, V85, P4478, DOI 10.1073/pnas.85.12.4478; HATTORI T, 1989, FEBS LETT, V248, P48, DOI 10.1016/0014-5793(89)80429-6; JAVAHERIAN K, 1990, SCIENCE, V250, P1590, DOI 10.1126/science.1703322; KIM SY, 1990, J VIROL, V64, P5600, DOI 10.1128/JVI.64.11.5600-5604.1990; KOENIG S, 1986, SCIENCE, V233, P1089, DOI 10.1126/science.3016903; KOYANAGI Y, 1987, SCIENCE, V236, P819, DOI 10.1126/science.3646751; LAROSA GJ, 1990, SCIENCE, V249, P932, DOI 10.1126/science.2392685; MADDON PJ, 1988, CELL, V54, P865, DOI 10.1016/S0092-8674(88)91241-X; MALIM MH, 1989, CELL, V58, P205, DOI 10.1016/0092-8674(89)90416-9; MCCLURE MO, 1988, EMBO J, V7, P513, DOI 10.1002/j.1460-2075.1988.tb02839.x; MCCLURE MO, 1990, J GEN VIROL, V71, P767, DOI 10.1099/0022-1317-71-4-767; MCCUNE JM, 1988, CELL, V53, P55, DOI 10.1016/0092-8674(88)90487-4; MELTZER MS, 1990, ANNU REV IMMUNOL, V8, P169, DOI 10.1146/annurev.iy.08.040190.001125; MOORE JP, 1991, J VIROL, V65, P1133, DOI 10.1128/JVI.65.3.1133-1140.1991; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; Nowell P.C, 1960, CANCER RES, V20, P562; OBRIEN WA, 1990, NATURE, V348, P69, DOI 10.1038/348069a0; OTSUKI K, 1981, ARCH VIROL, V70, P315, DOI 10.1007/BF01320246; PALKER TJ, 1988, P NATL ACAD SCI USA, V85, P1932, DOI 10.1073/pnas.85.6.1932; PAUZA CD, 1988, J CELL BIOL, V107, P959, DOI 10.1083/jcb.107.3.959; PERTOFT H, 1980, J IMMUNOL METHODS, V33, P221, DOI 10.1016/S0022-1759(80)80012-3; POMERANTZ RJ, 1991, J VIROL, V65, P1041, DOI 10.1128/JVI.65.2.1041-1045.1991; POTTS BJ, 1990, VIROLOGY, V175, P465, DOI 10.1016/0042-6822(90)90431-P; RUSCHE JR, 1988, P NATL ACAD SCI USA, V85, P3198, DOI 10.1073/pnas.85.9.3198; SCHEID A, 1976, VIROLOGY, V69, P265, DOI 10.1016/0042-6822(76)90213-0; SCHNITTMAN SM, 1989, SCIENCE, V245, P305, DOI 10.1126/science.2665081; SCHUITEMAKER H, 1991, J VIROL, V65, P356, DOI 10.1128/JVI.65.1.356-363.1991; SHAW GM, 1984, SCIENCE, V226, P1165, DOI 10.1126/science.6095449; SHIODA T, 1991, NATURE, V349, P167, DOI 10.1038/349167a0; SKINNER MA, 1988, J VIROL, V62, P4195, DOI 10.1128/JVI.62.11.4195-4200.1988; SMITH DH, 1987, SCIENCE, V238, P1704, DOI 10.1126/science.3500514; STEIN BS, 1987, CELL, V49, P659, DOI 10.1016/0092-8674(87)90542-3; STEPHENS PE, 1990, NATURE, V343, P219, DOI 10.1038/343219b0; STOLER MH, 1986, JAMA-J AM MED ASSOC, V256, P2360, DOI 10.1001/jama.256.17.2360; TERSMETTE M, 1989, J VIROL, V63, P2118, DOI 10.1128/JVI.63.5.2118-2125.1989; TOTH TE, 1982, AM J VET RES, V43, P967; ULMER AJ, 1979, J IMMUNOL METHODS, V30, P1, DOI 10.1016/0022-1759(79)90268-0; WHITE J, 1983, Q REV BIOPHYS, V16, P151, DOI 10.1017/S0033583500005072; WILEY CA, 1986, P NATL ACAD SCI USA, V83, P7089, DOI 10.1073/pnas.83.18.7089; WILLEY RL, 1989, J VIROL, V63, P3595, DOI 10.1128/JVI.63.9.3595-3600.1989; WOLFS TFW, 1990, P NATL ACAD SCI USA, V87, P9938, DOI 10.1073/pnas.87.24.9938; YOSHIKURA H, 1981, VIROLOGY, V113, P503, DOI 10.1016/0042-6822(81)90178-1	66	806	844	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 5	1991	253	5015					71	74		10.1126/science.1905842	http://dx.doi.org/10.1126/science.1905842			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FV177	1905842				2022-12-24	WOS:A1991FV17700036
J	VANOPSTAL, AJ; HEPP, K; HESS, BJM; STRAUMANN, D; HENN, V				VANOPSTAL, AJ; HEPP, K; HESS, BJM; STRAUMANN, D; HENN, V			2-DIMENSIONAL RATHER THAN 3-DIMENSIONAL REPRESENTATION OF SACCADES IN MONKEY SUPERIOR COLLICULUS	SCIENCE			English	Article							ALERT RHESUS-MONKEY; EYE-MOVEMENTS; OCULOMOTOR SYSTEM; LISTINGS LAW; STIMULATION; DEFICITS; NEURONS; COIL	Saccades are controlled by neurons in the brainstem reticular formation that receive input from the superior colliculus and cortex. Recently two quantitative models have been proposed for the role of the colliculus in the generation of three-dimensional eye movements. In order to test these models, three-dimensional eye movements were measured in the alert monkey to investigate whether the saccadic motor map of the superior colliculus is two-dimensional, representing retinal target vectors, or three-dimensional, representing three-dimensional motor error for the rotation of the eye. Electrical stimulation of the superior colliculus produced two-dimensional, not three-dimensional, eye movements. It is therefore concluded that the collicular motor map is two-dimensional.	UNIV HOSP ZURICH, DEPT NEUROL, CH-8091 ZURICH, SWITZERLAND; SWISS FED INST TECHNOL, DEPT PHYS, CH-8093 ZURICH, SWITZERLAND	University of Zurich; University Zurich Hospital; Swiss Federal Institutes of Technology Domain; ETH Zurich			van Opstal, John/D-1907-2010	van Opstal, John/0000-0001-5957-5712				ALBANO JE, 1982, J NEUROPHYSIOL, V48, P338, DOI 10.1152/jn.1982.48.2.338; FERMAN L, 1987, VISION RES, V27, P811, DOI 10.1016/0042-6989(87)90078-2; HAUSTEIN W, 1989, BIOL CYBERN, V60, P411, DOI 10.1007/BF00204696; HENN V, 1991, VESTIBULAR BRAIN STE; HEPP K, 1990, COMMUN MATH PHYS, V132, P285, DOI 10.1007/BF02278012; HEPP K, 1990, Society for Neuroscience Abstracts, V16, P1084; HEPP K, 1989, NEUROBIOLOGY SACCADI, P105; HESS BJM, 1990, VISION RES, V30, P597, DOI 10.1016/0042-6989(90)90070-2; HIKOSAKA O, 1986, EXP BRAIN RES, V61, P531; HIKOSAKA O, 1985, J NEUROPHYSIOL, V53, P266, DOI 10.1152/jn.1985.53.1.266; JAY MF, 1987, J NEUROPHYSIOL, V57, P35, DOI 10.1152/jn.1987.57.1.35; LEE CK, 1988, NATURE, V332, P357, DOI 10.1038/332357a0; RAYBOURN MS, 1977, J NEUROPHYSIOL, V40, P861, DOI 10.1152/jn.1977.40.4.861; ROBINSON DA, 1972, VISION RES, V12, P1795, DOI 10.1016/0042-6989(72)90070-3; ROBINSON DA, 1963, IEEE T BIO-MED ENG, VBM10, P137, DOI 10.1109/TBMEL.1963.4322822; SCHILLER PH, 1980, J NEUROPHYSIOL, V44, P1175, DOI 10.1152/jn.1980.44.6.1175; SCHILLER PH, 1971, J NEUROPHYSIOL, V34, P920, DOI 10.1152/jn.1971.34.5.920; SCHILLER PH, 1972, J NEUROPHYSIOL, V35, P915, DOI 10.1152/jn.1972.35.6.915; SPARKS DL, 1978, BRAIN RES, V156, P1, DOI 10.1016/0006-8993(78)90075-6; SPARKS DL, 1980, BRAIN RES, V190, P39, DOI 10.1016/0006-8993(80)91158-0; STRAUMANN D, 1990, EUR J NEUROSCI, V3, P163; STRAUMANN D, IN PRESS EXP BRAIN R; TWEED D, 1988, Society for Neuroscience Abstracts, V14, P958; TWEED D, 1987, J NEUROPHYSIOL, V58, P832, DOI 10.1152/jn.1987.58.4.832; TWEED D, 1988, ANN NY ACAD SCI, V545, P128; TWEED DB, 1990, NEURAL NETWORKS, V3, P75, DOI 10.1016/0893-6080(90)90046-N; VANOPSTAL AJ, 1990, EXP BRAIN RES, V79, P299, DOI 10.1007/BF00608239; VANOPSTAL AJ, 1990, SOC NEUR ABSTR, V16, P1084; von Helmholtz H, 1896, HDB PHYSL OPTIK; WURTZ RH, 1972, J NEUROPHYSIOL, V35, P575, DOI 10.1152/jn.1972.35.4.575	30	91	92	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 31	1991	252	5010					1313	1315		10.1126/science.1925545	http://dx.doi.org/10.1126/science.1925545			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FN857	1925545				2022-12-24	WOS:A1991FN85700042
J	OTTEN, GR; GERMAIN, RN				OTTEN, GR; GERMAIN, RN			SPLIT ANERGY IN A CD8+ T-CELL - RECEPTOR-DEPENDENT CYTOLYSIS IN THE ABSENCE OF INTERLEUKIN-2 PRODUCTION	SCIENCE			English	Article							LYMPHOCYTES-T; CLASS-I; ANTIGEN; CLONES; INDUCTION; ACTIVATION; RESPONSIVENESS; TOLERANCE; INVIVO; EVENTS	Engagement of the antigen-specific receptor (TCR) of CD4+ T lymphocytes without a second (costimulatory) signal prevents the subsequent production of interleukin-2 (IL-2) by these cells. Because IL-2 is a key immunoregulatory lymphokine and is also produced by a subset of CD8+ T cells that are able to kill target cells, the effect of engaging the TCR of one such clone in the absence of costimulatory signals was examined. The capacity for TCR-dependent IL-2 production was lost, indicating comparable costimulator-dependent signaling requirements for IL-2 production in CD4+ and CD8+ T cells. However, TCR-mediated cytotoxicity was not impaired, implying that costimulation is required for only certain TCR-dependent effector functions.			OTTEN, GR (corresponding author), NIAID,LYMPHOCYTE BIOL SECT,IMMUNOL LAB,BETHESDA,MD 20892, USA.		Germain, Ronald N./Z-1945-2019; Germain, Ronald/ABE-7090-2020					ASHWELL JD, 1987, J EXP MED, V165, P173, DOI 10.1084/jem.165.1.173; AZUMA T, 1989, J IMMUNOL, V143, P1; BAKER PE, 1979, J EXP MED, V149, P273, DOI 10.1084/jem.149.1.273; BLACKMAN M, 1990, SCIENCE, V248, P1335, DOI 10.1126/science.1972592; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; HSI ED, 1989, J BIOL CHEM, V264, P10836; JENKINS MK, 1988, J IMMUNOL, V140, P3324; JENKINS MK, 1987, J EXP MED, V165, P302, DOI 10.1084/jem.165.2.302; JENKINS MK, 1987, P NATL ACAD SCI USA, V84, P5409, DOI 10.1073/pnas.84.15.5409; LEGROS GS, 1985, J IMMUNOL, V135, P4009; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; MATIS LA, 1985, J IMMUNOL, V135, P703; MIZUOCHI T, 1986, J EXP MED, V163, P603, DOI 10.1084/jem.163.3.603; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; MUELLER DL, 1989, ANNU REV IMMUNOL, V7, P445, DOI 10.1146/annurev.iy.07.040189.002305; QUILL H, 1987, J IMMUNOL, V138, P3704; RAMSDELL F, 1989, SCIENCE, V246, P1038, DOI 10.1126/science.2511629; ROBERTS JL, 1990, J EXP MED, V171, P935, DOI 10.1084/jem.171.3.935; ROOPENIAN DC, 1983, J IMMUNOL, V130, P542; ROSENBERG AS, 1988, J EXP MED, V168, P33, DOI 10.1084/jem.168.1.33; SCHWARTZ RH, 1989, COLD SPRING HARB SYM, V54, P605; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; SHIMONKEVITZ R, 1983, J EXP MED, V158, P303, DOI 10.1084/jem.158.2.303; VITIELLO A, 1989, J IMMUNOL, V143, P1512; VONBOEHMER H, 1983, EUR J IMMUNOL, V13, P176, DOI 10.1002/eji.1830130216; WEISS A, 1986, ANNU REV IMMUNOL, V4, P593, DOI 10.1146/annurev.iy.04.040186.003113; WIDMER MB, 1981, NATURE, V294, P750, DOI 10.1038/294750a0	27	211	219	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 8	1991	251	4998					1228	1231		10.1126/science.1900952	http://dx.doi.org/10.1126/science.1900952			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FA691	1900952				2022-12-24	WOS:A1991FA69100040
J	LADIAS, JAA; KARATHANASIS, SK				LADIAS, JAA; KARATHANASIS, SK			REGULATION OF THE APOLIPOPROTEIN-A-I GENE BY ARP-1, A NOVEL MEMBER OF THE STEROID-RECEPTOR SUPERFAMILY	SCIENCE			English	Article							COUP TRANSCRIPTION FACTOR; MESSENGER-RNA; HORMONE RECEPTOR; THYROID-HORMONE; INVITRO TRANSCRIPTION; ESTROGEN-RECEPTOR; EXPRESSION; RAT; ELEMENT; BINDS	Apolipoprotein AI (apoAI) is a lipid-binding protein that participates in the transport of cholesterol and other lipids in the plasma. A complementary DNA clone for a protein that bound to regulatory elements of the apoAI gene was isolated. This protein, designed apoAI regulatory protein-1 (ARP-1), is a novel member of the steroid hormone receptor superfamily. ARP-1 bound to DNA as a dimer, and its dimerization domain was localized to the COOH-terminal region. ARP-1 also bound to a thyroid hormone-responsive element and to regulatory regions of the apoB, apoCIII, insulin, and ovalbumin genes. In cotransfection experiments, ARP-1 down-regulated the apoAI gene. The involvement of ARP-1 in the regulation of apoAI gene expression suggests that it may participate in lipid metabolism and cholesterol homeostasis.	HARVARD UNIV,SCH MED,DEPT CELLULAR & MOLEC PHYSIOL,BOSTON,MA 02115	Harvard University; Harvard Medical School	LADIAS, JAA (corresponding author), CHILDRENS HOSP MED CTR,DEPT CARDIOL,MOLEC & CELLULAR CARDIOL LAB,BOSTON,MA 02115, USA.							ARCHER TK, 1986, J BIOL CHEM, V261, P5067; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BRESLOW JL, 1989, METABOLIC BASIS INHE, P1251; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; COSTA RH, 1989, MOL CELL BIOL, V9, P1415, DOI 10.1128/MCB.9.4.1415; DALMAN FC, 1989, J BIOL CHEM, V264, P19815; DAVIDSON NO, 1988, J LIPID RES, V29, P1511; ELSHOURBAGY NA, 1985, P NATL ACAD SCI USA, V82, P8242, DOI 10.1073/pnas.82.23.8242; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GODOWSKI PJ, 1987, NATURE, V325, P365, DOI 10.1038/325365a0; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; HADDAD IA, 1986, J BIOL CHEM, V261, P3268; HWUNG YP, 1988, MOL CELL BIOL, V8, P2070, DOI 10.1128/MCB.8.5.2070; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KLEINHITPASS L, 1989, MOL CELL BIOL, V9, P43, DOI 10.1128/MCB.9.1.43; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LADIAS JAA, UNPUB; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; Maxam A M, 1980, Methods Enzymol, V65, P499; MILLER JCE, 1983, P NATL ACAD SCI-BIOL, V80, P1511, DOI 10.1073/pnas.80.6.1511; MIYAJIMA N, 1988, NUCLEIC ACIDS RES, V16, P11057, DOI 10.1093/nar/16.23.11057; MLODZIK M, 1990, CELL, V60, P211, DOI 10.1016/0092-8674(90)90737-Y; MONACI P, 1988, EMBO J, V7, P2075, DOI 10.1002/j.1460-2075.1988.tb03047.x; REUE K, 1988, J BIOL CHEM, V263, P6857; REUE K, 1988, J BIOL CHEM, V263, P11452; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J., 1989, MOL CLONING; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASTRY KN, 1988, MOL CELL BIOL, V8, P605, DOI 10.1128/MCB.8.2.605; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SORCITHOMAS M, 1989, J LIPID RES, V30, P1397; STAELS B, 1989, J LIPID RES, V30, P1137; TSAI SY, 1988, CELL, V55, P361, DOI 10.1016/0092-8674(88)90059-1; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; WANG LH, 1989, NATURE, V340, P163, DOI 10.1038/340163a0; WIDOM RL, 1991, MOL CELL BIOL, V11, P677, DOI 10.1128/MCB.11.2.677	41	378	400	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 1	1991	251	4993					561	565		10.1126/science.1899293	http://dx.doi.org/10.1126/science.1899293			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EV459	1899293				2022-12-24	WOS:A1991EV45900052
J	BAUD, FJ; BARRIOT, P; TOFFIS, V; RIOU, B; VICAUT, E; LECARPENTIER, Y; BOURDON, R; ASTIER, A; BISMUTH, C				BAUD, FJ; BARRIOT, P; TOFFIS, V; RIOU, B; VICAUT, E; LECARPENTIER, Y; BOURDON, R; ASTIER, A; BISMUTH, C			ELEVATED BLOOD CYANIDE CONCENTRATIONS IN VICTIMS OF SMOKE-INHALATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CARBON-MONOXIDE; COMBUSTION PRODUCTS; EXPOSURE DURATION; GLASGOW AREA; FIRE DEATHS; INTOXICATION; CARBOXYHEMOGLOBIN; TOXICITY; PYRUVATE; GLUCOSE	Background. The nature of the toxic gases that cause death from smoke inhalation is not known. In addition to carbon monoxide, hydrogen cyanide may be responsible, but its role is uncertain, because blood cyanide concentrations are often measured only long after exposure. Methods. We measured cyanide concentrations in blood samples obtained at the scene of residential fires from 109 fire victims before they received any treatment. We compared the results with those in 114 persons with drug intoxication (40 subjects), carbon monoxide intoxication (29 subjects), or trauma (45 subjects). The metabolic effect of smoke inhalation was assessed by measuring plasma lactate at the time of admission to the hospital in 39 patients who did not have severe burns. Results. The mean (+/- SD) blood cyanide concentrations in the 66 surviving fire victims (21.6 +/- 36.4-mu-mol per liter, P < 0.001) and the 43 victims who died (116.4 +/- 89.6-mu-mol per liter, P < 0.001) were significantly higher than those in the 114 control subjects (5.0 +/- 5.5-mu-mol per liter). Among the 43 victims who died, the blood cyanide concentrations were above 40-mu-mol per liter in 32 (74 percent), and above 100-mu-mol per liter in 20 of these (46 percent). There was a significant correlation between blood cyanide and carbon monoxide concentrations in the fire victims (P < 0.001). Plasma lactate concentrations at the time of hospital admission correlated more closely with blood cyanide concentrations than with blood carbon monoxide concentrations. Plasma lactate concentrations above 10 mmol per liter were a sensitive indicator of cyanide intoxication, as defined by the presence of a blood cyanide concentration above 40-mu-mol per liter. Conclusions. Residential fires may cause cyanide poisoning. At the time of a patient's hospital admission, an elevated plasma lactate concentration is a useful indicator of cyanide toxicity in fire victims who do not have severe burns.	BRIGADE SAPEURS POMPIERS PARIS,SERV MED,PARIS,FRANCE; UNIV PARIS 07,HOP FERNAND WIDAL,TOXIKOL LAB,F-75475 PARIS 10,FRANCE; HOP HENRI MONDOR,TOXIKOL LAB,F-94010 CRETEIL,FRANCE; ECOLE POLYTECH,LOAENSTA,INSERM,U275,F-91128 PALAISEAU,FRANCE; HOP BICETRE,F-94270 LE KREMLIN BICETR,FRANCE; UNIV PARIS 06,HOP PITIE SALPETRIERE,DEPT ANESTHESIE REANIMAT,PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut Polytechnique de Paris; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite	BAUD, FJ (corresponding author), UNIV PARIS 07,HOP FERNAND WIDAL,DEPT BIOPHYS,200 RUE FAUBOURG ST DENIS,F-75010 PARIS,FRANCE.							ALARIE Y, 1985, ANNU REV PHARMACOL, V25, P325, DOI 10.1146/annurev.pa.25.040185.001545; ANDERSON RA, 1982, MED SCI LAW, V22, P35, DOI 10.1177/002580248202200106; ANDERSON RA, 1981, MED SCI LAW, V21, P175, DOI 10.1177/002580248102100305; ANDERSON RC, 1986, ANAL METHODS HUMAN T, P289; Ballantyne B., 1987, CLIN EXPT TOXICOLOGY, P248; BERTOL E, 1983, FORENSIC SCI INT, V22, P111, DOI 10.1016/0379-0738(83)90002-6; BIRKY MM, 1981, B NEW YORK ACAD MED, V57, P997; BRIGHT JE, 1988, HUM TOXICOL, V7, P183, DOI 10.1177/096032718800700214; CLARK CJ, 1981, LANCET, V1, P1332; ELLENHORN MJ, 1988, MED TOXICOLOGY DIAGN, P888; FABRE R, 1960, PRECIS TOXICOLOGIE, V1, P120; FELDSTEIN M, 1954, J LAB CLIN MED, V44, P166; HALL AH, 1989, J TOXICOL CLIN EXPER, V9, P3; HOLLANDER M, 1973, NONPARAMETRIC STATIS; Karter Jr MJ, 1986, FIRE J, V80, P26; Linnell J. L., 1987, CLIN EXPT TOXICOLOGY, P427; Loke J, 1988, PATHOPHYSIOLOGY TREA, P453; MARBACH EP, 1967, CLIN CHEM, V13, P314; Marrs T., 1987, CLIN EXPT TOXICOLOGY, P217; Marrs T. C, 1987, CLIN EXPT TOXICOLOGY, P383; MIERLEY MC, 1983, JAMA-J AM MED ASSOC, V249, P1466, DOI 10.1001/jama.249.11.1466; MOORE SJ, 1987, J PHARMACOL EXP THER, V242, P70; MOUREU H, 1957, Arch Mal Prof, V18, P116; NORRIS JC, 1986, TOXICOLOGY, V40, P121, DOI 10.1016/0300-483X(86)90073-9; PURSER DA, 1984, ARCH ENVIRON HEALTH, V39, P394, DOI 10.1080/00039896.1984.10545871; Rieders F, 1975, METHODOLOGY ANAL TOX, VI, P113; RIOU B, 1990, J NEUROSURG ANESTH, V2, P296, DOI 10.1097/00008506-199012000-00008; RIOU B, 1991, ANESTHESIOLOGY, V74, P552, DOI 10.1097/00000542-199103000-00025; SILVERMAN SH, 1988, J TRAUMA, V28, P171, DOI 10.1097/00005373-198802000-00007; SOKAL JA, 1985, J APPL TOXICOL, V5, P395, DOI 10.1002/jat.2550050611; SOKAL JA, 1985, ARCH TOXICOL, V57, P196, DOI 10.1007/BF00290887; SYMINGTON IS, 1978, LANCET, V2, P91; TERRILL JB, 1978, SCIENCE, V200, P1343, DOI 10.1126/science.208143; Troup C. M., 1987, CLIN EXPT TOXICOLOGY, P22; Vogel S, 1987, CLIN EXPT TOXICOLOGY, P451; YAMAMOTO K, 1975, Z RECHTSMED, V76, P11, DOI 10.1007/BF02116793; ZIKRIA BA, 1972, J TRAUM, V12, P641, DOI 10.1097/00005373-197208000-00001	37	296	305	2	15	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 19	1991	325	25					1761	1766		10.1056/NEJM199112193252502	http://dx.doi.org/10.1056/NEJM199112193252502			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GV739	1944484				2022-12-24	WOS:A1991GV73900002
J	WUTHRICH, K; VONFREYBERG, B; WEBER, C; WIDER, G; TRABER, R; WIDMER, H; BRAUN, W				WUTHRICH, K; VONFREYBERG, B; WEBER, C; WIDER, G; TRABER, R; WIDMER, H; BRAUN, W			RECEPTOR-INDUCED CONFORMATION CHANGE OF THE IMMUNOSUPPRESSANT CYCLOSPORINE-A	SCIENCE			English	Editorial Material							NUCLEAR-MAGNETIC-RESONANCE; CIS-TRANS ISOMERASE; 2D H-1-NMR SPECTRA; DOUBLE-HALF-FILTER; NMR-SPECTROSCOPY; BINDING-PROTEIN; CYCLOPHILIN		SANDOZ PHARMA AG,PRAKLIN FORSCH,CH-4002 BASEL,SWITZERLAND	Novartis; Sandoz	WUTHRICH, K (corresponding author), SWISS FED INST TECHNOL,INST MOLEK BIOL & BIOPHYS,CH-8093 ZURICH,SWITZERLAND.		Braun, Werner/A-6642-2012	Wider, Gerhard/0000-0001-9366-7645				BOREL JF, 1986, CICLOSPORIN; FESIK SW, 1988, NATURE, V332, P865, DOI 10.1038/332865a0; FESIK SW, 1988, BIOCHEMISTRY-US, V27, P8297, DOI 10.1021/bi00422a001; FESIK SW, 1991, BIOCHEMISTRY-US, V30, P6575; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; GRIFFEY RH, 1987, Q REV BIOPHYS, V19, P51, DOI 10.1017/S0033583500004029; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; KALLEN J, 1991, NATURE, V353, P276, DOI 10.1038/353276a0; KAWAMUKAI M, 1989, J BACTERIOL, V171, P4525, DOI 10.1128/JB.171.8.4525-4529.1989; KESSLER H, 1990, HELV CHIM ACTA, V73, P1818, DOI 10.1002/hlca.19900730703; KOLETSKY AJ, 1986, J IMMUNOL, V137, P1054; Lautz J, 1987, J Comput Aided Mol Des, V1, P219, DOI 10.1007/BF01677046; LAUTZ J, 1990, BIOPOLYMERS, V29, P1969; LOOSLI HR, 1985, HELV CHIM ACTA, V68, P682, DOI 10.1002/hlca.19850680319; MICHNICK SW, 1991, SCIENCE, V252, P836, DOI 10.1126/science.1709301; MOORE JM, 1991, NATURE, V351, P248, DOI 10.1038/351248a0; OTTING G, 1986, J MAGN RESON, V70, P500, DOI 10.1016/0022-2364(86)90144-7; OTTING G, 1989, J MAGN RESON, V85, P586, DOI 10.1016/0022-2364(89)90249-7; OTTING G, 1990, Q REV BIOPHYS, V23, P39, DOI 10.1017/S0033583500005412; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; TAKAHASHI N, 1989, NATURE, V337, P473, DOI 10.1038/337473a0; VANDUYNE GD, 1991, SCIENCE, V252, P839, DOI 10.1126/science.1709302; WEBER C, 1991, BIOCHEMISTRY-US, V30, P6563, DOI 10.1021/bi00240a029; WENGER RM, 1985, ANGEW CHEM INT EDIT, V24, P77, DOI 10.1002/anie.198500773; WIDER G, 1990, J AM CHEM SOC, V112, P9015, DOI 10.1021/ja00180a076; WIDER G, 1991, J AM CHEM SOC, V113, P4676, DOI 10.1021/ja00012a044; WUTHRICH K, 1991, FEBS LETT, V285, P237, DOI 10.1016/0014-5793(91)80808-G	27	78	78	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 15	1991	254	5034					953	954		10.1126/science.1948082	http://dx.doi.org/10.1126/science.1948082			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GP883	1948082				2022-12-24	WOS:A1991GP88300030
J	STREMMEL, W; MEYERROSE, KW; NIEDERAU, C; HEFTER, H; KREUZPAINTNER, G; STROHMEYER, G				STREMMEL, W; MEYERROSE, KW; NIEDERAU, C; HEFTER, H; KREUZPAINTNER, G; STROHMEYER, G			WILSON DISEASE - CLINICAL PRESENTATION, TREATMENT, AND SURVIVAL	ANNALS OF INTERNAL MEDICINE			English	Review							TRIETHYLENE TETRAMINE DIHYDROCHLORIDE; COPPER; PENICILLAMINE; DIAGNOSIS; THERAPY; ZINC; DEFICIENCY; TRIENTINE	Objective: To evaluate the diagnostic features, clinical course, and overall long-term survival of patients with Wilson disease. Design: Retrospective cohort study with a mean follow-up period of 14.2 years. Setting: A university medical center and a community hospital. Patients: Fifty-one consecutive patients with Wilson disease were evaluated between 1957 and 1989. Interventions: Patients were treated with D-penicillamine (600 to 1800 mg/d). Two patients with end-stage liver disease had liver transplantation. Main Results: Initial symptoms occurred at a mean age of 15.5 years. At diagnosis, the most common neurologic signs were dysarthria, tremor, writing difficulties, and ataxia followed by hypersalivation and headache. Somatic symptoms included abdominal pain, hepatomegaly, splenomegaly, cirrhosis of the liver, and thrombocytopenia. The mean serum concentrations of ceruloplasmin and copper were 44 mg/L and 4.7-mu-mol/L, respectively. The mean basal urinary copper excretion was 5.5-mu-mol/d, and the mean hepatic copper concentration was 19.6-mu-mol/g dry weight. Free serum copper concentration (mean, 2.7-mu-mol/L) was a reliable indicator of disease and was useful in assessing the effectiveness of therapy (values < 1.6-mu-mol/L). Treatment with D-penicillamine improved most of the hematologic and neurologic abnormalities but had little effect on hepatomegaly and splenomegaly and did not reverse cirrhosis. Two patients died of fulminant hepatic failure during the observation period, whereas two others with end-stage liver disease had successful liver transplantation and remain asymptomatic. Long-term survival of patients with Wilson disease was similar to that of age- and sex-matched controls. Conclusion: Our results suggest that long-term treatment of patients with Wilson disease with D-penicillamine can relieve symptoms and improve prognosis.	UNIV HOSP DUSSELDORF, DUSSELDORF, GERMANY	Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf Hospital				Stremmel, Wolfgang/0000-0002-8545-1753				Bachmann H, 1979, Psychiatr Neurol Med Psychol (Leipz), V31, P393; BONNETAMIR B, 1990, ANN HUM GENET, V54, P155, DOI 10.1111/j.1469-1809.1990.tb00372.x; BREWER GJ, 1987, P SOC EXP BIOL MED, V184, P446; BREWER GJ, 1983, ANN INTERN MED, V99, P314, DOI 10.7326/0003-4819-99-3-314; CZAJA MJ, 1987, J CLIN INVEST, V80, P1200, DOI 10.1172/JCI113180; EDWARDS CQ, 1979, CLIN GENET, V15, P311; FRYDMAN M, 1985, P NATL ACAD SCI USA, V82, P1819, DOI 10.1073/pnas.82.6.1819; GIBBS K, 1980, LANCET, V2, P538; HALVERSON PB, 1978, JAMA-J AM MED ASSOC, V240, P1870, DOI 10.1001/jama.240.17.1870; HOOGENRAAD TU, 1987, J NEUROL SCI, V77, P137, DOI 10.1016/0022-510X(87)90116-X; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KREUZPAINTER G, 1990, KLIN WOCHENSCHR, V68, P60; NIEDERAU C, 1985, NEW ENGL J MED, V313, P1256, DOI 10.1056/NEJM198511143132004; POPPER H, 1979, LANCET, V1, P1205; SCHEINBERG IH, 1987, NEW ENGL J MED, V317, P209, DOI 10.1056/NEJM198707233170405; SCHEINBERG IH, 1975, NEW ENGL J MED, V293, P1300, DOI 10.1056/NEJM197512182932507; STERNLIEB I, 1979, GASTROENTEROLOGY, V77, P138; STROHMEYER G, 1984, METABOLISM NUTRITION, P211; VANDENHAMER CJA, 1989, LANCET, V2, P442; WALSHE JM, 1956, AM J MED, V21, P487, DOI 10.1016/0002-9343(56)90066-3; WALSHE JM, 1977, Q J MED, V46, P73; WALSHE JM, 1982, LANCET, V1, P643; WALSHE JM, 1984, SEMIN LIVER DIS, V4, P252, DOI 10.1055/s-2008-1041775; WALSHE JM, 1988, LANCET, V2, P435; WALSHE JM, 1973, Q J MED, V42, P441; Walshe JM, 1986, ORPHAN DIS ORPHAN DR, P76; WESCH H, 1980, DEUT MED WOCHENSCHR, V105, P483, DOI 10.1055/s-2008-1070692	27	211	217	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1991	115	9					720	726		10.7326/0003-4819-115-9-720	http://dx.doi.org/10.7326/0003-4819-115-9-720			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GL697	1929042				2022-12-24	WOS:A1991GL69700011
J	KLEIN, ML				KLEIN, ML			MACULAR DEGENERATION - IS ASPIRIN A RISK FOR PROGRESSIVE DISEASE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											KLEIN, ML (corresponding author), OREGON HLTH SCI UNIV,PORTLAND,OR 97201, USA.							KINGHAM JD, 1988, NEW ENGL J MED, V318, P1126; 1990, ARCH OPHTHALMOL-CHIC, V108, P825; 1986, ARCH OPHTHALMOL-CHIC, V104, P503	3	13	13	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 23	1991	266	16					2279	2279						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GK661	1920731				2022-12-24	WOS:A1991GK66100041
J	SAMUELS, B; GLANTZ, SA				SAMUELS, B; GLANTZ, SA			THE POLITICS OF LOCAL TOBACCO CONTROL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Until the nonsmokers' rights movement, tobacco control activity was at the federal or state levels, which is where the tobacco industry dominates. Since the appearance of the nonsmokers' rights movement, progress in tobacco control has occurred primarily at the local level. In response to the success of this movement, the tobacco industry has developed "smokers' rights" groups and other tactics to fight local legislation. Several recent local campaigns in California illustrate these tactics. Tobacco control forces follow many paths, from sitting on the sidelines to making a serious commitment to smoking control legislation. Despite the tobacco industry's superior financial resources, the outcome of proposed local tobacco control legislation appears to depend on how seriously the health advocates mobilize in support of the local legislation. When the health community makes a serious commitment of time and resources, it wins. When it fails to make such a commitment, the tobacco industry prevails, more by default than by its superior financial resources.	UNIV CALIF SAN FRANCISCO,DEPT MED,DIV CARDIOL,BOX 0124,ROOM 1186M,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,INST HLTH POLICY STUDIES,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco								ARNOLD R, 1987, LOS ANGELES TIM 0403; BEGAY ME, 1991, U CALIFORNIA I HLTH, P55; BLOOM S, 1991, SACRAMENTO BEE  0419, pB1; CHAVEZ K, 1990, SACRAMENTO BEE  1201, pB1; DEMPSTER D, 1990, SACRAMENTO BEE  0912, pA1; FERREL D, 1990, LOS ANGELES TIM 1017, pA1; FERRIS J, 1991, CONTRA COSTA TI 0623; FITCH A, 1990, MUNICIPAL LEGISLATIV; FREEDMAN A, 1988, WALL ST J       0411; GALLUP G, 1989, GALLUP POLL     0416; GLANTZ SA, 1987, CIRCULATION, V76, P746, DOI 10.1161/01.CIR.76.4.746; GLANTZ SA, 1991, CIRCULATION, V83, P1, DOI 10.1161/01.CIR.83.1.1; HAGER P, 1987, LOS ANGELES TIM 0521; HANAUER P, 1985, NEW YORK STATE J MED, V85, P369; HANAUER P, 1986, LEGISLATIVE APPROACH, P1; IFERGAN SJ, 1987, BEVERLY HILLS CO MAY; JACOBS C, 1991, LOS ANGELES BUS 1022; JOSON J, 1991, DAILY REV       0317, P1; KING J, 1991, CONTRA COSTA TI 0511, pA5; KONRAD W, 1990, BUSINESS WEEK   0806, P48; MATHEWS J, 1991, SACRAMENTO BEE  0422; MAXWELL JC, 1989, ADVERTISING AGE 1204; MORRIS P, 1990, INDEPENDENT MAJOR DO; PERTSCHUK M, 1989, MAJOR LOCAL SMOKING; Pritchard R., 1986, US TOBACCO CAND 0717, P86; REYNOLDS RJ, 1989, INDEPENDENT EXPENDIT; SAMUELS BE, 1991, U CALIFORNIA I HLTH; STILLMAN FA, 1990, JAMA-J AM MED ASSOC, V264, P1565, DOI 10.1001/jama.264.12.1565; STUMBO B, 1986, LOS ANGELES TIM 0824, P11; STUMBO B, 1986, LOS ANGELES TIM 0824, P24; SYLVESTER K, 1989, GOVERNING        MAY, P34; TAYLOR P, 1984, SMOKE RING, P189; WARNER KE, 1989, AM J PUBLIC HEALTH, V79, P144, DOI 10.2105/AJPH.79.2.144; 1991, P MORRIS MAGAZINE, V6, P22; 1990, PRELIMINARY ANAL IMP; 1982, KERN COUNTY SMOKING; 1991, 1991 92 DIRECTORY LO, P195; 1986, HLTH CONSEQUENCES IN; 1991, SLO RESTAURANTS JOIN; 1978, PUBLIC ATTITUDES CIG; 1990, GENERAL PURPOSE RECI; 1990, US EPA600690006A PUB; 1987, CHOICE, V1, P4	43	106	107	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 16	1991	266	15					2110	2117		10.1001/jama.266.15.2110	http://dx.doi.org/10.1001/jama.266.15.2110			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GJ474	1920699				2022-12-24	WOS:A1991GJ47400032
J	YAMAMURA, M; UYEMURA, K; DEANS, RJ; WEINBERG, K; REA, TH; BLOOM, BR; MODLIN, RL				YAMAMURA, M; UYEMURA, K; DEANS, RJ; WEINBERG, K; REA, TH; BLOOM, BR; MODLIN, RL			DEFINING PROTECTIVE RESPONSES TO PATHOGENS - CYTOKINE PROFILES IN LEPROSY LESIONS	SCIENCE			English	Article							T-CELL SUBSETS; MURINE LEISHMANIASIS; INTERFERON-GAMMA; RECIPROCAL EXPRESSION; SKIN-LESIONS; INTERLEUKIN-4; PROGRESSION; RESOLUTION; EXPANSION	The immunological mechanisms required to engender resistance have been defined in few infectious diseases of man, and the role of specific cytokines is unclear. Leprosy presents clinically as a spectrum in which resistance correlates with cell-mediated immunity to the pathogen. To assess in situ cytokine patterns, messenger RNA extracted from leprosy skin biopsy specimens was amplified by the polymerase chain reaction with 14 cytokine-specific primers. In lesions of the resistant form of the disease, messenger RNAs coding for interleukin-2 and interferon-gamma were most evident. In contrast, messenger RNAs for interleukin-4, interleukin-5, and interleukin-10 predominated in the multibacillary form. Thus, resistance and susceptibility were correlated with distinct patterns of cytokine production.	UNIV CALIF LOS ANGELES,SCH MED,DIV DERMATOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DEPT MICROBIOL & IMMUNOL,LOS ANGELES,CA 90024; UNIV SO CALIF,SCH MED,DEPT NEUROL,LOS ANGELES,CA 90033; UNIV SO CALIF,SCH MED,DEPT PEDIAT,LOS ANGELES,CA 90033; UNIV SO CALIF,SCH MED,DERMATOL SECT,LOS ANGELES,CA 90033; CHILDRENS HOSP LOS ANGELES,LOS ANGELES,CA 90054; YESHIVA UNIV ALBERT EINSTEIN COLL MED,HOWARD HUGHES MED INST,BRONX,NY 10461	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Southern California; University of Southern California; University of Southern California; Children's Hospital Los Angeles; Howard Hughes Medical Institute; Yeshiva University; Albert Einstein College of Medicine			Modlin, Robert L/M-7941-2014	Modlin, Robert L/0000-0003-4720-031X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R22AI022553, R01AI022553] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040312] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 22553, AI 07118] Funding Source: Medline; NIAMS NIH HHS [AR 40312] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ARNOLDI J, 1990, AM J PATHOL, V137, P749; BLOOM BR, 1989, NATURE, V342, P115, DOI 10.1038/342115a0; COOPER CL, 1989, J EXP MED, V169, P1565, DOI 10.1084/jem.169.5.1565; HEINZEL FP, 1989, J EXP MED, V169, P59, DOI 10.1084/jem.169.1.59; MODLIN RL, 1984, J IMMUNOL, V132, P3085; MODLIN RL, 1983, CLIN EXP IMMUNOL, V53, P17; MODLIN RL, 1983, J AM ACAD DERMATOL, V8, P182, DOI 10.1016/S0190-9622(83)70021-6; MODLIN RL, 1988, P NATL ACAD SCI USA, V85, P1213, DOI 10.1073/pnas.85.4.1213; MODLIN RL, 1986, NATURE, V322, P459, DOI 10.1038/322459a0; MODLIN RL, 1986, J IMMUNOL, V137, P2831; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; PEARCE EJ, 1991, J EXP MED, V173, P159, DOI 10.1084/jem.173.1.159; POND L, 1989, J IMMUNOL, V143, P4232; Ridley D S, 1966, Int J Lepr Other Mycobact Dis, V34, P255; SADICK MD, 1990, J EXP MED, V171, P115, DOI 10.1084/jem.171.1.115; SALGAME P, 1991, SCIENCE, V254, P279, DOI 10.1126/science.1681588; VANVOORHIS WC, 1982, NEW ENGL J MED, V307, P1593, DOI 10.1056/NEJM198212233072601	17	1175	1225	1	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 11	1991	254	5029					277	279		10.1126/science.1925582	http://dx.doi.org/10.1126/science.1925582			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GJ642	1925582				2022-12-24	WOS:A1991GJ64200036
J	LERMAN, A; EDWARDS, BS; HALLETT, JW; HEUBLEIN, DM; SANDBERG, SM; BURNETT, JC				LERMAN, A; EDWARDS, BS; HALLETT, JW; HEUBLEIN, DM; SANDBERG, SM; BURNETT, JC			CIRCULATING AND TISSUE ENDOTHELIN IMMUNOREACTIVITY IN ADVANCED ATHEROSCLEROSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SMOOTH-MUSCLE CELLS; INCREASED PLASMA ENDOTHELIN; ARTERIES; PROLIFERATION; PATHOGENESIS; RESPONSES; PRIMATES; DISEASE; ANGINA	Background. Atherosclerosis is characterized by endothelial injury and the proliferation of arterial smooth-muscle cells. The latter may be a result of the release of growth factors from the vessel wall; such growth factors may include an endothelium-derived vasoconstrictor peptide with mitogenic properties. We tested the hypothesis that plasma endothelin concentrations are elevated in persons with symptomatic atherosclerosis, independently of age. Methods. We measured plasma endothelin levels in 100 normal subjects and in 40 patients with atherosclerosis predominantly of the following types: aortic and peripheral vascular disease (14 patients), renovascular disease (9 patients), coronary artery disease (9 patients), and carotid disease (8 patients). We also performed immunohistochemical staining for endothelin in the walls of atherosclerotic vessels. Results. In the normal subjects, the mean (+/- SD) plasma endothelin concentration was 1.4 +/- 0.2 pmol per liter, with no correlation between age and plasma endothelin concentration (r = 0.13, P = 0.2). In the patients with symptomatic atherosclerosis, the mean plasma endothelin concentration was 3.2 +/- 1.2 pmol per liter (P < 0.001), and there was a significant correlation between plasma endothelin and the number of sites of disease involvement (r = 0.89, P < 0.001). In the immunohistochemical studies, endothelin-1-like immunoreactivity was observed in vascular smooth muscle as well as in endothelial cells. Conclusions. Endothelin may be a marker for arterial vascular disease. Whether it participates in the atherogenic process or is merely released from damaged endothelial cells is unclear.	MAYO CLIN & MAYO FDN,DIV CARDIOVASC SURG,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT SURG,ROCHESTER,MN 55905	Mayo Clinic; Mayo Clinic	LERMAN, A (corresponding author), MAYO CLIN & MAYO FDN,DEPT INTERNAL MED,CARDIORENAL RES LAB,200 1ST ST SW,ROCHESTER,MN 55905, USA.				NHLBI NIH HHS [HL36634, HL07111] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036634] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDO K, 1989, FEBS LETT, V245, P164, DOI 10.1016/0014-5793(89)80213-3; ARENDT RM, 1990, CIRCULATION, V82, P248; BOULANGER C, 1990, J CLIN INVEST, V85, P587, DOI 10.1172/JCI114477; CAVERO PG, 1990, AM J PHYSIOL, V259, pF312, DOI 10.1152/ajprenal.1990.259.2.F312; DREXLER H, 1990, Journal of the American College of Cardiology, V15, p158A; Dubin D, 1989, J VASC MED BIOL, V1, P150; EDWARDS BS, 1990, AM J HYPERTENS, V3, pA64; FINGERLE J, 1987, INT ANGIOL, V6, P65; GOETZ KL, 1988, AM J PHYSIOL, V255, pR1064, DOI 10.1152/ajpregu.1988.255.6.R1064; GUYTON JR, 1979, AM J PATHOL, V94, P585; HEUBLEIN DM, 1989, AM J HYPERTENS, V2, pA37; HIRATA Y, 1989, ATHEROSCLEROSIS, V78, P225, DOI 10.1016/0021-9150(89)90227-X; HIROE M, 1989, PEPTIDES, V10, P1281, DOI 10.1016/0196-9781(89)90021-1; KON V, 1989, CIRCULATION S2, V80, P483; LERMAN A, 1991, TRANSPLANTATION, V51, P646, DOI 10.1097/00007890-199103000-00020; LERMAN A, 1991, CIRCULATION, V83, P1808, DOI 10.1161/01.CIR.83.5.1808; LOPEZ JAG, 1989, CLIN RES, V37, pA883; LUDMER PL, 1986, NEW ENGL J MED, V315, P1046, DOI 10.1056/NEJM198610233151702; LUSCHER TF, 1989, EUR HEART J, V10, P847; LUSCHER TF, 1989, J CARDIOVASC PHARM, V14, pS63; MILLER WL, 1989, J CLIN INVEST, V83, P317, DOI 10.1172/JCI113876; MIYAUCHI T, 1989, LANCET, V2, P53, DOI 10.1016/S0140-6736(89)90303-6; MIYAUCHI T, 1990, CIRCULATION, V81, P1874, DOI 10.1161/01.CIR.81.6.1874; OBRIEN RF, 1987, J CELL PHYSIOL, V132, P263, DOI 10.1002/jcp.1041320210; RESINK TJ, 1990, MOL PHARMACOL, V38, P244; RESINK TJ, 1990, BIOCHEM BIOPH RES CO, V168, P1303, DOI 10.1016/0006-291X(90)91171-N; ROBERTS WC, 1982, AM J CARDIOL, V50, P203, DOI 10.1016/0002-9149(82)90030-3; ROSS R, 1981, ARTERIOSCLEROSIS, V1, P293, DOI 10.1161/01.ATV.1.5.293; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; ROSS R, 1976, NEW ENGL J MED, V295, P369, DOI 10.1056/NEJM197608122950707; SAITO T, 1989, Japanese Journal of Pharmacology, V49, p215P; SAITO Y, 1990, NEW ENGL J MED, V322, P205; SCHICHIRI M, 1989, CIRUCLATION S2, V80, P125; SCHWARTZ SM, 1990, PHYSIOL REV, V70, P1177, DOI 10.1152/physrev.1990.70.4.1177; STEMERMAN MB, 1972, J EXP MED, V136, P769, DOI 10.1084/jem.136.4.769; TAKAGI Y, 1990, BIOCHEM BIOPH RES CO, V168, P537, DOI 10.1016/0006-291X(90)92354-3; VITA J A, 1990, Journal of the American College of Cardiology, V15, p158A; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; YANG ZH, 1990, CIRCULATION, V82, P188, DOI 10.1161/01.CIR.82.1.188; YASUDA M, 1990, AM HEART J, V119, P801, DOI 10.1016/S0002-8703(05)80315-1	40	940	994	1	12	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 3	1991	325	14					997	1001		10.1056/NEJM199110033251404	http://dx.doi.org/10.1056/NEJM199110033251404			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GH447	1886637	Green Submitted			2022-12-24	WOS:A1991GH44700004
J	GLYNNE, R; POWIS, SH; BECK, S; KELLY, A; KERR, LA; TROWSDALE, J				GLYNNE, R; POWIS, SH; BECK, S; KELLY, A; KERR, LA; TROWSDALE, J			A PROTEASOME-RELATED GENE BETWEEN THE 2 ABC TRANSPORTER LOCI IN THE CLASS-II REGION OF THE HUMAN MHC	NATURE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; MOLECULAR-WEIGHT PROTEINASE; INFLUENZA NUCLEOPROTEIN; ANTIGEN PRESENTATION; T-CELLS; PURIFICATION; SEQUENCES; MACROPAIN; PATHWAY; LIVER	IT is now possible to paint a detailed picture of how cytoplasmic proteins are handled by the immune system 1-7. They are apparently degraded in the cytoplasm into peptides. These are then transported into the endoplasmic reticulum where they encounter class I major histocompatibility complex (MHC) molecules. Once loaded with peptide, the HLA molecules move through the Golgi apparatus to the cell membrane. Until recently, it had not been established how peptides without signal sequences cross the ER membrane. However, a number of papers have now described a pair of membrane transporter genes of the ABC (ATP-binding cassette) super-family which are attractive candidates for this function 8-12. Both transporter genes, which may encode two halves of a heterodimer, are situated in the class II region of the MHC. There is evidence that other putative components of the processing machinery, the LMPs (low molecular mass polypeptides), are also encoded in the MHC 13-15. Similarities between the properties of the LMPs and a large intracellular protease complex, called proteasome, have led to the suggestion that LMPs are involved in processing antigens 16. We have now identified a human gene with sequence homology to proteasome components. Remarkably, this gene maps between the two putative peptide transporter genes.	UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,LONDON SE1 9RT,ENGLAND	University of London; King's College London	GLYNNE, R (corresponding author), IMPERIAL CANC RES FUND,HUMAN IMMUNOGENET LAB,LINCOLNS INN FIELDS,LONDON WC2A 3PX,ENGLAND.							ARGOS P, 1987, J MOL BIOL, V193, P385, DOI 10.1016/0022-2836(87)90226-9; AUSABEL FM, 1987, CURRENT PROTOCOLS MO; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; DEVERSON EV, 1990, NATURE, V348, P738, DOI 10.1038/348738a0; FULLER RS, 1989, SCIENCE, V246, P482, DOI 10.1126/science.2683070; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LEE LW, 1990, BIOCHIM BIOPHYS ACTA, V1037, P178, DOI 10.1016/0167-4838(90)90165-C; LILLEY KS, 1990, FEBS LETT, V262, P327, DOI 10.1016/0014-5793(90)80220-D; MCGUIRE MJ, 1986, BIOCHIM BIOPHYS ACTA, V873, P279, DOI 10.1016/0167-4838(86)90055-5; MONACO JJ, 1990, SCIENCE, V250, P1723, DOI 10.1126/science.2270487; MONACO JJ, 1982, P NATL ACAD SCI-BIOL, V79, P3001, DOI 10.1073/pnas.79.9.3001; MONACO JJ, 1986, HUM IMMUNOL, V15, P416, DOI 10.1016/0198-8859(86)90019-4; MONACO JJ, 1984, NATURE, V309, P797, DOI 10.1038/309797a0; MOORE MW, 1988, CELL, V54, P777, DOI 10.1016/S0092-8674(88)91043-4; MORRISON LA, 1986, J EXP MED, V163, P903, DOI 10.1084/jem.163.4.903; PARHAM P, 1990, NATURE, V348, P674, DOI 10.1038/348674a0; RIVETT AJ, 1985, J BIOL CHEM, V260, P2600; RIVETT AJ, 1988, ARCH BIOCHEM BIOPHYS, V268, P1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; STERNBERG MJE, 1991, COMPUT APPL BIOSCI, V7, P257; TAMURA T, 1991, BIOCHIM BIOPHYS ACTA, V1089, P95, DOI 10.1016/0167-4781(91)90090-9; TANAKA K, 1986, J BIOL CHEM, V261, P5197; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X; TOWNSEND ARM, 1985, CELL, V42, P457, DOI 10.1016/0092-8674(85)90103-5; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; WEISS S, 1991, CELL, V64, P767, DOI 10.1016/0092-8674(91)90506-T; YEWDELL JW, 1990, CELL, V62, P203, DOI 10.1016/0092-8674(90)90356-J; ZWICKL P, 1991, FEBS LETT, V278, P217, DOI 10.1016/0014-5793(91)80120-R	32	417	427	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 26	1991	353	6342					357	360		10.1038/353357a0	http://dx.doi.org/10.1038/353357a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GG654	1922342				2022-12-24	WOS:A1991GG65400063
J	CASTELLANO, AR; NETTLEMAN, MD				CASTELLANO, AR; NETTLEMAN, MD			COST AND BENEFIT OF SECONDARY PROPHYLAXIS FOR PNEUMOCYSTIS-CARINII PNEUMONIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACQUIRED IMMUNODEFICIENCY SYNDROME; TRIMETHOPRIM-SULFAMETHOXAZOLE; AIDS; PENTAMIDINE; PREVENTION	Objective.-To determine the relative cost and benefit of aerosolized pentamidine and the combination product of sulfamethoxazole and trimethoprim sulfate as secondary prophylaxis for Pneumocystis carinii pneumonia. Design.-A Markov-based cost-benefit analysis was performed. Drug efficacies, toxicities, and mortality rates were drawn from the current literature. Setting.-Hypothetical. Patient Population.-Patients infected with the human immunodeficiency virus who had had at least one episode of P carinii pneumonia. Interventions.-Regimen 1 required the use of aerosolized pentamidine as the sole first-line prophylactic agent in all patients. Regimen 2 required the use of sulfamethoxazole-trimethoprim in all patients who had no history of a toxic reaction to the drug; only patients with a history of toxic effects and those who developed toxic effects while receiving the drug would receive aerosolized pentamidine. Regimen 3 required that no secondary prophylaxis be given. Main Outcome Measures.-Net cost, median patient survival, and 5-year survival for each regimen and for regimens 1 and 2 compared with regimen 3. Main Results.-Regimen 2 was dominant, with a net cost of $6332 per patient and a median survival of 2.050 years. Compared with no prophylaxis, regimen 2 resulted in a savings of $16 503 per patient and a 0.696-year increase in median survival. Compared with regimen 1, regimen 2 resulted in a savings of $2904 and a 0.067-year increase in median survival. Conclusions.-Secondary prophylaxis for P carinii saves money and extends survival. Current data suggest that sulfamethoxazole-trimethoprim should be given whenever it can be tolerated. Use of aerosolized pentamidine as a first-line agent would result in a modest increase in cost and a decrease in life expectancy.	UNIV IOWA,COLL MED,IOWA CITY,IA 52242	University of Iowa								BECK JR, 1983, MED DECIS MAKING, V3, P419, DOI 10.1177/0272989X8300300403; BERNARD E, 1988, 4TH INT C AIDS STOCK, P420; BERNARD EM, 1987, CLIN RES, V35, pA468; BIRGITTE NJ, 1989, 5TH INT C AIDS MONTR, P296; BRENNER M, 1987, AM REV RESPIR DIS, V136, P1199, DOI 10.1164/ajrccm/136.5.1199; CLOTET B, 1990, 6TH INT C AIDS SAN F, P225; CONTE JE, 1988, 4TH INT C AIDS STOCK, P419; CORCKERY KJ, 1988, RESPIR CARE, V33, P676; CREIGHKIRK T, 1988, JAMA-J AM MED ASSOC, V260, P3009; FISCHL MA, 1988, JAMA-J AM MED ASSOC, V259, P1185, DOI 10.1001/jama.259.8.1185; Friedberg G, 1988, J Palliat Care, V4, P38; GABIN SJ, 1988, 4TH INT C AIDS STOCK, P419; GOLDEN JA, 1989, LANCET, V1, P654; GORDIN FM, 1984, ANN INTERN MED, V100, P495, DOI 10.7326/0003-4819-100-4-495; GREEN J, 1990, JAMA-J AM MED ASSOC, V264, P1261, DOI 10.1001/jama.264.10.1261; KAPLAN LD, 1985, CLIN RES, V33, pA406; KELLY J, 1990, 6TH INT C AIDS SAN F, P225; KEYES C, 1989, 5TH INT C AIDS MONTR, P295; KOVACS JA, 1988, J INFECT DIS, V158, P254, DOI 10.1093/infdis/158.1.254; KOVACS JA, 1984, ANN INTERN MED, V100, P663, DOI 10.7326/0003-4819-100-5-663; LANG OS, 1989, 5TH INT C AIDS MONTR, P196; LEOUNG GS, 1988, 4TH INT C AIDS STOCK, P419; LEOUNG GS, 1989, 5TH INT C AIDS MONTR, P299; MASUR H, 1989, PRINCIPLES PRACTICE, P3; MEDINA I, 1987, 27TH INT C ANT AG CH, P261; METROKA CE, 1989, 5TH INT C AIDS MONTR, P196; MOON MW, 1989, 5TH INT C AIDS MONTR, P298; NETTLEMAN MD, 1988, INFECT CONT HOSP EP, V9, P88, DOI 10.2307/30144149; NIELSEN TL, 1990, 6TH INT C AIDS SAN F, P225; PAUKER SG, 1987, NEW ENGL J MED, V316, P250, DOI 10.1056/NEJM198701293160505; RUSKIN J, 1991, LANCET, V337, P468, DOI 10.1016/0140-6736(91)93402-U; SATTLER FR, 1988, ANN INTERN MED, V109, P280, DOI 10.7326/0003-4819-109-4-280; SHAFER RW, 1989, J ACQ IMMUN DEF SYND, V2, P389; SMITH DE, 1988, 4TH INT C AIDS STOCK, P418; STASZEWSKI S, 1989, 5TH INT C AIDS MONTR, P299; TORRES R, 1990, 6TH INT AIDS C SAN F, P223; TORRES RA, 1989, 5TH INT C AIDS MONTR, P299; VANGUNDY KP, 1988, 4TH INT C AIDS STOCK, P420; WEINKE T, 1988, 4TH INT C AIDS STOCK, P421; Weinstein MC, 1980, CLIN DECISION ANAL; WEISMAN J, 1989, 5TH INT C AIDS MONTR, P219; WHARTON JM, 1986, ANN INTERN MED, V105, P37, DOI 10.7326/0003-4819-105-1-37; WOFSY CB, 1987, REV INFECT DIS, V9, pS184; 1989, MMWR SS5, V38, P1	44	44	44	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 14	1991	266	6					820	824		10.1001/jama.266.6.820	http://dx.doi.org/10.1001/jama.266.6.820			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA073	1907671				2022-12-24	WOS:A1991GA07300034
J	HARPER, V; MACINNES, R; CAMPBELL, D; HALL, M				HARPER, V; MACINNES, R; CAMPBELL, D; HALL, M			INCREASED BIRTH-WEIGHT IN NORTHERLY ISLANDS - IS FISH CONSUMPTION A RED HERRING	BRITISH MEDICAL JOURNAL			English	Article									HLTH CTR,KIRKWALL,ORKNEY,SCOTLAND		HARPER, V (corresponding author), UNIV ABERDEEN,DEPT OBSTET & GYNAECOL,ABERDEEN AB9 2ZD,SCOTLAND.							BARBER SA, 1986, HUM NUTR-APPL NUTR, V40A, P462; OLSEN SF, 1985, J EPIDEMIOL COMMUN H, V39, P27, DOI 10.1136/jech.39.1.27; OLSEN SF, 1986, LANCET, V2, P367; PIRANI DH, 1978, OBSTET GYNECOL SURV, V33, P1	4	13	13	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 20	1991	303	6795					166	166		10.1136/bmj.303.6795.166	http://dx.doi.org/10.1136/bmj.303.6795.166			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FX578	1878642	Bronze, Green Published			2022-12-24	WOS:A1991FX57800024
J	KARESS, RE; CHANG, XJ; EDWARDS, KA; KULKARNI, S; AGUILERA, I; KIEHART, DP				KARESS, RE; CHANG, XJ; EDWARDS, KA; KULKARNI, S; AGUILERA, I; KIEHART, DP			THE REGULATORY LIGHT CHAIN OF NONMUSCLE MYOSIN IS ENCODED BY SPAGHETTI-SQUASH, A GENE REQUIRED FOR CYTOKINESIS IN DROSOPHILA	CELL			English	Article							HEAVY-CHAIN; CELL-CYCLE; CHROMOSOME MOVEMENT; SEQUENCE-ANALYSIS; DICTYOSTELIUM; MELANOGASTER; INVITRO; MUSCLE; ACTIN; DISSECTION	Two independent approaches to understanding the molecular mechanism of cytokinesis have converged on the gene spaghetti-squash (sqh). A genetic screen for mitotic mutants identified sqh1, a mutation that disrupts cytokinesis, which was then cloned by transposon tagging. Independently, the gene that encodes the regulatory light chain of the biochemically defined nonmuscle myosin (MRLC-C) was also cloned. We show here that sqh encodes MRLC-C and that in sqh1 mutants, the level of stable light chain transcript is greatly reduced. Reversion by transposon excision or transformation with a wild-type copy of the sqh transcription unit rescues cytokinesis failure and other defects in sqh1. Vertebrate homologs of MRLC-C are phosphorylatable and regulate myosin activity in vitro. These studies provide genetic proof that MRLC-C is required for cytokinesis, suggest a role for the protein in regulating contractile ring function, and establish a genetic system to evaluate its function.	HARVARD UNIV, DEPT CELLULAR & DEV IMMUNOL, CAMBRIDGE, MA 02138 USA	Harvard University	KARESS, RE (corresponding author), NYU MED CTR, DEPT BIOCHEM, NEW YORK, NY 10016 USA.		Aguilera, Isabel/K-2680-2017; Edwards, Kevin Andrew/GOE-3539-2022	Aguilera, Isabel/0000-0003-2165-4954; Edwards, Kevin Andrew/0000-0003-4721-5626; Karess, Roger/0000-0002-7299-0600	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037979, R01GM033830] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM33830, GM37979] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADELSTEIN RS, 1980, ANNU REV BIOCHEM, V49, P921, DOI 10.1146/annurev.bi.49.070180.004421; AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; ASHBURNER M, 1989, DROSOPHILA LABORATOR; BAKER BS, 1987, ANEUPLOIDY A; BERNAT RL, 1990, J CELL BIOL, V111, P1519, DOI 10.1083/jcb.111.4.1519; BIGGIN MD, 1983, P NATL ACAD SCI-BIOL, V80, P3963, DOI 10.1073/pnas.80.13.3963; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; BROWN NH, 1989, CELL, V59, P185, DOI 10.1016/0092-8674(89)90880-5; CITI S, 1987, BIOESSAYS, V7, P155, DOI 10.1002/bies.950070404; Conrad G. W., 1981, MITOSIS CYTOKINESIS, P365; DELOZANNE A, 1987, SCIENCE, V236, P1086, DOI 10.1126/science.3576222; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Engels W.R, 1989, MOBILE DNA, P437; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FUJIWARA K, 1976, J CELL BIOL, V71, P848, DOI 10.1083/jcb.71.3.848; FUKUI Y, 1990, J CELL BIOL, V110, P367, DOI 10.1083/jcb.110.2.367; GATTI M, 1989, GENE DEV, V3, P438, DOI 10.1101/gad.3.4.438; HATZFELD J, 1975, CELL, V5, P123, DOI 10.1016/0092-8674(75)90020-3; KARESS RE, 1989, J CELL BIOL, V109, P2951, DOI 10.1083/jcb.109.6.2951; KETCHUM AS, 1990, P NATL ACAD SCI USA, V87, P6316, DOI 10.1073/pnas.87.16.6316; KIEHART DP, 1982, J CELL BIOL, V94, P165, DOI 10.1083/jcb.94.1.165; KIEHART DP, 1990, CELL, V60, P347, DOI 10.1016/0092-8674(90)90583-Z; KIEHART DP, 1986, J CELL BIOL, V103, P1517, DOI 10.1083/jcb.103.4.1517; KIEHART DP, 1989, EMBO J, V8, P913, DOI 10.1002/j.1460-2075.1989.tb03452.x; KIEHART DP, 1990, ANN NY ACAD SCI, V582, P233; KITANISHIYUMURA T, 1989, CELL MOTIL CYTOSKEL, V12, P78, DOI 10.1002/cm.970120203; KNECHT DA, 1987, SCIENCE, V236, P1081, DOI 10.1126/science.3576221; LINDSLEY D, 1987, DROS INF SERV, V65; LINDSLEY D, 1986, DROS INF SERV, V64; LINDSLEY DL, 1985, DROS INF SERV, V62; MABUCHI I, 1986, INT REV CYTOL, V101, P175, DOI 10.1016/S0074-7696(08)60249-1; MABUCHI I, 1977, J CELL BIOL, V74, P251, DOI 10.1083/jcb.74.1.251; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OHARE K, 1983, CELL, V34, P25, DOI 10.1016/0092-8674(83)90133-2; Pardue ML, 1986, DROSOPHILA PRACTICAL, P111; PIROTTA V, 1988, VECTORS SURVEY MOL C, P437; POLLARD TD, 1990, ANN NY ACAD SCI, V582, P120; RAPPAPORT R, 1986, INT REV CYTOL, V105, P245, DOI 10.1016/S0074-7696(08)61065-7; RIPOLL P, 1987, BIOESSAYS, V7, P204, DOI 10.1002/bies.950070504; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P463; SATTERWHITE L, 1990, ANN NY ACAD SCI, V582, P307; SCHROEDER T, 1989, ANN NY ACAD SCI, V582, P78; SCHROEDER TE, 1973, P NATL ACAD SCI USA, V70, P1688, DOI 10.1073/pnas.70.6.1688; Sellers JR, 1987, ENZYMES, V18, ppp381, DOI 10.1016/S1874-6047(08)60264-4; Snedecor G.W., 1980, STAT METHODS, V7; SPUDICH JA, 1989, CELL REGUL, V1, P1; SUBBIAH S, 1989, J MOL BIOL, V209, P539, DOI 10.1016/0022-2836(89)90592-5; TRYBUS KM, 1991, CELL MOTIL CYTOSKEL, V18, P81, DOI 10.1002/cm.970180202; UMEMOTO S, 1989, J BIOL CHEM, V264, P1431; WARRICK HM, 1987, ANNU REV CELL BIOL, V3, P379, DOI 10.1146/annurev.cb.03.110187.002115; YOUNG PE, 1991, DEVELOPMENT, V111, P1; ZAVODNY P, 1988, NUCLEIC ACIDS RES, V16, P214	56	238	240	0	5	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 28	1991	65	7					1177	1189		10.1016/0092-8674(91)90013-O	http://dx.doi.org/10.1016/0092-8674(91)90013-O			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FU899	1905980	hybrid			2022-12-24	WOS:A1991FU89900010
J	MILLER, K; SHIPMAN, M; TROWBRIDGE, IS; HOPKINS, CR				MILLER, K; SHIPMAN, M; TROWBRIDGE, IS; HOPKINS, CR			TRANSFERRIN RECEPTORS PROMOTE THE FORMATION OF CLATHRIN LATTICES	CELL			English	Article							COATED PIT FORMATION; MEDIATED ENDOCYTOSIS; CARCINOMA A431-CELLS; VESICLES; CELLS; INTERNALIZATION; FIBROBLASTS; MICROSCOPY; FLOW	Gold conjugates have been used to quantitate human transferrin receptors (hTfnRs) on transfected chick embryo fibroblasts. No relationship could be found between the number of hTfnRs and the number of clathrin-coated pits. However, hTfnRs are also associated with flat clathrin lattices that lie outside invaginated pits. With increasing levels of receptor expression, the density of hTfnRs within flat lattices increases, and at the highest levels of expression the total area of flat lattice increases up to 3-fold. These results show that increased receptor numbers can promote clathrin lattice growth and suggest that the recruitment of receptors like hTfnRs is an essential step in lattice construction. We conclude that the process of invagination, which gives rise to coated pits, is regulated separately.	SALK INST BIOL STUDIES,DEPT CANC BIOL,SAN DIEGO,CA 92138	Salk Institute	MILLER, K (corresponding author), UNIV LONDON IMPERIAL COLL SCI & TECHNOL,DEPT BIOCHEM,LONDON SW7 2AZ,ENGLAND.							BEAUMELLE BD, 1990, J CELL BIOL, V7111, P1811; BRAY D, 1988, SCIENCE, V239, P883, DOI 10.1126/science.3277283; BRETSCHER MS, 1983, COLD SPRING HARB SYM, V46, P707; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; DEBRABANDER M, 1988, CELL MOTIL CYTOSKEL, V9, P30, DOI 10.1002/cm.970090105; GOLDSTEIN JL, 1979, NATURE, V279, P679, DOI 10.1038/279679a0; GOUD B, 1985, J CELL BIOL, V100, P521, DOI 10.1083/jcb.100.2.521; HEUSER J, 1980, J CELL BIOL, V84, P560, DOI 10.1083/jcb.84.3.560; HOPKINS C, 1985, MOL MECHANISMS TRANS, P337; HOPKINS CR, 1983, J CELL BIOL, V97, P508, DOI 10.1083/jcb.97.2.508; HOPKINS CR, 1983, CELL, V35, P321, DOI 10.1016/0092-8674(83)90235-0; HOPKINS CR, 1985, CELL, V40, P199, DOI 10.1016/0092-8674(85)90323-X; HOPKINS CR, 1985, J CELL SCI S, V3, P173; IACOPETTA BJ, 1988, CELL, V54, P485, DOI 10.1016/0092-8674(88)90069-4; JING SQ, 1990, J CELL BIOL, V110, P283, DOI 10.1083/jcb.110.2.283; LARKIN JM, 1983, CELL, V33, P273, DOI 10.1016/0092-8674(83)90356-2; LARKIN JM, 1986, J CELL BIOL, V103, P2619, DOI 10.1083/jcb.103.6.2619; MAHAFFEY DT, 1989, J CELL BIOL, V108, P1615, DOI 10.1083/jcb.108.5.1615; MARSH M, 1980, J MOL BIOL, V142, P439, DOI 10.1016/0022-2836(80)90281-8; MAUPIN P, 1983, J CELL BIOL, V96, P51, DOI 10.1083/jcb.96.1.51; Morris SA, 1989, CURR OPIN CELL BIOL, V1, P684, DOI 10.1016/0955-0674(89)90034-3; NICOL A, 1987, EUR J CELL BIOL, V43, P348; PEARSE BMF, 1987, EMBO J, V6, P2507, DOI 10.1002/j.1460-2075.1987.tb02536.x; PEARSE BMF, 1981, ANNU REV BIOCHEM, V50, P85, DOI 10.1146/annurev.bi.50.070181.000505; RINNERTHALER G, 1988, J CELL BIOL, V106, P747, DOI 10.1083/jcb.106.3.747; RUTTER G, 1985, European Journal of Cell Biology, V39, P443; SHEETZ MP, 1989, NATURE, V340, P284, DOI 10.1038/340284a0; SLOT JW, 1985, EUR J CELL BIOL, V38, P87; WATTS C, 1985, J CELL BIOL, V100, P633, DOI 10.1083/jcb.100.2.633	30	109	109	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 17	1991	65	4					621	632		10.1016/0092-8674(91)90094-F	http://dx.doi.org/10.1016/0092-8674(91)90094-F			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FM037	1903330				2022-12-24	WOS:A1991FM03700012
J	OGORMAN, S; FOX, DT; WAHL, GM				OGORMAN, S; FOX, DT; WAHL, GM			RECOMBINASE-MEDIATED GENE ACTIVATION AND SITE-SPECIFIC INTEGRATION IN MAMMALIAN-CELLS	SCIENCE			English	Article							FLP RECOMBINASE; YEAST PLASMID; HEAT-SHOCK; DNA; SEQUENCES; CIRCLE; GENOME	A binary system for gene activation and site-specific integration, based on the conditional recombination of transfected sequences mediated by the FLP recombinase from yeast, was implemented in mammalian cells. In several cell lines, FLP rapidly and precisely recombined copies of its specific target sequence to activate an otherwise silent beta-galactosidase reporter gene. Clones of marked cells were generated by excisional recombination within a chromosomally integrated copy of the silent reporter. By the reverse reaction, integration of transfected DNA was targeted to a specific chromosomal site. The results suggest that FLP could be used to mosaically activate or inactivate transgenes for analysis of vertebrate development, and to efficiently integrate transfected DNA at predetermined chromosomal locations.			OGORMAN, S (corresponding author), SALK INST BIOL STUDIES,GENE EXPRESS LAB,LA JOLLA,CA 92037, USA.							ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; BOLLAG RJ, 1989, ANNU REV GENET, V23, P199, DOI 10.1146/annurev.ge.23.120189.001215; BOND U, 1988, EMBO J, V7, P3509, DOI 10.1002/j.1460-2075.1988.tb03227.x; BROACH JR, 1980, CELL, V21, P501, DOI 10.1016/0092-8674(80)90487-0; DEWET J, 1987, MOL CELL BIOL, V72, P725; GOLIC KG, 1989, CELL, V59, P499, DOI 10.1016/0092-8674(89)90033-0; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GRONOSTAJSKI RM, 1985, J BIOL CHEM, V260, P2320; HALL C V, 1983, Journal of Molecular and Applied Genetics, V2, P101; HARTLEY JL, 1980, NATURE, V286, P860, DOI 10.1038/286860a0; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HUANG MTF, 1990, MOL CELL BIOL, V10, P1805, DOI 10.1128/MCB.10.4.1805; HUANG MTF, 1990, NUCLEIC ACIDS RES, V18, P937, DOI 10.1093/nar/18.4.937; JAYARAM M, 1985, P NATL ACAD SCI USA, V82, P5875, DOI 10.1073/pnas.82.17.5875; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; OGORMAN S, UNPUB; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; SAUER B, 1989, NUCLEIC ACIDS RES, V17, P147, DOI 10.1093/nar/17.1.147; SAUER B, 1990, New Biologist, V2, P441; SENECOFF JF, 1988, J MOL BIOL, V201, P405, DOI 10.1016/0022-2836(88)90147-7; SENECOFF JF, 1985, P NATL ACAD SCI USA, V82, P7270, DOI 10.1073/pnas.82.21.7270; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; YOST HJ, 1986, CELL, V45, P185, DOI 10.1016/0092-8674(86)90382-X	25	438	617	0	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 15	1991	251	4999					1351	1355		10.1126/science.1900642	http://dx.doi.org/10.1126/science.1900642			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FB733	1900642				2022-12-24	WOS:A1991FB73300042
J	ROSENZWEIG, A; WATKINS, H; HWANG, DS; MIRI, M; MCKENNA, W; TRAILL, TA; SEIDMAN, JG; SEIDMAN, CE				ROSENZWEIG, A; WATKINS, H; HWANG, DS; MIRI, M; MCKENNA, W; TRAILL, TA; SEIDMAN, JG; SEIDMAN, CE			PRECLINICAL DIAGNOSIS OF FAMILIAL HYPERTROPHIC CARDIOMYOPATHY BY GENETIC-ANALYSIS OF BLOOD-LYMPHOCYTES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MYOSIN HEAVY-CHAIN; LEFT-VENTRICULAR HYPERTROPHY; AMINO-ACID-SEQUENCE; MOLECULAR-BASIS; SUDDEN-DEATH; CLINICAL MANIFESTATIONS; PATHO-PHYSIOLOGY; SKELETAL-MUSCLE; DNA-SEQUENCE; ALPHA	Background. The clinical diagnosis of familial hypertrophic cardiomyopathy is usually made on the basis of the physical examination, electrocardiogram, and echocardiogram. Making an accurate diagnosis can be particularly difficult in children, who may not have cardiac hypertrophy until adulthood. Recently, we demonstrated that mutations in the cardiac myosin heavy-chain genes cause familial hypertrophic cardiomyopathy in some families. We report a diagnostic test for familial hypertrophic cardiomyopathy that relies on the detection of mutations in the beta-myosin heavy-chain gene in circulating lymphocytes that we used to evaluate three generations of a family, including the children. Methods and Results. Using the polymerase chain reaction, we found that normal and mutant beta-cardiac myosin heavy-chain genes are transcribed in circulating lymphocytes. This allowed us to examine beta-cardiac myosin heavy-chain messenger RNA from blood lymphocytes, even though ordinary expression of the gene is virtually restricted to the heart. Base sequences amplified from this messenger RNA were analyzed with a ribonuclease protection assay to identify small deletions, abnormal splicing, or missense mutations. Using this technique we identified a novel missense mutation in a patient with familial hypertrophic cardiomyopathy. We evaluated 15 of the patient' s adult relatives and found perfect agreement with the clinical diagnosis (8 affected and 7 not affected). Clinical analysis of 14 of the children (age, 1 to 20 years) of these affected family members revealed 1 child with echocardiographic findings diagnostic of familial hypertrophic cardiomyopathy. However, genetic analyses showed that six other children had also inherited the missense mutation and might later manifest the disease. Conclusions. Transcripts of beta-cardiac myosin heavy-chain gene can be detected in blood lymphocytes and used to screen for mutations that cause familial hypertrophic cardiomyopathy. This approach makes practical the identification of mutations responsible for this disorder and may be applicable to other diseases in which direct analysis is difficult because the mutated gene is expressed only in certain tissues. Preclinical or prenatal screening in an affected family will make it possible to study the disease longitudinally and to develop preventive interventions.	MASSACHUSETTS GEN HOSP,CARDIAC UNIT,BOSTON,MA 02114; BRIGHAM & WOMENS HOSP,DIV CARDIOL,BOSTON,MA 02115; ST GEORGE HOSP,SCH MED,DEPT CARDIOL SCI,LONDON,ENGLAND; TAICHUNG VET GEN HOSP,DIV CARDIOL,TAICHUNG,TAIWAN; JOHNS HOPKINS UNIV HOSP,DIV CARDIOL,BALTIMORE,MD 21205; HOWARD HUGHES MED INST,BOSTON,MA	Harvard University; Massachusetts General Hospital; Harvard University; Brigham & Women's Hospital; St Georges University London; Taichung Veterans General Hospital; Johns Hopkins University; Johns Hopkins Medicine; Howard Hughes Medical Institute	ROSENZWEIG, A (corresponding author), HARVARD UNIV,SCH MED,DEPT GENET,25 SHATTUCK ST,BOSTON,MA 02115, USA.		McKenna, William J/C-3243-2008; Rosenzweig, Anthony/AAD-7893-2019	McKenna, William J/0000-0001-7994-2460; Watkins, Hugh/0000-0002-5287-9016	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035877, R01HL046320] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL35877, HL02228, HL46320] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANTONARAKIS SE, 1989, NEW ENGL J MED, V320, P153, DOI 10.1056/NEJM198901193200305; Ausubel F, 1989, MOL REPROD DEV, V1, P146; CHELLY J, 1988, NATURE, V333, P858, DOI 10.1038/333858a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COTTON RGH, 1989, BIOCHEM J, V263, P1; DIBB NJ, 1989, J MOL BIOL, V205, P603, DOI 10.1016/0022-2836(89)90229-5; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; GEISTERFERLOWRANCE AAT, 1990, CELL, V62, P999, DOI 10.1016/0092-8674(90)90274-I; GREGOR P, 1989, INT J CARDIOL, V23, P335, DOI 10.1016/0167-5273(89)90193-9; GROSS-BELLARD MM, 1973, EUR J BIOCHEM, V36, P32, DOI 10.1111/j.1432-1033.1973.tb02881.x; HARBARTH P, 1988, DNA-J MOLEC CELL BIO, V7, P297, DOI 10.1089/dna.1988.7.297; HEJTMANCIK JF, 1991, CIRCULATION, V83, P1592, DOI 10.1161/01.CIR.83.5.1592; HOLCOMBE R F, 1987, Genomics, V1, P287, DOI 10.1016/0888-7543(87)90058-9; JAENICKE T, 1990, GENOMICS, V8, P194, DOI 10.1016/0888-7543(90)90272-V; JARCHO JA, 1989, NEW ENGL J MED, V321, P1372, DOI 10.1056/NEJM198911163212005; JUNG G, 1989, GENE, V82, P269, DOI 10.1016/0378-1119(89)90052-8; KARN J, 1983, P NATL ACAD SCI-BIOL, V80, P4253, DOI 10.1073/pnas.80.14.4253; KAUFMAN DL, 1990, GENOMICS, V8, P656, DOI 10.1016/0888-7543(90)90252-P; LICHTER P, 1986, EUR J BIOCHEM, V160, P419, DOI 10.1111/j.1432-1033.1986.tb09989.x; LIEW CC, 1990, NUCLEIC ACIDS RES, V18, P3647, DOI 10.1093/nar/18.12.3647; LOMPRE AM, 1984, J BIOL CHEM, V259, P6437; MAHDAVI V, 1982, NATURE, V297, P659, DOI 10.1038/297659a0; MARON BJ, 1976, CIRCULATION, V53, P9, DOI 10.1161/01.CIR.53.1.9; MARON BJ, 1986, J AM COLL CARDIOL, V7, P204, DOI 10.1016/S0735-1097(86)80283-2; MARON BJ, 1987, NEW ENGL J MED, V316, P844, DOI 10.1056/NEJM198704023161405; MARON BJ, 1981, AM J CARDIOL, V48, P418, DOI 10.1016/0002-9149(81)90068-0; MARON BJ, 1987, NEW ENGL J MED, V316, P780, DOI 10.1056/NEJM198703263161305; MARON BJ, 1980, CIRCULATION, V62, P218, DOI 10.1161/01.CIR.62.2.218; MARON BJ, 1978, AM J CARDIOL, V41, P803, DOI 10.1016/0002-9149(78)90717-8; MARON BJ, 1986, NEW ENGL J MED, V315, P610, DOI 10.1056/NEJM198609043151003; MCKENNA W, 1981, AM J CARDIOL, V47, P532, DOI 10.1016/0002-9149(81)90535-X; MCKENNA WJ, 1988, J AM COLL CARDIOL, V11, P351, DOI 10.1016/0735-1097(88)90101-5; MCKENNA WJ, 1989, DISEASES HEART, P933; MCKUSICK VA, 1989, NEW ENGL J MED, V320, P910, DOI 10.1056/NEJM198904063201406; MCNALLY EM, 1989, J MOL BIOL, V210, P665, DOI 10.1016/0022-2836(89)90141-1; MOLINA MI, 1987, J BIOL CHEM, V262, P6478; MYERS RM, 1985, SCIENCE, V230, P1242, DOI 10.1126/science.4071043; PERRY LW, 1980, J PEDIATR-US, V97, P677, DOI 10.1016/S0022-3476(80)80040-0; ROBERTS RG, 1990, LANCET, V336, P1523, DOI 10.1016/0140-6736(90)93305-9; ROZEK CE, 1986, P NATL ACAD SCI USA, V83, P2128, DOI 10.1073/pnas.83.7.2128; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARKAR G, 1989, SCIENCE, V244, P331, DOI 10.1126/science.2565599; SHAPIRO LM, 1983, J AM COLL CARDIOL, V2, P437, DOI 10.1016/S0735-1097(83)80269-1; SHOHET RV, 1989, P NATL ACAD SCI USA, V86, P7726, DOI 10.1073/pnas.86.20.7726; SMABROOK J, 1989, MOL CLONING LABORATO; SOLOMON SD, 1990, J CLIN INVEST, V86, P993, DOI 10.1172/JCI114802; SOLOMON SD, 1990, AM J HUM GENET, V47, P389; STEDMAN HH, 1990, J BIOL CHEM, V265, P3568; STREHLER EE, 1986, J MOL BIOL, V190, P291, DOI 10.1016/0022-2836(86)90003-3; Surawicz B, 1978, Am J Cardiol, V41, P130, DOI 10.1016/0002-9149(78)90147-9; TANIGAWA G, 1990, CELL, V62, P991, DOI 10.1016/0092-8674(90)90273-H; TONG SW, 1990, J BIOL CHEM, V265, P4893; WIGLE ED, 1985, PROG CARDIOVASC DIS, V28, P1, DOI 10.1016/0033-0620(85)90024-6; YANAGISAWA M, 1987, J MOL BIOL, V198, P143, DOI 10.1016/0022-2836(87)90302-0	54	156	164	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 19	1991	325	25					1753	1760		10.1056/NEJM199112193252501	http://dx.doi.org/10.1056/NEJM199112193252501			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GV739	1944483				2022-12-24	WOS:A1991GV73900001
J	EASTERBROOK, PJ; KERULY, JC; CREAGHKIRK, T; RICHMAN, DD; CHAISSON, RE; MOORE, RD				EASTERBROOK, PJ; KERULY, JC; CREAGHKIRK, T; RICHMAN, DD; CHAISSON, RE; MOORE, RD			RACIAL AND ETHNIC-DIFFERENCES IN OUTCOME IN ZIDOVUDINE-TREATED PATIENTS WITH ADVANCED HIV DISEASE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AIDS-RELATED COMPLEX; PLACEBO-CONTROLLED TRIAL; PNEUMOCYSTIS-CARINII PNEUMONIA; RECEIVING ZIDOVUDINE; AZIDOTHYMIDINE AZT; DOUBLE-BLIND; EXPERIENCE; EFFICACY; SURVIVAL	Objectives. - To determine if racial-ethnic differences exist in survival, disease progression, and development of myelosuppression in zidovudine-treated patients with advanced human immunodeficiency virus (HIV) disease. Design. - Prospective observational study. Setting. - Hospital and private clinics in 12 metropolitan centers. Patients. - The study included 754 non-Hispanic white, 165 black, and 106 Hispanic- patients with the acquired immunodeficiency syndrome (AIDS) or advanced AIDS-related complex (ARC) who received up to 2 years of zidovudine therapy. Outcome Measures. - Survival, development of Pneumocystis carinii pneumonia (PCP), other opportunistic infections, and myelosuppression. Results. - At initiation of zidovudine therapy, Hispanic and particularly black patients had more advanced HIV disease than white patients, as indicated by lower baseline CD4+ counts, hematocrits, and AIDS-defining diagnoses. Black patients with AIDS also had a worse prognosis compared with white and Hispanic patients with AIDS. The product-limit survival rates at 2 years for white, black, and Hispanic patients with AIDS were 40%, 27%, and 39%, respectively (black vs white, P = .01; Hispanic vs white, P = .32, by the log-rank test). The respective proportions of patients who developed PCP at 2 years were 46%, 66%, and 44% (black vs white, P = .0001; Hispanic vs white, P = .86) and for other opportunistic infections the proportions were 56%, 63%, and 63%, respectively (black vs white, P = .03; Hispanic vs white, P = .09). There were no significant racial-ethnic differences in survival or in the development of opportunistic infections for patients with ARC, and there were no differences in the incidence of myelosuppression or dose reduction or suspension for patients with either ARC or AIDS. After adjusting for more advanced HIV disease (mainly low CD4+ counts and hematocrits), black race was no longer a significant independent predictor of survival. Adjustment for racial differences in the use of PCP prophylaxis accounted for most of the excess risk for the development of PCP in black patients compared with white patients with AIDS. Conclusions. - Racial differences in survival and the development of opportunistic infections are mainly due to the more advanced HIV disease in black patients when zidovudine therapy is started and to their less frequent use of PCP prophylaxis. Innovative approaches are needed to ensure more widespread use of and earlier access to zidovudine therapy and PCP prophylaxis.	BURROUGHS WELLCOME CO,RES TRIANGLE PK,NC 27709; UNIV CALIF SAN DIEGO,DEPT MED,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT PATHOL,LA JOLLA,CA 92093	Burroughs Wellcome Fund; University of California System; University of California San Diego; University of California System; University of California San Diego	EASTERBROOK, PJ (corresponding author), JOHNS HOPKINS UNIV HOSP,SCH MED,DEPT MED,1830 MONUMENT ST,ROOM 8059,BALTIMORE,MD 21205, USA.		Easterbrook, Philippa J/A-3937-2009	Easterbrook, Philippa/0000-0002-2603-5418				BACCHETTI P, 1988, J INFECT DIS, V157, P1044, DOI 10.1093/infdis/157.5.1044; BAKEMAN R, 1987, J NATL MED ASSOC, V79, P921; COX DR, 1972, J R STAT SOC B, V34, P187; CREAGHKIRK T, 1988, JAMA-J AM MED ASSOC, V260, P3009, DOI 10.1001/jama.260.20.3009; DOURNON E, 1988, LANCET, V2, P1297; FISCHL MA, 1989, JAMA-J AM MED ASSOC, V262, P2405; FISCHL MA, 1988, JAMA-J AM MED ASSOC, V259, P1185, DOI 10.1001/jama.259.8.1185; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; FRIEDLAND GH, 1991, J ACQ IMMUN DEF SYND, V4, P144; GOLDEN JA, 1989, LANCET, V1, P654; HAMILTON JD, 1991, CLIN RES, V39, pA216; JACKSON L, 1990, 6TH INT C AIDS SAN F; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; MOORE RD, 1991, NEW ENGL J MED, V324, P1412, DOI 10.1056/NEJM199105163242006; MOORE RD, 1991, ARCH INTERN MED, V151, P981, DOI 10.1001/archinte.151.5.981; PINCHING AJ, 1989, J INFECTION, V18, P33, DOI 10.1016/S0163-4453(89)80078-7; RICHMAN DD, 1988, AM J MED, V85, P208; ROTHENBERG R, 1987, NEW ENGL J MED, V317, P1297, DOI 10.1056/NEJM198711193172101; SELIK RM, 1988, AM J PUBLIC HEALTH, V78, P1539, DOI 10.2105/AJPH.78.12.1539; SELTZER R, 1988, AIDS PUBLIC POLICY J, V3, P31; STAMBUK D, 1989, Q J MED, V262, P161; STEINBERG JP, 1989, J ACQ IMMUN DEF SYND, V2, P229; WILLIAMS I, 1989, J INFECTION, V18, P23, DOI 10.1016/S0163-4453(89)80077-5; 1987, MMWR, V36, pS1; 1988, MMWR, V37, P1	25	87	88	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 20	1991	266	19					2713	2718		10.1001/jama.266.19.2713	http://dx.doi.org/10.1001/jama.266.19.2713			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GP691	1942423				2022-12-24	WOS:A1991GP69100026
J	JAVITT, JC; MCBEAN, AM; NICHOLSON, GA; BABISH, JD; WARREN, JL; KRAKAUER, H				JAVITT, JC; MCBEAN, AM; NICHOLSON, GA; BABISH, JD; WARREN, JL; KRAKAUER, H			UNDERTREATMENT OF GLAUCOMA AMONG BLACK-AMERICANS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							OPEN-ANGLE GLAUCOMA; ARGON-LASER TRABECULOPLASTY; FOLLOW-UP; RETINOPATHY; POPULATION; BLINDNESS; WHITES; CARE	Background. Cross-sectional studies and those using national data sets estimate that glaucoma-related blindness is between six and eight times more common among black Americans than among whites. Community-based studies have found that glaucoma is four to six times more prevalent among blacks. It is not known why blacks with glaucoma are more likely to become blind than whites with glaucoma. Methods. To investigate the possibility that under-treatment of glaucoma is an important factor contributing to this higher rate of blindness, we studied the population-based rates of incisional and laser surgery tor open-angle glaucoma among blacks and whites in a 5 percent random sample of Medicare claims for 1986 through 1988. Results. For all U.S. census divisions combined, the rate of surgery for glaucoma among black Medicare beneficiaries was 2.2 times higher than the rate among white beneficiaries (95 percent confidence interval, 2.1 to 2.3). We calculated an expected rate of treatment among blacks on the basis of the rate of treatment among whites and the assumption that glaucoma is four times more prevalent among blacks - a conservative estimate. The observed rate of glaucoma surgery among blacks was 45 percent lower than the expected rate we calculated, which may in part account for the excess rate of blindness among blacks. The magnitude of this difference in treatment rates varied from 29 percent in the Middle Atlantic states to 50 percent in the South Atlantic states. Conclusions. Older black Americans are not receiving potentially sight-saving care for open-angle glaucoma at the same rate as older white Americans.	GEORGETOWN UNIV,DEPT COMMUNITY & FAMILY MED,PROGRAM TECHNOL ASSESSMENT,WASHINGTON,DC 20057; HLTH CARE FINANCING ADM,BUR HLTH STAND QUAL,OFF PROGRAM ASSESSMENT,BALTIMORE,MD; HLTH CARE FINANCING ADM,OFF RES,BALTIMORE,MD	Georgetown University	JAVITT, JC (corresponding author), CTR SIGHT,WORTHEN CTR EYE CARE RES,3800 RESERVOIR RD NW,WASHINGTON,DC 20007, USA.		Javitt, Jonathan/AAJ-5574-2021	Javitt, Jonathan/0000-0003-2371-1609	NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR006758, R24RR006758] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R21EY007744, R01EY008805] Funding Source: NIH RePORTER; NCRR NIH HHS [S10 RR0 6758] Funding Source: Medline; NEI NIH HHS [R01 EY08805, R21 EY07744] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		[Anonymous], HCFA COMMON PROCEDUR; CHASSIN MR, 1986, NEW ENGL J MED, V314, P285, DOI 10.1056/NEJM198601303140505; DASBACH EJ, 1991, MED CARE, V29, P20, DOI 10.1097/00005650-199101000-00003; EISENBERG JM, 1979, ANN INTERN MED, V90, P957, DOI 10.7326/0003-4819-90-6-957; FISHER E, IN PRESS AM J PUBLIC; FORD E, 1989, AM J PUBLIC HEALTH, V79, P437, DOI 10.2105/AJPH.79.4.437; GREENLAND S, 1985, BIOMETRICS, V41, P55, DOI 10.2307/2530643; HILLER R, 1975, AM J OPHTHALMOL, V80, P62, DOI 10.1016/0002-9394(75)90870-3; HSIA DC, 1988, NEW ENGL J MED, V318, P352, DOI 10.1056/NEJM198802113180604; JAVITT JC, 1991, OPHTHALMOLOGY, V98, P1565; JAVITT JC, 1990, OPHTHALMOLOGY, V97, P483, DOI 10.1016/S0161-6420(90)32573-3; JAVITT JC, 1989, OPHTHALMOLOGY, V96, P255; KAHN HA, 1973, DHEW NIH73427 NAT EY; KRUPIN T, 1986, OPHTHALMOLOGY, V93, P811; Lave J, 1983, Health Care Financ Rev, V5, P93; LESKE MC, 1989, BRIT J OPHTHALMOL, V73, P365, DOI 10.1136/bjo.73.5.365; MARTIN MJ, 1985, AM J OPHTHALMOL, V99, P383, DOI 10.1016/0002-9394(85)90001-7; MASON RP, 1989, OPHTHALMOLOGY, V96, P1363; MAYER WJ, 1989, AM J PUBLIC HEALTH, V79, P772, DOI 10.2105/AJPH.79.6.772; MILLER RD, 1981, OPHTHALMIC SURG LAS, V12, P46; PODGOR MJ, 1983, AM J EPIDEMIOL, V118, P206, DOI 10.1093/oxfordjournals.aje.a113628; ROBERTS J, 1977, VITAL HLTH STATI 201, V11; ROOS LL, 1990, JAMA-J AM MED ASSOC, V263, P2453, DOI 10.1001/jama.263.18.2453; SCHWARTZ AL, 1985, ARCH OPHTHALMOL-CHIC, V103, P1482; STROGATZ DS, 1990, AM J PUBLIC HEALTH, V80, P290, DOI 10.2105/AJPH.80.3.290; TIELSCH JM, 1991, JAMA-J AM MED ASSOC, V266, P369, DOI 10.1001/jama.266.3.369; TIELSCH JM, 1990, ARCH OPHTHALMOL-CHIC, V108, P286, DOI 10.1001/archopht.1990.01070040138048; WELSH NH, 1972, BRIT J OPHTHALMOL, V56, P32, DOI 10.1136/bjo.56.1.32; WENNBERG J, 1973, SCIENCE, V182, P1102, DOI 10.1126/science.182.4117.1102; WENNEKER MB, 1990, JAMA-J AM MED ASSOC, V264, P1255, DOI 10.1001/jama.264.10.1255; 1977, CPT4 AM MED ASS; 1986, INT CLASSIFICATION D; 1990, HCFA03301 HLTH CAR F, V2	33	98	99	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 14	1991	325	20					1418	1422		10.1056/NEJM199111143252005	http://dx.doi.org/10.1056/NEJM199111143252005			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GP524	1922253	Bronze			2022-12-24	WOS:A1991GP52400005
J	BLAKELY, RD; BERSON, HE; FREMEAU, RT; CARON, MG; PEEK, MM; PRINCE, HK; BRADLEY, CC				BLAKELY, RD; BERSON, HE; FREMEAU, RT; CARON, MG; PEEK, MM; PRINCE, HK; BRADLEY, CC			CLONING AND EXPRESSION OF A FUNCTIONAL SEROTONIN TRANSPORTER FROM RAT-BRAIN	NATURE			English	Article							IMIPRAMINE BINDING-SITES; TRITIATED IMIPRAMINE; DEPRESSED-PATIENTS; UPTAKE INHIBITOR; GABA TRANSPORTER; LIGAND-BINDING; POLYMERASE; PLATELETS; DOPAMINE; PROTEIN	SELECTIVE antagonism of serotonin (5-hydroxytryptamine, 5HT) and noradrenaline transport by antidepressants is a key element in the 'amine' hypothesis of affective disorders 1. Uptake 2,3 and/or transport sites 4-5 of 5HT have been reported to be reduced in platelets of patients suffering from depression and in post-mortem brain samples of depressed patients 6 and suicide victims 7. To date there has been little molecular information available on the structure and regulation of 5HT transporters. Using the polymerase chain reaction 8 with degenerate oligonucleotides 9 derived from two highly conserved regions of the transporters for noradrenaline 10 and gamma-aminobutyric acid 11 (GABA), we have identified a large family of related gene products expressed in rodent brain. One of these products hybridizes to a single 3.7-kilobase RNA restricted to rat midbrain and brainstem, where it is highly enriched within the serotonergic raphe complex. Transfection with a single 2.3-kilobase brainstem complementary DNA clone is sufficient to confer expression of a Na+-dependent 5HT transporter upon non-neural cells, with transport selectively and potently antagonized by 5HT uptake-specific antidepressants, including paroxetine, citalopram and fluoxetine.	EMORY UNIV, SCH MED, PROGRAM NEUROSCI, ATLANTA, GA 30322 USA; DUKE UNIV, SCH MED, DEPT NEUROBIOL, DURHAM, NC 27710 USA; DUKE UNIV, SCH MED, DEPT CELL BIOL & MED, DURHAM, NC 27710 USA	Emory University; Duke University; Duke University	BLAKELY, RD (corresponding author), EMORY UNIV, SCH MED, DEPT ANAT & CELL BIOL, ATLANTA, GA 30322 USA.							ANDERSEN PH, 1989, EUR J PHARMACOL, V166, P493, DOI 10.1016/0014-2999(89)90363-4; ASHTON H, 1987, BRIAN SYSTEMS DISORD, P283; BLAKELY RD, 1991, ANAL BIOCHEM, V194, P302, DOI 10.1016/0003-2697(91)90233-J; BRILEY MS, 1980, SCIENCE, V209, P303, DOI 10.1126/science.7384806; COOL DR, 1991, J BIOL CHEM, V266, P15750; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FREMEAU RT, 1991, P NATL ACAD SCI USA, V88, P3772, DOI 10.1073/pnas.88.9.3772; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; FULLER RW, 1990, ANN NY ACAD SCI, V600, P68, DOI 10.1111/j.1749-6632.1990.tb16873.x; GRAHAM D, 1989, BIOCHEM PHARMACOL, V38, P3819, DOI 10.1016/0006-2952(89)90591-1; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; HINSON JP, 1989, J ENDOCRINOL, V121, P253, DOI 10.1677/joe.0.1210253; HOLZWARTH MA, 1985, NEUROENDOCRINOLOGY, V41, P230, DOI 10.1159/000124182; HYTTEL J, 1977, PSYCHOPHARMACOLOGY, V51, P225, DOI 10.1007/BF00431629; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; KOE BK, 1976, J PHARMACOL EXP THER, V199, P649; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LASSEN J B, 1978, European Journal of Pharmacology, V47, P351; LEMBERGER L, 1978, CLIN PHARMACOL THER, V23, P421; MARCUSSON JO, 1989, PSYCHOPHARMACOLOGY, V99, P17, DOI 10.1007/BF00634446; MAXWELL RA, 1978, HDB PSYCHOPHARMACOLO, P83; MELTZER HY, 1981, ARCH GEN PSYCHIAT, V38, P1322; NELSON H, 1990, FEBS LETT, V269, P181, DOI 10.1016/0014-5793(90)81149-I; PACHOLCZYK T, 1991, NATURE, V350, P350, DOI 10.1038/350350a0; PAUL SM, 1981, ARCH GEN PSYCHIAT, V38, P1315; PERRY EK, 1983, BRIT J PSYCHIAT, V142, P188, DOI 10.1192/bjp.142.2.188; RATHE R, 1985, J MOL BIOL, V183, P1; RICHELSON E, 1990, MAYO CLIN PROC, V65, P1227, DOI 10.1016/S0025-6196(12)62747-5; RITZ MC, 1990, LIFE SCI, V46, P635, DOI 10.1016/0024-3205(90)90132-B; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J., 1989, MOL CLONING LAB MANU; STANLEY M, 1982, SCIENCE, V216, P1337, DOI 10.1126/science.7079769; Steinbusch H. W., 1983, CHEM NEUROANATOMY, P131; STRADER CD, 1989, FASEB J, V3, P1825, DOI 10.1096/fasebj.3.7.2541037; SURANYICADOTTE BE, 1985, LIFE SCI, V36, P795, DOI 10.1016/0024-3205(85)90201-2; VERHOFSTAD AAJ, 1983, NEUROSCIENCE, V10, P1443, DOI 10.1016/0306-4522(83)90125-2; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17	39	710	727	1	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 7	1991	354	6348					66	70		10.1038/354066a0	http://dx.doi.org/10.1038/354066a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GN829	1944572				2022-12-24	WOS:A1991GN82900059
J	KODISH, E; LANTOS, J; STOCKING, C; SINGER, PA; SIEGLER, M; JOHNSON, FL				KODISH, E; LANTOS, J; STOCKING, C; SINGER, PA; SIEGLER, M; JOHNSON, FL			BONE-MARROW TRANSPLANTATION FOR SICKLE-CELL DISEASE - A STUDY OF PARENTS DECISIONS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							APLASTIC-ANEMIA; CHILDREN; SURVIVAL; MORTALITY; LEUKEMIA; QUALITY; CANCER; LIFE	Background. Bone marrow transplantation has been shown to cure sickle cell disease, but it carries a 15 percent mortality risk. To determine whether parents would accept this risk to cure their children of sickle cell disease, we interviewed parents of children with sickle cell disease who were being followed in a university hospital clinic. Methods. We assessed parents' attitudes by using questions based on the standard reference-gamble paradigm. After we gave them descriptions of bone marrow transplantation and graft-versus-host disease (GVHD), the parents were presented with a series of hypothetical situations. In the first situation, bone marrow transplantation was described as offering certain (100 percent) survival with cure of sickle cell disease. In subsequent descriptions, the mortality rate associated with bone marrow transplantation was increased by 5 percent increments. The parents indicated the highest mortality risk at which they would consent to the procedure in order to cure their children. Results. In order to obtain a cure for their children, 36 of 67 parents (54 percent) were willing to accept some risk of short-term mortality, 25 of 67 (37 percent) were willing to accept at least the 15 percent short-term mortality risk we estimate to be the current figure for bone marrow transplantation, and 8 of 67 (12 percent) were willing to accept a short-term mortality risk of 50 percent or more. Nine parents (13 percent) said they would accept both a mortality risk of 15 percent or more and an additional 15 percent risk of GVHD. The parents' decisions were not related to the clinical severity of their children's illness. Conclusions. At current rates of mortality and morbidity with bone marrow transplantation, a substantial minority of the parents of children with sickle cell disease may consent to bone marrow transplantation for their children. Parental attitudes should be factored into decisions about whether to off er bone marrow transplantation to children with sickle cell disease.	UNIV TORONTO,CTR BIOETH,TORONTO M5S 1A1,ONTARIO,CANADA; UNIV CHICAGO,PRITZKER SCH MED,CTR CLIN MED ETH,CHICAGO,IL 60637; UNIV TORONTO,DEPT MED,TORONTO M5S 1A1,ONTARIO,CANADA	University of Toronto; University of Chicago; University of Toronto	KODISH, E (corresponding author), UNIV CHICAGO,PRITZKER SCH MED,DEPT PEDIAT,BOX 97,5841 S MARYLAND AVE,CHICAGO,IL 60637, USA.							BEUTLER E, 1983, HEMATOLOGY, P583; BRIGGS NC, 1986, TRANSFUSION, V26, P324, DOI 10.1046/j.1537-2995.1986.26486262738.x; DURBIN M, 1988, PEDIATRICS, V82, P774; FORMAN SJ, 1990, HEMATOL ONCOL CLIN N, V4, P517, DOI 10.1016/S0889-8588(18)30476-3; FROBERG DG, 1989, J CLIN EPIDEMIOL, V42, P459, DOI 10.1016/0895-4356(89)90136-4; Galimberti M, 1989, Prog Clin Biol Res, V309, P223; HARTH SC, 1990, BRIT MED J, V300, P1372, DOI 10.1136/bmj.300.6736.1372; JOHNSON FL, 1984, NEW ENGL J MED, V311, P780, DOI 10.1056/NEJM198409203111207; JOHNSON FL, 1985, AM J PEDIAT HEMATOL, V7, P254; KODISH E, 1990, CLIN RES, V38, P694; LEIKIN SL, 1989, PEDIATRICS, V84, P500; LOCASCIULLI A, 1990, BONE MARROW TRANSPL, V6, P211; LUCARELLI G, 1990, NEW ENGL J MED, V322, P417, DOI 10.1056/NEJM199002153220701; MCGLAVE P, 1990, SEMIN HEMATOL, V27, P23; MCNEIL BJ, 1978, NEW ENGL J MED, V299, P1397, DOI 10.1056/NEJM197812212992506; MCNEIL BJ, 1981, NEW ENGL J MED, V305, P982, DOI 10.1056/NEJM198110223051704; OR R, 1988, HEMOGLOBIN, V12, P609, DOI 10.3109/03630268808991651; PLATT OS, 1991, NEW ENGL J MED, V325, P11, DOI 10.1056/NEJM199107043250103; PLATT OS, 1987, HEMATOLOGY INFANCY C, P655; SARNAIK SA, 1982, AM J PEDIAT HEMATOL, V4, P386; SINGER PA, 1991, J CLIN ONCOL, V9, P328, DOI 10.1200/JCO.1991.9.2.328; SPRINKLE RH, 1986, AM J PEDIAT HEMATOL, V8, P105; STORB R, 1984, SEMIN HEMATOL, V21, P27; VERMYLEN C, 1988, LANCET, V1, P1427; 1986, ETHICS REGULATION CL, P1; 29TH WORLD MED ASS T; 1983, FED REGISTER, V48, P9814	27	106	106	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 7	1991	325	19					1349	1353		10.1056/NEJM199111073251905	http://dx.doi.org/10.1056/NEJM199111073251905			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GN470	1922237	Bronze			2022-12-24	WOS:A1991GN47000005
J	HARRINGTON, JM				HARRINGTON, JM			WORK RELATED DISEASE AND INJURIES	BRITISH MEDICAL JOURNAL			English	Article							HEALTH				HARRINGTON, JM (corresponding author), UNIV BIRMINGHAM,INST OCCUPAT HLTH,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND.							AW TC, 1989, BMJ, V303, P68; BAKER EL, 1989, AM J PUBLIC HLTH S1, V79, P64; CARTER JT, 1991, BRIT J IND MED, V48, P289; Doll R, 1981, THE CAUSES OF CANCER; FOX AJ, 1978, J EPIDEMIOL COMMUN H, V32, P73, DOI 10.1136/jech.32.2.73; HARRINGTON JM, 1990, J ROY COLL PHYS LOND, V24, P189; HARRINGTON JM, IN PRESS HUNTERS DIS; LEGGE T, 1934, IND MALADIES; MERIDITH SK, 1991, BR J IND MED, V48, P292; MULLAN RJ, 1991, AM J IND MED, V19, P775, DOI 10.1002/ajim.4700190610; OLSEN O, 1991, J EPIDEMIOL COMMUN H, V45, P4, DOI 10.1136/jech.45.1.4; PLESS IB, 1991, BRIT MED J, V303, P462, DOI 10.1136/bmj.303.6800.462; SCHILLING RSF, 1989, BRIT J IND MED, V46, P683; WILLIAMS CJ, 1991, BMJ, V303, P576; 1990, HLTH SAFETY STATISTI; 1991, CM1523	16	8	8	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 12	1991	303	6807					908	910		10.1136/bmj.303.6807.908	http://dx.doi.org/10.1136/bmj.303.6807.908			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GK221	1933008	Green Published, Bronze			2022-12-24	WOS:A1991GK22100028
J	KELLY, AP; MONACO, JJ; CHO, SG; TROWSDALE, J				KELLY, AP; MONACO, JJ; CHO, SG; TROWSDALE, J			A NEW HUMAN HLA CLASS-II-RELATED LOCUS, DM	NATURE			English	Article							DQ-SUBREGION; CHAIN GENE; MHC; MOLECULES; SEQUENCE; DISTINCT; REGION; BETA	HLA CLASS II molecules have a crucial role in the immune response to antigens. We have isolated two new class II-like complementary DNA sequences, RING6 and RING7, which map between the HLA-DNA and -DOB loci. They are novel members of the immunoglobulin gene family which may have diverged before the duplications that gave rise to the main class II loci. The RING6 and RING7 genes seem to encode alpha- and beta-chains of a previously undiscovered class II-related protein.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT MICROBIOL & IMMUNOL,RICHMOND,VA 23298	Virginia Commonwealth University	KELLY, AP (corresponding author), IMPERIAL CANC RES FUND,HUMAN IMMUNOGENET LAB,LINCOLNS INN FIELDS,LONDON WC2A 3PX,ENGLAND.							BANKIER AT, 1987, METHOD ENZYMOL, V155, P51; BLANCK G, 1988, J IMMUNOL, V141, P1734; BROWN JH, 1988, NATURE, V332, P845, DOI 10.1038/332845a0; CHO SG, 1991, NATURE, V353, P573, DOI 10.1038/353573a0; GUESSOW D, 1987, J IMMUNOL, V139, P3122; HANSON IM, 1991, IMMUNOGENETICS, V34, P5, DOI 10.1007/BF00212306; HOOD L, 1985, CELL, V40, P225, DOI 10.1016/0092-8674(85)90133-3; KELLY A, 1985, NUCLEIC ACIDS RES, V13, P1607, DOI 10.1093/nar/13.5.1607; Klein J., 1986, NATURAL HIST MAJOR H; LINDAHL KF, 1989, COLD SH Q B, V54, P563; OSULLIVAN DM, 1986, P NATL ACAD SCI USA, V83, P4484, DOI 10.1073/pnas.83.12.4484; RAGOUSSIS J, 1991, P NATL ACAD SCI USA, V88, P3753, DOI 10.1073/pnas.88.9.3753; Sambrook J., 1989, MOL CLONING LAB MANU; SHAWAR SM, 1990, J EXP MED, V171, P897, DOI 10.1084/jem.171.3.897; STADEN R, 1990, COMPUT APPL BIOSCI, V6, P387; TONNELLE C, 1985, EMBO J, V4, P2839, DOI 10.1002/j.1460-2075.1985.tb04012.x; TROWSDALE J, 1985, EMBO J, V4, P2231, DOI 10.1002/j.1460-2075.1985.tb03919.x; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0	18	254	265	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 10	1991	353	6344					571	573		10.1038/353571a0	http://dx.doi.org/10.1038/353571a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GJ643	1922365				2022-12-24	WOS:A1991GJ64300072
J	SIMILOWSKI, T; YAN, S; GAUTHIER, AP; MACKLEM, PT; BELLEMARE, F				SIMILOWSKI, T; YAN, S; GAUTHIER, AP; MACKLEM, PT; BELLEMARE, F			CONTRACTILE PROPERTIES OF THE HUMAN DIAPHRAGM DURING CHRONIC HYPERINFLATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							OBSTRUCTIVE PULMONARY-DISEASE; PHRENIC-NERVE STIMULATION; LUNG-VOLUME; EMPHYSEMATOUS HAMSTERS; RESPIRATORY MUSCLES; BODY-WEIGHT; ADAPTABILITY; ACTIVATION; PRESSURE; STRENGTH	Background. In patients with chronic obstructive pulmonary disease (COPD) and hyperinflation of the lungs, dysfunction of the diaphragm may contribute to respiratory decompensation. We evaluated the contractile function of the diaphragm in well-nourished patients with stable COPD, using supramaximal, bilateral phrenic-nerve stimulation, which provides information about the strength and inspiratory action of the diaphragm. Methods. In eight patients with COPD and five control subjects of similar age, the transdiaphragmatic pressure generated by the twitch response to phrenic-nerve stimulation was recorded at various base-line lung volumes, from functional residual capacity to total lung capacity, and during relaxation and graded voluntary efforts at functional residual capacity (twitch occlusion). Results. At functional residual capacity, the twitch transdiaphragmatic pressure ranged from 10.9 to 26.6 cm of water (1.07 to 2.60 kPa) in the patients and from 19.8 to 37.1 cm of water (1.94 to 3.64 kPa) in the controls, indicating considerable overlap between the two groups. The ratio of esophageal pressure to twitch transdiaphragmatic pressure, an index of the inspiratory action of the diaphragm, was -0.50 +/- 0.05 in the patients, as compared with -0.43 +/- 0.02 in the controls (indicating more efficient inspiratory action in the patients than in the controls). At comparable volumes, the twitch transdiaphragmatic pressure and esophageal-to-transdiaphragmatic pressure ratio were higher in the patients than in normal subjects, indicating that the strength and inspiratory action of the diaphragm in the patients were actually better than in the controls. Twitch occlusion (a measure of the maximal activation of the diaphragm) indicated near-maximal activation in the patients with COPD, and the maximal transdiaphragmatic pressure was 106.9 +/- 13.8 cm of water (10.48 +/- 1.35 kPa). Conclusions. The functioning of the diaphragms of the patients with stable COPD is as good as in normal subjects at the same lung volume. Compensatory phenomena appear to counterbalance the deleterious effects of hyperinflation on the contractility and inspiratory action of the diaphragm in patients with COPD. Our findings cast doubt on the existence of chronic fatigue of the diaphragm in such patients and therefore on the need for therapeutic interventions aimed at improving diaphragm function.	MCGILL UNIV, ROYAL VICTORIA HOSP, MEAKINS CHRISTIE LABS, 3626 ST URBAIN ST, MONTREAL H2X 2P2, QUEBEC, CANADA; MCGILL UNIV, CTR HOSP THORAC MONTREAL, MONTREAL H3A 2T5, QUEBEC, CANADA	McGill University; Royal Victoria Hospital; McGill University								AGOSTONI E, 1960, J APPL PHYSIOL, V15, P1087, DOI 10.1152/jappl.1960.15.6.1087; AGOSTONI E, 1985, THORAX A, V29, P259; ARORA NS, 1982, J APPL PHYSIOL, V52, P64, DOI 10.1152/jappl.1982.52.1.64; AUBIER M, 1985, J APPL PHYSIOL, V58, P58, DOI 10.1152/jappl.1985.58.1.58; BELLEMARE F, 1984, RESP PHYSIOL, V58, P263, DOI 10.1016/0034-5687(84)90003-3; BELLEMARE F, 1987, J APPL PHYSIOL, V62, P1307, DOI 10.1152/jappl.1987.62.3.1307; BELLEMARE F, 1983, J APPL PHYSIOL, V55, P8, DOI 10.1152/jappl.1983.55.1.8; BELLEMARE F, 1986, J APPL PHYSIOL, V61, P1153, DOI 10.1152/jappl.1986.61.3.1153; BRAUN NMT, 1982, J APPL PHYSIOL, V53, P405, DOI 10.1152/jappl.1982.53.2.405; BUTLER C, 1976, AM REV RESPIR DIS, V114, P155; DAVIS JN, 1967, J NEUROL NEUROSUR PS, V30, P420, DOI 10.1136/jnnp.30.5.420; DELHEZ L, 1965, ARCH INT PHYS BIOCH, V73, P832, DOI 10.3109/13813456509084906; FARKAS GA, 1983, J APPL PHYSIOL, V54, P1635, DOI 10.1152/jappl.1983.54.6.1635; FARKAS GA, 1982, J APPL PHYSIOL, V53, P1263, DOI 10.1152/jappl.1982.53.5.1263; GANDEVIA SC, 1990, J PHYSIOL-LONDON, V428, P387, DOI 10.1113/jphysiol.1990.sp018218; GIBSON GJ, 1981, AM REV RESPIR DIS, V124, P685; HUBMAYR RD, 1989, AM REV RESPIR DIS, V139, P647, DOI 10.1164/ajrccm/139.3.647; ISHIKAWA S, 1973, AM REV RESPIR DIS, V108, P135; LAPORTA D, 1985, J APPL PHYSIOL, V58, P1469, DOI 10.1152/jappl.1985.58.5.1469; LORING SH, 1985, J APPL PHYSIOL, V59, P1961, DOI 10.1152/jappl.1985.59.6.1961; LORING SH, 1982, J APPL PHYSIOL, V53, P756, DOI 10.1152/jappl.1982.53.3.756; MACKLEM PT, 1983, J APPL PHYSIOL, V55, P547, DOI 10.1152/jappl.1983.55.2.547; MERTON PA, 1954, J PHYSIOL-LONDON, V123, P553, DOI 10.1113/jphysiol.1954.sp005070; MILICEMILI J, 1964, J APPL PHYSIOL, V19, P207, DOI 10.1152/jappl.1964.19.2.207; MURCIANO D, 1989, NEW ENGL J MED, V320, P1521, DOI 10.1056/NEJM198906083202304; OLIVEN A, 1986, J APPL PHYSIOL, V60, P225, DOI 10.1152/jappl.1986.60.1.225; ROCHESTER DF, 1979, AM REV RESPIR DIS, V119, P151; SANCHEZ J, 1982, B EUR PHYSIOPATH RES, V18, P901; SARNOFF SJ, 1951, SURG GYNECOL OBSTET, V93, P190; SIMILOWSKI T, 1989, J APPL PHYSIOL, V67, P1311, DOI 10.1152/jappl.1989.67.4.1311; SMITH J, 1987, J APPL PHYSIOL, V62, P1893, DOI 10.1152/jappl.1987.62.5.1893; SUPINSKI GS, 1982, J CLIN INVEST, V70, P978, DOI 10.1172/JCI110709; TABARY JC, 1972, J PHYSIOL-LONDON, V224, P231, DOI 10.1113/jphysiol.1972.sp009891; THURLBECK WM, 1978, THORAX, V33, P483, DOI 10.1136/thx.33.4.483	34	300	310	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 26	1991	325	13					917	923		10.1056/NEJM199109263251304	http://dx.doi.org/10.1056/NEJM199109263251304			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GF856	1881417	Bronze			2022-12-24	WOS:A1991GF85600004
J	GRUSBY, MJ; JOHNSON, RS; PAPAIOANNOU, VE; GLIMCHER, LH				GRUSBY, MJ; JOHNSON, RS; PAPAIOANNOU, VE; GLIMCHER, LH			DEPLETION OF CD4+ T-CELLS IN MAJOR HISTOCOMPATIBILITY COMPLEX CLASS-II DEFICIENT MICE	SCIENCE			English	Article							EMBRYONIC STEM-CELLS; GERM-LINE TRANSMISSION; HOMOLOGOUS RECOMBINATION; POSITIVE SELECTION; GENE-EXPRESSION; PHENOTYPE; ANTIGENS; RECEPTOR	The maturation of T cells in the thymus is dependent on the expression of major histocompatibility complex (MHC) molecules. By disruption of the MHC class II A-beta-b gene in embryonic stem cells, mice were generated that lack cell surface expression of class II molecules. These MHC class II-deficient mice were depleted of mature CD4+ T cells and were deficient in cell-mediated immune responses. These results provide genetic evidence that class II molecules are required for the maturation and function of mature CD4+ T cells.	HARVARD UNIV, SCH PUBL HLTH, DEPT CANC BIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOLEC PHARMACOL, BOSTON, MA 02115 USA; TUFTS UNIV, SCH MED & VET MED, DEPT PATHOL, BOSTON, MA 02111 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DANA FARBER CANC INST, BOSTON, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Tufts University; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School			Johnson, Randall/AAM-1189-2021	Johnson, Randall/0000-0002-4084-6639; Papaioannou, Virginia/0000-0001-7558-8601	NIAID NIH HHS [AI21569] Funding Source: Medline; NICHD NIH HHS [HD27295] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD027295] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI021569, R01AI021569] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AUCHINCLOSS H, UNPUB; BENOIST C, 1989, CELL, V58, P1027, DOI 10.1016/0092-8674(89)90501-1; BERG LJ, 1989, CELL, V58, P1035, DOI 10.1016/0092-8674(89)90502-3; BILL J, 1989, NATURE, V341, P649, DOI 10.1038/341649a0; CHISAKA O, 1991, NATURE, V350, P473, DOI 10.1038/350473a0; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; FUNGLEUNG WP, 1991, CELL, V65, P443, DOI 10.1016/0092-8674(91)90462-8; GERMAIN R, COMMUNICATION; GRUSBY M, UNPUB; JOHNSON RS, 1989, SCIENCE, V245, P1234, DOI 10.1126/science.2506639; KARLSSON L, 1991, NATURE, V351, P485, DOI 10.1038/351485a0; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; KOLLER BH, 1990, SCIENCE, V248, P1227, DOI 10.1126/science.2112266; KRUISBEEK AM, 1985, J EXP MED, V161, P1029, DOI 10.1084/jem.161.5.1029; LARHAMMAR D, 1983, CELL, V34, P179, DOI 10.1016/0092-8674(83)90148-4; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MATHIS DJ, 1983, P NATL ACAD SCI-BIOL, V80, P273, DOI 10.1073/pnas.80.1.273; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; SCOTT B, 1989, NATURE, V338, P591, DOI 10.1038/338591a0; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; TEH HS, 1988, NATURE, V335, P229, DOI 10.1038/335229a0; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; THOMPSON S, 1989, CELL, V56, P313, DOI 10.1016/0092-8674(89)90905-7; VANEWIJK W, 1988, CELL, V53, P357, DOI 10.1016/0092-8674(88)90156-0; ZIJLSTRA M, 1989, NATURE, V342, P435, DOI 10.1038/342435a0; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0	27	635	646	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 20	1991	253	5026					1417	1420		10.1126/science.1910207	http://dx.doi.org/10.1126/science.1910207			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GF851	1910207				2022-12-24	WOS:A1991GF85100041
J	KLEVIT, RE				KLEVIT, RE			RECOGNITION OF DNA BY CYS2, HIS2 ZINC FINGERS	SCIENCE			English	Editorial Material							TRANSCRIPTION FACTOR-IIIA; YEAST ADR1; BINDING; DOMAIN; PROTEIN				KLEVIT, RE (corresponding author), UNIV WASHINGTON,DEPT BIOCHEM SJ-70,SEATTLE,WA 98195, USA.		Klevit, Rachel/AAI-7038-2021	Klevit, Rachel/0000-0002-3476-969X				BROWN RS, 1985, FEBS LETT, V186, P271, DOI 10.1016/0014-5793(85)80723-7; FAIRALL L, 1986, J MOL BIOL, V192, P577, DOI 10.1016/0022-2836(86)90278-0; KLEVIT RE, 1990, PROTEINS, V7, P215, DOI 10.1002/prot.340070303; KOCHOYAN M, 1991, BIOCHEMISTRY-US, V30, P3371, DOI 10.1021/bi00228a004; LEE MS, 1989, SCIENCE, V245, P635, DOI 10.1126/science.2503871; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; NAGAI K, 1988, NATURE, V332, P284, DOI 10.1038/332284a0; NARDELLI J, 1991, NATURE, V349, P175, DOI 10.1038/349175a0; OMICHINSKI JG, 1990, BIOCHEMISTRY-US, V29, P9324, DOI 10.1021/bi00492a004; PARRAGA G, 1988, SCIENCE, V241, P1489, DOI 10.1126/science.3047872; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; THUKRAL SK, 1991, MOL CELL BIOL, V11, P1566, DOI 10.1128/MCB.11.3.1566; XU RX, 1991, BIOCHEMISTRY-US, V30, P3365, DOI 10.1021/bi00228a003	14	122	124	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 20	1991	253	5026					1367	&		10.1126/science.1896847	http://dx.doi.org/10.1126/science.1896847			0	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GF851	1896847				2022-12-24	WOS:A1991GF85100028
J	KION, TA; HOFFMANN, GW				KION, TA; HOFFMANN, GW			ANTI-HIV AND ANTI-ANTI-MHC ANTIBODIES IN ALLOIMMUNE AND AUTOIMMUNE MICE	SCIENCE			English	Article							IMMUNODEFICIENCY VIRUS HIV; IMMUNE-SYSTEM; AIDS; CD4; INFECTION; IDENTIFICATION; PATHOGENESIS; DISEASE; BINDING	Alloimmune mice (mice that have been exposed to cells from another murine strain) were shown to make antibodies against gp120 and p24 of human immunodeficiency virus (HIV, and mice of the autoimmune strains MRL-lpr/lpr and MRL-+/+ made antibodies against gp120. This is surprising because the mice were not exposed to HIV. Furthermore, anti-anti-MHC antibodies (molecules that have shapes similar to those of major histocompatibility complex molecules) were detected in both alloimmune sera and MRL mice. These results are discussed in the context of a possible role for allogeneic stimuli in the pathogenesis of acquired immunodeficiency syndrome, as suggested by an idiotypic network model.	UNIV BRITISH COLUMBIA,DEPT MICROBIOL,VANCOUVER V6T 1W5,BC,CANADA; UNIV BRITISH COLUMBIA,DEPT PHYS,VANCOUVER V6T 1W5,BC,CANADA	University of British Columbia; University of British Columbia								ANDRIEU JM, 1986, AIDS RES HUM RETROV, V2, P163, DOI 10.1089/aid.1.1986.2.163; CLAYTON LK, 1989, NATURE, V339, P548, DOI 10.1038/339548a0; DIAMOND DC, 1988, J IMMUNOL, V141, P3715; FORSYTH RB, 1990, J IMMUNOL, V145, P215; GOLDING H, 1989, J CLIN INVEST, V83, P1430, DOI 10.1172/JCI114034; GOLDING H, 1988, J EXP MED, V167, P914, DOI 10.1084/jem.167.3.914; HABESHAW JA, 1989, J ACQ IMMUN DEF SYND, V2, P457; HOFFMANN GW, 1986, J IMMUNOL, V137, P61; HOFFMANN GW, 1991, P NATL ACAD SCI USA, V88, P3060, DOI 10.1073/pnas.88.8.3060; HOFFMANN GW, 1988, SEMIOTICS CELLULAR C, P257; Hsu D H, 1989, Int Immunol, V1, P197, DOI 10.1093/intimm/1.2.197; KAYE BR, 1989, ANN INTERN MED, V111, P158, DOI 10.7326/0003-4819-111-2-158; KION TA, UNPUB; LAMARRE D, 1989, SCIENCE, V245, P743, DOI 10.1126/science.2549633; SATTENTAU QJ, 1986, SCIENCE, V234, P1120, DOI 10.1126/science.2430333; SHEARER GM, 1983, NEW ENGL J MED, V308, P223, DOI 10.1056/NEJM198301273080415; THOMAS Y, 1983, IMMUNOL REV, V74, P113, DOI 10.1111/j.1600-065X.1983.tb01086.x; VEGA MA, 1990, NATURE, V345, P26, DOI 10.1038/345026a0; WEINHOLD KJ, 1989, J IMMUNOL, V142, P3091; YOUNG JAT, 1988, NATURE, V333, P215, DOI 10.1038/333215c0; ZIEGLER JL, 1986, CLIN IMMUNOL IMMUNOP, V41, P305, DOI 10.1016/0090-1229(86)90001-2	21	130	142	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 6	1991	253	5024					1138	1140		10.1126/science.1909456	http://dx.doi.org/10.1126/science.1909456			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GD808	1909456				2022-12-24	WOS:A1991GD80800032
J	HUSSEY, RM; CLARKE, CA				HUSSEY, RM; CLARKE, CA			DEATHS FROM RH HEMOLYTIC-DISEASE IN ENGLAND AND WALES IN 1988 AND 1989	BRITISH MEDICAL JOURNAL			English	Article									UNIV LIVERPOOL,DEPT GENET & MICROBIOL,LIVERPOOL L69 3BX,ENGLAND	University of Liverpool	HUSSEY, RM (corresponding author), UNIV LIVERPOOL,DEPT PUBL HLTH,POB 147,LIVERPOOL L69 3BX,ENGLAND.							CLARKE CA, 1989, J ROY COLL PHYS LOND, V23, P181; THOMSON A, 1990, LANCET, V336, P1147, DOI 10.1016/0140-6736(90)92767-C; 1956, VITAL STATISTICS U A, V2	3	14	14	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 24	1991	303	6800					445	446		10.1136/bmj.303.6800.445	http://dx.doi.org/10.1136/bmj.303.6800.445			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GC465	1912836	Green Published, Bronze, Green Submitted			2022-12-24	WOS:A1991GC46500016
J	DIMICHELE, L; PAYNTER, KT; POWERS, DA				DIMICHELE, L; PAYNTER, KT; POWERS, DA			EVIDENCE OF LACTATE DEHYDROGENASE-B ALLOZYME EFFECTS IN THE TELEOST, FUNDULUS-HETEROCLITUS	SCIENCE			English	Article							NICOTINAMIDE ADENINE-DINUCLEOTIDE; GENETIC-VARIATION; LDH-B; GENOTYPES; POLYMORPHISM; LOCI; ADAPTATION; FISH; CELL	The evolutionary significance of protein polymorphisms has long been debated. Exponents of the balanced theory advocate that selection operates to maintain polymorphisms, whereas the neoclassical school argues that most genetic variation is neutral. Some studies have suggested that protein polymorphisms are not neutral, but their significance has been questioned because one cannot eliminate the possibility that linked loci were responsible for the observed differences. Evidence is presented that an enzymatic phenotype can affect carbon flow through a metabolic pathway. Glucose flux differences between lactate dehydrogenase-B phenotypes of Fundulus heteroclitus were reversed by substituting the Ldh-B gene product of one homozygous genotype with that of another.	JOHNS HOPKINS UNIV,CHESAPEAKE BAY INST,SHADY SIDE,MD 20764; STANFORD UNIV,HOPKINS MARINE STN,PACIFIC GROVE,CA 93950	Johns Hopkins University; Stanford University	DIMICHELE, L (corresponding author), TEXAS A&M UNIV SYST,DEPT WILDLIFE & FISHERIES SCI,COLLEGE STN,TX 77843, USA.		Paynter, Kennedy/F-9717-2013					BURTON RS, 1983, BIOCHEM GENET, V21, P239, DOI 10.1007/BF00499136; CAVENER DR, 1981, P NATL ACAD SCI-BIOL, V78, P4444, DOI 10.1073/pnas.78.7.4444; DIMICHELE L, 1986, AM ZOOL, V26, P201; DIMICHELE L, 1982, NATURE, V296, P563, DOI 10.1038/296563a0; DIMICHELE L, 1984, PHYSIOL ZOOL, V57, P52, DOI 10.1086/physzool.57.1.30155967; GONZALEZVILLASENOR LI, 1990, EVOLUTION, V44, P27, DOI 10.1111/j.1558-5646.1990.tb04277.x; HARRIS H, 1976, FED PROC, V35, P2079; HILBISH TJ, 1982, NATURE, V298, P688, DOI 10.1038/298688a0; KACSER H, 1981, GENETICS, V97, P639; KLYACHKO OS, 1982, J EXP ZOOL, V222, P137, DOI 10.1002/jez.1402220205; KOEHN RK, 1980, P NATL ACAD SCI-BIOL, V77, P5385, DOI 10.1073/pnas.77.9.5385; KOEHN RK, 1986, AM SCI, V74, P659; LANGRIDGE R, 1985, BIOCHEMISTRY-US, V24, P629; Lewontin RC, 1974, GENETIC BASIS EVOLUT; Nei M, 1983, EVOLUTION GENES PROT; Newsholme E.A., 1973, REGULATION METABOLIS; PLACE AR, 1978, BIOCHEM GENET, V16, P577, DOI 10.1007/BF00484221; PLACE AR, 1979, P NATL ACAD SCI USA, V76, P2354, DOI 10.1073/pnas.76.5.2354; PLACE AR, 1984, J BIOL CHEM, V76, P1304; PLACE AR, 1978, BIOCH GENET, V16, P593; PLACE AR, 1984, J BIOL CHEM, V76, P1299; POWERS DA, 1983, ISOZYMES-CURR T BIOL, V10, P147; POWERS DA, 1986, AM ZOOL, V26, P131; SRIVASTAVA DK, 1987, ANNU REV BIOPHYS BIO, V16, P175; SRIVASTAVA DK, 1989, P NATL ACAD SCI USA, V86, P6464, DOI 10.1073/pnas.86.17.6464; SRIVASTAVA DK, 1985, BIOCHEMISTRY-US, V24, P623, DOI 10.1021/bi00324a013; SRIVASTAVA DK, 1984, BIOCHEMISTRY-US, V23, P4538, DOI 10.1021/bi00315a006; WATT WB, 1983, GENETICS, V103, P725; WATT WB, 1985, GENETICS, V109, P157; WATT WB, 1983, ISOZYMES, V15, P27; ZAMMER WE, 1989, P NATL ACAD SCI USA, V86, P2737; ZOUROS E, 1983, ISOZYMES, V13, P1; 1988, SAS STAT USERS GUIDE, P549	33	48	48	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 23	1991	253	5022					898	900		10.1126/science.1876847	http://dx.doi.org/10.1126/science.1876847			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC152	1876847				2022-12-24	WOS:A1991GC15200043
J	JEANNEL, D; TUPPIN, P; BRUCKER, G; DANIS, M; GENTILINI, M				JEANNEL, D; TUPPIN, P; BRUCKER, G; DANIS, M; GENTILINI, M			IMPORTED AND AUTOCHTHONOUS KALA-AZAR IN FRANCE	BRITISH MEDICAL JOURNAL			English	Article							VISCERAL LEISHMANIASIS; DISEASE	Objective - To study the epidemiological, clinical, and biological features of imported and autochthonous kala-azar in France. Design-Prospective survey of all patients in France with kala-azar diagnosed over the two years 1986-7. Information was obtained from parasitology laboratories in regional hospitals and all hospital laboratories and haematology departments capable of diagnosing leishmaniasis in the south of France. Setting-107 public hospitals in France. Patients-89 patients with kala-azar. Interventions-All patients were treated with drugs. In the first instance meglumine antimonate was given to all but two patients. Main outcome measures-Prevalence of the various clinical and biological features of kala-azar; proportion of patients with HIV infection. Results-Half (44) of the patients were children under 8 years old. Seventy patients acquired the disease in France. Imported kala-azar was acquired mainly in Mediterranean countries (9/18 cases). Only 46 (52%) of the patients had all three of the classic associated clinical features of fever, splenomegaly, and hepatomegaly. Anaemia was the commonest biological sign, and the association of the four usual biological signs-anaemia, leucopenia, thrombocytopenia, and hypergammaglobulinaemia -was present in only 14 (33%) of the children under 8 and 26 (60%) adults. Fourteen of the patients over 8 years old were infected with HIV. Conclusion-Doctors must be aware of kala-azar in Mediterranean areas, especially as patients often present without the characteristic features and the disease affects young children preferentially.	INST HLTH & DEV,NATL CTR IMPORTED DIS,F-75270 PARIS,FRANCE; HOP LA PITIE SALPETRIERE,DEPT TROP DIS & PARASITOL,F-75651 PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite								BADARO R, 1990, NEW ENGL J MED, V322, P16, DOI 10.1056/NEJM199001043220104; BRYCESON ADM, 1985, T ROY SOC TROP MED H, V79, P705, DOI 10.1016/0035-9203(85)90199-3; HEILMANN K, 1971, DEUT MED WOCHENSCHR, V96, P36, DOI 10.1055/s-0028-1108196; HILL FGH, 1975, BRIT MED J, V3, P334; JEANNEL D, 1989, LANCET, V2, P804, DOI 10.1016/S0140-6736(89)90868-4; KILLICKKENDRICK R, 1984, ANN PARASIT HUM COMP, V59, P555, DOI 10.1051/parasite/1984596555; KINMOND S, 1989, LANCET, V2, P325, DOI 10.1016/S0140-6736(89)90502-3; MONTALBAN C, 1987, J INFECTION, V15, P247, DOI 10.1016/S0163-4453(87)92728-9; NEVA FA, 1990, NEW ENGL J MED, V322, P55, DOI 10.1056/NEJM199001043220111; OGUNKOLADE BW, 1988, VET PARASITOL, V28, P33, DOI 10.1016/0304-4017(88)90016-7; PUGIN P, 1968, SCHWEIZ MED WOCHENSC, V93, P1320; QUILICI M, 1987, ANN PEDIATR-PARIS, V34, P369; ROCHA H, 1979, PRINCIPLES PRACTICE, P2210; WHEATLEY T, 1983, J INFECTION, V7, P166, DOI 10.1016/S0163-4453(83)90716-8; 1984, WHO TECH REP SER, V701; 1987, B EPIDEMIOLOGIQUE HE, V7, P3	16	27	27	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 10	1991	303	6798					336	338		10.1136/bmj.303.6798.336	http://dx.doi.org/10.1136/bmj.303.6798.336			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA606	1912774	Green Published, Bronze			2022-12-24	WOS:A1991GA60600019
J	CHEN, ZM; PETO, R; COLLINS, R; MACMAHON, S; LU, JR; LI, WX				CHEN, ZM; PETO, R; COLLINS, R; MACMAHON, S; LU, JR; LI, WX			SERUM-CHOLESTEROL CONCENTRATION AND CORONARY HEART-DISEASE IN POPULATION WITH LOW CHOLESTEROL CONCENTRATIONS	BRITISH MEDICAL JOURNAL			English	Article							FACTOR INTERVENTION TRIAL; PLASMA-CHOLESTEROL; CANCER MORTALITY; FOLLOW-UP; RISK; DEATH; MEN; REGRESSION; STROKE; LIPOPROTEIN	Objective-To examine the relation between serum cholesterol concentration and mortality (from coronary heart disease and from other causes) below the range of cholesterol values generally seen in Western populations. Design-Prospective observational study based on 8-13 years of follow up of subjects in a population with low cholesterol concentrations. Setting-Urban Shanghai, China. Subjects-9021 Chinese men and women aged 35-64 at baseline. Main outcome measure-Death from coronary heart disease and other causes. Results-The average serum cholesterol concentration was 4.2 mmol/l at baseline examination, and only 43 (7%) of the deaths that occurred during 8-13 years of follow up were attributed to coronary heart disease. There was a strongly positive, and apparently independent, relation between serum cholesterol concentration and death from coronary heart disease (z = 3.47, p < 0.001), and within the range of usual serum cholesterol concentration studied (3.8-4.7 mmol/l) there was no evidence of any threshold. After appropriate adjustment for the regression dilution bias, a 4 (SD 1)% difference in usual cholesterol concentration was associated with a 21 (SD 6)% (95% confidence interval 9% to 35%) difference in mortality from coronary heart disease. There was no significant relation between serum cholesterol concentration and death from stroke or all types of cancer. The 79 deaths due to liver cancer or other chronic liver disease were inversely related to cholesterol concentration at baseline. Conclusion-Blood cholesterol concentration was directly related to mortality from coronary heart disease even in those with what was, by Western standards, a "low" cholesterol concentration. There was no good evidence of an adverse effect of cholesterol on other causes of death.	SHANGHAI CHEST HOSP,SHANGHAI,PEOPLES R CHINA; SHANGHAI MED UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,SHANGHAI,PEOPLES R CHINA	Shanghai Jiao Tong University; Fudan University	CHEN, ZM (corresponding author), UNIV OXFORD,RADCLIFFE INFIRM,NUFFIELD DEPT CLIN MED,MRC,IMPERIAL CANC RES FUND,OXFORD OX2 6HE,ENGLAND.							USA Pooling Project Research Group, 1978, Journal of Chronic Diseases, V31, P201; BEAGLEHOLE R, 1980, BMJ-BRIT MED J, V280, P285, DOI 10.1136/bmj.280.6210.285; BEASLEY RP, 1981, LANCET, V2, P1129; BERKSON J, 1950, J AM STAT ASSOC, V45, P164, DOI 10.2307/2280676; CHEN DY, 1987, CHIN MED J, V7, P382; CHEN ZM, 1989, NEW ENGL J MED, V321, P1339; COX DR, 1972, J R STAT SOC B, V34, P187; Dawber TR., 1980, FRAMINGHAM STUDY EPI, DOI DOI 10.4159/HARVARD.9780674492097; DYER AR, 1981, J CHRON DIS, V34, P249, DOI 10.1016/0021-9681(81)90030-8; EDERER F, 1972, J CHRON DIS, V25, P277, DOI 10.1016/0021-9681(72)90164-6; FEINLEIB M, 1981, AM J EPIDEMIOL, V114, P5, DOI 10.1093/oxfordjournals.aje.a113173; GOLDBOURT U, 1985, BMJ-BRIT MED J, V290, P1239, DOI 10.1136/bmj.290.6477.1239; HAN QQ, 1984, ACTA ACAD MED PRIMAE, V11, P181; ISLES CG, 1989, BMJ-BRIT MED J, V298, P920, DOI 10.1136/bmj.298.6678.920; ISO H, 1989, NEW ENGL J MED, V320, P904, DOI 10.1056/NEJM198904063201405; JIANG YT, 1982, VIRAL HEPATITIS, P121; KEIL U, 1989, INT J EPIDEMIOL, V18, pS46; Keys A., 1980, SCIENCE, DOI DOI 10.1126/SCIENCE.208.4448.1138; LI SC, 1985, NEUROLOGY, V35, P1708, DOI 10.1212/WNL.35.12.1708; LI WX, 1979, ACTA ACAD MED PRIMAE, V6, P65; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MULDOON MF, 1990, BMJ-BRIT MED J, V301, P309, DOI 10.1136/bmj.301.6747.309; OLIVER MF, 1981, LANCET, V2, P1090; PEARSON S, 1953, ANAL CHEM, V25, P813, DOI 10.1021/ac60077a041; PEKKANEN J, 1989, ARCH INTERN MED, V149, P1589, DOI 10.1001/archinte.149.7.1589; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; PETO R, 1985, CIRCULATION, V72, P451; RAGLAND DR, 1988, AM J EPIDEMIOL, V127, P462, DOI 10.1093/oxfordjournals.aje.a114823; ROBERTSON TL, 1977, AM J CARDIOL, V39, P239, DOI 10.1016/S0002-9149(77)80197-5; ROSE G, 1986, BRIT MED J, V293, P306, DOI 10.1136/bmj.293.6542.306; ROSE G, 1980, LANCET, V1, P523; SCHATZKIN A, 1987, LANCET, V2, P298; SHERWIN RW, 1987, JAMA-J AM MED ASSOC, V257, P943; SIMONS LA, 1986, AM J CARDIOL SG, V57, P5; SOLONEN JT, 1982, AM J EPIDEMIOL, V116, P622; Speizer, 1976, NATURAL HIST CHRONIC, P218; STAMLER J, 1986, JAMA-J AM MED ASSOC, V256, P2823, DOI 10.1001/jama.256.20.2823; SZATROWSKI TP, 1984, J CHRON DIS, V37, P569, DOI 10.1016/0021-9681(84)90007-9; TORNBERG SA, 1986, NEW ENGL J MED, V315, P1629, DOI 10.1056/NEJM198612253152601; WILLIAMS RR, 1981, JAMA-J AM MED ASSOC, V245, P247, DOI 10.1001/jama.245.3.247; YANO K, 1984, AM J EPIDEMIOL, V119, P653, DOI 10.1093/oxfordjournals.aje.a113787; ZAK B, 1954, AM J CLIN PATHOL, V24, P1307, DOI 10.1093/ajcp/24.11_ts.1307; [No title captured]; 1982, JAMA-J AM MED ASSOC, V248, P2853	44	469	488	1	14	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 3	1991	303	6797					276	282		10.1136/bmj.303.6797.276	http://dx.doi.org/10.1136/bmj.303.6797.276			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FZ721	1888927	Green Published, Bronze			2022-12-24	WOS:A1991FZ72100018
J	SOLOMON, A; WEISS, DT; KATTINE, AA				SOLOMON, A; WEISS, DT; KATTINE, AA			NEPHROTOXIC POTENTIAL OF BENCE-JONES PROTEINS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LIGHT-CHAIN DEPOSITION; MOLECULAR-WEIGHT PROTEINS; MULTIPLE-MYELOMA; ISOELECTRIC POINT; RENAL-FAILURE; LYMPHOPLASMACYTIC DISORDERS; AMYLOID DEPOSITS; BETA-FIBRILLOSES; CAST NEPHROPATHY; RAT	Background. The renal manifestations of diseases associated with the production of monoclonal light chains - myeloma (cast) nephropathy, light-chain deposition disease, and amyloidosis AL - result from the deposition of certain Bence Jones proteins as tubular casts, basement-membrane precipitates, or fibrils, respectively. For unknown reasons, the severity of the renal manifestations of these diseases varies greatly from patient to patient. We employed an experimental in vivo model to determine the pathologic importance of various Bence Jones proteins. Methods. Mice were injected intraperitoneally with 300 mg of Bence Jones protein from 40 patients with multiple myeloma or amyloidosis AL and killed 48 hours later. The mouse kidneys were examined by light and electron microscopy, and light-chain deposits were identified immunohistochemically with highly specific antihuman lightchain antiserum. Results. Of the 40 different human Bence Jones proteins studied, 26 were deposited in the mouse kidneys predominantly as tubular casts, basement-membrane precipitates, or crystals; no light-chain deposits were detected in the kidneys of the mice that received the other 14 Bence Jones proteins. Of the 18 patients for whom renal tissue was available for study, the findings in 14 were comparable to those in the mice. Furthermore, the proteins obtained from 22 of the 27 patients whose serum creatinine concentrations equaled or exceeded 168-mu-mol per liter (1.9 mg per deciliter) were deposited in the mouse kidneys, whereas protein deposition occurred after the injection of proteins from only 4 of the 13 patients with serum creatinine concentrations below 168-mu-mol per liter. The repeated injection of Bence Jones proteins from two patients who had amyloidosis AL resulted in deposition of the protein in the mouse kidneys as amyloid. Conclusions. Particular Bence Jones proteins are primarily responsible for producing the distinctive types of protein deposition in renal tissue and the clinical manifestations that occur in patients with light-chain - associated diseases. This experimental model has potential value for the identification of nephrotoxic or amyloidogenic light chains.	UNIV TENNESSEE, MED CTR, GRAD SCH MED, DEPT PATHOL, KNOXVILLE, TN 37920 USA	University of Tennessee System; University of Tennessee Health Science Center	SOLOMON, A (corresponding author), UNIV TENNESSEE, MED CTR,GRAD SCH MED,DEPT MED, HUMAN IMMUNOL & CANC PROGRAM, 1924 ALCOA HWY, KNOXVILLE, TN 37920 USA.				NATIONAL CANCER INSTITUTE [R01CA010056] Funding Source: NIH RePORTER; NCI NIH HHS [CA-10056] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANIAN R, 1990, ARCH INTERN MED, V150, P1693; BUXBAUM J, 1986, J CLIN INVEST, V78, P798, DOI 10.1172/JCI112643; BUXBAUM JN, 1990, ANN INTERN MED, V112, P455, DOI 10.7326/0003-4819-76-3-112-6-455; Clyne D H, 1981, Contrib Nephrol, V24, P78; CLYNE DH, 1979, KIDNEY INT, V16, P345, DOI 10.1038/ki.1979.137; COOPER EH, 1984, J CLIN PATHOL, V37, P852, DOI 10.1136/jcp.37.8.852; COWARD RA, 1984, CLIN SCI, V66, P229, DOI 10.1042/cs0660229; FANG LST, 1985, KIDNEY INT, V27, P582, DOI 10.1038/ki.1985.50; GALLO G, 1989, SEMIN HEMATOL, V26, P234; GALLO GR, 1982, PATHOL ANNU, V17, P291; GANEVAL D, 1984, KIDNEY INT, V26, P1, DOI 10.1038/ki.1984.126; GLENNER GG, 1980, NEW ENGL J MED, V302, P1283, DOI 10.1056/NEJM198006053022305; GLENNER GG, 1980, NEW ENGL J MED, V302, P1333, DOI 10.1056/NEJM198006123022403; HILL GS, 1983, AM J KIDNEY DIS, V2, P423, DOI 10.1016/S0272-6386(83)80075-4; HILL GS, 1983, PATHOLOGY KIDNEY, V2, P993; JOHNS EA, 1986, J CLIN PATHOL, V39, P833, DOI 10.1136/jcp.39.8.833; JOHNSON WJ, 1990, ARCH INTERN MED, V150, P863, DOI 10.1001/archinte.150.4.863; KOSS MN, 1976, LAB INVEST, V34, P579; KYLE RA, 1989, ANNU REV MED, V40, P53; MELCION C, 1984, CLIN NEPHROL, V22, P138; NORDEN AGW, 1989, J CLIN PATHOL, V42, P59, DOI 10.1136/jcp.42.1.59; PALANT CE, 1986, AM J MED, V80, P98, DOI 10.1016/0002-9343(86)90055-0; PIRANI CL, 1982, CONTEMP ISS NEPHROL, V10, P287; PREUDHOMME JL, 1980, AM J MED, V69, P703, DOI 10.1016/0002-9343(80)90421-0; RANDALL RE, 1976, AM J MED, V60, P293, DOI 10.1016/0002-9343(76)90440-X; ROTA S, 1987, MEDICINE, V66, P126, DOI 10.1097/00005792-198703000-00004; SANDERS PW, 1987, KIDNEY INT, V32, P851, DOI 10.1038/ki.1987.286; SANDERS PW, 1988, J CLIN INVEST, V82, P2086, DOI 10.1172/JCI113830; SANDERS PW, 1990, J CLIN INVEST, V85, P570, DOI 10.1172/JCI114474; SMOLENS P, 1983, KIDNEY INT, V24, P192, DOI 10.1038/ki.1983.144; SMOLENS P, 1986, KIDNEY INT, V30, P874, DOI 10.1038/ki.1986.267; SOLLING K, 1984, ACTA MED SCAND, V216, P495; SOLOMON A, 1975, J CLIN INVEST, V55, P579, DOI 10.1172/JCI107965; SOLOMON A, 1986, SEMIN ONCOL, V13, P341; SOLOMON A, 1990, AM J PATHOL, V137, P855; SOLOMON A, 1982, J CLIN INVEST, V70, P453, DOI 10.1172/JCI110635; SOLOMON A, 1985, METHOD ENZYMOL, V116, P101; SOLOMON A, 1982, NEW ENGL J MED, V306, P605, DOI 10.1056/NEJM198203113061010; STURGILL BC, 1987, PATHOL ANNU, V22, P133; TUBBS RR, 1981, AM J MED, V71, P263, DOI 10.1016/0002-9343(81)90127-3; WEISS JH, 1981, KIDNEY INT, V20, P198, DOI 10.1038/ki.1981.122; WOCHNER RD, 1967, J EXP MED, V126, P207, DOI 10.1084/jem.126.2.207	42	219	223	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 27	1991	324	26					1845	1851		10.1056/NEJM199106273242603	http://dx.doi.org/10.1056/NEJM199106273242603			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FT580	1904132				2022-12-24	WOS:A1991FT58000003
J	NIGHTINGALE, SL				NIGHTINGALE, SL			SAFETY OF DENTAL AMALGAMS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 12	1991	265	22					2934	2934						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FP635	1903461				2022-12-24	WOS:A1991FP63500006
J	SHUFORD, W; RAFF, HV; FINLEY, JW; ESSELSTYN, J; HARRIS, LJ				SHUFORD, W; RAFF, HV; FINLEY, JW; ESSELSTYN, J; HARRIS, LJ			EFFECT OF LIGHT CHAIN V-REGION DUPLICATION ON IGG OLIGOMERIZATION AND INVIVO EFFICACY	SCIENCE			English	Article							COMPLEMENT; IMMUNOGLOBULIN; ACTIVATION; ANTIBODIES; PROTECTION; PROTEINS	A human immunoglobulin G1 (IgG1) antibody oligomer was isolated from a transfected myeloma cell line that produced a monoclonal antibody to group B streptococci. Compared to the IgG1 monomer, the oligomer was significantly more effective at protecting neonatal rats from infection in vivo. The oligomer was also shown to cross the placenta and to be stable in neonatal rats. Immunochemical analysis and complementary DNA sequencing showed that the transfected cell line produced two distinct kappa light chains: a normal light chain (L(n)) with a molecular mass of 25 kilodaltons and a 37-kilodalton species (L37), the domain composition of which was variable-variable-constant (V-V-C). Cotransfection of vectors encoding the heavy chain and L37 resulted in production of oligomeric IgG.	BRISTOL MYERS,SQUIBB PHARMACEUT RES INST,DEPT MOLEC IMMUNOL,SEATTLE,WA 98121; BRISTOL MYERS,SQUIBB PHARMACEUT RES INST,DEPT IMMUNE SCI,SEATTLE,WA 98121	Bristol-Myers Squibb; Bristol-Myers Squibb								CHIEN NC, 1989, P NATL ACAD SCI USA, V86, P5532, DOI 10.1073/pnas.86.14.5532; DAMERVAL C, 1987, ELECTROPHORESIS, V8, P158, DOI 10.1002/elps.1150080308; DAVIS AC, 1989, IMMUNOL TODAY, V10, P118, DOI 10.1016/0167-5699(89)90244-2; ENGVALL E, 1972, J IMMUNOL, V109, P129; FEINSTEIN A, 1986, IMMUNOL TODAY, V7, P169, DOI 10.1016/0167-5699(86)90168-4; HAMES BD, 1981, GEL ELECTROPHORESIS, P30; HARLOW E, 1988, ANTIBODIES LAB MANUA, P391; JESKE DJ, 1984, FUNDAMENTAL IMMUNOLO, P131; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARTIN TR, 1988, J INFECT DIS, V157, P91, DOI 10.1093/infdis/157.1.91; MORRISON SL, 1989, ADV IMMUNOL, V44, P65; RAFF HV, 1988, J EXP MED, V168, P905, DOI 10.1084/jem.168.3.905; RAFF HV, 1990, J INFECT DIS, V163, P346; ROSNER B, 1982, FUNDAMENTALS BIOSTAT, P308; SCHUMAKER VN, 1987, ANNU REV IMMUNOL, V5, P21, DOI 10.1146/annurev.iy.05.040187.000321; SHARON J, 1990, P NATL ACAD SCI USA, V87, P4814, DOI 10.1073/pnas.87.12.4814; SHIGEOKA AO, 1984, J INFECT DIS, V150, P63, DOI 10.1093/infdis/150.1.63; SHUFORD W, UNPUB; SHUMAKER RC, 1986, DRUG METAB REV, V17, P331, DOI 10.3109/03602538608998295; SMITH VH, UNPUB; TAN LK, 1990, P NATL ACAD SCI USA, V87, P162, DOI 10.1073/pnas.87.1.162	21	16	23	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 3	1991	252	5006					724	727		10.1126/science.1902593	http://dx.doi.org/10.1126/science.1902593			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FK185	1902593				2022-12-24	WOS:A1991FK18500055
J	NAKABEPPU, Y; NATHANS, D				NAKABEPPU, Y; NATHANS, D			A NATURALLY-OCCURRING TRUNCATED FORM OF FOSB THAT INHIBITS FOS JUN TRANSCRIPTIONAL ACTIVITY	CELL			English	Article							SERUM GROWTH-FACTORS; C-FOS; PROTO-ONCOGENE; MESSENGER-RNAS; FACTOR AP-1; AUTO-REGULATION; LEUCINE ZIPPER; 3T3 CELLS; GENE; EXPRESSION	Fos and Jun transcription factors are induced by a variety of extracellular signaling agents. We describe here an unusual member of the Fos family that is also induced, namely, a truncated form of FosB (DELTA-FosB) missing the C-terminal 101 amino acids of FosB. DELTA-FosB retains the dimerization and DNA-binding activities of FosB but has lost the ability in transfection assays to activate a promoter with an AP-1 site and to repress the c-fos promoter. Rather, DELTA-FosB inhibits gene activation by Jun or Jun + Fos and inhibits repression of the c-fos promoter by FosB or c-Fos, presumably by competing with full-length Fos proteins at the steps of dimerization with Jun and binding to DNA. In stimulated cells DELTA-FosB may act to limit the transcriptional effects of Fos and Jun proteins.	JOHNS HOPKINS UNIV,SCH MED,DEPT MOLEC BIOL & GENET,BALTIMORE,MD 21205	Johns Hopkins University	NAKABEPPU, Y (corresponding author), JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,BALTIMORE,MD 21205, USA.		Nakabeppu, Yusaku/A-8902-2011	Nakabeppu, Yusaku/0000-0002-6739-242X	NATIONAL CANCER INSTITUTE [P01CA016519] Funding Source: NIH RePORTER; NCI NIH HHS [5 PO1 CA16519] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BRAVO R, 1989, GROWTH FACTORS DIFFE; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; COLE AJ, 1990, IN PRESS J NEUROCHEM; DIECKMANN CL, 1985, J BIOL CHEM, V260, P1513; FROST E, 1978, VIROLOGY, V91, P39, DOI 10.1016/0042-6822(78)90353-7; GANTZ R, 1989, SCIENCE, V243, P1695; GIUS D, 1990, MOL CELL BIOL, V10, P4243, DOI 10.1128/MCB.10.8.4243; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HALL C V, 1983, Journal of Molecular and Applied Genetics, V2, P101; HARLOW E, 1988, ANTIBODIES LABORATOR; Higgins GM, 1931, ARCH PATHOL, V12, P186; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KONIG H, 1989, EMBO J, V8, P2559, DOI 10.1002/j.1460-2075.1989.tb08394.x; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; KRUIJER W, 1986, J BIOL CHEM, V261, P7929; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LAU LF, 1991, MOL ASPECTS CELLULAR, V6; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LINZER DIH, 1983, P NATL ACAD SCI-BIOL, V80, P4271, DOI 10.1073/pnas.80.14.4271; LUCIBELLO FC, 1989, CELL, V59, P999, DOI 10.1016/0092-8674(89)90756-3; MACGREGOR PF, 1990, ONCOGENE, V5, P451; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; Miller J.H., 1972, EXPT MOL GENETICS; MILLER R, 1984, NATURE, V312, P716; MORGAN JI, 1987, SCIENCE, V237, P192, DOI 10.1126/science.3037702; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NATHANS D, 1988, COLD SPRING HARB SYM, V53, P893, DOI 10.1101/SQB.1988.053.01.102; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RAUSCHER FJ, 1988, CELL, V52, P471, DOI 10.1016/S0092-8674(88)80039-4; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; SAFFEN DW, 1988, P NATL ACAD SCI USA, V85, P7795, DOI 10.1073/pnas.85.20.7795; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SHAW PE, 1989, EMBO J, V8, P2567, DOI 10.1002/j.1460-2075.1989.tb08395.x; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Swinyard E. A., 1972, EXPT MODELS EPILEPSY, P433; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; van der Eb A J, 1980, Methods Enzymol, V65, P826; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; WILSON T, 1988, EMBO J, V7, P4193, DOI 10.1002/j.1460-2075.1988.tb03316.x; YANOFSKY C, 1981, NUCLEIC ACIDS RES, V9, P6647, DOI 10.1093/nar/9.24.6647; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x; ZINN K, 1983, CELL, V34, P865, DOI 10.1016/0092-8674(83)90544-5	68	419	427	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 22	1991	64	4					751	759		10.1016/0092-8674(91)90504-R	http://dx.doi.org/10.1016/0092-8674(91)90504-R			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EZ478	1900040				2022-12-24	WOS:A1991EZ47800010
J	LEE, VMY; BALIN, BJ; OTVOS, L; TROJANOWSKI, JQ				LEE, VMY; BALIN, BJ; OTVOS, L; TROJANOWSKI, JQ			A68 - A MAJOR SUBUNIT OF PAIRED HELICAL FILAMENTS AND DERIVATIZED FORMS OF NORMAL-TAU	SCIENCE			English	Article							ALZHEIMERS-DISEASE; PROTEIN-TAU; NEUROFIBRILLARY TANGLES; MONOCLONAL-ANTIBODY; NERVOUS-SYSTEM; HUMAN-BRAIN; IDENTIFICATION; LOCALIZATION; ANTIGEN; MICROTUBULES	Putative Alzheimer disease (AD)-specific proteins (A68) were purified to homogeneity and shown to be major subunits of one form of paired helical filaments (PHFs). The amino acid sequence and immunological data indicate that the backbone of A68 is indistinguishable from that of the protein-tau (tau), but A68 could be distinguished from normal human-tau by the degree to which A68 was phosphorylated and by the specific residues in A 68 that served as phosphate acceptors. The larger apparent relative molecular mass (M(r)) of A68, compared to normal human-tau, was attributed to abnormal phosphorylation of A68 because enzymatic dephosphorylation of A68 reduced its M(r) to close to that of normal-tau. Moreover, the LysSerProVal motif in normal human-tau appeared to be an abnormal phosphorylation site in A68 because the Ser in this motif was a phosphate acceptor site in A68, but not in normal human-tau. Thus, the major subunits of a class of PHFs are A68 proteins and the excessive or inappropriate phosphorylation of normal-tau may change its apparent M(r), thus transforming-tau into A68.	WISTAR INST,PHILADELPHIA,PA 19104	The Wistar Institute	LEE, VMY (corresponding author), UNIV PENN,SCH MED,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19104, USA.							ARAI H, 1990, P NATL ACAD SCI USA, V87, P2249, DOI 10.1073/pnas.87.6.2249; CHUI HC, 1989, ARCH NEUROL-CHICAGO, V46, P806, DOI 10.1001/archneur.1989.00520430102025; CLEVELAND DW, 1990, CELL, V60, P701, DOI 10.1016/0092-8674(90)90083-Q; GOEDERT M, 1989, EMBO J, V8, P393, DOI 10.1002/j.1460-2075.1989.tb03390.x; GOEDERT M, 1988, P NATL ACAD SCI USA, V85, P4051, DOI 10.1073/pnas.85.11.4051; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; GREENBERG SG, 1990, P NATL ACAD SCI USA, V87, P5827, DOI 10.1073/pnas.87.15.5827; GRUNDKEIQBAL I, 1986, P NATL ACAD SCI USA, V83, P4913, DOI 10.1073/pnas.83.13.4913; IHARA Y, 1988, BRAIN RES, V459, P138, DOI 10.1016/0006-8993(88)90293-4; IQBAL K, 1989, P NATL ACAD SCI USA, V86, P5646, DOI 10.1073/pnas.86.14.5646; KONDO J, 1988, NEURON, V1, P827, DOI 10.1016/0896-6273(88)90130-4; KOSIK KS, 1988, NEURON, V1, P816; KOWALL NW, 1987, ANN NEUROL, V22, P639, DOI 10.1002/ana.410220514; KSIEZAKREDING H, 1990, J NEUROSCI RES, V25, P420, DOI 10.1002/jnr.490250320; KSIEZAKREDING H, 1988, J BIOL CHEM, V263, P7943; LEE G, 1989, NEURON, V2, P1615, DOI 10.1016/0896-6273(89)90050-0; LEE VMY, 1988, P NATL ACAD SCI USA, V85, P7384, DOI 10.1073/pnas.85.19.7384; LEE VMY, 1988, P NATL ACAD SCI USA, V85, P1998, DOI 10.1073/pnas.85.6.1998; LEE VY, UNPUB; LEWIS SA, 1989, NATURE, V342, P498, DOI 10.1038/342498a0; MCKEE AC, 1989, ANN NEUROL, V26, P652, DOI 10.1002/ana.410260511; MIYAKAWA T, 1989, VIRCHOWS ARCH B, V57, P267, DOI 10.1007/BF02899091; NUKINA N, 1988, NEUROSCI LETT, V87, P240, DOI 10.1016/0304-3940(88)90455-7; OTVOS L, 1989, INT J PEPT PROT RES, V34, P129; PRICE DL, 1989, BIOESSAYS, V10, P69, DOI 10.1002/bies.950100208; SCHMIDT ML, 1990, AM J PATHOL, V136, P1069; SELKOE DJ, 1989, ANNU REV NEUROSCI, V12, P463, DOI 10.1146/annurev.ne.12.030189.002335; STERN RA, 1989, AM J PATHOL, V134, P973; Trojanowski J Q, 1990, Annu Rev Gerontol Geriatr, V10, P167; TROJANOWSKI JQ, 1989, J HISTOCHEM CYTOCHEM, V37, P209, DOI 10.1177/37.2.2492045; VALLEE RB, 1982, J CELL BIOL, V92, P435, DOI 10.1083/jcb.92.2.435; Wischik CM, 1989, CURR OPIN CELL BIOL, V1, P115, DOI 10.1016/S0955-0674(89)80047-X; WISCHIK CM, 1988, P NATL ACAD SCI USA, V85, P4506, DOI 10.1073/pnas.85.12.4506; WOLOZIN B, 1988, P NATL ACAD SCI USA, V85, P6202, DOI 10.1073/pnas.85.16.6202; WOLOZIN BL, 1986, SCIENCE, V232, P648, DOI 10.1126/science.3083509	35	1333	1399	1	48	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 8	1991	251	4994					675	678		10.1126/science.1899488	http://dx.doi.org/10.1126/science.1899488			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EW399	1899488				2022-12-24	WOS:A1991EW39900046
J	CHOI, HK; TONG, L; MINOR, W; DUMAS, P; BOEGE, U; ROSSMANN, MG; WENGLER, G				CHOI, HK; TONG, L; MINOR, W; DUMAS, P; BOEGE, U; ROSSMANN, MG; WENGLER, G			STRUCTURE OF SINDBIS VIRUS CORE PROTEIN REVEALS A CHYMOTRYPSIN-LIKE SERINE PROTEINASE AND THE ORGANIZATION OF THE VIRION	NATURE			English	Article							SEMLIKI FOREST VIRUS; ALPHA-LYTIC PROTEASE; AMINO-ACID-SEQUENCE; CAPSID PROTEIN; RNA VIRUSES; NONSTRUCTURAL PROTEINS; CYSTEINE PROTEASES; MOSAIC-VIRUS; RESOLUTION; ALPHAVIRUSES	Sindbis virus consists of a nucleocapsid core surrounded by a lipid membrane through which penetrate 80 glycoprotein trimers. The structure of the core protein comprising the coat surrounding the genomic RNA has been determined. The polypeptide fold from residue 114 to residue 264 is homologous to that of chymotrypsin-like serine proteinases with catalytic residues His 141, Asp 163 and Ser 215 of the core protein positioned as in other serine proteinases. The C-terminal tryptophan remains in the P1 substrate site subsequent to the autocatalytic cis cleavage of the capsid protein, thus rendering the proteinase inactive. Model building of the Sindbis core protein dimer shows that the nucleocapsid is likely to have T = 4 quasisymmetry.	PURDUE UNIV, DEPT BIOL SCI, W LAFAYETTE, IN 47907 USA; UNIV ALBERTA, DEPT BIOCHEM, EDMONTON T6G 2H7, ALBERTA, CANADA; UNIV GIESSEN, INST VIROL, W-6300 GIESSEN, GERMANY	Purdue University System; Purdue University; Purdue University West Lafayette Campus; University of Alberta; Justus Liebig University Giessen			Minor, Wladek/F-3096-2014	Minor, Wladek/0000-0001-7075-7090; Tong, Liang/0000-0002-0563-6468				ABADZAPATERO C, 1980, NATURE, V286, P33, DOI 10.1038/286033a0; AHLQUIST P, 1985, J VIROL, V53, P536, DOI 10.1128/JVI.53.2.536-542.1985; ALIPERTI G, 1978, VIROLOGY, V90, P366, DOI 10.1016/0042-6822(78)90321-5; ANDINO R, 1990, CELL, V63, P369, DOI 10.1016/0092-8674(90)90170-J; ANTHONY RP, 1991, J VIROL, V65, P1187, DOI 10.1128/JVI.65.3.1187-1194.1991; BAZAN JF, 1988, P NATL ACAD SCI USA, V85, P7872, DOI 10.1073/pnas.85.21.7872; BIRKTOFT JJ, 1972, J MOL BIOL, V68, P187, DOI 10.1016/0022-2836(72)90210-0; BODE W, 1978, J MOL BIOL, V118, P99, DOI 10.1016/0022-2836(78)90246-2; BOEGE U, 1989, J MOL BIOL, V208, P79, DOI 10.1016/0022-2836(89)90089-2; BOEGE U, 1983, EUR J BIOCHEM, V133, P415, DOI 10.1111/j.1432-1033.1983.tb07479.x; BOEGE U, 1981, VIROLOGY, V113, P293, DOI 10.1016/0042-6822(81)90156-2; BONE R, 1987, BIOCHEMISTRY-US, V26, P7609, DOI 10.1021/bi00398a012; CASPAR DLD, 1962, COLD SPRING HARB SYM, V27, P1, DOI 10.1101/sqb.1962.027.001.005; CONNOLLY ML, 1985, J MOL GRAPHICS, V3, P19, DOI 10.1016/0263-7855(85)80009-6; COOMBS K, 1987, J MOL BIOL, V195, P359, DOI 10.1016/0022-2836(87)90657-7; COOMBS K, 1987, VIRUS RES, V7, P131, DOI 10.1016/0168-1702(87)90075-X; COOMBS K, 1984, VIRUS RES, V1, P297, DOI 10.1016/0168-1702(84)90018-2; COOMBS KM, 1989, J VIROL, V63, P883, DOI 10.1128/JVI.63.2.883-891.1989; DESSENS JT, 1991, VIROLOGY, V184, P738, DOI 10.1016/0042-6822(91)90444-G; ENZMANN PJ, 1979, VIROLOGY, V95, P501, DOI 10.1016/0042-6822(79)90504-X; FREEMAN R, 1981, J MICROSC-OXFORD, V122, P275, DOI 10.1111/j.1365-2818.1981.tb01267.x; FUJINAGA M, 1985, J MOL BIOL, V184, P479, DOI 10.1016/0022-2836(85)90296-7; FULLER SD, 1987, EMBO J, V6, P1099, DOI 10.1002/j.1460-2075.1987.tb04864.x; FULLER SD, 1987, CELL, V48, P923, DOI 10.1016/0092-8674(87)90701-X; GORBALENYA AE, 1989, FEBS LETT, V243, P103, DOI 10.1016/0014-5793(89)80109-7; HAHN CS, 1990, J VIROL, V64, P3069, DOI 10.1128/JVI.64.6.3069-3073.1990; HAHN CS, 1988, P NATL ACAD SCI USA, V85, P5997, DOI 10.1073/pnas.85.16.5997; HAHN CS, 1985, P NATL ACAD SCI USA, V82, P4648, DOI 10.1073/pnas.82.14.4648; HAMMERLE T, 1991, J BIOL CHEM, V266, P5412; Harrison S. C., 1986, TOGAVIRIDAE FLAVIVIR, P21; HARRISON SC, 1978, NATURE, V276, P368, DOI 10.1038/276368a0; HASELOFF J, 1984, P NATL ACAD SCI-BIOL, V81, P4358, DOI 10.1073/pnas.81.14.4358; HORZINEK M, 1969, J VIROL, V4, P514, DOI 10.1128/JVI.4.4.514-520.1969; Kaariainen L, 1978, Curr Top Microbiol Immunol, V82, P15; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KEAN KM, 1991, VIROLOGY, V181, P609, DOI 10.1016/0042-6822(91)90894-H; KRAULIS P, IN PRESS J APPL CRYS; KRAUSSLICH HG, 1988, ANNU REV BIOCHEM, V57, P701, DOI 10.1146/annurev.bi.57.070188.003413; Liljas A., 1974, ANNU REV BIOCHEM, V43, P475; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MCKENNA R, UNPUB NATURE; MELANCON P, 1987, J VIROL, V61, P1301, DOI 10.1128/JVI.61.5.1301-1309.1987; METSIKKO K, 1990, J VIROL, V64, P4678; NAMBA K, 1986, SCIENCE, V231, P1401, DOI 10.1126/science.3952490; ROSSMANN MG, 1989, ANNU REV BIOCHEM, V58, P533, DOI 10.1146/annurev.bi.58.070189.002533; ROSSMANN MG, 1962, ACTA CRYSTALLOGR, V15, P24, DOI 10.1107/S0365110X62000067; ROSSMANN MG, 1975, J BIOL CHEM, V250, P7525; ROSSMANN MG, IN PRESS J APPL CRYS; SCHEEFERS H, 1980, P NATL ACAD SCI-BIOL, V77, P7277, DOI 10.1073/pnas.77.12.7277; Schlesinger, 1986, TOGAVIRIDAE FLAVIVIR, P35, DOI 10.1007/978-1-4757-0785-4_3; Schlesinger S., 1986, TOGAVIRIDAE FLAVIVIR, P121, DOI [10.1007/978-1-4757-0785-4_5, DOI 10.1007/978-1-4757-0785-4_5]; SCUPHAM RK, 1977, J VIROL, V22, P568; SHOPE RE, 1980, TOGAVIRUSES BIOL STR, P47; SIMMONS DT, 1974, J MOL BIOL, V86, P397, DOI 10.1016/0022-2836(74)90027-8; SIMONS K, 1984, ADV PROTEIN CHEM, V36, P79, DOI 10.1016/S0065-3233(08)60296-X; STRAUSS EG, 1984, VIROLOGY, V133, P92, DOI 10.1016/0042-6822(84)90428-8; STRAUSS JH, 1988, ANNU REV MICROBIOL, V42, P657, DOI 10.1146/annurev.mi.42.100188.003301; Strauss JH, 1990, SEMIN VIROL, V1, P347; TSAO J, 1991, SCIENCE, V251, P1456, DOI 10.1126/science.2006420; ULMANEN I, 1979, VIROLOGY, V99, P265, DOI 10.1016/0042-6822(79)90006-0; VALEGARD K, 1990, NATURE, V345, P36, DOI 10.1038/345036a0; VANSTEEG H, 1984, EUR J BIOCHEM, V138, P473; VAUX DJT, 1988, NATURE, V336, P36, DOI 10.1038/336036a0; VOGEL RH, 1986, NATURE, V320, P533, DOI 10.1038/320533a0; VONBONSDORFF CH, 1975, J VIROL, V16, P141, DOI 10.1128/JVI.16.1.141-145.1975; WEISS B, 1989, J VIROL, V63, P5310, DOI 10.1128/JVI.63.12.5310-5318.1989; WENGLER G, 1984, VIROLOGY, V132, P401, DOI 10.1016/0042-6822(84)90045-X; WENGLER G, 1982, VIROLOGY, V118, P401, DOI 10.1016/0042-6822(82)90359-2	68	261	267	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 7	1991	354	6348					37	43		10.1038/354037a0	http://dx.doi.org/10.1038/354037a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GN829	1944569				2022-12-24	WOS:A1991GN82900049
J	GOLUMBEK, PT; LAZENBY, AJ; LEVITSKY, HI; JAFFEE, LM; KARASUYAMA, H; BAKER, M; PARDOLL, DM				GOLUMBEK, PT; LAZENBY, AJ; LEVITSKY, HI; JAFFEE, LM; KARASUYAMA, H; BAKER, M; PARDOLL, DM			TREATMENT OF ESTABLISHED RENAL-CANCER BY TUMOR-CELLS ENGINEERED TO SECRETE INTERLEUKIN-4	SCIENCE			English	Article							STIMULATORY FACTOR-I; CYTOLYTIC T-CELLS; LYMPHOCYTES-T; MONOCLONAL-ANTIBODY; GENERATION; EXPRESSION; PEPTIDE; GENE; DNA	The generation of antigen-specific antitumor immunity is the ultimate goal in cancer immunotherapy. When cells from a spontaneously arising murine renal cell tumor were engineered to secrete large doses of interleukin-4 (IL-4) locally, they were rejected in a predominantly T cell-independent manner. However, animals that rejected the IL-4-transfected tumors developed T cell-dependent systemic immunity to the parental tumor. This systemic immunity was tumor-specific and primarily mediated by CD8+ T cells. Established parental tumors could be cured by the systemic immune response generated by injection of the genetically engineered tumors. These results provide a rationale for the use of lymphokine gene-transfected tumor cells as a modality for cancer therapy.	JOHNS HOPKINS UNIV, DEPT MED, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, DEPT PATHOL, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, DEPT IMMUNOL, BALTIMORE, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University			Karasuyama, Hajime/A-7966-2011	Karasuyama, Hajime/0000-0003-0689-0836				DIALYNAS DP, 1983, J IMMUNOL, V131, P2445; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FEARON ER, 1990, CELL, V60, P397, DOI 10.1016/0092-8674(90)90591-2; FERNANDEZBOTRAN R, 1986, P NATL ACAD SCI USA, V83, P9689, DOI 10.1073/pnas.83.24.9689; GOLUMBEK P, UNPUB; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRUSBY MJ, 1990, CELL, V60, P451, DOI 10.1016/0092-8674(90)90596-7; HAVRAN WL, 1987, NATURE, V330, P170, DOI 10.1038/330170a0; HEWITT HB, 1976, BRIT J CANCER, V33, P241, DOI 10.1038/bjc.1976.37; HULI J, 1987, J EXP MED, V165, P157, DOI 10.1084/jem.165.1.157; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; LURQUIN C, 1989, CELL, V58, P293, DOI 10.1016/0092-8674(89)90844-1; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MARX JL, 1989, SCIENCE, V245, P813, DOI 10.1126/science.2672332; MARYANSKI JL, 1986, NATURE, V324, P578, DOI 10.1038/324578a0; Mathe G, 1971, Adv Cancer Res, V14, P1, DOI 10.1016/S0065-230X(08)60517-5; MOORE MW, 1988, CELL, V54, P777, DOI 10.1016/S0092-8674(88)91043-4; MULLIGAN RC, 1991, NOBEL SYMP, V80, P143; MURPHY GP, 1973, JNCI-J NATL CANCER I, V50, P1013, DOI 10.1093/jnci/50.4.1013; OHARA J, 1985, NATURE, V315, P333, DOI 10.1038/315333a0; PAUL WE, 1987, ANNU REV IMMUNOL, V5, P429, DOI 10.1146/annurev.iy.05.040187.002241; SALUP RR, 1985, J UROLOGY, V134, P1236, DOI 10.1016/S0022-5347(17)47702-0; SARMIENTO M, 1980, J IMMUNOL, V125, P2665; SPRINGER T, 1979, EUR J IMMUNOL, V9, P301, DOI 10.1002/eji.1830090410; TEPPER RI, 1989, CELL, V57, P503, DOI 10.1016/0092-8674(89)90925-2; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X; TRENN G, 1988, J IMMUNOL, V140, P1101; WIDMER MB, 1987, NATURE, V326, P795, DOI 10.1038/326795a0; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373	29	776	836	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 1	1991	254	5032					713	716		10.1126/science.1948050	http://dx.doi.org/10.1126/science.1948050			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GN474	1948050				2022-12-24	WOS:A1991GN47400042
J	POWARS, DR; ELLIOTTMILLS, DD; CHAN, L; NILAND, J; HITI, AL; OPAS, LM; JOHNSON, C				POWARS, DR; ELLIOTTMILLS, DD; CHAN, L; NILAND, J; HITI, AL; OPAS, LM; JOHNSON, C			CHRONIC-RENAL-FAILURE IN SICKLE-CELL DISEASE - RISK-FACTORS, CLINICAL COURSE, AND MORTALITY	ANNALS OF INTERNAL MEDICINE			English	Article						KIDNEY FAILURE, CHRONIC; ANEMIA, SICKLE CELL; HEMOGLOBIN-SC DISEASE; HYPERTENSION; NEPHROTIC SYNDROME	NATURAL-HISTORY; CONFIDENCE-INTERVAL; ENDOTHELIAL-CELLS; FETAL HEMOGLOBIN; BLOOD-PRESSURE; GLOBIN GENE; ANEMIA; NEPHROPATHY; TRANSPLANTATION; ERYTHROCYTES	Objective: To determine the incidence, clinical course, and risk factors associated with the onset of chronic renal failure in sickle cell anemia and sickle C disease. Design: A prospective, 25-year longitudinal demographic and clinical cohort study. A matched case-control study was conducted to determine risk factors. Patients: A total of 725 patients with sickle cell anemia and 209 patients with sickle C disease who received medical care from the hematology service in a large municipal hospital. Most were observed from birth or early childhood. Measurements: Thirty-six patients developed sickle renal failure: 4.2% of patients with sickle cell anemia and 2.4% of patients with sickle C disease. The median age of disease onset for these patients was 23.1 and 49.9 years, respectively. Survival time for patients with sickle cell anemia after the diagnosis of sickle renal failure, despite dialysis, was 4 years, and the median age at the time of death was 27 years. Relative risk for mortality was 1.42 (95% CI, 1.12 to 1.81; P = 0.02) compared with patients who did not develop renal insufficiency. Main Results: Histopathologic studies showed characteristic lesions of glomerular "drop out" and glomerulosclerosis. Case-control analysis showed that ineffective erythropoiesis with increasingly severe anemia, hypertension, proteinuria, the nephrotic syndrome, and microscopic hematuria were significant pre-azotemic predictors of chronic renal failure. The risk for sickle renal failure was increased in patients who had inherited the Central African Republic beta-S-gene cluster haplotype. Conclusions: The pre-azotemic manifestations of hypertension, proteinuria, and increasingly severe anemia predict end-stage renal failure in patients with sickle cell disease. The rate of progression of renal insufficiency is genetically determined. Treatment of the uremic phase has been dismal, underscoring the need for the development of useful pre-azotemic therapeutic modalities.			POWARS, DR (corresponding author), UNIV SO CALIF, SCH MED, PEDIAT PAVILION, 1129 N STATE ST, ROOM 2E19, LOS ANGELES, CA 90033 USA.				NHLBI NIH HHS [HL 15162] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P60HL015162] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1987, PEDIATRICS, V79, P1; ANTONARAKIS SE, 1984, P NATL ACAD SCI-BIOL, V81, P853, DOI 10.1073/pnas.81.3.853; BARANOWSKI T, 1988, PEDIATR RES, V23, P270, DOI 10.1203/00006450-198803000-00008; BRENNER BM, 1982, NEW ENGL J MED, V307, P652, DOI 10.1056/NEJM198209093071104; BRESLOW NE, 1984, INT J EPIDEMIOL, V13, P112, DOI 10.1093/ije/13.1.112; BUCKALEW VM, 1974, ARCH INTERN MED, V133, P660, DOI 10.1001/archinte.133.4.660; CHAN LS, 1982, J CHRON DIS, V35, P401, DOI 10.1016/0021-9681(82)90010-8; CHATTERJEE SN, 1987, TRANSPLANT P, V19, P33; COE FL, 1976, KIDNEY, V2, P767; CRUZ IA, 1982, J NATL MED ASSOC, V74, P1103; Dean A. G., 1990, EPI INFO VERSION 5 W; DEJONG PE, 1985, KIDNEY INT, V27, P711, DOI 10.1038/ki.1985.70; Diggs LW, 1934, SOUTH MED J, V27, P839; EATON WA, 1987, BLOOD, V70, P1245; ESCHBACH JW, 1987, NEW ENGL J MED, V316, P73, DOI 10.1056/NEJM198701083160203; FLEISS JL, 1973, STATISTICAL METHODS; FREEDMAN BI, 1990, AM J KIDNEY DIS, V15, P361, DOI 10.1016/S0272-6386(12)80082-5; FRIEDMAN EA, 1974, NEW ENGL J MED, V291, P431, DOI 10.1056/NEJM197408292910902; GONZALEZCARRILLO M, 1982, CLIN NEPHROL, V18, P209; GREEN MA, 1988, J CLIN INVEST, V81, P1669, DOI 10.1172/JCI113504; HADDY TB, 1982, AM J PEDIAT HEMATOL, V4, P191; HENDERSON AB, 1950, AM J MED, V9, P757, DOI 10.1016/0002-9343(50)90291-9; HOWE GR, 1983, BIOMETRICS, V39, P325, DOI 10.2307/2531005; HOWE GR, 1986, INT J EPIDEMIOL, V15, P257, DOI 10.1093/ije/15.2.257; JOHNSON CS, 1981, ARCH INTERN MED, V141, P891, DOI 10.1001/archinte.141.7.891; KAPLOW LS, 1968, J AMER MED ASSOC, V203, P1135; KAUL DK, 1989, P NATL ACAD SCI USA, V86, P3356, DOI 10.1073/pnas.86.9.3356; KEIDAN AJ, 1989, BRIT J HAEMATOL, V71, P551, DOI 10.1111/j.1365-2141.1989.tb06316.x; KLAHR S, 1988, NEW ENGL J MED, V318, P1657; KOSHY M, 1989, BLOOD, V74, P1403; LINDEMAN RD, 1990, AM J KIDNEY DIS, V16, P275, DOI 10.1016/S0272-6386(12)80002-3; MANTEL N, 1959, J NATL CANCER I, V22, P719; MCCOY RC, 1969, LAB INVEST, V21, P85; MEHTA CR, 1985, J AM STAT ASSOC, V80, P969, DOI 10.2307/2288562; MINER DJ, 1987, AM J KIDNEY DIS, V10, P306, DOI 10.1016/S0272-6386(87)80027-6; MOHANDAS N, 1984, BLOOD, V64, P282; MORGAN AG, 1981, BMJ-BRIT MED J, V282, P1181, DOI 10.1136/bmj.282.6271.1181; NAGEL RL, 1990, SEMIN HEMATOL, V27, P342; NAGPAL KC, 1977, SURV OPHTHALMOL, V21, P391, DOI 10.1016/0039-6257(77)90042-X; Nduke N, 1987, Folia Haematol Int Mag Klin Morphol Blutforsch, V114, P508; NISSENSON AR, 1989, Q J MED, V73, P1055; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; POWARS D, 1978, AM J MED, V65, P461, DOI 10.1016/0002-9343(78)90772-6; POWARS D, 1990, SEMIN HEMATOL, V27, P360; POWARS D, 1988, MEDICINE, V67, P66, DOI 10.1097/00005792-198801000-00005; POWARS DR, 1989, ANN NY ACAD SCI, V565, P262, DOI 10.1111/j.1749-6632.1989.tb24174.x; POWARS DR, 1975, SEMIN HEMATOL, V12, P267; POWARS DR, 1984, BLOOD, V63, P921, DOI 10.1182/blood.V63.4.921.921; QUADRACCI LJ, 1976, KIDNEY INT, V10, P179, DOI 10.1038/ki.1976.93; REID CDL, 1988, BRIT J HAEMATOL, V70, P375, DOI 10.1111/j.1365-2141.1988.tb02497.x; SANDLER DP, 1989, NEW ENGL J MED, V320, P1238, DOI 10.1056/NEJM198905113201903; SCHROEDER WA, 1989, HEMOGLOBIN, V13, P325, DOI 10.3109/03630268909003397; SCHROEDER WA, 1980, CHROMATOGRAPHY HEMOG; SHERWOOD JB, 1986, BLOOD, V67, P46; SPECTOR D, 1978, AM J MED, V64, P835, DOI 10.1016/0002-9343(78)90524-7; Statius van Eps LW, 1970, LANCET, V1, P450; STRAUSS J, 1986, NEPHRON, V43, P241, DOI 10.1159/000183848; STRAUSS J, 1975, AM J MED, V58, P382, DOI 10.1016/0002-9343(75)90604-X; SZWED JJ, 1980, AM J MED SCI, V279, P169, DOI 10.1097/00000441-198005000-00006; TEJANI A, 1985, NEPHRON, V39, P352, DOI 10.1159/000183404; WALKER BR, 1971, J AMER MED ASSOC, V215, P437, DOI 10.1001/jama.215.3.437; WEINSTEIN R, 1990, BLOOD, V76, P2146; WESTNEY LS, 1984, OBSTET GYNECOL, V63, P752; WICK TM, 1987, J CLIN INVEST, V80, P905, DOI 10.1172/JCI113151	64	242	249	1	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1991	115	8					614	620		10.7326/0003-4819-115-8-614	http://dx.doi.org/10.7326/0003-4819-115-8-614			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GJ902	1892333				2022-12-24	WOS:A1991GJ90200006
J	SAUER, F; JACKLE, H				SAUER, F; JACKLE, H			CONCENTRATION-DEPENDENT TRANSCRIPTIONAL ACTIVATION OR REPRESSION BY KRUPPEL FROM A SINGLE BINDING-SITE	NATURE			English	Article							ALCOHOL-DEHYDROGENASE GENE; EARLY DROSOPHILA EMBRYO; ARAC PROTEIN; HUNCHBACK; PRODUCTS; KNIRPS; EXPRESSION; PROMOTERS; PATTERN; REGION	ONE of the gap class of segmentation genes 1, Kruppel (Kr), is required for normal thorax and abdominal development of the Drosophila embryo. Its gene product, a zinc-finger type protein 2, forms a bell-shape concentration gradient in a central position of the blastoderm 3-6. Genetic and molecular studies suggested that the Kr protein (KR) may act both as a positive and as a negative regulator of transcription on several other genes 3-9 of the zygotic segmentation hierarchy 1. We have examined the regulatory potential of Kr by a series of cotransfection experiments in the Drosophila Schneider cell line system. Different doses of Kr expression plasmid were tested for their ability to drive reporter gene expression mediated by a single 11-base pair KR in vitro binding site common to several putative Kr target genes 4-6,8-10. Our results show that low amounts of Kr expression plasmid lead to transcriptional activation, whereas high amounts result in repression. Distinct portions of KR other than the DNA-binding domain are required for gene activation and repression, suggesting that KR itself can act as a concentration-dependent positive and negative regulator of transcription.			SAUER, F (corresponding author), MAX PLANCK INST BIOPHYS CHEM,MOLEK ENTWICKLUNGSBIOL ABT,FASSBERG,W-3400 GOTTINGEN,GERMANY.							BIGGIN MD, 1989, CELL, V58, P433, DOI 10.1016/0092-8674(89)90424-8; DRIEVER W, 1989, NATURE, V337, P138, DOI 10.1038/337138a0; GAUL U, 1987, CELL, V51, P549, DOI 10.1016/0092-8674(87)90124-3; GAUL U, 1989, DEVELOPMENT, V107, P651; GAUL U, 1988, THESUS U TUBINGEN; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOVIND S, 1991, TRENDS GENET, V7, P119, DOI 10.1016/0168-9525(91)90456-Z; HAN KH, 1989, CELL, V56, P573, DOI 10.1016/0092-8674(89)90580-1; HEBERLEIN U, 1985, CELL, V41, P965, DOI 10.1016/S0092-8674(85)80077-5; HEBERLEIN U, 1988, NATURE, V331, P410, DOI 10.1038/331410a0; HOCH MM, IN PRESS EMBO J; HULSKAMP M, 1990, NATURE, V346, P577, DOI 10.1038/346577a0; INGHAM PW, 1988, NATURE, V335, P25, DOI 10.1038/335025a0; KELEHER CA, 1988, CELL, V53, P927, DOI 10.1016/S0092-8674(88)90449-7; KRASNOW MA, 1989, CELL, V57, P1031, DOI 10.1016/0092-8674(89)90341-3; LEE N, 1987, P NATL ACAD SCI USA, V84, P8814, DOI 10.1073/pnas.84.24.8814; LICHT JD, 1990, NATURE, V346, P76, DOI 10.1038/346076a0; MANIATIS T, 1990, MOL CLONING; MARTIN K, 1986, P NATL ACAD SCI USA, V83, P3654, DOI 10.1073/pnas.83.11.3654; MEYER BJ, 1980, J MOL BIOL, V139, P163, DOI 10.1016/0022-2836(80)90303-4; PANKRATZ MJ, 1989, NATURE, V341, P337, DOI 10.1038/341337a0; PANKRATZ MJ, 1990, CELL, V61, P309, DOI 10.1016/0092-8674(90)90811-R; PING Z, 1991, GENE DEV, V5, P254; ROSENBERG UB, 1986, NATURE, V319, P336, DOI 10.1038/319336a0; ROTHE M, 1989, EMBO J, V8, P3087, DOI 10.1002/j.1460-2075.1989.tb08460.x; SAKAI DD, 1988, GENE DEV, V2, P1144, DOI 10.1101/gad.2.9.1144; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; SHORE D, 1987, CELL, V51, P721, DOI 10.1016/0092-8674(87)90095-X; STANOJEVIC D, 1989, NATURE, V341, P331, DOI 10.1038/341331a0; TAUTZ D, 1987, NATURE, V327, P383, DOI 10.1038/327383a0; THUMMEL CS, 1988, GENE, V74, P445, DOI 10.1016/0378-1119(88)90177-1; TREISMAN J, 1989, NATURE, V341, P335, DOI 10.1038/341335a0	32	142	145	1	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 10	1991	353	6344					563	566		10.1038/353563a0	http://dx.doi.org/10.1038/353563a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GJ643	1922363				2022-12-24	WOS:A1991GJ64300069
J	SMALL, PM; SCHECTER, GF; GOODMAN, PC; SANDE, MA; CHAISSON, RE; HOPEWELL, PC				SMALL, PM; SCHECTER, GF; GOODMAN, PC; SANDE, MA; CHAISSON, RE; HOPEWELL, PC			TREATMENT OF TUBERCULOSIS IN PATIENTS WITH ADVANCED HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NON-HAITIAN PATIENTS; PULMONARY TUBERCULOSIS; THERAPY; CHEMOTHERAPY; FLORIDA; HIV	Background and Methods. Infection with the human immunodeficiency virus (HIV) increases the risk of tuberculosis and may interfere with the effectiveness of antituberculosis chemotherapy. To examine the outcomes in patients with both diagnoses, we conducted a retrospective study of all 132 patients listed in both the acquired immunodeficiency syndrome (AIDS) and tuberculosis case registries in San Francisco from 1981 through 1988. Results. At the time of the diagnosis of tuberculosis, 78 patients (59 percent) did not yet have a diagnosis of AIDS, 18 patients (14 percent) were given a concomitant diagnosis of AIDS (as determined by the presence of an AIDS-defining disease other than tuberculosis), and the remaining 36 patients (27 percent) already had AIDS. The manifestations of tuberculosis were entirely pulmonary in 50 patients (38 percent), entirely extrapulmonary in 40 patients (30 percent), and both pulmonary and extrapulmonary in 42 patients (32 percent). The treatment regimens were as follows: isoniazid and rifampin supplemented by ethambutol for the first two months, 52 patients; isoniazid and rifampin supplemented by pyrazinamide and ethambutol for the first two months, 39 patients; isoniazid and rifampin, 13 patients; isoniazid and rifampin supplemented by pyrazinamide for the first two months, 4 patients; and other drug regimens, 17 patients. The intended duration of treatment for patients whose regimen included pyrazinamide was six months, and for patients who did not receive pyrazinamide, nine months. Seven patients received no treatment because tuberculosis was first diagnosed after death. Sputum samples became clear of acid-fast organisms after a median of 10 weeks of therapy. Abnormalities on all chest radiographs taken after three months of treatment were stable or improved except for those of patients who had new nontuberculous infections. The only treatment failure occurred in a man infected with multiple drug-resistant organisms who did not comply with therapy. Adverse drug reactions occurred in 23 patients (18 percent). For all 125 treated patients, median survival was 16 months from the diagnosis of tuberculosis. Tuberculosis was a major contributor to death in 5 of the 7 untreated patients and 8 of the 125 treated patients. Three of 58 patients who completed therapy had a relapse (5 percent); compliance was poor in all 3. Conclusions. Tuberculosis causes substantial mortality in patients with advanced HIV infection. In patients who comply with the regimen, conventional therapy results in rapid sterilization of sputum, radiographic improvement, and low rates of relapse.	SAN FRANCISCO GEN HOSP,MED CTR,MED SERV,SAN FRANCISCO,CA 94110; SAN FRANCISCO GEN HOSP,MED CTR,DEPT RADIOL,SAN FRANCISCO,CA 94110; DEPT PUBL HLTH,SAN FRANCISCO,CA; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT RADIOL,SAN FRANCISCO,CA 94143	San Francisco General Hospital Medical Center; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NIGMS NIH HHS [5-T32-GM07546] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007546] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRUDNEY K, 1989, 5TH INT C AIDS MONTR; CHAISSON RE, 1987, AM REV RESPIR DIS, V136, P570, DOI 10.1164/ajrccm/136.3.570; CHUCK SL, 1989, NEW ENGL J MED, V321, P794, DOI 10.1056/NEJM198909213211205; DUTT AK, 1981, CHEST, V80, P724, DOI 10.1378/chest.80.6.724; FARER LS, 1979, AM J EPIDEMIOL, V109, P205, DOI 10.1093/oxfordjournals.aje.a112675; GORDIN FM, 1984, ANN INTERN MED, V100, P495, DOI 10.7326/0003-4819-100-4-495; HANDWERGER S, 1987, CHEST, V91, P176, DOI 10.1378/chest.91.2.176; ISEMAN MD, 1987, AM REV RESPIR DIS, V136, P1326, DOI 10.1164/ajrccm/136.6.1325; KOVACS JA, 1988, J INFECT DIS, V158, P254, DOI 10.1093/infdis/158.1.254; LEMP GF, 1990, JAMA-J AM MED ASSOC, V263, P402, DOI 10.1001/jama.263.3.402; LOUIE E, 1986, CHEST, V90, P542, DOI 10.1378/chest.90.4.542; PERRIENS J, 1989, 5 INT C AIDS MONTR; PITCHENIK AE, 1984, ANN INTERN MED, V101, P641, DOI 10.7326/0003-4819-101-5-641; RIEDER HL, 1989, ARCH INTERN MED, V149, P1268, DOI 10.1001/archinte.149.6.1268; SLUTKIN G, 1988, AM REV RESPIR DIS, V138, P1622, DOI 10.1164/ajrccm/138.6.1622; SUNDERAM G, 1986, JAMA-J AM MED ASSOC, V256, P362, DOI 10.1001/jama.256.3.362; THEUER CP, 1990, J INFECT DIS, V162, P8, DOI 10.1093/infdis/162.1.8; WURTZ RM, 1989, LANCET, V1, P955; 1987, AM REV RESPIR DIS, V136, P492; 1989, MMWR, V38, P236	20	448	454	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 31	1991	324	5					289	294		10.1056/NEJM199101313240503	http://dx.doi.org/10.1056/NEJM199101313240503			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EU922	1898769				2022-12-24	WOS:A1991EU92200003
J	AELONY, Y; KING, R; BOUTIN, C				AELONY, Y; KING, R; BOUTIN, C			THORACOSCOPIC TALC POUDRAGE PLEURODESIS FOR CHRONIC RECURRENT PLEURAL EFFUSIONS	ANNALS OF INTERNAL MEDICINE			English	Article							CORYNEBACTERIUM-PARVUM; SYMPTOMATIC TREATMENT; TETRACYCLINE; MESOTHELIOMA; DIAGNOSIS	Objective: To assess the effectiveness of thoracoscopic talc poudrage for the treatment of chronic pleural effusions. Design: Prospective evaluation. Setting: Kaiser-Permanente Hospital. Patients: Forty-seven consecutive patients with recalcitrant pleural effusions, referred for thoracoscopy. Intervention: Patients received general or local anesthesia; 42 had a 7-mm rigid thoracoscopic examination followed by insufflation of 5 mL of talc. Patients then had chest-tube drainage. Measurements: We recorded clinical characteristics, final diagnosis, procedure-related pain and morbidity, days of hospitalization, patient-reported degree of symptom relief, and chest roentgenographic results at 1, 3, and 12 months. All patients were followed for 16 months or until death. Main Results: Of 39 evaluable patients, all reported prolonged relief of effusion-related dyspnea. Radiographic results confirmed the elimination of pleural effusions in 34 patients (87%), including all 11 with benign conditions and 23 of 28 (82%) with malignancies. Treatment failed in three patients because of entrapped lung and in two patients with mesotheliomas whose effusions recurred more than a year after treatment. No procedure-related mortality or morbidity was found. Ambulatory patients required hospitalization for a mean of 3.9 days (range, 2 to 11 days). Mild pain was reported by some patients. The mean duration of chest-tube drainage was 2.7 days (range, 1 to 9 days). Patients with malignant disease lived an average of 12.4 months (range, 1 to 61 months) after the procedure. Conclusions: Thoracoscopic talc poudrage is an effective pleural sclerosing technique and is relatively painless.	HOP CONCEPTION, F-13386 MARSEILLE 5, FRANCE	Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille	AELONY, Y (corresponding author), SO CALIF PERMANENTE MED GRP, DEPT INTERNAL MED, 25825 S VERMONT, HARBOR CITY, CA 90710 USA.							ANTONY VB, 1987, AM REV RESPIR DIS, V135, P775, DOI 10.1164/arrd.1987.135.4.775; BONIFACE E, 1989, REV MAL RESPIR, V6, P133; BOUTIN C, 1981, AM REV RESPIR DIS, V124, P588; Boutin C, 1991, PRACTICAL THORACOSCO; BOUTIN C, 1990, LUNG S, P1113; Boutin C, 1985, REV MAL RESPIR, V2, P374; BOUTIN C, 1985, PLEURA HLTH DISEASE; BRANDT HJ, 1985, ATLAS DIAGNOSTIC THO; CANTO A, 1985, MED CLIN-BARCELONA, V84, P806; CHRETIEN J, 1983, DISEASES PLEURA, P152; DAVIDSON AC, 1988, THORAX, V43, P327, DOI 10.1136/thx.43.4.327; DUNKEL TB, 1986, MINN MED, V69, P717; ELMES PC, 1976, Q J MED, V45, P427; FENTIMAN IS, 1987, CANCER TREAT REV, V14, P107, DOI 10.1016/0305-7372(87)90043-0; Frank W, 1989, Pneumologie, V43, P80; GAENSLER EA, 1964, NEW ENGL J MED, V270, P1319, DOI 10.1056/NEJM196406182702501; Gust R, 1989, Pneumologie, V43, P85; HAUPT GJ, 1960, JAMA-J AM MED ASSOC, V73, P173; HAUSHEER FH, 1985, SEMIN ONCOL, V12, P54; JONES DP, 1989, CHEST S, V96, pS276; LADJIMI S, 1989, REV MAL RESPIR, V6, P147; LANDVATER L, 1988, CHEST, V93, P1196, DOI 10.1378/chest.93.6.1196; LANGE P, 1988, THORAX, V43, P559, DOI 10.1136/thx.43.7.559; LEAHY BC, 1985, EUR J RESPIR DIS, V66, P50; LIGHT RW, 1972, ANN INTERN MED, V77, P507, DOI 10.7326/0003-4819-77-4-507; LIGHT RW, 1983, PLEURAL DISEASES, P84; LIGHT RW, 1983, PLEURAL DISEASES, P86; LIGHT RW, 1983, PLEURAL DISEASES, P77; MARTINI N, 1975, CANCER, V35, P734, DOI 10.1002/1097-0142(197503)35:3<734::AID-CNCR2820350328>3.0.CO;2-N; MUIR J F, 1987, American Review of Respiratory Disease, V135, pA244; NG TK, 1984, MED J AUSTRALIA, V140, P452, DOI 10.5694/j.1326-5377.1984.tb108157.x; RINALDO JE, 1983, J THORAC CARDIOV SUR, V85, P523; ROSSI GA, 1987, AM REV RESPIR DIS, V135, P885, DOI 10.1164/arrd.1987.135.4.885; SHERMAN S, 1988, CHEST, V93, P533, DOI 10.1378/chest.93.3.533; SHERMAN S, 1987, SOUTH MED J, V80, P716, DOI 10.1097/00007611-198706000-00013; TSANG V, 1990, THORAX, V45, P369, DOI 10.1136/thx.45.5.369; TZENG E, 1990, CHEST, V98, P890, DOI 10.1378/chest.98.4.890; Viskum K, 1981, Poumon Coeur, V37, P25; WEISSBERG D, 1980, ANN THORAC SURG, V29, P205, DOI 10.1016/S0003-4975(10)61868-1; Weissberg D, 1981, Poumon Coeur, V37, P291; WOOTEN S A, 1987, American Review of Respiratory Disease, V135, pA245	41	74	75	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1991	115	10					778	782		10.7326/0003-4819-115-10-778	http://dx.doi.org/10.7326/0003-4819-115-10-778			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GP800	1929026				2022-12-24	WOS:A1991GP80000006
J	BISCHOFF, FR; PONSTINGL, H				BISCHOFF, FR; PONSTINGL, H			CATALYSIS OF GUANINE-NUCLEOTIDE EXCHANGE ON RAN BY THE MITOTIC REGULATOR RCC1	NATURE			English	Article							CHROMOSOME CONDENSATION; HUMAN-GENE; PROTEIN; ONSET; CLONING; MUTANT; CDNA; DNA; GDP	THE product of the gene RCC1 (regulator of chromosome condensation) in a BHK cell line is involved in the control of mitotic events 1. Homologous genes have been found in Xenopus 2, Drosophila 3 and yeast 4,5. A human genomic DNA fragment and complementary DNA that complement a temperature-sensitive mutation of RCC1 in BHK21 cells 6,7 encode a protein of relative molecular mass 45,000 (M(r) 45K) which is located in the nucleus and binds to chromatin 8. We have recently isolated a protein from HeLa cells that strongly binds an anti-RCC1 antibody and has the same molecular mass, DNA-binding properties, and amino-acid sequence as the 205 residues already identified 9. HeLa cell RCC1 is complexed to a protein of M(r) 25K (ref. 9). We have shown 10 that this 25K protein has a sequence homologous to the translated reading frame of TC4, a cDNA found by screening a human teratocarcinoma cDNA library with oligonucleotides coding for a ras consensus sequence 11, and that the protein binds GDP and GTP. We have referred to this protein as the Ran protein (ras-related nuclear protein). In addition to the fraction of Ran protein complexed to RCC1, a 25-fold molar excess of the protein over RCC1 was found in the nucleoplasm of HeLa cells. Here we show that RCC1 specifically catalyses the exchange of guanine nucleotides on the Ran protein but not on the protein c-Ha-ras p2l (p21ras).	DEUTSCH KREBSFORSCHUNGSZENTRUM,MOLEC BIOL MITOSIS PROJECT,NEUENHEIMER FELD 280,W-6900 HEIDELBERG,GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ)								AEBI M, 1990, MOL GEN GENET, V224, P72, DOI 10.1007/BF00259453; BISCHOFF FR, 1990, P NATL ACAD SCI USA, V87, P8617, DOI 10.1073/pnas.87.21.8617; BISCHOFF FR, IN PRESS P NATN ACAD; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CHARDIN P, 1991, CANCER CELL-MON REV, V3, P117; CLARK KL, 1989, MOL CELL BIOL, V9, P2682, DOI 10.1128/MCB.9.6.2682; CRECHET JB, 1990, SCIENCE, V248, P866, DOI 10.1126/science.2188363; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; FRASCH M, 1991, EMBO J, V10, P1225, DOI 10.1002/j.1460-2075.1991.tb08064.x; JOHN J, 1988, J BIOL CHEM, V263, P11792; KAI R, 1986, MOL CELL BIOL, V6, P2027, DOI 10.1128/MCB.6.6.2027; MATSUMOTO T, 1991, CELL, V66, P347, DOI 10.1016/0092-8674(91)90624-8; NISHIMOTO T, 1978, CELL, V15, P475, DOI 10.1016/0092-8674(78)90017-X; NISHITANI H, 1991, EMBO J, V10, P1555, DOI 10.1002/j.1460-2075.1991.tb07675.x; NISHITANI H, 1990, J BIOCHEM-TOKYO, V107, P228, DOI 10.1093/oxfordjournals.jbchem.a123031; OHTSUBO M, 1987, GENE DEV, V1, P585, DOI 10.1101/gad.1.6.585; OHTSUBO M, 1989, J CELL BIOL, V109, P1389, DOI 10.1083/jcb.109.4.1389; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; WEST M, 1990, FEBS LETT, V259, P245, DOI 10.1016/0014-5793(90)80019-F; WOLFMAN A, 1990, SCIENCE, V248, P67, DOI 10.1126/science.2181667	20	559	571	1	21	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 7	1991	354	6348					80	82		10.1038/354080a0	http://dx.doi.org/10.1038/354080a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GN829	1944575				2022-12-24	WOS:A1991GN82900063
J	YASUDA, LF; YAO, MC				YASUDA, LF; YAO, MC			SHORT INVERTED REPEATS AT A FREE END SIGNAL LARGE PALINDROMIC DNA FORMATION IN TETRAHYMENA	CELL			English	Article							RIBOSOMAL-RNA GENES; NUCLEOTIDE-SEQUENCE; EXTRACHROMOSOMAL RDNA; CHROMOSOME BREAKAGE; DEVELOPING NUCLEI; AMPLIFICATION; THERMOPHILA; DUPLICATION; PYRIFORMIS; CONSERVATION	Large palindromic DNAs are formed in many cell types, but their molecular mechanism is unknown. During nuclear differentiation in Tetrahymena, the ribosomal RNA genes (rDNA) are converted from a single integrated copy to an extrachromosomal head-to-head palindrome. Using in vitro mutagenesis and Tetrahymena transformation, we show that two properties of the rDNA are necessary and sufficient for palindrome formation. The first is a pair of 42 bp inverted repeats found at the rDNA's 5' end. Its inverted symmetry, but not specific sequence, is important. The second is a free end next to the repeats. It is normally created by chromosome breakage in vivo, but can also be provided by restriction endonuclease cutting before transformation. We also demonstrate that the ability to form palindromes is not restricted to developing nuclei, but is present in vegetative cells as well. This process may represent a general mechanism for palindrome formation in eukaryotes.			YASUDA, LF (corresponding author), FRED HUTCHINSON CANC RES CTR,DIV BASIC SCI,SEATTLE,WA 98104, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026210, F32GM013293] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM26210, 5 F32 GM13293-02] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUSTERBERRY CF, 1984, P NATL ACAD SCI-BIOL, V81, P7383, DOI 10.1073/pnas.81.23.7383; AUSTERBERRY CF, 1987, MOL CELL BIOL, V7, P435, DOI 10.1128/MCB.7.1.435; BEVERLEY SM, 1984, CELL, V38, P431, DOI 10.1016/0092-8674(84)90498-7; BLACKBURN EH, 1978, J MOL BIOL, V120, P33, DOI 10.1016/0022-2836(78)90294-2; BRUNS PJ, 1985, P NATL ACAD SCI USA, V82, P2844, DOI 10.1073/pnas.82.9.2844; CHALLONER PB, 1986, NUCLEIC ACIDS RES, V14, P6299, DOI 10.1093/nar/14.15.6299; COCKBURN AF, 1978, CHROMOSOMA, V70, P19, DOI 10.1007/BF00292212; DIN N, 1979, J MOL BIOL, V134, P555, DOI 10.1016/0022-2836(79)90367-X; ENGBERG J, 1983, NUCLEIC ACIDS RES, V11, P4939, DOI 10.1093/nar/11.14.4939; ENGBERG J, 1976, J MOL BIOL, V104, P455, DOI 10.1016/0022-2836(76)90281-3; FORD M, 1986, CELL, V45, P425, DOI 10.1016/0092-8674(86)90328-4; FORD M, 1985, P NATL ACAD SCI USA, V82, P3370, DOI 10.1073/pnas.82.10.3370; GALL JG, 1974, P NATL ACAD SCI USA, V71, P3078, DOI 10.1073/pnas.71.8.3078; GODISKA R, 1990, CELL, V61, P1237, DOI 10.1016/0092-8674(90)90688-B; Gorovsky M A, 1975, Methods Cell Biol, V9, P311, DOI 10.1016/S0091-679X(08)60080-1; HYRIEN O, 1988, EMBO J, V7, P407, DOI 10.1002/j.1460-2075.1988.tb02828.x; KAN NC, 1981, J MOL BIOL, V153, P1151, DOI 10.1016/0022-2836(81)90472-1; KARRER KM, 1976, J MOL BIOL, V104, P421, DOI 10.1016/0022-2836(76)90280-1; KING BO, 1982, CELL, V31, P177, DOI 10.1016/0092-8674(82)90417-2; KISS GB, 1981, GENE, V13, P281, DOI 10.1016/0378-1119(81)90032-9; LARSON DD, 1986, CELL, V47, P229, DOI 10.1016/0092-8674(86)90445-9; LILLEY DMJ, 1984, CELL, V36, P413, DOI 10.1016/0092-8674(84)90234-4; ORIAS E, 1988, GENE, V70, P295, DOI 10.1016/0378-1119(88)90201-6; PAN WC, 1981, CELL, V23, P459, DOI 10.1016/0092-8674(81)90141-0; PASSANANTI C, 1987, EMBO J, V6, P1697, DOI 10.1002/j.1460-2075.1987.tb02420.x; RUIZ JC, 1988, MOL CELL BIOL, V8, P4302, DOI 10.1128/MCB.8.10.4302; Sambrook J., 1989, MOL CLONING LAB MANU; SPANGLER EA, 1985, J BIOL CHEM, V260, P6334; STARK GR, 1989, CELL, V57, P901, DOI 10.1016/0092-8674(89)90328-0; SWEENEY R, 1989, EMBO J, V8, P933, DOI 10.1002/j.1460-2075.1989.tb03454.x; TONDRAVI MM, 1986, P NATL ACAD SCI USA, V83, P4369, DOI 10.1073/pnas.83.12.4369; VOGT VM, 1976, J MOL BIOL, V106, P567, DOI 10.1016/0022-2836(76)90252-7; WALTON JD, 1986, CELL, V46, P857, DOI 10.1016/0092-8674(86)90067-X; WEST SC, 1985, P NATL ACAD SCI USA, V82, P6445, DOI 10.1073/pnas.82.19.6445; YAO MC, 1985, MOL CELL BIOL, V5, P1260, DOI 10.1128/MCB.5.6.1260; YAO MC, 1987, CELL, V48, P779, DOI 10.1016/0092-8674(87)90075-4; YAO MC, 1974, P NATL ACAD SCI USA, V71, P3082, DOI 10.1073/pnas.71.8.3082; YAO MC, 1990, CELL, V63, P763, DOI 10.1016/0092-8674(90)90142-2; YAO MC, 1989, MOL CELL BIOL, V9, P1092, DOI 10.1128/MCB.9.3.1092; YAO MC, 1977, CELL, V12, P121, DOI 10.1016/0092-8674(77)90190-8; YAO MC, 1981, CELL, V24, P765, DOI 10.1016/0092-8674(81)90102-1; YU GL, 1988, P NATL ACAD SCI USA, V85, P5151, DOI 10.1073/pnas.85.14.5151	42	53	53	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 1	1991	67	3					505	516		10.1016/0092-8674(91)90525-4	http://dx.doi.org/10.1016/0092-8674(91)90525-4			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GN664	1934058				2022-12-24	WOS:A1991GN66400007
J	SEGRAVES, RT				SEGRAVES, RT			REVERSING ANORGASMIA ASSOCIATED WITH SEROTONIN UPTAKE INHIBITORS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							FLUOXETINE				SEGRAVES, RT (corresponding author), CASE WESTERN RESERVE UNIV,CLEVELAND,OH 44106, USA.							HERMAN JB, 1990, J CLIN PSYCHIAT, V51, P25; KLINE MD, 1989, AM J PSYCHIAT, V146, P804; MCCORMICK S, 1990, J CLIN PSYCHIAT, V51, P383; MOINTIERO WO, 1985, BRIT J PSYCHIAT, V151, P107; MOSHER JS, 1990, AM J PSYCHIAT, V147, P949; PRICE J, 1990, J CLIN PSYCHIAT, V51, P32; SEGRAVES RT, 1989, ARCH GEN PSYCHIAT, V46, P275; ZAJECKA J, 1991, J CLIN PSYCHIAT, V52, P66	8	2	2	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 23	1991	266	16					2279	2279						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GK661	1920732				2022-12-24	WOS:A1991GK66100042
J	HOLMES, SJ; LUCAS, AH; OSTERHOLM, MT; FROESCHLE, JE; GRANOFF, DM				HOLMES, SJ; LUCAS, AH; OSTERHOLM, MT; FROESCHLE, JE; GRANOFF, DM			IMMUNOGLOBULIN DEFICIENCY AND IDIOTYPE EXPRESSION IN CHILDREN DEVELOPING HAEMOPHILUS-INFLUENZAE TYPE-B DISEASE AFTER VACCINATION WITH CONJUGATE VACCINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CAPSULAR POLYSACCHARIDE VACCINE; HEMOPHILUS DISEASE; ANTIBODIES; EFFICACY; SUBCLASS; AGE; IMMUNOGENICITY; IMMUNIZATION; MINNESOTA; INFANTS	Objective. Haemophilus influenzae type b (Hib) conjugate vaccines are effective in preventing Haemophilus disease in most children. The reasons why the vaccination fails in some children are unknown. This study investigated host factors in children who developed the disease despite conjugate vaccination. Design, Patients, Outcome Measures. A convenience sample of 23 patients in whom Hib disease developed 14 days or more after conjugate vaccination was investigated for the presence of subnormal serum immunoglobulin concentrations and anticapsular antibody responses to Hib disease. We also investigated expression of the Hib idiotype 1 (Hibld-1), a serological marker of a V(K)II chain that comprises a major portion of the normal variable region repertoire of the antibody response to Hib polysaccharide. The results were compared with those of 149 patients in whom the unconjugated Hib polysaccharide vaccine failed and of 90 unvaccinated patients who developed the disease. Results. Compared with children in whom the unconjugated polysaccharide vaccination failed, the relative risk of a subnormal serum concentration of IgM, IgA, IgG, and/or IgG2 in the children in whom the conjugate vaccination failed was 4.9 (95% confidence interval [Cl], 1.8 to 14; P < .003) and of IgG2 was 22 (95% Cl, 3.5 to 146; P < .001). With the exception of the children with subnormal serum immunoglobulin concentrations, most of the children with conjugate vaccination failure showed normal or high anticapsular antibody responses to the disease, whereas the children with polysaccharide vaccination failure showed impaired responses. The Hibld-1 was expressed by the majority of the children in both vaccination failure groups and of the unvaccinated patients. Conclusions. In most patients, vaccination failure is not attributable to lack of expression of the variable region gene encoding Hibld-1. However, children in whom conjugate vaccination has failed frequently have subnormal serum immunoglobulin concentrations and should be evaluated for immunodeficiency.	WASHINGTON UNIV,SCH MED,ST LOUIS CHILDRENS HOSP,EDWARD MALLINCKRODT DEPT PEDIAT,ST LOUIS,MO 63110; MINNESOTA DEPT HLTH,ACUTE DIS EPIDEMIOL SECT,MINNEAPOLIS,MN; CONNAUGHT LABS INC,SWIFTWATER,PA; CHILDRENS HOSP OAKLAND RES INST,OAKLAND,CA	St. Louis Children's Hospital; Washington University (WUSTL); Minnesota Department of Health (MHD); Children's Hospital Oakland Research Institute; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021842, R37AI025008, R01AI025008, R01AI017962] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 25008, AI 21842, AI 17962] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADDERSON EE, 1991, J IMMUNOL, V147, P1667; BLACK SB, 1988, PEDIATR INFECT DIS J, V7, P149, DOI 10.1097/00006454-198803000-00003; ESKOLA J, 1990, NEW ENGL J MED, V323, P1381, DOI 10.1056/NEJM199011153232004; GRANOFF DM, 1989, J PEDIATR-US, V114, P925, DOI 10.1016/S0022-3476(89)80432-9; GRANOFF DM, 1986, NEW ENGL J MED, V315, P1584, DOI 10.1056/NEJM198612183152505; GRANOFF DM, 1988, MONOGR ALLERGY, V23, P256; GRANOFF DM, 1986, J INFECT DIS, V154, P257, DOI 10.1093/infdis/154.2.257; GRANOFF DM, 1989, J INFECT DIS, V159, P908, DOI 10.1093/infdis/159.5.908; GRANOFF DM, 1988, PEDIATR RES, V24, P180, DOI 10.1203/00006450-198808000-00008; GREENBERG DP, 1991, JAMA-J AM MED ASSOC, V265, P987, DOI 10.1001/jama.265.8.987; HALDANE JBS, 1956, ANN HUM GENET, V20, P309; HARRISON LH, 1988, JAMA-J AM MED ASSOC, V260, P1413, DOI 10.1001/jama.260.10.1413; KAYHTY H, 1983, J INFECT DIS, V147, P1100; KAYHTY H, 1988, J INFECT DIS, V158, P973, DOI 10.1093/infdis/158.5.973; LUCAS AH, 1990, J CLIN INVEST, V85, P1158, DOI 10.1172/JCI114548; LUCAS AH, IN PRESS J CLIN INVE; MADASSERY JV, 1988, CLIN CHEM, V34, P1407; MADORE DV, 1990, PEDIATRICS, V86, P527; MURPHY TV, 1990, FEB W SOC PED RES CA; OSTERHOLM MT, 1988, JAMA-J AM MED ASSOC, V260, P1423, DOI 10.1001/jama.260.10.1423; OSTERHOLM MT, 1989, 29TH INT C ANT AG CH; PELTOLA H, 1977, PEDIATRICS, V60, P730; SCOTT MG, 1989, J IMMUNOL, V143, P293; SHACKELFORD PG, 1990, J PEDIATR-US, V116, P529, DOI 10.1016/S0022-3476(05)81598-7; SHAPIRO ED, 1988, JAMA-J AM MED ASSOC, V260, P1419, DOI 10.1001/jama.260.10.1419; SHAPIRO ED, 1990, 30TH INT C ANT AG CH; WEINBERG GA, 1990, PEDIATRICS, V86, P617	27	25	25	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 9	1991	266	14					1960	1965		10.1001/jama.266.14.1960	http://dx.doi.org/10.1001/jama.266.14.1960			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GH406	1895474				2022-12-24	WOS:A1991GH40600022
J	PANZA, JA; EPSTEIN, SE; QUYYUMI, AA				PANZA, JA; EPSTEIN, SE; QUYYUMI, AA			CIRCADIAN VARIATION IN VASCULAR TONE AND ITS RELATION TO ALPHA-SYMPATHETIC VASOCONSTRICTOR ACTIVITY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SUDDEN CARDIAC DEATH; ATHEROSCLEROTIC CORONARY-ARTERIES; ACUTE MYOCARDIAL-INFARCTION; ESSENTIAL-HYPERTENSION; MORNING INCREASE; ANGINA-PECTORIS; ADRENERGIC VASOCONSTRICTION; MEDIATED VASOCONSTRICTION; PLATELET AGGREGABILITY; DIURNAL-VARIATION	Background. The frequency of several cardiovascular events, such as myocardial infarction, sudden death, and stroke, is increased during the early morning hours. There is also a similar circadian pattern in several physiologic variables, including blood pressure, suggesting that certain dynamic processes may contribute to the circadian distribution and onset of acute events. Methods. To determine whether there are circadian variations in vascular tone and to investigate their underlying mechanisms, we measured blood flow and vascular resistance in the forearm and their responses to phentolamine (an alpha-adrenergic-antagonist drug) and sodium nitroprusside (a direct vasodilator) in 12 normal subjects 7 men and 5 women; mean age [+/- SD], 44 +/- 9 years) at three different times of day (7 a.m., 2 p.m., and 9 p.m.). The drugs were infused into the brachial artery, and the responses were measured by strain-gauge plethysmography. Results. The basal forearm vacular resistance was significantly higher, and the blood flow significantly lower, in the morning than in the afternoon and evening (mean vascular resistance, 31 +/- 8, 25 +/- 6, and 22 +/- 7 mm Hg per milliliter per minute per 100 ml of forearm volume, respectively; P < 0.01). The vasodilator effect of phentolamine was also significantly greater in the morning (mean decrease in vascular resistance, 38 +/- 6 percent) than in the afternoon (26 +/- 6 percent) and evening (21 +/- 7 percent) (P < 0.05). Consequently, there was no circadian variation in vascular resistance or blood flow after the infusion of this drug. In contrast, the vasodilation in response to sodium nitroprusside was similar at all three times of day. Conclusions. There is a circadian rhythm in basal vascular tone, due either partly or entirely to increased alpha-sympathetic vasoconstrictor activity during the morning. This variation may contribute to higher blood pressure and the increased incidence of cardiovascular events at this time of day.			PANZA, JA (corresponding author), NHLBI,BLDG 10,RM 7B-15,BETHESDA,MD 20892, USA.							AMANN FW, 1981, HYPERTENSION, V3, P119; ANDREOTTI F, 1988, AM J CARDIOL, V62, P635, DOI 10.1016/0002-9149(88)90669-8; BERKENBOOM GM, 1986, AM J CARDIOL, V57, P195, DOI 10.1016/0002-9149(86)90889-1; Bohme E, 1978, Adv Cyclic Nucleotide Res, V9, P131; BREZINSKI DA, 1988, CIRCULATION, V78, P35, DOI 10.1161/01.CIR.78.1.35; BROWN BG, 1984, CIRCULATION, V70, P18, DOI 10.1161/01.CIR.70.1.18; COCKS TM, 1983, NATURE, V305, P627, DOI 10.1038/305627a0; COHEN RA, 1988, AM J PHYSIOL, V254, pH871, DOI 10.1152/ajpheart.1988.254.5.H871; COLLINS P, 1985, BRIT HEART J, V53, P488; EGAN B, 1987, J CLIN INVEST, V80, P812, DOI 10.1172/JCI113138; EPSTEIN SE, 1981, AM J CARDIOL, V48, P797, DOI 10.1016/0002-9149(81)90160-0; FUJITA M, 1987, CIRCULATION, V76, P488, DOI 10.1161/01.CIR.76.2.488; GORDON RD, 1966, J CLIN INVEST, V45, P1587, DOI 10.1172/JCI105464; GREENFIELD ADM, 1963, BRIT MED BULL, V19, P101, DOI 10.1093/oxfordjournals.bmb.a070026; HOKANSON DE, 1975, IEEE T BIO-MED ENG, VBM22, P25, DOI 10.1109/TBME.1975.324535; KANEKO M, 1968, J APPL PHYSIOL, V25, P109, DOI 10.1152/jappl.1968.25.2.109; KERSLAKE DM, 1949, J PHYSIOL-LONDON, V108, P451, DOI 10.1113/jphysiol.1949.sp004348; KIOWSKI W, 1981, CLIN SCI, V60, P483, DOI 10.1042/cs0600483; KUKOVETZ WR, 1979, N-S ARCH PHARMACOL, V310, P129, DOI 10.1007/BF00500277; LINSELL CR, 1985, J CLIN ENDOCR METAB, V60, P1210, DOI 10.1210/jcem-60-6-1210; LUDMER PL, 1986, NEW ENGL J MED, V315, P1046, DOI 10.1056/NEJM198610233151702; MARLER JR, 1989, STROKE, V20, P473, DOI 10.1161/01.STR.20.4.473; MILLARCRAIG MW, 1978, LANCET, V1, P795; MUDGE GH, 1976, NEW ENGL J MED, V295, P1333, DOI 10.1056/NEJM197612092952401; MULCAHY D, 1988, LANCET, V2, P755; MULLER JE, 1987, CIRCULATION, V75, P131, DOI 10.1161/01.CIR.75.1.131; MULLER JE, 1985, NEW ENGL J MED, V313, P1315, DOI 10.1056/NEJM198511213132103; MULLER JE, 1989, CIRCULATION, V79, P733, DOI 10.1161/01.CIR.79.4.733; NABEL EG, 1988, CIRCULATION, V77, P43, DOI 10.1161/01.CIR.77.1.43; PANZA JA, 1990, NEW ENGL J MED, V323, P22, DOI 10.1056/NEJM199007053230105; ROCCO MB, 1987, CIRCULATION, V75, P395, DOI 10.1161/01.CIR.75.2.395; ROSENDORFF C, 1981, CIRC RES, V48, P320, DOI 10.1161/01.RES.48.3.320; ROSING DR, 1970, CIRC RES, V27, P171, DOI 10.1161/01.RES.27.2.171; SCHULTZ KD, 1977, NATURE, V265, P750, DOI 10.1038/265750a0; TESFAMARIAM B, 1988, CIRC RES, V63, P720, DOI 10.1161/01.RES.63.4.720; THOMPSON DR, 1985, INT J CARDIOL, V7, P139, DOI 10.1016/0167-5273(85)90354-7; TOFLER GH, 1987, NEW ENGL J MED, V316, P1514, DOI 10.1056/NEJM198706113162405; TSEMENTZIS SA, 1985, NEUROSURGERY, V17, P901, DOI 10.1227/00006123-198512000-00005; VERDECCHIA P, 1990, CIRCULATION, V81, P528, DOI 10.1161/01.CIR.81.2.528; WEITZMAN ED, 1971, J CLIN ENDOCR METAB, V33, P14, DOI 10.1210/jcem-33-1-14; WHITNEY RJ, 1953, J PHYSIOL-LONDON, V121, P1; WILLICH SN, 1987, AM J CARDIOL, V60, P801, DOI 10.1016/0002-9149(87)91027-7; YASUE H, 1979, CIRCULATION, V59, P938, DOI 10.1161/01.CIR.59.5.938	43	469	477	0	9	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 3	1991	325	14					986	990		10.1056/NEJM199110033251402	http://dx.doi.org/10.1056/NEJM199110033251402			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GH447	1886635				2022-12-24	WOS:A1991GH44700002
J	SCHAPIRA, DV; KUMAR, NB; LYMAN, GH; CAVANAGH, D; ROBERTS, WS; LAPOLLA, J				SCHAPIRA, DV; KUMAR, NB; LYMAN, GH; CAVANAGH, D; ROBERTS, WS; LAPOLLA, J			UPPER-BODY FAT DISTRIBUTION AND ENDOMETRIAL CANCER RISK	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PREMENOPAUSAL WOMEN; ADIPOSE-TISSUE; BREAST-CANCER; OBESITY; ASSOCIATION; METABOLISM; WEIGHT; TOPOGRAPHY; CARCINOMA; ESTROGEN	Study Objective. - To determine if body fat distribution affected endometrial cancer risk. Design. - Case-control study. Setting. - This study was carried out at the H. Lee Moffitt Cancer Center at the University of South Florida, Tampa, where all patients in the case group received their diagnoses and histological confirmations. Patients. - Forty consecutive women newly diagnosed with endometrial cancer and 40 controls matched for age and Quetelet index. Main Outcome Measures. - Anthropometric measurements were taken for the abdomen, thigh, suprailiac, subscapular, biceps, and triceps skin fold thicknesses; waist and hip circumferences, weight, and height. Relative risks for endometrial cancer were calculated according to these anthropometric measurements. Results. - Case patients with endometrial cancer had significantly greater waist-to-hip circumference ratios (P < .001), abdomen-to-thigh skin fold ratios (P < .01), and suprailiac-to-thigh skin fold ratios (P = .02) compared with control subjects matched for age and Quetelet index. The relative risk for endometrial cancer increased with an increasing waist-to-hip circumference ratio (less-than-or-equal-to 1.14 = 1.0; > 1.14 = 15.0), with an increasing abdomen-to-thigh skin fold ratio (less-than-or-equal-to 0.82 = 1.0; > 0.82 = 5.0), and with an increasing suprailiac to-thigh skin fold thickness ratio (less-than-or-equal-to 0.67 = 1.0; > 0.67 = 3.50). Conclusion. - Upper-body fat localization is a significant risk factor for endometrial cancer in women matched for age and Quetelet index.			SCHAPIRA, DV (corresponding author), UNIV S FLORIDA,COLL MED,H LEE MOFFITT CANC CTR & RES INST,CANC PREVENT SECT,TAMPA,FL 33612, USA.		Lyman, Gary H/K-5227-2019; Kumar, Nagi/AGI-6573-2022	Lyman, Gary H/0000-0002-0823-8086; 				AUSTIN H, 1991, CANCER RES, V51, P568; BALLARDBARBASH R, 1990, J NATL CANCER I, V82, P286, DOI 10.1093/jnci/82.4.286; Behnke AR, 1974, EVALUATION REGULATIO; Cornfield J, 1961, B INT STAT I, V38, P97; ELLIOTT EA, 1990, GYNECOL ONCOL, V39, P253, DOI 10.1016/0090-8258(90)90247-I; ELWOOD JM, 1977, J NATL CANCER I, V59, P1055, DOI 10.1093/jnci/59.4.1055; ENRIORI CL, 1984, GYNECOL ONCOL, V17, P1, DOI 10.1016/0090-8258(84)90055-6; EVANS DJ, 1983, J CLIN ENDOCR METAB, V57, P304, DOI 10.1210/jcem-57-2-304; EVANS DJ, 1984, METABOLISM, V33, P68, DOI 10.1016/0026-0495(84)90164-1; FOLSOM AR, 1989, CANCER RES, V49, P6828; HARTZ AJ, 1983, PREV MED, V12, P351, DOI 10.1016/0091-7435(83)90244-X; HARTZ AJ, 1984, AM J EPIDEMIOL, V119, P71, DOI 10.1093/oxfordjournals.aje.a113727; HULKA BS, 1980, AM J OBSTET GYNECOL, V137, P92, DOI 10.1016/0002-9378(80)90391-9; KALKHOFF RK, 1983, J LAB CLIN MED, V102, P621; KATCH FI, 1980, RES Q EXERCISE SPORT, V51, P249, DOI 10.1080/02701367.1980.10609286; KELSEY JL, 1982, AM J EPIDEMIOL, V116, P333, DOI 10.1093/oxfordjournals.aje.a113417; KELSEY JL, 1983, BREAST GYNECOLOGIC C, P71; KEYS A, 1956, HUM BIOL, V28, P111; KIRSCHNER MA, 1990, J CLIN ENDOCR METAB, V70, P473, DOI 10.1210/jcem-70-2-473; KISSEBAH AH, 1982, J CLIN ENDOCR METAB, V54, P254, DOI 10.1210/jcem-54-2-254; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES PR, P430; LAPIDUS L, 1988, INT J OBESITY, V12, P361; MIETTINEN OS, 1970, BIOMETRICS, V26, P75, DOI 10.2307/2529046; NISKER JA, 1980, AM J OBSTET GYNECOL, V138, P637, DOI 10.1016/0002-9378(80)90080-0; PAGEL J, 1984, DAN MED BULL, V31, P333; PEIRIS AN, 1986, J CLIN INVEST, V78, P1648, DOI 10.1172/JCI112758; PETTERSSON B, 1985, ACTA U UPPSAL, V6, P1; SCHAPIRA DV, 1991, CANCER, V67, P2215, DOI 10.1002/1097-0142(19910415)67:8<2215::AID-CNCR2820670836>3.0.CO;2-Q; SCHAPIRA DV, 1990, ANN INTERN MED, V112, P182, DOI 10.7326/0003-4819-112-3-182; SCHAPIRA DV, 1991, CANCER, V67, P523, DOI 10.1002/1097-0142(19910115)67:2<523::AID-CNCR2820670234>3.0.CO;2-O; SCHAPIRA DV, 1991, CANCER, V67, P2622, DOI 10.1002/1097-0142(19910515)67:10<2622::AID-CNCR2820671037>3.0.CO;2-J; SEGAL KR, 1987, J CLIN INVEST, V80, P1050, DOI 10.1172/JCI113159; SIITERI PK, 1978, CANCER RES, V38, P4360; SJOSTROM L, 1972, METABOLISM, V21, P1143, DOI 10.1016/0026-0495(72)90109-6; SMITH U, 1979, EUR J CLIN INVEST, V9, P327, DOI 10.1111/j.1365-2362.1979.tb00892.x; SPENGLER RF, 1981, AM J EPIDEMIOL, V114, P497, DOI 10.1093/oxfordjournals.aje.a113215; WYNDER EL, 1966, CANCER, V19, P489, DOI 10.1002/1097-0142(196604)19:4<489::AID-CNCR2820190406>3.0.CO;2-W	37	85	86	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 2	1991	266	13					1808	1811		10.1001/jama.266.13.1808	http://dx.doi.org/10.1001/jama.266.13.1808			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG551	1890709				2022-12-24	WOS:A1991GG55100033
J	DRESSLER, F; YOSHINARI, NH; STEERE, AC				DRESSLER, F; YOSHINARI, NH; STEERE, AC			THE T-CELL PROLIFERATIVE ASSAY IN THE DIAGNOSIS OF LYME-DISEASE	ANNALS OF INTERNAL MEDICINE			English	Article						LYME DISEASE; LYMPHOCYTES-T; BORRELIA-BURGDORFERI; T-CELL PROLIFERATIVE ASSAY; ARTHRITIS	LINKED IMMUNOSORBENT-ASSAY; POLYMERASE CHAIN-REACTION; BORRELIA-BURGDORFERI; IMMUNE-COMPLEXES; NEUROLOGIC MANIFESTATIONS; ARTHRITIS; ANTIBODY; RESPONSES; LYMPHOCYTES; EVOLUTION	Objective: To determine the sensitivity and specificity of the T-cell proliferative assay as a diagnostic test in Lyme disease. Design: Cross-sectional study of patients with Lyme arthritis or chronic neuroborreliosis who had a history of erythema migrans, positive antibody responses to Borrelia burgdorferi by enzyme-linked immunosorbent assay (ELISA), or both; patients with other diseases; and healthy subjects. Setting: Diagnostic Lyme disease clinic in a university hospital. Patients: Forty-two of the 67 patients with active Lyme arthritis or chronic neuroborreliosis who were seen during the study period; 16 patients with inactive late Lyme disease; 77 patients with other rheumatologic or neurologic diseases; 9 workers from the Borrelia laboratory; and 9 healthy subjects. Measurements and Main Results: Nineteen of 42 patients with Lyme arthritis or chronic neuroborreliosis and 4 of 77 patients with other diseases had positive T-cell proliferative responses to B. burgdorferi antigens. The sensitivity of the proliferative assay was 45% (95% Cl, 30% to 60%) and the specificity was 95% (95% Cl, 87% to 99%). Twelve of 27 patients with active Lyme arthritis, 7 of 15 patients with chronic neuroborreliosis, 4 of 16 patients with inactive Lyme disease, 4 of 9 healthy Borrelia laboratory workers, and 0 of 9 healthy subjects had positive responses. Three of five patients with Lyme disease who had negative or indeterminant antibody responses by ELISA had positive T-cell proliferative responses. Conclusion: The T-cell proliferative assay may be a helpful diagnostic test in the small subset of patients with late Lyme disease who have negative or indeterminant antibody responses by ELISA.	TUFTS UNIV, NEW ENGLAND MED CTR, SCH MED, BOSTON, MA 02111 USA	Tufts Medical Center; Tufts University			Yoshinari, Natalino Hajime/E-8853-2012	Steere, Allen/0000-0002-5268-9853	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040576, R01AR020358] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR-20358, AR-40576] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BERARDI VP, 1988, J INFECT DIS, V158, P754, DOI 10.1093/infdis/158.4.754; CRAFT JE, 1984, J INFECT DIS, V149, P789, DOI 10.1093/infdis/149.5.789; DATTWYLER RJ, 1988, ANN NY ACAD SCI, V539, P93, DOI 10.1111/j.1749-6632.1988.tb31842.x; DATTWYLER RJ, 1988, NEW ENGL J MED, V319, P1441, DOI 10.1056/NEJM198812013192203; GRODZICKI RL, 1988, J INFECT DIS, V157, P790, DOI 10.1093/infdis/157.4.790; HALPERIN JJ, 1987, NEUROLOGY, V37, P1700, DOI 10.1212/WNL.37.11.1700; HARDIN JA, 1979, J CLIN INVEST, V63, P468, DOI 10.1172/JCI109324; HARDIN JA, 1979, NEW ENGL J MED, V301, P1358, DOI 10.1056/NEJM197912203012502; KRAUSE A, 1991, ARTHRITIS RHEUM-US, V34, P393, DOI 10.1002/art.1780340404; LASTAVICA CC, 1989, NEW ENGL J MED, V320, P133, DOI 10.1056/NEJM198901193200301; LOGIGIAN EL, 1990, NEW ENGL J MED, V323, P1438, DOI 10.1056/NEJM199011223232102; MAGNARELLI LA, 1984, J CLIN MICROBIOL, V20, P181, DOI 10.1128/JCM.20.2.181-184.1984; MASSAROTTI E, 1990, Arthritis and Rheumatism, V33, pS37; NEUMANN A, 1989, RHEUMATOL INT, V9, P237; PACHNER AR, 1985, NEUROLOGY, V35, P47, DOI 10.1212/WNL.35.1.47; PACHNER AR, 1985, NEUROLOGY, V35, P1642, DOI 10.1212/WNL.35.11.1642; PERSING DH, 1990, J CLIN MICROBIOL, V28, P566, DOI 10.1128/JCM.28.3.566-572.1990; PREACMURSIC V, 1989, INFECTION, V17, P355, DOI 10.1007/BF01645543; ROSA PA, 1989, J INFECT DIS, V160, P1018, DOI 10.1093/infdis/160.6.1018; RUSSELL H, 1984, J INFECT DIS, V149, P465, DOI 10.1093/infdis/149.3.465; SCHUTZER SE, 1990, LANCET, V335, P312, DOI 10.1016/0140-6736(90)90606-6; SHRESTHA M, 1985, AM J MED, V78, P235, DOI 10.1016/0002-9343(85)90432-2; SIGAL LH, 1986, ARTHRITIS RHEUM, V29, P761, DOI 10.1002/art.1780290609; STEERE AC, 1983, ANN INTERN MED, V99, P76, DOI 10.7326/0003-4819-99-1-76; STEERE AC, 1980, ANN INTERN MED, V93, P8, DOI 10.7326/0003-4819-93-1-8; STEERE AC, 1989, NEW ENGL J MED, V321, P586, DOI 10.1056/NEJM198908313210906; STEERE AC, 1983, ANN INTERN MED, V99, P22, DOI 10.7326/0003-4819-99-1-22; STEERE AC, 1987, ANN INTERN MED, V107, P725, DOI 10.7326/0003-4819-107-5-725; YOSHINARI NH, 1991, ARTHRITIS RHEUM-US, V34, P707, DOI 10.1002/art.1780340611; ZOSCHKE DC, 1991, ANN INTERN MED, V114, P285, DOI 10.7326/0003-4819-114-4-285	30	72	72	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1991	115	7					533	539		10.7326/0003-4819-115-7-533	http://dx.doi.org/10.7326/0003-4819-115-7-533			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG283	1883122				2022-12-24	WOS:A1991GG28300005
J	FLEURY, S; LAMARRE, D; MELOCHE, S; RYU, SE; CANTIN, C; HENDRICKSON, WA; SEKALY, RP				FLEURY, S; LAMARRE, D; MELOCHE, S; RYU, SE; CANTIN, C; HENDRICKSON, WA; SEKALY, RP			MUTATIONAL ANALYSIS OF THE INTERACTION BETWEEN CD4 AND CLASS-II MHC - CLASS-II ANTIGENS CONTACT CD4 ON A SURFACE OPPOSITE THE GP120-BINDING SITE	CELL			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; T-CELL HYBRIDOMA; ENVELOPE GLYCOPROTEIN; MONOCLONAL-ANTIBODIES; POSSIBLE INVOLVEMENT; STRUCTURAL-ANALYSIS; LYMPHOCYTES-T; BINDING-SITE; HLA ANTIGENS; SB ANTIGENS	Using functional and adhesion assays, we have studied the ability of 30 human CD4 mutants to interact with class II major histocompatibility complex (MHC) molecules and also with gp120 from human immunodeficiency virus. The mutants cover the four domains (D1-D4) of CD4 and include several single-site substitutions. Analysis of the results, in the context of the CD4 crystal structure, shows that mutations that affect the interaction with class II MHC molecules are located on three exposed loops from CD4 domains 1 and 2. The specifically implicated residues, 19, 89, and 165, are separated from one another by 9 angstrom, 24 angstrom, and 24 angstrom on one face of the CD4 molecule. Moreover, the class II binding site does not include residues 43 to 49 of the CD4 molecule, a region on an opposite face known to be involved in the binding of gp120.	UNIV MONTREAL, DEPT MICROBIOL & IMMUNOL, MONTREAL H3C 3J7, QUEBEC, CANADA; COLUMBIA UNIV, DEPT BIOCHEM & MOLEC BIOPHYS, NEW YORK, NY 10027 USA; COLUMBIA UNIV, HOWARD HUGHES MED INST, NEW YORK, NY 10027 USA	Universite de Montreal; Columbia University; Columbia University; Howard Hughes Medical Institute	FLEURY, S (corresponding author), INST RECH CLIN MONTREAL, IMMUNOL LAB, MONTREAL H2W 1R7, QUEBEC, CANADA.							ARTHOS J, 1989, CELL, V57, P469, DOI 10.1016/0092-8674(89)90922-7; ASHKENAZI A, 1990, P NATL ACAD SCI USA, V87, P7150, DOI 10.1073/pnas.87.18.7150; BIDDISON WE, 1982, J EXP MED, V156, P1065, DOI 10.1084/jem.156.4.1065; BIDDISON WE, 1983, J IMMUNOL, V131, P152; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BOWMAN MR, 1990, P NATL ACAD SCI USA, V87, P9052, DOI 10.1073/pnas.87.22.9052; BRODSKY MH, 1990, J IMMUNOL, V144, P3078; BROWN JH, 1988, NATURE, V332, P845, DOI 10.1038/332845a0; CLAYTON LK, 1989, NATURE, V339, P548, DOI 10.1038/339548a0; CLAYTON LK, 1988, NATURE, V335, P363, DOI 10.1038/335363a0; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; DELEAN A, 1982, MOL PHARMACOL, V21, P5; DOYLE C, 1987, NATURE, V330, P256, DOI 10.1038/330256a0; EGLITIS MA, 1988, BIOTECHNIQUES, V6, P608; GAY D, 1987, NATURE, V328, P626, DOI 10.1038/328626a0; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREENSTEIN JL, 1984, J EXP MED, V159, P1213, DOI 10.1084/jem.159.4.1213; HEALEY D, 1990, J EXP MED, V172, P1233, DOI 10.1084/jem.172.4.1233; KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0; KLATZMANN D, 1984, SCIENCE, V225, P59, DOI 10.1126/science.6328660; KUPFER A, 1987, P NATL ACAD SCI USA, V84, P5888, DOI 10.1073/pnas.84.16.5888; LAMARRE D, 1989, EMBO J, V8, P3271, DOI 10.1002/j.1460-2075.1989.tb08487.x; LAMARRE D, 1989, SCIENCE, V245, P743, DOI 10.1126/science.2549633; LANDAU NR, 1988, NATURE, V334, P159, DOI 10.1038/334159a0; LANDEGREN U, 1984, J IMMUNOL METHODS, V67, P379, DOI 10.1016/0022-1759(84)90477-0; LITTMAN DR, 1987, ANNU REV IMMUNOL, V5, P561, DOI 10.1146/annurev.iy.05.040187.003021; LITTMAN DR, 1987, NATURE, V325, P453, DOI 10.1038/325453a0; MADDON PJ, 1987, P NATL ACAD SCI USA, V84, P9155, DOI 10.1073/pnas.84.24.9155; MADDON PJ, 1985, CELL, V42, P93, DOI 10.1016/S0092-8674(85)80105-7; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; MARCHALONIS JJ, 1969, BIOCHEM J, V113, P299, DOI 10.1042/bj1130299; MARRACK P, 1983, J EXP MED, V158, P1077, DOI 10.1084/jem.158.4.1077; MAZEROLLES F, 1988, CELL, V55, P497, DOI 10.1016/0092-8674(88)90036-0; MCDOUGAL JS, 1986, SCIENCE, V231, P382, DOI 10.1126/science.3001934; MERKENSCHLAGER M, 1990, J IMMUNOL, V145, P3181; MERKENSCHLAGER M, 1990, J IMMUNOL, V145, P2839; MITTLER RS, 1989, SCIENCE, V245, P1380, DOI 10.1126/science.2571187; MIZUKAMI T, 1988, P NATL ACAD SCI USA, V85, P9273, DOI 10.1073/pnas.85.23.9273; PETERSON A, 1988, CELL, V54, P65, DOI 10.1016/0092-8674(88)90180-8; ROSENSTEIN Y, 1990, J IMMUNOL, V144, P526; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; SAIZAWA K, 1987, NATURE, V328, P260, DOI 10.1038/328260a0; SATTENTAU QJ, 1989, J EXP MED, V170, P1319, DOI 10.1084/jem.170.4.1319; SATTENTAU QJ, 1986, SCIENCE, V234, P1120, DOI 10.1126/science.2430333; SLECKMAN BP, 1987, NATURE, V328, P351, DOI 10.1038/328351a0; SLECKMAN BP, 1988, J IMMUNOL, V141, P49; SWAIN SL, 1984, J IMMUNOL, V132, P1118; SWAIN SL, 1983, IMMUNOL REV, V74, P129, DOI 10.1111/j.1600-065X.1983.tb01087.x; VONHOEGEN P, 1989, J EXP MED, V170, P1879, DOI 10.1084/jem.170.6.1879; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; WILDE DB, 1983, J IMMUNOL, V131, P2178; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121	53	150	157	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 6	1991	66	5					1037	1049		10.1016/0092-8674(91)90447-7	http://dx.doi.org/10.1016/0092-8674(91)90447-7			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GE460	1889086				2022-12-24	WOS:A1991GE46000020
J	BORNER, C; FILIPUZZI, I; WEINSTEIN, IB; IMBER, R				BORNER, C; FILIPUZZI, I; WEINSTEIN, IB; IMBER, R			FAILURE OF WILD-TYPE OR A MUTANT FORM OF PROTEIN KINASE-C-ALPHA TO TRANSFORM FIBROBLASTS	NATURE			English	Article							RAS ONCOGENE; CELLS; GROWTH	A MUTANT form of the alpha-isoform of protein kinase C (PKC) was recently isolated from an ultraviolet radiation-induced murine fibrosarcoma cell line and reported to transform mouse BALB/c 3T3 fibroblasts on transfection 1. Four point mutations in the regulatory domain were assumed to be responsible for its oncogenicity and unusual preference for membrane localization. Here, we report that overexpression of the reported mutant PKC-alpha complementary DNA in three fibroblast cell lines, including BALB/c 3T3, does not enable these cells to grow in soft agar or nude mice. In addition, this mutant PKC-alpha form seems to be indistinguishable from the wild-type PKC-alpha with respect to its dependence on cofactors, phorbol ester binding, subcellular distribution and its effects on growth and morphology. These results fail to confirm the previous study 1 and indicate that overexpression of either the wild-type or the reported mutant form of PKC-alpha does not transform rodent fibroblasts.	COLUMBIA UNIV,CTR COMPREHENS CANC,NEW YORK,NY 10032; COLUMBIA UNIV,INST CANC RES,NEW YORK,NY 10032; UNIV BASEL CLIN,SCH MED,MOLEC TUMORBIOL LAB,CH-4031 BASEL,SWITZERLAND	Columbia University; Columbia University; University of Basel								BORNER C, 1987, INT J CANCER, V40, P344, DOI 10.1002/ijc.2910400310; BORNER C, 1990, CELL GROWTH DIFFER, V1, P653; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; COSTA SD, 1985, BIOCHEM BIOPH RES CO, V133, P814, DOI 10.1016/0006-291X(85)90977-5; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HSIAO WLW, 1989, MOL CELL BIOL, V9, P2641, DOI 10.1128/MCB.9.6.2641; IMBER R, 1991, CANCER RES, V51, P632; JAKEN S, 1989, J CELL BIOL, V109, P697, DOI 10.1083/jcb.109.2.697; MEGIDISH T, 1989, NATURE, V342, P807, DOI 10.1038/342807a0; OBRIAN CA, 1984, BIOCHEM BIOPH RES CO, V124, P296, DOI 10.1016/0006-291X(84)90951-3; REGAZZI R, 1986, INT J CANCER, V37, P731, DOI 10.1002/ijc.2910370514; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373	12	82	83	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 5	1991	353	6339					78	80		10.1038/353078a0	http://dx.doi.org/10.1038/353078a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GD805	1881450				2022-12-24	WOS:A1991GD80500063
J	MANGO, SE; MAINE, EM; KIMBLE, J				MANGO, SE; MAINE, EM; KIMBLE, J			CARBOXY-TERMINAL TRUNCATION ACTIVATES GLP-1 PROTEIN TO SPECIFY VULVAR FATES IN CAENORHABDITIS-ELEGANS	NATURE			English	Article							C-ELEGANS; CELL-INTERACTIONS; GROWTH-FACTOR; LIN-12 GENE; MUTATIONS; NEMATODE; DROSOPHILA; INDUCTION; STABILITY; DECISION	THE glp-1 and lin-12 genes encode homologous transmembrane proteins 1,2 that may act as receptors for cell interactions during development 3,4. The glp-1 product is required for induction of germ-line proliferation and for embryogenesis 3,5. By contrast, lin-12 mediates somatic cell interactions, including those between the precursor cells that form the vulval hypodermis (VPCs) 6. Here we analyse an unusual allele of glp-1, glp-1(q35), which displays a semidominant multivulva phenotype (Muv), as well as the typical recessive, loss-of-function Glp phenotypes (sterility and embryonic lethality) 3. We find that the effects of glp-1(q35) on VPC development mimic those of dominant lin-12 mutations, even in the absence of lin-12 activity. The glp-1(q35) gene bears a nonsense mutation predicted to eliminate the 122 C-terminal amino acids, including a ProGluSerThr (PEST) sequence thought to destabilize proteins. We suggest that the carboxy terminus bears a negative regulatory domain which normally inactivates glp-1 in the VPCs. We propose that inappropriate glp-1(q35) activity can substitute for lin-12 to determine vulval fate, perhaps by driving the VPCs to proliferate.	UNIV WISCONSIN,MOLEC BIOL LAB,1525 LINDEN DR,MADISON,WI 53706; UNIV WISCONSIN,DEPT BIOCHEM,MADISON,WI 53706; SYRACUSE UNIV,DEPT BIOL,SYRACUSE,NY 13214	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Syracuse University				Mango, Susan/0000-0002-2146-3237				AUSTIN J, 1987, CELL, V51, P589, DOI 10.1016/0092-8674(87)90128-0; AUSTIN J, 1989, CELL, V58, P565, DOI 10.1016/0092-8674(89)90437-6; BRENNER S, 1974, GENETICS, V77, P71; GREENWALD I, 1985, CELL, V43, P583, DOI 10.1016/0092-8674(85)90230-2; GREENWALD I, 1990, NATURE, V346, P197, DOI 10.1038/346197a0; GREENWALD IS, 1983, CELL, V34, P435, DOI 10.1016/0092-8674(83)90377-X; HERMAN RK, 1990, NATURE, V348, P169, DOI 10.1038/348169a0; HODGKIN J, 1989, GENETICS, V123, P301; HORVITZ HR, 1991, NATURE, V351, P535, DOI 10.1038/351535a0; KELLERMAN KA, 1990, GENE DEV, V4, P1936, DOI 10.1101/gad.4.11.1936; KIMBLE J, 1981, DEV BIOL, V87, P286, DOI 10.1016/0012-1606(81)90152-4; LAMBIE EJ, 1991, DEVELOPMENT, V112, P231; LOSSON R, 1979, P NATL ACAD SCI USA, V76, P5134, DOI 10.1073/pnas.76.10.5134; MYERS RM, 1985, SCIENCE, V230, P1242, DOI 10.1126/science.4071043; PRIESS JR, 1987, CELL, V51, P610; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SEYDOUX G, 1989, CELL, V57, P1237, DOI 10.1016/0092-8674(89)90060-3; SEYDOUX G, 1990, CELL, V61, P939, DOI 10.1016/0092-8674(90)90060-R; SEYDOUX G, 1991, THESIS U PRINCETON; STANLEY ER, 1983, J CELL BIOCHEM, V21, P151, DOI 10.1002/jcb.240210206; STERNBERG PW, 1986, CELL, V44, P761, DOI 10.1016/0092-8674(86)90842-1; STERNBERG PW, 1989, CELL, V58, P679, DOI 10.1016/0092-8674(89)90103-7; STERNBERG PW, 1988, NATURE, V335, P551, DOI 10.1038/335551a0; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1980, DEV BIOL, V78, P577, DOI 10.1016/0012-1606(80)90353-X; YOCHEM J, 1989, CELL, V58, P553, DOI 10.1016/0092-8674(89)90436-4; YOCHEM J, 1988, NATURE, V335, P547, DOI 10.1038/335547a0	27	60	78	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 29	1991	352	6338					811	815		10.1038/352811a0	http://dx.doi.org/10.1038/352811a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC964	1881436	Green Submitted			2022-12-24	WOS:A1991GC96400063
J	BIRD, AG; GORE, SM; LEIGHBROWN, AJ; CARTER, DC				BIRD, AG; GORE, SM; LEIGHBROWN, AJ; CARTER, DC			ESCAPE FROM COLLECTIVE DENIAL - HIV TRANSMISSION DURING SURGERY	BRITISH MEDICAL JOURNAL			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; BLOOD; AIDS		MRC,BIOSTAT UNIT,CAMBRIDGE CB2 2BW,ENGLAND; UNIV EDINBURGH,DIV BIOL SCI B,EDINBURGH EH9 3JN,MIDLOTHIAN,SCOTLAND; ROYAL INFIRM,DEPT ENVIRONM,EDINBURGH EH3 9YW,MIDLOTHIAN,SCOTLAND	MRC Biostatistics Unit; University of Edinburgh; Royal Infirmary of Edinburgh	BIRD, AG (corresponding author), ROYAL INFIRM,HIV IMMUNOL UNIT,EDINBURGH EH3 9YW,MIDLOTHIAN,SCOTLAND.							ARMSTRONG FP, 1987, MIL MED, V152, P414; BALFE P, 1990, J VIROL, V64, P6221, DOI 10.1128/JVI.64.12.6221-6233.1990; BERGLUND O, 1988, AIDS, V2, P51, DOI 10.1097/00002030-198802000-00009; BERKELMAN R, 1990, HIV HLTH CARE WORKER; DECLERCQ A, 1991, BRIT MED J, V302, P51, DOI 10.1136/bmj.302.6767.51; GERBERDING JL, 1990, NEW ENGL J MED, V322, P1788, DOI 10.1056/NEJM199006213222506; GERBERT B, 1991, JAMA-J AM MED ASSOC, V265, P1845, DOI 10.1001/jama.265.14.1845; HUSSAIN SA, 1988, BRIT J SURG, V75, P314, DOI 10.1002/bjs.1800750407; LANGE JMA, 1990, NEW ENGL J MED, V322, P1375, DOI 10.1056/NEJM199005103221907; LOT F, 1990, BEH, V49, P207; MANNING S, 1991, J MED DEF UNION, V2, P43; MARCUS R, 1988, NEW ENGL J MED, V319, P1118, DOI 10.1056/NEJM198810273191703; MISHU B, 1990, JAMA-J AM MED ASSOC, V264, P467, DOI 10.1001/jama.264.4.467; PORTER JD, 1990, LANCET, V335, P113, DOI 10.1016/0140-6736(90)90582-P; SACKS JJ, 1985, NEW ENGL J MED, V313, P1017, DOI 10.1056/NEJM198510173131610; SIMMONDS P, 1990, AIDS S1, V4, P577; WELCH J, 1989, LANCET, V1, P205; 1988, AIDS HIV INFECTED HE; 1991, JAMA-J AM MED ASSOC, V265, P1872; 1989, MMWR S56, V1, P3; 1991, MMWR, V40, P377; 1991, MMWR, V40, P21	22	16	16	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 10	1991	303	6798					351	352		10.1136/bmj.303.6798.351	http://dx.doi.org/10.1136/bmj.303.6798.351			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA606	1912780	Green Published, Bronze			2022-12-24	WOS:A1991GA60600026
J	DYNLACHT, BD; HOEY, T; TJIAN, R				DYNLACHT, BD; HOEY, T; TJIAN, R			ISOLATION OF COACTIVATORS ASSOCIATED WITH THE TATA-BINDING PROTEIN THAT MEDIATE TRANSCRIPTIONAL ACTIVATION	CELL			English	Article							RNA POLYMERASE-II; ANTENNAPEDIA GENE-COMPLEX; FUNCTIONAL-ANALYSIS; PREINITIATION COMPLEX; PROMOTER INTERACTIONS; DROSOPHILA; BOX; YEAST; INITIATION; DOMAINS	A key step in the regulation of transcription involves interactions between promoter-selective factors and various components of the transcriptional apparatus. Here we report the requirements for transcriptional activation directed by NTF-1, a developmentally regulated transcription factor in Drosophila. Reconstituted transcription with fractionated Drosophila basal factors reveals that activation by NTF-1 requires factors present in the endogenous TFIID fraction that are distinct from the purified TATA-binding protein (TBP). Glycerol gradient sedimentation and immunoprecipitation analyses indicate that TFIID is a multiprotein complex containing TBP and at least six tightly bound TBP-associated factors (TAFs). Preparations of TBP lacking TAFs after fractionation with denaturants no longer support activation by NTF-1 but retain basal level activity. Addition of immunopurified and renatured TAFs to free TBP restores the ability of NTF-1 to activate transcription without influencing basal transcription. These results suggest that one or more of the TAF polypeptides confer coactivator function.			DYNLACHT, BD (corresponding author), UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720, USA.							BERGER SL, 1990, CELL, V61, P1199, DOI 10.1016/0092-8674(90)90684-7; BIGGIN MD, 1988, CELL, V53, P699, DOI 10.1016/0092-8674(88)90088-8; BRAY SJ, 1989, GENE DEV, V3, P1130, DOI 10.1101/gad.3.8.1130; BURATOWSKI S, 1988, NATURE, V334, P37, DOI 10.1038/334037a0; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; CROSTON GE, 1991, SCIENCE, V251, P643, DOI 10.1126/science.1899487; DREIVER W, 1989, NATURE, V342, P149; DYNLACHT BD, 1989, GENE DEV, V3, P1677, DOI 10.1101/gad.3.11.1677; FLANAGAN PM, 1991, NATURE, V350, P436, DOI 10.1038/350436a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAN KH, 1989, CELL, V56, P573, DOI 10.1016/0092-8674(89)90580-1; HEBERLEIN U, 1988, NATURE, V331, P410, DOI 10.1038/331410a0; HOEY T, 1990, CELL, V61, P1179, DOI 10.1016/0092-8674(90)90682-5; HOEY T, 1988, NATURE, V332, P858, DOI 10.1038/332858a0; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; HORIKOSHI M, 1988, CELL, V54, P665, DOI 10.1016/S0092-8674(88)80011-4; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; HORIKOSHI M, 1989, NATURE, V341, P299, DOI 10.1038/341299a0; KADONAGA JT, 1990, J BIOL CHEM, V265, P2624; KELLEHER RJ, 1990, CELL, V61, P1209, DOI 10.1016/0092-8674(90)90685-8; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; PARKER CS, 1984, CELL, V36, P357, DOI 10.1016/0092-8674(84)90229-0; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; REINBERG D, 1987, J BIOL CHEM, V262, P3310; REINBERG D, 1987, J BIOL CHEM, V262, P3322; RUSHLOW C, 1987, GENE DEV, V1, P1268, DOI 10.1101/gad.1.10.1268; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCHMIDT MC, 1989, P NATL ACAD SCI USA, V86, P7785, DOI 10.1073/pnas.86.20.7785; SOELLER WC, 1988, GENE DEV, V2, P68, DOI 10.1101/gad.2.1.68; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; VANDYKE MW, 1988, SCIENCE, V241, P1335, DOI 10.1126/science.3413495; WAKIMOTO BT, 1984, DEV BIOL, V102, P147, DOI 10.1016/0012-1606(84)90182-9; WAMPLER SL, 1990, J BIOL CHEM, V265, P21223	40	606	622	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 9	1991	66	3					563	576		10.1016/0092-8674(81)90019-2	http://dx.doi.org/10.1016/0092-8674(81)90019-2			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GA941	1907890				2022-12-24	WOS:A1991GA94100017
J	WEEKS, KM; CROTHERS, DM				WEEKS, KM; CROTHERS, DM			RNA RECOGNITION BY TAT-DERIVED PEPTIDES - INTERACTION IN THE MAJOR GROOVE	CELL			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; SEQUENCE-SPECIFIC RECOGNITION; HIV-1 TAT; TRANS-ACTIVATION; MESSENGER-RNA; RESPONSIVE SEQUENCE; GENE-EXPRESSION; LOOP SEQUENCE; NUCLEIC-ACIDS; NASCENT RNA	Replication of human immunodeficiency virus requires binding of the viral Tat protein to its RNA target sequence TAR; peptides derived from Tat bind to a TAR "contact site" spanning 5 bp and a trinucleotide pyrimidine bulge. We find that high affinity binding requires a U residue in the bulge loop and 2 specific adjacent base pairs. Other bulged RNAs bind in a lower affinity nonspecific manner; sequence-specific binding requires a bulge loop of more than 1 nucleotide. Reaction with diethyl pyrocarbonate indicates that one effect of the bulge is to make the otherwise deep and narrow RNA major groove accessible. A model consistent with these data involves local distortion of A-form geometry at the bulge, which bends the helix and permits protein binding and interactive access in the RNA major groove.			WEEKS, KM (corresponding author), YALE UNIV,DEPT CHEM,NEW HAVEN,CT 06511, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021966, R37GM021966, P01GM039546] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 39546, GM 21966] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNOTT S, 1972, BIOCHEM BIOPH RES CO, V48, P1392, DOI 10.1016/0006-291X(72)90867-4; BERKHOUT B, 1989, CELL, V59, P273, DOI 10.1016/0092-8674(89)90289-4; BERKHOUT B, 1990, CELL, V62, P757, DOI 10.1016/0092-8674(90)90120-4; BHATTACHARYYA A, 1990, NATURE, V343, P484, DOI 10.1038/343484a0; CALNAN BJ, 1991, SCIENCE, V252, P1167, DOI 10.1126/science.252.5009.1167; CALNAN BJ, 1991, GENE DEV, V5, P201, DOI 10.1101/gad.5.2.201; CORDINGLEY MG, 1990, P NATL ACAD SCI USA, V87, P8985, DOI 10.1073/pnas.87.22.8985; CULLEN BR, 1989, CELL, V58, P423, DOI 10.1016/0092-8674(89)90420-0; DINGWALL C, 1989, P NATL ACAD SCI USA, V86, P6925, DOI 10.1073/pnas.86.18.6925; DINGWALL C, 1990, EMBO J, V9, P4145, DOI 10.1002/j.1460-2075.1990.tb07637.x; DONISKELLER H, 1977, NUCLEIC ACIDS RES, V4, P2527, DOI 10.1093/nar/4.8.2527; Endo S, 1989, Virus Genes, V3, P99; FAUS I, 1990, J MOL BIOL, V212, P53, DOI 10.1016/0022-2836(90)90304-5; FENG S, 1988, NATURE, V334, P165, DOI 10.1038/334165a0; FRANKEL AD, 1988, SCIENCE, V240, P70, DOI 10.1126/science.2832944; FRIED MG, 1984, J MOL BIOL, V172, P263, DOI 10.1016/S0022-2836(84)80026-1; HAUBER J, 1987, P NATL ACAD SCI USA, V84, P6364, DOI 10.1073/pnas.84.18.6364; HOLBROOK SR, 1983, BIOPOLYMERS, V22, P1145, DOI 10.1002/bip.360220410; JAEGER JA, 1990, METHODS ENZYMOL, V183, P281; JAKOBOVITS A, 1988, MOL CELL BIOL, V8, P2555, DOI 10.1128/MCB.8.6.2555; JEYAPAUL J, 1990, P NATL ACAD SCI USA, V87, P7030, DOI 10.1073/pnas.87.18.7030; KJEMS J, 1991, P NATL ACAD SCI USA, V88, P683, DOI 10.1073/pnas.88.3.683; LAZINSKI D, 1989, CELL, V59, P207, DOI 10.1016/0092-8674(89)90882-9; MARCINIAK RA, 1990, P NATL ACAD SCI USA, V87, P3624, DOI 10.1073/pnas.87.9.3624; MARCINIAK RA, 1990, CELL, V63, P791, DOI 10.1016/0092-8674(90)90145-5; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; MOHAMADI F, 1990, J COMPUT CHEM, V11, P440, DOI 10.1002/jcc.540110405; MOUGEL M, 1987, J MOL BIOL, V198, P91, DOI 10.1016/0022-2836(87)90460-8; MUESING MA, 1987, CELL, V48, P691, DOI 10.1016/0092-8674(87)90247-9; MYERS G, 1990, HUMAN RETROVIRUSES A; PEATTIE DA, 1980, P NATL ACAD SCI-BIOL, V77, P4679, DOI 10.1073/pnas.77.8.4679; PEATTIE DA, 1979, P NATL ACAD SCI USA, V76, P1760, DOI 10.1073/pnas.76.4.1760; PUGLISI JD, 1990, BIOCHEMISTRY-US, V29, P4215, DOI 10.1021/bi00469a026; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; ROY S, 1990, GENE DEV, V4, P1365, DOI 10.1101/gad.4.8.1365; ROY S, 1990, J VIROL, V64, P1402, DOI 10.1128/JVI.64.3.1402-1406.1990; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; SELBY MJ, 1990, CELL, V62, P769, DOI 10.1016/0092-8674(90)90121-T; SHARP PA, 1989, CELL, V59, P229, DOI 10.1016/0092-8674(89)90279-1; SOUTHGATE C, 1990, NATURE, V345, P640, DOI 10.1038/345640a0; SUBRAMANIAN T, 1990, VIROLOGY, V176, P178, DOI 10.1016/0042-6822(90)90242-J; SUSSMAN JL, 1976, SCIENCE, V192, P853, DOI 10.1126/science.775636; TANG RS, 1990, BIOCHEMISTRY-US, V29, P5232, DOI 10.1021/bi00474a003; VANSTOLK BJ, 1984, J MOL BIOL, V180, P151, DOI 10.1016/0022-2836(84)90435-2; VARANI G, 1989, BIOCHEMISTRY-US, V28, P7760, DOI 10.1021/bi00445a036; WEEKS KM, 1990, SCIENCE, V249, P1281, DOI 10.1126/science.2205002; WEINER SJ, 1986, J COMPUT CHEM, V7, P230, DOI 10.1002/jcc.540070216; WITHERELL GW, 1989, BIOCHEMISTRY-US, V28, P71, DOI 10.1021/bi00427a011	48	337	345	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 9	1991	66	3					577	588		10.1016/0092-8674(81)90020-9	http://dx.doi.org/10.1016/0092-8674(81)90020-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GA941	1907891				2022-12-24	WOS:A1991GA94100018
J	FISHER, BM; HEATLEY, C; SMALL, M				FISHER, BM; HEATLEY, C; SMALL, M			REUSE OF DISPOSABLE PLASTIC INSULIN SYRINGES	BRITISH MEDICAL JOURNAL			English	Article									GARTNAVEL ROYAL HOSP,DIABET CLIN,GLASGOW G12 0YN,SCOTLAND	Gartnavel Royal Hospital								ALEXANDER WD, 1988, BRIT MED J, V296, P877, DOI 10.1136/bmj.296.6626.877; BLOOM A, 1985, BRIT MED J, V290, P727, DOI 10.1136/bmj.290.6470.727; HEATLEY C, 1990, PRACTICAL DIABETES, V7, P33; LESTER E, 1984, BRIT MED J, V289, P1498, DOI 10.1136/bmj.289.6457.1498-a; 1983, BMJ, V286, P369	5	0	0	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 3	1991	303	6797					286	287		10.1136/bmj.303.6797.286	http://dx.doi.org/10.1136/bmj.303.6797.286			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FZ721	1888929	Green Published, Bronze			2022-12-24	WOS:A1991FZ72100021
J	KRAPF, R; BEELER, I; HERTNER, D; HULTER, HN				KRAPF, R; BEELER, I; HERTNER, D; HULTER, HN			CHRONIC RESPIRATORY ALKALOSIS - THE EFFECT OF SUSTAINED HYPERVENTILATION ON RENAL REGULATION OF ACID-BASE-EQUILIBRIUM	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHRONIC HYPOCAPNIA; RADIOIMMUNOASSAY; PLASMA; SERUM; H+	Background. In normal subjects, chronic hyperventilation lowers plasma bicarbonate concentration, primarily by inhibiting the urinary excretion of net acid. The quantitative relation between reduced arterial carbon dioxide tension (PaCO2) and the plasma bicarbonate concentration in the chronic steady state has not been studied in humans, however, and the laboratory criteria for the diagnosis of chronic respiratory alkalosis therefore remain undefined. We wished to provide such reference data for clinical use. Moreover, because chronic hyperventilation paradoxically lowers blood pH still further in dogs with metabolic acidosis, we desired to study the effect of chronic hypocapnia on the plasma bicarbonate concentration (and blood pH) in normal human subjects in whom acidosis had been induced with ammonium chloride. Methods. Under metabolic-balance conditions, we used altitude-induced hypobaric hypoxia to produce chronic hypocapnia in nine normal young men, five of whom received ammonium chloride daily to cause metabolic acidosis (the mean [+/- SE] steady-state plasma bicarbonate level in these five was 12.0 +/- 0.5 mmol per liter). Results. For each decrease of 1 mm Hg (0.13 kPa) in the PaCO2, the plasma bicarbonate concentration decreased by 0.41 mmol per liter in the subjects who started with a normal plasma bicarbonate concentration and by 0.42 mmol per liter in the subjects with acidosis. In contrast to the findings in previous studies of dogs, hypocapnia increased blood pH similarly in both groups; the blood hydrogen ion concentration decreased by about 0.4 nmol per liter for every decrease of 1 mm Hg (0.13 kPa) in PaCO2. Conclusions. These results provide reference data for the diagnosis of chronic respiratory alkalosis in humans. Although chronic hypocapnia decreased plasma bicarbonate levels similarly in normal subjects with acidosis and without acidosis, the percent reduction in PaCO2 was always greater than the corresponding percent reduction in the plasma bicarbonate concentration. Therefore, as was not true of the response in dogs, the subjects' blood pH always increased with hyperventilation, regardless of the initial plasma bicarbonate concentration.	UNIV CALIF SAN FRANCISCO,SAN FRANCISCO GEN HOSP,DEPT MED,DIV NEPHROL,SAN FRANCISCO,CA 94110	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco	KRAPF, R (corresponding author), INSELSPITAL BERN,DEPT MED,CH-3010 BERN,SWITZERLAND.							ADROGUE HJ, 1981, AM J MED, V71, P456, DOI 10.1016/0002-9343(81)90182-0; ALTMAN PL, 1971, RESP CIRC, P12; ARBUS GS, 1969, NEW ENGL J MED, V280, P117, DOI 10.1056/NEJM196901162800301; BARKER ES, 1957, J CLIN INVEST, V36, P515, DOI 10.1172/JCI103449; BRACKETT NC, 1965, NEW ENGL J MED, V272, P6, DOI 10.1056/NEJM196501072720102; BRACKETT NC, 1969, NEW ENGL J MED, V280, P124, DOI 10.1056/NEJM196901162800302; BRAZEAU P, 1953, AM J PHYSIOL, V175, P33, DOI 10.1152/ajplegacy.1953.175.1.33; BURNELL JM, 1956, J CLIN INVEST, V35, P935, DOI 10.1172/JCI103352; COHEN JJ, 1976, J CLIN INVEST, V57, P1483, DOI 10.1172/JCI108418; COTLOVE E, 1961, CLIN CHEM, V7, P285; DEMPSEY JA, 1972, RESP PHYSIOL, V16, P213, DOI 10.1016/0034-5687(72)90052-7; DEMPSEY JA, 1974, J CLIN INVEST, V53, P1001; DICKINSON JG, 1987, BRIT MED J, V295, P1161, DOI 10.1136/bmj.295.6607.1161; DOUGLAS C. G., 1933, JOUR PHYSIOL, V78, P404, DOI 10.1113/jphysiol.1933.sp003012; DUGGAN J, 1982, CLIN CHEM, V28, P1407; FISHMAN AP, 1988, PULMONARY DISEASES D, V3; FORSTER HV, 1975, J APPL PHYSIOL, V38, P1067, DOI 10.1152/jappl.1975.38.6.1067; FORSTER HV, 1972, J APPL PHYSIOL, V32, P134, DOI 10.1152/jappl.1972.32.1.134; FORWAND SA, 1968, NEW ENGL J MED, V279, P839, DOI 10.1056/NEJM196810172791601; FOSTER LB, 1974, CLIN CHEM, V20, P365; GENNARI FJ, 1972, J CLIN INVEST, V51, P1722, DOI 10.1172/JCI106973; GIEBISCH G, 1955, J CLIN INVEST, V34, P231, DOI 10.1172/JCI103076; GLEDHILL N, 1975, KIDNEY INT, V8, P376, DOI 10.1038/ki.1975.130; GRIMBERT F, 1977, B EUR PHYSIOPATH RES, V13, P659; HELGER R, 1974, Z KLIN CHEM KLIN BIO, V12, P344; LOGSDON EE, 1960, ANN NY ACAD SCI, V87, P801, DOI 10.1111/j.1749-6632.1960.tb23237.x; MADIAS NE, 1977, J CLIN INVEST, V60, P1393, DOI 10.1172/JCI108900; MOSTELLAR ME, 1964, J CLIN INVEST, V43, P138, DOI 10.1172/JCI104888; OGIHARA T, 1977, J CLIN ENDOCR METAB, V45, P726, DOI 10.1210/jcem-45-4-726; RELMAN AS, 1953, J CLIN INVEST, V32, P972, DOI 10.1172/JCI102823; ROSENTHAL TB, 1948, J BIOL CHEM, V173, P25; SCHAMBELAN M, 1987, AM J PHYSIOL, V252, pE454, DOI 10.1152/ajpendo.1987.252.4.E454; SENDROY J, 1932, J BIOL CHEM, V106, P463; SEVERINGHAUS JW, 1956, J APPL PHYSIOL, V9, P197, DOI 10.1152/jappl.1956.9.2.197; SEVERINGHAUS JW, 1963, J APPL PHYSIOL, V18, P1155, DOI 10.1152/jappl.1963.18.6.1155; YOUNG DB, 1988, AM J PHYSIOL, V255, pF811, DOI 10.1152/ajprenal.1988.255.5.F811	36	94	95	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 16	1991	324	20					1394	1401		10.1056/NEJM199105163242003	http://dx.doi.org/10.1056/NEJM199105163242003			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL125	1902283				2022-12-24	WOS:A1991FL12500003
J	ADELSTEIN, S; PRITCHARDBRISCOE, H; ANDERSON, TA; CROSBIE, J; GAMMON, G; LOBLAY, RH; BASTEN, A; GOODNOW, CC				ADELSTEIN, S; PRITCHARDBRISCOE, H; ANDERSON, TA; CROSBIE, J; GAMMON, G; LOBLAY, RH; BASTEN, A; GOODNOW, CC			INDUCTION OF SELF-TOLERANCE IN T-CELLS BUT NOT B-CELLS OF TRANSGENIC MICE EXPRESSING LITTLE SELF ANTIGEN	SCIENCE			English	Article							IMMUNOLOGICAL-TOLERANCE; LUPUS-ERYTHEMATOSUS; CLONAL ANALYSIS; LYMPHOCYTES-B; AUTOANTIBODIES; RECEPTOR; GENES; UNRESPONSIVENESS; DETERMINANT; SPECIFICITY	Self-tolerance to a transgene-encoded protein, hen egg lysozyme, was examined in the T and B cell repertoires of a series of lines of transgenic mice that expressed different serum concentrations of soluble lysozyme. T cells were tolerant in all lines in which lysozyme was expressed irrespective of the antigen concentration, whereas B cell tolerance did not occur when the serum lysozyme concentration was less than 1.5 nanograms per milliliter (0.1 nM). Induction of elevated transgene expression could restore B cell tolerance. These findings support the hypothesis that autoimmune disease may in some instances arise through a bypass of T cell tolerance.	UNIV SYDNEY, CENTENARY INST CANC MED & CELL BIOL, SYDNEY, NSW 2006, AUSTRALIA; UNIV CALIF LOS ANGELES, DEPT MICROBIOL, LOS ANGELES, CA 90024 USA	University of Sydney; Centenary Institute; University of California System; University of California Los Angeles			Goodnow, Christopher C/V-8108-2018; Adelstein, Stephen/I-7936-2016	Goodnow, Christopher C/0000-0001-5296-6155; Adelstein, Stephen/0000-0001-7221-6298				ADAMS TE, 1987, NATURE, V325, P223, DOI 10.1038/325223a0; ARNOLD B, 1990, IMMUNOL TODAY, V11, P69, DOI 10.1016/0167-5699(90)90026-6; BACCALA R, 1989, P NATL ACAD SCI USA, V86, P4624, DOI 10.1073/pnas.86.12.4624; Burnet F., 1959, CLONAL SELECTION THE, DOI DOI 10.5962/BHL.TITLE.8281; CASALI P, 1989, ANNU REV IMMUNOL, V7, P513, DOI 10.1146/annurev.immunol.7.1.513; CHILLER JM, 1971, SCIENCE, V171, P813, DOI 10.1126/science.171.3973.813; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; Dresser D W, 1968, Adv Immunol, V8, P129, DOI 10.1016/S0065-2776(08)60466-6; GAMMON G, 1987, IMMUNOL REV, V98, P53; GOODNOW CC, 1989, COLD SPRING HARB SYM, V54, P907, DOI 10.1101/SQB.1989.054.01.106; GOODNOW CC, 1989, NATURE, V342, P385, DOI 10.1038/342385a0; GOODNOW CC, 1988, NATURE, V334, P676, DOI 10.1038/334676a0; HANAHAN D, 1989, SCIENCE, V246, P1265, DOI 10.1126/science.2686032; HARRIS DE, 1982, J EXP MED, V156, P567, DOI 10.1084/jem.156.2.567; IVERSON GM, 1972, EUR J IMMUNOL, V2, P195, DOI 10.1002/eji.1830020302; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KAPPLER JW, 1988, NATURE, V332, P35, DOI 10.1038/332035a0; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; LEDERBERG J, 1959, SCIENCE, V129, P1649, DOI 10.1126/science.129.3364.1649; LINDSTROM J, 1985, ANNU REV IMMUNOL, V3, P109; LORENZ RG, 1989, NATURE, V337, P560, DOI 10.1038/337560a0; MACDONALD HR, 1988, NATURE, V332, P40, DOI 10.1038/332040a0; MCHEYZERWILLIAMS MG, 1988, J IMMUNOL, V141, P4118; MILLER JFAP, 1989, IMMUNOL REV, V107, P109, DOI 10.1111/j.1600-065X.1989.tb00005.x; NAPARSTEK Y, 1986, J EXP MED, V164, P614, DOI 10.1084/jem.164.2.614; NELL LJ, 1989, J IMMUNOL, V142, P3063; NEMAZEE DA, 1989, NATURE, V337, P562, DOI 10.1038/337562a0; NOSSAL GJV, 1983, ANNU REV IMMUNOL, V1, P33, DOI 10.1146/annurev.iy.01.040183.000341; PIERRES M, 1981, IMMUNOGENETICS, V14, P481, DOI 10.1007/BF00350120; RAJEWSKY K, 1974, EUR J IMMUNOL, V4, P120, DOI 10.1002/eji.1830040211; RAMSDELL F, 1989, SCIENCE, V246, P1038, DOI 10.1126/science.2511629; REUTER R, 1986, P NATL ACAD SCI USA, V83, P8689, DOI 10.1073/pnas.83.22.8689; SHA WC, 1988, NATURE, V336, P73, DOI 10.1038/336073a0; Siskind G W, 1969, Adv Immunol, V10, P1, DOI 10.1016/S0065-2776(08)60414-9; SMITH RT, 1961, ADV IMMUNOL, V1, P67, DOI 10.1016/S0065-2776(08)60763-4; TERNYNCK T, 1986, IMMUNOL REV, V94, P99; UNANUE ER, 1987, SCIENCE, V236, P551, DOI 10.1126/science.2437650; Weigle W O, 1973, Adv Immunol, V16, P61, DOI 10.1016/S0065-2776(08)60296-5; Weigle W O, 1980, Adv Immunol, V30, P159; WHITELEY PJ, 1990, J IMMUNOL, V145, P1376; ZINKERNAGEL RM, 1990, NATURE, V345, P68, DOI 10.1038/345068a0	41	199	201	1	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 8	1991	251	4998					1223	1225		10.1126/science.1900950	http://dx.doi.org/10.1126/science.1900950			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FA691	1900950				2022-12-24	WOS:A1991FA69100038
J	MANASCO, PK; GIRTON, ME; DIGGS, RL; DOPPMAN, JL; FEUILLAN, PP; BARNES, KM; CUTLER, GB; LORIAUX, DL; ALBERTSON, BD				MANASCO, PK; GIRTON, ME; DIGGS, RL; DOPPMAN, JL; FEUILLAN, PP; BARNES, KM; CUTLER, GB; LORIAUX, DL; ALBERTSON, BD			A NOVEL TESTIS-STIMULATING FACTOR IN FAMILIAL MALE PRECOCIOUS PUBERTY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LUTEINIZING-HORMONE; SEXUAL PRECOCITY; LEYDIG; RADIOIMMUNOASSAY; GONADOTROPIN; TESTOSTERONE; THERAPY	Background. Familial male precocious puberty is a gonadotropin-independent form of precocious puberty that occurs only in males. The cause of the disorder is unknown. To examine the hypothesis that the plasma of boys with familial male precocious puberty contains a novel stimulator of testicular testosterone production, we developed a bioassay using adult male cynomolgus monkeys. Methods. We collected plasma from 12 boys with familial male precocious puberty, 7 normal prepubertal boys of similar ages and with similar plasma gonadotropin levels, and 1 boy with hypogonadotropic hypogonadism and infused it into the testicular artery of adult male cynomolgus monkeys that had been pretreated with gonadotropin-releasing-hormone antaganist to inhibit the endogenous secretion of gonadotropins. Testicular venous effluent was collected at 15-minute intervals for 3 to 5 hours for the measurement of testosterone. Results. The mean (+/- SE) peak testosterone response, as compared with base line, was significantly greater in the monkeys infused with plasma from the 12 boys with familial male precocious puberty than in the monkeys infused with plasma from the 7 normal prepubertal boys and the boy with hypogonadotropic hypogonadism (385 +/- 51 vs. 184 +/- 25 percent, P < 0.005) in the three-hour studies. Plasma from 92 percent of the boys with familial male precocious puberty and 12.5 percent of the normal prepubertal boys stimulated a response greater than 195 percent of base-line values. In the animals studied for five hours after receiving a second dose of antagonist, the mean peak testosterone response, as compared with base line, was significantly greater in the monkeys infused with plasma from three boys with familial male precocious puberty than in the monkeys infused with plasma from three normal prepubertal boys (363 +/- 81 vs. 115 +/- 6 percent, P < 0.01). The mean area under the testosterone-response curve wa significantly larger in the monkeys infused with plasma from the boys with familial male precocious puberty in the five-hour studies (154 +/- 34 vs. -58 +/- 10 percent, P < 0.005), but not in the three-hour studies. Conclusions. These findings support the presence of a circulating testis-stimulating factor in the plasma of boys with familial male precocious puberty. The production of such a factor would explain the biologic nature of the disorder.	NICHHD,DEV ENDOCRINOL BRANCH,BLDG 10,RM 10N262,BETHESDA,MD 20892; NIH,CTR CLIN,DEPT RADIOL,BETHESDA,MD 20892; GEORGETOWN UNIV HOSP,DEPT RADIOL,WASHINGTON,DC 20007	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); Georgetown University								ADAMS LA, 1986, J CLIN ENDOCR METAB, V62, P58, DOI 10.1210/jcem-62-1-58; DUFAU ML, 1974, J CLIN ENDOCR METAB, V39, P610, DOI 10.1210/jcem-39-3-610; Greulich WW, 1959, RADIOGRAPHIC ATLAS S; HOLLAND F J, 1988, Pediatric Research, V23, p278A; LAUE L, 1989, NEW ENGL J MED, V320, P496, DOI 10.1056/NEJM198902233200805; NIESCHLAG E, 1972, Z KLIN CHEM KLIN BIO, V10, P164; NISWENDER GD, 1971, ENDOCRINOLOGY, V88, P1327, DOI 10.1210/endo-88-6-1327; ODELL WD, 1967, J LAB CLIN MED, V70, P973; ODELL WD, 1967, J CLIN INVEST, V46, P248, DOI 10.1172/JCI105527; PESCOVITZ OH, 1986, J PEDIATR-US, V108, P47, DOI 10.1016/S0022-3476(86)80767-3; REITER EO, 1984, NEW ENGL J MED, V311, P515, DOI 10.1056/NEJM198408233110807; ROSENTHAL SM, 1983, J CLIN ENDOCR METAB, V57, P571, DOI 10.1210/jcem-57-3-571; SCHEDEWIE HK, 1981, J CLIN ENDOCR METAB, V52, P271, DOI 10.1210/jcem-52-2-271; WIERMAN ME, 1985, NEW ENGL J MED, V312, P65, DOI 10.1056/NEJM198501103120201	14	20	20	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 24	1991	324	4					227	231		10.1056/NEJM199101243240404	http://dx.doi.org/10.1056/NEJM199101243240404			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EU022	1898671				2022-12-24	WOS:A1991EU02200004
J	KRASNOW, MA; CUMBERLEDGE, S; MANNING, G; HERZENBERG, LA; NOLAN, GP				KRASNOW, MA; CUMBERLEDGE, S; MANNING, G; HERZENBERG, LA; NOLAN, GP			WHOLE ANIMAL-CELL SORTING OF DROSOPHILA EMBRYOS	SCIENCE			English	Article							TRANSCRIPTIONAL ACTIVATION; FUSHI-TARAZU; EXPRESSION; PROTEINS; GENE; MELANOGASTER; ELEMENTS; CULTURES; INSITU; PCR	Use of primary culture cells has been limited by the inability to purify most types of cells, particularly cells from early developmental stages. In whole animal cell sorting (WACS), live cells derived from animals harboring a lacZ transgene are purified according to their level of beta-galactosidase expression with a fluorogenic beta-galactosidase substrate and fluorescence-activated cell sorting. With WACS, incipient posterior compartment cells that express the engrailed gene were purified from early Drosophila embryos. Neuronal precursor cells were also purified, and they differentiated into neurons with high efficiency in culture. Because there are many lacZ strains, it may be possible to purify most types of Drosophila cells. The same approach is also applicable to other organisms for which germ-line transformation is possible.	STANFORD UNIV, DEPT GENET, STANFORD, CA 94305 USA	Stanford University	KRASNOW, MA (corresponding author), STANFORD UNIV, DEPT BIOCHEM, STANFORD, CA 94305 USA.		Manning, Gerard/C-8308-2009; Nolan, Garry/AAE-7903-2019	Nolan, Garry/0000-0002-8862-9043; Manning, Gerard/0000-0002-5087-9151	NATIONAL CANCER INSTITUTE [T32CA009151] Funding Source: NIH RePORTER; NCI NIH HHS [CA09151] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBERTI S, 1987, CYTOMETRY, V8, P114, DOI 10.1002/cyto.990080203; ALLEN ND, 1988, NATURE, V333, P852, DOI 10.1038/333852a0; ARIAS AM, 1988, DEVELOPMENT, V103, P157; ASHBURNER M, 1989, DROSOPHILA LABORATOR; BELLEN HJ, 1989, GENE DEV, V3, P1288, DOI 10.1101/gad.3.9.1288; BELYAVSKY A, 1989, NUCLEIC ACIDS RES, V17, P2919, DOI 10.1093/nar/17.8.2919; BIER E, 1989, GENE DEV, V3, P1273, DOI 10.1101/gad.3.9.1273; CHEN CH, COMMUNICATION; CUMBERLEDGE S, UNPUB; DAVIDSON EH, 1990, DEVELOPMENT, V108, P365; DINARDO S, 1988, NATURE, V332, P604, DOI 10.1038/332604a0; FEDOROFF S, 1977, CELL TISSUE ORGAN CU; FIRE A, 1986, EMBO J, V5, P2673, DOI 10.1002/j.1460-2075.1986.tb04550.x; FJOSE A, 1985, NATURE, V313, P284, DOI 10.1038/313284a0; FURST A, 1985, DEV BIOL, V109, P184, DOI 10.1016/0012-1606(85)90359-8; FURST A, 1985, DEV BIOL, V112, P467, DOI 10.1016/0012-1606(85)90419-1; GURDON JB, 1987, DEVELOPMENT, V99, P285; HIROMI Y, 1985, CELL, V43, P603, DOI 10.1016/0092-8674(85)90232-6; HIROMI Y, COMMUNICATION; JACOBS JR, 1989, J NEUROSCI, V9, P2412; JAN LY, 1982, P NATL ACAD SCI-BIOL, V79, P2700, DOI 10.1073/pnas.79.8.2700; KOELLE M, COMMUNICATION; KORNBERG T, 1985, CELL, V40, P45, DOI 10.1016/0092-8674(85)90307-1; KRASNOW MA, 1989, CELL, V57, P1031, DOI 10.1016/0092-8674(89)90341-3; KRASNOW MA, UNPUB; MOORE W, 1986, HDB EXPT IMMUNOLOGY, V1; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; NOLAN GP, 1988, P NATL ACAD SCI USA, V85, P2603, DOI 10.1073/pnas.85.8.2603; OKANE CJ, 1987, P NATL ACAD SCI USA, V84, P9123, DOI 10.1073/pnas.84.24.9123; PARKS DR, 1989, FUNDAMENTAL IMMUNOLO, P781; PARKS DR, 1986, HDB EXPT IMMUNOLOGY, V1; PATEL NH, 1989, CELL, V58, P955, DOI 10.1016/0092-8674(89)90947-1; Sang JH, 1981, ADV CELL CULT, V1, P125; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; STORTI RV, 1978, CELL, V13, P589, DOI 10.1016/0092-8674(78)90210-6; WINSLOW GM, 1989, CELL, V57, P1017, DOI 10.1016/0092-8674(89)90340-1	36	37	43	1	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 4	1991	251	4989					81	85		10.1126/science.1898782	http://dx.doi.org/10.1126/science.1898782			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EQ603	1898782				2022-12-24	WOS:A1991EQ60300032
J	MCMURRY, MP; CERQUEIRA, MT; CONNOR, SL; CONNOR, WE				MCMURRY, MP; CERQUEIRA, MT; CONNOR, SL; CONNOR, WE			CHANGES IN LIPID AND LIPOPROTEIN LEVELS AND BODY-WEIGHT IN TARAHUMARA INDIANS AFTER CONSUMPTION OF AN AFFLUENT DIET	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PIMA-INDIANS; HDL CHOLESTEROL; PLASMA-LIPIDS; MEXICO; COUNTRIES; DISEASE; WOMEN; FOOD; FAT	Background. Major new public health problems occur in developing countries as they become more affluent and change their traditional dietary patterns. To study this phenomenon in microcosm, we substituted an "affluent" diet for the traditional diet of a group of Tarahumara Indians, a Mexican people known to consume a low-fat, high-fiber diet and to have a very low incidence of risk factors for coronary heart disease. Methods. Thirteen Tarahumara Indians (five women and eight men [including one adolescent]) consumed their traditional diet (2700 kcal per day) for one week, and were then fed a diet typical of affluent societies, which contained excessive calories (41 00 kcal per day), total fat, saturated fat, and cholesterol, for five weeks. Results. After five weeks of consuming the affluent diet, the subjects' mean (+/- SE) plasma cholesterol level increased by 31 percent, from 121 +/- 5 to 159 +/- 6 mg per deciliter (3.13 +/- 0.13 to 4.11 +/- 0.16 mmol per liter, P < 0.001). The increase in the plasma cholesterol level was primarily in the low-density lipoprotein (LDL) fraction, which rose 39 percent, from 72 +/- 3 to 100 +/- 4 mg per deciliter (1.86 +/- 0.08 to 2.59 +/- 0.10 mmol per liter, P < 0.001). High-density lipoprotein (HDL) cholesterol, usually low in this population, increased by 31 percent, from 32 +/- 2 to 42 +/- 3 mg per deciliter (0.83 +/- 0.05 to 1.09 +/- 0.08 mmol per liter). Consequently, the ratio of LDL to HDL levels changed little (2.25 with the base-line diet and 2.38 with the affluent diet). Plasma triglyceride levels increased by 18 percent, from 91 +/- 8 to 108 +/- 11 mg per deciliter (1.03 +/- 0.09 to 1.22 +/- 0.12 mmol per liter, P < 0.05), with a significant increase in the very-low-density lipoprotein triglyceride fraction. All the subjects gained weight, with a mean increase of 3.8 kg (7 percent). Conclusions. When Tarahumara Indians from a population with virtually no coronary risk factors consumed for a short time a hypercaloric diet typical of a more affluent society, they had dramatic increases in plasma lipid and lipoprotein levels and body weight. If sustained, such changes might increase their risk of coronary heart disease.	OREGON HLTH SCI UNIV, DEPT MED, CLIN NUTR & LIPID METAB SECT, L465, PORTLAND, OR 97201 USA	Oregon Health & Science University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037940] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK040566] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00334] Funding Source: Medline; NHLBI NIH HHS [HL37940] Funding Source: Medline; NIDDK NIH HHS [DK40566] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOUCHARD C, 1990, NEW ENGL J MED, V322, P1477, DOI 10.1056/NEJM199005243222101; CERQUEIRA MT, 1979, AM J CLIN NUTR, V32, P905, DOI 10.1093/ajcn/32.4.905; CONNOR SE, 1986, NEW AM DIET; CONNOR SL, 1982, CIRCULATION, V65, P1290, DOI 10.1161/01.CIR.65.7.1290; CONNOR SL, 1989, J AM DIET ASSOC, V89, P807; CONNOR SL, 1989, J AM DIET ASSOC, V89, P1236; CONNOR WE, 1978, AM J CLIN NUTR, V31, P1131, DOI 10.1093/ajcn/31.7.1131; DODU SRA, 1988, CARDIOLOGY, V75, P56, DOI 10.1159/000174349; GROOM D, 1971, AM HEART J, V81, P304, DOI 10.1016/0002-8703(71)90099-8; Health. & N.R.C.U.C.o.D.a., 1989, DIET HLTH IMPLICATIO; HOWARD BV, 1983, CIRCULATION, V68, P714, DOI 10.1161/01.CIR.68.4.714; KASHIWAGI A, 1985, METABOLISM, V34, P364, DOI 10.1016/0026-0495(85)90226-4; KNUIMAN JT, 1980, ATHEROSCLEROSIS, V36, P529, DOI 10.1016/0021-9150(80)90245-2; MCMURRY MP, 1985, AM J CLIN NUTR, V41, P1289, DOI 10.1093/ajcn/41.6.1289; MCMURRY MP, 1982, AM J CLIN NUTR, V35, P741, DOI 10.1093/ajcn/35.4.741; MILLER DS, 1967, AM J CLIN NUTR, V20, P1212, DOI 10.1093/ajcn/20.11.1212; MILLER GJ, 1982, LANCET, V2, P1270; NORMAN J, 1976, NATL GEOGR, V149, P702; PISUNYER FX, 1988, MODERN NUTRITION HLT, P797; REID JM, 1971, AM J CLIN NUTR, V24, P1281; SAAD MF, 1988, NEW ENGL J MED, V319, P1500, DOI 10.1056/NEJM198812083192302; Sims E A, 1968, Trans Assoc Am Physicians, V81, P153; SOWERS MF, 1981, J AM DIET ASSOC, V79, P536; Trowell HC, 1981, W DIS THEIR EMERGENC; TROWELL HC, 1981, W DISEASES THEIR EME, P427; WEST KM, 1981, W DISEASES THEIR EME, P129; 1987, CLINFO REFERENCE MAN, V2; 1988, DHHS PHS8850210 DEP, P83; 1988, CIRCULATION, V77, pA721; 1974, DHEW NIH75628 PUBL, P1	30	76	77	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 12	1991	325	24					1704	1708		10.1056/NEJM199112123252405	http://dx.doi.org/10.1056/NEJM199112123252405			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GU418	1944471				2022-12-24	WOS:A1991GU41800005
J	CHOW, JW; FINE, MJ; SHLAES, DM; QUINN, JP; HOOPER, DC; JOHNSON, MP; RAMPHAL, R; WAGENER, MM; MIYASHIRO, DK; YU, VL				CHOW, JW; FINE, MJ; SHLAES, DM; QUINN, JP; HOOPER, DC; JOHNSON, MP; RAMPHAL, R; WAGENER, MM; MIYASHIRO, DK; YU, VL			ENTEROBACTER BACTEREMIA - CLINICAL-FEATURES AND EMERGENCE OF ANTIBIOTIC-RESISTANCE DURING THERAPY	ANNALS OF INTERNAL MEDICINE			English	Article						CEPHALOSPORINS; DRUG RESISTANCE, MICROBIAL; ENTEROBACTER; SEPTICEMIA; AMINOGLYCOSIDES	SERIOUS BACTERIAL-INFECTIONS; GRAM-NEGATIVE BACTERIA; INDUCIBLE BETA-LACTAMASES; CEFTRIAXONE THERAPY; CEPHALOSPORINS; CEFTAZIDIME; CLOACAE; CEFAMANDOLE; PSEUDOMONAS; GENTAMICIN	Objectives: To study the effect of previously administered antibiotics on the antibiotic susceptibility profile of Enterobacter, the factors affecting mortality, and the emergence of antibiotic resistance during therapy for Enterobacter bacteremia. Design: Prospective, observational study of consecutive patients with Enterobacter bacteremia. Setting: Three university tertiary care centers, one major university-affiliated hospital, and two university-affiliated Veterans Affairs medical centers. Patients: A total of 129 adult patients were studied. Measurements: The two main end points were emergence of resistance during antibiotic therapy and death. Main Results: Previous administration of third-generation cephalosporins was more likely to be associated with multiresistant Enterobacter isolates in an initial, positive blood culture (22 of 32, 69%) than was administration of antibiotics that did not include a third-generation cephalosporin (14 of 71, 20%; P < 0.001). Isolation of multiresistant Enterobacter sp. in the initial blood culture was associated with a higher mortality rate (12 of 37, 32%) than was isolation of a more sensitive Enterobacter sp. (14 of 92, 15%; P = 0.03). Emergence of resistance to third-generation cephalosporin therapy (6 of 31, 19%) occurred more often than did emergence of resistance to aminoglycoside (1 of 89, 0.01%; P = 0.001) or other beta-lactam (0 of 50; P = 0.002) therapy. Conclusions: More judicious use of third-generation cephalosporins may decrease the incidence of nosocomial multiresistant Enterobacter spp., which in turn may result in a lower mortality for Enterobacter bacteremia. When Enterobacter organisms are isolated from blood, it may be prudent to avoid third-generation cephalosporin therapy regardless of in-vitro susceptibility.	UNIV PITTSBURGH, SCH MED, 968 SCAIFE, PITTSBURGH, PA 15261 USA; PITTSBURGH DEPT VET AFFAIRS MED CTR, PITTSBURGH, PA USA; MASSACHUSETTS GEN HOSP, BOSTON, MA 02114 USA; CLEVELAND DEPT VET AFFAIRS MED CTR, CLEVELAND, OH USA; MICHAEL REESE HOSP & MED CTR, CHICAGO, IL 60616 USA; UNIV FLORIDA, GAINESVILLE, FL 32611 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Harvard University; Massachusetts General Hospital; Michael Reese Hospital & Medical Center; State University System of Florida; University of Florida			Chow, Joseph W/W-4164-2017	Chow, Joseph W/0000-0002-5934-5877	PHS HHS [5T32A107333] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Ausubel F, 1990, CURRENT PROTOCOLS MO, V1; BECKWITH DG, 1980, J CLIN MICROBIOL, V12, P517, DOI 10.1128/JCM.12.4.517-520.1980; BITTNER MJ, 1983, ANTIMICROB AGENTS CH, V23, P261, DOI 10.1128/AAC.23.2.261; BOUZA E, 1985, ARCH INTERN MED, V145, P1024, DOI 10.1001/archinte.145.6.1024; BRYAN CS, 1985, AM J DIS CHILD, V139, P1086, DOI 10.1001/archpedi.1985.02140130024022; BURCHARD KW, 1986, SURGERY, V100, P857; BUSH K, 1982, ANTIMICROB AGENTS CH, V22, P414, DOI 10.1128/AAC.22.3.414; DWORZACK DL, 1987, EUR J CLIN MICROBIOL, V6, P456, DOI 10.1007/BF02013110; ERON LJ, 1983, J ANTIMICROB CHEMOTH, V12, P65, DOI 10.1093/jac/12.1.65; FOLLATH F, 1987, EUR J CLIN MICROBIOL, V6, P446, DOI 10.1007/BF02013108; FUNG CP, 1988, CHUNG HUA I HSUEH TS, V42, P297; GALLAGHER PG, 1990, REV INFECT DIS, V12, P808; GASTON MA, 1988, J HOSP INFECT, V11, P197, DOI 10.1016/0195-6701(88)90098-9; GRIBBLE MJ, 1983, ANTIMICROB AGENTS CH, V24, P388, DOI 10.1128/AAC.24.3.388; HILF M, 1989, AM J MED, V87, P540, DOI 10.1016/S0002-9343(89)80611-4; JARLIER V, 1984, PATHOL BIOL, V32, P399; KORVICK J, 1988, ANN M AM SOC MICROBI; KORVICK JA, 1991, SURGERY, V109, P62; LANDESMAN SH, 1981, AM J MED, V71, P693, DOI 10.1016/0002-9343(81)90240-0; LEVINE LR, 1978, J INFECT DIS, V137, pS125, DOI 10.1093/infdis/137.Supplement.S125; Maniatis T, 1982, MOL CLONING LABORATO, P89; MARIER RL, 1982, J ANTIMICROB CHEMOTH, V9, P85, DOI 10.1093/jac/9.suppl_B.85; MATTHEW M, 1975, J GEN MICROBIOL, V88, P169, DOI 10.1099/00221287-88-1-169; MILATOVIC D, 1987, EUR J CLIN MICROBIOL, V6, P234, DOI 10.1007/BF02017607; Miller G., 1980, DEV IND MICROBIOL, V21, P91; MURPHY TF, 1982, ANTIMICROB AGENTS CH, V21, P568, DOI 10.1128/AAC.21.4.568; MURRAY PR, 1983, J INFECT DIS, V147, P590, DOI 10.1093/infdis/147.3.590; NEU HC, 1990, AM J MED, V88, pS3, DOI 10.1016/0002-9343(90)90321-4; OLSON B, 1983, J ANTIMICROB CHEMOTH, V11, P299, DOI 10.1093/jac/11.4.299; PECHERE JC, 1983, J ANTIMICROB CHEMOTH, V12, P181, DOI 10.1093/jac/12.suppl_A.181; PERKINS RL, 1978, J INFECT DIS, V137, pS110, DOI 10.1093/infdis/137.Supplement.S110; QUINN JP, 1989, ANTIMICROB AGENTS CH, V33, P1451, DOI 10.1128/AAC.33.9.1451; QUINN JP, 1987, J INFECT DIS, V155, P942, DOI 10.1093/infdis/155.5.942; SANDERS CC, 1982, J INFECT DIS, V145, P118, DOI 10.1093/infdis/145.1.118; SANDERS CC, 1985, J INFECT DIS, V151, P399, DOI 10.1093/infdis/151.3.399; SANDERS CC, 1983, REV INFECT DIS, V5, P639; SANDERS WE, 1988, REV INFECT DIS, V10, P830; SCULLY BE, 1984, ARCH INTERN MED, V144, P57, DOI 10.1001/archinte.144.1.57; SPRATT BG, 1977, EUR J BIOCHEM, V72, P341, DOI 10.1111/j.1432-1033.1977.tb11258.x; WATANAKUNAKORN C, 1989, SCAND J INFECT DIS, V21, P1, DOI 10.3109/00365548909035673; WEINSTEIN RA, 1986, INFECT CONT HOSP EP, V7, P120, DOI 10.1017/S0195941700065632; Young LS, 1990, PRINCIPLES PRACTICE, P611; 1983, MMWR, V22, P155; 1988, PROPHET STATISTICS U, P115	44	709	725	1	45	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1991	115	8					585	590		10.7326/0003-4819-115-8-585	http://dx.doi.org/10.7326/0003-4819-115-8-585			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GJ902	1892329				2022-12-24	WOS:A1991GJ90200001
J	NIGHTINGALE, SL				NIGHTINGALE, SL			FDA-800 MEDICAL ADVERTISING INFORMATION LINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 2	1991	266	13					1751	1751						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG551	1890706				2022-12-24	WOS:A1991GG55100005
J	ALLEN, S; LINDAN, C; SERUFILIRA, A; VANDEPERRE, P; RUNDLE, AC; NSENGUMUREMYI, F; CARAEL, M; SCHWALBE, J; HULLEY, S				ALLEN, S; LINDAN, C; SERUFILIRA, A; VANDEPERRE, P; RUNDLE, AC; NSENGUMUREMYI, F; CARAEL, M; SCHWALBE, J; HULLEY, S			HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION IN URBAN RWANDA - DEMOGRAPHIC AND BEHAVIORAL-CORRELATES IN A REPRESENTATIVE SAMPLE OF CHILDBEARING WOMEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SEXUALLY-TRANSMITTED DISEASES; HIV-INFECTION; RISK-FACTORS; HETEROSEXUAL TRANSMISSION; FEMALE PROSTITUTES; GENITAL ULCERS; CENTRAL-AFRICA; AIDS; SEROPOSITIVITY; UGANDA	Objective. - To determine behavioral and demographic risk factors for human immunodeficiency virus (HIV) infection in central Africa. Design. - Cross-sectional survey. Setting. - Kigali, Rwanda. Participants. - A representative sample of 1458 childbearing women aged 19 to 37 years who were recruited from outpatient prenatal and pediatric clinics at the only community hospital in the city. Main Outcome Measure. - Antibodies to HIV assessed by enzyme immuno-assay and confirmed by Western blot or indirect immunofluorescence. Results. - The HIV seroprevalence was 32% overall. Infection rates were higher in women who were single, in those in steady relationships that began after 1981, and in the 33% of women reporting more than one lifetime sexual partner. Women in legal marriages or monogamous partnerships had lower rates of infection, but even low-riskrisk women had prevalences on the order of 20%. History of venereal diseases in the past 5 years, although the strongest risk factor in a multiple logistic analysis (odds ratio, 2.7; 95% confidence interval, 2.0 to 3.7), was reported by only 30% of those infected. Having a male sexual partner who drank alcohol or who had higher income were significant risk factors for HIV infection in the multivariate analysis, but use of oral contraceptives and having an uncircumcised partner were not. Conclusions. - The epidemic of the acquired immunodeficiency syndrome in Rwanda has spread beyond high-risk groups to the general population of women without known risk factors. For most of these women, a steady male partner is the source of their HIV risk and therefore a vital target for intervention efforts.	UNIV CALIF SAN FRANCISCO,DEPT PATHOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT EPIDEMIOL & BIOSTAT,DIV CLIN EPIDEMIOL,SAN FRANCISCO,CA 94143; MINIST HLTH,NATL AIDS PROGRAM,KIGALI,RWANDA; GLOBAL PROGRAMME AIDS,GENEVA,SWITZERLAND; MINIST HLTH,PROJET SAN FRANCISCO,KIGALI,RWANDA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	ALLEN, S (corresponding author), UNIV CALIF SAN FRANCISCO,CTR AIDS PREVENT STUDIES,UCSF BOX 0886,SAN FRANCISCO,CA 94143, USA.		Van de Perre, Philippe/B-9692-2008	Van de Perre, Philippe/0000-0002-3912-0427	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023980] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH042459] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-23980] Funding Source: Medline; NIMH NIH HHS [MH-42459] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALLEN S, 1991, J INFECT DIS, V164, P67, DOI 10.1093/infdis/164.1.67; BERKLEY SF, 1989, J INFECT DIS, V160, P22, DOI 10.1093/infdis/160.1.22; BONGAARTS J, 1989, AIDS, V3, P373, DOI 10.1097/00002030-198906000-00006; BUGINGO G, 1988, REV MED RWANDAISE, V20, P37; CARAEL M, 1988, AIDS, V2, P201; CARSWELL JW, 1987, AIDS, V1, P223; CHIN J, 1989, B WORLD HEALTH ORGAN, V87, P1; CLUMECK N, 1985, NEW ENGL J MED, V313, P182; CLUMECK N, 1985, JAMA-J AM MED ASSOC, V254, P2599, DOI 10.1001/jama.254.18.2599; Clumeck N, 1987, Antibiot Chemother (1971), V38, P41; COLEBUNDERS RL, 1989, EUR J CLIN MICROBIOL, V8, P505, DOI 10.1007/BF01967468; DELALLA F, 1988, AIDS, V2, P317, DOI 10.1097/00002030-198808000-00013; FLEMING AF, 1988, BIOMED PHARMACOTHER, V42, P309; GREENBERG AE, 1988, JAMA-J AM MED ASSOC, V259, P545, DOI 10.1001/jama.259.4.545; GREENBLATT RM, 1988, AIDS, V2, P47, DOI 10.1097/00002030-198802000-00008; HUDSON CP, 1988, AIDS, V2, P255, DOI 10.1097/00002030-198808000-00003; LATIF AS, 1989, AIDS, V3, P519, DOI 10.1097/00002030-198908000-00006; MANN JM, 1988, AIDS, V2, P249, DOI 10.1097/00002030-198808000-00002; MELBYE M, 1986, LANCET, V2, P1113; MERTENS TE, 1990, AIDS, V4, P57, DOI 10.1097/00002030-199001000-00008; NGALY B, 1988, J ACQ IMMUN DEF SYND, V1, P551; NZILAMBI N, 1988, NEW ENGL J MED, V318, P276, DOI 10.1056/NEJM198802043180503; PIOT P, 1989, BRIT MED J, V298, P623, DOI 10.1136/bmj.298.6674.623; PIOT P, 1987, AIDS, V1, P199; PIOT P, 1988, SCIENCE, V239, P573, DOI 10.1126/science.3277271; PIOT P, 1988, BRIT MED BULL, V44, P68, DOI 10.1093/oxfordjournals.bmb.a072247; PIOT P, 1987, J INFECT DIS, V155, P1108, DOI 10.1093/infdis/155.6.1108; PLUMMER FA, 1991, J INFECT DIS, V163, P233, DOI 10.1093/infdis/163.2.233; QUINN TC, 1986, SCIENCE, V234, P955, DOI 10.1126/science.3022379; RWANDAN HIV, 1989, LANCET, V1, P941; SCHMUTZHARD E, 1989, AM J EPIDEMIOL, V130, P309, DOI 10.1093/oxfordjournals.aje.a115337; SIMONSEN JN, 1988, NEW ENGL J MED, V319, P274, DOI 10.1056/NEJM198808043190504; STALL R, 1986, HEALTH EDUC QUART, V13, P359, DOI 10.1177/109019818601300407; VANDEPERRE P, 1987, AIDS, V1, P213; VANDEPERRE P, 1984, LANCET, V2, P62; VANDEPERRE P, 1985, LANCET, V2, P524; VANDEPERRE P, 1987, AIDS, V1, P207; VANDEPERRE P, 1988, GENITOURIN MED, V64, P30; WINKELSTEIN W, 1987, AM J PUBLIC HEALTH, V77, P685, DOI 10.2105/AJPH.77.6.685; ZUNZUNEGUI MV, 1986, AM J EPIDEMIOL, V123, P302, DOI 10.1093/oxfordjournals.aje.a114238; 1988, MMWR, V37, P565; 1990, AIDS, V4, P1305	42	181	181	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 25	1991	266	12					1657	1663		10.1001/jama.266.12.1657	http://dx.doi.org/10.1001/jama.266.12.1657			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GF419	1886188				2022-12-24	WOS:A1991GF41900031
J	PETRENKO, AG; PERIN, MS; DAVLETOV, BA; USHKARYOV, YA; GEPPERT, M; SUDHOF, TC				PETRENKO, AG; PERIN, MS; DAVLETOV, BA; USHKARYOV, YA; GEPPERT, M; SUDHOF, TC			BINDING OF SYNAPTOTAGMIN TO THE ALPHA-LATROTOXIN RECEPTOR IMPLICATES BOTH IN SYNAPTIC VESICLE EXOCYTOSIS	NATURE			English	Article							WIDOW SPIDER VENOM; FROG NEUROMUSCULAR-JUNCTION; LONG-TERM POTENTIATION; PROTEIN KINASE-C; NERVE-TERMINALS; PURIFICATION; MEMBRANE	A VERTEBRATE neurotoxin, alpha-latrotoxin, from black widow spider venom causes synaptic vesicle exocytosis and neurotransmitter release from presynaptic nerve terminals 1-4. Although the mechanism of action of alpha-latrotoxin is not known, it does require binding of alpha-latrotoxin to a high-affinity receptor on the presynaptic plasma membrane 5. The alpha-latrotoxin receptor seems to be exclusively at the presynaptic plasmamembrane 6. Here we report that the alpha-latrotoxin receptor specifically binds to a synaptic vesicle protein, synaptotagmin, and modulates its phosphorylation. Synaptotagmin is a synaptic vesicle-specific membrane protein that binds negatively charged phospholipids and contains two copies of a putative Ca2+-binding domain from protein kinase C (the C2-domain), suggesting a regulatory role in synaptic vesicle fusion 7,8. Our findings suggest that a physiological role of the alpha-latrotoxin receptor may be the docking of synaptic vesicles at the active zone. The direct interaction of the alpha-latrotoxin receptor with a synaptic vesicle protein also suggests a mechanism of action for this toxin in causing neurotransmitter release.	UNIV TEXAS,SW MED CTR,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235; SHEMYAKIN BIOORGAN CHEM INST,MOSCOW 117871,USSR	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Bioorganic Chemistry of the Russian Academy of Sciences			Davletov, Bazbek/ABA-8569-2021; Ushkaryov, Yuri/AAQ-2985-2020	Ushkaryov, Yuri/0000-0002-5712-8297; Davletov, Bazbek/0000-0003-4658-3275; Petrenko, Alexander/0000-0002-6689-6546				BEKKERS JM, 1990, NATURE, V346, P724, DOI 10.1038/346724a0; CLARK AW, 1970, NATURE, V225, P703, DOI 10.1038/225703a0; FRONTALI N, 1976, J CELL BIOL, V68, P462, DOI 10.1083/jcb.68.3.462; KELLY RB, 1988, NEURON, V1, P431, DOI 10.1016/0896-6273(88)90174-2; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; KNAUS P, 1990, NEURON, V5, P453, DOI 10.1016/0896-6273(90)90084-S; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; MCMAHON HT, 1990, J NEUROCHEM, V55, P2039, DOI 10.1111/j.1471-4159.1990.tb05793.x; OKAMOTO M, 1971, SCIENCE, V172, P733, DOI 10.1126/science.172.3984.733; PERIN MS, 1991, J BIOL CHEM, V266, P615; PERIN MS, 1991, J BIOL CHEM, V266, P623; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; PETRENKO AG, 1990, EMBO J, V9, P2023, DOI 10.1002/j.1460-2075.1990.tb08331.x; PUMPLIN DW, 1977, J PHYSIOL-LONDON, V273, P443, DOI 10.1113/jphysiol.1977.sp012103; ROSENTHAL L, 1989, PHARMACOL THERAPEUT, V42, P115, DOI 10.1016/0163-7258(89)90024-7; SCHEER H, 1985, EMBO J, V4, P323, DOI 10.1002/j.1460-2075.1985.tb03632.x; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; TZENG MC, 1979, J NEUROCHEM, V33, P263, DOI 10.1111/j.1471-4159.1979.tb11728.x; VALTORTA F, 1984, J CELL BIOL, V99, P124, DOI 10.1083/jcb.99.1.124; WANG JKT, 1988, J NEUROSCI, V8, P281	20	228	228	1	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 5	1991	353	6339					65	68		10.1038/353065a0	http://dx.doi.org/10.1038/353065a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GD805	1881448				2022-12-24	WOS:A1991GD80500058
J	CHANT, J; CORRADO, K; PRINGLE, JR; HERSKOWITZ, I				CHANT, J; CORRADO, K; PRINGLE, JR; HERSKOWITZ, I			YEAST BUD5, ENCODING A PUTATIVE GDP-GTP EXCHANGE FACTOR, IS NECESSARY FOR BUD SITE SELECTION AND INTERACTS WITH BUD FORMATION GENE BEM1	CELL			English	Article							MATING-TYPE LOCUS; SACCHAROMYCES-CEREVISIAE; CDC25 GENE; CELLULAR MORPHOGENESIS; BINDING PROTEINS; WILD-TYPE; RAS; ACTIN; PRODUCT; MUTANTS	Cells of the yeast S. cerevisiae choose bud sites in an axial or bipolar spatial pattern depending on their cell type. We have identified a gene, BUD5, that resembles BUD1 and BUD2 in being required for both patterns; bud5- mutants also exhibit random budding in all cell types. The BUD5 nucleotide sequence predicts a protein of 538 amino acids that has similarity to the S. cerevisiae CDC25 product, an activator of RAS proteins that catalyzes GDP-GTP exchange. Two potential targets of BUD5 are known: BUD1 (RSR1) and CDC42, proteins involved in bud site selection and bud formation, respectively, that have extensive similarity to RAS. We also show that BUD5 interacts functionally with a gene, BEM1, that is required for bud formation. This interaction provides further support for the view that products involved in bud site selection guide the positioning of a complex necessary for bud formation.	UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, PROGRAM CELL BIOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, PROGRAM GENET, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	CHANT, J (corresponding author), UNIV MICHIGAN, DEPT BIOL, ANN ARBOR, MI 48109 USA.				NIGMS NIH HHS [GM31006, GM07544] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM031006, R01GM031006] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS AEM, 1984, J CELL BIOL, V98, P934, DOI 10.1083/jcb.98.3.934; ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; ASTELL CR, 1981, CELL, V27, P15, DOI 10.1016/0092-8674(81)90356-1; BANUETT F, 1987, J BACTERIOL, V169, P4076, DOI 10.1128/jb.169.9.4076-4085.1987; BENDER A, 1991, MOL CELL BIOL, V11, P1295, DOI 10.1128/MCB.11.3.1295; BENDER A, 1989, P NATL ACAD SCI USA, V86, P9976, DOI 10.1073/pnas.86.24.9976; BENDER A, 1989, GENETICS, V121, P463; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BOYMARCOTTE E, 1989, GENE, V77, P21, DOI 10.1016/0378-1119(89)90355-7; BROEK D, 1987, CELL, V48, P789, DOI 10.1016/0092-8674(87)90076-6; CAMONIS JH, 1986, EMBO J, V5, P375, DOI 10.1002/j.1460-2075.1986.tb04222.x; CHANT J, 1991, CELL, V65; CRECHET JB, 1990, SCIENCE, V248, P866, DOI 10.1126/science.2188363; DANIEL J, 1987, MOL CELL BIOL, V7, P3857, DOI 10.1128/MCB.7.10.3857; DRUBIN DG, 1988, J CELL BIOL, V107, P2551, DOI 10.1083/jcb.107.6.2551; FINEGOLD AA, 1991, IN PRESS P NATL ACAD; HAARER BK, 1990, J CELL BIOL, V110, P105, DOI 10.1083/jcb.110.1.105; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HARTWELL LH, 1967, J BACTERIOL, V93, P1662, DOI 10.1128/JB.93.5.1662-1670.1967; HARTWELL LH, 1974, SCIENCE, V183, P46, DOI 10.1126/science.183.4120.46; HERSKOWITZ I, 1991, METHOD ENZYMOL, V194, P132; HERSKOWITZ IH, 1965, GENETICS; HUGHES DA, 1990, NATURE, V344, P355, DOI 10.1038/344355a0; HUTTER KJ, 1978, A VAN LEEUW J MICROB, V44, P269, DOI 10.1007/BF00394305; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; JONES S, 1991, MOL CELL BIOL, V11, P2641, DOI 10.1128/MCB.11.5.2641; KILMARTIN JV, 1982, J CELL BIOL, V93, P576, DOI 10.1083/jcb.93.3.576; KILMARTIN JV, 1984, J CELL BIOL, V98, P922, DOI 10.1083/jcb.98.3.922; LEVITZKI A, 1990, SCIENCE, V248, P794, DOI 10.1126/science.2188357; LILLIE SH, 1980, J BACTERIOL, V143, P1384, DOI 10.1128/JB.143.3.1384-1394.1980; MEEKSWAGNER D, 1986, CELL, V44, P43, DOI 10.1016/0092-8674(86)90483-6; NOVICK P, 1985, CELL, V40, P405, DOI 10.1016/0092-8674(85)90154-0; POWERS S, 1991, CELL, V65, P1225, DOI 10.1016/0092-8674(91)90017-S; POWERS S, 1989, MOL CELL BIOL, V9, P390, DOI 10.1128/MCB.9.2.390; Pringle J R, 1975, Methods Cell Biol, V11, P131, DOI 10.1016/S0091-679X(08)60320-9; PRINGLE JR, 1989, METHOD CELL BIOL, V31, P357; PRINGLE JR, 1981, MOL BIOL YEAST SACCH, P97; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; ROSE MD, 1987, METHOD ENZYMOL, V152, P481; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sherman F., 1982, METHODS YEAST GENETI; SLOAT BF, 1978, SCIENCE, V200, P1171, DOI 10.1126/science.349694; SLOAT BF, 1981, J CELL BIOL, V89, P395, DOI 10.1083/jcb.89.3.395; SPRAGUE GF, 1991, METHOD ENZYMOL, V194, P77; STRATHERN J, 1981, J MOL BIOL, V147, P357, DOI 10.1016/0022-2836(81)90488-5; TANAKA K, 1990, CELL, V60, P803, DOI 10.1016/0092-8674(90)90094-U; TATCHELL K, 1981, CELL, V27, P25, DOI 10.1016/0092-8674(81)90357-3; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; WICKNER RB, 1987, YEAST, V3, P51, DOI 10.1002/yea.320030108; WILKINSON LE, 1974, EXP CELL RES, V89, P175, DOI 10.1016/0014-4827(74)90200-6	52	222	225	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 28	1991	65	7					1213	1224		10.1016/0092-8674(91)90016-R	http://dx.doi.org/10.1016/0092-8674(91)90016-R			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FU899	1905981	Green Published			2022-12-24	WOS:A1991FU89900013
J	STEINGRIMSSON, E; PIGNONI, F; LIAW, GJ; LENGYEL, JA				STEINGRIMSSON, E; PIGNONI, F; LIAW, GJ; LENGYEL, JA			DUAL ROLE OF THE DROSOPHILA PATTERN GENE TAILLESS IN EMBRYONIC TERMINI	SCIENCE			English	Article							CROSS-REGULATORY INTERACTIONS; RECEPTOR TYROSINE KINASE; GAP GENES; TORSO; SEGMENTATION; REQUIREMENT; MUTATIONS; HUNCHBACK; ANTERIOR; PROTEIN	One of the first zygotically active genes required for formation of the terminal domains of the Drosophila embryo is tailless (tll). Expression of the tll gene is activated ectopically in gain-of-function mutants of the maternal terminal gene torso (tor); this suggests that tor normally activates the tll gene in the termini. Ectopic expression of tll under the control of an inducible promoter results in differentiation of ectopic terminal-specific structures, the Filzkorper, and leads to the activation of at least one gene, hunchback, that is required to form these structures. Ectopic expression of the tll gene also represses segmentation by repressing the gap genes Kruppel and knirps and probably also pair rule genes.	UNIV CALIF LOS ANGELES,DEPT BIOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles				Steingrimsson, Eirikur/0000-0001-5826-7486	PHS HHS [09948] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AMBROSIO L, 1989, NATURE, V342, P288, DOI 10.1038/342288a0; ANDERSON KV, 1989, GENES EMBRYOS, P1; CAPMOSORTEGA JA, 1985, EMBRYONIC DEV DROSOP; CASANOVA J, 1989, GENE DEV, V3, P2025, DOI 10.1101/gad.3.12b.2025; CASANOVA J, 1990, DEVELOPMENT, V110, P621; COULTER DE, 1988, GENE DEV, V2, P1812, DOI 10.1101/gad.2.12b.1812; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; FOE VE, 1983, J CELL SCI, V61, P31; HARDING K, 1986, SCIENCE, V233, P953, DOI 10.1126/science.3755551; INGHAM PW, 1988, NATURE, V335, P25, DOI 10.1038/335025a0; JACKLE H, 1986, NATURE, V324, P668, DOI 10.1038/324668a0; KLINGER M, 1989, THESIS U TUBINGEN TU; KLINGLER M, 1988, NATURE, V335, P275, DOI 10.1038/335275a0; LEHMANN R, 1987, DEV BIOL, V119, P402, DOI 10.1016/0012-1606(87)90045-5; MAHONEY PA, 1987, DEV BIOL, V122, P464, DOI 10.1016/0012-1606(87)90310-1; NAUBER U, 1988, NATURE, V336, P489, DOI 10.1038/336489a0; NUSSLEINVOLHARD C, 1987, SCIENCE, V238, P1675, DOI 10.1126/science.3686007; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; NUSSLEINVOLHARD C, 1985, COLD SPRING HARB SYM, V50, P145, DOI 10.1101/SQB.1985.050.01.020; PANKRATZ MJ, 1989, NATURE, V341, P337, DOI 10.1038/341337a0; PIGNONI F, 1990, CELL, V62, P151, DOI 10.1016/0092-8674(90)90249-E; PIGNONI F, UNPUB; POOLE SJ, 1985, CELL, V40, P37, DOI 10.1016/0092-8674(85)90306-X; ROSENBERG UB, 1986, NATURE, V319, P336, DOI 10.1038/319336a0; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; SCHNEUWLY S, 1987, NATURE, V325, P816, DOI 10.1038/325816a0; SCHUPBACH T, 1986, ROUX ARCH DEV BIOL, V195, P302, DOI 10.1007/BF00376063; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; SPRENGER F, 1989, NATURE, V338, P478, DOI 10.1038/338478a0; STEVENS LM, 1990, NATURE, V346, P660, DOI 10.1038/346660a0; STRECKER TR, 1989, SCIENCE, V243, P1062, DOI 10.1126/science.2922596; STRECKER TR, 1986, DEV BIOL, V113, P64, DOI 10.1016/0012-1606(86)90108-9; STRECKER TR, 1988, DEVELOPMENT, V102, P721; TAUTZ D, 1987, NATURE, V327, P383, DOI 10.1038/327383a0; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; WEIGEL D, 1990, SCIENCE, V248, P495, DOI 10.1126/science.2158673; Wieschaus E., 1986, P199	37	100	100	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 18	1991	254	5030					418	421		10.1126/science.1925599	http://dx.doi.org/10.1126/science.1925599			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GK729	1925599				2022-12-24	WOS:A1991GK72900045
J	HEALY, B				HEALY, B			CHEMOTHERAPY DURING CHILDHOOD DOES NOT ADVERSELY AFFECT OFFSPRING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											HEALY, B (corresponding author), NIH,BETHESDA,MD 20892, USA.							1991, JAMA-J AM MED ASSOC, V325, P141	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 16	1991	266	15					2054	2054						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GJ474	1920686				2022-12-24	WOS:A1991GJ47400007
J	ANDERSON, FA; WHEELER, HB; GOLDBERG, RJ; HOSMER, DW; FORCIER, A; PATWARDHAN, NA				ANDERSON, FA; WHEELER, HB; GOLDBERG, RJ; HOSMER, DW; FORCIER, A; PATWARDHAN, NA			PHYSICIAN PRACTICES IN THE PREVENTION OF VENOUS THROMBOEMBOLISM	ANNALS OF INTERNAL MEDICINE			English	Article						HEPARIN; INTERMITTENT CALF COMPRESSION; THROMBOEMBOLISM; VENA CAVA FILTER; WARFARIN	PULMONARY-EMBOLISM; SURGICAL PATIENTS; UNITED-STATES; MORTALITY; DIAGNOSIS	Objective: To determine the rate of use of prophylaxis for venous thromboembolism in high-risk hospital patients. Design: A retrospective medical record review. Setting: A community-wide study in 16 short-stay hospitals in central Massachusetts. Patients: A total of 2017 patients with multiple risk factors for venous thromboembolism. Measurements and Main Results: On the basis of age, length of hospitalization, and the presence of at least one additional major risk factor, 17% of 151 349 discharges (25 410 patients) were identified as being at high risk for venous thromboembolism. Eight percent of these discharges were randomly selected for medical record review. Prophylaxis for venous thromboembolism was received by 32% of these high-risk patients. Prophylaxis use among the 16 study hospitals varied widely, ranging from 9% to 56%, and was higher in teaching hospitals than in nonteaching hospitals (44% compared with 19%; P < 0.001). One or more of the following methods of prophylaxis was used: low-dose heparin (78%), intermittent calf compression (13%), warfarin (12%), and inferior vena caval filter (3%). Use of prophylaxis increased with the number of risk factors identified (P < 0.001). Conclusion: Prophylaxis for venous thromboembolism is underused, particularly in nonteaching hospitals.			ANDERSON, FA (corresponding author), UNIV MASSACHUSETTS, MED CTR, SCH MED, 55 LAKE AVE N, WORCESTER, MA 01655 USA.				NHLBI NIH HHS [HL RO1-35862] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035862] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON FA, 1991, ARCH INTERN MED, V151, P933, DOI 10.1001/archinte.151.5.933; [Anonymous], 1975, LANCET, V2, P45; BERGQVIST D, 1985, BRIT J SURG, V72, P105, DOI 10.1002/bjs.1800720211; BERGQVIST D, 1983, POSTOPERATIVE THROMB, P156; BERNSTEIN MJ, 1986, JAMA-J AM MED ASSOC, V256, P744; Carter C, 1982, HEMOSTASIS THROMBOSI, P805; CHAMBLESS LE, 1985, COMMUN STAT-THEOR M, V14, P1377, DOI 10.1080/03610928508828982; CLAGETT GP, 1988, ANN SURG, V208, P227, DOI 10.1097/00000658-198808000-00016; COLLINS R, 1988, NEW ENGL J MED, V318, P1162, DOI 10.1056/NEJM198805053181805; CONTI S, 1982, ARCH SURG-CHICAGO, V117, P1036; CONTI S, 1980, VASCULAR SURG, V14, P382, DOI 10.1177/153857448001400604; DALEN JE, 1975, PROG CARDIOVASC DIS, V17, P259, DOI 10.1016/S0033-0620(75)80017-X; DISMUKE SE, 1986, JAMA-J AM MED ASSOC, V255, P2039, DOI 10.1001/jama.255.15.2039; GILLUM RF, 1987, AM HEART J, V114, P1262, DOI 10.1016/0002-8703(87)90212-2; GOLDHABER SZ, 1982, AM J MED, V73, P822, DOI 10.1016/0002-9343(82)90764-1; GOLDHABER SZ, 1982, AM HEART J, V104, P305, DOI 10.1016/0002-8703(82)90207-1; HIRSH J, 1981, VENOUS THROMBOEMBOLI, P1; KOSECOFF J, 1987, JAMA-J AM MED ASSOC, V258, P2708, DOI 10.1001/jama.258.19.2708; NICOLAIDES AN, 1975, THROMBOEMBOLISM AETI, P193; SEVITT S, 1959, LANCET, V2, P981; SIMON TL, 1974, CLIN ORTHOP RELAT R, V102, P181; 1985, SAS USERS GUIDE STAT; 1977, CIRCULATION, V55, P423; 1975, AMA HEIGHT WEIGHT TA	24	176	180	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1991	115	8					591	595		10.7326/0003-4819-591	http://dx.doi.org/10.7326/0003-4819-591			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GJ902	1892330				2022-12-24	WOS:A1991GJ90200002
J	MILNER, MR; HAWLEY, RJ; JACHIM, M; LINDSAY, J; FLETCHER, RD				MILNER, MR; HAWLEY, RJ; JACHIM, M; LINDSAY, J; FLETCHER, RD			VENTRICULAR LATE POTENTIALS IN MYOTONIC-DYSTROPHY	ANNALS OF INTERNAL MEDICINE			English	Article						MYOTONIA DYSTROPHY; ELECTROCARDIOGRAPHY; VENTRICULAR LATE POTENTIALS; HEART CONDUCTION SYSTEM; ARRHYTHMIA	SIGNAL-AVERAGED ELECTROCARDIOGRAM; CARDIAC INVOLVEMENT; MUSCULAR-DYSTROPHY; CONDUCTION SYSTEM; NATURAL-HISTORY; SUDDEN-DEATH; TACHYCARDIA; DISEASE; ELECTROGRAMS; SURFACE	Objective: To determine the prevalence of ventricular late potentials, as determined by signal-averaged electrocardiography, in patients with myotonic dystrophy. Design: Cross sectional, with blinded analysis of all electrocardiographic data. Setting: Outpatient departments of a Veterans Affairs medical center and a tertiary care private hospital. Participants: Twenty-four patients with myotonic dystrophy. Patients were excluded from the study if they had either a history suggestive of significant ventricular arrhythmias or electrocardiographic evidence of a bundle-branch block. Two comparison groups were also formed; one group included 44 healthy employees at the tertiary hospital and the other, 30 cardiac patients with inducible ventricular tachycardia. Main Results: A time-domain analysis of the signal-averaged electrocardiograms showed that 75% of patients with myotonic dystrophy met one criterion for the presence of late potentials, 67% met two criteria, and 29% met all three criteria. Spectrotemporal mapping in these patients showed markedly abnormal spectral peaks with a mean factor of normality that was significantly lower than that of the normal volunteers; the frequency of electrocardiographic abnormalities approached that seen in patients with known ventricular tachycardia. The presence of late potentials correlated directly with the length of the PR interval and inversely with left ventricular fractional shortening. Conclusions: In our study, the prevalence of late potentials on signal-averaged electrocardiography in patients with myotonic dystrophy approached that seen in cardiac patients with inducible ventricular tachycardia. It is possible that ventricular arrhythmias play a role in the occurrence of sudden death in some patients with myotonic dystrophy.	GEORGETOWN UNIV, WASHINGTON HOSP CTR, VET AFFAIRS MED CTR, WASHINGTON, DC USA; GEORGE WASHINGTON UNIV, SCH MED, WASHINGTON, DC 20052 USA	Georgetown University; MedStar Washington Hospital Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); George Washington University								BACIARELLO G, 1986, AM HEART J, V111, P413, DOI 10.1016/0002-8703(86)90162-6; CANNOM DS, 1984, J AM COLL CARDIOL, V4, P625, DOI 10.1016/S0735-1097(84)80112-6; DENNISS AR, 1987, AM J CARDIOL, V59, P586, DOI 10.1016/0002-9149(87)91174-X; GARDNER PI, 1985, CIRCULATION, V72, P596, DOI 10.1161/01.CIR.72.3.596; GOMES JA, 1987, J AM COLL CARDIOL, V10, P349; GRIGG LE, 1985, J AM COLL CARDIOL, V6, P254, DOI 10.1016/S0735-1097(85)80286-2; HABERL R, 1989, EUR HEART J, V10, P316, DOI 10.1093/oxfordjournals.eurheartj.a059488; HAWLEY RJ, 1991, NEUROLOGY, V41, P259, DOI 10.1212/WNL.41.2_Part_1.259; HIROMASA S, 1988, AM HEART J, V115, P914, DOI 10.1016/0002-8703(88)90901-5; KUCHAR DL, 1987, J AM COLL CARDIOL, V9, P531, DOI 10.1016/S0735-1097(87)80045-1; MELACINI P, 1988, CLIN CARDIOL, V11, P231, DOI 10.1002/clc.4960110407; MIELKE U, 1985, J NEUROL, V232, P271, DOI 10.1007/BF00313863; MILNER MR, 1989, CLIN RES, V37, pA280; MOTTA J, 1979, AM J MED, V67, P467, DOI 10.1016/0002-9343(79)90795-2; MUNSAT TL, 1967, NEUROLOGY, V17, P359, DOI 10.1212/WNL.17.4.359; NGUYEN HH, 1988, J AM COLL CARDIOL, V11, P662, DOI 10.1016/0735-1097(88)91547-1; OLOFSSON BO, 1988, BRIT HEART J, V59, P47; PERLOFF JK, 1984, AM J CARDIOL, V54, P1074, DOI 10.1016/S0002-9149(84)80147-2; PRYSTOWSKY EN, 1979, CIRCULATION, V60, P1360, DOI 10.1161/01.CIR.60.6.1360; RENAUD JF, 1987, BIOCHIMIE, V69, P407, DOI 10.1016/0300-9084(87)90032-0; SAHN DJ, 1978, CIRCULATION, V58, P1072, DOI 10.1161/01.CIR.58.6.1072; SIMSON MB, 1983, AM J CARDIOL, V51, P105, DOI 10.1016/S0002-9149(83)80020-4; STREIB EW, 1985, MUSCLE NERVE, V8, P650, DOI 10.1002/mus.880080804; WALTON JN, 1981, DISORDERS VOLUNTARY, P510	24	24	24	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1991	115	8					607	613		10.7326/0003-4819-115-8-607	http://dx.doi.org/10.7326/0003-4819-115-8-607			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GJ902	1892332				2022-12-24	WOS:A1991GJ90200005
J	GRUNSTEIN, RR; HO, KY; SULLIVAN, CE				GRUNSTEIN, RR; HO, KY; SULLIVAN, CE			SLEEP-APNEA IN ACROMEGALY	ANNALS OF INTERNAL MEDICINE			English	Article						ACROMEGALY; SLEEP APNEA SYNDROMES; SOMATOTROPIN; INSULIN-LIKE GROWTH FACTOR-I; HYPERTENSION	EPIDEMIOLOGY; MORTALITY	Objective: To provide information on the nature, prevalence, and severity of sleep apnea in patients with acromegaly. Design: Consecutive case series. Setting: Tertiary referral hospital. Patients: Fifty-three patients with acromegaly were consecutively referred: 33 patients were referred because of clinical suspicion of sleep apnea and 20 patients were referred without suspected apnea. Measurements: Sleep studies as well as growth hormone and insulin-like growth factor 1 (IGF-1) measurements were done. Main Results: Thirty-one patients (93%; 95% Cl, 85% to 100%) referred because of suspicion of sleep apnea had sleep apnea compared with 12 patients (60%; Cl, 37% to 83%) referred without suspected sleep apnea. Patients with sleep apnea did not have biochemical evidence of increased disease activity (random growth hormone, 12.7 +/- 4.4-mu-g/L; mean growth hormone at 24-hour sampling, 10.8 +/- 8.4-mu-g/L; IGF-1, 90.0 +/- 7.5 nmol/L) compared with patients without sleep apnea (random growth hormone, 14.2 +/- 4.9-mu-g/L, P > 0.2; mean growth hormone, 12.4 +/- 3.5-mu-g/L, P > 0.2; IGF-1, 90.0 +/- 10.0 nmol/L, P > 0.2). Central sleep apnea was the predominant type of apnea in 33% (Cl, 18% to 47%) of patients and was associated with higher random growth hormone and IGF-1 levels than was obstructive apnea (random growth hormone, 23.4 +/- 3.9 compared with 8.8 +/- 3.1-mu-g/L, P < 0.001; IGF-1, 126 +/- 17.5 compared with 72.5 +/- 7.5 nmol/L, P < 0.01). Conclusions: Sleep apnea is common in acromegaly. The rate of central sleep apnea was unexpectedly high in patients with acromegaly, and biochemical evidence of increased disease activity was associated with the presence of central apnea rather than with the degree of sleep apnea. Altered respiratory control is a possible mechanism producing sleep apnea in acromegaly.	ST VINCENTS HOSP, GARVAN INST MED RES, DARLINGHURST, NSW 2010, AUSTRALIA	Garvan Institute of Medical Research; St Vincents Hospital Sydney	GRUNSTEIN, RR (corresponding author), ROYAL PRINCE ALFRED HOSP, SLEEP DISORDERS CTR, MISSENDEN RD, SYDNEY, NSW 2050, AUSTRALIA.							ALEXANDER L, 1980, CLIN ENDOCRINOL, V12, P71, DOI 10.1111/j.1365-2265.1980.tb03135.x; BAXTER RC, 1982, CLIN CHEM, V28, P488; BENGTSSON BA, 1988, ACTA MED SCAND, V223, P327; BENGTSSON BA, 1989, CLIN ENDOCRINOL, V30, P121, DOI 10.1111/j.1365-2265.1989.tb03733.x; BRADLEY TD, 1986, AM REV RESPIR DIS, V134, P217; CHAPPEL W, 1896, J LARYNGOL OTOL, V10, P142; DAUGHADAY WH, 1987, ACROMEGALY CENTURY S, P129; Guilleminault C., 1978, SLEEP APNEAS SYNDROM, V1, P1; HART TB, 1985, ARCH INTERN MED, V145, P865, DOI 10.1001/archinte.145.5.865; HE J, 1988, CHEST, V94, P9, DOI 10.1378/chest.94.1.9; HEDNER J, 1988, J HYPERTENS, V6, pS529, DOI 10.1097/00004872-198812040-00166; HO KY, 1990, ANN INTERN MED, V112, P173, DOI 10.7326/0003-4819-112-3-173; ISSA FG, 1986, CHEST, V90, P165, DOI 10.1378/chest.90.2.165; KALIA M, 1984, BRAIN RES, V296, P339, DOI 10.1016/0006-8993(84)90070-2; KARLBERG BE, 1982, ACTA ENDOCRINOL-COP, V100, P581, DOI 10.1530/acta.0.1000581; LAROCHE C, 1976, ANN MED INTERNE, V127, P381; LUGARESI E, 1980, SLEEP, V3, P221, DOI 10.1093/sleep/3.3-4.221; Marie P, 1886, REV MED-PARIS, V6, P297; MEZON BJ, 1980, AM J MED, V69, P615, DOI 10.1016/0002-9343(80)90477-5; PEKKARINEN T, 1987, CLIN ENDOCRINOL, V27, P649, DOI 10.1111/j.1365-2265.1987.tb02947.x; PERKS WH, 1980, BRIT MED J, V280, P894, DOI 10.1136/bmj.280.6218.894; Phillipson E.A., 1989, AM REV RESPIR DIS, V139, P559, DOI 10.1164/ajrccm/139.2.559; ROXBURGH F, 1896, BRIT MED J, V2, P63; SHEPARD JW, 1989, PRINCIPLES PRACTICE, P537; Sullivan C, 1984, LUNG BIOL HLTH DIS S, V21, P299; SULLIVAN CE, 1985, CLIN CHEST MED, V6, P633; VELDHUIS JD, 1986, AM J PHYSIOL, V250, pE486, DOI 10.1152/ajpendo.1986.250.4.E486; WHITE DP, 1989, PRINCIPLES PRACTICE, P513; WRIGHT AD, 1970, Q J MED, V39, P1	29	162	166	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1991	115	7					527	532		10.7326/0003-4819-115-7-527	http://dx.doi.org/10.7326/0003-4819-115-7-527			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG283	1883121				2022-12-24	WOS:A1991GG28300004
J	NIGHTINGALE, SL				NIGHTINGALE, SL			FDA ADOPTS COMMON FEDERAL-POLICY FOR PROTECTION OF HUMAN-SUBJECTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							FED REGISTER, V56, P28023	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 18	1991	266	11					1482	1482						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GE458	1880875				2022-12-24	WOS:A1991GE45800003
J	GERMAIN, RN; HENDRIX, LR				GERMAIN, RN; HENDRIX, LR			MHC CLASS-II STRUCTURE, OCCUPANCY AND SURFACE EXPRESSION DETERMINED BY POST-ENDOPLASMIC RETICULUM ANTIGEN-BINDING	NATURE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; B-CELL ALLOANTIGENS; HLA-DR ANTIGENS; INVARIANT CHAIN; MONOCLONAL-ANTIBODIES; T-CELLS; IMMUNOGENIC PEPTIDES; IA ANTIGENS; MOLECULES; RECOGNITION	Class II major histocompatibility complex molecules undergo a change in structure upon stable binding of peptide antigen. Analysis of the site and extent of this change among class II molecules of splenic antigen-presenting cells reveals the preference of class II for peptide acquisition outside the endoplasmic reticulum and indicates that the class II presentation system is not saturated with self peptides. There are numerous empty class II molecules on the cell surface and peptide antigen is evidently important in regulating surface class II expression.			GERMAIN, RN (corresponding author), NIAID,IMMUNOL LAB,LYMPHOCYTE BIOL SECT,BETHESDA,MD 20892, USA.		Germain, Ronald/ABE-7090-2020; Germain, Ronald N./Z-1945-2019					BABBITT BP, 1985, NATURE, V317, P359, DOI 10.1038/317359a0; BAKKE O, 1990, CELL, V63, P707, DOI 10.1016/0092-8674(90)90137-4; BHATTACHARYA A, 1981, J IMMUNOL, V127, P2488; BIKOFF EK, IN PRESS EUR J IMMUN; BILLING RJ, 1976, J IMMUNOL, V117, P1589; BRAUNSTEIN NS, 1990, J IMMUNOL, V145, P1635; BROOKS A, 1991, P NATL ACAD SCI USA, V88, P3290, DOI 10.1073/pnas.88.8.3290; BUUS S, 1987, SCIENCE, V235, P1353, DOI 10.1126/science.2435001; BUUS S, 1986, CELL, V47, P1071, DOI 10.1016/0092-8674(86)90822-6; CERUNDOLO V, 1990, NATURE, V345, P449, DOI 10.1038/345449a0; CHEN BP, 1990, J EXP MED, V172, P779, DOI 10.1084/jem.172.3.779; CRESSWELL P, 1977, EUR J IMMUNOL, V7, P636, DOI 10.1002/eji.1830070911; CULLEN SE, 1984, METHOD ENZYMOL, V108, P523; DEMOTZ S, 1989, NATURE, V342, P682, DOI 10.1038/342682a0; DEMOTZ S, 1990, SCIENCE, V249, P1028, DOI 10.1126/science.2118680; DORNMAIR K, 1989, COLD SPRING HARB SYM, V54, P409; GERMAIN RN, 1986, NATURE, V322, P687, DOI 10.1038/322687a0; GORGA JC, 1987, J BIOL CHEM, V262, P16087; GUAGLIARDI LE, 1990, NATURE, V343, P133, DOI 10.1038/343133a0; HARDING CV, 1990, P NATL ACAD SCI USA, V87, P5553, DOI 10.1073/pnas.87.14.5553; HARDING CV, 1990, CELL REGUL, V1, P499, DOI 10.1091/mbc.1.7.499; HARDING CV, 1991, P NATL ACAD SCI USA, V88, P7170; HOLT GD, 1985, J IMMUNOL, V135, P399; HUBBARD AL, 1972, J CELL BIOL, V55, P390, DOI 10.1083/jcb.55.2.390; JACOBSON S, 1989, J VIROL, V63, P1756, DOI 10.1128/JVI.63.4.1756-1762.1989; JANEWAY CA, 1984, J IMMUNOL, V132, P662; JIN Y, 1988, J EXP MED, V168, P293, DOI 10.1084/jem.168.1.293; JONES PP, 1979, MOL IMMUNOL, V16, P51, DOI 10.1016/0161-5890(79)90027-0; KAPPLER JW, 1981, J EXP MED, V153, P1198, DOI 10.1084/jem.153.5.1198; KOCH N, 1987, EMBO J, V6, P1677, DOI 10.1002/j.1460-2075.1987.tb02417.x; KVIST S, 1982, CELL, V29, P61, DOI 10.1016/0092-8674(82)90090-3; LEE JM, 1990, J IMMUNOL, V144, P1829; LIE WR, 1990, NATURE, V344, P439, DOI 10.1038/344439a0; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; LONG EO, 1989, IMMUNOL TODAY, V10, P232, DOI 10.1016/0167-5699(89)90259-4; LORENZ RG, 1990, J IMMUNOL, V144, P1600; LOTTEAU V, 1990, NATURE, V348, P600, DOI 10.1038/348600a0; MACHAMER CE, 1984, P NATL ACAD SCI-BIOL, V81, P1287, DOI 10.1073/pnas.81.5.1287; MACHAMER CE, 1982, J IMMUNOL, V129, P2564; MEHRINGER JH, 1991, J IMMUNOL, V146, P920; MELLINS E, 1990, NATURE, V343, P71, DOI 10.1038/343071a0; MURPHY DB, 1989, NATURE, V338, P76; NEEFJES JJ, 1990, CELL, V61, P171, DOI 10.1016/0092-8674(90)90224-3; NOWELL J, 1985, J EXP MED, V162, P1371, DOI 10.1084/jem.162.4.1371; NUCHTERN JG, 1990, NATURE, V343, P74, DOI 10.1038/343074a0; Oi V T, 1978, Curr Top Microbiol Immunol, V81, P115; OZATO K, 1980, J IMMUNOL, V124, P533; PETERS PJ, 1991, NATURE, V349, P669, DOI 10.1038/349669a0; RESKE K, 1985, EUR J IMMUNOL, V15, P1229, DOI 10.1002/eji.1830151216; ROCHE PA, 1990, NATURE, V345, P615, DOI 10.1038/345615a0; ROTHENHAUSLER B, 1990, P NATL ACAD SCI USA, V87, P352, DOI 10.1073/pnas.87.1.352; SADEGHNASSERI S, 1989, NATURE, V337, P274, DOI 10.1038/337274a0; SADEGHNASSERI S, 1991, NATURE, V353, P167, DOI 10.1038/353167a0; SHACKELFORD DA, 1981, J IMMUNOL, V127, P1403; SOBEL RA, 1986, J IMMUNOL, V137, P2132; SPRINGER TA, 1977, J BIOL CHEM, V252, P6201; SRINIVASAN M, 1990, P NATL ACAD SCI USA, V87, P919, DOI 10.1073/pnas.87.3.919; TEYTON L, 1990, NATURE, V348, P39, DOI 10.1038/348039a0; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; WEISS S, 1991, CELL, V64, P767, DOI 10.1016/0092-8674(91)90506-T; YEWDELL JW, 1990, CELL, V62, P203, DOI 10.1016/0092-8674(90)90356-J	63	405	414	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 12	1991	353	6340					134	139		10.1038/353134a0	http://dx.doi.org/10.1038/353134a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GE731	1891045				2022-12-24	WOS:A1991GE73100043
J	CROW, JF				CROW, JF			WAS WRIGHT RIGHT	SCIENCE			English	Editorial Material											CROW, JF (corresponding author), UNIV WISCONSIN,DEPT GENET,MADISON,WI 53706, USA.							BARTON NH, IN PRESS EVOLUTION; CROW JF, 1990, EVOLUTION, V44, P233, DOI [10.2307/2409403, 10.1111/j.1558-5646.1990.tb05194.x]; Fisher R. A., 1930, GENETICAL THEORY NAT, DOI 10.5962/bhl.title.27468; Haldane J. B. S., 1959, DARWINS BIOL WORK SO, P101; Provine William B., 1986, S WRIGHT EVOLUTIONAR; WADE MJ, 1991, SCIENCE, V253, P1015, DOI 10.1126/science.1887214; WRIGHT S, 1988, AM NAT, V131, P115, DOI 10.1086/284777; Wright S, 1931, GENETICS, V16, P0097	8	12	12	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 30	1991	253	5023					973	973		10.1126/science.1887230	http://dx.doi.org/10.1126/science.1887230			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC982	1887230				2022-12-24	WOS:A1991GC98200032
J	FERGUSON, CJ; WILLIAMS, JD; SILVER, A; WOODHEAD, JS; SALAMAN, JR				FERGUSON, CJ; WILLIAMS, JD; SILVER, A; WOODHEAD, JS; SALAMAN, JR			EFFECTS OF PARATHYROID-HORMONE ON DELAYED RENAL-ALLOGRAFT FUNCTION	BRITISH MEDICAL JOURNAL			English	Article									UNIV WALES COLL MED,DEPT MED BIOCHEM,CARDIFF CF4 4XN,S GLAM,WALES; CARDIFF ROYAL INFIRM,INST NEPHROL,CARDIFF CF2 1SZ,S GLAM,WALES	Cardiff University; Cardiff Royal Infirmary	FERGUSON, CJ (corresponding author), CARDIFF ROYAL INFIRM,DEPT SURG,CARDIFF CF2 1SZ,S GLAM,WALES.							BROWN RC, 1987, J CLIN ENDOCR METAB, V65, P407, DOI 10.1210/jcem-65-3-407; CHARBON GA, 1974, ENDOCRINOLOGY, V95, P621, DOI 10.1210/endo-95-2-621; ELLISON DH, 1984, AM J PHYSIOL, V246, pF551, DOI 10.1152/ajprenal.1984.246.5.F551; PANG PKT, 1983, ENDOCRINOLOGY, V112, P284, DOI 10.1210/endo-112-1-284; VARGHESE Z, 1988, BRIT MED J, V296, P393, DOI 10.1136/bmj.296.6619.393	5	10	10	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 3	1991	303	6797					287	288		10.1136/bmj.303.6797.287	http://dx.doi.org/10.1136/bmj.303.6797.287			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FZ721	1888930	Bronze, Green Published			2022-12-24	WOS:A1991FZ72100022
J	ROMEO, C; SEED, B				ROMEO, C; SEED, B			CELLULAR-IMMUNITY TO HIV ACTIVATED BY CD4 FUSED TO T-CELL OR FC RECEPTOR POLYPEPTIDES	CELL			English	Article							NATURAL-KILLER CELLS; RECOMBINANT SOLUBLE CD4; CLASS-II MHC; ANTIGEN RECEPTOR; ZETA-CHAIN; SURFACE EXPRESSION; MOLECULAR-CLONING; IMMUNODEFICIENCY VIRUS; TRANSFECTED CELLS; TRANS-ACTIVATOR	We describe functional simplified T cell and Fc receptor chimeras that are capable of directing CD8+ cytotoxic T lymphocytes (CTLs) to specifically recognize and lyse cells expressing HIV envelope proteins. Target cells bearing HLA-DR molecules are not recognized by CTL armed with the chimeras. The variety of cell types in which the native receptors are active suggests multiple possibilities for antiviral intervention through genetic means.	MASSACHUSETTS GEN HOSP,DEPT MOLEC BIOL,BOSTON,MA 02114	Harvard University; Massachusetts General Hospital	ROMEO, C (corresponding author), HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115, USA.							ACCOLLA RS, 1983, J EXP MED, V157, P1053, DOI 10.1084/jem.157.3.1053; ANDERSON P, 1989, NATURE, V341, P159, DOI 10.1038/341159a0; ANDERSON P, 1990, P NATL ACAD SCI USA, V87, P2274, DOI 10.1073/pnas.87.6.2274; ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; BANIYASH M, 1988, J BIOL CHEM, V263, P9874; BECKER MLB, 1989, CELL, V58, P911, DOI 10.1016/0092-8674(89)90943-4; BERKHOUT B, 1988, J BIOL CHEM, V263, P8528; BLANK U, 1989, NATURE, V337, P187, DOI 10.1038/337187a0; BLUMBERG RS, 1990, J BIOL CHEM, V265, P14036; BOYLE DB, 1988, GENE, V65, P123, DOI 10.1016/0378-1119(88)90424-6; BUONOCORE L, 1990, NATURE, V345, P625, DOI 10.1038/345625a0; BYRN RA, 1990, NATURE, V344, P667, DOI 10.1038/344667a0; CAPON DJ, 1989, NATURE, V337, P525, DOI 10.1038/337525a0; CHAKRABARTI S, 1986, NATURE, V320, P535, DOI 10.1038/320535a0; CHAUDHARY VK, 1988, NATURE, V335, P369, DOI 10.1038/335369a0; CLAYTON LK, 1990, J EXP MED, V172, P1243, DOI 10.1084/jem.172.4.1243; CLAYTON LK, 1989, NATURE, V339, P548, DOI 10.1038/339548a0; DEEN KC, 1988, NATURE, V331, P82, DOI 10.1038/331082a0; DOYLE C, 1987, NATURE, V330, P256, DOI 10.1038/330256a0; EARL PL, 1990, J VIROL, V64, P2448, DOI 10.1128/JVI.64.5.2448-2451.1990; FALKNER FG, 1988, J VIROL, V62, P1849, DOI 10.1128/JVI.62.6.1849-1854.1988; FANGER MW, 1989, IMMUNOL TODAY, V10, P92, DOI 10.1016/0167-5699(89)90234-X; FISHER RA, 1988, NATURE, V331, P76, DOI 10.1038/331076a0; FLEIT HB, 1982, P NATL ACAD SCI-BIOL, V79, P3275, DOI 10.1073/pnas.79.10.3275; FRANK SJ, 1990, SCIENCE, V249, P174, DOI 10.1126/science.2371564; FRIEDMAN AD, 1988, NATURE, V335, P452, DOI 10.1038/335452a0; GAY D, 1987, NATURE, V328, P626, DOI 10.1038/328626a0; GOVERMAN J, 1990, CELL, V60, P929, DOI 10.1016/0092-8674(90)90341-B; GREEN M, 1989, CELL, V58, P215, DOI 10.1016/0092-8674(89)90417-0; GROSS G, 1989, P NATL ACAD SCI USA, V86, P10024, DOI 10.1073/pnas.86.24.10024; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HIBBS ML, 1989, SCIENCE, V246, P1608, DOI 10.1126/science.2531918; HUSSEY RE, 1988, NATURE, V331, P78, DOI 10.1038/331078a0; JIN YJ, 1990, P NATL ACAD SCI USA, V87, P3319, DOI 10.1073/pnas.87.9.3319; JOHN S, 1989, EUR J IMMUNOL, V19, P335, DOI 10.1002/eji.1830190218; KUROSAKI T, 1989, NATURE, V342, P805, DOI 10.1038/342805a0; KUSTER H, 1990, J BIOL CHEM, V265, P6448; KUWANA Y, 1987, BIOCHEM BIOPH RES CO, V149, P960, DOI 10.1016/0006-291X(87)90502-X; LAMARRE D, 1989, SCIENCE, V245, P743, DOI 10.1126/science.2549633; LANIER LL, 1989, NATURE, V342, P803, DOI 10.1038/342803a0; MALIM MH, 1989, CELL, V58, P205, DOI 10.1016/0092-8674(89)90416-9; MERCEP M, 1989, SCIENCE, V246, P1162, DOI 10.1126/science.2531464; MERCEP M, 1988, SCIENCE, V242, P571, DOI 10.1126/science.2845582; MORLEY BJ, 1988, J EXP MED, V168, P1971, DOI 10.1084/jem.168.6.1971; OHASHI PS, 1985, NATURE, V316, P606, DOI 10.1038/316606a0; ORLOFF DG, 1989, J BIOL CHEM, V264, P14812; ORLOFF DG, 1990, NATURE, V347, P189, DOI 10.1038/347189a0; PERUSSIA B, 1989, J EXP MED, V170, P73, DOI 10.1084/jem.170.1.73; QIU WQ, 1990, SCIENCE, V248, P732, DOI 10.1126/science.2139735; RA C, 1989, NATURE, V341, P752, DOI 10.1038/341752a0; RA C, 1989, J BIOL CHEM, V264, P15323; RABINOVITCH PS, 1986, J IMMUNOL, V137, P952; RAVETCH JV, 1989, J EXP MED, V170, P481, DOI 10.1084/jem.170.2.481; ROSENBERG SA, 1990, NEW ENGL J MED, V323, P570, DOI 10.1056/NEJM199008303230904; ROSENBERG SA, 1990, SCI AM, V262, P62, DOI 10.1038/scientificamerican0590-62; SLECKMAN BP, 1987, NATURE, V328, P351, DOI 10.1038/328351a0; SMITH DH, 1987, SCIENCE, V238, P1704, DOI 10.1126/science.3500514; SUSSMAN JJ, 1988, CELL, V52, P85, DOI 10.1016/0092-8674(88)90533-8; TILL MA, 1988, SCIENCE, V242, P1166, DOI 10.1126/science.2847316; TRAUNECKER A, 1989, NATURE, V339, P68, DOI 10.1038/339068a0; TRAUNECKER A, 1988, NATURE, V331, P84, DOI 10.1038/331084a0; TRONO D, 1989, CELL, V59, P113, DOI 10.1016/0092-8674(89)90874-X; WATANABE M, 1989, NATURE, V337, P267, DOI 10.1038/337267a0; WEISS A, 1984, J IMMUNOL, V133, P123; WEISS A, 1984, J EXP MED, V160, P1284, DOI 10.1084/jem.160.5.1284; WEISSMAN AM, 1988, SCIENCE, V239, P1018, DOI 10.1126/science.3278377; WEISSMAN AM, 1988, P NATL ACAD SCI USA, V85, P9709, DOI 10.1073/pnas.85.24.9709; WEISSMAN AM, 1989, EMBO J, V8, P3651, DOI 10.1002/j.1460-2075.1989.tb08539.x; ZETTLMEISSL G, 1990, DNA CELL BIOL, V9, P347, DOI 10.1089/dna.1990.9.347	69	354	400	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 8	1991	64	5					1037	1046		10.1016/0092-8674(91)90327-U	http://dx.doi.org/10.1016/0092-8674(91)90327-U			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FA940	1900456				2022-12-24	WOS:A1991FA94000020
J	GRIBBEN, JG; FREEDMAN, AS; NEUBERG, D; ROY, DC; BLAKE, KW; WOO, SD; GROSSBARD, ML; RABINOWE, SN; CORAL, F; FREEMAN, GJ; RITZ, J; NADLER, LM				GRIBBEN, JG; FREEDMAN, AS; NEUBERG, D; ROY, DC; BLAKE, KW; WOO, SD; GROSSBARD, ML; RABINOWE, SN; CORAL, F; FREEMAN, GJ; RITZ, J; NADLER, LM			IMMUNOLOGICAL PURGING OF MARROW ASSESSED BY PCR BEFORE AUTOLOGOUS BONE-MARROW TRANSPLANTATION FOR B-CELL LYMPHOMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NON-HODGKINS-LYMPHOMA; ACUTE LYMPHOBLASTIC-LEUKEMIA; DOSE COMBINATION CHEMOTHERAPY; BREAKPOINT-CLUSTER REGION; MONOCLONAL-ANTIBODY; FOLLICULAR LYMPHOMAS; CHROMOSOMAL TRANSLOCATION; BREAST-CANCER; T(14-18); ANTIGEN	Background. The use of autologous bone marrow transplantation is increasing in the management of advanced cancers. Many investigators have attempted to "purge" autologous marrow of residual tumor cells because of concern that reinfused tumor cells might contribute to relapse. The efficacy of purging remains unproved. Methods. We performed clonogenic assays in a tumor cell line in culture to determine the efficiency of immunologic purging. Amplification by the polymerase chain reaction (PCR) was used to detect residual lymphoma cells before and after purging of bone marrow from 114 patients with B-cell non-Hodgkin's lymphoma in whom a translocation (t(l4;18)) that could be amplified by PCR was detected at the time of their initial evaluation. Results. Immunologic purging in vitro resulted in a 3-to-6-log destruction of cells in the tumor cell line. Residual lymphoma cells were detected by PCR in the bone marrow of all patients before purging. No lymphoma cells could be detected in the marrow of 57 patients after purging. Disease-free survival was increased in these 57 patients as compared with those whose marrow contained detectable residual lymphoma (P < 0.00001). The ability to purge residual lymphoma cells was not associated with the degree of bone marrow involvement (P = 0.4494) or the previous response to therapy (P = 0.1298). Conclusions. The inability to purge residual lymphoma cells was the most important prognostic indicator in predicting relapse. These results provide evidence of the clinical usefulness of ex vivo purging of autologous bone marrow in the treatment of patients with lymphoma and suggest that the reinfusion of malignant cells in autologous marrow contributes to relapse.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV BIOSTAT,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School	GRIBBEN, JG (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV TUMOR IMMUNOL,44 BINNEY ST,BOSTON,MA 02115, USA.		Jones, Jeffrey A/E-9827-2013; Freeman, Gordon/AAC-5380-2019	Freeman, Gordon/0000-0002-7210-5616; Roy, Denis-Claude/0000-0002-5921-1692; Grossbard, Michael/0000-0002-3919-3028	NATIONAL CANCER INSTITUTE [P01CA034183, R01CA040216] Funding Source: NIH RePORTER; FIC NIH HHS [TWO4496] Funding Source: Medline; NCI NIH HHS [CA-34183, CA-40216] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AISENBERG AC, 1988, BLOOD, V71, P969; ARMITAGE JO, 1989, BLOOD, V73, P1749; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; BALL ED, 1990, BLOOD, V75, P1199; BENJAMIN D, 1983, BLOOD, V61, P1017; BERLINER N, 1986, BLOOD, V67, P80; CLEARY ML, 1986, J EXP MED, V164, P315, DOI 10.1084/jem.164.1.315; CLEARY ML, 1984, P NATL ACAD SCI-BIOL, V81, P593, DOI 10.1073/pnas.81.2.593; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; COSSMAN J, 1984, AM J PATHOL, V115, P117; COX DR, 1972, J R STAT SOC B, V34, P187; Cox DR., 1970, ANAL BINARY DATA; CRESCENZI M, 1988, P NATL ACAD SCI USA, V85, P4869, DOI 10.1073/pnas.85.13.4869; FREEDMAN AS, 1987, LEUKEMIA, V1, P9; FREEDMAN AS, 1985, J IMMUNOL, V134, P2228; FREEDMAN AS, 1990, J CLIN ONCOL, V8, P784, DOI 10.1200/JCO.1990.8.5.784; FREI E, 1989, J CLIN ONCOL, V7, P515, DOI 10.1200/JCO.1989.7.4.515; GRANINGER WB, 1987, J CLIN INVEST, V80, P1512, DOI 10.1172/JCI113235; GRIBBEN JG, 1989, J CLIN ONCOL, V7, P1621, DOI 10.1200/JCO.1989.7.11.1621; GRIBBEN JG, 1989, BLOOD, V73, P340; GRIBBEN JG, IN PRESS BLOOD; HIGUCHI R, 1986, PCR TECHNOLOGY, P31; HURD DD, 1988, AM J MED, V85, P829; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KWOK S, 1989, NATURE, V339, P490; LEE MS, 1987, BLOOD, V70, P90; LEE MS, 1987, SCIENCE, V237, P175, DOI 10.1126/science.3110950; MEHTA CR, 1984, BIOMETRICS, V40, P819, DOI 10.2307/2530927; NADLER LM, 1984, LANCET, V2, P427; NADLER LM, 1981, J CLIN INVEST, V67, P134, DOI 10.1172/JCI110005; NADLER LM, 1980, J IMMUNOL, V125, P570; NEGRIN RS, 1991, BLOOD, V77, P654; NGAN BY, 1989, BLOOD, V73, P1759; PETERS WP, 1988, J CLIN ONCOL, V6, P1368, DOI 10.1200/JCO.1988.6.9.1368; PETO R, 1972, J R STAT SOC SER A-G, V135, P185, DOI 10.2307/2344317; PHILIP T, 1987, NEW ENGL J MED, V316, P1493, DOI 10.1056/NEJM198706113162401; RITZ J, 1981, BLOOD, V58, P648; RITZ J, 1980, NATURE, V283, P583, DOI 10.1038/283583a0; ROY DC, 1990, LEUKEMIA RES, V14, P407, DOI 10.1016/0145-2126(90)90026-6; STEIN RS, 1976, CANCER, V37, P629, DOI 10.1002/1097-0142(197602)37:2<629::AID-CNCR2820370204>3.0.CO;2-K; TAKVORIAN T, 1987, NEW ENGL J MED, V316, P1499, DOI 10.1056/NEJM198706113162402; TASWELL C, 1981, J IMMUNOL, V126, P1614; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; UCKUN FM, 1987, BLOOD, V69, P361; WALLERSTEIN R, 1990, J CLIN ONCOL, V8, P1782, DOI 10.1200/JCO.1990.8.11.1782; WEISS LM, 1987, NEW ENGL J MED, V317, P1185, DOI 10.1056/NEJM198711053171904; YUNIS JJ, 1989, NEW ENGL J MED, V320, P1047, DOI 10.1056/NEJM198904203201605; YUNIS JJ, 1982, NEW ENGL J MED, V307, P1231, DOI 10.1056/NEJM198211113072002	49	692	715	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 28	1991	325	22					1525	1533		10.1056/NEJM199111283252201	http://dx.doi.org/10.1056/NEJM199111283252201			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GR380	1944436				2022-12-24	WOS:A1991GR38000001
J	SEEMAN, H; TRAUBE, M				SEEMAN, H; TRAUBE, M			HICCUPS AND ACHALASIA	ANNALS OF INTERNAL MEDICINE			English	Note							GASTROESOPHAGEAL REFLUX		YALE UNIV, SCH MED, GASTROENTEROL UNIT, POB 3333, NEW HAVEN, CT 06510 USA	Yale University				traube, morris/0000-0002-7028-6695				FELDMAN M, 1988, AM J MED SCI, V295, P60, DOI 10.1097/00000441-198801000-00013; FISHER MJ, 1989, DIGEST DIS SCI, V34, P1277, DOI 10.1007/BF01537278; GLUCK M, 1986, ANN INTERN MED, V105, P219, DOI 10.7326/0003-4819-105-2-219; GOLDENBERG SP, 1991, GASTROENTEROLOGY, V101, P743, DOI 10.1016/0016-5085(91)90534-R; KAUFMANN HJ, 1982, GASTROENTEROLOGY, V82, P1443; LEWIS JH, 1985, J CLIN GASTROENTEROL, V7, P539, DOI 10.1097/00004836-198512000-00021; MARSHALL JB, 1990, AM J GASTROENTEROL, V85, P1172; SHAY SS, 1984, GASTROENTEROLOGY, V87, P204	8	14	14	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1991	115	9					711	712		10.7326/0003-4819-115-9-711	http://dx.doi.org/10.7326/0003-4819-115-9-711			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GL697	1929039				2022-12-24	WOS:A1991GL69700008
J	LIMAN, ER; HESS, P; WEAVER, F; KOREN, G				LIMAN, ER; HESS, P; WEAVER, F; KOREN, G			VOLTAGE-SENSING RESIDUES IN THE S4 REGION OF A MAMMALIAN K+ CHANNEL	NATURE			English	Article							POTASSIUM CHANNEL; SODIUM-CHANNEL; DROSOPHILA; OOCYTES	THE ability of ion-channel proteins to respond to a change of the transmembrane voltage is one of the basic mechanisms underlying electrical excitability of nerve and muscle membranes. The voltage sensor has been postulated to be the fourth putative transmembrane segment 1 (S4) of voltage-activated Na+, Ca2+ and K+ channels 1-5. Mutations of positively charged residues within S4 alter gating of Na 4 and Shaker-type K+ channels 5, but quantitative correlations between the charge or a residue in S4 and the gating valence of the channel have not yet been established. Here, with improved resolution of the voltage dependence of steady-state activation, we present estimates of the equivalent gating valence with sufficient precision to allow quantitative examination of the contribution of individual charged residues to the gating valence of a mammalian non-inactivating K+ channel. We conclude that at least part of the gating charge associated with channel activation is indeed contributed by charged residues within the S4 segment.	HARVARD UNIV,SCH MED,DEPT CELLULAR & MOLEC PHYSIOL,25 SHATTUCK ST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,PROGRAM NEUROSCI,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT CARDIOL,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital			Liman, Emily/AAC-7383-2021	liman, emily/0000-0003-4765-5496				Almers W, 1978, Rev Physiol Biochem Pharmacol, V82, P96, DOI 10.1007/BFb0030498; AULD VJ, 1990, P NATL ACAD SCI USA, V87, P323, DOI 10.1073/pnas.87.1.323; BAUMANN A, 1988, EMBO J, V7, P2457, DOI 10.1002/j.1460-2075.1988.tb03092.x; BENNDORF K, 1989, EUR BIOPHYS J BIOPHY, V17, P257, DOI 10.1007/BF00254283; BEZANILLA F, 1982, NATURE, V296, P657, DOI 10.1038/296657a0; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; CHRISTIE MJ, 1989, SCIENCE, V244, P221, DOI 10.1126/science.2539643; CONTI F, 1989, EUR BIOPHYS J BIOPHY, V17, P53, DOI 10.1007/BF00257102; GILLY WMF, 1982, J GEN PHYSIOL, V70, P965; GUY HR, 1990, TRENDS NEUROSCI, V13, P201; HILLE B, 1984, IONIC CHANNELS EXCIT, P1; KOREN G, 1990, NEURON, V4, P39, DOI 10.1016/0896-6273(90)90442-I; LOGOTHETIS D E, 1991, Biophysical Journal, V59, p196A; LOPEZ GA, 1991, NEURON, V7, P327, DOI 10.1016/0896-6273(91)90271-Z; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; MCCORMACK K, 1991, P NATL ACAD SCI USA, V88, P2931, DOI 10.1073/pnas.88.7.2931; NODA M, 1984, NATURE, V312, P121, DOI 10.1038/312121a0; PAPAZIAN DM, 1987, SCIENCE, V237, P749, DOI 10.1126/science.2441470; PAPAZIAN DM, 1991, NATURE, V349, P305, DOI 10.1038/349305a0; STUEHMER W, 1989, Nature (London), V339, P597; SWENSON RP, 1981, NATURE, V291, P427, DOI 10.1038/291427a0; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; YOOL AJ, 1991, NATURE, V349, P700, DOI 10.1038/349700a0; ZAGOTTA WN, 1990, J GEN PHYSIOL, V95, P29, DOI 10.1085/jgp.95.1.29	24	249	252	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 24	1991	353	6346					752	756		10.1038/353752a0	http://dx.doi.org/10.1038/353752a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GL696	1944534				2022-12-24	WOS:A1991GL69600068
J	CELIN, SE; BLUESTONE, CD; STEPHENSON, J; YILMAZ, HM; COLLINS, JJ				CELIN, SE; BLUESTONE, CD; STEPHENSON, J; YILMAZ, HM; COLLINS, JJ			BACTERIOLOGY OF ACUTE OTITIS-MEDIA IN ADULTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEMOPHILUS-INFLUENZAE; MIDDLE-EAR; CHEMOTHERAPY; CHILDREN	Objective. - The objective of this study was to determine the bacteriology of acute otitis media in adults. Although this has frequently been studied in children, no data have recently been reported from adults in the United States. Additionally, information on the prevalence of Haemophilus influenzae as a causative organism in acute otitis media in adults has not been available. Design. - Middle-ear aspirates for cultures were obtained by myringotomy from adults meeting entry criteria. Setting. - Emergency department, Eye and Ear Hospital of Pittsburgh, Pa. Patients. - Thirty-four patients (volunteer sample) met the eligibility requirements. Exclusion criteria included history of chronic otitis media, recent antibiotic therapy, immunosuppressive illnesses, or prior otologic surgery. Intervention. - Ten days of oral cefuroxime axetil (250 mg) was prescribed. Main Outcome Measures.-Patients were followed closely for at least 6 weeks. Aerobic and anaerobic cultures were incubated and evaluated per the scheduled protocol. Results. - Haemophilus influenzae and Streptococcus pneumoniae were grown on culture of specimens f rom nine and seven patients (26% and 21 %), respectively Twenty-two percent (2/9) of the H influenzae isolates and the single isolate of Moraxella catarrhalis produced beta-lactamase (9% overall). Conclusions. - The present results suggest that, as in children, amoxicillin would be an appropriate first-line agent for empiric therapy of acute otitis media in adults. Antimicrobials inactive against H influenzae (eg, penicillin V, cephalexin, erythromycin, or tetracyclines) are not appropriate for initial therapy. Antimicrobials with efficacy against organisms producing beta-lactamase, such as cefuroxime axetil, which was used to treat the study patients, do not appear to be required for routine initial therapy in adults. However, they would be appropriate when an organism producing beta-lactamase is isolated from the middle ear or when a patient fails to improve rapidly on amoxicillin therapy.	UNIV PITTSBURGH,SCH MED,DEPT OTOLARYNGOL,DIV PEDIAT OTOLARYNGOL,PITTSBURGH,PA 15261; CHILDRENS HOSP PITTSBURGH,DEPT PEDIAT OTOLARYNGOL,MICROBIOL LAB,PITTSBURGH,PA; GLAXO INC,RES INST,DEPT CLIN RES,RES TRIANGLE PK,NC	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; GlaxoSmithKline								Bluestone, 1990, PEDIATRIC OTOLARYNGO, P320; BRANEFORSHELANDER P, 1975, SCAND J INFECT DIS, V7, P103, DOI 10.3109/inf.1975.7.issue-2.05; CHONMAITREE T, 1986, PEDIATRICS, V77, P698; DADSWELL JV, 1967, LANCET, V1, P243; DUDLEY JP, 1980, JAMA-J AM MED ASSOC, V243, P2328; HAUGSTEN P, 1980, J LARYNGOL OTOL, V94, P169, DOI 10.1017/S0022215100088630; HERBERTS G, 1971, PRACT-OTO-RHINO-LARY, V33, P191; HOWIE VM, 1970, PEDIATRICS, V45, P29; HOWIE VM, 1972, CLIN PEDIATR, V11, P205, DOI 10.1177/000992287201100407; KLEIN JO, 1980, ANN OTOL RHINOL LA S, V89, pS98; SCHWARTZ R, 1977, JAMA-J AM MED ASSOC, V238, P1032, DOI 10.1001/jama.238.10.1032; Schwartz R H, 1981, Am J Otolaryngol, V2, P19, DOI 10.1016/S0196-0709(81)80004-X; SHAMBAUGH GE, 1980, OTOLARYNGOLOGY, V2, P1448; STIERNBERG CM, 1986, OTOLARYNG HEAD NECK, V94, P648; SUGITA R, 1983, INT J PEDIATR OTORHI, V6, P135; SUGITA R, 1985, J LARYNGOL OTOL, V99, P629, DOI 10.1017/S0022215100097395; WALLACE RJ, 1978, AM J MED, V64, P87, DOI 10.1016/0002-9343(78)90182-1; [No title captured]	18	32	33	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 23	1991	266	16					2249	2252		10.1001/jama.266.16.2249	http://dx.doi.org/10.1001/jama.266.16.2249			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GK661	1920724				2022-12-24	WOS:A1991GK66100033
J	SUTTER, TR; GUZMAN, K; DOLD, KM; GREENLEE, WF				SUTTER, TR; GUZMAN, K; DOLD, KM; GREENLEE, WF			TARGETS FOR DIOXIN - GENES FOR PLASMINOGEN-ACTIVATOR INHIBITOR-2 AND INTERLEUKIN-1-BETA	SCIENCE			English	Article							MESSENGER-RNA; TRANSCRIPTIONAL ACTIVATION; GROWTH-FACTORS; CDNA CLONING; CELL-LINE; C-FOS; 2,3,7,8-TETRACHLORODIBENZO-PARA-DIOXIN; EXPRESSION; MOUSE; DIFFERENTIATION	Dioxin (2,3,7,8-tetrachlorodibenzo-p-dioxin, TCDD), a widespread environmental contaminant, may elicit its effects by altering gene expression in susceptible cells. Five TCDD-responsive complementary DNA clones were isolated from a human keratinocyte cell line. One of these clones encodes plasminogen activator inhibitor-2, a factor that influences growth and differentiation by regulating proteolysis of the extracellular matrix. Another encodes the cytokine interleukin-1-beta. Thus, TCDD alters the expression of growth regulatory genes and has effects similar to those of other tumor-promoting agents that affect both inflammation and differentiation.	CHEM IND INST TOXICOL,RES TRIANGLE PK,NC 27709									ABBOTT BD, 1989, TOXICOL APPL PHARM, V100, P119, DOI 10.1016/0041-008X(89)90096-3; AKIRA S, 1990, FASEB J, V4, P2860, DOI 10.1096/fasebj.4.11.2199284; ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; ANDREASEN PA, 1990, MOL CELL ENDOCRINOL, V68, P1, DOI 10.1016/0303-7207(90)90164-4; AURON PE, 1984, P NATL ACAD SCI-BIOL, V81, P7907, DOI 10.1073/pnas.81.24.7907; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; Bailar J C 3rd, 1991, N Engl J Med, V324, P260, DOI 10.1056/NEJM199101243240409; BERGHARD A, 1990, J BIOL CHEM, V265, P21086; Bravo R, 1990, Semin Cancer Biol, V1, P37; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COOK JC, 1987, ENVIRON HEALTH PERSP, V76, P71, DOI 10.2307/3430467; DINARELLO CA, 1989, B NEW YORK ACAD MED, V65, P80; DOLD KM, 1990, ANAL BIOCHEM, V184, P67, DOI 10.1016/0003-2697(90)90013-Y; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; DUNIGAN DD, 1987, BIOTECHNIQUES, V5, P32; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FINGERHUT MA, 1991, NEW ENGL J MED, V324, P212, DOI 10.1056/NEJM199101243240402; GOUGH M, 1988, RISK ANAL, V8, P337, DOI 10.1111/j.1539-6924.1988.tb00496.x; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HANAHAN D, 1980, GENE, V10, P63, DOI 10.1016/0378-1119(80)90144-4; HART DA, 1988, COMP BIOCHEM PHYS B, V90, P691, DOI 10.1016/0305-0491(88)90323-9; HUDSON LG, 1986, TOXICOL APPL PHARM, V82, P481, DOI 10.1016/0041-008X(86)90283-8; ISRAEL DI, 1985, J BIOL CHEM, V260, P5648; KIMURA S, 1986, MOL CELL BIOL, V6, P1471, DOI 10.1128/MCB.6.5.1471; KOCIBA RJ, 1978, TOXICOL APPL PHARM, V46, P279, DOI 10.1016/0041-008X(78)90075-3; KRUITHOF EKO, 1988, BIOCHEM BIOPH RES CO, V156, P383, DOI 10.1016/S0006-291X(88)80852-0; LAIHO M, 1989, CANCER RES, V49, P2533; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; Maniatis T., 1982, MOL CLONING LAB MANU, P191; MARCH CJ, 1985, NATURE, V315, P641, DOI 10.1038/315641a0; MCCONKEY DJ, 1988, SCIENCE, V242, P256, DOI 10.1126/science.3262923; NEBERT DW, 1989, INT J BIOCHEM, V21, P243, DOI 10.1016/0020-711X(89)90182-1; NISHIDA T, 1987, BIOCHEM BIOPH RES CO, V143, P345, DOI 10.1016/0006-291X(87)90671-1; PASCO DS, 1988, J BIOL CHEM, V263, P8671; PHILLIPS CL, 1988, MOL ENDOCRINOL, V2, P641, DOI 10.1210/mend-2-7-641; POLAND A, 1982, ANNU REV PHARMACOL, V22, P517, DOI 10.1146/annurev.pa.22.040182.002505; PRATT RM, 1984, TERATOGEN CARCIN MUT, V4, P427, DOI 10.1002/tcm.1770040505; QUATTROCHI LC, 1986, P NATL ACAD SCI USA, V83, P6731, DOI 10.1073/pnas.83.18.6731; REINERS JJ, 1990, P NATL ACAD SCI USA, V87, P1825, DOI 10.1073/pnas.87.5.1825; SAATCIOGLU F, 1990, MOL CELL BIOL, V10, P6408, DOI 10.1128/MCB.10.12.6408; SAFE SH, 1986, ANNU REV PHARMACOL, V26, P371, DOI 10.1146/annurev.pa.26.040186.002103; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLEUNING WD, 1987, MOL CELL BIOL, V7, P4564, DOI 10.1128/MCB.7.12.4564; SHENG M, 1988, MOL CELL BIOL, V8, P2787, DOI 10.1128/MCB.8.7.2787; SKENE SA, 1989, HUM TOXICOL, V8, P173, DOI 10.1177/096032718900800301; SUSKIND RR, 1985, SCAND J WORK ENV HEA, V11, P165, DOI 10.5271/sjweh.2240; SUTTER TR, 1990, J BIOL CHEM, V265, P16428; SUTTER TR, 1989, BIOCHEM BIOPH RES CO, V160, P1257, DOI 10.1016/S0006-291X(89)80139-1; SUTTER TR, UNPUB; Taylor J S, 1979, Ann N Y Acad Sci, V320, P295, DOI 10.1111/j.1749-6632.1979.tb13155.x; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; VLASSARA H, 1988, SCIENCE, V240, P1546, DOI 10.1126/science.3259727; WHITLOCK JP, 1990, ANNU REV PHARMACOL, V30, P251; YE RD, 1987, J BIOL CHEM, V262, P3718	55	305	312	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 18	1991	254	5030					415	418		10.1126/science.1925598	http://dx.doi.org/10.1126/science.1925598			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GK729	1925598				2022-12-24	WOS:A1991GK72900044
J	HEALY, B				HEALY, B			BONE-MARROW TRANSPLANTATION FOR ADULTS WITH ACUTE LYMPHOBLASTIC-LEUKEMIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											HEALY, B (corresponding author), NIH,BETHESDA,MD 20892, USA.							1991, ANN INTERN MED, V115, P13	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 16	1991	266	15					2054	2054						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GJ474	1920686				2022-12-24	WOS:A1991GJ47400006
J	STANLEY, SL; JACKSON, TFHG; REED, SL; CALDERON, J; KUNZJENKINS, C; GATHIRAM, V; LI, E				STANLEY, SL; JACKSON, TFHG; REED, SL; CALDERON, J; KUNZJENKINS, C; GATHIRAM, V; LI, E			SERODIAGNOSIS OF INVASIVE AMEBIASIS USING A RECOMBINANT ENTAMOEBA-HISTOLYTICA PROTEIN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							ANTIBODY RESPONSE; ZYMODEMES; ANTIGEN	One hundred eight serum samples from 106 patients were examined by Western blot analysis for the presence of antibodies to a recombinant fusion protein containing the sequence of the newly described serine-rich Entamoeba histolytica protein (SREHP). Among patients with invasive amebiasis from Durban, Republic of South Africa; San Diego, Calif; Mexico City, Mexico; and St Louis, Mo, 53 (82%) of 65 had antibodies to SREHP. In contrast, only one patient (2%) of 43 without acute invasive amebiasis had antibodies to SREHP. The predictive value of a positive test for anti-SREHP antibodies in the detection of acute invasive amebiasis was most marked when analyzed in the patients from Durban, where 11 (92%) of 12 patients who were seropositive for SREHP had acute invasive amebiasis vs 17 (65%) of 26 patients who had a positive serologic diagnosis as determined by agar gel diffusion. The use of a serologic test based on the recombinant SREHP fusion protein may be a useful adjunct to the diagnosis of acute invasive amebiasis in endemic regions.	S AFRICAN MRC,DIS TROP ENVIRONM RES INST,DURBAN,SOUTH AFRICA; NATL POLYTECH INST,CTR INVEST & ESTUDIOS AVANZADOS,MEXICO CITY 14,DF,MEXICO; WASHINGTON UNIV,SCH MED,DEPT MOLEC MICROBIOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOCHEM & BIOPHYS,ST LOUIS,MO 63110; UNIV CALIF SAN DIEGO,DEPT MED,SAN DIEGO,CA 92103; UNIV CALIF SAN DIEGO,DEPT PATHOL,SAN DIEGO,CA 92103	South African Medical Research Council; CINVESTAV - Centro de Investigacion y de Estudios Avanzados del Instituto Politecnico Nacional; Instituto Politecnico Nacional - Mexico; Washington University (WUSTL); Washington University (WUSTL); University of California System; University of California San Diego; University of California System; University of California San Diego	STANLEY, SL (corresponding author), WASHINGTON UNIV,SCH MED,DEPT MED,BOX 8051,660 S EUCLID AVE,ST LOUIS,MO 63110, USA.							GATHIRAM V, 1985, LANCET, V1, P719; JACKSON TFHG, 1985, LANCET, V1, P716; JACKSON TFHG, 1984, T ROY SOC TROP MED H, V78, P342, DOI 10.1016/0035-9203(84)90115-9; JUNIPER K, 1972, AM J TROP MED HYG, V21, P157, DOI 10.4269/ajtmh.1972.21.157; KRUPP IM, 1970, AM J TROP MED HYG, V19, P57, DOI 10.4269/ajtmh.1970.19.57; KRUPP IM, 1971, AM J TROP MED HYG, V20, P421, DOI 10.4269/ajtmh.1971.20.421; LOBEL HO, 1978, ANNU REV MICROBIOL, V32, P329, DOI 10.1146/annurev.mi.32.100178.001553; STANLEY SL, 1990, P NATL ACAD SCI USA, V87, P4976, DOI 10.1073/pnas.87.13.4976; TORIAN BE, 1989, J INFECT DIS, V159, P794, DOI 10.1093/infdis/159.4.794; Walsh J.A., 1988, P93	10	39	43	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 9	1991	266	14					1984	1986		10.1001/jama.266.14.1984	http://dx.doi.org/10.1001/jama.266.14.1984			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GH406	1895478				2022-12-24	WOS:A1991GH40600026
J	HALPIN, SFS; YEOMAN, L; DUNDAS, DD				HALPIN, SFS; YEOMAN, L; DUNDAS, DD			RADIOGRAPHIC EXAMINATION OF THE LUMBAR SPINE IN A COMMUNITY-HOSPITAL - AN AUDIT OF CURRENT PRACTICE	BRITISH MEDICAL JOURNAL			English	Article							DIAGNOSTIC-RADIOLOGY; ROYAL-COLLEGE; GUIDELINES	Objective - To assess general practitioners' decisions to request lumbar spine radiographs according to the guidelines of the Royal College of Radiologists. Design - Prospective questionnaire survey of outpatients attending for lumbar spine radiography. Setting - London community hospital. Subjects - 100 consecutive adult outpatients attending for lumbar spine radiography at their general practitioner's request. Main outcome measures - Patient's history and clinical signs; radiological diagnosis; change in management of patients with significant radiological abnormality in response to the radiologist's report. Results - 60 patients were aged between 18 and 45, 27 (45%) of whom were women. Five patients were fully examined by their doctor before radiographs were requested, 76 were partially examined, and 19 were not examined. In 37 patients the examinations showed radiologically normal findings; 30 had radiologically significant disc or degenerative disease. Pain score and radiological diagnosis was not correlated (6.43 (range 1-10) for patients with significant disease v 6.14 (range 1-10) for those without, p > 0.05). There were no cases of malignancy or infection. One patient with radiologically significant disease was referred to a hospital specialist, and the management of only two such patients was altered by the report. 52 of the examinations should not have been requested if the guidelines had been strictly applied. Conclusions - There is a need to inform doctors of the efficacy of radiological examinations. An awareness of the college's guidelines among general practitioners should be actively promoted by radiologists.	BOLINGBROKE HOSP,DEPT RADIOL,LONDON SW11,ENGLAND									BUTT WP, 1989, CLIN RADIOL, V40, P6, DOI 10.1016/S0009-9260(89)80004-2; Edelstyn G A, 1967, Clin Radiol, V18, P158, DOI 10.1016/S0009-9260(67)80010-2; FOWKES FGR, 1987, CLIN RADIOL, V38, P45, DOI 10.1016/S0009-9260(87)80399-9; FOWKES FGR, 1984, LANCET, V2, P795; Her Majesty's Stationery Office, 1985, IONISING RAD REGULAT; KELEN GD, 1986, ANN EMERG MED, V15, P245, DOI 10.1016/S0196-0644(86)80556-X; NACHEMSON A, 1976, LUMBAR SPINE BACK PA, P355; PEARSON R, 1989, BRIT MED J, V299, P1175, DOI 10.1136/bmj.299.6709.1175; QUINET RJ, 1979, SEMIN ARTHRITIS RHEU, V8, P261, DOI 10.1016/0049-0172(79)90005-2; ROBERTS CJ, 1984, J ROY COLL PHYS LOND, V18, P62; ROBERTS CJ, 1981, LANCET, V2, P791; ROBERTS CJ, 1988, CLIN RADIOL, V39, P3, DOI 10.1016/S0009-9260(88)80325-8; RYAN M, 1991, RES MED PRACTICE VAR; WADDELL G, 1982, BRIT J HOSP MED, V28, P187; 1989, NRPBR227; 1990, PATIENT DOSE REDUCTI; 1987, NATIONAL RADIOLOGI S, V86; 1986, NRPBR200; 1990, MAKING BEST IMAGING; 1989, LIVING RAD; 1989, MAKING BEST USE DEP	21	40	40	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 5	1991	303	6806					813	815		10.1136/bmj.303.6806.813	http://dx.doi.org/10.1136/bmj.303.6806.813			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GH946	1932970	Green Published, Bronze			2022-12-24	WOS:A1991GH94600020
J	ERVASTI, JM; CAMPBELL, KP				ERVASTI, JM; CAMPBELL, KP			MEMBRANE ORGANIZATION OF THE DYSTROPHIN-GLYCOPROTEIN COMPLEX	CELL			English	Article							RABBIT SKELETAL-MUSCLE; DUCHENNE MUSCULAR-DYSTROPHY; MOLECULE N-CAM; SARCOPLASMIC-RETICULUM; CELL-ADHESION; ULTRASTRUCTURAL-LOCALIZATION; 1,4-DIHYDROPYRIDINE RECEPTOR; RYANODINE RECEPTOR; PROTEINS; IDENTIFICATION	The stoichiometry, cellular location, glycosylation, and hydrophobic properties of the components in the dystrophin-glycoprotein complex were examined. The 156, 59, 50, 43, and 35 kd dystrophin-associated proteins each possess unique antigenic determinants, enrich quantitatively with dystrophin, and were localized to the skeletal muscle sarcolemma. The 156, 50, 43, and 35 kd dystrophin-associated proteins contained Asn-linked oligosaccharides. The 156 kd dystrophin-associated glycoprotein contained terminally sialylated Ser/Thr-linked oligosaccharides. Dystrophin, the 156 kd, and the 59 kd dystrophin-associated proteins were found to be peripheral membrane proteins, while the 50 kd, 43 kd, and 35 kd dystrophin-associated glycoproteins and the 25 kd dystrophin-associated protein were confirmed as integral membrane proteins. These results demonstrate that dystrophin and its 59 kd associated protein are cytoskeletal elements that are tightly linked to a 156 kd extracellular glycoprotein by way of a complex of transmembrane proteins.	UNIV IOWA, COLL MED, DEPT PHYSIOL & BIOPHYS, IOWA CITY, IA 52242 USA	University of Iowa	ERVASTI, JM (corresponding author), UNIV IOWA, COLL MED, HOWARD HUGHES MED INST, IOWA CITY, IA 52242 USA.		Ervasti, James/AAZ-4786-2020; Pillay, Nischalan/F-9536-2012	Campbell, Kevin/0000-0003-2066-5889				ARAHATA K, 1988, NATURE, V333, P861, DOI 10.1038/333861a0; BENNETT V, 1990, PHYSIOL REV, V70, P1029, DOI 10.1152/physrev.1990.70.4.1029; BONILLA E, 1988, CELL, V54, P447, DOI 10.1016/0092-8674(88)90065-7; BRUNNER J, 1981, BIOCHEMISTRY-US, V20, P7174, DOI 10.1021/bi00528a019; CAMPBELL KP, 1987, J BIOL CHEM, V262, P6460; CAMPBELL KP, 1989, NATURE, V338, P259, DOI 10.1038/338259a0; CAMPBELL KP, 1991, INT CONGR SER, P321; Carney S.L., 1986, CARBOHYDRATE ANAL, P97; CARRAWAY KL, 1989, BIOCHIM BIOPHYS ACTA, V988, P147, DOI 10.1016/0304-4157(89)90017-8; CHANG HW, 1989, J BIOL CHEM, V264, P20831; CRAWFORD AW, 1991, J BIOL CHEM, V266, P5847; CULLEN MJ, 1990, PROC R SOC SER B-BIO, V240, P197, DOI 10.1098/rspb.1990.0034; CUMMINGS RD, 1983, J BIOL CHEM, V258, P5261; ERVASTI JM, 1991, J BIOL CHEM, V266, P9161; ERVASTI JM, 1990, NATURE, V345, P315, DOI 10.1038/345315a0; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; FONG P, 1990, SCIENCE, V250, P673, DOI 10.1126/science.2173137; FRANCO A, 1990, NATURE, V344, P670, DOI 10.1038/344670a0; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; HOLDEN KG, 1971, BIOCHEMISTRY-US, V10, P3105, DOI 10.1021/bi00792a019; JAY SD, 1991, J BIOL CHEM, V266, P3287; JENTOFT N, 1990, TRENDS BIOCHEM SCI, V15, P291, DOI 10.1016/0968-0004(90)90014-3; JORGENSEN AO, 1990, J CELL BIOL, V110, P1173, DOI 10.1083/jcb.110.4.1173; KOENIG M, 1990, J BIOL CHEM, V265, P4560; KOENIG M, 1988, CELL, V53, P219, DOI 10.1016/0092-8674(88)90383-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBERER E, 1989, J BIOL CHEM, V264, P3484; LEBERER E, 1990, J BIOL CHEM, V265, P10118; LEUNG AT, 1987, J BIOL CHEM, V262, P7943; MENKE A, 1991, NATURE, V349, P69, DOI 10.1038/349069a0; MOORE SE, 1987, J CELL BIOL, V105, P1377, DOI 10.1083/jcb.105.3.1377; MURAYAMA T, 1990, P JPN ACAD B-PHYS, V66, P96, DOI 10.2183/pjab.66.96; OHLENDIECK K, 1991, FEBS LETT, V283, P230, DOI 10.1016/0014-5793(91)80595-T; OHLENDIECK K, 1991, J CELL BIOL, V112, P135, DOI 10.1083/jcb.112.1.135; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; RUSSELL DW, 1984, CELL, V37, P577, DOI 10.1016/0092-8674(84)90388-X; RUTISHAUSER U, 1988, PHYSIOL REV, V68, P829; SHARP AH, 1987, J BIOL CHEM, V262, P12309; SHARP AH, 1989, J BIOL CHEM, V264, P2816; STECK T L, 1973, Journal of Supramolecular Structure, V1, P220, DOI 10.1002/jss.400010307; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WALSH FS, 1989, DEVELOPMENT, V105, P803; WATKINS SC, 1988, NATURE, V333, P863, DOI 10.1038/333863a0; WELLER B, 1990, J NEUROL SCI, V100, P9, DOI 10.1016/0022-510X(90)90005-8; YOSHIDA M, 1990, J BIOCHEM-TOKYO, V108, P748, DOI 10.1093/oxfordjournals.jbchem.a123276; ZARAINHERZBERG A, 1988, J BIOL CHEM, V263, P4807; ZUBRZYCKAGAARN EF, 1988, NATURE, V333, P466, DOI 10.1038/333466a0	49	1127	1145	2	62	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	SEP 20	1991	66	6					1121	1131		10.1016/0092-8674(91)90035-W	http://dx.doi.org/10.1016/0092-8674(91)90035-W			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GG552	1913804				2022-12-24	WOS:A1991GG55200007
J	JACKSON, R; SCRAGG, R; BEAGLEHOLE, R				JACKSON, R; SCRAGG, R; BEAGLEHOLE, R			ALCOHOL-CONSUMPTION AND RISK OF CORONARY HEART-DISEASE	BRITISH MEDICAL JOURNAL			English	Article							U-SHAPED CURVE; MORTALITY; MEN	Objective - To investigate the hypothesis that the apparent protective effect of habitual alcohol consumption on coronary heart disease is due to drinkers at high risk of coronary heart disease becoming non-drinkers. Design - Case-control population based study. Data were obtained from interviews with patients with non-fatal myocardial infarction and their controls and with the next of kin of those who had died of coronary heart disease and their controls. Setting - Auckland, New Zealand. Subjects - Two groups of cases were studied. The first comprised 227 men and 72 women with non-fatal myocardial infarction identified from a population based surveillance programme for coronary heart disease; controls were 525 men and 341 women randomly selected from the same population group and matched for age and sex. The second group comprised 128 men and 30 women who had died of coronary heart disease and had been identified from the surveillance programme; controls were a sample of the previous control group and comprised 330 men and 214 women matched for age and sex. All participants were aged 25-64 years and without diagnosed coronary heart disease. Main outcome measures - Regular alcohol consumption; high density lipoprotein cholesterol and low density lipoprotein concentrations. Results - Men with myocardial infarction and men who had died of coronary heart disease were more likely to have been never drinkers (had never drunk more than once a month) than controls (18% v 12% and 23% v 13% respectively). After possible confounding factors had been controlled for, people in all categories of drinking (up to more than 56 drinks per week) had at least a 40% reduction in risk of fatal and non-fatal coronary heart disease compared with never drinkers. Former drinkers also had a lower risk of non-fatal myocardial infarction than never drinkers (relative risks 0.41 and 0.10 in men and women respectively) but a similar risk of death from coronary heart disease. The reduction in risk was consistently greater in women than in men in all drinking categories but there was no clear dose-response effect in either sex. Conclusions - The results support the hypothesis that light and moderate alcohol consumption reduces the risk of coronary heart disease. This protective effect in this population was not due to the misclassification of former drinkers with a high risk of coronary heart disease as non-drinkers.			JACKSON, R (corresponding author), UNIV AUCKLAND,SCH MED,DEPT COMMUNITY HLTH,AUCKLAND 1,NEW ZEALAND.			Scragg, Robert/0000-0003-0013-2620; Jackson, Rod/0000-0001-5914-6934				ALANKO T, 1984, RES ADV ALCOHOL DRUG, V8, P299; BONITA R, 1983, COMMUNITY HEALTH ST, V7, P111; CRIQUI MH, 1990, BRIT J ADDICT, V85, P854; CRIQUI MH, 1987, AM J EPIDEMIOL, V126, P629, DOI 10.1093/oxfordjournals.aje.a114702; FRASER G, 1986, PREVENTIVE CARDIOLOG; HARREL F, 1983, LOGIST PROCEDURE; HASKELL WL, 1984, NEW ENGL J MED, V310, P805, DOI 10.1056/NEJM198403293101301; JACKSON R, 1988, NEW ZEAL MED J, V101, P658; JACKSON R, 1987, BRIT MED J, V294, P1588, DOI 10.1136/bmj.294.6587.1588; KITTNER SJ, 1983, AM J EPIDEMIOL, V117, P538, DOI 10.1093/oxfordjournals.aje.a113576; KLATSKY AL, 1986, AM J CARDIOL, V58, P710, DOI 10.1016/0002-9149(86)90342-5; KOZAREVIC DJ, 1981, LANCET, V1, P613; MACLURE M, 1987, AM J EPIDEMIOL, V126, P161, DOI 10.1093/aje/126.2.161; MACMAHON S, 1987, HYPERTENSION, V9, P111, DOI 10.1161/01.HYP.9.2.111; MARMOT MG, 1984, INT J EPIDEMIOL, V13, P160, DOI 10.1093/ije/13.2.160; MARMOT MG, 1981, LANCET, V1, P580; MEADE TW, 1979, BMJ-BRIT MED J, V1, P153, DOI 10.1136/bmj.1.6157.153; MIKHAILIDIS DP, 1983, BRIT MED J, V287, P1495, DOI 10.1136/bmj.287.6404.1495; PEARCE NE, 1983, NEW ZEAL MED J, V96, P281; Rose G, 1982, CARDIOVASCULAR SURVE; SHAPER AG, 1990, BRIT J ADDICT, V85, P837; SHAPER AG, 1988, LANCET, V2, P1267; STAMPFER MJ, 1988, NEW ENGL J MED, V319, P267, DOI 10.1056/NEJM198808043190503; YANO K, 1977, NEW ENGL J MED, V297, P405, DOI 10.1056/NEJM197708252970801; 1988, J CLIN EPIDEMIOL, V41, P105	25	202	203	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 27	1991	303	6796					211	216		10.1136/bmj.303.6796.211	http://dx.doi.org/10.1136/bmj.303.6796.211			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FZ563	1884056	Green Published, Bronze			2022-12-24	WOS:A1991FZ56300019
J	CHAVEZ, GF; MULINARE, J; EDMONDS, LD				CHAVEZ, GF; MULINARE, J; EDMONDS, LD			EPIDEMIOLOGY OF RH HEMOLYTIC-DISEASE OF THE NEWBORN IN THE UNITED-STATES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMMUNE GLOBULIN; IMMUNOGLOBULIN UTILIZATION; RHESUS ISOIMMUNIZATION; PREVENTION; IDENTIFICATION; SURVEILLANCE; MANAGEMENT	Nationwide surveillance of Rh hemolytic disease of the newborn (RhHDN) indicates that, after a substantial decline in incidence, reported rates reached a plateau in the late 1970s. We conducted a study designed to validate RhHDN surveillance data, to obtain corrected incidence estimates, and to identify potential reasons for the reported plateau. We obtained data from the Birth Defects Monitoring Program, a national surveillance system that collects data from public and private hospitals participating voluntarily. We asked hospitals for copies of the medical records for all infants discharged with a code for RhHDN and for a sample of the medical records of infants discharged with a code for other and unspecified hemolytic disease during 1986. The estimated incidence rate of RhHDN was 10.6 per 10 000 total births, with some regional variations. Our findings indicate that, despite the availability of an effective preventive measure, RhHDN continues to contribute significantly to infant morbidity and mortality in the United States.	CTR DIS CONTROL,CTR ENVIRONM HLTH & INJURY CONTROL,DIV BIRTH DEFECTS & DEV DISABIL,ATLANTA,GA 30333	Centers for Disease Control & Prevention - USA								ADAMS MM, 1981, AM J PUBLIC HEALTH, V71, P1031, DOI 10.2105/AJPH.71.9.1031; ADAMS MM, 1984, AM J OBSTET GYNECOL, V149, P633, DOI 10.1016/0002-9378(84)90248-5; BEHRMAN RE, 1987, NELSON TXB PEDIATRIC, P384; BOWMAN JM, 1983, CAN MED ASSOC J, V129, P343; BOWMAN JM, 1984, AM J OBSTET GYNECOL, V148, P1151, DOI 10.1016/0002-9378(84)90651-3; Bowman JM., 1978, PERINATAL CARE, V2, P24; Caiola G, 1984, Obstet Gynecol Surv, V39, P55, DOI 10.1097/00006254-198401000-00021; CLARKE CA, 1985, BRIT MED J, V291, P17, DOI 10.1136/bmj.291.6487.17; EDMONDS LD, 1981, INT J EPIDEMIOL, V10, P247, DOI 10.1093/ije/10.3.247; FREDA VJ, 1975, NEW ENGL J MED, V292, P1014, DOI 10.1056/NEJM197505082921906; FRIGOLETTO FD, 1979, CLIN PERINATOL, V6, P321, DOI 10.1016/S0095-5108(18)31150-3; GRIMES DA, 1983, SOUTHERN MED J, V76, P743, DOI 10.1097/00007611-198306000-00017; GRIMES DA, 1977, OBSTET GYNECOL, V50, P261; GRIMES DA, 1981, AM J OBSTET GYNECOL, V140, P246, DOI 10.1016/0002-9378(81)90268-4; HENRY G, 1976, OBSTET GYNECOL, V48, P557; HENSLEIGH PA, 1983, AM J OBSTET GYNECOL, V146, P749, DOI 10.1016/0002-9378(83)91071-2; KEITH L, 1978, PERINATAL CARE, V2, P37; KORNSTAD L, 1987, NIPH (National Institute of Public Health) Annals (Oslo), V10, P3; LIM OW, 1982, OBSTET GYNECOL, V59, P477; POLLACK W, 1978, PERINATAL CARE, V2, P8; WIBLEKANT J, 1983, CLIN PERINATOL, V10, P343, DOI 10.1016/S0095-5108(18)30970-9; WYSOWSKI DK, 1979, JAMA-J AM MED ASSOC, V242, P1376, DOI 10.1001/jama.242.13.1376; 1988, MONTHLY VITAL STATIS, V37; 1989, GUIDE CLIN PREVENTIV, P221; 1988, MMWR S5, V37, P1; 1981, MMWR, V30, P13; 1985, MMWR, V34, pSS1	27	95	99	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 26	1991	265	24					3270	3274		10.1001/jama.265.24.3270	http://dx.doi.org/10.1001/jama.265.24.3270			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FR835	1904504				2022-12-24	WOS:A1991FR83500033
J	PHILP, I; MAWHINNEY, S; MUTCH, WJ				PHILP, I; MAWHINNEY, S; MUTCH, WJ			SETTING STANDARDS FOR LONG-TERM CARE OF THE ELDERLY IN HOSPITAL	BRITISH MEDICAL JOURNAL			English	Article									UNIV DUNDEE,NINEWELLS HOSP & MED SCH,GERIATR MED,DUNDEE DD1 9SY,SCOTLAND	University of Dundee				philp, ian/0000-0002-3972-6496				DENHAM M, 1989, CARE ELDERLY, V1, P855; DONALDSON C, 1988, AGE AGEING, V17, P379, DOI 10.1093/ageing/17.6.379; Kane RA, 1987, LONG TERM CARE PRINC; PHILP I, IN PRESS INT J GERIA; WILSON L A, 1973, Age and Ageing, V2, P92, DOI 10.1093/ageing/2.2.92	5	3	3	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 4	1991	302	6784					1056	1056		10.1136/bmj.302.6784.1056	http://dx.doi.org/10.1136/bmj.302.6784.1056			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FK563	1903665	Green Published, Bronze			2022-12-24	WOS:A1991FK56300023
J	DEISS, LP; KIMCHI, A				DEISS, LP; KIMCHI, A			A GENETIC TOOL USED TO IDENTIFY THIOREDOXIN AS A MEDIATOR OF A GROWTH INHIBITORY SIGNAL	SCIENCE			English	Article							TUMOR SUPPRESSOR GENES; EPSTEIN-BARR VIRUS; C-MYC SUPPRESSION; INTERFERON-GAMMA; TRANSFORMED PHENOTYPE; NECROSIS FACTOR; CDNA LIBRARIES; EXPRESSION; CLONING; CELLS	Loss of sensitivity to growth inhibitory polypeptides is likely to be one of the events that participates in the formation of some tumors and might be caused by inactivation or loss of the genetic elements that transduce these extracellular signals. The isolation of such a gene was achieved by randomly inactivating genes by an anti-sense complementary DNA expression library followed by direct selection for growth in the presence of an inhibitory polypeptide. Thus, a gene whose inactivation conveyed growth resistance to interferon-gamma (IFN-gamma) was isolated. Sequence analysis showed complete identity with human thioredoxin, a dithiol reducing agent, implicated here in the IFN-gamma-mediated growth arrest of HeLa cells.	WEIZMANN INST SCI,DEPT MOLEC GENET & VIROL,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science								ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ABATE C, 1990, P NATL ACAD SCI USA, V87, P1032, DOI 10.1073/pnas.87.3.1032; AUNE TM, 1989, J CLIN INVEST, V84, P863, DOI 10.1172/JCI114247; BENNETT CF, 1988, NATURE, V334, P268, DOI 10.1038/334268a0; BERGSMA DJ, 1982, P NATL ACAD SCI-BIOL, V79, P381, DOI 10.1073/pnas.79.2.381; BERNARD JA, 1989, P NATL ACAD SCI USA, V86, P1578; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BROWN JM, 1990, P NATL ACAD SCI USA, V87, P5026, DOI 10.1073/pnas.87.13.5026; COHEN B, 1988, EMBO J, V7, P1411, DOI 10.1002/j.1460-2075.1988.tb02958.x; DEISS LP, UNPUB; DERYNCK R, 1985, NATURE, V316, P701, DOI 10.1038/316701a0; DIAZ MO, 1988, P NATL ACAD SCI USA, V85, P5259, DOI 10.1073/pnas.85.14.5259; DRINKWATER NR, 1986, P NATL ACAD SCI USA, V83, P3402, DOI 10.1073/pnas.83.10.3402; EINAT M, 1985, NATURE, V313, P597, DOI 10.1038/313597a0; EINAT M, 1988, ONCOGENE, V2, P485; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; ELLIS RW, 1980, J VIROL, V36, P408, DOI 10.1128/JVI.36.2.408-420.1980; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FINDLAY CA, 1989, CELL, V57, P1083; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAY PW, 1984, NATURE, V312, P721, DOI 10.1038/312721a0; GRIPPO JF, 1985, J BIOL CHEM, V260, P93; GROGER RK, 1989, GENE, V81, P285, DOI 10.1016/0378-1119(89)90189-3; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.biochem.54.1.237; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; IJZERMANS JNM, 1989, IMMUNOBIOLOGY, V179, P456, DOI 10.1016/S0171-2985(89)80049-X; KIMCHI A, 1988, MOL CELL BIOL, V8, P2828, DOI 10.1128/MCB.8.7.2828; KLEIN G, 1987, SCIENCE, V238, P1539, DOI 10.1126/science.3317834; LEE F, 1981, NATURE, V294, P228, DOI 10.1038/294228a0; LENGYEL P, 1982, ANNU REV BIOCHEM, V51, P521; MALIK N, 1989, MOL CELL BIOL, V9, P2847, DOI 10.1128/MCB.9.7.2847; MEISSNER PS, 1987, P NATL ACAD SCI USA, V84, P4171, DOI 10.1073/pnas.84.12.4171; MIKKELSEN T, 1990, CELL GROWTH DIFFER, V1, P201; NODA M, 1989, P NATL ACAD SCI USA, V86, P162, DOI 10.1073/pnas.86.1.162; PENNICA D, 1984, NATURE, V312, P724, DOI 10.1038/312724a0; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; PIETENPOL JA, 1990, P NATL ACAD SCI USA, V87, P3758, DOI 10.1073/pnas.87.10.3758; RESNITZKY D, 1986, CELL, V46, P31, DOI 10.1016/0092-8674(86)90857-3; RESNITZKY D, 1991, CELL GROWTH DIFFER, V2, P33; SAGER R, 1989, SCIENCE, V246, P1406, DOI 10.1126/science.2574499; SCHAEFER R, 1988, P NATL ACAD SCI USA, V85, P1590, DOI 10.1073/pnas.85.5.1590; SHOYAB M, 1989, SCIENCE, V243, P1074, DOI 10.1126/science.2466334; STEG P S, 1988, Cancer Research, V48, P6550; TAGAYA Y, 1989, EMBO J, V8, P757, DOI 10.1002/j.1460-2075.1989.tb03436.x; WATANABE Y, 1989, P NATL ACAD SCI USA, V86, P9456, DOI 10.1073/pnas.86.23.9456; WEINBERG RA, 1989, CANCER RES, V49, P3713; WOLLMAN EE, 1988, J BIOL CHEM, V263, P15506; YARDEN A, 1986, SCIENCE, V234, P1419, DOI 10.1126/science.3097823; YATES JL, 1985, NATURE, V313, P812, DOI 10.1038/313812a0	53	185	203	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 5	1991	252	5002					117	120		10.1126/science.1901424	http://dx.doi.org/10.1126/science.1901424			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FE952	1901424				2022-12-24	WOS:A1991FE95200047
J	GOLDMAN, L; WEINSTEIN, MC; GOLDMAN, PA; WILLIAMS, LW				GOLDMAN, L; WEINSTEIN, MC; GOLDMAN, PA; WILLIAMS, LW			COST-EFFECTIVENESS OF HMG-COA REDUCTASE INHIBITION FOR PRIMARY AND SECONDARY PREVENTION OF CORONARY HEART-DISEASE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA; STAGE RENAL-DISEASE; 2 NATIONAL SURVEYS; SERUM-CHOLESTEROL; POLICY MODEL; RISK-FACTORS; MORTALITY; THERAPY; DIET; CHOLESTYRAMINE	To determine the cost-effectiveness of HMG-CoA (3-hydroxy-3-methylglutaryl coenzyme A) reductase inhibitors (such as lovastatin) for the primary and secondary prevention of coronary heart disease, we used the Coronary Heart Disease Policy Model, a computer-simulated model that estimates the risk factor-specific annual incidence of coronary heart disease and the risk of recurrent coronary events in persons with prevalent coronary heart disease. When used for secondary prevention, 20 mg/d of lovastatin was estimated to save lives and save costs in younger men with cholesterol levels above 250 mg/dL (6.47 mmol/L) and to have a favorable cost-effectiveness ratio regardless of the cholesterol level except in young women with cholesterol levels below 250 mg/dL (6.47 mmol/L). Doses of 40 mg/d of lovastatin had favorable incremental cost-effectiveness ratios in men with cholesterol levels above 250 mg/dL (6.47 mmol/L). By comparison, primary prevention had favorable cost-effectiveness ratios only in selected subgroups based on cholesterol levels and other established risk factors. We conclude that current national recommendations regarding medication for secondary prevention are not as aggressive as our projections would suggest, while recommendations regarding the use of medications for primary prevention should consider the cost of medication as well as the risk factor profile of the individual patient.	HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; BETH ISRAEL HOSP, BOSTON, MA 02215 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT HLTH POLICY & MANAGEMENT, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard T.H. Chan School of Public Health	GOLDMAN, L (corresponding author), BRIGHAM & WOMENS HOSP, DEPT MED, DIV CLIN EPIDEMIOL, 75 FRANCIS ST, BOSTON, MA 02115 USA.				AHRQ HHS [HS06258] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		[Anonymous], 1965, LANCET, V2, P501; [Anonymous], 1968, LANCET, V2, P693; [Anonymous], 1975, JAMA-J AM MED ASSOC, V231, P360; BLANKENHORN DH, 1987, JAMA-J AM MED ASSOC, V257, P3233, DOI 10.1001/jama.257.23.3233; BRADFORD RH, 1991, ARCH INTERN MED, V151, P43, DOI 10.1001/archinte.151.1.43; BROWN G, 1990, NEW ENGL J MED, V323, P1289, DOI 10.1056/NEJM199011083231901; CANNER PL, 1986, J AM COLL CARDIOL, V8, P1245, DOI 10.1016/S0735-1097(86)80293-5; CLEEMAN JI, 1988, ARCH INTERN MED, V148, P36, DOI 10.1001/archinte.148.1.36; CORDAY E, 1989, J AM COLL CARDIOL, V13, P497, DOI 10.1016/0735-1097(89)90531-7; DAYTON S, 1969, CIRCULATION, V40, pII1; DRUMMOND MF, 1987, HEALTH POLICY, V7, P309, DOI 10.1016/0168-8510(87)90072-8; EDELSON JT, 1990, JAMA-J AM MED ASSOC, V263, P407, DOI 10.1001/jama.263.3.407; ELVEBACK LR, 1981, MAYO CLIN PROC, V56, P665; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; GARNER TI, 1987, MED CARE, V25, P25, DOI 10.1097/00005650-198701000-00004; GOLDMAN L, 1989, CIRCULATION, V80, P254, DOI 10.1161/01.CIR.80.2.254; HAVEL RJ, 1987, ANN INTERN MED, V107, P609, DOI 10.7326/0003-4819-107-5-609; HIMMELSTEIN DU, 1984, NEW ENGL J MED, V311, P1511, DOI 10.1056/NEJM198412063112311; HJERMANN I, 1981, LANCET, V2, P1303; HOEG JM, 1986, AM J CARDIOL, V57, P933, DOI 10.1016/0002-9149(86)90733-2; ILLINGWORTH DR, 1984, ANN INTERN MED, V101, P598, DOI 10.7326/0003-4819-101-5-598; KANNEL WB, 1990, AM J CARDIOL, V66, pB1, DOI 10.1016/0002-9149(90)90434-3; KANNEL WB, 1986, AM HEART J, V112, P825, DOI 10.1016/0002-8703(86)90481-3; KINOSIAN BP, 1988, JAMA-J AM MED ASSOC, V259, P2249, DOI 10.1001/jama.259.15.2249; LEAVERTON PE, 1987, J CHRON DIS, V40, P775, DOI 10.1016/0021-9681(87)90129-9; LEREN P, 1970, CIRCULATION, V42, P935, DOI 10.1161/01.CIR.42.5.935; MANTELL G, 1990, AM J CARDIOL, V66, pB11, DOI 10.1016/0002-9149(90)90435-4; MARTENS LL, 1989, AM J MED, V87, pS54, DOI 10.1016/S0002-9343(89)80600-X; MARTENS LL, 1990, AM J CARDIOL, V65, pF27; MCGEE D, 1976, NIH761083 PUBL; OLIVER M F, 1978, British Heart Journal, V40, P1069, DOI 10.1136/hrt.40.10.1069; OSTER G, 1987, JAMA-J AM MED ASSOC, V258, P2381, DOI 10.1001/jama.258.17.2381; PALUMBO PJ, 1989, JAMA-J AM MED ASSOC, V262, P91, DOI 10.1001/jama.262.1.91; PELL S, 1985, NEW ENGL J MED, V312, P1005, DOI 10.1056/NEJM198504183121601; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P365; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351; ROBERTS SD, 1980, ANN INTERN MED, V92, P243, DOI 10.7326/0003-4819-92-2-243; ROSSOUW JE, 1990, NEW ENGL J MED, V323, P1112, DOI 10.1056/NEJM199010183231606; RUSSELL LB, 1989, SCIENCE, V246, P892, DOI 10.1126/science.2510299; SCHUCKER B, 1987, JAMA-J AM MED ASSOC, V258, P3527, DOI 10.1001/jama.258.24.3527; SCHUCKER B, 1987, JAMA-J AM MED ASSOC, V258, P3521, DOI 10.1001/jama.258.24.3521; SEMPOS C, 1989, JAMA-J AM MED ASSOC, V262, P45, DOI 10.1001/jama.262.1.45; SHEKELLE RB, 1981, NEW ENGL J MED, V304, P65, DOI 10.1056/NEJM198101083040201; STAMLER J, 1986, JAMA-J AM MED ASSOC, V256, P2823, DOI 10.1001/jama.256.20.2823; TOBERT JA, 1986, JAMA-J AM MED ASSOC, V256, P2829; TOSTESON ANA, 1990, AM J PUBLIC HEALTH, V80, P1481, DOI 10.2105/AJPH.80.12.1481; TSEVAT J, IN PRESS CIRCULATION; TURPEINEN O, 1979, CIRCULATION, V59, P1; TYROLER HA, 1987, CIRCULATION, V76, P515, DOI 10.1161/01.CIR.76.3.515; WEINSTEIN MC, 1985, ANNU REV PUBL HEALTH, V6, P41; WEINSTEIN MC, 1987, AM J PUBLIC HEALTH, V77, P1417, DOI 10.2105/AJPH.77.11.1417; WILSON PWF, 1989, JAMA-J AM MED ASSOC, V262, P41, DOI 10.1001/jama.262.1.41; 1973, SOME CHARACTERISTICS; 1989, LANCET, V1, P1423; 1971, BMJ, V4, P775; 1988, TECHNICAL APPENDICES; 1971, BMJ, V4, P767; 1981, VITAL STATISTICS U A, V2; 1982, CURRENT POPULATI P25, V922; 1982, CURRENT POPULATI P25, V917; 1988, JAMA-J AM MED ASSOC, V260, P359; 1987, NIH872703 US DEP HLT; 1984, CURRENT POPULATI P25, V949	63	305	305	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 6	1991	265	9					1145	1151		10.1001/jama.265.9.1145	http://dx.doi.org/10.1001/jama.265.9.1145			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ474	1899896				2022-12-24	WOS:A1991EZ47400032
J	VEENSTRA, RJ; GLUCK, JC				VEENSTRA, RJ; GLUCK, JC			ACCESS TO INFORMATION ABOUT AIDS	ANNALS OF INTERNAL MEDICINE			English	Article								Medical information related to human immunodeficiency virus (HIV) infection is highly diverse, and the practicing physician or researcher may find specific information difficult to locate. To provide timely access to medical information on topics related to the acquired immunodeficiency syndrome (AIDS), several computer-based products have recently been developed. Some are available from vendors of online information systems, whereas others are available only on CD-ROM or floppy disk. We review several computer-based products. AIDSLINE is the most comprehensive bibliographic index, AIDSTRIALS contain specific information about ongoing unpublished investigational studies, and AIDS Knowledge Base from San Francisco General Hospital is an up-to-date electronic textbook covering all aspects of AIDS. COMPACT LIBRARY: AIDS operates on a microcomputer and combines several database, including full-text AIDS-related articles from nine major medical journals. AIDS References from the Bureau of Hygiene and Tropical Diseases provides critical analysis of publications worldwide. Although smaller in size than AIDSLINE, about one third of the publications covered by this resource are not covered by AIDSLINE.	MANCHESTER MEM HOSP, MANCHESTER, CT 06040 USA		VEENSTRA, RJ (corresponding author), HARTFORD HOSP, HLTH SCI LIB, 80 SEYMOUR ST, HARTFORD, CT 06115 USA.							BIND N, 1990, ONLINE 89 LOGON, V13, P9; Centers for Disease Control (CDC), 1981, MMWR-MORBID MORTAL W, V30, P250; CLANCY S, 1988, ONLINE, V12, P93; DUPONT G, 1989, NLM TECH B, V242, P1; DUPONT G, 1989, NLM TECH B, V242, P4; DUTCHER GA, 1989, NLM TECH B, V243, P17; MARMION D, 1990, LIBR SOFTWARE REV, V9, P139; SHORT R, 1989, BRIT J HOSP MED, V42, P166; 1989, CURRENT AIDS LIT, V2, P594	9	5	5	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1991	114	4					320	324		10.7326/0003-4819-114-4-320	http://dx.doi.org/10.7326/0003-4819-114-4-320			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX521	1888346				2022-12-24	WOS:A1991EX52100012
J	XIAO, H; PERISIC, O; LIS, JT				XIAO, H; PERISIC, O; LIS, JT			COOPERATIVE BINDING OF DROSOPHILA HEAT-SHOCK FACTOR TO ARRAYS OF A CONSERVED 5 BP UNIT	CELL			English	Article							HSP 70 GENE; TRANSCRIPTION FACTOR; PROTEIN-SYNTHESIS; DNA-BINDING; CONSENSUS SEQUENCE; ACTIVATOR PROTEIN; ELEMENTS; YEAST; MELANOGASTER; EXPRESSION	Drosophila heat shock factor (HSF) exists as a multimer in solution and when bound to its regulatory element (HSE). We have previously reported evidence that subunits of HSF associate to form homotrimers and that each subunit contacts a conserved 5 bp DNA sequence repeated within an HSE. Here we show that HSF binding is highly cooperative at two distinct levels: between subunits of the HSF multimer, and between multimers. The binding of HSF to one of a pair of adjacent trimeric binding sites facilitates HSF binding to the second by over 2000-fold. This cooperativity is particularly important in binding HSF at 37-degrees-C, and could account for the requirement for multiple binding sites in vivo and, in part, for the differential expression of heat shock genes.			XIAO, H (corresponding author), CORNELL UNIV,BIOCHEM MOLEC & CELL BIOL SECT,ITHACA,NY 14853, USA.			Perisic, Olga/0000-0002-3842-2896	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025232, R37GM025232] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM25232] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMIN J, 1988, MOL CELL BIOL, V8, P3761, DOI 10.1128/MCB.8.9.3761; AMIN J, 1985, MOL CELL BIOL, V5, P197, DOI 10.1128/MCB.5.1.197; BIENZ M, 1987, ADV GENET, V24, P31, DOI 10.1016/S0065-2660(08)60006-1; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; CLOS J, 1990, CELL, V63, P1085, DOI 10.1016/0092-8674(90)90511-C; COHEN RS, 1988, NATURE, V332, P856, DOI 10.1038/332856a0; DUDLER R, 1984, CELL, V38, P391, DOI 10.1016/0092-8674(84)90494-X; LI R, 1989, GENE DEV, V3, P510, DOI 10.1101/gad.3.4.510; LIN YS, 1990, NATURE, V345, P359, DOI 10.1038/345359a0; LINDQUIST S, 1980, DEV BIOL, V77, P463, DOI 10.1016/0012-1606(80)90488-1; Lis J.T., 1990, STRESS PROTEINS BIOL, P411; LIUJOHNSON HN, 1986, CELL, V47, P995, DOI 10.1016/0092-8674(86)90814-7; NOVER L, 1987, ENZYME MICROB TECH, V9, P130, DOI 10.1016/0141-0229(87)90066-4; PARKER CS, 1984, CELL, V37, P273, DOI 10.1016/0092-8674(84)90323-4; PERISIC O, 1989, CELL, V59, P797, DOI 10.1016/0092-8674(89)90603-X; Ptashne M., 1986, A GENETIC SWITCH; Sambrook J., 1989, MOL CLONING LAB MANU; SCHLEIF R, 1988, SCIENCE, V240, P127, DOI 10.1126/science.3353710; SCHLEIF R, 1988, SCIENCE, V241, P1182, DOI 10.1126/science.2842864; SHUEY DJ, 1986, J BIOL CHEM, V261, P7934; SIMON JA, 1985, CELL, V40, P805, DOI 10.1016/0092-8674(85)90340-X; SORGER PK, 1989, CELL, V59, P807, DOI 10.1016/0092-8674(89)90604-1; SORGER PK, 1988, CELL, V54, P855, DOI 10.1016/S0092-8674(88)91219-6; SORGER PK, 1989, PROTEIN FUNCTION PRA, P199; STRUHL G, 1989, CELL, V57, P1259, DOI 10.1016/0092-8674(89)90062-7; TOPOL J, 1985, CELL, V42, P527, DOI 10.1016/0092-8674(85)90110-2; TSAI SY, 1989, CELL, V57, P443, DOI 10.1016/0092-8674(89)90919-7; WEI R, 1986, NUCLEIC ACIDS RES, V14, P8183, DOI 10.1093/nar/14.20.8183; WIEDERRECHT G, 1988, CELL, V54, P841, DOI 10.1016/S0092-8674(88)91197-X; WU C, 1984, NATURE, V311, P81, DOI 10.1038/311081a0; WU C, 1987, SCIENCE, V238, P1247, DOI 10.1126/science.3685975; XIAO H, 1988, SCIENCE, V239, P1139, DOI 10.1126/science.3125608; XIAO H, 1989, MOL CELL BIOL, V9, P1746, DOI 10.1128/MCB.9.4.1746; YOST HJ, 1986, CELL, V45, P185, DOI 10.1016/0092-8674(86)90382-X; ZIMARINO V, 1990, MOL CELL BIOL, V10, P752, DOI 10.1128/MCB.10.2.752; ZIMARINO V, 1987, NATURE, V327, P727, DOI 10.1038/327727a0	36	215	220	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 8	1991	64	3					585	593		10.1016/0092-8674(91)90242-Q	http://dx.doi.org/10.1016/0092-8674(91)90242-Q			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EX361	1899357				2022-12-24	WOS:A1991EX36100014
J	ROUSSEAU, F; HEITZ, D; BIANCALANA, V; BLUMENFELD, S; KRETZ, C; BOUE, J; TOMMERUP, N; VANDERHAGEN, C; DELOZIERBLANCHET, C; CROQUETTE, MF; GILGENKRANTZ, S; JALBERT, P; VOELCKEL, MA; OBERLE, I; MANDEL, JL				ROUSSEAU, F; HEITZ, D; BIANCALANA, V; BLUMENFELD, S; KRETZ, C; BOUE, J; TOMMERUP, N; VANDERHAGEN, C; DELOZIERBLANCHET, C; CROQUETTE, MF; GILGENKRANTZ, S; JALBERT, P; VOELCKEL, MA; OBERLE, I; MANDEL, JL			DIRECT DIAGNOSIS BY DNA ANALYSIS OF THE FRAGILE X-SYNDROME OF MENTAL-RETARDATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INHERITANCE; EXPRESSION; CHROMOSOME	Background. The fragile X syndrome, the most common form of inherited mental retardation, is caused by mutations that increase the size of a specific DNA fragment of the X chromosome (in Xq27.3). Affected persons have both a full mutation and abnormal DNA methylation. Persons with a smaller increase in the size of this DNA fragment (a premutation) have little or no risk of retardation but are at high risk of having affected children or grandchildren. The passage from premutation to full-mutation status occurs only with transmission from the mother. We have devised a method of identifying carriers of these mutations by direct DNA analysis. Method. We studied 511 persons from 63 families with the fragile X syndrome. Mutations and abnormal methylation were detected by Southern blotting with a probe adjacent to the mutation target. Analysis of EcoRI and Eagl digests of DNA distinguished clearly in a single test between the normal genotype, the premutation, and the full mutation. Results. DNA analysis unambiguously established the genetic status at the fragile X locus for all samples tested. This method was much more powerful and reliable than cytogenetic testing or segregation studies with closely linked polymorphic markers. The frequency of mental retardation in persons with premutations was similar to that in the general population, whereas all 103 males and 31 of 59 females with full mutations had mental retardation. About 15 percent of those with full mutations had some cells carrying only the premutation. All the mothers of affected children were carriers of either a premutation or a full mutation. Conclusions. Direct diagnosis by DNA analysis is now an efficient and reliable primary test for the diagnosis of the fragile X syndrome after birth, as well as for prenatal diagnosis and genetic counseling.	FAC MED STRASBOURG, CNRS,GENET MOLEC EUCARYOTES LAB,INSERM,U184, 11 RUE HUMANN, F-67085 STRASBOURG, FRANCE; INSERM, U73, F-75005 PARIS, FRANCE; ULLEVAL HOSP, DEPT MED GENET, OSLO 1, NORWAY; JF KENNEDY INST, GLOSTRUP, DENMARK; UNIV GENEVA, INST GENET MED, CH-1211 GENEVA 4, SWITZERLAND; HOP ST ANTOINE, LILLE, FRANCE; CTR TRANSFUS, VANDOEUVRE LES NANCY, FRANCE; CHR UNIV GRENOBLE, GRENOBLE, FRANCE; INSERM, U242, F-13258 MARSEILLE 09, FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm); University of Oslo; University of Geneva; UDICE-French Research Universities; Sorbonne Universite; CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); Institut National de la Sante et de la Recherche Medicale (Inserm)			Tommerup, Niels/T-8776-2017	Tommerup, Niels/0000-0003-2304-0112				BUNDEY S, 1974, J MENT DEFIC RES, V18, P115; CRONISTER A, 1991, AM J MED GENET, V38, P503, DOI 10.1002/ajmg.1320380272; FRYNS JP, 1989, FRAGILE X SYNDROME, P1; HEITZ D, 1991, SCIENCE, V251, P1236, DOI 10.1126/science.2006411; JACKY PB, 1991, AM J MED GENET, V38, P400, DOI 10.1002/ajmg.1320380249; JENKINS EC, 1991, AM J MED GENET, V38, P447, DOI 10.1002/ajmg.1320380262; KREMER EJ, 1991, SCIENCE, V252, P1711, DOI 10.1126/science.1675488; LAIRD CD, 1990, AM J HUM GENET, V46, P696; LAIRD CD, 1987, GENETICS, V117, P587; LUBS HA, 1969, AM J HUM GENET, V21, P231; MIGEON BR, 1985, P NATL ACAD SCI USA, V82, P3390, DOI 10.1073/pnas.82.10.3390; NUSSBAUM RL, 1986, AM J MED GENET, V23, P715, DOI 10.1002/ajmg.1320230162; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; PEMBREY ME, 1985, AM J MED GENET, V21, P709, DOI 10.1002/ajmg.1320210413; ROUSSEAU F, 1991, AM J HUM GENET, V48, P108; ROUSSEAU F, IN PRESS J MED GENET; SHERMAN SL, 1985, HUM GENET, V71, P184; SHERMAN SL, 1985, HUM GENET, V69, P289, DOI 10.1007/BF00291644; SHERMAN SL, 1984, ANN HUM GENET, V48, P21, DOI 10.1111/j.1469-1809.1984.tb00830.x; SUTHERLAND GR, 1977, SCIENCE, V197, P265, DOI 10.1126/science.877551; SUTHERS GK, 1991, AM J HUM GENET, V48, P460; TONIOLO D, 1988, EMBO J, V7, P401, DOI 10.1002/j.1460-2075.1988.tb02827.x; TURNER G, 1986, NEW ENGL J MED, V315, P607, DOI 10.1056/NEJM198609043151002; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; VINCENT A, 1991, NATURE, V349, P624, DOI 10.1038/349624a0; VOGEL F, 1990, HUM GENET, V86, P25; WEBB T, 1989, FRAGILE X SYNDROME, P40; YU S, 1991, SCIENCE, V252, P1179, DOI 10.1126/science.252.5009.1179	28	573	584	0	15	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 12	1991	325	24					1673	1681		10.1056/NEJM199112123252401	http://dx.doi.org/10.1056/NEJM199112123252401			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GU418	1944467				2022-12-24	WOS:A1991GU41800001
J	KESSLER, DA				KESSLER, DA			COMMUNICATING WITH PATIENTS ABOUT THEIR MEDICATIONS	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											KESSLER, DA (corresponding author), US FDA,ROCKVILLE,MD 20857, USA.							JOYCE G, 1988, J PHARM MARK MANAGE, V3, P11; KORSCH BM, 1972, SCI AM, V227, P66, DOI 10.1038/scientificamerican0872-66; LEY P, 1972, J HEALTH SOC BEHAV, V13, P311, DOI 10.2307/2136768; MORRIS LA, 1986, NATIONAL SURVEY PRES; 1990, MED REGIMENS CAUSES, P12; 1984, PRESCRIPTION DRUG AD; 1991, DHHS PHS9150212 PUBL; 1988, MARKET FACTS	8	63	67	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 5	1991	325	23					1650	1652		10.1056/NEJM199112053252312	http://dx.doi.org/10.1056/NEJM199112053252312			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GR770	1944456				2022-12-24	WOS:A1991GR77000012
J	YEUNG, AC; VEKSHTEIN, VI; KRANTZ, DS; VITA, JA; RYAN, TJ; GANZ, P; SELWYN, AP				YEUNG, AC; VEKSHTEIN, VI; KRANTZ, DS; VITA, JA; RYAN, TJ; GANZ, P; SELWYN, AP			THE EFFECT OF ATHEROSCLEROSIS ON THE VASOMOTOR RESPONSE OF CORONARY-ARTERIES TO MENTAL STRESS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ENDOTHELIUM-DEPENDENT RELAXATION; SILENT MYOCARDIAL ISCHEMIA; BLOOD-FLOW VELOCITY; SUBSELECTIVE MEASUREMENT; VASCULAR RELAXATION; ANGINA-PECTORIS; RELAXING FACTOR; RABBIT AORTA; DISEASE; ACETYLCHOLINE	Background. Mental stress can cause angina in patients with coronary artery disease, but its effects on coronary vasomotion and blood flow are poorly understood. Because atherosclerosis affects the reactivity of coronary arteries to various stimuli, such as exercise, we postulated that atherosclerosis might also influence the vasomotor response of coronary arteries to mental stress. Methods. We studied 26 patients who performed mental arithmetic under stressful conditions during cardiac catheterization. (An additonal four patients who did not perform the mental arithmetic served as controls.) Coronary segments were classified on the basis of angiographic findings as smooth, irregular, or stenosed. In 15 of the patients without focal stenoses in the left anterior descending artery, acetylcholine (10(-8) to 10(-6) Mol per liter) was infused into the artery to test endothelium-dependent vasodilation. Changes in coronary blood flow were measured with an intracoronary Doppler catheter in these 15 patients. Results. The response of the coronary arteries to mental stress varied from 38 percent constriction to 29 percent dilation, whereas the change in coronary blood flow varied from a decrease of 48 percent to an increase of 42 percent. The direction and magnitude of the change in the coronary diameter were not predicted by the changes in the heart rate, blood pressure, or plasma norepinephrine level. Segments with stenoses (n = 7) were constricted by a mean (+/- SE) of 24 +/- 4 percent, and irregular segments (n = 20) by 9 +/- 3 percent, whereas smooth segments (n = 25) did not change significantly (dilation, 3 +/- 3 percent; P < 0.002). Coronary blood flow increased by 10 +/- 10 percent in smooth vessels, whereas the flow in irregular vessels decreased by 27 +/- 5 percent. The degree of constriction or dilation during mental stress correlated with the response to the infusions of acetylcholine (P < 0.0003, r = 0.58). Conclusions. Atherosclerosis disturbs the normal vasomotor response (no change or dilation) of large coronary arteries to mental stress; in patients with atherosclerosis paradoxical constriction occurs during mental stress, particularly at points of stenosis. This vasomotor response correlates with the extent of atherosclerosis in the artery and with the endothelium-dependent response to an infusion of acetylcholine. These data suggest that in atherosclerosis unopposed constriction caused by a local failure of endothelium-dependent dilation causes the coronary arteries to respond abnormally to mental stress.	UNIFORMED SERV UNIV HLTH SCI,DEPT MED PSYCHOL,BETHESDA,MD 20814; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Uniformed Services University of the Health Sciences - USA; Harvard University; Harvard Medical School	YEUNG, AC (corresponding author), BRIGHAM & WOMENS HOSP,DEPT MED,DIV CARDIOVASC,75 FRANCIS ST,BOSTON,MA 02115, USA.		Krantz, David S./L-5364-2015	Vita, Joseph/0000-0001-5607-1797; Ganz, Peter/0000-0002-0437-8882; Krantz, David/0000-0002-1671-1355				BARRY J, 1988, AM J CARDIOL, V61, P989, DOI 10.1016/0002-9149(88)90112-9; BASSAN MM, 1980, CIRCULATION, V62, P933, DOI 10.1161/01.CIR.62.5.933; BROWN BG, 1981, CIRCULATION, V64, P1089, DOI 10.1161/01.CIR.64.6.1089; COCKS TM, 1983, NATURE, V305, P627, DOI 10.1038/305627a0; COHEN RA, 1984, FED PROC, V43, P2862; COHEN RA, 1988, J PHARMACOL EXP THER, V244, P550; COHEN RA, 1988, AM J PHYSIOL, V254, pH871, DOI 10.1152/ajpheart.1988.254.5.H871; COX DA, 1989, CIRCULATION, V80, P458, DOI 10.1161/01.CIR.80.3.458; DEANFIELD JE, 1984, LANCET, V2, P1001; FISH RD, 1988, J CLIN INVEST, V81, P21, DOI 10.1172/JCI113297; FREYSCHUSS U, 1988, AM J PHYSIOL, V255, pH1443, DOI 10.1152/ajpheart.1988.255.6.H1443; FURCHGOTT RF, 1983, CIRC RES, V53, P557, DOI 10.1161/01.RES.53.5.557; GAGE JE, 1986, CIRCULATION, V73, P865, DOI 10.1161/01.CIR.73.5.865; GANZ W, 1971, CIRCULATION, V44, P181, DOI 10.1161/01.CIR.44.2.181; GORDON JB, 1989, J CLIN INVEST, V83, P1946, DOI 10.1172/JCI114103; HABIB JB, 1986, CIRC RES, V58, P305, DOI 10.1161/01.RES.58.2.305; HEUSCH G, 1990, CIRCULATION, V81, P1, DOI 10.1161/01.CIR.81.1.1; KIRKEEDIE RL, 1982, IEEE T COMPUT SOC CO, P215; LANGE RA, 1989, NEW ENGL J MED, V321, P1557, DOI 10.1056/NEJM198912073212301; LUDMER PL, 1986, NEW ENGL J MED, V315, P1046, DOI 10.1056/NEJM198610233151702; MARTIN W, 1986, J PHARMACOL EXP THER, V237, P529; MEREDITH IT, 1990, CIRCULATION, V82, P516; MINOR RL, 1990, J CLIN INVEST, V86, P2109, DOI 10.1172/JCI114949; NABEL EG, 1988, CIRCULATION, V77, P43, DOI 10.1161/01.CIR.77.1.43; NABEL EG, 1990, CIRCULATION, V81, P850, DOI 10.1161/01.CIR.81.3.850; OSBORNE JA, 1989, AM J PHYSIOL, V256, pC591, DOI 10.1152/ajpcell.1989.256.3.C591; PEULER JD, 1977, LIFE SCI, V21, P625, DOI 10.1016/0024-3205(77)90070-4; ROBERTSON D, 1979, CIRCULATION, V59, P637, DOI 10.1161/01.CIR.59.4.637; ROZANSKI A, 1988, NEW ENGL J MED, V318, P1005, DOI 10.1056/NEJM198804213181601; SANDOR T, 1985, COMPUT BIOMED RES, V18, P531, DOI 10.1016/0010-4809(85)90028-X; SELLKE FW, 1990, CIRCULATION, V81, P1586, DOI 10.1161/01.CIR.81.5.1586; SHIMOKAWA H, 1989, CIRC RES, V64, P900, DOI 10.1161/01.RES.64.5.900; SIBLEY DH, 1986, J AM COLL CARDIOL, V8, P1332, DOI 10.1016/S0735-1097(86)80305-9; SPECCHIA G, 1984, AM HEART J, V108, P56, DOI 10.1016/0002-8703(84)90544-1; SREEHARAN N, 1986, CAN J PHYSIOL PHARM, V64, P1451, DOI 10.1139/y86-246; TAGAWA H, 1991, CIRC RES, V68, P330, DOI 10.1161/01.RES.68.2.330; TODA N, 1986, AM J PHYSIOL, V250, pH718, DOI 10.1152/ajpheart.1986.250.5.H718; TREASURE CB, 1990, CIRCULATION, V81, P772, DOI 10.1161/01.CIR.81.3.772; VANHOUTTE PM, 1989, CIRCULATION, V80, P1, DOI 10.1161/01.CIR.80.1.1; VITA J A, 1990, Journal of the American College of Cardiology, V15, p158A; VITA JA, 1990, CIRCULATION, V81, P491, DOI 10.1161/01.CIR.81.2.491; WALLENSTEIN S, 1980, CIRC RES, V47, P1, DOI 10.1161/01.RES.47.1.1; WILSON RF, 1985, CIRCULATION, V72, P82, DOI 10.1161/01.CIR.72.1.82; YAMAMOTO H, 1988, J CLIN INVEST, V81, P1752, DOI 10.1172/JCI113516; YASUE H, 1990, CIRCULATION, V81, P482, DOI 10.1161/01.CIR.81.2.482	45	498	514	0	15	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 28	1991	325	22					1551	1556		10.1056/NEJM199111283252205	http://dx.doi.org/10.1056/NEJM199111283252205			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GR380	1944439				2022-12-24	WOS:A1991GR38000005
J	LAM, KS; SALMON, SE; HERSH, EM; HRUBY, VJ; KAZMIERSKI, WM; KNAPP, RJ				LAM, KS; SALMON, SE; HERSH, EM; HRUBY, VJ; KAZMIERSKI, WM; KNAPP, RJ			A NEW TYPE OF SYNTHETIC PEPTIDE LIBRARY FOR IDENTIFYING LIGAND-BINDING ACTIVITY	NATURE			English	Article							PHAGE	OUR aim was to improve techniques for drug development by facilitating the identification of small molecules that bind with high affinity to acceptor molecules (for example, cell-surface receptors, enzymes, antibodies) and so to mimic or block their interaction with the natural ligand 1,2. Previously such small molecules have been characterized individually on a serial basis. The systematic synthesis and screening of peptide libraries of defined structure represents a new approach. For relatively small libraries, predetermined sequence variations on solid-phase supports have been used 3,4, and large libraries have been produced using a bacteriophage vector into which random oligodeoxynucleotide sequences have been introduced 5-8, but these techniques have severe limitations. Here we investigate an alternative approach to synthesis and screening of peptide libraries. Our simple methodology greatly enhances the production and rapid evaluation of random libraries of millions of peptides so that acceptor-binding ligands of high affinity can be rapidly identified and sequenced, on the basis of a 'one-bead, one-peptide' approach.	UNIV ARIZONA,FAC SCI,DEPT CHEM,TUCSON,AZ 85721; SELECTIDE CORP,TUCSON,AZ 85737; COLL MED TUCSON,DEPT INTERNAL MED,TUCSON,AZ 85724	University of Arizona; Sanofi-Aventis	LAM, KS (corresponding author), COLL MED TUCSON,ARIZONA CANC CTR,TUCSON,AZ 85724, USA.							CWIRLA SE, 1990, P NATL ACAD SCI USA, V87, P6378, DOI 10.1073/pnas.87.16.6378; DEVLIN JJ, 1990, SCIENCE, V249, P404, DOI 10.1126/science.2143033; FODOR SPA, 1991, SCIENCE, V251, P767, DOI 10.1126/science.1990438; GEYSEN HM, 1984, P NATL ACAD SCI-BIOL, V81, P3998, DOI 10.1073/pnas.81.13.3998; HRUBY V, 1990, BIOCHEM J, V268, P246; HRUBY VJ, 1991, CURR OPIN BIOTECH, V2, P599, DOI 10.1016/0958-1669(91)90086-K; NIALL HD, 1972, CHEM BIOL PEPTIDES, P695; PARMLEY SF, 1988, GENE, V73, P305, DOI 10.1016/0378-1119(88)90495-7; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028	9	1700	2518	6	197	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 7	1991	354	6348					82	84		10.1038/354082a0	http://dx.doi.org/10.1038/354082a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GN829	1944576				2022-12-24	WOS:A1991GN82900064
J	OELLER, PW; WONG, LM; TAYLOR, LP; PIKE, DA; THEOLOGIS, A				OELLER, PW; WONG, LM; TAYLOR, LP; PIKE, DA; THEOLOGIS, A			REVERSIBLE INHIBITION OF TOMATO FRUIT SENESCENCE BY ANTISENSE RNA	SCIENCE			English	Article							ETHYLENE BIOSYNTHESIS; GENE-EXPRESSION; 1-AMINOCYCLOPROPANE-1-CARBOXYLATE SYNTHASE; POLYGALACTURONASE; PLANTS	Ethylene controls fruit ripening. Expression of antisense RNA to the rate-limiting enzyme in the biosynthetic pathway of ethylene, 1-aminocyclopropane-1-carboxylate synthase, inhibits fruit ripening in tomato plants. Administration of exogenous ethylene or propylene reverses the inhibitory effect. This result demonstrates that ethylene is the trigger and not the by-product of ripening and raises the prospect that the life-span of plant tissues can be extended, thereby preventing spoilage.	UNIV CALIF BERKELEY,USDA,CTR PLANT GENE EXPRESS,ALBANY,CA 94710	United States Department of Agriculture (USDA); University of California System; University of California Berkeley					NIGMS NIH HHS [GM-35447] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035447] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENNETT AB, 1989, BIOTECHNOLOGY FOOD Q, P167; BERG JM, 1989, CELL, V57, P1065, DOI 10.1016/0092-8674(89)90042-1; BIALE JACOB B., 1960, ADVANCES IN FOOD RES, V10, P293; BIALE JB, 1964, SCIENCE, V146, P880, DOI 10.1126/science.146.3646.880; BIALE JB, 1981, RECENT ADV BIOCH FRU, P1, DOI DOI 10.1111/J.1365-313X.2007.03170.X; BURG SP, 1965, SCIENCE, V148, P1190, DOI 10.1126/science.148.3674.1190; BURG SP, 1962, PLANT PHYSIOL, V37, P179, DOI 10.1104/pp.37.2.179; BURG SP, 1967, PLANT PHYSIOL, V42, P144, DOI 10.1104/pp.42.1.144; CHRISTOFFERSEN RE, 1982, PLANTA, V155, P52, DOI 10.1007/BF00402931; DELLAPENNA D, 1986, P NATL ACAD SCI USA, V83, P6420, DOI 10.1073/pnas.83.17.6420; HAMILTON AJ, 1990, NATURE, V346, P284, DOI 10.1038/346284a0; HOLLIDAY R, 1988, PERSPECT BIOL MED, V32, P109; KENDE H, 1981, PLANTA, V151, P476, DOI 10.1007/BF00386542; KENDE H, 1989, PLANT PHYSIOL, V91, P1, DOI 10.1104/pp.91.1.1; KIDD F, 1945, PLANT PHYSIOL, V20, P467, DOI 10.1104/pp.20.4.467; LATIES GG, 1987, MOL BIOL PLANT GROWT, V44, P107; LINCOLN JE, 1987, P NATL ACAD SCI USA, V84, P2793, DOI 10.1073/pnas.84.9.2793; LYONS JM, 1964, AM SOC HORTIC SCI J, V84, P491; MCMURCHIE EJ, 1972, NATURE, V237, P235, DOI 10.1038/237235a0; OW DW, 1987, P NATL ACAD SCI USA, V84, P4870, DOI 10.1073/pnas.84.14.4870; ROTTMAN WH, IN PRESS J MOL BIOL; Sambrook J., 1989, MOL CLONING; SMITH CJS, 1988, NATURE, V334, P724, DOI 10.1038/334724a0; VARNER JE, 1961, ANNU REV PLANT PHYS, V12, P245, DOI 10.1146/annurev.pp.12.060161.001333; YANG SF, 1984, ANNU REV PLANT PHYS, V35, P155, DOI 10.1146/annurev.pp.35.060184.001103; YOSHII H, 1982, PLANT CELL PHYSIOL, V23, P639	26	573	694	3	115	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 18	1991	254	5030					437	439		10.1126/science.1925603	http://dx.doi.org/10.1126/science.1925603			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GK729	1925603				2022-12-24	WOS:A1991GK72900051
J	SCHIRO, JA; CHAN, BMC; ROSWIT, WT; KASSNER, PD; PENTLAND, AP; HEMLER, ME; EISEN, AZ; KUPPER, TS				SCHIRO, JA; CHAN, BMC; ROSWIT, WT; KASSNER, PD; PENTLAND, AP; HEMLER, ME; EISEN, AZ; KUPPER, TS			INTEGRIN-ALPHA-2-BETA-1 (VLA-2) MEDIATES REORGANIZATION AND CONTRACTION OF COLLAGEN MATRICES BY HUMAN-CELLS	CELL			English	Article							FIBRONECTIN RECEPTOR EXPRESSION; FIBROBLAST TRACTION; SURFACE RECEPTORS; INTEGRIN; ADHESION; BINDING; MORPHOGENESIS; GLYCOPROTEIN; LATTICES; HOMOLOGY	The capacity of cells to organize and contract collagen fibrils is fundamental to processes as diverse as embryogenesis and wound healing. We analyzed different beta-1 integrins on diploid fibroblasts for their role in modifying the tertiary structure of collagen matrices. Using monoclonal antibodies that block the interaction of integrins with their ligands, evidence was obtained that alpha-2-beta-1 integrin is required for the contraction of a type I collagen matrix. Further supporting the role of alpha-2-beta-1, cell lines expressing minimal levels of this integrin uniformly failed to contract collagen matrices. In addition, transfection of a full-length alpha-2 cDNA into one such cell line led to enhanced cell surface expression of alpha-2-beta-1 and conferred the de novo capacity to contract collagen matrices.	WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115	Washington University (WUSTL); Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	SCHIRO, JA (corresponding author), WASHINGTON UNIV,SCH MED,DEPT MED,DIV DERMATOL,ST LOUIS,MO 63110, USA.		Kupper, Thomas/O-4962-2019	Kassner, Paul/0000-0002-1471-1191	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI025082, R37AI025082, R29AI025082] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040124, R37AR012129, R01AR012129] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 25082] Funding Source: Medline; NIAMS NIH HHS [AR 12129, AR 40124] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BAUVOIS B, 1987, CELL BIOCHEM FUNCT, V5, P281, DOI 10.1002/cbf.290050407; BELL E, 1979, P NATL ACAD SCI USA, V76, P1274, DOI 10.1073/pnas.76.3.1274; BUCK CA, 1987, ANNU REV CELL BIOL, V3, P179, DOI 10.1146/annurev.cb.03.110187.001143; BURN P, 1988, P NATL ACAD SCI USA, V85, P497, DOI 10.1073/pnas.85.2.497; CHAN BMC, 1991, SCIENCE, V251, P1600, DOI 10.1126/science.2011740; CLARK RAF, 1990, J INVEST DERMATOL, V94, pS128, DOI 10.1111/1523-1747.ep12876104; DEJANA E, 1988, J CELL BIOL, V107, P1215, DOI 10.1083/jcb.107.3.1215; EISEN AZ, 1987, J INVEST DERMATOL, V88, P741, DOI 10.1111/1523-1747.ep12470412; GRINNELL F, 1984, J CELL SCI, V66, P51; GULLBERG D, 1989, J BIOL CHEM, V264, P12686; GULLBERG D, 1990, EXP CELL RES, V186, P264, DOI 10.1016/0014-4827(90)90305-T; GULLBERG D, 1990, EXP CELL RES, V190, P254, DOI 10.1016/0014-4827(90)90194-F; Harlow E, 1988, ANTIBODIES LABORATOR, P359; HARRIS AK, 1981, NATURE, V290, P249, DOI 10.1038/290249a0; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; MILLER EJ, 1982, METHOD ENZYMOL, V82, P33; MOLLENHAUER J, 1983, EMBO J, V2, P45, DOI 10.1002/j.1460-2075.1983.tb01378.x; MUELLER SC, 1989, J CELL BIOL, V109, P3455, DOI 10.1083/jcb.109.6.3455; NAIDET C, 1987, NATURE, V325, P348, DOI 10.1038/325348a0; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; STAATZ WD, 1991, J BIOL CHEM, V266, P7363; STAATZ WD, 1989, J CELL BIOL, V108, P1917, DOI 10.1083/jcb.108.5.1917; STEINBERG BM, 1980, J CELL BIOL, V87, P304, DOI 10.1083/jcb.87.1.304; STOPAK D, 1982, DEV BIOL, V90, P383, DOI 10.1016/0012-1606(82)90388-8; TAKADA Y, 1989, EMBO J, V8, P1361, DOI 10.1002/j.1460-2075.1989.tb03516.x; TAKADA Y, 1989, J CELL BIOL, V109, P397, DOI 10.1083/jcb.109.1.397; WELCH MP, 1990, J CELL BIOL, V110, P133, DOI 10.1083/jcb.110.1.133; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877	30	356	362	0	15	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 18	1991	67	2					403	410		10.1016/0092-8674(91)90191-Z	http://dx.doi.org/10.1016/0092-8674(91)90191-Z			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GL470	1913826				2022-12-24	WOS:A1991GL47000019
J	HOWARD, AJ; DUNKIN, KT; MUSSER, JM; PALMER, SR				HOWARD, AJ; DUNKIN, KT; MUSSER, JM; PALMER, SR			EPIDEMIOLOGY OF HAEMOPHILUS-INFLUENZAE TYPE-B INVASIVE DISEASE IN WALES	BRITISH MEDICAL JOURNAL			English	Article							MEMBRANE PROTEIN SUBTYPES; 10 YEARS EXPERIENCE; HEMOPHILUS-INFLUENZAE; BACTERIAL-MENINGITIS; CONJUGATE VACCINES; CHILDREN; POPULATION; AMPICILLIN; PREVENTION; RESISTANCE	Objective-To investigate the epidemiology of invasive disease due to Haemophilus influenzae type b, the clones responsible, and the antibiotic resistance of the isolates. Design-Prospective population based analysis of clinical and epidemiological data collected for Gwynedd during 1980-90 and in the whole of Wales during 1988-90. Setting-19 hospitals in Wales; all medical microbiology laboratories in Wales participated. Patients-82 patients with confirmed invasive infections caused by H influenzae type b in Gwynedd during 1980-90 and 207 in Wales during 1988-90. Main outcome measures-Clinical and epidemiological measures; analysis of the clonal types of the isolates based on the electrophoretic mobilities of 17 metabolic enzymes; and antibiotic resistance. Results-The annual incidence of H influenzae type b infections in Gwynedd was 3.2 cases/100 000 and in Wales was 2.5 cases/100 000. Most cases occurred in children aged under 5 years, the highest annual incidence being in those aged under 1 (84.6/100 000 and 56.9/100 000 in Wales). The cumulative risk of acquiring H influenzae type b disease by the fifth birthday was one in 456 in Gwynedd and one in 578 in Wales. Fifteen per cent of cases in Gwynedd and 7% of those in Wales occurred in adults. Predominant clinical conditions were meningitis in children and pneumonia in adults. In Gwynedd 2/70 (3%) children and 5/12 (42%) adults died. Long term neurological sequelae occurred in 8% (4/48) of children who survived haemophilus meningitis. Children presenting with infection were usually the youngest members of their family. No secondary household cases were identified. 100 of 128 (78%) strains were of a single clone, electrophoretic type 12.5, and 4/207 (1.9%) isolates from Wales were resistant to both ampicillin and chloramphenicol. Conclusions-The annual rate of infection in children aged under 5 in four Welsh counties was 12-44% higher than that previously published for the United Kingdom. The study emphasises the potential value of a vaccine effective in early infancy and provides baseline data to assess its efficacy after its introduction. Alternatives to ampicillin and chloramphenicol should be used as first line, empirical treatment for severe infections that might be caused by H influenzae type b in Wales.	PENN STATE UNIV,INST MOLEC EVOLUT GENET,UNIVERSITY PK,PA 16802; COMMUNICABLE DIS SURVEILLANCE CTR,WELSH UNIT,CARDIFF CF4 3QX,WALES	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	HOWARD, AJ (corresponding author), GWYNEDD HOSP,DEPT MED MICROBIOL,BANGOR LL57 2PW,WALES.				PHS HHS [A1 24332] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BARENKAMP SJ, 1983, J INFECT DIS, V148, P1127, DOI 10.1093/infdis/148.6.1127; BROOME CV, 1987, PEDIATR INFECT DIS J, V6, P779, DOI 10.1097/00006454-198708000-00036; CAMPBELL H, 1990, PEDIATRICS, V86, P102; Cartwright K A, 1991, CDR (Lond Engl Rev), V1, pR2; DAVEY PG, 1982, J HYG-CAMBRIDGE, V88, P383, DOI 10.1017/S002217240007025X; DELRIO MDA, 1983, LANCET, V1, P1241; DYAS A, 1986, J INFECTION, V13, P179, DOI 10.1016/S0163-4453(86)93093-8; FEIGIN RD, 1976, J PEDIATR-US, V88, P542, DOI 10.1016/S0022-3476(76)80002-9; GOLDACRE MJ, 1976, LANCET, V1, P28; GRANOFF DM, 1986, J INFECT DIS, V153, P448, DOI 10.1093/infdis/153.3.448; GUNN BA, 1974, LANCET, V2, P845; HAMPTON CM, 1983, J CLIN MICROBIOL, V18, P596, DOI 10.1128/JCM.18.3.596-600.1983; HOWARD AJ, 1988, J ANTIMICROB CHEMOTH, V21, P251, DOI 10.1093/jac/21.2.251; MACHKA K, 1988, EUR J CLIN MICROBIOL, V7, P14, DOI 10.1007/BF01962165; MAKELA PH, 1990, PEDIATRICS, V85, P651; MUSSER JM, 1985, P NATL ACAD SCI USA, V82, P5078, DOI 10.1073/pnas.82.15.5078; MUSSER JM, 1990, REV INFECT DIS, V12, P75; SELL SHW, 1972, PEDIATRICS, V49, P206; SPROLES ET, 1969, J PEDIATR-US, V75, P782, DOI 10.1016/S0022-3476(69)80300-8; TAKALA AK, 1989, PEDIATR INFECT DIS J, V8, P297; TAKALA AK, 1990, ARCH INTERN MED, V150, P2573, DOI 10.1001/archinte.150.12.2573; TAKALA AK, 1990, 30TH INT C ANT AG CH, P187; TAYLOR HG, 1990, NEW ENGL J MED, V323, P1657, DOI 10.1056/NEJM199012133232403; TEJANI A, 1982, DEV MED CHILD NEUROL, V24, P338; THOMAS WJ, 1974, LANCET, V1, P313; TROLLFORS B, 1984, EUR J CLIN MICROBIOL, V3, P180, DOI 10.1007/BF02014874; WARD JI, 1979, NEW ENGL J MED, V301, P122, DOI 10.1056/NEJM197907193010302; WEINBERG GA, 1988, J PEDIATR-US, V113, P621, DOI 10.1016/S0022-3476(88)80369-X; WILLIAMS GT, 1989, ARCH DIS CHILD, V64, P517; 1985, DIGEST WELSH STATIST; 1989, DIGEST WELSH STATIST; 1984, PEDIATRICS, V74, P301	32	45	46	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 24	1991	303	6800					441	445		10.1136/bmj.303.6800.441	http://dx.doi.org/10.1136/bmj.303.6800.441			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GC465	1912835	Green Published, Bronze			2022-12-24	WOS:A1991GC46500015
J	SEURI, M				SEURI, M			RISK OF APPENDECTOMY IN OCCUPATIONS ENTAILING CONTACT WITH PIGS	BRITISH MEDICAL JOURNAL			English	Article							YERSINIA; INFECTION				SEURI, M (corresponding author), UNIV KUOPIO,DEPT COMMUNITY HLTH & GEN PRACTICE,POB 1627,SF-70211 KUOPIO,FINLAND.							ASPLUND K, 1990, ACTA VET SCAND, V31, P39; ATTWOOD SEA, 1987, LANCET, V1, P529; ATTWOOD SEA, 1989, BRIT J SURG, V76, P499, DOI 10.1002/bjs.1800760523; MERILAHTIPALO R, 1991, SCAND J INFECT DIS, V23, P55, DOI 10.3109/00365549109023375; TERTTI R, 1984, J INFECT DIS, V149, P245, DOI 10.1093/infdis/149.2.245	5	4	4	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 10	1991	303	6798					345	346		10.1136/bmj.303.6798.345-a	http://dx.doi.org/10.1136/bmj.303.6798.345-a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GA606	1912777	Green Published, Bronze			2022-12-24	WOS:A1991GA60600023
J	RUOHOLA, H; BREMER, KA; BAKER, D; SWEDLOW, JR; JAN, LY; JAN, YN				RUOHOLA, H; BREMER, KA; BAKER, D; SWEDLOW, JR; JAN, LY; JAN, YN			ROLE OF NEUROGENIC GENES IN ESTABLISHMENT OF FOLLICLE CELL FATE AND OOCYTE POLARITY DURING OOGENESIS IN DROSOPHILA	CELL			English	Article							EGF RECEPTOR HOMOLOG; FAINT-LITTLE-BALL; NOTCH LOCUS; C-ELEGANS; ANTEROPOSTERIOR POLARITY; CAENORHABDITIS-ELEGANS; TRANSMEMBRANE PROTEIN; BICOID RNA; MELANOGASTER; PATTERN	Oogenesis in Drosophila involves specification of both germ cells and the surrounding somatic follicle cells, as well as the determination of oocyte polarity. We found that two neurogenic genes, Notch and Delta, are required in oogenesis. These genes encode membrane proteins with epidermal growth factor repeats and are essential in the decision of an embryonic ectodermal cell to take on the fate of neuroblast or epidermoblast. In oogenesis, mutation in either gene leads to an excess of posterior follicle cells, a cell fate change reminiscent of the hyperplasia of neuroblasts seen in neurogenic mutant embryos. Furthermore, the Notch mutation in somatic cells causes mislocalization of bicoid in the oocyte. These results suggest that the neurogenic genes Notch and Delta are involved in both follicle cell development and the establishment of anterior-posterior polarity in the oocyte.	UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,GRAD GRP BIOPHYS,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	RUOHOLA, H (corresponding author), UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143, USA.		Baker, David/K-8941-2012	Baker, David/0000-0001-7896-6217; Swedlow, Jason/0000-0002-2198-1958; Jan, Yuh Nung/0000-0003-1367-6299; Jan, Lily/0000-0003-3938-8498				ANDERSON KV, 1987, TRENDS GENET, V3, P91, DOI 10.1016/0168-9525(87)90191-0; ARTAVANISTSAKONAS S, 1988, TRENDS GENET, V4, P95, DOI 10.1016/0168-9525(88)90096-0; AUSTIN J, 1989, CELL, V58, P565, DOI 10.1016/0092-8674(89)90437-6; BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; BIER E, 1989, GENE DEV, V3, P1273, DOI 10.1101/gad.3.9.1273; BODMER R, 1987, CELL, V51, P293, DOI 10.1016/0092-8674(87)90156-5; BROWER DL, 1981, J EMBRYOL EXP MORPH, V63, P233; BUSSON D, 1983, GENETICS, V105, P309; CAGAN RL, 1989, GENE DEV, V3, P1099, DOI 10.1101/gad.3.8.1099; CAMPOSORTEGA JA, 1988, TRENDS NEUROSCI, V11, P400, DOI 10.1016/0166-2236(88)90077-X; CAMPOSORTEGA JA, 1991, IN PRESS ANN REV NEU; COOLEY L, 1988, SCIENCE, V239, P1121, DOI 10.1126/science.2830671; DELACONCHA A, 1988, GENETICS, V118, P499; DOE CQ, 1985, DEV BIOL, V111, P206, DOI 10.1016/0012-1606(85)90446-4; DRIEVER W, 1990, DEVELOPMENT, V109, P811; EPHRUSSI A, 1991, IN PRESS CELL, V66; FASANO L, 1988, DEVELOPMENT, V104, P245; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; FROHNHOFER HG, 1987, GENE DEV, V1, P880, DOI 10.1101/gad.1.8.880; GOLIC KG, 1989, CELL, V59, P499, DOI 10.1016/0092-8674(89)90033-0; GOLIC KG, 1991, SCIENCE, V252, P958, DOI 10.1126/science.2035025; GREENWALD IS, 1983, CELL, V34, P435, DOI 10.1016/0092-8674(83)90377-X; GROSSNIKLAUS U, 1989, DEVELOPMENT, V107, P189; HAENLIN M, 1990, DEVELOPMENT, V110, P905; HARTENSTEIN V, 1990, DEV BIOL, V142, P13, DOI 10.1016/0012-1606(90)90147-B; HARTLEY DA, 1988, CELL, V55, P785, DOI 10.1016/0092-8674(88)90134-1; HAY B, 1988, DEVELOPMENT, V103, P625; HAY B, 1990, DEVELOPMENT, V109, P425; JAN LY, 1982, P NATL ACAD SCI-BIOL, V79, P2700, DOI 10.1073/pnas.79.8.2700; JIMENEZ F, 1982, ROUX ARCH DEV BIOL, V191, P191, DOI 10.1007/BF00848335; KIDD S, 1986, MOL CELL BIOL, V6, P3094, DOI 10.1128/MCB.6.9.3094; KIDD S, 1983, CELL, V34, P421, DOI 10.1016/0092-8674(83)90376-8; King R. C., 1970, OVARIAN DEV DROSOPHI; KLAMBT C, 1989, EMBO J, V8, P203, DOI 10.1002/j.1460-2075.1989.tb03365.x; KOCH EA, 1969, Z ZELLFORSCH MIK ANA, V102, P129, DOI 10.1007/BF00336421; KOPCZYNSKI CC, 1988, GENE DEV, V2, P1723, DOI 10.1101/gad.2.12b.1723; LEHMANN R, 1986, CELL, V47, P141, DOI 10.1016/0092-8674(86)90375-2; LEHMANN R, 1983, ROUX ARCH DEV BIOL, V192, P62, DOI 10.1007/BF00848482; LINDSLEY DL, 1968, CARNEGIE I WASH PUBL, V627; MAHOWALD AP, 1983, DEV BIOL, V98, P437, DOI 10.1016/0012-1606(83)90373-1; MAHOWALD AP, 1978, GENET BIOL DROSOPHIL, P141; MANSEAU LJ, 1989, TRENDS GENET, V5, P400, DOI 10.1016/0168-9525(89)90198-4; NUSSLEINVOLHARD C, 1987, SCIENCE, V238, P1675, DOI 10.1126/science.3686007; PATEL NH, 1987, CELL, V48, P975, DOI 10.1016/0092-8674(87)90706-9; PRICE JV, 1989, CELL, V56, P1085, DOI 10.1016/0092-8674(89)90641-7; RAO Y, 1990, NATURE, V345, P163, DOI 10.1038/345163a0; SCHEJTER ED, 1989, CELL, V56, P1093, DOI 10.1016/0092-8674(89)90642-9; SCHUPBACH T, 1987, CELL, V49, P699, DOI 10.1016/0092-8674(87)90546-0; SEYDOUX G, 1990, CELL, V61, P939, DOI 10.1016/0092-8674(90)90060-R; SHELLENBARGER DL, 1975, GENETICS, V81, P143; SMOLLER D, 1990, GENE DEV, V4, P1688, DOI 10.1101/gad.4.10.1688; STJOHNSTON D, 1989, DEVELOPMENT, V107, P13; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; VASSIN H, 1985, J NEUROGENET, V2, P291, DOI 10.3109/01677068509102325; VASSIN H, 1987, EMBO J, V6, P3431, DOI 10.1002/j.1460-2075.1987.tb02666.x; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; WIESCHAUS E, 1980, DEV NEUROBIOLOGY DRO, P85; XU T, 1990, GENE DEV, V4, P464, DOI 10.1101/gad.4.3.464; YOCHEM J, 1989, CELL, V58, P553, DOI 10.1016/0092-8674(89)90436-4; YOCHEM J, 1988, NATURE, V335, P547, DOI 10.1038/335547a0	60	329	330	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 9	1991	66	3					433	449		10.1016/0092-8674(81)90008-8	http://dx.doi.org/10.1016/0092-8674(81)90008-8			17	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GA941	1907889				2022-12-24	WOS:A1991GA94100006
J	RAMAIYA, KL; SWAI, ABM; MCLARTY, DG; BHOPAL, RS; ALBERTI, KGMM				RAMAIYA, KL; SWAI, ABM; MCLARTY, DG; BHOPAL, RS; ALBERTI, KGMM			PREVALENCES OF DIABETES AND CARDIOVASCULAR-DISEASE RISK-FACTORS IN HINDU INDIAN SUBCOMMUNITIES IN TANZANIA	BRITISH MEDICAL JOURNAL			English	Article							IMPAIRED GLUCOSE-TOLERANCE; CORONARY HEART-DISEASE; ASIAN COMMUNITY; EAST LONDON; MORTALITY; CHINESE; SINGAPORE; MORBIDITY; MELLITUS; PATTERNS	Objectives-To seek differences in the prevalence of diabetes mellitus and other coronary heart disease risk factors, and to identify factors associated with these differences within a Hindu Indian community. Design-Population based cross sectional survey. Setting-Dar-es-Salaam, Tanzania. Subjects-Of 20 Hindu subcommunities categorised by caste in Dar-es-Salaam, seven were randomly selected. 1147 (76.7%) of 1495 subjects aged 15 or over participated. Main outcome measures-Blood glucose concentrations (fasting and two hours after oral glucose loading), serum total cholesterol and serum triglyceride concentrations, blood pressure, and height and weight. Results-The subcommunities differed substantially in socioeconomic characteristics and lifestyle. Overall, 9.8% of subjects (109/1113) had diabetes, 17.0% (189/1113) impaired glucose tolerance, 14.5% (166/1143) hypertension, and 13.3% (151/1138) were obese. The mean fasting blood glucose concentration was 4.9 mmol/l, the blood glucose concentration two hours after oral loading (75 g) 6.0 mmol/l, the total cholesterol concentration 4.9 mmol/l, the serum triglyceride concentration 1.4 mmol/l, and body mass index (weight/height2; kg/m2) 24.3. Systolic and diastolic blood pressures were 121 and 77 mm Hg respectively. There were important intercommunity differences even after standardisation for age, sex, and body mass index - for example, in mean fasting blood glucose concentration (range 4.5 (Jains) to 5.9 mmol/l (Patels)), serum total cholesterol concentration (range 4.5 (Jains) to 6.2 mmol/l (Suthars)), systolic blood pressure (range 110 (Limbachias) to 127 mm Hg (Bhatias)), and prevalences of diabetes (range 3.4% (3/87 Limbachias) to 18% (20/111 Navnats)) and hypertension (range 5.7% (5/87 Limbachias) to 19.4% (43/222 Bhatias). Variables which showed significant linear correlation with subcommunity variations were entered into a multiple regression model. Intercommunity variations persisted. The Limbachia and Jain communities had the lowest prevalence of and mean values for coronary heart disease risk factors and the Bhatia and Patel communities had the highest. Conclusions-In this series intercommunity variations in disease and risk factors might have been related to genetic, dietary, socioeconomic, and lifestyle differences but could not be explained by the characteristics studied. Studies of Indian subcommunities are warranted to confirm and extend these descriptive findings and explore the genetic basis of diabetes. Communities of Indian origin should not be perceived as homogeneous.	UNIV NEWCASTLE UPON TYNE,SCH MED,DEPT MED,NEWCASTLE TYNE NE2 4HH,ENGLAND; HINDU MANDAL HOSP,DAR ES SALAAM,TANZANIA; UNIV NEWCASTLE UPON TYNE,SCH MED,DIV EPIDEMIOL & PUBL HLTH,NEWCASTLE TYNE NE2 4HH,ENGLAND; UNIV DAR ES SALAAM,MUHIMBILI MED CTR,DEPT MED,DAR ES SALAAM,TANZANIA	Newcastle University - UK; Newcastle University - UK; University of Dar es Salaam								ADELSTEIN AM, 1963, BRIT J PREV SOC MED, V17, P29; ARMITAGE P, 1987, STATISTICAL METHODS, P194; ARMITAGE P, 1987, STATISTICAL METHODS, P204; BALARAJAN R, 1984, BRIT MED J, V289, P1185, DOI 10.1136/bmj.289.6453.1185; BECKLES GLA, 1986, LANCET, V1, P1298; BHOPAL RS, 1986, COMMUNITY MED, V8, P315; Chen A J, 1980, Ann Acad Med Singap, V9, P411; DEEG R, 1982, CLIN CHEM, V28, P1574; DONALDSON LJ, 1983, BRIT MED J, V286, P949, DOI 10.1136/bmj.286.6369.949; DOWSE GK, 1990, DIABETES, V39, P390, DOI 10.2337/diabetes.39.3.390; Gupta O P, 1978, Adv Metab Disord, V9, P147; HENLEY A, 1979, ASIAN PATIENTS HOSPI; HUGHES K, 1990, J EPIDEMIOL COMMUN H, V44, P24, DOI 10.1136/jech.44.1.24; HUGHES K, 1990, J EPIDEMIOL COMMUN H, V44, P29, DOI 10.1136/jech.44.1.29; MALHOTRA SL, 1967, BRIT HEART J, V29, P895; MALHOTRA SL, 1988, BMJ, V207, P977; MCKEIGUE PM, 1988, BRIT MED J, V297, P903, DOI 10.1136/bmj.297.6653.903; MCKEIGUE PM, 1988, BRIT HEART J, V60, P390; MCKEIGUE PM, 1989, J CLIN EPIDEMIOL, V42, P597, DOI 10.1016/0895-4356(89)90002-4; MCKEIGUE PM, 1985, LANCET, V2, P1086; MCKEIGUE PM, 1989, DIABETIC MED S1, V6, pA41; MEGRAM ER, 1982, CLIN CHEM, V25, P273; MELIA RJW, 1988, BRIT MED J, V296, P1438, DOI 10.1136/bmj.296.6634.1438; NORUSIS MJ, 1986, SPSS IBM PC XT AT; OMAR MAK, 1985, S AFR MED J, V67, P924; PYORALA K, 1987, Diabetes Metabolism Reviews, V3, P463; SHAPER AG, 1959, LANCET, V2, P534; SHAUNAK S, 1986, BRIT MED J, V293, P1169, DOI 10.1136/bmj.293.6555.1169; SILMAN A, 1985, J EPIDEMIOL COMMUN H, V39, P301, DOI 10.1136/jech.39.4.301; SIMMONS D, 1989, BRIT MED J, V298, P18, DOI 10.1136/bmj.298.6665.18; SWAI ABM, 1990, DIABETES RES CLIN PR, V8, P227, DOI 10.1016/0168-8227(90)90121-9; THAI A C, 1987, Journal of the Medical Association of Thailand, V70, P63; TUOMILEHTO J, 1984, B WORLD HEALTH ORGAN, V62, P133; WYNDHAM CH, 1982, S AFR MED J, V61, P987; ZIMMET P, 1983, AM J EPIDEMIOL, V118, P673, DOI 10.1093/oxfordjournals.aje.a113678; 1978, WHO TECH REP SER, V628; 1985, WHO TECH REP SER, V727	37	32	32	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 3	1991	303	6797					271	276		10.1136/bmj.303.6797.271	http://dx.doi.org/10.1136/bmj.303.6797.271			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FZ721	1888926	Green Submitted, Green Published, Bronze			2022-12-24	WOS:A1991FZ72100017
J	FROMHERZ, P; OFFENHAUSSER, A; VETTER, T; WEIS, J				FROMHERZ, P; OFFENHAUSSER, A; VETTER, T; WEIS, J			A NEURON-SILICON JUNCTION - A RETZIUS CELL OF THE LEECH ON AN INSULATED-GATE FIELD-EFFECT TRANSISTOR	SCIENCE			English	Article							CENTRAL NERVOUS-SYSTEM; MICROELECTRODE ARRAY; PLANAR; POTENTIALS; CULTURE; INVITRO	An identified neuron of the leech, a Retzius cell, has been attached to the open gate of a p-channel field-effect transistor. Action potentials, spontaneous or stimulated, modulate directly the source-drain current in silicon. The electronic signals match the shape of the action potential. The average voltage on the gate was up to 25 percent of the intracellular voltage change. Occasionally weak signals that resemble the first derivative of the action potential were observed. The junctions can be described by a model that includes capacitive coupling of the plasma membrane and the gate oxide and that accounts for variable resistance of the seal.			FROMHERZ, P (corresponding author), UNIV ULM,BIOPHYS ABT,W-7900 ULM,GERMANY.		Offenhäusser, Andreas/E-7990-2012	Offenhäusser, Andreas/0000-0001-6143-2702				BERGVELD P, 1976, IEEE T BIO-MED ENG, V23, P136, DOI 10.1109/TBME.1976.324574; DIETZEL ID, 1986, J PHYSIOL-LONDON, V372, P191, DOI 10.1113/jphysiol.1986.sp016004; DRAKE KL, 1988, IEEE T BIO-MED ENG, V35, P719, DOI 10.1109/10.7273; GROSS GW, 1977, NEUROSCI LETT, V6, P101, DOI 10.1016/0304-3940(77)90003-9; JOBLING DT, 1981, MED BIOL ENG COMPUT, V19, P553, DOI 10.1007/BF02442768; KUPERSTEIN M, 1985, NEUROSCIENCE, V15, P703, DOI 10.1016/0306-4522(85)90072-7; NOVAK JL, 1986, IEEE T BIO-MED ENG, V33, P196, DOI 10.1109/TBME.1986.325891; PARSONS TD, 1989, BIOPHYS J, V56, P213, DOI 10.1016/S0006-3495(89)82666-9; PINE J, 1980, J NEUROSCI METH, V2, P19, DOI 10.1016/0165-0270(80)90042-4; REGEHR WG, 1988, IEEE T BIO-MED ENG, V35, P1023, DOI 10.1109/10.8687; SALZBERG BM, 1973, NATURE, V246, P508, DOI 10.1038/246508a0; TAKAHASHI K, 1984, SENSOR ACTUATOR, V5, P89, DOI 10.1016/0250-6874(84)87009-2; Wolf S., 1986, PROCESS TECHNOL INT, V1, P199	13	451	469	0	84	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 31	1991	252	5010					1290	1293		10.1126/science.1925540	http://dx.doi.org/10.1126/science.1925540			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FN857	1925540				2022-12-24	WOS:A1991FN85700034
J	HIRSHFELD, EB				HIRSHFELD, EB			SHOULD PRACTICE PARAMETERS BE THE STANDARD OF CARE IN MALPRACTICE LITIGATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							LIABILITY				HIRSHFELD, EB (corresponding author), AMER MED ASSOC,CHICAGO,IL 60610, USA.							BRENNAN TA, 1991, J HEALTH POLIT POLIC, V16, P67, DOI 10.1215/03616878-16-1-67; CHENEY FW, 1989, JAMA-J AM MED ASSOC, V261, P1599, DOI 10.1001/jama.261.11.1599; EDDY DM, 1990, JAMA-J AM MED ASSOC, V264, P389, DOI 10.1001/jama.264.3.389; FRYE R L, 1984, Journal of the American College of Cardiology, V4, P434; GARNICK DW, 1991, JAMA-J AM MED ASSOC, V266, P2856, DOI 10.1001/jama.266.20.2856; HIRSHFELD EB, 1990, JAMA-J AM MED ASSOC, V263, P1556; Holzer J F, 1990, QRB Qual Rev Bull, V16, P71; KELLIE SE, 1991, JAMA-J AM MED ASSOC, V265, P1265, DOI 10.1001/jama.265.10.1265; Kelly J T, 1990, QRB Qual Rev Bull, V16, P54; KELLY JT, 1990, ARCH PATHOL LAB MED, V114, P1119; KINNEY ED, 1989, UC DAVIS L REV, V22, P421; Leape L L, 1990, QRB Qual Rev Bull, V16, P42; Pierce E C Jr, 1990, QRB Qual Rev Bull, V16, P61; ROPER W, 1988, NEW ENGL J MED, V319, P1179; [No title captured]; 1990, LEGAL IMPLICATIONS P; 1991, US GAOPEMD9111 GEN A; 1988, 3RD SCOPE WORK CONTR	18	42	42	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 27	1991	266	20					2886	2891		10.1001/jama.266.20.2886	http://dx.doi.org/10.1001/jama.266.20.2886			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GQ722	1942459				2022-12-24	WOS:A1991GQ72200040
J	MIRKIN, G				MIRKIN, G			SIDE-EFFECTS OF RAW HONEY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											MIRKIN, G (corresponding author), GEORGETOWN UNIV HOSP,SCH MED,WASHINGTON,DC 20007, USA.							BEATY HN, 1987, PRINCIPLES INTERNAL, P561; BIBEROGLU S, 1988, JAMA-J AM MED ASSOC, V259, P1943, DOI 10.1001/jama.1988.03720130021010; LAMPE KF, 1988, JAMA-J AM MED ASSOC, V259, P2009; MCGEE MD, 1974, HOSP FORMUL MANAG, V9, P41; PATWARDHAN VN, 1973, TOXICANTS OCCURRING, P495; SEYAMA I, 1985, JPN J PHYSIOL, V35, P401, DOI 10.2170/jjphysiol.35.401	6	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 20	1991	266	19					2766	2766						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GP691	1942432				2022-12-24	WOS:A1991GP69100036
J	BUCHSBAUM, DG; BUCHANAN, RG; CENTOR, RM; SCHNOLL, SH; LAWTON, MJ				BUCHSBAUM, DG; BUCHANAN, RG; CENTOR, RM; SCHNOLL, SH; LAWTON, MJ			SCREENING FOR ALCOHOL-ABUSE USING CAGE SCORES AND LIKELIHOOD RATIOS	ANNALS OF INTERNAL MEDICINE			English	Article							HEALTH-MAINTENANCE-ORGANIZATION; DIAGNOSTIC INTERVIEW SCHEDULE; GENERAL-PRACTICE; QUESTIONNAIRE; RECOGNITION; PREVALENCE; CONSUMPTION; POPULATION; VALIDATION; SERVICES	Objective: To assess the performance of the CAGE (acronym referring to four questions, see below) questionnaire in discriminating between medicine outpatients with and without an alcohol abuse or dependence disorder. Design: A cross-sectional design of a sample of consecutive patients who received both the alcohol module of the diagnostic interview schedule and the CAGE (Cut down, Annoyed, Guilty, Eye-opener) screening questionnaire. Setting: The outpatient medical practice of an urban university teaching hospital. Patients: All patients 18 years or older who signed a consent form approved by the university's institutional review board. Measurement: Calculation of the sensitivity, specificity, receiver operating characteristic (ROC) curve, and likelihood ratio for CAGE Scores of 0 to 4. Results: Thirty-six percent of the sample group met criteria for a history of alcohol abuse or dependence. A CAGE score of 2 or more was associated with a sensitivitY and specificity of 74% and 91%. The calculated area under the ROC curve was 0.89, whereas the likelihood ratios for CAGE scores of 0 to 4 were 0.14, 1.5, 4.5, 13, and 100, respectively. These ratios were associated with posterior probabilities for an abuse or dependence disorder of 7%, 46%, 72%, 88%, and 98%, respectively. Conclusion: Clinicians can improve their ability to estimate a patient's risk for an alcohol abuse or dependence disorder using likelihood ratios for CAGE scores.			BUCHSBAUM, DG (corresponding author), VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, BOX 102, RICHMOND, VA 23298 USA.							BERESFORD TP, 1988, PREV MED, V17, P653, DOI 10.1016/0091-7435(88)90058-8; BUCHSBAUM DG, 1991, ALCOHOL ALCOHOLISM, V26, P215, DOI 10.1093/oxfordjournals.alcalc.a045103; BUSH B, 1987, AM J MED, V82, P231, DOI 10.1016/0002-9343(87)90061-1; CENTOR RM, 1989, 13TH P ANN S COMP AP; CLEARY PD, 1988, AM J MED, V85, P466; COULEHAN JL, 1987, ARCH INTERN MED, V147, P349, DOI 10.1001/archinte.147.2.349; EWING JA, 1984, JAMA-J AM MED ASSOC, V252, P1905, DOI 10.1001/jama.252.14.1905; FAGAN TJ, 1975, NEW ENGL J MED, V293, P257; Ford D E, 1990, J Gen Intern Med, V5, pS37, DOI 10.1007/BF02600839; GART JJ, 1988, BIOMETRICS, V44, P323, DOI 10.2307/2531848; GILL JS, 1986, NEW ENGL J MED, V315, P1041, DOI 10.1056/NEJM198610233151701; HELZER JE, 1987, ARCH GEN PSYCHIAT, V44, P1069; HOLDER HD, 1986, JAMA-J AM MED ASSOC, V256, P1456, DOI 10.1001/jama.256.11.1456; HSIAO JK, 1989, ARCH GEN PSYCHIAT, V46, P664; KING M, 1986, PSYCHOL MED, V16, P213, DOI 10.1017/S0033291700002658; KLATSKY AL, 1981, ANN INTERN MED, V95, P139, DOI 10.7326/0003-4819-95-2-139; KOOPMAN PAR, 1984, BIOMETRICS, V40, P513, DOI 10.2307/2531405; MAYFIELD D, 1974, AM J PSYCHIAT, V131, P1121; MOORE RD, 1989, JAMA-J AM MED ASSOC, V261, P403, DOI 10.1001/jama.261.3.403; PAUKER SG, 1980, NEW ENGL J MED, V302, P1109, DOI 10.1056/NEJM198005153022003; POSES RM, 1986, ANN INTERN MED, V105, P586, DOI 10.7326/0003-4819-105-4-586; PUDDEY IB, 1987, LANCET, V1, P647; REIFF S, 1981, ALCOHOL CLIN EXP RES, V5, P559, DOI 10.1111/j.1530-0277.1981.tb05361.x; ROBINS LN, 1981, ARCH GEN PSYCHIAT, V38, P381; ROBINSON KS, 1987, CLIN RES, V35, pA92; ROGHMANN KJ, 1981, J STUD ALCOHOL, V42, P312, DOI 10.15288/jsa.1981.42.312; SCHWARTZ WB, 1981, NEW ENGL J MED, V305, P917, DOI 10.1056/NEJM198110153051604; SKINNER HA, 1984, ANN INTERN MED, V101, P847, DOI 10.7326/0003-4819-101-6-847; WALLACE P, 1985, BRIT MED J, V290, P1949, DOI 10.1136/bmj.290.6486.1949; 1987, DIAGNOSTIC STATISTIC	30	264	264	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1991	115	10					774	777		10.7326/0003-4819-115-10-774	http://dx.doi.org/10.7326/0003-4819-115-10-774			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GP800	1929025				2022-12-24	WOS:A1991GP80000005
J	WINK, DA; KASPRZAK, KS; MARAGOS, CM; ELESPURU, RK; MISRA, M; DUNAMS, TM; CEBULA, TA; KOCH, WH; ANDREWS, AW; ALLEN, JS; KEEFER, LK				WINK, DA; KASPRZAK, KS; MARAGOS, CM; ELESPURU, RK; MISRA, M; DUNAMS, TM; CEBULA, TA; KOCH, WH; ANDREWS, AW; ALLEN, JS; KEEFER, LK			DNA DEAMINATING ABILITY AND GENOTOXICITY OF NITRIC-OXIDE AND ITS PROGENITORS	SCIENCE			English	Article							ESCHERICHIA-COLI; POINT MUTATIONS; 5-METHYLCYTOSINE; MACROPHAGES; NITROSATION; ACTIVATION; RATS; HYPOMETHYLATION; NUCLEOTIDES; CYTOSINE	Nitric oxide (NO), a multifaceted bioregulatory agent and an environmental pollutant, can also cause genomic alterations. In vitro, NO deaminated deoxynucleosides, deoxynucleotides, and intact DNA at physiological pH. That similar DNA damage can also occur in vivo was tested by treating Salmonella typhimurium strain TA1535 with three NO-releasing compounds, including nitroglycerin. All proved mutagenic. Observed DNA sequence changes were > 99% C --> T transitions in the hisG46 (CCC) target codon, consistent with a cytosine-deamination mechanism. Because exposure to endogenously and exogenously produced NO is extensive, this mechanism may contribute to the incidence of deamination-related genetic disease and cancer.	NCI,FREDERICK CANC RES & DEV CTR,COMPARAT CARCINOGENESIS NATL LAB,FREDERICK,MD 21701; US FDA,ROCKVILLE,MD 20852; GLAXO INC,RES TRIANGLE PK,NC 27709; US FDA,WASHINGTON,DC 20204; NCI,FREDERICK CANC RES & DEV CTR,PRI DYNCORP,FREDERICK,MD 21701	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; US Food & Drug Administration (FDA); GlaxoSmithKline; US Food & Drug Administration (FDA); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick			Keefer, Larry K/N-3247-2014	Keefer, Larry K/0000-0001-7489-9555; Wink, David/0000-0002-5652-7480; Azad, Mahan/0000-0002-8633-3513	OFFICE OF THE DIRECTOR, NCI [N01CO074102] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-74102] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BREDT DS, 1990, NATURE, V347, P768, DOI 10.1038/347768a0; BROWN TC, 1987, CELL, V50, P945, DOI 10.1016/0092-8674(87)90521-6; CEBULA TA, 1990, MUTAT RES, V229, P79, DOI 10.1016/0027-5107(90)90010-2; COPPER DN, 1990, HUM GENET, V85, P55; COULONDRE C, 1978, NATURE, V274, P775, DOI 10.1038/274775a0; EHRLICH M, 1990, MUTAT RES, V238, P277, DOI 10.1016/0165-1110(90)90019-8; FEDERN H, 1986, CHROMATOGRAPHIA, V22, P287, DOI 10.1007/BF02268776; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; FREDERICO LA, 1990, BIOCHEMISTRY-US, V29, P2532, DOI 10.1021/bi00462a015; GARTHWAITE J, 1988, NATURE, V336, P385, DOI 10.1038/336385a0; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; HIRSCHHORN R, 1990, P NATL ACAD SCI USA, V87, P6171, DOI 10.1073/pnas.87.16.6171; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HSIAO K, 1989, NATURE, V338, P342, DOI 10.1038/338342a0; IGNARRO LJ, 1990, ANNU REV PHARMACOL, V30, P535, DOI 10.1146/annurev.pa.30.040190.002535; JI XB, 1988, APPL ENVIRON MICROB, V54, P1791, DOI 10.1128/AEM.54.7.1791-1794.1988; KASPRZAK KS, 1990, CARCINOGENESIS, V11, P647, DOI 10.1093/carcin/11.4.647; KOCHETKOV NK, 1972, ORGANIC CHEM NUCLE B, P362; KOSAKA H, 1989, CARCINOGENESIS, V10, P563, DOI 10.1093/carcin/10.3.563; LANCASTER JR, 1990, P NATL ACAD SCI USA, V87, P1223, DOI 10.1073/pnas.87.3.1223; LEAF CD, 1991, CARCINOGENESIS, V12, P537, DOI 10.1093/carcin/12.3.537; LINDAHL T, 1990, MUTAT RES, V238, P305, DOI 10.1016/0165-1110(90)90022-4; LOEB LA, 1990, MUTAT RES, V238, P297, DOI 10.1016/0165-1110(90)90021-3; MARAGOS CM, IN PRESS J MED CHEM; MARLETTA MA, 1988, CHEM RES TOXICOL, V1, P249, DOI 10.1021/tx00005a001; MARON DM, 1983, MUTAT RES, V113, P173, DOI 10.1016/0165-1161(83)90010-9; MONCADA S, 1990, NITRIC OXIDE L ARGIN; MOSCHEL RC, 1989, TETRAHEDRON LETT, V30, P1467, DOI 10.1016/S0040-4039(00)99492-9; NGUYEN T, IN PRESS P NATL ACAD; NGUYEN TT, 1991, P AM ASS CANCER RES, V32; PATTINSON JK, 1990, BLOOD, V76, P2242; PERUTZ MF, 1990, BIOPHYS CHEM, V37, P25, DOI 10.1016/0301-4622(90)88004-C; RALT D, 1988, J BACTERIOL, V170, P359, DOI 10.1128/jb.170.1.359-364.1988; RIDEOUT WM, 1990, SCIENCE, V249, P1288, DOI 10.1126/science.1697983; SAGHER D, 1983, BIOCHEMISTRY-US, V22, P4518, DOI 10.1021/bi00288a026; SHAPIRO HS, 1966, BIOCHEMISTRY-US, V5, P3012, DOI 10.1021/bi00873a034; SHAPIRO R, 1966, BIOCHEMISTRY-US, V5, P2358, DOI 10.1021/bi00871a026; SHIVAPURKAR N, 1984, CARCINOGENESIS, V5, P989, DOI 10.1093/carcin/5.8.989; Singer B., 1983, MOL BIOL MUTAGENS CA; STUEHR DJ, 1985, P NATL ACAD SCI USA, V82, P7738, DOI 10.1073/pnas.82.22.7738; SUKUMAR S, 1983, NATURE, V306, P658, DOI 10.1038/306658a0; TANNENBAUM SR, 1991, AM J CLIN NUTR, V53, pS247, DOI 10.1093/ajcn/53.1.247S; WALLACE SS, 1988, ENVIRON MOL MUTAGEN, V12, P431, DOI 10.1002/em.2860120411; Williams D. L. H., 1988, NITROSATION; WINK DA, 1991, P AM ASS CANCER RES, V32; YANDELL DW, 1989, NEW ENGL J MED, V321, P1689, DOI 10.1056/NEJM198912213212501; 1977, WHO ENV HLTH CRITERI, V4	47	1119	1158	1	56	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 15	1991	254	5034					1001	1003		10.1126/science.1948068	http://dx.doi.org/10.1126/science.1948068			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GP883	1948068				2022-12-24	WOS:A1991GP88300043
J	ARAL, SO; MOSHER, WD; CATES, W				ARAL, SO; MOSHER, WD; CATES, W			SELF-REPORTED PELVIC INFLAMMATORY DISEASE IN THE UNITED-STATES, 1988	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SEXUALLY-TRANSMITTED DISEASES; BEHAVIOR; RISK; CHLAMYDIA	Objective. - To assess any changes in the characteristics of women with self-reported pelvic inflammatory disease (PID) between 1982 and 1988 and to evaluate the role of additional behavioral factors. In 1982, PID was a frequent problem among American women of reproductive age, occurring in one in seven. It was also more common among older (greater-than-or-equal-to 30 years) than younger women, more common among blacks than among whites, and more common among formerly married women than among those currently married. Design. - We analyzed data on self-reported PID from the cycle IV National Survey of Family Growth, conducted in 1988. Sample. - The survey was conducted with a multistage probability sample of 8450 women. Results. - The findings from 1982 were all replicated. Additional variables available in 1988 show that PID is more common among women with multiple (two or more) sexual partners (10% to 22%) compared with those with only one lifetime partner (7%) and among women who report a history of sexually transmitted disease (STD) (26%) compared with those with no STD history (10%). Controlling for other variables, age, race, vaginal douching, age at first intercourse, STD history, and number of lifetime partners emerged as independent predictors of self-reported PID among American women of reproductive age. Conclusion. - PID is still a widely prevalent condition among American women; PID is associated with a variety of risk factors for STD. Prevention of lower genital tract infection is crucial to avoiding PID and its sequelae.	CTR DIS CONTROL,NATL CTR HLTH STAT,NATL SURVEY FAMILY GROWTH,ATLANTA,GA 30333	Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS)	ARAL, SO (corresponding author), CTR DIS CONTROL,CTR PREVENT SERV,DIV STD HIV PREVENT,MAILSTOP E-44,ATLANTA,GA 30333, USA.							ARAL SO, 1985, AM J PUBLIC HEALTH, V75, P1216, DOI 10.2105/AJPH.75.10.1216; ARAL SO, 1989, SEX TRANSM DIS, V16, P173, DOI 10.1097/00007435-198910000-00003; ARAL SO, 1990, CURR OPIN INFECT DIS, V3, P20, DOI 10.1097/00001432-199002000-00004; ARAL SO, 1991, SEX TRANSM DIS, V18, P10, DOI 10.1097/00007435-199101000-00003; ARAL SO, 1990, SEXUALLY TRANSMITTED, P19; ARAL SO, 1991, SEX TRANSM DIS, V17, P208; BACHRACH CA, 1985, VITAL HLTH STAT 98, V2; CATES W, 1990, EPIDEMIOL REV, V12, P199, DOI 10.1093/oxfordjournals.epirev.a036054; CATES W, 1990, CURR OPIN INFECT DIS, V3, P10, DOI 10.1097/00001432-199002000-00003; NEWTON W, 1985, J REPROD MED, V30, P82; PADIAN N, 1990, SEX TRANSM DIS, V17, P200, DOI 10.1097/00007435-199010000-00010; ROLFS RT, 1979, IN PRESS AM J OBSTET; TEISALA K, 1988, ARCH GYNECOL OBSTET, V243, P225, DOI 10.1007/BF00932272; WASHINGTON AE, 1985, JAMA-J AM MED ASSOC, V253, P2246, DOI 10.1001/jama.253.15.2246; WOLNERHANSSEN P, 1990, JAMA-J AM MED ASSOC, V263, P1936, DOI 10.1001/jama.263.14.1936; WONNACOTT TH, 1984, INTRO STATISTICS BUS, P106; 1991, MMWR-MORBID M   SRR5, V40, P1; 1990, JAMA-J AM MED ASSOC, V263, P2344; 1989, 1989 CTR DIS CONTR D	19	96	99	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 13	1991	266	18					2570	2573		10.1001/jama.266.18.2570	http://dx.doi.org/10.1001/jama.266.18.2570			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GN660	1942402				2022-12-24	WOS:A1991GN66000033
J	SHARP, PA				SHARP, PA			5 EASY PIECES	SCIENCE			English	Editorial Material							RIBOSOMAL PROTEIN-S12		MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)	SHARP, PA (corresponding author), MIT,CTR CANC RES,CAMBRIDGE,MA 02139, USA.							CHAPDELAINE Y, 1991, CELL, V65, P465, DOI 10.1016/0092-8674(91)90464-A; FUKUZAWA H, 1986, FEBS LETT, V198, P11, DOI 10.1016/0014-5793(86)81174-7; GOLDSCHMIDTCLERMONT M, 1991, CELL, V65, P135, DOI 10.1016/0092-8674(91)90415-U; GUTHRIE C, 1991, SCIENCE, V253, P147; JARRELL KA, 1988, MOL CELL BIOL, V8, P2361, DOI 10.1128/MCB.8.6.2361; MICHEL F, 1989, GENE, V82, P5, DOI 10.1016/0378-1119(89)90026-7; WISSINGER B, 1991, CELL, V65, P473, DOI 10.1016/0092-8674(91)90465-B; ZAITA N, 1987, FEBS LETT, V210, P153, DOI 10.1016/0014-5793(87)81326-1	8	177	182	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 1	1991	254	5032					663	663		10.1126/science.1948046	http://dx.doi.org/10.1126/science.1948046			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GN474	1948046				2022-12-24	WOS:A1991GN47400028
J	SMEYNE, RJ; OBERDICK, J; SCHILLING, K; BERREBI, AS; MUGNAINI, E; MORGAN, JI				SMEYNE, RJ; OBERDICK, J; SCHILLING, K; BERREBI, AS; MUGNAINI, E; MORGAN, JI			DYNAMIC ORGANIZATION OF DEVELOPING PURKINJE-CELLS REVEALED BY TRANSGENE EXPRESSION	SCIENCE			English	Article							CENTRAL-NERVOUS-SYSTEM; RAT CEREBELLAR CORTEX; MUTANT MICE; MOUSE; NEURONS; MUTATIONS; MABQ113; BANDS; GENE	The cerebellum has many properties that make it a useful model for investigating neural development. Purkinje cells, the major output neurons of the cerebellar cortex, have drawn special attention because of the availability of biochemical markers and mutants that affect their development. The spatial expression of L7, a protein specific for Purkinje cells, and L7-beta-Gal, a gene expressed in transgenic mice that was constructed from the L7 promoter and the marker beta-galactosidase, delineated bands of Purkinje cells that increased in number during early postnatal development. Expression of the transgene in adult reeler mutant mice, which show inverted cortical lamination, and in primary culture showed that the initial expression of L7 is intrinsic to Purkinje cells and does not depend on extracellular signals. This may reflect an underlying developmental map in cerebellum.	ROCHE INST MOLEC BIOL, ROCHE RES CTR, DEPT NEUROSCI, NUTLEY, NJ 07110 USA; UNIV CONNECTICUT, NEUROMORPHOL LAB, GRAD DEGREE PROGRAM BIOBEHAV SCI, STORRS, CT 06269 USA; UNIV MED & DENT NEW JERSEY, NEWARK, NJ 07103 USA	Roche Holding; University of Connecticut; Rutgers State University New Brunswick; Rutgers State University Medical Center			Morgan, James/GRO-2905-2022; Morgan, James/N-8104-2018	Morgan, James/0000-0002-8920-1065; Smeyne, Richard/0000-0002-8459-5472	NINDS NIH HHS [NS-09904] Funding Source: Medline; NINR NIH HHS [NRSA 08-08601] Funding Source: Medline	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR))		AWGULEWITSCH A, 1986, NATURE, V320, P328, DOI 10.1038/320328a0; BERREBI AS, UNPUB; BERREBI AS, 1991, J COMP NEUROL, V309, P2; BROCHU G, 1990, J COMP NEUROL, V291, P538, DOI 10.1002/cne.902910405; CAVINESS VS, 1978, ANNU REV NEUROSCI, V1, P297, DOI 10.1146/annurev.ne.01.030178.001501; CHRISTAKOS S, 1989, ENDOCR REV, V10, P3, DOI 10.1210/edrv-10-1-3; FISCHER G, 1982, NEUROSCI LETT, V28, P325, DOI 10.1016/0304-3940(82)90079-9; GHETTI B, 1990, PROG BRAIN RES, V82, P197; GOFFINET AM, 1984, BRAIN RES REV, V7, P261, DOI 10.1016/0165-0173(84)90013-4; GOFFINET AM, 1983, ANAT EMBRYOL, V168, P73, DOI 10.1007/BF00305400; GREENBERG JM, 1990, NATURE, V344, P158, DOI 10.1038/344158a0; HAWKES R, 1987, J COMP NEUROL, V256, P29, DOI 10.1002/cne.902560104; HERRUP K, 1979, BRAIN RES, V178, P443, DOI 10.1016/0006-8993(79)90705-4; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; KAWAMURA K, 1979, NEUROSCIENCE, V4, P1615, DOI 10.1016/0306-4522(79)90024-1; LECLERC N, 1988, J COMP NEUROL, V273, P399, DOI 10.1002/cne.902730310; MIALE IL, 1961, EXP NEUROL, V4, P277, DOI 10.1016/0014-4886(61)90055-3; OBERDICK J, 1990, SCIENCE, V248, P223, DOI 10.1126/science.2109351; SCHILLING K, UNPUB; SCHILLING KL, 1988, J NEUROSCI RES, V19, P27, DOI 10.1002/jnr.490190105; SMEYNE RJ, 1990, DEV BRAIN RES, V52, P211, DOI 10.1016/0165-3806(90)90237-S; SOTELO C, 1987, NEUROSCIENCE, V20, P1, DOI 10.1016/0306-4522(87)90002-9; WASSEF M, 1985, DEV BIOL, V111, P129, DOI 10.1016/0012-1606(85)90441-5; WASSEF M, 1987, DEV BIOL, V124, P379, DOI 10.1016/0012-1606(87)90490-8; WASSEF M, 1984, NEUROSCIENCE, V13, P1217, DOI 10.1016/0306-4522(84)90295-1; WETTS R, 1982, J EMBRYOL EXP MORPH, V68, P87; WILKINSON DG, 1989, NATURE, V341, P405, DOI 10.1038/341405a0; WILKINSON DG, 1989, NATURE, V337, P461, DOI 10.1038/337461a0	28	99	100	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 1	1991	254	5032					719	721		10.1126/science.1948052	http://dx.doi.org/10.1126/science.1948052			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GN474	1948052				2022-12-24	WOS:A1991GN47400044
J	BUERSTEDDE, JM; TAKEDA, S				BUERSTEDDE, JM; TAKEDA, S			INCREASED RATIO OF TARGETED TO RANDOM INTEGRATION AFTER TRANSFECTION OF CHICKEN B-CELL LINES	CELL			English	Article							LIGHT-CHAIN GENE; BETA-ACTIN GENE; HOMOLOGOUS RECOMBINATION; MAMMALIAN-CELLS; OVALBUMIN GENE; NUCLEOTIDE-SEQUENCE; DNA-SEQUENCES; STEM-CELLS; EXPRESSION; REGION	Constructs of four different genetic loci were transfected into the avian leukosis virus-induced chicken B cell line DT40, which continues diversification of its rearranged light chain immunoglobulin gene by gene conversion. Analysis of stable transfectants revealed an unexpectedly high frequency of targeted integration into the homologous gene loci of DT40. Transcriptional activity of the target gene locus is not required, since a construct of the untranscribed ovalbumin gene also integrated predominantly by homologous recombination. A construct derived from the beta-actin locus was transfected into other chicken cell lines to determine the cell type specificity of the phenomenon. Targeted integration still occurred at high frequency in two other B cell lines that do not have the gene conversion activity. However, the ratios of targeted to random integration were reduced by at least one order of magnitude in three non-B cell lines.			BUERSTEDDE, JM (corresponding author), BASEL INST IMMUNOL, GRENZACHERSTR 487, CH-4005 BASEL, SWITZERLAND.			Takeda, Shunichi/0000-0002-7924-7991				ADAIR GM, 1989, P NATL ACAD SCI USA, V86, P4574, DOI 10.1073/pnas.86.12.4574; BARTH CF, 1988, MOL CELL BIOL, V8, P5358, DOI 10.1128/MCB.8.12.5358; BEUG H, 1982, J CELL PHYSIOL, P195; BOLLAG RJ, 1989, ANNU REV GENET, V23, P199, DOI 10.1146/annurev.ge.23.120189.001215; BUERSTEDDE JM, 1990, EMBO J, V9, P921, DOI 10.1002/j.1460-2075.1990.tb08190.x; CALNEK BW, 1981, INFECT IMMUN, V34, P483, DOI 10.1128/IAI.34.2.483-491.1981; CARLSON LM, 1991, CELL, V64, P201, DOI 10.1016/0092-8674(91)90221-J; CHANG XB, 1987, P NATL ACAD SCI USA, V84, P4959, DOI 10.1073/pnas.84.14.4959; CRUZ A, 1990, NATURE, V348, P171, DOI 10.1038/348171a0; FREGIEN N, 1986, GENE, V48, P1, DOI 10.1016/0378-1119(86)90346-X; HEILIG R, 1982, J MOL BIOL, V156, P1, DOI 10.1016/0022-2836(82)90455-7; JASIN M, 1988, GENE DEV, V2, P1353, DOI 10.1101/gad.2.11.1353; KIM S, 1990, MOL CELL BIOL, V10, P3224, DOI 10.1128/MCB.10.6.3224; KOST TA, 1983, NUCLEIC ACIDS RES, V11, P8287, DOI 10.1093/nar/11.23.8287; LAI EC, 1980, P NATL ACAD SCI-BIOL, V77, P244, DOI 10.1073/pnas.77.1.244; MANSIKKA A, 1990, P NATL ACAD SCI USA, V87, P9416, DOI 10.1073/pnas.87.23.9416; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MIYAZAKI J, 1989, GENE, V79, P269; MOSCOVICI C, 1982, EXPRESSION DIFFERENT; OMALLEY BW, 1974, SCIENCE, V183, P610, DOI 10.1126/science.183.4125.610; ORRWEAVER TL, 1981, P NATL ACAD SCI-BIOL, V78, P6354, DOI 10.1073/pnas.78.10.6354; PONTE P, 1984, NUCLEIC ACIDS RES, V12, P1687, DOI 10.1093/nar/12.3.1687; REYNAUD CA, 1989, CELL, V59, P171, DOI 10.1016/0092-8674(89)90879-9; REYNAUD CA, 1985, CELL, V40, P283, DOI 10.1016/0092-8674(85)90142-4; REYNAUD CA, 1987, CELL, V48, P379, DOI 10.1016/0092-8674(87)90189-9; RIELE HT, 1990, NATURE, V348, P649, DOI 10.1038/348649a0; SMITHIES O, 1985, NATURE, V317, P230, DOI 10.1038/317230a0; TENASBROEK ALMA, 1990, NATURE, V348, P174, DOI 10.1038/348174a0; THOMAS KR, 1986, CELL, V44, P419, DOI 10.1016/0092-8674(86)90463-0; THOMPSON CB, 1987, CELL, V48, P369, DOI 10.1016/0092-8674(87)90188-7; THOMPSON CB, 1987, CELL, V51, P371, DOI 10.1016/0092-8674(87)90633-7; WONG EA, 1987, MOL CELL BIOL, V7, P2294, DOI 10.1128/MCB.7.6.2294; WOO SLC, 1981, BIOCHEMISTRY-US, V20, P6437, DOI 10.1021/bi00525a024; ZHENG H, 1990, NATURE, V344, P170, DOI 10.1038/344170a0	34	467	482	1	15	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 4	1991	67	1					179	188		10.1016/0092-8674(91)90581-I	http://dx.doi.org/10.1016/0092-8674(91)90581-I			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GJ320	1913816				2022-12-24	WOS:A1991GJ32000016
J	MARTIN, K; HELENIUS, A				MARTIN, K; HELENIUS, A			NUCLEAR TRANSPORT OF INFLUENZA-VIRUS RIBONUCLEOPROTEINS - THE VIRAL MATRIX PROTEIN (M1) PROMOTES EXPORT AND INHIBITS IMPORT	CELL			English	Article							MESSENGER-RNA; A VIRUS; MONOCLONAL-ANTIBODIES; INFECTED-CELLS; MEDIATED TRANSLOCATION; XENOPUS OOCYTES; KINASE-C; NUCLEOPROTEIN; SEQUENCE; BINDING	Because influenza virus replicates in the nucleus and buds from the plasma membrane, its ribonucleoproteins (RNPs) must undergo bidirectional transport across the nuclear membrane. Export from the nucleus to the cytoplasm was found to depend on the viral matrix protein (M1). M1 associated with newly assembled viral RNPs (vRNPs) in the nucleus and escorted them to the cytoplasm through the nuclear pores. In contrast, during entry of the virus into a new host cell, M1 protein dissociated from the RNPs, allowing them to enter the nucleus. Amantadine, an antiviral agent that induces an early block in influenza A infection, was found to block the dissociation event and thereby to prevent import of incoming RNPs into the nucleus. Together, these results showed that M1 modulates the directionality of vRNP transport into and out of the nucleus.	YALE UNIV, SCH MED, DEPT CELL BIOL, NEW HAVEN, CT 06510 USA	Yale University	MARTIN, K (corresponding author), YALE UNIV, SCH MED, DEPT MOLEC BIOPHYS & BIOCHEM, NEW HAVEN, CT 06510 USA.				NIAID NIH HHS [AI18599] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI018599, R01AI018599] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BATAILLE N, 1990, J CELL BIOL, V111, P1571, DOI 10.1083/jcb.111.4.1571; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; BRADSHAW GL, 1989, J VIROL, V63, P1704, DOI 10.1128/JVI.63.4.1704-1714.1989; BREEUWER M, 1990, CELL, V60, P999, DOI 10.1016/0092-8674(90)90348-I; BUKRINSKAYA AG, 1982, J GEN VIROL, V60, P49, DOI 10.1099/0022-1317-60-1-49; CHANG DD, 1989, CELL, V59, P789, DOI 10.1016/0092-8674(89)90602-8; CHELSKY D, 1989, MOL CELL BIOL, V9, P2487, DOI 10.1128/MCB.9.6.2487; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; CHOPPIN PW, 1975, INFLUENZA VIRUSES IN, P15; COMPANS PM, 1975, COMPREHENSIVE VIROLO, P179; COMPANS RW, 1972, J VIROL, V10, P795, DOI 10.1128/JVI.10.4.795-800.1972; DAVEY J, 1985, CELL, V40, P667, DOI 10.1016/0092-8674(85)90215-6; DINGWALL C, 1986, ANNU REV CELL BIOL, V2, P367, DOI 10.1146/annurev.cellbio.2.1.367; DWORETZKY SI, 1988, J CELL BIOL, V106, P575, DOI 10.1083/jcb.106.3.575; FELBER BK, 1989, P NATL ACAD SCI USA, V86, P1495, DOI 10.1073/pnas.86.5.1495; FELDHERR CM, 1984, J CELL BIOL, V99, P2216, DOI 10.1083/jcb.99.6.2216; FLAWITH JWF, 1979, J GEN VIROL, V45, P527, DOI 10.1099/0022-1317-45-2-527; FRANKLIN RM, 1959, VIROLOGY, V8, P293, DOI 10.1016/0042-6822(59)90031-5; Goldfarb DS, 1989, CURR OPIN CELL BIOL, V1, P441, DOI 10.1016/0955-0674(89)90003-3; GOLDFARB DS, 1986, NATURE, V322, P641, DOI 10.1038/322641a0; GUDDAT U, 1990, CELL, V60, P619, DOI 10.1016/0092-8674(90)90665-2; HAMM J, 1990, CELL, V62, P569, DOI 10.1016/0092-8674(90)90021-6; HAMM J, 1990, CELL, V63, P109, DOI 10.1016/0092-8674(90)90292-M; HAY AJ, 1985, EMBO J, V4, P3021, DOI 10.1002/j.1460-2075.1985.tb04038.x; HAY AJ, 1975, NEGATIVE STRAND VIRU, P635; HEGGENESS MH, 1982, VIROLOGY, V118, P466, DOI 10.1016/0042-6822(82)90367-1; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HSU MT, 1987, P NATL ACAD SCI USA, V84, P8140, DOI 10.1073/pnas.84.22.8140; INGLIS SC, 1984, J GEN VIROL, V65, P153, DOI 10.1099/0022-1317-65-1-153; JONES IM, 1986, EMBO J, V5, P2371, DOI 10.1002/j.1460-2075.1986.tb04506.x; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KAWAKAMI K, 1983, J BIOCHEM-TOKYO, V93, P989, DOI 10.1093/oxfordjournals.jbchem.a134254; KEMP BE, 1988, METHOD ENZYMOL, V159, P173; KISTNER O, 1989, J GEN VIROL, V70, P2421, DOI 10.1099/0022-1317-70-9-2421; KRUG RM, 1989, INFLUENZA VIRUSES, P89; KUROKAWA M, 1990, J GEN VIROL, V71, P2149, DOI 10.1099/0022-1317-71-9-2149; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lamb R.A., 1989, INFLUENZA VIRUSES, P1; LAMB RA, 1985, CELL, V40, P627, DOI 10.1016/0092-8674(85)90211-9; LEGRAIN P, 1989, CELL, V57, P573, DOI 10.1016/0092-8674(89)90127-X; LERNER EA, 1981, P NATL ACAD SCI-BIOL, V78, P2737, DOI 10.1073/pnas.78.5.2737; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUBECK MD, 1978, J VIROL, V28, P710, DOI 10.1128/JVI.28.3.710-716.1978; MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0; MANDELL RB, 1990, J CELL BIOL, V111, P1775, DOI 10.1083/jcb.111.5.1775; MARSH M, 1989, ADV VIRUS RES, V36, P107, DOI 10.1016/S0065-3527(08)60583-7; MARTIN K, 1991, J VIROL, V65, P232, DOI 10.1128/JVI.65.1.232-244.1991; MATLIN KS, 1981, J CELL BIOL, V91, P601, DOI 10.1083/jcb.91.3.601; MATTAJ IW, 1985, CELL, V40, P111, DOI 10.1016/0092-8674(85)90314-9; MURTI KG, 1988, VIROLOGY, V164, P562, DOI 10.1016/0042-6822(88)90574-0; NATH ST, 1990, MOL CELL BIOL, V10, P4139, DOI 10.1128/MCB.10.8.4139; NEWMEYER DD, 1988, CELL, V52, P641, DOI 10.1016/0092-8674(88)90402-3; OHKUMA S, 1978, P NATL ACAD SCI USA, V75, P3327, DOI 10.1073/pnas.75.7.3327; PAINE PL, 1975, NATURE, V254, P109, DOI 10.1038/254109a0; PALESE P, 1977, CELL, V10, P1, DOI 10.1016/0092-8674(77)90133-7; PATTERSON S, 1988, J GEN VIROL, V69, P1859, DOI 10.1099/0022-1317-69-8-1859; REES PJ, 1981, J GEN VIROL, V53, P125, DOI 10.1099/0022-1317-53-1-125; REES PJ, 1982, J GEN VIROL, V59, P403, DOI 10.1099/0022-1317-59-2-403; RICHARDSON WD, 1988, CELL, V52, P655, DOI 10.1016/0092-8674(88)90403-5; RIGG RJ, 1989, J GEN VIROL, V70, P2097, DOI 10.1099/0022-1317-70-8-2097; RITCHEY MB, 1977, J VIROL, V21, P1196, DOI 10.1128/JVI.21.3.1196-1204.1977; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; RODRIGUEZBOULAN E, 1983, METHOD ENZYMOL, V98, P486; RUIGROK RWH, 1989, VIROLOGY, V173, P311, DOI 10.1016/0042-6822(89)90248-1; SCHNABEL E, 1989, EUR J CELL BIOL, V48, P313; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; SKEHEL JJ, 1971, VIROLOGY, V44, P396, DOI 10.1016/0042-6822(71)90270-4; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; SUGRUE RJ, 1990, EMBO J, V9, P3469, DOI 10.1002/j.1460-2075.1990.tb07555.x; SUGRUE RJ, 1991, VIROLOGY, V180, P617, DOI 10.1016/0042-6822(91)90075-M; TOKUYASU KT, 1989, HISTOCHEM J, V21, P163, DOI 10.1007/BF01007491; VANWYKE KL, 1980, J VIROL, V35, P24, DOI 10.1128/JVI.35.1.24-30.1980; VANWYKE KL, 1981, J VIROL, V39, P313, DOI 10.1128/JVI.39.1.313-317.1981; WINTER G, 1980, NUCLEIC ACIDS RES, V8, P1965, DOI 10.1093/nar/8.9.1965; WINTER G, 1981, VIROLOGY, V114, P423, DOI 10.1016/0042-6822(81)90223-3; YE ZP, 1989, J VIROL, V63, P3586, DOI 10.1128/JVI.63.9.3586-3594.1989; ZASLOFF M, 1983, P NATL ACAD SCI-BIOL, V80, P6436, DOI 10.1073/pnas.80.21.6436; ZHIRNOV OP, 1990, VIROLOGY, V176, P274, DOI 10.1016/0042-6822(90)90253-N	78	490	510	4	29	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 4	1991	67	1					117	130		10.1016/0092-8674(91)90576-K	http://dx.doi.org/10.1016/0092-8674(91)90576-K			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GJ320	1913813				2022-12-24	WOS:A1991GJ32000011
J	STRICKBERGER, SA; CANTILLON, CO; FRIEDMAN, PL				STRICKBERGER, SA; CANTILLON, CO; FRIEDMAN, PL			WHEN SHOULD PATIENTS WITH LETHAL VENTRICULAR ARRHYTHMIA RESUME DRIVING - AN ANALYSIS OF STATE REGULATIONS AND PHYSICIAN PRACTICES	ANNALS OF INTERNAL MEDICINE			English	Article						ARRHYTHMIA; ELECTRIC COUNTERSHOCK; DEATH, SUDDEN; AUTOMOBILE DRIVING; LEGISLATION, MEDICAL	IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR; HOSPITAL CARDIAC-ARREST; FOLLOW-UP; SURVIVORS; FIBRILLATION; THERAPY	Most states have specific laws governing whether patients with seizure disorders can drive. To learn whether similar laws exist for patients with lethal ventricular arrhythmias, we surveyed the Departments of Motor Vehicles in all 50 states. In addition, either an arrhythmia specialist (n = 25) or a general cardiologist (n = 25) was chosen randomly from each state and interviewed to study physician awareness of such laws and physician attitudes toward driving by patients with arrhythmias. Forty-two states (84%) have laws restricting driving by patients who have seizures; only 8 states (16%) have specific laws for patients with arrhythmias. No state makes a distinction between driving by patients with arrhythmias who are managed with an implantable cardioverter-defibrillator (ICD) compared with patients who are managed medically. Seventy-four percent of physicians did not know their own state's laws about driving by patients who have ventricular arrhythmias. Cardiologists were more likely to advise no driving restriction for medically treated patients than for ICD-treated patients. Cardiologists were also more likely to advise permanent restriction for patients with ICDs than for patients treated medically. We conclude that greater legal and medical consensus is needed to guide physicians in advising patients with lethal ventricular arrhythmias about driving restrictions.	BRIGHAM & WOMENS HOSP, DIV CARDIOVASC, 75 FRANCIS ST, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School								AXTELL KA, 1990, CIRCULATION, V82, P211; BAUM RS, 1974, CIRCULATION, V50, P1231, DOI 10.1161/01.CIR.50.6.1231; ECHT DS, 1985, CIRCULATION, V71, P289, DOI 10.1161/01.CIR.71.2.289; FOGOROS RN, 1989, PACE, V12, P1465, DOI 10.1111/j.1540-8159.1989.tb06151.x; LARSEN GC, 1990, CIRCULATION, V82, P83; LEHMANN MH, 1988, AM J CARDIOL, V62, P803, DOI 10.1016/0002-9149(88)91226-X; LIBERTHSON RR, 1974, NEW ENGL J MED, V291, P317, DOI 10.1056/NEJM197408152910701; MYERBURG RJ, 1982, JAMA-J AM MED ASSOC, V247, P1485, DOI 10.1001/jama.247.10.1485; MYERBURG RJ, 1987, CARDIAC ARRHYTHMIAS, P505; ROY D, 1983, AM J CARDIOL, V52, P969, DOI 10.1016/0002-9149(83)90514-3; RUSKIN JN, 1980, NEW ENGL J MED, V303, P607, DOI 10.1056/NEJM198009113031103; SKALE BT, 1986, AM J CARDIOL, V57, P113, DOI 10.1016/0002-9149(86)90962-8; TCHOU PJ, 1988, ANN INTERN MED, V109, P529, DOI 10.7326/0003-4819-109-7-529; WILBER DJ, 1988, NEW ENGL J MED, V318, P19, DOI 10.1056/NEJM198801073180105; WINKLE RA, 1989, J AM COLL CARDIOL, V13, P1353, DOI 10.1016/0735-1097(89)90310-0	15	39	39	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1991	115	7					560	563		10.7326/0003-4819-115-7-560	http://dx.doi.org/10.7326/0003-4819-115-7-560			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG283	1883126				2022-12-24	WOS:A1991GG28300009
J	KALLEN, J; SPITZFADEN, C; ZURINI, MGM; WIDER, G; WIDMER, H; WUTHRICH, K; WALKINSHAW, MD				KALLEN, J; SPITZFADEN, C; ZURINI, MGM; WIDER, G; WIDMER, H; WUTHRICH, K; WALKINSHAW, MD			STRUCTURE OF HUMAN CYCLOPHILIN AND ITS BINDING-SITE FOR CYCLOSPORINE-A DETERMINED BY X-RAY CRYSTALLOGRAPHY AND NMR-SPECTROSCOPY	NATURE			English	Article							CIS-TRANS ISOMERASE; PROTEIN; REFINEMENT	THE protein cyclophilin is the major intracellular receptor for the immunosuppressive drug cyclosporin A (ref. 1). Cyclosporin A acts as an inhibitor of T-cell activation and can prevent graft rejection in organ and bone marrow transplantation 2. Cyclophilin may be responsible for mediating this immunosuppressive response. Cyclophilin also catalyses the interconversion of the cis and trans isomers of the peptidyl-prolyl amide bonds of peptide and protein substrates 3,4. Here we report the X-ray crystal structure of human recombinant cyclophilin complexed with a tetrapeptide and the identification, by nuclear magnetic resonance spectroscopy, of the specific binding site for cyclosporin A. Cyclophilin has an eight-stranded antiparallel beta-barrel structure. The prolyl isomerase substrate-binding site is coincident with the cyclosporin-binding site. These results may help to provide a structural basis for rationalizing the immunosuppressive function of the cyclosporin-cyclophilin system and will also be important in the design of improved immunosuppressant drugs.	SANDOZ PHARMA AG,PRECLIN RES,CH-4002 BASEL,SWITZERLAND; SWISS FED INST TECHNOL,INST MOLEK BIOL & BIOPHYS,CH-8093 ZURICH,SWITZERLAND	Novartis; Sandoz; Swiss Federal Institutes of Technology Domain; ETH Zurich			walkinshaw, malcolm/AAB-7497-2019	Wider, Gerhard/0000-0001-9366-7645; walkinshaw, malcolm/0000-0001-5955-9325				BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; BLUNDELL TL, 1976, PROTEIN CRYSTALLOGRA, P357; BOREL JF, 1989, PHARMACOL REV, V41, P259; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; COWAN SW, 1990, PROTEINS, V8, P44, DOI 10.1002/prot.340080108; FESIK SW, 1991, BIOCHEMISTRY-US, V30, P6574, DOI 10.1021/bi00240a030; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KE H, IN PRESS P NATN ACAD; LIU J, 1991, BIOCHEMISTRY-US, V30, P2306, DOI 10.1021/bi00223a003; LIU J, 1990, P NATL ACAD SCI USA, V87, P2304, DOI 10.1073/pnas.87.6.2304; MICHNICK SW, 1991, SCIENCE, V252, P836, DOI 10.1126/science.1709301; MOORE JM, 1991, NATURE, V351, P248, DOI 10.1038/351248a0; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; TAKAHASHI N, 1989, NATURE, V337, P473, DOI 10.1038/337473a0; TROPSCHUG M, 1989, NATURE, V342, P953, DOI 10.1038/342953a0; VANDUYNE GD, 1991, SCIENCE, V252, P839, DOI 10.1126/science.1709302; WEBER C, 1991, BIOCHEMISTRY-US, V30, P6563, DOI 10.1021/bi00240a029; WUTHRICH K, IN PRESS FEBS LETT; ZURINI M, 1990, FEBS LETT, V276, P63, DOI 10.1016/0014-5793(90)80507-F; 1986, CCP4 SUITE PROGRAMS	22	255	261	3	42	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 19	1991	353	6341					276	279		10.1038/353276a0	http://dx.doi.org/10.1038/353276a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GF674	1896075				2022-12-24	WOS:A1991GF67400066
J	DAUNICHT, WJ				DAUNICHT, WJ			AUTOASSOCIATION AND NOVELTY DETECTION BY NEUROMECHANICS	SCIENCE			English	Article							NETWORKS	Many biomechanical systems contain ball joints with several clastic actuators (muscles) obliquely attached to the links. The problem, of calculating the optimum actuator commands to achieve a desired link orientation is a difficult one for any control system; however, the elasticity of the actuators may be part of the solution. Mechanoreceptors such as those found in muscles and tendons are capable of performing operations that can be regarded as autoassociation and novelty detection, respectively, by minimization of potential energy. The information provided by such sensors may then be exploited for optimization of muscle coordination.			DAUNICHT, WJ (corresponding author), UNIV DUSSELDORF,INST PHYS BIOL,BIOKYBERNET ABT,W-4000 DUSSELDORF 1,GERMANY.							ABUMOSTAFA YS, 1987, SCI AM, V256, P88, DOI 10.1038/scientificamerican0387-88; BENISRAEL A, 1974, GENERALIZED INVERSES; COOPER S, 1949, BRAIN, V72, P1, DOI 10.1093/brain/72.1.1; DAUNICHT WJ, 1988, BIOL CYBERN, V58, P225, DOI 10.1007/BF00364128; DAUNICHT WJ, UNPUB; GRAF HP, 1988, COMPUTER, V21, P41, DOI 10.1109/2.30; HOPFIELD JJ, 1982, P NATL ACAD SCI-BIOL, V79, P2554, DOI 10.1073/pnas.79.8.2554; KIRKPATRICK S, 1978, PHYS REV B, V17, P4384, DOI 10.1103/PhysRevB.17.4384; KLEIN CA, 1983, IEEE T SYST MAN CYB, V13, P245, DOI 10.1109/TSMC.1983.6313123; KOHONEN T, 1976, BIOL CYBERN, V21, P85, DOI 10.1007/BF01259390; KOHONEN T, 1989, SELF ORG ASS MEMORY, pCH4; MAEKAWA K, 1980, BRAIN RES, V191, P313, DOI 10.1016/0006-8993(80)91283-4; PELLIONISZ A, 1980, NEUROSCIENCE, V5, P1125, DOI 10.1016/0306-4522(80)90191-8; PELLIONISZ A, 1985, ADAPTIVE MECHANISMS, P281; Reilly D. L., 1990, INTRO NEURAL ELECT N, P227; RICHMOND FJR, 1984, INVEST OPHTH VIS SCI, V25, P471; Volkmann A.W., 1869, BER VERH SACHS GES W, V21, P28	17	10	10	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 13	1991	253	5025					1289	1291		10.1126/science.1891718	http://dx.doi.org/10.1126/science.1891718			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GE689	1891718				2022-12-24	WOS:A1991GE68900044
J	JOHNSON, AM				JOHNSON, AM			HIV AND AIDS	BRITISH MEDICAL JOURNAL			English	Article											JOHNSON, AM (corresponding author), UNIV COLL & MIDDLESEX SCH MED,ACAD DEPT GENITOURINARY MED,LONDON W1N 8AA,ENGLAND.			Johnson, Anne/0000-0003-1330-7100				ADES AE, 1991, LANCET, P1562; BROOKMEYER R, 1991, SCIENCE, V253, P37, DOI 10.1126/science.2063206; DUNNELL K, 1991, POPULATION TRENDS, V64, P38; JOHNSON AM, 1989, AIDS, V3, P135, DOI 10.1097/00002030-198903000-00003; JOHNSON AM, 1989, PHILOS T R SOC LOND, V325, P115; MCGINNIS JM, 1985, OXFORD TXB PUBLIC HL, P385; WELLINGS K, 1990, NATURE, V348, P276, DOI 10.1038/348276a0; WODAK A, 1990, AIDS (London), V4, pS105; 1988, REPORT; 1988, AIDS STRATEGIC MONIT; 1980, PROMOTING HLTH PERVE; 1988, MMWR, V37, P565; 1990, MMWR, V39, P54; 1990, NEW CASES NHS GENITO; 1991, UK LEVELS HLTH; 1991, HLTH NATION; 1990, MMWR, V40, P41; 1990, DHHS PHS9050212 PUBL; 1979, DHEW PHS7955071 PUBL; 1991, 1 PUBL HLTH LAB SERV, pR69	20	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 7	1991	303	6802					573	576		10.1136/bmj.303.6802.573	http://dx.doi.org/10.1136/bmj.303.6802.573			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GE948	1912891	Bronze, Green Published			2022-12-24	WOS:A1991GE94800030
J	FITZPATRICK, MM; SHAH, V; TROMPETER, RS; DILLON, MJ; BARRATT, TM				FITZPATRICK, MM; SHAH, V; TROMPETER, RS; DILLON, MJ; BARRATT, TM			LONG-TERM RENAL OUTCOME OF CHILDHOOD HEMOLYTIC UREMIC SYNDROME	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HEMOLYTIC-UREMIC SYNDROME; PROGNOSTIC FEATURES; ESCHERICHIA-COLI	Objective - To evaluate the long term outcome of renal function in infants and children after diarrhoea associated haemolytic uraemic syndrome. Setting - The Hospital for Sick Children, Great Ormond Street, and the Royal Free Hospital, London. Subjects - 103 children with the syndrome who presented between 1966 and 1985; 88 attended for follow up investigations (40 male, 48 female) with a mean age 11.6 (range 5.2-22.6) years and a mean duration of follow up of 8.5 (range 5.1-21.3) years. Main outcome measures - Blood pressure, ratio of early morning urine albumin to creatinine concentration, glomerular filtration rate, and plasma renin activity. Results - The mean (SD) systolic blood pressure standard deviation score was 0.38 (0.67) and diastolic blood pressure SD score was 0.10 (0.76). The geometric mean ratio of overnight urine albumin to creatinine concentration was 1.27 (range 0.03-48.2), significantly higher than the value observed in 77 normal children (0.32 (0.05-1.95), p < 0.0001). Glomerular filtration rate estimated from the plasma clearance of chromium-51 EDTA was 95.1 (22.7) ml/min/1.73 m2 surface area, and 16 children had a rate of less-than-or-equal-to 80 ml/min/1.73 m2. Significant negative correlations were found between glomerular filtration rate and urinary albumin to creatinine ratio (r = -0.41, p < 0.0001) and glomerular filtration rate and systolic blood pressure SD score (r = -0.48, p < 0.0001). A significant positive correlation was found between urinary albumin to creatinine ratio and systolic blood pressure SD score (r = 0.25, p = 0.02). Conclusions - After an acute episode of diarrhoea associated haemolytic uraemic syndrome 31% (27/88) of children had an increased albumin excretion, 18% (16/88) had a reduced glomerular filtration rate and 10% (9/88) had both, in association with a higher systolic blood pressure, indicating considerable residual nephropathy in this group.	INST CHILD HLTH, MED LAB, LONDON WC1N 1EH, ENGLAND	University of London; University College London	FITZPATRICK, MM (corresponding author), INST CHILD HLTH, DEPT PAEDIAT NEPHROL, LONDON WC1N 1EH, ENGLAND.							[Anonymous], 1987, PEDIATRICS, V79, P1; CHANTLER C, 1972, ARCH DIS CHILD, V47, P613, DOI 10.1136/adc.47.254.613; COAD NAG, 1991, CLIN NEPHROL, V35, P10; DILLON MJ, 1975, J CLIN PATHOL, V28, P625, DOI 10.1136/jcp.28.8.625; DONCKERWOLCKE RA, 1979, PAEDIATRICIAN, V8, P378; GASSER C, 1955, Schweiz Med Wochenschr, V85, P905; GIANANTONIO CA, 1973, NEPHRON, V11, P174; GIBB DM, 1990, THESIS U BRISTOL BRI; HABIB R, 1982, ADV NEPHROL, V14, P109; KAPLAN BS, 1971, J PEDIATR-US, V78, P420, DOI 10.1016/S0022-3476(71)80221-4; KAPLAN BS, 1977, CLIN NEPHROL, V8, P495; KARMALI MA, 1983, LANCET, V1, P619, DOI 10.1016/s0140-6736(83)91795-6; LEVIN M, 1984, ARCH DIS CHILD, V59, P397, DOI 10.1136/adc.59.5.397; Levin M, 1989, Adv Pediatr Infect Dis, V4, P51; LOIRAT C, 1984, ACTA PAEDIATR SCAND, V73, P505, DOI 10.1111/j.1651-2227.1984.tb09962.x; LONDE S, 1985, PEDIATRICS, V76, P460; MARTIN DL, 1990, NEW ENGL J MED, V323, P1161, DOI 10.1056/NEJM199010253231703; MILFORD DV, 1990, ARCH DIS CHILD, V65, P716, DOI 10.1136/adc.65.7.716; MILFORD DV, 1991, J PEDIATR-US, V118, P191, DOI 10.1016/S0022-3476(05)80481-0; MUAKA PBK, 1981, EUR J PEDIATR, V136, P237; PERELSTEIN EM, 1990, ARCH DIS CHILD, V65, P728, DOI 10.1136/adc.65.7.728; SIENIAWSKA M, 1990, PEDIATR NEPHROL, V4, P213, DOI 10.1007/BF00857656; TROMPETER RS, 1983, ARCH DIS CHILD, V58, P101, DOI 10.1136/adc.58.2.101; VANDYCK M, 1988, CLIN NEPHROL, V29, P109; WALTERS MDS, 1989, PEDIATR NEPHROL, V3, P130, DOI 10.1007/BF00852893; WRIGHT BM, 1970, LANCET, V1, P337	26	83	84	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 31	1991	303	6801					489	492		10.1136/bmj.303.6801.489	http://dx.doi.org/10.1136/bmj.303.6801.489			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GD804	1912857	Green Published, Bronze			2022-12-24	WOS:A1991GD80400014
J	MEYNAAR, IA; VANTWOUT, JW; VANDENBROUCKE, JP; VANFURTH, R				MEYNAAR, IA; VANTWOUT, JW; VANDENBROUCKE, JP; VANFURTH, R			USE OF INFLUENZA VACCINE IN THE NETHERLANDS	BRITISH MEDICAL JOURNAL			English	Article									LEIDEN UNIV,DEPT INFECT DIS,HOSP BLDG 1,CS-P,POB 9600,2300 RC LEIDEN,NETHERLANDS; LEIDEN UNIV,DEPT CLIN EPIDEMIOL,2300 RC LEIDEN,NETHERLANDS	Leiden University; Leiden University - Excl LUMC; Leiden University; Leiden University - Excl LUMC			Vandenbroucke, Jan/AAM-3928-2020	Vandenbroucke, Jan/0000-0001-5668-6716				FRANK JW, 1985, CAN MED ASSOC J, V132, P371; HOFSTRA ML, 1990, HUISARTS WET, V33, P429; MCKINNEY WP, 1989, AM J PUBLIC HEALTH, V79, P1422, DOI 10.2105/AJPH.79.10.1422; NICHOLSON KG, 1990, BRIT MED J, V301, P617, DOI 10.1136/bmj.301.6753.617; 1990, VACCINATIE TEGEN INF	5	13	13	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 31	1991	303	6801					508	508		10.1136/bmj.303.6801.508	http://dx.doi.org/10.1136/bmj.303.6801.508			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GD804	1912862	Bronze, Green Published			2022-12-24	WOS:A1991GD80400019
J	WASHBURN, JO; MERCER, DR; ANDERSON, JR				WASHBURN, JO; MERCER, DR; ANDERSON, JR			REGULATORY ROLE OF PARASITES - IMPACT ON HOST POPULATION SHIFTS WITH RESOURCE AVAILABILITY	SCIENCE			English	Article							LAMBORNELLA-CLARKI CILIOPHORA; AEDES-SIERRENSIS DIPTERA; CALIFORNIA TREEHOLES; MOSQUITO; CILIATE; TETRAHYMENIDAE; CULICIDAE	Effects of infections by the ciliate Lambornella clarki on larval populations of its mosquito host Aedes sierrensis were examined in laboratory and field studies. When host populations developed with sufficient food, mortality from parasites was additive and reduced the number of emerging mosquitoes. For food-limited populations, mortality was compensatory or depensatory; emerging adults were as or more abundant with higher average fitness than those from uninfected control populations. When nutrients were scarce, parasitic infections relaxed larval competition and increased per capita food by reducing host abundance. Food limitation altered larval feeding behavior, reducing horizontal transmission and subsequent mortality from parasitism.			WASHBURN, JO (corresponding author), UNIV CALIF BERKELEY, DEPT ENTOMOL, BERKELEY, CA 94720 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020245] Funding Source: NIH RePORTER; NIAID NIH HHS [AI20245] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGUDELOSILVA F, 1984, AM J TROP MED HYG, V33, P1267, DOI 10.4269/ajtmh.1984.33.1267; ANDERSON RM, 1979, NATURE, V279, P150, DOI 10.1038/279150a0; ANDERSON RM, 1978, J ANIM ECOL, V47, P219, DOI 10.2307/3933; CARPENTER SR, 1982, OIKOS, V39, P17, DOI 10.2307/3544526; CARPENTER SR, 1983, ECOLOGY, V64, P219, DOI 10.2307/1937068; CLARK TB, 1976, J INVERTEBR PATHOL, V28, P341, DOI 10.1016/0022-2011(76)90009-4; CORLISS JO, 1976, T AM MICROSC SOC, V95, P725, DOI 10.2307/3225400; EGERTER DE, 1985, J INVERTEBR PATHOL, V46, P296, DOI 10.1016/0022-2011(85)90072-2; EGERTER DE, 1986, P NATL ACAD SCI USA, V83, P7335, DOI 10.1073/pnas.83.19.7335; Esch G. W., 1990, PARASITE COMMUNITIES; Hassell M. P, 1982, POPULATION BIOL INFE, P15; Hawley W.A., 1985, P167; HAWLEY WA, 1985, J ANIM ECOL, V54, P955, DOI 10.2307/4389; Holmes J.C., 1982, Life Sciences Research Report, P37; Lounibos L. P., 1985, ECOLOGY MOSQUITOES; SCOTT ME, 1989, PROTOZOOL TODAY, V5, P179; Washburn J., UNPUB; WASHBURN JO, 1988, SCIENCE, V240, P1193, DOI 10.1126/science.3131877; WASHBURN JO, 1986, J INVERTEBR PATHOL, V48, P296, DOI 10.1016/0022-2011(86)90058-3; WASHBURN JO, 1989, J MED ENTOMOL, V26, P173, DOI 10.1093/jmedent/26.3.173; WASHBURN JO, IN PRESS J INVERT PA; WOODWARD DL, 1988, B SOC VECTOR ECOL, V13, P1	22	79	80	0	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 12	1991	253	5016					185	188		10.1126/science.1906637	http://dx.doi.org/10.1126/science.1906637			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FW160	1906637				2022-12-24	WOS:A1991FW16000033
J	SHON, KJ; KIM, YG; COLNAGO, LA; OPELLA, SJ				SHON, KJ; KIM, YG; COLNAGO, LA; OPELLA, SJ			NMR-STUDIES OF THE STRUCTURE AND DYNAMICS OF MEMBRANE-BOUND BACTERIOPHAGE-PFL COAT PROTEIN	SCIENCE			English	Article							N-15 CHEMICAL-SHIFT; PHOTOSYNTHETIC REACTION CENTER; SOLID-STATE; SPECTROSCOPY; BACTERIORHODOPSIN; RESOLUTION; MICELLES; TENSORS; MODEL	Filamentous bacteriophage coat protein undergoes a remarkable structural transition during the viral assembly process as it is transferred from the membrane environment of the cell, where it spans the phospholipid bilayer, to the newly extruded virus particles. Nuclear magnetic resonance (NMR) studies show the membrane-bound form of the 46-residue Pfl coat protein to be surprisingly complex with five distinct regions. The secondary structure consists of a long hydrophobic helix (residues 19 to 42) that spans the bilayer and a short amphipathic helix (residues 6 to 13) parallel to the plane of the bilayer. The NH2-terminus (residues 1 to 5), the COOH-terminus (residues 43 to 46), and residues 14 to 18 connecting the two helices are mobile. By comparing the structure and dynamics of the membrane-bound coat protein with that of the viral form as determined by NMR and neutron diffraction, essential features of assembly process can be identified.	UNIV PENN, DEPT CHEM, PHILADELPHIA, PA 19104 USA	University of Pennsylvania			Colnago, Luiz Alberto/E-9693-2012	Colnago, Luiz Alberto/0000-0002-9516-9022	NCRR NIH HHS [RR-02301] Funding Source: Medline; NIAID NIH HHS [AI20770-06] Funding Source: Medline; NIGMS NIH HHS [GM34343-06] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR002301] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020770] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOGUSKY MJ, 1985, BIOCHEM BIOPH RES CO, V127, P540, DOI 10.1016/S0006-291X(85)80193-5; BOGUSKY MJ, 1987, J MAGN RESON, V72, P186, DOI 10.1016/0022-2364(87)90187-9; BOWERS JL, 1988, BIOCHEMISTRY-US, V27, P5156, DOI 10.1021/bi00414a031; CHIRLIAN LE, 1990, ADV MAGN RESON, V14, P183; COLNAGO LA, 1986, BIOMOLECULAR STEREOD, V3, P147; CROSS TA, 1980, BIOCHEM BIOPH RES CO, V92, P478, DOI 10.1016/0006-291X(80)90358-7; DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0; HARBISON GS, 1984, J MAGN RESON, V60, P79, DOI 10.1016/0022-2364(84)90027-1; HARTZELL CJ, 1987, J AM CHEM SOC, V109, P5967; HENDERSON R, 1990, J MOL BIOL, V213, P899, DOI 10.1016/S0022-2836(05)80271-2; HENRY GD, 1990, BIOCHEMISTRY-US, V29, P6303, DOI 10.1021/bi00478a027; KENIRY MA, 1984, NATURE, V307, P383, DOI 10.1038/307383a0; LEO GC, 1987, BIOCHEMISTRY-US, V26, P854, DOI 10.1021/bi00377a029; NAMBUDRIPAD R, 1991, SCIENCE, V252, P1305, DOI 10.1126/science.1925543; OAS TG, 1987, J AM CHEM SOC, V109, P5962, DOI 10.1021/ja00254a011; Opella S J, 1986, Methods Enzymol, V131, P327; OPELLA SJ, 1987, Q REV BIOPHYS, V19, P7, DOI 10.1017/S0033583500004017; OPELLA SJ, 1989, METHOD ENZYMOL, V176, P242; REES DC, 1989, ANNU REV BIOCHEM, V58, P607; ROWITCH DH, 1987, J MOL BIOL, V195, P873, DOI 10.1016/0022-2836(87)90491-8; SCHIKSNIS RA, 1987, BIOCHEMISTRY-US, V26, P1373, DOI 10.1021/bi00379a025; SHON K, 1989, J MAGN RESON, V82, P193, DOI 10.1016/0022-2364(89)90182-0; SHON K, UNPUB; TENG Q, 1989, J MAGN RESON, V85, P439, DOI 10.1016/0022-2364(89)90235-7; Wuthrich K., 1986, NMR PROTEINS NUCL AC	25	152	152	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 31	1991	252	5010					1303	1304		10.1126/science.1925542	http://dx.doi.org/10.1126/science.1925542			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FN857	1925542				2022-12-24	WOS:A1991FN85700038
J	TATTERSALL, R; GREGORY, R; SELBY, C; KERR, D; HELLER, S				TATTERSALL, R; GREGORY, R; SELBY, C; KERR, D; HELLER, S			COURSE OF BRITTLE DIABETES - 12-YEAR FOLLOW-UP	BRITISH MEDICAL JOURNAL			English	Article							HYPOGLYCEMIA; IDDM	Objective - To determine the course of brittle diabetes. Design - 12 year follow up of patients identified in 1977-9 as having brittle diabetes; retrospective review of the case notes. Setting - Nottingham health district. Subjects - 25 brittle diabetic patients were identified in 1979-9; 11 (five men) had three or more admissions with ketoacidosis between June 1977 and 1979 and 14 (eight men) had three or more attendances at the accident and emergency department with hypoglycaemia in 1978. Two controls from our diabetic register were matched to each patient for age, sex, and duration of diabetes. Main outcome measures - Frequency of ketoacidosis and severe hypoglycaemia in the 12 years after ascertainment; diabetic control and complications in 1988-90; retrospective attribution of the cause of brittleness. Results - Patients with recurrent ketoacidosis had had a median (range) of 28 (8-67) episodes. One man died of a cerebral tumour but five of the surviving nine patients had not been admitted in the past two years, although diabetic control remained poor (median haemoglobin A1 concentration 14%). Seven patients had pure hypoglycaemic brittleness, and five had also had eight or more admissions with ketoacidosis (mixed brittleness). Two died of uraemia within a year after ascertainment and two others in hypoglycaemic coma seven and 12 years later. Brittle diabetes was in most cases related to a specific situation, usually unhappiness at home or school. Conclusions - Brittle diabetes is often episodic and almost always related to stressful life circumstances. Once the underlying cause is removed it tends to improve. Recurrent hypoglycaemic brittleness of psychological origin has a poor prognosis.			TATTERSALL, R (corresponding author), UNIV NOTTINGHAM HOSP,DEPT DIABET,NOTTINGHAM NG7 2UH,ENGLAND.			Heller, Simon/0000-0002-2425-9565				AMBLER J, 1983, CLIN CHEM, V29, P340; [Anonymous], 1968, CLIN DIABETES MELLIT, V15, P307; BRINK SJ, 1986, JAMA-J AM MED ASSOC, V255, P617; CHAPMAN J, 1988, DIABETIC MED, V5, P659, DOI 10.1111/j.1464-5491.1988.tb01075.x; CLAUSENSJOBOM N, 1989, DIABETOLOGIA, V32, P818; CRYER PE, 1989, DIABETES, V38, P1193, DOI 10.2337/diabetes.38.9.1193; FARBEROW NL, 1970, PSYCHOL REP, V27, P935, DOI 10.2466/pr0.1970.27.3.935; FLEXNER CW, 1984, AM J MED, V76, P691, DOI 10.1016/0002-9343(84)90297-3; GALE EAM, 1981, DIABETOLOGIA, V21, P25, DOI 10.1007/BF03216218; GILL GV, 1985, DIABETOLOGIA, V28, P579, DOI 10.1007/BF00281992; GRIFFITH DNW, 1989, DIABETIC MED, V6, P440, DOI 10.1111/j.1464-5491.1989.tb01201.x; HARDY KJ, 1991, DIABETIC MED, V8, P69, DOI 10.1111/j.1464-5491.1991.tb01518.x; HEDLEY AJ, 1982, BRIT MED J, V285, P509, DOI 10.1136/bmj.285.6340.509-a; JONES RB, 1983, METHOD INFORM MED, V22, P4; O'Brien I A, 1985, Diabet Med, V2, P392; POTTER J, 1982, BRIT MED J, V285, P1180, DOI 10.1136/bmj.285.6349.1180; SCHADE DS, 1985, DIABETES CARE, V8, P12, DOI 10.2337/diacare.8.1.12; SCHULER G, 1989, DIABETES RES CLIN PR, V6, P145, DOI 10.1016/0168-8227(89)90119-8; TATTERSALL R, 1977, CLIN ENDOCRINOL META, V6, P403, DOI 10.1016/S0300-595X(77)80045-5; TATTERSALL RB, 1985, BMJ, V291, P55; WILLIAMS G, 1988, DIABETES RES CLIN EX, V7, P13; Woodyatt RT., 1934, TXB MED AM AUTHORS, V3rd ed, P628; 1988, DIABETES CARE, V11, P669	23	36	36	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 25	1991	302	6787					1240	1243		10.1136/bmj.302.6787.1240	http://dx.doi.org/10.1136/bmj.302.6787.1240			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FP272	1904287	Green Published, Bronze			2022-12-24	WOS:A1991FP27200022
J	CHAPDELAINE, Y; BONEN, L				CHAPDELAINE, Y; BONEN, L			THE WHEAT MITOCHONDRIAL GENE FOR SUBUNIT-I OF THE NADH DEHYDROGENASE COMPLEX - A TRANSSPLICING MODEL FOR THIS GENE-IN-PIECES	CELL			English	Article							REVEALS EXTENSIVE HOMOLOGIES; RNA SECONDARY STRUCTURE; PLANT-MITOCHONDRIA; RIBOSOMAL PROTEIN-S12; MARCHANTIA-POLYMORPHA; SEQUENCE-ANALYSIS; READING FRAME; DNA-SEQUENCE; INTRONS; CHLOROPLAST	The nad1 gene encoding subunit I of the respiratory chain NADH dehydrogenase is fragmented into five unique-copy coding segments that are scattered over at least 40 kb and interspersed with other genes in the wheat mitochondrial genome. The nad1 segments are flanked by sequences with group II intron features, and transcript analysis demonstrates the presence of correctly spliced mRNAs. RNA editing occurs at sites asymmetrically distributed along the wheat nad1 coding region, and the initiation codon is created by RNA editing. The unusual organization of the wheat nad1 gene is attributed to mitochondrial DNA rearrangements within introns, and a trans-splicing model involving secondary structural interactions between group II-like intron pieces is proposed for its expression.			CHAPDELAINE, Y (corresponding author), UNIV OTTAWA,DEPT BIOL,OTTAWA K1N 6N5,ONTARIO,CANADA.							AGABIAN N, 1990, CELL, V61, P1157, DOI 10.1016/0092-8674(90)90674-4; ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; BLAND MM, 1986, MOL GEN GENET, V204, P8, DOI 10.1007/BF00330180; BOER PH, 1988, EMBO J, V7, P3501, DOI 10.1002/j.1460-2075.1988.tb03226.x; BOER PH, 1988, CELL, V55, P399, DOI 10.1016/0092-8674(88)90026-8; BONEN L, 1980, NUCLEIC ACIDS RES, V8, P319, DOI 10.1093/nar/8.2.319; BONEN L, 1988, GENE, V73, P47, DOI 10.1016/0378-1119(88)90311-3; BONEN L, 1984, EMBO J, V3, P2531, DOI 10.1002/j.1460-2075.1984.tb02168.x; BONEN L, 1987, NUCLEIC ACIDS RES, V15, P10393, DOI 10.1093/nar/15.24.10393; CECH TR, 1986, CELL, V44, P207, DOI 10.1016/0092-8674(86)90751-8; CHOQUET Y, 1988, CELL, V52, P903, DOI 10.1016/0092-8674(88)90432-1; COVELLO PS, 1989, NATURE, V341, P662, DOI 10.1038/341662a0; CUMMINGS DJ, 1988, CURR GENET, V14, P253, DOI 10.1007/BF00376746; DANDEKAR T, 1990, NUCLEIC ACIDS RES, V18, P4719, DOI 10.1093/nar/18.16.4719; FUKUZAWA H, 1986, FEBS LETT, V198, P11, DOI 10.1016/0014-5793(86)81174-7; GELIEBTER J, 1986, P NATL ACAD SCI USA, V83, P3371, DOI 10.1073/pnas.83.10.3371; GOLDSCHMIDTCLERMONT M, 1990, MOL GEN GENET, V223, P417, DOI 10.1007/BF00264448; GRAY MW, 1989, ANNU REV CELL BIOL, V5, P25, DOI 10.1146/annurev.cb.05.110189.000325; GUALBERTO JM, 1989, NATURE, V341, P660, DOI 10.1038/341660a0; HERRIN DL, 1988, J BIOL CHEM, V262, P14601; HIESEL R, 1989, SCIENCE, V246, P1632, DOI 10.1126/science.2480644; HILDEBRAND M, 1988, P NATL ACAD SCI USA, V85, P372, DOI 10.1073/pnas.85.2.372; JACQUIER A, 1990, TRENDS BIOCHEM SCI, V15, P351, DOI 10.1016/0968-0004(90)90075-M; JARRELL KA, 1988, MOL CELL BIOL, V8, P2361, DOI 10.1128/MCB.8.6.2361; KOHCHI T, 1988, NUCLEIC ACIDS RES, V16, P10025, DOI 10.1093/nar/16.21.10025; KUCK U, 1987, EMBO J, V6, P2185, DOI 10.1002/j.1460-2075.1987.tb02489.x; LAMBOWITZ AM, 1989, CELL, V56, P323, DOI 10.1016/0092-8674(89)90232-8; LANG BF, 1985, J MOL BIOL, V184, P353, DOI 10.1016/0022-2836(85)90286-4; LEJEUNE B, 1988, VARIABILITE GENETIQU, P201; LEVINGS CS, 1989, CELL, V56, P171, DOI 10.1016/0092-8674(89)90890-8; LONSDALE DM, 1989, COMPR TREAT, V15, P229; MAKAROFF CA, 1987, NUCLEIC ACIDS RES, V15, P5141, DOI 10.1093/nar/15.13.5141; Maniatis T., 1982, MOL CLONING; MATSUBAYASHI T, 1987, MOL GEN GENET, V210, P385, DOI 10.1007/BF00327187; MICHEL F, 1989, GENE, V82, P5, DOI 10.1016/0378-1119(89)90026-7; MICHEL F, 1982, BIOCHIMIE, V64, P867, DOI 10.1016/S0300-9084(82)80349-0; MICHEL F, 1985, NATURE, V316, P641, DOI 10.1038/316641a0; PALMER JD, 1990, TRENDS GENET, V6, P115, DOI 10.1016/0168-9525(90)90125-P; PERLMAN PS, 1989, SCIENCE, V246, P1106, DOI 10.1126/science.2479980; ROITGRUND C, 1990, CURR GENET, V17, P147, DOI 10.1007/BF00312860; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMELZER C, 1986, CELL, V46, P57; SMALL I, 1989, CELL, V58, P69, DOI 10.1016/0092-8674(89)90403-0; STERN DB, 1986, CURR GENET, V10, P857, DOI 10.1007/BF00418532; VANDERVEEN R, 1986, CELL, V44, P225, DOI 10.1016/0092-8674(86)90756-7; WAHLEITHNER JA, 1990, P NATL ACAD SCI USA, V87, P548, DOI 10.1073/pnas.87.2.548; WILSON AJ, 1984, PLANT CELL REP, V3, P237, DOI 10.1007/BF00269301; WISSINGER B, 1991, CELL, V65; WOLFE KH, 1989, P NATL ACAD SCI USA, V86, P6201, DOI 10.1073/pnas.86.16.6201; ZAITA N, 1987, FEBS LETT, V210, P153, DOI 10.1016/0014-5793(87)81326-1	50	179	188	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 3	1991	65	3					465	472		10.1016/0092-8674(91)90464-A	http://dx.doi.org/10.1016/0092-8674(91)90464-A			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FK182	1902143				2022-12-24	WOS:A1991FK18200013
J	BIGRIGG, MA; READ, MD				BIGRIGG, MA; READ, MD			MANAGEMENT OF WOMEN REFERRED TO EARLY-PREGNANCY ASSESSMENT UNIT - CARE AND COST-EFFECTIVENESS	BRITISH MEDICAL JOURNAL			English	Article								Objective - To assess the efficiency of an early pregnancy assessment unit in the care of women with bleeding or pain in early pregnancy. Design - Analysis of women attending in the first year of the unit's operation and in the six months immediately before its introduction. Setting - Early pregnancy assessment unit in a district general hospital serving a population of 310 000. Patients - 1141 women referred with bleeding or pain in early pregnancy. Main outcome measures - Length of stay in hospital required for diagnosis and treatment. Results - Before the unit was established the mean admission time was one and a half (range half to three) days for women who required no treatment and three (one and a half to five) days in women requiring evacuation of uterus. These times were reduced to two hours as an outpatient and one day respectively for most women after the unit was established . Between 318 and 505 women were estimated to have been saved from unnecessary admission and 233 had their stay reduced; the associated saving was between 95 000 pounds and 120 000 pounds in one year. Conclusions - The early pregnancy assessment unit improved the quality of care and also produced considerable savings in financial and staff resources.	GLOUCESTER ROYAL HOSP,OBSTET & GYNAECOL,GLOUCESTER GL1 3NN,ENGLAND									BUCK N, 1989, REPORT CONFIDENTIAL; 1982, MATERNITY CARE ACT 1; 1982, REPORT ROYAL COLLEGE; 1990, QUALITY MED CARE	4	86	87	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 9	1991	302	6776					577	579		10.1136/bmj.302.6776.577	http://dx.doi.org/10.1136/bmj.302.6776.577			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FB936	1902383	Green Published, Bronze			2022-12-24	WOS:A1991FB93600025
J	CROSTON, GE; KERRIGAN, LA; LIRA, LM; MARSHAK, DR; KADONAGA, JT				CROSTON, GE; KERRIGAN, LA; LIRA, LM; MARSHAK, DR; KADONAGA, JT			SEQUENCE-SPECIFIC ANTIREPRESSION OF HISTONE HL-MEDIATED INHIBITION OF BASAL RNA POLYMERASE-II TRANSCRIPTION	SCIENCE			English	Article							HIGHER-ORDER STRUCTURE; DNA-BINDING PROTEINS; MAJOR LATE PROMOTER; CHROMATIN STRUCTURE; INVITRO TRANSCRIPTION; FUNCTIONAL STEPS; NUCLEOSOMES; GENE; INITIATION; YEAST	To understand the principles of control and selectivity in gene expression, the biochemical mechanisms by which promoter- and enhancer-binding factors regulate transcription by RNA polymerase II were analyzed. A general observed repressor of transcription was purified and identified as histone H-1. Since many aspects of H-1 binding to naked DNA resemble its interaction with chromatin, purified H-1 bound to naked DNA was used as a model for the repressed state of the DNA template. Three sequence-specific transcription factors, Spl, GAL4-VP16, and GAGA factor, were shown to counteract H-1-mediated repression (antirepression). In addition, Spl and GAL4-VP16, but not the GAGA factor, activated transcription in the absence of H-1. Therefore, true activation and antirepression appear to be distinct activities of sequence-specific factors. Furthermore, transcription antirepression by GAL4-VP16 was sustained for several rounds of transcription. These findings, together with previous studies on H-1, suggest that H-1 participates in repression of the genome in the ground state and that sequence-specific transcription factors induce selected genes by a combination of true activation and release of basal repression that is mediated at least in part by H-1.	UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, CTR MOLEC GENET, LA JOLLA, CA 92093 USA; COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY 11724 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Cold Spring Harbor Laboratory								ALLAN J, 1980, NATURE, V288, P675, DOI 10.1038/288675a0; ALMER A, 1986, EMBO J, V5, P2689, DOI 10.1002/j.1460-2075.1986.tb04552.x; BATES DL, 1981, NUCLEIC ACIDS RES, V9, P5883, DOI 10.1093/nar/9.22.5883; BENEZRA R, 1986, CELL, V44, P697, DOI 10.1016/0092-8674(86)90835-4; BIGGIN MD, 1988, CELL, V53, P699, DOI 10.1016/0092-8674(88)90088-8; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BUTLER PJG, 1984, EMBO J, V3, P2599, DOI 10.1002/j.1460-2075.1984.tb02180.x; CAREY M, 1990, SCIENCE, V247, P710, DOI 10.1126/science.2405489; CARON F, 1981, J MOL BIOL, V146, P513, DOI 10.1016/0022-2836(81)90045-0; CARTWRIGHT IL, 1987, EMBO J, V6, P3097, DOI 10.1002/j.1460-2075.1987.tb02618.x; CARTWRIGHT IL, 1982, NUCLEIC ACIDS RES, V10, P5835, DOI 10.1093/nar/10.19.5835; CHASMAN DI, 1989, MOL CELL BIOL, V9, P4746, DOI 10.1128/MCB.9.11.4746; CLARK DJ, 1988, EUR J BIOCHEM, V178, P225, DOI 10.1111/j.1432-1033.1988.tb14447.x; CLARK DJ, 1986, J MOL BIOL, V187, P569, DOI 10.1016/0022-2836(86)90335-9; CLARKADAMS CD, 1988, GENE DEV, V2, P150, DOI 10.1101/gad.2.2.150; CROSTON GE, UNPUB; DEBERNARDIN W, 1986, J MOL BIOL, V189, P503, DOI 10.1016/0022-2836(86)90320-7; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Elgin SCR, 1990, CURR OPIN CELL BIOL, V2, P437, DOI 10.1016/0955-0674(90)90125-X; ERICSSON C, 1990, CELL, V60, P73, DOI 10.1016/0092-8674(90)90717-S; FEDOR MJ, 1989, MOL CELL BIOL, V9, P1721, DOI 10.1128/MCB.9.4.1721; GIDONI D, 1985, SCIENCE, V230, P511, DOI 10.1126/science.2996137; GOLDBERG ML, 1979, THESIS STANFORD U; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; HAN M, 1988, CELL, V55, P1137, DOI 10.1016/0092-8674(88)90258-9; HAN M, 1988, EMBO J, V7, P2221, DOI 10.1002/j.1460-2075.1988.tb03061.x; HAWLEY DK, 1987, J BIOL CHEM, V262, P3452; HAWLEY DK, 1985, J BIOL CHEM, V260, P8163; HEIERMANN R, 1985, NUCLEIC ACIDS RES, V13, P2709, DOI 10.1093/nar/13.8.2709; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KADONAGA JT, 1990, J BIOL CHEM, V265, P2624; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KAMAKAKA RT, 1990, EMBO J, V9, P3997, DOI 10.1002/j.1460-2075.1990.tb07621.x; KAMAKAKA RT, IN PRESS P NATL ACAD; KERRIGAN LA, 1991, J BIOL CHEM, V266, P574; KNEZETIC JA, 1986, CELL, V45, P95, DOI 10.1016/0092-8674(86)90541-6; KUMAR NM, 1980, NUCLEIC ACIDS RES, V8, P3535, DOI 10.1093/nar/8.16.3535; LAYBOURN PJ, UNPUB; LENNARD AC, 1985, EMBO J, V4, P3455, DOI 10.1002/j.1460-2075.1985.tb04104.x; LIN YS, 1988, CELL, V54, P659, DOI 10.1016/S0092-8674(88)80010-2; LORCH Y, 1987, CELL, V49, P203, DOI 10.1016/0092-8674(87)90561-7; MATSUI T, 1987, MOL CELL BIOL, V7, P1401, DOI 10.1128/MCB.7.4.1401; MCGHEE JD, 1983, CELL, V33, P831, DOI 10.1016/0092-8674(83)90025-9; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MURPHY TJ, 1986, NUCLEIC ACIDS RES, V14, P5563, DOI 10.1093/nar/14.13.5563; NACHEVA GA, 1989, CELL, V58, P27, DOI 10.1016/0092-8674(89)90399-1; PEDERSON DS, 1986, ANNU REV CELL BIOL, V2, P117, DOI 10.1146/annurev.cellbio.2.1.117; RICHARDFOY H, 1987, EMBO J, V6, P2321, DOI 10.1002/j.1460-2075.1987.tb02507.x; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SALTZMAN AG, 1989, FASEB J, V3, P1723, DOI 10.1096/fasebj.3.6.2649403; SCHLISSEL MS, 1989, EMBO J, V8, P527; SHIMAMURA A, 1989, MOL CELL BIOL, V9, P5573, DOI 10.1128/MCB.9.12.5573; SOELLER WC, 1988, GENE DEV, V2, P68, DOI 10.1101/gad.2.1.68; STAYNOV DZ, 1988, EMBO J, V7, P3685, DOI 10.1002/j.1460-2075.1988.tb03250.x; TAZI J, 1990, CELL, V60, P909, DOI 10.1016/0092-8674(90)90339-G; THOMA F, 1979, J CELL BIOL, V83, P403, DOI 10.1083/jcb.83.2.403; THOMAS GH, 1988, EMBO J, V7, P2191, DOI 10.1002/j.1460-2075.1988.tb03058.x; THOMAS JO, 1983, EUR J BIOCHEM, V134, P109, DOI 10.1111/j.1432-1033.1983.tb07538.x; THOMAS JO, 1980, EUR J BIOCHEM, V112, P501; van Holde K.E., 1988, CHROMATIN; WEINTRAUB H, 1985, CELL, V42, P705, DOI 10.1016/0092-8674(85)90267-3; WEINTRAUB H, 1984, CELL, V38, P17, DOI 10.1016/0092-8674(84)90522-1; WOLFFE A P, 1990, New Biologist, V2, P211; WOODCOCK CLF, 1984, J CELL BIOL, V99, P42, DOI 10.1083/jcb.99.1.42; WORKMAN JL, 1987, CELL, V51, P613, DOI 10.1016/0092-8674(87)90130-9; ZLATANOVA J, 1990, TRENDS BIOCHEM SCI, V15, P273, DOI 10.1016/0968-0004(90)90053-E	67	344	347	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 8	1991	251	4994					643	649		10.1126/science.1899487	http://dx.doi.org/10.1126/science.1899487			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EW399	1899487				2022-12-24	WOS:A1991EW39900037
J	ERIKSON, J; RADIC, MZ; CAMPER, SA; HARDY, RR; CARMACK, C; WEIGERT, M				ERIKSON, J; RADIC, MZ; CAMPER, SA; HARDY, RR; CARMACK, C; WEIGERT, M			EXPRESSION OF ANTI-DNA IMMUNOGLOBULIN TRANSGENES IN NON-AUTOIMMUNE MICE	NATURE			English	Article							SYSTEMIC LUPUS-ERYTHEMATOSUS; LYMPHOCYTES-B; ANTIBODIES; AUTOANTIBODIES; MOUSE; ACTIVATION; GENES; CELLS	SELF-REACTIVE B cells can be regulated by either deletion or inactivation 1. These manifestations of self-tolerance have been dramatically shown in transgenic mice in which the number of self-reactive cells has been artificially expanded 2,3. We have now extended these models to ask if B-cell tolerance as described for non-disease-associated antigens also operates for the targets of autoimmunity. The target we have chosen is DNA. Anti-DNA antibodies are diagnostic of certain autoimmune syndromes in humans and are a characteristic of the murine model of systemic autoimmunity, the MRI/Ipr mouse4. Antibodies to both single-stranded and double-stranded DNA have been implicated in disease 5,6. By generating anti-DNA transgenic mice, we have addressed the question of whether DNA-specific B cells are regulated in normal (non-autoimmune) mice. We indeed found that most transgenic B cells bind DNA, yet we failed to detect secreted anti-DNA. We suggest that as a consequence of their self-reactivity these B cells are developmentally arrested.	UNIV MICHIGAN, SCH MED, DEPT HUMAN GENET, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan	ERIKSON, J (corresponding author), FOX CHASE CANC INST, INST CANC RES, 7701 BURHOLME AVE, PHILADELPHIA, PA 19111 USA.			Camper, Sally/0000-0001-8556-3379; Radic, Marko/0000-0002-8004-282X				BASTEN A, 1989, PROGR IMMUNOLOGY, V7, P377; BENNETT RM, 1987, J EXP MED, V166, P850, DOI 10.1084/jem.166.4.850; CAMPBELL KS, 1990, EMBO J, V9, P441, DOI 10.1002/j.1460-2075.1990.tb08129.x; CAMPER SA, 1987, BIOTECHNIQUES, V5, P638; CHACE JH, 1988, J IMMUNOL, V141, P3258; COLECLOUGH C, 1981, NATURE, V290, P372, DOI 10.1038/290372a0; EATON RB, 1983, ARTHRITIS RHEUM, V26, P52, DOI 10.1002/art.1780260109; GOODNOW CC, 1988, NATURE, V334, P676, DOI 10.1038/334676a0; HARDY RR, 1982, NATURE, V297, P589, DOI 10.1038/297589a0; HAYAKAWA K, 1988, J EXP MED, V168, P1825, DOI 10.1084/jem.168.5.1825; HOLMBERG D, 1986, IMMUNOL REV, V93, P147, DOI 10.1111/j.1600-065X.1986.tb01506.x; KUROSAWA Y, 1982, J EXP MED, V155, P201, DOI 10.1084/jem.155.1.201; LOIZOU S, 1985, CLIN EXP IMMUNOL, V62, P738; MARCU KB, 1980, CELL, V22, P187, DOI 10.1016/0092-8674(80)90167-1; NEMAZEE DA, 1989, NATURE, V337, P562, DOI 10.1038/337562a0; NOSSAL GJV, 1989, SCIENCE, V245, P147, DOI 10.1126/science.2526369; PANKEWYCZ OG, 1987, J IMMUNOL, V139, P3287; PERRY RP, 1979, CELL, V18, P1333, DOI 10.1016/0092-8674(79)90243-5; RADIC MZ, 1989, COLD SPRING HARB SYM, V54, P933; RADIC MZ, IN PRESS J IMMUN; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SHLOMCHIK M, 1990, J EXP MED, V171, P265, DOI 10.1084/jem.171.1.265; SHLOMCHIK MJ, 1987, P NATL ACAD SCI USA, V84, P9150, DOI 10.1073/pnas.84.24.9150; SOUROUJON M, 1988, J IMMUNOL, V140, P4173; STALL AM, 1984, J IMMUNOL, V132, P787; TAN EM, 1989, ADV IMMUNOL, V44, P93, DOI 10.1016/S0065-2776(08)60641-0; THEOFILOPOULOS AN, 1985, ADV IMMUNOL, V37, P269, DOI 10.1016/S0065-2776(08)60342-9; VANSNICK JL, 1982, J EXP MED, V155, P219, DOI 10.1084/jem.155.1.219; WIENANDS J, 1990, EMBO J, V9, P449, DOI 10.1002/j.1460-2075.1990.tb08130.x; YANCOPOULOS GD, 1988, J EXP MED, V168, P417, DOI 10.1084/jem.168.1.417	30	453	455	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 24	1991	349	6307					331	334		10.1038/349331a0	http://dx.doi.org/10.1038/349331a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EU501	1898987	Green Published			2022-12-24	WOS:A1991EU50100053
J	CHEINGSONGPOPOV, R; PANAGIOTIDI, C; BOWCOCK, S; ARONSTAM, A; WADSWORTH, J; WEBER, J				CHEINGSONGPOPOV, R; PANAGIOTIDI, C; BOWCOCK, S; ARONSTAM, A; WADSWORTH, J; WEBER, J			RELATION BETWEEN HUMORAL RESPONSES TO HIV GAG AND ENV PROTEINS AT SEROCONVERSION AND CLINICAL OUTCOME OF HIV-INFECTION	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; LYMPHADENOPATHY-ASSOCIATED VIRUS; RETROVIRUSES HTLV-III; T-LYMPHOTROPIC VIRUS; ANTIBODY-RESPONSE; HOMOSEXUAL MEN; CORE ANTIBODIES; AIDS; ANTIGEN; RISK	Objective - To study the contribution of the humoral response to HIV-1 at seroconversion to disease outcome after 84 months. Design - A retrospective longitudinal study. Setting - Two haemophilia centres in the United Kingdom. Patients - 88 Haemophiliac patients infected with HIV-1 for whom sera were available from before seroconversion and in whom clinical follow up data were available. Results - Kaplan-Meier survival analysis showed a significant difference between a high titre (> 1600 p24 antibody response at seroconversion and prolonged time before the development of HIV related disease (p = 0.0008). In contrast, higher titres of antibody to gp120 at seroconversion (> 25 600) correlated with more rapid clinical deterioration (p = 0.025). Conclusions - The first humoral response to HIV proteins at seroconversion is associated with clinical outcome; patients with an initial low titre antibody response to the gagp24 protein have a significantly faster rate of progression to CDC stage IV disease. Patients with a high titre p24 antibody response progress to AIDS more slowly, and these data provide an explanation why p24 antigenaemia is not universally detected in patients with AIDS. It is unclear whether the association between a strong initial p24 antibody response and slower progression of HIV disease is causal and if so whether it is due to viral or host factors.	LORD MAYOR TRELOAR HOSP & COLL, TRELOAR HAEMOPHILIA CTR, ALTON, HANTS, ENGLAND; ST MARYS HOSP, SCH MED, ACAD DEPT PUBL HLTH, LONDON W2 1PG, ENGLAND; ROYAL POSTGRAD MED SCH, DEPT HAEMATOL, LONDON W12 0HS, ENGLAND; ROYAL POSTGRAD MED SCH, DEPT MED, INFECT DIS UNIT, LONDON W12 0HS, ENGLAND	Imperial College London; Imperial College London; Imperial College London								ALLAIN JP, 1986, LANCET, V2, P1233; BARIN F, 1985, SCIENCE, V228, P1094, DOI 10.1126/science.2986291; BIGGAR RJ, 1985, BRIT MED J, V291, P997, DOI 10.1136/bmj.291.6501.997; BRUNVEZINET F, 1984, LANCET, V1, P1253; CHEINGSONGPOPOV R, 1990, AIDS RES HUM RETROV, V6, P1099, DOI 10.1089/aid.1990.6.1099; CHEINGSONGPOPOV R, 1984, LANCET, V2, P477; COOMBS RW, 1989, NEW ENGL J MED, V321, P1626, DOI 10.1056/NEJM198912143212402; COOPER DA, 1987, J INFECT DIS, V155, P1113, DOI 10.1093/infdis/155.6.1113; DEWOLF F, 1987, BMJ-BRIT MED J, V295, P569, DOI 10.1136/bmj.295.6598.569; FORSTER SM, 1987, AIDS, V1, P235; GAINES H, 1987, LANCET, V1, P1249; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; KASLOW RA, 1990, LANCET, V335, P927, DOI 10.1016/0140-6736(90)90995-H; LANGE JMA, 1986, BRIT MED J, V292, P228, DOI 10.1136/bmj.292.6515.228; LANGE JMA, 1987, AIDS, V1, P15; LANGE JMA, 1986, BRIT MED J, V293, P1459, DOI 10.1136/bmj.293.6560.1459; MANCA F, 1990, LANCET, V335, P811, DOI 10.1016/0140-6736(90)90935-X; MCDOUGAL JS, 1987, J CLIN INVEST, V80, P316, DOI 10.1172/JCI113075; MITTLER RS, 1989, SCIENCE, V245, P1380, DOI 10.1126/science.2571187; MORROW WJW, 1986, CLIN IMMUNOL IMMUNOP, V40, P515, DOI 10.1016/0090-1229(86)90196-0; MOSS AR, 1988, BRIT MED J, V296, P745, DOI 10.1136/bmj.296.6624.745; NAYLOR PH, 1987, P NATL ACAD SCI USA, V84, P2951, DOI 10.1073/pnas.84.9.2951; PAN LZ, 1987, J INFECT DIS, V155, P626, DOI 10.1093/infdis/155.4.626; PAPSIDERO LD, 1989, J VIROL, V63, P267, DOI 10.1128/JVI.63.1.267-272.1989; PEDERSEN C, 1987, BRIT MED J, V295, P567, DOI 10.1136/bmj.295.6598.567; RANKI A, 1987, LANCET, V2, P589; ROBINSON WE, 1989, P NATL ACAD SCI USA, V86, P4710, DOI 10.1073/pnas.86.12.4710; SARNGADHARAN MG, 1984, SCIENCE, V224, P506, DOI 10.1126/science.6324345; SCHUPBACH J, 1985, NEW ENGL J MED, V312, P265, DOI 10.1056/NEJM198501313120502; SCHUPBACH J, 1984, SCIENCE, V224, P503, DOI 10.1126/science.6200937; SICILIANO RF, 1988, CELL, V54, P561; SIMMONDS P, 1988, BRIT MED J, V296, P593, DOI 10.1136/bmj.296.6622.593; STEEL CM, 1988, LANCET, V1, P1185; STEIMER KS, 1986, VIROLOGY, V150, P283, DOI 10.1016/0042-6822(86)90289-8; TAKEDA A, 1988, SCIENCE, V242, P580, DOI 10.1126/science.2972065; TSIQUAYE KN, 1988, AIDS, V2, P41, DOI 10.1097/00002030-198802000-00007; WEBER J, 1989, HUMAN RETROVIRUSES, P207; WEBER JN, 1987, LANCET, V1, P119, DOI 10.1016/S0140-6736(87)91964-7; 1986, ANN INTERN MED, V105, P234	39	75	76	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 5	1991	302	6767					23	26		10.1136/bmj.302.6767.23	http://dx.doi.org/10.1136/bmj.302.6767.23			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ER372	1899349	Green Published, Bronze			2022-12-24	WOS:A1991ER37200020
J	GERBERT, B; MAGUIRE, BT; BLEECKER, T; COATES, TJ; MCPHEE, SJ				GERBERT, B; MAGUIRE, BT; BLEECKER, T; COATES, TJ; MCPHEE, SJ			PRIMARY CARE PHYSICIANS AND AIDS - ATTITUDINAL AND STRUCTURAL BARRIERS TO CARE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HIV-INFECTION	Objective. - To explore the extent to which primary care physicians are providing health care for people with human immunodeficiency virus (HIV) infection and to document barriers to HIV care giving. Design. - National random-sample mailed survey Participants. - Population-based random sample of 2004 US general internists, family physicians, and general practitioners in 1990. Response rate was 59%. Main Outcome Measures. - HIV treatment experience, willingness to treat HIV-infected patients, negative attitudes toward homosexuals and intravenous drug users, fear of contagion of the acquired immunodeficiency syndrome (AIDS), perceived lack of information about AIDS, and time demands of HIV care. Results. - Most physicians (75%) had treated one or more patients with HIV infection. A majority (68%) believed that they had a responsibility to treat people with HIV infection, yet half (50%) indicated that they would not, if given a choice. Over 80% of respondents believed that they lacked information about AIDS and that caring for people with AIDS is time consuming. Further, 35% of respondents agreed that they "would feel nervous among a group of homosexuals" and 55% expressed discomfort about having intravenous drug users in their practice. Physicians who had treated 10 or more HIV-infected patients expressed less negativity toward members of these stigmatized groups who are likely to be HIV infected. Conclusions. - These data suggest that many primary care physicians are responding professionally to the AIDS epidemic but that attitudinal barriers may be hindering some physicians from providing treatment to HIV-infected patients.	UNIV CALIF SAN FRANCISCO,CTR AIDS PREVENT STUDIES,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,SCH MED,SAN FRANCISCO,CA 94143; UNIV WALES,DEPT PSYCHOL,BANGOR,WALES	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Bangor University	GERBERT, B (corresponding author), UNIV CALIF SAN FRANCISCO,SCH DENT,DIV BEHAV SCI,707 PARNASSUS D1012,SAN FRANCISCO,CA 94143, USA.				NIMH NIH HHS [MH42459] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH042459] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALLEN BL, 1990, NEW ENGL J MED, V323, P755; ARNOW PM, 1989, PUBLIC HEALTH REP, V104, P121; Babbie ER, 1973, SURVEY RES METHODS, P165; BLENDON RJ, 1990, AIDS HLTH CARE SYSTE, P77; COOKE M, 1988, AIDS PUBLIC POLICY J, V3, P59; FREDMAN L, 1989, AM J PREV MED, V5, P188, DOI 10.1016/S0749-3797(18)31079-1; GEMSON DH, 1991, ARCH INTERN MED, V151, P1102, DOI 10.1001/archinte.151.6.1102; GERBERT B, 1991, NEW ENGL J MED, V324, P926; HAYWARD RA, 1991, ANN INTERN MED, V114, P23, DOI 10.7326/0003-4819-114-1-23; KELLY JA, 1987, AM J PUBLIC HEALTH, V77, P789, DOI 10.2105/AJPH.77.7.789; LEWIS CE, 1987, AM J PUBLIC HEALTH, V77, P795, DOI 10.2105/AJPH.77.7.795; LINK RN, 1988, AM J PUBLIC HEALTH, V78, P455, DOI 10.2105/AJPH.78.4.455; MCKUSICK L, 1986, WESTERN J MED, V144, P751; RICHARDSON JL, 1987, MED CARE, V25, P675, DOI 10.1097/00005650-198708000-00001; RIZZO JA, 1990, MED CARE, V28, P251, DOI 10.1097/00005650-199003000-00005; ROTHMAN DJ, 1990, NEW ENGL J MED, V323, P764, DOI 10.1056/NEJM199009133231129; SHULTZ JM, 1988, MINN MED, V71, P277; SMITH MD, 1991, J GEN INTERN MED, V6, pS56, DOI 10.1007/BF02599259; WARTENBERG AA, 1991, J GEN INTERN MED, V6, pS35, DOI 10.1007/BF02599256; 1991, CDC HIV AIDS PRE FEB, P5; 1988, JAMA-J AM MED ASSOC, V259, P1360; 1991, HIV AIDS SURVEILLANC, P7; [No title captured]	23	173	173	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 27	1991	266	20					2837	2842		10.1001/jama.266.20.2837	http://dx.doi.org/10.1001/jama.266.20.2837			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GQ722	1942450				2022-12-24	WOS:A1991GQ72200030
J	SOUDAH, HC; HASLER, WL; OWYANG, C				SOUDAH, HC; HASLER, WL; OWYANG, C			EFFECT OF OCTREOTIDE ON INTESTINAL MOTILITY AND BACTERIAL OVERGROWTH IN SCLERODERMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PROGRESSIVE SYSTEMIC-SCLEROSIS; ANALOG SMS 201-995; MIGRATING MOTOR COMPLEX; ESOPHAGEAL DYSFUNCTION; MYOELECTRIC ACTIVITY; TRANSIT-TIME; SOMATOSTATIN; CISAPRIDE; PSEUDOOBSTRUCTION; ABSORPTION	Background. Patients with scleroderma may have abnormal motility of the small intestine, with pseudoobstruction and bacterial overgrowth. Standard stimulatory agents are often ineffective in such patients. Because the somatostatin analogue octreotide evokes intestinal motor activity in normal subjects, we hypothesized that it might increase motility in patients with scleroderma. Methods. We studied the effects of octreotide on intestinal motility and plasma motilin concentrations in five fasting patients with scleroderma who had bacterial overgrowth and in six fasting normal subjects. The motor effects of octreotide were correlated with its effects on abdominal symptoms and bacterial overgrowth as determined by the level of breath hydrogen excretion. Results. In the normal subjects, octreotide (l0-mu-g subcutaneously) increased the mean (+/- SD) frequency of intestinal migrating complexes, which reflect intestinal motility, from 1.5 +/- 1.0 to 4.1 +/- 1.1 every three hours. In the patients with scleroderma, who had no spontaneous migrating complexes, octreotide (100-mu-g) induced 3.6 +/- 2.3 complexes every three hours. These complexes propagated at the same velocity and had two-thirds the amplitude of the spontaneous complexes in normal subjects. Plasma motilin concentrations, which were higher in the patients with scleroderma (229 +/- 74 pmol per liter) than in the normal subjects (112 +/- 37 pmol per liter), were inhibited by octreotide, suggesting that intestinal activity evoked by octreotide is independent of motilin. Treatment of the patients with scleroderma with octreotide (50-mu-g every evening) for three weeks reduced breath hydrogen excretion while they were fasting from 25 +/- 5 to 4 +/- 2 ppm (P = 0.001) and breath hydrogen excretion after they ingested 50 g of glucose from 46 +/- 24 to 8 +/- 7 ppm (P = 0.015); these reductions were accompanied by a significant decrease in nausea, bloating, and abdominal pain and by less frequent emesis. Conclusions. Octreotide stimulates intestinal motility in normal subjects and in patients with scleroderma. In such patients, the short-term administration of octreotide reduces bacterial overgrowth and improves abdominal symptoms. This agent may be useful for the treatment of intestinal dysmotility in patients with scleroderma.	UNIV MICHIGAN,MED CTR,DEPT INTERNAL MED,GASTROENTEROL RES UNIT,3912 TAUBMAN CTR,BOX 0362,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan					NIDDK NIH HHS [R01 DK35783, P30 DK34933] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034933, R01DK035783] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKESSON A, 1987, SCAND J RHEUMATOL, V16, P291, DOI 10.3109/03009748709102931; ANDERSON IH, 1981, NEW ENGL J MED, V304, P891, DOI 10.1056/NEJM198104093041507; BAUER W, 1982, LIFE SCI, V31, P1133, DOI 10.1016/0024-3205(82)90087-X; BUENO L, 1975, J PHYSIOL-LONDON, V249, P69, DOI 10.1113/jphysiol.1975.sp011003; CAMILLERI M, 1989, GASTROENTEROLOGY, V96, P704; CAMILLERI M, 1986, GASTROENTEROLOGY, V91, P619, DOI 10.1016/0016-5085(86)90631-1; CLARK M, 1967, BRIT J DERMATOL, V79, P449, DOI 10.1111/j.1365-2133.1967.tb11531.x; COHEN S, 1972, J CLIN INVEST, V51, P2663, DOI 10.1172/JCI107084; CORAZZA GR, 1990, GASTROENTEROLOGY, V98, P302, DOI 10.1016/0016-5085(90)90818-L; DIMARINO AJ, 1973, NEW ENGL J MED, V289, P1220, DOI 10.1056/NEJM197312062892304; FUESSL HS, 1987, DIGESTION, V36, P101, DOI 10.1159/000199407; Goetz Robert H., 1945, CLIN PROCEED, V4, P337; GORDEN P, 1989, ANN INTERN MED, V110, P35, DOI 10.7326/0003-4819-110-1-35; GREYDANUS MP, 1989, GASTROENTEROLOGY, V96, P110, DOI 10.1016/0016-5085(89)90770-1; Hale CH, 1944, AM J ROENTGENOL RADI, V51, P407; HAMELROY J, 1985, GASTROENTEROLOGY, V88, P1; HOROWITZ M, 1987, GASTROENTEROLOGY, V93, P311, DOI 10.1016/0016-5085(87)91020-1; HORSWELL RR, 1961, GASTROENTEROLOGY, V40, P580; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; KAHN IJ, 1966, NEW ENGL J MED, V274, P1339, DOI 10.1056/NEJM196606162742402; KERLIN P, 1982, GASTROENTEROLOGY, V82, P701; KERLIN P, 1988, GASTROENTEROLOGY, V95, P982, DOI 10.1016/0016-5085(88)90173-4; KING CE, 1986, GASTROENTEROLOGY, V91, P1447, DOI 10.1016/0016-5085(86)90199-X; KREJS GJ, 1984, DIABETES, V33, P548, DOI 10.2337/diabetes.33.6.548; METZ G, 1976, LANCET, V1, P668; PEACHEY RDG, 1969, GUT, V10, P285, DOI 10.1136/gut.10.4.285; PEETERS TL, 1983, REGUL PEPTIDES, V5, P209, DOI 10.1016/0167-0115(83)90252-5; PEETERS TL, 1988, SCAND J GASTROENTERO, V23, P769, DOI 10.3109/00365528809090758; POITRAS P, 1980, AM J PHYSIOL, V239, pG215, DOI 10.1152/ajpgi.1980.239.3.G215; Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee, 1980, ARTHRITIS RHEUM, V23, P581; REES WDW, 1982, GASTROENTEROLOGY, V83, P575; REINHARDT JF, 1962, AMER J ROENTGENOL RA, V88, P687; ROHRMANN CA, 1981, AM J ROENTGENOL, V143, P933; SCHEMANN M, 1986, GASTROENTEROLOGY, V90, P1950, DOI 10.1016/0016-5085(86)90266-0; SCHUFFLER MD, 1981, MEDICINE, V60, P173, DOI 10.1097/00005792-198105000-00002; TREACY WL, 1962, MAYO CLIN PROC, V37, P607; VANTRAPPEN G, 1979, DIGEST DIS SCI, V24, P497, DOI 10.1007/BF01489315; VANTRAPPEN G, 1978, GASTROINTESTINAL MOT, P3; WHITEHEAD WE, 1989, GASTROENTEROLOGY, V96, P428, DOI 10.1016/0016-5085(89)91567-9; WITT K, 1989, SCAND J GASTROENTERO, V24, P1248, DOI 10.3109/00365528909090795	40	307	311	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 21	1991	325	21					1461	1467		10.1056/NEJM199111213252102	http://dx.doi.org/10.1056/NEJM199111213252102			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GQ406	1944424				2022-12-24	WOS:A1991GQ40600002
J	BI, E; LUTKENHAUS, J				BI, E; LUTKENHAUS, J			FTSZ RING STRUCTURE ASSOCIATED WITH DIVISION IN ESCHERICHIA-COLI	NATURE			English	Article							CELL-DIVISION; DNA-REPLICATION; INHIBITOR SULA; BEHAVIOR; MUTANTS; PROTEIN; SEPTUM; SHAPE; LOCUS	GENES for cell division have been identified in Escherichia coli by the isolation of conditional lethal mutations that block cell division, but do not affect DNA replication or segregation 1. Of these genes, ftsZ is of great interest as it acts earliest in the division pathway 2,3, is essential 4, its level dictates the frequency of division 5,6, and it is thought to be the target of two cell-division inhibitors 7-9, SulA, produced in response to DNA damage 10, and MinCD, which prevents division at old sites 11. Here we have used immunoelectronmicroscopy to localize the FtsZ protein to the division site. The results suggest that FtsZ self-assembles into a ring structure at the future division site and may function as a cytoskeletal element. The formation of this ring may be the point at which division is regulated.			BI, E (corresponding author), UNIV KANSAS,MED CTR,DEPT MICROBIOL MOLEC GENET & IMMUNOL,KANSAS CITY,KS 66103, USA.							BEALL B, 1991, GENE DEV, V5, P447, DOI 10.1101/gad.5.3.447; BEGG KJ, 1985, J BACTERIOL, V163, P615, DOI 10.1128/JB.163.2.615-622.1985; BI E, 1990, J BACTERIOL, V172, P2765, DOI 10.1128/jb.172.5.2765-2768.1990; BI E, 1990, J BACTERIOL, V172, P5602, DOI 10.1128/jb.172.10.5602-5609.1990; BI E, 1990, J BACTERIOL, V172, P5610, DOI 10.1128/jb.172.10.5610-5616.1990; BI E, IN PRESS PROKARYOTIC; BURTON P, 1983, MOL GEN GENET, V190, P309, DOI 10.1007/BF00330656; CASAREGOLA S, 1990, MOL MICROBIOL, V4, P505, DOI 10.1111/j.1365-2958.1990.tb00617.x; CORTON JC, J BACTERIOL, V169, P1; DAI K, 1991, J BACTERIOL, V172, P3500; DEBOER PAJ, 1989, CELL, V56, P641, DOI 10.1016/0092-8674(89)90586-2; DEBOER PAJ, 1990, P NATL ACAD SCI USA, V87, P1129, DOI 10.1073/pnas.87.3.1129; HUISMAN O, 1981, NATURE, V290, P797, DOI 10.1038/290797a0; ITO K, 1981, CELL, V24, P707, DOI 10.1016/0092-8674(81)90097-0; JAFFE A, 1986, J BACTERIOL, V165, P66, DOI 10.1128/jb.165.1.66-71.1986; NIKI H, 1991, EMBO J, V10, P183, DOI 10.1002/j.1460-2075.1991.tb07935.x; ROBIN A, 1990, J BACTERIOL, V172, P1392, DOI 10.1128/jb.172.3.1392-1399.1990; SCHROEDER TE, 1973, P NATL ACAD SCI USA, V70, P1688, DOI 10.1073/pnas.70.6.1688; TASCHNER PEM, 1988, J BACTERIOL, V170, P1533, DOI 10.1128/jb.170.4.1533-1540.1988; TEATHER RM, 1974, J BACTERIOL, V118, P407, DOI 10.1128/JB.118.2.407-413.1974; WARD JE, 1984, J BACTERIOL, V157, P815, DOI 10.1128/JB.157.3.815-820.1984; WARD JE, 1985, CELL, V42, P399; WIENTJES FB, 1989, J BACTERIOL, V171, P3412, DOI 10.1128/jb.171.6.3412-3419.1989	23	1132	1169	2	99	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 14	1991	354	6349					161	164		10.1038/354161a0	http://dx.doi.org/10.1038/354161a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GP880	1944597				2022-12-24	WOS:A1991GP88000064
J	HEALY, B				HEALY, B			RESULTS OF RADIAL KERATOTOMY EVALUATED	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											HEALY, B (corresponding author), NIH,BETHESDA,MD 20892, USA.							1991, OPHTHALMOLOGY, V98, P1164	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 6	1991	266	17					2341	2341						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GM790	1920737				2022-12-24	WOS:A1991GM79000007
J	STLOUIS, ME; CONWAY, GA; HAYMAN, CR; MILLER, C; PETERSEN, LR; DONDERO, TJ				STLOUIS, ME; CONWAY, GA; HAYMAN, CR; MILLER, C; PETERSEN, LR; DONDERO, TJ			HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION IN DISADVANTAGED ADOLESCENTS - FINDINGS FROM THE UNITED-STATES-JOB-CORPS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MILITARY SERVICE; SEROPREVALENCE; APPLICANTS; EPIDEMIC; RISK	Objective. - To describe the human immunodeficiency virus (HIV) epidemic among socially and educationally disadvantaged young persons in the United States. Design. - We analyzed demographic and geographic findings from the screening of Job Corps students for antibody to HIV. Setting. - The Job Corps is a federal training program for disadvantaged, out-of-school youth. Population Screened. - Residential students aged 16 to 21 years who entered the Job Corps from October 1987 through February 1990. Main Outcome Measure. - Rates of observed HIV infection in entering students, stratified by demographic and geographic features. Results. - Of 137 209 Job Corps students screened, 488 were HIV seropositive (3.6 per 1000), a seroprevalence rate higher than that among military applicants of the same age. Overall seroprevalence was slightly higher in male (3.7 per 1000) than in female (3.2 per 1000) Job Corps students, but among those students aged 16 and 17 years, seroprevalence was higher among females (2.3 per 1000) than among males (1.5 per 1000) (P < .05). For students aged 16 to 21 years, seroprevalence increased with year of age: 1.8 per 1000 per year for males and 0.7 per 1 000 per year for females. Among those aged 21 years, HIV prevalence was 8.9 per 1000. For black and Hispanic students from large Northeastern cities, seroprevalence increased by 4.3 per 1000 per year of age and reached 24.8 per 1000 (one of 40) in students aged 21 years. However, among students from rural areas and small towns, HIV seroprevalence was disproportionately high in the Southeast. Compared with recently described US patients with the acquired immunodeficiency syndrome, HIV-infected students who entered the Job Corps were much more likely to be female. Conclusions. - These findings show that disadvantaged, out-of-school adolescents are at high risk for HIV infection. The screening results identified surprisingly high seroprevalence in the southeastern United States and demonstrated a marked shift in the HIV epidemic to young women. Controlling the HIV epidemic among teenagers must include interventions that will reach adolescents early and outside of the formal educational system.	CTR DIS CONTROL,CTR INFECT DIS,DIV HIV AIDS,HIV SEROEPIDEMIOL BRANCH,1600 CLIFTON RD,ATLANTA,GA 30333; US DEPT LABOR,EMPLOYMENT AND TRAINING ADM,OFF JOB CORPS,WASHINGTON,DC 20210	Centers for Disease Control & Prevention - USA; United States Department of Labor								BELL T, 1984, SEXUALLY TRANSMITTED, P73; BRUNDAGE JF, 1990, J ACQ IMMUN DEF SYND, V3, P1168; BURKE DS, 1990, JAMA-J AM MED ASSOC, V263, P2074, DOI 10.1001/jama.263.15.2074; BURKE DS, 1987, NEW ENGL J MED, V317, P131, DOI 10.1056/NEJM198707163170302; EDLIN B, 1991, 7TH INT C AIDS FLOR, V2; FULLILOVE RE, 1990, JAMA-J AM MED ASSOC, V263, P851, DOI 10.1001/jama.263.6.851; GAYLE HD, 1990, NEW ENGL J MED, V323, P1538, DOI 10.1056/NEJM199011293232206; HEIN K, 1989, J PEDIATR-US, V114, P144, DOI 10.1016/S0022-3476(89)80622-5; KOMINSKI R, 1990, DEMOGRAPHY, V27, P303, DOI 10.2307/2061455; QUINN TC, 1988, NEW ENGL J MED, V318, P197, DOI 10.1056/NEJM198801283180401; SELIK RM, 1988, AM J PUBLIC HEALTH, V78, P1539, DOI 10.2105/AJPH.78.12.1539; STLOUIS ME, 1990, NEW ENGL J MED, V323, P213, DOI 10.1056/NEJM199007263230401; WENDELL D, 1990, 6TH INT C AIDS SAN F; 1990, MMWR, V39, P385; 1990, AIDS 2ND DECADE, P147; 1990, JOB CORPS BRIEF PROG; 1990, HIV AIDS SURVEILLANC, P1; 1989, SAS STAT USERS GUIDE, V2, P1351; 1990, MMWR, V39, P395; 1989, MMWR, V38, P1; 1988, SEXUALLY TRANSMITTED	21	106	106	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 6	1991	266	17					2387	2391		10.1001/jama.266.17.2387	http://dx.doi.org/10.1001/jama.266.17.2387			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GM790	1920745				2022-12-24	WOS:A1991GM79000024
J	BELLIVEAU, JW; KENNEDY, DN; MCKINSTRY, RC; BUCHBINDER, BR; WEISSKOFF, RM; COHEN, MS; VEVEA, JM; BRADY, TJ; ROSEN, BR				BELLIVEAU, JW; KENNEDY, DN; MCKINSTRY, RC; BUCHBINDER, BR; WEISSKOFF, RM; COHEN, MS; VEVEA, JM; BRADY, TJ; ROSEN, BR			FUNCTIONAL MAPPING OF THE HUMAN VISUAL-CORTEX BY MAGNETIC-RESONANCE-IMAGING	SCIENCE			English	Article							POSITRON-EMISSION TOMOGRAPHY; CEREBRAL BLOOD-VOLUME; HUMAN-BRAIN; COMPUTED-TOMOGRAPHY; COGNITIVE NEUROSCIENCE; STRIATE CORTEX; INSTANT IMAGES; FLOW; CONTRAST; NMR	Knowledge of regional cerebral hemodynamics has widespread application for both physiological research and clinical assessment because of the well-established interrelation between physiological function, energy metabolism, and localized blood supply. A magnetic resonance technique was developed for quantitative imaging of cerebral hemodynamics, allowing for measurement of regional cerebral blood volume during resting and activated cognitive states. This technique was used to generate the first functional magnetic resonance maps of human task activation, by using a visual stimulus paradigm. During photic stimulation, localized increases in blood volume (32 +/- 10 percent, n = 7 subjects) were detected in the primary visual cortex. Center-of-mass coordinates and linear extents of brain activation within the plane of the calcarine fissure are reported.	MASSACHUSETTS GEN HOSP,CTR NMR,DEPT RADIOL,BOSTON,MA 02114; HARVARD UNIV,SCH MED,BOSTON,MA 02115; MASSACHUSETTS GEN HOSP,CTR NMR,DEPT NEUROL,BOSTON,MA 02114	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital			Kennedy, David N/H-3627-2012; Cohen, Mark S/C-6610-2011	Cohen, Mark S/0000-0001-6731-4053	NCI NIH HHS [P01-CA48729, R01-CA40303] Funding Source: Medline; NHLBI NIH HHS [R01-HL39810] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040303, P01CA048729] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039810] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDREASEN NC, 1988, SCIENCE, V239, P1381, DOI 10.1126/science.3279509; AXEL L, 1983, INVEST RADIOL, V18, P94, DOI 10.1097/00004424-198301000-00018; AXEL L, 1980, RADIOLOGY, V137, P679, DOI 10.1148/radiology.137.3.7003648; Belliveau J W, 1991, J Neuroimaging, V1, P36; BELLIVEAU JW, 1990, MAGNET RESON MED, V14, P538, DOI 10.1002/mrm.1910140311; CAVINESS VS, 1989, BRAIN DEV-JPN, V11, P1; CHURCHLAND PS, 1988, SCIENCE, V242, P741, DOI 10.1126/science.3055294; COHEN MS, 1991, MAGN RESON IMAGING, V9, P1, DOI 10.1016/0730-725X(91)90094-3; FISEL CR, 1991, MAGNET RESON MED, V17, P336, DOI 10.1002/mrm.1910170206; FOX PT, 1984, J NEUROPHYSIOL, V51, P1109, DOI 10.1152/jn.1984.51.5.1109; FOX PT, 1986, NATURE, V323, P806, DOI 10.1038/323806a0; FOX PT, 1985, ANN NEUROL, V17, P303, DOI 10.1002/ana.410170315; FOX PT, 1987, J NEUROSCI, V7, P913; GAZZANIGA MS, 1989, SCIENCE, V245, P947, DOI 10.1126/science.2672334; KENNEDY DN, 1989, IEEE T MED IMAGING, V8, P1, DOI 10.1109/42.20356; KENT TA, 1989, AM J NEURORADIOL, V10, P335; KOSSLYN SM, 1988, SCIENCE, V240, P1621, DOI 10.1126/science.3289115; Lassen N. A., 1983, HDB PHYSL 2, VIII, P21; LASSEN NA, 1984, J CEREBR BLOOD F MET, V4, P633, DOI 10.1038/jcbfm.1984.90; MANSFIELD P, 1977, J PHYS C SOLID STATE, V10, pL55, DOI 10.1088/0022-3719/10/3/004; MINTUN MA, 1989, J CEREBR BLOOD F MET, V9, P96, DOI 10.1038/jcbfm.1989.13; MOONEN CTW, 1990, SCIENCE, V250, P53, DOI 10.1126/science.2218514; MOSELEY ME, 1990, 1990 P SOC MAGN RES, P56; PETERSEN SE, 1988, NATURE, V331, P585, DOI 10.1038/331585a0; PHELPS ME, 1981, SCIENCE, V211, P1445, DOI 10.1126/science.6970412; PHELPS ME, 1985, SCIENCE, V228, P799, DOI 10.1126/science.2860723; POSNER MI, 1988, SCIENCE, V240, P1627, DOI 10.1126/science.3289116; PYKETT IL, 1987, MAGNET RESON MED, V5, P563; Raichle M. E., 1987, HDB PHYSL NERVOUS SY, V1, P643; ROSEN B R, 1989, Magnetic Resonance Quarterly, V5, P263; ROSEN BR, 1990, MAGNET RESON MED, V14, P249, DOI 10.1002/mrm.1910140211; RZEDZIAN RR, 1987, AM J ROENTGENOL, V149, P245, DOI 10.2214/ajr.149.2.245; SAKAI F, 1985, J CEREBR BLOOD F MET, V5, P207, DOI 10.1038/jcbfm.1985.27; SANDMAN CA, 1984, SCIENCE, V224, P1355, DOI 10.1126/science.6729458; SOKOLOFF L, 1985, BRAIN IMAGING BRAIN; STARMER CF, 1970, J APPL PHYSIOL, V28, P219, DOI 10.1152/jappl.1970.28.2.219; Talairach J, 1967, ATLAS ANATOMIE STERE; Talairach J., 1988, COPLANAR STEREOTAXIC; THOMPSON HK, 1964, CIRC RES, V14, P502, DOI 10.1161/01.RES.14.6.502; VILLRINGER A, 1988, MAGNET RESON MED, V6, P164, DOI 10.1002/mrm.1910060205; ZEKI S, 1988, NATURE, V335, P311, DOI 10.1038/335311a0	42	1303	1363	12	128	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 1	1991	254	5032					716	719		10.1126/science.1948051	http://dx.doi.org/10.1126/science.1948051			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GN474	1948051				2022-12-24	WOS:A1991GN47400043
J	BARRERA, JM; BRUGUERA, M; ERCILLA, G; SANCHEZTAPIAS, JM; GIL, MP; GIL, C; COSTA, J; GELABERT, A; RODES, J; CASTILLO, R				BARRERA, JM; BRUGUERA, M; ERCILLA, G; SANCHEZTAPIAS, JM; GIL, MP; GIL, C; COSTA, J; GELABERT, A; RODES, J; CASTILLO, R			INCIDENCE OF NON-A, NON-B HEPATITIS AFTER SCREENING BLOOD-DONORS FOR ANTIBODIES TO HEPATITIS-C VIRUS AND SURROGATE MARKERS	ANNALS OF INTERNAL MEDICINE			English	Article						HEPATITIS, VIRAL, NON-A, NON-B; HEPATITIS-C VIRUS; HEPATITIS ANTIBODIES; BLOOD DONORS; BLOOD TRANSFUSION	TRANSFUSION-TRANSMITTED VIRUSES; CORE ANTIGEN; RECIPIENTS; EPIDEMIOLOGY; INFECTIVITY; AGENTS; ASSAY	Objective: To compare the effect of screening blood donors for antibodies to hepatitis C virus (anti-HCV) on the incidence of non-A, non-B hepatitis in recipients with that of screening blood donors for antibodies to hepatitis B core antigen (anti-HBc) and elevated alanine aminotransferase levels. Design: Cohort analysis of serum samples from donors and recipients. Recipients were followed for 12 months to determine the occurrence of non-A, non-B hepatitis. Setting: The blood-transmitted viruses unit and the liver unit of a university teaching hospital. Subjects: A total of 250 patients who had open heart surgery and their 3142 blood donors. Measurements: Donor sera were tested for anti-HCV by enzyme-linked immunosorbent assay (ELISA) and, in the event of a positive result, by recombinant immunoblot assay (RIBA). Antibodies to anti-HBc and serum alanine aminotransferase (ALT) levels were also measured. Measurements of anti-HCV and ALT activity in recipients were done before transfusion and at regular intervals during follow-up. Main Results: Of the 250 transfusion recipients, 40 developed non-A, non-B hepatitis. Of the 3142 donors, 70 were positive for anti-HCV by ELISA, 440 were positive for anti-HBc, and 177 had alanine aminotransferase levels between 0.67 and 1.33-mu-kat/L. The sensitivity (87%), specificity (89%), positive predictive value (59%), and negative predictive value (97%) of blood-donor screening were higher for anti-HCV than for anti-HBc (82%, 36%, 21%, and 91%, respectively) and for elevated alanine aminotransferase levels (65%, 70%, 29%, and 91%, respectively). The expected number of donors excluded because of the presence of anti-HCV was considerably smaller than that of donors with positive results for surrogate markers of hepatitis. Conclusions: Screening blood donors for the presence of anti-HCV is more accurate than screening for surrogate markers (anti-HBc and ALT) and protects more effectively against post-transfusion non-A, non-B hepatitis.	UNIV BARCELONA, HOSP CLIN & PROVINCIAL, VILLARROEL 170, E-08036 BARCELONA, SPAIN	University of Barcelona				Gil, M. Pilar/0000-0002-6281-0282; Gil, Cristina/0000-0002-2692-8814				AACH RD, 1981, NEW ENGL J MED, V304, P989, DOI 10.1056/NEJM198104233041701; ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; ALTER HJ, 1981, JAMA-J AM MED ASSOC, V246, P630, DOI 10.1001/jama.246.6.630; ALTER HJ, 1972, ANN INTERN MED, V77, P691, DOI 10.7326/0003-4819-77-5-691; BARRERA JM, 1987, MED CLIN-BARCELONA, V89, P759; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; DIENSTAG JL, 1983, GASTROENTEROLOGY, V85, P439; EBELING F, 1990, LANCET, V335, P982, DOI 10.1016/0140-6736(90)91055-F; ESTEBAN JI, 1990, NEW ENGL J MED, V323, P1107, DOI 10.1056/NEJM199010183231605; GRINER PF, 1981, ANN INTERN MED, V94, P553, DOI 10.7326/0003-4819-94-4-571; HOLLINGER FB, 1980, J INFECT DIS, V142, P400, DOI 10.1093/infdis/142.3.400; HOYOS M, 1989, HEPATOLOGY, V9, P449, DOI 10.1002/hep.1840090318; KOZIOL DE, 1986, ANN INTERN MED, V104, P488, DOI 10.7326/0003-4819-104-4-488; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; MOSLEY JW, 1990, JAMA-J AM MED ASSOC, V263, P77, DOI 10.1001/jama.263.1.77; SANCHEZTAPIAS JM, 1990, ANN INTERN MED, V112, P921, DOI 10.7326/0003-4819-112-12-921; STEVENS CE, 1990, JAMA-J AM MED ASSOC, V263, P49, DOI 10.1001/jama.263.1.49; STEVENS CE, 1984, ANN INTERN MED, V101, P733, DOI 10.7326/0003-4819-101-6-733; TREMOLADA F, 1991, ANN INTERN MED, V114, P277, DOI 10.7326/0003-4819-114-4-277; VANDERPOEL CL, 1990, LANCET, V335, P558, DOI 10.1016/0140-6736(90)90347-8; VANDERPOEL CL, 1989, LANCET, V2, P297	21	53	53	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1991	115	8					596	600		10.7326/0003-4819-115-8-596	http://dx.doi.org/10.7326/0003-4819-115-8-596			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GJ902	1909848				2022-12-24	WOS:A1991GJ90200003
J	NIGHTINGALE, SL				NIGHTINGALE, SL			PUBLIC HEARING ON ORGAN AND TISSUE-TRANSPLANTATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							1991, FED REG         0830	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 2	1991	266	13					1751	1751						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG551	1890706				2022-12-24	WOS:A1991GG55100003
J	VONAHSEN, U; DAVIES, J; SCHROEDER, R				VONAHSEN, U; DAVIES, J; SCHROEDER, R			ANTIBIOTIC INHIBITION OF GROUP-I RIBOZYME FUNCTION	NATURE			English	Article							CATALYTIC CORE; RIBOSOMAL-RNA; BINDING-SITE; INTRONS; BACTERIOPHAGE-T4; SEQUENCE; PROTEIN	THE discovery of catalytically active RNA has provided the basis for the evolutionary concept of an RNA world. It has been proposed that during evolution the functions of ancient catalytic RNA were modulated by low molecular weight effectors, related to antibiotics, present in the primordial soup. Antibiotics and RNA may have coevolved in the formation of the modern ribosome 1. Here we report that a set of aminoglycoside antibiotics, which are known to interact with the decoding region of the 16S ribosomal RNA of Escherichia coli 2-4, inhibit the second step of splicing of the T4 phage-derived td intron. Thus catalytic RNA seems to interact not only with a mononucleotide 5 and an amino acid 6, but also with another class of biomolecules, the sugars. Splicing of other group I introns but not group II introns was inhibited. The similarity in affinity and specificity of these antibiotics for group I introns and rRNAs may result from recognition of evolutionarily conserved structures.	INST PASTEUR,UNITE GENIE MICROBIOL,F-75724 PARIS 15,FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	VONAHSEN, U (corresponding author), UNIV VIENNA,INST MIKROBIOL & GENET,ALTHANSTR 14,A-1090 VIENNA,AUSTRIA.							AKINS RA, 1987, CELL, V50, P331, DOI 10.1016/0092-8674(87)90488-0; BASS BL, 1986, BIOCHEMISTRY-US, V25, P4473, DOI 10.1021/bi00364a001; BENVENISTE R, 1973, ANTIMICROB AGENTS CH, V4, P2402; BURKE JM, 1990, NATURE, V344, P80, DOI 10.1038/344080a0; CECH TR, 1990, ANNU REV BIOCHEM, V59, P543, DOI 10.1146/annurev.bi.59.070190.002551; CUNDLIFFE E, 1990, RIBOSOME, P479; DAVIES J, 1990, MOL MICROBIOL, V4, P1227, DOI 10.1111/j.1365-2958.1990.tb00701.x; DAVIES JE, 1983, BIOCH GENETIC REGULA, P329; EHRENMAN K, 1986, P NATL ACAD SCI USA, V83, P5875, DOI 10.1073/pnas.83.16.5875; GALE EF, 1966, BIOCH STUDIES ANTIMI, P1; HERBERT CJ, 1988, EMBO J, V7, P473, DOI 10.1002/j.1460-2075.1988.tb02835.x; MICHEL F, 1990, GENE DEV, V4, P777, DOI 10.1101/gad.4.5.777; MICHEL F, 1989, NATURE, V342, P391, DOI 10.1038/342391a0; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; MOAZED D, 1987, NATURE, V327, P389, DOI 10.1038/327389a0; NOLLER HF, 1984, ANNU REV BIOCHEM, V53, P119, DOI 10.1146/annurev.bi.53.070184.001003; SALVO JLG, 1990, J MOL BIOL, V211, P537, DOI 10.1016/0022-2836(90)90264-M; SCHROEDER R, 1991, BIOCHEMISTRY-US, V30, P3295, DOI 10.1021/bi00227a018; SERAPHIN B, 1989, NATURE, V337, P84, DOI 10.1038/337084a0; VONAHSEN U, 1990, NATURE, V346, P801; VONAHSEN U, 1991, NUCLEIC ACIDS RES, V19, P2261, DOI 10.1093/nar/19.9.2261; YARUS M, 1988, SCIENCE, V240, P1751, DOI 10.1126/science.3381099; YARUS M, 1990, NATURE, V342, P349	23	233	244	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 26	1991	353	6342					368	370		10.1038/353368a0	http://dx.doi.org/10.1038/353368a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GG654	1922343				2022-12-24	WOS:A1991GG65400066
J	SHAMANSKI, FL; ORRWEAVER, TL				SHAMANSKI, FL; ORRWEAVER, TL			THE DROSOPHILA PLUTONIUM AND PAN GU GENES REGULATE ENTRY INTO S-PHASE AT FERTILIZATION	CELL			English	Article							PROTO-ONCOGENE PRODUCT; CELL-CYCLE; EARLY EMBRYOGENESIS; DNA-REPLICATION; XENOPUS-LAEVIS; MELANOGASTER; EGGS; DIVISION; NUCLEAR; MUTATION	Mutations in the Drosophila maternal genes plutonium (plu) and pan gu (png) have the striking phenotype that DNA replication initiates in unfertilized eggs. Fertilized eggs from plu or png mutant mothers also have a mutant phenotype; DNA replication is uncoupled from nuclear division, resulting in giant, polyploid nuclei. Analysis of multiple alleles of these genes indicates that their wild-type function is required to maintain repression of DNA replication until fertilization. The phenotype of two png alleles suggests that this gene also may play a direct role in coupling S phase and mitosis during the early cleavage divisions. We describe genetic interactions among png, plu, and the previously identified gene gnu that demonstrate these three genes regulate the same process.	WHITEHEAD INST,CAMBRIDGE,MA 02142	Massachusetts Institute of Technology (MIT); Whitehead Institute	SHAMANSKI, FL (corresponding author), MIT,DEPT BIOL,CAMBRIDGE,MA 02139, USA.				NCI NIH HHS [CA09541-06] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009541] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BELLEN HJ, 1988, ROUX ARCH DEV BIOL, V197, P258, DOI 10.1007/BF00380019; BERG CA, 1991, GENETICS, V127, P515; BIER E, 1989, GENE DEV, V3, P1273, DOI 10.1101/gad.3.9.1273; BLOW JJ, 1988, NATURE, V332, P546, DOI 10.1038/332546a0; Blumenthal AB, 1974, COLD SPRING HARB SYM, V38, P205, DOI 10.1101/sqb.1974.038.01.024; CASADABAN MJ, 1983, METHOD ENZYMOL, V100, P293; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COOLEY L, 1988, SCIENCE, V239, P1121, DOI 10.1126/science.2830671; COPPOCK DL, 1987, MOL CELL BIOL, V7, P2925, DOI 10.1128/MCB.7.8.2925; DECICCO DV, 1984, CELL, V38, P45, DOI 10.1016/0092-8674(84)90525-7; DIXON WJ, 1951, INTRO STATISTICAL AN; DOANE WW, 1960, SCIENCE, V132, P677, DOI 10.1126/science.132.3428.677; EDGAR BA, 1986, CELL, V44, P365, DOI 10.1016/0092-8674(86)90771-3; EDGAR BA, 1989, CELL, V57, P177, DOI 10.1016/0092-8674(89)90183-9; ELLEDGE SJ, 1990, GENE DEV, V4, P740, DOI 10.1101/gad.4.5.740; Ephrussi B, 1936, AM NAT, V70, P218, DOI 10.1086/280658; FREEMAN M, 1986, CELL, V46, P457, DOI 10.1016/0092-8674(86)90666-5; FREEMAN M, 1987, GENE DEV, V1, P924, DOI 10.1101/gad.1.9.924; GERHART J, 1984, J CELL BIOL, V98, P1247, DOI 10.1083/jcb.98.4.1247; GONZALEZ C, 1990, J CELL SCI, V96, P605; HARA K, 1980, P NATL ACAD SCI-BIOL, V77, P462, DOI 10.1073/pnas.77.1.462; HARLAND RM, 1980, CELL, V21, P761, DOI 10.1016/0092-8674(80)90439-0; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; KELLOGG DR, 1989, J CELL BIOL, V109, P2977, DOI 10.1083/jcb.109.6.2977; KONGSUWAN K, 1985, NATURE, V317, P555, DOI 10.1038/317555a0; LEHMANN R, 1986, CELL, V47, P141, DOI 10.1016/0092-8674(86)90375-2; LIN HF, 1991, CELL, V64, P49, DOI 10.1016/0092-8674(91)90208-G; LINDREN BW, 1978, PROBABILITY STATISTI; LINDSLEY D, 1987, DROS INF SERV, V65; LINDSLEY D, 1990, DROS INF SERV, V68; LINDSLEY DL, 1968, CARNEGIE I WASH PUBL, V627; MAHOWALD AP, 1983, DEV BIOL, V98, P437, DOI 10.1016/0012-1606(83)90373-1; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; MCKNIGHT SL, 1976, CELL, V8, P305, DOI 10.1016/0092-8674(76)90014-3; Mohler D., 1984, DROSOPHILA INFORMATI, V60, P236; MOHLER JD, 1977, GENETICS, V85, P259; NEWPORT JW, 1984, CELL, V37, P731, DOI 10.1016/0092-8674(84)90409-4; ORRWEAVER TL, 1986, MOL CELL BIOL, V6, P4624, DOI 10.1128/MCB.6.12.4624; PERRIMON N, 1989, GENETICS, V121, P333; PICARD A, 1987, NATURE, V327, P170, DOI 10.1038/327170a0; RAFF JW, 1988, J CELL BIOL, V107, P2009, DOI 10.1083/jcb.107.6.2009; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SANDER K, 1985, BIOL FERTILIZATION, V2, P409; SCHUPBACH T, 1989, GENETICS, V121, P101; SHELLENBARGER DL, 1978, MUTAT RES, V52, P395, DOI 10.1016/0027-5107(78)90178-1; Sokal Robert R., 1969, BIOMETRY; Sonnenblick B., 1950, BIOL DROSOPHILA, P62; WATANABE N, 1989, NATURE, V342, P505, DOI 10.1038/342505a0; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H; ZALOKAR M, 1976, J MICROSC BIOL CELL, V25, P97; ZALOKAR M, 1975, DEV BIOL, V47, P419, DOI 10.1016/0012-1606(75)90295-X	51	87	87	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 20	1991	66	6					1289	1300		10.1016/0092-8674(91)90050-9	http://dx.doi.org/10.1016/0092-8674(91)90050-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GG552	1913810				2022-12-24	WOS:A1991GG55200022
J	LAVERICK, MD; CROAL, SA; MOLLAN, RAB				LAVERICK, MD; CROAL, SA; MOLLAN, RAB			ORTHOPEDIC SURGEONS AND THROMBOPROPHYLAXIS	BRITISH MEDICAL JOURNAL			English	Article							DEEP VENOUS THROMBOSIS; TOTAL HIP-REPLACEMENT; VEIN THROMBOSIS; PREVENTION; THROMBOEMBOLISM; COMPRESSION; STOCKINGS; HEPARIN	Objective - To assess attitudes to the use of thromboprophylaxis among orthopaedic surgeons in the United Kingdom. Design and subjects - Single page postal questionnaire to all 926 active orthopaedic surgeons who are members of the British Orthopaedic Association. Results - The response rate was 70% (659 surgeons), of whom 595 (90%) used some form of prophylaxis. Most (548; 83%) used drugs but 47 (7%) used only elasticated stockings. A history of thromboembolic disease, hip surgery, and obesity was seen as the main risk factor. Ineffectiveness was the principal reason for not using prophylaxis. Conclusions - Most orthopaedic surgeons use regimens of thromboprophylaxis, though many of these are of limited value. Improvements in the efficacy and safety of prophylactic agents, combined with ease of administration, would increase the use of such agents and make orthopaedic surgery safer for the patient.			LAVERICK, MD (corresponding author), QUEENS UNIV BELFAST,MUSGRAVE PK HOSP,DEPT ORTHOPAED SURG,BELFAST BT9 7JB,NORTH IRELAND.							BEISAW NE, 1988, J BONE JOINT SURG AM, V70A, P2, DOI 10.2106/00004623-198870010-00002; BRENKEL I, 1989, BRIT J HOSP MED, V42, P282; CHRISMAN OD, 1976, J BONE JOINT SURG AM, V58, P918, DOI 10.2106/00004623-197658070-00003; COTTON LT, 1977, SURGERY, V81, P228; EVARTS CM, 1971, J BONE JOINT SURG AM, VA 53, P1271, DOI 10.2106/00004623-197153070-00002; JOHNSON R, 1986, CLIN ORTHOPAEDICS, V211, P151; Ljungstrom K G, 1988, Acta Chir Scand Suppl, V543, P26; NICOLAIDES AN, 1983, SURGERY, V94, P21; PLANES A, 1986, HAEMOSTASIS, V16, P152; PLANES A, 1990, J BONE JOINT SURG BR, V72, P9, DOI 10.1302/0301-620X.72B1.2298803; SALZMAN EW, 1976, J BONE JOINT SURG AM, V58, P903, DOI 10.2106/00004623-197658070-00001; SCURR JH, 1988, BRIT MED J, V297, P28, DOI 10.1136/bmj.297.6640.28; STRINGER MD, 1989, J BONE JOINT SURG BR, V71, P492, DOI 10.1302/0301-620X.71B3.2785998; STULBERG BN, 1984, J BONE JOINT SURG AM, V66A, P194, DOI 10.2106/00004623-198466020-00005; TORNGREN S, 1980, BRIT J SURG, V67, P482, DOI 10.1002/bjs.1800670710; WHITEHOUSE G, 1987, BRIT MED J, V295, P801, DOI 10.1136/bmj.295.6602.801; WOLFE JHN, 1987, BMJ, V295, P1365; 1986, JAMA-J AM MED ASSOC, V256, P744	18	77	78	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 7	1991	303	6802					549	550		10.1136/bmj.303.6802.549	http://dx.doi.org/10.1136/bmj.303.6802.549			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GE948	1912884	Bronze, Green Published			2022-12-24	WOS:A1991GE94800021
J	QUON, D; WANG, Y; CATALANO, R; SCARDINA, JM; MURAKAMI, K; CORDELL, B				QUON, D; WANG, Y; CATALANO, R; SCARDINA, JM; MURAKAMI, K; CORDELL, B			FORMATION OF BETA-AMYLOID PROTEIN DEPOSITS IN BRAINS OF TRANSGENIC MICE	NATURE			English	Article							PRECURSOR MESSENGER-RNA; ALZHEIMERS-DISEASE; DIFFERENTIAL EXPRESSION; SENILE PLAQUES; RAT-BRAIN; ANTIBODY; NEURONS; CORTEX; GENE; DNA	DEPOSITS of beta-amyloid are one of the main pathological characteristics of Alzheimer's disease. The beta-amyloid peptide constituent (relative molecular mass 4,200) of the deposits is derived from the beta-amyloid precursor protein (beta-APP) which is expressed in several different isoforms 1-6. The two most prevalent beta-APP isoforms are distinguished by either the presence (beta-APP751) or absence (beta-APP695) of a Kunitz serine protease inhibitor domain. Changes in the abundance of different beta-APP messenger RNAs in brains of Alzheimer's disease victims have been widely reported 7-12. Although these results have been controversial, most evidence favours an increase in the mRNAs encoding protease inhibitor-containing isoforms of beta-APP and it is proposed that this change contributes to beta-amyloid formation 9-12. We have now produced an imbalance in the normal neuronal ratio of beta-APP isoforms by preparing transgenic mice expressing additional beta-APP751 under the control of a neural-specific promoter. The cortical and hippocampal brain regions of the transgenic mice display extracellular beta-amyloid immunoreactive deposits varying in size (< 5-50-mu-m) and abundance. These results suggest that one mechanism of beta-amyloid formation may involve a disruption of the normal ratio of neuronal beta-APP isoform expression and support a direct relationship between increased expression of Kunitz inhibitor-bearing beta-APP isoforms and beta-amyloid deposition.	CALIF BIOTECHNOL INC,2450 BAYSHORE PKWY,MT VIEW,CA 94043									ALLSOP D, 1989, NEUROPATH APPL NEURO, V15, P531, DOI 10.1111/j.1365-2990.1989.tb01252.x; BUGIANI O, 1989, NEUROSCI LETT, V103, P263, DOI 10.1016/0304-3940(89)90110-9; EKLUND J, 1976, ANIM PROD, V22, P127, DOI 10.1017/S0003356100035509; FORSSPETTER S, 1990, NEURON, V5, P187, DOI 10.1016/0896-6273(90)90308-3; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; IKEDA S, 1989, LAB INVEST, V60, P113; JOHNSON SA, 1990, SCIENCE, V248, P854, DOI 10.1126/science.2111579; JOHNSON SA, 1988, EXP NEUROL, V102, P264, DOI 10.1016/0014-4886(88)90104-5; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MURPHY GM, 1990, PROG NEURO-PSYCHOPH, V14, P309, DOI 10.1016/0278-5846(90)90019-D; NEVE RL, 1990, NEURON, V5, P329, DOI 10.1016/0896-6273(90)90169-G; NEVE RL, 1988, NEURON, V1, P669, DOI 10.1016/0896-6273(88)90166-3; OKAYAMA H, 1983, MOL CELL BIOL, V3, P280, DOI 10.1128/MCB.3.2.280; PALMERT MR, 1988, SCIENCE, V241, P1080, DOI 10.1126/science.2457949; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SAKIMURA K, 1987, GENE, V60, P103, DOI 10.1016/0378-1119(87)90218-6; SHIVERS BD, 1988, EMBO J, V7, P1365, DOI 10.1002/j.1460-2075.1988.tb02952.x; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TAGGART RT, 1983, SCIENCE, V219, P1228, DOI 10.1126/science.6402815; TAGLIAVINI F, 1988, NEUROSCI LETT, V93, P191, DOI 10.1016/0304-3940(88)90080-8; TAKIO K, 1989, BIOCHEM BIOPH RES CO, V160, P1296, DOI 10.1016/S0006-291X(89)80144-5; TANAKA S, 1988, BIOCHEM BIOPH RES CO, V157, P472, DOI 10.1016/S0006-291X(88)80273-0; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; Towbin H, 1979, 10 1073 PNAS 76 9 43, V76, P4350, DOI [10.1073/pnas.76.9.4350, DOI 10.1073/PNAS.76.9.4350]; YAMAGUCHI H, 1988, ACTA NEUROPATHOL, V76, P541, DOI 10.1007/BF00689591	30	357	402	1	17	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 18	1991	352	6332					239	241		10.1038/352239a0	http://dx.doi.org/10.1038/352239a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FX185	1906990				2022-12-24	WOS:A1991FX18500065
J	RAUB, W				RAUB, W			PREDICTORS OF TYPE-II DIABETES IDENTIFIED	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											RAUB, W (corresponding author), NIH,BLDG 31,ROOM 2B23,BETHESDA,MD 20892, USA.							1990, ANN INTERN MED, V113, P909	1	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 3	1991	265	13					1633	1633						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD659	1900541				2022-12-24	WOS:A1991FD65900005
J	ROSE, EH; ALEDORT, LM				ROSE, EH; ALEDORT, LM			NASAL SPRAY DESMOPRESSIN (DDAVP) FOR MILD HEMOPHILIA-A AND VONWILLEBRAND DISEASE	ANNALS OF INTERNAL MEDICINE			English	Article							BIOLOGICAL RESPONSE; VASOPRESSIN; INTRANASAL; HYPONATREMIA; SEIZURES	Objective: To evaluate the effect of a nasal spray preparation of desmopressin (DDAVP) on levels of factor VIII activity, ristocetin cofactor activity, and von Willebrand antigen as well as the length of bleeding time in patients with mild hemophilia A and von Willebrand disease; to determine whether effective hemostatic levels can be attained; and to compare the effect of this spray with that of standard intravenous desmopressin treatment. Design: Before-and-after trial in patients known to respond to intravenous desmopressin. Setting: Regional, comprehensive, hemophilia diagnosis and treatment center. Patients: A total of 22 patients, including 11 patients with von Willebrand disease, 8 patients with mild hemophilia A, and 3 symptomatic hemophilia carriers. Interventions: Patients were infused with desmopressin, 0.3-mu-g/kg body weight. At least 1 week later, they were taught to self-administer desmopressin nasal spray, 150-mu-g to each nostril. Measurements: In patients with hemophilia, the level of factor VIII activity was measured; in patients with von Willebrand disease, levels of factor VIII activity, ristocetin cofactor activity, and von Willebrand antigen as well as bleeding time were measured before and after each administration of desmopressin. Main Results: Desmopressin, when administered intravenously or intranasally, elevated levels of factor VIII, ristocetin cofactor, and von Willebrand antigen in both mildly hemophiliac patients and patients with von Willebrand disease when compared with baseline measures (P < 0.05). Factor VIII levels adequate for hemostasis were achieved by 82% of the hemophiliac patients. An abnormal bleeding time was corrected in the majority (62%) of patients with von Willebrand disease. Conclusion: A nasal spray preparation of desmopressin apparently was effective both in treating bleeding episodes and when used prophylactically for minor surgical procedures in several patients.	CUNY MT SINAI SCH MED, NEW YORK, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R18HL030567] Funding Source: NIH RePORTER; NCI NIH HHS [MCB-360001-04-01] Funding Source: Medline; NHLBI NIH HHS [HL-30567-02] Funding Source: Medline; PHS HHS [000217-01-2] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Cochran W. G., 1963, SAMPLING TECHNIQUES, DOI [10.1002/bimj.19650070312, DOI 10.1002/BIMJ.19650070312]; DELAFUENTE B, 1985, ANN INTERN MED, V103, P6, DOI 10.7326/0003-4819-103-1-6; DESIO L, 1985, THROMB HAEMOSTASIS, V54, P387; HARRIS AS, 1988, J PHARM SCI-US, V77, P337, DOI 10.1002/jps.2600770412; HARRIS AS, 1986, J PHARM SCI, V75, P1085, DOI 10.1002/jps.2600751113; KOHLER M, 1984, KLIN WOCHENSCHR, V62, P543, DOI 10.1007/BF01727749; KOHLER M, 1986, THROMB HAEMOSTASIS, V55, P108; LETHAGEN S, 1990, BLUT, V60, P187, DOI 10.1007/BF01720274; LETHAGEN S, 1987, THROMB HAEMOSTASIS, V58, P1033; MANNUCCI PM, 1977, LANCET, V1, P869; MANNUCCI PM, 1987, THROMB HAEMOSTASIS, V58, P1037; MARIANA G, 1984, CLIN LAB HAEMATOL, V6, P229; SHEPHERD LL, 1989, J PEDIATR-US, V114, P470, DOI 10.1016/S0022-3476(89)80575-X; SMITH TJ, 1989, AM J HEMATOL, V31, P199, DOI 10.1002/ajh.2830310310; WARRIER AI, 1983, J PEDIATR-US, V102, P228, DOI 10.1016/S0022-3476(83)80526-5; [No title captured]	16	94	94	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1991	114	7					563	568		10.7326/0003-4819-114-7-563	http://dx.doi.org/10.7326/0003-4819-114-7-563			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD661	1900403				2022-12-24	WOS:A1991FD66100007
J	AUWERX, J; SASSONECORSI, P				AUWERX, J; SASSONECORSI, P			IP-1 - A DOMINANT INHIBITOR OF FOS/JUN WHOSE ACTIVITY IS MODULATED BY PHOSPHORYLATION	CELL			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; CELLULAR FOS PROTEINS; DNA-BINDING PROTEINS; PROTO-ONCOGENE FOS; C-FOS; TRANSCRIPTION FACTOR; LEUCINE ZIPPER; JUN ENCODES; KINASE-C; AP-1	Transcription factor AP-1 is inducible by phorbol esters and thus could be considered to be one final target of the protein kinase C signal transduction pathway. AP-1 consists of the products of the fos and jun oncogenes, which associate as dimers to bind TPA-responsive promoter elements (TRE) efficiently. We show that AP-1 activity is modulated by an inhibitory protein (IP-1), present both in the nucleus and cytoplasm of several cell types. IP-1 specifically blocks DNA binding of AP-1 from nuclear extracts and of in vitro synthesized Fos/Jun proteins. It is a labile protein of 30-40 kd, which exerts its activity only in the nonphosphorylated form. Block of IP-1 function is obtained by PKA-mediated phosphorylation, possibly suggesting a cross talk mechanism at transcriptional level. Competition experiments with synthetic peptides suggest that IP-1 could interact with Fos and/or Jun leucine zippers. We speculate that IP-1 might act as a transcriptional antioncogene.			AUWERX, J (corresponding author), FAC MED STRASBOURG,CNRS,GENET MOLEC EUCARYOTES LAB,INSERM,F-67085 STRASBOURG,FRANCE.		Sassone-Corsi, Paolo/H-6182-2011	Auwerx, Johan/0000-0002-5065-5393				ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; AUWERX J, 1990, NUCLEIC ACIDS RES, V18, P221, DOI 10.1093/nar/18.2.221; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BARBER JR, 1987, MOL CELL BIOL, V7, P2201, DOI 10.1128/MCB.7.6.2201; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BERK AJ, 1986, ANNU REV GENET, V20, P45, DOI 10.1146/annurev.ge.20.120186.000401; BISHOP JM, 1985, CELL, V42, P23, DOI 10.1016/S0092-8674(85)80098-2; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BUSCH SJ, 1990, TRENDS GENET, V6, P36, DOI 10.1016/0168-9525(90)90071-D; BUSCH SJ, 1990, ONCOGENE, V5, P1549; CAMBIER JC, 1987, NATURE, V327, P629, DOI 10.1038/327629a0; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CURRAN T, 1984, VIROLOGY, V135, P218, DOI 10.1016/0042-6822(84)90132-6; CURRAN T, 1985, MOL CELL BIOL, V5, P167, DOI 10.1128/MCB.5.1.167; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; CURRAN T, 1984, CELL, V36, P259; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DISTEL RJ, 1987, CELL, V49, P835, DOI 10.1016/0092-8674(87)90621-0; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GREEN MR, 1989, CELL, V56, P1, DOI 10.1016/0092-8674(89)90975-6; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HOEFFLER JP, 1989, MOL ENDOCRINOL, V3, P868, DOI 10.1210/mend-3-5-868; HUNT T, 1989, CELL, V59, P949, DOI 10.1016/0092-8674(89)90747-2; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; MILLER AD, 1984, CELL, V36, P51; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NEUBERG M, 1989, NATURE, V338, P589, DOI 10.1038/338589a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; PICARD D, 1988, CELL, V54, P1073, DOI 10.1016/0092-8674(88)90122-5; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; RAUSCHER FJ, 1988, CELL, V52, P471, DOI 10.1016/S0092-8674(88)80039-4; RENZ M, 1987, NUCLEIC ACIDS RES, V15, P277, DOI 10.1093/nar/15.1.277; SAMBUCETTI LC, 1986, SCIENCE, V234, P1417, DOI 10.1126/science.3491427; SASSONECORSI P, 1989, MOL CELL BIOL, V9, P3174, DOI 10.1128/MCB.9.8.3174; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SASSONECORSI P, 1990, ONCOGENE, V5, P427; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; VERMA IM, 1987, CELL, V51, P513, DOI 10.1016/0092-8674(87)90115-2; VOGT PK, 1989, TRENDS BIOCHEM SCI, V14, P172, DOI 10.1016/0968-0004(89)90268-5; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; YOSHIMASA T, 1987, NATURE, V327, P67, DOI 10.1038/327067a0	52	226	229	1	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 8	1991	64	5					983	993		10.1016/0092-8674(91)90322-P	http://dx.doi.org/10.1016/0092-8674(91)90322-P			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FA940	1900458				2022-12-24	WOS:A1991FA94000015
J	PRIOR, TI; FITZGERALD, DJ; PASTAN, I				PRIOR, TI; FITZGERALD, DJ; PASTAN, I			BARNASE TOXIN - A NEW CHIMERIC TOXIN COMPOSED OF PSEUDOMONAS EXOTOXIN-A AND BARNASE	CELL			English	Article							GENOMIC SEQUENCES; ESCHERICHIA-COLI; BARSTAR; CELLS; RIBONUCLEASE; IMMUNOTOXINS; AERUGINOSA; EXPRESSION; ANTIBODY; PROTEINS	We have constructed a chimeric toxin composed of Pseudomonas exotoxin A (PE) and the extracellular ribonuclease of Bacillus amyloliquefaciens, barnase. The chimeric protein, termed PE-Bar, reacted with both anti-PE and anti-barnase antisera and had both ADP ribosylation and ribonuclease activities. The chimeric toxin was cytotoxic to the murine fibroblast cell line L929 and to a murine hybridoma resistant to PE. A mutant form of PE-Bar lacking ADP-ribosylating activity was still cytotoxic to L929 cells. Because treatment of cells prelabeled with [H-3]uridine resulted in a decrease in their RNA content, we conclude that this cytotoxic effect was due to the ribonuclease activity of barnase molecules that had been translocated to the cytosol. It is now possible to construct chimeric toxins with two or more enzymatic activities that can be delivered to the cytosol of the target cells.			PRIOR, TI (corresponding author), NCI,DIV CANC BIOL & DIAG,MOLEC BIOL LAB,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.		pastan, ira/P-9319-2019	pastan, ira/0000-0002-9223-0270				ALLURED VS, 1986, P NATL ACAD SCI USA, V83, P1320, DOI 10.1073/pnas.83.5.1320; CHAUDHARY VK, 1989, NATURE, V339, P394, DOI 10.1038/339394a0; CHAUDHARY VK, 1990, P NATL ACAD SCI USA, V87, P308, DOI 10.1073/pnas.87.1.308; DOUGLAS CM, 1987, J BACTERIOL, V169, P4967, DOI 10.1128/jb.169.11.4967-4971.1987; ENDO Y, 1987, J BIOL CHEM, V262, P5908; FITZGERALD D, 1989, J NATL CANCER I, V81, P1455, DOI 10.1093/jnci/81.19.1455; FITZGERALD DJP, 1983, CELL, V32, P607, DOI 10.1016/0092-8674(83)90480-4; HARTLEY RW, 1973, J BIOL CHEM, V248, P5624; HARTLEY RW, 1989, TRENDS BIOCHEM SCI, V14, P450, DOI 10.1016/0968-0004(89)90104-7; HARTLEY RW, 1988, J MOL BIOL, V202, P913, DOI 10.1016/0022-2836(88)90568-2; HWANG J, 1987, CELL, V48, P129, DOI 10.1016/0092-8674(87)90363-1; KONDO T, 1988, J BIOL CHEM, V263, P9470; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LORBERBOUMGALSKI H, 1988, P NATL ACAD SCI USA, V85, P1922, DOI 10.1073/pnas.85.6.1922; MAUGUEN Y, 1982, NATURE, V297, P162, DOI 10.1038/297162a0; PADDON CJ, 1986, GENE, V40, P231, DOI DOI 10.1016/0378-1119(85)90045-9; PASTAN I, 1986, CELL, V47, P641, DOI 10.1016/0092-8674(86)90506-4; PASTAN I, 1989, J BIOL CHEM, V264, P15157; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SCHARF SJ, 1986, SCIENCE, V233, P1076, DOI 10.1126/science.3461561; SENIOR BW, 1971, P NATL ACAD SCI USA, V68, P959, DOI 10.1073/pnas.68.5.959; SIEGALL CB, 1988, P NATL ACAD SCI USA, V85, P9738, DOI 10.1073/pnas.85.24.9738; SIEGALL CB, 1989, J BIOL CHEM, V264, P14256; SMEATON JR, 1967, BIOCHIM BIOPHYS ACTA, V145, P547, DOI 10.1016/0005-2787(67)90115-3; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; WILLINGHAM MC, 1987, P NATL ACAD SCI USA, V84, P2474, DOI 10.1073/pnas.84.8.2474	26	64	77	1	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 8	1991	64	5					1017	1023		10.1016/0092-8674(91)90325-S	http://dx.doi.org/10.1016/0092-8674(91)90325-S			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FA940	1900455				2022-12-24	WOS:A1991FA94000018
J	NIGHTINGALE, SL				NIGHTINGALE, SL			SHILEY HEART-VALVE PHYSICIAN AND PATIENT NOTIFICATION PROGRAM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	21	21	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 20	1991	265	7					847	847		10.1001/jama.265.7.847	http://dx.doi.org/10.1001/jama.265.7.847			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX587	1899454				2022-12-24	WOS:A1991EX58700011
J	KELLEY, PW; PETRUCCELLI, BP; STEHRGREEN, P; ERICKSON, RL; MASON, CJ				KELLEY, PW; PETRUCCELLI, BP; STEHRGREEN, P; ERICKSON, RL; MASON, CJ			THE SUSCEPTIBILITY OF YOUNG-ADULT AMERICANS TO VACCINE-PREVENTABLE INFECTIONS - A NATIONAL SEROSURVEY OF UNITED-STATES-ARMY RECRUITS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LINKED IMMUNOSORBENT-ASSAY; VARICELLA-ZOSTER VIRUS; EPIDEMIC MEASLES; RUBELLA; POPULATION; IMMUNIZATION; ANTIBODY; MUMPS	Objective. - Due to recent resurgences of measles, mumps, and rubella among young US adults, we sought to generate antibody prevalence data for national and military immunization policy evaluations. Design. - We used a questionnaire and serological survey of Army recruits to assess antibody status to measles, mumps, rubella, and varicella by enzyme-linked immunosorbent assay and to poliovirus types 1, 2, and 3 by microneutralization assay. Setting. - Basic training reception centers at Fort Benning, Ga, and Fort Jackson, SC. Patients. - The study included 1547 US Army recruits who were inducted during September and October 1989. Outcome Measures. - Seronegativity by various demographic factors. Results. - Seronegativity rates, directly adjusted to the 15- to 24-year-old US population in 1980, were 20.7% for measles, 15.6% for mumps, 17.5% for rubella, and 6.9% for varicella. For measles, mumps, and rubella, susceptibility was less in females, blacks, and college-educated recruits, and varicella susceptibility was greater in females and blacks. Recruits who were born after 1969 lacked measles, mumps, and rubella antibodies more often than older recruits. The adjusted seronegativity rates for poliovirus types 1, 2, and 3 were 2.3%, 0.6%, and 14.6%, respectively; trends by age, sex, and race-ethnicity were generally unremarkable. Conclusions. - Among young adult Americans, susceptibility to measles, mumps, and rubella is unevenly distributed and may be substantial. Our findings support national objectives to further improve immunization coverage in school-age and adult populations and provide further impetus for legislation requiring college entrants to present evidence of having received at least two doses of measles vaccine, with one on or after entry into elementary school.	CTR DIS CONTROL,CTR PREVENT SERV,DIV IMMUNIZAT,ATLANTA,GA 30333	Centers for Disease Control & Prevention - USA	KELLEY, PW (corresponding author), WALTER REED ARMY MED CTR,DIV PREVENT MED,ADV PREVENT MED STUDIES BRANCH,WASHINGTON,DC 20307, USA.		Mason, Carl J/F-3538-2010; Mason, Carl/ABH-3298-2021	Mason, Carl J/0000-0002-3676-2811; Mason, Carl/0000-0002-3676-2811				ARDAY DR, 1989, AM J PUBLIC HEALTH, V79, P471, DOI 10.2105/AJPH.79.4.471; ARMITAGE P, 1987, STATISTICAL METHODS, P400; BURKE DS, 1979, J INFECT DIS, V139, P225, DOI 10.1093/infdis/139.2.225; BURKE DS, 1987, NEW ENGL J MED, V317, P131, DOI 10.1056/NEJM198707163170302; CHEN RT, 1990, J INFECT DIS, V162, P1036, DOI 10.1093/infdis/162.5.1036; COCHI SL, 1988, AM J DIS CHILD, V142, P499, DOI 10.1001/archpedi.1988.02150050037025; COCHI SL, 1988, AM J DIS CHILD, V142, P1021, DOI 10.1001/archpedi.1988.02150100015006; COHEN ZB, 1985, CLIN PEDIATR, V24, P387, DOI 10.1177/000992288502400705; CRAWFORD GE, 1981, J INFECT DIS, V144, P403, DOI 10.1093/infdis/144.5.403; DEFOREST A, 1989, 89TH ANN M AM SOC MI, P136; DEMMLER GJ, 1988, J INFECT DIS, V157, P2211; DORFMAN SF, 1985, MT SINAI J MED, V52, P248; Fleiss JL, 1981, STAT METHODS RATES P, P218; GERSHON AA, 1976, PEDIATRICS, V58, P692; Hardy I R, 1990, Infect Dis Clin North Am, V4, P159; LIAO SJ, 1954, AM J HYG, V59, P273, DOI 10.1093/oxfordjournals.aje.a119640; LONGFIELD JN, 1990, ARCH INTERN MED, V150, P970, DOI 10.1001/archinte.150.5.970; MARKOWITZ LE, 1990, NEW ENGL J MED, V322, P580, DOI 10.1056/NEJM199003013220903; MARKOWITZ LE, 1990, PEDIATR INFECT DIS J, V9, P101, DOI 10.1097/00006454-199002000-00008; MCKINNEY WP, 1989, AM J INFECT CONTROL, V17, P26, DOI 10.1016/S0196-6553(89)80009-4; Melnick JL, 1979, DIAGNOSTIC PROCEDURE, V5th, P471; MUMM AH, 1990, PROGRAM ABSTRACTS PR; MURRAY DL, 1988, AM J PUBLIC HEALTH, V78, P836, DOI 10.2105/AJPH.78.7.836; NEUMANN PW, 1985, J CLIN MICROBIOL, V22, P296, DOI 10.1128/JCM.22.2.296-298.1985; NKOWANE BM, 1987, JAMA-J AM MED ASSOC, V257, P1335, DOI 10.1001/jama.257.10.1335; Orenstein W A, 1986, Dev Biol Stand, V65, P75; PAUL JR, 1964, AM J HYG, V80, P286, DOI 10.1093/oxfordjournals.aje.a120477; SHASBY DM, 1977, NEW ENGL J MED, V296, P585, DOI 10.1056/NEJM197703172961102; SHEHAB Z, 1983, J INFECT DIS, V148, P472; STRASSBURG MA, 1984, INFECT CONT HOSP EP, V5, P123, DOI 10.1017/S019594170005997X; Wharton M, 1990, Infect Dis Clin North Am, V4, P47; 1989, PEDIATRICS, V84, P1110; 1990, GUIDE ADULT IMMUNIZA; 1988, MMWR, V37, P527; 1989, MMWR, V38, P101; 1985, REV INFECT IDS, V7, pS177; 1990, MMWR, V38, P35; 1983, 1980 CENSUS POPULATI; 1988, IOM8804 NAT AC SCI I; 1989, MMWR, V38, P1; 1990, MMWR, V39, P353; 1991, MMWR, V40, P93	42	119	121	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 20	1991	266	19					2724	2729		10.1001/jama.266.19.2724	http://dx.doi.org/10.1001/jama.266.19.2724			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GP691	1942425				2022-12-24	WOS:A1991GP69100028
J	MULLER, F; WICKY, C; SPICHER, A; TOBLER, H				MULLER, F; WICKY, C; SPICHER, A; TOBLER, H			NEW TELOMERE FORMATION AFTER DEVELOPMENTALLY REGULATED CHROMOSOMAL BREAKAGE DURING THE PROCESS OF CHROMATIN DIMINUTION IN ASCARIS-LUMBRICOIDES	CELL			English	Article							GERM-LINE; DNA; SEQUENCE; ORGANIZATION; GENOME	During the process of chromatin diminution, which takes place in all presomatic cells of the early Ascaris embryo, the heterochromatic termini of the chromosomes are lost. Here we show that the newly formed ends of the reduced somatic chromosomes carry tandem repeats of the telomeric sequence TTAGGC. Comparison of a cloned somatic telomere with the corresponding germline chromosomal region revealed that these telomeric repeats are not present at or near the chromosomal breakage site. They are most likely added by a telomerase-mediated event. Chromosomal breakage, which precedes the telomere addition process, takes place within a short, specific chromosomal region (CBR); however, it does not occur at a single locus, but rather at many different sites. Altogether, our data show that chromatin diminution in Ascaris is a complex molecular process that includes site-specific chromosomal breakage, new telomere formation, and DNA degradation.			MULLER, F (corresponding author), UNIV FRIBOURG,INST ZOOL,CH-1700 FRIBOURG,SWITZERLAND.			Wicky, Chantal/0000-0002-0034-4992				AEBY P, 1986, EMBO J, V5, P3353, DOI 10.1002/j.1460-2075.1986.tb04650.x; ALLSHIRE RC, 1988, NATURE, V332, P656, DOI 10.1038/332656a0; BACK E, 1984, NUCLEIC ACIDS RES, V12, P1313, DOI 10.1093/nar/12.3.1313; BAROIN A, 1987, NUCLEIC ACIDS RES, V15, P1717, DOI 10.1093/nar/15.4.1717; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; Boveri T., 1910, ZUGLEICHEIN BEITRAG, P131; Boveri T, 1887, ANAT ANZEIGER, V2, P688; BOWERI T, 1910, ANAT ANZEIGER, V3, P131; ETTER A, 1991, P NATL ACAD SCI USA, V88, P1593, DOI 10.1073/pnas.88.5.1593; FORNEY JD, 1988, MOL CELL BIOL, V8, P251, DOI 10.1128/MCB.8.1.251; GREIDER CW, 1990, BIOESSAYS, V12, P363, DOI 10.1002/bies.950120803; Maniatis T., 1982, MOL CLONING; MORITZ KB, 1976, NATURE, V259, P55, DOI 10.1038/259055a0; MULLER F, 1982, NUCLEIC ACIDS RES, V10, P7493, DOI 10.1093/nar/10.23.7493; PIMPINELLI S, 1989, TRENDS GENET, V5, P310, DOI 10.1016/0168-9525(89)90114-5; PONZI M, 1985, EMBO J, V4, P2991, DOI 10.1002/j.1460-2075.1985.tb04034.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TARTOF KD, 1991, CELL, V65, P201, DOI 10.1016/0092-8674(91)90153-P; TOBLER H, 1972, DEV BIOL, V27, P190, DOI 10.1016/0012-1606(72)90097-8; TOBLER H, 1985, EXPERIENTIA, V41, P1311, DOI 10.1007/BF01952073; TOBLER H, 1986, CELL DIFFER, V13, P2; YAO MC, 1990, CELL, V63, P763, DOI 10.1016/0092-8674(90)90142-2; Yao MC, 1989, MOBILE DNA, P715; ZAKIAN VA, 1989, ANNU REV GENET, V23, P579, DOI 10.1146/annurev.genet.23.1.579	24	116	131	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 15	1991	67	4					815	822		10.1016/0092-8674(91)90076-B	http://dx.doi.org/10.1016/0092-8674(91)90076-B			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GQ407	1934070				2022-12-24	WOS:A1991GQ40700018
J	BURROWS, A				BURROWS, A			THE MAN WHO DIDNT KNOW HE HAD CANCER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 13	1991	266	18					2550	2550						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GN660	1942391				2022-12-24	WOS:A1991GN66000009
J	VANTWUYVER, E; MOOIJAART, RJD; TENBERGE, IJM; VANDERHORST, AR; WILMINK, JM; KAST, WM; MELIEF, CJM; DEWAAL, LP				VANTWUYVER, E; MOOIJAART, RJD; TENBERGE, IJM; VANDERHORST, AR; WILMINK, JM; KAST, WM; MELIEF, CJM; DEWAAL, LP			PRETRANSPLANTATION BLOOD-TRANSFUSION REVISITED	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LYMPHOCYTE-T PRECURSORS; CLASS-II DISPARITY; H-2 CLASS-I; TRANSPLANTATION TOLERANCE; ADULT MICE; ALLOGRAFT ENHANCEMENT; CELL REPERTOIRE; INDUCTION; CYCLOSPORINE; RECIPIENTS	Background. Blood transfusion before organ transplantation has a beneficial effect on allograft survival; the mechanism of this effect has remained a mystery. In murine models, the presence of common histocompatibility antigens in the blood donor and the recipient favors the induction of allograft tolerance. Methods. To investigate the effect of HLA compatibility between blood donor and recipient on the induction of allograft tolerance, we determined the relative frequency of cytotoxic T-lymphocyte precursors specific for donor cells before and at several times after blood transfusion in 23 patients awaiting a first renal transplant. We correlated the results with the presence of shared HLA antigens. Results. T-cell nonresponsiveness against donor cells developed after blood transfusion in 10 of the 23 patients. Tolerance developed only if the blood donor and the recipient had one HLA haplotype or at least one HLA-B and one HLA-DR antigen in common (as was observed in 9 of these 10 patients). Tolerance developed relatively late after blood transfusion (one to two months) and was long-lasting. No decline in the T-cell response against donor alloantigens was observed in any of the 13 patients who received transfusions without having HLA-antigen compatibility with the donor. Conclusions. Blood transfusion in which there is a common HLA haplotype or shared HLA-B and HLA-DR antigens induces tolerance to donor antigens. This finding may lead to the development of new strategies with which to induce tolerance for transplantation after blood transfusion. Perhaps transplant donors will be selected not only by HLA-antigen matching, but also on the basis of acceptable HLA-antigen mismatches associated with T-cell non-responsiveness induced by selected blood transfusion.	NETHERLANDS RED CROSS,BLOOD TRANSFUS SERV,CENT LAB,PUBLICAT SECRETARIAT,POB 9406,1006 AK AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,EXPTL & CLIN IMMUNOL LAB,AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,ACAD MED CTR,DEPT INTERNAL MED,RENAL TRANSPLANT UNIT,1105 AZ AMSTERDAM,NETHERLANDS; LEIDEN UNIV HOSP,DEPT IMMUNOHEMATOL,2333 AA LEIDEN,NETHERLANDS; LEIDEN UNIV HOSP,DEPT BLOOD BANK,2333 AA LEIDEN,NETHERLANDS	University of Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University Medical Center (LUMC)				Kast, W Martin/0000-0003-2321-3159				BREURVRIESENDORP BS, 1990, HUM IMMUNOL, V27, P1, DOI 10.1016/0198-8859(90)90091-3; DEWAAL LP, 1991, CRIT REV IMMUNOL, V10, P417; HEEG K, 1990, J EXP MED, V172, P719, DOI 10.1084/jem.172.3.719; HENON P, 1991, LANCET, P961; HERZOG WR, 1987, TRANSPLANTATION, V43, P384, DOI 10.1097/00007890-198703000-00013; IRSCHICK E, 1989, TRANSPLANTATION, V48, P986, DOI 10.1097/00007890-198912000-00018; KAMINSKI E, 1989, TRANSPLANTATION, V48, P608; KAST WM, 1988, EUR J IMMUNOL, V18, P2105; LAGAAIJ EL, 1989, NEW ENGL J MED, V321, P701, DOI 10.1056/NEJM198909143211101; LAZDA VA, 1990, TRANSPLANTATION, V49, P1084, DOI 10.1097/00007890-199006000-00011; LEIVESTAD T, 1984, TRANSPLANTATION, V37, P175, DOI 10.1097/00007890-198402000-00012; MAYUMI H, 1989, J EXP MED, V169, P213, DOI 10.1084/jem.169.1.213; MCCARTHY DM, 1984, CRC CR REV CL LAB SC, V20, P1; OPELZ G, 1987, TRANSPLANT P, V19, P149; QIN SX, 1989, J EXP MED, V169, P779, DOI 10.1084/jem.169.3.779; SALVATIERRA O, 1987, TRANSPL P, V19, P160; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; SHARABI Y, 1989, J EXP MED, V169, P493, DOI 10.1084/jem.169.2.493; SHARROCK CEM, 1990, IMMUNOL TODAY, V11, P281, DOI 10.1016/0167-5699(90)90113-N; VANDEKERCKHOVE BAE, 1989, TRANSPLANTATION, V48, P672; VANROOD JJ, 1990, SCIENCE, V248, P1388, DOI 10.1126/science.1972596; VANTWUYVER E, 1989, TRANSPLANTATION, V48, P844; VANTWUYVER E, 1990, EUR J IMMUNOL, V20, P441, DOI 10.1002/eji.1830200232; 1988, LANCET, V1, P567	24	176	180	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 24	1991	325	17					1210	1213		10.1056/NEJM199110243251704	http://dx.doi.org/10.1056/NEJM199110243251704			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GL282	1922208				2022-12-24	WOS:A1991GL28200004
J	ALBERTI, KGMM				ALBERTI, KGMM			THE HEALTH OF THE NATION - RESPONSES - ROLE OF DIABETES	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PREVALENCE				ALBERTI, KGMM (corresponding author), UNIV NEWCASTLE UPON TYNE, DEPT MED, NEWCASTLE UPON TYNE NE2 4HH, ENGLAND.							ANDERSEN AR, 1983, DIABETOLOGIA, V25, P496; [Anonymous], 1988, DIABETES, V37, P1574, DOI 10.2337/diabetes.37.11.15742903105; CAMPBELL I, 1991, DIABETIC MED, V8, P3, DOI 10.1111/j.1464-5491.1991.tb01507.x; CULLINAN TR, 1982, DIABETOLOGIA, V23, P504; DCCT Res Grp, 1987, DIABETES CARE, V10, P1; DOWSE GK, 1991, DIABETES CARE, V14, P271, DOI 10.2337/diacare.14.4.271; GALE EAM, 1981, DIABETOLOGIA, V21, P25, DOI 10.1007/BF03216218; HELMRICH SP, 1991, NEW ENGL J MED, V325, P147, DOI 10.1056/NEJM199107183250302; HOME PD, IN PRESS DIABETES AN; MARSHALL SM, 1989, Q J MED, V70, P61; MATHER HM, 1985, BRIT MED J, V291, P1081, DOI 10.1136/bmj.291.6502.1081; MILLER LV, 1972, NEW ENGL J MED, V286, P1388, DOI 10.1056/NEJM197206292862605; MOGENSEN CE, 1988, DIABETES ANN 4, P411; NEIL HAW, 1987, DIABETIC MED, V4, P539, DOI 10.1111/j.1464-5491.1987.tb00926.x; POTTER J, 1982, BRIT MED J, V285, P1180, DOI 10.1136/bmj.285.6349.1180; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; SCULPHER MJ, 1991, DIABETIC MED, V8, P644, DOI 10.1111/j.1464-5491.1991.tb01671.x; TUNBRIDGE WMG, 1981, LANCET, V2, P569; Williams D R, 1985, Diabet Med, V2, P27; 1989, VINCENT DECLARATION; 1983, DIABETOLOGIA, V24, P404; [No title captured]; 1985, PROVISION MED CARE A; 1991, CM1523; 1988, DIABETIC MED, V5, P79	25	6	6	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 28	1991	303	6805					769	772		10.1136/bmj.303.6805.769	http://dx.doi.org/10.1136/bmj.303.6805.769			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG981	1932942	Bronze, Green Published			2022-12-24	WOS:A1991GG98100027
J	BARKER, DJP; GODFREY, KM; FALL, C; OSMOND, C; WINTER, PD; SHAHEEN, SO				BARKER, DJP; GODFREY, KM; FALL, C; OSMOND, C; WINTER, PD; SHAHEEN, SO			RELATION OF BIRTH-WEIGHT AND CHILDHOOD RESPIRATORY-INFECTION TO ADULT LUNG-FUNCTION AND DEATH FROM CHRONIC OBSTRUCTIVE AIRWAYS DISEASE	BRITISH MEDICAL JOURNAL			English	Article							AIR-FLOW OBSTRUCTION; POCKET SPIROMETER; WHOOPING-COUGH; CHILDREN; BRONCHIOLITIS; BRONCHITIS; INFANCY	Objective - To examine whether birth weight, infant weight, and childhood respiratory infection are associated with adult lung function and death from chronic obstructive airways disease. Design - Follow up study of men born during 1911-30 whose birth weights, weights at 1 year, and childhood illnesses were recorded at the time by health visitors. Setting - Hertfordshire, England. Subjects - 5718 men born in the county during 1911-30 and a subgroup of 825 men born in the county during 1920-30 and still living there. Main outcome measures - Death from chronic obstructive airways disease, mean forced expiratory volume in one second (FEV1) and forced vital capacity (FVC), and respiratory symptoms. Results - 55 men died of chronic obstructive airways disease. Death rates fell with increasing birth weight and weight at 1 year. Mean FEV1 at age 59 to 70 years, adjusted for height and age, rose by 0.06 litre (95% confidence interval 0.02 to 0.09) with each pound (450 g) increase in birth weight, independently of smoking habit and social class. Bronchitis or pneumonia in infancy was associated with a 0.17 litre (0.02 to 0.32) reduction in adult FEV1 and with an increased odds ratio of wheezing and persistent sputum production in adult life independently of birth weight, smoking habit, and social class. Whooping cough in infancy was associated with a 0.22 litre (0.02 to 0.42) reduction in adult FEV1.			BARKER, DJP (corresponding author), UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,MRC,ENVIRONM EPIDEMIOL UNIT,SOUTHAMPTON S09 4XY,ENGLAND.			Godfrey, Keith/0000-0002-4643-0618; Osmond, Clive/0000-0002-9054-4655	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BARKER DJP, 1986, BRIT MED J, V293, P1271, DOI 10.1136/bmj.293.6557.1271; BOCK GR, 1991, CIBA F S, V156; Breslow N, 1980, STATISTICAL METHODS, V32; BRITTEN N, 1987, BRIT MED J, V294, P1317, DOI 10.1136/bmj.294.6583.1317; BRITTEN N, 1986, BRIT MED J, V292, P441, DOI 10.1136/bmj.292.6518.441; BUCHER U., 1961, THORAX, V16, P207, DOI 10.1136/thx.16.3.207; CHAN KN, 1989, ARCH DIS CHILD, V64, P1284, DOI 10.1136/adc.64.9.1284; CHEN Y, 1989, LANCET, V2, P54; DAVIS DL, 1991, LANCET, V337, P123; FLETCHER C, 1977, BMJ-BRIT MED J, V1, P1645, DOI 10.1136/bmj.1.6077.1645; GUNAWARDENA KA, 1987, THORAX, V42, P689, DOI 10.1136/thx.42.9.689; HALLIDAY JL, 1928, MRC SPECIAL REPORT S, V120; HOSIE HE, 1988, ANAESTHESIA, V43, P233; JOHNSTON IDA, 1983, LANCET, V2, P1104; KATTAN M, 1977, PEDIATRICS, V59, P683; MCCALL MG, 1968, J CHRON DIS, V21, P349, DOI 10.1016/0021-9681(68)90043-X; MOK JYQ, 1984, ARCH DIS CHILD, V59, P306, DOI 10.1136/adc.59.4.306; OSMOND C, 1990, SERIES DS, V9; PETO R, 1983, AM REV RESPIR DIS, V128, P491, DOI 10.1164/arrd.1983.128.3.491; PULLAN CR, 1982, BRIT MED J, V284, P1665, DOI 10.1136/bmj.284.6330.1665; REID DD, 1969, P ROY SOC MED, V62, P311, DOI 10.1177/003591576906200401; REID DD, 1971, BRIT MED BULL, V27, P59, DOI 10.1093/oxfordjournals.bmb.a070816; ROWLAND MGM, 1988, AM J CLIN NUTR, V47, P134, DOI 10.1093/ajcn/47.1.134; THJURLBECK WM, 1982, THORAX, V37, P564; WINICK M, 1966, J NUTR, V89, P300, DOI 10.1093/jn/89.3.300; 1985, BMJ, V290, P1937; 1986, QUESTIONNAIRE RESPIR	27	604	618	1	20	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 21	1991	303	6804					671	675		10.1136/bmj.303.6804.671	http://dx.doi.org/10.1136/bmj.303.6804.671			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG980	1912913	Green Published, Bronze			2022-12-24	WOS:A1991GG98000017
J	DELVAL, M; SCHLICHT, HJ; RUPPERT, T; REDDEHASE, MJ; KOSZINOWSKI, UH				DELVAL, M; SCHLICHT, HJ; RUPPERT, T; REDDEHASE, MJ; KOSZINOWSKI, UH			EFFICIENT PROCESSING OF AN ANTIGENIC SEQUENCE FOR PRESENTATION BY MHC CLASS-I MOLECULES DEPENDS ON ITS NEIGHBORING RESIDUES IN THE PROTEIN	CELL			English	Article							HEPATITIS-B VIRUS; CYTOLYTIC LYMPHOCYTE-T; IMMEDIATE-EARLY PROTEIN-PP89; RECOMBINANT VACCINIA VIRUS; INFLUENZA HEMAGGLUTININ; VIRAL PEPTIDES; CORE PROTEIN; CELL-SURFACE; RECOGNITION; GENE	Processing of endogenously synthesized proteins generates short peptides that are presented by MHC class I molecules to CD8 T lymphocytes. Here it is documented that not only the sequence of the presented peptide but also the residues by which it is flanked in the protein determine the efficiency of processing and presentation. This became evident when a viral sequence of proven antigenicity was inserted at different positions into an unrelated carrier protein. Not different peptides, but different amounts of the antigenic insert itself were retrieved by isolation of naturally processed peptides from cells expressing the different chimeric proteins. Low yield of antigenic peptide from an unfavorable integration site could be overcome by flanking the insert with oligo-alanine to space it from disruptive neighboring sequences. Notably, the degree of protection against lethal virus disease related directly to the amount of naturally processed antigenic peptide.			DELVAL, M (corresponding author), UNIV ULM, DEPT VIROL, ALBERT EINSTEIN ALLEE 11, W-7900 ULM, GERMANY.		Ruppert, Thomas/AAC-2467-2021; Del Val, Margarita/E-4769-2010	Ruppert, Thomas/0000-0001-9152-2266; Del Val, Margarita/0000-0001-6769-4279; Reddehase, Matthias/0000-0002-3509-7573				BRACIALE TJ, 1987, J EXP MED, V166, P678, DOI 10.1084/jem.166.3.678; CHIMINI G, 1989, J EXP MED, V169, P297, DOI 10.1084/jem.169.1.297; COLBEREGARAPIN F, 1981, J MOL BIOL, V150, P1, DOI 10.1016/0022-2836(81)90321-1; DELISI C, 1985, P NATL ACAD SCI USA, V82, P7048, DOI 10.1073/pnas.82.20.7048; DELVAL M, 1988, J VIROL, V62, P3965, DOI 10.1128/JVI.62.11.3965-3972.1988; DELVAL M, 1989, CELL, V58, P305, DOI 10.1016/0092-8674(89)90845-3; DELVAL M, 1991, J VIROL, V65, P3641, DOI 10.1128/JVI.65.7.3641-3646.1991; FALK K, 1990, NATURE, V348, P248, DOI 10.1038/348248a0; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; GANEM D, 1987, ANNU REV BIOCHEM, V56, P651, DOI 10.1146/annurev.biochem.56.1.651; JONJIC S, 1988, J VIROL, V62, P1653; JUNKER M, 1987, NUCLEIC ACIDS RES, V15, P10117, DOI 10.1093/nar/15.24.10117; KEIL GM, 1987, J VIROL, V61, P1901, DOI 10.1128/JVI.61.6.1901-1908.1987; NASSAL M, 1988, GENE, V66, P279, DOI 10.1016/0378-1119(88)90364-2; OU JH, 1986, P NATL ACAD SCI USA, V83, P1578, DOI 10.1073/pnas.83.6.1578; PARHAM P, 1990, NATURE, V348, P674, DOI 10.1038/348674a0; PONTA H, 1985, EMBO J, V4, P3447, DOI 10.1002/j.1460-2075.1985.tb04103.x; REDDEHASE MJ, 1989, NATURE, V337, P651, DOI 10.1038/337651a0; REDDEHASE MJ, 1991, EUR J IMMUNOL, V21, P1697, DOI 10.1002/eji.1830210717; ROTHBARD JB, 1988, EMBO J, V7, P93, DOI 10.1002/j.1460-2075.1988.tb02787.x; ROTZSCHKE O, 1990, SCIENCE, V249, P283, DOI 10.1126/science.1695760; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; SCHLICHT HJ, 1989, J VIROL, V63, P5399, DOI 10.1128/JVI.63.12.5399-5404.1989; SCHLICHT HJ, 1991, J VIROL, V65, P3489, DOI 10.1128/JVI.65.7.3489-3495.1991; TOWNSEND A, 1988, J EXP MED, V168, P1211, DOI 10.1084/jem.168.4.1211; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X; TOWNSEND ARM, 1986, NATURE, V324, P575, DOI 10.1038/324575a0; VANBLEEK GM, 1990, NATURE, V348, P213; VOLKMER H, 1987, J EXP MED, V166, P668, DOI 10.1084/jem.166.3.668; YEWDELL JW, 1990, CELL, V62, P203, DOI 10.1016/0092-8674(90)90356-J	32	237	242	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 20	1991	66	6					1145	1153		10.1016/0092-8674(91)90037-Y	http://dx.doi.org/10.1016/0092-8674(91)90037-Y			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GG552	1913805	Green Published			2022-12-24	WOS:A1991GG55200009
J	NIGHTINGALE, SL				NIGHTINGALE, SL			NEW REQUIREMENTS PROPOSED FOR PANCREATIC-ENZYME PRODUCTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							FED REGISTER, V56, P32282	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 18	1991	266	11					1482	1482						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GE458	1880875				2022-12-24	WOS:A1991GE45800004
J	BRADLEY, SF; TERPENNING, MS; RAMSEY, MA; ZARINS, LT; JORGENSEN, KA; SOTTILE, WS; SCHABERG, DR; KAUFFMAN, CA				BRADLEY, SF; TERPENNING, MS; RAMSEY, MA; ZARINS, LT; JORGENSEN, KA; SOTTILE, WS; SCHABERG, DR; KAUFFMAN, CA			METHICILLIN-RESISTANT STAPHYLOCOCCUS-AUREUS - COLONIZATION AND INFECTION IN A LONG-TERM CARE FACILITY	ANNALS OF INTERNAL MEDICINE			English	Article						METHICILLIN RESISTANCE; STAPHYLOCOCCUS-AUREUS; LONG-TERM CARE; COST BENEFIT ANALYSIS; CROSS INFECTION	NURSING-HOME; NOSOCOMIAL INFECTIONS; UNITED-STATES; OUTBREAK; ERADICATION; EPIDEMIC; CARRIAGE; REHABILITATION; CIPROFLOXACIN; MUPIROCIN	Objective: To assess methicillin-resistant Staphylococcus aureus (MRSA) colonization, transmission, and infection over a 1-year period in a long-term care facility with endemic MRSA. Design: Monthly surveillance for MRSA colonization of nares, perineum, rectum, and wounds. Setting: Long-term care facility attached to an acute care Veterans Affairs medical center. Patients: All 341 patients in the facility had monthly surveillance cultures for 1 year. Outcome Measurements: Colonization and infection with MRSA. Main Results: The monthly MRSA colonization rate was 23% +/- 1.0%; colonization occurred most commonly in the nares and wounds. Poor functional status was associated with MRSA colonization. Most patients (65%) never acquired MRSA; 25% of patients were already colonized at admission to the facility or at the start of the study, and only 10% of newly admitted patients acquired MRSA while in the facility. These latter patients acquired several different strains in a pattern of acquisition similar to that generally seen within the facility. In the course of 1 year, only nine patients who acquired MRSA had a roommate with the same phage type; no clustering was evident, and none of these patients developed infection. Nine other patients (3%) developed MRSA infection; five of these patients required hospitalization, but none died as a result of infection. Conclusions: In the long-term care facility in which our study took place, MRSA was endemic, and the infection rate was low. In such settings, the cost effectiveness of aggressive management of MRSA (wide-spread screening for MRSA and eradication with antimicrobial agents) needs to be assessed.	UNIV MICHIGAN, SCH MED, ANN ARBOR, MI 48104 USA; MICHIGAN DEPT PUBL HLTH, HOUGHTON, MI 49931 USA	University of Michigan System; University of Michigan	BRADLEY, SF (corresponding author), DEPT VET AFFAIRS MED CTR, 2215 FULLER RD, ANN ARBOR, MI 48105 USA.							AEILTS GD, 1982, J CLIN MICROBIOL, V16, P218, DOI 10.1128/JCM.16.2.218-223.1982; BARTZOKAS CA, 1984, NEW ENGL J MED, V311, P1422, DOI 10.1056/NEJM198411293112207; BITAR CM, 1987, INFECT CONT HOSP EP, V8, P15, DOI 10.1017/S0195941700066935; BOYCE JM, 1982, INFECT CONT HOSP EP, V3, P377, DOI 10.1017/S0195941700057337; BOYCE JM, 1981, INFECT CONT HOSP EP, V2, P110, DOI 10.1017/S0195941700053881; BOYCE JM, 1990, INFECT CONT HOSP EP, V11, P639; CEDERNA JE, 1990, INFECT CONT HOSP EP, V11, P13, DOI 10.1086/646072; COOKSON B, 1989, J CLIN MICROBIOL, V27, P1471, DOI 10.1128/JCM.27.7.1471-1476.1989; CROSSLEY K, 1979, J INFECT DIS, V139, P280, DOI 10.1093/infdis/139.3.280; DAUM TE, 1990, ANTIMICROB AGENTS CH, V34, P1862, DOI 10.1128/AAC.34.9.1862; GARNER JS, 1988, AM J INFECT CONTROL, V16, P128, DOI 10.1016/0196-6553(88)90053-3; HALEY RW, 1982, ANN INTERN MED, V97, P297, DOI 10.7326/0003-4819-97-3-297; HSU CCS, 1988, ARCH INTERN MED, V148, P569, DOI 10.1001/archinte.148.3.569; KAUFFMAN CA, 1990, INFECT CONT HOSP EP, V11, P600; LINNEMANN CC, 1990, 3RD P DEC INT C NOS; MAKI DG, 1990, 3RD P DEC INT C NOS; MUDER RR, 1991, ANN INTERN MED, V114, P107, DOI 10.7326/0003-4819-114-2-1-107; MULLIGAN ME, 1987, AM J MED, V82, P215; MURRAYLEISURE KA, 1990, INFECT CONT HOSP EP, V11, P343; OTOOLE RD, 1970, J AMER MED ASSOC, V213, P257, DOI 10.1001/jama.213.2.257; PEACOCK JE, 1980, ANN INTERN MED, V93, P526, DOI 10.7326/0003-4819-93-4-526; PENINGTON GR, 1982, AUST NZ J SURG, V52, P534, DOI 10.1111/j.1445-2197.1982.tb06047.x; PREHEIM LC, 1987, INFECT CONT HOSP EP, V8, P191, DOI 10.1017/S0195941700065929; RAHMAN M, 1989, EPIDEMIOL INFECT, V102, P261, DOI 10.1017/S0950268800029939; REAGAN DR, 1991, ANN INTERN MED, V114, P101, DOI 10.7326/0003-4819-114-2-101; REBOLI AC, 1990, INFECT CONT HOSP EP, V11, P291, DOI 10.1086/646174; REBOLI AC, 1989, AM J DIS CHILD, V143, P34, DOI 10.1001/archpedi.1989.02150130044013; RUTALA WA, 1983, J CLIN MICROBIOL, V18, P683, DOI 10.1128/JCM.18.3.683-688.1983; SMITH PB, 1972, STAPHYLOCOCCI, P431; STORCH GA, 1987, INFECT CONT HOSP EP, V8, P24, DOI 10.1017/S0195941700066947; STRAUSBAUGH LJ, 1991, INFECT CONT HOSP EP, V12, P36, DOI 10.2307/30147087; THOMAS JC, 1989, INFECT CONT HOSP EP, V10, P106, DOI 10.1086/645976; THOMPSON RL, 1982, ANN INTERN MED, V97, P309, DOI 10.7326/0003-4819-97-3-309; THORNSBERRY C, 1983, J CLIN MICROBIOL, V18, P1084, DOI 10.1128/JCM.18.5.1084-1091.1983; WARD TT, 1981, INFECT CONT HOSP EP, V2, P453, DOI 10.1017/S0195941700055715; YU VL, 1986, NEW ENGL J MED, V315, P91, DOI 10.1056/NEJM198607103150204	36	243	246	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1991	115	6					417	422		10.7326/0003-4819-115-6-417	http://dx.doi.org/10.7326/0003-4819-115-6-417			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GE810	1908198				2022-12-24	WOS:A1991GE81000001
J	EGGER, M; SMITH, GD; IMHOOF, H; TEUSCHER, A				EGGER, M; SMITH, GD; IMHOOF, H; TEUSCHER, A			RISK OF SEVERE HYPOGLYCEMIA IN INSULIN TREATED DIABETIC-PATIENTS TRANSFERRED TO HUMAN INSULIN - A CASE CONTROL STUDY	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RARE DISEASE ASSUMPTION; PORCINE INSULIN; HYPOGLYCEMIA UNAWARENESS; AWARENESS	Objective - To examine whether transfer from animal insulin to human insulin is associated with an increased risk of severe hypoglycaemia. Design - Matched case-control study of insulin treated diabetic patients admitted to hospital because of hypoglycaemia during 1984-7, the period when human insulin was introduced into treatment. Setting - Case admissions and control admissions were obtained from eight public hospitals within the Swiss canton of Berne and a second control group comprised members of the Bernese section of the Swiss Diabetes Association. Subjects - 94 patients with insulin treated diabetes with a total of 112 admissions for hypoglycaemia during 1984-7 (case admissions), 182 patients with insulin treated diabetes seen in the same hospitals for reasons other than hypoglycaemia with a total of 225 admissions (control admissions), and 86 insulin treated diabetic patients who were members of the Bernese section of the Swiss Diabetes Association. Main outcome measures - Type of insulin used at time of admission, glycaemic control as measured by amount of glycated haemoglobin or glucose concentration; severity of hypoglycaemia. Results - Treatment with human insulin at admission was more common in cases than controls (52/112 (46%) admissions v 77/225 (34%); p = 0.003). 116 out of 129 (90%) of admissions taking human insulin had been transferred from animal insulin, mainly because of non-availability of porcine insulins. The ratio of rate of hypoglycaemia in those taking human insulin to the rate in those taking animal insulin was 2.4 (95% confidence interval 1.3 to 4.4). Other risk factors for hypoglycaemia were a history of hypoglycaemic coma (rate ratio of history to no history 3.8, 2.3 to 6.4) and good glycaemic control (rate ratio of good to poor control 3.9, 1.4 to 7.5). With multivariate analysis the increase in rate ratio associated with use of human insulin rose to 3.0 (1.4 to 6.4). Comparison with the diabetes association controls also showed an increased risk associated with use of human insulin (2.2; 1.1 to 4.8). Conclusions - Transfer of treatment from animal insulin to human insulin was associated with an increased risk of severe hypoglycaemia. Caution should be exercised when transferring diabetic patients to human insulin. Further studies are required to elucidate why this effect occurs,	UNIV BERN, DEPT MED, DIABET SECT, CH-3000 BERN, SWITZERLAND; UNIV LONDON LONDON SCH HYG & TROP MED, DEPT EPIDEMIOL & POPULAT SCI, LONDON WC1E 7HT, ENGLAND	University of Bern; University of London; London School of Hygiene & Tropical Medicine			Davey Smith, George/A-7407-2013	Davey Smith, George/0000-0002-1407-8314; Egger, Matthias/0000-0001-7462-5132				BERGER W, 1989, LANCET, V1, P1041, DOI 10.1016/S0140-6736(89)92444-6; BERGER WG, 1987, DIABETES CARE, V10, P260, DOI 10.2337/diacare.10.2.260; CASPARIE AF, 1985, DIABETES CARE, V8, P141, DOI 10.2337/diacare.8.2.141; CLARK AJL, 1982, LANCET, V2, P354; CRYER PE, 1990, DIABETES CARE, V13, P536, DOI 10.2337/diacare.13.5.536; DCCT Res Grp, 1987, DIABETES CARE, V10, P1; DCCT Res Grp, 1990, DIABETES CARE, V13, P427; EGGER M, 1988, DIABETOLOGIA, V31, P453, DOI 10.1007/BF00271592; EGGER M, 1991, BMJ-BRIT MED J, V303, P622, DOI 10.1136/bmj.303.6803.622; GORDEN P, 1990, NEW ENGL J MED, V322, P1007; GREENLAND S, 1982, AM J EPIDEMIOL, V116, P547, DOI 10.1093/oxfordjournals.aje.a113439; HEINE RJ, 1989, LANCET, V2, P946; HEPBURN DA, 1989, DIABETIC MED, V6, P586, DOI 10.1111/j.1464-5491.1989.tb01233.x; Home P D, 1984, Diabet Med, V1, P93; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; NIULSSON A, 1988, ACTA MED SCAND, V224, P257; PEACOCK I, 1983, LANCET, V1, P149; PHILLIPS AN, IN PRESS J CLIN EPID; POTTER J, 1982, BRIT MED J, V285, P1180, DOI 10.1136/bmj.285.6349.1180; RIFKIN H, 1988, PHYSICIANS GUIDE NON; RODRIGUES L, 1990, INT J EPIDEMIOL, V19, P205, DOI 10.1093/ije/19.1.205; SACKETT DL, 1979, J CHRON DIS, V32, P51, DOI 10.1016/0021-9681(79)90012-2; SCHLESSELMAN JJ, 1974, AM J EPIDEMIOL, V99, P381, DOI 10.1093/oxfordjournals.aje.a121625; SMITH GD, 1990, J EPIDEMIOL COMMUN H, V44, P257, DOI 10.1136/jech.44.4.257; STEPHENSON J, 1990, LANCET, V335, P661, DOI 10.1016/0140-6736(90)90448-E; TEUSCHER A, 1987, LANCET, V2, P382; 1983, PROJEKTBESCHRIEB DIA; 1986, BMJ, V292, P155	28	48	48	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 14	1991	303	6803					617	621		10.1136/bmj.303.6803.617	http://dx.doi.org/10.1136/bmj.303.6803.617			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GF675	1932902	Bronze, Green Published			2022-12-24	WOS:A1991GF67500022
J	SHAW, J; HOLLOWAY, J				SHAW, J; HOLLOWAY, J			WHO IS YOUR GENERAL-PRACTITIONER	BRITISH MEDICAL JOURNAL			English	Article											SHAW, J (corresponding author), PRESTWICH HOSP,REG SECURE UNIT,SALFORD,ENGLAND.			shaw, jennifer/0000-0003-2569-7687				BLUEGLASS R, 1983, GUIDE MENTAL HLTH AC	1	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 14	1991	303	6803					628	628		10.1136/bmj.303.6803.628	http://dx.doi.org/10.1136/bmj.303.6803.628			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GF675	1932906	Bronze, Green Published			2022-12-24	WOS:A1991GF67500026
J	MEISTERERNST, M; ROY, AL; LIEU, HM; ROEDER, RG				MEISTERERNST, M; ROY, AL; LIEU, HM; ROEDER, RG			ACTIVATION OF CLASS-II GENE-TRANSCRIPTION BY REGULATORY FACTORS IS POTENTIATED BY A NOVEL ACTIVITY	CELL			English	Article							RNA POLYMERASE-II; MAJOR LATE PROMOTER; IMMEDIATE EARLY PROTEIN; TATA BINDING-PROTEIN; SACCHAROMYCES-CEREVISIAE; FUNCTIONAL DOMAINS; UPSTREAM ELEMENT; FACTOR USF; INITIATION; INVITRO	A novel activity (USA) stimulated activator-dependent transcription in a reconstituted system in conjunction with natural TFIID, resulting in 10- to 50-fold levels of induction by regulatory factors. USA mediated a modest induction by USF in conjunction with either recombinant human TFIID, intact yeast TFIID, or the evolutionarily conserved C-terminal portion of yeast TFIID. Upon further purification, USA was resolved into two components that had opposite effects on core promoter activity and that in combination potentiated activator function. Gel mobility shift experiments indicated physical interactions between the inhibitory activity and TFIID, suggesting that the additional components (cofactors) associate with the preinitiation complex both to reduce promoter activity in the absence and to increase promoter activity in the presence of transcriptional activators.			MEISTERERNST, M (corresponding author), ROCKEFELLER UNIV,BIOCHEM & MOLEC BIOL LAB,NEW YORK,NY 10021, USA.				NATIONAL CANCER INSTITUTE [R35CA042567] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI027397] Funding Source: NIH RePORTER; NCI NIH HHS [CA42567] Funding Source: Medline; NIAID NIH HHS [AI27397] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABMAYR SM, 1988, GENE DEV, V2, P542, DOI 10.1101/gad.2.5.542; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BERGER SL, 1990, CELL, V61, P1199, DOI 10.1016/0092-8674(90)90684-7; BITTER GA, 1983, ANAL BIOCHEM, V128, P294, DOI 10.1016/0003-2697(83)90378-0; BROWN DD, 1984, CELL, V37, P359, DOI 10.1016/0092-8674(84)90366-0; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; CORMACK BP, 1991, CELL, V65, P341, DOI 10.1016/0092-8674(91)90167-W; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; EISENMANN DM, 1989, CELL, V58, P1183, DOI 10.1016/0092-8674(89)90516-3; FLANAGAN PM, 1991, NATURE, V350, P436, DOI 10.1038/350436a0; GASCH A, 1990, NATURE, V346, P390, DOI 10.1038/346390a0; GILL G, 1991, CELL, V65, P333, DOI 10.1016/0092-8674(91)90166-V; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; HAHN S, 1989, CELL, V58, P1173, DOI 10.1016/0092-8674(89)90515-1; HAN M, 1988, CELL, V55, P1137, DOI 10.1016/0092-8674(88)90258-9; HAWLEY DK, 1985, J BIOL CHEM, V260, P8163; HIMMELFARB HJ, 1990, CELL, V63, P1299, DOI 10.1016/0092-8674(90)90425-E; HOEY T, 1990, CELL, V61, P1179, DOI 10.1016/0092-8674(90)90682-5; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; HOFFMANN A, 1990, GENE DEV, V4, P1141, DOI 10.1101/gad.4.7.1141; HORIKOSHI M, 1988, CELL, V54, P665, DOI 10.1016/S0092-8674(88)80011-4; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; HORIKOSHI M, 1989, NATURE, V341, P299, DOI 10.1038/341299a0; HORIKOSHI M, 1990, CELL, V61, P1172; JACKSON SP, 1989, P NATL ACAD SCI USA, V86, P1781, DOI 10.1073/pnas.86.6.1781; JONES KA, 1986, SCIENCE, V232, P755, DOI 10.1126/science.3008338; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; KATO H, 1991, SCIENCE, V251, P1476, DOI 10.1126/science.2006421; KELLEHER RJ, 1990, CELL, V61, P1209, DOI 10.1016/0092-8674(90)90685-8; KIM WY, 1988, J BIOL CHEM, V263, P18880; KNEZETIC JA, 1986, CELL, V45, P95, DOI 10.1016/0092-8674(86)90541-6; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; MEISTERERNST M, 1990, P NATL ACAD SCI USA, V87, P9153, DOI 10.1073/pnas.87.23.9153; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MIYAMOTO NG, 1985, EMBO J, V4, P3563, DOI 10.1002/j.1460-2075.1985.tb04118.x; MUHICH ML, 1990, P NATL ACAD SCI USA, V87, P9148, DOI 10.1073/pnas.87.23.9148; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PINA B, 1990, CELL, V60, P719, DOI 10.1016/0092-8674(90)90087-U; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; REDDY P, 1991, CELL, V65, P349, DOI 10.1016/0092-8674(91)90168-X; REINBERG D, 1987, J BIOL CHEM, V262, P3322; ROSEN CA, 1985, CELL, V41, P813, DOI 10.1016/S0092-8674(85)80062-3; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; SUMIMOTO H, 1990, P NATL ACAD SCI USA, V87, P9158, DOI 10.1073/pnas.87.23.9158; VANDYKE MW, 1989, MOL CELL BIOL, V9, P342, DOI 10.1128/MCB.9.1.342; WORKMAN JL, 1988, CELL, V55, P211, DOI 10.1016/0092-8674(88)90044-X; WORKMAN JL, 1987, CELL, V51, P613, DOI 10.1016/0092-8674(87)90130-9; WORKMAN JL, 1990, EMBO J, V9, P1299, DOI 10.1002/j.1460-2075.1990.tb08239.x	58	280	285	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 6	1991	66	5					981	993		10.1016/0092-8674(91)90443-3	http://dx.doi.org/10.1016/0092-8674(91)90443-3			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GE460	1889091				2022-12-24	WOS:A1991GE46000016
J	NUNEZ, G; HOCKENBERY, D; MCDONNELL, TJ; SORENSEN, CM; KORSMEYER, SJ				NUNEZ, G; HOCKENBERY, D; MCDONNELL, TJ; SORENSEN, CM; KORSMEYER, SJ			BCL-2 MAINTAINS B-CELL MEMORY	NATURE			English	Article							ANTIGEN-DRIVEN SELECTION; IMMUNOLOGICAL MEMORY; GERMINAL-CENTERS; BONE-MARROW; SECONDARY; EXPRESSION; SURVIVAL; MICE; POPULATION; RESPONSES	THE number of lymphocytes in an animal is remarkably constant despite antigen-driven proliferation and a high rate of B-cell lymphopoiesis. This reflects the relatively brief lifespan of many newly generated B cells and argues for a well-regulated death mechanism 1-3. Even so, a secondary immune response can be generated years after a primary exposure to antigen 4. Antigen that might restimulate B cells persists for extended periods on follicular dendritic cells in the light zone of germinal centres 5-13. Antigen binding B cells have also been found months after the end of obvious cell division 14. The precise signal that enables certain B cells to emerge as long-term surviving memory cells 14-17 is unknown. Bcl-2, an inner mitochondrial membrane protein 18, blocks programmed cell death in B cells 18-20. We report here that this proto-oncogene maintains immune responsiveness. Transgenic mice overproducing Bcl-2 have a long-term persistence of immunoglobulin-secreting cells and an extended lifetime for memory B cells.	WASHINGTON UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MOLEC MICROBIOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	NUNEZ, G (corresponding author), WASHINGTON UNIV,SCH MED,HOWARD HUGHES MED INST,ST LOUIS,MO 63110, USA.		Nuñez, Gabriel/A-7160-2014					BEREK C, 1987, EUR J IMMUNOL, V17, P1121, DOI 10.1002/eji.1830170808; CELADA F, 1967, J EXP MED, V125, P199, DOI 10.1084/jem.125.2.199; COICO RF, 1983, J IMMUNOL, V131, P2254; COLLE JH, 1988, EUR J IMMUNOL, V18, P1307, DOI 10.1002/eji.1830180902; FLIEDNER TM, 1964, ANN NY ACAD SCI, V113, P578, DOI 10.1111/j.1749-6632.1964.tb40692.x; FORSTER I, 1990, P NATL ACAD SCI USA, V87, P4781, DOI 10.1073/pnas.87.12.4781; GOWANS JL, 1966, J EXP MED, V124, P1017, DOI 10.1084/jem.124.5.1017; GRANINGER WB, 1987, J CLIN INVEST, V80, P1512, DOI 10.1172/JCI113235; GRAY D, 1988, J EXP MED, V167, P805, DOI 10.1084/jem.167.3.805; GRAY D, 1988, NATURE, V336, P70, DOI 10.1038/336070a0; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOCKENBERY DM, IN PRESS P NATN ACAD; KLAUS GGB, 1980, IMMUNOL REV, V53, P3, DOI 10.1111/j.1600-065X.1980.tb01038.x; KOSKO MH, 1989, IMMUNOLOGY, V68, P312; KRAAL G, 1982, NATURE, V298, P377, DOI 10.1038/298377a0; KRAAL G, 1988, CELL IMMUNOL, V115, P78, DOI 10.1016/0008-8749(88)90163-3; LINTON PJ, 1989, CELL, V59, P1049, DOI 10.1016/0092-8674(89)90761-7; LIU YJ, 1989, NATURE, V342, P929, DOI 10.1038/342929a0; MACLENNAN ICM, 1986, IMMUNOL REV, V91, P61, DOI 10.1111/j.1600-065X.1986.tb01484.x; MCDONNELL TJ, 1990, MOL CELL BIOL, V10, P1901, DOI 10.1128/MCB.10.5.1901; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; NUNEZ G, 1990, J IMMUNOL, V144, P3602; OPSTELTEN D, 1983, J IMMUNOL, V131, P2635; PEZELLA F, 1990, AM J PATHOL, V137, P225; SCHITTEK B, 1990, NATURE, V346, P749, DOI 10.1038/346749a0; SIEKEVITZ M, 1987, CELL, V48, P757, DOI 10.1016/0092-8674(87)90073-0; TEW TG, 1979, IMMUNOLOGY, V37, P69; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0	28	213	216	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 5	1991	353	6339					71	73		10.1038/353071a0	http://dx.doi.org/10.1038/353071a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GD805	1908951				2022-12-24	WOS:A1991GD80500060
J	ACSADI, G; DICKSON, G; LOVE, DR; JANI, A; WALSH, FS; GURUSINGHE, A; WOLFF, JA; DAVIES, KE				ACSADI, G; DICKSON, G; LOVE, DR; JANI, A; WALSH, FS; GURUSINGHE, A; WOLFF, JA; DAVIES, KE			HUMAN DYSTROPHIN EXPRESSION IN MDX MICE AFTER INTRAMUSCULAR INJECTION OF DNA CONSTRUCTS	NATURE			English	Article							MUSCLE; MOUSE; INVIVO; TRANSFECTION; MYOPATHY; PROTEIN; REPEAT	DUCHENNE'S muscular dystrophy (DMD), which affects one in 3,500 males, causes progressive myopathy of skeletal and cardiac muscles and premature death 1. One approach to treatment would be to introduce the normal dystrophin gene into diseased muscle cells. When pure plasmid DNA is injected into rodent skeletal 2 or cardiac muscle 3-5, the cells express reporter genes. We now show that a 12-kilobase full-length human dystrophin complementary DNA gene and a 6.3-kilobase Becker-like gene 6 can be expressed in cultured cells and in vivo. When the human dystrophin expression plasmids are injected intramuscularly into dystrophin-deficient mdx mice, the human dystrophin proteins are present in the cytoplasm and sarcolemma of approximately 1% of the myofibres. Myofibres expressing human dystrophin contain an increased proportion of peripheral nuclei. The results indicate that transfer of the dystrophin gene into the myofibres of DMD patients could be beneficial, but a larger number of genetically modified myofibres will be necessary for clinical efficacy.	UNIV WISCONSIN,WAISMAN CTR MENTAL RETARDAT & HUMAN DEV,DEPT PEDIAT,MADISON,WI 53706; UNIV WISCONSIN,WAISMAN CTR MENTAL RETARDAT & HUMAN DEV,DEPT MED GENET,MADISON,WI 53706; UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,GUYS HOSP,DEPT EXPTL PATHOL,LONDON SE1 9RT,ENGLAND; JOHN RADCLIFFE HOSP,INST MOLEC MED,MOLEC GENET GRP,OXFORD OX3 9DU,ENGLAND	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; University of Oxford				Love, Donald/0000-0003-4669-8769				ACSADI G, 1991, NEW BIOL, V3, P71; COULTON GR, 1988, NEUROPATH APPL NEURO, V14, P53, DOI 10.1111/j.1365-2990.1988.tb00866.x; DICKSON G, IN PRESS HUMAN GENET; ELLIS JM, 1990, LANCET, V336, P881, DOI 10.1016/0140-6736(90)92392-U; ENGLAND SB, 1990, NATURE, V343, P180, DOI 10.1038/343180a0; ERVASTI JM, 1990, NATURE, V345, P315, DOI 10.1038/345315a0; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FORREST S M, 1988, Genomics, V2, P109, DOI 10.1016/0888-7543(88)90091-2; FRITZ JD, 1989, ANAL BIOCHEM, V180, P205, DOI 10.1016/0003-2697(89)90116-4; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; HOFFMAN EP, 1990, J NEUROL SCI, V99, P9, DOI 10.1016/0022-510X(90)90195-S; KARPATI G, 1989, AM J PATHOL, V135, P27; KITSIS RN, 1991, P NATL ACAD SCI USA, V88, P4138, DOI 10.1073/pnas.88.10.4138; KOENIG M, 1990, J BIOL CHEM, V265, P4560; KOENIG M, 1988, CELL, V53, P219, DOI 10.1016/0092-8674(88)90383-2; LEE CC, 1991, NATURE, V349, P334, DOI 10.1038/349334a0; LIDOV HGW, 1990, NATURE, V348, P725, DOI 10.1038/348725a0; LIN H, 1990, CIRCULATION, V82, P2217, DOI 10.1161/01.CIR.82.6.2217; LOVE DR, 1991, P NATL ACAD SCI USA, V88, P3243, DOI 10.1073/pnas.88.8.3243; MORGAN JE, 1990, J CELL BIOL, V111, P2437, DOI 10.1083/jcb.111.6.2437; NORTON PA, 1985, MOL CELL BIOL, V5, P281, DOI 10.1128/MCB.5.2.281; OHLENDIECK K, 1991, J CELL BIOL, V112, P135, DOI 10.1083/jcb.112.1.135; PARTRIDGE TA, 1989, NATURE, V337, P176, DOI 10.1038/337176a0; TANABE Y, 1986, ACTA NEUROPATHOL, V69, P91, DOI 10.1007/BF00687043; TORRES LFB, 1987, BRAIN, V110, P269, DOI 10.1093/brain/110.2.269; WANG AM, 1990, PCR PROTOCOLS GUIDE, P70; WESSEL HB, 1990, PEDIATR NEUROL, V6, P3, DOI 10.1016/0887-8994(90)90071-8; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918; WOLFF JA, IN PRESS BIOTECHNIQU	30	391	498	0	14	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 29	1991	352	6338					815	818		10.1038/352815a0	http://dx.doi.org/10.1038/352815a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC964	1881437				2022-12-24	WOS:A1991GC96400064
J	LEE, JY; GOLDFARB, A				LEE, JY; GOLDFARB, A			LAC REPRESSOR ACTS BY MODIFYING THE INITIAL TRANSCRIBING COMPLEX SO THAT IT CANNOT LEAVE THE PROMOTER	CELL			English	Article							COLI RNA-POLYMERASE; LAC UV5 PROMOTER; RIBONUCLEIC-ACID POLYMERASE; TRANSCRIPTION INITIATION; TERNARY COMPLEXES; CHAIN ELONGATION; LACTOSE OPERON; SIGMA-SUBUNIT; INVITRO; PROTEIN	RNA polymerase engaged in the joint complex with the lac repressor at the lac UV5 promoter cannot escape into elongation but generates abortive RNA oligomers. The joint complex actively transcribes a few initial base pairs in a reaction unusually sensitive to a decrease in the substrate concentration. The joint complex, however, fails to traverse a point in the initial transcribed sequence that normally requires a high concentration of the elongating substrate. Thus, the repressor acts by augmenting a natural high "k(NTP)" site (pause site) embedded in the promoter. A lethal RNA polymerase mutation that mimics the effect of the repressor leads to an analogous block of promoter clearance and shortened abortive product pattern on several promoters, reflecting the widespread occurrence of high k(NTP) sites in promoters.			LEE, JY (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,DEPT MICROBIOL,NEW YORK,NY 10032, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030717] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM30717] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CAHMBERLIN MJ, 1974, ANN REV BIOCH, V43, P721; CARPOUSIS AJ, 1985, J MOL BIOL, V183, P165, DOI 10.1016/0022-2836(85)90210-4; CARPOUSIS AJ, 1980, BIOCHEMISTRY-US, V19, P3245, DOI 10.1021/bi00555a023; CHAN PT, 1989, J BIOL CHEM, V264, P21277; CHEN B, 1971, NATURE-NEW BIOL, V233, P67, DOI 10.1038/newbio233067a0; De Crombrugghe B, 1971, Nat New Biol, V231, P139; GILBERT W, 1966, P NATL ACAD SCI USA, V56, P1891, DOI 10.1073/pnas.56.6.1891; GRALLA JD, 1980, BIOCHEMISTRY-US, V19, P5864, DOI 10.1021/bi00566a031; GRIBSKOV M, 1983, GENE, V26, P109, DOI 10.1016/0378-1119(83)90180-4; GUIDIRONTANI C, 1985, J MOL BIOL, V186, P527, DOI 10.1016/0022-2836(85)90127-5; HANSEN UM, 1980, J BIOL CHEM, V255, P9564; IWABE N, 1991, J MOL EVOL, V32, P70, DOI 10.1007/BF02099931; JACOB F, 1961, J MOL BIOL, V3, P318, DOI 10.1016/S0022-2836(61)80072-7; JOHNSTON DE, 1976, RNA POLYM, P101; KAMMERER W, 1986, EMBO J, V5, P2995, DOI 10.1002/j.1460-2075.1986.tb04597.x; KASSAVETIS GA, 1981, J BIOL CHEM, V256, P2777; KRUMMEL B, 1989, BIOCHEMISTRY-US, V28, P7829, DOI 10.1021/bi00445a045; LEE JY, 1991, P NATL ACAD SCI USA, V88, P6018, DOI 10.1073/pnas.88.14.6018; LEVIN JR, 1987, J MOL BIOL, V196, P61, DOI 10.1016/0022-2836(87)90511-0; MAJORS J, 1975, P NATL ACAD SCI USA, V72, P4394, DOI 10.1073/pnas.72.11.4394; MALAN TP, 1984, CELL, V39, P173, DOI 10.1016/0092-8674(84)90203-4; MALIK S, 1984, J BIOL CHEM, V4259, P13292; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; MENENDEZ M, 1987, EMBO J, V6, P4227, DOI 10.1002/j.1460-2075.1987.tb02771.x; METZGER W, 1989, EMBO J, V8, P2745, DOI 10.1002/j.1460-2075.1989.tb08416.x; Miller J. H., 1980, OPERON; PACE HC, 1990, P NATL ACAD SCI USA, V87, P1870, DOI 10.1073/pnas.87.5.1870; RHODES G, 1974, J BIOL CHEM, V249, P6675; ROZOVSKAYA TA, 1982, FEBS LETT, V137, P100, DOI 10.1016/0014-5793(82)80323-2; SCHMIDT MC, 1984, BIOCHEMISTRY-US, V23, P197, DOI 10.1021/bi00297a004; SCHMITZ A, 1979, NUCLEIC ACIDS RES, V6, P111, DOI 10.1093/nar/6.1.111; SPASSKY A, 1984, EMBO J, V3, P43, DOI 10.1002/j.1460-2075.1984.tb01759.x; STRANEY SB, 1987, CELL, V51, P699, DOI 10.1016/0092-8674(87)90093-6; STRANEY SB, 1987, BIOCHEMISTRY-US, V26, P5063, DOI 10.1021/bi00390a027; VONHIPPEL PH, 1984, ANNU REV BIOCHEM, V53, P389, DOI 10.1146/annurev.bi.53.070184.002133; YAGER TD, 1987, ESCHERICHIA COLI SAL, P1242; ZALENSKAYA K, 1990, GENE, V89, P7, DOI 10.1016/0378-1119(90)90199-2	37	67	68	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 23	1991	66	4					793	798		10.1016/0092-8674(91)90122-F	http://dx.doi.org/10.1016/0092-8674(91)90122-F			6	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GC745	1878972				2022-12-24	WOS:A1991GC74500017
J	SONG, WC; BRASH, AR				SONG, WC; BRASH, AR			PURIFICATION OF AN ALLENE OXIDE SYNTHASE AND IDENTIFICATION OF THE ENZYME AS A CYTOCHROME-P-450	SCIENCE			English	Article							MICROSOMAL CYTOCHROME-P-450; HYDROPEROXIDE ISOMERASE; MARINE PROSTANOIDS; PLEXAURA-HOMOMALLA; LINOLENIC ACID; BIOSYNTHESIS; CYCLASE; CORAL; LIPOXYGENASE; METABOLISM	Fatty acid hydroperoxides (lipoxygenase products) are metabolized to allene oxides by a type of dehydrase that has been detected in plants, corals, and starfish oocytes. The allene oxides are unstable epoxide precursors of more complex products such as jasmonic acid, the plant growth hormone. Characterization of the dehydrase enzyme of flaxseed revealed that it is a 55-kilodalton hemoprotein. The spectral characteristics of this dehydrase revealed it to be a cytochrome P-450. It operates with the remarkable activity of greater-than-or-equal-to 1000 turnovers per second. The results establish a new catalytic activity for a cytochrome P-450 and illustrate the cooperation of different oxygenases in pathways of fatty acid metabolism.	VANDERBILT UNIV,MED CTR,SCH MED,DEPT PHARMACOL,NASHVILLE,TN 37232	Vanderbilt University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035275] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-35275] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAERTSCHI SW, 1988, BIOCHEMISTRY-US, V27, P18, DOI 10.1021/bi00401a004; BLACK SD, 1986, CYTOCHROME P 450 STR, pCH6; BRASH AR, 1989, J AM CHEM SOC, V111, P1891, DOI 10.1021/ja00187a060; BRASH AR, 1987, J BIOL CHEM, V262, P15829; BRASH AR, UNPUB; CAMP RL, 1968, J AM CHEM SOC, V90, P7349, DOI 10.1021/ja01028a032; CHAN TH, 1978, J ORG CHEM, V43, P2994, DOI 10.1021/jo00409a013; CHAN TH, 1980, TETRAHEDRON, V36, P2269, DOI 10.1016/0040-4020(80)80123-2; COREY EJ, 1987, J AM CHEM SOC, V109, P289, DOI 10.1021/ja00235a053; COREY EJ, 1988, TETRAHEDRON LETT, V29, P2555, DOI 10.1016/S0040-4039(00)86110-9; CRANDALL JK, 1968, J HETEROCYCLIC CHEM, V6, P777; CROMBIE L, 1988, J CHEM SOC CHEM COMM, P558, DOI 10.1039/c39880000558; GROSSMAN S, 1983, BIOCHIM BIOPHYS ACTA, V572, P65; GUENGERICH FP, 1990, CRIT REV BIOCHEM MOL, V25, P97; HAMBERG M, 1988, BIOCHEM BIOPH RES CO, V156, P543, DOI 10.1016/S0006-291X(88)80876-3; HAMBERG M, 1990, ARCH BIOCHEM BIOPHYS, V276, P518, DOI 10.1016/0003-9861(90)90753-L; HAMBERG M, 1987, BIOCHIM BIOPHYS ACTA, V920, P76, DOI 10.1016/0005-2760(87)90313-4; HAUGEN DA, 1976, J BIOL CHEM, V251, P7929; HIGASHI K, 1985, AGR BIOL CHEM TOKYO, V49, P2399, DOI 10.1080/00021369.1985.10867084; IWASAKI M, 1991, J BIOL CHEM, V266, P3380; JEFCOATE CR, 1969, BIOCHEMISTRY-US, V8, P3464, DOI 10.1021/bi00836a050; PETERSON JA, 1971, ARCH BIOCHEM BIOPHYS, V144, P678, DOI 10.1016/0003-9861(71)90375-4; VICK BA, 1981, PLANT PHYSIOL, V67, P92, DOI 10.1104/pp.67.1.92; VICK BA, 1987, PLANT PHYSIOL, V85, P1073, DOI 10.1104/pp.85.4.1073; VICK BA, 1983, BIOCHEM BIOPH RES CO, V111, P470, DOI 10.1016/0006-291X(83)90330-3; VICK BA, 1970, PLANT PHYSIOL, V46, P445; ZIMMERMAN DC, 1978, LIPIDS, V13, P313, DOI 10.1007/BF02533720; ZIMMERMAN DC, 1966, BIOCHEM BIOPH RES CO, V23, P398, DOI 10.1016/0006-291X(66)90740-6	28	232	241	1	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 16	1991	253	5021					781	784		10.1126/science.1876834	http://dx.doi.org/10.1126/science.1876834			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GB295	1876834				2022-12-24	WOS:A1991GB29500035
J	OHASHI, PS; OEHEN, S; BUERKI, K; PIRCHER, H; OHASHI, CT; ODERMATT, B; MALISSEN, B; ZINKERNAGEL, RM; HENGARTNER, H				OHASHI, PS; OEHEN, S; BUERKI, K; PIRCHER, H; OHASHI, CT; ODERMATT, B; MALISSEN, B; ZINKERNAGEL, RM; HENGARTNER, H			ABLATION OF TOLERANCE AND INDUCTION OF DIABETES BY VIRUS-INFECTION IN VIRAL-ANTIGEN TRANSGENIC MICE	CELL			English	Article								To address the mechanisms of tolerance to extrathymic proteins, we have generated transgenic mice expressing the lymphocytic choriomeningitis viral (LCMV) glycoprotein (GP) in the beta-islet cells of the pancreas. The fate of LCMV GP-specific T cells was followed by breeding the GP transgenic mice with T cell receptor transgenic mice, specific for LCMV and H-2D(b). These studies suggest that "peripheral tolerance" of self-reactive T cells does not involve clonal deletion, clonal anergy, or a decrease in the density of T cell receptors or accessory molecules. Instead, this model indicates that self-reactive cytotoxic T cells may remain functionally unresponsive, owing to a lack of appropriate T cell activation. Infection of transgenic mice with LCMV readily abolishes peripheral unresponsiveness to the self LCMV GP antigen, resulting in a CD8+ T cell-mediated diabetes. These data suggest that similar mechanisms may operate in several so-called "T cell-mediated autoimmune diseases."	SANDOZ PHARMA LTD, PRECLIN RES, CH-4002 BASEL, SWITZERLAND; CNRS, INSERM, CTR IMMUNOL, F-13288 MARSEILLE 9, FRANCE	Novartis; Sandoz; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)	OHASHI, PS (corresponding author), UNIV HOSP ZURICH, INST PATHOL, DEPT EXPTL PATHOL, CH-8091 ZURICH, SWITZERLAND.		; Malissen, Bernard/AAK-4659-2020	Ohashi, Pamela S./0000-0003-2915-9317; Malissen, Bernard/0000-0003-1340-9342				ABE R, 1988, NATURE, V335, P827, DOI 10.1038/335827a0; ADAMS TE, 1987, NATURE, V325, P223, DOI 10.1038/325223a0; AHMED R, 1988, J VIROL, V62, P2102, DOI 10.1128/JVI.62.6.2102-2106.1988; ALLISON J, 1988, NATURE, V333, P529, DOI 10.1038/333529a0; BAEKKESKOV S, 1981, P NATL ACAD SCI-BIOL, V78, P6456, DOI 10.1073/pnas.78.10.6456; BENDELAC A, 1987, J EXP MED, V166, P823, DOI 10.1084/jem.166.4.823; BERG LJ, 1989, NATURE, V340, P559, DOI 10.1038/340559a0; BLACKMAN MA, 1990, NATURE, V345, P540, DOI 10.1038/345540a0; BOHME J, 1989, SCIENCE, V244, P1179, DOI 10.1126/science.2499048; BOON T, 1989, IMMUNOGENETICS, V29, P75, DOI 10.1007/BF00395854; BRINSTER RL, 1981, CELL, V27, P223, DOI 10.1016/0092-8674(81)90376-7; Buchmeier M J, 1980, Adv Immunol, V30, P275, DOI 10.1016/S0065-2776(08)60197-2; BURKLY LC, 1990, SCIENCE, V248, P1364, DOI 10.1126/science.1694042; BURKLY LC, 1989, NATURE, V342, P564, DOI 10.1038/342564a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COBBOLD SP, 1984, NATURE, V312, P548, DOI 10.1038/312548a0; DIALYNAS DP, 1983, IMMUNOL REV, V74, P29, DOI 10.1111/j.1600-065X.1983.tb01083.x; FAUSTMAN D, 1980, J EXP MED, V151, P1563, DOI 10.1084/jem.151.6.1563; FERRICK DA, 1990, IMMUNOL REV, V118, P257, DOI 10.1111/j.1600-065X.1990.tb00819.x; FREI K, 1988, J EXP MED, V168, P449, DOI 10.1084/jem.168.1.449; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HANAHAN D, 1990, ANNU REV CELL BIOL, V6, P493, DOI 10.1146/annurev.cellbio.6.1.493; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; HANY M, 1989, EUR J IMMUNOL, V19, P417, DOI 10.1002/eji.1830190302; HASKINS K, 1984, J EXP MED, V160, P452, DOI 10.1084/jem.160.2.452; Hogan B., 1986, MANIPULATING MOUSE E; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KAPPLER JW, 1988, NATURE, V332, P35, DOI 10.1038/332035a0; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; KOURILSKY P, 1989, CELL, V56, P327, DOI 10.1016/0092-8674(89)90233-X; LAFFERTY KJ, 1983, ANNU REV IMMUNOL, V1, P143, DOI 10.1146/annurev.iy.01.040183.001043; LAMB JR, 1983, J EXP MED, V157, P1434, DOI 10.1084/jem.157.5.1434; LEDBETTER JA, 1979, IMMUNOL REV, V47, P63, DOI 10.1111/j.1600-065X.1979.tb00289.x; LEHMANNGRUBE F, 1971, VIROL MONOGR, V10, P1; LEIST TP, 1989, SCAND J IMMUNOL, V30, P679, DOI 10.1111/j.1365-3083.1989.tb02476.x; LIKE AA, 1982, SCIENCE, V216, P644, DOI 10.1126/science.7041259; LINDAHL P, 1973, P NATL ACAD SCI USA, V70, P2785, DOI 10.1073/pnas.70.10.2785; LO D, 1989, J EXP MED, V170, P87, DOI 10.1084/jem.170.1.87; LO D, 1988, CELL, V53, P159, DOI 10.1016/0092-8674(88)90497-7; MACDONALD HR, 1988, NATURE, V332, P40, DOI 10.1038/332040a0; MATZINGER P, 1989, NATURE, V338, P74, DOI 10.1038/338074a0; MILLER BJ, 1988, J IMMUNOL, V140, P52; MILLER J, 1990, J IMMUNOL, V144, P334; MILLER JFA, 1989, IMMUNOLOGY, V1, P137; MOMBURG F, 1986, J IMMUNOL, V136, P940; MORAHAN G, 1989, NATURE, V339, P622, DOI 10.1038/339622a0; MOSKOPHIDIS D, 1991, IN PRESS J VIROL; MURPHY KM, 1989, P NATL ACAD SCI USA, V86, P10034, DOI 10.1073/pnas.86.24.10034; NAGATA M, 1989, J IMMUNOL, V143, P1155; OHASHI PS, 1990, NATURE, V346, P861, DOI 10.1038/346861a0; PATERSON PY, 1960, J EXP MED, V111, P119, DOI 10.1084/jem.111.1.119; PIRCHER H, 1987, EUR J IMMUNOL, V17, P1843, DOI 10.1002/eji.1830171226; PIRCHER H, 1989, EMBO J, V8, P719, DOI 10.1002/j.1460-2075.1989.tb03431.x; PIRCHER H, 1990, NATURE, V346, P629, DOI 10.1038/346629a0; PIRCHER H, 1989, NATURE, V342, P559, DOI 10.1038/342559a0; PIRCHER H, 1987, EUR J IMMUNOL, V17, P159, DOI 10.1002/eji.1830170202; PUJOLBORRELL R, 1987, NATURE, V326, P304, DOI 10.1038/326304a0; PULLEN AM, 1988, NATURE, V335, P796, DOI 10.1038/335796a0; QIN SX, 1989, J EXP MED, V169, P779, DOI 10.1084/jem.169.3.779; RAMMENSEE HG, 1989, NATURE, V339, P541, DOI 10.1038/339541a0; RAMSDELL F, 1989, SCIENCE, V246, P1038, DOI 10.1126/science.2511629; ROBERTS JL, 1990, J EXP MED, V171, P935, DOI 10.1084/jem.171.3.935; ROMAN LM, 1990, CELL, V61, P383, DOI 10.1016/0092-8674(90)90521-F; ROSA F, 1984, IMMUNOL TODAY, V5, P261, DOI 10.1016/0167-5699(84)90135-X; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SARVETNICK N, 1988, CELL, V52, P773, DOI 10.1016/0092-8674(88)90414-X; SARVETNICK N, 1990, NATURE, V346, P844, DOI 10.1038/346844a0; SCHULZ M, 1989, EUR J IMMUNOL, V19, P1657, DOI 10.1002/eji.1830190921; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; SHA WC, 1988, NATURE, V336, P73, DOI 10.1038/336073a0; SPEISER DE, 1990, J EXP MED, V172, P1305, DOI 10.1084/jem.172.5.1305; TEH HS, 1989, J EXP MED, V169, P795, DOI 10.1084/jem.169.3.795; TOMONARI K, 1988, IMMUNOGENETICS, V28, P455, DOI 10.1007/BF00355379; WOOD PJ, 1987, J IMMUNOL, V139, P3236; ZAMVIL SS, 1990, ANNU REV IMMUNOL, V8, P579, DOI 10.1146/annurev.iy.08.040190.003051	75	1087	1093	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 19	1991	65	2					305	317		10.1016/0092-8674(91)90164-T	http://dx.doi.org/10.1016/0092-8674(91)90164-T			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FH092	1901764				2022-12-24	WOS:A1991FH09200013
J	OCONNOR, DW; POLLITT, PA; BROOK, CPB; REISS, BB; ROTH, M				OCONNOR, DW; POLLITT, PA; BROOK, CPB; REISS, BB; ROTH, M			DOES EARLY INTERVENTION REDUCE THE NUMBER OF ELDERLY PEOPLE WITH DEMENTIA ADMITTED TO INSTITUTIONS FOR LONG-TERM CARE	BRITISH MEDICAL JOURNAL			English	Article							MINI-MENTAL STATE; COMMUNITY; SERVICES; VALIDITY	Objective-To test whether early diagnosis and practical help reduce the number of elderly people with dementia admitted to institutions. Design-Controlled trial of effect of help from a multidisciplinary team on admission rates of people with dementia. Setting-Seven general practices in Cambridge. Subjects-2889 subjects aged 75 and over, of whom 159 were identified as having dementia with a two stage community survey. Eighty six subjects were referred for extra help if they or their supporters wished. The other 73 subjects had access to the usual services and served as controls. Intervention-Subjects and families in the action group were offered a wide range of help, including financial benefits, physical aids, home helps, respite admissions, practical advice, and psychiatric assessments. Main outcome measure-Permanent admission to long term care within two years after diagnosis. Results-Early intervention did not affect admission rates in subjects who lived with supporters. By contrast, nine of the 14 (64%) subjects with moderate or severe dementia living alone were admitted in the action group in the study's second year compared with only one of 13 (8%) controls (p = 0.004). Conclusions-Some people with moderate or severe dementia who lived alone and were at serious risk may have been identified earlier by the resource team. Without the team these people would not have become known to the responsible authorities until families, neighbours, and wardens became unable to cope. The study was conducted during the team's formative period, however, and greater experience might have allowed some subjects to remain at home for longer.	HUGHES HALL PROJECT LATER LIFE,CAMBRIDGE CB1 2EW,ENGLAND	University of Cambridge				O'Connor, Daniel/0000-0003-0188-1340				ASKHAM J, 1990, DEMENTIA HOME CARE; BLENKNER M, 1971, SOC CASEWORK-JCSW, V52, P483, DOI 10.1177/104438947105200801; BOAS JW, 1971, BRIT J RADIOL, V44, P122; BRANCH LG, 1982, AM J PUBLIC HEALTH, V72, P1373, DOI 10.2105/AJPH.72.12.1373; CARPENTER GI, 1990, BMJ-BRIT MED J, V300, P1253, DOI 10.1136/bmj.300.6734.1253; Challis D, 1986, CASE MANAGEMENT COMM; Challis D., 1990, CASE MANAGEMENT SOCI; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Gilleard C. J., 1984, LIVING DEMENTIA COMM; GODBER C, 1977, AGE AGEING, V6, P100; OCONNOR DW, 1989, INT J GERIATR PSYCH, V4, P203, DOI 10.1002/gps.930040405; OCONNOR DW, 1989, J PSYCHIAT RES, V23, P87, DOI 10.1016/0022-3956(89)90021-6; OCONNOR DW, 1989, ACTA PSYCHIAT SCAND, V79, P190, DOI 10.1111/j.1600-0447.1989.tb08587.x; OCONNOR DW, 1990, BRIT J PSYCHIAT, V156, P835, DOI 10.1192/bjp.156.6.835; OCONNOR DW, 1990, ACTA PSYCHIAT SCAND, V81, P78, DOI 10.1111/j.1600-0447.1990.tb06453.x; OCONNOR DW, 1989, INT J GERIATR PSYCH, V4, P339, DOI 10.1002/gps.930040607; OPIT LJ, 1977, BRIT MED J, V1, P30, DOI 10.1136/bmj.1.6052.30; Pollitt PA, 1989, AGEING SOC, V9, P261; ROTH M, 1986, BRIT J PSYCHIAT, V149, P698, DOI 10.1192/bjp.149.6.698; 1987, DIAGNOSTIC STATISTIC; 1989, CARING PEOPLE	21	66	66	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 13	1991	302	6781					871	875		10.1136/bmj.302.6781.871	http://dx.doi.org/10.1136/bmj.302.6781.871			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FG421	1902752	Bronze, Green Published			2022-12-24	WOS:A1991FG42100019
J	GORVEL, JP; CHAVRIER, P; ZERIAL, M; GRUENBERG, J				GORVEL, JP; CHAVRIER, P; ZERIAL, M; GRUENBERG, J			RAB5 CONTROLS EARLY ENDOSOME FUSION INVITRO	CELL			English	Article							GTP-BINDING PROTEINS; CELL-FREE SYSTEM; RECEPTOR-MEDIATED ENDOCYTOSIS; ENDOPLASMIC-RETICULUM; ONCOGENE PRODUCT; GOLGI-APPARATUS; PLASMA-MEMBRANE; YEAST YPT1; TRANSPORT; SECRETION	The small GTP-binding protein rab5 was previously localized on early endosomes and on the cytoplasmic face of the plasma membrane. Using a cell-free assay, we have now tested whether rab5 is involved in controlling an early endocytic fusion event. Fusion could be inhibited by cytosol containing the overexpressed mutant rab5IIe133, which does not bind GTP on blots, and by antibodies against rab5, but not against rab2 or rab7. In contrast, fusion was stimulated with cytosol containing overexpressed wild-type rab5. Cytosols containing high levels of rab2 or mutant rab5 with the 9 carboxy-terminal amino acids deleted, which bind GTP on blots, had no effects. Finally, the inhibition mediated by anti-rab5 antibodies could be overcome by complementing the assay with the cytosol containing wild-type rab5, but not with the same cytosol depleted of rab5, nor with cytosol containing the rab5 mutants or rab2. These in vitro finding strongly suggest that rab5 is involved in the process of early endosome fusion.			GORVEL, JP (corresponding author), EUROPEAN MOLEC BIOL LAB,POSTFACH 102209,W-6900 HEIDELBERG,GERMANY.		CHAVRIER, Philippe/B-4707-2010; Gorvel, Jean-Pierre/O-1332-2018; CHAVRIER, Philippe/AAG-2645-2020	CHAVRIER, Philippe/0000-0002-7351-733X; Gorvel, Jean-Pierre/0000-0002-2829-9804; CHAVRIER, Philippe/0000-0002-7351-733X				BAKER D, 1990, P NATL ACAD SCI USA, V87, P355, DOI 10.1073/pnas.87.1.355; BECKERS CJM, 1989, J CELL BIOL, V108, P1245, DOI 10.1083/jcb.108.4.1245; BEKCERS CJM, 1989, NATURE, V339, P397; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; BOMSEL M, 1990, CELL, V62, P719, DOI 10.1016/0092-8674(90)90117-W; BOURNE HR, 1988, CELL, V53, P669, DOI 10.1016/0092-8674(88)90081-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAELL WA, 1987, P NATL ACAD SCI USA, V84, P1137, DOI 10.1073/pnas.84.5.1137; BUCCI C, 1988, NUCLEIC ACIDS RES, V16, P9979, DOI 10.1093/nar/16.21.9979; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; CHAVRIER P, 1990, MOL CELL BIOL, V10, P6578, DOI 10.1128/MCB.10.12.6578; DAVEY J, 1985, CELL, V43, P643, DOI 10.1016/0092-8674(85)90236-3; DESCHENES RJ, 1987, MOL CELL BIOL, V7, P2344, DOI 10.1128/MCB.7.7.2344; DIAZ R, 1988, J BIOL CHEM, V263, P6093; DIAZ R, 1989, NATURE, V339, P398, DOI 10.1038/339398a0; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GALLWITZ D, 1983, NATURE, V306, P704, DOI 10.1038/306704a0; GODA Y, 1988, CELL, V55, P309, DOI 10.1016/0092-8674(88)90054-2; GOUD B, 1990, NATURE, V345, P553, DOI 10.1038/345553a0; GOUD B, 1988, CELL, V53, P753, DOI 10.1016/0092-8674(88)90093-1; GRIFFITHS G, 1988, CELL, V52, P329, DOI 10.1016/S0092-8674(88)80026-6; GRIFFITHS G, 1990, J CELL SCI, V95, P441; GRIFFITHS G, 1989, J CELL BIOL, V109, P2703, DOI 10.1083/jcb.109.6.2703; GRUENBERG J, 1987, P NATL ACAD SCI USA, V84, P5758, DOI 10.1073/pnas.84.16.5758; GRUENBERG J, 1989, J CELL BIOL, V108, P1301, DOI 10.1083/jcb.108.4.1301; GRUENBERG J, 1989, ANNU REV CELL BIOL, V5, P453; GRUENBERG JE, 1986, EMBO J, V5, P3091, DOI 10.1002/j.1460-2075.1986.tb04615.x; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HAUBRUCK H, 1987, EMBO J, V6, P4049, DOI 10.1002/j.1460-2075.1987.tb02750.x; HUBBARD AL, 1972, J CELL BIOL, V55, P390, DOI 10.1083/jcb.55.2.390; LEBIVIC A, 1989, P NATL ACAD SCI USA, V86, P9313; Maizel JV, 1971, METHOD VIROL, V5, P179; MALHOTRA V, 1988, CELL, V54, P221, DOI 10.1016/0092-8674(88)90554-5; MARSH M, 1986, P NATL ACAD SCI USA, V83, P2899, DOI 10.1073/pnas.83.9.2899; MATSUI Y, 1988, J BIOL CHEM, V263, P11071; MAYORGA LS, 1989, SCIENCE, V244, P1475, DOI 10.1126/science.2499930; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; MIZOGUCHI A, 1990, J BIOL CHEM, V265, P11872; MOLENAAR CMT, 1988, EMBO J, V7, P971, DOI 10.1002/j.1460-2075.1988.tb02903.x; NAKANO A, 1989, J CELL BIOL, V109, P2677, DOI 10.1083/jcb.109.6.2677; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PARTON RG, 1989, J CELL BIOL, V109, P3259, DOI 10.1083/jcb.109.6.3259; POLAKIS PG, 1989, J BIOL CHEM, V264, P16383; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; SCHMITT HD, 1986, CELL, V47, P401, DOI 10.1016/0092-8674(86)90597-0; SEGEV N, 1988, CELL, V52, P915, DOI 10.1016/0092-8674(88)90433-3; SEWELL JL, 1988, P NATL ACAD SCI USA, V85, P4620, DOI 10.1073/pnas.85.13.4620; STEARNS T, 1990, P NATL ACAD SCI USA, V87, P1238, DOI 10.1073/pnas.87.3.1238; TOOZE SA, 1990, NATURE, V347, P207, DOI 10.1038/347207a0; TOUCHOT N, 1987, P NATL ACAD SCI USA, V84, P8210, DOI 10.1073/pnas.84.23.8210; TUOMIKOSKI T, 1989, NATURE, V342, P942, DOI 10.1038/342942a0; VONFISCHER M, 1990, P NATL ACAD SCI USA, V87, P1988; WALWORTH NC, 1989, EMBO J, V8, P1685, DOI 10.1002/j.1460-2075.1989.tb03560.x; WILLUMSEN BM, 1984, EMBO J, V3, P2581, DOI 10.1002/j.1460-2075.1984.tb02177.x; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0; WOODMAN PG, 1988, EUR J BIOCHEM, V173, P101, DOI 10.1111/j.1432-1033.1988.tb13972.x; ZAHRAOUI A, 1989, J BIOL CHEM, V264, P12394	59	928	941	2	56	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 8	1991	64	5					915	925		10.1016/0092-8674(91)90316-Q	http://dx.doi.org/10.1016/0092-8674(91)90316-Q			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FA940	1900457				2022-12-24	WOS:A1991FA94000009
J	RORSMAN, P; BOKVIST, K; AMMALA, C; ARKHAMMAR, P; BERGGREN, PO; LARSSON, O; WAHLANDER, K				RORSMAN, P; BOKVIST, K; AMMALA, C; ARKHAMMAR, P; BERGGREN, PO; LARSSON, O; WAHLANDER, K			ACTIVATION BY ADRENALINE OF A LOW-CONDUCTANCE G- PROTEIN-DEPENDENT K+ CHANNEL IN MOUSE PANCREATIC B-CELLS	NATURE			English	Article							INSULIN-SECRETING CELLS; FREE CA-2+ CONCENTRATION; BETA-CELLS; SULFONYLUREAS; INHIBITION; GALANIN	INSULIN is produced and secreted by the B cells in the endocrine pancreas. In vivo, insulin secretion is under the control of a number of metabolic, neural and hormonal substances. It is now clear that stimulation of insulin release by fuel secretagogues, such as glucose, involves the closure of K+ channels that are sensitive ot the intracellular ATP concentration (K(ATP) channels)1. This leads to membrane depolarization and the generation of Ca2+-dependent action potentials2. The mechanisms whereby hormones and neurotransmitters such as adrenaline, galanin and somatostatin, which are released by intraislet nerve endings and the pancreatic D cells, produce inhibition of insulin secretion are not clear3. Here we show that adrenaline suppresses B-cell electrical activity (and thus insulin secretion) by a G protein-dependent mechanism, which culminates in the activation of a sulphonylurea-insensitive low-conductance K+ channel distinct from the K(ATP) channel.	KAROLINSKA INST,DEPT ENDOCRINOL,S-10401 STOCKHOLM 60,SWEDEN; KAROLINSKA INST,DEPT PHARMACOL,S-10401 STOCKHOLM 60,SWEDEN	Karolinska Institutet; Karolinska Institutet	RORSMAN, P (corresponding author), GOTHENBURG UNIV,DEPT MED PHYS,BOX 33031,S-40033 GOTHENBURG,SWEDEN.		Rorsman, Patrik/A-4331-2016	Rorsman, Patrik/0000-0001-7578-0767; Berggren, Per-Olof/0000-0001-8991-413X				ARKHAMMAR P, 1987, J BIOL CHEM, V262, P5448; ASHCROFT FM, 1990, BIOCHEM SOC T, V18, P109, DOI 10.1042/bst0180109; ASHCROFT FM, 1988, ANNU REV NEUROSCI, V11, P97, DOI 10.1146/annurev.neuro.11.1.97; BOKVIST K, 1990, J PHYSIOL-LONDON, V423, P327, DOI 10.1113/jphysiol.1990.sp018025; DEWEILLE J, 1988, P NATL ACAD SCI USA, V85, P1312; DUNNE MJ, 1989, EMBO J, V8, P413, DOI 10.1002/j.1460-2075.1989.tb03392.x; HENQUIN JC, 1984, EXPERIENTIA, V40, P1043, DOI 10.1007/BF01971450; HILLE B, 1984, IONIC CHANNELS EXCIT, P211; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; NILSSON T, 1988, J BIOL CHEM, V263, P1855; SCHMIDANTOMARCHI H, 1987, J BIOL CHEM, V262, P15840; SMITH PA, 1990, FEBS LETT, V261, P187, DOI 10.1016/0014-5793(90)80667-8; TRUBE G, 1986, PFLUG ARCH EUR J PHY, V407, P493, DOI 10.1007/BF00657506	13	122	126	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 3	1991	349	6304					77	79		10.1038/349077a0	http://dx.doi.org/10.1038/349077a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EQ601	1898674				2022-12-24	WOS:A1991EQ60100056
J	GRAY, WA; CAPONE, RJ; MOST, AS				GRAY, WA; CAPONE, RJ; MOST, AS			UNSUCCESSFUL EMERGENCY MEDICAL RESUSCITATION - ARE CONTINUED EFFORTS IN THE EMERGENCY DEPARTMENT JUSTIFIED	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HOSPITAL CARDIAC-ARREST; CARDIOPULMONARY RESUSCITATION; SURVIVAL; DEATH; DEFIBRILLATION; EXPERIENCE; OUTCOMES; CPR	Background. The majority of attempts to resuscitate victims of prehospital cardiopulmonary arrest are unsuccessful, and patients are frequently transported to the emergency department for further resuscitation efforts. We evaluated the efficacy and costs of continued hospital resuscitation for patients in whom resuscitation efforts outside the hospital have failed. Methods. We reviewed the records of 185 patients presenting to our emergency department after an initially unsuccessful, but ongoing, resuscitation for a prehospital arrest (cardiac, respiratory, or both) by an emergency medical team. Prehospital and hospital characteristics of treatment for the arrest were identified, and the patients' outcomes in the emergency room were ascertained. The hospital course and the hospital costs for the patients who were revived were determined. Results. Over a 19-month period, only 16 of the 185 patients (9 percent) were successfully resuscitated in the emergency department and admitted to the hospital. A shorter duration of prehospital resuscitation was the only characteristic of the resuscitation associated with an improved outcome in the emergency department. No patient survived until hospital discharge, and all but one were comatose throughout hospitalization. The mean stay in the hospital was 12.6 days (range, 1 to 132), with an average of 2.3 days (range, 1 to 11) in an intensive care unit. The total hospital cost for the 16 patients admitted was $180,908 (range per patient, $1,984 to $95,144). Conclusions. In general, continued resuscitation efforts in the emergency department tor victims of cardiopulmonary arrest in whom prehospital resuscitation has tailed are not worthwhile, and they consume precious institutional and economic resources without gain.	BROWN UNIV,PROGRAM MED,PROVIDENCE,RI 02912; UNIV ROCHESTER,MED CTR,DIV CARDIOL,ROCHESTER,NY 14642	Brown University; University of Rochester	GRAY, WA (corresponding author), RHODE ISL HOSP,DIV CARDIOL,593 EDDY ST,PROVIDENCE,RI 02903, USA.							APRAHAMIAN C, 1986, ANN EMERG MED, V15, P445, DOI 10.1016/S0196-0644(86)80185-8; BACHMAN JW, 1986, JAMA-J AM MED ASSOC, V256, P477, DOI 10.1001/jama.256.4.477; BEDELL SE, 1983, NEW ENGL J MED, V309, P569, DOI 10.1056/NEJM198309083091001; BLACKHALL LJ, 1987, NEW ENGL J MED, V317, P1281, DOI 10.1056/NEJM198711123172009; BRETT AS, 1986, NEW ENGL J MED, V315, P1347, DOI 10.1056/NEJM198611203152109; COBB LA, 1980, MOD CONC CARDIOV DIS, V49, P31; CUMMINS RO, 1985, AM J EMERG MED, V3, P114, DOI 10.1016/0735-6757(85)90032-4; CUMMINS RO, 1985, JAMA-J AM MED ASSOC, V253, P2408, DOI 10.1001/jama.253.16.2408; EINARSSON O, 1989, J INTERN MED, V225, P129, DOI 10.1111/j.1365-2796.1989.tb00052.x; EISENBERG M, 1979, AM J PUBLIC HEALTH, V69, P30, DOI 10.2105/AJPH.69.1.30; Hallstorm AP, 1983, EMERG HLTH SERV Q, V1, P41; HALLSTROM AP, 1985, CRIT CARE MED, V13, P927, DOI 10.1097/00003246-198511000-00019; KELLERMANN AL, 1988, ANN EMERG MED, V17, P589, DOI 10.1016/S0196-0644(88)80398-6; KOUWENHOVEN WB, 1960, JAMA-J AM MED ASSOC, V173, P1064, DOI 10.1001/jama.1960.03020280004002; McIntyre KM, 1983, TXB ADV CARDIAC LIFE; MURPHY DJ, 1989, ANN INTERN MED, V111, P199, DOI 10.7326/0003-4819-111-3-199; MYERBURG RJ, 1982, JAMA-J AM MED ASSOC, V247, P1485, DOI 10.1001/jama.247.10.1485; MYERBURG RJ, 1980, AM J MED, V68, P568, DOI 10.1016/0002-9343(80)90307-1; OROURKE PP, 1986, CRIT CARE MED, V14, P466, DOI 10.1097/00003246-198605000-00006; ROTH R, 1984, ANN EMERG MED, V13, P237, DOI 10.1016/S0196-0644(84)80470-9; SAPHIR R, 1968, MEDICINE, V47, P73, DOI 10.1097/00005792-196801000-00004; SCHNEIDERMAN LJ, 1990, ANN INTERN MED, V112, P949, DOI 10.7326/0003-4819-112-12-949; SHIMAZU S, 1983, J TRAUMA, V23, P213, DOI 10.1097/00005373-198303000-00006; STULTS KR, 1984, NEW ENGL J MED, V310, P219, DOI 10.1056/NEJM198401263100403; TAFFET GE, 1988, JAMA-J AM MED ASSOC, V260, P2069, DOI 10.1001/jama.260.14.2069; Talbott J., 1965, FUNDAMENTALS CARDIOP, P1; THOMPSON RG, 1979, ANN INTERN MED, V90, P437; TOMLINSON T, 1988, NEW ENGL J MED, V318, P43, DOI 10.1056/NEJM198801073180109; TRESCH DD, 1981, ARCH INTERN MED, V141, P1154, DOI 10.1001/archinte.141.9.1154; TWEED WA, 1984, CAN MED ASSOC J, V131, P429; WEAVER WD, 1976, CIRCULATION, V54, P895, DOI 10.1161/01.CIR.54.6.895; WEAVER WD, 1984, CIRCULATION, V69, P943, DOI 10.1161/01.CIR.69.5.943; WEAVER WD, 1988, NEW ENGL J MED, V319, P661, DOI 10.1056/NEJM198809153191101; WEAVER WD, 1986, ANN EMERG MED, V15, P1181; 1983, EUTHANASIA AIDING SU; 1980, JAMA-J AM MED ASSOC, V24, P453	36	202	204	1	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 14	1991	325	20					1393	1398		10.1056/NEJM199111143252001	http://dx.doi.org/10.1056/NEJM199111143252001			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GP524	1922249				2022-12-24	WOS:A1991GP52400001
J	JULIER, C; HYER, RN; DAVIES, J; MERLIN, F; SOULARUE, P; BRIANT, L; CATHELINEAU, G; DESCHAMPS, I; ROTTER, JI; FROGUEL, P; BOITARD, C; BELL, JI; LATHROP, GM				JULIER, C; HYER, RN; DAVIES, J; MERLIN, F; SOULARUE, P; BRIANT, L; CATHELINEAU, G; DESCHAMPS, I; ROTTER, JI; FROGUEL, P; BOITARD, C; BELL, JI; LATHROP, GM			INSULIN-IGF2 REGION ON CHROMOSOME-11P ENCODES A GENE IMPLICATED IN HLA-DR4-DEPENDENT DIABETES SUSCEPTIBILITY	NATURE			English	Article							WIEDEMANN-BECKWITH SYNDROME; MELLITUS; DNA; SEQUENCE; LOCUS; IDDM; INHERITANCE; LINKAGE; HLA	A CLASS of alleles at the VNTR (variable number of tandem repeat) locus in the 5' region of the insulin gene (INS) on chromosome 11p is associated with increased risk of insulin-dependent diabetes mellitus (IDDM) 1-6, but family studies have failed to demonstrate linkage 5,7. INS is thought to contribute to IDDM susceptibility but this view has been difficult to reconcile with the lack of linkage evidence 6-8. We thus investigated polymorphisms of INS and neighbouring loci in random diabetics, IDDM multiplex families and controls. HLA-DR4-positive diabetics showed an increased risk associated with common variants at polymorphic sites in a 19-kilobase segment spanned by the 5' INS VNTR and the third intron of the gene for insulin-like growth factor II (IGF2). As INS is the major candidate gene from this region, diabetic and control sequences were compared to identify all INS polymorphisms that could contribute to disease susceptibility. In multiplex families the IDDM-associated alleles were transmitted preferentially to HLA-DR4-positive diabetic offspring from heterozygous parents. The effect was strongest in paternal meioses, suggesting a possible role for maternal imprinting. Our results strongly support the existence of a gene or genes affecting HLA-DR4 IDDM susceptibility which is located in a 19-kilobase region of INS-IGF2. Our results also suggest new ways to map susceptibility loci in other common diseases.	JOHN RADCLIFFE HOSP,INST MOLEC MED,MOLEC IMMUNOL GRP,OXFORD OX3 9DU,ENGLAND; CTR ETUD POLYMORHISME HUMAIN,F-75010 PARIS,FRANCE; HOP ST LOUIS,SERV ENDOCRINOL,F-75010 PARIS,FRANCE; HOP NECKER ENFANTS MALAD,INSERM,U25,F-75730 PARIS 15,FRANCE; CEDARS SINAI MED CTR,DIV MED GENET,LOS ANGELES,CA 90048; UNIV CALIF LOS ANGELES,SCH MED,LOS ANGELES,CA 90024	University of Oxford; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA			JULIER, Cécile/M-9824-2017; FROGUEL, Philippe/O-6799-2017; Briant, Laurence/AAB-9281-2021	JULIER, Cécile/0000-0002-1538-0240; FROGUEL, Philippe/0000-0003-2972-0784; Briant, Laurence/0000-0002-1995-3501	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BEECHEY CV, 1990, MOUSE GENOME, V87, P64; BELL G I, 1985, American Journal of Human Genetics, V37, pA188; BELL GI, 1980, NATURE, V284, P26, DOI 10.1038/284026a0; BELL GI, 1982, NATURE, V295, P31, DOI 10.1038/295031a0; BELL GI, 1984, DIABETES, V33, P176, DOI 10.2337/diabetes.33.2.176; BELL GI, 1981, P NATL ACAD SCI-BIOL, V78, P5759, DOI 10.1073/pnas.78.9.5759; BELL GI, 1987, CIBA F S, V130; BELL GI, 1990, MOL BIOL ISLETS LANG; BIDWELL JL, 1988, TRANSPLANTATION, V45, P640, DOI 10.1097/00007890-198803000-00027; BROWN KW, 1990, AM J HUM GENET, V46, P1000; COX NJ, 1988, AM J HUM GENET, V43, P495; COX NJ, 1989, GENET EPIDEMIOL, V6, P65, DOI 10.1002/gepi.1370060113; COX NJ, 1988, AM J HUM GENET, V42, P167; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; DIXON WJ, 1988, BMDP STATISTICAL SOF; FERNS GAA, 1986, J MED GENET, V23, P210, DOI 10.1136/jmg.23.3.210; GRUNT JA, 1972, YALE J BIOL MED, V45, P15; HITMAN GA, 1985, DIABETOLOGIA, V28, P218; HITMAN GA, 1990, J MED GENET, V27, P97; HYER RN, 1991, AM J HUM GENET, V48, P243; KOUFOS A, 1989, AM J HUM GENET, V44, P711; OWERBACH D, 1990, DIABETES, V39, P1504, DOI 10.2337/diabetes.39.12.1504; PETTENATI MJ, 1986, HUM GENET, V74, P143, DOI 10.1007/BF00282078; SPIELMAN RS, 1989, GENET EPIDEMIOL, V6, P43, DOI 10.1002/gepi.1370060111; SURES I, 1980, SCIENCE, V208, P57, DOI 10.1126/science.6927840; THOMSON G, 1989, GENET EPIDEMIOL, V6, P155, DOI 10.1002/gepi.1370060129; THOMSON G, 1988, AM J HUM GENET, V43, P799; ULLRICH A, 1980, SCIENCE, V209, P612, DOI 10.1126/science.6248962; ULLRICH A, 1982, NUCLEIC ACIDS RES, V10, P2225, DOI 10.1093/nar/10.7.2225; WARRAM JH, 1984, NEW ENGL J MED, V311, P149, DOI 10.1056/NEJM198407193110304; 1990, CYTOGENET CELL GENET, V55, P1; 1989, CYTOGENET CELL GENET, V51, P1	32	367	372	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 14	1991	354	6349					155	159		10.1038/354155a0	http://dx.doi.org/10.1038/354155a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GP880	1944595				2022-12-24	WOS:A1991GP88000062
J	MONTELL, DJ; KESHISHIAN, H; SPRADLING, AC				MONTELL, DJ; KESHISHIAN, H; SPRADLING, AC			LASER ABLATION STUDIES OF THE ROLE OF THE DROSOPHILA OOCYTE NUCLEUS IN PATTERN-FORMATION	SCIENCE			English	Article							MELANOGASTER; GENE; VASA; ANTEROPOSTERIOR; LOCALIZATION; OOGENESIS; EMBRYO; LOCI	Somatic and germline cells interact during oogenesis to establish the pattern axes of the Drosophila eggshell and embryo. The role of the oocyte nucleus in pattern formation was tested with the use of laser ablation. Ablation in stage 6 to 9 egg chambers caused partial or complete ventralization of the eggshell, phenotypes similar to those of eggs produced by gurken or torpedo females. Accumulation of vasa protein at the posterior pole of treated oocytes was also disrupted. Thus the oocyte nucleus is required as late as stage 9 for dorsoventral patterning within the follicle cells and for polar plasm assembly in the oocyte.	HOWARD HUGHES MED INST,BALTIMORE,MD 21210; YALE UNIV,DEPT BIOL,NEW HAVEN,CT 06510	Howard Hughes Medical Institute; Yale University	MONTELL, DJ (corresponding author), CARNEGIE INST WASHINGTON,BALTIMORE,MD 21210, USA.				Howard Hughes Medical Institute Funding Source: Medline	Howard Hughes Medical Institute(Howard Hughes Medical Institute)		ASHBURNER M, 1990, GENETICS, V126, P679; GUTZEIT HO, 1982, J EMBRYOL EXP MORPH, V67, P101; HAY B, 1988, DEVELOPMENT, V103, P625; HAY B, 1990, DEVELOPMENT, V109, P425; LASKO PF, 1990, GENE DEV, V4, P905, DOI 10.1101/gad.4.6.905; LASKO PF, 1988, NATURE, V335, P611, DOI 10.1038/335611a0; Mahowald A.P., 1980, Genetics and Biology of Drosophila, V2d, P141; MAHOWALD AP, 1970, ROUX ARCH DEV BIOL, V165, P8; MANSEAU LJ, 1989, TRENDS GENET, V5, P400, DOI 10.1016/0168-9525(89)90198-4; MANSEAU LJ, 1989, GENE DEV, V3, P1437, DOI 10.1101/gad.3.9.1437; MLODZIK M, 1990, CELL, V60, P211, DOI 10.1016/0092-8674(90)90737-Y; OKANE CJ, 1987, P NATL ACAD SCI USA, V84, P9123, DOI 10.1073/pnas.84.24.9123; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; SCHUPBACH T, 1987, CELL, V49, P699, DOI 10.1016/0092-8674(87)90546-0; STEVENS L, 1990, NATURE, V335, P275; WIESCHAUS E, 1978, ROUX ARCH DEV BIOL, V184, P75, DOI 10.1007/BF00848670	16	42	42	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 11	1991	254	5029					290	293		10.1126/science.1925585	http://dx.doi.org/10.1126/science.1925585			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GJ642	1925585				2022-12-24	WOS:A1991GJ64200041
J	INFANTERIVARD, C; DAVID, M; GAUTHIER, R; RIVARD, GE				INFANTERIVARD, C; DAVID, M; GAUTHIER, R; RIVARD, GE			LUPUS ANTICOAGULANTS, ANTICARDIOLIPIN ANTIBODIES, AND FETAL LOSS - A CASE CONTROL STUDY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VIPER VENOM TIME; ANTIPHOSPHOLIPID ANTIBODIES; SPONTANEOUS-ABORTION; HABITUAL ABORTION; WOMEN; MISCARRIAGE; DIAGNOSIS; ABORTERS; DEATH	Background. Lupus anticoagulants and anticardiolipin antibodies are antiphospholipid antibodies that have been associated with fetal loss, but they have not been shown unequivocally to be a risk factor for this event. Methods. To estimate the risk of fetal loss in association with these antibodies, we conducted a hospital-based case-control study of 331 women with spontaneous abortion or fetal death (case patients) and 993 controls. The subjects were included in the study only if they reported that they had had no previous spontaneous fetal loss. Each control was a pregnant woman who, in the same period of pregnancy as a case patient, had not had a fetal loss. Lupus anticoagulants were identified in blood samples through a series of coagulation tests, and IgG anticardiolipins by an enzyme-linked immunosorbent assay. Each subject was interviewed in person to obtain information on potential confounding variables, such as sociodemographic characteristics and medical conditions. Results. Lupus anticoagulants were found in blood from 17 case patients (5.1 percent) and 38 controls (3.8 percent). The crude odds ratio for the association between lupus anticoagulants and fetal loss was 1.36 (95 percent confidence interval, 0.75 to 2.43); the odds ratio adjusted for confounders was 1.42 (95 percent confidence interval, 0.72 to 2.80). An IgG anticardiolipin level of 5 units or more was found in 4 case patients (1.2 percent) and 15 controls (1.5 percent). The crude and adjusted odds ratios for fetal loss were 0.80 (95 percent confidence interval, 0.26 to 2.41) and 1.28 (95 percent confidence interval, 0.38 to 4.21), respectively. Conclusions. There is no apparent justification for considering lupus anticoagulants or IgG anticardiolipins to be risk factors for fetal loss among women who present with spontaneous abortion or fetal death and have had no previous spontaneous fetal loss.	UNIV MONTREAL,HOP ST JUSTINE,DEPT OBSTET & GYNECOL,MONTREAL H3T 1C5,QUEBEC,CANADA; UNIV MONTREAL,HOP ST JUSTINE,DEPT COMMUNITY HLTH,MONTREAL H3T 1C5,QUEBEC,CANADA; UNIV MONTREAL,HOP ST JUSTINE,DEPT HEMATOL,MONTREAL H3T 1C5,QUEBEC,CANADA	Universite de Montreal; Universite de Montreal; Universite de Montreal	INFANTERIVARD, C (corresponding author), MCGILL UNIV,SCH OCCUPAT HLTH,1130 PINE AVE W,MONTREAL H3A 1A3,QUEBEC,CANADA.							Bakketeig L. S., 1984, PERINATAL EPIDEMIOLO, P99; BARBUI T, 1988, FERTIL STERIL, V50, P589; BRANDT JT, 1989, ARCH PATHOL LAB MED, V113, P1376; Breslow N, 1980, STATISTICAL METHODS, V32; EDELMAN P, 1986, PRESSE MED, V15, P961; ELIAS M, 1984, ARCH INTERN MED, V144, P510, DOI 10.1001/archinte.144.3.510; FIRKIN BG, 1978, AM J HEMATOL, V5, P81, DOI 10.1002/ajh.2830050202; FRANCOIS A, 1988, ANN INTERN MED, V109, P993, DOI 10.7326/0003-4819-109-12-993; GLADEN BC, 1986, STAT MED, V5, P557, DOI 10.1002/sim.4780050602; GREENLAND S, 1989, AM J PUBLIC HEALTH, V79, P340, DOI 10.2105/AJPH.79.3.340; HARRIS EN, 1990, BRIT J HAEMATOL, V74, P1, DOI 10.1111/j.1365-2141.1990.tb02530.x; HARRIS EN, 1990, AM J CLIN PATHOL, V94, P476, DOI 10.1093/ajcp/94.4.476; HOWARD MA, 1987, AM J HEMATOL, V26, P175, DOI 10.1002/ajh.2830260208; KACZOR DA, 1991, AM J CLIN PATHOL, V95, P408, DOI 10.1093/ajcp/95.3.408; Kline J., 1984, PERINATAL EPIDEMIOLO, P23; LESPERANCE B, 1988, THROMB HAEMOSTASIS, V60, P217; LOCKSHIN MD, 1985, NEW ENGL J MED, V313, P152, DOI 10.1056/NEJM198507183130304; LOCKSHIN MD, 1989, AM J OBSTET GYNECOL, V160, P439, DOI 10.1016/0002-9378(89)90468-7; LOCKWOOD CJ, 1989, AM J OBSTET GYNECOL, V161, P369, DOI 10.1016/0002-9378(89)90522-X; MAIER DB, 1989, FERTIL STERIL, V51, P280; MODVIG J, 1990, AM J EPIDEMIOL, V132, P1021, DOI 10.1093/oxfordjournals.aje.a115744; PETRI M, 1987, ARTHRITIS RHEUM, V30, P601, DOI 10.1002/art.1780300601; RODRIGUES L, 1990, INT J EPIDEMIOL, V19, P205, DOI 10.1093/ije/19.1.205; ROSOVE MH, 1990, OBSTET GYNECOL, V75, P630; STIRRAT GM, 1990, LANCET, V336, P673, DOI 10.1016/0140-6736(90)92159-F; THIAGARAJAN P, 1986, BLOOD, V68, P869; TRIPLETT DA, 1983, AM J CLIN PATHOL, V79, P678, DOI 10.1093/ajcp/79.6.678; TRIPLETT DA, 1989, AM J REPROD IMMUNOL, V20, P52, DOI 10.1111/j.1600-0897.1989.tb00639.x; WALLENBURG HCS, 1987, AM J OBSTET GYNECOL, V157, P1230, DOI 10.1016/S0002-9378(87)80300-9	29	164	169	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 10	1991	325	15					1063	1066		10.1056/NEJM199110103251503	http://dx.doi.org/10.1056/NEJM199110103251503			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GJ108	1909770				2022-12-24	WOS:A1991GJ10800003
J	KJEMS, J; FRANKEL, AD; SHARP, PA				KJEMS, J; FRANKEL, AD; SHARP, PA			SPECIFIC REGULATION OF MESSENGER-RNA SPLICING INVITRO BY A PEPTIDE FROM HIV-1 REV	CELL			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TRANS-ACTIVATOR; GENE-PRODUCT; SEXUAL-DIFFERENTIATION; MUTATIONAL ANALYSIS; STRUCTURED REGION; TARGET SEQUENCE; TYPE-1 AFFECTS; PROTEIN; EXPRESSION	The Rev protein of HIV-1 regulates the synthesis of partially spliced forms of cytoplasmic viral mRNA by binding to a cis-acting RNA sequence, the Rev response element (RRE). We have investigated the regulation of splicing in vitro and have shown that Rev specifically inhibits splicing of pre-mRNAs containing an RRE by 3- to 4-fold. A synthetic peptide of 17 amino acids containing the RNA-binding domain of Rev is highly functional and specifically inhibits splicing by up to 30-fold. Other peptides that bind to the RRE with high affinity, but with low specificity, do not specifically inhibit splicing. Six repeated monomeric binding sites for the peptide can substitute for the RRE, indicating that regulation by Rev requires interactions with multiple sites. The peptide acts at a step in the assembly of splicing complexes, suggesting that one of the functions of the basic region of Rev is to prevent formation of a functional spliceosome.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139; WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Whitehead Institute	KJEMS, J (corresponding author), MIT,CTR CANC RES,CAMBRIDGE,MA 02139, USA.		Kjems, Jorgen/I-3490-2016	Kjems, Jorgen/0000-0003-4128-9317	NATIONAL CANCER INSTITUTE [P30CA014051] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029135] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034277, R01GM034277] Funding Source: NIH RePORTER; NCI NIH HHS [CA 14051] Funding Source: Medline; NIAID NIH HHS [AI29135] Funding Source: Medline; NIGMS NIH HHS [GM34277] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGRIS CH, 1989, MOL CELL BIOL, V9, P259, DOI 10.1128/MCB.9.1.259; ANDREADIS A, 1987, ANNU REV CELL BIOL, V3, P207, DOI 10.1146/annurev.cellbio.3.1.207; BAKER BS, 1989, NATURE, V340, P521, DOI 10.1038/340521a0; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; BELL LR, 1991, CELL, V65, P229, DOI 10.1016/0092-8674(91)90157-T; BURTIS KC, 1989, CELL, V56, P997, DOI 10.1016/0092-8674(89)90633-8; CALNAN BJ, 1991, SCIENCE, V252, P1167, DOI 10.1126/science.252.5009.1167; CALNAN BJ, 1991, GENE DEV, V5, P201, DOI 10.1101/gad.5.2.201; CHANG DD, 1990, SCIENCE, V249, P614, DOI 10.1126/science.2143313; CHANG DD, 1989, CELL, V59, P789, DOI 10.1016/0092-8674(89)90602-8; COCHRANE AW, 1990, P NATL ACAD SCI USA, V87, P1198, DOI 10.1073/pnas.87.3.1198; COOK KS, 1991, NUCLEIC ACIDS RES, V19, P1577, DOI 10.1093/nar/19.7.1577; CULLEN BR, 1989, CELL, V58, P423, DOI 10.1016/0092-8674(89)90420-0; DALY TJ, 1990, BIOCHEMISTRY-US, V29, P9791, DOI 10.1021/bi00494a005; DALY TJ, 1989, NATURE, V342, P816, DOI 10.1038/342816a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EMERMAN M, 1989, CELL, V57, P1155, DOI 10.1016/0092-8674(89)90053-6; FEINBERG MB, 1986, CELL, V46, P807, DOI 10.1016/0092-8674(86)90062-0; FELBER BK, 1989, P NATL ACAD SCI USA, V86, P1495, DOI 10.1073/pnas.86.5.1495; FU XD, 1991, GENE DEV, V5, P211, DOI 10.1101/gad.5.2.211; GALLO RC, 1984, SCIENCE, V224, P500, DOI 10.1126/science.6200936; GARCIABLANCO MA, 1989, GENE DEV, V3, P1874, DOI 10.1101/gad.3.12a.1874; GE H, 1990, CELL, V62, P25, DOI 10.1016/0092-8674(90)90236-8; GRABOWSKI PJ, 1985, CELL, V42, P345, DOI 10.1016/S0092-8674(85)80130-6; HADZOPOULOUCLADARAS M, 1989, J VIROL, V63, P1265, DOI 10.1128/JVI.63.3.1265-1274.1989; HAMMARSKJOLD ML, 1989, J VIROL, V63, P1959; HEAPHY S, 1990, CELL, V60, P685, DOI 10.1016/0092-8674(90)90671-Z; HEDLEY ML, 1991, CELL, V65, P579, DOI 10.1016/0092-8674(91)90090-L; HOPE TJ, 1990, J VIROL, V64, P5360, DOI 10.1128/JVI.64.11.5360-5366.1990; HUANG XJ, 1991, J VIROL, V65, P2131, DOI 10.1128/JVI.65.4.2131-2134.1991; INOUE K, 1990, NATURE, V344, P461, DOI 10.1038/344461a0; KATZ RA, 1990, MOL CELL BIOL, V10, P696, DOI 10.1128/MCB.10.2.696; KIM SY, 1989, J VIROL, V63, P3708, DOI 10.1128/JVI.63.9.3708-3713.1989; KJEMS J, 1991, P NATL ACAD SCI USA, V88, P683, DOI 10.1073/pnas.88.3.683; KONARSKA MM, 1986, CELL, V46, P845, DOI 10.1016/0092-8674(86)90066-8; KRAINER AR, 1990, CELL, V62, P35, DOI 10.1016/0092-8674(90)90237-9; LAMOND AI, 1987, GENE DEV, V1, P532, DOI 10.1101/gad.1.6.532; LU XB, 1990, P NATL ACAD SCI USA, V87, P7598, DOI 10.1073/pnas.87.19.7598; MALIM MH, 1988, NATURE, V335, P181, DOI 10.1038/335181a0; MALIM MH, 1990, CELL, V60, P675, DOI 10.1016/0092-8674(90)90670-A; MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0; MALIM MH, 1989, CELL, V58, P205, DOI 10.1016/0092-8674(89)90416-9; MALIM MH, 1991, CELL, V65, P251; MANIATIS T, 1991, SCIENCE, V251, P33, DOI 10.1126/science.1824726; NAGOSHI RN, 1988, CELL, V53, P229, DOI 10.1016/0092-8674(88)90384-4; OLSEN HS, 1990, GENE DEV, V4, P1357, DOI 10.1101/gad.4.8.1357; OLSEN HS, 1990, SCIENCE, V247, P845, DOI 10.1126/science.2406903; PADGETT RA, 1985, P NATL ACAD SCI USA, V82, P8349, DOI 10.1073/pnas.82.24.8349; ROSEN CA, 1988, P NATL ACAD SCI USA, V85, P2071, DOI 10.1073/pnas.85.7.2071; SOSNOWSKI BA, 1989, CELL, V58, P449, DOI 10.1016/0092-8674(89)90426-1; VARMUS H, 1988, SCIENCE, V240, P1427, DOI 10.1126/science.3287617; ZAPP ML, 1989, NATURE, V342, P714, DOI 10.1038/342714a0	52	111	113	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 4	1991	67	1					169	178		10.1016/0092-8674(91)90580-R	http://dx.doi.org/10.1016/0092-8674(91)90580-R			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GJ320	1913815				2022-12-24	WOS:A1991GJ32000015
J	WARE, RE; HALL, SE; ROSSE, WF				WARE, RE; HALL, SE; ROSSE, WF			PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA WITH ONSET IN CHILDHOOD AND ADOLESCENCE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ERYTHROCYTE-MEMBRANE-PROTEIN; GLYCOSYL-PHOSPHATIDYLINOSITOL; APLASTIC-ANEMIA; REACTIVE LYSIS; RED-CELLS; COMPLEMENT; CD14; DEFICIENCY; INHIBITOR; RECEPTOR	Background. Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired clonal hematologic disorder characterized by hemoglobinuria, thrombosis, infection, and a tendency toward bone marrow aplasia. Onset usually occurs in adulthood. Few children and adolescents with PNH have been described, and data on diagnosis, clinical course, and survival in young patients are unavailable. Methods. We retrospectively reviewed clinical and laboratory data on all patients 21 years old or younger in whom PNH had been diagnosed at Duke University Medical Center from 1966 to 1991. Results. Medical records and clinical follow-up data were available for 26 young patients. Although 50 percent of adult patients present with hemoglobinuria, only four of our patients (15 percent) presented with this feature. In contrast, 15 of our patients (58 percent) had moderate or severe bone marrow failure at presentation, as compared with about 25 percent of adults in cases from the literature; all 26 patients eventually had evidence of bone marrow dysfunction. Eight patients (31 percent) have died, with a median survival of 13.5 years since their initial symptoms. Conclusions. Children and adolescents with PNH have a greater prevalence of bone marrow failure than do adults with this disorder, and their morbidity and mortality are high. Bone marrow transplantation should be considered for selected young patients with PNH.	DUKE UNIV,MED CTR,DEPT PEDIAT,DIV HEMATOL ONCOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT MED,DIV HEMATOL ONCOL,DURHAM,NC 27710	Duke University; Duke University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK031379] Funding Source: NIH RePORTER; NIDDK NIH HHS [5-R37-DK-31379] Funding Source: Medline; PHS HHS [K11-H02015] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AUDITORE JV, 1960, ARCH PATHOL, V69, P534; DACIE JV, 1961, BRIT J HAEMATOL, V7, P442, DOI 10.1111/j.1365-2141.1961.tb00354.x; DACIE JV, 1963, P ROY SOC MED, V56, P587, DOI 10.1177/003591576305600723; DEVINE DV, 1987, J CLIN INVEST, V79, P131, DOI 10.1172/JCI112773; DEVINE DV, 1987, J CLIN INVEST, V79, P314, DOI 10.1172/JCI112802; DOERING TL, 1990, J BIOL CHEM, V265, P611; GOYERT SM, 1988, SCIENCE, V239, P497, DOI 10.1126/science.2448876; Gull WW, 1866, GUYS HOSP REP, V12, P381; HARTMANN RC, 1977, ANNU REV MED, V28, P187, DOI 10.1146/annurev.me.28.020177.001155; HIRSCH VJ, 1981, ARCH INTERN MED, V141, P525, DOI 10.1001/archinte.141.4.525; HOLGUIN MH, 1989, J CLIN INVEST, V84, P1387, DOI 10.1172/JCI114311; HOLGUIN MH, 1989, J CLIN INVEST, V84, P7, DOI 10.1172/JCI114172; KUNSTLING TR, 1969, BLOOD-J HEMATOL, V33, P607, DOI 10.1182/blood.V33.4.607.607; LEWIS SM, 1965, BRIT J HAEMATOL, V11, P549, DOI 10.1111/j.1365-2141.1965.tb00099.x; LEWIS SM, 1967, BRIT J HAEMATOL, V13, P236, DOI 10.1111/j.1365-2141.1967.tb08736.x; LOW MG, 1988, SCIENCE, V239, P268, DOI 10.1126/science.3276003; MOORE JG, 1986, EXP HEMATOL, V14, P222; NICHOLSONWELLER A, 1982, J IMMUNOL, V129, P184; NICHOLSONWELLER A, 1983, P NATL ACAD SCI-BIOL, V80, P5066, DOI 10.1073/pnas.80.16.5066; ONI SB, 1970, BLOOD-J HEMATOL, V36, P145, DOI 10.1182/blood.V36.2.145.145; PANGBURN MK, 1983, P NATL ACAD SCI-BIOL, V80, P5430, DOI 10.1073/pnas.80.17.5430; POLLI E, 1973, EMOGLOBINURIA PAROSS; ROSSE WF, 1985, CLIN HAEMATOL, V14, P105; ROSSE WF, 1966, J CLIN INVEST, V45, P736, DOI 10.1172/JCI105388; ROSSE WF, 1974, BRIT J HAEMATOL, V28, P181; ROSSE WF, 1978, CLIN HAEMATOL, V7, P541; ROSSE WF, 1973, BRIT J HAEMATOL, V24, P327, DOI 10.1111/j.1365-2141.1973.tb01657.x; ROSSE WF, 1990, BLOOD, V75, P1595; ROTOLI B, 1982, BLOOD, V60, P157; SCHONERMARK S, 1986, J IMMUNOL, V136, P1772; SELVARAJ P, 1988, NATURE, V333, P565, DOI 10.1038/333565a0; SELVARAJ P, 1987, J EXP MED, V166, P1011, DOI 10.1084/jem.166.4.1011; SIMMONS DL, 1989, BLOOD, V73, P284; SIRCHIA G, 1975, CLIN HAEMATOL, V4, P199; Strubing P., 1882, DMW DTSCH MED WOCHEN, V8, P1, DOI [DOI 10.1055/S-0029-1196307, 10.1055/s-0029-1196307]; TICHELLI A, 1988, BRIT J HAEMATOL, V69, P413, DOI 10.1111/j.1365-2141.1988.tb02382.x; VANDERSCHOOT CE, 1989, LEUCOCYTE TYPING, V4, P887; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; ZALMAN LS, 1986, P NATL ACAD SCI USA, V83, P6975, DOI 10.1073/pnas.83.18.6975	39	118	121	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 3	1991	325	14					991	996		10.1056/NEJM199110033251403	http://dx.doi.org/10.1056/NEJM199110033251403			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GH447	1886636				2022-12-24	WOS:A1991GH44700003
J	RASHBASS, P; COOKE, LA; HERRMANN, BG; BEDDINGTON, RSP				RASHBASS, P; COOKE, LA; HERRMANN, BG; BEDDINGTON, RSP			A CELL AUTONOMOUS FUNCTION OF BRACHYURY IN T/T EMBRYONIC STEM-CELL CHIMERAS	NATURE			English	Article							MESODERM FORMATION; MOUSE EMBRYO; T-GENE; INVERSION; MUTATION; COMPLEX; LOCUS	DEVELOPMENTAL genetics has shown that the Brachyury (T) gene has a key role in mesoderm formation during gastrulation in the mouse 1,2. Homozygous embryos (Fig. 1) have a defective allantois, degenerate or absent notochord and disrupted primitive streak and node. The neural tube is kinked and somite formation interrupted 3-6. The T gene has been cloned 7 and is expressed during the early stages of gastrulation, being restricted to the primitive streak region, nascent mesoderm and notochord 8. Neither the sequence of the gene nor its expression pattern define its developmental function 7,9. To study the cell autonomy of the T mutation we have isolated and genetically characterized embryonic stem cell lines and studied their behaviour in chimaeras. T/+ embryonic stem cells form normal chimaeras, whereas T/T <-> +/+ chimaeras mimic the T/T mutant phenotype. The results indicate that the T gene acts cell autonomously in the primitive streak and notochord but may activate a signalling pathway involved in the specification of other mesodermal tissues.	MAX PLANCK INST ENTWICKLUNGSBIOL,W-7400 TUBINGEN,GERMANY	Max Planck Society	RASHBASS, P (corresponding author), AFRC,CTR GENOME RES,KINGS BLDG,EDINBURGH EH9 3JQ,MIDLOTHIAN,SCOTLAND.		Pillay, Nischalan/F-9536-2012					BENNETT D, 1978, NATURE, V272, P539, DOI 10.1038/272539a0; Chesley P, 1935, J EXP ZOOL, V70, P429, DOI 10.1002/jez.1400700306; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Dobrovolskaia-Zavadskaia N, 1927, CR SOC BIOL, V97, P114; EICHER EM, 1978, P NATL ACAD SCI USA, V75, P949; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FUJIMOTO H, 1983, DIFFERENTIATION, V25, P44; Gluecksohn-Schoenheimer S, 1944, P NATL ACAD SCI USA, V30, P134, DOI 10.1073/pnas.30.6.134; GRUNEBERG H, 1958, J EMBRYOL EXP MORPH, V6, P424; HERRMANN B, 1986, CELL, V44, P469, DOI 10.1016/0092-8674(86)90468-X; HERRMANN BG, 1987, CELL, V48, P813, DOI 10.1016/0092-8674(87)90078-X; HERRMANN BG, 1990, NATURE, V343, P617, DOI 10.1038/343617a0; LYON M. F., 1959, JOUR HEREDITY, V50, P140; MACMURRAY A, 1988, GENETICS, V120, P545; MCLAREN A, 1981, GENET RES CAMB, V37, P305; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; SEARLE AG, 1966, GENET RES, V7, P86, DOI 10.1017/S0016672300009496; TAM PPL, 1987, DEVELOPMENT, V99, P109; WILKINSON DG, 1990, NATURE, V343, P657, DOI 10.1038/343657a0; WILLISON K, 1990, TRENDS GENET, V6, P104, DOI 10.1016/0168-9525(90)90106-G; YANAGISAWA KO, 1990, JPN J GENET, V65, P287, DOI 10.1266/jjg.65.287; YANAGISAWA KO, 1981, DEV BIOL, V87, P242, DOI 10.1016/0012-1606(81)90147-0	22	87	88	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 26	1991	353	6342					348	351		10.1038/353348a0	http://dx.doi.org/10.1038/353348a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GG654	1922339				2022-12-24	WOS:A1991GG65400059
J	VANLOHUIZEN, M; FRASCH, M; WIENTJENS, E; BERNS, A				VANLOHUIZEN, M; FRASCH, M; WIENTJENS, E; BERNS, A			SEQUENCE SIMILARITY BETWEEN THE MAMMALIAN BMI-1 PROTOONCOGENE AND THE DROSOPHILA REGULATORY GENES PSC AND SU(Z)2	NATURE			English	Article							ZESTE; EXPRESSION; MELANOGASTER; TRANSVECTION; COMPLEX	THE bmi-1 proto-oncogene can be activated by Moloney murine leukaemia proviral insertions in E-mu-myc transgenic mice 1,2. It encodes a highly conserved nuclear protein of 324 amino acids which belongs to a family of proteins containing a putative new zinc-finger. Another closely related member of this family is the mouse protein Mel-18 (ref. 3). Here we report on the cloning and characterization of a homologous gene (D-bmi) from Drosophila melanogaster. Our analysis indicates that distinct domains of the mouse Bmi-1 protein, including the putative zinc-finger motif, are highly conserved within the much larger D-Bmi protein. Chromosomal localization and sequence comparison reveal that D-bmi is identical to Posterior Sex Combs (Psc) 4-6 and indicate that the conserved domains between mouse bmi and Psc are also conserved within Suppressor-2 of Zeste (Su(z)2) 6-8.	UNIV AMSTERDAM,DEPT BIOCHEM,AMSTERDAM,NETHERLANDS; MAX PLANCK INST ENTWICKLUNGSBIOL,GENET ABT,W-7400 TUBINGEN,GERMANY	University of Amsterdam; Max Planck Society	VANLOHUIZEN, M (corresponding author), NETHERLANDS CANC INST,DIV MOLEC GENET,PLESMANLAAN 121,1066 CX AMSTERDAM,NETHERLANDS.		Frasch, Manfred/H-7002-2013	Frasch, Manfred/0000-0003-1373-9798				ADLER P, IN PRESS DEV GENET; ADLER PN, 1989, DEV GENET, V10, P249, DOI 10.1002/dvg.1020100314; BICKEL S, 1990, EMBO J, V9, P2959, DOI 10.1002/j.1460-2075.1990.tb07488.x; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; BRUNK BP, 1990, GENETICS, V124, P145; BRUNK BP, 1991, GENETICS, V128, P119; BRUNK BP, 1991, NATURE, V353, P351, DOI 10.1038/353351a0; GAUNT SJ, 1990, TRENDS GENET, V6, P208; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; JURGENS G, 1985, NATURE, V316, P153, DOI 10.1038/316153a0; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; LOCKE J, 1988, GENETICS, V120, P181; PARO R, 1991, P NATL ACAD SCI USA, V88, P263, DOI 10.1073/pnas.88.1.263; PARO R, 1990, TRENDS GENET, V6, P416, DOI 10.1016/0168-9525(90)90303-N; TAGAWA M, 1990, J BIOL CHEM, V265, P20021; TARTOF KD, 1991, CELL, V65, P201, DOI 10.1016/0092-8674(91)90153-P; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; WU CT, 1989, MOL GEN GENET, V218, P559, DOI 10.1007/BF00332424; WU CT, 1989, TRENDS GENET, V5, P189, DOI 10.1016/0168-9525(89)90074-7; ZINK B, 1989, NATURE, V337, P468, DOI 10.1038/337468a0; ZINK B, 1991, EMBO J, V10, P153, DOI 10.1002/j.1460-2075.1991.tb07931.x	22	199	212	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 26	1991	353	6342					353	355		10.1038/353353a0	http://dx.doi.org/10.1038/353353a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GG654	1922340				2022-12-24	WOS:A1991GG65400061
J	QIZILBASH, N; JONES, L; WARLOW, C; MANN, J				QIZILBASH, N; JONES, L; WARLOW, C; MANN, J			FIBRINOGEN AND LIPID CONCENTRATIONS AS RISK-FACTORS FOR TRANSIENT ISCHEMIC ATTACKS AND MINOR ISCHEMIC STROKES	BRITISH MEDICAL JOURNAL			English	Article							SERUM-CHOLESTEROL; ISCHEMIC ATTACKS; CEREBROVASCULAR-DISEASE; CARDIOVASCULAR-DISEASE; MYOCARDIAL-INFARCTION; CEREBRAL INFARCTION; MEN BORN; COMMUNITY; MORTALITY; COHORT	Objective - To determine whether fibrinogen and lipid concentrations are risk factors for ischaemic stroke. Design-Case - control study with a population based comparison within the overall study. Setting - Oxfordshire community stroke project and a neurology clinic. Subjects - 105 patients who had a transient ischaemic attack or minor ischaemic stroke and 352 randomly chosen controls matched for age and sex from the same general practitioners as the incident cases. 52 controls were ineligible or refused interview. 104 cases and 241 controls gave blood samples for analysis. Main outcome measures - Response to structured questionnaire, height, weight, blood pressure, and serum concentrations of fibrinogen and lipids. Results - Adjusted for other variables, odds ratios of ischaemic stroke were 1.78 (95% confidence interval 0.91 to 3.48; p = 0.009) for fibrinogen concentrations > 3.6 g/l; 1.73 (0.90 to 3.29; p = 0.009) for total cholesterol concentrations > 6.0 mmol/l; 1.34 (0.69 to 2.61; p > 0.4) for low density lipoprotein cholesterol concentrations > 3.5 mmol/l; and 0.32 (0.15 to 0.69; p = 0.002) for high density lipoprotein cholesterol concentration > 1.2 mmol/l. Similar results emerged comparing only community derived cases with transient ischaemic attacks and controls. The effects of fibrinogen, total cholesterol, and high density lipoprotein cholesterol were significant in a test of trend after adjusting for all other variable in the study (chi-2 = 4.14, p < 0.05; chi-2 = 4.31, p < 0.05, and chi-2 = 12.15, p > 0.001, respectively). History of ischaemic heart disease and hypertension were the only other variables that showed significance, though both lost significance after adjustment (2.06, p = 0.08 and 1.53, p = 0.2, respectively). Conclusions - Fibrinogen and lipids are important risk factors for ischaemic stroke. The pattern of changes mirrors that found in ischaemic heart disease.	RADCLIFFE INFIRM,DEPT COMMUNITY MED & GEN PRACTICE,OXFORD OX2 6HE,ENGLAND; UNIV OXFORD,RADCLIFFE INFIRM,DEPT CLIN NEUROL,OXFORD OX2 6HE,ENGLAND	Radcliffe Infirmary; Radcliffe Infirmary; University of Oxford					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAMFORD J, 1988, J NEUROL NEUROSUR PS, V51, P1373, DOI 10.1136/jnnp.51.11.1373; Breslow N, 1980, STATISTICAL METHODS, V32; BURSTEIN M, 1970, J LIPID RES, V11, P583; DENNIS MS, 1989, STROKE, V20, P1494, DOI 10.1161/01.STR.20.11.1494; DIPERRI T, 1985, CEPHALALGIA S2, V51, P71; ELLIS BC, 1961, J LAB CLIN MED, V58, P477; GAMBINA G, 1984, ITAL J NEUROL SCI, V5, P157, DOI 10.1007/BF02043217; GLOMSET JA, 1968, J LIPID RES, V9, P155; Heyman A, 1971, STROKE, V2, P509, DOI 10.1161/01.STR.2.6.509; HOSSMANN V, 1977, BRAIN HEART INFARCT, P81; HUMPHREY PRD, 1981, STROKE, V12, P765, DOI 10.1161/01.STR.12.6.765; ISO H, 1989, NEW ENGL J MED, V320, P904, DOI 10.1056/NEJM198904063201405; KANNEL WB, 1987, JAMA-J AM MED ASSOC, V258, P1183, DOI 10.1001/jama.258.9.1183; KHAW KT, 1984, STROKE, V15, P244, DOI 10.1161/01.STR.15.2.244; MARKOWE HLJ, 1982, EUR HEART J SB, V3, P5; MENDEZ I, 1987, NEUROLOGY, V37, P507, DOI 10.1212/WNL.37.3.507; ONONOGBU IC, 1976, CLIN CHIM ACTA, V71, P397, DOI 10.1016/0009-8981(76)90090-5; OSTFELD AM, 1974, AM J PUBLIC HEALTH, V64, P450, DOI 10.2105/AJPH.64.5.450; OTT E, 1983, EUR NEUROL, V22, P35, DOI 10.1159/000115609; OTT E, 1979, CEREBRAL VASCULAR DI, P216; PARTINEN M, 1985, LANCET, V1, P893; PEACOCK PB, 1972, TRENDS EPIDEMIOLOGY, P231; RHOADS GG, 1980, STROKE, V11, P21, DOI 10.1161/01.STR.11.1.21; RHOADS GG, 1983, ARTERIOSCLEROSIS, V3, P316, DOI 10.1161/01.ATV.3.4.316; SADOSHIMA S, 1979, ATHEROSCLEROISIS, V34, P43; SALONEN JT, 1983, INT J EPIDEMIOL, V12, P26, DOI 10.1093/ije/12.1.26; SHINTON R, 1989, BMJ-BRIT MED J, V298, P789, DOI 10.1136/bmj.298.6676.789; SIEDEL J, 1981, J CLIN CHEM CLIN BIO, V19, P838; SIRTORI CR, 1979, ATHEROSCLEROSIS, V32, P205, DOI 10.1016/0021-9150(79)90084-4; SPRIGGS DA, 1990, AGE AGEING, V19, P288; SZATROWSKI TP, 1984, J CHRON DIS, V37, P569, DOI 10.1016/0021-9681(84)90007-9; TANAKA H, 1982, STROKE, V13, P62, DOI 10.1161/01.STR.13.1.62; UEDA K, 1980, J CHRON DIS, V33, P13, DOI 10.1016/0021-9681(80)90081-8; WARLOW CP, 1976, THROMB HAEMOSTASIS, V36, P127, DOI 10.1055/s-0038-1648016; WARLOW CP, 1987, OXFORD TXB MED; WELIN L, 1987, NEW ENGL J MED, V317, P521, DOI 10.1056/NEJM198708273170901; WILHELMSEN L, 1984, NEW ENGL J MED, V311, P501, DOI 10.1056/NEJM198408233110804; Wolf P A, 1983, Neurol Clin, V1, P317; 1985, SAS USERS GUIDE STAT; 1982, JAMA-J AM MED ASSOC, V248, P2853	40	160	162	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 14	1991	303	6803					605	609		10.1136/bmj.303.6803.605	http://dx.doi.org/10.1136/bmj.303.6803.605			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GF675	1932900	Green Published, Bronze			2022-12-24	WOS:A1991GF67500019
J	PAGE, DL; DUPONT, WD				PAGE, DL; DUPONT, WD			PROLIFERATIVE BREAST DISEASE - DIAGNOSIS AND IMPLICATIONS	SCIENCE			English	Article							TERM FOLLOW-UP; CANCER; LESIONS; WOMEN		VANDERBILT UNIV,MED CTR,SCH MED,DEPT PREVENT MED,DIV BIOSTAT,NASHVILLE,TN 37232	Vanderbilt University	PAGE, DL (corresponding author), VANDERBILT UNIV,MED CTR,SCH MED,DEPT PATHOL,NASHVILLE,TN 37232, USA.		Dupont, William D./I-4430-2012	Bishop, Tim/0000-0002-8752-8785; albright, lisa/0000-0003-2602-3668				BIBBO M, 1988, ACTA CYTOL, V32, P193; CARTER CL, 1988, AM J EPIDEMIOL, V128, P467, DOI 10.1093/oxfordjournals.aje.a114995; DUPONT WD, 1985, NEW ENGL J MED, V312, P146, DOI 10.1056/NEJM198501173120303; DUPONT WD, 1987, AM J EPIDEMIOL, V125, P769, DOI 10.1093/oxfordjournals.aje.a114594; PAGE DL, 1985, CANCER, V55, P2698, DOI 10.1002/1097-0142(19850601)55:11<2698::AID-CNCR2820551127>3.0.CO;2-A; SKOLNICK MH, 1990, SCIENCE, V250, P1715, DOI 10.1126/science.2270486; TAVASSOLI FA, 1990, CANCER, V65, P518, DOI 10.1002/1097-0142(19900201)65:3<518::AID-CNCR2820650324>3.0.CO;2-O	7	19	19	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 23	1991	253	5022					915	915		10.1126/science.1876848	http://dx.doi.org/10.1126/science.1876848			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC152	1876848				2022-12-24	WOS:A1991GC15200049
J	CLACKSON, T; HOOGENBOOM, HR; GRIFFITHS, AD; WINTER, G				CLACKSON, T; HOOGENBOOM, HR; GRIFFITHS, AD; WINTER, G			MAKING ANTIBODY FRAGMENTS USING PHAGE DISPLAY LIBRARIES	NATURE			English	Article							IMMUNOGLOBULIN VARIABLE DOMAINS; POLYMERASE CHAIN-REACTION; ESCHERICHIA-COLI; IMMUNE-RESPONSE; EXPRESSION; PROTEIN; LAMBDA; DNA; ANTI-2-PHENYLOXAZOLONE; REPERTOIRE	To by-pass hybridoma technology and animal immunization, we are trying to build antibodies in bacteria by mimicking features of immune selection1. Recently we used fd phage2 to display antibody fragments fused to a minor coat protein3,4, allowing enrichment of phage with antigen3. Using a random combinatorial library of the rearranged heavy (VH) and kappa (V-kappa) light chains5-8 from mice immune to the hapten 2-phenyloxazol-5-one (phOx), we have now displayed diverse libraries of antibody fragments on the surface of fd phage. After a single pass over a hapten affinity column, fd phage with a range of phOx binding activities were detected, at least one with high affinity (dissociation constant, K(d) = 10(-8) M). A second pass enriched for the strong binders at the expense of the weak. The binders were encoded by V genes similar to those found in anti-phOx hybridomas but in promiscuous combinations (where the same V gene is found with several different partners). By combining a promiscuous VH or V-kappa gene with diverse repertoires of partners to create hierarchical libraries, we elicited many more pairings with strong binding activities. Phage display offers new ways of making antibodies from V-gene libraries, altering V-domain pairings and selecting for antibodies with good affinities.	CTR PROT ENGN, CAMBRIDGE CB2 2QH, ENGLAND	University of Cambridge	CLACKSON, T (corresponding author), MRC, MOLEC BIOL LAB, HILLS RD, CAMBRIDGE CB2 2QH, ENGLAND.		Griffiths, Andrew D/A-1370-2010; Baird, Cheryl L/F-6569-2011	Griffiths, Andrew D/0000-0002-0808-3539; 				ALZARI PM, 1990, EMBO J, V9, P3807, DOI 10.1002/j.1460-2075.1990.tb07598.x; BASS S, 1990, PROTEINS, V8, P309, DOI 10.1002/prot.340080405; BEREK C, 1985, NATURE, V316, P412, DOI 10.1038/316412a0; BETTER M, 1988, SCIENCE, V240, P1041, DOI 10.1126/science.3285471; CATON AJ, 1990, P NATL ACAD SCI USA, V87, P6450, DOI 10.1073/pnas.87.16.6450; CATON AJ, 1991, P NATL ACAD SCI USA, V88, P1590; CLACKSON T, IN PRESS PCR PRACTIC; CWIRLA SE, 1990, P NATL ACAD SCI USA, V87, P6378, DOI 10.1073/pnas.87.16.6378; DEBELLIS D, 1990, NUCLEIC ACIDS RES, V18, P1311; DEVLIN JJ, 1990, SCIENCE, V249, P404, DOI 10.1126/science.2143033; DILDROP R, 1984, IMMUNOL TODAY, V5, P85, DOI 10.1016/0167-5699(84)90034-3; DOWER WJ, 1988, NUCLEIC ACIDS RES, V16, P6127, DOI 10.1093/nar/16.13.6127; EISEN H N, 1964, Methods Med Res, V10, P115; FOOTE J, IN PRESS NATURE; GHERARDI E, 1990, J IMMUNOL METHODS, V126, P61, DOI 10.1016/0022-1759(90)90012-K; Gibson T.J., 1984, THESIS U CAMBRIDGE; GLOCKSHUBER R, 1990, BIOCHEMISTRY-US, V29, P1362, DOI 10.1021/bi00458a002; GOTTESMAN ME, 1980, J MOL BIOL, V140, P57, DOI 10.1016/0022-2836(80)90356-3; GUSSOW D, 1989, NUCLEIC ACIDS RES, V17, P4000; HARLOW E, 1988, ANTIBODIES LABORATOR; HOOGENBOOM HR, 1991, NUCLEIC ACIDS RES, V19, P4133, DOI 10.1093/nar/19.15.4133; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; HUDSON NW, 1987, J IMMUNOL, V139, P2715; HUSE WD, 1989, SCIENCE, V246, P1275, DOI 10.1126/science.2531466; HUSTON JS, 1988, P NATL ACAD SCI USA, V85, P5879, DOI 10.1073/pnas.85.16.5879; Kabat E. A., 1987, SEQUENCES PROTEINS I, DOI 10.1016/0003-2697(84)90805-4; MAKELA O, 1978, J EXP MED, V148, P1644, DOI 10.1084/jem.148.6.1644; MCCAFFERTY J, 1990, NATURE, V348, P552, DOI 10.1038/348552a0; MCMANUS S, 1991, BIOCHEMISTRY-US, V30, P5851, DOI 10.1021/bi00238a007; MULLINAX RL, 1990, P NATL ACAD SCI USA, V87, P8095, DOI 10.1073/pnas.87.20.8095; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; NAGAI K, 1987, METHOD ENZYMOL, V153, P461; ORLANDI R, 1989, P NATL ACAD SCI USA, V86, P3833, DOI 10.1073/pnas.86.10.3833; PERELSON AS, 1989, IMMUNOL REV, V110, P5, DOI 10.1111/j.1600-065X.1989.tb00025.x; PERSSON MAA, 1991, P NATL ACAD SCI USA, V88, P2432, DOI 10.1073/pnas.88.6.2432; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; SEGAL I, 1975, ENZYME KINETICS, P73; SHIMATAKE H, 1981, NATURE, V292, P128, DOI 10.1038/292128a0; SMITH GP, 1985, SCIENCE, V228, P1315, DOI 10.1126/science.4001944; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WARD ES, 1989, NATURE, V341, P544, DOI 10.1038/341544a0; WINTER G, 1991, NATURE, V349, P293, DOI 10.1038/349293a0	45	929	2467	4	151	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	AUG 15	1991	352	6336					624	628		10.1038/352624a0	http://dx.doi.org/10.1038/352624a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GB211	1907718				2022-12-24	WOS:A1991GB21100057
J	AYLETT, M; KETCHIN, S				AYLETT, M; KETCHIN, S			STOPPING TREATMENT IN PATIENTS WITH HYPERTENSION	BRITISH MEDICAL JOURNAL			English	Article											AYLETT, M (corresponding author), GLENDALE SURG,WOOLER NE71 6DN,NORTHD,ENGLAND.							BERGLUND G, 1976, BRIT MED J, V2, P554, DOI 10.1136/bmj.2.6035.554; HART JT, 1987, HYPERTENSION, P132; SAUNDERS JB, 1987, BRIT MED J, V294, P1045, DOI 10.1136/bmj.294.6579.1045; WETHERALL DJ, 1987, OXFORD TXB MED, V13, P360; 1989, BMJ, V298, P694	5	23	23	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 10	1991	303	6798					345	345		10.1136/bmj.303.6798.345	http://dx.doi.org/10.1136/bmj.303.6798.345			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA606	1912776	Bronze, Green Published			2022-12-24	WOS:A1991GA60600022
J	NIGHTINGALE, SL				NIGHTINGALE, SL			INTERFERON ALFA APPROVED FOR NON-A, NON-B HEPATITIS TYPE-C	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 12	1991	265	22					2934	2934						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FP635	1903461				2022-12-24	WOS:A1991FP63500008
J	BINETRUY, B; SMEAL, T; KARIN, M				BINETRUY, B; SMEAL, T; KARIN, M			HA-RAS AUGMENTS C-JUN ACTIVITY AND STIMULATES PHOSPHORYLATION OF ITS ACTIVATION DOMAIN	NATURE			English	Article							TRANSCRIPTION FACTOR AP-1; PROTO-ONCOGENE; MOUSE FIBROBLASTS; GENE-EXPRESSION; TRANSFORMATION; INTERACTS; ENCODES; ELEMENT; PRODUCT; CELLS	Ha-Ras augments c-Jun-mediated transactivation by potentiating the activity of the c-Jun activation domain. Ha-Ras also causes a corresponding increase in phosphorylation of specific sites in that part of the c-Jun protein. A Ha-Ras-induced protein kinase cascade resulting in hyperphosphorylation of the c-Jun activation domain could explain how these oncoproteins cooperate to transform rat embryo fibroblasts.	UNIV CALIF SAN DIEGO, SCH MED, CTR MOLEC GENET, DEPT PHARMACOL, 0636, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, SCH MED, CTR MOLEC GENET, DEPT BIOL, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego			Binetruy, Bernard/AFL-7188-2022; Binetruy, Bernard/S-2062-2019; Binetruy, Bernard/A-6465-2009; Binetruy, Bernard/AAG-7139-2022	Binetruy, Bernard/0000-0001-8012-7092; 				ANGEL P, 1989, New Biologist, V1, P35; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; BODNER M, 1988, CELL, V55, P505, DOI 10.1016/0092-8674(88)90037-2; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; DOTTO GP, 1985, NATURE, V318, P472; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HARLOW E, 1988, ANTIBODIES LABORATOR; HERRLICH P, 1989, TRENDS GENET, V5, P112, DOI 10.1016/0168-9525(89)90041-3; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; IMLER JL, 1988, NUCLEIC ACIDS RES, V16, P3005, DOI 10.1093/nar/16.7.3005; IMLER JL, 1988, NATURE, V332, P275, DOI 10.1038/332275a0; JAGGI R, 1986, EMBO J, V5, P2609, DOI 10.1002/j.1460-2075.1986.tb04541.x; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KARIN M, 1990, MOL ASPECTS CELLULAR, V6, P143; LACAL JC, 1987, MOL CELL BIOL, V7, P4146, DOI 10.1128/MCB.7.11.4146; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LAND H, 1986, MOL CELL BIOL, V6, P1917, DOI 10.1128/MCB.6.6.1917; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LUCIBELLO FC, 1990, EMBO J, V9, P2827, DOI 10.1002/j.1460-2075.1990.tb07471.x; MCCORMICK A, 1990, NATURE, V345, P829, DOI 10.1038/345829a0; MCCORMICK F, 1989, ONCOGENES MOL ORIGIN, P125; OFIR R, 1990, NATURE, V348, P80, DOI 10.1038/348080a0; PIETTE J, 1988, P NATL ACAD SCI USA, V85, P3401, DOI 10.1073/pnas.85.10.3401; QUANTIN B, 1988, NATURE, V334, P538, DOI 10.1038/334538a0; RADLER-POHL A, 1990, New Biologist, V2, P566; RULEY HE, 1990, CANCER CELL-MON REV, V2, P258; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SISTONEN L, 1989, EMBO J, V8, P815, DOI 10.1002/j.1460-2075.1989.tb03442.x; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; STACEY DW, 1987, MOL CELL BIOL, V7, P523, DOI 10.1128/MCB.7.1.523; THEILL LE, 1989, NATURE, V342, P945, DOI 10.1038/342945a0; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x; WEINBERG RA, 1989, CANCER RES, V49, P3713; WISDOM R, 1990, MOL CELL BIOL, V10, P5626, DOI 10.1128/MCB.10.11.5626; YANG-YEN H-F, 1990, New Biologist, V2, P351; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; ZARBL H, 1987, CELL, V51, P357, DOI 10.1016/0092-8674(87)90632-5	50	622	641	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 9	1991	351	6322					122	127		10.1038/351122a0	http://dx.doi.org/10.1038/351122a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL035	1903181				2022-12-24	WOS:A1991FL03500041
J	RAUB, W				RAUB, W			TAMOXIFEN FOUND TO LOWER GROWTH-FACTOR LEVELS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											RAUB, W (corresponding author), NIH,BLDG 31,ROOM 2B23,BETHESDA,MD 20892, USA.							1990, J NATL CANCER I, V82, P1693	1	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 3	1991	265	13					1633	1633						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD659	1900541				2022-12-24	WOS:A1991FD65900004
J	MANTLE, J; VERSI, E				MANTLE, J; VERSI, E			PHYSIOTHERAPY FOR STRESS URINARY-INCONTINENCE - A NATIONAL SURVEY	BRITISH MEDICAL JOURNAL			English	Article								Objective-To study the physiotherapeutic treatment of urinary stress incontinence in England. Design-Postal questionnaire survey. Setting-All 192 English district health authorities. Subjects-One physiotherapist from each district who was primarily concerned with urinary incontinence. A consensus view was requested. Main outcome measures-Responses to questionnaire and analysis of a visual analogue scale to indicate effectiveness. Results-There was a 98% response rate. Treatment was often by senior physiotherapists (108 senior I grade or above) who, in 117 districts, claimed to have made a specialty of treating the condition. Gynaecologists and obstetricians were far more likely to refer patients than any other agency (147 respondents said that they were the commonest source of referral). One hundred and fifty four respondents stated that physiotherapy was usually used as the first line of treatment. Pelvic floor exercises and interferential treatment were most commonly used (by 178 and 144 respondents respectively) and thought to be the most effective, especially in combination, though various techniques were used in applying them. Positive motivation (108), recent onset of symptoms (55), and youth (40) were viewed optimistically, and obesity (60), previous surgery (59), prolapse (42), and a chronic cough (36) were considered to be bad prognostic features. The number of patients treated varied greatly (range 10-360) between districts and was poorly correlated with catchment size (correlation coefficient 0.3). Conclusions-As physiotherapists are treating considerable numbers of patients with stress incontinence research is urgently needed to produce efficacy data to enable rationalisation of resources to cater for the whole population.	ROYAL LONDON HOSP,DEPT OBSTET & GYNAECOL,LONDON E1 1BB,ENGLAND; POLYTECH E LONDON,DIV PHYSIOTHERAPY,LONDON E15 4LZ,ENGLAND	Barts Health NHS Trust; Royal London Hospital; University of East London								Bo K, 1989, NEUROLOGY URODYNAMIC, V8, P355; Harrison S M, 1973, Physiotherapy, V59, P363; KEGEL A H, 1948, Ann West Med Surg, V2, P213; KLARSKOV P, 1986, UROL INT, V41, P129, DOI 10.1159/000281181; PEATTIE AB, 1988, BRIT J OBSTET GYNAEC, V95, P1049, DOI 10.1111/j.1471-0528.1988.tb06512.x; STANTON SL, 1990, CLIN OBSTET GYNAECOL, P346; STODDART GD, 1983, PHYSIOTHERAPY, V69, P143; SWITZER D, 1988, IRISH MED J, V81, P30; Tapp AJ, 1989, NEUROUROL URODYNAM, V8, P356; TAPP AJS, 1988, NEUROLOGY URODYNAMIC, V7, P259; TEHON D, 1988, PHYS THER, V68, P652; VERSI E, 1989, BRIT J OBSTET GYNAEC, V96, P752, DOI 10.1111/j.1471-0528.1989.tb03306.x; WILSON PD, 1987, BRIT J OBSTET GYNAEC, V94, P575, DOI 10.1111/j.1471-0528.1987.tb03153.x; 1987, SERIES VS OFFICE POP, V14, P74	14	34	34	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 30	1991	302	6779					753	755		10.1136/bmj.302.6779.753	http://dx.doi.org/10.1136/bmj.302.6779.753			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF229	1888358	Bronze, Green Published			2022-12-24	WOS:A1991FF22900021
J	MARTINEZ, C; MODOLELL, J				MARTINEZ, C; MODOLELL, J			CROSS-REGULATORY INTERACTIONS BETWEEN THE PRONEURAL ACHAETE AND SCUTE GENES OF DROSOPHILA	SCIENCE			English	Article							HAIRY-WING MUTATIONS; PATTERN FORMATION; FATE MAP; MELANOGASTER; COMPLEX; REGENERATION; DUPLICATION; HUNCHBACK; ELEMENTS; SYSTEM	The achaete (ac) and scute (sc) genes of Drosophila allow cells to become sensory organ mother cells. Although ac and sc have similar patterns of expression, deletion of either gene removes specific subsets of sensory organs. This specificity was shown to reside in the peculiar regulation of ac and sc expression. These genes are first activated in complementary spatial domains in response to different cis-regulatory sequences. Each gene product then stimulates expression of the other gene, thus generating similar patterns of expression. Therefore, removal of one gene leads to the absence of both proneural gene products and sensory organs in the sites specified by its cis-regulatory sequences.	UNIV AUTONOMA MADRID,MADRID 34,SPAIN	Autonomous University of Madrid	MARTINEZ, C (corresponding author), CSIC,CTR BIOL MOLEC,E-28049 MADRID,SPAIN.							ALONSO LAG, 1988, ROUX ARCH DEV BIOL, V197, P328, DOI 10.1007/BF00375952; ALONSO LG, 1986, ROUX ARCH DEV BIOL, V195, P259, DOI 10.1007/BF02438959; BALCELLS L, 1988, EMBO J, V7, P3899, DOI 10.1002/j.1460-2075.1988.tb03276.x; BRYANT PJ, 1975, J EXP ZOOL, V193, P49, DOI 10.1002/jez.1401930106; CAMPUZANO S, 1985, CELL, V40, P327, DOI 10.1016/0092-8674(85)90147-3; CAMPUZANO S, COMMUNICATION; DELPRADO JM, 1984, W ROUX ARCH DEV BIOL, V193, P242; ELLIS HM, 1990, CELL, V61, P27, DOI 10.1016/0092-8674(90)90212-W; GARCIABELLIDO A, 1979, GENETICS, V91, P491; GARRELL J, 1990, CELL, V61, P39, DOI 10.1016/0092-8674(90)90213-X; GHYSEN A, 1989, TRENDS GENET, V5, P251, DOI 10.1016/0168-9525(89)90097-8; GHYSEN A, 1989, DEVELOPMENT, V105, P35; HUANG F, IN PRESS DEVELOPMENT; LEYNS L, 1989, ROUX ARCH DEV BIOL, V198, P227, DOI 10.1007/BF00375909; MARTINEZ CJ, UNPUB; MURRAY MA, 1984, DEV BIOL, V104, P259, DOI 10.1016/0012-1606(84)90082-4; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; RODRIGUEZ I, 1990, EMBO J, V11, P3583; ROMANI S, 1989, GENE DEV, V3, P997, DOI 10.1101/gad.3.7.997; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; RUIZGOMEZ M, 1987, GENE DEV, V1, P1238, DOI 10.1101/gad.1.10.1238; SCHRODER C, 1988, EMBO J, V7, P2881, DOI 10.1002/j.1460-2075.1988.tb03145.x; SEIFERT HS, 1986, P NATL ACAD SCI USA, V83, P735, DOI 10.1073/pnas.83.3.735; SKEATH J, COMMUNICATION; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; VAESSIN H, COMMUNICATION; VILLARES R, 1987, CELL, V50, P415, DOI 10.1016/0092-8674(87)90495-8	28	105	105	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 22	1991	251	5000					1485	1487		10.1126/science.1900954	http://dx.doi.org/10.1126/science.1900954			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FC853	1900954				2022-12-24	WOS:A1991FC85300048
J	DANESHDOOST, L; GENNARELLI, TA; BASHEY, HM; SAVINO, PJ; SERGOTT, RC; BOSLEY, TM; SNYDER, PJ				DANESHDOOST, L; GENNARELLI, TA; BASHEY, HM; SAVINO, PJ; SERGOTT, RC; BOSLEY, TM; SNYDER, PJ			RECOGNITION OF GONADOTROPH ADENOMAS IN WOMEN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SECRETING PITUITARY-ADENOMAS; THYROTROPIN-RELEASING-HORMONE; CELL ADENOMAS; LUTEINIZING-HORMONE; ALPHA-SUBUNIT; FSH; CULTURE; INVITRO; INVIVO; BROMOCRIPTINE	Background. Pituitary adenomas that arise from the gonadotroph cells are being recognized with increasing frequency in men, but they are still rarely recognized in women. This rarity could be the result of an actual difference in occurrence or of greater difficulty in recognition. The tumors are usually recognized in men more than 50 years old, but elevated serum gonadotropin levels in women of that age could be produced by normal gonadotroph cells. Methods. Because the stimulation of follicle-stimulating hormone (FSH), luteinizing hormone (LH), and the beta subunit of LH (LH-beta) by thyrotropin-releasing hormone (TRH) is a characteristic of gonadotroph adenomas in men, we administered TRH to 16 women with apparently nonsecreting pituitary macroadenomas and measured serum FSH, LH, LH-beta, and the glycoprotein hormone alpha-subunit every 15 minutes for 90 minutes before and 90 minutes after. The results were compared with the responses in 16 healthy women matched for age and in 10 women with macroadenomas secreting prolactin, growth hormone, or corticotropin. The tumors from 12 of the women with nonsecreting adenomas were cultured, and the secretion of FSH, LH, and LH-beta in culture was determined. Results. Eleven of the 16 women with apparently nonsecreting adenomas had significant increases in serum LH-beta in response to TRH, 3 had FSH responses, and 4 had LH responses. None of the 16 healthy women and none of the 10 women with secreting macroadenomas had LH-beta, FSH, or LH responses to TRH. Ten of the 12 adenomas that were cultured secreted readily detectable amounts of FSH, LH, and LH-beta, and their secretion in vitro correlated with the patients' responses to TRH in vivo. Conclusions. Most apparently nonsecreting pituitary macroadenomas in women arise from gonadotroph cells. The majority of these can be recognized, even in postmenopausal women, by the serum LH-beta responses to TRH, and some can be recognized by the responses of serum FSH and LH.	WILLS EYE HOSP & RES INST,NEUROOPHTHALMOL SERV,PHILADELPHIA,PA 19107; UNIV PENN,SCH MED,DEPT MED,ENDOCRINOL SECT,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DIV NEUROSURG,PHILADELPHIA,PA 19104	Jefferson University; University of Pennsylvania; University of Pennsylvania					NCRR NIH HHS [RR-40] Funding Source: Medline; NIDDK NIH HHS [DK-42139] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042139] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASA SL, 1986, J CLIN ENDOCR METAB, V62, P1011, DOI 10.1210/jcem-62-5-1011; BECKERS A, 1985, J CLIN ENDOCR METAB, V61, P525, DOI 10.1210/jcem-61-3-525; BECKPECCOZ P, 1985, J CLIN ENDOCR METAB, V61, P541, DOI 10.1210/jcem-61-3-541; BLACK PM, 1987, J NEUROSURG, V66, P244, DOI 10.3171/jns.1987.66.2.0244; CUNNINGHAM GR, 1977, J CLIN ENDOCR METAB, V44, P248, DOI 10.1210/jcem-44-2-248; FRIEND JN, 1976, J CLIN ENDOCR METAB, V43, P650, DOI 10.1210/jcem-43-3-650; JAMESON JL, 1987, J CLIN INVEST, V80, P1472, DOI 10.1172/JCI113228; KOVACS K, 1978, FERTIL STERIL, V29, P622; KWEKKEBOOM DJ, 1989, J CLIN ENDOCR METAB, V68, P1128, DOI 10.1210/jcem-68-6-1128; LAMBERTS SWJ, 1987, J CLIN ENDOCR METAB, V64, P524, DOI 10.1210/jcem-64-3-524; MASHITER K, 1981, CLIN ENDOCRINOL, V15, P103, DOI 10.1111/j.1365-2265.1981.tb00643.x; SNYDER PJ, 1980, J CLIN ENDOCR METAB, V51, P744, DOI 10.1210/jcem-51-4-744; SNYDER PJ, 1984, J CLIN ENDOCR METAB, V59, P1169, DOI 10.1210/jcem-59-6-1169; SNYDER PJ, 1985, ENDOCR REV, V6, P552, DOI 10.1210/edrv-6-4-552; SNYDER PJ, 1985, J CLIN ENDOCR METAB, V61, P1061, DOI 10.1210/jcem-61-6-1061; SNYDER PJ, 1976, J CLIN ENDOCR METAB, V42, P544, DOI 10.1210/jcem-42-3-544; TROUILLAS J, 1986, SEMIN DIAGN PATHOL, V3, P42; WHITE MC, 1986, CLIN ENDOCRINOL, V25, P173, DOI 10.1111/j.1365-2265.1986.tb01679.x; WHITE MC, 1990, CLIN ENDOCRINOL, V32, P681, DOI 10.1111/j.1365-2265.1990.tb00914.x; WIDE L, 1981, J CLIN ENDOCR METAB, V53, P923, DOI 10.1210/jcem-53-5-923; WOOLF PD, 1974, J CLIN ENDOCR METAB, V38, P561, DOI 10.1210/jcem-38-4-561	21	109	113	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 28	1991	324	9					589	594		10.1056/NEJM199102283240904	http://dx.doi.org/10.1056/NEJM199102283240904			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EY886	1899470				2022-12-24	WOS:A1991EY88600004
J	NARDELLI, J; GIBSON, TJ; VESQUE, C; CHARNAY, P				NARDELLI, J; GIBSON, TJ; VESQUE, C; CHARNAY, P			BASE SEQUENCE DISCRIMINATION BY ZINC-FINGER DNA-BINDING DOMAINS	NATURE			English	Article							TRANSCRIPTION FACTOR TFIIIA; REPRESSOR-OPERATOR INTERACTIONS; RNA-POLYMERASE; NUCLEIC-ACIDS; FACTOR-IIIA; PROTEINS; EXPRESSION; GENE; RECOGNITION; RESOLUTION	Zinc fingers 1,2 constitute important eukaryotic DNA-binding domains, being present in many transcription factors 3-5. The Cys2/His2 zinc-finger class has conserved motifs of 28-30 amino acids which are usually present as tandem repeats 1,2. The structure of a Cys2/His2 zinc finger has been determined by nuclear magnetic resonance 6, but details of its interaction with DNA were not established. Here we identify amino acids governing DNA-binding specificity using in vitro directed mutagenesis guided by similarities between the zinc fingers of transcription factors Sp1 (ref. 7) and Krox-20 (ref. 8). Krox-20 is a serum-inducible transcription activator 8,9 which is possibly involved in the regulation of hindbrain development 10; it contains three zinc fingers similar to those of Ap1 (refs 7, 8, 11) and binds to a 9-base-pair target sequence which is related to that of Sp1 (ref. 9). Our results show that each finger spans three nucleotides and indicate two positions in Krox-20 zinc fingers that are important for base-pair selectivity. Modelling with molecular graphics suggests that these residues could bind directly with the bases and that other amino acid-base contracts are also possible.	EUROPEAN MOLEC BIOL LAB,W-6900 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)	NARDELLI, J (corresponding author), ECOLE POLYTECH,GENET MOLEC LAB,CNRS,D1302,46 RUE ULM,F-75230 PARIS 05,FRANCE.		Nardelli, Jeannette/N-5739-2017; Vesque, Christine/Q-8461-2019; Vesque, Christine/L-9839-2017	Vesque, Christine/0000-0001-7983-4953; Charnay, Patrick/0000-0002-3847-6042; Gibson, Toby James/0000-0003-0657-5166				AGGARWAL AK, 1988, SCIENCE, V242, P899, DOI 10.1126/science.3187531; BERG JA, 1990, REV BIOPHYS CHEM, V19, P405; BERG JM, 1988, P NATL ACAD SCI USA, V85, P99, DOI 10.1073/pnas.85.1.99; BROWN RS, 1985, FEBS LETT, V186, P271, DOI 10.1016/0014-5793(85)80723-7; BROWN RS, 1986, NATURE, V324, P215, DOI 10.1038/324215a0; CHAVRIER P, 1989, MOL CELL BIOL, V9, P787, DOI 10.1128/MCB.9.2.787; CHAVRIER P, 1988, EMBO J, V7, P29, DOI 10.1002/j.1460-2075.1988.tb02780.x; CHAVRIER P, 1990, EMBO J, V9, P1209, DOI 10.1002/j.1460-2075.1990.tb08228.x; Dayhoff M., 1978, ATLAS PROTEIN SEQ ST, V5; DAYRINGER HE, 1986, J MOL GRAPHICS, V4, P82; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GIBSON TJ, 1988, PROTEIN ENG, V2, P209, DOI 10.1093/protein/2.3.209; HARTSHORNE TA, 1986, NATURE, V320, P283, DOI 10.1038/320283a0; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; JORDAN SR, 1988, SCIENCE, V242, P893, DOI 10.1126/science.3187530; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KADONAGA JT, 1988, SCIENCE, V242, P1566, DOI 10.1126/science.3059495; LEE MS, 1989, SCIENCE, V245, P635, DOI 10.1126/science.2503871; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; RAYMONDJEAN M, 1988, P NATL ACAD SCI USA, V85, P757, DOI 10.1073/pnas.85.3.757; RHODES D, 1986, CELL, V46, P123, DOI 10.1016/0092-8674(86)90866-4; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; STRAUSS F, 1984, CELL, V37, P889, DOI 10.1016/0092-8674(84)90424-0; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VRANA KE, 1988, MOL CELL BIOL, V8, P1684, DOI 10.1128/MCB.8.4.1684; WILKINSON DG, 1989, NATURE, V337, P461, DOI 10.1038/337461a0	30	246	276	0	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 10	1991	349	6305					175	178		10.1038/349175a0	http://dx.doi.org/10.1038/349175a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ER418	1898772				2022-12-24	WOS:A1991ER41800065
J	SVENSSON, BG; NILSSON, A; HANSSON, M; RAPPE, C; AKESSON, B; SKERFVING, S				SVENSSON, BG; NILSSON, A; HANSSON, M; RAPPE, C; AKESSON, B; SKERFVING, S			EXPOSURE TO DIOXINS AND DIBENZOFURANS THROUGH THE CONSUMPTION OF FISH	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY HEART-DISEASE; POLYCHLORINATED-BIPHENYLS; ADIPOSE-TISSUE; VIETNAM VETERANS; MATCHED CONTROLS; BLOOD; 2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN; MORTALITY; SAMPLES; PCDDS	Background. In some regions, including the Baltic Sea, fatty fish such as salmon and herring contain high levels of polychlorinated dibenzodioxins and dibenzofurans. We investigated human exposure to these potentially toxic substances in relation to the consumption of fish from the Baltic Sea. Methods. Plasma levels of 10 different dibenzofurans and 7 dioxins were analyzed in three groups of Swedish men: one group with a high intake of fish (fish eaten almost daily; n = 11), one with a moderate intake of fish (about once per week; n = 9), and one with no consumption of fish (usually because of allergy; n = 9). Results. Plasma levels of several of the compounds we measured were higher in the men with a high intake of fish than in those who consumed moderate amounts, and the levels were higher in those who ate moderate amounts of fish than in those who ate none. The median amounts of the most toxic dioxin (2,3,7,8-tetrachlorodibenzo-p-dioxin) were 8.0 pg per gram of plasma lipid (range, 2.0 to 13) in the high-intake group, 2.6 pg per gram (range, 1.2 to 4.2) in the moderate-intake group, and 1.8 pg per gram (range, 1.0 to 2.5) in the nonconsumers (P = 0.001 and 0.02, respectively). There were consistent and statistically significant associations between the reported amount of fish eaten and the plasma levels of several of the dibenzofurans and dioxins. Conclusions. Contaminated fish such as those from the Baltic Sea are an important source of exposure to polychlorinated dibenzofurans and dibenzodioxins in persons who eat fish regularly. However, the clinical consequences of such exposure remain uncertain.	UNIV LUND,DEPT MED & PHYSIOL CHEM,S-22101 LUND,SWEDEN; UMEA UNIV,INST ENVIRONM CHEM,S-90187 UMEA,SWEDEN	Lund University; Umea University	SVENSSON, BG (corresponding author), UNIV LUND HOSP,DEPT OCCUPAT & ENVIRONM MED,S-22185 LUND,SWEDEN.		Akesson, Bjorn/Q-9163-2017					ASPLUND L, 1990, CHEMOSPHERE, V20, P1481, DOI 10.1016/0045-6535(90)90301-9; BERGQVIST PA, 1989, CHEMOSPHERE, V19, P513, DOI 10.1016/0045-6535(89)90361-5; CHEN PHS, 1984, AM J IND MED, V5, P133; EKSTROM B, 1989, EUR J CLIN INVEST, V19, P259, DOI 10.1111/j.1365-2362.1989.tb00228.x; FEIN GG, 1984, J PEDIATR-US, V105, P315, DOI 10.1016/S0022-3476(84)80139-0; HAGBERG J, 1987, OKAD DIOXINHALT BLOD, P207; KAHN PC, 1988, JAMA-J AM MED ASSOC, V259, P1661, DOI 10.1001/jama.259.11.1661; KOLMODIN-HEDMAN B, 1973, Work-Environment-Health, V10, P100; KROMHOUT D, 1985, NEW ENGL J MED, V312, P1205, DOI 10.1056/NEJM198505093121901; KUEHL DW, 1989, CHEMOSPHERE, V18, P1997, DOI 10.1016/0045-6535(89)90483-9; LINDSTROM G, 1988, THESIS U UMEA UMEA; MASUDA Y, 1984, AM J IND MED, V5, P31; NYGREN M, 1988, CHEMOSPHERE, V17, P1663, DOI 10.1016/0045-6535(88)90095-1; PAPKE O, 1989, CHEMOSPHERE, V19, P941, DOI 10.1016/0045-6535(89)90437-2; PATTERSON DG, 1986, JAMA-J AM MED ASSOC, V256, P2683, DOI 10.1001/jama.256.19.2683; PATTERSON DG, 1989, AM J IND MED, V16, P135, DOI 10.1002/ajim.4700160205; RAPPE C, 1990, CHEMOSPHERE, V20, P1649, DOI 10.1016/0045-6535(90)90325-N; RAPPE C, 1984, ENVIRON SCI TECHNOL, V18, pA78, DOI 10.1021/es00121a711; RAPPE C, 1989, CHEMOSPHERE, V18, P651, DOI 10.1016/0045-6535(89)90178-1; RAPPE C, 1987, ENVIRON SCI TECHNOL, V21, P964, DOI 10.1021/es50001a009; RAPPE C, 1982, CHLORINATED DIOXINS, P495; RONDAHL L, 1989, IVL PUBLICATION B, V951; SCHWARTZ PM, 1983, AM J PUBLIC HEALTH, V73, P293, DOI 10.2105/AJPH.73.3.293; SHEKELLE RB, 1985, NEW ENGL J MED, V313, P820; SKENE SA, 1989, HUM TOXICOL, V8, P173, DOI 10.1177/096032718900800301; SVENSSON BG, 1987, SCI TOTAL ENVIRON, V67, P101, DOI 10.1016/0048-9697(87)90204-X; YRJANHEIKKI E, IN PRESS WHO REG PUB; 1988, NORDISK DIOXINRISKBE, P7	28	139	145	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 3	1991	324	1					8	12		10.1056/NEJM199101033240102	http://dx.doi.org/10.1056/NEJM199101033240102			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EQ503	1898530	Bronze			2022-12-24	WOS:A1991EQ50300002
